Identifier,StructureData,,,,,,,,,,,,,,,Polymer EntityData,,,,,,
Entry ID,EM Resolution (Å),Experimental Method,Matthews Coefficient,Percent Solvent Content,Crystallization Method,pH,Crystal Growth Procedure,Temp (K),DOI,Ligand,PDB ID,Molecular Weight per Deposited Model,Resolution (Å),High Resolution Limit,Structure Title,Sequence,Source Organism,Gene Name,Macromolecule Name,Entity ID,Entry Id (Polymer Entity Identifiers),
"4YGL",,"X-RAY DIFFRACTION",2.11,41.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,"10.1021/jacs.5b00187","LCP","4YGL",29.38,"1.51","1.51","NaClO4--Interactions between Hofmeister Anions and the Binding Pocket of a Protein","HHWGYGGHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YGL"
"4YGN",,"X-RAY DIFFRACTION",2.13,42.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"100 mM Tris-Cl, 1.15 M sodium citrate, pH 7.8",277,"10.1021/jacs.5b00187",,"4YGN",29.7,"1.23","1.23","NaI--Interactions between Hofmeister Anions and the Binding Pocket of a Protein","HHWGYGGHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YGN"
"4YGV",,"X-RAY DIFFRACTION",2.43,49.42,"VAPOR DIFFUSION, SITTING DROP",,"100 mM PCB buffer (pH 6) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364",,"4YGV",95.91,"1.76","1.76","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab2a heavy chain","1","4YGV"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab2a light chain","2","4YGV"
"4YGZ",,"X-RAY DIFFRACTION",3.24,62,"VAPOR DIFFUSION, HANGING DROP",,"12% PEG3350, 0.1M Malonate pH=6.0",277,"10.1021/jacs.6b03681",,"4YGZ",15.86,"2.06","2.06","CRYSTAL STRUCTURE OF THE R111K:Y134F:T54V:R132Q:P39Y:R59Y MUTANT OF HUMAN CELLULAR RETINOIC ACID BINDING PROTEIN II WITH RETINAL AT 2.06 ANGSTROM RESOLUTION - VISIBLE LIGHT IRRADIATED CRYSTAL -3RD CYCLE","PNFSGNWKIIRSENFEELLKVLGVNVMLRKIAVAAASKYAVEIKQEGDTFYIKVSTTVYTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTKELTNDGELILTMTADDVVCTQVFVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","4YGZ"
"4YH0",,"X-RAY DIFFRACTION",3.26,62.33,"VAPOR DIFFUSION, HANGING DROP",,"12% PEG3350, 0.1M Malonate pH=6.0",277,"10.1021/jacs.6b03681",,"4YH0",15.86,"2.144","2.144","Crystal structure of the R111K:Y134F:T54V:R132Q:P39Y:R59Y mutant of human Cellular Retinoic Acid Binding Protein II in complex with Retinal at 2.14 angstrom resolution - UV irradiated crystal - 3rd cycle","PNFSGNWKIIRSENFEELLKVLGVNVMLRKIAVAAASKYAVEIKQEGDTFYIKVSTTVYTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTKELTNDGELILTMTADDVVCTQVFVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","4YH0"
"4YH3",,"X-RAY DIFFRACTION",2.15,42.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG3350, 0.1 M HEPES, pH 7.5, 0.2 M L-proline, soaked in 20 mM ligand for 3 hours at room temperature",298,"10.1016/j.bmcl.2015.04.107","Y80","4YH3",15.71,"1.6","1.6","Crystal structure of human BRD4(1) in complex with 4-[(2E)-3-(4-methoxyphenyl)-2-phenylprop-2-enoyl]-3,4-dihydroquinoxalin-2(1H)-one (compound 19a)","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4YH3"
"4YH4",,"X-RAY DIFFRACTION",2.15,42.82,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M potassium thiocyanate, 20% w/v PEG3350, 0.6 mM ligand",298,"10.1016/j.bmcl.2015.04.107","Y81","4YH4",15.77,"1.33","1.33","Crystal structure of human BRD4(1) in complex with 4-[(5-phenylpyridin-3-yl)carbonyl]-3,4-dihydroquinoxalin-2(1H)-one (compound 19d)","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4YH4"
"4YHF",,"X-RAY DIFFRACTION",2.29,46.21,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 0.2 M (NH4)SO4, and 30% (w/v) PEG 5000 MME",293,"10.1038/nchembio.1817",,"4YHF",67.17,"2.2","2.2","Bruton's tyrosine kinase in complex with a t-butyl cyanoacrylamide inhibitor","KNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","4YHF"
"4YHI",,"X-RAY DIFFRACTION",2.1,41.44,"VAPOR DIFFUSION, SITTING DROP",,"100 mM SPG buffer (pH 6) and 25% PEG 1500",294,"10.1080/19420862.2015.1057364","4CC","4YHI",96.67,"1.9","1.9","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab2a heavy chain","1","4YHI"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab2a light chain","2","4YHI"
"4YHJ",,"X-RAY DIFFRACTION",2.61,52.85,"VAPOR DIFFUSION, SITTING DROP",,"in 0.1 M sodium citrate, pH 5-6.5, 15-27.5 % (w/v) polyethylene glycol 3350 (PEG3350)",277,"10.1074/jbc.M115.648907",,"4YHJ",135.75,"2.6","2.6","Structure and Function of the Hypertension Variant A486V of G Protein-coupled Receptor Kinase 4 (GRK4)","MELENIVANSLLLKARQGGYGKKSGRSKKWKEILTLPPVSQCSELRHSIEKDYSSLCDKQPIGRRLFRQFCDTKPTLKRHIEFLDAVAEYEVADDEDRSDCGLSILDRFFNDKLAAPLPEIPPDVVTECRLGLKEENPSKKAFEECTRVAHNYLRGEPFEEYQESSYFSQFLQWKWLERQPVTKNTFRHYRVLGKGGFGEVCACQVRATGKMYACKKLQKKRIKKRKGEAMALNEKRILEKVQSRFVVSLAYAYETKDALCLVLTIMNGGDLKFHIYNLGNPGFDEQRAVFYAAELCCGLEDLQRERIVYRDLKPENILLDDRGHIRISDLGLATEIPEGQRVRGRVGTVGYMAPEVVNNEKYTFSPDWWGLGCLIYEMIQGHSPFKKYKEKVKWEEVDQRIKNDTEEYSEKFSEDAKSICRMLLTKNPSKRLGCRGEGAAGVKQHPVFKDINFRRLEANMLEPPFCPDPHAVYCKDVLDIEQFSVVKGIYLDTADEDFYARFATGCVSIPWQNEMIESGCFKDINKSESEEALPLDLDKNIHTPVSRPNRGFFYRLFRRGGSLTMVPSEKEVEPKQSENLYFQ","Homo sapiens","GRK4, GPRK2L, GPRK4","G protein-coupled receptor kinase 4","1","4YHJ"
"4YHK",,"X-RAY DIFFRACTION",1.92,35.96,"VAPOR DIFFUSION, SITTING DROP",,"100 mM SPG buffer (pH 6) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364","4CC","4YHK",48.52,"2.21","2.21","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab2a heavy chain","1","4YHK"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab2a light chain","2","4YHK"
"4YHL",,"X-RAY DIFFRACTION",2.76,55.45,"VAPOR DIFFUSION, SITTING DROP",,"100 mM PCB buffer (pH 6) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364",,"4YHL",47.73,"2.09","2.09","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab2b heavy chain","1","4YHL"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTGFTLKISRVEAEDVGVYYCFQASHVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab2b light chain","2","4YHL"
"4YHM",,"X-RAY DIFFRACTION",2.16,43.01,"VAPOR DIFFUSION, SITTING DROP",,"100 mM SPG buffer (pH 7) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364","4CC","4YHM",48.2,"2.16","2.16","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGYDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab2b heavy chain","1","4YHM"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTGFTLKISRVEAEDVGVYYCFQASHVPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab2b light chain","2","4YHM"
"4YHN",,"X-RAY DIFFRACTION",2.32,47.06,"VAPOR DIFFUSION, SITTING DROP",,"100 mM PCB buffer (pH 6) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364",,"4YHN",95.77,"2.31","2.31","Dabigatran Reversal Agent","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGWDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab3 heavy chain","1","4YHN"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab3 light chain","2","4YHN"
"4YHO",,"X-RAY DIFFRACTION",2.29,46.4,"VAPOR DIFFUSION, SITTING DROP",,"100 mM SPG buffer (pH 6) and 25% PEG 1500",293,"10.1080/19420862.2015.1057364","4CC","4YHO",48.36,"1.82","1.82","Reversal Agent for Dabigatran","QVQLVQSGAEVKKPGASVKVSCKASGYTFTDYYMHWVRQAPGQGLEWMGETNPRNGGTTYNEKFKGKATMTRDTSTSTAYMELSSLRSEDTAVYYCTIGTSGWDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"aDabi-Fab3 heavy chain","1","4YHO"
,,,,,,,,,,,,,,,,"DIVMTQTPLSLSVTPGQPASISCRSSQSIVHSDGNIYLEWYLQKPGQSPKLLIYKVSYRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCFQASHVPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"aDabi-Fab3 light chain","2","4YHO"
"4YHT",,"X-RAY DIFFRACTION",3.24,62.09,"VAPOR DIFFUSION, SITTING DROP",8,"100 mM Tris pH 8.0, 650 mM NaCl,
3-6 % PEG 8000",293,"10.1016/j.bmcl.2016.05.033","4EF","4YHT",62.99,"3.05","3.05","bRaf complexed with an inhibitor","DWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHTNETKFEMTKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPTFPQILASIETLARS","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","4YHT"
"4YHY",,"X-RAY DIFFRACTION",2.76,55.38,"VAPOR DIFFUSION, HANGING DROP",7,"24% PEG 3350, 10% Tacsimate (pH7.0), 10 mM EDTA, 1% MPD, 10 mM Sarcosine",292,"10.1073/pnas.1522691113",,"4YHY",96.26,"1.9","1.9","Crystal structure of 309M3-B in complex with trimethylated Lys","SYVLTQPPSVSVAPGQTARITCGGTNIGDISVHWYQQRPGQAPLVVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDDSINAYVFGTGTKVTVLRTVAAPSVFIFPPSDSQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"Fab Light Chain","1","4YHY"
,,,,,,,,,,,,,,,,"EVQLVETGGGVVQPGRSLRLSCTASGFTFRDYWMSWVRQAPGKGLEWVADINPDGITRYYIDAVKGRFTISRDNAKSSLYLQMNSLGAEDTAVYYCAREFHSGLGWHFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT","Homo sapiens",,"Fab Heavy Chain","2","4YHY"
"4YIA",,"X-RAY DIFFRACTION",2.45,44.89,"EVAPORATION",,"PEG 4000",290,,,"4YIA",46.26,"1.58","1.58","Structural mechanism of hormone release in thyroxine binding globulin","MSPFLYLVLLVLGLHATIHCASPEGKVTACHSSQPNATLYKMSSINADFAFNLYRRFTVETPDKNIFFSPVSISAALVMLSFGACCSTQTEIVETLGFNLTDTPMVEIQHGFQHLICSLNFPKKELELQIGNALFIGKHLKPLAKFLNDVKTLYETEVFSTDFSNISAAKQEINSHVEMQTKGKVVGLIQDLKPNTIMVLVNYIHFKAQWANPFDPSKTEDSSSFLIDKTTTVQVPMMHQMEQYYHLVDMELNCTVLQMDYSKNALALFVLPKEGQMESVEAAMSSKTLKKWNRLLQKGWVDLFVPKFSISATYDLGATLLKMGIQHAYSENADFSGLTEDNGLKLSNAAHKAVLHIGEKGTEAAGAMFLEAIPR","Homo sapiens","SERPINA7, TBG","Thyroxine-binding globulin","1","4YIA"
,,,,,,,,,,,,,,,,"HPIIQIDRSFMLLILERSTRSILFLGKVVNPTEA","Homo sapiens","SERPINA7, TBG","Thyroxine-binding globulin","2","4YIA"
"4YIH",,"X-RAY DIFFRACTION",2.2,44,"VAPOR DIFFUSION, HANGING DROP",4,"40 mM potassium phosphate monobasic, 6% PEG8000, 20% gycerol, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293,,,"4YIH",46.95,"1.82","1.82","Crystal structure of human cytosolic 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PVU","MARSVRVLVDMDGVLADFEAGLLRGFRRRFPEEPHVPLEQRRGFLAREQYRALRPDLADKVASVYEAPGFFLDLEPIPGALDAVREMNDLPDTQVFICTSPLLKYHHCVGEKYRWVEQHLGPQFVERIILTRDKTVVLGDLLIDDKDTVRGQEETPSWEHILFTCCHNRHLVLPPTRRRLLSWSDNWREILDSKR","Homo sapiens","NT5C, DNT1, UMPH2","5'(3')-deoxyribonucleotidase, cytosolic type","1","4YIH"
"4YIK",,"X-RAY DIFFRACTION",3.13,60.66,"VAPOR DIFFUSION, HANGING DROP",4,"20 mM potassium phosphate monobasic, 8% PEG8000, 10% gycerol, pH 4, VAPOR DIFFUSION, HANGING DROP, temperature 293K",293,,,"4YIK",24.81,"1.483","1.483","Crystal structure of human cytosolic 5'(3')-deoxyribonucleotidase in complex with the inhibitor PB-PVU","SNAASGGRALRVLVDMDGVLADFEGGFLRKFRARFPDQPFIALEDRRGFWVSEQYGRLRPGLSEKAISIWESKNFFFELEPLPGAVEAVKEMASLQNTDVFICTSPIKMFKYCPYEKYAWVEKYFGPDFLEQIVLTRDKTVVSADLLIDDRPDITGAEPTPSWEHVLFTACHNQHLQLQPPRRRLHSWADDWKAILDSKRP","Homo sapiens","NT5M, DNT2","5'(3')-deoxyribonucleotidase, mitochondrial","1","4YIK"
"4YJ5",,"X-RAY DIFFRACTION",2.34,47.49,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1 M KCl, 0.2M Na tartrate, 18% PEG3350",298,,,"4YJ5",228.62,"2.41","2.41","Crystal structure of PKM2 mutant","QTQQLHAAMADTFLEHMCRLDIDSPPITARNTGIICTIGPASRSVETLKEMIKSGMNVARLNFSHGTHEYHAETIKNVRTATESFASDPILYRPVAVALDTKGPEIRTGLIKGSGTAEVELKKGATLKITLDNAYMEKCDENILWLDYKNICKVVEVGSKIYVDDGLISLQVKQKGADFLVTEVENGGSLGSKKGVNLPGAAVDLPAVSEKDIQDLKFGVEQDVDMVFASFIRKASDVHEVRKVLGEKGKNIKIISKIENHEGVRRFDEILEASDGIMVARGDLGIEIPAEKVFLAQKMMIGRCNRAGKPVICATQMLESMIKKPRPTRAEGSDVANAVLDGADCIMLSGETAKGDYPLEAVRMQHLIAREAEAAIYYLQLFEELRRLAPITSDPTEATAVGAVEASFKCCSGAIIVLTKSGRSAHQVARYRPRAPIIAVTRNPQTARQAHLYRGIFPVLCKDPVQEAWAEDVDLRVNFAMNVGKARGFFKKGDVVIVLTGWRPGSGFTNTMRVVPVP","Homo sapiens","PKM, OIP3, PK2, PK3, PKM2","Pyruvate kinase PKM","1","4YJ5"
"4YJO",,"X-RAY DIFFRACTION",2.07,40.55,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DF","4YJO",33.2,"1.6","1.6","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000222","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJO"
"4YJP",,"X-RAY DIFFRACTION",1.98,38.02,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DL","4YJP",33.17,"1.83","1.83","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000223","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJP"
"4YJQ",,"X-RAY DIFFRACTION",2.1,41.56,"VAPOR DIFFUSION, HANGING DROP",6,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DK","4YJQ",33.25,"1.34","1.34","SYK kinase domain in complex with inhibitor GTC000224","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJQ"
"4YJR",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",6,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DJ","4YJR",33.23,"1.32","1.32","SYK kinase domain in complex with inhibitor GTC000225","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJR"
"4YJS",,"X-RAY DIFFRACTION",1.95,36.8,"VAPOR DIFFUSION, HANGING DROP",6.8,"32.5% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM DTT",293,"10.1016/j.bmcl.2011.07.082","4DN","4YJS",33.1,"2.22","2.22","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000226","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJS"
"4YJT",,"X-RAY DIFFRACTION",2.11,41.74,"VAPOR DIFFUSION, HANGING DROP",6,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DQ","4YJT",33.34,"1.52","1.52","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000233","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJT"
"4YJU",,"X-RAY DIFFRACTION",2.09,41.21,"VAPOR DIFFUSION, HANGING DROP",6.8,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.8, 5mM TCEP",293,"10.1016/j.bmcl.2011.07.082","4DO","4YJU",33.24,"1.67","1.67","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000249","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJU"
"4YJV",,"X-RAY DIFFRACTION",2.12,42.03,"VAPOR DIFFUSION, HANGING DROP",6,"30% Jeffamine ED-2001, 10% Glycerol, 0.1M MES pH6.0, 5mM TCEP",293,,,"4YJV",33.26,"1.652","1.652","THE KINASE DOMAIN OF HUMAN SPLEEN TYROSINE (SYK) IN COMPLEX WITH GTC000250","PEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVN","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","4YJV"
"4YK0",,"X-RAY DIFFRACTION",2.15,42.84,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris, pH 6.5
27% PEG3350
0.1M magnesium chloride",277,"10.1074/jbc.M115.708560","098","4YK0",55.41,"1.65","1.65","Crystal structure of the CBP bromodomain in complex with CPI098","KIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSL","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","4YK0"
"4YK5",,"X-RAY DIFFRACTION",4.05,69.63,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 8.5 + 32.5% PEG 1K",294.15,"10.1021/acs.jmedchem.5b00330","4DV","4YK5",18.97,"1.42","1.42","Crystal Structures of mPGES-1 Inhibitor Complexes","GSLPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","4YK5"
"4YKC",,"X-RAY DIFFRACTION",4.41,72.08,"VAPOR DIFFUSION, HANGING DROP",7,"45% Tacsimate",293,"10.1016/j.str.2015.04.003",,"4YKC",18.68,"2.7","2.7","Crystal structure of cerebral cavernous malformation 2 C-terminal adaptor domain","MELSASATELLQDYMLTLRTKLSSQEIQQFAALLHEYRNGASIHEFCINLRQLYGDSRKFLLLGLRPFIPEKDSQHFENFLETIGVKDGRGIITDSFGRHRRALSTTSSSTTNGNRATGSSDDRSAPSEGDEWDRMISDISSDIEALGCSMDQDSALEHHHHHH","Homo sapiens","CCM2, C7orf22, PP10187","Malcavernin","1","4YKC"
"4YKD",,"X-RAY DIFFRACTION",2.31,46.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M Bis-Tris, 30%(w/v) polyethylene glycol 550, 50 mM calcium chloride",293,"10.1016/j.str.2015.04.003",,"4YKD",11.3,"1.932","1.932","Crystal structure of truncated cerebral cavernous malformation 2 C-terminal adaptor domain","MELSASATELLQDYMLTLRTKLSSQEIQQFAALLHEYRNGASIHEFCINLRQLYGDSRKFLLLGLRPFIPEKDSQHFENFLETIGVKDLEHHHHHH","Homo sapiens","CCM2, C7orf22, PP10187","Malcavernin","1","4YKD"
"4YKH",,"X-RAY DIFFRACTION",3.15,61.03,"VAPOR DIFFUSION, HANGING DROP",9,"2.0 M magnesium chloride, 0.1 M Bicine pH 9.0",281,"10.1107/S1399004715013073",,"4YKH",22.33,"1.52","1.52","Thirty minutes iron loaded human H ferritin","MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","4YKH"
"4YKM",,"X-RAY DIFFRACTION",2.5,50.82,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.1M Bis Tris Propane pH=6.0, 0.2M Sodium Floride",277,"10.1021/jacs.6b03681",,"4YKM",31.85,"1.58","1.58","Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y:A32W:F3Q mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 1.58 angstrom resolution","PNQSGNWKIIRSENFEELLKVLGVNVMLRKIWVAAASKQAVEIKQEGDTFYIKVSTTVYTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTKELTNDGELILTMTADDVVCTQVFVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","4YKM"
"4YKO",,"X-RAY DIFFRACTION",2.5,50.89,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG3350, 0.1M Malonate pH=6.0",277,"10.1021/jacs.6b03681",,"4YKO",31.8,"1.57","1.57","Crystal structure of the R111K:Y134F:T54V:R132Q:P39Q:R59Y:A32Y:F3Q mutant of human Cellular Retinoic Acid Binding Protein II with Retinal at 1.58 angstrom resolution","PNQSGNWKIIRSENFEELLKVLGVNVMLRKIYVAAASKQAVEIKQEGDTFYIKVSTTVYTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTKELTNDGELILTMTADDVVCTQVFVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","4YKO"
"4YKQ",,"X-RAY DIFFRACTION",2.69,54.22,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, cryo conditions: 35% Peg 4000, 10% glycerol",277,,"4EO","4YKQ",27.01,"1.91","1.91","Heat Shock Protein 90 Bound to CS301","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKQ"
"4YKR",,"X-RAY DIFFRACTION",2.7,54.41,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol",277,,"4EP","4YKR",27.3,"1.61","1.61","Heat Shock Protein 90 Bound to CS302","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKR"
"4YKT",,"X-RAY DIFFRACTION",2.69,54.24,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol",277,,,"4YKT",27.19,"1.85","1.85","Heat Shock Protein 90 Bound to CS307","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKT"
"4YKU",,"X-RAY DIFFRACTION",2.7,54.37,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol",277,,"4ER","4YKU",26.96,"1.7","1.7","Heat Shock Protein 90 Bound to CS311","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKU"
"4YKW",,"X-RAY DIFFRACTION",2.13,42.12,"VAPOR DIFFUSION, SITTING DROP",7,"20% Peg 1000, 0.1 M Tris pH 7.0, Cryo Conditions: 35% Peg 4000, 10% glycerol",277,,,"4YKW",54.02,"1.85","1.85","Heat Shock Protein 90 Bound to CS312","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKW"
"4YKX",,"X-RAY DIFFRACTION",2.66,53.69,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo Conditions: 35% Peg 4000, 10% glycerol",277,,"4ET","4YKX",27.08,"1.8","1.8","Heat Shock Protein 90 Bound to CS318","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKX"
"4YKY",,"X-RAY DIFFRACTION",2.68,54.17,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo conditions: 35% Peg 4000, 10% glycerol",277,,"4EU","4YKY",27.07,"1.78","1.78","Heat Shock Protein 90 Bound to CS319","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKY"
"4YKZ",,"X-RAY DIFFRACTION",2.66,53.82,"VAPOR DIFFUSION, SITTING DROP",8,"26% Peg 4000, 0.2 M MgCl2, 0.1 M Tris pH 8.0, Cryo conditions: 35% Peg 4000, 10% glycerol",277,,"4EV","4YKZ",26.97,"1.85","1.85","Heat Shock Protein 90 Bound to CS320","SNAPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","4YKZ"
"4YL0",,"X-RAY DIFFRACTION",4.16,70.46,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 9, 35% PEG 1K",294.15,"10.1021/acs.jmedchem.5b00330","4DZ","4YL0",18.27,"1.52","1.52","Crystal Structures of mPGES-1 Inhibitor Complexes","SLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","4YL0"
"4YL1",,"X-RAY DIFFRACTION",4.18,70.55,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 8.5 + 35% PEG 1K",294.15,"10.1021/acs.jmedchem.5b00330","4U8","4YL1",18.31,"1.41","1.41","Crystal Structures of mPGES-1 Inhibitor Complexes","SLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","4YL1"
"4YL3",,"X-RAY DIFFRACTION",4.15,70.35,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 8.5 
32.5% PEG 1K",294.15,"10.1021/acs.jmedchem.5b00330","4U9","4YL3",18.29,"1.41","1.41","Crystal Structures of mPGES-1 Inhibitor Complexes","SLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","4YL3"
"4YLI",,"X-RAY DIFFRACTION",2.94,58.17,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.0 10% v/v ethanol and 4 mM calcium chloride",293,"10.1186/s12915-015-0136-2",,"4YLI",105.83,"2.45","2.45","CL-K1 trimer","SQLRKAIGEMDNQVSQLTSELKFIKNAVAGVRETESKIYLLVKEEKRYADAQLSCQGRGGTLSMPKDEAANGLMAAYLAQAGLARVFIGINDLEKEGAFVYSDHSPMRTFNKWRSGEPNNAYDEEDCVEMVASGGWNDVACHTTMYFMCEFDKEN","Homo sapiens","COLEC11, UNQ596/PRO1182","Collectin-11","1","4YLI"
"4YLJ",,"X-RAY DIFFRACTION",3.27,62.43,"VAPOR DIFFUSION, SITTING DROP",8.8,"37% PEG400, 0.2 M lithium sulfate, 0.1 M Tris, pH 8.8",277,"10.1021/jm501994d","4E1","4YLJ",172.2,"2.58","2.58","Crystal structure of DYRK1A in complex with 10-Iodo-substituted 11H-indolo[3,2-c]quinoline-6-carboxylic acid inhibitor 5j","SMSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","Dual specificity tyrosine-phosphorylation-regulated kinase 1A","1","4YLJ"
"4YLK",,"X-RAY DIFFRACTION",2.49,50.67,"VAPOR DIFFUSION, SITTING DROP",5.6,"2 M ammonium sulfate, 0.1 M citrate, pH 5.6, 0.2 M potassium/sodium tartrate",277,"10.1021/jm501994d","4E2","4YLK",43.95,"1.4","1.4","Crystal structure of DYRK1A in complex with 10-Chloro-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5s","SMSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","Dual specificity tyrosine-phosphorylation-regulated kinase 1A","1","4YLK"
"4YLL",,"X-RAY DIFFRACTION",2.5,50.71,"VAPOR DIFFUSION, SITTING DROP",5.6,"2 M ammonium sulfate, 0.1 M citrate, pH 5.6, 0.2 M potassium/sodium tartrate",277,"10.1021/jm501994d","4E3","4YLL",43.59,"1.4","1.4","Crystal structure of DYRK1AA in complex with 10-Bromo-substituted 11H-indolo[3,2-c]quinolone-6-carboxylic acid inhibitor 5t","SMSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","Dual specificity tyrosine-phosphorylation-regulated kinase 1A","1","4YLL"
"4YLR",,"X-RAY DIFFRACTION",2.71,54.63,"VAPOR DIFFUSION, SITTING DROP",,"PEG 8000, magnesium acetate",289,"10.1016/j.cell.2015.04.003",,"4YLR",57.69,"2.55","2.55","Tubulin Glutamylase","GSFTKKKGTITANVAGTKFEIVRLVIDEMGFMKTPDEDETSNLIWCDSAVQQEKISELQNYQRINHFPGMGEICRKDFLARNMTKMIKSRPLDYTFVPRTWIFPAEYTQFQNYVKELKKKRKQKTFIVKPANGAMGHGISLIRNGDKLPSQDHLIVQEYIEKPFLMEGYKFDLRIYILVTSCDPLKIFLYHDGLVRMGTEKYIPPNESNLTQLYMHLTNYSVNKHNEHFERDETENKGSKRSIKWFTEFLQANQHDVAKFWSDISELVVKTLIVAEPHVLHAYRMCRPGQPPGSESVCFEVLGFDILLDRKLKPWLLQINRAPSFGTDQKIDYDVKRGVLLNALKLLNIRTSDKRRNLAKQKAEAQRRLYGQNSIKRLLPGSSDWEQQRHQLERRKEELKERLAQVRKQISREEHENRHMGNYRRIYPPEDKALLEKYENLLAVAFQTFLSGRAASFQRELNNPLKRMKEEDILDLLEQCEIDDEKL","Homo sapiens","TTLL7","Tubulin polyglutamylase TTLL7","1","4YLR"
"4YLS",,"X-RAY DIFFRACTION",2.73,55.02,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, magnesium acetate",279,"10.1016/j.cell.2015.04.003",,"4YLS",57.77,"2.6","2.6","Tubulin Glutamylase","GSFTKKKGTITANVAGTKFEIVRLVIDEMGFMKTPDEDETSNLIWCDSAVQQEKISELQNYQRINHFPGMGEICRKDFLARNMTKMIKSRPLDYTFVPRTWIFPAEYTQFQNYVKELKKKRKQKTFIVKPANGAMGHGISLIRNGDKLPSQDHLIVQEYIEKPFLMEGYKFDLRIYILVTSCDPLKIFLYHDGLVRMGTEKYIPPNESNLTQLYMHLTNYSVNKHNEHFERDETENKGSKRSIKWFTEFLQANQHDVAKFWSDISELVVKTLIVAEPHVLHAYRMCRPGQPPGSESVCFEVLGFDILLDRKLKPWLLQINRAPSFGTDQKIDYDVKRGVLLNALKLLNIRTSDKRRNLAKQKAEAQRRLYGQNSIKRLLPGSSDWEQQRHQLERRKEELKERLAQVRKQISREEHENRHMGNYRRIYPPEDKALLEKYENLLAVAFQTFLSGRAASFQRELNNPLKRMKEEDILDLLEQCEIDDEKL","Homo sapiens","TTLL7","Tubulin polyglutamylase TTLL7","1","4YLS"
"4YLW",,"X-RAY DIFFRACTION",3.43,64.11,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM UDAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate",293,,,"4YLW",44.61,"1.79","1.79","Crystal structure of human dihydroorotate dehydrogenase (DHODH) with No.33 compound","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","4YLW"
"4YLZ",,"X-RAY DIFFRACTION",1.9,35.33,"VAPOR DIFFUSION, HANGING DROP",7,"1.2 M ammonium sulfate, 0.1 M HEPES, 4 % v/v PEG 400",293.15,"10.1111/febs.13348",,"4YLZ",71.35,"2.1","2.1","Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lacto-N-neotetraose (LNnT)","HCHQQLNSLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","4YLZ"
"4YM0",,"X-RAY DIFFRACTION",1.96,37.18,"VAPOR DIFFUSION, HANGING DROP",7,"1.2 M ammonium sulfate, 0.1 M HEPES pH 7.0, 4 % v/v PEG 400",293.15,"10.1111/febs.13348",,"4YM0",70.08,"2.3","2.3","Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lacto-N-tetraose (LNT)","HCHQQLNSLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","4YM0"
"4YM1",,"X-RAY DIFFRACTION",1.95,36.81,"VAPOR DIFFUSION, HANGING DROP",7,"1.2 M Ammonium sulfate, 0.1 M HEPES, 4 % v/v PEG 400",293.15,"10.1111/febs.13348",,"4YM1",69.11,"2","2","Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with 2'-fucosyllactose","HCHQQLNSLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","4YM1"
"4YM2",,"X-RAY DIFFRACTION",2.12,36.39,"VAPOR DIFFUSION, HANGING DROP",7,"1.2 M ammonium sulfate, 0.1 M HEPES, 4 % v/v PEG 400",293.15,"10.1111/febs.13348",,"4YM2",69.38,"2.1","2.1","Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lactose-3'-sulfate","HCHQQLNSLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","4YM2"
"4YM3",,"X-RAY DIFFRACTION",1.97,37.61,"VAPOR DIFFUSION, HANGING DROP",7,"1.2 M Ammonium sulfate, 0.1 M HEPES pH 7.0, 4 % v/v PEG 400",293.15,"10.1111/febs.13348",,"4YM3",69.22,"1.89","1.89","Crystal structure of the human galectin-4 C-terminal carbohydrate recognition domain in complex with lactose","HCHQQLNSLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","4YM3"
"4YMD",,"X-RAY DIFFRACTION",2.89,57.43,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES, 10% v/v ethanol and 4 mM calcium chloride",293,"10.1186/s12915-015-0136-2",,"4YMD",106.62,"2.87","2.87","CL-K1 trimer bound to man(alpha1-2)man","SQLRKAIGEMDNQVSQLTSELKFIKNAVAGVRETESKIYLLVKEEKRYADAQLSCQGRGGTLSMPKDEAANGLMAAYLAQAGLARVFIGINDLEKEGAFVYSDHSPMRTFNKWRSGEPNNAYDEEDCVEMVASGGWNDVACHTTMYFMCEFDKEN","Homo sapiens","COLEC11, UNQ596/PRO1182","Collectin-11","1","4YMD"
"4YMJ",,"X-RAY DIFFRACTION",3.14,60.85,"VAPOR DIFFUSION, SITTING DROP",6.2,"2.5 M NACL, 0.1 M NA/K PHOSPHATE PH 6.2",294,"10.1021/acsmedchemlett.5b00050","4EJ","4YMJ",70.69,"2","2","(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors","GAMGSGIHVQHIKRRDIVLKRELGEGAFGKVFLAECYNLSPTKDKMLVAVKALKDPTLAARKDFQREAELLTNLQHEHIVKFYGVCGDGDPLIMVFEYMKHGDLNKFLRAHGPDAMILVDGQPRQAKGELGLSQMLHIASQIASGMVYLASQHFVHRDLATRNCLVGANLLVKIGDFGMSRDVYSTDYYRVGGHTMLPIRWMPPESIMYRKFTTESDVWSFGVILWEIFTYGKQPWFQLSNTEVIECITQGRVLERPRVCPKEVYDVMLGCWQREPQQRLNIKEIYKILHALGKATPIYLDILG","Homo sapiens","NTRK3, TRKC","NT-3 growth factor receptor","1","4YMJ"
"4YMQ",,"X-RAY DIFFRACTION",2.32,46.94,"VAPOR DIFFUSION, HANGING DROP",7,"PEG 4000 (2-8%), NaCl 0.5M, PIPES (0.1M)",298,"10.1016/j.bmcl.2015.03.042","ZBD","4YMQ",33.16,"2","2","X-ray co-structure of nuclear receptor ROR-GAMMAT + SRC2 peptide with a benzothiadiazole dioxide inverse agonist","MGSSHHHHHHLVPRGSPEAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSGGGEKHKILHRLLQDS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","4YMQ"
"4YND",,"X-RAY DIFFRACTION",2.1,41.53,"VAPOR DIFFUSION, HANGING DROP",,"The protein ligand complex was made using a slight molar excess of S adenomethionine (SAM) and A-893 from concentrated DMSO stocks. Co-crystals were grown using the hanging drop format with a 1:1 v/v drop composition of the protein complex: well solution (20% w/v PEG 10,000, 0.1 HEPES pH 7.5) at 17C.",290,"10.1021/acsmedchemlett.5b00124","4GQ","4YND",54.38,"2.79","2.79","The Discovery of A-893, A New Cell-Active Benzoxazinone Inhibitor of Lysine Methyltransferase SMYD2","MSYYHHHHHHDYDIPTTENLYFQGAMDPMRAEGLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLGFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-lysine methyltransferase SMYD2","1","4YND"
"4YNE",,"X-RAY DIFFRACTION",3.23,62,"VAPOR DIFFUSION, SITTING DROP",5,"0.8M (NH4)2SO4, 0.1M Citrate pH 5.0",277,"10.1021/acsmedchemlett.5b00050","4EK","4YNE",35.19,"2.0229","2.0229","(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors","GAMGSGIRVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","4YNE"
"4YNM",,"X-RAY DIFFRACTION",2.34,47.41,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,"10.1021/acs.biochem.5b00697",,"4YNM",53.22,"2.19","2.19","ASH1L wild-type SET domain in complex with S-adenosyl methionine (SAM)","GAMAGSYKKIRSNVYVDVKPLSGYEATTCNCKKPDDDTRKGCVDDCLNRMIFAECSPNTCPCGEQCCNQRIQRHEWVQCLERFRAEEKGWGIRTKEPLKAGQFIIEYLGEVVSEQEFRNRMIEQYHNHSDHYCLNLDSGMVIDSYRMGNEARFINHSCDPNCEMQKWSVNGVYRIGLYALKDMPAGTELTYDYNFHSFNVEKQQLCKCGFEKCRGIIGGKSQRVNG","Homo sapiens","ASH1L, KIAA1420, KMT2H","Histone-lysine N-methyltransferase ASH1L","1","4YNM"
"4YNO",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG 3350",290,"10.1172/JCI64896",,"4YNO",42.63,"1.7","1.7","Crystal structure of MAPK13 at INACTIVE FORM","MGSSHHHHHHSSGLVPRGSMSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPFQSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGMEFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMTGYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAAQALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPI","Homo sapiens","MAPK13, PRKM13, SAPK4","Mitogen-activated protein kinase 13","1","4YNO"
"4YNP",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,"10.1021/acs.biochem.5b00697",,"4YNP",53.31,"2.9","2.9","ASH1L SET domain S2259M mutant in complex with S-adenosyl methionine (SAM)","GAMAGSYKKIRSNVYVDVKPLSGYEATTCNCKKPDDDTRKGCVDDCLNRMIFAECSPNTCPCGEQCCNQRIQRHEWVQCLERFRAEEKGWGIRTKEPLKAGQFIIEYLGEVVSEQEFRNRMIEQYHNHSDHYCLNLDSGMVIDSYRMGNEARFINHSCDPNCEMQKWSVNGVYRIGLYALKDMPAGTELTYDYNFHMFNVEKQQLCKCGFEKCRGIIGGKSQRVNG","Homo sapiens","ASH1L, KIAA1420, KMT2H","Histone-lysine N-methyltransferase ASH1L","1","4YNP"
"4YO4",,"X-RAY DIFFRACTION",1.92,36.1,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium chloride, 0.1 M HEPES, 1.6 M ammonium sulfate",295,,,"4YO4",34.22,"1.6","1.6","Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment phthalazine","TVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSSAWSHPQFEK","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","4YO4"
"4YO6",,"X-RAY DIFFRACTION",2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1021/acsmedchemlett.5b00106","4GD","4YO6",137.42,"2.32","2.32","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","4YO6"
"4YOL",,"X-RAY DIFFRACTION",2.97,58.65,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.7 M sodium citrate, 0.1 M imidazole, pH 8.5",298,"10.1016/j.xphs.2016.02.010",,"4YOL",34,"1.97","1.97","Human fibroblast growth factor-1 C16S/A66C/C117A/P134A","MHHHHHHFNLPPGNYKKPKLLYSSNGGHFLRILPDGTVDGTRDRSDQHIQLQLSAESVGEVYIKSTETGQYLCMDTDGLLYGSQTPNEECLFLERLEENHYNTYISKKHAEKNWFVGLKKNGSAKRGPRTHYGQKAILFLALPVSSD","Homo sapiens","FGF1, FGFA","Fibroblast growth factor 1","1","4YOL"
"4YP8",,"X-RAY DIFFRACTION",2.65,53.57,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1021/acsmedchemlett.5b00106","4GF","4YP8",137.78,"2.641","2.641","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","4YP8"
"4YPA",,"X-RAY DIFFRACTION",2.34,47.34,"VAPOR DIFFUSION, SITTING DROP",,"PEG 4000, magnesium chloride, Tris",290,"10.1021/acs.biochem.5b00697",,"4YPA",106.22,"2.3","2.3","ASH1L SET domain Q2265A mutant in complex with S-adenosyl methionine (SAM)","GAMAGSYKKIRSNVYVDVKPLSGYEATTCNCKKPDDDTRKGCVDDCLNRMIFAECSPNTCPCGEQCCNQRIQRHEWVQCLERFRAEEKGWGIRTKEPLKAGQFIIEYLGEVVSEQEFRNRMIEQYHNHSDHYCLNLDSGMVIDSYRMGNEARFINHSCDPNCEMQKWSVNGVYRIGLYALKDMPAGTELTYDYNFHSFNVEKAQLCKCGFEKCRGIIGGKSQRVNG","Homo sapiens","ASH1L, KIAA1420, KMT2H","Histone-lysine N-methyltransferase ASH1L","1","4YPA"
"4YPC",,"X-RAY DIFFRACTION",2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",6.6,"protein in 10 mM Tris pH 8, 38 mM NaCl mixed in ratio 1:1 with 1M Sodium citrate tribasic dihydrate, 0.1 M Sodium cacodylate trihydrate pH 6.5",298,"10.1016/bs.mie.2015.09.024",,"4YPC",9.92,"1.44","1.44","Trimeric crystal structure of vimentin coil1B fragment","VDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLHEEEIQ","Homo sapiens","VIM","Vimentin","1","4YPC"
"4YPD",,"X-RAY DIFFRACTION",1.91,35.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 1.7 M ammonium sulfate",295,,,"4YPD",34.02,"1.4","1.4","Crystal Structure of DAPK1 catalytic domain in complex with the hinge binding fragment 4-methylpyridazine","TVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSSAWSHPQFEK","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","4YPD"
"4YPE",,"X-RAY DIFFRACTION",2.31,46.69,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mM Tris",277,"10.1021/acs.biochem.5b00697",,"4YPE",53.24,"2.2","2.2","ASH1L SET domain H2193F mutant in complex with S-adenosyl methionine (SAM)","GAMAGSYKKIRSNVYVDVKPLSGYEATTCNCKKPDDDTRKGCVDDCLNRMIFAECSPNTCPCGEQCCNQRIQRHEWVQCLERFRAEEKGWGIRTKEPLKAGQFIIEYLGEVVSEQEFRNRMIEQYHNHSDFYCLNLDSGMVIDSYRMGNEARFINHSCDPNCEMQKWSVNGVYRIGLYALKDMPAGTELTYDYNFHSFNVEKQQLCKCGFEKCRGIIGGKSQRVNG","Homo sapiens","ASH1L, KIAA1420, KMT2H","Histone-lysine N-methyltransferase ASH1L","1","4YPE"
"4YPQ",,"X-RAY DIFFRACTION",3.45,64.36,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M magnesium chloride, 0.1M Tris pH 8.5, 7% PEG 6000",293,"10.1038/ncomms9833","4F1","4YPQ",28.78,"2.32","2.32","Crystal structure of the ROR(gamma)t ligand binding domain in complex with 4-(1-(2-chloro-6-(trifluoromethyl)benzoyl)-1H-indazol-3-yl)benzoic acid","ASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","4YPQ"
"4YPS",,"X-RAY DIFFRACTION",3.26,62.23,"VAPOR DIFFUSION, SITTING DROP",5,"0.8M (NH4)2SO4, 0.1M Citrate pH 5.0",277,"10.1021/acsmedchemlett.5b00050","4F6","4YPS",35.05,"2.1012","2.1012","(R)-2-Phenylpyrrolidine Substitute Imidazopyridazines: a New Class of Potent and Selective Pan-TRK Inhibitors","GAMGSGIRVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","4YPS"
"4YPU",,"X-RAY DIFFRACTION",2.19,43.89,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, 20 mm Tris",277,"10.1021/acs.biochem.5b00697",,"4YPU",53.19,"2.6","2.6","ASH1L SET domain K2264L mutant in complex with S-adenosyl methionine (SAM)","GAMAGSYKKIRSNVYVDVKPLSGYEATTCNCKKPDDDTRKGCVDDCLNRMIFAECSPNTCPCGEQCCNQRIQRHEWVQCLERFRAEEKGWGIRTKEPLKAGQFIIEYLGEVVSEQEFRNRMIEQYHNHSDHYCLNLDSGMVIDSYRMGNEARFINHSCDPNCEMQKWSVNGVYRIGLYALKDMPAGTELTYDYNFHSFNVELQQLCKCGFEKCRGIIGGKSQRVNG","Homo sapiens","ASH1L, KIAA1420, KMT2H","Histone-lysine N-methyltransferase ASH1L","1","4YPU"
"4YQF",,"X-RAY DIFFRACTION",2.63,53.28,"VAPOR DIFFUSION, HANGING DROP",6.9,"24% PEG 1500, 20% glycerol",291,,,"4YQF",68.23,"2.73","2.73","GTPase domain of Human Septin 9","MGSSHHHHHHSSGLVPRGSHGFEFNIMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTVIDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGHSLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDEDSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLLIRTHMQNIKDITSSIHFEAYRVKRL","Homo sapiens","SEPT9, KIAA0991, MSF, SEPTIN9","Septin-9","1","4YQF"
"4YQH",,"X-RAY DIFFRACTION",2.2,43.97,"BATCH MODE",,"magnesium chloride, PEG3350",291,"10.1016/j.bmcl.2015.03.050","4F7","4YQH",75.1,"2.308","2.308","2-[2-(4-Phenyl-1H-imidazol-2-yl)ethyl]quinoxaline (Sunovion Compound 14) co-crystallized with PDE10A","SICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","4YQH"
"4YQM",,"X-RAY DIFFRACTION",2.34,47.36,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 3350 and 100 mM MES pH 6.5 with a drop configuration of 2 uL of complex, 1.8 uL well and 0.2 uL 40% tert-butanol.",293,"10.1038/ncomms13084","4G9","4YQM",85.14,"2.38","2.38","Glutathione S-transferase Omega 1 bound to covalent inhibitor C1-27","SNAMSGESARSLGKGSAPPGPVPEGSIRIYSMRFCPFAERTRLVLKAKGIRHEVININLKNKPEWFFKKNPFGLVPVLENSQGQLIYESAITCEYLDEAYPGKKLLPDDPYEKACQKMILELFSKVPSLVGSFIRSQNKEDYAGLKEEFRKEFTKLEEVLTNKKTTFFGGNSISMIDYLIWPWFERLEAMKLNECVDHTPKLKLWMAAMKEDPTVSALLTSEKDWQGFLELYLQNSPEACDYGL","Homo sapiens","GSTO1, GSTTLP28","Glutathione S-transferase omega-1","1","4YQM"
"4YQU",,"X-RAY DIFFRACTION",2.46,49.95,"VAPOR DIFFUSION, SITTING DROP",6.5,"The GSTO1-C1-31 complex was concentrated to 23.9 mg/mL prior to crystallization. Crystals formed from drops containing equal volumes of complex and well solution (22.5% PEG 3350, 90 mM MES pH 6.5 and 4% tert-butanol).",293,"10.1038/ncomms13084",,"4YQU",56.91,"1.94","1.94","Glutathione S-transferase Omega 1 bound to covalent inhibitor C1-31","SNAMSGESARSLGKGSAPPGPVPEGSIRIYSMRFCPFAERTRLVLKAKGIRHEVININLKNKPEWFFKKNPFGLVPVLENSQGQLIYESAITCEYLDEAYPGKKLLPDDPYEKACQKMILELFSKVPSLVGSFIRSQNKEDYAGLKEEFRKEFTKLEEVLTNKKTTFFGGNSISMIDYLIWPWFERLEAMKLNECVDHTPKLKLWMAAMKEDPTVSALLTSEKDWQGFLELYLQNSPEACDYGL","Homo sapiens","GSTO1, GSTTLP28","Glutathione S-transferase omega-1","1","4YQU"
"4YQV",,"X-RAY DIFFRACTION",2.38,48.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"Complex was concentrated to 26.2 mg/mL. Crystals of the complex grew from sitting drops containing equal volumes of protein complex and well solution (22.5% PEG 3350, 90 mM MES pH 6.5 and 10 mM BaCl2).",293,"10.1038/ncomms13084",,"4YQV",84.48,"2.06","2.06","Glutathione S-transferase Omega 1 bound to covalent inhibitor C4-10","SNAMSGESARSLGKGSAPPGPVPEGSIRIYSMRFCPFAERTRLVLKAKGIRHEVININLKNKPEWFFKKNPFGLVPVLENSQGQLIYESAITCEYLDEAYPGKKLLPDDPYEKACQKMILELFSKVPSLVGSFIRSQNKEDYAGLKEEFRKEFTKLEEVLTNKKTTFFGGNSISMIDYLIWPWFERLEAMKLNECVDHTPKLKLWMAAMKEDPTVSALLTSEKDWQGFLELYLQNSPEACDYGL","Homo sapiens","GSTO1, GSTTLP28","Glutathione S-transferase omega-1","1","4YQV"
"4YS1",,"X-RAY DIFFRACTION",2.15,42.72,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml. Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor.",291,"10.1021/acschembio.7b00062","4G7","4YS1",36.99,"1.07","1.07","Human Aldose Reductase complexed with a ligand with an IDD structure (2) at 1.07 A.","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","4YS1"
"4YS7",,"X-RAY DIFFRACTION",2.2,44.09,"BATCH MODE",,"PEG3350, magnesium chloride",291,"10.1016/j.bmcl.2015.03.050","4GK","4YS7",75.36,"2.502","2.502","Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3H-imidazo[4,5-f]quinoline (compound 39) with PDE10A","ASICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","4YS7"
"4YT1",,"X-RAY DIFFRACTION",2.52,51.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.8M SODIUM CITRATE, 0.1M HEPES",293,"10.1016/j.bmcl.2015.05.025",,"4YT1",65.61,"2.2","2.2","Human PPAR Gamma Ligand Binding Domain in complex with a Gammma Selective Synthetic Partial Agonist MEKT76","GSHMAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDL","Homo sapiens","PPARG, NR1C3","Peroxisome proliferator-activated receptor gamma","1","4YT1"
"4YT6",,"X-RAY DIFFRACTION",3.89,68.4,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM calcium chloride, 17.5% w/v PEG6000",277,"10.1016/j.bmcl.2015.03.062","4JY","4YT6",35.56,"2.07","2.07","Factor VIIa in complex with the inhibitor 4-{[(R)-[5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl](4-phenyl-1H-imidazol-2-yl)methyl]amino}benzenecarboximidamide","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (heavy chain)","1","4YT6"
,,,,,,,,,,,,,,,,"QLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (light chain)","2","4YT6"
"4YT7",,"X-RAY DIFFRACTION",3.53,65.13,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM calcium chloride, 17.5% w/v PEG6000",277,"10.1016/j.bmcl.2015.03.062","4K1","4YT7",35.51,"2.3","2.3","Factor VIIa in complex with the inhibitor 2-(2-{(R)-[(4-carbamimidoylphenyl)amino][5-ethoxy-2-fluoro-3-(propan-2-yloxy)phenyl]methyl}-1H-imidazol-4-yl)benzamide","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (heavy chain)","1","4YT7"
,,,,,,,,,,,,,,,,"QLICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (light chain)","2","4YT7"
"4YTC",,"X-RAY DIFFRACTION",2.35,47.69,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1M dl-malic acid, pH 7.0, 2mM DTT",293,"10.1021/acs.jmedchem.5b00301",,"4YTC",35.24,"2.16","2.16","Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease","GSHNMTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4YTC"
"4YTF",,"X-RAY DIFFRACTION",2.33,47.22,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 M DL-malic acid pH 7.0, 2mM DTT",293,"10.1021/acs.jmedchem.5b00301","4HZ","4YTF",35.31,"1.78","1.78","Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases","GSHNMTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4YTF"
"4YTH",,"X-RAY DIFFRACTION",2.35,47.72,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 DL -malic acid pH 7.0, 2mM DTT",293,"10.1021/acs.jmedchem.5b00301","467","4YTH",35.32,"2.04","2.04","Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Diseases","GSHNMTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4YTH"
"4YTI",,"X-RAY DIFFRACTION",2.41,49.05,"VAPOR DIFFUSION, HANGING DROP",,"1.7-2.1 DL-malic acid pH 7.0, 2mM DTT",293,"10.1021/acs.jmedchem.5b00301","VJK","4YTI",35.29,"2.52","2.52","Discovery of VX-509 (Decernotinib): A Potent and Selective Janus kinase (JAK) 3 Inhibitor for the Treatment of Autoimmune Disease","GSHNMTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4YTI"
"4YTO",,"X-RAY DIFFRACTION",4.23,70.95,"VAPOR DIFFUSION, HANGING DROP",4.6,"ammonium chloride, 0.1 M sodium acetate",293,,,"4YTO",35.48,"2","2","Structure of coiled-coil domain of SYCP1","DTYQKEIEDKKISEENLLEEVEKAKVIADEAVKLQKEIDKRCQHKIAEMVALMEKHKHQYDKIIEERDSELGLYKSKEQEQSSLRASLEIELSNLKAELLSVKKQLEIEREEKEKLKREAKENTATLKEKKDKKTQTFLLLEHHHHHH","Homo sapiens","SYCP1, SCP1","Synaptonemal complex protein 1","1","4YTO"
"4YU1",,"X-RAY DIFFRACTION",2.15,42.9,"VAPOR DIFFUSION, HANGING DROP",5,"Crystallization solution: 50 mM di-Ammoniumhydrogen citrate pH 5.0 PEG6000= 5 % (m/V) DTT= 5.15 g/L NADP+= 0.66 g/L and Human Aldose Reductase= 15 mg/ml.Afterwards the crystals were soaked into Tris 100 mM 25% (m/V) PEG6000 pH 8.0 saturated with the inhibitor.",291,,,"4YU1",36.92,"1.02","1.02","Human Aldose Reductase complexed with Schl12134 (3-[5-(3-nitrophenyl)-2-thienyl]propanoic acid) at 1.02 A","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","4YU1"
"4YU2",,"X-RAY DIFFRACTION",3.26,62.25,"VAPOR DIFFUSION, SITTING DROP",9,"31% PEG 400, 0.2 M lithium sulfate, 0.1 M Tris, pH 9.0",277,"10.3390/molecules25245962","4H5","4YU2",170.38,"2.9","2.9","Crystal structure of DYRK1A with harmine-derivatized AnnH-75 inhibitor","SMSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","Dual specificity tyrosine-phosphorylation-regulated kinase 1A","1","4YU2"
"4YU8",,"X-RAY DIFFRACTION",1.68,26.71,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG3350 25 %w/v, Magnesium Chloride	0.2M,	 bis-Tris 0.1M",293,,,"4YU8",15.42,"1.8","1.8","Crystal structure of Neuroblastoma suppressor of tumorigenicity 1","MLRVLVGAVLPAMLLAAPPPINKLALFPDKSAWCEAKNITQIVGHSGCEAKSIQNRACLGQCFSYSVPNTFPQSTESLVHCDSCMPAQSMWEIVTLECPGHEEVPRVDKLVEKILHCSCQACGKEPSHEGLSVYVQGED","Homo sapiens","NBL1, DAN, DAND1","Neuroblastoma suppressor of tumorigenicity 1","1","4YU8"
"4YU9",,"X-RAY DIFFRACTION",2.75,55.24,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 1.6 M Ammonium Sulfate",281,"10.1107/S2053230X15010389",,"4YU9",113.88,"2.1","2.1","Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase","ASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPEGERSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL","Homo sapiens","QPCT","Glutaminyl-peptide cyclotransferase","1","4YU9"
"4YUB",,"X-RAY DIFFRACTION",2.42,49.07,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Sodium cacodylate pH 6.5 and 1.7 M Sodium acetate",277,"10.1016/j.fob.2015.05.002",,"4YUB",115.26,"2.9","2.9","Crystal structure of human Nicotinic Acid Phosphoribosyltransferase","MAAEQDPEARAAARPLLTDLYQATMALGYWRAGRARDAAEFELFFRRCPFGGAFALAAGLRDCVRFLRAFRLRDADVQFLASVLPPDTDPAFFEHLRALDCSEVTVRALPEGSLAFPGVPLLQVSGPLLVVQLLETPLLCLVSYASLVATNAARLRLIAGPEKRLLEMGLRRAQGPDGGLTASTYSYLGGFDSSSNVLAGQLRGVPVAGTLAHSFVTSFSGSEVPPDPMLAPAAGEGPGVDLAAKAQVWLEQVCAHLGLGVQEPHPGERAAFVAYALAFPRAFQGLLDTYSVWRSGLPNFLAVALALGELGYRAVGVRLDSGDLLQQAQEIRKVFRAAAAQFQVPWLESVLIVVSNNIDEEALARLAQEGSEVNVIGIGTSVVTCPQQPSLGGVYKLVAVGGQPRMKLTEDPEKQTLPGSKAAFRLLGSDGSPLMDMLQLAEEPVPQAGQELRVWPPGAQEPCTVRPAQVEPLLRLCLQQGQLCEPLPSLAESRALAQLSLSRLSPEHRRLRSPAQYQVVLSERLQALVNSLCAGQSP","Homo sapiens","NAPRT, FHIP, NAPRT1","Nicotinate phosphoribosyltransferase","1","4YUB"
"4YUD",,"X-RAY DIFFRACTION",1.96,37.39,"VAPOR DIFFUSION, SITTING DROP",,"20% polyethylene glycol 3350, 0.20M sodium fluoride, 1mM RNA-6b UAAUAA",293,,,"4YUD",10.3,"1.28","1.28","Crystal structure of a RNA binding motif protein 39 (RBM39) from Homo sapiens at 1.28 A resolution","GNLTPEERDARTVFCMQLAARIRPRDLEEFFSTVGKVRDVRMISDRNSRRSKGIAYVEFVDVSSVPLAIGLTGQRVLGVPIIVQASQAEKNR","Homo sapiens","RBM39, HCC1, RNPC2","RNA-binding protein 39","1","4YUD"
"4YUG",,"X-RAY DIFFRACTION",2.68,54.04,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUG",18.04,"1.48","1.48","Multiconformer synchrotron model of CypA at 100 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUG"
"4YUH",,"X-RAY DIFFRACTION",2.7,54.5,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUH",18.04,"1.34","1.34","Multiconformer synchrotron model of CypA at 150 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUH"
"4YUI",,"X-RAY DIFFRACTION",2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUI",18.04,"1.38","1.38","Multiconformer synchrotron model of CypA at 180 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUI"
"4YUJ",,"X-RAY DIFFRACTION",2.86,56.92,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUJ",18.04,"1.42","1.42","Multiconformer synchrotron model of CypA at 240 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUJ"
"4YUK",,"X-RAY DIFFRACTION",2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUK",18.04,"1.48","1.48","Multiconformer synchrotron model of CypA at 260 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUK"
"4YUL",,"X-RAY DIFFRACTION",2.84,56.62,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUL",18.04,"1.42","1.42","Multiconformer synchrotron model of CypA at 280 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUL"
"4YUM",,"X-RAY DIFFRACTION",2.84,56.73,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUM",18.04,"1.5","1.5","Multiconformer synchrotron model of CypA at 300 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUM"
"4YUN",,"X-RAY DIFFRACTION",2.83,56.58,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUN",18.04,"1.58","1.58","Multiconformer synchrotron model of CypA at 310 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUN"
"4YUO",,"X-RAY DIFFRACTION",2.82,56.36,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUO",18.04,"1.2","1.2","High-resolution multiconformer synchrotron model of CypA at 273 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUO"
"4YUP",,"X-RAY DIFFRACTION",2.7,54.44,"VAPOR DIFFUSION, HANGING DROP",,"Crystals were grown by mixing equal volumes of well solution (100 mM HEPES pH 7.5, 23% PEG 3350, 5 mM TCEP) and protein (60 mg/mL in 20 mM HEPES pH 7.5, 100 mM NaCl, 0.5 mM TCEP) in the hanging-drop format.",291,"10.7554/eLife.07574",,"4YUP",18.04,"1.75","1.75","Multiconformer fixed-target X-ray free electron (XFEL) model of CypA at 273 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","4YUP"
"4YUR",,"X-RAY DIFFRACTION",2.62,53.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, 0.2 M MgCl2, 30% PEG 400",297,"10.1126/science.aaa5111",,"4YUR",32.27,"2.65","2.65","Crystal Structure of Plk4 Kinase Domain Bound to Centrinone","GPGSATCIGEKIEDFKVGNLLGKGSFAGVYRAESIHTGLEVAIKMIDKKAMYKAGMVQRVQNEVKIHCQLKHPSILELYNYFEDSNYVYLVLEMCHNGEMNRYLKNRVKPFSENEARHFMHQIITGMLYLHSHGILHRDLTLSNLLLTRNMNIKIADFGLATQLKMPHEKHYTLCGTPNYISPEIATRSAHGLESDVWSLGCMFYTLLIGRPPFDTDTVKNTLNKVVLADYEMPSFLSIEAKDLIHQLLRRNPADRLSLSSVLDHPFMSRNSSTKSKD","Homo sapiens","PLK4, SAK, STK18","Serine/threonine-protein kinase PLK4","1","4YUR"
"4YV3",,"X-RAY DIFFRACTION",2,38.57,"VAPOR DIFFUSION, SITTING DROP",6,"10mg/ml protein in 10mM Tris-HCl pH 8, 38 mM NaCl mixed in v/v ratio 1:1 with ammonium sulphate 2.2M, sodium thiocyanate 0.2 M",298,"10.1016/bs.mie.2015.09.024",,"4YV3",28.3,"2","2","Trimeric crystal structure of vimentin coil1B fragment","VDQLTNDKARVEVERDNLAEDIMRLREKLQEEMLQREEAENTLQSFRQDVDNASLARLDLERKVESLQEEIAFLKKLH","Homo sapiens","VIM","Vimentin","1","4YV3"
"4YVA",,"X-RAY DIFFRACTION",2.22,44.62,"VAPOR DIFFUSION, SITTING DROP",6.5,"24% PEG 8000, 0.2M Ammonium sulfate",294.15,"10.1021/acs.jnatprod.6b00215",,"4YVA",23.62,"1.8","1.8","Cathepsin K co-crystallized with actinomycetes extract","APDSVDYRKKGYVTPVKNQGQCGSCWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM","Homo sapiens","CTSK, CTSO, CTSO2","Cathepsin K","1","4YVA"
"4YVC",,"X-RAY DIFFRACTION",4.51,72.71,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.45 mM protein, 5% PEG3350, 100 mM MES, 50 mM calcium chloride, 10 mM DTT",298,"10.1021/acs.jmedchem.5b00424","4KH","4YVC",96.62,"3.2","3.2","ROCK 1 bound to thiazole inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","4YVC"
"4YVD",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M CaCl",293,,,"4YVD",41.87,"1.7","1.7","Crytsal structure of human Pleiotropic Regulator 1 (PRL1)","TAPSGSEYRHPGASDRPQPTAMNSIVMETGNTKNSALMAKKAPTMPKPQWHPPWKLYRVISGHLGWVRCIAVEPGNQWFVTGSADRTIKIWDLASGKLKLSLTGHISTVRGVIVSTRSPYLFSCGEDKQVKCWDLEYNKVIRHYHGHLSAVYGLDLHPTIDVLVTCSRDSTARIWDVRTKASVHTLSGHTNAVATVRCQAAEPQIITGSHDTTIRLWDLVAGKTRVTLTNHKKSVRAVVLHPRHYTFASGSPDNIKQWKFPDGSFIQNLSGHNAIINTLTVNSDGVLVSGADNGTMHLWDWRTGYNFQRVHAAVQPGSLDSESGIFACAFDQSESRLLTAEADKTIKVYREDDTATEETHPVSWKPEIIKRKRF","Homo sapiens","PLRG1","Pleiotropic regulator 1","1","4YVD"
"4YVE",,"X-RAY DIFFRACTION",4.51,72.71,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.45 mM protein, 5% PEG3350, 100 mM MES, 50 mM calcium chloride, 10 mM DTT",298,"10.1021/acs.jmedchem.5b00424","4KK","4YVE",96.68,"3.4","3.4","ROCK 1 bound to methoxyphenyl thiazole inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","4YVE"
"4YVF",,"X-RAY DIFFRACTION",3,58.94,"VAPOR DIFFUSION, SITTING DROP",,"HEPES, PEG 4000, 2-propanol, ethyl acetate",293,"10.1016/j.bmc.2015.05.018",,"4YVF",97.99,"2.7","2.7","Structure of S-adenosyl-L-homocysteine hydrolase","MSDKLPYKVADIGLAAWGRKALDIAENEMPGLMRMRERYSASKPLKGARIAGCLHMTVETAVLIETLVTLGAEVQWSSCNIFSTQDHAAAAIAKAGIPVYAWKGETDEEYLWCIEQTLYFKDGPLNMILDDGGDLTNLIHTKYPQLLPGIRGISEETTTGVHNLYKMMANGILKVPAINVNDSVTKSKFDNLYGCRESLIDGIKRATDVMIAGKVAVVAGYGDVGKGCAQALRGFGARVIITEIDPINALQAAMEGYEVTTMDEACQEGNIFVTTTGCIDIILGRHFEQMKDDAIVCNIGHFDVEIDVKWLNENAVEKVNIKPQVDRYRLKNGRRIILLAEGRLVNLGCAMGHPSFVMSNSFTNQVMAQIELWTHPDKYPVGVHFLPKKLDEAVAEAHLGKLNVKLTKLTEKQAQYLGMSCDGPFKPDHYRY","Homo sapiens","AHCY, SAHH","Adenosylhomocysteinase","1","4YVF"
"4YVP",,"X-RAY DIFFRACTION",2.3,46.58,"VAPOR DIFFUSION, HANGING DROP",7.3,"23-27% (w/v) PEG 4000, 100 mM Hepes, 10mM CaCl2, 0.4M NaCl",289,"10.1016/j.cbi.2015.09.006",,"4YVP",76.15,"2.6","2.6","Crystal Structure of AKR1C1 complexed with glibenclamide","MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPVSVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLNRNVRYLTLDIFAGPPNYPFSDEY","Homo sapiens","AKR1C1, DDH, DDH1","Aldo-keto reductase family 1 member C1","1","4YVP"
"4YVV",,"X-RAY DIFFRACTION",2.41,49.06,"VAPOR DIFFUSION, HANGING DROP",6,"15-20% (w/v) PEG 8000, 100 mM MES, 0.14M NaCl",289,"10.1016/j.cbi.2015.09.006","GBM","4YVV",76.29,"2.3","2.3","Crystal structure of AKR1C3 complexed with glibenclamide","MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY","Homo sapiens","AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS","Aldo-keto reductase family 1 member C3","1","4YVV"
"4YVX",,"X-RAY DIFFRACTION",2.44,49.52,"VAPOR DIFFUSION, HANGING DROP",6,"15-20% (w/v) PEG 8000, 100 mM MES, 0.14M NaCl",289,"10.1016/j.cbi.2015.09.006","GMR","4YVX",76.28,"2.3","2.3","Crystal structure of AKR1C3 complexed with glimepiride","MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY","Homo sapiens","AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS","Aldo-keto reductase family 1 member C3","1","4YVX"
"4YVY",,"X-RAY DIFFRACTION",2.09,41.19,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M sodium citrate and 0.1 M Tris-HCl, pH 8.5",293,,,"4YVY",29.34,"1.45","1.45","Crystal structure of human carbonic anhydrase II in complex with hydroxylamine-O-sulfonamide, a molecule incorporating two zinc-binding groups.","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YVY"
"4YWP",,"X-RAY DIFFRACTION",2.1,41.43,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCL pH 7.4",298,"10.1107/S2053230X1501239X",,"4YWP",29.25,"1.45","1.45","Sucrose Binding Site in genetically engineered Carbonic anhydrase IX","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YWP"
"4YWQ",,"X-RAY DIFFRACTION",1.92,36.01,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein mixed with elastase at 1:1000 (w/w) ratio right before crystallization, 25% PEG8000, 0.2 M sodium chloride, 0.1 M HEPES, pH 7.5",293,,,"4YWQ",39.48,"1.7","1.7","Crystal structure of the ROQ domain of human Roquin-1","RSLGERTVTELILQHQNPQQLSSNLWAAVRARGCQFLGPAMQEEALKLVLLALEDGSALSRKVLVLFVVQRLEPRFPQASKTSIGHVVQLLYRASCFKVTKRDEDSSLMQLKEEFRTYEALRREHDSQIVQIAMEAGLRIAPDQWSSLLYGDQSHKSHMQSIIDKLQTPA","Homo sapiens","RC3H1, KIAA2025, RNF198","Roquin-1","1","4YWQ"
"4YWT",,"X-RAY DIFFRACTION",2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",8,"PEG 6000, Tris-HCl and CaCl2",298,"10.1074/jbc.M115.660878",,"4YWT",235.27,"2.38","2.38","Crystal structure of full-length glypican-1 core protein after controlled crystal dehydration to 87% relative humidity","APQLHHHHHHDLYENLYFQGKLDPASKSRSCGEVRQIYGAKGFSLSDVPQAEISGEHLRICPQGYTCCTSEMEENLANRSHAELETALRDSSRVLQAMLATQLRSFDDHFQHLLNDSERTLQATFPGAFGELYTQNARAFRDLYSELRLYYRGANLHLEETLAEFWARLLERLFKQLHPQLLLPDDYLDCLGKQAEALRPFGEAPRELRLRATRAFVAARSFVQGLGVASDVVRKVAQVPLGPECSRAVMKLVYCAHCLGVPGARPCPDYCRNVLKGCLANQADLDAEWRNLLDSMVLITDKFWGTSGVESVIGSVHTWLAEAINALQDNRDTLTAKVIQGCGNPKVNPQGPGPEEKRRRGKLAPRERPPSGTLEKLVSEAKAQLRDVQDFWISLPGTLCSEKMALSTASDDRCWNGMARGRYLPEVMGDGLANQINNPEVEVDITKPDMTIRQQIMQLKIMTNRLRSAYNGNDVDFQDASDDGAGAGAGDGCLDDLCSRKVSRKSSSSRTPLTHALPGLSEQEGQ","Homo sapiens","GPC1","Glypican-1","1","4YWT"
"4YWY",,"X-RAY DIFFRACTION",2.52,51.16,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES buffer pH 6.5, 1.6 M ammonium sulfate",281,"10.1107/S2053230X15010389","PBD","4YWY",125.48,"1.95","1.95","Crystal Structure of double mutant Y115E Y117E human Glutaminyl Cyclase in complex with inhibitor PBD-150","MAGGRHRRVVGTLHLLLLVAALPWASRGVSPSASAWPEEKNYHQPAILNSSALRQIAEGTSISEMWQNDLQPLLIERYPGSPGSYAARQHIMQRIQRLQADWVLEIDTFLSQTPEGERSFSNIISTLNPTAKRHLVLACHYDSKYFSHWNNRVFVGATDSAVPCAMMLELARALDKKLLSLKTVSDSKPDLSLQLIFFDGEEAFLHWSPQDSLYGSRHLAAKMASTPHPPGARGTSQLHGMDLLVLLDLIGAPNPTFPNFFPNSARWFERLQAIEHELHELGLLKDHSLEGRYFQNYSYGGVIQDDHIPFLRRGVPVLHLIPSPFPEVWHTMDDNEENLDESTIDNLNKILQVFVLEYLHL","Homo sapiens","QPCT","Glutaminyl-peptide cyclotransferase","1","4YWY"
"4YX4",,"X-RAY DIFFRACTION",2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,"10.1021/acs.jmedchem.5b01643","FB2","4YX4",29.93,"1.01","1.01","Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (1).","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YX4"
"4YXI",,"X-RAY DIFFRACTION",2.08,40.86,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",293,"10.1021/acs.jmedchem.5b01643","4J8","4YXI",30.11,"0.96","0.96","Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (2).","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YXI"
"4YXO",,"X-RAY DIFFRACTION",2.08,40.75,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,"10.1021/acs.jmedchem.5b01643","4JC","4YXO",30.14,"1.06","1.06","Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (3).","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YXO"
"4YXU",,"X-RAY DIFFRACTION",2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",7.8,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,"10.1021/acs.jmedchem.5b01643","4JE","4YXU",30.17,"1.08","1.08","Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (4).","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YXU"
"4YY4",,"X-RAY DIFFRACTION",2.55,51.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES, pH 7.5, 25% w/v PEG3350",277,"10.1016/j.str.2015.08.004",,"4YY4",12.52,"1.47","1.47","Crystal structure of BRD9 Bromodomain bound to DMSO","GSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSK","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","4YY4"
"4YYT",,"X-RAY DIFFRACTION",2.09,41.03,"VAPOR DIFFUSION, HANGING DROP",,"2.5 uL of the protein solution (10 mg/ml hCAII in 50 mM Tris pH 7.8) were mixed with 2.5 uL of the well solution (2.7 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with p-chloromercurybenzoicacid) and placed as a hanging drop. Crystals appeared after several days. The crystals were soaked in 3.0 M (NH4)SO4, 100 mM Tris, pH 7.8, saturated with the inhibitor, for 1 day.",291,"10.1021/acs.jmedchem.5b01643","S2O","4YYT",30.57,"1.07","1.07","Human Carbonic Anhydrase II complexed with an inhibitor with a benzenesulfonamide group (5).","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4YYT"
"4YYZ",,"X-RAY DIFFRACTION",4.03,69.48,"VAPOR DIFFUSION, HANGING DROP",8,"20mM HEPES, 100mM NaCl, 2mM TCEP, 10uM NADP",293,,,"4YYZ",58.94,"3.2","3.2","11B-HYDROXYSTEROID DEHYDROGENASE TYPE I IN COMPLEX WITH INHIBITOR","EFRPEMLQGKKVIVTGASKGIGREMAYHLAKMGAHVVVTARSKETLQKVVSHCLELGAASAHYIAGTMEDMTFAEQFVAQAGKLMGGLDMLILNHITNTSLNLFHDDIHHVRKSMEVNFLSYVVLTVAALPMLKQSNGSIVVVSSLAGKVAYPLVAAYSASKFALDGFFSSIRKEYSVSRVNVSITLCVLGLIDTETAMKAVSGIVHMQAAPKEECALEIIKGGALRQEEVYYDSSRWTTLLIRNPSRKILEELYSTSY","Homo sapiens","HSD11B1, HSD11, HSD11L, SDR26C1","Corticosteroid 11-beta-dehydrogenase isozyme 1","1","4YYZ"
"4YZ9",,"X-RAY DIFFRACTION",3.01,59.12,"VAPOR DIFFUSION, SITTING DROP",7,"Crystals of pIRE1alpha (547 - 977) with GSK2850163 were prepared by mixing pIRE1alpha with 0.5 mM GSK2850163 and incubating overnight on ice. The crystals were grown at 20 C by vapor diffusion in sitting drops containing 2 ul of protein (13 mg/ml in 50 mM Hepes, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA , 0.5 mM GSK2850163, 0.25% DMSO ) and 2 ul reservoir solution containing PEG 3350 (16%-22%), 100 mM Hepes pH 7.0, 200 mM Ca2+ acetate.  The crystals were thick rods that appeared over 2-5 days and reached full size (0.05 X 0.025 X 0.3 mm) in 2 weeks. Seeding was used to improve crystal quality. The pIRE1alpha + GSK2850163 crystals were frozen in a solution of 20% ethylene glycol, 22% PEG 3350, 0.2 M calcium acetate added in a stepwise manner to the protein drop before mounting the crystal on the loop.",293,"10.1124/mol.115.100917","4K7","4YZ9",141.17,"2.463","2.463","Crystal Structure of human phosphorylated IRE1alpha in complex with a type III kinase inhibitor (GSK2850163A)","SVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPP","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","4YZ9"
"4YZC",,"X-RAY DIFFRACTION",3.2,61.6,"VAPOR DIFFUSION, SITTING DROP",7.5,"The complex of pIRE1a (547-977) with staurosporine was prepared by mixing the protein with 0.5 mM staurosporine and incubated overnight on ice.  The crystals were grown at 20C by vapor diffusion in sitting drop containing 2 ul of protein (13 mg/ml in 50 mM Hepes, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA) and 2ul reservoir solution containing PEG 300 (30%-40%), 100 mM Hepes pH 7.5, 200 mM KCl. Small hexagonal plates appeared over 5-10 days and reached full size (0.05 X 0.75 X 0.15 mm) in ~20 days. The crystals were flash-frozen in liquid N2 directly from the crystallization drop. All diffraction data was collected at the Advanced Photon Source, Argonne National Laboratories, Life Sciences CAT, Sector 21",293,"10.1124/mol.115.100917","STU","4YZC",94.63,"2.494","2.494","Crystal structure of pIRE1alpha in complex with staurosporine","SVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPP","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","4YZC"
"4YZD",,"X-RAY DIFFRACTION",3.13,60.73,"VAPOR DIFFUSION, SITTING DROP",6,"The crystals of pIRE1a with Mg2+-ADP were grown by mixing 2 ul protein solution (10 mg/ml pIRE1a (547-977) in 50 mM Hepes, pH 7.5, 200 mM NaCl, 5 mM DTT, 1 mM EDTA, 1 mM ADP (100mM ADP stock was ~ pH 7.0), 1 mM MgCl2) with 2 ul reservoir solution (16 % PEG 3350, 200 mM Na+ Malonate pH 6.0) in sitting drops at room temperature. Seeding was used to initiate crystal growth.  Crystals appeared the next day and grew to full size in 3 weeks. For data collection, the crystals were frozen in a solution of 20% ethylene glycol, 22% PEG 3350, 200 mM Na+ Malonate pH 6.0 and added to the protein drop before mounting the crystals on the loop.",293,"10.1124/mol.115.100917",,"4YZD",141.16,"3.102","3.102","Crystal Structure of human phosphorylated IRE1alpha in complex with ADP-Mg","SVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPP","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","4YZD"
"4YZS",,"X-RAY DIFFRACTION",2.4,48.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Tris (pH 8.5), 0.2 M MgCl2, 25% w/v PEG3350, 7% glycerol",291,"10.15252/embj.201489183",,"4YZS",68.6,"3.14","3.14","Crystal structures reveal transient PERK luminal domain tetramerization in ER stress signaling","GPHMASLVIISTLDGRIAALDPENHGKKQWDLDVGSGSLVSSSLSKPEVFGNKMIIPSLDGALFQWDRDRESMETVPFTVESLLESSYKFGDDVVLVGGKSLTTYGLSAYSGKVRYICSALGCRQWDSDEMEQEEDILLLQRTQKTVRAVGPRSGNEKWNFSVGHFELRYIPDMETRAGFIESTFKPNENTEESKIISDVEEQEAAIMDIVIKVSVADWKVMAFSKKGGHLEWEYQFCTPIASAWLLKDGKVIPISLFDDTSYTSNDDVLEDEEDIVEAARGATENSVYLGMYRGQLYLQSSVRI","Homo sapiens","EIF2AK3, PEK, PERK","Eukaryotic translation initiation factor 2-alpha kinase 3","1","4YZS"
"4YZU",,"X-RAY DIFFRACTION",2.75,55.31,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.05 M Tris, pH 7.2, 1.2 M ammonium sulfate, 2.0 M sodium chloride",295,"10.1016/j.bmcl.2015.04.025","4K6","4YZU",33.57,"1.41","1.41","Rapid development of two Factor IXa inhibitors from Hit to Lead","VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGASALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","1","4YZU"
,,,,,,,,,,,,,,,,"MDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","2","4YZU"
"4Z02",,"X-RAY DIFFRACTION",2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",6.5,"28% PEG 2K MME, 0.1 M Bis-Tris pH6.5",293,,,"4Z02",28.91,"1.87","1.87","Crystal structure of BRD1 in complex with Isoquinoline-3-carboxylic acid","SVLEPLKVVWAKCSGYPSYPALIIDPKMPRVPGHHNGVTIPAPPLDVLKIGEHMQTKSDEKLFLVLFFDNKRSWQWLPKSKMVPLGIDETIDKLKMMEGRNSSIRKAVRIAFDRAMNHLSRVHGE","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","4Z02"
"4Z07",,"X-RAY DIFFRACTION",2.84,56.71,"VAPOR DIFFUSION, HANGING DROP",8,"0.2 M ammonium sulfate, 17.5% PEG 8000 (w/v), 10% Isopropanol, 0.1 M HEPES, pH 8.0",295,"10.1016/j.str.2016.03.009",,"4Z07",89.93,"2.5","2.5","Co-crystal structure of the tandem CNB (CNB-A/B) domains of human PKG I beta with cGMP","GSSHVTLPFYPKSPQSKDLIKEAILDNDFMKNLELSQIQEIVDCMYPVEYGKDSCIIKEGDVGSLVYVMEDGKVEVTKEGVKLCTMGPGKVFGELAILYNCTRTATVKTLVNVKLWAIDRQCFQTIMMRTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAY","Homo sapiens","PRKG1, PRKG1B, PRKGR1A, PRKGR1B","cGMP-dependent protein kinase 1","1","4Z07"
"4Z0K",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION, HANGING DROP",7.2,"50 mM Tris, pH 7.2,  1.2 M ammonium sulfate, 2.0 M sodium chloride",295,"10.1016/j.bmcl.2015.04.025","4LN","4Z0K",33.61,"1.41","1.41","Rapid development of two Factor IXa inhibitors from Hit to Lead","VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGASALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","1","4Z0K"
,,,,,,,,,,,,,,,,"MDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","2","4Z0K"
"4Z0O",,"X-RAY DIFFRACTION",2.27,45.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"2 M ammonium sulfate, 2% PEG400, 0.1 M HEPES sodium",293,,,"4Z0O",7.14,"1.57","1.57","CW-type zinc finger of ZCWPW2 with F78D mutation","GVENMYVNKVWVQCENENCLKWRLLSSEDSAKVDHDEPWYCFMNTDSRYNNCSISEEDD","Homo sapiens","ZCWPW2","Zinc finger CW-type PWWP domain protein 2","1","4Z0O"
"4Z0Q",,"X-RAY DIFFRACTION",2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,"10.1016/j.ejmech.2015.07.049","4K9","4Z0Q",29.45,"1.45","1.45","Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4Z0Q"
"4Z0V",,"X-RAY DIFFRACTION",2.23,44.73,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M MgCl2
0.1M Tris pH 8.5
24% PEG 3350",277,"10.1074/jbc.M115.653113",,"4Z0V",50.23,"1.78","1.78","The structure of human PDE12 residues 161-609","YKVERNPPAFTELQLPRYIMAGFPVCPKLSLEFGDPASSLFRWYKEAKPGAAGSSWTETDVEERVYTPSNADIGLRLKLHCTPGDGQRFGHSRELESVCVVEAGPGTCTFDHRHLYTKKVTEDALIRTVSYNILADTYAQTEFSRTVLYPYCAPYALELDYRQNLIQKELTGYNADVICLQEVDRAVFSDSLVPALEAFGLEGVFRIKQHEGLATFYRKSKFSLLSQHDISFYEALESDPLHKELLEKLVLYPSAQEKVLQRSSVLQVSVLQSTKDSSKRICVANTHLYWHPKGGYIRLIQMAVALAHIRHVSCDLYPGIPVIFCGDFNSTPSTGMYHFVINGSIPEDHEDWASNGEEERCNMSLTHFFKLKSACGEPAYTNYVGGFHGCLDYIFIDLNALEVEQVIPLPSHEEVTTHQALPSVSHPSDHIALVCDLKWK","Homo sapiens","PDE12","2',5'-phosphodiesterase 12","1","4Z0V"
"4Z15",,"X-RAY DIFFRACTION",2.71,54.62,"VAPOR DIFFUSION, HANGING DROP",,"Tris, ammonium sulfate, isopropanol",295,"10.1111/jcmm.12949",,"4Z15",37.83,"1.6","1.6","MIF in complex with 3-(2-furylmethyl)-2-thioxo-1,3-thiazolan-4-one","XMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","4Z15"
"4Z16",,"X-RAY DIFFRACTION",2.71,54.54,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-tris pH 6.5, 16% PEG 3350, 0.2 M ammonium sulfate, 5 mM TCEP",277,"10.1021/acs.jmedchem.5b00710","4LH","4Z16",145.88,"2.9","2.9","Crystal Structure of the Jak3 Kinase Domain Covalently Bound to N-(3-(((5-chloro-2-((2-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)methyl)phenyl)acrylamide","GSCQDPTIFEERHLKYISQLGKGNFGSVELCRYDPLGDNTGALVAVKQLQHSGPDQQRDFQREIQILKALHSDFIVKYRGVSYGPGRPELRLVMEYLPSGCLRDFLQRHRARLDASRLLLYSSQICKGMEYLGSRRCVHRDLAARNILVESEAHVKIADFGLAKLLPLDKDYYVVREPGQSPIFWYAPESLSDNIFSRQSDVWSFGVVLYELFTYCDKSCSPSAEFLRMMGCERDVPALCRLLELLEEGQRLPAPPACPAEVHELMKLCWAPSPQDRPSFSALGPQLDMLWSGSRGCETHAFTAHPEGKHHSLSFS","Homo sapiens","JAK3","Tyrosine-protein kinase JAK3","1","4Z16"
"4Z18",,"X-RAY DIFFRACTION",2.2,44,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, sodium chloride, hepes",293,,,"4Z18",50.95,"1.952","1.952","CRYSTAL STRUCTURE OF HUMAN PD-L1","MFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYNKINQRILVVDPVTSEHELTCQAEGYPKAEVIWTSSDHQVLSGKTTTTNSKREEKLFNVTSTLRINTTTNEIFYCTFRRLDPEENHTAELVIPELPLAHPPNERT","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","4Z18"
"4Z1E",,"X-RAY DIFFRACTION",2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,"10.1016/j.ejmech.2015.07.049","DF5","4Z1E",29.57,"2.01","2.01","Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4Z1E"
"4Z1F",,"X-RAY DIFFRACTION",2.62,53.01,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG 8K, 100mM calcium acetate, 100mM sodium cacodylate",295,"10.1021/ja511893n","H71","4Z1F",57.93,"2.703","2.703","Crystal structure of human Trap1 with PU-H71","STQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDIVVDHYKE","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","4Z1F"
"4Z1G",,"X-RAY DIFFRACTION",2.64,53.38,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG 8K, 100 mM calcium acetate, and 100 mM sodium cacodylate",295,"10.1021/ja511893n","94M","4Z1G",57.74,"3.1","3.1","Crystal structure of human Trap1 with BIIB-021","STQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDIVVDHYKE","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","4Z1G"
"4Z1H",,"X-RAY DIFFRACTION",2.66,53.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"16% PEG 8K, 100mM calcium acetate, 100mM sodium cacodylate.",295,"10.1021/ja511893n",,"4Z1H",58.18,"2.9","2.9","Crystal structure of human Trap1 with SMTIN-P01","STQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDIVVDHYKE","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","4Z1H"
"4Z1I",,"X-RAY DIFFRACTION",2.83,56.6,"VAPOR DIFFUSION, HANGING DROP",8.5,"23% PEG 4K, 100mM Tris, 0.35M ammonium sulfate.",277,"10.1021/ja511893n",,"4Z1I",231.81,"3.3","3.3","Crystal structure of human Trap1 with AMPPNP","STQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDIVVDHYKE","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","4Z1I"
"4Z1J",,"X-RAY DIFFRACTION",2.09,41.13,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,"10.1016/j.ejmech.2015.07.049","4KC","4Z1J",29.45,"1.27","1.27","Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4Z1J"
"4Z1K",,"X-RAY DIFFRACTION",2.1,41.37,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,"10.1016/j.ejmech.2015.07.049","4KB","4Z1K",29.35,"1.35","1.35","Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4Z1K"
"4Z1N",,"X-RAY DIFFRACTION",2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",7.8,"50mM Tris-HCl, 1,6 M Sodium Citrate",291,"10.1016/j.ejmech.2015.07.049","4KD","4Z1N",29.51,"1.47","1.47","Carbonic anhydrase inhibitors: Design and synthesis of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms (hCA VII, hCA IX, and hCA XIV)","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4Z1N"
"4Z1Q",,"X-RAY DIFFRACTION",2.19,43.88,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M sodium chloride, 0.1 M Bis-Tris pH 6.5, and 25% polyethylene glycol (PEG) 3350",277,"10.1021/ml500411h","558","4Z1Q",30.83,"1.399","1.399","Crystal structure of the first bromodomain of human BRD4 bound to benzotriazolo-diazepine scaffold","GSTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4Z1Q"
"4Z1S",,"X-RAY DIFFRACTION",2.18,43.64,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium sodium tartrate and 20% PEG 3350",277,"10.1021/ml500411h","559","4Z1S",30.57,"1.06","1.06","Crystal structure of the first bromodomain of human BRD4 with benzotriazolo-diazepine scaffold","GSTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPT","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4Z1S"
"4Z1T",,"X-RAY DIFFRACTION",2.74,55.16,"VAPOR DIFFUSION, HANGING DROP",,"Tris, ammonium sulfate, isopropanol",295,"10.1111/jcmm.12949",,"4Z1T",38.09,"1.5","1.5","MIF in complex with 4-[(4-oxo-2-thioxo-1,3-thiazolan-3-yl)methyl]benzonitrile","XMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","4Z1T"
"4Z1U",,"X-RAY DIFFRACTION",3.57,65.51,"VAPOR DIFFUSION, HANGING DROP",,"Tris, ammonium sulfate, isopropanol",295,"10.1111/jcmm.12949",,"4Z1U",77.63,"2.05","2.05","MIF in complex with 1-(4-methylphenyl)-3-phenylprop-2-yn-1-one","XMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","4Z1U"
"4Z1V",,"X-RAY DIFFRACTION",3.41,63.97,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.6mM ammonium sulfate, 3% PEG 400",298,"10.1021/acs.biochem.5b01003","OGA","4Z1V",41.43,"2.1","2.1","Structure of Factor Inhibiting HIF (FIH) in complex with Fe, NO, and NOG","GSHMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYDEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","4Z1V"
"4Z21",,"X-RAY DIFFRACTION",2.33,47.36,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 25% PEG 3350",293,,,"4Z21",23.42,"2.05","2.05","Crystal structure of ARNO Sec7","EANEGSKTLQRNRKMAMGRKKFNMDPKKGIQFLVENELLQNTPEEIARFLYKGEGLNKTAIGDYLGEREELNLAVLHAFVDLHEFTDLNLVQALRQFLWSFRLPGEAQKIDRMMEAFAQRYCLCNPGVFQSTDTCYVLSFAVIMLNTSLHNPNVRDKPGLERFVAMNRGINEGGDLPEELLRNLYDSIRNEPFKIPEDDGND","Homo sapiens","CYTH2, ARNO, PSCD2, PSCD2L","Cytohesin-2","1","4Z21"
"4Z2A",,"X-RAY DIFFRACTION",2.36,47.94,"VAPOR DIFFUSION, SITTING DROP",,"Well 13% PEG 8K, 0.110M K-dihydrogen phosphate, 0.1M HEPES pH 7.5, 350 uL protein with 350uL well drops, MRC sitting drop",277,,,"4Z2A",50.92,"1.89","1.89","Crystal structure of unglycosylated apo human furin @1.89A","YQEPTDPKFPQQWYLSGVTQRDLNVKAAWAQGYTGHGIVVSILDDGIEKNHPDLAGNYDPGASFDVNDQDPDPQPRYTQMNDNRHGTRCAGEVAAVANNGVCGVGVAYNARIGGVRMLDGEVTDAVEARSLGLNPNHIHIYSASWGPEDDGKTVDGPARLAEEAFFRGVSQGRGGLGSIFVWASGNGGREHDSCNCDGYTNSIYTLSISSATQFGNVPWYSEACSSTLATTYSSGNQNEKQIVTTDLRQKCTESHTGTSASAPLAAGIIALTLEANKDLTWRDMQHLVVQTSKPAHLNANDWATNGVGRKVSHSYGYGLLDAGAMVALAQDWTTVAPQRKCIIDILTEPKDIGKRLEVRKTVTACLGEPNHITRLEHAQARLTLSYNRRGDLAIHLVSPMGTRSTLLAARPHDYSADGFNDWAFMTTHSWDEDPSGEWVLEIENTSEANNYGTLTKFTLVLYGTA","Homo sapiens","FURIN, FUR, PACE, PCSK3","Furin","1","4Z2A"
"4Z2B",,"X-RAY DIFFRACTION",2.32,47.07,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris Ph 8.5
15% Peg20000
25% Ethylene Glycol",295,"10.1074/jbc.M115.653113","4LC","4Z2B",52,"1.8","1.8","The structure of human PDE12 residues 161-609 in complex with GSK3036342A","YKVERNPPAFTELQLPRYIMAGFPVCPKLSLEFGDPASSLFRWYKEAKPGAAEPEVGVPSSLSPSSPSSSWTETDVEERVYTPSNADIGLRLKLHCTPGDGQRFGHSRELESVCVVEAGPGTCTFDHRHLYTKKVTEDALIRTVSYNILADTYAQTEFSRTVLYPYCAPYALELDYRQNLIQKELTGYNADVICLQEVDRAVFSDSLVPALEAFGLEGVFRIKQHEGLATFYRKSKFSLLSQHDISFYEALESDPLHKELLEKLVLYPSAQEKVLQRSSVLQVSVLQSTKDSSKRICVANTHLYWHPKGGYIRLIQMAVALAHIRHVSCDLYPGIPVIFCGDFNSTPSTGMYHFVINGSIPEDHEDWASNGEEERCNMSLTHFFKLKSACGEPAYTNYVGGFHGCLDYIFIDLNALEVEQVIPLPSHEEVTTHQALPSVSHPSDHIALVCDLKWK","Homo sapiens","PDE12","2',5'-phosphodiesterase 12","1","4Z2B"
"4Z2N",,"X-RAY DIFFRACTION",2.39,48.57,"VAPOR DIFFUSION, HANGING DROP",4.4,"5% PEG1000, 100mM citrate",277,"10.1101/gad.274183.115",,"4Z2N",33.37,"1.923","1.923","Crystal structure of human FACT SPT16 middle domain","GIVKQDSLVINLNRSNPKLKDLYIRPNIAQKRMQGSLEAHVNGFRFTSVRGDKVDILYNNIKHALFQPCDGEMIIVLHFHLKNAIMFGKKRHTDVQFYTEVGEITTDLGKHQHMHDRDDLYAEQMEREMRHKLKTAFKNFIEKVEALTKEELEFEVPFRDLGFNGAPYRSTCLLQPTSSALVNATEWPPFVVTLDEVELIHFERVQFHLKNFDMVIVYKDYSKKVTMINAIPVASLDPIKEWLNSCDLKYTEGVQSLNWTKIMKTIVDDPEGFFEQGGWSFLEPEGE","Homo sapiens","SUPT16H, FACT140, FACTP140","FACT complex subunit SPT16","1","4Z2N"
"4Z2W",,"X-RAY DIFFRACTION",3.4,63.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.6mM ammonium sulfate, 3% PEG 400",298,"10.1021/acs.biochem.5b01003",,"4Z2W",41.4,"2.5","2.5","Factor Inhibiting HIF in Complex with Fe, and Alpha-Ketoglutarate","GSHMAATAAEAVASGSGEPREEAGALGPAWDESQLRSYSFPTRPIPRLSQSDPRAEELIENEEPVVLTDTNLVYPALKWDLEYLQENIGNGDFSVYSASTHKFLYYDEKKMANFQNFKPRSNREEMKFHEFVEKLQDIQQRGGEERLYLQQTLNDTVGRKIVMDFLGFNWNWINKQQGKRGWGQLTSNLLLIGMEGNVTPAHYDEQQNFFAQIKGYKRCILFPPDQFECLYPYPVHHPCDRQSQVDFDNPDYERFPNFQNVVGYETVVGPGDVLYIPMYWWHHIESLLNGGITITVNFWYKGAPTPKRIEYPLKAHQKVAIMRNIEKMLGEALGNPQEVGPLLNTMIKGRYN","Homo sapiens","HIF1AN, FIH1","Hypoxia-inducible factor 1-alpha inhibitor","1","4Z2W"
"4Z30",,"X-RAY DIFFRACTION",4.01,69.33,"VAPOR DIFFUSION, SITTING DROP",4.6,"mixing 2 uL protein with 1 uL well solution consisting of 3.2 M NaCl, 0.1 M NaOAc pH4.6",298,"10.1038/srep15660",,"4Z30",36.68,"2.71","2.71","Crystal structure of the ROQ domain of human Roquin-2","MSNLGENKHYEVAKKCVEDLALYLKPLSGGKGVASLNQSALSRPMQRKLVTLVNCQLVEEEGRVRAMRAARSLGERTVTELILQHQNPQQLSANLWAAVRARGCQFLGPAMQEEALKLVLLALEDGSALSRKVLVLFVVQRLEPRFPQASKTSIGHVVQLLYRASCFKVTKRDEDSSLMQLKEEFRSYEALRREHDAQIVHIAMEAGLRISPEQWSSLLYGDLAHKSHMQSIIDKLQSPESFAKSVQELTIVLQRTGDPANLNRLRPHLELLANIDPNPDAVSPTWEQLENAMVAVKTVVHGLVDFIQNYSRKGHETPQHHHHHH","Homo sapiens","RC3H2, MNAB, RNF164","Roquin-2","1","4Z30"
"4Z32",,"X-RAY DIFFRACTION",2.62,57.94,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Na Citrate, 11-13% PEG 3350, 1.05% 1-butanol, 5 mM TCEP",298,"10.1371/journal.pone.0156218",,"4Z32",461.45,"3.04","3.04","Crystal Structure of the FERM-SH2 Domains of Jak2","GSMKQIDPVLQVYLYHSLGKSEADYLTFPSGEYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYFPRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLGMAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQFSQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSRGKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLREALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQTGLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNCYQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGLEHHHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4Z32"
"4Z3D",,"X-RAY DIFFRACTION",2.59,52.49,"EVAPORATION",4.6,"0.2M Ammonium acetate, 0.1M Sodium acetate trihydrate pH 4.6, 28% w/v Polyethylene glycol 4000",293,"10.1016/j.jsb.2015.09.005","GSH","4Z3D",125.35,"1.8","1.8","Human carbonyl reductase 1 with glutathione in a protective configuration","SSGIHVALVTGGNKGIGLAIVRDLCRLFSGDVVLTARDVTRGQAAVQQLQAEGLSPRFHQLDIDDLQSIRALRDFLRKEYGGLDVLVNNAGIAFKVADPTPFHIQAEVTMKTNFFGTRDVCTELLPLIKPQGRVVNVSSIMSVRALKSCSPELQQKFRSETITEEELVGLMNKFVEDTKKGVHQKEGWPSSAYGVTKIGVTVLSRIHARKLSEQRKGDKILLNACCPGWVRTDMAGPKATKSPEEGAETPVYLALLPPDAEGPHGQFVSEKRVEQW","Homo sapiens","CBR1, CBR, CRN, SDR21C1","Carbonyl reductase [NADPH] 1","1","4Z3D"
"4Z3K",,"X-RAY DIFFRACTION",4.89,74.86,"VAPOR DIFFUSION, HANGING DROP",7.5,"2% W/V PEG1000, 1.9 M Ammonium sulfate, 0.1 M Hepes pH7.5",277,"10.1074/jbc.C115.680488","4KL","4Z3K",124,"2.35","2.35","Human sepiapterin reductase in complex with the cofactor NADP+ and the trypthophan metabolite xanthurenic acid","MHHHHHHENLYFQGMEGGLGRAVCLLTGASRGFGRTLAPLLASLLSPGSVLVLSARNDEALRQLEAELGAERSGLRVVRVPADLGAEAGLQQLLGALRELPRPKGLQRLLLINNAGSLGDVSKGFVDLSDSTQVNNYWALNLTSMLCLTSSVLKAFPDSPGLNRTVVNISSLCALQPFKGWALYCAGKAARDMLFQVLALEEPNVRVLNYAPGPLDTDMQQLARETSVDPDMRKGLQELKAKGKLVDCKVSAQKLLSLLEKDEFKSGAHVDFYDK","Homo sapiens","SPR","Sepiapterin reductase","1","4Z3K"
"4Z3V",,"X-RAY DIFFRACTION",2.29,46.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277,"10.1021/acs.jmedchem.5b00734","4L6","4Z3V",33.27,"1.6","1.6","Fragment-Based Discovery of a Small Molecule Reversible Inhibitor of Bruton's Tyrosine Kinase","GPLPGKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","4Z3V"
"4Z49",,"X-RAY DIFFRACTION",2.24,45.03,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG-3350, 0.2M potassium chloride",277,"10.1021/acs.jcim.5b00185",,"4Z49",62.07,"1.7","1.7","Homo Sapiens Fatty Acid Synthetase, Thioesterase Domain at 1.7 Angstroms Resolution","SLLVNPEGPTLMRLNSVQSSERPLFLVHPIEGSTTVFHSLASRLSIPTYGLQCTRAAPLDSIHSLAAYYIDCIRQVQPEGPYRVAGYSYGACVAFEMCSQLQAQQSPAPTHNSLFLFDGSPTYVLAYTQSYRAKLTPGCEAEAETEAICFFVQQFTDMEHNRVLEALLPLKGLEERVAAAVDLIIKSHQGLDRQELSFAARSFYYKLRAAEQYTPKAKYHGNVMLLRAKTGGAYGEDLGADYNLSQVCDGKVSVHVIEGDHRTLLEGSGLESIISIIHSSLA","Homo sapiens","FASN, FAS","Fatty acid synthase","1","4Z49"
"4Z4P",,"X-RAY DIFFRACTION",1.9,35.15,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris-HCl
20 % Ethanol",295,"10.1016/j.str.2015.07.018",,"4Z4P",20.15,"2.2","2.2","Structure of the MLL4 SET Domain","MTLHSKSSQYRRLRTEWKNNVYLARSRIQGLGLYAAKDLEKHTMVIEYIGTIIRNEVANRREKIYEEQNRGIYMFRINNEHVIDATLTGGPARYINHSCAPNCVAEVVTFDKEDKIIIISSRRIPKGEELTYDYQFDFEDDQHEIPCHCGAWNCRKWMKGHHHHHH","Homo sapiens","KMT2D, ALR, MLL2, MLL4","Histone-lysine N-methyltransferase 2D","1","4Z4P"
"4Z51",,"X-RAY DIFFRACTION",2.26,45.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"50 mM magnesium acetate, 10mM Sodium Acetate, 15% PEG8000",291,,,"4Z51",32.17,"1.86","1.86","High Resolution Human Septin 3 GTPase domain","FDFNIMVVGQSGLGKSTLVNTLFKSQVSRKASSWNREEKIPKTVEIKAIGHVIEEGGVKMKLTVIDTPGFGDQINNENCWEPIEKYINEQYEKFLKEEVNIARKKRIPDTRVHCCLYFISPTGHSLRPLDLEFMKHLSKVVNIIPVIAKADTMTLEEKSEFKQRVRKELEVNGIEFYPQKEFDEDLEDKTENDKIRQESMPFAVVGSDKEYQVNGKRVLGRKTPWGIIEVENLNHCEFALLRDFVIRTHLQDLKEVTHNIHYETYRAKRLN","Homo sapiens","SEPT3, SEP3, SEPTIN3","Neuronal-specific septin-3","1","4Z51"
"4Z54",,"X-RAY DIFFRACTION",2.07,40.52,"VAPOR DIFFUSION, HANGING DROP",7.8,"100mM Magnesium Formate, 15% PEG 3350",291,,,"4Z54",67.82,"1.83","1.83","High Resolution Human Septin3 GTPase domain with alpha-zero helix in complex with GDP","GIDTIIEQMRKKTMKTGFDFNIMVVGQSGLGKSTLVNTLFKSQVSRKASSWNREEKIPKTVEIKAIGHVIEEGGVKMKLTVIDTPGFGDQINNENCWEPIEKYINEQYEKFLKEEVNIARKKRIPDTRVHCCLYFISPTGHSLRPLDLEFMKHLSKVVNIIPVIAKADTMTLEEKSEFKQRVRKELEVNGIEFYPQKEFDEDLEDKTENDKIRQESMPFAVVGSDKEYQVNGKRVLGRKTPWGIIEVENLNHCEFALLRDFVIRTHLQDLKEVTHNIHYETYRAKRL","Homo sapiens","SEPT3, SEP3, SEPTIN3","Neuronal-specific septin-3","1","4Z54"
"4Z55",,"X-RAY DIFFRACTION",2.04,39.83,"VAPOR DIFFUSION, HANGING DROP",7.6,"citric acid, bis-tris propane, PEG3350",277,"10.1016/j.bmcl.2015.11.049","4LO","4Z55",39,"1.55","1.55","Anaplastic lymphoma kinase catalytic domain complexed with pyrazolopyrimidine derivative of LDK378","ELQSPEYKLSKLRTSTIMTDYNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRAGYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEK","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","4Z55"
"4Z69",,"X-RAY DIFFRACTION",2.51,50.97,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, potassium phosphate, glycerol, DMSO",285,"10.1111/cbdd.12583","DIF","4Z69",136.81,"2.187","2.187","Human serum albumin complexed with palmitic acid and diclofenac","DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","4Z69"
"4Z6G",,"X-RAY DIFFRACTION",5.22,76.45,"VAPOR DIFFUSION, HANGING DROP",6.5,"MES, (NH4)2SO4, (NH4)2HPO4",288,"10.1038/ncomms11692",,"4Z6G",41,"2.654","2.654","Structure of NT domain","DERDRVQKKTFTKWVNKHLMKVRKHINDLYEDLRDGHNLISLLEVLSGIKLPREKGRMRFHRLQNVQIALDFLKQRQVKLVNIRNDDITDGNPKLTLGLIWTIILHFQISDIYISGESGDMSAKEKLLLWTQKVTAGYTGIKCTNFSSCWSDGKMFNALIHRYRPDLVDMERVQIQSNRENLEQAFEVAERLGVTRLLDAEDVDVPSPDEKSVITYVSSIYDAFPKVPEGGEGISATEVDSRWQEYQSRVDSLIPWIKQHTILMSDKTFPQNPVELKALYNQYIHFKETEILAKEREKGRIEELYKLLEVWIEFGRIKLPQGYHPNDVEEEWGKLIIEMLEREKSLRP","Homo sapiens","MACF1, ABP620, ACF7, KIAA0465, KIAA1251, KIAA0754","Microtubule-actin cross-linking factor 1, isoforms 1/2/3/5","1","4Z6G"
"4Z6H",,"X-RAY DIFFRACTION",2.33,47.32,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M PCB pH 8, 30% PEG1K",277.15,"10.1002/anie.201501394","4L2","4Z6H",29.04,"1.8","1.8","Crystal structure of BRD9 bromodomain in complex with a valerolactam quinolone ligand","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","4Z6H"
"4Z6I",,"X-RAY DIFFRACTION",2.19,43.91,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M MMT pH6, 30% PEG 1k",277.15,"10.1002/anie.201501394","4L3","4Z6I",29.42,"1.95","1.95","Crystal structure of BRD9 bromodomain in complex with a substituted valerolactam quinolone ligand","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","4Z6I"
"4Z79",,"X-RAY DIFFRACTION",2.28,46.11,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes, 10% Propanol, 20% Peg 3350",291.5,"10.1038/ncomms9314",,"4Z79",21.93,"1.54","1.54","Leiomodin-1 Actin-Binding Site 2 (ABS2)","PTKPSEGPAKVEEEAAPSIFDEPLERVKNNDPEMTEVNVNNSDCITNEILVRFTEALEFNTVVKLFALANTRADDHVAFAIAIMLKANKTITSLNLDSNHITGKGILAIFRALLQNNTLTELRFHNQRHICGGKTEMEIAKLLKENTTLLKLGYHFELAGPRMTVTNLLSRNMDKQRQKRLQEQRQAQ","Homo sapiens","LMOD1","Leiomodin-1 Actin-Binding Site 2 (ABS2)","1","4Z79"
"4Z7G",,"X-RAY DIFFRACTION",2.8,56.08,"VAPOR DIFFUSION, HANGING DROP",,"Apo-hIRE1 was crystallized by hanging-drop vapor diffusion by mixing IRE1 (at 2 mg/mL) with reservoir solution containing 18-20% PEG3350, 0.2 M sodium malonate and 0.1 Bis-Trispropane (pH 6.5) in a 1:1 ratio",291,"10.18632/oncotarget.3864",,"4Z7G",95.56,"2.6","2.6","Crystal structure of human IRE1 cytoplasmic kinase-RNase region - apo","SVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","4Z7G"
"4Z7H",,"X-RAY DIFFRACTION",2.83,56.52,"VAPOR DIFFUSION, HANGING DROP",,"Apo-hIRE1 was crystallized by hanging-drop vapor diffusion by mixing IRE1 (at 2 mg/mL) with reservoir solution containing 18-20% PEG3350, 0.2 M sodium malonate and 0.1 Bis-Trispropane (pH 6.5) in a 1:1 ratio.  Crystals were briefly (30 sec) soaked in 22% PEG3350, 0.2 M Na Malonate, 0.1 M Bis-Trispropane (pH 7.5) and 25% ethylene glycol before plunging into liquid N2.",291,"10.18632/oncotarget.3864",,"4Z7H",96.26,"2.9","2.9","Crystal structure of human IRE1 cytoplasmic kinase-RNase region - complex with imidazopyridine compound 3","SVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","4Z7H"
"4Z8E",,"X-RAY DIFFRACTION",2.32,47.03,"VAPOR DIFFUSION, SITTING DROP",6.5,"7-10 mg/mL protein, ammonium sulfate, MES/Tris-HCl, dioxane/PEG5000 MME",277,"10.1016/j.jmb.2016.03.008",,"4Z8E",24.53,"2.092","2.092","TEAD DBD mutant -deltaL1","MDNDAEGVWSPDIEQSFQEALSIYPGKMYGRNELIARYIKLRTGKTRTRKQVSSHIQVLARRKSRDLVPR","Homo sapiens","TEAD1, TCF13, TEF1","Transcriptional enhancer factor TEF-1","1","4Z8E"
"4Z93",,"X-RAY DIFFRACTION",2.28,46.12,"VAPOR DIFFUSION, SITTING DROP",8,"Peg 400, Imidizole, ATP",293,"10.1021/acs.jmedchem.5b00613","4LD","4Z93",13.73,"1.27","1.27","BRD4 bromodomain 2 in complex with gamma-carboline-containing compound, number 18.","KVSEQLKCCSGILKEMFAKKHAAYAWPFYKPVDVEALGLHDYCDIIKHPMDMSTIKSKLEAREYRDAQEFGADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMPDE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4Z93"
"4Z99",,"X-RAY DIFFRACTION",2.46,50,"VAPOR DIFFUSION, HANGING DROP",7,"27% (w/v) PEG 2000, 0.1 M malic acid:Tris, molar ratio 1:2, pH 7.0",291,"10.1016/j.bmc.2015.06.017",,"4Z99",18.76,"2.3","2.3","Crystal structure of the apo Low Molecular Weight Protein Tyrosine Phosphatase isoform A","GSHMEFMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","4Z99"
"4Z9A",,"X-RAY DIFFRACTION",2.46,49.97,"VAPOR DIFFUSION, HANGING DROP",6.5,"26% (w/v) PEG 5000, 0.2 M ammonium sulfate, 0.2 M MES buffer pH 6.5",291,"10.1016/j.bmc.2015.06.017",,"4Z9A",19.21,"2.1","2.1","Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with phenylmethanesulfonic acid","GSHMEFMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","4Z9A"
"4Z9B",,"X-RAY DIFFRACTION",2.36,47.87,"VAPOR DIFFUSION, HANGING DROP",7,"32% (w/v) PEG 5000, 0.1 M malic acid:Tris, molar ratio 1:2, pH 7.0",291,"10.1016/j.bmc.2015.06.017",,"4Z9B",18.93,"2.41","2.41","Crystal structure of Low Molecular Weight Protein Tyrosine Phosphatase isoform A complexed with benzylphosphonic acid","GSHMEFMAEQATKSVLFVCLGNICRSPIAEAVFRKLVTDQNISENWRVDSAATSGYEIGNPPDYRGQSCMKRHGIPMSHVARQITKEDFATFDYILCMDESNLRDLNRKSNQVKTCKAKIELLGSYDPQKQLIIEDPYYGNDSDFETVYQQCVRCCRAFLEKAH","Homo sapiens","ACP1","Low molecular weight phosphotyrosine protein phosphatase","1","4Z9B"
"4Z9L",,"X-RAY DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, HANGING DROP",7,"PEG MME 550, ETHYLENE GLYCOL,  HEPES",293,"10.1016/s1074-5521(03)00159-5","880","4Z9L",43.02,"2.1","2.1","THE STRUCTURE OF JNK3 IN COMPLEX WITH AN IMIDAZOLE-PYRIMIDINE INHIBITOR","MASKSKVDNQFYSVEVGDSTFTVLKRYQNLKPIGSGAQGIVCAAYDAVLDRNVAIKKLSRPFQNQTHAKRAYRELVLMKCVNHKNIISLLNVFTPQKTLEEFQDVYLVMELMDANLCQVIQMELDHERMSYLLYQMLCGIKHLHSAGIIHRDLKPSNIVVKSDCTLKILDFGLARTAGTSFMMTPYVVTRYYRAPEVILGMGYKENVDIWSVGCIMGEMVRHKILFPGRDYIDQWNKVIEQLGTPCPEFMKKLQPTVRNYVENRPKYAGLTFPKLFPDSLFPADSEHNKLKASQARDLLSKMLVIDPAKRISVDDALQHPYINVWYDPAEVEAPPPQIYDKQLDEREHTIEEWKELIYKEVMNS","Homo sapiens","MAPK10, JNK3, JNK3A, PRKM10, SAPK1B","Mitogen-activated protein kinase 10","1","4Z9L"
"4Z9M",,"X-RAY DIFFRACTION",2.78,55.7,"VAPOR DIFFUSION, SITTING DROP",6,"17% PEG-3350, 10mM DTT, 0.2M diammonium citrate, 0.1M Bis-TRIS, protein buffer also contained magnesium chloride, creatine, ADP",291,,,"4Z9M",360.91,"2.1","2.1","Crystal structure of human sarcomeric mitochondrial creatine kinase","GSTTGYLLNRQKVCAEVREQPRLFPPSADYPDLRKHNNCMAECLTPAIYAKLRNKVTPNGYTLDQCIQTGVDNPGHPFIKTVGMVAGDEESYEVFADLFDPVIKLRHNGYDPRVMKHTTDLDASKITQGQFDEHYVLSSRVRTGRSIRGLSLPPACTRAERREVENVAITALEGLKGDLAGRYYKLSEMTEQDQQRLIDDHFLFDKPVSPLLTCAGMARDWPDARGIWHNYDKTFLIWINEEDHTRVISMEKGGNMKRVFERFCRGLKEVERLIQERGWEFMWNERLGYILTCPSNLGTGLRAGVHVRIPKLSKDPRFSKILENLRLQKRGTGGVDTAAVADVYDISNIDRIGRSEVELVQIVIDGVNYLVDCEKKLERGQDIKVPPPLPQF","Homo sapiens","CKMT2","Creatine kinase S-type, mitochondrial","1","4Z9M"
"4Z9O",,"X-RAY DIFFRACTION",2.99,58.86,"VAPOR DIFFUSION, HANGING DROP",6.3,"PEG3350, NH4Cl",298,"10.1074/jbc.M115.659680",,"4Z9O",60.36,"2.3","2.3","Crystal Structure of human GGT1","SASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDAVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGG","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1","1","4Z9O"
,,,,,,,,,,,,,,,,"TAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1","2","4Z9O"
"4ZA0",,"X-RAY DIFFRACTION",2.18,43.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM Bis-Tris, pH 6.5, 200 mM ammonium acetate, 18-22% w/v PEG3350, overnight crystal soak in 2 mM PhaH, 100 mM Bis-Tris, 200 mM ammonium acetate, 32% w/v PEG3350, pH 6.5",293,"10.1038/nchembio.2195","PAH","4ZA0",96.71,"2.31","2.31","Structure of Human Enolase 2 in complex with Phosphonoacetohydroxamate","MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVLHHHHHH","Homo sapiens","ENO2","Gamma-enolase","1","4ZA0"
"4ZAE",,"X-RAY DIFFRACTION",2.82,56.33,"VAPOR DIFFUSION, HANGING DROP",9,"50 mM CHES, pH 9.0, 1.3 M tri-sodium citrate and 3 mM compound (cross seeded with crystals grown from 50 mM Tris, pH 7.2, 1.45 M ammonium sulfate, 2.0 M sodium chloride and 3 mM compound)",295,"10.1016/j.bmcl.2015.04.057","4M1","4ZAE",33.68,"1.86","1.86","Development of a novel class of potent and selective FIXa inhibitors","VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGASALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","1","4ZAE"
,,,,,,,,,,,,,,,,"MDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","2","4ZAE"
"4ZAJ",,"X-RAY DIFFRACTION",2.63,53.17,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% PEG 1000",293,,,"4ZAJ",68.94,"2.22","2.22","2.2 Angstrom Crystal Structure of a Human Arginyl-tRNA Synthetase","MINIISRLQEVFGHAIKAAYPDLENPPLLVTPSQQAKFGDYQCNSAMGISQMLKTKEQKVNPREIAENITKHLPDNECIEKVEIAGPGFINVHLRKDFVSEQLTSLLVNGVQLPALGENKKVIVDFSSPNIAKEMHVGHLRSTIIGESISRLFEFAGYDVLRLNHVGDWGTQFGMLIAHLQDKFPDYLTVSPPIGDLQVFYKESKKRFDTEEEFKKRAYQCVVLLQGKNPDITKAWKLICDVSRQELNKIYDALDVSLIERGESFYQDRMNDIVKEFEDRGFVQVDDGRKIVFVPGCSIPLTIVKSDGGYTYDTSDLAAIKQRLFEEKADMIIYVVDNGQSVHFQTIFAAAQMIGWYDPKVTRVFHAGFGVVLGEDKKKFKTRSGETVRLMDLLGEGLKRSMDKLKEKERDKVLTAEELNAAQTSVAYGCIKYADLSHNRLNDYIFSFDKMLDDRGNTAAYLLYAFTRIRSIARLANIDEEMLQKAARETKILLDHEKEWKLGRCILRFPEILQKILDDLFLHTLCDYIYELATAFTEFYDSCYCVEKDRQTGKILKVNMWRMLLCEAVAAVMAKGFDILGIKPVQRMENLYFQSHHHHHH","Homo sapiens","RARS, RARS1","Arginine--tRNA ligase, cytoplasmic","1","4ZAJ"
"4ZAO",,"X-RAY DIFFRACTION",2.06,40.4,"VAPOR DIFFUSION, SITTING DROP",7.8,"10 mg/ml in 50 mM Tris-HCl at ph 7.8",298,"10.1107/S2053230X1501239X",,"4ZAO",29.27,"1.8","1.8","Genetically engineered Carbonic anhydrase IX","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZAO"
"4ZAU",,"X-RAY DIFFRACTION",3.37,63.54,"VAPOR DIFFUSION, HANGING DROP",7,"0.1 M MES, 1 M sodium citrate",291,"10.1016/j.jsb.2015.10.018","YY3","4ZAU",38.06,"2.8","2.8","AZD9291 complex with wild type EGFR","GAMGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","4ZAU"
"4ZBF",,"X-RAY DIFFRACTION",2.62,53.06,"EVAPORATION",,"PEG 3350, magnesium chloride, Bis-Tris",291,"10.1021/jm501984f","4M7","4ZBF",219.41,"2.2","2.2","Mcl-1 complexed with small molecules","GDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGG","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","4ZBF"
"4ZBI",,"X-RAY DIFFRACTION",2.61,52.87,"EVAPORATION",,"PEG3350, magnesium chloride, Bis-Tris",,"10.1021/jm501984f","4M6","4ZBI",218.83,"2.5","2.5","Mcl-1 complexed with small molecules","GDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGG","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","4ZBI"
"4ZBK",,"X-RAY DIFFRACTION",2.93,58.06,"VAPOR DIFFUSION, HANGING DROP",6.3,"PEG3350, NH4Cl",298,"10.1074/jbc.M115.659680",,"4ZBK",60.56,"2.18","2.18","Crystal Structure of human GGT1 in complex with GGsTop inhibitor","SASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDAVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGG","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1","1","4ZBK"
,,,,,,,,,,,,,,,,"TAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1","2","4ZBK"
"4ZBW",,"X-RAY DIFFRACTION",2.6,54.26,"EVAPORATION",8.5,"0.2M sodium chloride,  25% PEG3350",293,"10.1016/j.bbrc.2015.05.054",,"4ZBW",44.98,"2.2","2.2","Crystal structure of death effector domain of Caspase8 in Homo Sapiens","GSMDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKALLQEEDSKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSS","Homo sapiens","CASP8, MCH5","Caspase-8","1","4ZBW"
"4ZC4",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.225 M ammonium chloride, pH 6.3, 23% PEG 3350",304,"10.1093/nar/gkv748",,"4ZC4",78.66,"1.86","1.86","Crystal structure of LARP1-unique domain DM15","GHSGGGGGGHMQHPSHELLKENGFTQHVYHKYRRRCLNERKRLGIGQSQEMNTLFRFWSFFLRDHFNKKMYEEFKQLALEDAKEGYRYGLECLFRYYSYGLEKKFRLDIFKDFQEETVKDYEAGQLYGLEKFWAFLKYSKAKNLDIDPKLQEYLGKFRRLED","Homo sapiens","LARP1, KIAA0731, LARP","La-related protein 1","1","4ZC4"
"4ZC6",,"X-RAY DIFFRACTION",2.89,57.49,"VAPOR DIFFUSION, HANGING DROP",6,"PEG3350, NH4Cl",298,"10.1074/jbc.M115.659680",,"4ZC6",60.14,"2.1","2.1","Crystal Structure of human GGT1 in complex with Serine Borate","SASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDAVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGG","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1 heavy chain","1","4ZC6"
,,,,,,,,,,,,,,,,"TAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1 light chain","2","4ZC6"
"4ZC9",,"X-RAY DIFFRACTION",2.16,43.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% PEG3350, 0.1 M Succinate",298,"10.1126/science.aab1433",,"4ZC9",15.88,"0.99","0.99","Crystal Structure of the BRD4a/DB-2-190 complex","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4ZC9"
"4ZCA",,"X-RAY DIFFRACTION",2.31,46.7,"VAPOR DIFFUSION, HANGING DROP",,"200 mM NaNO3, 20-25% PEG 3350, 100 mM MES pH 5.5-5.7, 5-10% glycerol",277,,,"4ZCA",83.21,"2.3","2.3","Eg5 motor domain mutant Y231F","MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLEIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAFSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKL","Homo sapiens","KIF11, EG5, KNSL1, TRIP5","Kinesin-like protein KIF11","1","4ZCA"
"4ZCB",,"X-RAY DIFFRACTION",2,38.44,"VAPOR DIFFUSION, HANGING DROP",4.6,"30% PEG 4000, 0.1M CH3COONa.3H2O, pH 4.6, 0.1M CH3COONH4",294,"10.1016/j.str.2016.05.022",,"4ZCB",31.24,"1.7","1.7","Human CRBPII mutant - Y60W dimer","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNWDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZCB"
"4ZCG",,"X-RAY DIFFRACTION",2.93,57.99,"VAPOR DIFFUSION, HANGING DROP",6,"PEG3350, NH4Cl",298,"10.1074/jbc.M115.659680",,"4ZCG",60.12,"2.22","2.22","Crystal Structure of human GGT1 in complex with Glutamate (with all atoms of glutamate)","SASKEPDNHVYTRAAVAADAKQCSKIGRDALRDGGSAVDAAIAALLCVGLMNAHSMGIGGGLFLTIYNSTTRKAEVINAREVAPRLAFATMFNSSEQSQKGGLSVAVPGEIRGYELAHQRHGRLPWARLFQPSIQLARQGFPVGKGLAAALENKRTVIEQQPVLCEVFCRDRKVLREGERLTLPQLADTYETLAIEGAQAFYNGSLTAQIVKDIQAAGGIVTAEDLNNYRAELIEHPLNISLGDAVLYMPSAPLSGPVLALILNILKGYNFSRESVESPEQKGLTYHRIVEAFRFAYAKRTLLGDPKFVDVTEVVRNMTSEFFAAQLRAQISDDTTHPISYYKPEFYTPDDGG","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1 heavy chain","1","4ZCG"
,,,,,,,,,,,,,,,,"TAHLSVVAEDGSAVSATSTINLYFGSKVRSPVSGILFNNEMDDFSSPSITNEFGVPPSPANFIQPGKQPLSSMCPTIMVGQDGQVRMVVGAAGGTQITTATALAIIYNLWFGYDVKRAVEEPRLHNQLLPNVTTVERNIDQAVTAALETRHHHTQIASTFIAVVQAIVRTAGGWAAASDSRKGGEPAGY","Homo sapiens","GGT1, GGT","Gamma-glutamyltranspeptidase 1 light chain","2","4ZCG"
"4ZCU",,"X-RAY DIFFRACTION",2.86,56.98,"VAPOR DIFFUSION, SITTING DROP",,"29% (w/v) PEG 8000, 0.2 M ammonium sulfate",293,"10.1016/j.bbabio.2015.07.002",,"4ZCU",58.32,"2.1","2.1","Structure of calcium-bound regulatory domain of the human ATP-Mg/Pi carrier in the P2 form","TSEDACQDAEQPTRYETLFQALDRNGDGVVDIGELQEGLRNLGIPLGQDAEEKIFTTGDVNKDGKLDFEEFMKYLKDHEKKMKLAFKSLDKNNDGKIEASEIVQSLQTLGLTISEQQAELILQSIDVDGTMTVDWNEWRDYFLFNPVTDIEEIIRFWKHSTGIDI","Homo sapiens","SLC25A24, APC1, MCSC1, SCAMC1","Calcium-binding mitochondrial carrier protein SCaMC-1","1","4ZCU"
"4ZCV",,"X-RAY DIFFRACTION",2.5,50.78,"VAPOR DIFFUSION, SITTING DROP",,"25-30% (w/v) PEG 8000, 0.2 M lithium sulfate",293,"10.1016/j.bbabio.2015.07.002",,"4ZCV",76.85,"2.8","2.8","Structure of calcium-bound regulatory domain of the human ATP-Mg/Pi carrier in the P212121 form","TSEDACQDAEQPTRYETLFQALDRNGDGVVDIGELQEGLRNLGIPLGQDAEEKIFTTGDVNKDGKLDFEEFMKYLKDHEKKMKLAFKSLDKNNDGKIEASEIVQSLQTLGLTISEQQAELILQSIDVDGTMTVDWNEWRDYFLFNPVTDIEEIIRFWKHSTGIDI","Homo sapiens","SLC25A24, APC1, MCSC1, SCAMC1","Calcium-binding mitochondrial carrier protein SCaMC-1","1","4ZCV"
"4ZCW",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM Bis-Tris, pH 6.5, 200 mM ammonium acetate, 18-22% w/v PEG3350, overnight crystal soak in 4 mM SF2312, 100 mM Bis-Tris, 200 mM ammonium acetate, 32% w/v PEG3350, pH 6.5",293,"10.1038/nchembio.2195","4NG","4ZCW",96.79,"1.992","1.992","Structure of Human Enolase 2 in complex with SF2312","MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVLHHHHHH","Homo sapiens","ENO2","Gamma-enolase","1","4ZCW"
"4ZD3",,"X-RAY DIFFRACTION",2.52,51.17,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.01 M nickel (II) chloride hexahydrate, 0.1 M Tris pH=8.5, 20% w/v polyethylene glycol monomethyl ether 2000",293,"10.1074/jbc.M115.669895",,"4ZD3",47.7,"2.4","2.4","Structure of a transglutaminase 2-specific autoantibody Fab fragment","EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARPHYYDSLDAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC","Homo sapiens",,"679-14-14E06 Fab fragment heavy chain","1","4ZD3"
,,,,,,,,,,,,,,,,"DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQRPGKAPKLLIYKASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQHYNSYSPGYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"679-14-14E06 Fab fragment light chain","2","4ZD3"
"4ZDL",,"X-RAY DIFFRACTION",2.45,49.75,"VAPOR DIFFUSION, SITTING DROP",,"0.28-0.34 M lithium citrate
16-18% (w/v) PEG 3,350",285,"10.1038/srep32563",,"4ZDL",112.23,"2.26","2.26","The crystal structure of the T325S mutant of the human holo SepSecS","MNRESFAAGERLVSPAYVRQGCEARRSHEHLIRLLLEKGKCPENGWDESTLELFLHELAIMDSNNFLGNCGVGEREGRVASALVARRHYRFIHGIGRSGDISAVQPKAAGSSLLNKITNSLVLDIIKLAGVHTVANCFVVPMATGMSLTLCFLTLRHKRPKAKYIIWPRIDQKSCFKSMITAGFEPVVIENVLEGDELRTDLKAVEAKVQELGPDCILCIHSTTSCFAPRVPDRLEELAVICANYDIPHIVNNAYGVQSSKCMHLIQQGARVGRIDAFVQSLDKNFMVPVGGAIIAGFNDSFIQEISKMYPGRASASPSLDVLISLLSLGSNGYKKLLKERKEMFSYLSNQIKKLSEAYNERLLHTPHNPISLAMTLKTLDEHRDKAVTQLGSMLFTRQVSGARVVPLGSMQTVSGYTFRGFMSHTNNYPCAYLNAASAIGMKMQDVDLFIKRLDRCLKAVRKERSKESDDNYDKTEDVDIEEMALKLDNVLLDTYQDASS","Homo sapiens","SEPSECS, TRNP48","O-phosphoseryl-tRNA(Sec) selenium transferase","1","4ZDL"
"4ZDV",,"X-RAY DIFFRACTION",2.42,49.15,"VAPOR DIFFUSION, SITTING DROP",,"8% Tacsimate (Hampton Research) pH 8.0, 20% Poly ethylene glycol 3350",293,"10.1038/nature14498",,"4ZDV",15.39,"1.8","1.8","Crystal structure of LC3 in complex with FAM134B LIR","GPEEGDDFELLDGPSDRPFKQRRSFADRCKEVQQIRDQHPSKIPVIIERYKGEKQLPVLDKTKFLVPDHVNMSELVKIIRRRLQLNPTQAFFLLVNQHSMVSVSTPIADIYEQEKDEDGFLYMVYASQETFG","Homo sapiens","MAP1LC3A","Microtubule-associated proteins 1A/1B light chain 3A","1","4ZDV"
"4ZEG",,"X-RAY DIFFRACTION",3.23,61.94,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M MgCl2, 0.1M Tris pH 8.5, 25% PEG 3500",293,,,"4ZEG",33.54,"2.33","2.33","Crystal structure of TTK kinase domain in complex with a pyrazolopyrimidine inhibitor","NECISVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQT","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","4ZEG"
"4ZEL",,"X-RAY DIFFRACTION",2.65,53.51,"VAPOR DIFFUSION, SITTING DROP",,"12% PEG3350, 0.2 M potassium nitrate",298,"10.1126/sciadv.1500980",,"4ZEL",132.88,"2.9","2.9","Human dopamine beta-hydroxylase","SAPRESPLPYHIPLDPEGSLELSWNVSYTQEAIHFQLLVRRLKAGVLFGMSDRGELENADLVVLWTDGDTAYFADAWSDQKGQIHLDPQQDYQLLQVQRTPEGLTLLFKRPFGTCDPKDYLIEDGTVHLVYGILEEPFRSLEAINGSGLQMGLQRVQLLKPNIPEPELPSDACTMEVQAPNIQIPSQETTYWCYIKELPKGFSRHHIIKYEPIVTKGNEALVHHMEVFQCAPEMDSVPHFSGPCDSKMKPDRLNYCRHVLAAWALGAKAFYYPEEAGLAFGGPGSSRYLRLEVHYHNPLVIEGRNDSSGIRLYYTAKLRRFNAGIMELGLVYTPVMAIPPRETAFILTGYCTDKCTQLALPPSGIHIFASQLHTHLTGRKVVTVLVRDGREWEIVNQDNHYSPHFQEIRMLKKVVSVHPGDVLITSCTYNTEDRELATVGGFGILEEMCVNYVHYYPQTQLELCKSAVDAGFLQKYFHLINRFNNEDVCTCPQASVSQQFTSVPWNSFNRDVLKALYSFAPISMHCNKSSAVRFQGEWNLQPLPKVISTLEEPTPQCPTSQGRSPAGPTVVSIGGGKG","Homo sapiens","DBH","Dopamine beta-hydroxylase","1","4ZEL"
"4ZES",,"X-RAY DIFFRACTION",2.25,45.25,"VAPOR DIFFUSION, SITTING DROP",8,"protein solution comprising 5 mg/ml BDCA-2, 5 mM CaCl2, 10 mM Tris-Cl, pH 8.0, 25 mM NaCl and 50 mM methyl mannoside. The reservoir solution contained 0.2 M MgCl2, 20% polyethylene glycol 3.35K, mannoside",295,"10.1074/jbc.M115.660613","MMA","4ZES",34.83,"1.65","1.65","Blood dendritic cell antigen 2 (BDCA-2) complexed with methyl-mannoside","ALTCVMEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLSDPGGRRHWQWVDQTPYNENVTFWHSGEPNNLDERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI","Homo sapiens","CLEC4C, BDCA2, CLECSF11, CLECSF7, DLEC, HECL, UNQ9361/PRO34150","C-type lectin domain family 4 member C","1","4ZES"
"4ZET",,"X-RAY DIFFRACTION",2.19,43.76,"VAPOR DIFFUSION, SITTING DROP",8,"protein solution comprising 6.2 mg/ml BDCA-2, 5 mM CaCl2, 10 mM Tris-Cl, pH 8.0, 25 mM NaCl and 20 mM GalGlcNAcMan. The reservoir solution contained 0.2 NH4Cl and 20% polyethylene glycol 3.35K",295,"10.1074/jbc.M115.660613",,"4ZET",35.48,"2.9","2.9","Blood dendritic cell antigen 2 (BDCA-2) complexed with GalGlcNAcMan","ALTCVMEGKDIEDWSCCPTPWTSFQSSCYFISTGMQSWTKSQKNCSVMGADLVVINTREEQDFIIQNLKRNSSYFLGLSDPGGRRHWQWVDQTPYNENVTFWHSGEPNNLDERCAIINFRSSEEWGWNDIHCHVPQKSICKMKKIYI","Homo sapiens","CLEC4C, BDCA2, CLECSF11, CLECSF7, DLEC, HECL, UNQ9361/PRO34150","C-type lectin domain family 4 member C","1","4ZET"
"4ZEY",,"X-RAY DIFFRACTION",2.08,40.83,"VAPOR DIFFUSION, SITTING DROP",,"25.0% Glycerol, 1.50M ammonium sulfate",293,,,"4ZEY",10.05,"1.5","1.5","Crystal structure of a nuclear receptor binding factor 2 MIT domain (NRBF2) from Homo sapiens at 1.50 A resolution","GMEGPLNLAHQQSRRADRLLAAGKYEEAISCHKKAAAYLSEAMKLTQSEQAHLSLELQRDSHMKQLLLIQERWKRAQREERLKA","Homo sapiens","NRBF2, COPR","Nuclear receptor-binding factor 2","1","4ZEY"
"4ZFC",,"X-RAY DIFFRACTION",2.41,48.94,"VAPOR DIFFUSION, HANGING DROP",6,"15%-20% PEG8000, 100mM MES, 0.14M NaCl",289,"10.1016/j.cbi.2015.09.006","GCZ","4ZFC",75.95,"2","2","Crystal structure of AKR1C3 complexed with glicazide","MDSKHQCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYSDEY","Homo sapiens","AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS","Aldo-keto reductase family 1 member C3","1","4ZFC"
"4ZFH",,"X-RAY DIFFRACTION",2.25,45.32,"VAPOR DIFFUSION, HANGING DROP",4.2,"PEG 1000, reagent alcohol, sodium-phosphate dibasic/citric acid",291.15,,,"4ZFH",17.23,"1.89","1.89","Crystal structure of Artificial ankyrin repeat protein_Ank(GAG)1D4 mutant -Y56A","ADLGKKLLEAARAGQDDEVRLLLEHGADVNARDSIGSTPLHLAAAYGHLEIVRLLLEHGADVNARDSTGTTPLHYAARLGHLEIVRLLLEHGADVNARDAMGWTPLHLAAKKGHLEIVRLLLKHGADVNANDHFGKTAFDISIDNGNEDLAEILQSFSG","Homo sapiens",,"Artificial ankyrin repeat protein_Ank(GAG)1D4 mutant -Y56A","1","4ZFH"
"4ZFI",,"X-RAY DIFFRACTION",2.46,50.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5, 0.2 M sodium chloride, 25% (w/v) PEG 3350",277,"10.1021/acschembio.6b00596","4NJ","4ZFI",47.64,"2","2","Structure of Mdm2 with low molecular weight inhibitor","MQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQ","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","4ZFI"
"4ZFX",,"X-RAY DIFFRACTION",3.24,62.02,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112",,"4ZFX",64.23,"2.55","2.55","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZFX"
"4ZG4",,"X-RAY DIFFRACTION",2.86,56.99,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG8k, 50 mM MES, pH 6.5, 1% DMSO",277,"10.1073/pnas.1516598113",,"4ZG4",177.02,"2.36","2.36","Myosin Vc Pre-powerstroke","MAVAELYTQYNRVWIPDPEEVWKSAEIAKDYRVGDKVLRLLLEDGTELDYSVNPESLPPLRNPDILVGENDLTALSYLHEPAVLHNLRIRFAESKLIYTYSGIILVAMNPYKQLPIYGDAIIHAYSGQNMGDMDPHIFAVAEEAYKQMARNNRNQSIIVSGESGAGKTVSARYAMRYFATVSKSGSNAHVEDKVLASNPITEAVGNAKTTRNDNSSRFGKYTEISFDEQNQIIGANMSTYLLEKSRVVFQSENERNYHIFYQLCASAQQSEFKHLKLGSAEEFNYTRMGGNTVIEGVNDRAEMVETQKTFTLLGFKEDFQMDVFKILAAILHLGNVQITAVGNERSSVSEDDSHLKVFCELLGLESGRVAQWLCNRKIVTSSETVVKPMTRPQAVNARDALAKKIYAHLFDFIVERINQALQFSGKQHTFIGVLDIYGFETFDVNSFEQFCINYANEKLQQQFNMHVFKLEQEEYMKEDIPWTLIDFYDNQPVIDLIEAKMGILELLDEECLLPHGTDENWLQKLYNNFVNRNPLFEKPRMSNTSFVIQHFADKVEYKCEGFLEKNRDTVYDMLVEILRASKFHLCANFFQENPTPPSPFGSMITVKSAKQVIKPNSKHFRTTVGSKFRSSLYLLMETLNATTPHYVRCIKPNDEKLPFEFDSKRIVQQLRACGVLETIRISAQSYPSRWTYIEFYSRYGILMTKQELSFSDKKEVCKVVLHRLIQDSNQYQFGKTKIFFRAGQVAYLEKLRLDKGDYKDDDDK","Homo sapiens","MYO5C","myosin-Vc","1","4ZG4"
"4ZG6",,"X-RAY DIFFRACTION",2.42,49.2,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.4 M NaSCN",298,"10.1124/mol.115.100404","4NY","4ZG6",200.01,"1.8","1.8","Structural basis for inhibition of human autotaxin by four novel compounds","TFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIAALTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEIHHHHHHHH","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","4ZG6"
"4ZG7",,"X-RAY DIFFRACTION",2.23,44.88,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M NaCl",298,"10.1124/mol.115.100404","4O0","4ZG7",95.01,"1.75","1.75","Structural basis for inhibition of human autotaxin by four novel compounds","ISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIAALTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGPTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYE","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","4ZG7"
"4ZG9",,"X-RAY DIFFRACTION",3.18,61.27,"VAPOR DIFFUSION, SITTING DROP",6,"10% PEG 3350, 4% Tacsimate pH 6.0",298,"10.1124/mol.115.100404","4O2","4ZG9",201.57,"2.95","2.95","Structural basis for inhibition of human autotaxin by four novel compounds","MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","4ZG9"
"4ZGA",,"X-RAY DIFFRACTION",2.23,44.93,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.3 M KSCN",298,"10.1124/mol.115.100404","4O3","4ZGA",100.53,"2.6","2.6","Structural basis for inhibition of human autotaxin by four novel compounds","MARRSSFQSCQIISLFTFAVGVNICLGFTAHRIKRAEGWEEGPPTVLSDSPWTNISGSCKGRCFELQEAGPPDCRCDNLCKSYTSCCHDFDELCLKTARGWECTKDRCGEVRNEENACHCSEDCLARGDCCTNYQVVCKGESHWVDDDCEEIKAAECPAGFVRPPLIIFSVDGFRASYMKKGSKVMPNIEKLRSCGTHSPYMRPVYPTKTFPNLYTLATGLYPESHGIVGNSMYDPVFDATFHLRGREKFNHRWWGGQPLWITATKQGVKAGTFFWSVVIPHERRILTILQWLTLPDHERPSVYAFYSEQPDFSGHKYGPFGPEMTNPLREIDKIVGQLMDGLKQLKLHRCVNVIFVGDHGMEDVTCDRTEFLSNYLTNVDDITLVPGTLGRIRSKFSNNAKYDPKAIIANLTCKKPDQHFKPYLKQHLPKRLHYANNRRIEDIHLLVERRWHVARKPLDVYKKPSGKCFFQGDHGFDNKVNSMQTVFVGYGSTFKYKTKVPPFENIELYNVMCDLLGLKPAPNNGTHGSLNHLLRTNTFRPTMPEEVTRPNYPGIMYLQSDFDLGCTCDDKVEPKNKLDELNKRLHTKGSTEERHLLYGRPAVLYRTRYDILYHTDFESGYSEIFLMPLWTSYTVSKQAEVSSVPDHLTSCVRPDVRVSPSFSQNCLAYKNDKQMSYGFLFPPYLSSSPEAKYDAFLVTNMVPMYPAFKRVWNYFQRVLVKKYASERNGVNVISGPIFDYDYDGLHDTEDKIKQYVEGSSIPVPTHYYSIITSCLDFTQPADKCDGPLSVSSFILPHRPDNEESCNSSEDESKWVEELMKMHTARVRDIEHLTSLDFFRKTSRSYPEILTLKTYLHTYESEI","Homo sapiens","ENPP2, ATX, PDNP2","Ectonucleotide pyrophosphatase/phosphodiesterase family member 2","1","4ZGA"
"4ZGG",,"X-RAY DIFFRACTION",3.01,59.13,"VAPOR DIFFUSION, SITTING DROP",8,"5.00% polyethylene glycol 6000, 0.1M TRIS pH 8.0",277,,,"4ZGG",20.83,"1.23","1.23","Crystal structure of a DJ-1 (PARK7) from Homo sapiens at 1.23 A resolution","GMASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFGSKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD","Homo sapiens","PARK7","Protein deglycase DJ-1","1","4ZGG"
"4ZGI",,"X-RAY DIFFRACTION",2.34,47.53,"VAPOR DIFFUSION, SITTING DROP",,"80mM LiCl, 0.2M trimethylamine N-oxide, 15% PEG 3350, 100mM HEPES",293,"10.1021/acs.biochem.5b00500",,"4ZGI",16.72,"2.701","2.701","Structure of Truncated Human TIFA","EETVTCLQMTVYHPGQLQCGIFQSISFNREKLPSSEVVKFGRNSNICHYTFQDKQVSRVQFSLQLFKKFNSSVLSFEIKNMSKKTNLIVDSRELGYLNKMDLPYRCMVRFGEYQFLMEKEDGESLEFFETQFILSPRSLL","Homo sapiens","TIFA, T2BP","TRAF-interacting protein with FHA domain-containing protein A","1","4ZGI"
"4ZGK",,"X-RAY DIFFRACTION",2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.5 containing 30% PEG 1000",277.15,"10.1021/acschembio.6b00596","4NX","4ZGK",24.05,"2","2","Structure of Mdm2 with low molecular weight inhibitor.","MQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQE","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","4ZGK"
"4ZGU",,"X-RAY DIFFRACTION",1.96,37.4,"VAPOR DIFFUSION, HANGING DROP",4.6,"30% PEG 4000, 0.1M CH3COONa.3H2O pH4.6, 0.1M CH3COONH4",294.15,"10.1016/j.str.2016.05.022",,"4ZGU",62.95,"1.49","1.49","Crystal structure of monomer Y60W hCRBPII","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNWDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZGU"
"4ZGX",,"X-RAY DIFFRACTION",2.77,55.52,"VAPOR DIFFUSION, SITTING DROP",,"ammonium acetate, bis-tris, PEG3350",293,"10.1021/acs.jmedchem.5b00851","QHC","4ZGX",685.63,"3.2","3.2","Structure of aldosterone synthase (CYP11B2) in complex with (+)-(R)-N-(4-(4-chloro-3-fluorophenyl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide","MATKAARAPRTVLPFEAMPQHPGNRWLRLLQIWREQGYEHLHLEMHQTFQELGPIFRYNLGGPRMVCVMLPEDVEKLQQVDSLHPCRMILEPWVAYRQHRGHKCGVFLLNGPEWRFNRLRLNPDVLSPKAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWISPKVWKEHFEAWDCIFQYGDNCIQKIYQELAFNRPQHYTGIVAELLLKAELSLEAIKANSMELTAGSVDTTAFPLLMTLFELARNPDVQQILRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHIPAGTLVQVFLYSLGRNAALFPRPERYNPQRWLDIRGSGRNFHHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHFLVETLTQEDIKMVYSFILRPGTSPLLTFRAINGGRHHHHHH","Homo sapiens","CYP11B2","Cytochrome P450 11B2, mitochondrial","1","4ZGX"
"4ZH6",,"X-RAY DIFFRACTION",2.27,45.88,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 4000 (40%), 0.1M Sodium Acetate pH 4.5, Ammonium Acetate 0.1M",298,"10.1016/j.str.2016.05.022",,"4ZH6",15.67,"1.5497","1.5497","Crystal Structure of the Domain-Swapped Dimer Y60L mutant of Human Cellular Retinol Binding Protein II","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNLDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZH6"
"4ZH8",,"X-RAY DIFFRACTION",1.9,35.34,"VAPOR DIFFUSION, HANGING DROP",,"16-20% PEG 6K, 50 mM Mes=NaOH pH 5.7-6.0, 5 mM CaCl2 and 50 mM NaCl",293,,,"4ZH8",44.18,"1.8","1.8","Factor Xa complex with GTC000006","IVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK","Homo sapiens","F10","Coagulation factor X","1","4ZH8"
,,,,,,,,,,,,,,,,"EEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLER","Homo sapiens","F10","Coagulation factor X","2","4ZH8"
"4ZH9",,"X-RAY DIFFRACTION",2.29,46.28,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 4000 (40%), 0.1M Sodium Acetate pH 4.5, Ammonium Acetate 0.1M",298,"10.1016/j.str.2016.05.022",,"4ZH9",15.6,"2.66","2.66","Crystal Structure of the Domain-Swapped Dimer Wild-Type of Human Cellular Retinol Binding Protein II","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZH9"
"4ZHA",,"X-RAY DIFFRACTION",1.85,33.59,"VAPOR DIFFUSION, HANGING DROP",,"16-20% PEG 6K, 50 mM Mes-NaOH (pH 5.7-6.0), 5 mM CaCl2, and 50 mM NaCl",293,,,"4ZHA",44.28,"1.86","1.86","Factor Xa complex with GTC000102","IVGGQECKDGECPWQALLINEENEGFCGGTILSEFYILTAAHCLYQAKRFKVRVGDRNTEQEEGGEAVHEVEVVIKHNRFTKETYDFDIAVLRLKTPITFRMNVAPACLPERDWAESTLMTQKTGIVSGFGRTHEKGRQSTRLKMLEVPYVDRNSCKLSSSFIITQNMFCAGYDTKQEDACQGDSGGPHVTRFKDTYFVTGIVSWGEGCARKGKYGIYTKVTAFLKWIDRSMKTRGLPKAKSHAPEVITSSPLK","Homo sapiens","F10","Coagulation factor X","1","4ZHA"
,,,,,,,,,,,,,,,,"EEMKKGHLERECMEETCSYEEAREVFEDSDKTNEFWNKYKDGDQCETSPCQNQGKCKDGLGEYTCTCLEGFEGKNCELFTRKLCSLDNGDCDQFCHEEQNSVVCSCARGYTLADNGKACIPTGPYPCGKQTLER","Homo sapiens","F10","Coagulation factor X","2","4ZHA"
"4ZHC",,"X-RAY DIFFRACTION",3.23,61.91,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112","TC2","4ZHC",64.77,"2.04","2.04","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZHC"
"4ZHD",,"X-RAY DIFFRACTION",3.21,61.66,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112",,"4ZHD",64.06,"2.05","2.05","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZHD"
"4ZHF",,"X-RAY DIFFRACTION",3.14,60.77,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112","4OL","4ZHF",131.52,"2.45","2.45","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZHF"
"4ZHG",,"X-RAY DIFFRACTION",3.14,60.77,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112","4OL","4ZHG",130.85,"2.05","2.05","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZHG"
"4ZHH",,"X-RAY DIFFRACTION",3.14,60.8,"VAPOR DIFFUSION",4,"NaCl, Li2SO4, Acetate, Ammonium Sulfate",298,"10.1073/pnas.1508902112",,"4ZHH",130.83,"2.04","2.04","Siderocalin-mediated recognition and cellular uptake of actinides","GSQDSTSDLIPAPPLSKVPLQQNFQDNQFQGKWYVVGLAGNAILREDKDPQKMYATIYELKEDKSYNVTSVLFRKKKCDYWIRTFVPGSQPGEFTLGNIKSYPGLTSYLVRVVSTNYNQHAMVFFKKVSQNREYFKITLYGRTKELTSELKENFIRFSKSLGLPENHIVFPVPIDQCIDG","Homo sapiens","LCN2, HNL, NGAL","Neutrophil gelatinase-associated lipocalin","1","4ZHH"
"4ZHI",,"X-RAY DIFFRACTION",2.14,42.63,"VAPOR DIFFUSION, HANGING DROP",,"200 mM NaF and 18-20% PEG 3350",277,,,"4ZHI",83.11,"2.3","2.3","Eg5 motor domain mutant E162S","MASQPNSSAKKKEEKGKNIQVVVRCRPFNLAERKASAHSIVECDPVRKEVSVRTGGLADKSSRKTYTFDMVFGASTKQIDVYRSVVCPILDEVIMGYNCTIFAYGQTGTGKTFTMEGERSPNEEYTWEEDPLAGIIPRTLHQIFEKLTDNGTEFSVKVSLLSIYNEELFDLLNPSSDVSERLQMFDDPRNKRGVIIKGLEEITVHNKDEVYQILEKGAAKRTTAATLMNAYSSRSHSVFSVTIHMKETTIDGEELVKIGKLNLVDLAGSENIGRSGAVDKRAREAGNINQSLLTLGRVITALVERTPHVPYRESKLTRILQDSLGGRTRTSIIATISPASLNLEETLSTLEYAHRAKNILNKPEVNQKL","Homo sapiens","KIF11, EG5, KNSL1, TRIP5","Kinesin-like protein KIF11","1","4ZHI"
"4ZHT",,"X-RAY DIFFRACTION",2.15,42.87,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium acetate, 0.1 M HEPES, pH 7.1, 19% PEG 3350",277,"10.1038/srep23274",,"4ZHT",192.6,"2.69","2.69","Crystal structure of UDP-GlcNAc 2-epimerase","MEKNGNNRKLRVCVATCNRADYSKLAPIMFGIKTEPEFFELDVVVLGSHLIDDYGNTYRMIEQDDFDINTRLHTIVRGEDEAAMVESVGLALVKLPDVLNRLKPDIMIVHGDRFDALALATSAALMNIRILHIEGGEVSGTIDDSIRHAITKLAHYHVCCTRSAEQHLISMCEDHDRILLAGCPSYDKLLSAKNKDYMSIIRMWLGDDVKSKDYIVALQHPVTTDIKHSIKMFELTLDALISFNKRTLVLFPNIDAGSKEMVRVMRKKGIEHHPNFRAVKHVPFDQFIQLVAHAGCMIGNSSCGVREVGAFGTPVINLGTRQIGRETGENVLHVRDADTQDKILQALHLQFGKQYPCSKIYGDGNAVPRILKFLKSIDLQEPLQKKFCFPPVKENISQDIDHILEHHHHHH","Homo sapiens","GNE, GLCNE","Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase","1","4ZHT"
"4ZIM",,"X-RAY DIFFRACTION",2.95,58.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES buffer, 100mM NaCl, 28% (w/v) PEG3350, 2mM DTT and 200mM tri-sodium citrate",295,"10.1016/j.bmcl.2015.04.101","4OK","4ZIM",76.67,"2.65","2.65","CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH A 9H-CARBAZOLE-1-CARBOXAMIDE INHIBITOR","MGSSHHHHHHSSGLVPRGSHMRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAGHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","4ZIM"
"4ZJ0",,"X-RAY DIFFRACTION",2.03,39.34,"VAPOR DIFFUSION, HANGING DROP",4.6,"30% PEG4000, 0.1M CH3COONa.3H2O, pH 4.6, 0.1M CH3COONH4",294,"10.1016/j.str.2016.05.022",,"4ZJ0",31.9,"1.5","1.5","The crystal structure of monomer Q108K:K40L:Y60W CRBPII bound to all-trans-retinal","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTLVIDQDGDNFKTKTTSTFRNWDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZJ0"
"4ZJI",,"X-RAY DIFFRACTION",2.77,55.56,"VAPOR DIFFUSION, HANGING DROP",,"Equal volumes (1.0 uL) of reservoir solution and protein solution were mixed. Reservoir solution: 17.2% (w/v) PEG3350, 0.2 M magnesium formate (dihydrate)",298,"10.1021/acsmedchemlett.5b00102","4OQ","4ZJI",135.19,"1.99","1.99","PAK1 in complex with 2-chloro-5-ethyl-8-fluoro-11-(4-methylpiperazin-1-yl)-dibenzodiazepine","GPSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZJI"
"4ZJJ",,"X-RAY DIFFRACTION",2.73,54.99,"VAPOR DIFFUSION, HANGING DROP",,"Equal volumes (0.8 uL) of reservoir solution and protein solution were mixed. Reservoir solution: 16.8% (w/v) PEG3350, 0.2 M magnesium formate (dihydrate)",298,"10.1021/acsmedchemlett.5b00102","4OR","4ZJJ",135.53,"2.2","2.2","PAK1 in complex with (S)-N-(tert-butyl)-3-((2-chloro-5-ethyl-8-fluoro-dibenzodiazepin-11-yl)amino)pyrrolidine-1-carboxamide","GPSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZJJ"
"4ZJK",,"X-RAY DIFFRACTION",3.06,59.83,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 Bicine pH 9.0, 2.0 M Magnesium Chloride",281,"10.1107/S1399004715013073",,"4ZJK",22.02,"1.56","1.56","FIVE MINUTES IRON LOADED HUMAN H FERRITIN","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","4ZJK"
"4ZJR",,"X-RAY DIFFRACTION",3.54,65.28,"VAPOR DIFFUSION, SITTING DROP",8,"1.0M Sodium Acetate, 0.2M Sodium Chloride, 0.1M TRIS pH 8.0",298,"10.1016/j.bmcl.2015.05.026","4P3","4ZJR",106.7,"2.702","2.702","RORgamma in complex with inverse agonist 48","GSASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQ","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","4ZJR"
"4ZJW",,"X-RAY DIFFRACTION",2.21,44.38,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2M Ammonium Acetate. 15% PEG3350, 0.1M BisTRIS pH 5.5",298,"10.1016/j.bmcl.2015.05.026","4P1","4ZJW",52.78,"2.5","2.5","RORgamma in complex with inverse agonist 16","GSASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQ","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","4ZJW"
"4ZK0",,"X-RAY DIFFRACTION",2.8,57,"VAPOR DIFFUSION, SITTING DROP",8.5,"22% PEGMME 5K, 0.1 M Bicine pH 8.5, 0.06 M Zn acetate, 4.5% Hexanediol",298,"10.1016/j.bbrep.2015.06.001",,"4ZK0",44.75,"2.15","2.15","Psoriasis pathogenesis - Pso p27 constitute a compact structure forming large aggregates. High pH structure","MNSLSEANTKFMFDLFQQFRKSKENNIFYSPISITSALGMVLLGAKDNTAQQIKKVLHFDQVTENTTGKAATYHVDRSGNVHHQFQKLLTEFNKSTDAYELKIANKLFGEKTYLFLQEYLDAIKKFYQTSVESVDFANAPEESRKKINSWVESQTNEKIKNLIPEGNIGSNTTLVLVNAIYFKGQWEKKFNKEDTKEEKFWPNKNTYKSIQMMRQYTSFHFASLEDVQAKVLEIPYKGKDLSMIVLLPNEIDGLQKLEEKLTAEKLMEWTSLQNMRETRVDLHLPRFKVEESYDLKDTLRTMGMVDIFNGDADLSGMTGSRGLVLSGVLHKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTNSILFYGRFSSP","Homo sapiens","SERPINB4, PI11, SCCA2, SERPINB3, SCCA, SCCA1","Serpin B4","1","4ZK0"
"4ZK3",,"X-RAY DIFFRACTION",2.8,57,"VAPOR DIFFUSION, SITTING DROP",4.5,"27% PEGMME 2K, 0.1 M Na acetate pH 4.5",298,"10.1016/j.bbrep.2015.06.001",,"4ZK3",44.62,"2","2","Psoriasis pathogenesis - Pso p27 constitute a compact structure forming large aggregates. Low pH structure","MNSLSEANTKFMFDLFQQFRKSKENNIFYSPISITSALGMVLLGAKDNTAQQIKKVLHFDQVTENTTGKAATYHVDRSGNVHHQFQKLLTEFNKSTDAYELKIANKLFGEKTYLFLQEYLDAIKKFYQTSVESVDFANAPEESRKKINSWVESQTNEKIKNLIPEGNIGSNTTLVLVNAIYFKGQWEKKFNKEDTKEEKFWPNKNTYKSIQMMRQYTSFHFASLEDVQAKVLEIPYKGKDLSMIVLLPNEIDGLQKLEEKLTAEKLMEWTSLQNMRETRVDLHLPRFKVEESYDLKDTLRTMGMVDIFNGDADLSGMTGSRGLVLSGVLHKAFVEVTEEGAEAAAATAVVGFGSSPTSTNEEFHCNHPFLFFIRQNKTNSILFYGRFSSP","Homo sapiens","SERPINB3, SCCA, SCCA1","Serpin B3","1","4ZK3"
"4ZK5",,"X-RAY DIFFRACTION",2.13,42.24,"VAPOR DIFFUSION, SITTING DROP",8.3,"0.2 M potassium citrate pH 8.3, 20% PEG 3350",292,"10.1021/acsmedchemlett.5b00174","4P4","4ZK5",76.37,"2.89","2.89","MAP4K4 in complex with inhibitor GNE-495","GSANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTRKKRGEKDETEYEYSGSEEGNS","Homo sapiens","MAP4K4, HGK, KIAA0687, NIK","Mitogen-activated protein kinase kinase kinase kinase 4","1","4ZK5"
"4ZKA",,"X-RAY DIFFRACTION",2.07,40.68,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 3350 12.5%w/v
PEG 1000 12.5%w/v
NPS 6.6%
MPD 12.5%w/v
MES 0.1M, pH 6.5",293,,,"4ZKA",70.15,"1.8","1.8","High Resolution Crystal Structure of Fox1 RRM","NTENKSQPKRLHVSNIPFRFRDPDLRQMFGQFGKILDVEIIFNERGSKGFGFVTFENSADADRAREKLHGTVVEGRKIEVNNATARVMTNKKTVNPYTNG","Homo sapiens","RBFOX1, A2BP, A2BP1, FOX1, HRNBP1","RNA binding protein fox-1 homolog 1","1","4ZKA"
"4ZKF",,"X-RAY DIFFRACTION",2.31,46.68,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, sodium chloride",293,,,"4ZKF",51.95,"1.82","1.82","Crystal structure of human phosphodiesterase 12","GIDPFTKYKVERNPPAFTELQLPRYIMAGFPVCPKLSLEFGDPASSLFRWYKEAKPGAAEPEVGVPSSLSPSSPSSSWTETDVEERVYTPSNADIGLRLKLHCTPGDGQRFGHSRELESVCVVEAGPGTCTFDHRHLYTKKVTEDALIRTVSYNILADTYAQTEFSRTVLYPYCAPYALELDYRQNLIQKELTGYNADVICLQEVDRAVFSDSLVPALEAFGLEGVFRIKQHEGLATFYRKSKFSLLSQHDISFYEALESDPLHKELLEKLVLYPSAQEKVLQRSSVLQVSVLQSTKDSSKRICVANTHLYWHPKGGYIRLIQMAVALAHIRHVSCDLYPGIPVIFCGDFNSTPSTGMYHFVINGSIPEDHEDWASNGEEERCNMSLTHFFKLKSACGEPAYTNYVGGFHGCLDYIFIDLNALEVEQVIPLPSHEEVTTHQALPSVSHPSDHIALVCDLKWK","Homo sapiens","PDE12","2',5'-phosphodiesterase 12","1","4ZKF"
"4ZKL",,"X-RAY DIFFRACTION",3.03,59.45,"VAPOR DIFFUSION, HANGING DROP",5.5,"19% w/v PEG4000, 0.1 M sodium cacodylate pH 5.5",281,"10.1016/j.ijbiomac.2016.02.047",,"4ZKL",56.79,"2.34","2.34","Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) complexed with JB419 (AP4A analog)","MADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","4ZKL"
"4ZKV",,"X-RAY DIFFRACTION",2.27,45.92,"VAPOR DIFFUSION, HANGING DROP",6.8,"18% PEG 4000, 0.1M sodium cacodylate pH 6.8",281,"10.1016/j.ijbiomac.2016.02.047",,"4ZKV",55.49,"1.92","1.92","Crystal structure of human histidine triad nucleotide-binding protein 1 (hHINT1) refined to 1.92A at P21 space group","MADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","4ZKV"
"4ZL1",,"X-RAY DIFFRACTION",3.47,64.53,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM UDAO, 20.8mM N,N-dimethyldecylamine-N-oxide(DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1mM inhibitor",293,,,"4ZL1",44,"1.86","1.86","Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18X at 1.86 A resolution","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","4ZL1"
"4ZLC",,"X-RAY DIFFRACTION",2.23,44.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% PEG6000, 100 mM Hepes, 100 mM KCl",293,"10.1107/S2053230X15011887",,"4ZLC",70.37,"2.7","2.7","Crystal structure of the ROQ domain of human Roquin-2","QNPQQLSANLWAAVRARGCQFLGPAMQEEALKLVLLALEDGSALSRKVLVLFVVQRLEPRFPQASKTSIGHVVQLLYRASCFKVTKRDEDSSLMQLKEEFRSYEALRREHDAQIVHIAMEAGLRISPEQWSSLLYGDLAHKSHMQSIIDKLQSPE","Homo sapiens","RC3H2, MNAB, RNF164","Roquin-2","1","4ZLC"
"4ZLO",,"X-RAY DIFFRACTION",2.36,47.94,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-27% PEG3350, 500-700MM NACL, 100MM BIS-TRIS, PH 6.5",291,"10.1021/acsmedchemlett.5b00102","4PV","4ZLO",67.1,"2.5","2.5","Serine/threonine-protein kinase PAK1 complexed with a dibenzodiazepine: identification of an allosteric site on PAK1","SDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZLO"
"4ZLP",,"X-RAY DIFFRACTION",2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",5.4,"20% isopropanol, 20% PEG4000, and 0.1 M tri-sodium citrate",295,"10.1016/j.str.2015.05.001",,"4ZLP",61.8,"2.479","2.479","Crystal Structure of Notch3 Negative Regulatory Region","APEVSEEPRCPRAACQAKRGDQRCDRECNSPGCGWDGGDCSLSVGDPWRQCEALQCWRLFNNSRCDPACSSPACLYDNFDCHAGGRERTCNPVYEKYCADHFADGRCDQGCNTEECGWDGLDCASEVPALLARGVLVLTVLLPPEELLRSSADFLQRLSAILRTSLRFRLDAHGQAMVFPYHRPSPGSEPRARRELAPEVIGSVVMLEIDNRLCLQSPENDHCFPDAQSAADYLGALSAVERLDFPYPLRDVRGEPLEPPEPSGSHHHHHH","Homo sapiens","NOTCH3","Neurogenic locus notch homolog protein 3","1","4ZLP"
"4ZLY",,"X-RAY DIFFRACTION",2.3,46.46,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277,"10.1021/acs.jmedchem.5b00734","4RU","4ZLY",31.98,"1.65","1.65","Crystal Structure of Bruton's Tyrosine Kinase bound to a Cinnoline Fragment","GLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEE","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","4ZLY"
"4ZLZ",,"X-RAY DIFFRACTION",2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% polyethylene glycol 4000, 20% glycerol, 0.1M imidazole/MES, pH 6.5, 0.12M alcohol mixture",277,"10.1021/acs.jmedchem.5b00734","4RV","4ZLZ",32.07,"2","2","Crystal Structure of Bruton's Tyrosine Kinase in complex with a substituted Cinnoline","GLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEE","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","4ZLZ"
"4ZM9",,"X-RAY DIFFRACTION",2.63,53.2,"VAPOR DIFFUSION, SITTING DROP",4.6,"24 % PEG4000, 4 mM DTT, 0.15 mM Sodium citrate, pH4.6
Microseeding",297,"10.1021/acs.biochem.5b01157",,"4ZM9",137,"2.51","2.51","Crystal structure of circularly permuted human asparaginase-like protein 1","GNPIVVVHGGGAGPISKDRKERVHQGMVRAATVGYGILREGGSAVDAVEGAVVALEDDPEFNAGCGSVLNTNGEVEMDASIMDGKDLSAGAVSAVQCIANPIKLARLVMEKTPHCFLTDQGAAQFAAAMGVPEIPGEKLVTERNKKRLEKEKHEKGAQKTDCQKNLGHHHHHHMTVGAVALDCKGNVAYATSTGGIVNKMVGRVGDSPCLGAGGYADNDIGAVSTTGHGESILKVNLARLTLFHIEQGKTVEEAADLSLGYMKSRVKGLGGLIVVSKTGDWVAKWTSTSMPWAAAKDGKLHFGIDPDDTTITDLPGAGSGAGSGAGG","Homo sapiens","ASRGL1, ALP, CRASH","Isoaspartyl peptidase/L-asparaginase","1","4ZM9"
"4ZMG",,"X-RAY DIFFRACTION",3.44,64.28,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40 mM UDAO, 20.8 mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8M ammonium sulfate, 1 mM inhibitor",293,,,"4ZMG",43.86,"1.9","1.9","Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with DH03A338","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","4ZMG"
"4ZML",,"X-RAY DIFFRACTION",4.89,74.85,"VAPOR DIFFUSION, HANGING DROP",7.5,"31% PEG 400
15 mM CaCl2
5% glycerol",293,"10.1016/j.str.2016.07.002",,"4ZML",24.04,"1.85","1.85","Crystal structure of human P-cadherin (ss-dimer)","DWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZML"
"4ZMN",,"X-RAY DIFFRACTION",3.15,61,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 550-MME
100 mM CaCl2
100 mM HEPES",293,"10.1016/j.str.2016.07.002",,"4ZMN",25.57,"2.6","2.6","Crystal structure of human P-cadherin (ss-dimer long)","DWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVP","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMN"
"4ZMO",,"X-RAY DIFFRACTION",4.87,74.72,"VAPOR DIFFUSION, HANGING DROP",8.5,"26% PEG 4,000
170 lithium sulfate
15% glycerol
85 mM TRIS",293,"10.1016/j.str.2016.07.002",,"4ZMO",23.37,"2.48","2.48","Crystal structure of human P-cadherin (ss-dimer K14E)","DWVVAPISVPENGEGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMO"
"4ZMP",,"X-RAY DIFFRACTION",4.79,74.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"30% PEG 400
150 mM CaCl2
5% glycerol
95 mM HEPES",293,"10.1016/j.str.2016.07.002",,"4ZMP",23.4,"2.15","2.15","Crystal structure of human P-cadherin (ss-dimer Q101L)","DWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDLNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMP"
"4ZMQ",,"X-RAY DIFFRACTION",4.19,70.66,"VAPOR DIFFUSION, HANGING DROP",7.5,"28% PEG 400
250 mM CaCl2
HEPES 100 mM",293,"10.1016/j.str.2016.07.002",,"4ZMQ",47.4,"2.2","2.2","Crystal structure of human P-cadherin (ss-X-dimer)","MDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMQ"
"4ZMT",,"X-RAY DIFFRACTION",2.64,53.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% PEG 3,550
200 mM MgCl2",293,"10.1016/j.str.2016.07.002",,"4ZMT",153.42,"2.7","2.7","Crystal structure of human P-cadherin (ss-X-dimer-long)","MDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILDANDNAPMFDPQKYEAHVP","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMT"
"4ZMV",,"X-RAY DIFFRACTION",4.55,72.96,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.2 M Lithium sulfate
10 mM nickel sulfate
100 mM TRIS",293,"10.1016/j.str.2016.07.002",,"4ZMV",47.8,"2.4","2.4","Crystal structure of human P-cadherin (ss-X-dimer pocket I)","MDWVIPPISVPENGKGPFPQRLVQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMV"
"4ZMW",,"X-RAY DIFFRACTION",4.16,70.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.15 M Lithium sulfate
7.5 mM nickel sulfate
100 mM TRIS",293,"10.1016/j.str.2016.07.002",,"4ZMW",47.76,"2.3","2.3","Crystal structure of human P-cadherin (enc-X-dimer)","MDWVVAPISVPENGKGPFPQRLVQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMW"
"4ZMX",,"X-RAY DIFFRACTION",4.18,70.55,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% PEG 4,000
10% 2-isopropanol
HEPES 100 mM",293,"10.1016/j.str.2016.07.002",,"4ZMX",46.59,"3.1","3.1","Crystal structure of human P-cadherin (int-X-dimer)","DAVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMX"
"4ZMY",,"X-RAY DIFFRACTION",2.38,48.34,"VAPOR DIFFUSION, HANGING DROP",8.5,"20% PEG 4,000
100 mM CaCl2
100 mM TRIS",293,"10.1016/j.str.2016.07.002",,"4ZMY",23.7,"1.5","1.5","Crystal structure of human P-cadherin (monomer 1)","MDWVVAPISVPENGEGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMY"
"4ZMZ",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"28% PEG 400
200 mM CaCl2
95 mM HEPES",293,"10.1016/j.str.2016.07.002",,"4ZMZ",23.61,"2.05","2.05","Crystal structure of human P-cadherin (monomer 2)","RDWVVAPISVPENGKGPFPQRLNQLKSNKDRDTKIFYSITGPGADSPPEGVFAVEKETGWLLLNKPLDREEIAKYELFGHAVSENGASVEDPMNISIIVTDQNDHKPKFTQDTFRGSVLEGVLPGTSVMQVTATDEDDAIYTYNGVVAYSIHSQEPKDPHDLMFTIHRSTGTISVISSGLDREKVPEYTLTIQATDMDGDGSTTTAVAVVEILD","Homo sapiens","CDH3, CDHP","Cadherin-3","1","4ZMZ"
"4ZNF",,"SOLUTION NMR",,,,,,,"10.1021/bi00492a004",,"4ZNF",3.63,,,"HIGH-RESOLUTION THREE-DIMENSIONAL STRUCTURE OF A SINGLE ZINC FINGER FROM A HUMAN ENHANCER BINDING PROTEIN IN SOLUTION","RPYHCSYCNFSFKTKGNLTKHMKSKAHSKK","Homo sapiens","HIVEP1, ZNF40","ZINC FINGER","1","4ZNF"
"4ZNN",,"ELECTRON CRYSTALLOGRAPHY",,,"BATCH MODE",7,"1 mg of synthetic peptide GVVHGVTTVA was dissolved in 200 microliters of 50 mM phosphate buffer pH 7.0 and 0.1% w/v DMSO and shaken overnight in an orbital mixing plate",310,"10.1038/nature15368",,"4ZNN",0.94,"1.41","1.41","MicroED structure of the segment, GVVHGVTTVA, from the A53T familial mutant of Parkinson's disease protein, alpha-synuclein residues 47-56","GVVHGVTTVA","Homo sapiens","SNCA, NACP, PARK1","Alpha-synuclein","1","4ZNN"
"4ZO5",,"X-RAY DIFFRACTION",2.21,44.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1016/j.bmcl.2015.05.080","4Q0","4ZO5",75.87,"2.5","2.5","PDE10 complexed with 4-isopropoxy-2-(2-(3-(4-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)isoindoline-1,3-dione","HMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","4ZO5"
"4ZOG",,"X-RAY DIFFRACTION",3.18,61.37,"VAPOR DIFFUSION, SITTING DROP",6.6,"PEG MME2000 (31% w/v), MES (100 mM, pH 6.5) and sodium acetate (260mM).",277,,"VX6","4ZOG",66.89,"2.3","2.3","VX-680/MK-0457 binds to human ABL1 also in inactive DFG conformations.","SPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQESSISDEVEKELG","Homo sapiens","ABL1, ABL, JTK7","Tyrosine-protein kinase ABL1","1","4ZOG"
"4ZOM",,"X-RAY DIFFRACTION",3.53,65.15,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M TRIS pH 8.0, 1.8M Na formate",298,"10.1016/j.bmcl.2015.05.028","4Q3","4ZOM",106.68,"2.27","2.27","RORgamma in complex with inverse agonist 4j.","GSASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQ","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","4ZOM"
"4ZOU",,"X-RAY DIFFRACTION",3.74,67.14,"VAPOR DIFFUSION, SITTING DROP",7.6,"4-6% PEG 6000, 0.1 M HEPES, pH 7.6, 5% glycerol",277,,,"4ZOU",13.02,"2.15","2.15","Crystal structure of the BTB domain of SLX4","RTLLSLGLLVADFGAMVNNPHLSDVQFQTDSGEVLYAHKFVLYARCPLLIQYVNNEGFSAVEDGVLTQRVLLGDVSTEAARTFLHYLYTADTGLPPGLSSELSSLAHRFGVSELVHLCE","Homo sapiens","SLX4, BTBD12, KIAA1784, KIAA1987","Structure-specific endonuclease subunit SLX4","1","4ZOU"
"4ZP5",,"X-RAY DIFFRACTION",2.55,51.68,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350",293,,"4QG","4ZP5",70.88,"2.29","2.29","MAP4K4 in complex with inhibitor","MANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRT","Homo sapiens","MAP4K4, HGK, KIAA0687, NIK","Mitogen-activated protein kinase kinase kinase kinase 4","1","4ZP5"
"4ZPE",,"X-RAY DIFFRACTION",3.11,60.44,"VAPOR DIFFUSION, HANGING DROP",,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER PH 7.50",293,"10.1016/j.bmcl.2015.06.082","4QA","4ZPE",45.62,"1.7","1.7","BACE1 in complex with 4-(cyclohexylamino)-1-(3-fluorophenyl)-8-(3-isopropoxybenzyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one","MLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGAWAGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZPE"
"4ZPF",,"X-RAY DIFFRACTION",3.08,60.08,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER,",293,"10.1016/j.bmcl.2015.06.082","4QD","4ZPF",45.63,"1.8","1.8","BACE1 in complex with 8-(3-((1-aminopropan-2-yl)oxy)benzyl)-4-(cyclohexylamino)-1-(3-fluorophenyl)-1,3,8-triazaspiro[4.5]dec-3-en-2-one","MLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGAWAGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZPF"
"4ZPG",,"X-RAY DIFFRACTION",3.11,60.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"1.5M LITHIUM SULFATE, 0.1M HEPES BUFFER,",293,"10.1016/j.bmcl.2015.06.082","4QF","4ZPG",45.57,"2","2","BACE1 in complex with 8-benzyl-4-(cyclohexylamino)-1-(3-fluorophenyl)-7-methyl-1,3,8-triazaspiro[4.5]dec-3-en-2-one","MLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGAWAGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZPG"
"4ZPZ",,"X-RAY DIFFRACTION",2.08,40.92,"VAPOR DIFFUSION, HANGING DROP",5,"50 mM sodium cacodylate, 25% PEG 4000",291,"10.1002/cbic.201500185",,"4ZPZ",17.38,"1.54","1.54","Crystal Structure of Semi-synthetic Ubiquitin with Phospho-Ser65 and Ala46Cys","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFCGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","4ZPZ"
"4ZQL",,"X-RAY DIFFRACTION",2.4,48.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5, 2M ammonium sulfate, 2%(v/v) PEG 400",293.15,,"4QH","4ZQL",44.08,"1.79","1.79","Crystal structure of TRIM24 with 3,4-dimethoxy-N-(6-(4-methoxyphenoxy)-1,3-dimethyl-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)benzenesulfonamide inhibitor","HMNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYP","Homo sapiens","TRIM24, RNF82, TIF1, TIF1A","Transcription intermediary factor 1-alpha","1","4ZQL"
"4ZQS",,"X-RAY DIFFRACTION",1.86,33.75,"VAPOR DIFFUSION, HANGING DROP",8,"0.1M Tris-HCl pH 8.0, 0.1M magnesium acetate, 20% PEG 3350, 20% PEG 400",295,"10.1107/S2059798316001510",,"4ZQS",35.08,"1.804","1.804","New compact conformation of linear Ub2 structure","GAMGSMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGGMQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","ubiquitin","1","4ZQS"
"4ZR2",,"X-RAY DIFFRACTION",2,38.45,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 4000 (40%), 0.1M Sodium Acetate pH 4.5, Ammonium Acetate 0.1M",298,"10.1016/j.str.2016.05.022",,"4ZR2",31.79,"1.8024","1.8024","Crystal Structure of the Domain-Swapped Dimer K40L:Q108K:Y60W mutant of Human Cellular Retinol Binding Protein II","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTLVIDQDGDNFKTKTTSTFRNWDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","4ZR2"
"4ZRJ",,"X-RAY DIFFRACTION",1.97,37.45,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M Bis-Tris, 21% PEG 3000",293,"10.1038/cr.2015.69",,"4ZRJ",49.22,"2.3","2.3","Structure of Merlin-FERM and CTD","MAGAIASRMSFSSLKRKQPKTFTVRIVTMDAEMEFNCEMKWKGKDLFDLVCRTLGLRETWFFGLQYTIKDTVAWLKMDKKVLDHDVSKEEPVTFHFLAKFYPENAEEELVQEITQHLFFLQVKKQILDEKIYCPPEASVLLASYAVQAKYGDYDPSVHKRGFLAQEELLPKRVINLYQMTPEMWEERITAWYAEHRGRARDEAEMEYLKIAQDLEMYGVNYFAIRNKKGTELLLGVDALGLHIYDPENRLTPKISFPWNEIRNISYSDKEFTIKPLDKKIDVFKFNSSKLRVNKLILQLCIGNHDLFMRRRKADSLEVQQ","Homo sapiens","NF2, SCH","Merlin","1","4ZRJ"
,,,,,,,,,,,,,,,,"SFDFKDTDMKRLDMEIEKEKVEYMEKSKHLQEQLNELKTEIEALKLKERETALDILHNENSDRGGSSKHNTIKKLTLQSWKSRVAFFEEL","Homo sapiens","NF2, SCH","Merlin","2","4ZRJ"
"4ZS0",,"X-RAY DIFFRACTION",2.58,52.4,"VAPOR DIFFUSION, HANGING DROP",8,"4% v/v Tacsimate pH 8.0, 12% w/v PEG 3350",291,"10.1021/acs.jmedchem.6b00709","4QV","4ZS0",33.22,"3","3","Human Aurora A catalytic domain bound to SB-6-OH","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","4ZS0"
"4ZS2",,"X-RAY DIFFRACTION",2.97,58.54,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium citrate (pH 5.8), 10% PEG 3350, 8% isopropanol",289,"10.1021/jacs.5b06690","FLU","4ZS2",55.47,"2.16","2.16","Structural complex of FTO/fluorescein","GSHMTPKDDEFYQQWQLKYPKLILREASSVSEELHKEVQEAFLTLHKHGCLFRDLVRIQGKDLLTPVSRILIGNPGCTYKYLNTRLFTVPWPVKGSNIKHTEAEIAAACETFLKLNDYLQIETIQALEELAAKEKANEDAVPLCMSADFPRVGMGSSYNGQDEVDIKSRAAYNVTLLNFMDPQKMPYLKEEPYFGMGKMAVSWHHDENLVDRSAVAVYSYSCEGPEEESEDDSHLEGRDPDIWHVGFKISWDIETPGLAIPLHQGDCYFMLDDLNATHQHCVLAGSQPRFSSTHRVAECSTGTLDYILQRCQLALQNVCDDVDNDDVSLKSFEPAVLKQGEEIHNEVEFEWLRQFWFQGNRYRKCTDWWCQPMAQLEALWKKMEGVTNAVLHEVKREGLPVEQRNEILTAILASLTARQNLRREWHARCQSRIARTLPADQKPECRPYWEKDDASMPLPFDLTDIVSELRGQLLEAKP","Homo sapiens","FTO, KIAA1752","Alpha-ketoglutarate-dependent dioxygenase FTO","1","4ZS2"
"4ZS3",,"X-RAY DIFFRACTION",2.96,58.4,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium citrate, 11% PEG3350, 10% isopropanol",289,"10.1021/jacs.5b06690","A4F","4ZS3",55.48,"2.45","2.45","Structural complex of 5-aminofluorescein bound to the FTO protein","GSHMTPKDDEFYQQWQLKYPKLILREASSVSEELHKEVQEAFLTLHKHGCLFRDLVRIQGKDLLTPVSRILIGNPGCTYKYLNTRLFTVPWPVKGSNIKHTEAEIAAACETFLKLNDYLQIETIQALEELAAKEKANEDAVPLCMSADFPRVGMGSSYNGQDEVDIKSRAAYNVTLLNFMDPQKMPYLKEEPYFGMGKMAVSWHHDENLVDRSAVAVYSYSCEGPEEESEDDSHLEGRDPDIWHVGFKISWDIETPGLAIPLHQGDCYFMLDDLNATHQHCVLAGSQPRFSSTHRVAECSTGTLDYILQRCQLALQNVCDDVDNDDVSLKSFEPAVLKQGEEIHNEVEFEWLRQFWFQGNRYRKCTDWWCQPMAQLEALWKKMEGVTNAVLHEVKREGLPVEQRNEILTAILASLTARQNLRREWHARCQSRIARTLPADQKPECRPYWEKDDASMPLPFDLTDIVSELRGQLLEAKP","Homo sapiens","FTO, KIAA1752","Alpha-ketoglutarate-dependent dioxygenase FTO","1","4ZS3"
"4ZSA",,"X-RAY DIFFRACTION",2.67,54.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 0.3M (NH4)2SO4, 15-20% PEG10000, 5% EG",277,"10.1039/c5ob00778j","4UT","4ZSA",71.07,"2","2","Crystal structure of FGFR1 kinase domain in complex with 7n","AGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","Fibroblast growth factor receptor 1","1","4ZSA"
"4ZSC",,"X-RAY DIFFRACTION",2.1,41.36,"VAPOR DIFFUSION, SITTING DROP",7.3,"30% PEG4000",291,"10.1107/S1399004715010342",,"4ZSC",17.9,"1.5","1.5","Human Cyclophilin D Complexed with an Inhibitor at room temperature","GNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","4ZSC"
"4ZSD",,"X-RAY DIFFRACTION",2.11,41.59,"VAPOR DIFFUSION, SITTING DROP",7.3,"30% PEG4000",291,"10.1107/S1399004715010342",,"4ZSD",18.12,"1.45","1.45","Human Cyclophilin D Complexed with an Inhibitor at room temperature","GNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","4ZSD"
"4ZSE",,"X-RAY DIFFRACTION",2.1,41.47,"VAPOR DIFFUSION, HANGING DROP",6,"25% PEG 3350, 100mM Bis-Tris pH 6.0",293,,,"4ZSE",153.08,"1.97","1.97","Crystal structure of EGFR 696-1022 T790M/V948R, crystal form II","GSTSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","4ZSE"
"4ZSG",,"X-RAY DIFFRACTION",2.89,57.49,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",293,"10.1107/S2059798316004502",,"4ZSG",40.51,"1.79","1.79","MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR","VTFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARRE","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","4ZSG"
"4ZSJ",,"X-RAY DIFFRACTION",3.04,59.5,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",293,"10.1107/S2059798316004502","4R0","4ZSJ",40.09,"2.48","2.48","MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR","DVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARRE","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","4ZSJ"
"4ZSL",,"X-RAY DIFFRACTION",3.05,59.63,"VAPOR DIFFUSION, HANGING DROP",6.25,"4-6 % w/v PEG 6000, 0.1 M MES, 5 mM DTT",297,"10.1107/S2059798316004502",,"4ZSL",39.95,"2.25","2.25","MITOGEN ACTIVATED PROTEIN KINASE 7 IN COMPLEX WITH INHIBITOR","DEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARRE","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","4ZSL"
"4ZSM",,"X-RAY DIFFRACTION",2.69,54.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, SODIUM CACODYLATE, AMMONIUM SULFATE",277,"10.1016/j.bmc.2015.04.062","4RW","4ZSM",98.37,"1.96","1.96","BACE crystal structure with bicyclic aminothiazine fragment","MAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZSM"
"4ZSP",,"X-RAY DIFFRACTION",2.66,53.77,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, sodium cacodylate, ammonium sulfate",277,"10.1016/j.bmc.2015.04.062","4RZ","4ZSP",98.77,"1.91","1.91","BACE crystal structure with bicyclic aminothiazine inhibitor","MAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZSP"
"4ZSQ",,"X-RAY DIFFRACTION",2.69,54.2,"VAPOR DIFFUSION, HANGING DROP",,"PEG8000, sodium cacodylate, ammonium sulfate",277,"10.1016/j.bmc.2015.04.062","4RX","4ZSQ",98.86,"2.3","2.3","BACE crystal structure with tricyclic aminothiazine inhibitor","MAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZSQ"
"4ZSR",,"X-RAY DIFFRACTION",2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",7.4,"PEG8000, sodium cacodylate, ammonium sulfate",277,"10.1016/j.bmc.2015.04.062","4RY","4ZSR",98.67,"1.65","1.65","BACE crystal structure with tricyclic aminothiazine inhibitor","MAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","4ZSR"
"4ZT1",,"X-RAY DIFFRACTION",3.46,64.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"TRIS 0.1 M, ammonium sulfate 1.3 M, calcium chloride 50 mM",298,"10.1021/acs.jmedchem.5b01487",,"4ZT1",45.94,"1.92","1.92","Crystal structure of human E-Cadherin (residues 3-213) in x-dimer conformation","VIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTD","Homo sapiens","CDH1, CDHE, UVO","Cadherin-1","1","4ZT1"
"4ZTE",,"X-RAY DIFFRACTION",3.44,64.25,"VAPOR DIFFUSION, HANGING DROP",8.5,"TRIS 0.1 M, ammonium sulfate 1.3 M, calcium chloride 80 mM",298,"10.1021/acs.jmedchem.5b01487",,"4ZTE",47.09,"2.13","2.13","Crystal structure of human E-Cadherin (residues 3-213) in complex with a peptidomimetic inhibitor","VIPPISCPENEKGPFPKNLVQIKSNKDKEGKVFYSITGQGADTPPVGVFIIERETGWLKVTEPLDRERIATYTLFSHAVSSNGNAVEDPMEILITVTDQNDNKPEFTQEVFKGSVMEGALPGTSVMEVTATDADDDVNTYNAAIAYTILSQDPELPDKNMFTINRNTGVISVVTTGLDRESFPTYTLVVQAADLQGEGLSTTATAVITVTD","Homo sapiens","CDH1, CDHE, UVO","Cadherin-1","1","4ZTE"
"4ZTH",,"X-RAY DIFFRACTION",2.16,43.17,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M Ammonium Acetate, 0.1 BisTris (pH 5.5), 17% PEG 10,000, VAPOR DIFFUSION, SITTING DROP, temperature 295K",295,"10.1021/acs.jmedchem.9b00058","GG5","4ZTH",44.54,"2.15","2.15","Structure of human p38aMAPK-arylpyridazinylpyridine fragment complex used in inhibitor discovery","MHHHHHHSSGVDLGTENLYFQSNASQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","4ZTH"
"4ZTL",,"X-RAY DIFFRACTION",2.65,53.65,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1021/acsmedchemlett.5b00279","4S1","4ZTL",137.49,"2.39","2.39","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","4ZTL"
"4ZTM",,"X-RAY DIFFRACTION",2.64,53.39,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1021/acsmedchemlett.5b00279","4S2","4ZTM",137.54,"2.66","2.66","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","4ZTM"
"4ZTN",,"X-RAY DIFFRACTION",2.62,53.01,"VAPOR DIFFUSION, HANGING DROP",6.4,"1.80 to 2.0 M Sodium Malonate, 0.2 M Sodium Acetate, 25 mM Hexamminecobalt(III)chloride, 0.05%w/v Pluronic-F-68",289,"10.1021/acsmedchemlett.5b00279","4S3","4ZTN",137.47,"2.23","2.23","Irak4-inhibitor co-structure","VSDTRFHSFSFYELKNVTNNFDERPISVGGNKMGEGGFGVVYKGYVNNTTVAVKKLAAMVDITTEELKQQFDQEIKVMAKCQHENLVELLGFSSDGDDLCLVYVYMPNGSLLDRLSCLDGTPPLSWHMRCKIAQGAANGINFLHENHHIHRDIKSANILLDEAFTAKISDFGLARASEKFAQTVMTSRIVGTTAYMAPEALRGEITPKSDIYSFGVVLLEIITGLPAVDEHREPQLLLDIKEEIEDEEKTIEDYIDKKMNDADSTSVEAMYSVASQCLHEKKNKRPDIKKVQQLLQEMTAS","Homo sapiens","IRAK4","Interleukin-1 receptor-associated kinase 4","1","4ZTN"
"4ZTQ",,"X-RAY DIFFRACTION",2.58,52.41,"VAPOR DIFFUSION, HANGING DROP",,"0.3 M Ammonium citrate dibasic, 
25% PEG 3350",292,"10.1021/acs.jmedchem.6b00709","4RM","4ZTQ",33.43,"2.8","2.8","Human Aurora A catalytic domain bound to FK932","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","4ZTQ"
"4ZTR",,"X-RAY DIFFRACTION",2.6,52.74,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M Tris pH 8.0, 
28% PEG 4k",292,"10.1021/acs.jmedchem.6b00709","4RJ","4ZTR",33.41,"2.85","2.85","Human Aurora A catalytic domain bound to FK1141","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","4ZTR"
"4ZTS",,"X-RAY DIFFRACTION",2.81,56.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"5% MPD, 0.1 M Hepes pH 7.5, 10% PEG 10K",292,"10.1021/acs.jmedchem.6b00709","4RK","4ZTS",33.55,"2.9","2.9","Human Aurora A catalytic domain bound to FK1142","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNCQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","4ZTS"
"4ZUK",,"X-RAY DIFFRACTION",2.24,45.05,"VAPOR DIFFUSION, SITTING DROP",,"Protein stock solution contained 3 mg/mL ALDH7A1 and 5 mM NAD+.  The reservoir contained 0.2 M ammonium sulfate and 20% PEG 3350, 0.1 mM Bis-Tris pH 6.5.",293,"10.1021/acs.biochem.5b00754",,"4ZUK",451.82,"2.001","2.001","Structure ALDH7A1 complexed with NAD+","GHMSTLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQRCTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ","Homo sapiens","ALDH7A1, ATQ1","Alpha-aminoadipic semialdehyde dehydrogenase","1","4ZUK"
"4ZUL",,"X-RAY DIFFRACTION",2.23,44.82,"VAPOR DIFFUSION, SITTING DROP",8,"The reservoir contained 0.1 M MgCl2, 0.1 M sodium acetate trihydrate, 0.1 M Tris-HCl pH 8.0, and 20% w/v PEG 4000.   The protein stock solution contained 3 mg/mL ALDH7A1 and 50 millimolar alpha-aminoadipate.",293,"10.1021/acs.biochem.5b00754",,"4ZUL",447.69,"1.76","1.76","Structure ALDH7A1 complexed with alpha-aminoadipate","GHMSTLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQRCTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ","Homo sapiens","ALDH7A1, ATQ1","Alpha-aminoadipic semialdehyde dehydrogenase","1","4ZUL"
"4ZV8",,"X-RAY DIFFRACTION",3.22,62,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, pH 7.5, 20% w/v Polyethylene glycol 10,000",291,"10.1021/acs.biochem.5b01330",,"4ZV8",56.41,"2.24","2.24","Structure of CYP2B6 (Y226H/K262R) with additional mutation Y244W in complex with alpha-Pinene","MAKKTSSKGKLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNRWKVLRRFSVTTMRDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKHFPGAHRQVYKNLQEINAWIGHSVEKHRETLDPSAPRDLIDTYLLHMEKEKSNAHSEFSHQNLNLNTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKPDAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKIPPTYQIRFLPRHHHH","Homo sapiens","CYP2B6","Cytochrome P450 2B6","1","4ZV8"
"4ZVJ",,"X-RAY DIFFRACTION",2.09,41.28,"VAPOR DIFFUSION, SITTING DROP",7.5,"35% PEG 2000 MME, 50 mM KBr, Tris pH 7.5",277,"10.1016/j.bbadis.2014.10.010",,"4ZVJ",54.52,"1.6996","1.6996","Structure of human triose phosphate isomerase K13M","GDITHMAPSRKFFVGGNWMMNGRKQSLGELIGTLNAAKVPADTEVVCAPPTAYIDFARQKLDPKIAVAAQNCYKVTNGAFTGEISPGMIKDCGATWVVLGHSERRHVFGESDELIGQKVAHALAEGLGVIACIGEKLDEREAGITEKVVFEQTKVIADNVKDWSKVVLAYEPVWAIGTGKTATPQQAQEVHEKLRGWLKSNVSDAVAQSTRIIYGGSVTGATCKELASQPDVDGFLVGGASLKPEFVDIINAKQ","Homo sapiens","TPI1, TPI","Triosephosphate isomerase","1","4ZVJ"
"4ZVK",,"X-RAY DIFFRACTION",2.42,49.15,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M Ammonium sulfate, 0.1M Hepes",298,"10.1021/acs.biochem.5b00884",,"4ZVK",54.34,"1.867","1.867","Reduced quinone reductase 2 in complex with ethidium","AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","4ZVK"
"4ZVL",,"X-RAY DIFFRACTION",2.41,48.88,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M Ammonium sulfate, 0.1M Hepes",298,"10.1021/acs.biochem.5b00884","AO","4ZVL",54,"1.899","1.899","Oxidized quinone reductase 2 in complex with acridine orange","AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","4ZVL"
"4ZVM",,"X-RAY DIFFRACTION",2.42,49.09,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M Ammonium sulfate, 0.1M Hepes pH 7.0",298,"10.1021/acs.biochem.5b00884","DM2","4ZVM",54.49,"1.973","1.973","Oxidized quinone reductase 2 in complex with doxorubicin","AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","4ZVM"
"4ZVN",,"X-RAY DIFFRACTION",2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M Ammonium sulfate, 0.1M Hepes",298,"10.1021/acs.biochem.5b00884","AO","4ZVN",54,"1.866","1.866","Reduced quinone reductase 2 in complex with acridine orange","AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","4ZVN"
"4ZVV",,"X-RAY DIFFRACTION",2.23,44,"VAPOR DIFFUSION, SITTING DROP",7,"PEG3350, malonate pH 7.0",293,"10.1038/nchembio.2143","GN0","4ZVV",152.26,"2.2","2.2","Lactate dehydrogenase A in complex with a trisubstituted piperidine-2,4-dione inhibitor GNE-140","MATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF","Homo sapiens","LDHA, PIG19","L-lactate dehydrogenase A chain","1","4ZVV"
"4ZVW",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, SITTING DROP",,"The reservoir contained 0.2 M ammonium sulfate, 20% (w/v) polyethylene glycol (PEG) 3350, and 0.1 mM Bis-Tris pH 6.5.",293,"10.1021/acs.biochem.5b00754",,"4ZVW",444.96,"2.4","2.4","Structure of apo human ALDH7A1 in space group C2","GHMSTLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQRCTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ","Homo sapiens","ALDH7A1, ATQ1","Alpha-aminoadipic semialdehyde dehydrogenase","1","4ZVW"
"4ZVX",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",,"The reservoir contained 0.1 M Hepes pH 7.5, 0.1 M magnesium chloride hexahydrate, and 20% (w/v) PEG 3350.",293,"10.1021/acs.biochem.5b00754",,"4ZVX",111.24,"1.9","1.9","Structure of apo human ALDH7A1 in space group P4212","GHMSTLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQRCTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ","Homo sapiens","ALDH7A1, ATQ1","Alpha-aminoadipic semialdehyde dehydrogenase","1","4ZVX"
"4ZVY",,"X-RAY DIFFRACTION",2.27,45.73,"VAPOR DIFFUSION, SITTING DROP",,"The reservoir contained 0.1 M Hepes pH 7.5, 0.1 M magnesium chloride hexahydrate, and 20% (w/v) PEG 3350.",293,"10.1021/acs.biochem.5b00754",,"4ZVY",111.9,"1.9","1.9","Structure of human ALDH7A1 complexed with NAD+ in space group P4212","GHMSTLLINQPQYAWLKELGLREENEGVYNGSWGGRGEVITTYCPANNEPIARVRQASVADYEETVKKAREAWKIWADIPAPKRGEIVRQIGDALREKIQVLGSLVSLEMGKILVEGVGEVQEYVDICDYAVGLSRMIGGPILPSERSGHALIEQWNPVGLVGIITAFNFPVAVYGWNNAIAMICGNVCLWKGAPTTSLISVAVTKIIAKVLEDNKLPGAICSLTCGGADIGTAMAKDERVNLLSFTGSTQVGKQVGLMVQERFGRSLLELGGNNAIIAFEDADLSLVVPSALFAAVGTAGQRCTTARRLFIHESIHDEVVNRLKKAYAQIRVGNPWDPNVLYGPLHTKQAVSMFLGAVEEAKKEGGTVVYGGKVMDRPGNYVEPTIVTGLGHDASIAHTETFAPILYVFKFKNEEEVFAWNNEVKQGLSSSIFTKDLGRIFRWLGPKGSDCGIVNVNIPTSGAEIGGAFGGEKHTGGGRESGSDAWKQYMRRSTCTINYSKDLPLAQGIKFQ","Homo sapiens","ALDH7A1, ATQ1","Alpha-aminoadipic semialdehyde dehydrogenase","1","4ZVY"
"4ZVZ",,"X-RAY DIFFRACTION",1.97,37.65,"VAPOR DIFFUSION, HANGING DROP",8,"25% MPD, 6% PEG, 10 mM Tris, pH 8.0",289,"10.1016/j.bcp.2016.03.011",,"4ZVZ",153.26,"2","2","Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid","GASMTIEDEYSGPKLEDGKVTISFMKELMQWYKDQKKLHRKCAYQILVQVKEVLSKLSTLVETTLKETEKITVCGDTHGQFYDLLNIFELNGLPSETNPYIFNGDFVDRGSFSVEVILTLFGFKLLYPDHFHLLRGNHETDNMNQIYGFEGEVKAKYTAQMYELFSEVFEWLPLAQCINGKVLIMHGGLFSEDGVTLDDIRKIERNRQPPDSGPMCDLLWSDPQPQNGRSISKRGVSCQFGPDVTKAFLEENNLDYIIRSHEVKAEGYEVAHGGRCVTVFSAPNYCDQMGNKASYIHLQGSDLRPQFHQFTAVPHPNVKPMAYANTLLQLGMM","Homo sapiens","PPP5C, PPP5","Serine/threonine-protein phosphatase 5","1","4ZVZ"
"4ZW1",,"X-RAY DIFFRACTION",2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium phosphate dibasic, 20% PEG 3350",293,,"4V1","4ZW1",17.22,"1.75","1.75","Crystal structure of hBRD4 in complex with BL-BI06 reveals a novel synthesized inhibitor that induces Beclin1-independent/ATG5-dependent autophagic cell death in breast cancer","MHHHHHHLEVLFQGMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","4ZW1"
"4ZW9",,"X-RAY DIFFRACTION",2.53,51.43,"LIPIDIC CUBIC PHASE",6.8,"28%(v/v) PEG400, 0.1M HEPES, 50 mM ammonium citrate",293,"10.1038/nature14655",,"4ZW9",57.9,"1.502","1.502","Crystal structure of human GLUT3 bound to D-glucose in the outward-occluded conformation at 1.5 angstrom","MHHHHHHHHHHSGDEVDAGSGHMGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFITKTLTDKGNAPPSEVLLTSLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLIVNLLAVTGGCFMGLCKVAKSVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVVGILVAQIFGLEFILGSEELWPLLLGFTILPAILQSAALPFCPESPRFLLINRKEEENAKQILQRLWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGINAVFYYSTGIFKDAGVQEPIYATIGAGVVNTIFTVVSLFLVERAGRRTLHMIGLGGMAFCSTLMTVSLLLKDNYNGMSFVCIGAILVFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHYLGAYVFIIFTGFLITFLAFTFFKVPETRGRTFEDITRAFEGQAHGADRSGKDGVMEMNSIEPAKETTTNV","Homo sapiens","SLC2A3, GLUT3","Solute carrier family 2, facilitated glucose transporter member 3","1","4ZW9"
"4ZWB",,"X-RAY DIFFRACTION",2.68,54.18,"LIPIDIC CUBIC PHASE",6.5,"38-40% PEG 400, 100 mM Mg (CHO2)2, 50 mM maltose, 100 mM ADA",293,"10.1038/nature14655",,"4ZWB",56.82,"2.4","2.4","Crystal structure of maltose-bound human GLUT3 in the outward-occluded conformation at 2.4 angstrom","MHHHHHHHHHHSGDEVDAGSGHMGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFITKTLTDKGNAPPSEVLLTSLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLIVNLLAVTGGCFMGLCKVAKSVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVVGILVAQIFGLEFILGSEELWPLLLGFTILPAILQSAALPFCPESPRFLLINRKEEENAKQILQRLWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGINAVFYYSTGIFKDAGVQEPIYATIGAGVVNTIFTVVSLFLVERAGRRTLHMIGLGGMAFCSTLMTVSLLLKDNYNGMSFVCIGAILVFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHYLGAYVFIIFTGFLITFLAFTFFKVPETRGRTFEDITRAFEGQAHGADRSGKDGVMEMNSIEPAKETTTNV","Homo sapiens","SLC2A3, GLUT3","Solute carrier family 2, facilitated glucose transporter member 3","1","4ZWB"
"4ZWC",,"X-RAY DIFFRACTION",3.85,68.03,"LIPIDIC CUBIC PHASE",6.9,"34% PEG 400, 400 mM (NH4)2HPO4, 50 mM Maltose, 100 mM ADA",293,"10.1038/nature14655",,"4ZWC",114.7,"2.6","2.6","Crystal structure of maltose-bound human GLUT3 in the outward-open conformation at 2.6 angstrom","MHHHHHHHHHHSGDEVDAGSGHMGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFITKTLTDKGNAPPSEVLLTSLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLIVNLLAVTGGCFMGLCKVAKSVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVVGILVAQIFGLEFILGSEELWPLLLGFTILPAILQSAALPFCPESPRFLLINRKEEENAKQILQRLWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGINAVFYYSTGIFKDAGVQEPIYATIGAGVVNTIFTVVSLFLVERAGRRTLHMIGLGGMAFCSTLMTVSLLLKDNYNGMSFVCIGAILVFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHYLGAYVFIIFTGFLITFLAFTFFKVPETRGRTFEDITRAFEGQAHGADRSGKDGVMEMNSIEPAKETTTNV","Homo sapiens","SLC2A3, GLUT3","Solute carrier family 2, facilitated glucose transporter member 3","1","4ZWC"
"4ZWE",,"X-RAY DIFFRACTION",2.46,49.9,"BATCH MODE",7.4,"SPG buffer, PEG 1500",298,"10.1074/jbc.M115.677435",,"4ZWE",244.62,"2.81","2.81","Crystal structure of the dGTP-bound catalytic core of SAMHD1 T592V mutant","DTMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCRNLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQDGDVIAPLIVPQKKEWNDSTSVQNPTRLREASKSRVQLFKDDPM","Homo sapiens","SAMHD1, MOP5","Deoxynucleoside triphosphate triphosphohydrolase SAMHD1","1","4ZWE"
"4ZWG",,"X-RAY DIFFRACTION",2.02,39.14,"BATCH MODE",7.4,"SPG buffer, PEG 1500",298,"10.1074/jbc.M115.677435",,"4ZWG",244.65,"2.3","2.3","Crystal structure of the GTP-dATP-bound catalytic core of SAMHD1 phosphomimetic T592E mutant","DTMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCRNLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQDGDVIAPLIEPQKKEWNDSTSVQNPTRLREASKSRVQLFKDDPM","Homo sapiens","SAMHD1, MOP5","Deoxynucleoside triphosphate triphosphohydrolase SAMHD1","1","4ZWG"
"4ZWI",,"X-RAY DIFFRACTION",2.1,41.51,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl, pH 7.8",293,"10.1002/pro.2771",,"4ZWI",30.03,"1.6","1.6","Surface Lysine Acetylated Human Carbonic Anhydrase II in Complex with a Sulfamate-Based Inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZWI"
"4ZWX",,"X-RAY DIFFRACTION",2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCL, pH 7.8",293,"10.1021/acs.jmedchem.5b00845","5KZ","4ZWX",29.64,"1.696","1.696","Engineered Carbonic Anhydrase IX mimic in complex with glucosyl sulfamate inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZWX"
"4ZWY",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",293,"10.1021/acs.jmedchem.5b00845","4SN","4ZWY",29.67,"1.5","1.5","Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZWY"
"4ZWZ",,"X-RAY DIFFRACTION",2.06,40.32,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl pH 7.8",293,"10.1021/acs.jmedchem.5b00845",,"4ZWZ",29.52,"1.62","1.62","Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZWZ"
"4ZX0",,"X-RAY DIFFRACTION",2.12,42.11,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl",293,"10.1021/acs.jmedchem.5b00845",,"4ZX0",29.58,"1.6","1.6","Human Carbonic Anhydrase II in complex with a glucosyl sulfamate inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZX0"
"4ZX1",,"X-RAY DIFFRACTION",2.09,41.28,"VAPOR DIFFUSION, HANGING DROP",7.8,"1.6 M sodium citrate, 50 mM Tris-HCl",293,"10.1021/acs.jmedchem.5b00845",,"4ZX1",29.51,"1.501","1.501","Engineered Carbonic Anhydrase IX mimic in complex with a glucosyl sulfamate inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAECVTWIVLKQPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","4ZX1"
"4ZX2",,"X-RAY DIFFRACTION",2.36,47.95,"VAPOR DIFFUSION, HANGING DROP",8,"25% MPD, 6% PEG, 10 mM Tris, pH 8.0",289,"10.1016/j.bcp.2016.03.011",,"4ZX2",38.43,"1.23","1.23","Co-crystal structures of PP5 in complex with 5-methyl-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic acid","GASMTIEDEYSGPKLEDGKVTISFMKELMQWYKDQKKLHRKCAYQILVQVKEVLSKLSTLVETTLKETEKITVCGDTHGQFYDLLNIFELNGLPSETNPYIFNGDFVDRGSFSVEVILTLFGFKLLYPDHFHLLRGNHETDNMNQIYGFEGEVKAKYTAQMYELFSEVFEWLPLAQCINGKVLIMHGGLFSEDGVTLDDIRKIERNRQPPDSGPMCDLLWSDPQPQNGRSISKRGVSCQFGPDVTKAFLEENNLDYIIRSHEVKAEGYEVAHGGRCVTVFSAPNYCDQMGNKASYIHLQGSDLRPQFHQFTAVPHPNVKPMAYANTLLQLGMM","Homo sapiens","PPP5C, PPP5","Serine/threonine-protein phosphatase 5","1","4ZX2"
"4ZXT",,"X-RAY DIFFRACTION",2.28,46.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.1-1.3 M ammonium sulfate, 2% PEG500 MME, 0.1 M HEPES/NaOH, crystals soaked in precipitant solution containing 2.5 mM catechol in 2.5% DMSO for one week",293,"10.18632/oncotarget.9223",,"4ZXT",42.11,"2","2","Complex of ERK2 with catechol","MAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","4ZXT"
"4ZXX",,"X-RAY DIFFRACTION",3.93,68.7,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1021/acs.jmedchem.5b00788","4T0","4ZXX",35.05,"2.6","2.6","FACTOR VIIA IN COMPLEX WITH THE INHIBITOR N-{3-[(2R)-1-{(2R)-2-[(1-aminoisoquinolin-6-yl)amino]-2-phenylacetyl}pyrrolidin-2-yl]-4-(propan-2-ylsulfonyl)phenyl}acetamide","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VIIa heavy chain","1","4ZXX"
,,,,,,,,,,,,,,,,"ICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VIIa light chain","2","4ZXX"
"4ZXY",,"X-RAY DIFFRACTION",3.52,65.05,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1021/acs.jmedchem.5b00788","4T1","4ZXY",35.02,"2.06","2.06","FACTOR VIIA IN COMPLEX WITH THE INHIBITOR (2R)-2-[(1-aminoisoquinolin-6-yl)amino]-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VIIa heavy chain","1","4ZXY"
,,,,,,,,,,,,,,,,"ICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VIIa light chain","2","4ZXY"
"4ZY4",,"X-RAY DIFFRACTION",2.4,48.74,"VAPOR DIFFUSION, SITTING DROP",8,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292,"10.1021/acs.jmedchem.5b00572","4T3","4ZY4",68.03,"2.6","2.6","Crystal structure of P21 activated kinase 1 in complex with an inhibitor compound 4","GSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNHGNS","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZY4"
"4ZY5",,"X-RAY DIFFRACTION",2.41,49.02,"VAPOR DIFFUSION, SITTING DROP",8,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292,"10.1021/acs.jmedchem.5b00572","4T5","4ZY5",68.07,"2.35","2.35","Crystal Structure of p21-activated kinase 1 in complex with an inhibitor compound 17","GSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNHGNS","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZY5"
"4ZY6",,"X-RAY DIFFRACTION",2.44,49.53,"VAPOR DIFFUSION, SITTING DROP",8,"25% PEG 3500, 0.2M Ammonium Sulfate and 0.1M Tris pH 8",292,"10.1021/acs.jmedchem.5b00572","4T6","4ZY6",68,"2.15","2.15","Crystal structure of P21-activated kinase 1 in complex with an inhibitor compound 29","GSDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNHGNS","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","4ZY6"
"4ZYA",,"X-RAY DIFFRACTION",1.83,32.92,"VAPOR DIFFUSION, HANGING DROP",,"zinc sulfate, MES, PEG 550 MME",295,"10.1016/j.ijbiomac.2018.08.171",,"4ZYA",18.35,"1.65","1.65","The N-terminal extension domain of human asparaginyl-tRNA synthetase","GHMAELYVSDREGSDATGDGTKEKPFKTGLKALMTVGKEPFPTIYVDSQKENERWNVISKSQLKNIKKMWHREQMKS","Homo sapiens","NARS, NARS1, NRS","Asparagine--tRNA ligase, cytoplasmic","1","4ZYA"
"4ZYC",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",8,"reservoir: 2.2M ammonium sulphate, 0.2M KNa tartrate, protein: 10mg/ml Hdm2 in 50mM TRIS pH 8.0, 200mM NaCl, 1mM TCEP, 10% glycerol, drop: 0.2ul reservoir + 0.2ul protein",298,"10.1016/j.bmcl.2015.06.058","4SS","4ZYC",35.21,"1.95","1.95","Discovery of dihydroisoquinolinone derivatives as novel inhibitors of the p53-MDM2 interaction with a distinct binding mode: Hdm2 (MDM2) complexed with cpd5","GSQIPASEQETLVRPKPELLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","4ZYC"
"4ZYF",,"X-RAY DIFFRACTION",2.17,43.22,"VAPOR DIFFUSION, HANGING DROP",4.5,"reservoir: 2M AmSulfate, 0.1M cictric acid, pH4.5, protein: 7mg/ml Hdm2 in 50mM TRIS pH8.0, 200mM NaCl, 1mM TCEP, 10% glycerol, drop: 1ul reservoir + 1ul protein",298,"10.1021/acs.jmedchem.5b00810","4T4","4ZYF",11.85,"1.8","1.8","Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with NVP-CGM097","GSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","4ZYF"
"4ZYI",,"X-RAY DIFFRACTION",2.16,43,"VAPOR DIFFUSION, HANGING DROP",4.7,"reservoir: 2.2M AmmoniumSulfate, 0.1M cictric acid, pH4.7. protein: 7mg/ml Hdm2 in 50mM TRIS pH8.0, 200mM NaCl, 1mM TCEP, 10% glycerol. drop: 1ul reservoir + 1ul protein",298,"10.1021/acs.jmedchem.5b00810","4TH","4ZYI",11.75,"1.67","1.67","Discovery of NVP-CGM097 - a highly potent and selective MDM2 inhibitor undergoing phase 1 clinical trials in p53wt tumors: Hdm2 (MDM2) complexed with cpd2","GSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","4ZYI"
"4ZYK",,"X-RAY DIFFRACTION",2.54,51.58,"VAPOR DIFFUSION, HANGING DROP",4.5,"8.69mg/mL AM14Fab, 0.1M Sodium acetate pH4.5, 0.2M ammonium sulfate, 25% PEG4000",293,"10.1371/journal.ppat.1005035",,"4ZYK",96.52,"2","2","Crystal Structure of Quaternary-Specific RSV-Neutralizing Human Antibody AM14","EVQLVESGGGVVQPGRSLRLSCAASGFSFSHYAMHWVRQAPGKGLEWVAVISYDGENTYYADSVKGRFSISRDNSKNTVSLQMNSLRPEDTALYYCARDRIVDDYYYYGMDVWGQGATVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"AM14 Fab heavy chain","1","4ZYK"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCQASQDIKKYLNWYHQKPGKVPELLMHDASNLETGVPSRFSGRGSGTDFTLTISSLQPEDIGTYYCQQYDNLPPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"AM14 light chain","2","4ZYK"
"4ZYO",,"X-RAY DIFFRACTION",7.94,,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Tris-HCl (pH 8.5), 30-35% (v/v) PEG400, 220 mM sodium citrate",277,"10.1038/nsmb.3049",,"4ZYO",38.47,"3.25","3.25","Crystal Structure of Human Integral Membrane Stearoyl-CoA Desaturase with Substrate","GGSDIRPDIKDDIYDPTYADAAGPSPKVEYVWRNIILMSLLHLGALYGITLIPTCKFYTWLWGVFYYFVSALGITAGAHRLWSHRSYKARLPLRLFLIIANTMAFQNDVYEWARDHRAHHKFSETHADPHNSRRGFFFSHVGWLLVRKHPAVKEKGSTLDLSDLEAEKLVMFQRRYYKPGLLMMCFILPTLVPWYFWGETFQNSVFVATFLRYAVVLNATWLVNSAAHLFGYRPYDKNISPRENILVSLGAVGEGFHNYHHSFPYDYSASEYRWHINFTTFFIDCMAALGLAYDRKKVSKAAILARIKRTGDGNYKSG","Homo sapiens","SCD, FADS5, SCD1, SCDOS","Acyl-CoA desaturase","1","4ZYO"
"4ZYT",,"X-RAY DIFFRACTION",3.85,68.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3Y9","4ZYT",23.55,"1.702","1.702","Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl]benzoyl}-L-glutamic acid (AGF23)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYT"
"4ZYU",,"X-RAY DIFFRACTION",3.88,68.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3YA","4ZYU",23.57,"1.95","1.95","Human GAR transformylase in complex with GAR and N-{4-[4-(2-Amino-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-6-yl)-butyl]benzoyl}-L-glutamic acid (AGF50)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYU"
"4ZYV",,"X-RAY DIFFRACTION",3.59,65.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","G71","4ZYV",23.56,"2.053","2.053","Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)butyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF71)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYV"
"4ZYW",,"X-RAY DIFFRACTION",3.86,68.17,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","G94","4ZYW",23.54,"2.05","2.05","Human GAR transformylase in complex with GAR and N-({5-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)propyl]thiophen-2-yl}carbonyl)-L-glutamic acid (AGF94)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYW"
"4ZYX",,"X-RAY DIFFRACTION",3.88,68.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3YB","4ZYX",23.56,"1.65","1.65","Human GAR transformylase in complex with GAR and (S)-2-({4-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-2-carbonyl}amino)pentanedioic acid (AGF117)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYX"
"4ZYY",,"X-RAY DIFFRACTION",3.88,68.3,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3YC","4ZYY",23.56,"1.85","1.85","Human GAR transformylase in complex with GAR and (S)-2-({5-[4-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]-pyrimidin-6-yl)butyl]thiophene-3-carbonyl}amino)pentanedioic acid (AGF118)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYY"
"4ZYZ",,"X-RAY DIFFRACTION",3.89,68.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3YD","4ZYZ",23.5,"1.6","1.6","Human GAR transformylase in complex with GAR and (S)-2-(7-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)heptanamido)pentanedioic acid (AGF145)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZYZ"
"4ZZ0",,"X-RAY DIFFRACTION",3.83,67.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.biochem.6b00412","3YE","4ZZ0",23.52,"1.65","1.65","Human GAR transformylase in complex with GAR and (S)-2-(8-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)octanamido)pentanedioic acid (AGF147)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZZ0"
"4ZZ1",,"X-RAY DIFFRACTION",3.86,68.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.jmedchem.5b00801","3YF","4ZZ1",23.54,"1.351","1.351","HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({4-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-2-CARBONYL}-AMINO)-PENTANEDIOIC ACID","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZZ1"
"4ZZ2",,"X-RAY DIFFRACTION",3.9,68.47,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.jmedchem.5b00801","3YG","4ZZ2",23.54,"1.451","1.451","HUMAN GAR TRANSFORMYLASE IN COMPLEX WITH GAR AND (S)-2-({5-[3-(2-AMINO-4-OXO-4,7-DIHYDRO-3H-PYRROLO[2,3-D]PYRIMIDIN-6-YL)-PROPYL]-THIOPHENE-3-CARBONYL}-AMINO)-PENTANEDIOIC ACID","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZZ2"
"4ZZ3",,"X-RAY DIFFRACTION",3.92,68.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"18 % PEG4000, 2 % PEG400, 0.33 M NaCl",277,"10.1021/acs.jmedchem.5b00801","4DW","4ZZ3",23.52,"2.504","2.504","Human GAR transformylase in complex with GAR and pemetrexed","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVQKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","4ZZ3"
"4ZZH",,"X-RAY DIFFRACTION",4.57,73.09,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Magnesium chloride, 0.1 M Tris pH 8.5, and 16 % w/v PEG 4000",298,"10.1038/ncomms8645",,"4ZZH",40.68,"3.1001","3.1001","SIRT1/Activator Complex","GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVGGGSGGGSQYLFLPPNRYIFHGAEVYSDSEDDV","Homo sapiens","SIRT1, SIR2L1","NAD-dependent protein deacetylase sirtuin-1","1","4ZZH"
"4ZZI",,"X-RAY DIFFRACTION",2.82,56.32,"VAPOR DIFFUSION, HANGING DROP",,"0.55 M Sodium chloride, 0.1 M MES pH 6.5, and 20 % w/v PEG 4000",298,"10.1038/ncomms8645","1NS","4ZZI",41.07,"2.7346","2.7346","SIRT1/Activator/Inhibitor Complex","GPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVGGGSGGGSQYLFLPPNRYIFHGAEVYSDSEDDV","Homo sapiens","SIRT1, SIR2L1","NAD-dependent protein deacetylase sirtuin-1","1","4ZZI"
"4ZZM",,"X-RAY DIFFRACTION",2.41,48.94,,,,,"10.1021/acs.jmedchem.5b00466","CQ6","4ZZM",41.21,"1.89","1.89","Human ERK2 in complex with an irreversible inhibitor","PEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","MITOGEN-ACTIVATED PROTEIN KINASE 1","1","4ZZM"
"4ZZN",,"X-RAY DIFFRACTION",2.36,47.97,,,,,"10.1021/acs.jmedchem.5b00466","CQ8","4ZZN",41.25,"1.33","1.33","Human ERK2 in complex with an inhibitor","PEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","MITOGEN-ACTIVATED PROTEIN KINASE 1","1","4ZZN"
"4ZZO",,"X-RAY DIFFRACTION",2.38,48.32,,,,,"10.1021/acs.jmedchem.5b00466","CQ3","4ZZO",41.26,"1.63","1.63","Human ERK2 in complex with an irreversible inhibitor","PEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNLNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","MITOGEN-ACTIVATED PROTEIN KINASE 1","1","4ZZO"
"4ZZX",,"X-RAY DIFFRACTION",2.2,44.6,,,"25% PEG4000, 0.2M MAGNESIUM CHLORIDE, 0.1 M TRIS PH 8.5, 277K",277,"10.1021/acs.jmedchem.5b00680","FSU","4ZZX",82.7,"1.65","1.65","Structure of PARP2 catalytic domain bound to an isoindolinone inhibitor","GPSLKSPLKPESQLDLRVQELIKLICNVQAMEEMMMEMKYNTKKAPLGKLTVAQIKAGYQSLKKIEDCIRAGQHGRALMEACNEFYTRIPHDFGLRTPPLIRTQKELSEKIQLLEALGDIEIAIKLVKTELQSPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAPTHSDYTMTLLDLFEVEKDGEKEAFREDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEAPITGYMFGKGIYFADMSSKSANYCFASRLKNTGLLLLSEVALGQCNELLEANPKAEGLLQGKHSTKGLGKMAPSSAHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQVRMRYLLKVQFNFLQLW","Homo sapiens","PARP2, ADPRT2, ADPRTL2","POLY [ADP-RIBOSE] POLYMERASE 2","1","4ZZX"
"4ZZY",,"X-RAY DIFFRACTION",2.54,51.2,,,"25% PEG4000, 0.2M MAGNESIUM CLORIDE, 0.1 M TRIS PH 8.5",,"10.1021/acs.jmedchem.5b00680","D7N","4ZZY",41.5,"2.2","2.2","Structure of human PARP2 catalytic domain bound to an isoindolinone inhibitor","GPSLKSPLKPESQLDLRVQELIKLICNVQAMEEMMMEMKYNTKKAPLGKLTVAQIKAGYQSLKKIEDCIRAGQHGRALMEACNEFYTRIPHDFGLRTPPLIRTQKELSEKIQLLEALGDIEIAIKLVKTELQSPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAPTHSDYTMTLLDLFEVEKDGEKEAFREDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEAPITGYMFGKGIYFADMSSKSANYCFASRLKNTGLLLLSEVALGQCNELLEANPKAEGLLQGKHSTKGLGKMAPSSAHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQVRMRYLLKVQFNFLQLW","Homo sapiens","PARP2, ADPRT2, ADPRTL2","POLY [ADP-RIBOSE] POLYMERASE 2","1","4ZZY"
"4ZZZ",,"X-RAY DIFFRACTION",2.6,52.2,,,"2M AMMONIUM SULFATE, 2% PEG400 0.1 M TRIS PH 8.0, TEMPERATURE 277K",277,"10.1021/acs.jmedchem.5b00680","FSU","4ZZZ",82,"1.9","1.9","Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitor","GPLTVNPGTKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTSLW","Homo sapiens","PARP1, ADPRT, PPOL","POLY [ADP-RIBOSE] POLYMERASE 1","1","4ZZZ"
"521P",,"X-RAY DIFFRACTION",2.02,38.96,,,,,"10.1016/0092-8674(90)90018-a",,"521P",19.49,"2.6","2.6","THREE-DIMENSIONAL STRUCTURES OF H-RAS P21 MUTANTS: MOLECULAR BASIS FOR THEIR INABILITY TO FUNCTION AS SIGNAL SWITCH MOLECULES","MTEYKLVVVGAVGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTTGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQH","Homo sapiens","HRAS, HRAS1","H-RAS P21 PROTEIN","1","521P"
"5A00",,"X-RAY DIFFRACTION",2.74,54.7,,,"2M AMMONIUM SULFATE, 2% PEG400 0.1 M TRIS PH 8.0 TEMPERATURE 277K -",277,"10.1021/acs.jmedchem.5b00680","D7N","5A00",41.01,"2.75","2.75","Structure of human PARP1 catalytic domain bound to an isoindolinone inhibitor","GPLTVNPGTKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTSLW","Homo sapiens","PARP1, ADPRT, PPOL","POLY [ADP-RIBOSE] POLYMERASE 1","1","5A00"
"5A09",,"X-RAY DIFFRACTION",2.28,46.1,,,"28%PEG4000, 0.1MTRIS/HCL AT PH 8.2, 0.7MLICL",,"10.1002/cmdc.201500131","JJD","5A09",24.73,"1.81","1.81","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5A09"
"5A0A",,"X-RAY DIFFRACTION",2.28,45.98,,,"28%PEG4000,0.1MTRIS/HCL AT PH 8.2,0.7MLICL",,"10.1002/cmdc.201500131","JJS","5A0A",24.91,"1.78","1.78","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5A0A"
"5A0B",,"X-RAY DIFFRACTION",2.84,56.65,,,"15% PEG6000, 0.2M AMMONIUM CITRATE",,"10.1002/cmdc.201500131","JJX","5A0B",24.9,"2.23","2.23","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5A0B"
"5A0C",,"X-RAY DIFFRACTION",2.4,48.71,,,"0.1M MES AT PH6.5,1.2M SODIUMMALONATE",,"10.1002/cmdc.201500131","JJV","5A0C",50.28,"2.1","2.1","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5A0C"
"5A0F",,"X-RAY DIFFRACTION",2.93,58.07,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M SODIUM ACETATE, PH 5 AND 1.5 M AMMONIUM SULFATE; SITTING-DROP VAPOR-DIFFUSION AT 293.15 K",293.15,"10.1038/ncomms8807",,"5A0F",21.23,"2","2","Crystal structure of Yersinia Afp18-modified RhoA","MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQA","Homo sapiens","RHOA, ARH12, ARHA, RHO12","TRANSFORMING PROTEIN RHOA","1","5A0F"
"5A14",,"X-RAY DIFFRACTION",2.85,56.8,,7.5,"10%(W/V) PEG4000, 0.1M HEPES PH 7.5, 0.05M AMMONIUM SULPHATE",,"10.1021/acschembio.5b00398","LQ5","5A14",35.01,"2","2","Human CDK2 with type II inhibitor","XMENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5A14"
"5A15",,"X-RAY DIFFRACTION",3.1,60.3,,6,"21% PEG3350, 0.1M BIS-TRIS PH 6.0",,"10.1042/BCJ20170527",,"5A15",209.44,"2.76","2.76","Crystal structure of the BTB domain of human KCTD16","SMGSAVPNSFPEVVELNVGGQVYFTRHSTLISIPHSLLWKMFSPKRDTANDLAKDSKGRFFIDRDGFLFRYILDYLRDRQVVLPDHFPEKGRLKREAEYFQLPDLVKLLTPDEIKQSPDE","Homo sapiens","KCTD16, KIAA1317","BTB/POZ DOMAIN-CONTAINING PROTEIN KCTD16","1","5A15"
"5A19",,"X-RAY DIFFRACTION",2,39,,7.5,"0.1 M HEPES PH 7.5, 30 % PEG 600",,"10.1073/pnas.1510959113",,"5A19",44.72,"2.34","2.34","The structure of MAT2A in complex with PPNP.","MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY","Homo sapiens","MAT2A, AMS2, MATA2","S-ADENOSYLMETHIONINE SYNTHASE ISOFORM TYPE-2","1","5A19"
"5A1F",,"X-RAY DIFFRACTION",4.18,70.37,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","OGA","5A1F",56.14,"2.1","2.1","Crystal structure of the catalytic domain of PLU1 in complex with N-oxalylglycine.","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5A1F"
"5A1G",,"X-RAY DIFFRACTION",2,39,,7,"0.1 M IMIDAZOLE PH 7.0, 50 % MPD",,"10.1073/pnas.1510959113",,"5A1G",44.78,"1.83","1.83","The structure of Human MAT2A in complex with S-adenosylethionine and PPNP.","MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY","Homo sapiens","MAT2A, AMS2, MATA2","S-ADENOSYLMETHIONINE SYNTHASE ISOFORM TYPE-2","1","5A1G"
"5A1H",,"X-RAY DIFFRACTION",2.48,50.4,,9,"0.1M TRIS PH 8.4, 38% PEG3350",,,,"5A1H",102.19,"2","2","Crystal structure of human Spindlin3","MPRGNIVGCRIQHGWKDGDEPLTQWKGTVLDQVPVNPSLYLIKYDGFDCVYGLELHRDERVSSLEVLPNRVASSRISDTHLAEIMVGKAVEHIFETEEGSKNEWRGMVLAQAPVMNTWFYITYEKDPVLYMYQLLDDYKDGDLRILQDSNDSPLAEREPGEVIDSLVGKQVEYAKDDGSKRTGMVIHQVEAKPSVYFIKFDDDFHIYVYDLVKTSAENLYFQ","Homo sapiens","SPIN3","SPINDLIN-3","1","5A1H"
"5A1I",,"X-RAY DIFFRACTION",2,39.65,,7.5,"0.1 M HEPES PH 7.5, 30 % PEG 600",,"10.1073/pnas.1510959113",,"5A1I",45.28,"1.09","1.09","The structure of Human MAT2A in complex with SAM, Adenosine, Methionine and PPNP.","MNGQLNGFHEAFIEEGTFLFTSESVGEGHPDKICDQISDAVLDAHLQQDPDAKVACETVAKTGMILLAGEITSRAAVDYQKVVREAVKHIGYDDSSKGFDYKTCNVLVALEQQSPDIAQGVHLDRNEEDIGAGDQGLMFGYATDETEECMPLTIVLAHKLNAKLAELRRNGTLPWLRPDSKTQVTVQYMQDRGAVLPIRVHTIVISVQHDEEVCLDEMRDALKEKVIKAVVPAKYLDEDTIYHLQPSGRFVIGGPQGDAGLTGRKIIVDTYGGWGAHGGGAFSGKDYTKVDRSAAYAARWVAKSLVKGGLCRRVLVQVSYAIGVSHPLSISIFHYGTSQKSERELLEIVKKNFDLRPGVIVRDLDLKKPIYQRTAAYGHFGRDSFPWEVPKKLKY","Homo sapiens","MAT2A, AMS2, MATA2","S-ADENOSYLMETHIONINE SYNTHASE ISOFORM TYPE-2","1","5A1I"
"5A1K",,"X-RAY DIFFRACTION",2.67,47.3,,,"20 % POLYETHYLENE GLYCOL 3350, 100 MM BIS-TRIS PROPANE PH 7.5",,"10.1038/ncomms9254",,"5A1K",77.6,"2.9","2.9","Crystal structure of calcium-free human adseverin domains A1-A3","YHEEFARAGKQAGLQVWRIEKLELVPVPQSAHGDFYVGDAYLVLHTAKTSRGFTYRLHFWLGKECSQDESTAAAIFTVQMDDYLGGKPVQNRELQGYESNDFVSYFKGGLKYKAGGVASGLNHVLTNDLTAKRLLHVKGRRVVRATEVPLSWDSFNKGDCFIIDLGTEIYQWCGSSCNKYERLKANQVATGIRYNERKGRSELIVVEEGSEPSELIKVLGEKPELPDGGDDDDIIADISNRKMAKLYMVSDASGSMRVTVVAEENPFSMAMLLSEECFILDHGAAKQIFVWKGKDANPQERKAAMKTAEEFLQQMNYSKNTQIQVLPEGGETPIFKQFFKDWRD","Homo sapiens","SCIN, KIAA1905","ADSEVERIN","1","5A1K"
"5A1L",,"X-RAY DIFFRACTION",2.78,55.84,,,"25% PEG3350, 0.1M BIS-TRIS PH 6.5",,,,"5A1L",111.69,"2","2","Crystal structure of JmjC domain of human histone demethylase UTY with S21056a","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","UBIQUITOUSLY TRANSCRIBED TETRATRICOPEPTIDE REPEAT PROTEIN Y-LINKED TRANSCRIPT VARIANT 57","1","5A1L"
"5A1M",,"X-RAY DIFFRACTION",3.17,61.24,,,"30 % POLYETHYLENE GLYCOL 6000, 100 MM HEPES PH 7.0",,"10.1038/ncomms9254",,"5A1M",11.97,"1.81","1.81","Crystal structure of calcium-bound human adseverin domain A3","KMAKLYMVSDASGSMRVTVVAEENPFSMAMLLSEECFILDHGAAKQIFVWKGKDANPQERKAAMKTAEEFLQQMNYSKNTQIQVLPEGGETPIFKQFFKDWRDK","Homo sapiens","SCIN, KIAA1905","ADSEVERIN","1","5A1M"
"5A1P",,"X-RAY DIFFRACTION",2.26,45.5,,6.4,"6% PEG 3350, 20 MM BIS-TRIS PROPANE PH 6.4, 12 MM AMMONIUM CITRATE, 5% GLYCEROL",,"10.1021/acs.biochem.5b00510",,"5A1P",56.88,"2.5","2.5","Crystal structure of cytochrome P450 3A4 bound to progesterone and citrate","MAYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH","Homo sapiens","CYP3A4, CYP3A3","CYTOCHROME P450 3A4","1","5A1P"
"5A1R",,"X-RAY DIFFRACTION",2.36,47.36,,5,"12% PEG 3350, 4% TACSIMATE PH 5.0",,"10.1021/acs.biochem.5b00510",,"5A1R",56.69,"2.45","2.45","Crystal structure of cytochrome P450 3A4 bound to progesterone","MAYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH","Homo sapiens","CYP3A4, CYP3A3","CYTOCHROME P450 3A4","1","5A1R"
"5A2E",,"X-RAY DIFFRACTION",5.46,77.49,,6.5,"0.1M AMMONIUM SULFATE, 0.3M SODIUM FORMATE, 0.1M SODIUM CACODYLATE, 3% W/V PGA-LM, 20% MPD, PH 6.5",,"10.1016/j.str.2015.05.019",,"5A2E",40.21,"3.15","3.15","Extracellular SRCR domains of human CD6","MWLFFGITGLLTAALSGHPSPAPPDQLNTSSAESELWEPGERLPVRLTNGSSSCSGTVEVRLEASWEPACGALWDSRAAEAVCRALGCGGAEAASQLAPPTPELPPPPAAGNTSVAANATLAGAPALLCSGAEWRLCEVVEHACRSDGRRARVTCAENRALRLVDGGGACAGRVEMLEHGEWGSVCDDTWDLEDAHVVCRQLGCGWAVQALPGLHFTPGRGPIHRDQVNCSGAEAYLWDCPGLPGQHYCGHKEDAGVVCSEHQSWRLTGGADRCEGQVEVHFRGVWNTVCDSEWYPSEAKVLCQSLGCGTAVERPKGLPHSLSGRMYYSCNGEELTLSNCSWRFNNSNLCSQSLAARVLCSASRGHHHHHH","Homo sapiens","CD6","T-CELL DIFFERENTIATION ANTIGEN CD6","1","5A2E"
"5A2F",,"X-RAY DIFFRACTION",2.75,55.32,,7.5,"0.1M SODIUM HEPES, PH 7.5, 25% PEG-2000 MME",,"10.1016/j.str.2015.05.019",,"5A2F",66.61,"1.86","1.86","Two membrane distal IgSF domains of CD166","MESKGASSCRLLFCLLISATVFRPGLGWYTVNSAYGDTIIIPCRLDVPQNLMFGKWKYEKPDGSPVFIAFRSSTKKSVQYDDVPEYKDRLNLSENYTLSISNARISDEKRFVCMLVTEDNVFEAPTIVKVFKQPSKPEIVSKALFLETEQLKKLGDCISEDSYPDGNITWYRNGKVLHPLEGAVVIIFKKEMDPVTQLYTMTSTLEYKTTKADIQMPFTCSVTYYGPSGQKTIHSEQAVFDIYYPTEQVTIQVLPPKNAIKEGDNITLKCLGNGNPPPEEFLFYLPGQPEGIRSSNTYTLTDVRRNATGDYKCSLIDKKSMIASTAITVHYLDLSLNPSGEVTRQIGDALPVSCTISASRNATVVWMKDNIRLRSSPSFSSLHYQDAGNYVCETALQEVEGLKKRESLTLIVEGKPQIKMTKKTDPSGLSKTIICHVEGFPKPAIQWTITGSGSVINQTEESPYINGRYYSKIIISPEENVTLTCTAENQLERTVNSLNVSAISIPEHDEADEISDENREKVNDQAKLIVGIVVGLLLAALVAGVVYWLYMKKSKTASKHVNKDLGNMEENKKLEENNHKTEA","Homo sapiens","ALCAM, MEMD","CD166 ANTIGEN","1","5A2F"
"5A2S",,"X-RAY DIFFRACTION",2.1,40,,,"24% W/V PEG 3350, 0.2 M AMMONIUM ACETATE, 0.1 M BIS-TRIS PH 5.5, 10 MM PROLINE",,"10.1021/acsmedchemlett.5b00302","OTF","5A2S",86.55,"2.65","2.65","Potent, selective and CNS-penetrant tetrasubstituted cyclopropane class IIa histone deacetylase (HDAC) inhibitors","MGSTKPRFTTGLVYDTLMLKHQCTCGSSSSHPEHAGRIQSIWSRLQETGLRGKCECIRGRKATLEELQTVHSEAHTLLYGTNPANRQKLDSKKLLGSLASVFVRLPCGGVGVDSDTIWNEVHSAGAARLAVGCVVELVFKVATGELKNGFAVVRPPGHHAEESTPMGFCYFNSVAVAAKLLQQRLSVSKILIVDWDVHHGNGTQQAFYSDPSVLYMSLHRYDDGNFFPGSGAPDEVGTGPGVGFNVNMAFTGGLDPPMGDAEYLAAFRTVVMPIASEFAPDVVLVSSGFDAVEGHPTPLGGYNLSARCFGYLTKQLMGLAGGRIVLALEGGHDLTAICDASEACVSALLGNELDPLPEKVLQQRPNANAVRSMEKVMEIHSKYWRCLQRHHHHHH","Homo sapiens","HDAC4, KIAA0288","HISTONE DEACETYLASE 4","1","5A2S"
"5A36",,"X-RAY DIFFRACTION",2.2,43,,7.5,"30% POLYETHYLENE GLYCOL 1500, pH 7.5",,"10.1042/BCJ20160421",,"5A36",57.17,"2","2","Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.","GPYMIQEEEWDRDLLLDPAWEKQQRKTFTAWCNSHLRKAGTQIENIEEDFRNGLKLMLLLEVISGERLPKPDRGKMRFHKIANVNKALDYIASKGVKLVSIGAEEIVDGNVKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYRNVNIQNFHTSWKDGLGLCALIHRHRPDLIDYSKLNKDDPIGNINLAMEIAEKHLDIPKMLDAEDIVNTPKPDERAIMTYVSCFYHAFAGAEQAETAA","Homo sapiens","ACTN2","ALPHA-ACTININ-2","1","5A36"
"5A37",,"X-RAY DIFFRACTION",2,39,,7.5,"28% POLYETHYLENE GLYCOL 2000, pH 7.5",,"10.1042/BCJ20160421",,"5A37",57.26,"1.88","1.88","Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.","GPYMIQEEEWDRDLLLDPAWEKQQRKTFTAWCNSHLRKAGTQIENIEEDFRNGLKLMLLLEVISGERLPKPDRGKMRFHKIANVNKALDYIASKVVKLVSIGAEEIVDGNVKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYRNVNIQNFHTSWKDGLGLCALIHRHRPDLIDYSKLNKDDPIGNINLAMEIAEKHLDIPKMLDAEDIVNTPKPDERAIMTYVSCFYHAFAGAEQAETAA","Homo sapiens","ACTN2","HUMAN ALPHA-ACTININ-2","1","5A37"
"5A38",,"X-RAY DIFFRACTION",2,40,,7.5,"22% POLYETHYLENE GLYCOL 3350, pH 7.5",,"10.1042/BCJ20160421",,"5A38",57.17,"1.9","1.9","Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.","GPYMIQEEEWDRDLLLDPAWEKQQRKTFTAWCNSHLRKAGTQIENIEEDFRNGLKLMLLLEVISGERLPKPDRGKMRFHKIANVNKALDYIASKGVKLVSIGAEEIVDGNVKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYRNVNIQNFHTSWKDGLGLCALIHRHRPDLIDYSKLNKDDPIGNINLAMEIAEKHLDIPKMLDAEDIVNTPKPDERAIMTYVSCFYHAFAGAEQAETAA","Homo sapiens","ACTN2","ALPHA-ACTININ-2","1","5A38"
"5A3F",,"X-RAY DIFFRACTION",2.79,55.9,,6.5,"15% MPD, 100MM MES/NAOH (PH 6.5)",,"10.1038/nature14880",,"5A3F",343.38,"3.7","3.7","Crystal structure of the dynamin tetramer","MGNREMEELIPLVNRLQDAFSALGQSCLLELPQIAVVGGQSAGKSSVLENFVGRDFLPRGSGIVTRRPLVLQLVTSKAEYAEFLHCKGKKFTDFDEVRLEIEAETDRVTGMNKGISSIPINLRVYSPHVLNLTLIDLPGITKVPVGDQPPDIEYQIREMIMQFITRENCLILAVTPANTDLANSDALKLAKEVDPQGLRTIGVITKLDLMDEGTDARDVLENKLLPLRRGYVGVVNRSQKDIDGKKDIKAAMLAERKFFLSHPAYRHIADRMGTPHLQKVLNQQLTNHIRDTLPNFRNKLQGQLLSIEHEVEAYKNFKPEDPTRKTKALLQMVQQFAVDFEKRIEGSGDQVDTLELSGGASINRIFHERFPFEIVKMEFNEKELRREISYAIKNIHGIRTGLFTPDMAFEAIVKKQIVKLKGPSLKSVDLVIQELINTVKKCTKKLANFPRLCEETERIVANHIREREGKTKDQVLLLIDIQVSYINTNHEDFIGFANAQQRSSQVHKKTTVGNQVIRKGWLTISNIGIMKGGSKGYWFVLTAESLSWYKDDEEKEKKYMLPLDNLKVRDVEKSFMSSKHIFALFNTEQRNVYKDYRFLELACDSQEDVDSWKASLLRAGVYPDKSVAENDENGQAENFSMDPQLERQVETIRNLVDSYMSIINKCIRDLIPKTIMHLMINNVKDFINSELLAQLYSSEDQNTLMEESAEQAQRRDEMLRMYQALKEALGIIGDISTATVSTPAPPPVDDSWIQ","Homo sapiens","DNM3, KIAA0820","DYNAMIN 3","1","5A3F"
"5A3N",,"X-RAY DIFFRACTION",2.07,40.7,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1016/j.chembiol.2017.02.006","LQT","5A3N",56.84,"2","2","Crystal structure of human PLU-1 (JARID1B) in complex with KDOAM25a","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5A3N"
"5A3P",,"X-RAY DIFFRACTION",2.1,41.57,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087",,"5A3P",56.43,"2.008","2.008","Crystal structure of the catalytic domain of human PLU1 (JARID1B).","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5A3P"
"5A3T",,"X-RAY DIFFRACTION",2.07,40.7,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","MMK","5A3T",56.62,"1.9","1.9","Crystal structure of human PLU-1 (JARID1B) in complex with KDM5-C49 (2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl) isonicotinic acid).","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5A3T"
"5A3U",,"X-RAY DIFFRACTION",3.51,64.96,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.6 M SODIUM CITRATE/CITRIC ACID PH 6.5, SITTING DROP, 293K",293,"10.1371/journal.pone.0132004",,"5A3U",85.27,"3.3","3.3","HIF prolyl hydroxylase 2 (PHD2/EGLN1) in complex with 6-(5-oxo-4-(1H- 1,2,3-triazol-1-yl)-2,5-dihydro-1H-pyrazol-1-yl)nicotinic acid","GSHMASPNGQTKPLPALKLALEYIVPCMNKHGICVVDDFLGKETGQQIGDEVRALHDTGKFTDGQLVSQKSDSSKDIRGDKITWIEGKEPGCETIGLLMSSMDDLIRHCNGKLGSYKINGRTKAMVACYPGNGTGYVRHVDNPNGDGRCVTCIYYLNKDWDAKVSGGILRIFPEGKAQFADIEPKFDRLLFFWSDRRNPHEVQPAYATRYAITVWYFDADERARAKVKYLTGEKGVRVELNKPSDSVGKDVF","Homo sapiens","EGLN1, C1orf12, PNAS-118, PNAS-137","EGL NINE HOMOLOG 1","1","5A3U"
"5A3W",,"X-RAY DIFFRACTION",2.07,40.7,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","PD2","5A3W",56.35,"2","2","Crystal structure of human PLU-1 (JARID1B) in complex with Pyridine-2, 6-dicarboxylic Acid (PDCA)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5A3W"
"5A3X",,"X-RAY DIFFRACTION",2.6,53,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086","QIV","5A3X",171.45,"2.26","2.26","DYRK1A in complex with hydroxy benzothiazole fragment","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","1","5A3X"
"5A46",,"X-RAY DIFFRACTION",2.14,42.63,,,"20% PEG8000, 20MM AMMONIUM SULPHATE, 20% ETHYLENE GLYCOL, 100MM PCTP PH6.7.",,"10.1038/ncomms8877",,"5A46",88.56,"2.63","2.63","FGFR1 in complex with dovitinib","MNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1","5A46"
"5A4B",,"X-RAY DIFFRACTION",2,39,,7.5,"24% POLYETHYLENE GLYCOL 3350, pH 7.5",,"10.1042/BCJ20160421",,"5A4B",56.93,"2.01","2.01","Mutations in the Calponin homology domain of Alpha-Actinin-2 affect Actin binding and incorporation in muscle.","YMIQEEEWDRDLLLDPAWEKQQRKTFTAWCNSHLRKAGTQIENIEEDFRNGLKLMLLLEVISGERLPKPDRGKMRFHKIANVNKALDYIASKGVKLVSIGTEEIVDGNVKMTLGMIWTIILRFAIQDISVEETSAKEGLLLWCQRKTAPYRNVNIQNFHTSWKDGLGLCALIHRHRPDLIDYSKLNKDDPIGNINLAMEIAEKHLDIPKMLDAEDIVNTPKPDERAIMTYVSCFYHAFAGAEQAETAA","Homo sapiens","ACTN2","HUMAN ALPHA-ACTININ-2","1","5A4B"
"5A4C",,"X-RAY DIFFRACTION",2.68,54.15,,,,,"10.1038/ncomms8877","XOJ","5A4C",72.17,"2.09","2.09","FGFR1 ligand complex","GASEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","FIBROBLAST GROWTH FACTOR RECEPTOR 1 (FMS-RELATED TYROSINE KINASE 2, PFEIFFER SYNDROME), ISOFORM CRA_B","1","5A4C"
"5A4E",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086",,"5A4E",171.51,"2.68","2.68","DYRK1A in complex with methoxy benzothiazole fragment","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","1","5A4E"
"5A4K",,"X-RAY DIFFRACTION",2.3,46.57,,,"200 MM LI2SO4, 100 MM BISTRIS (PH 6.5), 25% W/V PEG 3350, PROTEIN CONCENTRATION: 6.1 MG/ML",,"10.1111/febs.14051","FAD","5A4K",135.99,"2.093","2.093","Crystal structure of the R139W variant of human NAD(P)H:quinone oxidoreductase","MGSSHHHHHHSSGLVPRGSHMVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFWSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK","Homo sapiens","NQO1, DIA4, NMOR1","NAD(P)H DEHYDROGENASE [QUINONE] 1","1","5A4K"
"5A4L",,"X-RAY DIFFRACTION",2.6,53,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.05M LICL; 10% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086",,"5A4L",171.46,"2.73","2.73","DYRK1A IN COMPLEX WITH FLUORO BENZOTHIAZOLE FRAGMENT","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION- REGULATED KINASE 1A","1","5A4L"
"5A4P",,"X-RAY DIFFRACTION",1.79,31,,,"17% (W/V) PEG1500, 0.1M MMT PH 6.5",,"10.1074/jbc.M115.671545",,"5A4P",38.97,"2.1","2.1","Structure of UBE2Z provides functional insight into specificity in the FAT10 conjugation machinery","MAESPTEEAATAGAGAAGPGASSVAGVVGVSGSGGGFGPPFLPDVWAAAAAAGGAGGPGSGLAPLPGLPPSAAAHGAALLSHWDPTLSSDWDGERTAPQCLLRIKRDIMSIYKEPPPGMFVVPDTVDMTKIHALITGPFDTPYEGGFFLFVFRCPPDYPIHPPRVKLMTTGNNTVRFNPNFYRNGKVCLSILGTWTGPAWSPAQSISSVLISIQSLMTENPYHNEPGFEQERHPGDSKNYNECIRHETIRVAVCDMMEGKCPCPEPLRGVMEKSFLEYYDFYEVACKDRLHLQGQTMQDPFGEKRGHFDYQSLLMRLGLIRQKVLERLHNENAEMDSDSSSSGTETDLHGSLRV","Homo sapiens","UBE2Z, HOYS7","UBIQUITIN-CONJUGATING ENZYME E2 Z","1","5A4P"
"5A4Q",,"X-RAY DIFFRACTION",2.65,53.5,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M NACL; 16% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086","Y3L","5A4Q",171.52,"2.37","2.37","DYRK1A IN COMPLEX WITH CHLORO BENZOTHIAZOLE FRAGMENT","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","1","5A4Q"
"5A4T",,"X-RAY DIFFRACTION",2.6,57,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M NACL; 16% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086","AJG","5A4T",171.48,"2.15","2.15","DYRK1A IN COMPLEX WITH NITRILE BENZOTHIAZOLE FRAGMENT","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION- REGULATED KINASE 1A","1","5A4T"
"5A54",,"X-RAY DIFFRACTION",2.6,52.7,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M KSCN; 0.1M KCL; 14% PEG 3350, PH 6.8, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",293,"10.1021/acs.jmedchem.6b01086",,"5A54",171.56,"2.63","2.63","DYRK1A IN COMPLEX WITH NITRO BENZOTHIAZOLE FRAGMENT","GASDSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADEGTNTS","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DUAL SPECIFICITY TYROSINE-PHOSPHORYLATION-REGULATED KINASE 1A","1","5A54"
"5A5I",,"X-RAY DIFFRACTION",2.57,52.08,,,,,,,"5A5I",55.32,"2","2","Cytochrome 2C9 P450 inhibitor complex","MAKKTSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPIHHHH","Homo sapiens","CYP2C9, CYP2C10","CYTOCHROME P450 2C9","1","5A5I"
"5A5J",,"X-RAY DIFFRACTION",2.57,52.08,,,,,,,"5A5J",55.38,"2.9","2.9","Cytochrome 2C9 P450 inhibitor complex","MAKKTSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGMGKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKMEKEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDPHHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPIHHHH","Homo sapiens","CYP2C9, CYP2C10","CYTOCHROME P450 2C9","1","5A5J"
"5A5N",,"X-RAY DIFFRACTION",4.03,69.48,,,"50MM BIS-TRIS PROPANE, PH7, 300MM NACL, 1MM DTT, 10% GLYCEROL",,"10.1021/acs.jmedchem.5b00772",,"5A5N",16.01,"1.95","1.95","Crystal structure of human ATAD2 bromodomain in complex with (2S)-2,6- diacetamido-N-methylhexanamide","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A5N"
"5A5O",,"X-RAY DIFFRACTION",4.04,69.57,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,"10.1021/acs.jmedchem.5b00772","J5I","5A5O",15.89,"2.04","2.04","Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 1,2-dihydroquinolin-2-one","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A5O"
"5A5P",,"X-RAY DIFFRACTION",4.03,69.48,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,"10.1021/acs.jmedchem.5b00772","JTF","5A5P",15.92,"2.03","2.03","Crystal structure of human ATAD2 bromodomain in complex with 8-2-(dimethylamino)ethylamino-3-methyl-1,2-dihydroquinolin-2-one","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A5P"
"5A5Q",,"X-RAY DIFFRACTION",4.08,69.83,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,"10.1021/acs.jmedchem.5b00772","6XC","5A5Q",16.03,"1.97","1.97","Crystal structure of human ATAD2 bromodomain in complex with 3-methyl- 8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one hydrochloride","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A5Q"
"5A5R",,"X-RAY DIFFRACTION",4.06,69.74,,,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE,20-25% PEG3350",,"10.1021/acs.jmedchem.5b00772","NP8","5A5R",16.23,"2.01","2.01","Crystal structure of human ATAD2 bromodomain in complex with 5-5- methoxypyridin-3-yl-3-methyl-8-piperidin-4-ylamino-1,2-dihydro-1,7- naphthyridin-2-one","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A5R"
"5A5S",,"X-RAY DIFFRACTION",1.91,35.52,,,"0.2NAF, 20% PEG3350",,"10.1021/acs.jmedchem.5b00772","NP8","5A5S",15.53,"1.36","1.36","NN-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 5-5-methoxypyridin-3-yl-3- methyl-8-piperidin-4-ylamino-1,2-dihydro-1,7-naphthyridin-2-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHKFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","BROMODOMAIN-CONTAINING PROTEIN 4","1","5A5S"
"5A6C",,"X-RAY DIFFRACTION",4.66,73.6,,8.25,"1.5 M AMMONIUM SULPHATE, 0.1 M TRIS-HCL PH 8.25",,"10.1038/nsmb.3152",,"5A6C",83.29,"2.901","2.901","Concomitant binding of Afadin to LGN and F-actin directs planar spindle orientation","ASCLELALEGERLCKSGDCRAGVSFFEAAVQVGTEDLKTLSAIYSQLGNAYFYLHDYAKALEYHHHDLTLARTIGDQLGEAKASGNLGNTLKVLGNFDEAIVCCQRHLDISRELNDKVGEARALYNLGNVYHAKGKSFGCPGPQDVGEFPEEVRDALQAAVDFYEENLSLVTALGDRAAQGRAFGNLGNTHYLLGNFRDAVIAHEQRLLIAKEFGDKAAERRAYSNLGNAYIFLGEFETASEYYKKTLLLARQLKDRAVEAQSCYSLGNTYTLLQDYEKAIDYHLKHLAIAQELNDRIGEGRACWSLGNAYTALGNHDQAMHFAEKHLEISREVGDQRNASYLKTQVLSPDSLFTAKFVAYNEEEEEEDCSLAG","Homo sapiens","GPSM2, LGN, MLLT4, AF6, AFDN","G-PROTEIN-SIGNALING MODULATOR 2, AFADIN","1","5A6C"
"5A6H",,"X-RAY DIFFRACTION",2.11,41.8,"VAPOR DIFFUSION",8,"EQUAL VOLUMES OF PROTEIN AND RESERVOIR (250 NL EACH) AT 8C WITH THE PROTEIN AT 7.5 MG/ML AND THE RESERVOIR BEING 2.6 M AMMONIUM SULFATE, 100 MM TRIS PH 8",281,"10.1021/acs.jmedchem.6b00443","OE2","5A6H",30.57,"1.57","1.57","Synthesis, carbonic anhydrase inhibition and protein X-ray structure of the unusual natural product primary sulfonamide Psammaplin C","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5A6H"
"5A6I",,"X-RAY DIFFRACTION",2.02,39.12,,,,,"10.1038/ncomms10787","TCW","5A6I",14.2,"1.86","1.86","V122I Transthyretin structure in complex with Tolcalpone","MGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVITNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5A6I"
"5A6N",,"X-RAY DIFFRACTION",2.49,50.6,,6.2,"23% PROPANEDIOL, 0.1M NA/K PHOSPHATE PH 6.2, 10% GLYCEROL",,"10.1002/anie.201508055","U7E","5A6N",65.65,"1.7","1.7","Crystal structure of human death associated protein kinase 3 (DAPK3) in complex with compound 2","SMVEDHYEMGEELGSGQFAIVRKCRQKGTGKEYAAKFIKKRRLSSSRRGVSREEIEREVNILREIRHPNIITLHDIFENKTDVVLILELVSGGELFDFLAEKESLTEDEATQFLKQILDGVHYLHSKRIAHFDLKPENIMLLDKNVPNPRIKLIDFGIAHKIEAGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEYFSNTSELAKDFIRRLLVKDPKRRMTIAQSLEHSWIKAIRRRNVRGEDSG","Homo sapiens","DAPK3, ZIPK","DEATH-ASSOCIATED PROTEIN KINASE 3","1","5A6N"
"5A6O",,"X-RAY DIFFRACTION",2.46,50.01,,6.2,"23% PROPANEDIOL, 0.1M NA/K PHOSPHATE PH 6.2, 10% GLYCEROL",,"10.1002/anie.201508055",,"5A6O",65.52,"1.6","1.6","Crystal structure of the apo form of the unphosphorylated human death associated protein kinase 3 (DAPK3)","SMVEDHYEMGEELGSGQFAIVRKCRQKGTGKEYAAKFIKKRRLSSSRRGVSREEIEREVNILREIRHPNIITLHDIFENKTDVVLILELVSGGELFDFLAEKESLTEDEATQFLKQILDGVHYLHSKRIAHFDLKPENIMLLDKNVPNPRIKLIDFGIAHKIEAGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGETKQETLTNISAVNYDFDEEYFSNTSELAKDFIRRLLVKDPKRRMTIAQSLEHSWIKAIRRRNVRGEDSG","Homo sapiens","DAPK3, ZIPK","DEATH-ASSOCIATED PROTEIN KINASE 3","1","5A6O"
"5A6R",,"X-RAY DIFFRACTION",4.13,70,,8.5,"18% MPD -- 0.1M TRIS PH 8.5",,"10.1042/BCJ20170527",,"5A6R",76.85,"2.85","2.85","Crystal structure of the BTB domain of human KCTD17","MHHHHHHSSGVDLGTENLYFQSMGAGGRAAGGWGKWVRLNVGGTVFLTTRQTLCREQKSFLSRLCQGEELQSDRDETGAYLIDRDPTYFGPILNFLRHGKLVLDKDMAEEGVLEEAEFYNIGPLIRIIKDRMEEK","Homo sapiens","KCTD17","BTB/POZ DOMAIN-CONTAINING PROTEIN KCTD17","1","5A6R"
"5A7B",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"CRYSTALLIZATION CONDITIONS: SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 30 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1021/acschembio.5b00515","KMN","5A7B",50.03,"1.4","1.4","Structure of the p53 cancer Y220C bound to the stabilizing small molecule PhiKan5211","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5A7B"
"5A7C",,"X-RAY DIFFRACTION",2.89,57.5,,7,"19% PEG 6000, 0.1M HEPES PH 7.0",,"10.1158/0008-5472.CAN-15-2721","5D4","5A7C",54.34,"1.9","1.9","Crystal structure of the second bromodomain of human BRD3 in complex with compound","SMGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLSTVKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDHEVVAMARKLQDVFEMRFAKMP","Homo sapiens","BRD3, KIAA0043, RING3L","BROMODOMAIN-CONTAINING PROTEIN 3","1","5A7C"
"5A7F",,"X-RAY DIFFRACTION",2.5,50.8,,6.5,"CRYSTALS WERE GROWN AT 20C IN 0.1 M MES/IMIDAZOLE, PH 6.5 CONTAINING 0.03 M EACH OF DIETHYLENE GLYCOL, TRIETHYLENE GLYCOL, TETRAETHYLENE GLYCOL, PENTAETHYLENE GLYCOL, 10 % (W/V) POLYETHYLENE GLYCOL 4000, 20% (W/V) GLYCEROL",293,"10.1371/journal.pone.0143919",,"5A7F",59.08,"1.86","1.86","Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1","SSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPLGPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLNIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFSTGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLFHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLKMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIPMLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDLIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPFLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLKDKEVAFWTNLFAK","Homo sapiens","CES1, CES2, SES1","LIVER CARBOXYLESTERASE 1","1","5A7F"
"5A7G",,"X-RAY DIFFRACTION",2.5,50.8,,8.5,"CRYSTALS WERE GROWN AT 4C IN 0.1 M BICINE/TRIZMA BASE, PH 8.5, CONTAINING 0.03 M EACH OF DIETHYLENE GLYCOL, TRIETHYLENE GLYCOL, TETRAETHYLENE GLYCOL, PENTAETHYLENE GLYCOL, 10 % (W/V) PEG 4000, 20 % (V/V) GLYCEROL",277,"10.1371/journal.pone.0143919",,"5A7G",58.88,"1.48","1.48","Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1","SSPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPLGPLRFTPPQPAEPWSFVKNATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLNIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFSTGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGEAAGGESVSVLVLSPLAKNLFHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLKMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIPMLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDLIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPFLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLKDKEVAFWTNLFAK","Homo sapiens","CES1, CES2, SES1","LIVER CARBOXYLESTERASE 1","1","5A7G"
"5A7H",,"X-RAY DIFFRACTION",2.5,50.8,,7.5,"CRYSTALS WERE GROWN AT 4C IN 0.1 M BIS-TRIS PROPANE, PH 7.5, CONTAINING 20 % (W/V) POLYETHYLENE GLYCOL 3350, 0.2 M NAI",277,"10.1371/journal.pone.0143919",,"5A7H",59.61,"2.01","2.01","Comparison of the structure and activity of glycosylated and aglycosylated Human Carboxylesterase 1","SPPVVDTVHGKVLGKFVSLEGFAQPVAIFLGIPFAKPPLGPLRFTPPQPAEPWSFVKQATSYPPMCTQDPKAGQLLSELFTNRKENIPLKLSEDCLYLNIYTPADLTKKNRLPVMVWIHGGGLMVGAASTYDGLALAAHENVVVVTIQYRLGIWGFFSTGDEHSRGNWGHLDQVAALRWVQDNIASFGGNPGSVTIFGESAGGESVSVLVLSPLAKNLFHRAISESGVALTSVLVKKGDVKPLAEQIAITAGCKTTTSAVMVHCLRQKTEEELLETTLKMKFLSLDLQGDPRESQPLLGTVIDGMLLLKTPEELQAERNFHTVPYMVGINKQEFGWLIPMLMSYPLSEGQLDQKTAMSLLWKSYPLVCIAKELIPEATEKYLGGTDDTVKKKDLFLDLIADVMFGVPSVIVARNHRDAGAPTYMYEFQYRPSFSSDMKPKTVIGDHGDELFSVFGAPFLKEGASEEEIRLSKMVMKFWANFARNGNPNGEGLPHWPEYNQKEGYLQIGANTQAAQKLKDKEVAFWTNLFAK","Homo sapiens","CES1, CES2, SES1","LIVER CARBOXYLESTERASE 1","1","5A7H"
"5A7I",,"X-RAY DIFFRACTION",4.96,75.2,,6.2,"10% GLYCEROL, 25% PROPANEDIOL AND 0.1 M SODIUM/POTASSIUM PHOSPHATE PH 6.2",,"10.1021/acs.biochem.5b00838",,"5A7I",37.37,"2.89","2.89","Crystal structure of INPP5B in complex with biphenyl 3,3',4,4',5,5'- hexakisphosphate","MYTYIQNFRFFAGTYNVNGQSPKECLRLWLSNGIQAPDVYCVGFQELDLSKEAFFFHDTPKEEEWFKAVSEGLHPDAKYAKVKLIRLVGIMLLLYVKQEHAAYISEVEAETVGTGIMGRMGNKGGVAIRFQFHNTSICVVNSHLAAHIEEYERRNQDYKDICSRMQFCQPDPSLPPLTISNHDVILWLGDLNYRIEELDVEKVKKLIEEKDFQMLYAYDQLKIQVAAKTVFEGFTEGELTFQPTYKYDTGSDDWDTSEKCRAPAWCDRILWKGKNITQLSYQSHMALKTSDHKPVSSVFDIGVRVVAHHHHHH","Homo sapiens","INPP5B, OCRL2","TYPE II INOSITOL 1,4,5-TRISPHOSPHATE 5-PHOSPHATASE","1","5A7I"
"5A7J",,"X-RAY DIFFRACTION",2.61,52.89,,5.5,"0.2 M LI2SO4, 0.1 M BIS-TRIS PH 5.5 AND 25% PEG3350",,"10.1021/acs.biochem.5b00838",,"5A7J",73.8,"2.9","2.9","Crystal structure of INPP5B in complex with benzene 1,2,4,5- tetrakisphosphate","MYTYIQNFRFFAGTYNVNGQSPKECLRLWLSNGIQAPDVYCVGFQELDLSKEAFFFHDTPKEEEWFKAVSEGLHPDAKYAKVKLIRLVGIMLLLYVKQEHAAYISEVEAETVGTGIMGRMGNKGGVAIRFQFHNTSICVVNSHLAAHIEEYERRNQDYKDICSRMQFCQPDPSLPPLTISNHDVILWLGDLNYRIEELDVEKVKKLIEEKDFQMLYAYDQLKIQVAAKTVFEGFTEGELTFQPTYKYDTGSDDWDTSEKCRAPAWCDRILWKGKNITQLSYQSHMALKTSDHKPVSSVFDIGVRVVAHHHHHH","Homo sapiens","INPP5B, OCRL2","TYPE II INOSITOL 1,4,5-TRISPHOSPHATE 5-PHOSPHATASE","1","5A7J"
"5A7N",,"X-RAY DIFFRACTION",2.72,54.76,,7.5,"22% PEG3350 -- 0.1M BIS-TRIS PH 7.5 -- 0.25M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7N",90,"2.39","2.39","Crystal structure of human JMJD2A in complex with compound 43","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7N"
"5A7O",,"X-RAY DIFFRACTION",2.62,53,,8.5,"PEG3350 -- 0.1M TRIS PH 8.5 -- 0.25M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7O",90.87,"2.15","2.15","Crystal structure of human JMJD2A in complex with compound 42","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFEKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7O"
"5A7P",,"X-RAY DIFFRACTION",2.66,53.78,,5.5,"28% PEG3350, 0.1M BIS-TRIS PH 5.5, 0.15M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7P",90.42,"2.28","2.28","Crystal structure of human JMJD2A in complex with compound 36","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7P"
"5A7Q",,"X-RAY DIFFRACTION",2.62,53,,6.5,"28% PEG3350 -- 0.1M BIS-TRIS PH 6.5 -- 0.15M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7Q",89.63,"2","2","Crystal structure of human JMJD2A in complex with compound 30","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7Q"
"5A7R",,"X-RAY DIFFRACTION",2.54,51,,8,"20% PEG3350, 0.2 M AMMONIUM SULFATE, 0.1 M PCTP PH 7.5",,"10.1021/ja512528p",,"5A7R",64.26,"1.95","1.95","Human poly(ADP-ribose) glycohydrolase in complex with synthetic dimeric ADP-ribose","GSSPDKKWLGTPIEEMRRMPRCGIRLPLLRPSANHTVTIRVDLLRAGEVPKPFPTHYKDLWDNKHVKMPCSEQNLYPVEDENGERTAGSRWELIQTALLNKFTRPQNLKDAILKYNVAYSKKWDFTALIDFWDKVLEEAEAQHLYQSILPDMVKIALCLPNICTQPIPLLAAAMNHSITMSQEQIASLLANAFFCTFPRRNAKMKSEYSSYPDINFNRLFEGRSSRKPEKLKTLFCYFRRVTAAAPTGLVTFTRQSLEDFPEWERCEKPLTRLHVTYEGTIEENGQGMLQVDFANRFVGGGVTSAGLVQENIRFLINPELIISRLFTEVLDHNECLIITGTEQYSEYTGYAETYRWSRSHEDGSERDDWQRRCTEIVAIDALHFRRYLDQFVPEKMRRELNKAYCGFLRPGVSSENLSAVATGNWGCGAFGGDARLKALIQILAAAAAERDVVYFTFGDSELMRDIYSMHIFLTERKLTVGDVYKLLLRYYNEECRNCSTPGPDIKLYPFIYHAVESCAETADHSGQRTGT","Homo sapiens","PARG","POLY(ADP-RIBOSE) GLYCOHYDROLASE","1","5A7R"
"5A7S",,"X-RAY DIFFRACTION",2.66,2.66,,8.5,"30% PEG3350 -- 0.1M TRIS PH 8.5 -- 0.25M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7S",90.53,"2.2","2.2","Crystal structure of human JMJD2A in complex with compound 44","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7S"
"5A7W",,"X-RAY DIFFRACTION",2.69,54.37,,6,"30% PEG3350 -- 0.1M BIS-TRIS PH 6.0 -- 0.25M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A7W",90.25,"2.27","2.27","Crystal structure of human JMJD2A in complex with compound 35","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A7W"
,,,,,,,,,,,,,,,,"MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAESCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","2","5A7W"
"5A80",,"X-RAY DIFFRACTION",2.69,54.29,,8.5,"30% PEG3350, 0.1M TRIS PH 8.5, 0.2M AMMONIUM SULFATE",,"10.1021/acs.jmedchem.5b01527",,"5A80",90.46,"2.28","2.28","Crystal structure of human JMJD2A in complex with compound 40","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5A80"
"5A81",,"X-RAY DIFFRACTION",4.08,69.88,,,,,"10.1021/acs.jmedchem.5b00773","78J","5A81",16.14,"2.03","2.03","Crystal structure of human ATAD2 bromodomain in complex with 8-(3R,4R) -3-(cyclohexylmethoxy)piperidin-4-yl-amino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A81"
"5A82",,"X-RAY DIFFRACTION",4.01,69.36,,7.5,"0.1M TRISHCL PH 7.0-8.0, 1.2-1.5M AMMONIUM SULPHATE AND 20-25% PEG3350",,"10.1021/acs.jmedchem.5b00773","YEJ","5A82",16.16,"1.86","1.86","Crystal structure of human ATAD2 bromodomain in complex with 4-(3R,4R) -4-(3-methyl-2-oxo-1,2-dihydro-1,7-naphthyridin-8-yl)aminopiperidin-3- yloxymethyl)-1-thiane-1,1-dione","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A82"
"5A83",,"X-RAY DIFFRACTION",4.03,69.47,,,"0.05M TRIS PH 7.5, 20-25% PEG3350. 1.5M AMSO4 4C",277,"10.1021/acs.jmedchem.5b00773","YD3","5A83",16.34,"2.09","2.09","Crystal structure of human ATAD2 bromodomain in complex with 4-((3R, 4R)-4-3-methyl-5-(5-methylpyridin-3-yl)-2-oxo-1,2-dihydroquinolin-8- yl-aminopiperidin-3-yloxymethyl)-1-thiane-1,1-dione","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPASE FAMILY AAA DOMAIN-CONTAINING PROTEIN 2","1","5A83"
"5A85",,"X-RAY DIFFRACTION",2.12,42.09,,,"0.1M HEPES PH 7.0, 20% PEG 6000, 0.2M LICL",,"10.1021/acs.jmedchem.5b00773","78J","5A85",15.53,"1.72","1.72","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 8-(3R,4R)-3-(cyclohexylmethoxy)piperidin-4-ylamino-3-methyl-1,2-dihydro-1,7- naphthyridin-2-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","BROMODOMAIN-CONTAINING PROTEIN 4","1","5A85"
"5A8X",,"X-RAY DIFFRACTION",2.36,47.88,,,,,"10.1002/cmdc.201500269","IUY","5A8X",24.73,"2.23","2.23","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","Neutrophil elastase","1","5A8X"
"5A8Y",,"X-RAY DIFFRACTION",2.31,46.64,,,,,"10.1002/cmdc.201500269","VBM","5A8Y",25.03,"1.9","1.9","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5A8Y"
"5A8Z",,"X-RAY DIFFRACTION",2.32,47.02,,,,,"10.1002/cmdc.201500269","IUL","5A8Z",24.7,"2","2","Crystal Structure of human neutrophil elastase in complex with a dihydropyrimidone inhibitor","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","Neutrophil elastase","1","5A8Z"
"5A9F",,"X-RAY DIFFRACTION",3.4,64,,,"19% PEG 3350, 0.2M POTASSIUM CITRATE TRIBASIC",,"10.1016/j.str.2015.10.014",,"5A9F",93.69,"3.2","3.2","Crystal structure of the Helicase domain of human DNA polymerase theta in complex with ADP","SMDKLLLANWGLPKAVLEKYHSFGVKKMFEWQAECLLLGQVLEGKNLVYSAPTSAGKTLVAELLILKRVLEMRKKALFILPFVSVAKEKKYYLQSLFQEVGIKVDGYMGSTSPSRHFSSLDIAVCTIERANGLINRLIEENKMDLLGMVVVDELHMLGDSHRGYLLELLLTKICYITRKSASCQADLASSLSNAVQIVGMSATLPNLELVASWLNAELYHTDFRPVPLLESVKVGNSIYDSSMKLVREFEPMLQVKGDEDHVVSLCYETICDNHSVLLFCPSKKWCEKLADIIAREFYNLHHQAEGLVKPSECPPVILEQKELLEVMDQLRRLPSGLDSVLQKTVPWGVAFHHAGLTFEERDIIEGAFRQGLIRVLAATSTLSSGVNLPARRVIIRTPIFGGRPLDILTYKQMVGRAGRKGVDTVGESILICKNSEKSKGIALLQGSLKPVRSCLQRREGEEVTGSMIRAILEIIVGGVASTSQDMHTYAACTFLAASMKEGKQGIQRNQESVQLGAIEACVMWLLENEFIQSTEASDGTEGKVYHPTHLGSATLSSSLSPADTLDIFADLQRAMKGFVLENDLHILYLVTPMFEDWTTIDWYRFFCLWEKLPTSMKRVAELVGVEEGFLARCVKGKVVARTERQHRQMAIHKRFFTSLVLLDLISEVPLREINQKYGCNRGQIQSLQQSAAVYAGMITVFSNRLGWHNMELLLSQFQKRLTFGIQRELCDLVRVSLLNAQRARVLYASGFHTVADLARANIVEVEVILKNAVPFKSARKAVDEEEEAVEERRNMRTIWVTGRKGLTEREAAALIVEEARMILQQDLVEM","Homo sapiens","POLQ, POLH","DNA POLYMERASE THETA","1","5A9F"
"5A9J",,"X-RAY DIFFRACTION",3.5,65,,,"0.2M NACL, 20% PEG 6K, 10% ETHYLENE GLYCOL, 0.1 M HEPES PH 7.0",,"10.1016/j.str.2015.10.014",,"5A9J",400.08,"3.55","3.55","Crystal structure of the Helicase domain of human DNA polymerase theta, apo-form","SMMNLLRRSGKRRRSESGSDSFSGSGGDSSASPQFLSGSVLSPPPGLGRCLKAAAAGECKPTVPDYERDKLLLANWGLPKAVLEKYHSFGVKKMFEWQAECLLLGQVLEGKNLVYSAPTSAGKTLVAELLILKRVLEMRKKALFILPFVSVAKEKKYYLQSLFQEVGIKVDGYMGSTSPSRHFSSLDIAVCTIERANGLINRLIEENKMDLLGMVVVDELHMLGDSHRGYLLELLLTKICYITRKSASCQADLASSLSNAVQIVGMSATLPNLELVASWLNAELYHTDFRPVPLLESVKVGNSIYDSSMKLVREFEPMLQVKGDEDHVVSLCYETICDNHSVLLFCPSKKWCEKLADIIAREFYNLHHQAEGLVKPSECPPVILEQKELLEVMDQLRRLPSGLDSVLQKTVPWGVAFHHAGLTFEERDIIEGAFRQGLIRVLAATSTLSSGVNLPARRVIIRTPIFGGRPLDILTYKQMVGRAGRKGVDTVGESILICKNSEKSKGIALLQGSLKPVRSCLQRREGEEVTGSMIRAILEIIVGGVASTSQDMHTYAACTFLAASMKEGKQGIQRNQESVQLGAIEACVMWLLENEFIQSTEASDGTEGKVYHPTHLGSATLSSSLSPADTLDIFADLQRAMKGFVLENDLHILYLVTPMFEDWTTIDWYRFFCLWEKLPTSMKRVAELVGVEEGFLARCVKGKVVARTERQHRQMAIHKRFFTSLVLLDLISEVPLREINQKYGCNRGQIQSLQQSAAVYAGMITVFSNRLGWHNMELLLSQFQKRLTFGIQRELCDLVRVSLLNAQRARVLYASGFHTVADLARANIVEVEVILKNAVPFKSARKAVDEEEEAVEERRNMRTIWVTGRKGLTEREAAALIVEEARMILQQDLVEM","Homo sapiens","POLQ, POLH","DNA POLYMERASE THETA","1","5A9J"
"5A9U",,"X-RAY DIFFRACTION",2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,"10.1056/NEJMoa1508887","5P8","5A9U",37.38,"1.6","1.6","Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVYSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5A9U"
"5AA8",,"X-RAY DIFFRACTION",2.1,41.35,,8,"pH 8",,"10.1056/NEJMoa1508887","5P8","5AA8",37.41,"1.86","1.86","Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVYSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLEFMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5AA8"
"5AA9",,"X-RAY DIFFRACTION",2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,"10.1056/NEJMoa1508887","5P8","5AA9",37.35,"1.93","1.93","Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with PF-06463922 ((10R)-7-amino-12-fluoro-2,10,16-trimethyl- 15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11) benzoxadiazacyclotetradecine-3-carbonitrile).","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLEFMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5AA9"
"5AAA",,"X-RAY DIFFRACTION",2.1,0.41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,"10.1056/NEJMoa1508887","VGH","5AAA",37.39,"1.73","1.73","Structure of L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLEFMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5AAA"
"5AAB",,"X-RAY DIFFRACTION",2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,"10.1056/NEJMoa1508887","VGH","5AAB",37.45,"2.2","2.2","Structure of C1156Y,L1198F Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVYSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLEFMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5AAB"
"5AAC",,"X-RAY DIFFRACTION",2.1,41,"VAPOR DIFFUSION, HANGING DROP",8,"HANGING DROP VAPOR DIFFUSION AT 13 DEGREES C. 2 MICROLITERS OF PURIFIED PROTEIN SOLUTION (11-15 MG/ML) CONTAINING INHIBITOR COMPOUND AT A 2X STOICHIOMETRY OF INHIBITOR TO PROTEIN WERE COMBINED WITH 2 MICROLITERS OF SOLUTIONS CONTAINING: 0.2 M LITHIUM SULFATE, 17-21% PEG3350 AND 0.1M TRIS PH 7.6-8.5.",286,"10.1056/NEJMoa1508887","VGH","5AAC",37.42,"1.7","1.7","Structure of C1156Y Mutant Human Anaplastic Lymphoma Kinase in Complex with Crizotinib","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVYSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5AAC"
"5AAD",,"X-RAY DIFFRACTION",2.51,50.97,,,,,"10.1016/j.bmcl.2015.08.003",,"5AAD",33.48,"3.1","3.1","Aurora A kinase bound to an imidazopyridine inhibitor (7a)","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNAQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","AURORA KINASE A","1","5AAD"
"5AAE",,"X-RAY DIFFRACTION",2.49,50.68,,8.9,"0.1 M TRIS PH 8.9 0.2 M LITHIUM SULFATE 30 % PEG 4000",,"10.1016/j.bmcl.2015.08.003",,"5AAE",33.29,"3.11","3.11","Aurora A kinase bound to an imidazopyridine inhibitor (14d)","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNAQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","AURORA KINASE A","1","5AAE"
"5AAF",,"X-RAY DIFFRACTION",2.56,52.07,,8.9,"0.1 M TRIS PH 8.9, 0.2 M LITHIUM SULFATE, 30 % PEG 4000",,"10.1016/j.bmcl.2015.08.003",,"5AAF",33.36,"2.78","2.78","Aurora A kinase bound to an imidazopyridine inhibitor (14a)","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNAQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","AURORA KINASE A","1","5AAF"
"5AAG",,"X-RAY DIFFRACTION",2.56,51.93,,8.9,"0.1 M TRIS PH 8.9 0.2 M LITHIUM SULFATE 30 % PEG 4000",,"10.1016/j.bmcl.2015.08.003",,"5AAG",33.41,"2.85","2.85","Aurora A kinase bound to an imidazopyridine inhibitor (14b)","GAMESKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLAGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPSNAQNKESASKQS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","AURORA KINASE A","1","5AAG"
"5AAQ",,"SOLUTION NMR",,,,,,,"10.15252/embj.201694491",,"5AAQ",6.87,,,"TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy","GSPSPLSIKKCPICKADDICDHTLEQQQMQPLCFNCPICDKIFPATEKQIFEDHVFCHSL","Homo sapiens","CALCOCO2, NDP52","CALCIUM-BINDING AND COILED-COIL DOMAIN-CONTAINING PROTEIN 2","1","5AAQ"
"5AAS",,"SOLUTION NMR",,,,,,,"10.1371/journal.ppat.1005174",,"5AAS",7.83,,,"The selective autophagy receptor TAX1BP1 is required for autophagy- dependent capture of cytosolic Salmonella typhimurium","GSSFDVHKKCPLCELMFPPNYDQSKFEEHVESHWKVCPMCSEQFPPDYDQQVFERHVQTHFDQN","Homo sapiens","TAX1BP1, T6BP, PRO0105","TAX1-BINDING PROTEIN 1","1","5AAS"
"5AAU",,"X-RAY DIFFRACTION",2.07,40.5,,6.5,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acs.jmedchem.5b00984","XBR","5AAU",58.05,"1.9","1.9","Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist","GSHMALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5AAU"
"5AAV",,"X-RAY DIFFRACTION",2.02,39.22,,6.5,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acs.jmedchem.5b00984","GW5","5AAV",58,"1.95","1.95","Optimization of a novel binding motif to to (E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H- pyrido(3,4-b)indol-1-yl)phenyl)acrylic acid (AZD9496), a potent and orally bioavailable selective estrogen receptor downregulator and antagonist","GSHMALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKSKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5AAV"
,,,,,,,,,,,,,,,,"GSHLALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKSKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","2","5AAV"
"5AAY",,"SOLUTION NMR",,,,,,,"10.15252/embj.201694491",,"5AAY",3.47,,,"TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy","GSPPDFCCPKCQYQAPDMDTLQIHVMECIE","Homo sapiens","IKBKG, FIP3, NEMO","NF-KAPPA-B ESSENTIAL MODULATOR","1","5AAY"
"5AAZ",,"SOLUTION NMR",,,,,,,"10.15252/embj.201694491",,"5AAZ",3.59,,,"TBK1 recruitment to cytosol-invading Salmonella induces anti- bacterial autophagy","GSRNIPIHSCPKCGEVLPDIDTLQIHVMDCII","Homo sapiens","OPTN, FIP2, GLC1E, HIP7, HYPL, NRP","OPTINEURIN","1","5AAZ"
"5AB9",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 40 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","92O","5AB9",50.21,"1.36","1.36","Structure of the p53 cancer mutant Y220C with bound small molecule 7- ethyl-3-(piperidin-4-yl)-1H-indole","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AB9"
"5ABA",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 30 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","UL7","5ABA",50,"1.62","1.62","Structure of the p53 cancer mutant Y220C with bound small-molecule stabilizer PhiKan5149","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5ABA"
"5ABD",,"X-RAY DIFFRACTION",2.91,57.75,"VAPOR DIFFUSION",7.5,"VAPOR DIFFUSION METHOD, MOTHER LIQUOR: 1.5MICROM VERGFR1-D2, 15MM TRIS/HCL PH 8.1, 25MM NACL, 5MM CUSO4 RESERVOIR: 19.5% (W/V) PEG8000, 100MM SA,",291,"10.1371/journal.pone.0167755",,"5ABD",33.28,"1.995","1.995","CRYSTAL STRUCTURE OF VEGFR-1 DOMAIN 2 IN PRESENCE OF CU","GRPFVEMYSEIPEIIHMTEGRELVIPCRVTSPNITVTLKKFPLDTLIPDGKRIIWDSRKGFIISNATYKEIGLLTCEATVNGHLYKTNYLTHRQT","Homo sapiens","FLT1, FLT, FRT, VEGFR1","VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1","1","5ABD"
"5ABS",,"X-RAY DIFFRACTION",2.82,56.4,"VAPOR DIFFUSION, SITTING DROP",7,"0.05M ZN ACETATE, 20% PEG3350, VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 298K, pH 7",298,"10.1126/scisignal.aad6275",,"5ABS",8.15,"1.74","1.74","CRYSTAL STRUCTURE OF THE C-TERMINAL COILED-COIL DOMAIN OF CIN85 IN SPACE GROUP P321","GHMEPAASSQAAVEELRTQVRELRSIIETMKDQQKREIKQLLSELDEEKKIRLRLQMEVNDIKKAL","Homo sapiens","SH3KBP1, CIN85","SH3 DOMAIN-CONTAINING KINASE-BINDING PROTEIN 1","1","5ABS"
"5ABW",,"X-RAY DIFFRACTION",2.34,47.41,,,,,"10.1016/j.bmcl.2015.08.049","WQQ","5ABW",24.52,"1.6","1.6","Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases","IVGGRRARPHAWPFMVSLQLRGGHFCGATLIAPNFVMSAAHCVANVNVRAVRVVLGAHNLSRREPTRQVFAVQRIFENGYDPVNLLNDIVILQLNGSATINANVQVAQLPAQGRRLGNGVQCLAMGWGLLGRNRGIASVLQELNVTVVTSLCRRSNVCTLVRGRQAGVCFGDSGSPLVCNGLIHGIASFVRGGCASGLYPDAFAPVAQFVNWIDSIIQ","Homo sapiens","ELANE, ELA2","NEUTROPHIL ELASTASE","1","5ABW"
"5AC2",,"X-RAY DIFFRACTION",2.25,31.6,,,,,"10.1002/anie.201505749",,"5AC2",56.41,"1.85","1.85","human aldehyde dehydrogenase 1A1 with duocarmycin analog","MSSSGTPDLPVLLTDLKIQYTKIFINNEWHDSVSGKKFPVFNPATEEELCQVEEGDKEDVDKAVKAARQAFQIGSPWRTMDASERGRLLYKLADLIERDRLLLATMESMNGGKLYSNAYLNDLAGCIKTLRYCAGWADKIQGRTIPIDGNFFTYTRHEPIGVCGQIIPWNFPLVMLIWKIGPALSCGNTVVVKPAEQTPLTALHVASLIKEAGFPPGVVNIVPGYGPTAGAAISSHMDIDKVAFTGSTEVGKLIKEAAGKSNLKRVTLELGGKSPCIVLADADLDNAVEFAHHGVFYHQGQCCIAASRIFVEESIYDEFVRRSVERAKKYILGNPLTPGVTQGPQIDKEQYDKILDLIESGKKEGAKLECGGGPWGNKGYFVQPTVFSNVTDEMRIAKEEIFGPVQQIMKFKSLDDVIKRANNTFYGLSAGVFTKDIDKAITISSALQAGTVWVNCYGVVSAQCPFGGFKMSGNGRELGEYGFHEYTEVKTVTVKISQKNS","Homo sapiens","ALDH1A1, ALDC, ALDH1, PUMB1","RETINAL DEHYDROGENASE 1","1","5AC2"
"5ACC",,"X-RAY DIFFRACTION",2.45,49.87,,6.5,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acs.jmedchem.5b00984","KE9","5ACC",28.68,"1.88","1.88","A Novel Oral Selective Estrogen Receptor Down-regulator, AZD9496, drives Tumour Growth Inhibition in Estrogen Receptor positive and ESR1 Mutant Models","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKSKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5ACC"
"5ACK",,"X-RAY DIFFRACTION",2.2,44,,7.5,"1.2 M NA CITRATE, 0.1 M HEPES PH 7.5, 0.01 M DTT",,"10.1002/anie.201506310",,"5ACK",36.59,"1.24","1.24","Human PDK1 Kinase Domain in Complex with Allosteric Compound 7 Bound to the PIF-Pocket","GAMDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEGLIFAKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE 1","1","5ACK"
"5ACL",,"X-RAY DIFFRACTION",1.9,37,,8.5,"0.2 M TRI-POTASSIUM CITRATE, 2.2 M (NH4)2SO4, 0.5 M SULFASALAZINE, pH 8.5",,"10.7554/eLife.10935",,"5ACL",12.06,"1.49","1.49","Mcg immunoglobulin variable domain with sulfasalazine","GQSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVL","Homo sapiens","IGLV2-8","MCG","1","5ACL"
"5ACM",,"X-RAY DIFFRACTION",1.9,35,,8.5,"0.2 M NH4CL, 2.2 M (NH4)2SO4, 0.5 M METHYLENE BLUE, pH 8.5",,"10.7554/eLife.10935",,"5ACM",24.08,"1.05","1.05","Mcg immunoglobulin variable domain with methylene blue","GQSALTQPPSASGSLGQSVTISCTGTSSDVGGYNYVSWYQQHAGKAPKVIIYEVNKRPSGVPDRFSGSKSGNTASLTVSGLQAEDEADYYCSSYEGSDNFVFGTGTKVTVL","Homo sapiens","IGLV2-8","MCG","1","5ACM"
"5ACY",,"X-RAY DIFFRACTION",2.24,45.15,,,"0.1M MIB PH 4.0 25% PEG1500",,"10.1084/jem.20151271","9S3","5ACY",31.29,"2.01","2.01","N-TERMINAL BROMODOMAIN OF HUMAN BRD4 WITH 1-(2R,4S)-2-methyl-4-(phenylamino)-6-4-(piperidin-1-ylmethyl)phenyl-1,2,3,4- tetrahydroquinolin-1-yl-ethan-1-one","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","BROMODOMAIN-CONTAINING PROTEIN 4","1","5ACY"
"5AD2",,"X-RAY DIFFRACTION",2.19,43.92,,,"NACL 0.2M, PEG 3350 5.9%W/V, EG 10%V/V, HEPES 0.1M PH 7.4",,"10.1038/nchembio.2210","ETU","5AD2",30.68,"2.01","2.01","Bivalent binding to BET bromodomains","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","BROMODOMAIN-CONTAINING PROTEIN 4","1","5AD2"
"5AD3",,"X-RAY DIFFRACTION",2.26,45.63,,,"PEG 4K 20%W/V, (NH4)2HPO4 0.2M",,"10.1038/nchembio.2210","K6K","5AD3",30.73,"1.49","1.49","Bivalent binding to BET bromodomains","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","BROMODOMAIN-CONTAINING PROTEIN 4","1","5AD3"
"5ADF",,"X-RAY DIFFRACTION",2.69,54.3,,6.2,"8-9% PED3350 40MM CITRIC ACID 60MM BISTRISPROPANE 10% GLYCEROL 5MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.5b01330","2SN","5ADF",99.96,"1.966","1.966","Structure of human nNOS R354A G357D mutant heme domain in complex with 7-(((3-((Dimethylamino)methyl)phenyl)amino)methyl)quinolin-2- amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5ADF"
"5ADG",,"X-RAY DIFFRACTION",2.69,54.3,,6.2,"8-9% PED3350 40MM CITRIC ACID 60MM BISTRISPROPANE 10% GLYCEROL 5MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.5b01330","XEB","5ADG",100.43,"1.982","1.982","Structure of human nNOS R354A G357D mutant heme domain in complex with 7-((4-Chloro-3-((methylamino)methyl)phenoxy)methyl)quinolin-2- amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5ADG"
"5ADI",,"X-RAY DIFFRACTION",2.69,54,,6.2,"8-9% PED3350 40MM CITRIC ACID 60MM BISTRISPROPANE 10% GLYCEROL 5MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.5b01330","TUE","5ADI",100.23,"2.2","2.2","Structure of human nNOS R354A G357D mutant heme domain in complex with 7-(((5-((Methylamino)methyl)pyridin-3-yl)oxy)methyl)quinolin-2- amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5ADI"
"5ADO",,"X-RAY DIFFRACTION",2.2,45,,6.5,"0.18 M MGCL2 16% (W/V) POLYETHYLENE GLYCOL 6000 0.1 M N-(2-ACETAMIDO) IMINODIACETIC ACID (ADA) PH 7.5",,"10.1126/sciadv.1501695",,"5ADO",54.22,"1.55","1.55","Crystal structure of the paraoxon-modified A.17 antibody FAB fragment - Light chain S35R mutant","QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGLTQSSHNDANWGQGTLTTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCLAMDYKDHDGDYKDHDIDYKDDDDKVDHHHHHH","Homo sapiens",,"FAB A.17","1","5ADO"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVRWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNPVFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECIDAAAAASFLEQKLISEEDLNSAVDHHHHHH","Homo sapiens",,"FAB A.17","2","5ADO"
"5ADP",,"X-RAY DIFFRACTION",2.2,45,,6.5,"0.15 M MGCL2 18% (W/V) POLYETHYLENE GLYCOL 6000 0.1 M N-(2-ACETAMIDO) IMINODIACETIC ACID (ADA) PH 7.5",,"10.1126/sciadv.1501695",,"5ADP",54.08,"2.13","2.13","Crystal structure of the A.17 antibody FAB fragment - Light chain S35R mutant","QVQLQESGPGLVKPSETLSLTCAVSGYSISSGYYWGWIRQPPGKGLEWIGSIYHSGSTYYNPSLKSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAGLTQSSHNDANWGQGTLTTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCLAMDYKDHDGDYKDHDIDYKDDDDKVDHHHHHH","Homo sapiens",,"FAB A.17","1","5ADP"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVRWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLNPVFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGECIDAAAAASFLEQKLISEEDLNSAVDHHHHHH","Homo sapiens",,"FAB A.17","2","5ADP"
"5ADQ",,"X-RAY DIFFRACTION",2.4,50,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22 % PEG 3350, PH 8.5",,"10.1016/j.bmcl.2015.12.018","A95","5ADQ",28.03,"2.1","2.1","Crystal structure of human tankyrase 2 in complex with JW55","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5ADQ"
,,,,,,,,,,,,,,,,"MAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","2","5ADQ"
"5ADR",,"X-RAY DIFFRACTION",2.4,49,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22 % PEG 3350, PH 8.5",,"10.1016/j.bmcl.2015.12.018","QS5","5ADR",27.96,"2.1","2.1","Crystal structure of human tankyrase 2 in complex with OD38","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5ADR"
,,,,,,,,,,,,,,,,"MAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","2","5ADR"
"5ADS",,"X-RAY DIFFRACTION",2.4,49,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22 % PEG 3350, PH 8.5",,"10.1016/j.bmcl.2015.12.018","QNS","5ADS",28.27,"1.8","1.8","Crystal structure of human tankyrase 2 in complex with OD39","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5ADS"
,,,,,,,,,,,,,,,,"MAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","2","5ADS"
"5ADT",,"X-RAY DIFFRACTION",2.4,50,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22 % PEG 3350, PH 8.5",,"10.1016/j.bmcl.2015.12.018","1TC","5ADT",27.99,"2.15","2.15","Crystal structure of human tankyrase 2 in complex with OD73","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5ADT"
,,,,,,,,,,,,,,,,"MAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","2","5ADT"
"5AEA",,"X-RAY DIFFRACTION",2.05,40,,6.88,"1.45 M TRI-SODIUM CITRATE PH 6.88",,"10.1074/jbc.M116.721050",,"5AEA",26.02,"1.9","1.9","Crystal structure of human NCAM domain 1","LQVDIVPSQGEISVGESKFFLCQVAGDAKDKDISWFSPNGEKLTPNQQRISVVWNDDSSSTLTIYNANIDDAGIYKCVVTGEDGSESEATVNVKIFQAAADYKDDDDKAADYKDDDDK","Homo sapiens","NCAM1, NCAM","NEURAL CELL ADHESION MOLECULE 1","1","5AEA"
"5AEF","5","ELECTRON MICROSCOPY",,,,,,,"10.1073/pnas.1503455112",,"5AEF",5.67,"5, 5",,"Electron cryo-microscopy of an Abeta(1-42)amyloid fibril","QKLVFFAEDVGSNKGAIIGLMVGGVVIA","Homo sapiens","APP, A4, AD1","AMYLOID BETA A4 PROTEIN","1","5AEF"
"5AEH",,"X-RAY DIFFRACTION",2.1,42,,9,"0.1M BICINE PH9.0, 20% PEG6K",,"10.1016/j.bmcl.2015.12.018","8IR","5AEH",55.65,"1.85","1.85","Crystal structure of human tankyrase 2 in complex with OD332","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5AEH"
"5AEJ",,"X-RAY DIFFRACTION",2.21,44.4,,4.5,"2.1 M NACL, 0.1 M NA ACETATE, 0.3 M LI SULFATE, PH 4.5",,"10.1042/BCJ20160254",,"5AEJ",70.33,"1.904","1.904","Crystal structure of human Gremlin-1","MNTIHHHHHHNTSGSGGGGGRLVPRGSMSENLYFQGSMSEVLESSQEALHVTERKYLKRDWCKTQPLKQTIHEEGCNSRTIINRFCYGQCNSFYIPRHIRKEEGSFQSCSFCKPKKFTTMMVTLNCPELQPPTKKKRVTRVKQCRCISIDLD","Homo sapiens","GREM1, CKTSF1B1, DAND2, DRM, PIG2","GREMLIN-1","1","5AEJ"
"5AEN",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",6,"1 MICROLITTER OF PROTEIN SOLUTION CONTAINING 10MM TRIS-HCL, 25MM KCL, AND 4 MG/ML TO 8 MG/ML LTA4H (PH 8) WAS MIXED AT DIFFERENT RATIOS (0.5:1, 1:1, AND 1:2) WITH PRECIPITATE SOLUTION CONTAINING 0:15M IMIDAZOLE, 0:1M SODIUM ACETATE PH 6, 14% PEG-8000, AND 5MM YBCL3, AND CRYSTALLIZED AT 17:4 C FOR TWO WEEKS BY HANGING DROP VAPOR-DIFFUSION METHOD",,"10.1021/ci500618u","DP8","5AEN",70.16,"1.864","1.864","Structure of human Leukotriene A4 hydrolase in complex with inhibitor dimethyl(2- (4-phenoxyphenoxy)ethyl)amine","IVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","LEUKOTRIENE A-4 HYDROLASE","1","5AEN"
"5AEP",,"X-RAY DIFFRACTION",2.29,46.32,"VAPOR DIFFUSION, HANGING DROP",7,"1.5-2.2 M SODIUM MALONATE PH 7, HANGING DROP AT 20 DEGREES CELSIUS",293,"10.1016/j.bmc.2015.03.059","QUP","5AEP",35.55,"1.95","1.95","Novel pyrrole carboxamide inhibitors of JAK2 as potential treatment of myeloproliferative disorders","AFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","TYROSINE-PROTEIN KINASE JAK2","1","5AEP"
"5AF4",,"X-RAY DIFFRACTION",2.45,49.7,,8,"3M AMMONIUM SULPHATE, 100 MM TRIS PH 8.0",,"10.1016/j.molcel.2015.01.042",,"5AF4",70.24,"1.85","1.85","Structure of Lys33-linked diUb","MQIFVKTLTGRTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBC","UBIQUITIN","1","5AF4"
"5AF5",,"X-RAY DIFFRACTION",1.8,31.9,,8.5,"10% PEG 20K, 20% PEG 550 MME, 0.02 M D-GLUCOSE, 0.02M D-MANNOSE, 0.02M D-GALACTOSE, 0.02 M L-FRUCTOSE, 0.02 M D-XYLOSE, 0.02 M N-ACETYL-D-GLUCOSAMINE, 100 MM TRIS/BICINE PH 8.5",,"10.1016/j.molcel.2015.01.042",,"5AF5",8.33,"1.68","1.68","Structure of Lys33-linked triUb S.G. P 212121","MQIFVKTLTGRTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRL","Homo sapiens","UBC","POLYUBIQUITIN-C","1","5AF5"
"5AFB",,"X-RAY DIFFRACTION",2.19,43.84,,6,"0.1 M MES BUFFER, 4M NACL, 0.6 M NON- DETERGENT SULFO-BETAINE NDSB195, PH 6.0",,"10.1016/j.str.2015.01.013",,"5AFB",44.51,"2.16","2.16","Crystal structure of the Latrophilin3 Lectin and Olfactomedin Domains","ETGPIPMAVVRRELSCESYPIELRCPGTDVIMIESANYGRTDDKICDSDPAQMENIRCYLPDAYKIMSQRCNNRTQCAVVAGPDVFPDPCPGTYKYLEVQYECVPYKVEQKVFLCPGLLKGVYQSEHLFESDHQSGAWCKDPLQASDKIYYMPWTPYRTDTLTEYSSKDDFIAGRPTTTYKLPHRVDGTGFVVYDGALFFNKERTRNIVKFDLRTRIKSGEAIIANANYHDTSPYRWGGKSDIDLAVDENGLWVIYATEQNNGKIVISQLNPYTLRIEGTWDTAYDKRSASNAFMICGILYVVKSVYEDDDNEATGNKIDYIYNTDQSKDSLVDVPFPNSYQYIAAVDYNPRDNLLYVWNNYHVVKYSLDFGPLDGTKHHHHHH","Homo sapiens","ADGRL3, KIAA0768, LEC3, LPHN3","LATROPHILIN-3","1","5AFB"
"5AFV",,"X-RAY DIFFRACTION",2.51,51.01,,8.5,"PH 8.5",,"10.1002/minf.201400140","JH5","5AFV",90.1,"2.25","2.25","Pharmacophore-based virtual screening to discover new active compounds for human choline kinase alpha1.","DEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","CHOLINE KINASE ALPHA","1","5AFV"
"5AGA",,"X-RAY DIFFRACTION",3.23,61.97,,,"19% PEG 3350, 0.2M POTASSIUM CITRATE TRIBASIC",,"10.1016/j.str.2015.10.014",,"5AGA",93.96,"2.9","2.9","Crystal structure of the Helicase domain of human DNA polymerase theta in complex with AMPPNP","SMDKLLLANWGLPKAVLEKYHSFGVKKMFEWQAECLLLGQVLEGKNLVYSAPTSAGKTLVAELLILKRVLEMRKKALFILPFVSVAKEKKYYLQSLFQEVGIKVDGYMGSTSPSRHFSSLDIAVCTIERANGLINRLIEENKMDLLGMVVVDELHMLGDSHRGYLLELLLTKICYITRKSASCQADLASSLSNAVQIVGMSATLPNLELVASWLNAELYHTDFRPVPLLESVKVGNSIYDSSMKLVREFEPMLQVKGDEDHVVSLCYETICDNHSVLLFCPSKKWCEKLADIIAREFYNLHHQAEGLVKPSECPPVILEQKELLEVMDQLRRLPSGLDSVLQKTVPWGVAFHHAGLTFEERDIIEGAFRQGLIRVLAATSTLSSGVNLPARRVIIRTPIFGGRPLDILTYKQMVGRAGRKGVDTVGESILICKNSEKSKGIALLQGSLKPVRSCLQRREGEEVTGSMIRAILEIIVGGVASTSQDMHTYAACTFLAASMKEGKQGIQRNQESVQLGAIEACVMWLLENEFIQSTEASDGTEGKVYHPTHLGSATLSSSLSPADTLDIFADLQRAMKGFVLENDLHILYLVTPMFEDWTTIDWYRFFCLWEKLPTSMKRVAELVGVEEGFLARCVKGKVVARTERQHRQMAIHKRFFTSLVLLDLISEVPLREINQKYGCNRGQIQSLQQSAAVYAGMITVFSNRLGWHNMELLLSQFQKRLTFGIQRELCDLVRVSLLNAQRARVLYASGFHTVADLARANIVEVEVILKNAVPFKSARKAVDEEEEAVEERRNMRTIWVTGRKGLTEREAAALIVEEARMILQQDLVEM","Homo sapiens","POLQ, POLH","DNA POLYMERASE THETA","1","5AGA"
"5AGQ",,"SOLUTION NMR",,,,,,,"10.1093/nar/gkv365",,"5AGQ",13.42,,,"Solution structure of the TAM domain of human TIP5 BAZ2A involved in epigenetic regulation of rRNA genes","GAMERRRIATPEEVRLPLQHGWRREVRIKKGSHRWQGETWYYGPCGKRMKQFPEVIKYLSRNVVHSVRREHFSFSPRMPVGDFFEERDTPEGLQWVQLSAEEIPSRIQAITGS","Homo sapiens","BAZ2A, KIAA0314, TIP5","BROMODOMAIN ADJACENT TO ZINC FINGER DOMAIN PROTEIN 2A","1","5AGQ"
"5AHO",,"X-RAY DIFFRACTION",3.22,61.82,,,"0.4M K/NA(TART)",,"10.1093/nar/gkv1256",,"5AHO",38.7,"2.16","2.16","Crystal structure of human 5' exonuclease Apollo","SMNGVLIPHTPIAVDFWSLRRAGTARLFFLSHMHSDHTVGLSSTWARPLYCSPITAHLLHRHLQVSKQWIQALEVGESHVLPLDEIGQETMTVTLLDANHCPGSVMFLFEGYFGTILYTGDFRYTPSMLKEPALTLGKQIHTLYLDNTNCNPALVLPSRQEAAHQIVQLIRKHPQHNIKIGLYSLGKESLLEQLALEFQTWVVLSPRRLELVQLLGLADVFTVEEKAGRIHAVDHMEICHSNMLRWNQTHPTIAILPTSRKIHSSHPDIHVIPYSDHSSYSELRAFVAALKPCQVVPIVSRRPCGGFQDSLSPRISVPLIPDSVQQYMSSFSRKPS","Homo sapiens","DCLRE1B, SNM1B","5' EXONUCLEASE APOLLO","1","5AHO"
"5AHR",,"X-RAY DIFFRACTION",,,,,"0.20M NAF; 0.1M BTPROP PH 8.5; 20.0% PEG 3350; 10.0% ETGLY",,"10.1093/nar/gkv1256",,"5AHR",39.01,"2.19","2.19","Crystal structure of human DNA cross-link repair 1A, crystal form B","SMTCPFYKKIPGTGFTVDAFQYGVVEGCTAYFLTHFHSDHYAGLSKHFTFPVYCSEITGNLLKNKLHVQEQYIHPLPLDTECIVNGVKVVLLDANHCPGAVMILFYLPNGTVILHTGDFRADPSMERSLLADQKVHMLYLDTTYCSPEYTFPSQQEVIRFAINTAFEAVTLNPHALVVCGTYSIGKEKVFLAIADVLGSKVGMSQEKYKTLQCLNIPEINSLITTDMCSSLVHLLPMMQINFKGLQSHLKKCGGKYNQILAFRPTGWTHSNKFTRIADVIPQTKGNISIYGIPYSEHSSYLEMKRFVQWLKPQKIIPTVNVGTWKSRSTMEKYFREWKLEAGY","Homo sapiens","DCLRE1A, KIAA0086, SNM1, SNM1A","DNA CROSS-LINK REPAIR 1A PROTEIN","1","5AHR"
"5AHT",,"SOLUTION NMR",,,,,,,"10.1021/acs.biochem.5b01028",,"5AHT",4.97,,,"Third WW domain from the E3 ubiquitin-protein ligase NEDD4","GSMEQGFLPKGWEVRHAPNGRPFFIDHNTKTTTWEDPRLKIPA","Homo sapiens","NEDD4, KIAA0093, NEDD4-1, PIG53","E3 UBIQUITIN-PROTEIN LIGASE NEDD4","1","5AHT"
"5AHX",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005",,"5AHX",62.29,"2","2","Apo structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AHX"
"5AI0",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","JF6","5AI0",62.72,"1.75","1.75","Ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI0"
"5AI4",,"X-RAY DIFFRACTION",2.44,49.56,,,,,"10.1016/j.drudis.2015.04.005","4VY","5AI4",63.03,"1.93","1.93","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI4"
"5AI5",,"X-RAY DIFFRACTION",2.48,50.33,,,,,"10.1016/j.drudis.2015.04.005","BSU","5AI5",62.37,"2.28","2.28","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI5"
"5AI6",,"X-RAY DIFFRACTION",2.43,49.44,,,,,"10.1016/j.drudis.2015.04.005","4XH","5AI6",62.56,"2.3","2.3","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI6"
"5AI8",,"X-RAY DIFFRACTION",2.45,49.73,,,,,"10.1016/j.drudis.2015.04.005","K2T","5AI8",62.55,"1.85","1.85","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI8"
"5AI9",,"X-RAY DIFFRACTION",2.44,49.58,,,,,"10.1016/j.drudis.2015.04.005","K78","5AI9",62.76,"1.8","1.8","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AI9"
"5AIA",,"X-RAY DIFFRACTION",2.44,49.59,,,,,"10.1016/j.drudis.2015.04.005","KWB","5AIA",62.65,"2.26","2.26","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AIA"
"5AIB",,"X-RAY DIFFRACTION",2.46,50,,,,,"10.1016/j.drudis.2015.04.005","KJU","5AIB",62.47,"1.95","1.95","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AIB"
"5AIC",,"X-RAY DIFFRACTION",2.41,49.03,,,,,"10.1016/j.drudis.2015.04.005","TGX","5AIC",62.48,"1.89","1.89","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AIC"
"5AIK",,"X-RAY DIFFRACTION",2.7,54,,7.5,"0.2M NA/KPO4, 20% PEG 3350, 10% ETHYLENE GLYCOL, pH 7.5",,,,"5AIK",180.51,"2.7","2.7","Human DYRK1A in complex with LDN-211898","MHHHHHHSSGVDLGTENLYFQSMSSHKKERKVYNDGYDDDNYDYIVKNGEKWMDRYEIDSLIGKGSFGQVVKAYDRVEQEWVAIKIIKNKKAFLNQAQIEVRLLELMNKHDTEMKYYIVHLKRHFMFRNHLCLVFEMLSYNLYDLLRNTNFRGVSLNLTRKFAQQMCTALLFLATPELSIIHCDLKPENILLCNPKRSAIKIVDFGSSCQLGQRIYQYIQSRFYRSPEVLLGMPYDLAIDMWSLGCILVEMHTGEPLFSGANEVDQMNKIVEVLGIPPAHILDQAPKARKFFEKLPDGTWNLKKTKDGKREYKPPGTRKLHNILGVETGGPGGRRAGESGHTVADYLKFKDLILRMLDYDPKTRIQPYYALQHSFFKKTADE","Homo sapiens","DYRK1A, DYRK, MNB, MNBH","DYRK1A DUAL-SPECIFICITY TYROSINE-PHOSPHORYLATION REGULATED KINASE 1A","1","5AIK"
"5AIL",,"X-RAY DIFFRACTION",2.42,49.2,,6,"30% PEG1000, 0.1M SPG PH 6.0",,,,"5AIL",47.49,"1.55","1.55","Human PARP9 2nd macrodomain","SMNAMVVNNLTLQIVQGHIEWQTADVIVNSVNPHDITVGPVAKSILQQAGVEMKSEFLATKAKQFQRSQLVLVTKGFNLFCKYIYHVLWHSEFPKPQILKHAMKECLEKCIEQNITSISFPALGTGNMEIKKETAAEILFDEVLTFAKDHVKHQLTVKFVIFPTDLEIYKAFSSEMAKRSKMLSLN","Homo sapiens","PARP9, BAL, BAL1","POLY [ADP-RIBOSE] POLYMERASE 9","1","5AIL"
"5AIS",,"X-RAY DIFFRACTION",2.23,44.73,,,,,"10.1016/j.bmcl.2015.04.065","CWC","5AIS",96.08,"1.85","1.85","Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.","HPNYKLTYFNMRGRAEIIRYIFAYLDIQYEDHRIEQADWPEIKSTLPFGKIPILEVDGLTLHQSLAIARYLTKNTDLAGNTEMEQCHVDAIVDTLDDFMSCFPWAEKKQDVKEQMFNELLTYNAPHLMQDLDTYLGGREWLIGNSVTWADFYWEICSTTLLVFKPDLLDNHPRLVTLRKKVQAIPAVANWIKRRPQTKL","Homo sapiens","HPGDS, GSTS, PGDS, PTGDS2","HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE","1","5AIS"
"5AIV",,"X-RAY DIFFRACTION",2.19,43.84,,,,,"10.1016/j.bmcl.2015.04.065","M1W","5AIV",95.99,"2.04","2.04","Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.","HPNYKLTYFNMRGRAEIIRYIFAYLDIQYEDHRIEQADWPEIKSTLPFGKIPILEVDGLTLHQSLAIARYLTENTDLAGNTEMEQCHVDAIVDTLDDFMSCFPWAEKKQDVKEQMFNELLTYNAPHLMQDLDTYLGGREWLIGNSVTWADFYWEICSTTLLVFKPDLLDNHPRLVTLRKKVQAIPAVANWIKRRPQTKL","Homo sapiens","HPGDS, GSTS, PGDS, PTGDS2","HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE","1","5AIV"
"5AIX",,"X-RAY DIFFRACTION",2.12,41.91,,,,,"10.1016/j.bmcl.2015.04.065","KRX","5AIX",94.96,"2.1","2.1","Complex of human hematopoietic prostagandin D2 synthase (hH-PGDS) in complex with an active site inhibitor.","HPNYKLTYFNMRGRAEIIRYIFAYLDIQYEDHRIEQADWPEIKSTLPFGKIPILEVDGLTLHQSLAIARYLTENTDLAGNTEMEQCHVDAIVDTLDDFMSCFPWAEKKQDVKEQMFNELLTYNAPHLMQDLDTYLGGREWLIGNSVTWADFYWEICSTTLLVFKPDLLDNHPRLVTLRKKVQAIPAVANWIKRRPQTKL","Homo sapiens","HPGDS, GSTS, PGDS, PTGDS2","HEMATOPOIETIC PROSTAGLANDIN D SYNTHASE","1","5AIX"
"5AIZ",,"X-RAY DIFFRACTION",2.3,46.67,,4.5,"2.5 M SODIUM CHLORIDE, 0.2 M LITHIUM SULFATE AND 0.1 M SODIUM ACETATE PH4.5",,"10.1016/j.immuni.2015.10.007",,"5AIZ",14.35,"1.7","1.7","The PIAS-like coactivator Zmiz1 is a direct and selective cofactor of Notch1 in T-cell development and leukemia","GPAMAHMNSMDRHIQQTNDRLQCIKQHLQNPANFHNAATELLDWCGDPRAFQRPFEQSLMGCLTVVSRVAAQQGFDLDLGYRLLAVCAANRDKFTPKSAALLSSWCEELGRLLLLRHQKSRQSD","Homo sapiens","ZMIZ1, KIAA1224, RAI17, ZIMP10","ZINC FINGER MIZ DOMAIN-CONTAINING PROTEIN 1","1","5AIZ"
"5AJ1",,"SOLUTION NMR",,,,,,,"10.1016/j.str.2015.04.021",,"5AJ1",13,,,"Solution Structure of the Smarc Domain","GGSMMMALSKTFGQKPVKFQLEDDGEFYMIGSEVGNYLRMFRGSLYKRYPSLWRRLATVEERKKIVASSHGKKTKPNTKDHGYTTLATSVTLLKASEVEEILDGNDEKYKAVSIS","Homo sapiens","SMARCB1, BAF47, INI1, SNF5L1","SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY B MEMBER 1","1","5AJ1"
"5AJQ",,"X-RAY DIFFRACTION",2.34,47.5,,8.1,"0.1M TRIS PH 8.1, 0.1M MAGNESIUM CHLORIDE, 30%(W/V) PEG 10000",,,"DB8","5AJQ",68.03,"2.2","2.2","Human LOK (STK10) in complex with Bosutinib","SMREYEHVRRDLDPNEVWEIVGELGDGAFGKVYKAKNKETGALAAAKVIETKSEEELEDYIVEIEILATCDHPYIVKLLGAYYHDGKLWIMIEFCPGGAVDAIMLELDRGLTEPQIQVVCRQMLEALNFLHSKRIIHRDLKAGNVLMTLEGDIRLADFGVSAKNLKTLQKRDSFIGTPYWMAPEVVMCETMKDTPYDYKADIWSLGITLIEMAQIEPPHHELNPMRVLLKIAKSDPPTLLTPSKWSVEFRDFLKIALDKNPETRPSAAQLLEHPFVSSITSNKALRELVAEAKAE","Homo sapiens","STK10, LOK","SERINE/THREONINE-PROTEIN KINASE 10","1","5AJQ"
"5AJS",,"X-RAY DIFFRACTION",2.53,51.4,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1 M NA/K PHOSPHATE PH 6.2, 0.2 M NACL, 40% (V/V) MPD, HANGING DROP VAPOUR DIFFUSION, T = 285 K",285,"10.1016/j.jsb.2016.03.010",,"5AJS",32.03,"2.3","2.3","Crystal structure of a coiled-coil domain from human THAP11","SLSSGTTEEELLRKLNEQRDILALMEVKMKEMKGSIRHLRLTEAKLREELREKDRLLAMAVIRKKHGM","Homo sapiens","THAP11, HRIHFB2206","THAP DOMAIN-CONTAINING PROTEIN 11","1","5AJS"
"5AJV",,"X-RAY DIFFRACTION",4,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","8R2","5AJV",60.67,"3.01","3.01","Human PFKFB3 in complex with an indole inhibitor 1","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","HUMAN PFKFB3","1","5AJV"
"5AJW",,"X-RAY DIFFRACTION",3.31,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","S6L","5AJW",60.54,"2.5","2.5","Human PFKFB3 in complex with an indole inhibitor 2","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3","1","5AJW"
"5AJX",,"X-RAY DIFFRACTION",3.28,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","FD9","5AJX",60.59,"2.58","2.58","Human PFKFB3 in complex with an indole inhibitor 3","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3","1","5AJX"
"5AJY",,"X-RAY DIFFRACTION",3.35,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","87T","5AJY",60.49,"2.37","2.37","Human PFKFB3 in complex with an indole inhibitor 4","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3","1","5AJY"
"5AJZ",,"X-RAY DIFFRACTION",3.29,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","MJP","5AJZ",60.44,"2.35","2.35","Human PFKFB3 in complex with an indole inhibitor 5","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3","1","5AJZ"
"5AK0",,"X-RAY DIFFRACTION",3.37,64,,,"0.2M SODIUM MALONATE, 18W/V% PEG3350 AND 0.1 M PCTP BUFFER PH 7.0",,"10.1021/acs.jmedchem.5b00352","8V1","5AK0",60.64,"2.03","2.03","Human PFKFB3 in complex with an indole inhibitor 6","MPLELTQSRVQKIWVPVDHRPSLPRSCGPKLTNSPTVIVMVGLPARGKTYISKKLTRYLNWIGVPTKVFNVGEYRREAVKQYSSYNFFRPDNEEAMKVRKQCALAALRDVKSYLAKEGGQIAVFDATNTTRERRHMILHFAKENDFKAFFIESVCDDPTVVASNIMEVKISSPDYKDCNSAEAMDDFMKRISCYEASYQPLDPDKCDRDLSLIKVIDVGRRFLVNRVQDHIQSRIVYYLMNIHVQPRTIYLCRHGENEHNLQGRIGGDSGLSSRGKKFASALSKFVEEQNLKDLRVWTSQLKSTIQTAEALRLPYEQWKALNEIDAGVCEELTYEEIRDTYPEEYALREQDKYYYRYPTGESYQDLVQRLEPVIMELERQENVLVICHQAVLRCLLAYFLDKSAEEMPYLKCPLHTVLKLTPVAYGCRVESIYLNVESVCTHRERSEDAKKGPNPLMRRNSVTPLASPEPTKKPRINSFEEHVASTSAALPSCLPPEVPTQLPGQNMKGSRSSADSSRKH","Homo sapiens","PFKFB3","6-PHOSPHOFRUCTO-2-KINASE/FRUCTOSE-2,6-BISPHOSPHATASE 3","1","5AK0"
"5AK2",,"X-RAY DIFFRACTION",2.22,44.62,,,"OF 0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acs.jmedchem.5b00066","85Z","5AK2",62.02,"2.19","2.19","Oxyphenylpropenoic acids as Oral Selective Estrogen Receptor Down- Regulators.","MHHHHHHGGGENLYFQGSHMALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKSKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5AK2"
"5AK3",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","XM0","5AK3",62.56,"2.28","2.28","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AK3"
"5AK4",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","GVG","5AK4",62.63,"1.79","1.79","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AK4"
"5AK5",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","V2Z","5AK5",62.45,"2.22","2.22","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AK5"
"5AK6",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","YPN","5AK6",63.07,"2.15","2.15","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AK6"
"5AKE",,"X-RAY DIFFRACTION",2.44,49.54,,,,,"10.1016/j.drudis.2015.04.005","6N0","5AKE",62.82,"2.26","2.26","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKE"
"5AKG",,"X-RAY DIFFRACTION",2.45,49.74,,,,,"10.1016/j.drudis.2015.04.005",,"5AKG",62.36,"2.51","2.51","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKG"
"5AKH",,"X-RAY DIFFRACTION",2.45,49.77,,,,,"10.1016/j.drudis.2015.04.005","6NM","5AKH",62.64,"2.1","2.1","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKH"
"5AKI",,"X-RAY DIFFRACTION",2.44,49.69,,,,,"10.1016/j.drudis.2015.04.005","6NF","5AKI",63.12,"1.81","1.81","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKI"
"5AKJ",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","6N4","5AKJ",62.78,"2.03","2.03","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKJ"
"5AKK",,"X-RAY DIFFRACTION",2.44,49.56,,,,,"10.1016/j.drudis.2015.04.005","1P8","5AKK",62.62,"1.9","1.9","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKK"
"5AKL",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","6N8","5AKL",62.69,"2","2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKL"
"5AKS",,"X-RAY DIFFRACTION",2.31,46.76,"VAPOR DIFFUSION, HANGING DROP",7,"CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).",,"10.1074/jbc.M115.690172",,"5AKS",28.63,"1.25","1.25","Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O- glucuronide","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5AKS"
"5AKT",,"X-RAY DIFFRACTION",2.31,46.76,"VAPOR DIFFUSION, HANGING DROP",7,"CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).",,"10.1074/jbc.M115.690172",,"5AKT",28.56,"1.35","1.35","Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-4'-O- glucuronide","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5AKT"
"5AKU",,"X-RAY DIFFRACTION",2.4,49,,8.5,"0.2 M LISO4, 0.1 M TRIS HCL, 22% PEG3350, PH 8.5",,"10.1016/j.bmc.2015.06.063","29F","5AKU",56.04,"1.8","1.8","Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1,2, 3,4-tetrahydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5AKU"
"5AKV",,"X-RAY DIFFRACTION",2.3,46.7,"VAPOR DIFFUSION, HANGING DROP",7,"CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).",,"10.1074/jbc.M115.690172",,"5AKV",28.45,"1.52","1.52","Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: genistein-7-O- glucuronide","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5AKV"
"5AKW",,"X-RAY DIFFRACTION",2.4,49,,8.5,"pH 8.5",,"10.1016/j.bmc.2015.06.063","NKI","5AKW",55.72,"2.07","2.07","Crystal structure of TNKS2 in complex with 2-(4-chlorophenyl)-1,2,3,4- tetrahydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5AKW"
"5AKX",,"X-RAY DIFFRACTION",2.45,49.76,,,,,"10.1016/j.drudis.2015.04.005",,"5AKX",62.5,"2.09","2.09","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","SOLUBLE EPOXIDE HYDROLASE","1","5AKX"
"5AKY",,"X-RAY DIFFRACTION",2.43,49.42,,,,,"10.1016/j.drudis.2015.04.005",,"5AKY",62.78,"2.18","2.18","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKY"
"5AKZ",,"X-RAY DIFFRACTION",2.43,49.32,,,,,"10.1016/j.drudis.2015.04.005","6NX","5AKZ",62.73,"2.18","2.18","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AKZ"
"5AL0",,"X-RAY DIFFRACTION",2.3,46.7,"VAPOR DIFFUSION, HANGING DROP",7,"CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).",,"10.1074/jbc.M115.690172",,"5AL0",28.44,"1.388","1.388","Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: resveratrol-3-O-sulfate","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5AL0"
"5AL1",,"X-RAY DIFFRACTION",2.4,49,,8.5,"pH 8.5",,"10.1016/j.bmc.2015.06.063","GN5","5AL1",55.95,"1.75","1.75","Crystal structure of TNKS2 in complex with 2-(4-tert-butylphenyl)-1H, 2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE 2","1","5AL1"
"5AL2",,"X-RAY DIFFRACTION",2.4,49,,8.5,"PH 8.5",,"10.1016/j.bmc.2015.06.063","O53","5AL2",55.74,"1.9","1.9","Crystal structure of TNKS2 in complex with 2-(4-(propan-2-yl)phenyl)- 1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5AL2"
"5AL3",,"X-RAY DIFFRACTION",2.4,49,,8.5,"pH 8.5",,"10.1016/j.bmc.2015.06.063","TGW","5AL3",56.1,"1.75","1.75","Crystal structure of TNKS2 in complex with 2-(2,4-dichlorophenyl)-1- methyl-1H,2H,3H,4H-pyrido(2,3-d)pyrimidin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE 2","1","5AL3"
"5AL4",,"X-RAY DIFFRACTION",2.4,49,,8.5,"pH 8.5",,"10.1016/j.bmc.2015.06.063","WLH","5AL4",55.8,"1.9","1.9","Crystal structure of TNKS2 in complex with 2-(4-methylpiperazin-1-yl)- 3,4,5,6,7,8-hexahydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE 2","1","5AL4"
"5AL5",,"X-RAY DIFFRACTION",2.4,49,,8.5,"pH 8.5",,"10.1016/j.bmc.2015.06.063","JL9","5AL5",55.95,"2.05","2.05","Crystal structure of TNKS2 in complex with 2-(4-((pyridin-4-yl)methyl) piperazin-1-yl)-3,4,5,6,7,8-hexahydroquinazolin-4-one","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5AL5"
"5AL8",,"X-RAY DIFFRACTION",2.3,46.7,"VAPOR DIFFUSION, HANGING DROP",7,"CRYSTALS OF WT HUMAN TTR- LIGAND COMPLEXES WERE OBTAINED AT ROOM TEMPERATURE IN ABOUT ONE WEEK BY CO-CRYSTALLIZATION, USING THE HANGING-DROP VAPOR DIFFUSION METHOD. THE PROTEIN (5 MG/ML), IN 20 MM SODIUM PHOSPHATE, PH 7, WAS INCUBATED WITH A FOUR-FOLD MOLAR EXCESS OF LIGANDS SOLUBILIZED IN DMSO. DROPS WERE FORMED BY MIXING EQUAL VOLUMES OF THE SOLUTION CONTAINING LIGAND-TTR COMPLEXES AND OF THE RESERVOIR/PRECIPITANT SOLUTION (2.2 M AMMONIUM SULPHATE, 0.1 M KCL, 0.03 M SODIUM PHOSPHATE, PH 7.0).",,"10.1074/jbc.M115.690172",,"5AL8",28.42,"1.5","1.5","Transthyretin binding heterogeneity and anti-amyloidogenic activity of natural polyphenols and their metabolites: daidzein-7-O- glucuronide","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5AL8"
"5ALB",,"X-RAY DIFFRACTION",2.7,54.36,,,,,"10.1182/blood-2015-01-622928",,"5ALB",48.01,"2.16","2.16","Ticagrelor antidote candidate MEDI2452 in complex with ticagrelor","QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSFDYYFWSASHPPNDALAIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"MEDI2452 HEAVY CHAIN","1","5ALB"
,,,,,,,,,,,,,,,,"QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWLYDRAVGLFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"MEDI2452 LIGHT CHAIN","2","5ALB"
"5ALC",,"X-RAY DIFFRACTION",2.12,41.91,,,,,"10.1182/blood-2015-01-622928",,"5ALC",47.82,"1.7","1.7","Ticagrelor antidote candidate Fab 72 in complex with ticagrelor","QSVVTQPPSVSAAPGQKVTISCSGSNSDIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLAITGLQAGDEADYYCGTWDISLSAGLFGGGTKVTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"ANTI-TICAGRELOR FAB 72, LIGHT CHAIN","2","5ALC"
,,,,,,,,,,,,,,,,"QVQLQESGAEVKKPGSSVRVSCKASGGTFDSYSIHWVRQAPGQGLEWMGGIIPAFGTLSSAQDFQARVTISADKSTSTAYMELSGLRSEDTAVYYCARGSHLYDFWSASHPPNDALAIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSDCK","Homo sapiens",,"ANTI-TICAGRELOR FAB 72, HEAVY CHAIN","1","5ALC"
"5ALD",,"X-RAY DIFFRACTION",2.42,49.26,,,,,"10.1016/j.drudis.2015.04.005","FCW","5ALD",62.47,"2.26","2.26","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALD"
"5ALE",,"X-RAY DIFFRACTION",2.42,49.17,,,,,"10.1016/j.drudis.2015.04.005","ONR","5ALE",62.76,"1.95","1.95","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALE"
"5ALF",,"X-RAY DIFFRACTION",2.46,50.03,,,,,"10.1016/j.drudis.2015.04.005","OE1","5ALF",62.36,"2.32","2.32","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALF"
"5ALG",,"X-RAY DIFFRACTION",2.44,49.55,,,,,"10.1016/j.drudis.2015.04.005","R4N","5ALG",62.75,"2.4","2.4","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALG"
"5ALH",,"X-RAY DIFFRACTION",2.46,49.99,,,,,"10.1016/j.drudis.2015.04.005","4UA","5ALH",62.78,"1.9","1.9","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALH"
"5ALI",,"X-RAY DIFFRACTION",2.44,49.55,,,,,"10.1016/j.drudis.2015.04.005","Q3B","5ALI",63.14,"1.85","1.85","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALI"
"5ALJ",,"X-RAY DIFFRACTION",2.46,49.94,,,,,"10.1016/j.drudis.2015.04.005","T5J","5ALJ",62.67,"2.1","2.1","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALJ"
"5ALK",,"X-RAY DIFFRACTION",2.47,50.22,,,,,"10.1016/j.drudis.2015.04.005","WMR","5ALK",62.56,"2.33","2.33","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALK"
"5ALL",,"X-RAY DIFFRACTION",2.45,49.84,,,,,"10.1016/j.drudis.2015.04.005","II6","5ALL",62.6,"2.2","2.2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","SOLUBLE EPOXIDE HYDROLASE","1","5ALL"
"5ALM",,"X-RAY DIFFRACTION",2.46,49.91,,,,,"10.1016/j.drudis.2015.04.005","7GM","5ALM",62.51,"2","2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALM"
"5ALN",,"X-RAY DIFFRACTION",2.4,48.81,,,,,"10.1016/j.drudis.2015.04.005","5ZM","5ALN",62.74,"2","2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALN"
"5ALO",,"X-RAY DIFFRACTION",2.47,50.12,,,,,"10.1016/j.drudis.2015.04.005","A0J","5ALO",62.55,"2","2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALO"
"5ALP",,"X-RAY DIFFRACTION",2.46,50.01,,,,,"10.1016/j.drudis.2015.04.005","QYD","5ALP",62.93,"2.06","2.06","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALP"
"5ALQ",,"X-RAY DIFFRACTION",2.44,49.65,,,,,"10.1016/j.drudis.2015.04.005",,"5ALQ",62.42,"2.78","2.78","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALQ"
"5ALR",,"X-RAY DIFFRACTION",2.45,49.72,,,,,"10.1016/j.drudis.2015.04.005",,"5ALR",62.61,"2.6","2.6","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALR"
"5ALS",,"X-RAY DIFFRACTION",2.5,50.88,,,,,"10.1016/j.drudis.2015.04.005",,"5ALS",62.7,"2.57","2.57","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALS"
"5ALT",,"X-RAY DIFFRACTION",2.44,49.53,,,,,"10.1016/j.drudis.2015.04.005","9XZ","5ALT",62.78,"2.15","2.15","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALT"
"5ALU",,"X-RAY DIFFRACTION",2.42,49.25,,,,,"10.1016/j.drudis.2015.04.005","HD2","5ALU",63.59,"1.87","1.87","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALU"
"5ALV",,"X-RAY DIFFRACTION",2.45,49.75,,,,,"10.1016/j.drudis.2015.04.005","6TZ","5ALV",62.52,"1.8","1.8","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALV"
"5ALW",,"X-RAY DIFFRACTION",2.44,49.67,,,,,"10.1016/j.drudis.2015.04.005","JQN","5ALW",62.55,"2.2","2.2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALW"
"5ALX",,"X-RAY DIFFRACTION",2.45,49.72,,,,,"10.1016/j.drudis.2015.04.005","DUL","5ALX",62.52,"2.23","2.23","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALX"
"5ALY",,"X-RAY DIFFRACTION",2.41,48.96,,,,,"10.1016/j.drudis.2015.04.005","B7H","5ALY",62.87,"1.9","1.9","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALY"
"5ALZ",,"X-RAY DIFFRACTION",2.43,49.46,,,,,"10.1016/j.drudis.2015.04.005","XQ9","5ALZ",62.65,"2.3","2.3","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5ALZ"
"5AM0",,"X-RAY DIFFRACTION",2.43,49.34,,,,,"10.1016/j.drudis.2015.04.005","LWS","5AM0",62.69,"1.88","1.88","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM0"
"5AM1",,"X-RAY DIFFRACTION",2.46,50,,,,,"10.1016/j.drudis.2015.04.005","I5T","5AM1",62.75,"2.15","2.15","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM1"
"5AM2",,"X-RAY DIFFRACTION",2.45,49.84,,,,,"10.1016/j.drudis.2015.04.005","KUF","5AM2",63.02,"1.7","1.7","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM2"
"5AM3",,"X-RAY DIFFRACTION",2.44,49.6,,,,,"10.1016/j.drudis.2015.04.005","AUB","5AM3",62.82,"2.2","2.2","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM3"
"5AM4",,"X-RAY DIFFRACTION",2.41,48.87,,,,,"10.1016/j.drudis.2015.04.005","MVJ","5AM4",63.03,"1.87","1.87","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM4"
"5AM5",,"X-RAY DIFFRACTION",2.43,49.29,,,,,"10.1016/j.drudis.2015.04.005","6NZ","5AM5",62.68,"2.26","2.26","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5AM5"
"5AM6",,"X-RAY DIFFRACTION",2.7,56,,8,"20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4",,"10.1016/j.ebiom.2015.02.009","38O","5AM6",71.51,"1.96","1.96","Native FGFR1 with an inhibitor","MVAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1","5AM6"
"5AM7",,"X-RAY DIFFRACTION",2.74,56,,8,"20 % PEG 5K MME, 0.1 M TRIS, PH 7.5, 0.2 M (NH4)2SO4",,"10.1016/j.ebiom.2015.02.009","38O","5AM7",71.57,"1.957","1.957","FGFR1 mutant with an inhibitor","MVAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIMEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1","5AM7"
"5AM9",,"X-RAY DIFFRACTION",2.95,58,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,"10.1111/febs.13647",,"5AM9",300.49,"1.8","1.8","Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 10-16","LDPGLQPGQFSADEAGAQLFAQSYQSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQQFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSQMSRIYSTAKVCLPQKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWQATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLRAGSSRPWQEVLKDMVGLDALDAQPLLKYFQLVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDL","Homo sapiens","ACE, DCP, DCP1","ANGIOTENSIN-CONVERTING ENZYME","1","5AM9"
"5AMA",,"X-RAY DIFFRACTION",2.95,58,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,"10.1111/febs.13647",,"5AMA",299.94,"1.8","1.8","Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta 1-16","LDPGLQPGQFSADEAGAQLFAQSYQSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQQFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSQMSRIYSTAKVCLPQKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWQATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLRAGSSRPWQEVLKDMVGLDALDAQPLLKYFQLVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDL","Homo sapiens","ACE, DCP, DCP1","ANGIOTENSIN-CONVERTING ENZYME","1","5AMA"
"5AMC",,"X-RAY DIFFRACTION",2.85,57,,8.5,"0.06 M DIVALENT CATIONS, 0.1 M TRIS/BICINE PH 8.5, 30 % PEG550MME/PEG20000",,"10.1111/febs.13647",,"5AMC",150.03,"1.65","1.65","Crystal structure of the Angiotensin-1 converting enzyme N-domain in complex with amyloid-beta fluorogenic fragment 4-10","LDPGLQPGQFSAEDAGAQLFAQSYQSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQQFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSQMSRIYSTAKVCLPQKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWQATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLRAGSSRPWQEVLKDMVGLDALDAQPLLKYFQLVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDL","Homo sapiens","ACE, DCP, DCP1","ANGIOTENSIN-CONVERTING ENZYME","1","5AMC"
,,,,,,,,,,,,,,,,"LDPGLQPGQFSADEAGAQLFAQSYQSSAEQVLFQSVAASWAHDTNITAENARRQEEAALLSQEFAEAWGQKAKELYEPIWQQFTDPQLRRIIGAVRTLGSANLPLAKRQQYNALLSQMSRIYSTAKVCLPQKTATCWSLDPDLTNILASSRSYAMLLFAWEGWHNAAGIPLKPLYEDFTALSNEAYKQDGFTDTGAYWRSWYNSPTFEDDLEHLYQQLEPLYLNLHAFVRRALHRRYGDRYINLRGPIPAHLLGDMWAQSWENIYDMVVPFPDKPNLDVTSTMLQQGWQATHMFRVAEEFFTSLELSPMPPEFWEGSMLEKPADGREVVCHASAWDFYNRKDFRIKQCTRVTMDQLSTVHHEMGHIQYYLQYKDLPVSLRRGANPGFHEAIGDVLALSVSTPEHLHKIGLLDRVTNDTESDINYLLKMALEKIAFLPFGYLVDQWRWGVFSGRTPPSRYNFDWWYLRTKYQGICPPVTRNETHFDAGAKFHVPNVTPYIRYFVSFVLQFQFHEALCKEAGYEGPLHQCDIYRSTKAGAKLRKVLRAGSSRPWQEVLKDMVGLDALDAQPLLKYFQLVTQWLQEQNQQNGEVLGWPEYQWHPPLPDNYPEGIDLVTDEAEASKFVEEYDL","Homo sapiens","ACE, DCP, DCP1","ANGIOTENSIN-CONVERTING ENZYME","2","5AMC"
"5AMD",,"X-RAY DIFFRACTION",2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,"10.1039/c5cc01854d","45I","5AMD",29.61,"1.5","1.5","Three dimensional structure of human carbonic anhydrase II in complex with 2-((2-Phenylethyl)sulfamoyl)-4-sulfamoylbenzoic acid","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5AMD"
"5AME",,"X-RAY DIFFRACTION",2.57,52.17,,6.2,"0.1M BIS-TRIS PH 6.2 , 31% PEG3350, 293 K, 12 HOURS",293,,,"5AME",31.67,"1.578","1.578","Crystal structure of the bromodomain of human surface epitope engineered BRD1A in complex with 3D Consortium fragment 4-acetyl- piperazin-2-one (SGC - Diamond I04-1 fragment screening)","SMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","BROMODOMAIN-CONTAINING PROTEIN 1","1","5AME"
"5AMF",,"X-RAY DIFFRACTION",2.56,52.02,,6.2,"0.1M BIS-TRIS PH 7.0 , 30% PEG3350, 293 K, 12 HOURS",293,,,"5AMF",31.72,"1.75","1.75","Crystal structure of the bromodomain of human surface epitope engineered BRD1A in complex with 3D Consortium fragment Ethyl 4,5,6,7- tetrahydro-1H-indazole-5-carboxylate (SGC - Diamond I04-1 fragment screening)","SMEQVAMELRLTELTRLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","BROMODOMAIN-CONTAINING PROTEIN 1","1","5AMF"
"5AMG",,"X-RAY DIFFRACTION",2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,"10.1039/c5cc01854d","IW7","5AMG",29.57,"1.55","1.55","Three dimensional structure of human carbonic anhydrase II in complex with 2-(Pentylsulfamoyl)-4-sulfamoylbenzoic acid","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5AMG"
"5AML",,"X-RAY DIFFRACTION",2.1,42,"VAPOR DIFFUSION, SITTING DROP",9,"1,54 M SODIUM CITRATE 60 MM TRIS- HCL, PH 9.0, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K, TIME 2-5 DAYS",294,"10.1039/c5cc01854d","51J","5AML",29.56,"1.36","1.36","Three dimensional structure of human carbonic anhydrase II in complex with 2-(But-2-yn-1-ylsulfamoyl)-4-sulfamoylbenzoic acid","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5AML"
"5AMN",,"X-RAY DIFFRACTION",2.31,46.7,,4.4,"3.4M SODIUM FORMATE 0.1M SODIUM ACETATE PH 4.4",,"10.1016/j.ejmech.2016.01.039","DTQ","5AMN",34.97,"2.57","2.57","The Discovery of 2-Substituted Phenol Quinazolines as Potent and Selective RET Kinase Inhibitors","GPLSLSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKR","Homo sapiens","RET, CDHF12, CDHR16, PTC, RET51","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1","5AMN"
"5AN4",,"X-RAY DIFFRACTION",2.19,43.8,,,"0.1 M SODIUM CITRATE, PH=5.5, 0.2 M AMMONIUM SULFATE, 24 % PEG 3350",,"10.1107/S2059798316000954",,"5AN4",35.28,"1.6","1.6","Crystal structure of the human 8-oxoguanine glycosylase (OGG1) processed with the CrystalDirect automated mounting and cryo-cooling technology","GHRTLASTPALWASIPCPRSELRLDLVLPSGQSFRWREQSPAHWSGVLADQVWTLTQTEEQLHCTVYRGDKSQASRPTPDELEAVRKYFQLDVTLAQLYHHWGSVDSHFQEVAQKFQGVRLLRQDPIECLFSFICSSNNNIARITGMVERLCQAFGPRLIQLDDVTYHGFPSLQALAGPEVEAHLRKLGLGYRARYVSASARAILEEQGGLAWLQQLRESSYEEAHKALCILPGVGTKVADCICLMALDKPQAVPVDVHMWHIAQRDYSWHPTTSQAKGPSPQTNKELGNFFRSLWGPYAGWAQAVLFSADL","Homo sapiens","OGG1, MMH, MUTM, OGH1","N-GLYCOSYLASE/DNA LYASE","1","5AN4"
"5AND",,"X-RAY DIFFRACTION",2.02,39.02,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5AND",34.16,"2.3","2.3","Crystal structure of CDK2 in complex with 2-imidazol-1-yl-1H- benzimidazole processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5AND"
"5ANE",,"X-RAY DIFFRACTION",1.99,38.19,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANE",34.13,"1.7","1.7","Crystal structure of CDK2 in complex with 6-methoxy-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANE"
"5ANG",,"X-RAY DIFFRACTION",2.05,40.11,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANG",34.24,"1.9","1.9","Crystal structure of CDK2 in complex with 7-hydroxy-4-(morpholinomethyl)chromen-2-one processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANG"
"5ANI",,"X-RAY DIFFRACTION",2.01,38.78,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANI",34.13,"1.9","1.9","Crystal structure of CDK2 in complex with 6-chloro-7H-purine processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANI"
"5ANJ",,"X-RAY DIFFRACTION",2.03,39.45,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANJ",34.22,"1.6","1.6","Crystal structure of CDK2 in complex with N-(9H-purin-6-yl)thiophene- 2-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANJ"
"5ANK",,"X-RAY DIFFRACTION",1.87,34.33,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANK",34.22,"1.9","1.9","Crystal structure of CDK2 in complex with 2,4,6-trioxo-1-phenyl- hexahydropyrimidine-5-carboxamide processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANK"
"5ANL",,"X-RAY DIFFRACTION",2.88,57.3,,,"0.1 M TRIS, PH=7.5, 1.8 M AMMONIUM SULFATE",,"10.1107/S2059798316000954",,"5ANL",68.99,"2.7","2.7","Crystal structure of VPS34 in complex with (2S)-8-((3R)-3- Methylmorpholin-4-yl)-1-(3-methyl-2-oxo- butyl)-2-(trifluoromethyl)-3, 4-dihydro-2H-pyrimido(1,2-a)pyrimidin-6- one, processed with the CrystalDirect automated mounting and cryo-cooling technology","GAMSDHDLKPNAATRDQLNIIVSYPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALELLGKWKPMDVEDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQALKYENFDDIKNGLEPTKKDSQSSVSENVSNSGINSAEIDSSQIITSPLPSVSSPPPASKTKEVPDGENLEQDLCTFLISRACKNSTLANYLYWYVIVECEDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRSLLAAQQTFVDRLVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVKIRGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQIISLMDKLLRKENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQNFFRKYAPSENGPNGISAEVMDTYVKSCAGYCVITYILGVGDRHLDNLLLTKTGKLFHIDFGYILGRDPKPLPPPMKLNKEMVEGMGGTQSEQYQEFRKQCYTAFLHLRRYSNLILNLFSLMVDANIPDIALEPDKTVKKVQDKFRLDLSDEEAVHYMQSLIDESVHALFAAVVEQIH","Homo sapiens","PIK3C3, VPS34","PHOSPHATIDYLINOSITOL 3-KINASE CATALYTIC SUBUNIT TYPE 3","1","5ANL"
"5ANO",,"X-RAY DIFFRACTION",2.02,39.17,,,"0.02 M HEPES, PH=7.0, 5% GLYCEROL, 12% PEG 3350",,"10.1107/S2059798316000954",,"5ANO",33.98,"1.7","1.7","Crystal structure of CDK2 processed with the CrystalDirect automated mounting and cryo-cooling technology","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5ANO"
"5ANQ",,"X-RAY DIFFRACTION",2.59,52,,,"0.233 M LITHIUM SULFATE, 24% PEG 3350, 0.1 M HEPES PH 7.5",,"10.4155/fmc.15.188","5YQ","5ANQ",84.92,"2","2","inhibitors of JumonjiC domain-containing histone demethylases","MASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5ANQ"
"5ANS",,"X-RAY DIFFRACTION",2.2,44,,,,,"10.1021/acs.jmedchem.5b01760","RX8","5ANS",20.33,"1.6","1.6","Potent and selective inhibitors of MTH1 probe its role in cancer cell survival","GSSHHHHHHSSGLVPRGSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5ANS"
"5ANT",,"X-RAY DIFFRACTION",3.1,60,,,,,"10.1021/acs.jmedchem.5b01760","RJE","5ANT",61.02,"2","2","Potent and selective inhibitors of MTH1 probe its role in cancer cell survival","GSSHHHHHHSSGLVPRGSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5ANT"
"5ANU",,"X-RAY DIFFRACTION",2.01,38.68,,4.5,"PH 4.5",,"10.1021/acs.jmedchem.5b01760","58T","5ANU",18.54,"1.8","1.8","MTH1 in complex with compound 15","GAMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5ANU"
"5ANV",,"X-RAY DIFFRACTION",1.99,38.3,,4.5,"PH 4.5",,"10.1021/acs.jmedchem.5b01760","RGJ","5ANV",18.49,"1.16","1.16","MTH1 in complex with compound 15","GAMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5ANV"
"5ANW",,"X-RAY DIFFRACTION",2.01,38.72,,4.5,"pH 4.5",,"10.1021/acs.jmedchem.5b01760","9CQ","5ANW",18.41,"1.37","1.37","MTH1 in complex with compound 24","GAMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5ANW"
"5AO0",,"X-RAY DIFFRACTION",2.66,53.71,,,"160 MM SUCCINIC ACID, 11% PEG 3350, PH 7",,"10.1371/journal.ppat.1005194",,"5AO0",132.89,"3.731","3.731","Crystal structure of human SAMHD1 (amino acid residues 41-583) bound to ddGTP","MASWSHPQFEKGALEVLFQGPGDYKTWGPEQVCSFLRRGGFEEPVLLKNIRENEITGALLPCLDESRFENLGVSSLGERKKLLSYIQRLVQIHVDTMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQD","Homo sapiens","SAMHD1, MOP5","DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE SAMHD1","1","5AO0"
"5AO1",,"X-RAY DIFFRACTION",2.41,49.1,,,"100 MM BIS TRIS PROPANE-HCL, 150 MM NA2SO4, 13.5% PEG 3350 PH 6.5",,"10.1371/journal.ppat.1005194",,"5AO1",232.17,"2.545","2.545","Crystal structure of human SAMHD1 (amino acid residues 115-583) bound to ddGTP","MASWSHPQFEKGALEVLFQGPGMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQD","Homo sapiens","SAMHD1, MOP5","DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE SAMHD1","1","5AO1"
"5AO2",,"X-RAY DIFFRACTION",2.57,52.08,,,"0.2 M SODIUM CITRATE, 0.1 M BIS TRIS PROPANE-HCL, 20% PEG 3350, PH 8.5",,"10.1371/journal.ppat.1005194",,"5AO2",229.44,"2.966","2.966","Crystal structure of human SAMHD1 (amino acid residues 115-583) R164A variant bound to dGTP","MASWSHPQFEKGALEVLFQGPGMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNAFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQD","Homo sapiens","SAMHD1, MOP5","DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE SAMHD1","1","5AO2"
"5AO3",,"X-RAY DIFFRACTION",2.71,54.61,,,"0.2 M AMMONIUM SULPHATE, 20% PEG 3350",,"10.1371/journal.ppat.1005194",,"5AO3",252.47,"3.004","3.004","Crystal structure of human SAMHD1 (amino acid residues 115-626) bound to GTP","MASWSHPQFEKGALEVLFQGPGYQDPMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQDGDVIAPLITPQKKEWNDSTSVQNPTRLREASKSRVQLFKDDPM","Homo sapiens","SAMHD1, MOP5","DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE SAMHD1","1","5AO3"
"5AO4",,"X-RAY DIFFRACTION",2.25,45.46,,,"0.2 M SODIUM FORMATE, 20% PEG 3350",,"10.1371/journal.ppat.1005194",,"5AO4",251.41,"3.7","3.7","Crystal structure of in vitro phosphorylated human SAMHD1 (amino acid residues 115-626) bound to GTP","MASWSHPQFEKGALEVLFQGPGYQDPMKVINDPIHGHIELHPLLVRIIDTPQFQRLRYIKQLGGGYYVFPGASHNRFEHSLGVGYLAGCLVHALGEKQPELQISERDVLCVQIAGLCHDLGHGPFSHMFDGRFIPLARPEVKWTHEQGSVMMFEHLINSNGIKPVMEQYGLIPEEDICFIKEQIVGPLESPVEDSLWPYKGRPENKSFLYEIVSNKRNGIDVDKWDYFARDCHHLGIQNNFDYKRFIKFARVCEVDNELRICARDKEVGNLYDMFHTRNSLHRRAYQHKVGNIIDTMITDAFLKADDYIEITGAGGKKYRISTAIDDMEAYTKLTDNIFLEILYSTDPKLKDAREILKQIEYRNLFKYVGETQPTGQIKIKREDYESLPKEVASAKPKVLLDVKLKAEDFIVDVINMDYGMQEKNPIDHVSFYCKTAPNRAIRITKNQVSQLLPEKFAEQLIRVYCKKVDRKSLYAARQYFVQWCADRNFTKPQDGDVIAPLITPQKKEWNDSTSVQNPTRLREASKSRVQLFKDDPM","Homo sapiens","SAMHD1, MOP5","DEOXYNUCLEOSIDE TRIPHOSPHATE TRIPHOSPHOHYDROLASE SAMHD1","1","5AO4"
"5AO5",,"X-RAY DIFFRACTION",3.36,62,,7.5,"pH 7.5",,"10.1016/j.str.2015.09.004",,"5AO5",109.66,"2.48","2.48","Endo180 D1-4, monoclinic form","APLADAALPEPNVFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLSG","Homo sapiens","MRC2, CLEC13E, ENDO180, KIAA0709, UPARAP","C-TYPE MANNOSE RECEPTOR 2","1","5AO5"
"5AO6",,"X-RAY DIFFRACTION",3.15,59,,7.5,"PH 7.5",,"10.1016/j.str.2015.09.004",,"5AO6",111.27,"3.36","3.36","Endo180 D1-4, trigonal form","APLADAALPEPNVFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLSGAAAHHHHHH","Homo sapiens","MRC2, CLEC13E, ENDO180, KIAA0709, UPARAP","C-TYPE MANNOSE RECEPTOR 2","1","5AO6"
"5AOI",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 30 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","RZH","5AOI",49.58,"1.78","1.78","Structure of the p53 cancer mutant Y220C in complex with an indole- based small molecule","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AOI"
"5AOJ",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 23 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","Y0V","5AOJ",50.21,"1.47","1.47","Structure of the p53 cancer mutant Y220C in complex with 2-hydroxy-3, 5-diiodo-4-(1H-pyrrol-1-yl)benzoic acid","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AOJ"
"5AOK",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 38 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016",,"5AOK",49.97,"1.35","1.35","Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan7099","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AOK"
"5AOL",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: 30 MM COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","UFV","5AOL",49.45,"1.5","1.5","Structure of the p53 cancer mutant Y220C with bound 3-bromo-5-(trifluoromethyl)benzene-1,2-diamine","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AOL"
"5AOM",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: SATURATED SOLUTION OF COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1016/j.str.2015.10.016","FY8","5AOM",50.3,"1.74","1.74","Structure of the p53 cancer mutant Y220C with bound small molecule PhiKan883","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5AOM"
"5AP0",,"X-RAY DIFFRACTION",3.1,60.34,,7.5,"30% (V/V) PEG300, PH 7.5",,"10.1158/0008-5472.CAN-14-3272","AU5","5AP0",38.34,"2.15","2.15","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP0"
"5AP1",,"X-RAY DIFFRACTION",3.04,59.49,,6.5,"0.1M MES PH 6.5, 0.2M MGCL2, 10% (W/V) PEG4000, CO-CRYSTALLISED WITH 1MM INHIBITOR",,"10.1158/0008-5472.CAN-14-3272",,"5AP1",37.3,"2.05","2.05","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP1"
"5AP2",,"X-RAY DIFFRACTION",2.82,56.31,,7.5,"0.1M BIS-TRIS PROPANE PH 7.5, 22% (W/V) PEG3350, 0.1M MGCL2, 0.1M NA FORMATE CO-CRYSTAL WITH 1MM INHIBITOR",,"10.1158/0008-5472.CAN-14-3272",,"5AP2",36.58,"2.8","2.8","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP2"
"5AP3",,"X-RAY DIFFRACTION",3.05,59.62,,7.5,"38% (V/V) PEG300, pH 7.5",,"10.1158/0008-5472.CAN-14-3272","AU5","5AP3",38.12,"2.7","2.7","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNGWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP3"
"5AP4",,"X-RAY DIFFRACTION",3.1,60.32,,7.5,"38% (V/V) PEG300, PH 7.5",,"10.1158/0008-5472.CAN-14-3272",,"5AP4",37.34,"2.85","2.85","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNGWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP4"
"5AP5",,"X-RAY DIFFRACTION",3.09,60.23,,7.5,"38% (V/V) PEG300, PH 7.5",,"10.1158/0008-5472.CAN-14-3272","7RO","5AP5",36.96,"2.8","2.8","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNGWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP5"
"5AP6",,"X-RAY DIFFRACTION",2.82,56.37,,7.5,"38% (V/V) PEG300, PH 7.5",,"10.1158/0008-5472.CAN-14-3272",,"5AP6",37.37,"2.1","2.1","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEWGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","DUAL SPECIFICITY PROTEIN KINASE TTK","1","5AP6"
"5AP7",,"X-RAY DIFFRACTION",3.18,61.28,,8,"0.1M TRIS, PH 8.0, 0.2M MGCL2, 20% (W/ V) PEG6000",,"10.1158/0008-5472.CAN-14-3272","SVE","5AP7",37.26,"2.45","2.45","Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMEWGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","MONOPOLAR SPINDLE KINASE 1","1","5AP7"
"5APA",,"X-RAY DIFFRACTION",4.47,72.52,,,"50MM SODIUM MALATE, 20% PEG3350, 3% DEXTRAN SULFATE, 20MM NISO4",,"10.1038/s41467-019-12711-7",,"5APA",25.9,"2.05","2.05","Crystal structure of human aspartate beta-hydroxylase isoform a","MHHHHHHSSGVDLGTENLYFQSMRSLYNVNGLKAQPWWTPKETGYTELVKSLERNWKLIRDEGLAVMDKAKGLFLPEDENLREKGDWSQFTLWQQGRRNENACKGAPKTCTLLEKFPETTGCRRGQIKYSIMHPGTHVWPHTGPTNCRLRMHLGLVIPKEGCKIRCANETKTWEEGKVLIFDDSFEHEVWQDASSFRLIFIVDVWHPELTPQQRRSLPAI","Homo sapiens","ASPH, BAH","ASPARTYL/ASPARAGINYL BETA-HYDROXYLASE","1","5APA"
"5APK",,"X-RAY DIFFRACTION",2.93,58.03,,,,,"10.1002/cmdc.201500432","76E","5APK",64.53,"2.1","2.1","Ligand complex of RORg LBD","MHNHNHNHNHNHNGGENLYFQGASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","NUCLEAR RECEPTOR ROR-GAMMA","1","5APK"
,,,,,,,,,,,,,,,,"VERLQIFQHLHPI","Homo sapiens","RORC, NR1F3, RORG, RZRG","NUCLEAR RECEPTOR ROR-GAMMA","2","5APK"
"5AQ0",,"X-RAY DIFFRACTION",2.22,44.67,,,,,,,"5AQ0",17.61,"0.95","0.95","The structure of the Transthyretin-like domain of the first catalytic domain of the HUMAN Carboxypeptidase D","SGVKGFVKDSITGSGLENATISVAGINHNITTGRFGDFYRLLVPGTYNLTVVLTGYMPLTVTNVVVKEGPATEVDFSLRPHH","Homo sapiens","CPD","CARBOXYPEPTIDASE D","1","5AQ0"
"5AQW",,"X-RAY DIFFRACTION",2.37,48.2,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM ADENOSINE, THEN BACKSOAKED WITH 100 MM INHIBITOR (20% DMSO) FOR 16H AT 18 DEGREES C",291,"10.1038/srep34701",,"5AQW",44.49,"1.53","1.53","Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","HEAT SHOCK 70 KDA PROTEIN 1A","1","5AQW"
"5AQX",,"X-RAY DIFFRACTION",2.32,47.07,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM ADENOSINE, THEN BACKSOAKED WITH 100 MM INHIBITOR (20% DMSO) FOR 16H AT 18 DEGREES C",291,"10.1038/srep34701",,"5AQX",43.77,"2.12","2.12","Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","HEAT SHOCK 70 KDA PROTEIN 1A","1","5AQX"
"5AQY",,"X-RAY DIFFRACTION",2.4,48.8,,7.5,"17-28% (W/V) PEG3350, 0.1M HEPES PH 7.5, 2MM MGCL2, 2MM NAH2PO4 AND 5MM ADENOSINE",,"10.1038/srep34701","ADN","5AQY",44.87,"1.56","1.56","Fragment-based screening of HSP70 sheds light on the functional role of ATP-binding site residues","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","HEAT SHOCK 70 KDA PROTEIN 1A","1","5AQY"
"5AQZ",,"X-RAY DIFFRACTION",2.41,48.89,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM INHIBITOR",,"10.1021/acs.jmedchem.5b02001","SGV","5AQZ",43.75,"1.65","1.65","HSP72 with adenosine-derived inhibitor","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","HEAT SHOCK 70 KDA PROTEIN 1A","1","5AQZ"
"5AR0",,"X-RAY DIFFRACTION",2.08,40.73,,7.5,"17-28% (W/V) PEG3350, 0.1 M HEPES PH 7.5, 2 MM MGCL2, 2 MM NAH2PO4 AND 5 MM INHIBITOR",,"10.1021/acs.jmedchem.5b02001","GB8","5AR0",44.09,"1.9","1.9","HSP72 with adenosine-derived inhibitor","GPLGSMAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILIKSTRAAAS","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","HEAT SHOCK 70 KDA PROTEIN 1A","1","5AR0"
"5AR2",,"X-RAY DIFFRACTION",3.64,66.16,,7.5,"28% PEG400, 5% GLYCEROL, 0.1M HEPES PH7.5, 0.2M CACL2",,"10.1016/j.bmc.2015.09.038",,"5AR2",75.25,"2.44","2.44","RIP2 Kinase Catalytic Domain (1 - 310)","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR2"
"5AR3",,"X-RAY DIFFRACTION",3.54,65.26,,,"20% PEG3350, 0.2M NAKTARTRATE",,"10.1016/j.bmc.2015.09.038",,"5AR3",76.27,"3.23","3.23","RIP2 Kinase Catalytic Domain (1 - 310) complex with AMP-PCP","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR3"
"5AR4",,"X-RAY DIFFRACTION",3.53,65.18,,8.5,"0.1M TRIS HCL PH8.5, 0.7M DINH4TARTRATE.",,"10.1016/j.bmc.2015.09.038",,"5AR4",75.97,"2.7","2.7","RIP2 Kinase Catalytic Domain (1 - 310) complex with SB-203580","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR4"
"5AR5",,"X-RAY DIFFRACTION",3.61,65.93,,7.5,"0.2M CACL2, 5% GLYCEROL, 0.1M HEPES PH 7.5, 26.6% PEG400",,"10.1016/j.bmc.2015.09.038","IQ7","5AR5",76.16,"2.66","2.66","RIP2 Kinase Catalytic Domain (1 - 310) complex with Benzimidazole","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR5"
"5AR7",,"X-RAY DIFFRACTION",3.57,65.59,,6.5,"30% PEG300, 0.1M MES PH6.5",,"10.1016/j.bmc.2015.09.038","SR8","5AR7",75.92,"2.71","2.71","RIP2 Kinase Catalytic Domain (1 - 310) complex with Biaryl Urea","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR7"
"5AR8",,"X-RAY DIFFRACTION",3.61,65.95,,4.6,"30% GLYCEROL, 0.07M NA OAC PH4.6, 1.4M NA FORMATE",,"10.1016/j.bmc.2015.09.038","XYW","5AR8",76.58,"2.79","2.79","RIP2 Kinase Catalytic Domain (1 - 310) complex with Biphenylsulfonamide","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","RECEPTOR-INTERACTING SERINE/THREONINE-PROTEIN KINASE 2","1","5AR8"
"5ARF",,"X-RAY DIFFRACTION",2.41,49,,7,"SMYD2 CO-CRYSTALLIZED WITH 2 MMOL SAM. RESERVOIR 23% PEG 3350, 100 MMOL HEPES PH 7.0. CO-COMPLEX WITH INHIBITOR FORMED BY SOAKING SMYD2-SAM CRYSTALS WITH 5 MILLIMOLAR COMPOUND-2 FOR 1 HOUR. CRYO WITH ADDITIONAL 20% GLYCEROL AND 1 MMOL COMPOUND-2.",,"10.1021/acs.jmedchem.5b01890","I9H","5ARF",50.77,"1.92","1.92","SMYD2 in complex with small molecule inhibitor compound-2","GRAEGLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLGFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-LYSINE METHYLTRANSFERASE SMYD2","1","5ARF"
"5ARG",,"X-RAY DIFFRACTION",2.45,49.9,,7,"22% PEG 3350, 100 MMOL HEPES PH 7.0. CRYO BUFFER CONTAINS AN ADDTIONAL 20% GLYCEROL AND 1 MMOL LIGAND. OTHER CRYSTALISATION REMARKS:4 MILLIMOLAR COFACTOR SAM ADDED AND MIXTURE INCUBATED FOR 2 HOURS AT 4 DEGREE CELSIUS PRIOR TO CRYSTALLIZATION. CO- COMPLEX WITH BAY-598 FORMED BY SOAKING SMYD2-SAM CRYSTALS WITH 5 MILLIMOLAR LIGAND FOR 4 DAYS.",277,"10.1021/acs.jmedchem.5b01890","H41","5ARG",50.9,"1.99","1.99","SMYD2 in complex with SGC probe BAY-598","GRAEGLGGLERFCSPGKGRGLRALQPFQVGDLLFSCPAYAYVLTVNERGNHCEYCFTRKEGLSKCGRCKQAFYCNVECQKEDWPMHKLECSPMVVFGENWNPSETVRLTARILAKQKIHPERTPSEKLLAVKEFESHLDKLDNEKKDLIQSDIAALHHFYSKHLGFPDNDSLVVLFAQVNCNGFTIEDEELSHLGSAIFPDVALMNHSCCPNVIVTYKGTLAEVRAVQEIKPGEEVFTSYIDLLYPTEDRNDRLRDSYFFTCECQECTTKDKDKAKVEIRKLSDPPKAEAIRDMVRYARNVIEEFRRAKHYKSPSELLEICELSQEKMSSVFEDSNVYMLHMMYQAMGVCLYMQDWEGALQYGQKIIKPYSKHYPLYSLNVASMWLKLGRLYMGLEHKAAGEKALKKAIAIMEVAHGKDHPYISEIKQEIESH","Homo sapiens","SMYD2, KMT3C","N-LYSINE METHYLTRANSFERASE SMYD2","1","5ARG"
"5AUT",,"X-RAY DIFFRACTION",1.91,35.56,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","2AN","5AUT",34.1,"1.7","1.7","Crystal structure of DAPK1 in complex with ANS.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUT"
"5AUU",,"X-RAY DIFFRACTION",1.92,35.81,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","LU2","5AUU",34.08,"1.7","1.7","Crystal structure of DAPK1 in complex with luteolin.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUU"
"5AUV",,"X-RAY DIFFRACTION",1.91,35.56,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","AGI","5AUV",34.1,"1.5","1.5","Crystal structure of DAPK1 in complex with apigenin.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUV"
"5AUW",,"X-RAY DIFFRACTION",1.91,35.45,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","QUE","5AUW",34.1,"1.5","1.5","Crystal structure of DAPK1 in complex with quercetin.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUW"
"5AUX",,"X-RAY DIFFRACTION",1.91,35.44,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","KMP","5AUX",34.12,"1.5","1.5","Crystal structure of DAPK1 in complex with kaempferol.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUX"
"5AUY",,"X-RAY DIFFRACTION",1.9,35.38,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","MRI","5AUY",34.1,"2","2","Crystal structure of DAPK1 in complex with morin.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUY"
"5AUZ",,"X-RAY DIFFRACTION",1.91,35.57,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","GEN","5AUZ",34.07,"1.6","1.6","Crystal structure of DAPK1 in complex with genistein.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AUZ"
"5AV0",,"X-RAY DIFFRACTION",1.89,34.95,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","47X","5AV0",34.07,"1.85","1.85","Crystal structure of DAPK1 in complex with 7,3',4'-trihydroxyisoflavone.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AV0"
"5AV1",,"X-RAY DIFFRACTION",1.91,35.53,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893",,"5AV1",34.36,"1.5","1.5","Crystal structure of DAPK1 in the presence of bromide ions.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AV1"
"5AV2",,"X-RAY DIFFRACTION",1.91,35.54,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","KMP","5AV2",34.64,"1.502","1.502","Crystal structure of DAPK1-kaempferol complex in the presence of bromide ions.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AV2"
"5AV3",,"X-RAY DIFFRACTION",1.91,35.61,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","KMP","5AV3",35.22,"1.9","1.9","Crystal structure of DAPK1-kaempferol complex in the presence of iodide ions.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AV3"
"5AV4",,"X-RAY DIFFRACTION",1.91,35.5,"VAPOR DIFFUSION, HANGING DROP",,"2 M ammonium sulfate, 0.1 M MES",293,"10.1021/acs.jmedchem.5b00893","GEN","5AV4",34.39,"1.4","1.4","Crystal structure of DAPK1-genistein complex in the presence of bromide ions.","MTVFRQENVDDYYDTGEELGSGQFAVVKKCREKSTGLQYAAKFIKKRRTKSSRRGVSREDIEREVSILKEIQHPNVITLHEVYENKTDVILILELVAGGELFDFLAEKESLTEEEATEFLKQILNGVYYLHSLQIAHFDLKPENIMLLDRNVPKPRIKIIDFGLAHKIDFGNEFKNIFGTPEFVAPEIVNYEPLGLEADMWSIGVITYILLSGASPFLGDTKQETLANVSAVNYEFEDEYFSNTSALAKDFIRRLLVKDPKKRMTIQDSLQHPWIKPKDTQQALSLEHHHHHH","Homo sapiens","DAPK1, DAPK","Death-associated protein kinase 1","1","5AV4"
"5AWA",,"X-RAY DIFFRACTION",2.65,53.5,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, potassium formate, sodium citrate",293,,"M8D","5AWA",96.42,"2.2","2.2","Crystal structure of human TLR8 in complex with MB-568","RSPWEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTEFLVPR","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5AWA"
"5AWB",,"X-RAY DIFFRACTION",2.69,54.28,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, potassium formate, sodium citrate",293,"10.1021/acs.jmedchem.5b01087","M0A","5AWB",95.62,"2.1","2.1","Crystal structure of human TLR8 in complex with N1-3-aminomethylbenzyl (meta-amine)","RSPWEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTEFLVPR","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5AWB"
"5AWC",,"X-RAY DIFFRACTION",2.99,58.82,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, potassium formate, sodium citrate",293,,"M4D","5AWC",380.86,"2.5","2.5","Crystal structure of human TLR8 in complex with MB-564","RSPWEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTEFLVPR","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5AWC"
"5AWD",,"X-RAY DIFFRACTION",2.7,54.44,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, potassium formate, sodium citrate",293,"10.1021/acs.jmedchem.5b01087","IDQ","5AWD",96.67,"2.05","2.05","Crystal structure of human TLR8 in complex with N1-4-aminomethylbenzyl (IMDQ)","RSPWEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTEFLVPR","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5AWD"
"5AWN",,"X-RAY DIFFRACTION",2.3,46.45,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M sodium citrate pH 5.6, 20% 2-propanol, 20% PEG 4000",298,"10.1038/ncomms9167",,"5AWN",48.13,"1.887","1.887","Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC176 Fab","QVQLMQSGAQLRDPGDSLKISCKASGYNFIDYHIHWVRLAPGRGLEWMGWIDPVGGITKYAGQFQGRLSLTRDTSTNTLFLELSRLTAGDTAVYFCARSMRPVDHGIDYSGLFVFHFWGRGSDVLVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"Heavy chain of 3BC176 Fab","1","5AWN"
,,,,,,,,,,,,,,,,"QSVLTQPASVSASPGQSITVSCTGSRNDVGGYDFVSWYQRHPGGVPKLIIYEISKRPSGIPQRFSGSRSGNTASLTISGLQDDDEADYYCCSYASYDRLIFGGGTRVSVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Light chain of 3BC176 Fab","2","5AWN"
"5AWR",,"X-RAY DIFFRACTION",3.85,68.06,"VAPOR DIFFUSION, HANGING DROP",5.1,"PEG 3350, zinc acetate, sodium acetate, sodium iodide",293,"10.1038/srep19565",,"5AWR",31.39,"2.502","2.502","Crystal structure of the SGIP1 mu homology domain in the P4212 space group","GPLGSLTMGAQDTLPVAAAFTETVNAYFKGADPSKCIVKITGEMVLSFPAGITRHFANNPSPAALTFRVINFSRLEHVLPNPQLLCCDNTQNDANTKEFWVNMPNLMTHLKKVSEQKPQATYYNVDMLKYQVSAQGIQSTPLNLAVNWRCEPSSTDLRIDYKYNTDAMTTAVALNNVQFLVPIDGGVTKLQAVLPPAVWNAEQQRILWKIPDISQKSENGGVGSLLARFQLSEGPSKPSPLVVQFTSEGSTLSGCDIELVGAGYRFSLIKKRFAAGKYLADN","Homo sapiens","SGIP1","SH3-containing GRB2-like protein 3-interacting protein 1","1","5AWR"
"5AWS",,"X-RAY DIFFRACTION",2.39,48.53,"VAPOR DIFFUSION, HANGING DROP",5.1,"PEG 3350, zinc acetate, sodium acetate, sodium iodide",293,"10.1038/srep19565",,"5AWS",62.47,"2.001","2.001","Crystal structure of the SGIP1 mu homology domain in the P1 space group","GPLGSLTMGAQDTLPVAAAFTETVNAYFKGADPSKCIVKITGEMVLSFPAGITRHFANNPSPAALTFRVINFSRLEHVLPNPQLLCCDNTQNDANTKEFWVNMPNLMTHLKKVSEQKPQATYYNVDMLKYQVSAQGIQSTPLNLAVNWRCEPSSTDLRIDYKYNTDAMTTAVALNNVQFLVPIDGGVTKLQAVLPPAVWNAEQQRILWKIPDISQKSENGGVGSLLARFQLSEGPSKPSPLVVQFTSEGSTLSGCDIELVGAGYRFSLIKKRFAAGKYLADN","Homo sapiens","SGIP1","SH3-containing GRB2-like protein 3-interacting protein 1","1","5AWS"
"5AWX",,"X-RAY DIFFRACTION",2.63,53.27,"VAPOR DIFFUSION, SITTING DROP",8.5,"10% (w/v) PEG8000, 20% (v/v) ethylene glycol, 30mM sodium fluoride, 30mM sodium bromide, 30mM sodium iodide",277,"10.1038/srep20473",,"5AWX",34.27,"1.86","1.86","Crystal structure of Human PTPRZ D1 domain","GPAIPIKHFPKHVADLHASSGFTEEFEEVQSCTVDLGITADSSNHPDNKHKNRYINIVAYDHSRVKLAQLAEKDGKLTDYINANYVDGYNRPKAYIAAQGPLKSTAEDFWRMIWEHNVEVIVMITNLVEKGRRKCDQYWPADGSEEYGNFLVTQKSVQVLAYYTVRNFTLRNTKIKKGSQKGRPSGRVVTQYHYTQWPDMGVPEYSLPVLTFVRKAAYAKRHAVGPVVVHCSAGVGRTGTYIVLDSMLQQIQHEGTVNIFGFLKHIRSQRNYLVQTEEQYVFIHDTLVEAILSKETEV","Homo sapiens","PTPRZ1, HTPZP2, PTPRZ, PTPRZ2, PTPZ","Receptor-type tyrosine-protein phosphatase zeta","1","5AWX"
"5AX8",,"X-RAY DIFFRACTION",2.14,42.58,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.1 M HEPES pH 6.8, 25% (v/v) Jeffamine ED-2001 pH 6.8",277,"10.5582/bst.2015.01150",,"5AX8",182.33,"2.989","2.989","Recombinant expression, purification and preliminary crystallographic studies of the mature form of human mitochondrial aspartate aminotransferase","SSWWTHVEMGPPDPILGVTEAFKRDTNSKKMNLGVGAYRDDNGKPYVLPSVRKAEAQIAAKNLDKEYLPIGGLAEFCKASAELALGENSEVLKSGRFVTVQTISGTGALRIGASFLQRFFKFSRDVFLPKPTWGNHTPIFRDAGMQLQGYRYYDPKTCGFDFTGAVEDISKIPEQSVLLLHACAHNPTGVDPRPEQWKEIATVVKKRNLFAFFDMAYQGFASGDGDKDAWAVRHFIEQGINVCLCQSYAKNMGLYGERVGAFTMVCKDADEAKRVESQLKILIRPMYSNPPLNGARIAAAILNTPDLRKQWLQEVKGMADRIIGMRTQLVSNLKKEGSTHNWQHITDQIGMFCFTGLKPEQVERLIKEFSIYMTKDGRISVAGVTSSNVGYLAHAIHQVTKHHHHHH","Homo sapiens","GOT2, KYAT4","Aspartate aminotransferase, mitochondrial","1","5AX8"
"5AX9",,"X-RAY DIFFRACTION",2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",5.6,"24% PEG3350, 0.2M ammonium sulfate, 
0.1M Bis-tris (5.6)",293,"10.1038/ncomms12586","4KT","5AX9",106.67,"2.4","2.4","Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase in complex with compund 9","GSGADEIDLSALRDPAGIFELVELVGNGTYGQVYKGRHVKTGQLAAIKVMDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNTKGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDFKSDLWSLGITAIEMAEGAPPLCDMHPMRALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRIQLKDHIDRTKKKRG","Homo sapiens","TNIK, KIAA0551","TRAF2 and NCK-interacting protein kinase","1","5AX9"
"5AXP",,"X-RAY DIFFRACTION",2.22,44.71,"VAPOR DIFFUSION",8,"100 mM HEPES pH 8.0, 100 mM mM  magnesium chloride hexahydrate, 25.7% PEG 3350",277,"10.1016/j.bmc.2015.10.002","4LK","5AXP",78.85,"1.95","1.95","Crystal structure of the catalytic domain of PDE10A complexed with 1-(2-fluoro-4-(2-oxo-1,3-oxazolidin-3-yl)phenyl)-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one","TSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5AXP"
"5AXQ",,"X-RAY DIFFRACTION",2.09,41.09,"VAPOR DIFFUSION",7.4,"200 mM HEPES pH 7.4, 100 mM mM  magnesium chloride hexahydrate, 27.4% PEG 3350",277,"10.1016/j.bmc.2015.10.002","4LP, 4LK","5AXQ",78.91,"1.77","1.77","Crystal structure of the catalytic domain of PDE10A complexed with highly potent and brain-penetrant PDE10A Inhibitor with 2-oxindole scaffold","TSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5AXQ"
"5AYF",,"X-RAY DIFFRACTION",2.33,47.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris-HCl pH 8.5, 31% PEG 6000",277,"10.1021/acs.jmedchem.5b01732","C7H","5AYF",29.67,"2.005","2.005","Crystal structure of SET7/9 in complex with cyproheptadine","GSSGSSGKDNIRHGVCWIYYPDGGSLVGEVNEDGEMTGEKIAYVYPDERTALYGKFIDGEMIEGKLATLMSTEEGRPHFELMPGNSVYHFDKSTSSCISTNALLPDPYESERVYVAESLISSAGEGLFSKVAVGPNTVMSFYNGVRITHQEVDSRDWALNGNTLSLDEETVIDVPEPYNHVSKYCASLGHKANHSFTPNCIYDMFVHPRFGPIKCIRTLRAVEADEELTVAYGXXXXXXXXXXXXXPEWYQVELKAFQATQQK","Homo sapiens","SETD7, KIAA1717, KMT7, SET7, SET9","Histone-lysine N-methyltransferase SETD7","1","5AYF"
"5AYG",,"X-RAY DIFFRACTION",3.13,60.73,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Tris-HCl , pH 7.5, 0.5M Na/K tartrate, 2.5M, MPD",293,"10.1021/acsmedchemlett.5b00253","4LQ","5AYG",60.61,"2.6","2.6","Crystal Structure of the Human ROR gamma Ligand Binding Domain With 3g","EAPYASLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFSTETESPVGLSK","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5AYG"
"5AYT",,"X-RAY DIFFRACTION",1.74,29.41,"VAPOR DIFFUSION, HANGING DROP",7,"18% polyethylene glycol 400, 0.1 M HEPES-NaOH, 0.2 M CaCl2, 1 mM L6",293,"10.1016/j.jphs.2015.09.006","L6Y","5AYT",35.26,"1.4","1.4","Crystal structure of transthyretin in complex with L6","MRGSHHHHHHGSMASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5AYT"
"5AYX",,"X-RAY DIFFRACTION",2.45,49.88,"VAPOR DIFFUSION",5,"100MM MES-NAOH (PH 5.0), 7-15% (W/V)
 PEG-MME 2000, 10MM KSCN, VAPOR DIFFUSION, HANGING DROP,
 TEMPERATURE 294K",294,"10.1038/srep19681",,"5AYX",191.68,"2.8","2.8","Crystal structure of Human Quinolinate Phosphoribosyltransferase","MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKSPGVLAGQPFFDAIFTQLNCQVSWFLPEGSKLVPVARVAEVRGPAHCLLLGERVALNTLARCSGIASAAAAAVEAARGAGWTGHVAGTRKTTPGFRLVEKYGLLVGGAASHRYDLGGLVMVKDNHVVAAGGVEKAVRAARQAADFTLKVEVECSSLQEAVQAAEAGADLVLLDNFKPEELHPTATVLKAQFPSVAVEASGGITLDNLPQFCGPHIDVISMGMLTQAAPALDFSLKLFAKEVAPVPKIHLEHHHHHH","Homo sapiens","QPRT","Nicotinate-nucleotide pyrophosphorylase [carboxylating]","1","5AYX"
"5AYY",,"X-RAY DIFFRACTION",3.23,61.91,"VAPOR DIFFUSION, HANGING DROP",8,"8% PEG8000, 0.1M MEGNESIUM ACETATE, PH
 8.0, VAPOR DIFFUSION, TEMPERATURE 273.0K",294,"10.1038/srep19681",,"5AYY",288.75,"3.09","3.09","CRYSTAL STRUCTURE OF HUMAN QUINOLINATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH THE REACTANT QUINOLINATE","MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKSPGVLAGQPFFDAIFTQLNCQVSWFLPEGSKLVPVARVAEVRGPAHCLLLGERVALNTLARCSGIASAAAAAVEAARGAGWTGHVAGTRKTTPGFRLVEKYGLLVGGAASHRYDLGGLVMVKDNHVVAAGGVEKAVRAARQAADFALKVEVECSSLQEAVQAAEAGADLVLLDNFKPEELHPTATVLKAQFPSVAVEASGGITLDNLPQFCGPHIDVISMGMLTQAAPALDFSLKLFAKEVAPVPKIHLEHHHHHH","Homo sapiens","HEL-S-90n, QPRT","Nicotinate-nucleotide pyrophosphorylase [carboxylating]","1","5AYY"
"5AYZ",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, HANGING DROP",5,"10% PEG MME 2K, 0.01M POTASSIUM
 THIOCYANATE, PH 5.0, VAPOR DIFFUSION, TEMPERATURE 273.0K",294,"10.1038/srep19681",,"5AYZ",387.02,"2.6","2.6","CRYSTAL STRUCTURE OF HUMAN QUINOLINATE PHOSPHORIBOSYLTRANSFERASE IN COMPLEX WITH THE PRODUCT NICOTINATE MONONUCLEOTIDE","MDAEGLALLLPPVTLAALVDSWLREDCPGLNYAALVSGAGPSQAALWAKSPGVLAGQPFFDAIFTQLNCQVSWFLPEGSKLVPVARVAEVRGPAHCLLLGERVALNTLARCSGIASAAAAAVEAARGAGWTGHVAGTRKTTPGFRLVEKYGLLVGGAASHRYDLGGLVMVKDNHVVAAGGVEKAVRAARQAADFALKVEVECSSLQEAVQAAEAGADLVLLDNFKPEELHPTATVLKAQFPSVAVEASGGITLDNLPQFCGPHIDVISMGMLTQAAPALDFSLKLFAKEVAPVPKIHLEHHHHHH","Homo sapiens","HEL-S-90n, QPRT","Nicotinate-nucleotide pyrophosphorylase [carboxylating]","1","5AYZ"
"5AZ5",,"X-RAY DIFFRACTION",2.85,56.89,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, potassium formate, sodium citrate",293,,,"5AZ5",382.39,"2.4","2.4","Crystal structure of human TLR8 in complex with MB-343","RSPWEENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHIRKRRSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVTEFLVPR","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5AZ5"
"5AZE",,"X-RAY DIFFRACTION",2.23,44.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"20.0% PEG 4000, 0.1M HEPES",293,"10.1080/19420862.2015.1110660",,"5AZE",47.26,"2.2","2.2","Fab fragment of calcium-dependent antigen binding antibody, 6RL#9","QSVLTQPPSVSGAPGQRVTISCTGSRSNMGAGYDVHWYQLLPGAAPKLLISHNTHRPSGVPDRFSGSKSGASASLAITGLQAEDEADYYCQSHDSSLSAVVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"6RL#9 FAB LIGHT CHAIN","1","5AZE"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGASVKVSCKASGYTFTSYYMHWVRQAPGQGLEWMGIINPSGGSTSYAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDDPGGGEYYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT","Homo sapiens",,"6RL#9 FAB HEAVY CHAIN","2","5AZE"
"5AZV",,"X-RAY DIFFRACTION",2.59,52.52,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1 M Tris-HCl, 0.825 M sodium citrate",293,"10.1021/acschembio.6b00338",,"5AZV",63.59,"2.7","2.7","Crystal structure of hPPARgamma ligand binding domain complexed with 17-oxoDHA","GALNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY","Homo sapiens","PPARG, NR1C3","Peroxisome proliferator-activated receptor gamma","1","5AZV"
"5AZW",,"X-RAY DIFFRACTION",1.97,37.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl (pH 8.5), 0.2 M sodium chloride and 25 % (w/v) PEG 3,350",293,"10.1016/j.jmb.2016.08.023",,"5AZW",21.46,"1.5","1.5","Crystal structure of p24beta1 GOLD domain","SGYFVSIDAHAEECFFERVTSGTKMGLIFEVAEGGFLDIDVEITGPDNKGIYKGDRESSGKYTFAAHMDGTYKFCFSNRMSTMTPKIVMFTIDIGE","Homo sapiens","TMED2, RNP24","Transmembrane emp24 domain-containing protein 2","1","5AZW"
"5B0H",,"X-RAY DIFFRACTION",2.05,39.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG8000, 0.2M AMMONIUM SULFATE, 0.1M HEPES",293,"10.1074/jbc.M116.720375",,"5B0H",29.72,"1.94","1.94","CRYSTAL STRUCTURE OF HUMAN LEUKOCYTE CELL-DERIVED CHEMOTAXIN 2","GPGPWANICAGKSSNEIRTCDRHGCGQYSAQRSQRPHQGVDVLCSAGSTVYAPFTGMIVGQEKPYQNKNAINNGVRISGRGFCVKMFYIKPIKYKGPIKKGEKLGTLLPLQKVYPGIQSHVHIENCDSSDPTAYL","Homo sapiens","LECT2","Leukocyte cell-derived chemotaxin-2","1","5B0H"
"5B0X",,"X-RAY DIFFRACTION",1.97,37.69,"VAPOR DIFFUSION, SITTING DROP",,"ethylene glycol",277,"10.1016/j.bmc.2016.01.043","HCK","5B0X",40.83,"2.3","2.3","Crystal structure of the CK2a/benzoic acid derivative complex","GPLGSMSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CK2A1, CSNK2A1","Casein kinase II subunit alpha","1","5B0X"
"5B1W",,"X-RAY DIFFRACTION",2.8,56.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris-HCl (pH 8.5), 0.2M sodium acetate and 30%(w/v) polyethylene glycol 4,000",293,"10.1002/1873-3468.12162",,"5B1W",63.57,"3.05","3.05","Crystal structure of human dendritic cell inhibitory receptor (DCIR) C-type lectin domain in ligand-free form","GSCPKNWKSFSSNCYFISTESASWQDSEKDCARMEAHLLVINTQEEQDFIFQNLQEESAYFVGLSDPEGQRHWQWVDQTPYNESSTFWHPREPSDPNERCVVLNFRKSPKRWGWNDVNCLGPQRSVCEMMKIHL","Homo sapiens","CLEC4A, CLECSF6, DCIR, LLIR, HDCGC13P","C-type lectin domain family 4 member A","1","5B1W"
"5B1X",,"X-RAY DIFFRACTION",2.78,55.77,"VAPOR DIFFUSION, HANGING DROP",,"0.1M potassium thiocyanate and 20%(w/v) polyethylene glycol monomethyl ether 2,000",293,"10.1002/1873-3468.12162",,"5B1X",65.1,"2.902","2.902","Crystal structure of human dendritic cell inhibitory receptor (DCIR) C-type lectin domain in complex with biantennary glycan","GSCPKNWKSFSSNCYFISTESASWQDSEKDCARMEAHLLVINTQEEQDFIFQNLQEESAYFVGLSDPEGQRHWQWVDQTPYNESSTFWHPREPSDPNERCVVLNFRKSPKRWGWNDVNCLGPQRSVCEMMKIHL","Homo sapiens","CLEC4A, CLECSF6, DCIR, LLIR, HDCGC13P","C-type lectin domain family 4 member A","1","5B1X"
"5B25",,"X-RAY DIFFRACTION",2.54,51.66,"VAPOR DIFFUSION, SITTING DROP",8,"1.75 M ammonium sulfate, 0.1 M Tris-HCl",277,"10.1021/acs.jmedchem.5b01751","4QJ","5B25",158.38,"1.9","1.9","Crystal structure of human PDE1B with inhibitor 3","VGPTYSTAVLNCLKNLDLWCFDVFSLNQAADDHALRTIVFELLTRHNLISRFKIPTVFLMSFLDALETGYGKYKNPYHNQIHAADVTQTVHCFLLRTGMVHCLSEIELLAIIFAAAIHDYEHTGTTNSFHIQTKSECAIVYNDRSVLENHHISSVFRLMQDDEMNIFINLTKDEFVELRALVIEMVLATDMSCHFQQVKTMKTALQQLERIDKPKALSLLLHAADISHPTKQWLVHSRWTKALMEEFFRQGDKEAELGLPFSPLCDRTSTLVAQSQIGFIDFIVEPTFSVLTDVAEKSVQPLAGDPNPDVVSFRSTWVKRIQENKQKWKERAASGITN","Homo sapiens","PDE1B, PDE1B1, PDES1B","Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B","1","5B25"
"5B27",,"X-RAY DIFFRACTION",2.19,43.9,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris-HCl (pH8.0), 45% (v/v) PEG 400",293,,,"5B27",15.29,"1.02","1.02","The 1.02A structure of human FABP3 M20S mutant complexed with palmitic acid","MVDAFLGTWKLVDSKNFDDYSKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA","Homo sapiens","FABP3, FABP11, MDGI","Fatty acid-binding protein, heart","1","5B27"
"5B28",,"X-RAY DIFFRACTION",2.18,43.6,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris-HCl (pH8.0), 55% (v/v) PEG 400",293,,,"5B28",15.33,"0.9","0.9","The 0.90A structure of human FABP3 F16V mutant complexed with palmitic acid","MVDAFLGTWKLVDSKNVDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA","Homo sapiens","FABP3, FABP11, MDGI","Fatty acid-binding protein, heart","1","5B28"
"5B29",,"X-RAY DIFFRACTION",2.28,45.9,"VAPOR DIFFUSION, SITTING DROP",8,"0.1M Tris-HCl (pH8.0), 45-55% (v/v) PEG 400",277,,,"5B29",14.96,"1.28","1.28","The 1.28A structure of human FABP3 F16V mutant complexed with palmitic acid at room temperature","VDAFLGTWKLVDSKNVDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA","Homo sapiens","FABP3, FABP11, MDGI","Fatty acid-binding protein, heart","1","5B29"
"5B2K",,"X-RAY DIFFRACTION",2.6,52.78,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, sodium citrate tribasic, Hepes",277,"10.1016/j.bbrc.2016.03.036",,"5B2K",37,"2.75","2.75","A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7","MTGYLTIGGQRYQAEINDLENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIVQCFGTFITNTDVFIAMELMGTCAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFRHHHHHH","Homo sapiens","MAP2K7, JNKK2, MEK7, MKK7, PRKMK7, SKK4","Dual specificity mitogen-activated protein kinase kinase 7","1","5B2K"
"5B2L",,"X-RAY DIFFRACTION",2.23,44.82,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350, sodium citrate tribasic, HEPES",310,"10.1016/j.bbrc.2016.03.036",,"5B2L",37.55,"2.1","2.1","A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7","MTGYLTIGGQRYQAEINDLENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIVQCFGTFITNTDVFIAMELMGTSAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFRHHHHHH","Homo sapiens","MAP2K7, JNKK2, MEK7, MKK7, PRKMK7, SKK4","Dual specificity mitogen-activated protein kinase kinase 7","1","5B2L"
"5B2M",,"X-RAY DIFFRACTION",2.64,53.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 3350, sodium citrate tribasic, HEPES, AMPPCP, MgCl2",310,"10.1016/j.bbrc.2016.03.036",,"5B2M",37,"3.06","3.06","A crucial role of Cys218 in the stabilization of an unprecedented auto-inhibition form of MAP2K7","MTGYLTIGGQRYQAEINDLENLGEMGSGTCGQVWKMRFRKTGHVIAVKQMRRSGNKEENKRILMDLDVVLKSHDCPYIVQCFGTFITNTDVFIAMELMGTCAEKLKKRMQGPIPERILGKMTVAIVKALYYLKEKHGVIHRDVKPSNILLDERGQIKLCDFGISGRLVDSKAKTRSAGCAAYMAPERIDPPDPTKPDYDIRADVWSLGISLVELATGQFPYKNCKTDFEVLTKVLQEEPPLLPGHMGFSGDFQSFVKDCLTKDHRKRPKYNKLLEHSFIKRYETLEVDVASWFKDVMAKTESPRTSGVLSQPHLPFFRHHHHHH","Homo sapiens","MAP2K7, JNKK2, MEK7, MKK7, PRKMK7, SKK4","Dual specificity mitogen-activated protein kinase kinase 7","1","5B2M"
"5B2Z",,"X-RAY DIFFRACTION",2.57,52.09,"VAPOR DIFFUSION, SITTING DROP",4.5,"PEG400, SODIUM ACETATE, CALCIUM ACETATE, MAGNESIUM CHLORIDE",293,"10.1038/srep25931",,"5B2Z",19.91,"1.56","1.56","H-Ras WT in complex with GppNHp (state 2*) before structural transition by humidity control","GPLGSMTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQH","Homo sapiens","HRAS, HRAS1","GTPase HRas","1","5B2Z"
"5B30",,"X-RAY DIFFRACTION",2.55,51.8,"VAPOR DIFFUSION, SITTING DROP",4.5,"PEG400, SODIUM ACETATE, CALCIUM ACETATE, MAGNESIUM CHLORIDE",293,"10.1038/srep25931",,"5B30",19.94,"1.6","1.6","H-Ras WT in complex with GppNHp (state 1) after structural transition by humidity control","GPLGSMTEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCVFAINNTKSFEDIHQYREQIKRVKDSDDVPMVLVGNKCDLAARTVESRQAQDLARSYGIPYIETSAKTRQGVEDAFYTLVREIRQH","Homo sapiens","HRAS, HRAS1","GTPase HRas","1","5B30"
"5B4K",,"X-RAY DIFFRACTION",2.11,41.73,"VAPOR DIFFUSION, SITTING DROP",,"100 mM HEPES pH 7.6, 100 mM magnesium chloride hexahydrate, 24.182% PEG 3350",277,"10.1016/j.bmc.2016.05.049",,"5B4K",78.67,"2.9","2.9","Crystal structure of the catalytic domain of human PDE10A complexed with N-(4-((5-methyl-5H-pyrrolo[3,2-d]pyrimidin-4-yl)oxy)phenyl)-1H-benzimidazol-2-amine","TSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5B4K"
"5B4L",,"X-RAY DIFFRACTION",2.05,39.98,"VAPOR DIFFUSION, SITTING DROP",7.88,"100 mM HEPES pH 7.88, 100 mM magnesium chloride hexahydrate, 25.7% PEG 3350",277,"10.1016/j.bmc.2016.05.049","6DW","5B4L",78.95,"2.4","2.4","Crystal structure of the catalytic domain of human PDE10A complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1H-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one","TSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5B4L"
"5B4O",,"X-RAY DIFFRACTION",3.65,66.26,"VAPOR DIFFUSION, SITTING DROP",9,"2.4M ammonium sulfate, 0.1M bicine pH 9.0
, 2.4 mM BTZO-14",293,"10.1016/j.chembiol.2010.10.011",,"5B4O",38.95,"1.37","1.37","Crystal structure of Macrophage Migration Inhibitory Factor in complex with BTZO-14","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5B4O"
"5B4Y",,"X-RAY DIFFRACTION",1.86,33.95,"VAPOR DIFFUSION, SITTING DROP",7,"20%(wt./vol.) PEG monomethylether 2000, 100 mM Tris-Cl (pH 7.0)",293,,,"5B4Y",9.7,"1.9","1.9","Crystal structure of the LA12 fragment of ApoER2","GSGPAKECEKDQFQCRNERCIPSVWRCDEDDDCLDHSDEDDCPKKTCADSDFTCDNGHCIHERWKCDGEEECPDGSDESEATCTK","Homo sapiens","LRP8, APOER2","Low-density lipoprotein receptor-related protein 8","1","5B4Y"
"5B5O",,"X-RAY DIFFRACTION",2.31,46.79,"VAPOR DIFFUSION, SITTING DROP",8.5,"100mM TrisHCl, 1500mM ammonium formate, 10.4% PEG8000",293,"10.1021/acs.jmedchem.6b01007","WMM","5B5O",39.84,"1.2","1.2","Crystal structure of the catalytic domain of MMP-13 complexed with N-phenyl-4-((4H-1,2,4-triazol-3-ylsulfanyl)methyl)-1,3-thiazol-2-amine","EYNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPN","Homo sapiens","MMP13","Collagenase 3","1","5B5O"
"5B5P",,"X-RAY DIFFRACTION",2.36,47.86,"VAPOR DIFFUSION, SITTING DROP",8.5,"100mM TrisHCl, 1000mM ammonium formate, 15.3% PEG8000",293,"10.1021/acs.jmedchem.6b01007","WNN","5B5P",40.08,"1.6","1.6","Crystal structure of the catalytic domain of MMP-13 complexed with 4-oxo-N-(3-(2-(1H-1,2,4-triazol-3-ylsulfanyl)ethoxy)benzyl)-3,4-dihydroquinazoline-2-carboxamide","EYNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPN","Homo sapiens","MMP13","Collagenase 3","1","5B5P"
"5B6M",,"X-RAY DIFFRACTION",2.76,55.44,"VAPOR DIFFUSION, HANGING DROP",,"100 mM magnesium formate, 18% polyethylene glycol 3350",277,"10.1016/j.bbrc.2016.06.125",,"5B6M",150.41,"2.496","2.496","Crystal structure of human peroxiredoxin 6 in reduced state","MPGGLLLGDVAPNFEANTTVGRIRFHDFLGDSWGILFSHPRDFTPVCTTELGRAAKLAPEFAKRNVKLIALSIDSVEDHLAWSKDINAYNCEEPTEKLPFPIIDDRNRELAILLGMLDPAEKDEKGMPVTARVVFVFGPDKKLKLSILYPATTGRNFDEILRVVISLQLTAEKRVATPVDWKDGDSVMVLPTIPEEEAKKLFPKGVFTKELPSGKKYLRYTPQP","Homo sapiens","PRDX6, AOP2, KIAA0106","Peroxiredoxin-6","1","5B6M"
"5B6N",,"X-RAY DIFFRACTION",2.8,56.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM HEPES, 20% PEG 8000",277,"10.1016/j.bbrc.2016.06.125",,"5B6N",150.6,"2.895","2.895","Crystal structures of human peroxiredoxin 6 in sulfinic acid state","MPGGLLLGDVAPNFEANTTVGRIRFHDFLGDSWGILFSHPRDFTPVCTTELGRAAKLAPEFAKRNVKLIALSIDSVEDHLAWSKDINAYNCEEPTEKLPFPIIDDRNRELAILLGMLDPAEKDEKGMPVTARVVFVFGPDKKLKLSILYPATTGRNFDEILRVVISLQLTAEKRVATPVDWKDGDSVMVLPTIPEEEAKKLFPKGVFTKELPSGKKYLRYTPQP","Homo sapiens","PRDX6, AOP2, KIAA0106","Peroxiredoxin-6","1","5B6N"
"5B73",,"X-RAY DIFFRACTION",2.05,40.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"HEPES, sodium citrate tribasic",291,"10.1016/j.molcel.2016.06.035",,"5B73",39.26,"1.8","1.8","Crystal structure of human ZMYND8 PHD-Bromo-PWWP domain","GPLGSLTTDPVDVVPQDGRNDFYCWVCHREGQVLCCELCPRVYHAKCLRLTSEPEGDWFCPECEKITVAECIETQSKAMTMLTIEQLSYLLKFAIQKMKQPGTDAFQKPVPLEQHPDYAEYIFHPMDLCTLEKNAKKKMYGCTEAFLADAKWILHNCIIYNGGNHKLTQIAKVVIKICEHEMNEIEVCPECYLAACQKRDNWFCEPCSNPHPLVWAKLKGFPFWPAKALRDKDGQVDARFFGQHDRAWVPINNCYLMSKEIPFSVKKTKSIFNSAMQEMEVYVENIRRKFGVFNYSPFRTPYTPNSQYQMLLDPTNPSAGTAKIDKQEKVKLNFDMTAS","Homo sapiens","ZMYND8, KIAA1125, PRKCBP1, RACK7","Protein kinase C-binding protein 1","1","5B73"
"5B79",,"X-RAY DIFFRACTION",2.72,54.82,"VAPOR DIFFUSION, SITTING DROP",,"ammonium citrate tribasic, Bis-Tris propane",291,"10.1038/nchembio.2218",,"5B79",14.08,"2.601","2.601","Crystal structure of DPF2 double PHD finger","SNNYCDFCLGDSKINKKTGQPEELVSCSDCGRSGHPSCLQFTPVMMAAVKTYRWQCIECKCCNICGTSENDDQLLFCDDCDRGYHMYCLTPSMSEPPEGSWSCHLCLDLLKEKASIYQNQNSS","Homo sapiens","DPF2, BAF45D, REQ, UBID4","Zinc finger protein ubi-d4","1","5B79"
"5B7A",,"SOLUTION NMR",,,,,,,,,"5B7A",12.81,,,"SOLUTION STRUCTURE OF LYS37 ACETYLATED HUMAN SUMO1","MGSSHHHHHHSQDPMSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGG","Homo sapiens","SUMO1, SMT3C, SMT3H3, UBL1, OK/SW-cl.43","Small ubiquitin-related modifier 1","1","5B7A"
"5B7V",,"X-RAY DIFFRACTION",2.7,53.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 10000, (NH4)2SO4, BIS-TRIS",277,"10.1158/1535-7163.MCT-14-0248","LWJ","5B7V",71.43,"2.15","2.15","Human FGFR1 kinase in complex with CH5183284","MVAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","Fibroblast growth factor receptor 1","1","5B7V"
"5B8D",,"X-RAY DIFFRACTION",2.17,43.26,"VAPOR DIFFUSION, SITTING DROP",4.6,"2M Na-formate, 0.2M Na-acetate pH4.6, 5% ethylene glycol",291,"10.1021/acs.jmedchem.7b00933",,"5B8D",12.4,"1.05","1.05","Crystal structure of a low occupancy fragment candidate (N-(4-Methyl-1,3-thiazol-2-yl)propanamide) bound adjacent to the ubiquitin binding pocket of the HDAC6 zinc-finger domain","GSPLPWCPHLVAVCPIPAAGLDVTQPCGDCGTIQENWVCLSCYQVYCGRYINGHMLQHHGNSGHPLVLSYIDLSAWCYYCQAYVHHQALLDVKNIAHQNKFGEDMPH","Homo sapiens","HDAC6, KIAA0901, JM21","Histone deacetylase 6","1","5B8D"
"5BK3",,"X-RAY DIFFRACTION",3.34,63.19,"VAPOR DIFFUSION, SITTING DROP",5,"100 mM MES pH 5, 1.6 M (NH4)2SO4",294,"10.1016/j.immuni.2017.11.007",,"5BK3",198.21,"2.8","2.8","Crystal structure of the neutralizing anti-circumsporozoite protein 580 antibody","DIVMTQSPDSLAVSLGERATINCKSSQSVFFSSNNRTYFAWYQQKPGQPPKVLISWASTRESGVPDRFSGSGSGTDFTLTINSLQAEDVAVYFCQQYYSSPITFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"580 Antibody, light chain","1","5BK3"
,,,,,,,,,,,,,,,,"EVQLLESGGGLVQPGGSLRLSCGASGFIFGHYAMSWVRQAPQKGLEWVSGISGGGESTNYADSVKGRFTISRDNSRNTVYLQMNSLRAEDTAIYYCAKDPGGDSSPAGRTWFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"580 Antibody, heavy chain","2","5BK3"
"5BK5",,"X-RAY DIFFRACTION",2.5,50.85,"VAPOR DIFFUSION, SITTING DROP",8.5,"100 mM Tris pH 8.5, 200 mM MgCl2, 20% (w/v) PEG 4000",294,"10.1016/j.immuni.2017.11.007",,"5BK5",191.64,"3","3","Crystal structure of the anti-circumsporozoite protein 663 germline antibody","EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSVIYSGGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCTTLLILESDVGVDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"663 germline antibody, heavy chain","1","5BK5"
,,,,,,,,,,,,,,,,"DIVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCMQALQTPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"663 germline antibody, light chain","2","5BK5"
"5BK8",,"X-RAY DIFFRACTION",1.99,38.34,"VAPOR DIFFUSION, HANGING DROP",,"16% PEG3350, 200 mM LiCl",293,"10.1074/jbc.RA119.010274",,"5BK8",61.79,"2.25","2.25","Cancer-associated SHP2/T507K mutant","MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQKEAQYRFIYMAVQHYIETLQRRLEHHHHHH","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5BK8"
"5BMF",,"X-RAY DIFFRACTION",4.63,73.46,"VAPOR DIFFUSION",8.5,"2M Na-Formate,
0.1 M Tris",293,"10.1080/19420862.2015.1068492",,"5BMF",49.41,"2.8","2.8","Crystal Structure of a Theophylline binding antibody Fab fragment","QVQLQESGPGLVKPSQTLSLTCTVSGYSITSDYAWNWIRQHPGKGLEWIGYIRYSGHTGYNPSLKSRVTISRDTSKNQFSLKLSSVTAADTAVYYCARWVDYFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT","Homo sapiens",,"Fab fragment heavy chain","1","5BMF"
,,,,,,,,,,,,,,,,"DVVMTQSPLSLPVTLGQPASISCRSSQSIVYNNRYTYLEWFQQRPGQSPRLLIYGVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYYCYQGTHAPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"Fab fragment light chain","2","5BMF"
"5BML",,"X-RAY DIFFRACTION",4.58,73.14,"VAPOR DIFFUSION, HANGING DROP",5.5,"4.5% PEG3350, 100mM MES, pH 5.5, 50mM CaCl2, 10mM DTT, 0.45 mM protein, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,"10.1021/acs.jmedchem.5b00424","4TW","5BML",96.84,"2.95","2.95","ROCK 1 bound to a pyridine thiazole inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","5BML"
"5BMS",,"X-RAY DIFFRACTION",2.9,57.64,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Tri-Potassium citrate and 20% PEG3350",277,"10.1021/acs.jmedchem.5b00572",,"5BMS",33.45,"2.903","2.903","Crystal structure of P21-activated kinase 4 in complex with an inhibitor compound 29","GSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR","Homo sapiens","PAK4, KIAA1142","Serine/threonine-protein kinase PAK 4","1","5BMS"
"5BN8",,"X-RAY DIFFRACTION",2.39,48.62,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 % PEG-3350 W/V, 0.1 M HEPES",293,,,"5BN8",43.48,"1.34","1.34","Crystal structure of nucleotide-free human Hsp70 NBD.","MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKRTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENV","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5BN8"
"5BN9",,"X-RAY DIFFRACTION",2.39,48.62,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 % PEG-3350 W/V, 0.1 M HEPES",293,,"ADP","5BN9",43.55,"1.689","1.689","Crystal structure of ADP bound human Hsp70 NBD mutant R272K.","MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKKTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENV","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5BN9"
"5BNL",,"X-RAY DIFFRACTION",2.12,42.08,"VAPOR DIFFUSION, HANGING DROP",,"Tris.HCl pH 7.7-7.8 , sodium 4-(hydroxymercury)benzoate",277,"10.1021/jm901287j","2HC","5BNL",29.36,"2","2","Deciphering the Mechanism of Carbonic Anhydrase Inhibition with Coumarins and Thiocoumarins","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5BNL"
"5BO6",,"X-RAY DIFFRACTION",2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",5.8,"0.2 M (NH4)3PO4, 50 mM PIPES, 18-22% PEG2000",293,"10.1038/nsmb.3060",,"5BO6",79.94,"2.07","2.07","Structure of human sialyltransferase ST8SiaIII in complex with CDP","APEHHHHHHDYDIPTTENLYFQGQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA","Homo sapiens","ST8SIA3, SIAT8C","Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase","1","5BO6"
"5BO7",,"X-RAY DIFFRACTION",2.83,56.52,"VAPOR DIFFUSION, HANGING DROP",5.8,"0.2 M (NH4)3PO4, 50 mM PIPES, 18-22% PEG2000",293,"10.1038/nsmb.3060",,"5BO7",80.14,"1.85","1.85","Structure of human sialyltransferase ST8SiaIII in complex with CTP","APEHHHHHHDYDIPTTENLYFQGQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA","Homo sapiens","ST8SIA3, SIAT8C","Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase","1","5BO7"
"5BO8",,"X-RAY DIFFRACTION",3.27,62.33,"VAPOR DIFFUSION, HANGING DROP",5.5,"18-21% PEG3350, 30 mM sodium tartrate, 100 mM sodium citrate",293,"10.1038/nsmb.3060",,"5BO8",84.27,"2.7","2.7","Structure of human sialyltransferase ST8SiaIII","APEHHHHHHDYDIPTTENLYFQGSQFALKFLDPSFVPITNSLTQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA","Homo sapiens","ST8SIA3, SIAT8C","Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase","1","5BO8"
"5BO9",,"X-RAY DIFFRACTION",2.51,50.91,"VAPOR DIFFUSION, HANGING DROP",5.5,"18-21% PEG3350, 30 mM sodium tartrate, 100 mM sodium citrate",293,"10.1038/nsmb.3060",,"5BO9",81.54,"2.3","2.3","Structure of human sialyltransferase ST8SiaIII in complex with CMP-3FNeu5Ac and Sia-6S-LacNAc","APEHHHHHHDYDIPTTENLYFQGQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA","Homo sapiens","ST8SIA3, SIAT8C","Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase","1","5BO9"
"5BOJ",,"X-RAY DIFFRACTION",2.1,41.55,"VAPOR DIFFUSION, HANGING DROP",,"TTRwt was dialyzed against 10 mM sodium phosphate with 100 mM KCl pH 7.6 and concentrated to 5 mg/ml. The resevoir contained 1.3-1.6 M sodium citrate and 3.5% glycerol at pH 5.5. Drop size 3 plus 3 microliter.",291,"10.1021/acs.jmedchem.5b00544","4TX","5BOJ",28.08,"1.75","1.75","Crystal Structure of Human Transthyretin in Complex with Gemfibrozil","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5BOJ"
"5BON",,"X-RAY DIFFRACTION",2.45,49.73,"VAPOR DIFFUSION",7.5,"Full length NUDT15 (20 mg/ml) was crystallized in the presence of alpha-Chymotrypsin (0.2 mg/ml) in 20 mM HEPES, pH 7.5, 300 mM NaCl, 10% Glycerol, and 1 mM TCEP. Sitting drop vapour diffusion experiments at 18 degrees C were performed, and NUDT15 was mixed with reservoir solution (30% PEG3350, 0.1 M Tris pH 8.5, and 0.05 M MgCl) in a 1:1 or 1:2 ratio.",291.2,"10.1038/ncomms8871",,"5BON",149.86,"1.799","1.799","Crystal structure of human Nudt15 (MTH2)","MTASAQPRGRRPGVGVGVVVTSCKHPRCVLLGKRKGSVGAGSFQLPGGHLEFGETWEECAQRETWEEAALHLKNVHFASVVNSFIEKENYHYVTILMKGEVDVTHDSEPKNVEPEKNESWEWVPWEELPPLDQLFWGLRCLKEQGYDPFKEDLNHLVGYKGNHL","Homo sapiens","NUDT15, MTH2","Probable 8-oxo-dGTP diphosphatase NUDT15","1","5BON"
"5BOQ",,"X-RAY DIFFRACTION",2.37,48,"VAPOR DIFFUSION, HANGING DROP",3,"0.1 M (NH4)2SO4, 1% (v/v) dioxane",293,"10.1038/srep19431",,"5BOQ",23.46,"1.7","1.7","Human insulin with intra-chain chemical crosslink between modified B24 and B29","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5BOQ"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGXFYTPLT","Homo sapiens","INS","Insulin","2","5BOQ"
"5BOT",,"X-RAY DIFFRACTION",2.28,46.11,"VAPOR DIFFUSION, HANGING DROP",,"14-28% PEG 4000 0.6M Ammonium Formate 0.
M Tris pH 8",293,"10.1021/jm201129m","4UM","5BOT",39.44,"1.85","1.85","X-RAY Co-structure of MMP-13 with ethyl 5-carbamoyl-1H-indole-2-carboxylate","YNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPN","Homo sapiens","MMP13","Collagenase 3","1","5BOT"
"5BOW",,"X-RAY DIFFRACTION",1.81,32.21,"VAPOR DIFFUSION, SITTING DROP",5.5,"PEG 3350, NAACETATE, PH 5.5, VAPOR
 DIFFUSION, SITTING DROP, TEMPERATURE 298K",298,,,"5BOW",17.22,"1.31","1.31","CRYSTAL STRUCTURE OF IL-38","SSLPMARYYIIKYADQKALYTRDGQLLVGDPVADNCCAEKICTLPNRGLDRTKVPIFLGIQGGSRCLACVETEEGPSLQLEDVNIEELYKGGEEATRFTFFQSSSGSAFRLEAAAWPGWFLCGPAEPQQPVQLTKESEPSARTKFYFEQSW","Homo sapiens","IL1F10, FIL1T, IL1HY2, IL38, FKSG75, UNQ6119/PRO20041","Interleukin-1 family member 10","1","5BOW"
"5BOY",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",,"10% PEG 4000, 1M Ammonimum Formate, 100 mM Tris pH 8",293,"10.1021/jm201129m","4UE","5BOY",39.51,"2.03","2.03","X-RAY Co-structure of MMP-13 with ethyl 5-(1-methyl-1H-imidazol-5-yl)-1H-indole-2-Carboxylate","YNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPN","Homo sapiens","MMP13","Collagenase 3","1","5BOY"
"5BPA",,"X-RAY DIFFRACTION",2.29,46.23,"VAPOR DIFFUSION",8,"10% PEG4000, 1M Ammonium Formate, 100 mM Tris",293,"10.1021/jm201129m","4UF","5BPA",39.87,"1.79","1.79","X-RAY Co-structure of MMP-13 with 4-[({5-[2-(ethoxycarbonyl)-1H-indol-5-yl]-1-methyl-1H-pyrazol-3-yl}formamido)methyl]benzoate","YNVFPRTLKWSKMNLTYRIVNYTPDMTHSEVEKAFKKAFKVWSDVTPLNFTRLHDGIADIMISFGIKEHGDFYPFDGPSGLLAHAFPPGPNYGGDAHFDDDETWTSSSKGYNLFLVAAHEFGHSLGLDHSKDPGALMFPIYTYTGKSHFMLPDDDVQGIQSLYGPGDEDPN","Homo sapiens","MMP13","Collagenase 3","1","5BPA"
"5BPB",,"X-RAY DIFFRACTION",3.23,61.95,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.6 M tri-sodium citrate, pH 6.5",294,"10.7554/eLife.06554",,"5BPB",67.71,"2.2","2.2","Crystal structure of the cysteine-rich domain of human Frizzled 4 - Crystal Form I","DTGERRCDPIRISMCQNLGYNVTKMPNLVGHELQTDAELQLTTFTPLIQYGCSSQLQFFLCSVYVPMCTEKINIPIGPCGGMCLSVKRRCEPVLKEFGFAWPESLNCSKFPPQNDHNHMCMEGPGDEEVPLPHKTPIQPGEGTLEVLFQ","Homo sapiens","FZD4","Frizzled-4","1","5BPB"
"5BPL",,"X-RAY DIFFRACTION",2.4,48.8,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 % PEG-3350 W/V, 0.1 M HEPES",293,,"ADP","5BPL",43.79,"1.93","1.93","Crystal structure of ADP and Pi bound human Hsp70 NBD mutant R272K.","MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACERAKKTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENV","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5BPL"
"5BPM",,"X-RAY DIFFRACTION",2.48,50.39,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 % PEG-3350 W/V, 0.1 M HEPES",293,,,"5BPM",43.35,"1.83","1.83","Crystal structure of unhydrolyzed ATP bound human Hsp70 NBD double mutant E268Q+R272K.","MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACQRAKKTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENV","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5BPM"
"5BPN",,"X-RAY DIFFRACTION",2.16,43.2,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 % PEG-3350 W/V, 0.1 M HEPES",293,,,"5BPN",43.08,"2.1","2.1","Crystal structure of nucleotide-free human Hsp70 NBD double mutant E268Q+R272K.","MAKAAAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVALNPQNTVFDAKRLIGRKFGDPVVQSDMKHWPFQVINDGDKPKVQVSYKGETKAFYPEEISSMVLTKMKEIAEAYLGYPVTNAVITVPAYFNDSQRQATKDAGVIAGLNVLRIINEPTAAAIAYGLDRTGKGERNVLIFDLGGGTFDVSILTIDDGIFEVKATAGDTHLGGEDFDNRLVNHFVEEFKRKHKKDISQNKRAVRRLRTACQRAKKTLSSSTQASLEIDSLFEGIDFYTSITRARFEELCSDLFRSTLEPVEKALRDAKLDKAQIHDLVLVGGSTRIPKVQKLLQDFFNGRDLNKSINPDEAVAYGAAVQAAILMGDKSENV","Homo sapiens","HSPA1A, HSPA1, HSX70, HSP72","Heat shock 70 kDa protein 1A","1","5BPN"
"5BPO",,"X-RAY DIFFRACTION",2.1,41.45,"VAPOR DIFFUSION, HANGING DROP",3,"0.05 M Li2SO4",293,"10.1038/srep19431",,"5BPO",11.65,"1.9","1.9","Human insulin with intra-chain chemical crosslink between modified B27 and B29","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5BPO"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYVPXT","Homo sapiens","INS","Insulin","2","5BPO"
"5BPP",,"X-RAY DIFFRACTION",2.45,49.86,"VAPOR DIFFUSION, HANGING DROP",6,"10MM TRIS-HCL, 25MM KCL, 4(MG/ML) TO 8(MG/ML) LTA4H (PH 8) WAS MIXED AT DIFFERENT RATIOS (0.5:1, 1:1, AND 1:2) WITH PRECIPITATE SOLUTION CONTAINING 0.15M IMIDAZOLE, 0.1M SODIUM ACETATE, 14% PEG8000, 5MM YBCL3",293,"10.1038/srep25298","A4Z","5BPP",72.4,"2.03","2.03","Structure of human Leukotriene A4 hydrolase in complex with inhibitor 4AZ","MGSSHHHHHHSSGLVPRGSHMPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVD","Homo sapiens","LTA4H, LTA4","Leukotriene A-4 hydrolase","1","5BPP"
"5BPQ",,"X-RAY DIFFRACTION",2.56,51.88,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES, pH 7.5, 0.1 M NaCl, 1.6 M ammonium sulfate",294,"10.7554/eLife.06554",,"5BPQ",67.74,"2.4","2.4","Crystal structure of the cysteine-rich domain of human Frizzled 4 - Crystal Form II","DTGERRCDPIRISMCQNLGYNVTKMPNLVGHELQTDAELQLTTFTPLIQYGCSSQLQFFLCSVYVPMCTEKINIPIGPCGGMCLSVKRRCEPVLKEFGFAWPESLNCSKFPPQNDHNHMCMEGPGDEEVPLPHKTPIQPGEGTLEVLFQ","Homo sapiens","FZD4","Frizzled-4","1","5BPQ"
"5BPW",,"X-RAY DIFFRACTION",4.36,71.76,"VAPOR DIFFUSION, SITTING DROP",8,"Apc4 crystals were grown by vapour-diffusion in a buffer containing 10 mM malic acid, 20 mM MES, 20 mM Tris.HCl (pH 8.0), 160 mM NDSB 196, 10 mM EDTA and 19% (v/v) PEG 1500. Crystals were incubated in a cryoprotection buffer comprising 10 mM malic acid, 20 mM MES, 20 mM Tris.HCl (pH 8.0), 160 mM NDSB 196, 10 mM EDTA, 22% (v/v) PEG 1500 and 20% (v/v) ethylene glycol prior to freezing in liquid nitrogen.",293,"10.1016/j.jmb.2015.08.023",,"5BPW",95.96,"3.4","3.4","Atomic-resolution structures of the APC/C subunits Apc4 and the Apc5 N-terminal domain","MLRFPTCFPSFRVVGEKQLPQEIIFLVWSPKRDLIALANTAGEVLLHRLASFHRVWSFPPNENTGKEVTCLAWRPDGKLLAFALADTKKIVLCDVEKPESLHSFSVEAPVSCMHWMEVTVESSVLTSFYNAEDESNLLLPKLPTLPKNYSNTSKIFSEENSDEIIKLLGDVRLNILVLGGSSGFIELYAYGMFKIARVTGIAGTCLALCLSSDLKSLSVVTEVSTNGASEVSYFQLETNLLYSFLPEVTRMARKFTHISALLQYINLSLTCMCEAWEEILMQMDSRLTKFVQEKNTTTSVQDEFMHLLLWGKASAELQTLLMNQLTVKGLKKLGQSIESSYSSIQKLVISHLQSGSESLLYHLSELKGMASWKQKYEPLGLDAAGIEEAITAVGSFILKANELLQVIDSSMKNFKAFFRWLYVAMLRMTEDHVLPELNKMTQKDITFVAEFLTEHFNEAPDLYNRKGKYFNVERVGQYLKDEDDDLVSPPNTEGNQWYDFLQNSSHLKESPLLFPYYPRKSLHFVKRRMENIIDQCLQKPADVIGKSMNQAICIPLYRDTRSEDSTRRLFKFPFLWNNKTSNLHYLLFTILEDSLYKMCILRRHTDISQSVSNGLIAIKFGSFTYATTEKVRRSIYSCLDAQFYDDETVTVVLKDTVGREGRDRLLVQLPLSLVYNSEDSAEYQFTGTYSTRLDEQCSAIPTRTMHFEKHWRLLESMKAQYVAGNGFRKVSCVLSSNLRHVRVFEMDIDDEWELDESSDEEEEASNKPVKIKEEVLSESEAENQQAGAAALAPEIVIKVEKLDPELDSENLYFQSWSHPQFEKGGGSGGGSGGGSWSHPQFEK","Homo sapiens","ANAPC4, APC4","Anaphase-promoting complex subunit 4","1","5BPW"
"5BPY",,"X-RAY DIFFRACTION",2.3,46.43,"VAPOR DIFFUSION, HANGING DROP",8,"25% MEPEG5K, pH 8.0, 298K, Vapor Diffusion, Hanging Drop",298,"10.1016/j.bmcl.2015.07.102",,"5BPY",63.58,"2.31","2.31","Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide","GHMEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5BPY"
"5BQ0",,"X-RAY DIFFRACTION",2.19,43.88,"VAPOR DIFFUSION, HANGING DROP",,,298,"10.1016/j.bmcl.2015.07.102","4US","5BQ0",33.33,"1.57","1.57","Crystal structure of bruton agammaglobulinemia tyrosine kinase complexed with BMS-824171 AKA 6-[(3R)-3-(4-tert-bu tylbenzamido)piperidin-1-yl]-2-{[4-(morpholine-4-carbonyl) phenyl]amino}pyridine-3-carboxamide","GPLGSKNAPSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5BQ0"
"5BQ7",,"X-RAY DIFFRACTION",2.26,45.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% 2-propanol, 25% PEG-4000, 50mM HEPES buffer pH 7.5",293,"10.1128/JVI.02364-15",,"5BQ7",50.57,"2.738","2.738","Crystal structure of chikungunya virus-human Fab 5F-10 fragment","QVQLVQSGSELKKPGASVKVSCKASGYTLTRYAMTWVRQAPGQGLEWMGWINTYTGNPTYVQGFTGRFVFSLDTSVSTAFLHITSLKAEDTAVYFCAREGGARGFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAAKGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV","Homo sapiens",,"Fab 5F-10-Heavy Chain","1","5BQ7"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSGAPGQRVTISCTGSSSNIGASHDVHWYQQLPGTAPTLLIYVNSNRPSGVPDRFSGSKSGTSASLAITGLQAEDEADYYCQSYDSNLSGSAVFGGGTKLTVLGQPLAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Fab 5F-10-Light Chain","2","5BQ7"
"5BQ8",,"X-RAY DIFFRACTION",2.41,49.1,"VAPOR DIFFUSION, SITTING DROP",,"0.1 sodium acetate, pH 5.0, 5% PGA-LM, 4% PEG2000MME, 24% PEG550MME",294,"10.7554/eLife.06554",,"5BQ8",54.97,"2","2","Crystal structure of Norrin, a Wnt signalling activator, Crystal Form II","GPGKTDSSFIMDSDPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYILSCHCEECNSGTETSQVAPA","Homo sapiens","NDP, EVR2","Norrin","1","5BQ8"
,,,,,,,,,,,,,,,,"GPGKTDSSFIMDSDPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYILSCHCEECNSGTETSQVAPA","Homo sapiens","NDP, EVR2","Norrin","2","5BQ8"
,,,,,,,,,,,,,,,,"GPGKTDSSFIMDSDPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYILSCHCEECNSGTETSQVAPA","Homo sapiens","NDP, EVR2","Norrin","3","5BQ8"
"5BQB",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, SITTING DROP",,"0.1M citrate, pH 5.0, 30% PEG6000",294,"10.7554/eLife.06554",,"5BQB",55.3,"2.3","2.3","Crystal structure of Norrin, a Wnt signalling activator, Crystal Form III","GPGKTDSSFIMDSDPRRCMRHHYVDSISHPLYKCSSKMVLLARCEGHCSQASRSEPLVSFSTVLKQPFRSSCHCCRPQTSKLKALRLRCSGGMRLTATYRYILSCHCEECNSGTETSQVAPA","Homo sapiens","NDP, EVR2","Norrin","1","5BQB"
"5BQD",,"X-RAY DIFFRACTION",3.05,59.63,"VAPOR DIFFUSION, HANGING DROP",6.4,"100mM Sodium Cacodylate pH 6.4
10mM MgSO4
1.8M Ammonium Sulphate",298,"10.1021/acs.biochem.6b00171",,"5BQD",53.67,"2.583","2.583","Crystal Structure of TBX5 (1-239) Dimer","MADADEGFGLAHTPLEPDAKDLPCDSKPESALGAPSKSPSSPQAAFTQQGMEGIKVFLHERELWLKFHEVGTEMIITKAGRRMFPSYKVKVTGLNPKTKYILLMDIVPADDHRYKFADNKWSVTGKAEPAMPGRLYVHPDSPATGAHWMRQLVSFQKLKLTNNHLDPFGHIILNSMHKYQPRLHIVKADENNGFGSKNTAFCTHVFPETAFIAVTSYQNHKITQLKIENNPFAKGFRGS","Homo sapiens","TBX5","T-box transcription factor TBX5","1","5BQD"
"5BQG",,"X-RAY DIFFRACTION",4.11,70.06,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 9.2 + 32% PEG 1K",294.15,"10.1021/acs.jmedchem.5b01249","4UJ","5BQG",18.74,"1.436","1.436","Crystal Structure of mPGES-1 Bound to an Inhibitor","MALPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","5BQG"
"5BQH",,"X-RAY DIFFRACTION",4.02,69.43,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 9.2 + 32% PEG 1K",294.15,"10.1021/acs.jmedchem.5b01249","4UK","5BQH",18.94,"1.601","1.601","Discovery of a Potent and Selective mPGES-1 Inhibitor for the Treatment of Pain","MALPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","5BQH"
"5BQI",,"X-RAY DIFFRACTION",4,69.27,"VAPOR DIFFUSION, SITTING DROP",,"100mM Tris HCl pH 8.5 + 33% PEG 2000 MME + 100mM Potassium Thiocyanate",294.15,"10.1021/acs.jmedchem.5b01249","4UL","5BQI",18.99,"1.88","1.88","Discovery of a Potent and Selective mPGES-1 Inhibitor for the Treatment of Pain","MALPAHSLVMSSPALPAFLLCSTLLVIKMYVVAIITGQVRLRKKAFANPEDALRHGGPQYCRSDPDVERCLRAHRNDMETIYPFLFLGFVYSFLGPNPFVAWMHFLVFLVGRVAHTVAYLGKLRAPIRSVTYTLAQLPCASMALQILWEAARHL","Homo sapiens","PTGES, MGST1L1, MPGES1, PGES, PIG12","Prostaglandin E synthase","1","5BQI"
"5BQQ",,"X-RAY DIFFRACTION",2.27,45.93,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.6 M Na2SO4, 0.3 M Tris pH 7.5, 0.6 mM Zn(Ac)2, 0.06% (w/v) phenol",293,"10.1038/srep19431",,"5BQQ",35.83,"1.54","1.54","Human insulin with intra-chain chemical crosslink between modified B27 and B30","FVNQHLCGSHLVEALYLVCGERGFFYVPGX","Homo sapiens","INS","Insulin","2","5BQQ"
,,,,,,,,,,,,,,,,"GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5BQQ"
"5BQX",,"X-RAY DIFFRACTION",2.04,39.58,"VAPOR DIFFUSION, HANGING DROP",5.8,"0.2 M ammonium acetate, 0.1 M trisodium citrate, pH 5.8, 25% PEG4000",293,"10.1073/pnas.1507317112","4UR","5BQX",27.86,"2","2","Crystal structure of human STING in complex with 3'2'-cGAMP","GLAPAEISAVCEKGNFNVAHGLAWSYYIGYLRLILPELQARIRTYNQHYNNLLRGAVSQRLYILLPLDCGVPDNLSMADPNIRFLDKLPQQTGDRAGIKDRVYSNSIYELLENGQRAGTCVLEYATPLQTLFAMSQYSQAGFSREDRLEQAKLFCRTLEDILADAPESQNNCRLIAYQEPADDSSFSLSQEVLRHLRQEEKEEVTVGSLKTSAVPSTSTMSQEPELLISGMEKPLPLRTDFS","Homo sapiens","TMEM173, ERIS, MITA, STING, STING1","Stimulator of interferon genes protein","1","5BQX"
"5BRN",,"X-RAY DIFFRACTION",2.15,42.85,"VAPOR DIFFUSION, HANGING DROP",7.4,"20% PEG3000, 0.2 M  calcium acetate, 0.1 M Tris-HCl pH 7.4",291,"10.1002/cmdc.201500322","4X2","5BRN",99.43,"2.3","2.3","Human HGPRT in complex with (S)-HPEPHx, an acyclic nucleoside phosphonate","MATRSPGVVISDDEPGYDLDLFAIPNHYAEDLERVFIPHGLIMDRTERLARDVMKEMGGHHIVALCVLKGGYKFFADLLDYIKALNRNSDRSIPMTVDFIRLKSYANDQSTGDIKVIGGDDLSTLTGKNVLIVEDIIDTGKTMQTLLSLVRQYNPKMVKVASLLVKRTPRSVGYKPDFVGFEIPDKFVVGYALDYNEYFRDLNHVAVISETGKAKYKA","Homo sapiens","HPRT1, HPRT","Hypoxanthine-guanine phosphoribosyltransferase","1","5BRN"
"5BRO",,"X-RAY DIFFRACTION",3,59,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2 M Sodium Formate, 20% PEG 3350",288,"10.1172/JCI85300",,"5BRO",59.73,"2.4","2.4","Crystal structure of modified HexB (modB)","ARAPSVSAKPGPALWPLPLSVKMTPNLLHLAPENFYISHSPNSTAGPSCTLLEEAFRRYHGYIFGFYKWHHEPAEFQAKTQVQQLLVSITLQSECDAFPNISSDESYTLLVKEPVAVLKANRVWGALRGLETFSQLVYQDSYGTFTINESTIIDSPRFSHRGILIDTSRHYLPVKIILKTLDAMAFNKFNVLHWHIVDDQSFPYQSITFPELSNKGSYSLSHVYTPNDVRMVIEYARLRGIRVLPEFDTPGHTLSWGKGQKDLLTPCYSGSEPLDSFGPINPTLNTTYSFLTTFFKEISEVFPDQFIHLGGDEVEFKCWESNPKIQDFMRQKGFGTDFKKLESFYIQKVLDIIATINKGSIVWQEVFDDKAKLAPGTIVEVWKDSAYPEELSRVTASGFPVILSAPWYLNRISYGQDWRKYYKVEPLDFGGTQKQKQLFIGGEACLWGEYVDATNLTPRLWPRASAVGERLWSSKDVRDMDDAYDRLTRHRCRMVERGIAAQPLYAGYCNHENM","Homo sapiens","HEXB, HCC7","Beta-hexosaminidase subunit beta","1","5BRO"
"5BRU",,"X-RAY DIFFRACTION",2.11,41.73,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,"10.1021/jacs.5b06622","SO4","5BRU",30.34,"1.6","1.6","Catalytic Improvement of an Artificial Metalloenzyme by Computational Design","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGMAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSMTTPPLLESVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKLRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5BRU"
"5BRV",,"X-RAY DIFFRACTION",2.09,41.29,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,"10.1021/jacs.5b06622","9TH","5BRV",30.12,"1.6","1.6","Catalytic Improvement of an Artificial Metalloenzyme by Computational Design","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGMAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSMTTPPLLESVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKLRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5BRV"
"5BRW",,"X-RAY DIFFRACTION",2.06,40.42,"VAPOR DIFFUSION, HANGING DROP",7.9,"2.6 M ammonium sulfate, 50 mM Tris-HCl",298,"10.1021/jacs.5b06622","ACT, SO4","5BRW",29.67,"1.4","1.4","Catalytic Improvement of an Artificial Metalloenzyme by Computational Design","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGMAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSMTTPPLLESVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKLRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5BRW"
"5BS9",,"X-RAY DIFFRACTION",2.67,54,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,"10.1016/j.chembiol.2015.08.006",,"5BS9",37.68,"1.98","1.98","Crystal structure of N109A mutant of human macrophage migration inhibitory factor","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWANSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5BS9"
"5BSC",,"X-RAY DIFFRACTION",2.7,54.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,"10.1016/j.chembiol.2015.08.006",,"5BSC",37.07,"1.89","1.89","Crystal structure of K66A mutant of human macrophage migration inhibitory factor","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGAIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5BSC"
"5BSI",,"X-RAY DIFFRACTION",6.75,81.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,"10.1016/j.chembiol.2015.08.006",,"5BSI",99.42,"2","2","Crystal structure of Y36A mutant of human macrophage migration inhibitory factor","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQAIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5BSI"
"5BSJ",,"X-RAY DIFFRACTION",3.72,66.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,,,"5BSJ",37.8,"2","2","Crystal structure of S63A mutant of human macrophage migration inhibitory factor","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHAIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5BSJ"
"5BSK",,"X-RAY DIFFRACTION",2.28,46.17,"VAPOR DIFFUSION, HANGING DROP",7.4,"15% PEG 3000, 0.2 M calcium acetate, 0.1 M Tris-HCl pH 7.4",291,"10.1002/cmdc.201500322",,"5BSK",99.5,"2.61","2.61","Human HGPRT in complex with (S)-HPEPG, an acyclic nucleoside phosphonate","MATRSPGVVISDDEPGYDLDLFAIPNHYAEDLERVFIPHGLIMDRTERLARDVMKEMGGHHIVALCVLKGGYKFFADLLDYIKALNRNSDRSIPMTVDFIRLKSYANDQSTGDIKVIGGDDLSTLTGKNVLIVEDIIDTGKTMQTLLSLVRQYNPKMVKVASLLVKRTPRSVGYKPDFVGFEIPDKFVVGYALDYNEYFRDLNHVAVISETGKAKYKA","Homo sapiens","HPRT1, HPRT","Hypoxanthine-guanine phosphoribosyltransferase","1","5BSK"
"5BT3",,"X-RAY DIFFRACTION",2.3,46.49,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.1 M tri-sodium citrate dihydrate pH 5.6, 20% iso-propanol, 20% PEG 4000",277,,"2LO","5BT3",14.4,"1.05","1.05","Crystal structure of EP300 bromodomain in complex with SGC-CBP30 chemical probe","SMIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKSPMDLSTIKRKLDTGQYQEPWQYVDDIWLMFNNAWLYNRKTSRVYKYCSKLSEVFEQEIDPVMQSLG","Homo sapiens","EP300, P300","Histone acetyltransferase p300","1","5BT3"
"5BT4",,"X-RAY DIFFRACTION",2.42,49.18,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M succinic acid, 20% PEG 3350",277,,"2LO","5BT4",46.95,"1.5","1.5","Crystal structure of BRD4 first bromodomain in complex with SGC-CBP30 chemical probe","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5BT4"
"5BT5",,"X-RAY DIFFRACTION",2.27,45.84,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium/potassium tartrate, 20% PEG 3350, 10% ethylene glycol",277,,,"5BT5",14.13,"1.4","1.4","Crystal structure of BRD2 second bromodomain in complex with SGC-CBP30 chemical probe","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5BT5"
"5BTM",,"X-RAY DIFFRACTION",2.07,40.71,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM ammonium acetate, 5 mM Mg sulfate, 50 mM MES pH 6.0, and 600 mM NaCl",296,"10.1021/acs.biochem.5b00551",,"5BTM",35.14,"2.778","2.778","Crystal structure of AUUCU repeating RNA that causes spinocerebellar ataxia type 10 (SCA10)","GUCAUUCUAUUCUAUCGGCUAAGGAUGAAAGUCUAUGCCGAUUCUAUUCUAUGGC","Homo sapiens",,"RNA (55-mer)","1","5BTM"
"5BTQ",,"X-RAY DIFFRACTION",2.21,44.35,"VAPOR DIFFUSION, HANGING DROP",7.4,"100mM HEPES
2.1M Ammonium sulfate
0.9% 1,6-hexanediol",293,"10.1021/acs.biochem.6b00562",,"5BTQ",55.92,"2.08","2.08","Crystal structure of human heme oxygenase 1 H25R with biliverdin bound","GSHMMERPQPDSMPQDLSEALKEATKEVRTQAENAEFMRNFQKGQVTRDGFKLVMASLYHIYVALEEEIERNKESPVFAPVYFPEELHRKAALEQDLAFWYGPRWQEVIPYTPAMQRYVKRLHEVGRTEPELLVAHAYTRYLGDLSGGQVLKKIAQKALDLPSSGEGLAFFTFPNIASATKFKQLYRSRMNSLEMTPAVRQRVIEEAKTAFLLNIQLFEELQELLTHDTKDQSPSRA","Homo sapiens","HMOX1, HO, HO1","Heme oxygenase 1","1","5BTQ"
"5BTS",,"X-RAY DIFFRACTION",3.45,64.35,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M Ammonium sulfate, 0.1 M Hepes, 25% w/v PEG3350",291,"10.1016/j.xphs.2016.01.003",,"5BTS",5.82,"1.77","1.77","Structural and biophysical characterization of a covalent insulin dimer formed during storage of neutral formulation of human insulin","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin A chain","1","5BTS"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin B chain","2","5BTS"
"5BUC",,"X-RAY DIFFRACTION",2.42,49.22,"VAPOR DIFFUSION, SITTING DROP",7,"1.7M Ammonium sulfate, 0.1M Hepes",298,,,"5BUC",54.44,"1.867","1.867","Oxidized quinone reductase 2 in complex with ethidium","AGKKVLIVYAHQEPKSFNGSLKNVAVDELSRQGCTVTVSDLYAMNFEPRATDKDITGTLSNPEVFNYGVETHEAYKQRSLASDITDEQKKVREADLVIFQFPLYWFSVPAILKGWMDRVLCQGFAFDIPGFYDSGLLQGKLALLSVTTGGTAEMYTKTGVNGDSRYFLWPLQHGTLHFCGFKVLAPQISFAPEIASEEERKGMVAAWSQRLQTIWKEEPIPCTAHWHFGQ","Homo sapiens","NQO2, NMOR2","Ribosyldihydronicotinamide dehydrogenase [quinone]","1","5BUC"
"5BUE",,"X-RAY DIFFRACTION",2.26,45.47,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 0.2M MAGNESIUM FORMATE, 20% PEG 3350 
          
PROTEIN SOLUTION   : 20.7MG/ML IN 20MM TRIS PH 7.5, 150MM NACL, 1MM TCEP(NO GLYCEROL)                          

SOAKING PROTOCOL: COMPOUND WAS INCUBATED WITH THE PROTEIN AT 1MM FINAL CONCENTRATION BEFORE SETUP.  EQUAL VOLUMES OF PROTEIN AND CRYSTALLANT WERE ADDED TO COVERSLIP            

CRYO PROTOCOL : SOAKING BUFFER: 0.2M MAGNESIUM FORMATE, 20% PEG 3350, 20% GLYCEROL, 2MM COMPOUND A CRYSTAL WAS TRANSFERRED TO A 5UL SOAKING BUFFER ON A SCREWED CUP LID. 100UL  OF RESERVOIR VOLUME WAS USED TO KEEP THE DROP FROM DRYING-OUT",291,"10.1016/j.bmcl.2015.06.063","4V8","5BUE",41.91,"2.4","2.4","ERK2 complexed with N-benzylpyridone tetrahydroazaindazole","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BUE"
"5BUG",,"X-RAY DIFFRACTION",3.13,60.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrat, 7.5% glycerol",293,"10.1002/anie.201506338",,"5BUG",149.83,"2.4","2.4","Crystal structure of human phosphatase PTEN oxidized by H2O2","RRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEEDNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTV","Homo sapiens","PTEN, MMAC1, TEP1","Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN","1","5BUG"
"5BUI",,"X-RAY DIFFRACTION",2.26,45.58,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION : 200MM CALCIUM ACETATE; 20% PEG3350             

PROTEIN SOLUTION   : 20.7MG/ML IN 20MM TRIS PH 7.5, 150MM NACL,1MM TCEP(NO GLYCEROL)                          
FORMATION METHOD   : CO-CRYSTALLIZATION                             
PROTOCOL           : COMPOUND (NVP-LLG040) WAS INCUBATED WITH THE PROTEIN AT 1MM FINAL CONCENTRATION BEFORE SETUP.  EQUAL VOLUMES OF PROTEIN AND    
CRYSTALLANT WERE ADDED TO COVERSLIP            
METHOD: VAPOR DIFFUSION - HANGING DROP                 
TEMPERATURE: 291.0                                          
CRYO PROTOCOL: MOTHER LIQUOR (200MM CALCIUM ACETATE; 20% PEG3350) + 20% GLYCEROL",291,"10.1016/j.bmcl.2015.06.063","4V9","5BUI",41.82,"2.12","2.12","ERK2 complexed with 2-pyridiyl tetrahydroazaindazole","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BUI"
"5BUJ",,"X-RAY DIFFRACTION",2.26,45.58,"VAPOR DIFFUSION, HANGING DROP",,"RESERVOIR SOLUTION: 20% PEG 3350, 20MM MAGNESIUM FORMATE,          

PROTEIN SOLUTION 20MM TRIS PH 7.5, 150 MM NACL, 1MM TCEP        

FORMATION METHOD: SOAKING                                        

PROTOCOL: Low affinity compound WAS INCUBATED WITH THE PROTEIN AT 2MM FINAL CONCENTRATION BEFORE SETUP. EQUAL VOLUMES OF PROTEIN AND CRYSTALLANT WERE ADDED TO COVER-SLIP. CRYSTAL APPEAR AFTER SEVEAL DAYS.   EXCHANGE SOAKING WAS PERFORMED USING 2MM COMPOUND AT LEAST OVERNIGHT.                            

METHOD: VAPOR DIFFUSION - HANGING DROP                 

TEMPERATURE: 291.0                                          

CRYO PROTOCOL: MOTHER LIQUOR (200MM AMMONIUM SULFATE; 30% PEG MME 5K) + 20% GLYCEROL",291,"10.1016/j.bmcl.2015.06.063","4VB","5BUJ",41.76,"1.85","1.85","ERK2 complexed with a N-H tetrahydroazaindazole","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BUJ"
"5BUO",,"X-RAY DIFFRACTION",1.08,65.65,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, ammonium acetate, bis-tris, zinc, thiocyanate",293,,,"5BUO",80.06,"2.31","2.31","A receptor molecule","MSTPDAVDKYLETPGDENEHAHFQKAKERLEAKHRERMSQVMREWEEAERQAKNLPKADKKAVIQHFQEKVESLEQEAANERQQLVETHMARVEAMLNDRRRLALENYITALQAVPPRPRHVFNMLKKYVRAEQKDRQHTLKHFEHVRMVDPKKAAQIRSQVMTHLRVIYERMNQSLSLLYNVPAVAEEIQDEVDELLQKEQNYSDDVLANMISEPRISYGNDALMPSLTETKTTVELLPVNGEFSLDDLQPWHSFGADSVPANTENEVEPVDARPAADRGLTTRPGSGLTNIKTEEISEVKMDAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGV","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5BUO"
"5BV6",,"X-RAY DIFFRACTION",2.02,39.24,"VAPOR DIFFUSION, HANGING DROP",4.6,"20 mM CaCl2, 100 mM NaOAc, 30% MPD",277,"10.1074/jbc.M115.691303","35G","5BV6",17.9,"1.94","1.94","PKG II's Carboxyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with cGMP","GSTAQARDEQYRNFLRSVSLLKNLPEDKLTKIIDCLEVEYYDKGDYIIREGEEGSTFFILAKGKVKVTQSTEGHDQPQLIKTLQKGEYFGEKALISDDVRSANIIAEENDVACLVIDRETFNQTVGTFEELQKYLEGYVANLNRDDEKRHAK","Homo sapiens","PRKG2, PRKGR2","cGMP-dependent protein kinase 2","1","5BV6"
"5BV8",,"X-RAY DIFFRACTION",2.61,52.81,"VAPOR DIFFUSION, HANGING DROP",10.5,"30% PEG 400, 100 mM CAPS/Sodium hydroxide",298,"10.1074/jbc.M115.703850",,"5BV8",28.31,"1.59","1.59","G1324S mutation in von Willebrand Factor A1 domain","MRGSHHHHHHGSQEPGGLVVPPTDAPVSPTTLYVEDISEPPLHDFYCSRLLDLVFLLDGSSRLSEAEFEVLKAFVVDMMERLRISQKWVRVAVVEYHDSSHAYIGLKDRKRPSELRRIASQVKYAGSQVASTSEVLKYTLFQIFSKIDRPEASRIALLLMASQEPQRMSRNFVRYVQGLKKKKVIVIPVGIGPHANLKQIRLIEKQAPENKAFVLSSVDELEQQRDEIVSYLCDLAPEAPPPTLPPKLN","Homo sapiens","VWF, F8VWF","von Willebrand factor","1","5BV8"
"5BVD",,"X-RAY DIFFRACTION",2.29,46.33,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293,"10.1016/j.bmcl.2015.07.091","4VF","5BVD",42.42,"1.9","1.9","Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BVD"
"5BVE",,"X-RAY DIFFRACTION",2.27,45.76,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293,"10.1016/j.bmcl.2015.07.091","4VG","5BVE",42.33,"2","2","Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BVE"
"5BVF",,"X-RAY DIFFRACTION",2.22,44.65,"VAPOR DIFFUSION, SITTING DROP",,"20mM Mg Sulfate, 20% PEG 3350",293,"10.1016/j.bmcl.2015.07.091","4VJ","5BVF",42.43,"1.9","1.9","Tetrahydropyrrolo-diazepenones as inhibitors of ERK2 kinase","GPAAAAAAGAGPEMVRGQVFDVGPRYTNLSYIGEGAYGMVCSAYDNVNKVRVAIKKISPFEHQTYCQRTLREIKILLRFRHENIIGINDIIRAPTIEQMKDVYIVQDLMETDLYKLLKTQHLSNDHICYFLYQILRGLKYIHSANVLHRDLKPSNLLLNTTCDLKICDFGLARVADPDHDHTGFLTEYVATRWYRAPEIMLNSKGYTKSIDIWSVGCILAEMLSNRPIFPGKHYLDQLNHILGILGSPSQEDLNCIINLKARNYLLSLPHKNKVPWNRLFPNADSKALDLLDKMLTFNPHKRIEVEQALAHPYLEQYYDPSDEPIAEAPFKFDMELDDLPKEKLKELIFEETARFQPGYRS","Homo sapiens","MAPK1, ERK2, PRKM1, PRKM2","Mitogen-activated protein kinase 1","1","5BVF"
"5BVJ",,"X-RAY DIFFRACTION",2.28,45.94,"VAPOR DIFFUSION, HANGING DROP",5,"12% PEG MME 5000, 50mM sodium citrate pH 5.0",292,"10.1080/19420862.2015.1081323",,"5BVJ",190.24,"2","2","The molecular mode of action and species specificity of canakinumab, a human monoclonal antibody neutralizing IL-1beta","EIVLTQSPDFQSVTPKEKVTITCRASQSIGSSLHWYQQKPDQSPKLLIKYASQSFSGVPSRFSGSGSGTDFTLTINSLEAEDAAAYYCHQSSSLPFTFGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"canakinumab Fab light-chain","1","5BVJ"
,,,,,,,,,,,,,,,,"QVQLVESGGGVVQPGRSLRLSCAASGFTFSVYGMNWVRQAPGKGLEWVAIIWYDGDNQYYADSVKGRFTISRDNSKNTLYLQMNGLRAEDTAVYYCARDLRTGPFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTH","Homo sapiens",,"canakinumab Fab heavy-chain","2","5BVJ"
"5BVK",,"X-RAY DIFFRACTION",2.33,47.29,"VAPOR DIFFUSION",,"15-25% (W/V) PEG3350, 0.2M NH4I",277,"10.1021/acsmedchemlett.5b00143","4VC","5BVK",37.46,"2.29","2.29","Fragment-based discovery of potent and selective DDR1/2 inhibitors","GAMGSAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5BVK"
"5BVN",,"X-RAY DIFFRACTION",2.45,49.78,"VAPOR DIFFUSION",,"10.0%w/v PEG 3350, 0.1M KNO3",277,"10.1021/acsmedchemlett.5b00143",,"5BVN",36.98,"2.21","2.21","Fragment-based discovery of potent and selective DDR1/2 inhibitors","GAMGSAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5BVN"
"5BVO",,"X-RAY DIFFRACTION",2.52,51.22,"VAPOR DIFFUSION",,"17.4%w/v PEG 3350, 0.2M NH4I",277,"10.1021/acsmedchemlett.5b00143",,"5BVO",37.75,"1.98","1.98","Fragment-based discovery of potent and selective DDR1/2 inhibitors","GAMGSAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5BVO"
"5BVW",,"X-RAY DIFFRACTION",2.33,47.28,"VAPOR DIFFUSION",,"18.0%w/v PEG 3350, 0.2M NH4I",277,"10.1021/acsmedchemlett.5b00143","1N1","5BVW",37.94,"1.94","1.94","Fragment-based discovery of potent and selective DDR1/2 inhibitors","GAMGSAVGDGPPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5BVW"
"5BWR",,"X-RAY DIFFRACTION",2.36,47.99,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2 supplemented with 10mM DTT",293,"10.1021/acs.jmedchem.5b00313","4VT","5BWR",85.21,"2.2","2.2","X-RAY CRYSTAL STRUCTURE AT 2.20A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE FRAGMENT AND AN INTERNAL ALDIMINE LINKED PLP.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWR"
"5BWT",,"X-RAY DIFFRACTION",2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2 + 10mM DTT",293,"10.1021/acs.jmedchem.5b00313","4VS","5BWT",84.92,"2.2","2.2","X-RAY CRYSTAL STRUCTURE AT 2.20A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE FRAGMENT AND AN INTERNAL ALDIMINE LINKED PLP.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWT"
"5BWU",,"X-RAY DIFFRACTION",2.37,48.15,"VAPOR DIFFUSION",6.5,"MDL Morpheus screen condition B2 + 10mM DTT",293,"10.1021/acs.jmedchem.5b00313","4VR","5BWU",85.54,"2.17","2.17","X-RAY CRYSTAL STRUCTURE AT 2.17A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TRIAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWU"
"5BWV",,"X-RAY DIFFRACTION",2.39,48.43,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2 + 10mM DTT.",293,"10.1021/acs.jmedchem.5b00313","775","5BWV",85.86,"1.86","1.86","X-RAY CRYSTAL STRUCTURE AT 1.86A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWV"
"5BWW",,"X-RAY DIFFRACTION",2.36,47.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2 + 10mM DTT.",293,"10.1021/acs.jmedchem.5b00313","4W6","5BWW",85.77,"1.82","1.82","X-RAY CRYSTAL STRUCTURE AT 1.82A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A PYRROLIDINE AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWW"
"5BWX",,"X-RAY DIFFRACTION",2.4,48.66,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2 + 10mM DTT.",293,"10.1021/acs.jmedchem.5b00313","4W4","5BWX",86.08,"1.703","1.703","X-RAY CRYSTAL STRUCTURE AT 1.70A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A 4-CHLORO-2-FLUORO SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5BWX"
"5BWZ",,"X-RAY DIFFRACTION",2.43,49.38,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M BisTris (pH 6.5), 6% (w/v) PEG 8000, 4 mM TCEP",294,"10.1021/acs.biochem.9b00653",,"5BWZ",87.41,"1.59","1.59","Crystal structure of S39E HDAC8 in complex with Droxinostat","MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRAEMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVVIEGRGSHHHHHH","Homo sapiens","HDAC8, HDACL1, CDA07","Histone deacetylase 8","1","5BWZ"
"5BX0",,"X-RAY DIFFRACTION",2.35,47.59,"EVAPORATION",7.65,"PEG4000 20%
CaCl2 200mM
Glycerol 25%
ph7.7",277,"10.1177/1087057115618347",,"5BX0",39.11,"2.93","2.93","An Automated Microscale Thermophoresis Screening Approach for Fragment-Based Lead Discovery","GLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLNKKGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQ","Homo sapiens","MAP2K1, MEK1, PRKMK1","Dual specificity mitogen-activated protein kinase kinase 1","1","5BX0"
"5BX1",,"X-RAY DIFFRACTION",2.17,43.32,"VAPOR DIFFUSION, HANGING DROP",,"1.9 M amino sulfate, 100 mM sodium acetate, pH 4.6 ~ 4.9",310,,,"5BX1",18.56,"1.9","1.9","Crystal Structure of PRL-1 complex with compound analogy 3","MNRPAPVEVTYKNMRFLITHNPTNATLNKFIEELKKYGVTTIVRVCEATYDTTLVEKEGIHVLDWPFDDGAPPSNQIVDDWLSLVKIKFREEPGCCIAVHCVAGLGRAPVLVALALIEGGMKYEDAVQFIRQKRRGAFNSKQLLYLEKYRPKMRLRF","Homo sapiens","PTP4A1, PRL1, PTPCAAX1","Protein tyrosine phosphatase type IVA 1","1","5BX1"
"5BXB",,"X-RAY DIFFRACTION",2.19,43.8,"VAPOR DIFFUSION, HANGING DROP",,"10 mg/mL KCTD1 BTB domain with: 0.1 M MES pH 6, 5% w/v PEG 1000, 30% w/v PEG 600, 10% v/v glycerol. 1:1 ratio",295,"10.1016/j.jmb.2015.08.019",,"5BXB",127.11,"2.171","2.171","Crystal structure of pentameric KCTD1 BTB domain form 1","SNANAPVHIDVGGHMYTSSLATLTKYPESRIGRLFDGTEPIVLDSLKQHYFIDRDGQMFRYILNFLRTSKLLIPDDFKDYTLLYEEAKYFQLQPMLLEMERWKQDRE","Homo sapiens","KCTD1, C18orf5","BTB/POZ domain-containing protein KCTD1","1","5BXB"
"5BXC",,"X-RAY DIFFRACTION",2.27,45.77,"VAPOR DIFFUSION, HANGING DROP",,"1 % PEG 4000, 4.5-5 % 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[2-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5-8 mM cobalt chloride, pH 7.5",277,"10.1074/jbc.M115.682401",,"5BXC",35.58,"1.4","1.4","Crystal structure of GTA + UDP + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5BXC"
"5BXD",,"X-RAY DIFFRACTION",2.22,44.6,"VAPOR DIFFUSION, HANGING DROP",,"25 mg/mL KCTD1 BTB domain with: 0.1 M MES pH 5, 10% w/v PEG 6000. 1:1 ratio",295,"10.1016/j.jmb.2015.08.019",,"5BXD",63.56,"1.796","1.796","Crystal structure of pentameric KCTD1 BTB domain form 2","SNANAPVHIDVGGHMYTSSLATLTKYPESRIGRLFDGTEPIVLDSLKQHYFIDRDGQMFRYILNFLRTSKLLIPDDFKDYTLLYEEAKYFQLQPMLLEMERWKQDRE","Homo sapiens","KCTD1, C18orf5","BTB/POZ domain-containing protein KCTD1","1","5BXD"
"5BXH",,"X-RAY DIFFRACTION",2.62,53,"VAPOR DIFFUSION, HANGING DROP",7.5,"25 mg/mL KCTD9 BTB domain with: 0.17 M Lithium citrate, 16% w/v PEG 3350. 1:1 ratio",277,"10.1016/j.jmb.2015.08.019",,"5BXH",60.46,"2.76","2.76","Crystal structure of pentameric KCTD9 BTB domain","SNADWLTLNVGGRYFTTTRSTLVNKEPDSMLAHMFKDKGVWGNKQDHRGAFLIDRSPEYFEPILNYLRHGQLIVNDGINLLGVLEEARFFGIDSLIEHLEVAIKNS","Homo sapiens","KCTD9","BTB/POZ domain-containing protein KCTD9","1","5BXH"
"5BXJ",,"X-RAY DIFFRACTION",2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 3350, 0.2 M Ammonium Acetate and 0.1 M HEPES pH 7.5",289,"10.1016/j.jhazmat.2015.12.045","NPO","5BXJ",14.3,"1.24","1.24","Complex of the Fk1 domain mutant A19T of FKBP51 with 4-Nitrophenol","MGAPATVTEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGE","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5BXJ"
"5BYA",,"X-RAY DIFFRACTION",2.79,55.96,"VAPOR DIFFUSION, HANGING DROP",7,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight, while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM analog.",277,"10.1039/c5cc05017k",,"5BYA",39.48,"1.9","1.9","Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PCP)2-IP4","GSFTERQIVVGICSMAKKSKSKPMKEILERISLFKYITVVVFEEEVILNEPVENWPLCDCLISFHSKGFPLDKAVAYAKLRNPFVINDLNMQYLIQDRREVYSILQAEGILLPRYAILNRDPNNPKECNLIEGEDHVEVNGEVFQKPFVEKPVSAEDHNVYIYYPTSAGGGSQRLFRKIGSRSSVYSPESNVRKTGSYIYEEFMPTDGTDVKVYTVGPDYAHAEARKSPALDGKVERDSEGKEVRYPVILNAREKLIAWKVCLAFKQTVCGFDLLRANGQSYVCDVNGFSFVKNSMKYYDDCAKILGNIVMRELAPQFHIPWSIPLEAED","Homo sapiens","PPIP5K2, HISPPD1, KIAA0433, VIP2","Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2","1","5BYA"
"5BYB",,"X-RAY DIFFRACTION",2.81,56.24,"VAPOR DIFFUSION, HANGING DROP",7,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight, while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM analog.",277,"10.1039/c5cc05017k",,"5BYB",39.24,"2.3","2.3","Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 1,5-(PA)2-IP4","GSFTERQIVVGICSMAKKSKSKPMKEILERISLFKYITVVVFEEEVILNEPVENWPLCDCLISFHSKGFPLDKAVAYAKLRNPFVINDLNMQYLIQDRREVYSILQAEGILLPRYAILNRDPNNPKECNLIEGEDHVEVNGEVFQKPFVEKPVSAEDHNVYIYYPTSAGGGSQRLFRKIGSRSSVYSPESNVRKTGSYIYEEFMPTDGTDVKVYTVGPDYAHAEARKSPALDGKVERDSEGKEVRYPVILNAREKLIAWKVCLAFKQTVCGFDLLRANGQSYVCDVNGFSFVKNSMKYYDDCAKILGNIVMRELAPQFHIPWSIPLEAED","Homo sapiens","PPIP5K2, HISPPD1, KIAA0433, VIP2","Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2","1","5BYB"
"5BYC",,"X-RAY DIFFRACTION",2.41,49.05,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M sodium HEPES, 10% isopropanol, 20% PEG 4000, 0.1M ammonium sulfate",277,,,"5BYC",70.53,"1.95","1.95","Crystal structure of human ribokinase in C2 spacegroup","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5BYC"
"5BYD",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M sodium HEPES, 25% PEG 6000",277,,,"5BYD",70.54,"2.1","2.1","Crystal structure of human ribokinase in P21 spacegroup","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5BYD"
"5BYE",,"X-RAY DIFFRACTION",2.36,47.86,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, 8% PEG 8000",277,,,"5BYE",70.56,"1.75","1.75","Crystal structure of human ribokinase in P212121 spacegroup","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5BYE"
"5BYF",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, 8% PEG 8000",277,,,"5BYF",71.3,"2","2","Crystal structure of human ribokinase in complex with AMP","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5BYF"
"5BYI",,"X-RAY DIFFRACTION",2.1,40.5,"VAPOR DIFFUSION, HANGING DROP",8.5,"3 M Ammoniumsulfate, 50 mM Tris, 2mM PCMB",293,"10.3762/bjoc.11.127","4WA","5BYI",30.05,"1.15","1.15","Human carbonic anhydrase II with an azobenzene inhibitor (1d)","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5BYI"
"5BYY",,"X-RAY DIFFRACTION",2.97,58.58,"VAPOR DIFFUSION, SITTING DROP",,"0.01 M Tris 8.50
0.01 M MgCl2
13 % PEG4000
0.18 M Na-formiate
0.10 M MES, pH=6.50",293,"10.1107/S2059798316004502","4WG","5BYY",40.09,"2.79","2.79","ERK5 IN COMPLEX WITH SMALL MOLECULE","FDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREG","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","5BYY"
"5BYZ",,"X-RAY DIFFRACTION",3.24,62.05,"VAPOR DIFFUSION, HANGING DROP",,"11 % PEG4000
0.01 M MgCl2
0.18 M Na-Formiate
0.10 M MES, pH=6.50
0.01 M Tris/Cl, pH=8.50",277,"10.1107/S2059798316004502","4WE","5BYZ",40.84,"1.65","1.65","ERK5 in complex with small molecule","TFDVGDEYEIIETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEFKSVYVVLDLMESDLHQIIHSSQPLTLEHVRYFLYQLLRGLKYMHSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCTSPAEHQYFMTEYVATRWYRAPELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFPGKNYVHQLQLIMMVLGTPSPAVIQAVGAERVRAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARISAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGI","Homo sapiens","MAPK7, BMK1, ERK5, PRKM7","Mitogen-activated protein kinase 7","1","5BYZ"
"5BZD",,"X-RAY DIFFRACTION",2.9,57.6,"VAPOR DIFFUSION, SITTING DROP",,"16% (w/v) PEG 8000, 20% (v/v) glycerol and 0.04 M potassium dihydrogen phosphate",293.15,,,"5BZD",96.58,"2.7","2.7","Crystal Structure of PCDN-27A, an antibody from the PCDN family of HIV-1 antibodies","EIVLTQSPGTLSLSAGERATLSCRASQSVSARNLAWYQQKPGQAPRLLLYGVSIRNTGVPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGDSPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"5G8 HIV Antibody light chain","1","5BZD"
,,,,,,,,,,,,,,,,"QVQLQQWGAGLLKPSETLSLTCAVYGESFSAFSWSWIRQPPGKGLEWIGEIDHTGSANYNPSLKSRISMSVDTSMNQFSLELLSMTVADTAVYYCARGGRKVYHAYWSGYVNNCFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD","Homo sapiens",,"5G8 HIV Antibody heavy chain","2","5BZD"
"5BZW",,"X-RAY DIFFRACTION",2.51,51.08,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG 3350, 10% (v/v) ethylene glycol and 0.2M ammonium sulfate",293.15,"10.1016/j.immuni.2016.04.016",,"5BZW",49.13,"2.9","2.9","Crystal Structure of PCDN-27B, an antibody from the PCDN family of HIV-1 antibodies","EIVLTQSPGTLSLSPGERATLSCRASQSVSAKNLAWYQQKPGQTPRLLMYGVSLRNTGVPDRFSGSGSGTDFTLTISRLEPEDSAVYFCQQYGTSPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"2B3 HIV Antibody light chain","1","5BZW"
,,,,,,,,,,,,,,,,"QVQLQQWGAGLLKPSETLSLTCAVYNESLSAFSWSWIRQFPGQGLEWIGEIDHTTSSNYNPSLKRRINISIDTSKKQFSLKLYSVTAADTAVYYCARGGRKVYHAYWSGYVNNCFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCD","Homo sapiens",,"2B3 HIV Antibody heavy chain","2","5BZW"
"5BZX",,"X-RAY DIFFRACTION",3.15,60.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrat, 7.5% glycerol",293,"10.1002/anie.201506338",,"5BZX",149.91,"2.5","2.5","Crystal structure of human phosphatase PTEN treated with a bisperoxovanadium complex","RRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEEDNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTV","Homo sapiens","PTEN, MMAC1, TEP1","Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN","1","5BZX"
"5BZZ",,"X-RAY DIFFRACTION",3.16,61.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES pH 6.5, 1.25 M L-tartrate, 7.5% glycerol",293,"10.1002/anie.201506338",,"5BZZ",149.83,"2.2","2.2","Crystal structure of human phosphatase PTEN in its reduced state","RRYQEDGFDLDLTYIYPNIIAMGFPAERLEGVYRNNIDDVVRFLDSKHKNHYKIYNLCAERHYDTAKFNCRVAQYPFEDHNPPQLELIKPFCEDLDQWLSEDDNHVAAIHCKAGKGRTGVMICAYLLHRGKFLKAQEALDFYGEVRTRDKKGVTIPSQRRYVYYYSYLLKNHLDYRPVALLFHKMMFETIPMFSGGTCNPQFVVCQLKVKIYSSNSGPTRREDKFMYFEFPQPLPVCGDIKVEFFHKQNKMLKKDKMFHFWVNTFFIPGPEEDNDKEYLVLTLTKNDLDKANKDKANRYFSPNFKVKLYFTKTV","Homo sapiens","PTEN, MMAC1, TEP1","Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN","1","5BZZ"
"5C01",,"X-RAY DIFFRACTION",2.01,38.83,"VAPOR DIFFUSION, SITTING DROP",8.5,"18-22% PEG 4000, 0.1 M Tris, pH 8.5, 200 mM CaCl2",293,"10.1074/jbc.M115.672048",,"5C01",77.23,"2.15","2.15","Crystal Structure of kinase","MSYYHHHHHHDYDIPTTENLYFQGAMGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQP","Homo sapiens","TYK2","NON-RECEPTOR TYROSINE-PROTEIN KINASE TYK2","1","5C01"
"5C03",,"X-RAY DIFFRACTION",2.12,42,"VAPOR DIFFUSION, SITTING DROP",8.5,"18-22% PEG 4000, 0.1 M Tris, pH 8.5, 200 mM CaCl2",293,"10.1074/jbc.M115.672048","AGS","5C03",78.88,"1.9","1.9","Crystal Structure of kinase","MSYYHHHHHHDYDIPTTENLYFQGAMGETSNLIIMRGARASPRTLNLSQLSFHRVDQKEITQLSHLGQGTRTNVYEGRLRVEGSGDPEEGKMDDEDPLVPGRDRGQELRVVLKVLDPSHHDIALAFYETASLMSQVSHTHLAFVHGVCVRGPENIMVTEYVEHGPLDVWLRRERGHVPMAWKMVVAQQLASALSYLENKNLVHGNVCGRNILLARLGLAEGTSPFIKLSDPGVGLGALSREERVERIPWLAPECLPGGANSLSTAMDKWGFGATLLEICFDGEAPLQSRSPSEKEHFYQRQHRLPEPSCPQLATLTSQCLTYEPTQRPSFRTILRDLTRLQP","Homo sapiens","TYK2","Non-receptor tyrosine-protein kinase TYK2","1","5C03"
"5C0K",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.5,"3.9M NaCl, 0.1M HEPES/NaOH pH=7.5",277,"10.1021/acs.jmedchem.5b00706","4WK","5C0K",13.06,"2.2","2.2","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 3","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C0K"
"5C0L",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.5,"3.9M NaCl, 0.1M HEPES/NaOHpH=7.5",277,"10.1021/acs.jmedchem.5b00706",,"5C0L",12.98,"2.6","2.6","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 2","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C0L"
"5C0V",,"X-RAY DIFFRACTION",2.25,45.22,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.2 M Ammonium nitrate, 20% PEG 3350",295,"10.1093/nar/gkv748",,"5C0V",79.22,"2.2","2.2","Structure of the LARP1-unique domain DM15","GHSGGGGGGHMQHPSHELLKENGFTQHVYHKYRRRCLNERKRLGIGQSQEMNTLFRFWSFFLRDHFNKKMYEEFKQLALEDAKEGYRYGLECLFRYYSYGLEKKFRLDIFKDFQEETVKDYEAGQLYGLEKFWAFLKYSKAKNLDIDPKLQEYLGKFRRLED","Homo sapiens","LARP1, KIAA0731, LARP","La-related protein 1","1","5C0V"
"5C14",,"X-RAY DIFFRACTION",3.89,68.36,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris pH 8.5, 0.1 M MgNO3, 20% PEG 3350",292,"10.1182/blood-2015-07-660092",,"5C14",50.77,"2.8","2.8","Crystal structure of PECAM-1 D1D2 domain","RSQENSFTINSVDMKSLPDWTVQNGKNLTLQCFADVSTTSHVKPQHQMLFYKDDVLFYNISSMKSTESYFIPEVRIYDSGTYKCTVIVNNKEKTTAEYQLLVEGVPSPRVTLDKKEAIQGGIVRVNCSVPEEKAPIHFTIEKLELNEKMVKLKREKNSRDQNFVILEFPVEEQDRVLSFRCQARIISGIHMQTSESTKSELVTVSRENLYFQ","Homo sapiens","PECAM1","Platelet endothelial cell adhesion molecule","1","5C14"
,,,,,,,,,,,,,,,,"RSQENSFTINSVDMKSLPDWTVQNGKNLTLQCFADVSTTSHVKPQHQMLFYKDDVLFYNISSMKSTESYFIPEVRIYDSGTYKCTVIVNNKEKTTAEYQLLVEGVPSPRVTLDKKEAIQGGIVRVNCSVPEEKAPIHFTIEKLELNEKMVKLKREKNSRDQNFVILEFPVEEQDRVLSFRCQARIISGIHMQTSESTKSELVTVSRENLYFQ","Homo sapiens","PECAM1","Platelet endothelial cell adhesion molecule","2","5C14"
"5C16",,"X-RAY DIFFRACTION",2.36,47.8,"VAPOR DIFFUSION, HANGING DROP",,"Sodium-HEPES, PEG 20000",277,"10.1371/journal.pone.0152611",,"5C16",262.18,"2.07","2.07","Myotubularin-related proetin 1","MEEAPLFPGESIKAIVKDVMYICPFMGAVSGTLTVTDFKLYFKNVERDPHFILDVPLGVISRVEKIGAQSHGDNSCGIEIVCKDMRNLRLAYKQEEQSKLGIFENLNKHAFPLSNGQALFAFSYKEKFPINGWKVYDPVSEYKRQGLPNESWKISKINSNYEFCDTYPAIIVVPTSVKDDDLSKVAAFRAKGRVPVLSWIHPESQATITRCSQPLVGPNDKRCKEDEKYLQTIMDANAQSHKLIIFDARQNSVADTNKTKGGGYESESAYPNAELVFLEIHNIHVMRESLRKLKEIVYPSIDEARWLSNVDGTHWLEYIRMLLAGAVRIADKIESGKTSVVVHSSDGWDRTAQLTSLAMLMLDSYYRTIKGFETLVEKEWISFGHRFALRVGHGNDNHADADRSPIFLQFVDCVWQMTRQFPSAFEFNELFLITILDHLYSCLFGTFLCNCEQQRFKEDVYTKTISLWSYINSQLDEFSNPFFVNYENHVLYPVASLSHLELWVNYYVRWNPRMRPQMPIHQNLKELLAVRAELQKRVEGLQREVATRAVSSSSERGSSPSHSATSVHTSV","Homo sapiens","MTMR1","Myotubularin-related protein 1","1","5C16"
"5C18",,"X-RAY DIFFRACTION",3.1,60.27,"VAPOR DIFFUSION, HANGING DROP",,"6.5-7% PEG 4000, 0.4-0.6 M potassium acetate, 0.1 M MES pH 5.75",298,"10.1016/j.str.2015.10.026",,"5C18",528.38,"3.3","3.3","p97-delta709-728 in complex with ATP-gamma-S","ASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","Transitional endoplasmic reticulum ATPase","1","5C18"
"5C19",,"X-RAY DIFFRACTION",2.6,52.69,"VAPOR DIFFUSION, HANGING DROP",,"12% PEG 4000, 0.15 M ammonium sulfate, 0.1 M MES pH 6.5",298,"10.1016/j.str.2015.10.026",,"5C19",536.56,"4.2","4.2","p97 variant 2 in the apo state","ASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDDDIDKYEDFADTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","Transitional endoplasmic reticulum ATPase","1","5C19"
"5C1A",,"X-RAY DIFFRACTION",2.94,58.1,"VAPOR DIFFUSION, HANGING DROP",,"9-9.5% PEG 4000, 0.4-0.5 M magnesium acetate, 0.1 M sodium-citrate pH 5.6",298,"10.1016/j.str.2015.10.026",,"5C1A",1083.97,"3.8","3.8","p97-N750D/R753D/M757D/Q760D in complex with ATP-gamma-S","ASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDDDIDKYEDFADTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","Transitional endoplasmic reticulum ATPase","1","5C1A"
"5C1G",,"X-RAY DIFFRACTION",2.28,46.13,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C1G",35.91,"1.46","1.46","Crystal structure of ABBA + UDP + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C1G"
"5C1H",,"X-RAY DIFFRACTION",2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C1H",35.95,"1.55","1.55","Crystal structure of ABBB + UDP + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C1H"
"5C1L",,"X-RAY DIFFRACTION",2.34,47.41,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C1L",35.7,"1.4","1.4","Crystal structure of GTB + UDP-Gal + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C1L"
"5C1Q",,"X-RAY DIFFRACTION",3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",9.5,"0.4 M potassium sodium tartrate tetrahydrate",291,,,"5C1Q",33.49,"3","3","Serine/threonine-protein kinase pim-1","GPHMKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5C1Q"
"5C1V",,"X-RAY DIFFRACTION",3.59,65.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, 25% PEG 3350, PH 7.5,
 VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 293K",290,"10.1371/journal.pone.0134569",,"5C1V",79.98,"3.35","3.35","CRYSTAL STRUCTURE ANALYSIS OF CATALYTIC SUBUNIT OF HUMAN CALCINEURIN","SEPKAIDPKLSTTDRVVKAVPFPPSHRLTAKEVFDNDGKPRVDILKAHLMKEGRLEESVALRIITEGASILRQEKNLLDIDAPVTVCGDIHGQFFDLMKLFEVGGSPANTRYLFLGDYVDRGYFSIECVLYLWALKILYPKTLFLLRGNHECRHLTEYFTFKQECKIKYSERVYDACMDAFDCLPLAALMNQQFLCVHGGLSPEINTLDDIRKLDRFKEPPAYGPMCDILWSDPLEDFGNEKTQEHFTHNTVRGCSYFYSYPAVCEFLQHNNLLSILRAHEAQDAGYRMYRKSQTTGFPSLITIFSAPNYLDVYNNKAAVLKYENNVMNIRQFNCSPHPSWAPNFD","Homo sapiens","PPP3CA, CALNA, CNA","Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform","1","5C1V"
"5C1W",,"X-RAY DIFFRACTION",1.87,34.37,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4XS","5C1W",83.37,"1.7","1.7","PDE10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C1W"
"5C1Z",,"X-RAY DIFFRACTION",2.56,51.9,"VAPOR DIFFUSION",5.5,"LiSO4, PEG3350",277,"10.15252/embj.201592337",,"5C1Z",92.93,"1.79","1.79","Parkin (UblR0RBR)","MIVFVRFNSSHGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQSIVHIVQRPWRKGQEMNATNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHCPGTSAEFFFKCGAHPTSDKETSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDRQFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEGECSAVFEASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV","Homo sapiens","PARK2, PRKN","E3 ubiquitin-protein ligase parkin","1","5C1Z"
"5C23",,"X-RAY DIFFRACTION",2.47,50.22,"VAPOR DIFFUSION",5.5,"PEG3350, LiSO4",277,"10.15252/embj.201592337",,"5C23",93.04,"2.37","2.37","Parkin (S65DUblR0RBR)","MIVFVRFNSSHGFPVEVDSDTSIFQLKEVVAKRQGVPADQLRVIFAGKELRNDWTVQNCDLDQQDIVHIVQRPWRKGQEMNATNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHCPGTSAEFFFKCGAHPTSDKETSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDRQFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYGAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEGECSAVFEASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV","Homo sapiens","PARK2, PRKN","E3 ubiquitin-protein ligase parkin","1","5C23"
"5C28",,"X-RAY DIFFRACTION",1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4XV","5C28",83.35,"1.56","1.56","PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C28"
"5C29",,"X-RAY DIFFRACTION",1.85,33.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4XY","5C29",83.4,"2.05","2.05","PDE10 complexed with 6-chloro-2-cyclopropyl-5-methyl-N-propyl-pyrimidin-4-amine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C29"
"5C2A",,"X-RAY DIFFRACTION",1.94,36.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4Y2","5C2A",83.79,"2","2","PDE10 complexed with 6-chloro-2-cyclopropyl-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C2A"
"5C2E",,"X-RAY DIFFRACTION",1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4Y1","5C2E",83.91,"2.1","2.1","PDE10 complexed with6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C2E"
"5C2H",,"X-RAY DIFFRACTION",1.88,34.42,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1021/acs.jmedchem.5b00983","4XU","5C2H",83.97,"2.09","2.09","PDE10 complexed with 6-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine","MGSSHHHHHHSSGLVPRGSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5C2H"
"5C36",,"X-RAY DIFFRACTION",2.33,47.13,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C36",35.58,"1.55","1.55","Crystal structure of GTA + UDP-C-Gal + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C36"
"5C37",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION, HANGING DROP",8,"PEG3350, Tris, KCl",298,,"4XN","5C37",146.72,"2.3","2.3","Structure of the beta-ketoacyl reductase domain of human fatty acid synthase bound to a spiro-imidazolone inhibitor","EQQVPILEKFCFTPHTEEGCLSERAALQEELQLCKGLVQALQTKVTQQGLKMVVPGLDGAQIPRDPSQQELPRLLSAACRLQLNGNLQLELAQVLAQERPKLPEDPLLSGLLDSPALKACLDTAVENMPSLKMKVVEVLAGHGHLYSRIPGLLSPHPLLQLSYTATDRHPQALEAAQAELQQHDVAQGQWDPADPAPSALGSADLLVCNCAVAALGDPASALSNMVAALREGGFLLLHTLLRGHPLGDIVAFLTSTEPQYGQGILSQDAWESLFSRVSLRLVGLKKSFYGSTLFLCRRPTPQDSPIFLPVDDTSFRWVESLKGILADEDSSRPVWLKAINCATSGVVGLVNCLRREPGGNRLRCVLLSNLSSTSHVPEVDPGSAELQKVLQGDLVMNVYRDGAWGAFRHFLLEEDKGGSKTGCPAHKSYIIAGGLGGFGLELAQWLIQRGVQKLVLTSRSGIRTGYQAKQVRRWRRQGVQVQVSTSNISSLEGARGLIAEAAQLGPVGGVFNLAVVLRDGLLENQTPEFFQDVCKPKYSGTLNLDRVTREACPELDYFVVFSSVSCGRGNAGQSNYGFANSAMERICEKRRHEGLPGLAVQWGAIGDVGILVETMSTNDTIVSGTLPQRMASCLEVLDLFLNQPHMVLSSFVLAEKAAAYRDRD","Homo sapiens","FASN, FAS","Fatty acid synthase","1","5C37"
"5C38",,"X-RAY DIFFRACTION",2.33,47.13,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C38",35.77,"1.45","1.45","Crystal structure of AABB + UDP-C-Gal + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C38"
"5C3A",,"X-RAY DIFFRACTION",2.35,47.65,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C3A",35.36,"1.33","1.33","Crystal structure of ABBA + UDP-C-Gal (short soak) + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C3A"
"5C3B",,"X-RAY DIFFRACTION",2.33,47.28,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C3B",35.78,"1.4","1.4","Crystal structure of ABBA + UDP-C-Gal (long soak) + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C3B"
"5C3D",,"X-RAY DIFFRACTION",2.35,47.61,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C3D",35.5,"1.39","1.39","Crystal structure of ABBB + UDP-C-Gal (short soak) + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C3D"
"5C3H",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706",,"5C3H",12.96,"2.65","2.65","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 1","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C3H"
"5C3K",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706","4XF","5C3K",12.93,"2.02","2.02","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 4","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C3K"
"5C3T",,"X-RAY DIFFRACTION",2.14,42.44,"VAPOR DIFFUSION, SITTING DROP",,"1.84 Na Formate",295.15,"10.1016/j.str.2015.09.010",,"5C3T",14.4,"1.8","1.8","PD-1 binding domain from human PD-L1","AFTVTVPKDLYVVEYGSNMTIECKFPVEKELDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5C3T"
"5C3Y",,"X-RAY DIFFRACTION",2.58,52.29,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.1M sodium HEPES, 7% PEG 8000",277,,,"5C3Y",428.56,"2.6","2.6","Structure of human ribokinase crystallized with AMPPNP","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5C3Y"
"5C3Z",,"X-RAY DIFFRACTION",3.08,60.01,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M sodium HEPES, 10% PEG 8000",277,,,"5C3Z",71.69,"1.9","1.9","Crystal structure of human ribokinase in complex with AMPPCP in C2 spacegroup","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5C3Z"
"5C40",,"X-RAY DIFFRACTION",2.18,43.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M sodium HEPES, 10% PEG 8000",277,,,"5C40",71.87,"1.5","1.5","Crystal structure of human ribokinase in complex with AMPPCP in P21 spacegroup","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5C40"
"5C41",,"X-RAY DIFFRACTION",2.35,47.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M sodium HEPES, 10% PEG 8000",277,,,"5C41",143.26,"1.95","1.95","Crystal structure of human ribokinase in complex with AMPPCP in P21 spacegroup and with 4 protomers","MAASGEPQRQWQEEVAAVVVVGSCMTDLVSLTSRLPKTGETIHGHKFFIGFGGKGANQCVQAARLGAMTSMVCKVGKDSFGNDYIENLKQNDISTEFTYQTKDAATGTASIIVNNEGQNIIVIVAGANLLLNTEDLRAAANVISRAKVMVCQLEITPATSLEALTMARRSGVKTLFNPAPAIADLDPQFYTLSDVFCCNESEAEILTGLTVGSAADAGEAALVLLKRGCQVVIITLGAEGCVVLSQTEPEPKHIPTEKVKAVDTTGAGDSFVGALAFYLAYYPNLSLEDMLNRSNFIAAVSVQAAGTQSSYPYKKDLPLTLFLEHHHHHH","Homo sapiens","RBKS, RBSK","Ribokinase","1","5C41"
"5C47",,"X-RAY DIFFRACTION",2.29,46.37,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C47",35.92,"1.39","1.39","Crystal structure of ABBB + UDP-C-Gal (long soak) + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C47"
"5C48",,"X-RAY DIFFRACTION",2.33,47.14,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C48",35.7,"1.46","1.46","Crystal structure of GTB + UDP-C-Gal + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C48"
"5C49",,"X-RAY DIFFRACTION",2.34,47.45,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C49",35.68,"1.49","1.49","Crystal structure of GTB + UDP-C-Gal + H-antigen","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C49"
"5C4B",,"X-RAY DIFFRACTION",2.32,47.08,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C4B",35.89,"1.54","1.54","Crystal structure of GTA + UDP-Glc + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C4B"
"5C4C",,"X-RAY DIFFRACTION",2.3,46.6,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C4C",35.92,"1.43","1.43","Crystal structure of ABBB + UDP-Glc + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C4C"
"5C4D",,"X-RAY DIFFRACTION",2.35,47.57,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C4D",35.82,"1.4","1.4","Crystal structure of GTB + UDP-Glc + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C4D"
"5C4E",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C4E",35.65,"1.55","1.55","Crystal structure of GTB + UDP-Glc + H-antigen acceptor","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C4E"
"5C4F",,"X-RAY DIFFRACTION",2.31,46.86,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C4F",35.77,"1.41","1.41","Crystal structure of AABB + UDP-Glc + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C4F"
"5C4M",,"X-RAY DIFFRACTION",2.03,39.27,"VAPOR DIFFUSION, SITTING DROP",,"24% (w/v) PEG 3350, 0.3 NaCl",293,,,"5C4M",22.23,"1.3","1.3","RhoA GDP with novel switch II conformation","MAAIRKKLVIVGDGACGKTCLLIVNSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQARRGKKKSGCLVL","Homo sapiens","RHOA, ARH12, ARHA, RHO12","Transforming protein RhoA","1","5C4M"
"5C4O",,"X-RAY DIFFRACTION",3.15,61.01,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.2 to 1.8M Ammonium sulfate, 0.1 M Tris HCl",290,"10.1038/ncomms9833","4F1","5C4O",29.09,"2.24","2.24","Identification of a Novel Allosteric Binding Site for RORgt Inhibitors","LTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLHKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5C4O"
"5C4S",,"X-RAY DIFFRACTION",3.2,61.54,"VAPOR DIFFUSION, HANGING DROP",8,"1.2 to 1.8M Ammonium sulfate, 0.1 M Tris HCl",290,"10.1038/ncomms9833","4Y5","5C4S",28.85,"2.23","2.23","Identification of a Novel Allosteric Binding Site for RORgt Inhibitors","LTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLHKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5C4S"
"5C4T",,"X-RAY DIFFRACTION",2.96,58.43,"VAPOR DIFFUSION, HANGING DROP",8,"1.2 to 1.8M Ammonium sulfate, 0.1 M Tris HCl",290,"10.1038/ncomms9833","4Y6","5C4T",29.5,"1.77","1.77","Identification of a Novel Allosteric Binding Site for RORgt Inhibitors","LTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLHKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5C4T"
"5C4U",,"X-RAY DIFFRACTION",3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",8,"1.2 to 1.8M Ammonium sulfate, 0.1 M Tris HCl",290,"10.1038/ncomms9833","4Y7","5C4U",28.94,"2.08","2.08","Identification of a Novel Allosteric Binding Site for RORgt Inhibitors","LTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLHKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQHLHPIVVQAAFPPLYKELFS","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5C4U"
"5C5A",,"X-RAY DIFFRACTION",2.19,43.9,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Potassium iodide, 2.2M Ammonium Sulfate",293,,"NUT","5C5A",23.47,"1.146","1.146","Crystal Structure of HDM2 in complex with Nutlin-3a","PASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5C5A"
"5C5C",,"X-RAY DIFFRACTION",2.6,52.64,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M K2PO4",291,,,"5C5C",54.01,"1.862","1.862","Human metabotropic glutamate receptor 7, extracellular ligand binding domain","GAMDMYAPHSIRIEGDVTLGGLFPVHAKGPSGVPCGDIKRENGIHRLEAMLYALDQINSDPNLLPNVTLGARILDTCSRDTYALEQSLTFVQALIQKDTSDVRCTNGEPPVFVKPEKVVGVIGASGSSVSIMVANILRLFQIPQISYASTAPELSDDRRYDFFSRVVPPDSFQAQAMVDIVKALGWNYVSTLASEGSYGEKGVESFTQISKEAGGLSIAQSVRIPQERKDRTIDFDRIIKQLLDTPNSRAVVIFANDEDIKQILAAAKRADQVGHFLWVGSDSWGSKINPLHQHEDIAEGAITIQPKRATVEGFDAYFTSRTLENNRRNVWFAEYWEENFNCKLTISGSKKEDTDRKCTGQERIGKDSNYEQEGKVQFVIDAVYAMAHALHHMNKDLCADYRGVCPEMEQAGGKKLLKYIRNVNFNGSAGTPVMFNKNGDAPGRYDIFQYQTTNTSNPGYRLIGQWTDELQLNIEDMQWGK","Homo sapiens","GRM7, GPRC1G, MGLUR7","Metabotropic glutamate receptor 7","1","5C5C"
"5C5P",,"X-RAY DIFFRACTION",2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM SULFATE, 0.1M TRIS PH 8.5",298,"10.1021/acsmedchemlett.5b00251","0E0","5C5P",55.7,"1.75","1.75","CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5C5P"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5C5P"
"5C5Q",,"X-RAY DIFFRACTION",2.43,49.31,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM  SULFATE, 0.1M TRIS PH 8.5",298,"10.1021/acsmedchemlett.5b00251","G9W","5C5Q",55.67,"2","2","CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5C5Q"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5C5Q"
"5C5R",,"X-RAY DIFFRACTION",2.44,49.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"30-40% PEG 3350, 5% SATURATED AMMONIUM SULFATE, 0.1M TRIS PH 8.5",298,"10.1021/acsmedchemlett.5b00251","0E1","5C5R",55.59,"1.55","1.55","CRYSTAL STRUCTURE OF HUMAN TANKYRASE-2 IN COMPLEX WITH A PYRANOPYRIDONE INHIBITOR","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5C5R"
,,,,,,,,,,,,,,,,"KMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","2","5C5R"
"5C5S",,"X-RAY DIFFRACTION",2.16,42.93,"VAPOR DIFFUSION, SITTING DROP",6,"0.2 M NH4Ac, 0.1 M Bis-Tris and 20% w/v PEG 3350",298,"10.1172/JCI81673",,"5C5S",104.24,"2.2","2.2","Crystal Structure of human Myosin 9b RhoGAP domain at 2.2 angstrom","GPGSEFPGVEPGHFGVCVDSLTSDKASVPIVLEKLLEHVEMHGLYTEGLYRKSGAANRTRELRQALQTDPAAVKLENFPIHAITGVLKQWLRELPEPLMTFAQYGDFLRAVELPEKQEQLAAIYAVLEHLPEANHNSLERLIFHLVKVALLEDVNRMSPGALAIIFAPCLLRCPDNSDPLTSMKDVLKITTCVEMLIKEQMRKYKVKMEEISQLEAAESIAFRRLSLLRQNA","Homo sapiens","MYO9B, MYR5","Unconventional myosin-IXb","1","5C5S"
"5C5X",,"X-RAY DIFFRACTION",3.87,68.25,"VAPOR DIFFUSION, HANGING DROP",7.9,"RESERVOIR SOLUTION (100MM TRIS-HCL
 PH7.9, 100MM NACL, 21% PEG400) MIXED WITH EACH OF 1,6-HEXANEDIOL
 (30%, V/V) AND 1,3-PROPANEDIOL (40%, V/V) AND MIXED WITH THE
 TEMPERATURE 281K",281,"10.1371/journal.pone.0143027",,"5C5X",207.19,"2.6","2.6","CRYSTAL STRUCTURE OF THE S156E MUTANT OF HUMAN AQUAPORIN 5","MKKEVCSVAFLKAVFAEFLATLIFVFFGLGSALKWPSALPTILQIALAFGLAIGTLAQALGPVSGGHINPAITLALLVGNQISLLRAFFYVAAQLVGAIAGAGILYGVAPLNARGNLAVNALNNNTTQGQAMVVELILTFQLALCIFASTDSRRTEPVGSPALSIGLSVTLGHLVGIYFTGCSMNPARSFGPAVVMNRFSPAHWVFWVGPIVGAVLAAILYFYLLFPNSLSLSERVAIIKGTYEP","Homo sapiens","AQP5","Aquaporin-5","1","5C5X"
"5C65",,"X-RAY DIFFRACTION",3.37,63.55,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M citrate pH 5.5, 29% PEG400, 0.1M lithium sulfate",293,,,"5C65",111.13,"2.65","2.65","Structure of the human glucose transporter GLUT3 / SLC2A3","MGTQKVTPALIFAITVATIGSFQFGYNTGVINAPEKIIKEFIQKTLTDKGNAPPSEVLLTSLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLIVNLLAVTGGCFMGLCKVAKSVEMLILGRLVIGLFCGLCTGFVPMYIGEISPTALRGAFGTLNQLGIVVGILVAQIFGLEFILGSEELWPLLLGFTILPAILQSAALPFCPESPRFLLINRKEEENAKQILQRLWGTQDVSQDIQEMKDESARMSQEKQVTVLELFRVSSYRQPIIISIVLQLSQQLSGINAVFYYSTGIFKDAGVQEPIYATIGAGVVNTIFTVVSLFLVERAGRRTLHMIGLGGMAFCSTLMTVSLLLKDNYNGMSFVCIGAILVFVAFFEIGPGPIPWFIVAELFSQGPRPAAMAVAGCSNWTSNFLVGLLFPSAAHYLGAYVFIIFTGFLITFLAFTFFKVPETRGRTFEDITRAFEGQAHGADRAENLYFQ","Homo sapiens","SLC2A3, GLUT3","Solute carrier family 2, facilitated glucose transporter member 3","1","5C65"
"5C6C",,"X-RAY DIFFRACTION",2.24,44.98,"VAPOR DIFFUSION, HANGING DROP",,"200 mM calcium chloride, 200 mM cadmium chloride, 200 mM cobalt (II) chloride, 20% polyethylene glycol 3350",296,"10.1074/jbc.M115.691303","CMP","5C6C",34.89,"2.05","2.05","PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cAMP","GSNKPPEFSFEKARVRKDSSEKKLITDALNKNQFLKRLDPQQIKDMVECMYGRNYQQGSYIIKQGEPGNHIFVLAEGRLEVFQGEKLLSSIPMWTTFGELAILYNCTRTASVKAITNVKTWALDREVFQNIMRRTAQARDEQY","Homo sapiens","PRKG2, PRKGR2","cGMP-dependent protein kinase 2","1","5C6C"
"5C6S",,"X-RAY DIFFRACTION",2.06,40.36,"VAPOR DIFFUSION, HANGING DROP",7.5,"25% PEG 3350, 0.2M LiSO4, 0.1M HEPES pH7.5",293,,,"5C6S",15.52,"1.3","1.3","Human Bromodomain and PHD Finger Containing 1, PWWP domain in complex with XST005904a","GEDSPLDALDLVWAKCRGYPSYPALIIDPKMPREGMFHHGVPIPVPPLEVLKLGEQMTQEAREHLYLVLFFDNKRTWQWLPRTKLVPLGVNQDLDKEKMLEGRKSNIRKSVQIAYHRALQHRSKVQGEQS","Homo sapiens","BRPF1, BR140","Peregrin","1","5C6S"
"5C7A",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCL",277,"10.1021/acs.jmedchem.5b00706",,"5C7A",13.01,"2.36","2.36","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 7","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C7A"
"5C7B",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706",,"5C7B",12.96,"2.68","2.68","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 5","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C7B"
"5C7C",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706","4YC","5C7C",13.07,"2.32","2.32","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 18","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C7C"
"5C7D",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706","4YF","5C7D",13.05,"2.25","2.25","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 17","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C7D"
"5C7G",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION, HANGING DROP",,"25% PEG550 mme 5%,  PEG 20 000,  60mM MgCl2,  Na-Bicine 100 mM, pH 8.5",293,,,"5C7G",18.61,"1.45","1.45","Crystal Structure of the b1 Domain of Human Neuropilin-1 in complex with a bicine molecule","HHHHHHFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5C7G"
"5C7L",,"X-RAY DIFFRACTION",2.37,48.06,"VAPOR DIFFUSION",6.5,"mix 1:1 volume of protein at 10 mg/mL with 0.2 M sodium sulfate, 0.1 M Bis-Tris propane pH 6.5, 20% PEG 3350",273,"10.1093/molehr/gaw016",,"5C7L",73.48,"1.862","1.862","Structure of human testis-specific glyceraldehyde-3-phosphate dehydrogenase apo form","RELTVGINGFGRIGRLVLRACMEKGVKVVAVNDPFIDPEYMVYMFKYDSTHGRYKGSVEFRNGQLVVDNHEISVYQCKEPKQIPWRAVGSPYVVESTGVYLSIQAASDHISAGAQRVVISAPSPDAPMFVMGVNENDYNPGSMNIVSNASCTTNCLAPLAKVIHERFGIVEGLMTTVHSYTATQKTVDGPSRKAWRDGRGAHQNIIPASTGAAKAVTKVIPELKGKLTGMAFRVPTPDVSVVDLTCRLAQPAPYSAIKEAVKAAAKGPMAGILAYTEDEVVSTDFLGDTHSSIFDAKAGIALNDNFVKLISWYDNEYGYSHRVVDLLRYMFSRDAE","Homo sapiens","GAPDHS, GAPD2, GAPDH2, GAPDS, HSD-35, HSD35","Glyceraldehyde-3-phosphate dehydrogenase, testis-specific","1","5C7L"
"5C7N",,"X-RAY DIFFRACTION",2.43,49.45,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% PEG3350, 0.1 M sodium acetate, 0.15 M sodium nitrate, pH 5.5",277,"10.1021/acs.jmedchem.6b00215","BMF","5C7N",14.17,"1.75","1.75","Crystal structure of the human BRPF1 bromodomain in complex with Bromosporine","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5C7N"
"5C7O",,"X-RAY DIFFRACTION",2.4,48.74,"VAPOR DIFFUSION",,"1:1 mixture of protein:NAD+ complex at 10 mg/mL with 0.2 M sodium nitrate, 20% PEG3350",273,"10.1093/molehr/gaw016",,"5C7O",74.85,"1.729","1.729","Structure of human testis-specific glyceraldehyde-3-phosphate dehydrogenase holo form with NAD+","RELTVGINGFGRIGRLVLRACMEKGVKVVAVNDPFIDPEYMVYMFKYDSTHGRYKGSVEFRNGQLVVDNHEISVYQCKEPKQIPWRAVGSPYVVESTGVYLSIQAASDHISAGAQRVVISAPSPDAPMFVMGVNENDYNPGSMNIVSNASCTTNCLAPLAKVIHERFGIVEGLMTTVHSYTATQKTVDGPSRKAWRDGRGAHQNIIPASTGAAKAVTKVIPELKGKLTGMAFRVPTPDVSVVDLTCRLAQPAPYSAIKEAVKAAAKGPMAGILAYTEDEVVSTDFLGDTHSSIFDAKAGIALNDNFVKLISWYDNEYGYSHRVVDLLRYMFSRDK","Homo sapiens","GAPDHS, GAPD2, GAPDH2, GAPDS, HSD-35, HSD35","Glyceraldehyde-3-phosphate dehydrogenase, testis-specific","1","5C7O"
"5C83",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706","4YN","5C83",13.18,"2.33","2.33","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 21","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C83"
"5C84",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes-NaOH 7.5, 3.9M NaCl",277,"10.1021/acs.jmedchem.5b00706","4YL","5C84",13.12,"2.36","2.36","Fragment-Based Drug Discovery Targeting Inhibitor of Apoptosis Proteins: Compound 20","GSHMNFPNSTNLPRNPSMADYEARIFTFGTWIYSVNKEQLARAGFYALGEGDKVKCFHCGGGLTDWKPSEDPWEQHAKWYPGCKYLLEQKGQEYINNIHLTHSLEECLVR","Homo sapiens","XIAP, API3, BIRC4, IAP3","E3 ubiquitin-protein ligase XIAP","1","5C84"
"5C85",,"X-RAY DIFFRACTION",2.4,48.81,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane, pH6.5, 0.2 M sodium nitrate, 20%PEG33500",277,"10.1021/acs.jmedchem.6b00215","4YO","5C85",13.99,"1.7","1.7","Crystal structure of the human BRPF1 bromodomain in complex with SEED1","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5C85"
"5C87",,"X-RAY DIFFRACTION",2.46,49.93,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris propane, pH6.5, 0.2 M sodium nitrate, 20%PEG33500",277,"10.1021/acs.jmedchem.6b00215","4YS","5C87",13.91,"1.55","1.55","Crystal structure of the human BRPF1 bromodomain in complex with SEED2","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5C87"
"5C89",,"X-RAY DIFFRACTION",2.47,50.17,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium acetate, pH 5.5, 0.15 M potassium thiocynate, 20% PEG3350",277,,,"5C89",13.94,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with 917","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5C89"
"5C8H",,"X-RAY DIFFRACTION",2.39,48.62,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG-3350, 0.2 M magnesium formate",293,,,"5C8H",13.81,"2.01","2.01","Crystal structure of ORC2 C-terminal domain","GTSYENSLLVKQSGSLPLSSLTHVLRSLTPNARGIFRLLIKYQLDNQDNPSYIGLSFQDFYQQCREAFLVNSDLTLRAQLTEFRDHKLIRTKKGTDGVEYLLIPVDNGTLTDFLEKEEEEA","Homo sapiens","ORC2, ORC2L","Origin recognition complex subunit 2","1","5C8H"
"5C8I",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.16,43.03,"VAPOR DIFFUSION, SITTING DROP",7.8,"1.6M Na-citrate, 50 mM Tris",298,"10.1107/S2052252516010514","MZM","5C8I",29.59,"1.56, 2.2","1.56, 2.2","Joint X-ray/neutron structure of Human Carbonic Anhydrase II in complex with Methazolamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5C8I"
"5C8K",,"X-RAY DIFFRACTION",3.49,64.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4YV","5C8K",37.94,"3","3","EGFR kinase domain mutant ""TMLR"" with compound 1","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5C8K"
"5C8M",,"X-RAY DIFFRACTION",3.74,67.12,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4YW","5C8M",37.98,"2.9","2.9","EGFR kinase domain mutant ""TMLR"" with compound 17","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5C8M"
"5C8N",,"X-RAY DIFFRACTION",3.45,64.33,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4YX","5C8N",38.07,"2.401","2.401","EGFR kinase domain mutant ""TMLR"" with compound 23","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5C8N"
"5C8R",,"X-RAY DIFFRACTION",2.32,46.89,"VAPOR DIFFUSION, HANGING DROP",,"Grown in 1% polyethylene glycol (PEG) 4000, 4.5-5% 2-methyl-2,4-pentanediol (MPD), 100 mM ammonium sulfate, 70 mM sodium chloride, 50 mM N-[-acetamido]-2-iminodiacetic acid (ADA), 30 mM sodium acetate, 5 mM manganese chloride. Grown 5-10 days.",277,"10.1074/jbc.M115.682401",,"5C8R",35.89,"1.45","1.45","Crystal structure of ABBA + UDP-Glc + DI","AIGEFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDESHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5C8R"
"5C8W",,"X-RAY DIFFRACTION",2.14,42.59,"VAPOR DIFFUSION, HANGING DROP",5,"33 mM cGMP, 200 mM sodium malonate, 5-10% ethylene glycol, 20% PEG",293,"10.1074/jbc.M115.691303","PCG","5C8W",102.33,"1.8","1.8","PKG II's Amino Terminal Cyclic Nucleotide Binding Domain (CNB-A) in a complex with cGMP","GSNKPPEFSFEKARVRKDSSEKKLITDALNKNQFLKRLDPQQIKDMVECMYGRNYQQGSYIIKQGEPGNHIFVLAEGRLEVFQGEKLLSSIPMWTTFGELAILYNCTRTASVKAITNVKTWALDREVFQNIMRRTAQARDEQY","Homo sapiens","PRKG2, PRKGR2","cGMP-dependent protein kinase 2","1","5C8W"
"5C91",,"X-RAY DIFFRACTION",2.29,46.18,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 35 mM calcium chloride, 5 mM TCEP, 6% PEG400",293,"10.1021/jacs.5b06839",,"5C91",45.06,"2.44","2.44","NEDD4 HECT with covalently bound indole-based inhibitor","SRDYKRKYEFFRRKLKKQNDIPNKFEMKLRRATVLEDSYRRIMGVKRADFLKARLWIEFDGEKGLDYGGVAREWFFLISKEMFNPYYGLFEYSATDNYTLQINPNSGLCNEDHLSYFKFIGRVAGMAVYHGKLLDGFFIRPFYKMMLHKPITLHDMESVDSEYYNSLRWILENDPTELDLRFIIDEELFGQTHQHELKNGGSEIVVTNKNKKEYIYLVIQWRFVNRIQKQMAAFKEGFFELIPQDLIKIFDENELELLMCGLGDVDVNDWREHTKYKNGYSANHQVIQWFWKAVLMMDSEKRIRLLQFVTGTSRVPMNGFAELYGSNGPQSFTVEQWGTPEKLPRAHTCFNRLDLPPYESFEELWDKLQMAIENT","Homo sapiens","NEDD4, KIAA0093, NEDD4-1, PIG53","E3 ubiquitin-protein ligase NEDD4","1","5C91"
"5C97",,"X-RAY DIFFRACTION",2.72,54.78,"VAPOR DIFFUSION, SITTING DROP",8.5,"10% w/v PEG 4000, 20% v/v glycerol, 0.1M bicine/Trizma base, 0.2 M sodium L-glutamate, 0.2M DL-alanine, 0.2M glycine, 0.2M DL-lysine HCl, 0.2M DL-serine",291,"10.4049/jimmunol.1501103",,"5C97",214.01,"3.37","3.37","Insulin regulated aminopeptidase","MGILPSPGNPALLSLVSLLSVLLMGCVAETGATNGKLFPWAQIRLPTAVVPLRYELSLHPNLTSMTFRGSVTISVQALQVTWNIILHSTGHNISRVTFMSAVSSQEKQAEILEYAYHGQIAIVAPEALLAGHNYTLKIEYSANISSSYYGFYGFSYTDESNEKKYFAATQFEPLAARSAFPCFDEPAFKATFIIKIIRDEQYTALSNMPKKSSVVLDDGLVQDEFSESVKMSTYLVAFIVGEMKNLSQDVNGTLVSIYAVPEKIGQVHYALETTVKLLEFFQNYFEIQYPLKKLDLVAIPDFEAGAMENWGLLTFREETLLYDSNTSSMADRKLVTKIIAHELAHQWFGNLVTMKWWNDLWLNEGFATFMEYFSLEKIFKELSSYEDFLDARFKTMKKDSLNSSHPISSSVQSSEQIEEMFDSLSYFKGSSLLLMLKTYLSEDVFQHAVVLYLHNHSYASIQSDDLWDSFNEVTNQTLDVKRMMKTWTLQKGFPLVTVQKKGKELFIQQERFFLNMKPEIQPSDTSYLWHIPLSYVTEGRNYSKYQSVSLLDKKSGVINLTEEVLWVKVNINMNGYYIVHYADDDWEALIHQLKINPYVLSDKDRANLINNIFELAGLGKVPLKRAFDLINYLGNENHTAPITEALFQTDLIYNLLEKLGYMDLASRLVTRVFKLLQNQIQQQTWTDEGTPSMRELRSALLEFACTHNLGNCSTTAMKLFDDWMASNGTQSLPTDVMTTVFKVGAKTDKGWSFLLGKYISIGSEAEKNKILEALASSEDVRKLYWLMKSSLNGDNFRTQKLSFIIRTVGRHFPGHLLAWDFVKENWNKLVQKFPLGSYTIQNIVAGSTYLFSTKTHLSEVQAFFENQSEATFRLRCVQEALEVIQLNIQWMEKNLKSLTWWLRTETSQVAPA","Homo sapiens","LNPEP, OTASE","Leucyl-cystinyl aminopeptidase","1","5C97"
"5C9C",,"X-RAY DIFFRACTION",2.59,52.5,"VAPOR DIFFUSION, SITTING DROP",,"26% PEG 3350, 50 MM AMMONIUM
 CITRATE, 50 MM SODIUM FLORIDE, 2 MG/ML PROTEIN, 5-FOLD MOLAR
 EXCESS DP4978; CRYSTAL ID 215552F10, SITTING DROP VAPOR
 DIFFUSION, TEMPERATURE 289K",289,"10.1016/j.ccell.2015.08.002","4Z5","5C9C",71.38,"2.7","2.7","CRYSTAL STRUCTURE OF BRAF(V600E) IN COMPLEX WITH LY3009120 COMPND","MDRGSHHHHHHGSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATEKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHR","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5C9C"
"5C9K",,"X-RAY DIFFRACTION",2.69,54.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"SOLUTION 7 FROM CRYSTAL         
REMARK 280  SCREEN I (HAMPTON RESEARCH), PH 6.5, VAPOR DIFFUSION, HANGING       
REMARK 280  DROP, TEMPERATURE 291K",291,,,"5C9K",95.13,"1.92","1.92","Crystal structure of a highly fibrillogenic Arg24Gly mutant of the Recombinant variable domain 6AJL2","NFMLTQPHSVSESPGKTVTISCTGSSGSIASNYVQWYQQRPGSSPTTVIYEDNQRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYCQSYDSSNHVVFGGGTKLTVL","Homo sapiens","VL GENE SEGMENT 6A AND JL2/3 GENE SEGMENT","Amyloid lambda 6 light chain variable region PIP","1","5C9K"
"5C9N",,"X-RAY DIFFRACTION",3.64,66.24,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Hepes buffer pH 7.5, 
7% Ethanol, 
10% 2-Methyl-2,4-pentanediol (MPD) 
0.01 M Ethylene-diamine-tetra-acetic acid disodium salt dihydrate.",293,"10.1107/S1399004715016892",,"5C9N",20.36,"2.2","2.2","Crystal structure of GEMC1 coiled-coil domain","DSNFPLPDLCSWEEAQLSSQLYRNKQLQDTLVQKEEELARLHEENNHLRQYLNSALVKCEEEKAKKELSSDEFSKAYGKFRKGKR","Homo sapiens","GMNC, GEMC1","Geminin coiled-coil domain-containing protein 1","1","5C9N"
"5C9V",,"X-RAY DIFFRACTION",3.63,66.1,"VAPOR DIFFUSION, SITTING DROP",5.6,"1.8 M lithium sulphate, 0.01 M MgCl2, 0.05 M MES pH 5.6",291,"10.1038/nature14879",,"5C9V",38.27,"2.35","2.35","Structure of human Parkin G319A","GPAGRSIYNSFYVYCKGPCQRVQPGKLRVQCSTCRQATLTLTQGPSCWDDVLIPNRMSGECQSPHCPGTSAEFFFKCGAHPTSDKETSVALHLIATNSRNITCITCTDVRSPVLVFQCNSRHVICLDCFHLYCVTRLNDRQFVHDPQLGYSLPCVAGCPNSLIKELHHFRILGEEQYNRYQQYAAEECVLQMGGVLCPRPGCGAGLLPEPDQRKVTCEGGNGLGCGFAFCRECKEAYHEGECSAVFEASGTTTQAYRVDERAAEQARWEAASKETIKKTTKPCPRCHVPVEKNGGCMHMKCPQPQCRLEWCWNCGCEWNRVCMGDHWFDV","Homo sapiens","PARK2, PRKN","E3 ubiquitin-protein ligase parkin","1","5C9V"
"5CA2",,"X-RAY DIFFRACTION",2.15,42.71,,,,,"10.1021/bi00102a005",,"5CA2",29.54,"2.1","2.1","CONFORMATIONAL MOBILITY OF HIS-64 IN THE THR-200 (RIGHT ARROW) SER MUTANT OF HUMAN CARBONIC ANHYDRASE II","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTSPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE II","1","5CA2"
"5CAC",,"X-RAY DIFFRACTION",2.15,42.89,,,,,"10.1002/prot.340040406",,"5CAC",29.3,"2.2","2.2","REFINED STRUCTURE OF HUMAN CARBONIC ANHYDRASE II AT 2.0 ANGSTROMS RESOLUTION","SHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE FORM C","1","5CAC"
"5CAL",,"X-RAY DIFFRACTION",3.45,64.36,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4Z8","5CAL",37.93,"2.7","2.7","EGFR kinase domain mutant ""TMLR"" with compound 24","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAL"
"5CAN",,"X-RAY DIFFRACTION",3.5,64.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZB","5CAN",38.04,"2.8","2.8","EGFR kinase domain mutant ""TMLR"" with compound 27","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAN"
"5CAO",,"X-RAY DIFFRACTION",3.68,66.6,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethlyene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZG","5CAO",37.97,"2.6","2.6","EGFR kinase domain mutant ""TMLR"" with compound 29","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAO"
"5CAP",,"X-RAY DIFFRACTION",3.67,66.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZH","5CAP",38.16,"2.4","2.4","EGFR kinase domain mutant ""TMLR"" with compound 30","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAP"
"5CAQ",,"X-RAY DIFFRACTION",3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, erthylene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZJ","5CAQ",38.04,"2.5","2.5","EGFR kinase domain mutant ""TMLR"" with compound 33","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAQ"
"5CAS",,"X-RAY DIFFRACTION",3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZQ","5CAS",38.13,"2.1","2.1","EGFR kinase domain mutant ""TMLR"" with compound 41a","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAS"
"5CAU",,"X-RAY DIFFRACTION",3.47,64.52,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10000, ethylene glycol",292,"10.1021/acs.jmedchem.5b01412","4ZR","5CAU",38.13,"2.25","2.25","EGFR kinase domain mutant ""TMLR"" with compound 41b","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAU"
"5CAV",,"X-RAY DIFFRACTION",3.47,64.51,"VAPOR DIFFUSION, HANGING DROP",7,"sodium/potassium tartrate",292,"10.1021/acs.jmedchem.5b01412",,"5CAV",38.13,"2.73","2.73","EGFR kinase domain with compound 41a","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CAV"
"5CB1",,"X-RAY DIFFRACTION",4.01,73.17,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES, 3.0M Sodium Chloride",277,"10.1021/jacs.5b13368",,"5CB1",73.1,"3.3","3.3","Apo enzyme of human Polymerase lambda","TNHNLHITEKLEVLAKAYSVQGDKWRALGYAKAINALKSFHKPVTSYQEACSIPGIGKRMAEKIIEILESGHLRKLDHISESVPVLELFSNIWGAGTKTAQMWYQQGFRSLEDIRSQASLTTQQAIGLKHYSDFLERMPREEATEIEQTVQKAAQAFNSGLLCVACGSYRRGKATCGDVDVLITHPDGRSHRGIFSRLLDSLRQEGFLTDDLVSQEENGQQQKYLGVCRLPGPGRRHRRLDIIVVPYSEFACALLYFTGSAHFNRSMRALAKTKGMSLSEHALSTAVVRNTHGCKVGPGRVLPTPTEKDVFRLLGLPYREPAERDW","Homo sapiens","POLL","DNA polymerase lambda","1","5CB1"
"5CBL",,"X-RAY DIFFRACTION",1.98,37.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris-HCl pH 8.5, 25% a 35% PEG 4000-10000, 0.2 to 0.4 M lithium or ammonium sulfate",294,"10.1016/j.pep.2015.09.026",,"5CBL",67.23,"1.781","1.781","Crystal structure of the C-terminal domain of human galectin-4 with lactose","SEFLPTMEGPPTFNPPVPYFGRLQGGLTARRTIIIKGYVPPTGKSFAINFKVGSSGDIALHINPRMGNGTVVRNSLLNGSWGSEEKKITHNPFGPGQFFDLSIRCGLDRFKVYANGQHLFDFAHRLSAFQRVDTLEIQGDVTLSYVQI","Homo sapiens","LGALS4","Galectin-4","1","5CBL"
"5CBT",,"X-RAY DIFFRACTION",2.69,54.31,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",291,,,"5CBT",18.55,"1.45","1.45","Human Cyclophilin D Complexed with Inhibitor","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CBT"
"5CBU",,"X-RAY DIFFRACTION",2.68,54.09,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,,,"5CBU",18.86,"1.4","1.4","Human Cyclophilin D Complexed with Inhibitor.","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CBU"
"5CBV",,"X-RAY DIFFRACTION",2.62,53.06,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG 2000mme",291,,,"5CBV",18.53,"1.8","1.8","Human Cyclophilin D Complexed with Inhibitor","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Human Cyclophilin D","1","5CBV"
"5CBW",,"X-RAY DIFFRACTION",2.66,53.74,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,,,"5CBW",18.55,"1.8","1.8","Human Cyclophilin D Complexed with Inhibitor.","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CBW"
"5CCK",,"X-RAY DIFFRACTION",1.97,37.61,"VAPOR DIFFUSION, SITTING DROP",10.3,"0.1M CAPS pH 10.3, 0.25 M NaCl, 20% PEG8000",298,"10.1038/ncomms9167",,"5CCK",48.23,"1.95","1.95","Crystal structure of Human anti-HIV-1 broadly neutralizing antibody 3BC315 Fab","QVQLVQSGAEMKDPGASVKVSCRASGYKFTDYYMHWVRQAPGQGLEWVGWVNTNGGFTKYGAKFQGRVTVTRDTSTNTVFLELSRLTFGDTAMYFCARPMRPVSHGIDYSGLFVFQFWGRGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"Antibody 3BC315 Fab heavy chain","1","5CCK"
,,,,,,,,,,,,,,,,"QSALTQPASVSASPGQSITISCSGTRSDVGGYDFVSWYQQHPGKVPKLIIYEVTKRPSGIPQRFSGSKSGNTASLTISGLQADDEADYYCCSYANYDKLILGGGTKLTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Antibody 3BC315 Fab light chain","2","5CCK"
"5CCL",,"X-RAY DIFFRACTION",2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",8,"0.10 M Magnesium formate, 0.1M Tris 8.0, 14% w/v PEG 3350.  Crystals of SMYD3-SAM were produced and compound was soaked into the pre-formed crystals",293,"10.1021/acsmedchemlett.5b00272",,"5CCL",50.85,"1.5","1.5","Crystal structure of SMYD3 with SAM and oxindole compound","MEPLKVEKFATANRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCDRCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPDSVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMTFQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPSISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERRKQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHWKWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFYGTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIMRVTHGREHSLIEDLILLLEECDANIRASFULL","Homo sapiens","SMYD3, ZMYND1, ZNFN3A1","Histone-lysine N-methyltransferase SMYD3","1","5CCL"
"5CCM",,"X-RAY DIFFRACTION",2.2,44.11,"VAPOR DIFFUSION, HANGING DROP",8,"0.10 M Magnesium formate, 0.1M Tris 8.0, 14% w/v PEG 3350",293,"10.1021/acsmedchemlett.5b00272","4ZX","5CCM",50.32,"2.3","2.3","Crystal structure of SMYD3 with SAM and EPZ030456","MEPLKVEKFATANRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCDRCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPDSVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMTFQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPSISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERRKQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHWKWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFYGTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIMRVTHGREHSLIEDLILLLEECDANIRAS","Homo sapiens","SMYD3, ZMYND1, ZNFN3A1","Histone-lysine N-methyltransferase SMYD3","1","5CCM"
"5CCN",,"X-RAY DIFFRACTION",2.67,53.86,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane, 2% w/v PEG2000mme",294,,,"5CCN",18.52,"1.8","1.8","Human Cyclophilin D Complexed with Inhibitor","GNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CCN"
"5CCQ",,"X-RAY DIFFRACTION",2.66,53.79,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH 9, 2% w/v PEG2000mme",294,,,"5CCQ",18.37,"1.8","1.8","Human Cyclophilin D Complexed with Inhibitor","GNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CCQ"
"5CCR",,"X-RAY DIFFRACTION",2.61,52.79,"VAPOR DIFFUSION, SITTING DROP",9,"4M potassium formate, 0.1M BIS-TRIS propane pH9, 2% w/v PEG2000mme",294,,,"5CCR",18.83,"1.9","1.9","Human Cyclophilin D Complexed with Inhibitor","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGKHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CCR"
"5CCS",,"X-RAY DIFFRACTION",2.37,48.08,"VAPOR DIFFUSION, SITTING DROP",8,"25% w/v  PEG3350, 0.1M TRIS-HCL pH 8",294,,,"5CCS",18.13,"2.1","2.1","Human Cyclophilin D Complexed with Inhibitor","MGNPLVYLDVDANGKPLGRVVLELKADVVPKTAENFRALCTGEKGFGYKGSTFHRVIPSFMCQAGDFTNHNGTGGKSIYGSRFPDENFTLKHVGPGVLSMANAGPNTNGSQFFICTIKTDWLDGQHVVFGHVIEGMDVVKKIESFGSKSGRTSKKIVITDCGQLS","Homo sapiens","PPIF, CYP3","Peptidyl-prolyl cis-trans isomerase F, mitochondrial","1","5CCS"
"5CCW",,"X-RAY DIFFRACTION",2.44,49.52,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG400, lithium sulphate, sodium cacodylate",296,"10.1002/anie.201511999",,"5CCW",9.21,"1.89","1.89","Structure of the complex of a human telomeric DNA with Au(caffein-2-ylidene)2","TAGGGTTAGGGTTAGGGTTAGGG","Homo sapiens",,"human telomeric DNA","1","5CCW"
"5CD3",,"X-RAY DIFFRACTION",2.64,53.48,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.16 M ammonium sulfate, 20% (w/v) PEG 4000, 20% (v/v) glycerol and 0.08 M sodium acetate, pH 4.6",292,"10.1016/j.immuni.2016.03.006",,"5CD3",189.02,"2.9","2.9","Structure of immature VRC01-class antibody DRVIA7","QVQLVESGTQFRRPGASVRLSCEASGYTFISSFIHWIRQGPGQGLEWMGWMNPRHGAVNYPRRFQGKVTMTRDTSIDTAYMELRDLRSDDTAMYFCVTSRTKDYDWDFVWGQGTLVVVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEP","Homo sapiens",,"DRVIA7 Heavy Chain","1","5CD3"
,,,,,,,,,,,,,,,,"DIQMTQSPVTLSASIGDRVTITCRASQRIDNWVAWYQQKPGRAPKLLIYKASILETGVPSRFSGSGSGTEFTLSINSLQPDDVATYYCQQFEEFGRGTKIDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"DRVIA7 Light Chain","2","5CD3"
"5CDB",,"X-RAY DIFFRACTION",2,38.35,"VAPOR DIFFUSION, SITTING DROP",6.5,"ammonium sulphate, lithium sulphate, sodium cacodylate",296,"10.1002/asia.201600116",,"5CDB",8.17,"1.7","1.7","Structure of the complex of a bimolecular human telomeric DNA with a 13-diphenylalkyl Berberine derivative","TAGGGTTAGGGT","Homo sapiens",,"human telomeric DNA","1","5CDB"
"5CE1",,"X-RAY DIFFRACTION",2.06,40.19,"VAPOR DIFFUSION, SITTING DROP",6,"Activated hepsin was incubated with 10 mM Benzamidine at 4 oC for 2 hours and concentrated to7 mg/ml using 10 KDa cut off centricon [Millipore]. 1microlit of protein was mixed with 1 microlit of reservoir buffer containing 100 mM sodium Cacodylate (6.0), 22% PEG 3350, and 200 mM ammonium fluoride. Plate clusters with a dimension of 50 micron m x 100 micron m were observed after 2 days of crystallization set up.",293,,"50K","5CE1",40.83,"2.5","2.5","Crystal Structure of Serine protease Hepsin in complex with Inhibitor","SDQEPLYPVQVSSADARLMVFDKTEGTWRLLCSSRSNARVAGLSCEEMGFLRALTHSELDVRTAGANGTSGFFCVDEGRLPHTQRLLEVISVCDCPRGRFLAAICQDCGRRKLPVDRIVGGRDTSLGRWPWQVSLRYDGAHLCGGSLLSGDWVLTAAHCFPERNRVLSRWRVFAGAVAQASPHGLQLGVQAVVYHGGYLPFRDPNSEENSNDIALVHLSSPLPLTEYIQPVCLPAAGQALVDGKICTVTGWGNTQYYGQQAGVLQEARVPIISNDVCNGADFYGNQIKPKMFCAGYPEGGIDACQGDSGGPFVCEDSISRTPRWRLCGIVSWGTGCALAQKPGVYTKVSDFREWIFQAIKTHSEASGMVTQL","Homo sapiens","HPN, TMPRSS1","Serine protease hepsin","1","5CE1"
"5CE4",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.3,46.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"20mM Tris 
22% PEG 4000 
Heavy water",290,"10.1107/S2052252515024161",,"5CE4",15.09,"0.98","0.98","High Resolution X-Ray and Neutron diffraction structure of H-FABP","MVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKE","Homo sapiens","FABP3, FABP11, MDGI","Fatty acid-binding protein, heart","1","5CE4"
"5CEH",,"X-RAY DIFFRACTION",3.73,67.06,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 0.1 M HEPES, pH 7.3, 12% glycerol",291,"10.1038/nchembio.2085","50P","5CEH",92.04,"3.14","3.14","Structure of histone lysine demethylase KDM5A in complex with selective inhibitor","SEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRLDFLDQLAKFWELQGSTLKIPVVERKILDLYALSKIVASKGGFEMVTKEKKWSKVGSRLGYLPGKGTGSLLKSHYERILYPYELFQSGVSLMGVQMPNLDLKEKVEPEVLSTDTQTSPEPGTRMNILPKRTRRVKTQSESGDVSRNTELKKLQIFGAGPKVVGLAMGTKDKEDEVTRRRKVTNRSDAFNMQMRQRKGTLSVNFVDLYVCMFCGRGNNEDKLLLCDGCDDSYHTFCLIPPLPDVPKGDWRCPKCVAEECSKPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYRRLRRHCVFSHEELIFKMAADPECLDVGLAAMVCKELTLMTEEETRLRESVVQMGVLMSEEEVFELVPDDERQCSACRTTCFLSALTCSCNPERLVCLYHPTDLCPCPMQKKCLRYRYPLEDLPSLLYGVKVRAQSYDTWVSRVTEALSANFNHKKDLIELRVMLEDAEDRKYPENDLFRKLRDAVKEAETCASVGNS","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5CEH"
,,,,,,,,,,,,,,,,"XXXXXXXXXX","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Unknown Peptide","2","5CEH"
"5CEK",,"X-RAY DIFFRACTION",3.53,65.13,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, 2-3 M NaCl, 0.1 M Sodium Citrate and 0.01 M reduced L-Glutathione, 0.01 M oxidized L-Glutathione",290,"10.1016/j.str.2015.08.017",,"5CEK",29.96,"2.8","2.8","Pseudokinase domain of Human Tribbles Homolog 1","GPGSAPGPSRIADYLLLPLAEREHVSRALCIHTGRELRCKVFPIKHYQDKIRPYIQLPSHSNITGIVEVILGETKAYVFFEKDFGDMHSYVRSRKRLREEEAARLFKQIVSAVAHCHQSAIVLGDLKLRKFVFSTEERTQLRLESLEDTHIMKGEDDALSDKHGCPAYVSPEILNTTGTYSGKAADVWSLGVMLYTLLVGRYPFHDSDPSALFSKIRRGQFCIPEHISPKARCLIRSLLRREPSERLTAPEILLHPWFESVLE","Homo sapiens","TRIB1, C8FW, GIG2, TRB1","Tribbles homolog 1","1","5CEK"
"5CEM",,"X-RAY DIFFRACTION",2.48,50.32,"VAPOR DIFFUSION, SITTING DROP",,"1.0 M Ammonium sulfate, 0.1 M Bis-Tris (pH 5.5), 1% w/v Polyethylene glycol 3,350",290,"10.1016/j.str.2015.08.017",,"5CEM",33.55,"2.1","2.1","Pseudokinase and C-terminal extension of Human Tribbles Homolog 1","GPGSAPGPSRIADYLLLPLAEREHVSRALCIHTGRELRCKVFPIKHYQDKIRPYIQLPSHSNITGIVEVILGETKAYVFFEKDFGDMHSYVRSRKRLREEEAARLFKQIVSAVAHCHQSAIVLGDLKLRKFVFSTEERTQLRLESLEDTHIMKGEDDALSDKHGCPAYVSPEILNTTGTYSGKAADVWSLGVMLYTLLVGRYPFHDSDPSALFSKIRRGQFCIPEHISPKARCLIRSLLRREPSERLTAPEILLHPWFESVLEPGYIDSEIGTSDQIVPEYQEDSDISSFFS","Homo sapiens","TRIB1, C8FW, GIG2, TRB1","Tribbles homolog 1","1","5CEM"
"5CEN",,"X-RAY DIFFRACTION",1.94,36.51,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292,"10.1021/acs.jmedchem.5b01072",,"5CEN",34.02,"1.7","1.7","Crystal structure of DLK (kinase domain)","MGSEDLWEVPFEEILDLQWVGSGAQGAVFLGRFHGEEVAVKKVRDLKETDIKHLRKLKHPNIITFKGVCTQAPCYCILMEFCAQGQLYEVLRAGRPVTPSLLVDWSMGIAGGMNYLHLHKIIHRDLKSPNMLITYDDVVKISDFGTSKELSDKSTKMSFAGTVAWMAPEVIRNEPVSEKVDIWSFGVVLWELLTGEIPYKDVDSSAIIWGVGSNSLHLPVPSSCPDGFKILLRQCWNSKPRNRPSFRQILLHLDIASADVLSTPQETYFKSQAEWREEVKLHFEKIKSEGTGNSHHHHHH","Homo sapiens","MAP3K12, ZPK","Mitogen-activated protein kinase kinase kinase 12","1","5CEN"
"5CEO",,"X-RAY DIFFRACTION",1.99,38.14,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292,"10.1021/acs.jmedchem.5b01072","50D","5CEO",34.46,"2.28","2.28","DLK in complex with inhibitor 2-((6-(3,3-difluoropyrrolidin-1-yl)-4-(1-(oxetan-3-yl)piperidin-4-yl)pyridin-2-yl)amino)isonicotinonitrile","MGSEDLWEVPFEEILDLQWVGSGAQGAVFLGRFHGEEVAVKKVRDLKETDIKHLRKLKHPNIITFKGVCTQAPCYCILMEFCAQGQLYEVLRAGRPVTPSLLVDWSMGIAGGMNYLHLHKIIHRDLKSPNMLITYDDVVKISDFGTSKELSDKSTKMSFAGTVAWMAPEVIRNEPVSEKVDIWSFGVVLWELLTGEIPYKDVDSSAIIWGVGSNSLHLPVPSSCPDGFKILLRQCWNSKPRNRPSFRQILLHLDIASADVLSTPQETYFKSQAEWREEVKLHFEKIKSEGTGNSHHHHHH","Homo sapiens","MAP3K12, ZPK","Mitogen-activated protein kinase kinase kinase 12","1","5CEO"
"5CEP",,"X-RAY DIFFRACTION",2.02,39.06,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292,"10.1021/acs.jmedchem.5b01072","50E","5CEP",34.37,"1.99","1.99","DLK in complex with inhibitor N-(1-isopropyl-5-(piperidin-4-yl)-1H-pyrazol-3-yl)-4-(trifluoromethyl)pyridin-2-amine","MGSEDLWEVPFEEILDLQWVGSGAQGAVFLGRFHGEEVAVKKVRDLKETDIKHLRKLKHPNIITFKGVCTQAPCYCILMEFCAQGQLYEVLRAGRPVTPSLLVDWSMGIAGGMNYLHLHKIIHRDLKSPNMLITYDDVVKISDFGTSKELSDKSTKMSFAGTVAWMAPEVIRNEPVSEKVDIWSFGVVLWELLTGEIPYKDVDSSAIIWGVGSNSLHLPVPSSCPDGFKILLRQCWNSKPRNRPSFRQILLHLDIASADVLSTPQETYFKSQAEWREEVKLHFEKIKSEGTGNSHHHHHH","Homo sapiens","MAP3K12, ZPK","Mitogen-activated protein kinase kinase kinase 12","1","5CEP"
"5CEQ",,"X-RAY DIFFRACTION",1.91,35.73,"VAPOR DIFFUSION, HANGING DROP",7.7,"0.2 M magnesium acetate, 20% PEG 3350, 0.1 M HEPES pH 7.7",292,"10.1021/acs.jmedchem.5b01072","50F","5CEQ",34.41,"1.911","1.911","DLK in complex with inhibitor 2-((1-cyclopentyl-5-(1-(oxetan-3-yl)piperidin-4-yl)-1H-pyrazol-3-yl)amino)isonicotinonitrile","MGSEDLWEVPFEEILDLQWVGSGAQGAVFLGRFHGEEVAVKKVRDLKETDIKHLRKLKHPNIITFKGVCTQAPCYCILMEFCAQGQLYEVLRAGRPVTPSLLVDWSMGIAGGMNYLHLHKIIHRDLKSPNMLITYDDVVKISDFGTSKELSDKSTKMSFAGTVAWMAPEVIRNEPVSEKVDIWSFGVVLWELLTGEIPYKDVDSSAIIWGVGSNSLHLPVPSSCPDGFKILLRQCWNSKPRNRPSFRQILLHLDIASADVLSTPQETYFKSQAEWREEVKLHFEKIKSEGTGNSHHHHHH","Homo sapiens","MAP3K12, ZPK","Mitogen-activated protein kinase kinase kinase 12","1","5CEQ"
"5CEX",,"X-RAY DIFFRACTION",2.91,57.68,"VAPOR DIFFUSION, SITTING DROP",,"5% (w/v) PEG 1000, 28% (v/v) PEG 600, 10% (v/v) glycerol and 0.1 M MES pH 6.0",293.14,"10.1016/j.immuni.2015.11.007",,"5CEX",99.17,"2.105","2.105","Crystal Structure of Fab 32H+109L, a putative precursor of the PGT121 family of potent HIV-1 antibodies","SYVLTQPSQLSVAPGETARISCGGRSLGSRAVQWYQQKPGQAPVLVIYNNQDRPSGIPERFSGSPDSNFGTTATLTISRVEAGDEADYYCHMWDSRSAINWVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Antibody 9H+3L Fab light chain","1","5CEX"
,,,,,,,,,,,,,,,,"QVQLQESGPGLVKPSETLSLTCSVSGASISDHYWSWIRQSPGKGLEWIGYVYDSGDTNYNPSLKSRVNLSLDTSKNQVSLSLTAVTAADSAIYYCARTQHGRRIYGIVAFREWFTYFYMDVWGQGTPVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"Antibody 9H+3L Fab heavy chain","2","5CEX"
"5CEY",,"X-RAY DIFFRACTION",2.23,44.89,"VAPOR DIFFUSION, SITTING DROP",,"40% (v/v) PEG 600, 0.1M NaCl and 0.1 M Na citrate pH 5.5",293.14,"10.1016/j.immuni.2015.11.007",,"5CEY",98.5,"2.387","2.387","Crystal Structure of Fab 9H+3L, a putative precursor of the PGT121 family of potent HIV-1 antibodies","GSVTSYVRPLSVALGETASISCGRQALGSRAVQWYQHRPGQAPILLIYNNQDRPSGIPERFSGTPDINFGTRATLTISGVEAGDEADYYCHMWDSRSGFSWSFGGATRLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Antibody 9H+3L Fab light chain","1","5CEY"
,,,,,,,,,,,,,,,,"QVQLQESGPGLVKPSETLSVTCIVSGGSISNYYWTWIRQSPGKGLEWIGYISDRETTTYNPSLKSRVVISRDTSKNQLSLKLNSVTAADTAIYYCATARRGQRIYGVVSFGEFFYYYYMDVWGKGTAVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"Antibody 9H+3L Fab heavy chain","2","5CEY"
"5CF0",,"X-RAY DIFFRACTION",2.93,58.05,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris-HCl, 20% PEG 4000, 200 mM MgCl2",277,,,"5CF0",26.15,"1.8","1.8","Crystal Structure of the human Hsp90-alpha N-domain bound to the hsp90 inhibitor FJ6","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5CF0"
"5CF4",,"X-RAY DIFFRACTION",2.94,52.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (w/v) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295,"10.1021/acsmedchemlett.5b00225","50Y","5CF4",76.55,"2.38","2.38","CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE","MGSSHHHHHHSSGLVPRGSHMRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAGHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5CF4"
"5CF5",,"X-RAY DIFFRACTION",2.91,57.66,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (W/V) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295,"10.1021/acsmedchemlett.5b00225","50W","5CF5",76.63,"2.45","2.45","CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-7-[(DIMETHYL-1,3-THIAZOL-2-YL)AMINO]-10-ETHYL-3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.02,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE","MGSSHHHHHHSSGLVPRGSHMRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAGHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5CF5"
"5CF6",,"X-RAY DIFFRACTION",3,58.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (W/V) PEG3350, 2MM DTT AND 200MM TRI-SODIUM CITRATE",295,"10.1021/acsmedchemlett.5b00225","50O","5CF6",76.53,"2.5","2.5","CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-[(2S)-2,3-DIHYDROXYPROPYL]-3-METHYL-7-(METHYLAMINO)-3,5,8,10-TETRAAZATRICYCLO [7.3.0.02,6]DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE","MGSSHHHHHHSSGLVPRGSHMRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAGHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5CF6"
"5CF8",,"X-RAY DIFFRACTION",3,58.95,"VAPOR DIFFUSION, HANGING DROP",6.5,"100MM MES BUFFER, 100MM NACL, 28% (w/v) PEG3350, 2MM DTT, AND 200MM TRI-SODIUM CITRATE",295,"10.1021/acsmedchemlett.5b00226","50V","5CF8",72.26,"1.8","1.8","CRYSTAL STRUCTURE OF JANUS KINASE 2 IN COMPLEX WITH N,N-DICYCLOPROPYL-10-ETHYL-7-[(3-METHOXYPROPYL)AMINO] -3-METHYL-3,5,8,10-TETRAAZATRICYCLO[7.3.0.0,6] DODECA-1(9),2(6),4,7,11-PENTAENE-11-CARBOXAMIDE","MRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAGHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5CF8"
"5CFB",,"X-RAY DIFFRACTION",4.32,71.52,"VAPOR DIFFUSION, HANGING DROP",4,"30-33% PEG-400, 200 mM magnesium chloride, 100 mM potassium chloride, 25 mM sodium citrate",277,"10.1038/nature14972","SY9","5CFB",212.47,"3.04","3.04","Crystal Structure of Human Glycine Receptor alpha-3 Bound to Strychnine","ARSRSAPMSPSDFLDKLMGRTSGYDARIRPNFKGPPVNVTCNIFINSFGSIAETTMDYRVNIFLRQKWNDPRLAYSEYPDDSLDLDPSMLDSIWKPDLFFANEKGANFHEVTTDNKLLRIFKNGNVLYSIRLTLTLSCPMDLKNFPMDVQTCIMQLESFGYTMNDLIFEWQDEAPVQVAEGLTLPQFLLKEEKDLRYCTKHYNTGKFTCIEVRFHLERQMGYYLIQMYIPSLLIVILSWVSFWINMDAAPARVALGITTVLTMTTQSSGSRASLPKVSYVKAIDIWMAVCLLFVFSALLEYAAVNFVSRAGTKVFIDRAKKIDTISRACFPLAFLIFNIFYWVIYKILRHEDIHWSHPQFEK","Homo sapiens","GLRA3","Glycine receptor subunit alpha-3,Glycine receptor subunit alpha-3","1","5CFB"
"5CFG",,"X-RAY DIFFRACTION",2.36,47.9,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 8000, 0.2 M MgAc and 0.1 M Cacodylate",295,"10.1016/j.biochi.2016.06.011",,"5CFG",31.14,"1.8","1.8","C2 crystal form of APE1 with Mg2+","LYEDPPDQKTSPSGKPATLKICSWNVDGLRAWIKKKGLDWVKEEAPDILCLQETKCSENKLPAELQELPGLSHQYWSAPSDKEGYSGVGLLSRQCPLKVSYGIGDEEHDQEGRVIVAEFDSFVLVTAYVPNAGRGLVRLEYRQRWDEAFRKFLKGLASRKPLVLCGDLNVAHEEIDLRNPKGNKKNAGFTPQERQGFGELLQAVPLADSFRHLYPNTPYAYTFWTYMMNARSKNVGWRLDYFLLSHSLLPALCDSKIRSKALGSDHCPITLYLAL","Homo sapiens","APEX1, APE, APE1, APEX, APX, HAP1, REF1","DNA-(apurinic or apyrimidinic site) lyase","1","5CFG"
"5CFH",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10000, HEPES",293,"10.1038/srep25559",,"5CFH",11.77,"1.49","1.49","human beta-2 microglobulin double mutant W60G-Y63W","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDGSFWLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CFH"
"5CFW",,"X-RAY DIFFRACTION",1.89,34.78,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350",293,"10.1016/j.chembiol.2015.10.013","53W","5CFW",15.56,"1.15","1.15","Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CFW"
"5CG5",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.78,55.73,"VAPOR DIFFUSION, SITTING DROP",5,"0.5M NaCl, 0.1M acetate buffer",293,"10.1021/acs.jmedchem.5b01147","RIS","5CG5",41.39,"1.402, 2.4","1.402, 2.4","Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate","MDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRKLEHHHHHH","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5CG5"
"5CG6",,"X-RAY DIFFRACTION, NEUTRON DIFFRACTION",2.75,55.34,"VAPOR DIFFUSION, SITTING DROP",,"1.0 M NaCl, 0.08 M sodium acetate, 0.02 M acetic acid",293,"10.1021/acs.jmedchem.5b01147","RIS","5CG6",41.63,"1.7, 2.4","1.7, 2.4","Neutron crystal structure of human farnesyl pyrophosphate synthase in complex with risedronate and isopentenyl pyrophosphate","MDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRKLEHHHHHH","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5CG6"
"5CGP",,"X-RAY DIFFRACTION",2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",,"15-20% PEG 8000, 0.2M CaAcetate, 0.1 M cacodylate ph 6-7",293,"10.1016/j.chembiol.2015.10.013","53W","5CGP",14.68,"1.96","1.96","Selective pharmacological inhibition of the CREB binding protein bromodomain regulates inflammatory cytokines in macrophages and RGS4 in neurons","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5CGP"
"5CGY",,"X-RAY DIFFRACTION",2.23,44.95,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG2000, Tris, ammonium acetate",298,"10.1073/pnas.1515558112",,"5CGY",93.61,"2.07","2.07","Fab fragment of Chikungunya virus neutralizing human monoclonal antibody 4J21","QVQLVQSGSELKKPGASVKVSCKASGYSFTSYSINWVRQAPGQGPEWMGWIDTNTGNPTYAQDFAGRFVFSLDTSVTTAYLQISSLKAGDTAVYYCATYYVDLWGSYRQDYYGMDVWGHGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPK","Homo sapiens",,"Heavy Chain of Fab","1","5CGY"
,,,,,,,,,,,,,,,,"ASVVTQPPSVSGTPGQGVTISCSGGSSNIGSNPVNWYQMVPGTAPKLLLYTNNQRPSGVPDRFSGSKSGTSASLAINGLQSEDEADYYCAVWDDSLSGRWVFGGGTKVTVLRQPKAAPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAP","Homo sapiens",,"Light Chain of Fab","2","5CGY"
"5CHN",,"X-RAY DIFFRACTION",2.5,51.07,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG3350, Tris, ammonium formate",298,"10.1073/pnas.1515558112",,"5CHN",94.85,"2.047","2.047","Fab fragments of chikungunya virus neutralizing human monoclonal antibody 5M16","QVQLVQSGAEVKKPGASVRVSCKASGYTFTSYFMHWVRQAPGQGLEWMAITYPGGGSPSYAPQFQGRLTMTDDTSATTVYMDLSDLTSKDTAVYYCARGAHRSIGTTPLDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEP","Homo sapiens",,"Antibody 5M16 Fab Heavy Chain","1","5CHN"
,,,,,,,,,,,,,,,,"IVMTQTPLSLSVTPGQPASISCKSSQSLLHSDGKTYLYWYLQKPGQSPQLLIYEVSNRLSGVPDRFSGSGSGTDFTLKISRVETEDVGVYYCMQSIQVPLYTFGQGTRLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE","Homo sapiens",,"Antibody 5M16 Fab Light Chain","2","5CHN"
"5CI7",,"X-RAY DIFFRACTION",2.02,38.99,"VAPOR DIFFUSION, HANGING DROP",5,"1.55 M sodium malonate pH 7.0, 0.35 M sodium malonate pH 5.0",298,"10.1016/j.bmc.2015.07.034","51W","5CI7",33.08,"1.74","1.74","Structure of ULK1 bound to a selective inhibitor","GGGSMEPGRGGTETVGKFEFSRKDLIGHGAFAVVFKGRHRAAHDLEVAVKCINKKNLAKSQTLLGKEIKILKELKHENIVALYDFQEMANSVYLVMEYCNGGDLADYLHAMRTLSEDTIRLFLQQIAGAMRLLHSKGIIHRDLKPQNILLSNPAGRRANPNSIRVKIADFGFARYLQSNMMAATLCGSPMYMAPEVIMSQHYDGKADLWSIGTIVYQCLTGKAPFQASSPQDLRLFYEKNKTLVPTIPRETSAPLRQLLLALLQRNHKDRMDFDEFFHHPFLDASPS","Homo sapiens","ULK1, KIAA0722","Serine/threonine-protein kinase ULK1","1","5CI7"
"5CI8",,"X-RAY DIFFRACTION",1.296461,5.126324,"VAPOR DIFFUSION, HANGING DROP",5,"0.1 M Citric acid pH 5.0, 3.0 M Sodium chloride, 5% DMSO",293,"10.1007/s13238-015-0225-6",,"5CI8",38.65,"2.328","2.328","Crystal structure of human Tob in complex with inhibitor fragment 1","HHMQLEIQVALNFIISYLYNKLPRRRVNIFGEELERLLKKKYEGHWYPEKPYKGSGFRCIHIGEKVDPVIEQASKESGLDIDDVRGNLPQDLSVWIDPFEVSYQIGEKGPVKVLYVDDNNENGCELDKEIKNSFNPEAQVFMPISDPASSVSSSPSPPFGHSAAVSPTFMPRSTQPLTFTTATFAATKFGSTKMKNSGRSNKVARTSPINLGLNVNDLLKQKAISSSMHSLYGLGLGSQQQPQQQQQPAQPPPPPPPPQQQQQQKTSALSPNAKEFIFPNMQGQGSSTNGMFPGDSPLNLSPLQYSNAFDVFAAYGGLNEKSFVDGLNFSLNNMQYSNQQFQPVMAN","Homo sapiens","TOB1, TOB, TROB1","Protein Tob1","1","5CI8"
"5CI9",,"X-RAY DIFFRACTION",1.301063,5.461893,"VAPOR DIFFUSION, HANGING DROP",5,"0.1 M Citric acid pH 5.0, 3.0 M Sodium chloride, 5% DMSO",293,"10.1007/s13238-015-0225-6",,"5CI9",38.76,"2.3","2.3","Crystal structure of human Tob in complex with inhibitor fragment 6","HMQLEIQVALNFIISYLYNKLPRRRVNIFGEELERLLKKKYEGHWYPEKPYKGSGFRCIHIGEKVDPVIEQASKESGLDIDDVRGNLPQDLSVWIDPFEVSYQIGEKGPVKVLYVDDNNENGCELDKEIKNSFNPEAQVFMPISDPASSVSSSPSPPFGHSAAVSPTFMPRSTQPLTFTTATFAATKFGSTKMKNSGRSNKVARTSPINLGLNVNDLLKQKAISSSMHSLYGLGLGSQQQPQQQQQPAQPPPPPPPPQQQQQQKTSALSPNAKEFIFPNMQGQGSSTNGMFPGDSPLNLSPLQYSNAFDVFAAYGGLNEKSFVDGLNFSLNNMQYSNQQFQPVMAN","Homo sapiens","TOB1, TOB, TROB1","Protein Tob1","1","5CI9"
"5CIQ",,"X-RAY DIFFRACTION",2.34,47.37,"VAPOR DIFFUSION, HANGING DROP",8,"30% PEG 1000, 50 mM TRIS pH 8, 20 mM MgCl2",291,"10.1074/jbc.M115.648071",,"5CIQ",49.85,"1.65","1.65","Ran GDP wild type tetragonal crystal form","MAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGEFEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLRDGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIVLCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKPFLWLARKLIGDPNLEFVAMPALAPPEVVMDPALAAQYEHDLEVAQTTALPDEDDDL","Homo sapiens","RAN, ARA24, OK/SW-cl.81","GTP-binding nuclear protein Ran","1","5CIQ"
"5CIT",,"X-RAY DIFFRACTION",2.45,41.93,"VAPOR DIFFUSION, HANGING DROP",7.2,"32 % PEG 1000, 50 mM HEPES pH 7.2, 20 mM MgCl2, 1mM BeF",291,"10.1074/jbc.M115.648071",,"5CIT",49.85,"1.75","1.75","Ran GDP wild type monoclinic crystal form","MAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGEFEKKYVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLRDGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIVLCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKPFLWLARKLIGDPNLEFVAMPALAPPEVVMDPALAAQYEHDLEVAQTTALPDEDDDL","Homo sapiens","RAN, ARA24, OK/SW-cl.81","GTP-binding nuclear protein Ran","1","5CIT"
"5CIW",,"X-RAY DIFFRACTION",2.45,41.96,"VAPOR DIFFUSION, HANGING DROP",7.2,"34 % PEG 1000, 50 mM HEPES pH 7.2, 20 mM MgCl2, 1 mM BeF",291,"10.1074/jbc.M115.648071",,"5CIW",49.66,"1.75","1.75","Ran GDP Y39A mutant monoclinic crystal form","MAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGEFEKKAVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLRDGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIVLCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKPFLWLARKLIGDPNLEFVAMPALAPPEVVMDPALAAQYEHDLEVAQTTALPDEDDDL","Homo sapiens","RAN, ARA24, OK/SW-cl.81","GTP-binding nuclear protein Ran","1","5CIW"
"5CJ2",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, HANGING DROP",8.5,"35% PEG 1000, 50mM Tris pH 8.5, 20mM MgCl2, 1 mM BeF",291,"10.1074/jbc.M115.648071",,"5CJ2",198.94,"1.75","1.75","Ran GDP Y39A mutant triclinic crystal form","MAAQGEPQVQFKLVLVGDGGTGKTTFVKRHLTGEFEKKAVATLGVEVHPLVFHTNRGPIKFNVWDTAGQEKFGGLRDGYYIQAQCAIIMFDVTSRVTYKNVPNWHRDLVRVCENIPIVLCGNKVDIKDRKVKAKSIVFHRKKNLQYYDISAKSNYNFEKPFLWLARKLIGDPNLEFVAMPALAPPEVVMDPALAAQYEHDLEVAQTTALPDEDDDL","Homo sapiens","RAN, ARA24, OK/SW-cl.81","GTP-binding nuclear protein Ran","1","5CJ2"
"5CJ8",,"X-RAY DIFFRACTION",2.08,40.74,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium fluoride, 20% w/v polyethylene glycol 3,350",291.15,"10.1073/pnas.1522572113",,"5CJ8",20.37,"2.015","2.015","Human Osteoclast Associated Receptor (OSCAR) extracellular domain","PKPWLGAQPATVVTPGVNVTLRCRAPQPAWRFGLFKPGEIAPLLFRDVSSELAEFFLEEVTPAQGGIYRCCYRRPDWGPGVWSQPSDVLELLVTEELPRPSLVALPGPVVGPGANVSLRCAGRLRNMSFVLYREGVAAPLQYRHSAQPWADFTLLGARAPGTYSCYYHTPSAPYVLSQRSEVLVI","Homo sapiens","OSCAR","Osteoclast-associated immunoglobulin-like receptor","1","5CJ8"
"5CJF",,"X-RAY DIFFRACTION",3.54,65.21,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.9 M ammonium sulfate, 0.1 M TRIS-HCl",293,"10.1021/acs.jmedchem.5b01144","520","5CJF",32.93,"1.83","1.83","The crystal structure of the human carbonic anhydrase XIV in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor.","ADGGQHWTYEGPHGQDHWPASYPECGNNAQSPIDIQTDSVTFDPDLPALQPHGYDQPGTEPLDLHNNGHTVQLSLPSTLYLGGLPRKYVAAQLHLHWGQKGSPGGSEHQINSEATFAELHIVHYDSDSYDSLSEAAERPQGLAVLGILIEVGETKNIAYEHILSHLHEVRHKDQKTSVPPFNLRELLPKQLGQYFRYNGSLTTPPCYQSVLWTVFYRRSQISMEQLEKLQGTLFSTEEEPSKLLVQNYRALQPLNQRMVFASFIQAGSSYTTGEMLVPR","Homo sapiens","CA14, UNQ690/PRO1335","Carbonic anhydrase 14","1","5CJF"
"5CKA",,"X-RAY DIFFRACTION",2.12,42.11,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES, 21% w/v PEG 4000, 15%
glycerol, 0.2 M ammonium acetate",293,"10.1038/srep25559",,"5CKA",12.14,"1.7","1.7","Human beta-2 microglobulin double mutant W60G-N83V","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDGSFYLLYYTEFTPTEKDEYACRVVHVTLSQPKIVKWDRDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CKA"
"5CKG",,"X-RAY DIFFRACTION",2.21,44.35,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M sodium acetate, 30% w/v PEG 4000, 15% glycerol, 0.2 M ammonium acetate",293,"10.1038/srep25559",,"5CKG",24.03,"1.75","1.75","Human beta-2 microglobulin mutant V85E","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHETLSQPKIVKWDRDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CKG"
"5CLM",,"X-RAY DIFFRACTION",2.87,57.11,"VAPOR DIFFUSION, HANGING DROP",,"12% (m/v) PEG4000, 100mM MES/NaOH pH 5.5",293,"10.1021/acs.jmedchem.5b01101","52K","5CLM",45.39,"2.61","2.61","1,4-Oxazine BACE1 inhibitors","ETDEEPEEPGTTGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5CLM"
"5CLP",,"X-RAY DIFFRACTION",2.26,45.63,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1039/c6sc02335e","42J","5CLP",85.2,"1.684","1.684","Crystal Structure of CK2alpha with 3,4-dichlorophenethylamine bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CLP"
"5CLS",,"X-RAY DIFFRACTION",2.74,55.08,"VAPOR DIFFUSION, SITTING DROP",5.4,"Na Citrate, Tert-butanol",292,"10.1021/acschembio.5b00755",,"5CLS",42.51,"1.75","1.75","Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31a","GPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5CLS"
"5CLT",,"X-RAY DIFFRACTION",3.23,61.9,"VAPOR DIFFUSION, SITTING DROP",,"0.1M sodium formate , 3% PEG 3350",293,,,"5CLT",233.05,"2.79","2.79","Crystal structure of human glycogen branching enzyme (GBE1) in complex with acarbose","YFQSMLKPYAVDFQRRYKQFSQILKNIGENEGGIDKFSRGYESFGVHRCADGGLYCKEWAPGAEGVFLTGDFNGWNPFSYPYKKLDYGKWELYIPPKQNKSVLVPHGSKLKVVITSKSGEILYRISPWAKYVVREGDNVNYDWIHWDPEHSYEFKHSRPKKPRSLRIYESHVGISSHEGKVASYKHFTCNVLPRIKGLGYNCIQLMAIMEHAYYASFGYQITSFFAASSRYGSPEELQELVDTAHSMGIIVLLDVVHSHASKNSADGLNMFDGTDSCYFHSGPRGTHDLWDSRLFAYSSWEVLRFLLSNIRWWLEEYRFDGFRFDGVTSMLYHHHGVGQGFSGDYSEYFGLQVDEDALTYLMLANHLVHTLCPDSITIAEDVSGMPALCSPISQGGGGFDYRLAMAIPDKWIQLLKEFKDEDWNMGDIVYTLTNRRYLEKCIAYAESHDQALVGDKSLAFWLMDAEMYTNMSVLTPFTPVIDRGIQLHKMIRLITHGLGGEGYLNFMGNEFGHPEWLDFPRKGNNESYHYARRQFHLTDDDLLRYKFLNNFDRDMNRLEERYGWLAAPQAYVSEKHEGNKIIAFERAGLLFIFNFHPSKSYTDYRVGTALPGKFKIVLDSDAAEYGGHQRLDHSTDFFSEAFEHNGRPYSLLVYIPSRVALILQNVDL","Homo sapiens","GBE1","1,4-alpha-glucan-branching enzyme","1","5CLT"
"5CLU",,"X-RAY DIFFRACTION",2.1,41.44,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M (NH4)2SO4, 0.3 M NaCl, 100 mM Tris-HCl (pH 8.2)",293,"10.1002/chem.201503748","S8A","5CLU",29.33,"1.55","1.55","THE CRYSTAL STRUCTURE OF THE COMPLEX of HCAII WITH A SACCHARINE DERIVATIVE","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5CLU"
"5CLW",,"X-RAY DIFFRACTION",3.25,62.18,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG 3350 , 0.2M sodium succinate",277,,,"5CLW",234.59,"2.8","2.8","Crystal structure of human glycogen branching enzyme (GBE1) in complex with maltoheptaose","YFQSMLKPYAVDFQRRYKQFSQILKNIGENEGGIDKFSRGYESFGVHRCADGGLYCKEWAPGAEGVFLTGDFNGWNPFSYPYKKLDYGKWELYIPPKQNKSVLVPHGSKLKVVITSKSGEILYRISPWAKYVVREGDNVNYDWIHWDPEHSYEFKHSRPKKPRSLRIYESHVGISSHEGKVASYKHFTCNVLPRIKGLGYNCIQLMAIMEHAYYASFGYQITSFFAASSRYGSPEELQELVDTAHSMGIIVLLDVVHSHASKNSADGLNMFDGTDSCYFHSGPRGTHDLWDSRLFAYSSWEVLRFLLSNIRWWLEEYRFDGFRFDGVTSMLYHHHGVGQGFSGDYSEYFGLQVDEDALTYLMLANHLVHTLCPDSITIAEDVSGMPALCSPISQGGGGFDYRLAMAIPDKWIQLLKEFKDEDWNMGDIVYTLTNRRYLEKCIAYAESHDQALVGDKSLAFWLMDAEMYTNMSVLTPFTPVIDRGIQLHKMIRLITHGLGGEGYLNFMGNEFGHPEWLDFPRKGNNESYHYARRQFHLTDDDLLRYKFLNNFDRDMNRLEERYGWLAAPQAYVSEKHEGNKIIAFERAGLLFIFNFHPSKSYTDYRVGTALPGKFKIVLDSDAAEYGGHQRLDHSTDFFSEAFEHNGRPYSLLVYIPSRVALILQNVDL","Homo sapiens","GBE1","1,4-alpha-glucan-branching enzyme","1","5CLW"
"5CLX",,"X-RAY DIFFRACTION",2.31,46.87,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.1M di-sodium malonate",298,,,"5CLX",28.19,"1.28","1.28","X-ray structure of perdeuterated TTR mutant - S52P at 1.28A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSEPGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CLX"
"5CLY",,"X-RAY DIFFRACTION",2.32,47.09,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.5M di-sodium malonate",298,,,"5CLY",28.19,"1.23","1.23","X-ray structure of TTR mutant - S52P at 1.23A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSEPGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CLY"
"5CLZ",,"X-RAY DIFFRACTION",2.29,46.24,"VAPOR DIFFUSION, HANGING DROP",6,"2.1M di-sodium malonate",298,,,"5CLZ",28.13,"1.22","1.22","X-ray structure of TTR mutant - T119M at 1.22A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTMAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CLZ"
"5CM1",,"X-RAY DIFFRACTION",2.31,46.78,"VAPOR DIFFUSION, SITTING DROP",5.5,"2.4M di-sodium malonate",298,,,"5CM1",28.13,"1.22","1.22","X-ray structure of perdeuterated TTR mutant - T119M at 1.22A","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTMAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CM1"
"5CM4",,"X-RAY DIFFRACTION",3.93,65,"VAPOR DIFFUSION, HANGING DROP",5.6,"1.8 M ammonium sulfate, 0.1 M tri-Na citrate pH 5.6 and 0.2 M Na/K tartrate",293,"10.1038/cr.2015.92",,"5CM4",29.38,"2.4","2.4","Crystal structure of human Frizzled 4 Cysteine-Rich Domain (CRD)","EEERRCDPIRISMCQNLGYNVTKMPNLVGHELQTDAELQLTTFTPLIQYGCSSQLQFFLCSVYVPMCTEKINIPIGPCGGMCLSVKRRCEPVLKEFGFAWPESLNCSKFPPQNDHNHMCMEGPGD","Homo sapiens","FZD4","Frizzled-4","1","5CM4"
"5CMD",,"X-RAY DIFFRACTION",6.33,80.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Tris, 1.8 M Ammonium sulfate",303.15,"10.1073/pnas.1523981113",,"5CMD",46.14,"3.086","3.086","Oligomer crystal structure of CC chemokine 5 (CCL5)","SSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS","Homo sapiens","CCL5, D17S136E, SCYA5","C-C motif chemokine 5","1","5CMD"
"5CMF",,"X-RAY DIFFRACTION",2.33,47.2,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CMF",33.89,"1.95","1.95","GTA mutant with mercury - E303A","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDASHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVP","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CMF"
"5CMG",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CMG",35.1,"1.83","1.83","GTA mutant with mercury- E303C","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDCSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CMG"
"5CMH",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CMH",35.24,"1.61","1.61","GTA mutant with mercury - E303D","EFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDDSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CMH"
"5CMI",,"X-RAY DIFFRACTION",2.24,45.07,"VAPOR DIFFUSION, HANGING DROP",,"30-40 mg/ml protein, 1% PEG (w/v) 4000, 4.5% MPD (v/v), 0.1 M ammonium sulfate, 0.07 M NaCl, 0.05 M ADA buffer, pH 7.5, 5 mM MnCl2 against a reservoir containing 2.7% (w/v) PEG 4000, 7% (v/v) MPD, 0.32 M ammonium sulfate, 0.25 M NaCl, and 0.2 M ADA pH 7.5",291,"10.1093/glycob/cww117",,"5CMI",34.31,"1.85","1.85","GTA mutant without mercury - E303D","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDDSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CMI"
"5CMJ",,"X-RAY DIFFRACTION",2.27,45.93,"VAPOR DIFFUSION",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CMJ",35.33,"1.73","1.73","GTA mutant with mercury - E303Q","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVRAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPGFYGSSREAFTYERRPQSQAYIPKDEGDFYYLGGFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDQSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CMJ"
"5CMP",,"X-RAY DIFFRACTION",2.25,45.3,"EVAPORATION",7,"0.1M Tris pH7, 50% (v/v) PEG200",295,"10.1016/j.str.2015.06.024",,"5CMP",152.73,"2.601","2.601","human FLRT3 LRR domain","ADPGKSCPSVCRCDAGFIYCNDRFLTSIPTGIPEDATTLYLQNNQINNAGIPSDLKNLLKVERIYLYHNSLDEFPTNLPKYVKELHLQENNIRTITYDSLSKIPYLEELHLDDNSVSAVSIEEGAFRDSNYLRLLFLSRNHLSTIPWGLPRTIEELRLDDNRISTISSPSLQGLTSLKRLVLDGNLLNNHGLGDKVFFNLVNLTELSLVRNSLTAAPVNLPGTNLRKLYLQDNHINRVPPNAFSYLRQLYRLDMSNNNLSNLPQGIFDDLDNITQLILRNNPWYCGCKMKWVRDWLQSLPVKVNVRGLMCQAPEKVRGMAIKDLNAELFDCKD","Homo sapiens","FLRT3, KIAA1469, UNQ856/PRO1865","Leucine-rich repeat transmembrane protein FLRT3","1","5CMP"
"5CMQ",,"X-RAY DIFFRACTION",2.89,57.47,"VAPOR DIFFUSION, SITTING DROP",8,"25 mM Tris, 10 mM calcium chloride, 10 mM zinc chloride, 2% PEG 3350",298,"10.1021/jacs.5b07463",,"5CMQ",21.71,"1.935","1.935","Crystal Structure of Zn-bound Human H-Ferritin variant 122H-delta C-star","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPDEDDWESGLNAMEAALHLEKNVNQSLLELHKLAHDKNDPHLADFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5CMQ"
"5CMR",,"X-RAY DIFFRACTION",3.71,66.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"50 mM CHES, 150 mM sodium chloride, 0.3 mM zinc chloride, 1 mM H2BDH",298,"10.1021/jacs.5b07463",,"5CMR",21.46,"3.792","3.792","Crystal Structure of Linker-Mediated Zn-bound Human H-Ferritin variant 122H-delta C-star","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIAKPDEDDWESGLNAMEAALHLEKNVNQSLLELHKLAHDKNDPHLADFIETHYLNEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5CMR"
"5CN3",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",5,"2.15M di-sodium malonate",298,"10.1002/anie.201602747",,"5CN3",28.07,"1.3","1.3","X-ray structure of wild-type TTR at 1.30A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CN3"
"5CNH",,"X-RAY DIFFRACTION",2.31,46.74,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.4M di-sodium malonate",298,"10.1002/anie.201602747",,"5CNH",28.07,"1.42","1.42","X-ray structure of perdeuterated wild-type TTR at 1.42A resolution","GAMGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5CNH"
"5CNI",,"X-RAY DIFFRACTION",2.6,52.7,"VAPOR DIFFUSION",,"100mM Sodium Acetate pH 4.6 + 15% PEG 20K",295,"10.1021/acs.jmedchem.5b01124","GGL","5CNI",112.72,"2.69","2.69","mGlu2 with Glutamate","MALGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNISVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALEEVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGEGHHHHHH","Homo sapiens","GRM2, GPRC1B, MGLUR2","Metabotropic glutamate receptor 2","1","5CNI"
"5CNJ",,"X-RAY DIFFRACTION",2.74,55.12,"VAPOR DIFFUSION",,"100mM Hepes pH 7 + 20% PEG 3350 + 200mM Magnesium Chloride",295,"10.1021/acs.jmedchem.5b01124",,"5CNJ",112.13,"2.65","2.65","mGlur2 with glutamate analog","MALGSLLALLALLLLWGAVAEGPAKKVLTLEGDLVLGGLFPVHQKGGPAEDCGPVNEHRGIQRLEAMLFALDRINRDPHLLPGVRLGAHILDSCSKDTHALEQALDFVRASLSRGADGSRHICPDGSYATHGDAPTAITGVIGGSYSDVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFFQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFELEARARNISVATSEKVGRAMSRAAFEGVVRALLQKPSARVAVLFTRSEDARELLAASQRLNASFTWVASDGWGALESVVAGSEGAAEGAITIELASYPISDFASYFQSLDPWNNSRNPWFREFWEQRFRCSFRQRDCAAHSLRAVPFEQESKIMFVVNAVYAMAHALHNMHRALCPNTTRLCDAMRPVNGRRLYKDFVLNVKFDAPFRPADTHNEVRFDRFGDGIGRYNIFTYLRAGSGRYRYQKVGYWAEGLTLDTSLIPWASPSAGEGHHHHHH","Homo sapiens","GRM2, GPRC1B, MGLUR2","Metabotropic glutamate receptor 2","1","5CNJ"
"5CNK",,"X-RAY DIFFRACTION",2.46,50,"VAPOR DIFFUSION",,"16% PEG 3350 + 200mM Ammonium Iodide, 50mM Tris pH 8.0 / 150mM NaCl",295,"10.1021/acs.jmedchem.5b01124","GGL","5CNK",177.75,"3.15","3.15","mglur3 with glutamate","MALKMLTRLQVLTLALFSKGFLLSLGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEECGRINEDRGIQRLEAMLFAIDEINKDDYLLPGVKLGVHILDTCSRDTYALEQSLEFVRASLTKVDEAEYMCPDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFYQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQEARLRNISIATAEKVGRSNIRKSYDSVIRELLQKPNARVVVLFMRSDDSRELIAAASRANASFTWVASDGWGAQESIIKGSEHVAYGAITLELASQPVRQFDRYFQSLNPYNNHRNPWFRDFWEQKFQCSLQNKRNHRRVCDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKMQRTLCPNTTKLCDAMKILDGKKLYKDYLLKINFTAPFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSYLKVGHWAETLSLDVNSIHWSRNSVPTSEGHHHHHH","Homo sapiens","GRM3, GPRC1C, MGLUR3","Metabotropic glutamate receptor 3","1","5CNK"
"5CNM",,"X-RAY DIFFRACTION",2.54,51.67,"VAPOR DIFFUSION",,"100mM Hepes pH 7.7 + 19% PEG 8K + 50mM Magnesium Sulfate",295,"10.1021/acs.jmedchem.5b01124",,"5CNM",59.25,"2.84","2.84","mGluR3 complexed with glutamate analog","MALKMLTRLQVLTLALFSKGFLLSLGDHNFLRREIKIEGDLVLGGLFPINEKGTGTEECGRINEDRGIQRLEAMLFAIDEINKDDYLLPGVKLGVHILDTCSRDTYALEQSLEFVRASLTKVDEAEYMCPDGSYAIQENIPLLIAGVIGGSYSSVSIQVANLLRLFQIPQISYASTSAKLSDKSRYDYFARTVPPDFYQAKAMAEILRFFNWTYVSTVASEGDYGETGIEAFEQEARLRNISIATAEKVGRSNIRKSYDSVIRELLQKPNARVVVLFMRSDDSRELIAAASRANASFTWVASDGWGAQESIIKGSEHVAYGAITLELASQPVRQFDRYFQSLNPYNNHRNPWFRDFWEQKFQCSLQNKRNHRRVCDKHLAIDSSNYEQESKIMFVVNAVYAMAHALHKMQRTLCPNTTKLCDAMKILDGKKLYKDYLLKINFTAPFNPNKDADSIVKFDTFGDGMGRYNVFNFQNVGGKYSYLKVGHWAETLSLDVNSIHWSRNSVPTSEGHHHHHH","Homo sapiens","GRM3, GPRC1C, MGLUR3","Metabotropic glutamate receptor 3","1","5CNM"
"5CNN",,"X-RAY DIFFRACTION",2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",5.5,"PEG 6000, morpholineethanesulfonic acid, ammonium chloride",293,"10.1128/MCB.00248-15",,"5CNN",80.33,"1.9","1.9","Crystal structure of the EGFR kinase domain mutant I682Q","GAMGEAPNQALLRQLKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGFFSSPSTSRTPLLSSLSATS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CNN"
"5CNO",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, HANGING DROP",8,"ammonium nitrate, PEG 3350",293,"10.1128/MCB.00248-15",,"5CNO",113.93,"1.55","1.55","Crystal structure of the EGFR kinase domain mutant V924R","GAMGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5CNO"
"5CNY",,"X-RAY DIFFRACTION",1.87,34.05,"VAPOR DIFFUSION, HANGING DROP",5.5,"2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)",293,,,"5CNY",11.84,"1.7","1.7","Crystal Structure of human zinc insulin at pH 5.5","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5CNY"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5CNY"
"5CO2",,"X-RAY DIFFRACTION",1.84,33.08,"VAPOR DIFFUSION, HANGING DROP",5.5,"2 mcL protein (6 mg/mL in 2 mM HCl) + 2  mcL well solution (0.1 M Na2HPO4 pH 5.5, 10 % m/v PEG 6,000)",298,,,"5CO2",11.84,"1.7","1.7","Crystalization of human zinc insulin at pH 5.5","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5CO2"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5CO2"
"5CO6",,"X-RAY DIFFRACTION",1.86,34.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 mcL protein (6 mg/mL) + 2 mcL well 0.1 M MES buffer pH 6.5, 1.6 M MgSO4 (directly from the commercially available kit Hampton Crystal Screen II, formulation 20)",293,,,"5CO6",11.86,"1.8","1.8","Crystal structure of human zinc insulin at pH 6.5","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5CO6"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5CO6"
"5CO9",,"X-RAY DIFFRACTION",1.85,33.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"2 mcL protein (6 mg/mL) + 2 mcL well (0.1 M MES buffer pH 6.5, 1.6 M MgSO4, directly from the commercially available kit Hampton Crystal Screen II, formulation #20)",293,,,"5CO9",11.84,"1.92","1.92","Crystal structure of human zinc insulin at pH 6.5","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5CO9"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5CO9"
"5COE",,"X-RAY DIFFRACTION",2.27,45.78,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5COE",42.58,"2.18","2.18","The structure of the NK1 fragment of HGF/SF complexed with HEPES","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5COE"
"5COI",,"X-RAY DIFFRACTION",1.91,35.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly, pH 7.5",277,"10.1021/acs.jmedchem.5b01511","55K","5COI",17.17,"1.62","1.62","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5COI"
"5COR",,"X-RAY DIFFRACTION",3.69,66.68,"VAPOR DIFFUSION, HANGING DROP",,"0.01 M Cobalt (II) chloride hexahydrate, 0.1 M Sodium acetate trihydrate pH 4.6, 1.0 M 1,6-Hexanediol",291.16,"10.1073/pnas.1523981113",,"5COR",79.3,"2.548","2.548","X-RAY STRUCTURE OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (CCL3) N-TERMINAL-SWITCH POLYMER","ASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA","Homo sapiens","CCL3, G0S19-1, MIP1A, SCYA3","C-C motif chemokine 3","1","5COR"
"5COY",,"X-RAY DIFFRACTION",2.08,40.79,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M Potassium phosphate monobasic, 20% w/v Polyethylene glycol 3,350",291.15,"10.1073/pnas.1523981113",,"5COY",15.77,"1.443","1.443","Crystal structure of CC chemokine 5 (CCL5)","SSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS","Homo sapiens","CCL5, D17S136E, SCYA5","C-C motif chemokine 5","1","5COY"
"5CP5",,"X-RAY DIFFRACTION",1.95,37.03,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2M (NH4)2SO4, 0.1M HEPES, 10% EtGhly, pH7.5",277,"10.1021/acs.jmedchem.5b01511","EB0","5CP5",17.26,"1.79","1.79","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CP5"
"5CP9",,"X-RAY DIFFRACTION",2.29,46.18,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CP9",42.55,"1.9","1.9","The structure of the NK1 fragment of HGF/SF complexed with MB605","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CP9"
"5CPE",,"X-RAY DIFFRACTION",1.95,36.84,"VAPOR DIFFUSION, SITTING DROP",7.2,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES,10% EtGhly, pH7.2",277,"10.1021/acs.jmedchem.5b01511","EB2","5CPE",17.26,"1.62","1.62","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CPE"
"5CPR",,"X-RAY DIFFRACTION",2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",8.5,"The purified protein was concentrated to 10 mg/mL and with 1 mM SAM. SAM bound protein crystals were obtained by hanging drop vapor diffusion method at 17C using 10% (w/v) ethanol, 5% (w/v) glycerol, 0.1 M tris pH 8.5 as the well solution. A-196 was soaked into the crystals",298,"10.1038/nchembio.2282","539","5CPR",31.75,"2.22","2.22","The novel SUV4-20 inhibitor A-196 verifies a role for epigenetics in genomic integrity","GSSGMSAKELCENDDLATSLVLDPYLGFQTHKMNTSAFPSRSSRHFSKSDSFSHNNPVRFRPIKGRQEELKEVIERFKKDEHLEKAFKCLTSGEWARHYFLNKNKMQEKLFKEHVFIYLRMFATDSGFEILPCNRYSSEQNGAKIVATKEWKRNDKIELLVGCIAELSEIEENMLLRHGENDFSVMYSTRKNCAQLWLGPAAFINHDCRPNCKFVSTGRDTACVKALRDIEPGEEISCYYGDGFFGENNEFCECYTCERRGTGAFKSR","Homo sapiens","SUV420H1, KMT5B, CGI-85","Histone-lysine N-methyltransferase SUV420H1","1","5CPR"
"5CQ3",,"X-RAY DIFFRACTION",4.04,69.58,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG600 , 0.1M MES pH 6.0",277,,,"5CQ3",14.49,"1.925","1.925","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 6-Hydroxypicolinic acid (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ3"
"5CQ4",,"X-RAY DIFFRACTION",4.06,69.71,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG600 , 0.1M MES pH 6.0",277,,,"5CQ4",14.39,"1.782","1.782","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 3'-Hydroxyacetophenone (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ4"
"5CQ5",,"X-RAY DIFFRACTION",4.1,69.99,"VAPOR DIFFUSION, SITTING DROP",6.3,"25% PEG600 , 0.1M MES pH 6.3",277,,,"5CQ5",14.54,"1.961","1.961","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2,3-Ethylenedioxybenzoic Acid (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ5"
"5CQ6",,"X-RAY DIFFRACTION",4.05,69.64,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG600 , 0.1M MES pH 6.0",277,,,"5CQ6",14.52,"1.97","1.97","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2,6-Pyridinedicarboxylic acid (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ6"
"5CQ7",,"X-RAY DIFFRACTION",4.51,72.72,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000 , 10% ethylene glycol , 0.1M MES pH 6.0 , 0.1M calcium chloride",277,,,"5CQ7",13.7,"1.86","1.86","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N,N-dimethylquinoxaline-6-carboxamide (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ7"
"5CQ8",,"X-RAY DIFFRACTION",4.11,70.07,"VAPOR DIFFUSION, SITTING DROP",6.7,"31.5% PEG600 , 0.1M MES pH 6.7",277,,,"5CQ8",14.32,"1.651","1.651","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 4'-Hydroxyacetophenone (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQ8"
"5CQA",,"X-RAY DIFFRACTION",4.56,73.03,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000 , 10% ethylene glycol , 0.1M MES pH 6.0 , 0.1M calcium chloride",277,,"2LY","5CQA",13.69,"2.13","2.13","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N-methyl-2,3-dihydrothieno[3,4-b][1,4]dioxine-5-carboxamide (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CQA"
"5CQD",,"X-RAY DIFFRACTION",2.16,42.99,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293,"10.1074/jbc.M115.679951",,"5CQD",44.55,"2.08","2.08","Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B","MEILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCNESGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIKAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQL","Homo sapiens","APOBEC3B","DNA dC->dU-editing enzyme APOBEC-3B","1","5CQD"
"5CQH",,"X-RAY DIFFRACTION",2.06,40.4,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, MES-NaOH",293,"10.1074/jbc.M115.679951",,"5CQH",22.64,"1.73","1.73","Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B","MEILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCNESGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIKAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQL","Homo sapiens","APOBEC3B","DNA dC-dU-editing enzyme APOBEC-3B","1","5CQH"
"5CQI",,"X-RAY DIFFRACTION",2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293,"10.1074/jbc.M115.679951",,"5CQI",22.32,"1.68","1.68","Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B","MEILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCNESGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIKAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQL","Homo sapiens","APOBEC3B","DNA dC-dU-editing enzyme APOBEC-3B","1","5CQI"
"5CQK",,"X-RAY DIFFRACTION",2.07,40.5,"VAPOR DIFFUSION, HANGING DROP",,"PEG3350, MES-NaOH",293,"10.1074/jbc.M115.679951",,"5CQK",22.55,"1.88","1.88","Crystal Structure of the Cancer Genomic DNA Mutator APOBEC3B","MEILRYLMDPDTFTSNFNNDPLVLRRRQTYLCYEVERLDNGTSVKMDQHMGFLCNESGRHAELRFLDLVPSLQLDPAQIYRVTWFISWSPCFSWGCAGEVRAFLQENTHVRLRIKAARIYDYDPLYKEALQMLRDAGAQVSIMTYDEFEYCWDTFVYRQGCPFQPWDGLEEHSQALSGRLRAILQL","Homo sapiens","APOBEC3B","DNA dC->dU-editing enzyme APOBEC-3B","1","5CQK"
"5CQL",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CQL",35.23,"1.69","1.69","GTB mutant with mercury - E303A","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDASHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CQL"
"5CQM",,"X-RAY DIFFRACTION",2.28,46.02,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CQM",35.39,"1.65","1.65","GTB mutant with mercury - E303C","EFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDCSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CQM"
"5CQN",,"X-RAY DIFFRACTION",2.25,45.29,"VAPOR DIFFUSION, HANGING DROP",,"30-40 mg/ml protein, 1% PEG (w/v) 4000, 4.5% MPD (v/v), 0.1 M ammonium sulfate, 0.07 M NaCl, 0.05 M ADA buffer, pH 7.5, 5 mM MnCl2 against a reservoir containing 2.7% (w/v) PEG 4000, 7% (v/v) MPD, 0.32 M ammonium sulfate, 0.25 M NaCl, and 0.2 M ADA pH 7.5",291,"10.1093/glycob/cww117",,"5CQN",34.26,"1.61","1.61","GTB mutant without mercury - E303C","FMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDCSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CQN"
"5CQO",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CQO",35.2,"1.69","1.69","GTB mutant with mercury - E303D","EFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDDSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CQO"
"5CQP",,"X-RAY DIFFRACTION",2.29,46.3,"VAPOR DIFFUSION, HANGING DROP",,"10 ul drops with 6-8 mg/ml protein, 70 mM N-(2-acetamido)-2-iminodiacetic acid (ADA) pH 7.5, 50 mM, sodium acetate pH 4.6, 40 mM NaCl, 5-8 mM MnCl2, 2.5% (v/v) 2-methyl-2,4-pentanediol (MPD), 5%(v/v) glycerol, 2%(w/v) PEG 4000, and 0.3-0.5 mM 3-chloromercuri-2-methoxypropylurea suspended over 1 ml of a resevoir solution: 50 mM ADA pH 7.5, 10 mM MnCl2, 100 mM ammonium sulfate, 5%(v/v) MPD, 10%(v/v) glycerol, and 8-10%(w/v) PEG 4000",291,"10.1093/glycob/cww117",,"5CQP",35.22,"1.83","1.83","GTB mutant with mercury - E303Q","EFMVSLPRMVYPQPKVLTPCRKDVLVVTPWLAPIVWEGTFNIDILNEQFRLQNTTIGLTVFAIKKYVAFLKLFLETAEKHFMVGHRVHYYVFTDQPAAVPRVTLGTGRQLSVLEVGAYKRWQDVSMRRMEMISDFCERRFLSEVDYLVCVDVDMEFRDHVGVEILTPLFGTLHPSFYGSSREAFTYERRPQSQAYIPKDEGDFYYMGAFFGGSVQEVQRLTRACHQAMMVDQANGIEAVWHDQSHLNKYLLRHKPTKVLSPEYLWDQQLLGWPAVLRKLRFTAVPKNHQAVRNPE","Homo sapiens","ABO","Histo-blood group ABO system transferase","1","5CQP"
"5CQR",,"X-RAY DIFFRACTION",2.59,52.56,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM HEPES, pH 7.0, 20% PEG 3350, 200 mM potassium citrate",277,"10.1073/pnas.1502597112",,"5CQR",71.17,"3.015","3.015","Dimerization of Elp1 is essential for Elongator complex assembly","GPGSNLEVVHHRALVLAQIRKWLDKLMFKEAFECMRKLRINLNLIYDHNPKVFLGNVETFIKQIDSVNHINLFFTELKEEDVTKTMYPAPVTSSVYLSRDPDGNKIDLVCDAMRAVMESINPHKYCLSILTSHVKKTTPELEIVLQKVHELQGNAPSDPDAVSAEEALKYLLHLVDVNELYDHSLGTYDFDLVLMVAEKSQKDPKEYLPFLNTLKKMETNYQRFTIDKYLKRYEKAIGHLSKCGPEYFPECLNLIKDKNLYNEALKLYSPSSQQYQDISIAYGEHLMQEHMYEPAGLMFARCGAHEKALSAFLTCGNWKQALCVAAQLNFTKDQLVGLGRTLAGKLVEQRKHIDAAMVLEECAQDYEEAVLLLLEGAAWEEALRLVYKYNRLDIIETNVKPSILEAQKNYMAFLDSQTATFSRHKKRLLVVRELKEQAQQAGLDDEVPHGQESDLFSETSSVVSGSEMSGKYSHSNSRISARSSKNRRKAERKKHSLKEGSPLEDLALLEALSEVVQNTENLKDEVYHILKVLFLFEFDEQGRELQKAFEDTLQLMERSLPEIWTLTYQQNSATPVLGPNSTANSIMASYQQQKTSVPVLDAELFIPPKINRRTQWKLSLLD","Homo sapiens","IKBKAP, ELP1, IKAP","Elongator complex protein 1","1","5CQR"
"5CQT",,"X-RAY DIFFRACTION",1.89,35.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly, pH 7.5",277,"10.1021/acs.jmedchem.5b01511","EB3","5CQT",17.13,"1.6","1.6","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CQT"
"5CQU",,"X-RAY DIFFRACTION",2.02,39.11,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein solution: 6 mg/ml CK2alpha, 0.44 mM AMPPNP, 0.89 mM magnesium chloride, 250 mM NaCl, 12.5 mM Tris/HCl, pH 8.5; Reservoir: 30%(w/v) PEG4000, 0.2 M Lithiumsulfate, 0.1 M Tris/HCL, pH 8.5; the inhibitor JRJ was introduced by extensive soaking for one week",298,,,"5CQU",41.14,"2.35","2.35","Monoclinic Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CQU"
"5CQW",,"X-RAY DIFFRACTION",3.2,61.51,"VAPOR DIFFUSION, SITTING DROP",,"Protein solution: 6 mg/ml CK2alpha, 1 mM Inhibitor, 10 %(v/v) DMSO, 250 mM NaCl, 12.5 mM Tris/HCl, pH 8.5; Reservoir: 25 %(w/v) PEG 3350, 0.2 M Lithiumsulfate, 0.1 M Bis-Tris/HCl, pH 5.5; drop: 1 Mikroliter pre-incubated CK2alpha/Inhibitor solution and 1 Mikroliter reservoir",298,,,"5CQW",82.83,"2.65","2.65","Tetragonal Complex Structure of Protein Kinase CK2 Catalytic Subunit with a Benzotriazole-Based Inhibitor Generated by click-chemistry","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQARMG","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CQW"
"5CQZ",,"X-RAY DIFFRACTION",2.81,58,"VAPOR DIFFUSION, SITTING DROP",8.5,"MgSO4, Tris and ligand",277,"10.1021/acs.jmedchem.5b01616",,"5CQZ",130.14,"2.9","2.9","Human cytosolic 5'-nucleotidase II in complex with 3-(3-Imidazol-1-ylphenyl)-N-(9H-purin-6-yl)benzamide","MGSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5CQZ"
"5CR1",,"X-RAY DIFFRACTION",2.29,46.34,"VAPOR DIFFUSION, HANGING DROP",7,"The protein (5 mg/ml), in 20 mM sodium phosphate, pH 7 was incubated with a reservoir solution containing 2.2 M ammonium sulphate, 0.1 M KCl, 0.03 M sodium phosphate, pH 7.0.",298,"10.1074/jbc.M115.690172","STL, T44","5CR1",26.36,"1.545","1.545","Crystal structure of TTR/resveratrol/T4 complex","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGSSPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNP","Homo sapiens","TTR, PALB","Transthyretin","1","5CR1"
"5CR5",,"X-RAY DIFFRACTION",2.36,47.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL Morpheus screen condition B2, DTT",293,"10.1021/acsmedchemlett.5b00179","EL1","5CR5",85.62,"1.61","1.61","X-RAY CRYSTAL STRUCTURE AT 1.61A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIPHENYL PYRROLIDINE ETHER COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5CR5"
"5CR7",,"X-RAY DIFFRACTION",2.84,58,"VAPOR DIFFUSION, SITTING DROP",5.5,"ammonium acetate, Bis-Tris, 2-methyl-2,4-pentanediol",277,"10.1021/acs.jmedchem.5b01616",,"5CR7",130.8,"2.9","2.9","Human cytosolic 5'-nucleotidase II in complex with N-(9H-Purin-6-yl)-3-(3-pyrrol-1-ylphenyl)benzamide","GSSHHHHHHSSGLVPRGSMSTSWSDRLQNAADMPANMDKHALKKYRREAYHRVFVNRSLAMEKIKCFGFDMDYTLAVYKSPEYESLGFELTVERLVSIGYPQELLSFAYDSTFPTRGLVFDTLYGNLLKVDAYGNLLVCAHGFNFIRGPETREQYPNKFIQRDDTERFYILNTLFNLPETYLLACLVDFFTNCPRYTSCETGFKDGDLFMSYRSMFQDVRDAVDWVHYKGSLKEKTVENLEKYVVKDGKLPLLLSRMKEVGKVFLATNSDYKYTDKIMTYLFDFPHGPKPGSSHRPWQSYFDLILVDARKPLFFGEGTVLRQVDTKTGKLKIGTYTGPLQHGIVYSGGSSDTICDLLGAKGKDILYIGDHIFGDILKSKKRQGWRTFLVIPELAQELHVWTDKSSLFEELQSLDIFLAELYKHLDSSSNERPDISSIQRRIKKVTHDMDMCYGMMGSLFRSGSRQTLFASQVMRYADLYAASFINLLYYPFSYLFRAAHVLMPHESTVEHTHVDINEMESPLATRNRTSVDFKDTDYKRHQLTRSISEIKPPNL","Homo sapiens","NT5C2, NT5B, NT5CP, PNT5","Cytosolic purine 5'-nucleotidase","1","5CR7"
"5CRD",,"X-RAY DIFFRACTION",2.84,56.63,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS, 27.5 % (v/v) 2-methyl-2,4-pentanediol, 0.2 M NaCl",277,"10.1074/jbc.M115.686261",,"5CRD",42.12,"2.08","2.08","Wild-type human skeletal calsequestrin","QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDD","Homo sapiens","CASQ1, CASQ","Calsequestrin-1","1","5CRD"
"5CRE",,"X-RAY DIFFRACTION",3.05,59.72,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS, 27.5 % (v/v) 2-methyl-2,4-pentanediol, 0.2 M NaCl",277,"10.1074/jbc.M115.686261",,"5CRE",41.98,"3.315","3.315","Human skeletal calsequestrin, D210G mutant low-calcium complex","QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPGKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDD","Homo sapiens","CASQ1, CASQ","Calsequestrin-1","1","5CRE"
"5CRG",,"X-RAY DIFFRACTION",2.9,57.56,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS, 27.5 % (v/v) 2-methyl-2,4-pentanediol, 0.2 M NaCl",277,"10.1074/jbc.M115.686261",,"5CRG",169.94,"1.97","1.97","Human skeletal calsequestrin, D210G mutant high-calcium complex","QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFEMEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPGKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDD","Homo sapiens","CASQ1, CASQ","Calsequestrin-1","1","5CRG"
"5CRH",,"X-RAY DIFFRACTION",2.68,54.05,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MOPS, 27.5 % (v/v) 2-methyl-2,4-pentanediol, 0.2 M NaCl",277,"10.1074/jbc.M115.686261",,"5CRH",84.47,"2.03","2.03","Human skeletal calsequestrin, M53T mutant high-calcium complex","QEGLDFPEYDGVDRVINVNAKNYKNVFKKYEVLALLYHEPPEDDKASQRQFETEELILELAAQVLEDKGVGFGLVDSEKDAAVAKKLGLTEVDSMYVFKGDEVIEYDGEFSADTIVEFLLDVLEDPVELIEGERELQAFENIEDEIKLIGYFKSKDSEHYKAFEDAAEEFHPYIPFFATFDSKVAKKLTLKLNEIDFYEAFMEEPVTIPDKPNSEEEIVNFVEEHRRSTLRKLKPESMYETWEDDMDGIHIVAFAEEADPDGFEFLETLKAVAQDNTENPDLSIIWIDPDDFPLLVPYWEKTFDIDLSAPQIGVVNVTDADSVWMEMDDEEDLPSAEELEDWLEDVLEGEINTEDDDDDDDD","Homo sapiens","CASQ1, CASQ","Calsequestrin-1","1","5CRH"
"5CRM",,"X-RAY DIFFRACTION",1.91,35.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly, 
PH 6.5",277,"10.1021/acs.jmedchem.5b01511","EB5","5CRM",17.51,"1.99","1.99","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CRM"
"5CRU",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.03 M HEPES sodium, 16%(w/v) polyethylene glycol 3350, 0.67%(w/v) tryptone, 0.03 M urea",293,"10.1371/journal.pone.0149113",,"5CRU",162.88,"2.4","2.4","Crystal structure of the Bro domain of HD-PTP","MEAVPRMPMIWLDLKEAGDFHFQPAVKKFVLKNYGENPEAYNEELKKLELLRQNAVRVPRDFEGCSVLRKYLGQLHYLQSRVPMGSGQEAAVPVTWTEIFSGKSVAHEDIKYEQACILYNLGALHSMLGAMDKRVSEEGMKVSCTHFQCAAGAFAYLREHFPQAYSVDMSRQILTLNVNLMLGQAQECLLEKSMLDNRKSFLVARISAQVVDYYKEACRALENPDTASLLGRIQKDWKKLVQMKIYYFAAVAHLHMGKQAEEQQKFGERVAYFQSALDKLNEAIKLAKGQPDTVQDALRFTMDVIGGKYNSAKKDNDFIYHEAVPALDTLQPVKGAPLVKPLPVNPTDPAVTGPDIFAKLV","Homo sapiens","PTPN23, KIAA1471","Tyrosine-protein phosphatase non-receptor type 23","1","5CRU"
"5CRZ",,"X-RAY DIFFRACTION",1.94,36.71,"VAPOR DIFFUSION, SITTING DROP",8,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly, pH 8.0",277,"10.1021/acs.jmedchem.5b01511","EB7","5CRZ",17.45,"2.12","2.12","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CRZ"
"5CS1",,"X-RAY DIFFRACTION",2.29,46.39,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 nM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CS1",42.34,"2","2","The structure of the NK1 fragment of HGF/SF","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CS1"
"5CS3",,"X-RAY DIFFRACTION",2.29,46.18,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CS3",42.6,"2.5","2.5","The structure of the NK1 fragment of HGF/SF complexed with (H)EPPS","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CS3"
"5CS5",,"X-RAY DIFFRACTION",2.31,46.73,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CS5",42.65,"1.9","1.9","The structure of the NK1 fragment of HGF/SF complexed with PIPES","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CS5"
"5CS6",,"X-RAY DIFFRACTION",2.25,45.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1039/c6sc02335e","K82","5CS6",84.07,"1.88","1.88","Crystal Structure of CK2alpha with Compound 3 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CS6"
"5CS7",,"X-RAY DIFFRACTION",2.36,47.86,"VAPOR DIFFUSION, SITTING DROP",4.5,"30% PEG 4000, 0.1M sodium acetate, 15% glycerol, 0.2M ammonium acetate",293,"10.1038/s41467-018-04078-y",,"5CS7",11.88,"2.1","2.1","The crystal structure of wt beta2-microglobulin at room temperature","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CS7"
"5CS8",,"X-RAY DIFFRACTION",1.93,36.38,"VAPOR DIFFUSION, SITTING DROP",8.3,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly, pH 8.3",277,"10.1021/acs.jmedchem.5b01511","EB8","5CS8",17.76,"1.62","1.62","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CS8"
"5CS9",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000. 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CS9",42.6,"2","2","The structure of the NK1 fragment of HGF/SF complexed with MES","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CS9"
"5CSB",,"X-RAY DIFFRACTION",2.18,43.47,"VAPOR DIFFUSION, SITTING DROP",4.5,"30% PEG 4000, 0.1M sodium acetate, 15% glycerol, 0.2M ammonium acetate",293,"10.1038/s41467-018-04078-y",,"5CSB",11.88,"1.719","1.719","The crystal structure of beta2-microglobulin D76N mutant at room temperature","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKNEYACRVNHVTLSQPKIVKWDRDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CSB"
"5CSG",,"X-RAY DIFFRACTION",2.13,42.33,"VAPOR DIFFUSION, SITTING DROP",5.5,"27% PEG 4000, 0.1 M sodium acetate, 15% glycerol, 0.2 M ammonium acetate",293,"10.1038/s41467-018-04078-y",,"5CSG",11.91,"1.5","1.5","The crystal structure of beta2-microglobulin R97Q mutant","MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDQDM","Homo sapiens","B2M, CDABP0092, HDCMA22P","Beta-2-microglobulin","1","5CSG"
"5CSH",,"X-RAY DIFFRACTION",2.24,45.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1039/c6sc02335e","54E","5CSH",84.94,"1.59","1.59","Crystal Structure of CK2alpha with Compound 4 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CSH"
"5CSP",,"X-RAY DIFFRACTION",2.02,39.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c6sc02335e","54G","5CSP",39.3,"1.5","1.5","Crystal Structure of CK2alpha with Compound 5 bound","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CSP"
"5CSQ",,"X-RAY DIFFRACTION",2.31,46.67,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM NA Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CSQ",42.76,"1.95","1.95","The structure of the NK1 fragment of HGF/SF complexed with MOPS","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CSQ"
"5CSV",,"X-RAY DIFFRACTION",2.01,38.71,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c6sc02335e","GAB","5CSV",39.29,"1.375","1.375","Crystal Structure of CK2alpha with Compound 6 bound","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CSV"
"5CSW",,"X-RAY DIFFRACTION",2.25,45.49,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350",277,"10.1158/1535-7163.MCT-15-0617","P06","5CSW",65.13,"2.66","2.66","B-RAF in complex with Dabrafenib","GPRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5CSW"
"5CSX",,"X-RAY DIFFRACTION",2.39,48.58,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350",277,"10.1158/1535-7163.MCT-15-0617","54J","5CSX",32.78,"2.51","2.51","CRYSTAL STRUCTURE OF B-RAF IN COMPLEX WITH BI 882370","GPRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5CSX"
"5CT0",,"X-RAY DIFFRACTION",2.2,44.18,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5CT0",83.61,"2.008","2.008","Crystal structure of CK2alpha with 3-(3-chloro-4-(phenyl)benzylamino)propan-1-ol bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CT0"
"5CT1",,"X-RAY DIFFRACTION",2.31,46.66,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CT1",42.55,"2","2","The structure of the NK1 fragment of HGF/SF complexed with CHES","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CT1"
"5CT2",,"X-RAY DIFFRACTION",2.31,46.8,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CT2",42.79,"2","2","The structure of the NK1 fragment of HGF/SF complexed with CAPS","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CT2"
"5CT3",,"X-RAY DIFFRACTION",2.26,45.62,"VAPOR DIFFUSION, HANGING DROP",,"19% PEG 4000, 200 mM Na Acetate, 150 mM Tris",293,"10.1039/c5sc02155c",,"5CT3",42.48,"2","2","The structure of the NK1 fragment of HGF/SF complexed with 2FA","YVEGQRKRRNTIHEFKKSAKTTLIKIDPALKIKTKKVNTADQCANRCTRNKGLPFTCKAFVFDKARKQCLWFPFNSMSSGVKKEFGHEFDLYENKDYIRNCIIGKGRSYKGTVSITKSGIKCQPWSSMIPHEHSFLPSSYRGKDLQENYCRNPRGEEGGPWCFTSNPEVRYEVCDIPQCSEVE","Homo sapiens","HGF, HPTA","Hepatocyte growth factor","1","5CT3"
"5CT7",,"X-RAY DIFFRACTION",3.71,66.8,"VAPOR DIFFUSION, SITTING DROP",8.4,"12% PEG8000, 0.1 M NaCl, and 0.1 M Tris pH 8.4",277,"10.1021/ml500526p","55J","5CT7",64.86,"3.17","3.17","BRAF in Complex with RAF265","GSDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPK","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5CT7"
"5CTL",,"X-RAY DIFFRACTION",1.92,35.86,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly,pH 7.0",277,"10.1021/acs.jmedchem.5b01511","EB9","5CTL",17.12,"2.51","2.51","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CTL"
"5CTP",,"X-RAY DIFFRACTION",2.25,45.44,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5CTP",83.9,"2.033","2.033","Crystal structure of CK2alpha with N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CTP"
"5CTQ",,"X-RAY DIFFRACTION",2.88,57.26,"VAPOR DIFFUSION, HANGING DROP",,"200mM sodium formate pH 7.5, 30% PEG4000",293,"10.1093/nar/gkw218",,"5CTQ",263.28,"2.6","2.6","Crystal structure of human SART3/TIP110 half-a TPR (HAT) domain","MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGRGSEFENLYFQGNQLEIERLEEQLSINVYDYNCHVDLIRLLRLEGELTKVRMARQKMSEIFPLTEELWLEWLHDEISMAQDGLDREHVYDLFEKAVKDYICPNIWLEYGQYSVGGIGQKGGLEKVRSVFERALSSVGLHMTKGLALWEAYREFESAIVEAARLEKVHSLFRRQLAIPLYDMEATFAEYEEWSEDPIPESVIQNYNKALQQLEKYKPYEEALLQAEAPRLAEYQAYIDFEMKIGDPARIQLIFERALVENCLVPDLWIRYSQYLDRQLKVKDLVLSVHNRAIRNCPWTVALWSRYLLAMERHGVDHQVISVTFEKALNAGFIQATDYVEIWQAYLDYLRRRVDFKQDSSKELEELRAAFTRALEYLKQEVEERFNESGDPSCVIMQNWARIEARLCNNMQKARELWDSIMTRGNAKYANMWLEYYNLERAHGDTQHCRKALHRAVQCTSDYPEHVCEVLLTMERTEGSLEDWDIAVQKTETRLARVNEQRMKAAEKEAALVQQEEEKAEQRKRARAEKKAL","Homo sapiens","SART3, KIAA0156, TIP110","Squamous cell carcinoma antigen recognized by T-cells 3","1","5CTQ"
"5CU0",,"X-RAY DIFFRACTION",2.23,44.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037","54G","5CU0",84.57,"2.18","2.18","Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and N-(3-(3-chloro-4-(phenyl)benzylamino)propyl)acetamide bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CU0"
"5CU2",,"X-RAY DIFFRACTION",2.23,44.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037","54G","5CU2",85.48,"1.705","1.705","Crystal structure of CK2alpha with 2-hydroxy-5-methylbenzoic acid and (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoat bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CU2"
"5CU3",,"X-RAY DIFFRACTION",2.18,43.51,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1039/c6sc02335e","54S","5CU3",84.44,"1.787","1.787","Crystal Structure of CK2alpha with compound 10 bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CU3"
"5CU4",,"X-RAY DIFFRACTION",2,38.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c6sc02335e","54S","5CU4",39.69,"1.56","1.56","Crystal Structure of CK2alpha with Compound 10 bound","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CU4"
"5CU5",,"X-RAY DIFFRACTION",2.86,57,"VAPOR DIFFUSION, HANGING DROP",6.5,"6 mg/ml protein, 7 %(w/v) PEG 8000, 20 %(v/v) ethylene glycol, 69 mM MES, 31 mM imidazole",277,"10.1074/jbc.M115.685909",,"5CU5",227.24,"3.02","3.02","Crystal structure of ERAP2 without catalytic Zn(II) atom","MVHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLKEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESDFTSGGVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCSLRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRHILKSKTDTLDLPEKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVIDRQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVYSVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNLAALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNTRHHHHHH","Homo sapiens","ERAP2, LRAP","Endoplasmic reticulum aminopeptidase 2","1","5CU5"
"5CU6",,"X-RAY DIFFRACTION",2.02,39.23,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c6sc02335e",,"5CU6",39.66,"1.36","1.36","Crystal Structure of CK2alpha","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CU6"
"5CU8",,"X-RAY DIFFRACTION",4.49,72.6,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000, 10% ethylene glycol, 0.1M MES pH 6.0, 0.1M calcium chloride",277,,,"5CU8",13.86,"2.05","2.05","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 2-Amino-6-chlorobenzothiazole (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CU8"
"5CUA",,"X-RAY DIFFRACTION",4.15,70.34,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG600, 0.1M MES pH 6.0",277,,,"5CUA",14.34,"1.89","1.89","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 1-Acetyl-4-(4-hydroxyphenyl)piperazine (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUA"
"5CUB",,"X-RAY DIFFRACTION",4.5,72.7,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000 , 10% ethylene glycol , 0.1M MES pH 6.0 , 0.1M calcium chloride",277,,,"5CUB",13.74,"2.1","2.1","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 314268-40-1 (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUB"
"5CUC",,"X-RAY DIFFRACTION",4.66,73.63,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000, 10% ethylene glycol, 0.1M MES pH 6.0, 0.1M calcium chloride",277,,,"5CUC",13.66,"1.85","1.85","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with N-Acetyl-2-phenylethylamine (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUC"
"5CUD",,"X-RAY DIFFRACTION",4.08,69.85,"VAPOR DIFFUSION, SITTING DROP",6.7,"31.5% PEG600, 0.1M MES pH 6.7",277,,,"5CUD",14.27,"1.75","1.75","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 6-CHLOROPURINE (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUD"
"5CUE",,"X-RAY DIFFRACTION",4.53,72.87,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG6000, 10% ethylene glycol, 0.1M MES pH 6.0, 0.1M calcium chloride",277,,,"5CUE",13.67,"2.08","2.08","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with AGN-PC-04G0SS (SGC - Diamond I04-1 fragment screening)","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFK","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUE"
"5CUF",,"X-RAY DIFFRACTION",3.79,67.52,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES
1.15 M sodium malonate",298,"10.1038/ncomms10025",,"5CUF",277.21,"3.5","3.5","X-ray crystal structure of SeMet human Sestrin2","SNAMIVADSECRAELKDYLRFAPGGVGDSGPGEEQRESRARRGPRGPSAFIPVEEVLREGAESLEQHLGLEALMSSGRVDNLAVVMGLHPDYFTSFWRLHYLLLHTDGPLASSWRHYIAIMAAARHQCSYLVGSHMAEFLQTGGDPEWLLGLHRAPEKLRKLSEINKLLAHRPWLITKEHIQALLKTGEHTWSLAELIQALVLLTHCHSLSSFVFGCGILPEGDADGSPAPQAPTPPSEQSSPPSRDPLNNSGGFESARDVEALMERMQQLQESLLRDEGTSQEEMESRFELEKSESLLVTPSADILEPSPHPDMLCFVEDPTFGYEDFTRRGAQAPPTFRAQDYTWEDHGYSLIQRLYPEGGQLLDEKFQAAYSLTYNTIAMHSGVDTSVLRRAIWNYIHCVFGIRYDDYDYGEVNQLLERNLKVYIKTVACYPEKTTRRMYNLFWRHFRHSEKVHVNLLLLEARMQAALLYALRAITRYMT","Homo sapiens","SESN2, SEST2, Hi95","Sestrin-2","1","5CUF"
"5CUG",,"X-RAY DIFFRACTION",4.12,70.16,"VAPOR DIFFUSION, SITTING DROP",6,"30% PEG600, 0.1M MES pH 6.0",277,,,"5CUG",14.3,"1.78","1.78","Crystal structure of the bromodomain of bromodomain adjacent to zinc finger domain protein 2B (BAZ2B) in complex with 4-Acetamidobenzoic acid (SGC - Diamond I04-1 fragment screening)","YFQSMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKVS","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5CUG"
"5CUH",,"X-RAY DIFFRACTION",2.2,44.03,"VAPOR DIFFUSION, SITTING DROP",7.25,"40% MPEG 5K, pH 7.25, 18% MPEG 2K",293,"10.1016/j.ejmech.2016.01.053","LTQ","5CUH",38.48,"1.83","1.83","Crystal structure MMP-9 complexes with a constrained hydroxamate based inhibitor LT4","GFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYG","Homo sapiens","MMP9, CLG4B","Matrix metalloproteinase-9,Matrix metalloproteinase-9","1","5CUH"
"5CUI",,"X-RAY DIFFRACTION",3.85,68.05,"VAPOR DIFFUSION, HANGING DROP",5.5,"2.5 M sodium chloride, 12% PEG 1500, 1.5% MPD, and 0.1M sodium acetate pH 5.5",294,"10.1016/j.immuni.2018.04.014",,"5CUI",22.51,"2.403","2.403","Crystal structure of Human Defensin-5 R28A mutant.","ATCYCRTGRCATRESLSGVCEISGRLYALCCR","Homo sapiens","DEFA5, DEF5","Defensin-5","1","5CUI"
"5CUJ",,"X-RAY DIFFRACTION",2.4,48.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"3 M sodium chloride, 5% MPD, 0.1 M calcium chloride, and 0.1 M imidazole pH 6.5",294,"10.1016/j.immuni.2018.04.014",,"5CUJ",21.87,"2.08","2.08","Crystal structure of Human Defensin-5 Y27A mutant crystal form 2.","ATCYCRTGRCATRESLSGVCEISGRLARLCCR","Homo sapiens","DEFA5, DEF5","Defensin-5","1","5CUJ"
"5CUM",,"X-RAY DIFFRACTION",2.42,49.2,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.429 M sodium chloride, 9.9% isopropanol, 0.1 M calcium chloride, and 0.1 M imidazole pH 6.5",294,"10.1016/j.immuni.2018.04.014",,"5CUM",10.94,"1.752","1.752","Crystal structure of Human Defensin-5 Y27A mutant crystal form 1.","ATCYCRTGRCATRESLSGVCEISGRLARLCCR","Homo sapiens","DEFA5, DEF5","Defensin-5","1","5CUM"
"5CUZ",,"X-RAY DIFFRACTION",1.8,32.2,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % PEG3350, 0.1M Tris-HCl, pH 7.5, 0.185 M MgCl2, 0.12 M NaF",293,"10.1074/jbc.M115.682435",,"5CUZ",22.07,"2.31","2.31","Crystal structure of SeMet-substituted N-terminal truncated human B12-chaperone CblD (108-296)","GHMSSERHEFVMAQYVNEFQGNDAPVEQEINSAETYFESARVECAIQTCPELLRKDFESLFPEVANGKLMILTVTQKTKNDMTVWSEEVEIEREVLLEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATPDSHIMKKLSGN","Homo sapiens","MMADHC, C2orf25, CL25022, HSPC161, My011","Methylmalonic aciduria and homocystinuria type D protein, mitochondrial","1","5CUZ"
"5CV0",,"X-RAY DIFFRACTION",2.3,46.8,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 % PEG3350, 0.1M Tris-HCl, pH 7.5, 0.2 M MgCl2, 0.1 M NaF",293,"10.1074/jbc.M115.682435",,"5CV0",43.68,"1.9","1.9","Crystal structure of N-terminal truncated human B12-chaperone CblD (108-296)","GHMSSERHEFVMAQYVNEFQGNDAPVEQEINSAETYFESARVECAIQTCPELLRKDFESLFPEVANGKLMILTVTQKTKNDMTVWSEEVEIEREVLLEKFINGAKEICYALRAEGYWADFIDPSSGLAFFGPYTNNTLFETDERYRHLGFSVDDLGCCKVIRHSLWGTHVVVGSIFTNATPDSHIMKKLSGN","Homo sapiens","MMADHC, C2orf25, CL25022, HSPC161, My011","Methylmalonic aciduria and homocystinuria type D protein, mitochondrial","1","5CV0"
"5CVF",,"X-RAY DIFFRACTION",2.01,38.93,"VAPOR DIFFUSION, HANGING DROP",6.5,"112.5mM Mes pH 6.5, 35% glycerol ethoxylate, 180 mM ammonium acetate",298,"10.1039/c6sc02335e",,"5CVF",39.88,"1.63","1.63","Crystal Structure of CK2alpha with Compound 5 bound","SGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVAAAKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CVF"
"5CVG",,"X-RAY DIFFRACTION",1.78,31.05,"VAPOR DIFFUSION, HANGING DROP",6.5,"92mM Mes pH 6.5, 33% glycerol ethoxylate, 750mM ammonium acetate",298,"10.1039/c6sc02335e",,"5CVG",41.62,"1.25","1.25","Crystal Structure of CK2alpha with a novel closed conformation of the aD loop","GSMDIEFDDDADDDGSGSGSGSGSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CVG"
"5CVH",,"X-RAY DIFFRACTION",2.22,44.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1039/c6sc02335e",,"5CVH",85.22,"1.848","1.848","Crystal Structure of CK2alpha","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CVH"
"5CVL",,"X-RAY DIFFRACTION",4.26,71.12,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.72 M sodium phosphate, 0.72 M potassium phosphate, 90 mM HEPES pH 7.5",292,"10.1016/j.str.2015.08.010",,"5CVL",68.72,"3","3","WDR48 (UAF-1), residues 2-580","MHHHHHHGENLYFQGSAAHHRQNTAGRRKVQVSYVIRDEVEKYNRNGVNALQLDPALNRLFTAGRDSIIRIWSVNQHKQDPYIASMEHHTDWVNDIVLCCNGKTLISASSDTTVKVWNAHKGFCMSTLRTHKDYVKALAYAKDKELVASAGLDRQIFLWDVNTLTALTASNNTVTTSSLSGNKDSIYSLAMNQLGTIIVSGSTEKVLRVWDPRTCAKLMKLKGHTDNVKALLLNRDGTQCLSGSSDGTIRLWSLGQQRCIATYRVHDEGVWALQVNDAFTHVYSGGRDRKIYCTDLRNPDIRVLICEEKAPVLKMELDRSADPPPAIWVATTKSTVNKWTLKGIHNFRASGDYDNDCTNPITPLCTQPDQVIKGGASIIQCHILNDKRHILTKDTNNNVAYWDVLKACKVEDLGKVDFEDEIKKRFKMVYVPNWFSVDLKTGMLTITLDESDCFAAWVSAKDAGFSSPDGSDPKLNLGGLLLQALLEYWPRTHVNPMDEEENEVNHVNGEQENRVQKGNGYFQVPPHTPVIFGEAGGRTLFRLLCRDSGGETESMLLNETVPQWVIDITVDKNMPKFNKIPFYLQPHASSGAKTLGNS","Homo sapiens","WDR48, KIAA1449, UAF1","WD repeat-containing protein 48","1","5CVL"
"5CWZ",,"X-RAY DIFFRACTION",2.44,49.54,"VAPOR DIFFUSION, SITTING DROP",6.2,"0.2M Ammonium sulfate, 0.1M Bis-tris (6.2), 35% PEG3350, 9% Ethylene glycol",293,"10.1038/ncomms12586",,"5CWZ",105.23,"2.9","2.9","Crystal structure of the kinase domain of human TRAF2 and NCK-interacting protein kinase","GSGADEIDLSALRDPAGIFELVELVGNGTYGQVYKGRHVKTGQLAAIKVMDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNTKGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDFKSDLWSLGITAIEMAEGAPPLCDMHPMRALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRIQLKDHIDRTKKKRG","Homo sapiens","TNIK, KIAA0551","TRAF2 and NCK-interacting protein kinase","1","5CWZ"
"5CX9",,"X-RAY DIFFRACTION",2.22,44.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"107mM Mes pH 6.5, 29% glycerol ethoxylate, 1 M ammonium acetate",298,"10.1016/j.bmc.2017.04.037",,"5CX9",85.26,"1.732","1.732","Crystal structure of CK2alpha with (methyl 4-((3-(3-chloro-4-(phenyl)benzylamino)propyl)amino)-4-oxobutanoate bound","GSMDIEFDDDADDDGSGSGSGSGSSGPVPSRARVYTDVNTHRPSEYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVK","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5CX9"
"5CXA",,"X-RAY DIFFRACTION",2.29,46.18,"VAPOR DIFFUSION, SITTING DROP",10,"Protein:  hMMP12 F171D K241A at 608 micro-M + 10 milli-M AHA + 0.552 milli-M inhibitor. precipitant: 26% PEG4000, 3% dioxane, 0.114 M TRIS pH 10. cryoprotectant: 10 % diethylene glycol + 5 % glycerol + 10 % 2,3-butanediol + 5 % 1,4-dioxane, 25% PEG 6K, 0.1 M TRIS-HCl, pH 8.0",293,"10.1021/acs.jmedchem.6b01420",,"5CXA",18.45,"1.3","1.3","Crystal structure of the catalytic domain of Human MMP12 in complex with a carboxylate inhibitor related to RXP470","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYAYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5CXA"
"5CXH",,"X-RAY DIFFRACTION",2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",7.3,"20% PEG3350, 0.2M potassium fluoride, no buffer pH 7.3",277,"10.1016/j.bmcl.2015.08.037","55M","5CXH",34.07,"1.9","1.9","SYK catalytic domain complexed with a potent orally bioavailable thiazole inhibitor","MALEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVTDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVNHHHHHH","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5CXH"
"5CXY",,"X-RAY DIFFRACTION",2.9,61.69,"VAPOR DIFFUSION, HANGING DROP",7.3,"130 mM (NH)4H2PO4, 22% PEG2000 and 50 mM PIPES pH 7.3",293,,,"5CXY",80.24,"2.15","2.15","Structure of a Glycosyltransferase in Complex with Inhibitor","APEHHHHHHDYDIPTTENLYFQGQELQEKPSKWKFNRTAFLHQRQEILQHVDVIKNFSLTKNSVRIGQLMHYDYSSHKYVFSISNNFRSLLPDVSPIMNKHYNICAVVGNSGILTGSQCGQEIDKSDFVFRCNFAPTEAFQRDVGRKTNLTTFNPSILEKYYNNLLTIQDRNNFFLSLKKLDGAILWIPAFFFHTSATVTRTLVDFFVEHRGQLKVQLAWPGNIMQHVNRYWKNKHLSPKRLSTGILMYTLASAICEEIHLYGFWPFGFDPNTREDLPYHYYDKKGTKFTTKWQESHQLPAEFQLLYRMHGEGLTKLTLSHCA","Homo sapiens","ST8SIA3, SIAT8C","Sia-alpha-2,3-Gal-beta-1,4-GlcNAc-R:alpha 2,8-sialyltransferase","1","5CXY"
"5CXZ",,"X-RAY DIFFRACTION",2.44,49.68,"VAPOR DIFFUSION, SITTING DROP",,"PEG 3350 15%, cesium chloride 0.15M",293,"10.1016/j.bmcl.2015.08.037","55U","5CXZ",34.12,"1.7","1.7","SYK catalytic domain complexed with naphthyridine inhibitor","MALEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVTDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVNHHHHHH","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5CXZ"
"5CY3",,"X-RAY DIFFRACTION",2.17,43.38,"VAPOR DIFFUSION, SITTING DROP",7.1,"PEG 3350 20%, ammonium acetate 0.2M",293,"10.1016/j.bmcl.2015.08.037","55Y","5CY3",34.2,"1.76","1.76","SYK catalytic domain complexed with a potent and orally bioavailable benzisothiazole inhibitor","MALEEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVTDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVNEGHHHHHH","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5CY3"
"5CY9",,"X-RAY DIFFRACTION",2.57,52.13,"VAPOR DIFFUSION, SITTING DROP",7.8,"20% PEG3350, 0.2M NaCl, 0.1M HEPES, 10% EtGhly,pH 7.8",277,"10.1021/acs.jmedchem.5b01511","E0A","5CY9",17.38,"1.55","1.55","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5CY9"
"5CYH",,"X-RAY DIFFRACTION",2.66,53.81,,,,,"10.1021/bi960278x",,"5CYH",18.1,"2.1","2.1","CYCLOPHILIN A COMPLEXED WITH DIPEPTIDE GLY-PRO","VNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","CYCLOPHILIN, PPIA, CYPA","CYCLOPHILIN A","1","5CYH"
"5CYJ",,"X-RAY DIFFRACTION",2.03,39.38,"VAPOR DIFFUSION",8.5,"0.2 M lithium sulfate, 0.1M Tris-HCl pH 8.5, 40% (v/v) PEG 400",293,"10.1017/S0033583515000207",,"5CYJ",22.37,"1.79","1.79","X-ray structure of human RBPMS","SEANLQEEEVRTLFVSGLPLDIKPRELYLLFRPFKGYEGSLIKLTSKQPVGFVSFDSRSEAEAAKNAMNGIRFDPEIPQTLRLEFAKANTKMAKNKLV","Homo sapiens","RBPMS, HERMES","RNA-binding protein with multiple splicing","1","5CYJ"
"5CYO",,"X-RAY DIFFRACTION",2.64,53.47,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG1500, 20% Glycerol",291,,,"5CYO",64.74,"2.0354","2.0354","High resolution Septin 9 GTPase domain in complex with GDP","QGFEFNIMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTVIDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGHSLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDEDSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLLIRTHMQNIKDITSSIHFEAYRVKRLNEG","Homo sapiens","SEPT9, KIAA0991, MSF, SEPTIN9","Septin-9","1","5CYO"
"5CYP",,"X-RAY DIFFRACTION",2.48,50.32,"VAPOR DIFFUSION, HANGING DROP",6.9,"20% PEG1500, 20% Glycerol",291,,,"5CYP",130.16,"2.893","2.893","GTPase domain of Septin 9 in complex with GTP-gamma-S","MKQGFEFNIMVVGQSGLGKSTLINTLFKSKISRKSVQPTSEERIPKTIEIKSITHDIEEKGVRMKLTVIDTPGFGDHINNENCWQPIMKFINDQYEKYLQEEVNINRKKRIPDTRVHCCLYFIPATGHSLRPLDIEFMKRLSKVVNIVPVIAKADTLTLEERVHFKQRITADLLSNGIDVYPQKEFDEDSEDRLVNEKFREMIPFAVVGSDHEYQVNGKRILGRKTKWGTIEVENTTHCEFAYLRDLLIRTHMQNIKDITSSIHFEAYRVKRLN","Homo sapiens","SEPT9, KIAA0991, MSF, SEPTIN9","Septin-9","1","5CYP"
"5CZM",,"X-RAY DIFFRACTION",2.23,44.89,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : MMP12h F67D K241A 850 micro-M + 10mM AHA
Drop : 1 micro-L protein + 0.35 micro-l inhibitor(1.5 milli-M, DMSO)
Precipitant : 20% PEG4K, 0.2 M TRIS pH9.5
Cryo protectant : 5% diethylene glycol, 0% ethylene glycol, 5% MPD + 5% glycerol, 5% 2,3-butanediol, 5mM NDSB 201, 25% PEG 6K, 100mM TRIS HCl, pH 8.0",293,"10.1021/acs.jmedchem.6b01420","R47","5CZM",18.63,"1.303","1.303","Crystal structure of a mutated catalytic domain of Human MMP12 in complex with RXP470","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYAYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5CZM"
"5CZR",,"X-RAY DIFFRACTION",3.09,60.2,"VAPOR DIFFUSION, SITTING DROP",7.3,"0.2 M MgCl
0.1 M HEPES pH 7.3
10% PEF 4000",277,,,"5CZR",99.67,"2.3","2.3","Crystal Structure of Human Protocadherin-24 EC1-2","MNVAPKFLANMTSVILPEDLPVGAQAFWLVAEDQDNDPLTYGMSGPNAYFFAVTPKTGEVKLASALDYETLYTFKVTISVSDPYIQVQREMLVIVEDRNDNAPVFQNTAFSTSINETLPVGSVVFSVLAVDKDMGSAGMVVYSIEKVIPSTGDSEHLFRILANGSIVLNGSLSYNNKSAFYQLELKACDLGGMYHNTFTIQCSLPVFLSISVVDQPDLEHHHHHH","Homo sapiens","CDHR2, PCDH24, PCLKC","Cadherin-related family member 2","1","5CZR"
"5D0C",,"X-RAY DIFFRACTION",1.95,36.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly,pH 7.5",277,"10.1021/acs.jmedchem.5b01511","E0B","5D0C",17.59,"1.49","1.49","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","MKKGHHHHHHLVPRGSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D0C"
"5D0I",,"X-RAY DIFFRACTION",3.4,63.86,"VAPOR DIFFUSION, HANGING DROP",,"HEPES, sodium chloride, ammonium sulfate, ethylene glycol",291.15,"10.1038/nsmb.3142",,"5D0I",22.39,"1.9","1.9","Structure of RING finger protein 165","GPLGSGAVQNTIERFTFPHKYKKRRPQDGKGKKDEGEESDTDEKCTICLSMLEDGEDVRRLPCMHLFHQLCVDQWLAMSKKCPICRVDIETQLGADS","Homo sapiens","RNF165","RING finger protein 165","1","5D0I"
"5D0R",,"X-RAY DIFFRACTION",2.63,53.25,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M SODIUM ACETATE PH 4.8, 0.2 M TRI-SODIUM-CITRATE, 15% (W/V) PEG 4000, 10% (V/V) GLYCEROL",277,"10.1074/jbc.M115.708255","B1T","5D0R",55.48,"2.24","2.24","Crystal structure of human soluble Adenylyl Cyclase with the inhibitor bithionol","MNTPKEEFQDWPIVRIAAHLPDLIVYGHFSPERPFMDYFDGVLMFVDISGFTAMTEKFSSAMYMDRGAEQLVEILNYHISAIVEKVLIFGGDILKFAGDALLALWRVERKQLKNIITVVIKCSLEIHGLFETQEWEEGLDIRVKIGLAAGHISMLVFGDETHSHFLVIGQAVDDVRLAQNMAQMNDVILSPNCWQLCDRSMIEIESVPDQRAVKVNFLKPPPNFNFDEFFTKCTTFMHYYPSGEHKNLLRLACTLKPDPELEMSLQKYVMESILKQIDNKQLQGYLSELRPVTIVFVNLMFEDQDKAEEIGPAIQDAYMHITSVLKIFQGQINKVFMFDKGCSFLCVFGFPGEKVPDELTHALECAMDIFDFCSQVHKIQTVSIGVASGIVFCGIVGHTVRHEYTVIGQKVNLAARMMMYYPGIVTCDSVTYNGSNLPAYFFKELPKKVMKGVADSGPLYQYWGRTEKVHHHHHH","Homo sapiens","ADCY10, SAC","Adenylate cyclase type 10","1","5D0R"
"5D14",,"X-RAY DIFFRACTION",2.49,50.65,"VAPOR DIFFUSION",5.6,"0.17 M Ammonium acetate, 0.085 M Sodium citrate tribasic dihydrate pH 5.6, 20% w/v Polyethylene glycol 4,000, 15% v/v Glycerol. All crystals were grown at 18 deg C.",291,,,"5D14",8.24,"1","1","The atomic resolution crystal structure of human IL-8","KELRCQCIKTYSKPFHPKFIKELRVIESGPHCANTEIIVKLSDGRELCLDPKENWVQRVVEKFLKRAENS","Homo sapiens","CXCL8, IL8","Interleukin-8","1","5D14"
"5D1B",,"X-RAY DIFFRACTION",2.4,48.81,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM BisTris (pH 6.5), 10% (w/v) PEG 35000, 4 mM TCEP",294,"10.1021/acs.biochem.5b00881","TSN","5D1B",87.5,"2.9","2.9","Crystal structure of G117E HDAC8 in complex with TSA","MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGEATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVVIEGRGSHHHHHH","Homo sapiens","HDAC8, HDACL1, CDA07","Histone deacetylase 8","1","5D1B"
"5D1J",,"X-RAY DIFFRACTION",2.09,41.06,"VAPOR DIFFUSION, HANGING DROP",,"35% poly(ethylene glycol) 5000 monomethyl ester, 0.2 M ammonium acetate, 0.1 M HEPES, pH 7.0,",316,"10.1021/jm0305568","56H","5D1J",34.36,"1.8","1.8","CRYSTAL STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2-WT) COMPLEX WITH N-[5-[[[5-(1,1-DIMETHYLETHYL)-2-OXAZOLYL] METHYL]THIO]-2-THIAZOLYL]-4-PIPERIDINECARBOXAMIDE (BMS-387032)","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5D1J"
"5D1Y",,"X-RAY DIFFRACTION",10.3,88,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM HEPES, 32% v/v Jeffamine M600, 10 mM DTT",293,"10.1021/acs.biochem.5b01207",,"5D1Y",184.7,"9.005","9.005","Low resolution crystal structure of human ribonucleotide reductase alpha6 hexamer in complex with dATP","MGSSHHHHHHSSGLVPRGSHMHVIKRDGRQERVMFDKITSRIQKLCYGLNMDFVDPAQITMKVIQGLYSGVTTVELDTLAAETAATLTTKHPDYAILAARIAVSNLHKETKKVFSDVMEDLYNYINPHNGKHSPMVAKSTLDIVLANKDRLNSAIIYDRDFSYNYFGFKTLERSYLLKINGKVAERPQHMLMRVSVGIHKEDIDAAIETYNLLSERWFTHASPTLFNAGTNRPQLSSCFLLSMKDDSIEGIYDTLKQCALISKSAGGIGVAVSCIRATGSYIAGTNGNSNGLVPMLRVYNNTARYVDQGGNKRPGAFAIYLEPWHLDIFEFLDLKKNTGKEEQRARDLFFALWIPDLFMKRVETNQDWSLMCPNECPGLDEVWGEEFEKLYASYEKQGRVRKVVKAQQLWYAIIESQTETGTPYMLYKDSCNRKSNQQNLGTIKCSNLCTEIVEYTSKDEVAVCNLASLALNMYVTSEHTYDFKKLAEVTKVVVRNLNKIIDINYYPVPEACLSNKRHRPIGIGVQGLADAFILMRYPFESAEAQLLNKQIFETIYYGALEASCDLAKEQGPYETYEGSPVSKGILQYDMWNVTPTDLWDWKVLKEKIAKYGIRNSLLIAPMPTASTAQILGNNESIEPYTSNIYTRRVLSGEFQIVNPHLLKDLTERGLWHEEMKNQIIACNGSIQSIPEIPDDLKQLYKTVWEISQKTVLKMAAERGAFIDQSQSLNIHIAEPNYGKLTSMHFYGWKQGLKTGMYYLRTRPAANPIQFTLNKEKLKDKEKVSKEEEEKERNTAAMVCSLENRDECLMCGS","Homo sapiens","RRM1, RR1","Ribonucleoside-diphosphate reductase large subunit","1","5D1Y"
"5D24",,"X-RAY DIFFRACTION",2.17,43.36,"VAPOR DIFFUSION, SITTING DROP",,"ammonium acetate, (+/-)-2-Methyl-2,4-methylpentanediol, Bis-tris",298,"10.1021/acs.jmedchem.5b01267","L26","5D24",15.6,"1.65","1.65","First bromodomain of BRD4 bound to inhibitor XD26","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D24"
"5D25",,"X-RAY DIFFRACTION",1.9,35.1,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Hepes",293,"10.1021/acs.jmedchem.5b01267","56M","5D25",15.6,"1.7","1.7","First bromodomain of BRD4 bound to inhibitor XD27","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D25"
"5D26",,"X-RAY DIFFRACTION",1.89,34.76,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Hepes, magnesium chloride",293,"10.1021/acs.jmedchem.5b01267","L28","5D26",15.7,"1.82","1.82","First bromodomain of BRD4 bound to inhibitor XD28","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D26"
"5D27",,"X-RAY DIFFRACTION",2.23,44.86,"VAPOR DIFFUSION, HANGING DROP",5.7,"Bis Tris, Magnesium chloride, PEG 3350",294,"10.1016/j.str.2016.02.022",,"5D27",19.35,"1.92","1.92","Crystal Structure of the P-Rex1 PH domain","GEFEKLEALEQLQSHIEGWEGSNLTDICTQLLLQGTLLKISAGNIQERAFFLFDNLLVYCKRKSRVTGSKKSTKRTKSINGSLYIFRGRINTEVMEVENVEDGTADYHSNGYTVTNGWKIHNTAKNKWFVCMAKTAEEKQKWLDAIIREREQRESLKLGMERDAYVM","Homo sapiens","PREX1, KIAA1415","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein","1","5D27"
"5D29",,"X-RAY DIFFRACTION",3.28,62.48,"VAPOR DIFFUSION, HANGING DROP",8,"34% (v/v) pentaerythritol propoxylate PO/OH 5/4, 2 % (w/v) PEG 3350, and 100 mM Tris-HCl, pH 8.0",288,"10.1021/acs.jmedchem.5b01806","5Q1","5D29",81.37,"1.8","1.8","X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a hydroxamate inhibitor JHU241","HNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5D29"
"5D2B",,"X-RAY DIFFRACTION",2.27,45.81,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : hMMP12 F171D at 820 micro-M + 10 milli-M AHA + 0.708 milli-M inhibitor.
Precipitant : 20% PEG4000, 0.2 M TRIS pH 9.5
Cryoprotectant : 10 % diethylene glycol + 5 % glycerol + 10 % 1,2-propanediol + 5 % 1,4-dioxane + 25% PEG6000 +  0.1 M TRIS HCl pH 8.0",293,"10.1021/acs.jmedchem.6b01420",,"5D2B",18.52,"1.2","1.2","Crystal structure of a mutated catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5D2B"
"5D3A",,"X-RAY DIFFRACTION",3.61,65.92,"VAPOR DIFFUSION, HANGING DROP",4,"0.1 M citric acid, 10 % w/v PEG 6000",293.15,,,"5D3A",19.17,"2.495","2.495","KIF21A regulatory coiled coil","GSMTISNMEADMNRLLKQREELTKRREKLSKRREKIVKENGEGDKNVANINEEMESLTANIDYINDSISDCQANIMQMEEAK","Homo sapiens","KIF21A, KIAA1708, KIF2","Kinesin-like protein KIF21A","1","5D3A"
"5D3C",,"X-RAY DIFFRACTION",2.25,45.38,"VAPOR DIFFUSION, SITTING DROP",9.5,"Protein : MMP12 F67D K241A, 1 mili-M + 10 mili-M AHA
Drop : 1 micro-L protein + 0.2 micro-L inhibitor (5 mili-M in DMSO)
Precipitant : 20% PEG4000, 0.2 M TRIS pH 9.5
Cryoprotectant : 10 % diethylene glycol + 5 % glycerol + 10 % 2,3-butanediol + 5 % 1,4-dioxane +25% PEG6000,+ 100 mili-M TRIS HCl, pH 8.",293,"10.1021/acs.jmedchem.6b01420",,"5D3C",18.47,"1.314","1.314","Crystal structure of a double mutant catalytic domain of Human MMP12 in complex with an hydroxamate analogue of RXP470","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYAYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5D3C"
"5D3H",,"X-RAY DIFFRACTION",1.86,34.03,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Bis-tris",293,"10.1021/acs.jmedchem.5b01267","57G","5D3H",15.45,"1.7","1.7","First bromodomain of BRD4 bound to inhibitor XD29","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3H"
"5D3J",,"X-RAY DIFFRACTION",1.88,34.72,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Hepes, magnesium chloride",293,"10.1021/acs.jmedchem.5b01267","L33","5D3J",15.42,"1.7","1.7","First bromodomain of BRD4 bound to inhibitor XD33","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3J"
"5D3L",,"X-RAY DIFFRACTION",1.92,36.1,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Bis-tris, ammonium acetate",293,"10.1021/acs.jmedchem.5b01267","57F","5D3L",15.53,"1.5","1.5","First bromodomain of BRD4 bound to inhibitor XD35","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3L"
"5D3N",,"X-RAY DIFFRACTION",2.24,45.08,"VAPOR DIFFUSION, SITTING DROP",,"Tacsimate",293,"10.1021/acs.jmedchem.5b01267","L40","5D3N",15.39,"2.15","2.15","First bromodomain of BRD4 bound to inhibitor XD40","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3N"
"5D3O",,"X-RAY DIFFRACTION",2.79,55.85,"VAPOR DIFFUSION, HANGING DROP",8,"15% PEG6000, 1.0M LiCl, 0.1M Tris-HCL, pH8.0",293,,,"5D3O",116.05,"2.791","2.791","Crystal structure of full length human glutaminase C expressed in E.coli","LSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTADGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5D3O"
"5D3P",,"X-RAY DIFFRACTION",2.24,45.19,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Bis-Tris, lithium sulfate",293,"10.1021/acs.jmedchem.5b01267","57E","5D3P",15.55,"1.95","1.95","First bromodomain of BRD4 bound to inhibitor XD41","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3P"
"5D3Q",,"X-RAY DIFFRACTION",2.25,45.4,"VAPOR DIFFUSION, HANGING DROP",8,"Before crystallization set-ups, GG1 at a concentration of 10 mg/ml was supplemented with 2 mM GDP and 2 mM MgCl2 and incubated for 1 h on ice. GG1GDP was crystallized by hanging drop vapour diffusion mixing 1.5 ul protein solution with 1.5 ul reservoir solution containing 0.1 M Tris (pH 8.0), 26 % PEG 3350 and 0.2 M NaSCN. The drops were equilibrated against 700 ul of reservoir.",277,"10.1016/j.bbrc.2015.11.074",,"5D3Q",78.06,"1.7","1.7","Dynamin 1 GTPase-BSE fusion dimer complexed with GDP","GMEDLIPLVNRLQDAFSAIGQNADLDLPQIAVVGGQSAGKSSVLENFVGRDFLPRGSGIVTRRPLVLQLVNATTEYAEFLHCKGKKFTDFEEVRLEIEAETDRVTGTNKGISPVPINLRVYSPHVLNLTLVDLPGMTKVPVGDQPPDIEFQIRDMLMQFVTKENCLILAVSPANSDLANSDALKVAKEVDPQGQRTIGVITKLDLMDEGTDARDVLENKLLPLRRGYIGVVNRSQKDIDGKKDITAALAAERKFFLSHPSYRHLADRMGTPYLQKVLNQQLTNHIRDTLPGLRNKLQSQLLSIEKEVEEYKNFRPDKHGTDSRVDEMLRMYHALKEALSIIGDIN","Homo sapiens","DNM1, DNM","Dynamin-1,Dynamin-1","1","5D3Q"
,,,,,,,,,,,,,,,,,"Homo sapiens","DNM1, DNM"
"5D3R",,"X-RAY DIFFRACTION",1.87,34.3,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Bis-tris, sodium chloride",293,"10.1021/acs.jmedchem.5b01267",,"5D3R",15.54,"2.2","2.2","First bromodomain of BRD4 bound to inhibitor XD42","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3R"
"5D3S",,"X-RAY DIFFRACTION",1.88,34.61,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, Bis-Tris",293,"10.1021/acs.jmedchem.5b01267","579","5D3S",15.62,"1.75","1.75","First bromodomain of BRD4 bound to inhibitor XD44","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3S"
"5D3T",,"X-RAY DIFFRACTION",2.16,43.11,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, succinic acid",293,"10.1021/acs.jmedchem.5b01267","56Y","5D3T",15.53,"1.93","1.93","First bromodomain of BRD4 bound to inhibitor XD47","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5D3T"
"5D3V",,"X-RAY DIFFRACTION",2.09,41.29,"VAPOR DIFFUSION, HANGING DROP",5,"Sodium citrate, PEG 8000",294,"10.1016/j.str.2016.02.022",,"5D3V",38.76,"1.852","1.852","Crystal Structure of the P-Rex1 PH domain with Citrate Bound","GEFEKLEALEQLQSHIEGWEGSNLTDICTQLLLQGTLLKISAGNIQERAFFLFDNLLVYCKRKSRVTGSKKSTKRTKSINGSLYIFRGRINTEVMEVENVEDGTADYHSNGYTVTNGWKIHNTAKNKWFVCMAKTAEEKQKWLDAIIREREQRESLKLGMERDAYVM","Homo sapiens","PREX1, KIAA1415","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein","1","5D3V"
"5D3W",,"X-RAY DIFFRACTION",2.13,42.32,"VAPOR DIFFUSION, HANGING DROP",5.7,"Bis Tris, Ammonium sulfate, PEG 3350",294,"10.1016/j.str.2016.02.022",,"5D3W",38.86,"1.852","1.852","Crystal Structure of the P-Rex1 PH domain with Sulfate Bound","GEFEKLEALEQLQSHIEGWEGSNLTDICTQLLLQGTLLKISAGNIQERAFFLFDNLLVYCKRKSRVTGSKKSTKRTKSINGSLYIFRGRINTEVMEVENVEDGTADYHSNGYTVTNGWKIHNTAKNKWFVCMAKTAEEKQKWLDAIIREREQRESLKLGMERDAYVM","Homo sapiens","PREX1, KIAA1415","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein","1","5D3W"
"5D3X",,"X-RAY DIFFRACTION",2.06,40.33,"VAPOR DIFFUSION, HANGING DROP",6.5,"HEPES, Jeffamine ED-2001 pH 7",294,"10.1016/j.str.2016.02.022","4IP","5D3X",39.57,"1.69","1.69","Crystal Structure of the P-Rex1 PH domain with Inositol-(1,3,4,5)-Tetrakisphosphate Bound","GEFEKLEALEQLQSHIEGWEGSNLTDICTQLLLQGTLLKISAGNIQERAFFLFDNLLVYCKRKSRVTGSKKSTKRTKSINGSLYIFRGRINTEVMEVENVEDGTADYHSNGYTVTNGWKIHNTAKNKWFVCMAKTAEEKQKWLDAIIREREQRESLKLGMERDAYVM","Homo sapiens","PREX1, KIAA1415","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein","1","5D3X"
"5D3Y",,"X-RAY DIFFRACTION",2.2,44.01,"VAPOR DIFFUSION, HANGING DROP",6.2,"Bis Tris, polypropylene glycol P400",294,"10.1016/j.str.2016.02.022","4IP","5D3Y",39.57,"1.95","1.95","Crystal Structure of the P-Rex1 PH domain with Inositol-(1,3,4,5)-Tetrakisphosphate Bound","GEFEKLEALEQLQSHIEGWEGSNLTDICTQLLLQGTLLKISAGNIQERAFFLFDNLLVYCKRKSRVTGSKKSTKRTKSINGSLYIFRGRINTEVMEVENVEDGTADYHSNGYTVTNGWKIHNTAKNKWFVCMAKTAEEKQKWLDAIIREREQRESLKLGMERDAYVM","Homo sapiens","PREX1, KIAA1415","Phosphatidylinositol 3,4,5-trisphosphate-dependent Rac exchanger 1 protein","1","5D3Y"
"5D41",,"X-RAY DIFFRACTION",2.84,56.65,"VAPOR DIFFUSION, HANGING DROP",5.5,"Bis-Tris, PEG3350",298,"10.1038/nature17960","57N","5D41",76.86,"2.31","2.31","EGFR kinase domain in complex with mutant selective allosteric inhibitor","GSTSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5D41"
"5D45",,"X-RAY DIFFRACTION",1.93,36.42,"VAPOR DIFFUSION, SITTING DROP",,"2.4 M NaH2PO4/K2HPO4",296,"10.1021/acsmedchemlett.6b00040","57P","5D45",17.29,"1.65","1.65","Crystal Structure of FABP4 in complex with 3-(5-cyclopropyl-2,3-diphenyl-1H-indol-1-yl)propanoic acid","MGSSHHHHHHSSGLVPRGSHMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5D45"
"5D47",,"X-RAY DIFFRACTION",1.92,36.08,"VAPOR DIFFUSION, SITTING DROP",,"2.4 M NaH2PO4/K2HPO4",296,"10.1021/acsmedchemlett.6b00040","L19","5D47",17.32,"1.7","1.7","Crystal Structure of FABP4 in complex with 3-[5-cyclopropyl-3-(3-methoxypyridin-4-yl)-2-phenyl-1H-indol-1-yl] propanoic acid","MGSSHHHHHHSSGLVPRGSHMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5D47"
"5D48",,"X-RAY DIFFRACTION",1.9,35.41,"VAPOR DIFFUSION, SITTING DROP",,"2.4 M NaH2PO4/K2HPO4",296,"10.1021/acsmedchemlett.6b00040","L96","5D48",17.56,"1.81","1.81","Crystal Structure of FABP4 in complex with 3-{5-cyclopropyl-3-(3,5-dimethyl-1H-pyrazol-4-yl)-2-[3-(propan-2-yloxy) phenyl]-1H-indol-1-yl}propanoic acid","MGSSHHHHHHSSGLVPRGSHMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5D48"
"5D4A",,"X-RAY DIFFRACTION",1.9,35.17,"VAPOR DIFFUSION, SITTING DROP",,"2.4 M NaH2PO4/K2HPO4",296,"10.1021/acsmedchemlett.6b00040","57Q","5D4A",17.18,"1.7","1.7","Crystal Structure of FABP4 in complex with 3-(2-phenyl-1H-indol-1-yl)propanoic acid","MGSSHHHHHHSSGLVPRGSHMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5D4A"
"5D4K",,"X-RAY DIFFRACTION",3.45,64.38,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M ammonium sulfate, 0.1M BisTris pH 5.5, 31% Polyethylene glycol 3350",295,"10.7554/eLife.10640",,"5D4K",125.41,"2.599","2.599","Crystal structure of the human polymeric Ig receptor (pIgR) ectodomain","KSPIFGPEEVNSVEGNSVSITCYYPPTSVNRHTRKYWCRQGARGGCITLISSEGYVSSKYAGRANLTNFPENGTFVVNIAQLSQDDSGRYKCGLGINSRGLSFDVSLEVSQGPGLLNDTKVYTVDLGRTVTINCPFKTENAQKRKSLYKQIGLYPVLVIDSSGYVNPNYTGRIRLDIQGTGQLLFSVVINQLRLSDAGQYLCQAGDDSNSNKKNADLQVLKPEPELVYEDLRGSVTFHCALGPEVANVAKFLCRQSSGENCDVVVNTLGKRAPAFEGRILLNPQDKDGSFSVVITGLRKEDAGRYLCGAHSDGQLQEGSPIQAWQLFVNEESTIPRSPTVVKGVAGSSVAVLCPYNRKESKSIKYWCLWEGAQNGRCPLLVDSEGWVKAQYEGRLSLLEEPGNGTFTVILNQLTSRDAGFYWCLTNGDTLWRTTVEIKIIEGEPNLKVPGNVTAVLGETLKVPCHFPCKFSSYEKYWCKWNNTGCQALPSQDEGPSKAFVNCDENSRLVSLTLNLVTRADEGWYWCGVKQGHFYGETAAVYVAVEERGSWSHPQFEK","Homo sapiens","PIGR","Polymeric immunoglobulin receptor","1","5D4K"
"5D4Q",,"X-RAY DIFFRACTION",2.53,51.31,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M ammonium formate and 20% (w/v) PEG 3350",293.15,"10.1016/j.jsb.2016.02.001",,"5D4Q",53.06,"2.39","2.39","Crystal structure of GASDALIE IgG1 Fc","CPPCPAPELLAGPDVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPLPEEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPG","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5D4Q"
"5D65",,"X-RAY DIFFRACTION",4.7,73.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Tris, pH 7.0; 1.8M (NH4)2SO4;",291.15,"10.1073/pnas.1523981113",,"5D65",42.03,"3.1","3.1","X-RAY STRUCTURE OF MACROPHAGE INFLAMMATORY PROTEIN-1 ALPHA (CCL3) WITH HEPARIN COMPLEX","ASLAADTPTACCFSYTSRQIPQNFIADYFETSSQCSKPGVIFLTKRSRQVCADPSEEWVQKYVSDLELSA","Homo sapiens","CCL3, G0S19-1, MIP1A, SCYA3","C-C motif chemokine 3","1","5D65"
"5D67",,"X-RAY DIFFRACTION",2.15,42.91,"VAPOR DIFFUSION, SITTING DROP",,"30% polyethylene glycol 4000, 0.2M ammonium sulfate",277,,,"5D67",48.56,"2","2","Crystal structure of an EF-Hand calcium binding domain of CAP-Binding Protein Complex-Interacting Protein 1 (EFCAB6) from Homo sapiens at 2.00 A resolution","GATADRDILARLHKAVTSHYHAITQEFENFDTMKTNTISREEFRAICNRRVQILTDEQFGRLWNEMPVNAKGRLKYPDFLSRFSSETAATPMATGDSAVAQR","Homo sapiens","EFCAB6, DJBP, KIAA1672","EF-hand calcium-binding domain-containing protein 6","1","5D67"
"5D68",,"X-RAY DIFFRACTION",3.19,61.44,"VAPOR DIFFUSION, HANGING DROP",7.3,"0.05 M HEPES, pH 7.3, 8% ethylene glycol, 8% PEG8000",298,"10.1016/j.jsb.2015.10.006",,"5D68",168.46,"2.908","2.908","Crystal structure of KRIT1 ARD-FERM","GSDILQGTDYSKIQIPKQEKWQRSMSSVTEDKERQWVDDFPLHRSACEGDSELLSRLLSERFSVNQLDSDHWAPIHYACWYGKVEATRILLEKGKCNPNLLNGQLSSPLHFAAGGGHAEIVQILLNHPETDRHITDQQGRSPLNICEENKQNNWEEAAKLLKEAINKPYEKVRIYRMDGSYRSVELKHGNNTTVQQIMEGMRLSQETQQYFTIWICSENLSLQLKPYHKPLQHVRDWPEILAELTNLDPQRETPQLFLRRDVRLPLEVEKQIEDPLAILILFDEARYNLLKGFYTAPDAKLITLASLLLQIVYGNYESKKHKQGFLNEENLKSIVPVTKLKSKAPHWTNRILHEYKNLSTSEGVSKEMHHLQRMFLQNCWEIPTYGAAFFTGQIFTKASPSNHKVIPVYVGVNIKGLHLLNMETKALLISLKYGCFMWQLGDTDTCFQIHSMENKMSFIVHTKQAGLVVKLLMKLNGQLMPTERNS","Homo sapiens","KRIT1, CCM1","Krev interaction trapped protein 1","1","5D68"
"5D69",,"X-RAY DIFFRACTION",2.84,56.74,"VAPOR DIFFUSION, SITTING DROP",,"12% PEG6000, 20 MM CACL2, 50 MM CACODYLATE BUFFER, PH7.4",293,"10.1039/c5sc01158b",,"5D69",41.67,"1.97","1.97","Human calpain PEF(S) with (2Z,2Z')-2,2'-disulfanediylbis(3-(6-iodoindol-3-yl)acrylic acid) bound","EEVRQFRRLFAQLAGDDMEVSATELMNILNKVVTRHPDLKTDGFGIDTCRSMVAVMDSDTTGKLGFEEFKYLWNNIKRWQAIYKQFDTDRSGTICSSELPGAFEAAGFHLNEHLYNMIIRRYSDESGNMDFDNFISCLVRLDAMFRAFKSLDKDGTGQIQVNIQEWLQLTMYS","Homo sapiens","CAPNS1, CAPN4, CAPNS","Calpain small subunit 1","1","5D69"
"5D6B",,"X-RAY DIFFRACTION",2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",5,"100 mM sodium malonate, 12% polyethylene glycol (PEG) 3350",293,"10.1107/S2053230X13033955",,"5D6B",49.74,"2.1","2.1","Human fumarase (wild type)","SFRIEYDTFGELKVPNDKYYGAQTVRSTMNFKIGGVTERMPTPVIKAFGILKRAAAEVNQDYGLDPKIANAIMKAADEVAEGKLNDHFPLVVWQTGSGTQTNMNVNEVISNRAIEMLGGELGSKIPVHPNDHVNKSQSSNDTFPTAMHIAAAIEVHEVLLPGLQKLHDALDAKSKEFAQIIKIGRTHTQDAVPLTLGQEFSGYVQQVKYAMTRIKAAMPRIYELAAGGTAVGTGLNTRIGFAEKVAAKVAALTGLPFVTAPNKFEALAAHDALVELSGAMNTTACSLMKIANDIRFLGSGPRSGLGELILPENEPGSSIMPGKVNPTQCEAMTMVAAQVMGNHVAVTVGGSNGHFELNVFKPMMIKNVLHSARLLGDASVSFTENCVVGIQANTERINKLMNESLMLVTALNPHIGYDKAAKIAKTAHKNGSTLKETAIELGYLTAEQFDEWVKPKDMLGPK","Homo sapiens","FH","Fumarate hydratase, mitochondrial","1","5D6B"
"5D6C",,"X-RAY DIFFRACTION",2.91,57.78,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.08M sodium cacodylate pH 6.5, 0.16M calcium acetate,
14.4% PEG-8000, and 20% glycerol",293,"10.1038/nature16057",,"5D6C",97.77,"1.72","1.72","Structure of 4497 Fab bound to synthetic wall teichoic acid fragment","DIQLTQSPDSLAVSLGERATINCKSSQSIFRTSRNKNLLNWYQQRPGQPPRLLIHWASTRKSGVPDRFSGSGFGTDFTLTITSLQAEDVAIYYCQQYFSPPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"4497 antibody IgK (VL and CL)","1","5D6C"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVQPGGSLRLSCSASGFSFNSFWMHWVRQVPGKGLVWISFTNNEGTTTAYADSVRGRFIISRDNAKNTLYLEMNNLRGEDTAVYYCARGDGGLDDWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHT","Homo sapiens",,"4497 antibody IgG1 (VH and CH1)","2","5D6C"
"5D6E",,"X-RAY DIFFRACTION",2.71,54.57,"VAPOR DIFFUSION, HANGING DROP",5.4,"Na Citrate, Tert-butanol",292,"10.1021/acschembio.5b00755",,"5D6E",42.15,"1.49","1.49","Structure of human methionine aminopeptidase 2 with covalent spiroepoxytriazole inhibitor (-)-31b","GPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5D6E"
"5D6F",,"X-RAY DIFFRACTION",2.74,55.05,"VAPOR DIFFUSION, HANGING DROP",5.6,"Na Citrate, Tert-butanol",292,"10.1021/acschembio.5b00755",,"5D6F",42.22,"1.55","1.55","Structure of human methionine aminopeptidase-2 complexed with spiroepoxytriazole inhibitor (+)-31b","GPKVQTDPPSVPICDLYPNGVFPKGQECEYPPTQDGRTAAWRTTSEEKKALDQASEEIWNDFREAAEAHRQVRKYVMSWIKPGMTMIEICEKLEDCSRKLIKENGLNAGLAFPTGCSLNNCAAHYTPNAGDTTVLQYDDICKIDFGTHISGRIIDCAFTVTFNPKYDTLLKAVKDATNTGIKCAGIDVRLCDVGEAIQEVMESYEVEIDGKTYQVKPIRNLNGHSIGQYRIHAGKTVPIVKGGEATRMEEGEVYAIETFGSTGKGVVHDDMECSHYMKNFDVGHVPIRLPRTKHLLNVINENFGTLAFCRRWLDRLGESKYLMALKNLCDLGIVDPYPPLCDIKGSYTAQFEHTILLRPTCKEVVSRGDDY","Homo sapiens","METAP2, MNPEP, P67EIF2","Methionine aminopeptidase 2","1","5D6F"
"5D6W",,"X-RAY DIFFRACTION",3.72,66.98,"VAPOR DIFFUSION, SITTING DROP",4.6,"Protein Solution (30mg/ml KDM4A DTD, 20mM HEPES pH 7.5, 150mM NaCl and 0.5mM TCEP) mixed in a 1:1 ratio with the well solution (1.0M ammonium tartrate dibasic and 0.1M sodium acetate trihydrate pH4.6) Cryoprotected with additional 20% glycerol",293,"10.1038/ncomms13387",,"5D6W",55.51,"1.992","1.992","Crystal structure of double tudor domain of human lysine demethylase KDM4A","GSHMALQSITAGQKVISKHKNGRFYQCEVVRLTTETFYEVNFDDGSFSDNLYPEDIVSQDCLQFGPPAEGEVVQVRWTDGQVYGAKFVASHPIQMYQVEFEDGSQLVVKRDDVYTLDEELP","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5D6W"
"5D6X",,"X-RAY DIFFRACTION",3.72,66.93,"VAPOR DIFFUSION, SITTING DROP",,"Protein Solution (30mg/ml KDM4A DTD, 20mM HEPES pH 7.5, 150mM NaCl and 0.5mM TCEP) mixed in a 1:1 ratio with the well solution (1.0M ammonium sulfate, 1% w/v peg3350 and 0.1M Bis-Tris pH5.5) Cryoprotected with additional 20% glycerol",293,"10.1038/ncomms13387",,"5D6X",27.84,"2.153","2.153","Crystal structure of double tudor domain of human lysine demethylase KDM4A","GSHMALQSITAGQKVISKHKNGRFYQCEVVRLTTETFYEVNFDDGSFSDNLYPEDIVSQDCLQFGPPAEGEVVQVRWTDGQVYGAKFVASHPIQMYQVEFEDGSQLVVKRDDVYTLDEELP","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5D6X"
"5D75",,"X-RAY DIFFRACTION",2.57,52.08,"VAPOR DIFFUSION, HANGING DROP",7,"30% v/v Jeffamine ED-2001, 0.1M HEPES pH 7.0",291,"10.1002/pro.2875","FK5","5D75",16.03,"1.83","1.83","Crystal structure of Human FKBD25 in complex with FK506","PKYTKSVLKKGDKTNFPKKGDVVHCWYTGTLQDGTVFDTNIQTSAKKKKNAKPLSFKVGVGKVIRGWDEALLTMSKGEKARLEIEPEWAYGKKGQPDAKIPPNAKLTFEVELVDIDLEHHHHHH","Homo sapiens","FKBP3, FKBP25","Peptidyl-prolyl cis-trans isomerase FKBP3","1","5D75"
"5D7A",,"X-RAY DIFFRACTION",3.13,60.71,"VAPOR DIFFUSION, SITTING DROP",5.6,"0.2M Ammonium sulfate
0.1M Bis-tris (5.6)
15% PEG3350
7% Ethyleneglycol",293,"10.1038/ncomms12586",,"5D7A",106.64,"2.9","2.9","Crystal structure of the kinase domain of TRAF2 and NCK-interacting protein kinase with NCB-0846","GSGADEIDLSALRDPAGIFELVELVGNGTYGQVYKGRHVKTGQLAAIKVMDVTGDEEEEIKQEINMLKKYSHHRNIATYYGAFIKKNPPGMDDQLWLVMEFCGAGSVTDLIKNTKGNTLKEEWIAYICREILRGLSHLHQHKVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDFKSDLWSLGITAIEMAEGAPPLCDMHPMRALFLIPRNPAPRLKSKKWSKKFQSFIESCLVKNHSQRPATEQLMKHPFIRDQPNERQVRIQLKDHIDRTKKKRG","Homo sapiens","TNIK, KIAA0551","TRAF2 and NCK-interacting protein kinase","1","5D7A"
"5D7N",,"X-RAY DIFFRACTION",2.61,52.92,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M magnesium chloride, 25 % (w/v) PEG 3350",277,"10.1107/S2053230X15019986",,"5D7N",189.34,"1.83","1.83","Crystal structure of human Sirt3 at an improved resolution","GHMSDKGKLSLQDVAELIRARACQRVVVMVGAGISTPSGIPDFRSPGSGLYSNLQQYDLPYPEAIFELPFFFHNPKPFFTLAKELYPGNYKPNVTHYFLRLLHDKGLLLRLYTQNIDGLERVSGIPASKLVEAHGTFASATCTVCQRPFPGEDIRADVMADRVPRCPVCTGVVKPDIVFFGEPLPQRFLLHVVDFPMADLLLILGTSLEVEPFASLTEAVRSSVPRLLINRDLVGPLAWHPRSRDVAQLGDVVHGVESLVELLGWTEEMRDLVQRETGKLD","Homo sapiens","SIRT3, SIR2L3","NAD-dependent protein deacetylase sirtuin-3, mitochondrial","1","5D7N"
"5D7O",,"X-RAY DIFFRACTION",2.49,50.53,"VAPOR DIFFUSION, SITTING DROP",6.25,"0.2 M sodium chloride, 30 % (w/v) PEG 3350, 0.1 M Bis-Tris",277,"10.1107/S2053230X15019986",,"5D7O",71.44,"1.63","1.63","Crystal structure of Sirt2-ADPR at an improved resolution","GHMSLGSQKERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5D7O"
"5D7P",,"X-RAY DIFFRACTION",2.46,50.03,"VAPOR DIFFUSION, SITTING DROP",5.75,"18 % (w/v) PEG 10000, 0.1 M Bis-Tris",293,"10.1107/S2053230X15019986","OCZ","5D7P",71.18,"1.76","1.76","Crystal structure of human Sirt2 in complex with ADPR and EX-243","GHMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5D7P"
"5D7Q",,"X-RAY DIFFRACTION",2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",5.75,"18 % (w/v) PEG 10000, 0.1 M Bis-Tris",293,"10.1107/S2053230X15019986","4I5","5D7Q",71.13,"2.01","2.01","Crystal structure of human Sirt2 in complex with ADPR and CHIC35","GHMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5D7Q"
"5D7S",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",8.25,"26 % PEG3350, 0.2 M NaCl and 0.1 M Tris, pH 8.25, 10.5 mg/mL protein",293,"10.1080/19420862.2015.1099774",,"5D7S",47.87,"1.88","1.88","Crystal structure of MOR04357, a neutralizing anti-human GM-CSF antibody Fab fragment","DIELTQPPSVSVAPGQTARISCSGDSIGKKYAYWYQQKPGQAPVLVIYKKRPSGIPERFSGSNSGNTATLTISGTQAEDEADYYCSAWGDKGMVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEA","Homo sapiens",,"Immunglobulin G1 Fab fragment, light chain","1","5D7S"
,,,,,,,,,,,,,,,,"QVQLVESGGGLVQPGGSLRLSCAASGFTFSSYWMNWVRQAPGKGLEWVSGIENKYAGGATYYAASVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARGFGTDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSEFDYKDDDDKGAPHHHHHH","Homo sapiens",,"Immunglobulin G1 Fab fragment, heavy chain","2","5D7S"
"5D7V",,"X-RAY DIFFRACTION",2.48,50.39,"VAPOR DIFFUSION, SITTING DROP",,"0.23M Diammonium Phosphate, 18% PEG 3350, 1M Lithium chloride",298,"10.1016/j.bbrc.2016.07.121",,"5D7V",126.05,"2.33","2.33","Crystal structure of PTK6 kinase domain","MERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPTFKALRERLSSFTSHHHHHH","Homo sapiens","PTK6, BRK","Protein-tyrosine kinase 6","1","5D7V"
"5D7X",,"X-RAY DIFFRACTION",2.44,49.62,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris Propane, pH6.5, 0.2M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.5b01757","XZ8","5D7X",14.02,"1.35","1.35","Crystal structure of the human BRPF1 bromodomain in complex with XZ08","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5D7X"
"5D8E",,"X-RAY DIFFRACTION",4.45,72.37,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M MES pH 6.0, 16% Jeffamine M-600",293,,,"5D8E",52.08,"3","3","crystal structure of SSB from homo sapiens","MTTETFVKDIKPGLKNLNLIFIVLETGRVTKTKDGHEVRTCKVADKTGSINISVWDDVGNLIQPGDIIRMTKGYASVFKGCLTLYTGRGGDLQKIGEFCMVYSEVPNFSHHHHHH","Homo sapiens","NABP2, OBFC2B, SSB1, LP3587","SOSS complex subunit B1","1","5D8E"
"5D9K",,"X-RAY DIFFRACTION",2.51,51.04,"VAPOR DIFFUSION",,"20% PEG3350, 0.075 M lithium citrate",291,"10.1021/acs.jmedchem.5b00450","584","5D9K",76.93,"2.55","2.55","Rsk2 N-terminal Kinase in Complex with BI-D1870","GPNPQTEEVSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDPEFTAKTP","Homo sapiens","RPS6KA3, ISPK1, MAPKAPK1B, RSK2","Ribosomal protein S6 kinase alpha-3","1","5D9K"
"5D9L",,"X-RAY DIFFRACTION",2.03,39.52,"VAPOR DIFFUSION",,"20% PEG3350, 0.2 M lithium citrate",291,"10.1021/acs.jmedchem.5b00450","583","5D9L",37.55,"2.15","2.15","Rsk2 N-terminal Kinase in Complex with bis-phenol pyrazole","GPNPQTEEVSIKEIAITHHVKEGHEKADPSQFELLKVLGQGSFGKVFLVKKISGSDARQLYAMKVLKKATLKVRDRVRTKMERDILVEVNHPFIVKLHYAFQTEGKLYLILDFLRGGDLFTRLSKEVMFTEEDVKFYLAELALALDHLHSLGIIYRDLKPENILLDEEGHIKLTDFGLSKESIDHEKKAYSFCGTVEYMAPEVVNRRGHTQSADWWSFGVLMFEMLTGTLPFQGKDRKETMTMILKAKLGMPQFLSPEAQSLLRMLFKRNPANRLGAGPDGVEEIKRHSFFSTIDWNKLYRREIHPPFKPATGRPEDTFYFDP","Homo sapiens","RPS6KA3, ISPK1, MAPKAPK1B, RSK2","Ribosomal protein S6 kinase alpha-3","1","5D9L"
"5DA3",,"X-RAY DIFFRACTION",2.48,50.45,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M tri-Lithium citrate, 20% (w/v) PEG 3350",294,"10.1016/j.bbrc.2016.12.030","58V","5DA3",31.24,"1.7","1.7","Crystal structure of PTK6 Kinase domain with inhibitor","MERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPTFKALRERLSSFTSHH","Homo sapiens","PTK6, BRK","Protein-tyrosine kinase 6","1","5DA3"
"5DAB",,"X-RAY DIFFRACTION",2.92,61.65,"VAPOR DIFFUSION, HANGING DROP",5.6,"10%(w/v) polyethylene glycol (PEG) 3350, 0.1 M trisodium citrate dehydrate, 3.0 mM N-oxalylglycine (NOG)",293,,"58W","5DAB",55.93,"2.1","2.1","Crystal structure of FTO-IN115","LESHMTPKDDEFYQQWQLKYPKLILREASSVSEELHKEVQEAFLTLHKHGCLFRDLVRIQGKDLLTPVSRILIGNPGCTYKYLNTRLFTVPWPVKGSNIKHTEAEIAAACETFLKLNDYLQIETIQALEELAAKEKANEDAVPLCMSADFPRVGMGSSYNGDVEVDIKSRAAYNVTLLNFMDPQKMPYLKEEPYFGMGKMAVSWHHDENLVDRSAVAVYSYSCEGPEEESEDDSHLEGRDPDIWHVGFKISWDIETPGLAIPLHQGDCYFMLDDLNATHQHCVLAGSQPRFSSTHRVAECSTGTLDYILQRCQLALQNVCDDVDNDDVSLKSFEPAVLKQGEEIHNEVEFEWLRQFWFQGNRYRKCTDWWCQPMAQLEALWKKMEGVTNAVLHEVKREGLPVEQRNEILTAILASLTARQNLRREWHARCQSRIARTLPADQKPECRPYWEKDDASMPLPFDLTDIVSELRGQLLEAKP","Homo sapiens","FTO, KIAA1752","Alpha-ketoglutarate-dependent dioxygenase FTO","1","5DAB"
"5DAD",,"X-RAY DIFFRACTION",2.34,47.37,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Potassium Thiocyanate, 30% w/v PEG MME 2000",293,"10.1016/j.bbagen.2016.07.026",,"5DAD",15.89,"2.61","2.61","Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64014","GSHMASNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPS","Homo sapiens","KEAP1, INRF2, KIAA0132, KLHL19","Kelch-like ECH-associated protein 1","1","5DAD"
"5DAF",,"X-RAY DIFFRACTION",2.24,44.98,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M CHES, pH 9.5, 30% w/v PEG 3000",293,"10.1016/j.bbagen.2016.07.026",,"5DAF",15.93,"2.37","2.37","Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64063","GSHMASNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACSDFLVQQLDPS","Homo sapiens","KEAP1, INRF2, KIAA0132, KLHL19","Kelch-like ECH-associated protein 1","1","5DAF"
"5DAG",,"X-RAY DIFFRACTION",2.17,43.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"Crystals were grown from a solution containing 0.1 M Tris-HCl pH 8.5, 25% PEG3350 using the hanging drop vapor diffusion method",293,"10.1016/j.molcel.2015.08.019",,"5DAG",23.35,"1.6","1.6","Crystal structure of PZP domain of human AF10 protein","MVSSDRPVSLEDEVSHSMKEMIGGCCVCSDERGWAENPLVYCDGHGCSVAVHQACYGIVQVPTGPWFCRKCESQERAARVRCELCPHKDGALKRTDNGGWAHVVCALYIPEVQFANVSTMEPIVLQSVPHDRYNKTCYICDEQGRESKAATGACMTCNKHGCRQAFHVTCAQFAGLLCEEEGNGADNVQYCGYCKYHFSKLKKSKRGS","Homo sapiens","MLLT10, AF10","Protein AF-10","1","5DAG"
"5DAK",,"X-RAY DIFFRACTION",2.57,52.22,"VAPOR DIFFUSION, HANGING DROP",,"100MM MES, PH 6.0, 28% (W/V) PEG 8000, 20MM CACL2 10MM DTT. Soaked in 2mM PAO dissolved in DMSO",293,,,"5DAK",47.31,"2.11","2.11","Crystal Structure of human Glutathione Transferase Pi complexed with a metalloid in the absence of Glutathione","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DAK"
,,,,,,,,,,,,,,,,"MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","2","5DAK"
"5DAL",,"X-RAY DIFFRACTION",2.54,51.63,"VAPOR DIFFUSION, HANGING DROP",6,"100MM MES, PH 6.0, 28% (W/V) PEG 8000, 20MM CACL2, 10MM DTT, 10MM GSH. Soaked in 2MM PAO dissolved in DMSO",293,,,"5DAL",49.74,"1.5","1.5","Crystal Structure of human Glutathione Transferase Pi complexed with a metalloid in the presence of Glutathione","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DAL"
,,,,,,,,,,,,,,,,"MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","2","5DAL"
"5DB0",,"X-RAY DIFFRACTION",2.23,44.92,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES pH 7.5 and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl (pH 8.0), 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen, VAPOR DIFFUSION, SITTING DROP, temperature 283K",283,"10.1021/acs.jmedchem.5b01305","58P, 6E6","5DB0",56.94,"1.5","1.5","Menin in complex with MI-352","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DB0"
"5DB1",,"X-RAY DIFFRACTION",2.2,44.21,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES pH 7.5 and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl (pH 8.0), 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen, VAPOR DIFFUSION, SITTING DROP, temperature 283K",283,"10.1021/acs.jmedchem.5b01305","58O","5DB1",56.37,"1.86","1.86","Menin in complex with MI-336","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DB1"
"5DB2",,"X-RAY DIFFRACTION",2.24,45.04,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES pH 7.5 and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl (pH 8.0), 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen, VAPOR DIFFUSION, SITTING DROP, temperature 283K",283,"10.1021/acs.jmedchem.5b01305","58R","5DB2",56.11,"1.54","1.54","Menin in complex with MI-389","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DB2"
,,,,,,,,,,,,,,,,,"Homo sapiens","MEN1, SCG2"
"5DB3",,"X-RAY DIFFRACTION",2.25,45.45,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b01305","58Q","5DB3",56.28,"1.71","1.71","Menin in complex with MI-574","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DB3"
"5DBM",,"X-RAY DIFFRACTION",2.56,51.98,"VAPOR DIFFUSION, SITTING DROP",9,"0.1 M BICINE:NaOH pH 9.0, 20% (w/v) PEG 6000 (CPI703)",277,"10.1074/jbc.M115.708560","58N","5DBM",42.87,"1.86","1.86","Crystal structure of the CBP bromodomain in complex with CPI703","GSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5DBM"
"5DC5",,"X-RAY DIFFRACTION",2.32,46.88,"VAPOR DIFFUSION, SITTING DROP",7.3,"100 mM imidazole (pH 7.0), 15% (w/v) PEG 1500, and 4 mM TCEP",294,"10.1021/acs.biochem.5b01327",,"5DC5",87.29,"1.94","1.94","Crystal structure of D176N HDAC8 in complex with M344","MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVNLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVVIEGRGSHHHHHH","Homo sapiens","HDAC8, HDACL1, CDA07","Histone deacetylase 8","1","5DC5"
"5DCG",,"X-RAY DIFFRACTION",2.55,51.75,"VAPOR DIFFUSION, HANGING DROP",6,"100MM MES, PH 6.0, 28% (W/V) PEG 8000, 20MM CACL2, 10MM DTT",293,,,"5DCG",47.38,"2.01","2.01","Crystal Structure of WT Apo Human Glutathione Transferase Pi","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DCG"
"5DCN",,"X-RAY DIFFRACTION",3.58,65.65,"VAPOR DIFFUSION, SITTING DROP",,"1.8M Lithium sulphate, 0.01M Magnesium chloride, 0.05M MES monohydrate, pH5.6",293,"10.1016/j.molcel.2015.09.010",,"5DCN",15.23,"2","2","Crystal structure of LC3 in complex with TECPR2 LIR","DEWEVIGGPSEKTFKQRRTFEQRVEDVRLIREQHPTKIPVIIERYKGEKQLPVLDKTKFLVPDHVNMSELIKIIRRRLQLNANQAFFLLVNGHSMVSVSTPISEVYESEKDEDGFLYMVYASQETF","Homo sapiens","MAP1LC3B, MAP1ALC3","Microtubule-associated proteins 1A/1B light chain 3B","1","5DCN"
"5DCP",,"X-RAY DIFFRACTION",2.95,58.34,"VAPOR DIFFUSION, HANGING DROP",7,"3.5 M Sodium formate",298,"10.1038/s41598-017-04441-x",,"5DCP",37.5,"2.49","2.49","Crystal structure of the human filamin B Ig-like domains 16-17","SMMNGLGFKPFDLVIPFAVRKGEITGEVHMPSGKTATPEIVDNKDGTVTVRYAPTEVGLHEMHIKYMGSHIPESPLQFYVNYPNSGSVSAYGPGLVYGVANKTATFTIVTEDAGEGGLDLAIEGPSKAEISCIDNKDGTCTVTYLPTLPGDYSILVKYNDKHIPGSPFTAKITDD","Homo sapiens","FLNB, FLN1L, FLN3, TABP, TAP","Filamin-B","1","5DCP"
"5DCZ",,"X-RAY DIFFRACTION",2.44,49.51,"VAPOR DIFFUSION, HANGING DROP",8.2,"Crystals were obtained by hanging drop vapor diffusion at 22 deg in droplets consisting of 0.2 uL protein and 0.2 uL of 1.4-1.6 M Na/KPO4 pH 8.2",295,,"59B","5DCZ",26.62,"2.23","2.23","Tankyrase 2 complexed with a selective inhibitor","GQQGLNPYLTLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEGMVDG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","Tankyrase-2","1","5DCZ"
"5DD2",,"X-RAY DIFFRACTION",1.82,32.57,"VAPOR DIFFUSION, SITTING DROP",5,"Peg 6000 (20%), 100mM Sodium acetate, 200mM Calcium Chloride Dihydrate, pH 5",293,,,"5DD2",30.54,"2.6","2.6","Human gelsolin from residues Glu28 to Arg161 with Calcium","EHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQR","Homo sapiens","GSN","Gelsolin","1","5DD2"
"5DD9",,"X-RAY DIFFRACTION",2.25,45.29,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES pH 7.5 and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl (pH 8.0), 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen, VAPOR DIFFUSION, SITTING DROP, temperature 283K",283,"10.1021/acs.jmedchem.5b00975","59K","5DD9",56.28,"1.62","1.62","Menin in complex with MI-326","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DD9"
"5DDA",,"X-RAY DIFFRACTION",2.2,44.09,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",293,"10.1021/acs.jmedchem.5b00975","59M","5DDA",56.14,"1.83","1.83","Menin in complex with MI-333","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDA"
"5DDB",,"X-RAY DIFFRACTION",2.22,44.48,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b00975","59Q","5DDB",56.28,"1.54","1.54","Menin in complex with MI-319","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDB"
"5DDC",,"X-RAY DIFFRACTION",2.26,45.65,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b00975","59V","5DDC",55.83,"1.62","1.62","Menin in complex with MI-2-3","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDC"
"5DDD",,"X-RAY DIFFRACTION",2.2,44.15,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b00975","59X","5DDD",55.95,"2.14","2.14","menin in complex with MI-836","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDD"
"5DDE",,"X-RAY DIFFRACTION",2.22,44.54,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b00975","5A0","5DDE",56.32,"1.78","1.78","Menin in complex with MI-859","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDE"
"5DDF",,"X-RAY DIFFRACTION",2.23,44.85,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium acetate, 0.1 M HEPES and 25% w/v PEG 3,350. This solution was mixed 1:1 with 2.5mg/mL protein in 50mM Tris-HCl, 50mM NaCl, and 1mM TCEP. Prior to data collection, crystals were transferred into a cryo-solution containing 20% PEG550 MME and flash-frozen in liquid nitrogen",283,"10.1021/acs.jmedchem.5b00975","5A1","5DDF",55.92,"1.66","1.66","Menin in complex with MI-273","GGSSSMGLKAAQKTLFPLRSIDDVVRLFAAELGREEPDLVLLSLVLGFVEHFLAVNRVGLTYFPVADLSIIAALYARFTAQIRGAVDLSLYPREGGVSSRELVKKVSDVIWNSLSRSYFKDRAHIQSLFSFITGTKLDSSGVAFAVVGACQALGLRDVHLALSEDHAWVVFGPNGEQTAEVTWHGKGNEDRRGQTVNAGVAERSWLYLKGSYMRCDRKMEVAFMVCAINPSIDLHTDSLELLQLQQKLLWLLYDLGHLERYPMALGNLADLEELEPTPGRPDPLTLYHKGIASAKTYYRDEHIYPYMYLAGYHCRNRNVREALQAWADTATVIQDYNYCREDEEIYKEFFEVANDVIPNLLKEAASLLEAGSQGSALQDPECFAHLLRFYDGICKWEEGSPTPVLHVGWATFLVQSLGRFEGQVRQKVRIVSVPAPAASPPPEGPVLTFQSEKMKGMKELLVATKINSSAIKLQLTAQSQVQMKKQKVS","Homo sapiens","MEN1, SCG2","Menin","1","5DDF"
"5DDL",,"X-RAY DIFFRACTION",2.54,51.61,"VAPOR DIFFUSION, HANGING DROP",6,"100MM MES, PH 6.0, 28% (W/V) PEG 8000, 20MM CACL2, 10MM DTT. Soaked in 2mM PAO dissolved in DMSO, Then back soaked in 10mM GSH after 2 days",293,,,"5DDL",49.47,"1.98","1.98","Crystal Structure of WT Human Glutathione Transferase Pi soaked with a metalloid then back-soaked with glutathione","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DDL"
"5DDY",,"X-RAY DIFFRACTION",4.04,69.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES, 3.0M Sodium Chloride",277,"10.1021/jacs.5b13368",,"5DDY",152.32,"3.36","3.36","Binary complex of human Polymerase lambda with dCTP","MAQPSSQKATNHNLHITEKLEVLAKAYSVQGDKWRALGYAKAINALKSFHKPVTSYQEACSIPGIGKRMAEKIIEILESGHLRKLDHISESVPVLELFSNIWGAGTKTAQMWYQQGFRSLEDIRSQASLTTQQAIGLKHYSDFLERMPREEATEIEQTVQKAAQAFNSGLLCVACGSYRRGKATCGDVDVLITHPDGRSHRGIFSRLLDSLRQEGFLTDDLVSQEENGQQQKYLGVCRLPGPGRRHRRLDIIVVPYSEFACALLYFTGSAHFNRSMRALAKTKGMSLSEHALSTAVVRNTHGCKVGPGRVLPTPTEKDVFRLLGLPYREPAERDW","Homo sapiens","POLL","DNA polymerase lambda","1","5DDY"
"5DE1",,"X-RAY DIFFRACTION",2.79,55.89,"VAPOR DIFFUSION, SITTING DROP",7,"18-23% PEG3350, 0.2M ammonium sulfate, 0.1M Bis-Tris, pH 7.0, 10mM NADP+",298,"10.1038/nchembio.1930","59D","5DE1",95.63,"2.25","2.25","Crystal structure of human IDH1 in complex with GSK321A","SKKISGGSVVEMQGDEMTRIIWELIKEKLIFPYVELDLHSYDLGIENRDATNDQVTKDAAEAIKKHNVGVKCATITPDEKRVEEFKLKQMWKSPNGTIRNILGGTVFREAIICKNIPRLVSGWVKPIIIGHHAYGDQYRATDFVVPGPGKVEITYTPSDGTQKVTYLVHNFEEGGGVAMGMYNQDKSIEDFAHSSFQMALSKGWPLYLSTKNTILKKYDGRFKDIFQEIYDKQYKSQFEAQKIWYEHRLIDDMVAQAMKSEGGFIWACKNYDGDVQSDSVAQGYGSLGMMTSVLVCPDGKTVEAEAAHGTVTRHYRMYQKGQETSTNPIASIFAWTRGLAHRAKLDNNKELAFFANALEEVSIETIEAGFMTKDLAACIKGLPNVQRSDYLNTFEFMDKLGENLKIKLAQAKL","Homo sapiens","IDH1, PICD","Isocitrate dehydrogenase [NADP] cytoplasmic","1","5DE1"
"5DEJ",,"X-RAY DIFFRACTION",2.21,44.27,"VAPOR DIFFUSION, HANGING DROP",,"100 mM HEPES, 200 mM CaCl2 and 28% PEG400, pH 7.5",291,,,"5DEJ",25.53,"1.37","1.37","Transthyretin natural mutant A19D","CPLMVKVLDDVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNP","Homo sapiens","TTR, PALB","Transthyretin","1","5DEJ"
"5DEW",,"X-RAY DIFFRACTION",2.43,49.37,"VAPOR DIFFUSION, SITTING DROP",7,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid pH 7.0, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292,,"59N","5DEW",67.58,"1.9","1.9","Crystal structure of PAK1 in complex with an inhibitor compound 5","SDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSEMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5DEW"
"5DEY",,"X-RAY DIFFRACTION",2.4,48.69,"VAPOR DIFFUSION, SITTING DROP",,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid pH 7.0, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292,"10.1021/acsmedchemlett.5b00398","59T","5DEY",67.56,"2.1","2.1","Crystal structure of PAK1 in complex with an inhibitor compound G-5555","SDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSEMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5DEY"
"5DFB",,"X-RAY DIFFRACTION",2.27,45.92,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M Hepes pH 7, 0.2M Imidiazole, 41% PEG 400",293.15,"10.1021/acs.jmedchem.5b01135",,"5DFB",13.9,"1.4","1.4","Crystal structure of BRD2(BD2) mutant W370F in the free form","SMGKLSEQLKHCNGILKELLSKKHAAYAFPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5DFB"
"5DFC",,"X-RAY DIFFRACTION",2.25,45.38,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M Hepes pH 7, 0.2M Imidiazole, 41% PEG 400",293.15,"10.1021/acs.jmedchem.5b01135",,"5DFC",14.33,"1.5","1.5","Crystal structure of BRD2(BD2) W370F mutant with ligand I-BET 762 bound","SMGKLSEQLKHCNGILKELLSKKHAAYAFPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5DFC"
"5DFD",,"X-RAY DIFFRACTION",2.28,46.01,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M Hepes pH 7, 0.2M Imidiazole, 41% PEG 400",293.15,"10.1021/acs.jmedchem.5b01135",,"5DFD",13.84,"1.5","1.5","Crystal structure of BRD2(BD2) W370F mutant with ligand 28 bound","SMGKLSEQLKHCNGILKELLSKKHAAYAFPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5DFD"
"5DFP",,"X-RAY DIFFRACTION",2.5,50.74,"VAPOR DIFFUSION, HANGING DROP",7,"1 uL of PAK1 (9 mg/ml) with 1 uL of crystallization solution (0.1 M HEPES pH 7.0, 1 M NaCl, 25% PEG 3350, 10 mM DTT) at 4C",277,"10.1021/acsmedchemlett.5b00398","59U","5DFP",33.96,"2.2","2.2","Crystal structure of PAK1 in complex with an inhibitor compound FRAX1036","SDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIRQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRDIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSTMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNH","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5DFP"
"5DFT",,"X-RAY DIFFRACTION",2.16,43.09,"VAPOR DIFFUSION, SITTING DROP",,"1.1M sodium citrate, 0.1M citric acid and 0.1M sodium iodine",293,,,"5DFT",107.97,"2.5","2.5","Structure of the Eleventh Type III Domain from Human Fibronectin","GSHMRTEIDKPSQMQVTDVQDNSISVKWLPSSSPVTGYRVTTTPKNGPGPTKTKTAGPDQTEMTIEGLQPTVEYVVSVYAQNPSGESQPLVQTAVTTIPAP","Homo sapiens","FN1, FN","Fibronectin","1","5DFT"
"5DG1",,"X-RAY DIFFRACTION",2.16,43.1,"VAPOR DIFFUSION, HANGING DROP",,"Sodium citrate, Amino Sulfate",298,"10.1093/abbs/gmw089",,"5DG1",90.7,"3.2","3.2","Sugar binding protein - human galectin-2","GSHMTGELEVKNMDMKPGSTLKITGSIADGTDGFVINLGQGTDKLNLHFNPRFSESTIVCNSLDGSNWGQEQREDHLCFSPGSEVKFTVTFESDKFKVKLPDGHELTFPNRLGHSHLSYLSVRGGFNMSSFKLKE","Homo sapiens","LGALS2","Galectin-2","1","5DG1"
"5DG2",,"X-RAY DIFFRACTION",2.3,46.54,"VAPOR DIFFUSION, HANGING DROP",,"Sodium citrate, amino sulfate",298,"10.1093/abbs/gmw089",,"5DG2",30.23,"1.612","1.612","Sugar binding protein - human galectin-2 (dimer)","GSHMTGELEVKNMDMKPGSTLKITGSIADGTDGFVINLGQGTDKLNLHFNPRFSESTIVCNSLDGSNWGQEQREDHLCFSPGSEVKFTVTFESDKFKVKLPDGHELTFPNRLGHSHLSYLSVRGGFNMSSFKLKE","Homo sapiens","LGALS2","Galectin-2","1","5DG2"
"5DG4",,"X-RAY DIFFRACTION",2.02,39.1,"VAPOR DIFFUSION, HANGING DROP",4.6,"30% PEG 4000, 0.1 M sodium acetate, 0.1 M ammonium acetate, pH 4.6",298,"10.1016/j.str.2016.05.022",,"5DG4",62.37,"1.5","1.5","Crystal structure of monomer human cellular retinol binding protein II-Y60L","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNLDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5DG4"
"5DG5",,"X-RAY DIFFRACTION",2.69,54,"VAPOR DIFFUSION, SITTING DROP",,"Protein at 9.5mg/ml in 20 mM Tris pH 8.5, 100mM NaCl, 14mM 2-mercaptoethanol with 5-molar excess of compound; crystallization condition: 1.0M diammonium hydrogen phosphate, 0.2M sodium chloride, 0.1M citrate pH 5.0 and 7.5% glycerol",290,"10.1158/1535-7163.MCT-14-1105",,"5DG5",73,"2.6","2.6","CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF THE HEPATOCYTE GROWTH FACTOR RECEPTOR C-MET IN COMPLEX WITH ALTIRATINIB ANALOG DP-4157","MGHHHHHHMGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIG","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5DG5"
"5DGH",,"X-RAY DIFFRACTION",2.66,53.8,"VAPOR DIFFUSION, HANGING DROP",7,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM AMP-PNP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight. The crystals were soaked under the above stabilizing buffer for three days with 2 mM compound.",277,"10.1002/chem.201601754",,"5DGH",39.43,"2.1","2.1","Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with AMP-PNP and 5-(PCP)-IP5","GSFTERQIVVGICSMAKKSKSKPMKEILERISLFKYITVVVFEEEVILNEPVENWPLCDCLISFHSKGFPLDKAVAYAKLRNPFVINDLNMQYLIQDRREVYSILQAEGILLPRYAILNRDPNNPKECNLIEGEDHVEVNGEVFQKPFVEKPVSAEDHNVYIYYPTSAGGGSQRLFRKIGSRSSVYSPESNVRKTGSYIYEEFMPTDGTDVKVYTVGPDYAHAEARKSPALDGKVERDSEGKEVRYPVILNAREKLIAWKVCLAFKQTVCGFDLLRANGQSYVCDVNGFSFVKNSMKYYDDCAKILGNIVMRELAPQFHIPWSIPLEAED","Homo sapiens","PPIP5K2, HISPPD1, KIAA0433, VIP2","Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2","1","5DGH"
"5DGI",,"X-RAY DIFFRACTION",2.67,53.92,"VAPOR DIFFUSION, HANGING DROP",7,"12% (w/v) PEG 3350, 20 mM MgCl2, 0.1 M HEPES, pH 7.0, 1 mM ATP and 2 mM CdCl2. The crystals were transferred to a stabilizing buffer containing 22% (w/v) PEG 3350, 10 mM MgCl2, 0.1 M sodium acetate, pH 5.2 at 4 oC overnight,while ATP in the crystals was hydrolyzed to ADP. The crystals were soaked under the above stabilizing buffer for three days with 2 mM compound.",277,"10.1002/chem.201601754",,"5DGI",39.37,"1.85","1.85","Crystal structure of the catalytic domain of human diphosphoinositol pentakisphosphate kinase 2 (PPIP5K2) in complex with ADP and 3,5-(PCP)2-IP4","GSFTERQIVVGICSMAKKSKSKPMKEILERISLFKYITVVVFEEEVILNEPVENWPLCDCLISFHSKGFPLDKAVAYAKLRNPFVINDLNMQYLIQDRREVYSILQAEGILLPRYAILNRDPNNPKECNLIEGEDHVEVNGEVFQKPFVEKPVSAEDHNVYIYYPTSAGGGSQRLFRKIGSRSSVYSPESNVRKTGSYIYEEFMPTDGTDVKVYTVGPDYAHAEARKSPALDGKVERDSEGKEVRYPVILNAREKLIAWKVCLAFKQTVCGFDLLRANGQSYVCDVNGFSFVKNSMKYYDDCAKILGNIVMRELAPQFHIPWSIPLEAED","Homo sapiens","PPIP5K2, HISPPD1, KIAA0433, VIP2","Inositol hexakisphosphate and diphosphoinositol-pentakisphosphate kinase 2","1","5DGI"
"5DGM",,"X-RAY DIFFRACTION",2.93,57.99,"VAPOR DIFFUSION, HANGING DROP",4.7,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/anie.201507064",,"5DGM",40.64,"2.86","2.86","Crystal structure of human FPPS in complex with monophosphonate compound 7","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DGM"
"5DGN",,"X-RAY DIFFRACTION",2.9,57.57,"VAPOR DIFFUSION, HANGING DROP",5.3,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/cmdc.201500338","59Y","5DGN",40.48,"2.08","2.08","Crystal structure of human FPPS in complex with compound 13","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DGN"
"5DGO",,"X-RAY DIFFRACTION",4.09,69.91,"VAPOR DIFFUSION, SITTING DROP",,"Buffer condition C2 of the Morpheus HT 96 crystallisation screen (Molecular Dimensions)",292,"10.1038/ncomms11638",,"5DGO",64.94,"2.1","2.1","Crystal structure of cell division cycle protein 45 (Cdc45)","MFVSDFRKEFYEVVQSQRVLLFVASDVDALCACKILQALFQCDHVQYTLVPVSGWQELETAFLEHKEQFHYFILINCGANVDLLDILQPDEDTIFFVCDTHRPVNVVNVYNDTQIKLLIKQDDDLEVPAYEDIFRDEEEDEEHSGNDSDGSEPVEQTMRRRQRREWEARRRDILFDYEQYEYHGTSSAMVMFELAWMLSKDLNDMLWWAIVGLTDQWVQDKITQMKYVTDVGVLQRHVSRHNHRNEDEENTLSVDCTRISFEYDLRLVLYQHWSLHDSLCNTSYTAARFKLWSVHGQKRLQEFLADMGLPLKQVKQKFQAMDISLKENLREMIEESANKFGMKDMRVQTFSIHFGFKHKFLASDVVFATMSLMESPEKDGSGTDHFIQALDSLSRSNLDKLYHGLELAKKQLRATQQTIASCLCTNLVISQGPFLYCSLMEGTPDVMLFSRPASLSLLSKHLLKSFVCSTKNRRCKLLPLVMAAPLSMEHGTVTVVGIPPETDSSDRKNFFGRAFEKAAESTSSRMLHNHFDLSVIELKAEDRSKFLDALISLLS","Homo sapiens","CDC45, CDC45L, CDC45L2, UNQ374/PRO710","Cell division control protein 45 homolog","1","5DGO"
"5DGS",,"X-RAY DIFFRACTION",2.86,57.05,"VAPOR DIFFUSION, HANGING DROP",4.7,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/anie.201507064",,"5DGS",40.6,"2.62","2.62","Crystal structure of human FPPS in complex with the monophosphonate compound 15","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DGS"
"5DGZ",,"X-RAY DIFFRACTION",3.56,65.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289,"10.1016/j.bmcl.2015.09.052","L20","5DGZ",35.03,"2.502","2.502","Discovery of 3,5-substituted 6-azaindazoles as potent pan-Pim inhibitors","MKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSKKLAAALEHHHHHH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5DGZ"
"5DH3",,"X-RAY DIFFRACTION",2.66,53.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 28% PEG3350, 0.2M (NH4)2SO4",293,"10.1126/scitranslmed.aaf2304","5BS","5DH3",72.44,"2.468","2.468","Crystal structure of MST2 in complex with XMU-MP-1","GSHMASMTGGQQMGRGSEDSLTKQPEEVFDVLEKLGEGSYGSVFKAIHKESGQVVAIKQVPVESDLQEIIKEISIMQQCDSPYVVKYYGSYFKNTDLWIVMEYCGAGSVSDIIRLRNKTLIEDEIATILKSTLKGLEYLHFMRKIHRDIKAGNILLNTEGHAKLADFGVAGQLTDTMAKRNTVIGTPFWMAPEVIQEIGYNCVADIWSLGITSIEMAEGKPPYADIHPMRAIFMIPTNPPPTFRKPELWSDDFTDFVKKCLVKNPEQRATATQLLQHPFIKNAKPVSILRDLITEAMEIKAKRHEEQQRELEEEE","Homo sapiens","STK3, KRS1, MST2","Serine/threonine-protein kinase 3","1","5DH3"
"5DH4",,"X-RAY DIFFRACTION",1.98,37.9,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1016/j.bmcl.2015.11.013","5AV","5DH4",80.33,"2.2","2.2","PDE10 complexed with 5-chloro-N-[(2,4-dimethylthiazol-5-yl)methyl]pyrazolo[1,5-a]pyrimidin-7-amine","GSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5DH4"
"5DH5",,"X-RAY DIFFRACTION",2.07,40.65,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM HEPES pH 7.0, 20% PEG3350, 200mM MgCl2, and 10mM 2-Mercaptoethanol",298,"10.1016/j.bmcl.2015.11.013","5AY","5DH5",80.14,"2","2","PDE10 complexed with N-[(1-methylpyrazol-4-yl)methyl]-5-[[(1S,2S)-2-(2-pyridyl)cyclopropyl]methoxy]pyrazolo[1,5-a]pyrimidin-7-amine","GSHMSICTSEEWQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETATWISSPSVAQKAAASED","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5DH5"
"5DHJ",,"X-RAY DIFFRACTION",3.54,65.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289,"10.1016/j.bmcl.2015.09.052","5E5","5DHJ",34.85,"2.457","2.457","PIM1 in complex with Cpd4 (3-methyl-5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridine)","MKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSKKLAAALEHHHHHH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5DHJ"
"5DI1",,"X-RAY DIFFRACTION",2.52,51.18,"VAPOR DIFFUSION, HANGING DROP",7,"20 mM HEPES pH7.0, 0.3 M NaCl, 30% PEG NNE 2000m 0.1 M KSCN",293,"10.1021/acsmedchemlett.5b00215","5DF","5DI1",71.24,"2.9","2.9","MAP4K4 in complex with an inhibitor","MANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTR","Homo sapiens","MAP4K4, HGK, KIAA0687, NIK","Mitogen-activated protein kinase kinase kinase kinase 4","1","5DI1"
"5DIA",,"X-RAY DIFFRACTION",3.19,61.4,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 4000, 0.2M LiSO4, 0.1M Tris-HCl",289,"10.1016/j.bmcl.2015.09.052","5E6","5DIA",34.83,"1.964","1.964","PIM1 in complex with Cpd36 ((1S,3S)-N1-(6-(5-(pyridin-3-yl)-1H-pyrazolo[3,4-c]pyridin-3-yl)pyridin-2-yl)cyclohexane-1,3-diamine)","MKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSKKLAAALEHHHHHH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5DIA"
"5DIN",,"X-RAY DIFFRACTION",2.52,51.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES monohydrate, 12% w/v Polyethylene glycol 20000",298,"10.18632/oncotarget.5326",,"5DIN",31.4,"1.864","1.864","Structural Basis for the Indispensable Role of a Unique Zinc Finger Motif in LNX2 Ubiquitination","EFNPLCFECGQQHWTRENHLYNYQNEVDDDLVCHICLQPLLQPLDTPCGHTFCYKCLRNFLQEKDFCPLDRKRLHFKLCKKSSILVHKLLDKLLVLCPFSSVCKDVMQRCDLEAHLKNRCPGASHRRVAL","Homo sapiens","LNX2, PDZRN1","Ligand of Numb protein X 2","1","5DIN"
"5DIQ",,"X-RAY DIFFRACTION",2.98,58.7,"VAPOR DIFFUSION, HANGING DROP",5.3,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/cmdc.201500338",,"5DIQ",40.77,"2.1","2.1","Crystal structure of human FPPS in complex with salicylic acid derivative 3a","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DIQ"
"5DIT",,"X-RAY DIFFRACTION",2.4,48.74,"VAPOR DIFFUSION, HANGING DROP",7.5,"22 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,"10.1021/acs.jmedchem.5b00785","5B8","5DIT",14.71,"2.25","2.25","The Fk1 domain of FKBP51 in complex with the new synthetic ligand (1R)-3-(3,4-dimethoxyphenyl)-1-f3-[2-(morpholin-4-yl)ethoxy]phenylgpropyl(2S)-1-[(2S,3R)-2-cyclohexyl-3-hydroxybutanoyl]piperidine-2-carboxylate","GAPATVTEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGE","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5DIT"
"5DIU",,"X-RAY DIFFRACTION",2.21,44.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"10 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,"10.1021/acs.jmedchem.5b01355","5BG","5DIU",14.77,"1.3","1.3","The Fk1 domain of FKBP51 in complex with the new synthetic ligand 2-(3-((R)-1-((S)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamido)-3-(3,4-dimethoxyphenyl)propyl)phenoxy)acetic acid","GAPATVTEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKGE","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5DIU"
"5DIV",,"X-RAY DIFFRACTION",3.54,65.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"16 % PEG-3350, 0.2 M NH4-acetate and 0.1 M HEPES-NaOH pH 7.5",293,"10.1021/acs.jmedchem.5b01355","5BH","5DIV",14.43,"1.65","1.65","The Fk1 domain of FKBP51 in complex with the new synthetic ligand (S)-N-(1-carbamoylcyclopentyl)-1-((S)-2-cyclohexyl-2-(3,4,5-trimethoxyphenyl)acetyl)piperidine-2-carboxamide","GAPATVTEQGEDITSKKDRGVLKIVKRVGNGEETPMIGDKVYVHYKGKLSNGKKFDSSHDRNEPFVFSLGKGQVIKAWDIGVATMKKGEICHLLCKPEYAYGSAGSLPKIPSNATLFFEIELLDFKG","Homo sapiens","FKBP5, AIG6, FKBP51","Peptidyl-prolyl cis-trans isomerase FKBP5","1","5DIV"
"5DJ4",,"X-RAY DIFFRACTION",3.84,67.99,"VAPOR DIFFUSION, HANGING DROP",6,"1.2 M disodium malonate, 0.1 M MES pH 6.0, 1% (v/v) Jeffamine ED 2001",291,"10.1126/science.aad2087",,"5DJ4",273.46,"2.697","2.697","Leucine-bound Sestrin2 from Homo sapiens","MIVADSECRAELKDYLRFAPGGVGDSGPGEEQRESRARRGPRGPSAFIPVEEVLREGAESLEQHLGLEALMSSGRVDNLAVVMGLHPDYFTSFWRLHYLLLHTDGPLASSWRHYIAIMAAARHQCSYLVGSHMAEFLQTGGDPEWLLGLHRAPEKLRKLSEINKLLAHRPWLITKEHIQALLKTGEHTWSLAELIQALVLLTHCHSLSSFVFGCGILPEGDADGSPAPQAPTPPSEQSSPPSRDPLNNSGGFESARDVEALMERMQQLQESLLRDEGTSQEEMESRFELEKSESLLVTPSADILEPSPHPDMLCFVEDPTFGYEDFTRRGAQAPPTFRAQDYTWEDHGYSLIQRLYPEGGQLLDEKFQAAYSLTYNTIAMHSGVDTSVLRRAIWNYIHCVFGIRYDDYDYGEVNQLLERNLKVYIKTVACYPEKTTRRMYNLFWRHFRHSEKVHVNLLLLEARMQAALLYALRAITRYMT","Homo sapiens","SESN2, SEST2, Hi95","Sestrin-2","1","5DJ4"
"5DJL",,"X-RAY DIFFRACTION",2.54,51.51,"VAPOR DIFFUSION, HANGING DROP",,"100MM MES, PH 5.5, PH 6.0, 28% (W/V) PEG 8000, 20MM CACL2 10MM DTT, 10MM GSH. Soaked in 0.1MM Cisplatin for 24hrs.",293,,,"5DJL",48.58,"1.8","1.8","Structure of WT Human Glutathione Transferase in complex with cisplatin in the presence of glutathione.","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DJL"
"5DJM",,"X-RAY DIFFRACTION",2.55,51.79,"VAPOR DIFFUSION, HANGING DROP",,"100MM MES, PH 5.5, PH 6.0, 28% (W/V)  PEG 8000, 20MM CACL2 10MM DTT. Soaked in 0.1MM Cisplatin for 24hrs",293,,,"5DJM",47.73,"1.9","1.9","Structure of WT Human Glutathione Transferase in complex with cisplatin in the absence of glutathione.","MPPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5DJM"
"5DJP",,"X-RAY DIFFRACTION",2.77,55.63,"VAPOR DIFFUSION, HANGING DROP",5.3,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/cmdc.201500338",,"5DJP",40.57,"2.4","2.4","Crystal structure of human FPPS in complex with biaryl compound 5","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DJP"
"5DJR",,"X-RAY DIFFRACTION",2.98,58.73,"VAPOR DIFFUSION, HANGING DROP",5.3,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/cmdc.201500338",,"5DJR",40.74,"2.4","2.4","Crystal structure of human FPPS in complex with biaryl compound 6","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DJR"
"5DJV",,"X-RAY DIFFRACTION",2.89,57.4,"VAPOR DIFFUSION, HANGING DROP",4.7,"1.2M sodium potassium phosphate, 25% glycerol",292,"10.1002/cmdc.201500338",,"5DJV",40.55,"2.3","2.3","Crystal structure of human FPPS in complex with biaryl compound 8e","GPNSDVYAQEKQDFVQHFSQIVRVLTEDEMGHPEIGDAIARLKEVLEYNAIGGKYNRGLTVVVAFRELVEPRKQDADSLQRAWTVGWCVELLQAFFLVADDIMDSSLTRRGQICWYQKPGVGLDAINDANLLEACIYRLLKLYCREQPYYLNLIELFLQSSYQTEIGQTLDLLTAPQGNVDLVRFTEKRYKSIVKYKTAFYSFYLPIAAAMYMAGIDGEKEHANAKKILLEMGEFFQIQDDYLDLFGDPSVTGKIGTDIQDNKCSWLVVQCLQRATPEQYQILKENYGQKEAEKVARVKALYEELDLPAVFLQYEEDSYSHIMALIEQYAAPLPPAVFLGLARKIYKRRK","Homo sapiens","FDPS, FPS, KIAA1293","Farnesyl pyrophosphate synthase","1","5DJV"
"5DK3",,"X-RAY DIFFRACTION",3.22,61.75,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.8-2.2 M NH4H2PO4, 100 mM TRIS",303,"10.1038/nsmb.3129",,"5DK3",149.95,"2.28","2.28","Crystal Structure of Pembrolizumab, a full length IgG4 antibody","EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQKPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"Light Chain","1","5DK3"
,,,,,,,,,,,,,,,,"QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYWVRQAPGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAYMELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS","Homo sapiens",,"Heavy Chain","2","5DK3"
"5DK8",,"X-RAY DIFFRACTION",1.96,37.12,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2M magnesium chloride hexahydrate, 30% w/v PEG 4000, 0.1 M Tris pH 8.5",288,"10.1107/S2053230X15023390",,"5DK8",17.35,"1.32","1.32","Human ubiquitin in the P1 space group","HHQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRG","Homo sapiens","UBB","Polyubiquitin-B","1","5DK8"
"5DKA",,"X-RAY DIFFRACTION",,,"EVAPORATION",,"0.1 M HEPES, 10% PEG 8K",273,"10.1038/srep29232",,"5DKA",53.54,"1.55","1.55","A C2HC zinc finger is essential for the activity of the RING ubiquitin ligase RNF125","MGSVLSTDSGKSAPASATARALERRRDPELPVTSFDCAVCLEVLHQPVRTRCGHVFCRSCIATSLKNNKWTCPYCRAYLPSEGVPATDVAKRMKSEYKNCAECDTLVCLSEMRAHIRTCQKYIDKYGPLQELEETAARCVCPFCQRELYEDSLLDHCITHHRSERRPVFCPLCRLIPDENPSSFSGSLIRHLQVSHTLFYDDFIDFNIIEEALIRRVLDRSLLEYVNHSNTT","Homo sapiens","RNF125","E3 ubiquitin-protein ligase RNF125","1","5DKA"
"5DKC",,"X-RAY DIFFRACTION",3.34,63.15,"VAPOR DIFFUSION, SITTING DROP",7,"19% PEG 6K, 4% ethyleneglycol, 0.01M ZnCl2",277.15,,"5BW","5DKC",14.77,"1.6","1.6","Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with PFI-3 chemical probe","SMAEKLSPNPPKLTKQMNAIIDTVINYKDSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCHNAQTFNLEGSQIYEDSIVLQSVFKSARQKIAKEEE","Homo sapiens","SMARCA2, BAF190B, BRM, SNF2A, SNF2L2","Probable global transcription activator SNF2L2","1","5DKC"
"5DKD",,"X-RAY DIFFRACTION",2.98,58.78,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.1 M Bis Tris pH 7.2, 0.1 M ammonium acetate, 0.1 M ZnCl2, 15% PEG smear high (mixture from PEG8k to 20k)",277.15,,"5BW","5DKD",29.61,"2","2","Crystal structure of the bromodomain of human BRG1 (SMARCA4) in complex with PFI-3 chemical probe","SMLSPNPPNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKEDD","Homo sapiens","SMARCA4, BAF190A, BRG1, SNF2B, SNF2L4","Transcription activator BRG1","1","5DKD"
"5DKH",,"X-RAY DIFFRACTION",2.45,49.77,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG 6K, 10% ethyleneglycol, 0.1 Hepes pH 7, 0.01M ZnCl2",277.15,,"5C0","5DKH",44.38,"1.7","1.7","Crystal structure of the bromodomain of human BRM (SMARCA2) in complex with a hydroxyphenyl propenone inhibitor 17","SMAEKLSPNPPKLTKQMNAIIDTVINYKDSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLGDLEKDVMLLCHNAQTFNLEGSQIYEDSIVLQSVFKSARQKIAKEEE","Homo sapiens","SMARCA2, BAF190B, BRM, SNF2A, SNF2L2","Probable global transcription activator SNF2L2","1","5DKH"
"5DLI",,"X-RAY DIFFRACTION",2.69,54.33,"VAPOR DIFFUSION, HANGING DROP",5,"reservoir contained 13% PEG 6000, 0.2M Sodium Citrate",298,"10.1073/pnas.1705091114",,"5DLI",10.09,"2.1","2.1","Corkscrew assembly of SOD1 residues 28-38","KVKVWGSIKGL","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn]","1","5DLI"
"5DLS",,"X-RAY DIFFRACTION",2.8,55.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"10-15% PEG8K, 0.1 M Hepes pH
7.5, and 15% (v/v) 2-propanol.",292,"10.18632/oncotarget.5929","5CV","5DLS",34.78,"2.15","2.15","Identification of Novel, in vivo Active Chk1 Inhibitors Utilizing Structure Guided Drug Design","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGAKRPRVTSGGVSESPSGHHHHHHHH","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5DLS"
"5DLX",,"X-RAY DIFFRACTION",1.96,37.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"Ratio 1:1 (protein:precipitant). 12 mg/mL Brd4_BD1 protein. Protein buffer 10 mM HEPES (pH 7.5) 150 mM NaCl. Precipitant agent 22 % (w/v) PEG 3350, 10% (w/v) ethylene glycol 30 % (w/v), 0.3 M NaFormate. 1.0 mM inhibitor (in DMSO) final concentration. Cryoprotection with 10 % (w/v) glycerol",292,"10.1021/acschembio.6b00286","5D2","5DLX",15.6,"1.9","1.9","FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR N-{3-[4-(3-chlorophenyl)piperazin-1-yl]propyl}-1-{3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl}piperidine-4-carboxamide","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5DLX"
"5DLZ",,"X-RAY DIFFRACTION",2.15,42.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"Ratio 1:1 (protein:precipitant) 12 mg/mL Brd4_BD1 protein. Protein buffer 10 mM HEPES (pH 7.5) 150 mM NaCl.Precipitant agent 22 % (w/v) PEG 3350, 10% (w/v) ethylene glycol 30 % (w/v), 0.3 M NaNO3.  5.0 mM inhibitor (in DMSO) final concentration. Cryoprotection with 10% (w/v) glycerol.",292,"10.1021/acschembio.6b00286","5D1","5DLZ",15.56,"1.7","1.7","FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 4-[(1-methyl-2-oxo-1,2-dihydroquinolin-4-yl)oxy]-N-({1-[(3-methylphe methyl]piperidin-4-yl}methyl)butanamide","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5DLZ"
"5DMZ",,"X-RAY DIFFRACTION",2.6,52.72,"VAPOR DIFFUSION, SITTING DROP",7.6,"0.2 M NaCl, 15% PEG 3350",277,"10.1371/journal.pone.0144673",,"5DMZ",84.75,"2.4","2.4","Structure of human Bub1 kinase domain phosphorylated at Ser969","GPMDPSSLGTVDAPNFIVGNPWDDKLIFKLLSGLSKPVSSYPNTFEWQCKLPAIKPKTEFQLGSKLVYVHHLLGEGAFAQVYEATQGDLNDAKNKQKFVLKVQKPANPWEFYIGTQLMERLKPSMQHMFMKFYSAHLFQNGSVLVGELYSYGTLLNAINLYKNTPEKVMPQGLVISFAMRMLYMIEQVHDCEIIHGDIKPDNFILGNGFLEQDDEDDLSAGLALIDLGQSIDMKLFPKGTIFTAKCETSGFQCVEMLSNKPWNYQIDYFGVAATVYCMLFGTYMKVKNEGGECKPEGLFRRLPHLDMWNEFFHVMLNIPDCHHLPSLDLLRQKLKKVFQQHYTNKIRALRNRLIVLLLECKRSRK","Homo sapiens","BUB1, BUB1L","Mitotic checkpoint serine/threonine-protein kinase BUB1","1","5DMZ"
"5DN3",,"X-RAY DIFFRACTION",3.62,66,"VAPOR DIFFUSION, SITTING DROP",7,"50 mM HEPES, 200 mM magnesium sulfate, 20% PEG 3350",292,"10.1038/srep28528","5DN","5DN3",32.51,"2.05","2.05","Aurora A in complex with ATP and AA35.","GSMGSKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DN3"
"5DNF",,"X-RAY DIFFRACTION",5.83,78.89,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Tris, pH 7.5; 1.8 M (NH4)2SO4",303.15,"10.1073/pnas.1523981113",,"5DNF",73.68,"2.549","2.549","Crystal structure of CC chemokine 5 (CCL5) oligomer in complex with heparin","SSDTTPCCFAYIARPLPRAHIKEYFYTSGKCSNPAVVFVTRKNRQVCANPEKKWVREYINSLEMS","Homo sapiens","CCL5, D17S136E, SCYA5","C-C motif chemokine 5","1","5DNF"
"5DNR",,"X-RAY DIFFRACTION",3.61,65.96,"VAPOR DIFFUSION, SITTING DROP",7,"100 mM HEPES, 200 mM magnesium sulfate, 2-20% PEG 3350",292,"10.1038/srep28528",,"5DNR",32.19,"1.95","1.95","Aurora A Kinase in complex with ATP in space group P41212","GSMGSKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPS","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DNR"
"5DOG",,"X-RAY DIFFRACTION",2.04,39.2,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,"10.1002/cmdc.201600509",,"5DOG",30.17,"1.7","1.7","Crystal structure of human carbonic anhydrase isozyme II with 2-(Benzylamino)-3,5,6-trifluoro-4-[(2-phenylethyl)thio]benzene- sulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DOG"
"5DOH",,"X-RAY DIFFRACTION",2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,"10.1002/cmdc.201600509","5DU","5DOH",60.03,"1.05","1.05","Crystal structure of human carbonic anhydrase isozyme II with 2-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-3,5,6-trifluoro-4-[(2-hydroxyethyl)thio]benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DOH"
"5DOS",,"X-RAY DIFFRACTION",2.65,53.64,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM Hepes pH7.4, 200 mM magnesium sulfate, 2-20% PEG 3350",292,"10.1038/srep28528",,"5DOS",32.69,"2.98","2.98","Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DOS"
"5DOT",,"X-RAY DIFFRACTION",2.82,56.37,"VAPOR DIFFUSION, SITTING DROP",7.2,"20% PEG3350, 0.2 M tri-sodium citrate",294,"10.1038/srep16950",,"5DOT",328.92,"2.4","2.4","Crystal Structure of Human Carbamoyl phosphate synthetase I (CPS1), apo form","MSYYHHHHHHDYDIPTTENLYFQGAMDPSVKAQTAHIVLEDGTKMKGYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYKGQILTMANPIIGNGGAPDTTALDELGLSKYLESNGIKVSGLLVLDYSKDYNHWLATKSLGQWLQEEKVPAIYGVDTRMLTKIIRDKGTMLGKIEFEGQPVDFVDPNKQNLIAEVSTKDVKVYGKGNPTKVVAVDCGIKNNVIRLLVKRGAEVHLVPWNHDFTKMEYDGILIAGGPGNPALAEPLIQNVRKILESDRKEPLFGISTGNLITGLAAGAKTYKMSMANRGQNQPVLNITNKQAFITAQNHGYALDNTLPAGWKPLFVNVNDQTNEGIMHESKPFFAVQFHPEVTPGPIDTEYLFDSFFSLIKKGKATTITSVLPKPALVASRVEVSKVLILGSGGLSIGQAGEFDYSGSQAVKAMKEENVKTVLMNPNIASVQTNEVGLKQADTVYFLPITPQFVTEVIKAEQPDGLILGMGGQTALNCGVELFKRGVLKEYGVKVLGTSVESIMATEDRQLFSDKLNEINEKIAPSFAVESIEDALKAADTIGYPVMIRSAYALGGLGSGICPNRETLMDLSTKAFAMTNQILVEKSVTGWKEIEYEVVRDADDNCVTVCNMENVDAMGVHTGDSVVVAPAQTLSNAEFQMLRRTSINVVRHLGIVGECNIQFALHPTSMEYCIIEVNARLSRSSALASKATGYPLAFIAAKIALGIPLPEIKNVVSGKTSACFEPSLDYMVTKIPRWDLDRFHGTSSRIGSSMKSVGEVMAIGRTFEESFQKALRMCHPSIEGFTPRLPMNKEWPSNLDLRKELSEPSSTRIYAIAKAIDDNMSLDEIEKLTYIDKWFLYKMRDILNMEKTLKGLNSESMTEETLKRAKEIGFSDKQISKCLGLTEAQTRELRLKKNIHPWVKQIDTLAAEYPSVTNYLYVTYNGQEHDVNFDDHGMMVLGCGPYHIGSSVEFDWCAVSSIRTLRQLGKKTVVVNCNPETVSTDFDECDKLYFEELSLERILDIYHQEACGGCIISVGGQIPNNLAVPLYKNGVKIMGTSPLQIDRAEDRSIFSAVLDELKVAQAPWKAVNTLNEALEFAKSVDYPCLLRPSYVLSGSAMNVVFSEDEMKKFLEEATRVSQEHPVVLTKFVEGAREVEMDAVGKDGRVISHAISEHVEDAGVHSGDATLMLPTQTISQGAIEKVKDATRKIAKAFAISGPFNVQFLVKGNDVLVIECNLRASRSFPFVSKTLGVDFIDVATKVMIGENVDEKHLPTLDHPIIPADYVAIKAPMFSWPRLRDADPILRCEMASTGEVACFGEGIHTAFLKAMLSTGFKIPQKGILIGIQQSFRPRFLGVAEQLHNEGFKLFATEATSDWLNANNVPATPVAWPSQEGQNPSLSSIRKLIRDGSIDLVINLPNNNTKFVHDNYVIRRTAVDSGIPLLTNFQVTKLFAEAVQKSRKVDSKSLFHYRQYSAGKAA","Homo sapiens","CPS1","Carbamoyl-phosphate synthase [ammonia], mitochondrial","1","5DOT"
"5DOU",,"X-RAY DIFFRACTION",2.52,51.15,"VAPOR DIFFUSION, SITTING DROP",7.2,"0.4 M MgCl2, 0.2 M ammonium tartrate",277,"10.1038/srep16950",,"5DOU",662.38,"2.6","2.6","Crystal Structure of Human Carbamoyl phosphate synthetase I (CPS1), ligand-bound form","MSYYHHHHHHDYDIPTTENLYFQGAMDPSVKAQTAHIVLEDGTKMKGYSFGHPSSVAGEVVFNTGLGGYPEAITDPAYKGQILTMANPIIGNGGAPDTTALDELGLSKYLESNGIKVSGLLVLDYSKDYNHWLATKSLGQWLQEEKVPAIYGVDTRMLTKIIRDKGTMLGKIEFEGQPVDFVDPNKQNLIAEVSTKDVKVYGKGNPTKVVAVDCGIKNNVIRLLVKRGAEVHLVPWNHDFTKMEYDGILIAGGPGNPALAEPLIQNVRKILESDRKEPLFGISTGNLITGLAAGAKTYKMSMANRGQNQPVLNITNKQAFITAQNHGYALDNTLPAGWKPLFVNVNDQTNEGIMHESKPFFAVQFHPEVTPGPIDTEYLFDSFFSLIKKGKATTITSVLPKPALVASRVEVSKVLILGSGGLSIGQAGEFDYSGSQAVKAMKEENVKTVLMNPNIASVQTNEVGLKQADTVYFLPITPQFVTEVIKAEQPDGLILGMGGQTALNCGVELFKRGVLKEYGVKVLGTSVESIMATEDRQLFSDKLNEINEKIAPSFAVESIEDALKAADTIGYPVMIRSAYALGGLGSGICPNRETLMDLSTKAFAMTNQILVEKSVTGWKEIEYEVVRDADDNCVTVCNMENVDAMGVHTGDSVVVAPAQTLSNAEFQMLRRTSINVVRHLGIVGECNIQFALHPTSMEYCIIEVNARLSRSSALASKATGYPLAFIAAKIALGIPLPEIKNVVSGKTSACFEPSLDYMVTKIPRWDLDRFHGTSSRIGSSMKSVGEVMAIGRTFEESFQKALRMCHPSIEGFTPRLPMNKEWPSNLDLRKELSEPSSTRIYAIAKAIDDNMSLDEIEKLTYIDKWFLYKMRDILNMEKTLKGLNSESMTEETLKRAKEIGFSDKQISKCLGLTEAQTRELRLKKNIHPWVKQIDTLAAEYPSVTNYLYVTYNGQEHDVNFDDHGMMVLGCGPYHIGSSVEFDWCAVSSIRTLRQLGKKTVVVNCNPETVSTDFDECDKLYFEELSLERILDIYHQEACGGCIISVGGQIPNNLAVPLYKNGVKIMGTSPLQIDRAEDRSIFSAVLDELKVAQAPWKAVNTLNEALEFAKSVDYPCLLRPSYVLSGSAMNVVFSEDEMKKFLEEATRVSQEHPVVLTKFVEGAREVEMDAVGKDGRVISHAISEHVEDAGVHSGDATLMLPTQTISQGAIEKVKDATRKIAKAFAISGPFNVQFLVKGNDVLVIECNLRASRSFPFVSKTLGVDFIDVATKVMIGENVDEKHLPTLDHPIIPADYVAIKAPMFSWPRLRDADPILRCEMASTGEVACFGEGIHTAFLKAMLSTGFKIPQKGILIGIQQSFRPRFLGVAEQLHNEGFKLFATEATSDWLNANNVPATPVAWPSQEGQNPSLSSIRKLIRDGSIDLVINLPNNNTKFVHDNYVIRRTAVDSGIPLLTNFQVTKLFAEAVQKSRKVDSKSLFHYRQYSAGKAA","Homo sapiens","CPS1","Carbamoyl-phosphate synthase [ammonia], mitochondrial","1","5DOU"
"5DPQ",,"X-RAY DIFFRACTION",2.21,44.28,"VAPOR DIFFUSION, HANGING DROP",4,"30% PEG 4000, 0.1 M sodium acetate, 0.1 M ammonium acetate, pH 4.6, EVAPORATION, temperature 298K",298,"10.1016/j.str.2016.05.022",,"5DPQ",31.32,"1.775","1.775","Crystal Structure of E72A mutant of domain swapped dimer Human Cellular Retinol Binding Protein","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTKVIDQDGDNFKTKTTSTFRNYDVDFTVGVEFDAYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKQWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5DPQ"
"5DPS",,"X-RAY DIFFRACTION",2.5,50.89,"VAPOR DIFFUSION, SITTING DROP",8,"4% v/v Tacsimate pH 8.0, 12% w/v Polyethylene glycol 3,350",278,"10.15252/embr.201643587",,"5DPS",46.74,"2","2","Crystal structure of PLEKHM1 LIR-fused human GABARAP_2-117","GSVRPQQEDEWVNVGSKFVYKEEHPFEKRRSEGEKIRKKYPDRVPVIVEKAPKARIGDLDKKKYLVPSDLTVGQFYFLIRKRIHLRAEDALFFFVNNVIPPTSATMGQLYQEHHEEDFFLYIAYSDESVYGL","Homo sapiens","PLEKHM1, GABARAP, KIAA0356, FLC3B, HT004","Pleckstrin homology domain-containing family M member 1,Gamma-aminobutyric acid receptor-associated protein","1","5DPS"
"5DPT",,"X-RAY DIFFRACTION",3.48,64.69,"VAPOR DIFFUSION, SITTING DROP",7.2,"20% w/v Polyethylene glycol 3,350, 0.2 M NaCl, 8% MPD pH 7.2",278,"10.15252/embr.201643587",,"5DPT",31.65,"2.9","2.9","Crystal structure of PLEKHM1 LIR-fused human GABARAPL1_2-117","GSVRPQQEDEWVNVGSKFQYKEDHPFEYRKKEGEKIRKKYPDRVPVIVEKAPKARVPDLDKRKYLVPSDLTVGQFYFLIRKRIHLRPEDALFFFVNNTIPPTSATMGQLYEDNHEEDYFLYVAYSDESVYGK","Homo sapiens","PLEKHM1, GABARAPL1, KIAA0356, GEC1","Pleckstrin homology domain-containing family M member 1, Gamma-aminobutyric acid receptor-associated protein-like 1,Gamma-aminobutyric acid receptor-associated protein-like 1","1","5DPT"
"5DPV",,"X-RAY DIFFRACTION",2.77,55.58,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292,"10.1038/srep28528","SKE","5DPV",32.55,"2.285","2.285","Aurora A Kinase in Complex with AA35 and JNJ-7706621 in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DPV"
"5DQ0",,"X-RAY DIFFRACTION",3.26,62.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"25 % PEG 550 MME, 0.1 M MES pH 6.5, 0.01 M ZnSO4",289.15,,,"5DQ0",18.96,"1.8","1.8","Structure of human neuropilin-2 b1 domain with novel and unique zinc binding site","GHMFQCNVPLGMESGRIANEQISASSTYSDGRWTPQQSRLHGDDNGWTPNLDSNKEYLQVDLRFLTMLTAIATQGAISRETQNGYYVKSYKLEVSTNGEDWMVYRHGKNHKVFQANNDATEVVLNKLHAPLLTRFVRIRPQTWHSGIALRLELFGCRVTSGS","Homo sapiens","NRP2, VEGF165R2","Neuropilin-2","1","5DQ0"
"5DQ8",,"X-RAY DIFFRACTION",2.41,48.9,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1 M HEPES pH 7.2, 2.4 M sodium formate",293,"10.1016/j.str.2015.09.009","FLF","5DQ8",55.82,"2.305","2.305","Crystal structure of human transcription factor TEAD2 in complex with flufenamic acid","MAWQARGLGTARLQLVEFSAFVEPPDAVDSYQRHLFVHISQHCPSPGAPPLESVDVRQIYDKFPEKKGGLRELYDRGPPHAFFLVKFWADLNWGPSGEEAGAGGSISSGGFYGVSSQYESLEHMTLTCSSKVCSFGKQVVEKVETERAQLEDGRFVYRLLRSPMCEYLVNFLHKLRQLPERYMMNSVLENFTILQVVTNRDTQELLLCTAYVFEVSTSERGAQHHIYRLVRDVEHHHHHH","Homo sapiens","TEAD2, TEF4","Transcriptional enhancer factor TEF-4","1","5DQ8"
"5DQC",,"X-RAY DIFFRACTION",3.21,61.66,"VAPOR DIFFUSION, HANGING DROP",,"PEG400
Na citrate
MgSO4",293,"10.1039/C5SC03718B","5E7","5DQC",132.37,"2.4651","2.4651","Co-crystal of BACE1 with compound 0211","GSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNI","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5DQC"
"5DQE",,"X-RAY DIFFRACTION",2.42,49.21,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.1 M HEPES pH 7.2 and 2.4 M sodium formate.",293,"10.1016/j.str.2015.09.009",,"5DQE",55.85,"2.183","2.183","Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid","MAWQARGLGTARLQLVEFSAFVEPPDAVDSYQRHLFVHISQHCPSPGAPPLESVDVRQIYDKFPEKKGGLRELYDRGPPHAFFLVKFWADLNWGPSGEEAGAGGSISSGGFYGVSSQYESLEHMTLTCSSKVCSFGKQVVEKVETERAQLEDGRFVYRLLRSPMCEYLVNFLHKLRQLPERYMMNSVLENFTILQVVTNRDTQELLLCTAYVFEVSTSERGAQHHIYRLVRDVEHHHHHH","Homo sapiens","TEAD2, TEF4","Transcriptional enhancer factor TEF-4","1","5DQE"
"5DQO",,"X-RAY DIFFRACTION",2.87,57.1,"VAPOR DIFFUSION, HANGING DROP",,"300 mM lithium sulfate, 100 mM Tris, pH 8.5, 20% PEG3350",295,"10.1126/science.aag1789",,"5DQO",92.03,"2.3","2.3","Crystal structure of Y347F mutant of human primase p58 iron-sulfur cluster domain","GSPNSLDQIDLLSTKSFPPCMRQLHKALRENHHLRHGGRMQYGLFLKGIGLTLEQALQFWKQEFIKGKMDPDKFDKGYSFNIRHSFGKEGKRTDYTPFSCLKIILSNPPSQGDYHGCPFRHSDPELLKQKLQSYKISPGGISQILDLVKGTHYQVACQKYFEMIHNVDDCGFSLNHPNQFFCESQRILNGGKDIKKE","Homo sapiens","PRIM2, PRIM2A","DNA primase large subunit","1","5DQO"
"5DQY",,"X-RAY DIFFRACTION",2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",7,"Ammonium citrate, Bis-Tris propane",294.15,"10.1016/j.bbrc.2015.10.003",,"5DQY",12,"1.4","1.4","A fully oxidized human thioredoxin","MVKQIESKTAFQEALDAAGDKLVVVDFSATWCGPCKMIKPFFHSLSEKYSNVIFLEVDVDDCQDVASECEVKCMPTFQFFKKGQKVGEFSGANKEKLEATINELV","Homo sapiens","TXN, TRDX, TRX, TRX1","Thioredoxin","1","5DQY"
"5DR2",,"X-RAY DIFFRACTION",2.58,52.27,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulphate, 2-20 PEG3350",292,"10.1038/srep28528",,"5DR2",32.67,"2.46","2.46","Aurora A Kinase in Complex with AA30 and ATP in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DR2"
"5DR5",,"X-RAY DIFFRACTION",2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",7.5,"20% (w/v) PEG3350, 0.1M HEPES pH 7.5, 10mM zinc chloride",294,,,"5DR5",50.25,"1.85","1.85","Crystal structure of the sclerostin-neutralizing Fab AbD09097","QVQLVESGGGLVQPGGSLRLSCAASGFTFTNYYMHWVRQAPGKGLEWVSTIAYDGSSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARWFTDDIWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSEFLVPRGSGAPEQKLISEEDLNDAPHHHHHH","Homo sapiens",,"AbD09097 Fab heavy chain","1","5DR5"
,,,,,,,,,,,,,,,,"DIVLTQSPATLSLSPGERATLSCRASQSISSNELAWYQQKPGQAPRLLIYDTSNRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQYYSYPITFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEA","Homo sapiens",,"AbD09097 Fab light chain","2","5DR5"
"5DR6",,"X-RAY DIFFRACTION",2.82,56.31,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292,"10.1038/srep28528","SKE","5DR6",32.53,"2.534","2.534","Aurora A Kinase in Complex with AA30 and JNJ-7706621 in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DR6"
"5DR9",,"X-RAY DIFFRACTION",2.81,56.28,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292,"10.1038/srep28528","SKE","5DR9",32.56,"2.47","2.47","Aurora A Kinase in Complex with AA29 and JNJ-7706621 in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DR9"
"5DRD",,"X-RAY DIFFRACTION",2.66,53.74,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292,"10.1038/srep28528",,"5DRD",32.34,"2.13","2.13","Aurora A Kinase in Complex with ATP in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DRD"
"5DRS",,"X-RAY DIFFRACTION",1.99,37.7,"VAPOR DIFFUSION, SITTING DROP",7,"Crystallization buffer: 0.1M sodium BICINE, pH 9, 0.2 M ammonium sulfate and 2M sodium malonate pH 7 made from 1M sodium BICINE and 3.4M sodium malonate",291,"10.1002/cmdc.201600509","5EF","5DRS",30.24,"1.1","1.1","Crystal structure of human carbonic anhydraseisozyme II with 3-[(1S)-2,3-Dihydro-1H-inden-1-ylamino]-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DRS"
"5DRT",,"X-RAY DIFFRACTION",3.48,64.67,"VAPOR DIFFUSION",,"1.3M K/Na tartrate
0.1M Hepes pH7.2",293,"10.1021/acsmedchemlett.6b00167",,"5DRT",77.82,"2.69","2.69","Crystal structure of Dot1L in complex with inhibitor CPD2 [2-(2-(5-((2-chlorophenoxy)methyl)-1H-tetrazol-1-yl)acetyl)-N-(4-chlorophenyl)hydrazinecarboxamide]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DRT"
"5DRY",,"X-RAY DIFFRACTION",3.52,65.08,"VAPOR DIFFUSION",,"1.2M K/Na tartrate
0.1M Hepes pH7.2",293,"10.1021/acsmedchemlett.6b00167","5EK","5DRY",78.03,"2.41","2.41","Crystal structure of Dot1L in complex with inhibitor CPD3 [N-(1-(2-chlorophenyl)-1H-indol-6-yl)-2-(2-(5-(2-chlorophenyl)-1H-tetrazol-1-yl)acetyl)hydrazinecarboxamide]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DRY"
"5DS3",,"X-RAY DIFFRACTION",2.82,56.32,"VAPOR DIFFUSION, SITTING DROP",5.5,"20-25% PEG 3350, 0.2 M Ammonium Sulfate, 0.1 M Bis-Tris, pH 5.5",298,"10.1016/j.molcel.2015.10.013","09L","5DS3",30.87,"2.6","2.6","Crystal structure of constitutively active PARP-1","MGSSHHHHHHSSGLVPRGSHMTKSKLPKPVQDLIKMIFGSGSGSGGDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKTS","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5DS3"
"5DSK",,"X-RAY DIFFRACTION",2.08,40.85,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSK",29.45,"1.3","1.3","Structure of CO2 released holo-form of human carbonic anhydrase II with 3 min warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSK"
"5DSL",,"X-RAY DIFFRACTION",2.08,40.77,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSL",29.45,"1.45","1.45","Structure of CO2 released holo-form of human carbonic anhydrase II with 10 min warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSL"
"5DSM",,"X-RAY DIFFRACTION",2.08,40.78,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSM",29.45,"1.3","1.3","Structure of CO2 released holo-form of human carbonic anhydrase II with 25 min warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSM"
"5DSO",,"X-RAY DIFFRACTION",2.06,40.19,"VAPOR DIFFUSION, HANGING DROP",,"1.3M sodium citrate, 100mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSO",29.47,"1.4","1.4","Structure of CO2 bound apo-form of human carbonic anhydrase II with 0 sec (no) warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSO"
"5DSP",,"X-RAY DIFFRACTION",2.07,40.46,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSP",29.38,"1.4","1.4","Structure of CO2 released apo-form of human carbonic anhydrase II with 40 sec warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSP"
"5DSQ",,"X-RAY DIFFRACTION",2.05,40.11,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSQ",29.38,"1.5","1.5","Structure of CO2 released apo-form of human carbonic anhydrase II with 3 min warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSQ"
"5DSR",,"X-RAY DIFFRACTION",2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",,"1.3 M sodium citrate
100 mM TrisHCl pH 7.8",293,"10.1073/pnas.1520786113",,"5DSR",29.38,"1.3","1.3","Structure of CO2 released apo-form of human carbonic anhydrase II with 10 min warming","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5DSR"
"5DST",,"X-RAY DIFFRACTION",3.17,61.18,"VAPOR DIFFUSION, SITTING DROP",,"Tris-Cl, NaCl, PEG6000",293,"10.1016/j.jmb.2016.02.007",,"5DST",583.45,"2.963","2.963","Crystal structure of human PRMT8 in complex with SAH","GPLGSEEMTSRDYYFDSYAHFGIHEEMLKDEVRTLTYRNSMYHNKHVFKDKVVLDVGSGTGILSMFAAKAGAKKVFGIECSSISDYSEKIIKANHLDNIITIFKGKVEEVELPVEKVDIIISEWMGYCLFYESMLNTVIFARDKWLKPGGLMFPDRAALYVVAIEDRQYKDFKIHWWENVYGFDMTCIRDVAMKEPLVDIVDPKQVVTNACLIKEVDIYTVKTEELSFTSAFCLQIQRNDYVHALVTYFNIEFTKCHKKMGFSTAPDAPYTHWKQTVFYLEDYLTVRRGEEIYGTISMKPNAKNVRDLDFTVDLDFKGQLCETSVSNDYKMR","Homo sapiens","PRMT8, HRMT1L3, HRMT1L4","Protein arginine N-methyltransferase 8","1","5DST"
"5DSU",,"X-RAY DIFFRACTION",1.97,37.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"37% PEG 400, 100 mM HEPES, 250 MM CaCl2",290,"10.1016/j.bbapap.2017.03.003",,"5DSU",9.02,"1.93","1.93","Crystal structure of double mutant of N-domain of human calmodulin","MDQLTEEQIAEFKEAFSLYDKDGDGTITTKELGTVMRSLGLNPTEAELQDMINEVDADGNGTIDFPEFLTMMARIMKY","Homo sapiens","CALM1, CALM, CAM, CAM1, CALM2, CAM2, CAMB, CALM3, CALML2, CAM3, CAMC, CAMIII","Calmodulin","1","5DSU"
"5DSV",,"X-RAY DIFFRACTION",2.45,49.74,"VAPOR DIFFUSION, SITTING DROP",7.4,"24% PEG400, 100 mM Tris-HCl (pH 7.5), 0.2 M magnesium chloride",293,"10.1038/srep18167",,"5DSV",398.57,"3.75","3.75","Crystal structure of human proteasome alpha7 tetradecamer","MSSIGTGYDLSASTFSPDGRVFQVEYAMKAVENSSTAIGIRCKDGVVFGVEKLVLSKLYEEGSNKRLFNVDRHVGMAVAGLLADARSLADIAREEASNFRSNFGYNIPLKHLADRVAMYVHAYTLYSAVRPFGCSFMLGSYSVNDGAQLYMIDPSGVSYGYWGCAIGKARQAAKTEIEKLQMKEMTCRDIVKEVAKIIYIVHDEVKDKAFELELSWVGELTNGRHEIVPKDIREEAEKYAKESLKEEDESDDDNM","Homo sapiens","PSMA3, HC8, PSC8","Proteasome subunit alpha type-3","1","5DSV"
"5DSX",,"X-RAY DIFFRACTION",3.47,64.57,"VAPOR DIFFUSION",,"1.4M K/Na tartrate tetrahydrate,  0.1M Hepes pH6.8",293,"10.1021/acsmedchemlett.6b00167","5EW","5DSX",77.96,"2.41","2.41","Crystal structure of Dot1L in complex with inhibitor CPD10 [6'-chloro-1,4-dimethyl-5'-(2-methyl-6-((4-(methylamino)pyrimidin-2-yl)amino)-1H-indol-1-yl)-[3,3'-bipyridin]-2(1H)-one]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DSX"
"5DSY",,"X-RAY DIFFRACTION",2.63,53.28,"VAPOR DIFFUSION, SITTING DROP",8,"2.55-2.65 M NaCl and 0.1 M Tris",298,"10.1016/j.molcel.2015.10.013",,"5DSY",128.85,"2.7","2.7","Crystal structure of constitutively active PARP-2","MGSSHHHHHHSSGLVPRGSHPESQLDLRVQELIKLICNVQAMEEKTELQSPEHPLDQHYRNLHCALRPLDHESYEFKVISQYLQSTHAPTHSDYTMTLLDLFEVEKDGEKEAFREDLHNRMLLWHGSRMSNWVGILSHGLRIAPPEAPITGYMFGKGIYFADMSSKSANYCFASRLKNTGLLLLSEVALGQCNELLEANPKAEGLLQGKHSTKGLGKMAPSSAHFVTLNGSTVPLGPASDTGILNPDGYTLNYNEYIVYNPNQVRMRYLLKVQFNFLQLW","Homo sapiens","PARP2, ADPRT2, ADPRTL2","Poly [ADP-ribose] polymerase 2","1","5DSY"
"5DT0",,"X-RAY DIFFRACTION",2.64,53.46,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG3350",292,"10.1038/srep28528","SKE","5DT0",32.2,"2.15","2.15","Aurora A Kinase in Complex with JNJ-7706621 in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRATLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DT0"
"5DT1",,"X-RAY DIFFRACTION",2.54,51.61,"VAPOR DIFFUSION",7.5,"Crystals grown in a reservoir solution of 23% PEG 8000 and 0.1M HEPES pH 7.5 and flash frozen in liquid nitrogen with 20% PEG 400 as a cryoprotectant",293,"10.1128/JVI.01791-15",,"5DT1",51.72,"1.954","1.954","Crystal structure of human Fab CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody","QVQLVESGGGVVQPGTSLRLSCAASQFRFDGYGMHWVRQAPGKGLEWVASISHDGIKKYHAEKVWGRFTISRDNSKNTLYLQMNSLRPEDTALYYCAKDLREDECEEWWSDYYDFGKQLPCAKSRGGLVGIADNWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKGLEVLFQ","Homo sapiens",,"Fab Heavy chain of broadly neutralizing antibody VRC26.25","1","5DT1"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSAAPGQKVTISCSGNTSNIGNNFVSWYQQRPGRAPQLLIYETDKRPSGIPDRFSASKSGTSGTLAITGLQTGDEADYYCATWAASLSSARVFGTGTKVIVLVQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Fab Light chain of broadly neutralizing antibody VRC26.25","2","5DT1"
"5DT2",,"X-RAY DIFFRACTION",3.51,64.93,"VAPOR DIFFUSION",,"1.4M lithium sulfate
0.1M sodium citrate tribasic dihydrate
0.3M ammonium sulfate",293,"10.1021/acsmedchemlett.6b00167","5EV","5DT2",78.14,"2.3","2.3","Crystal structure of Dot1L in complex with inhibitor CPD11 [N4-methyl-N2-(2-methyl-1-(2-phenoxyphenyl)-1H-indol-6-yl)pyrimidine-2,4-diamine]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DT2"
"5DT3",,"X-RAY DIFFRACTION",2.75,55.34,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20 % PEG3350",292,"10.1038/srep28528",,"5DT3",32.55,"2.33","2.33","Aurora A Kinase in Complex with ATP in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DT3"
"5DT4",,"X-RAY DIFFRACTION",2.62,53.11,"VAPOR DIFFUSION, SITTING DROP",7.4,"100 mM HEPES pH 7.4, 200 mM magnesium sulfate, 2-20% PEG 3350",292,"10.1038/srep28528",,"5DT4",32.72,"2.86","2.86","Aurora A Kinase in Complex with AA35 and ATP in Space Group P6122","MGRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKPHHHHHH","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5DT4"
"5DTM",,"X-RAY DIFFRACTION",3.46,64.48,"VAPOR DIFFUSION",,"1.0M K/Na tartrate
0.1M Hepes pH6.8",293,"10.1021/acsmedchemlett.6b00168","5F4","5DTM",77.51,"2.2","2.2","Crystal structure of Dot1L in complex with inhibitor CPD1 [4-(2,6-dichlorobenzoyl)-N-methyl-1H-pyrrole-2-carboxamide]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DTM"
"5DTQ",,"X-RAY DIFFRACTION",3.5,64.9,"VAPOR DIFFUSION",,"1.6M K/Na tartrate, 0.1M Hepes pH6.6",293,"10.1021/acsmedchemlett.6b00168",,"5DTQ",77.52,"2.61","2.61","Crystal structure of Dot1L in complex with inhibitor CPD3 [(2,6-dichlorophenyl)(quinolin-6-yl)methanone]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DTQ"
"5DTR",,"X-RAY DIFFRACTION",3.48,64.69,"VAPOR DIFFUSION",,"1.2M K/Na tartrate, 0.1M Hepes pH6.6",293,"10.1021/acsmedchemlett.6b00168","5F7","5DTR",77.58,"2.34","2.34","Crystal structure of Dot1L in complex with inhibitor CPD5 [N-(2,6-dichlorophenyl)-4-methoxy-N-methylquinolin-6-amine]","GPGEKLELRLKSPVGAEPAVYPWPLPVYDKHHDAAHEIIETIRWVCEEIPDLKLAMENYVLIDYDTKSFESMQRLCDKYNRAIDSIHQLWKGTTQPMKLNTRPSTGLLRHILQQVYNHSVTDPEKLNNYEPFSPEVYGETSFDLVAQMIDEIKMTDDDLFVDLGSGVGQVVLQVAAATNCKHHYGVEKADIPAKYAETMDREFRKWMKWYGKKHAEYTLERGDFLSEEWRERIANTSVIFVNNFAFGPEVDHQLKERFANMKEGGRIVSSKPFAPLNFRINSRNLSDIGTIMRVVELSPLKGSVSWTGKPVSYYLHTIDRTILENYFSSLKNPG","Homo sapiens","DOT1L, KIAA1814, KMT4","Histone-lysine N-methyltransferase, H3 lysine-79 specific","1","5DTR"
"5DU3",,"X-RAY DIFFRACTION",2.58,52.31,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG3350 w/v and 200 mM KF with a crystallization drop size of 1 microlitre and a protein content of 70% w/v",293,"10.1016/j.str.2016.09.013",,"5DU3",85.56,"2.1","2.1","Active form of human C1-inhibitor","TGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFVLWDQQHKFPVFMGRVYDPRA","Homo sapiens","SERPING1, C1IN, C1NH","Plasma protease C1 inhibitor","1","5DU3"
"5DUQ",,"X-RAY DIFFRACTION",3.64,66.2,"VAPOR DIFFUSION, SITTING DROP",9,"11 mg/ml of C1-inhibitor was mixed with 5kDa dextran sulfate in a 1:2 molar ratio and incubated on ice for an hour.  Crystals grew in0.1 M SPG (pH 9), 25% w/v PEG 1500 0.1 M MgCl hexahydrate after 10 days.",293,"10.1016/j.str.2016.09.013",,"5DUQ",86.87,"2.9","2.9","Active human c1-inhibitor in complex with dextran sulfate","TTGSFCPGPVTLCSDLESHSTEAVLGDALVDFSLKLYHAFSAMKKVETNMAFSPFSIASLLTQVLLGAGENTKTNLESILSYPKDFTCVHQALKGFTTKGVTSVSQIFHSPDLAIRDTFVNASRTLYSSSPRVLSNNSDANLELINTWVAKNTNNKISRLLDSLPSDTRLVLLNAIYLSAKWKTTFDPKKTRMEPFHFKNSVIKVPMMNSKKYPVAHFIDQTLKAKVGQLQLSHNLSLVILVPQNLKHRLEDMEQALSPSVFKAIMEKLEMSKFQPTLLTLPRIKVTTSQDMLSIMEKLEFFDFSYDLNLCGLTEDPDLQVSAMQHQTVLELTETGVEAAAASAISVARTLLVFEVQQPFLFMLWDQQHKFPVFMGRVYDPRA","Homo sapiens","SERPING1, C1IN, C1NH","Plasma protease C1 inhibitor","1","5DUQ"
"5DUU",,"X-RAY DIFFRACTION",1.89,34.86,"VAPOR DIFFUSION, HANGING DROP",8,"3.5 M Sodium formate, 0.1 M Tris",293.15,"10.1038/srep20289",,"5DUU",70.26,"2","2","Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with glycerol","MAYVPAPGYQPTYNPTLPYYQPIPGGLNVGMSVYIQGVASEHMKRFFVNFVVGQDPGSDVAFHFNPRFDGWDKVVFNTLQGGKWGSEERKRSMPFKKGAAFELVFIVLAEHYKVVVNGNPFYEYGHRLPLQMVTHLQVDGDLQLQSINFIGGQPL","Homo sapiens","LGALS4","Galectin-4","1","5DUU"
"5DUV",,"X-RAY DIFFRACTION",1.88,34.52,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.2 M calcium acetate, 20 % w/v PEG 3350",293.15,"10.1038/srep20289",,"5DUV",71.54,"1.9","1.9","Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with lactose","MAYVPAPGYQPTYNPTLPYYQPIPGGLNVGMSVYIQGVASEHMKRFFVNFVVGQDPGSDVAFHFNPRFDGWDKVVFNTLQGGKWGSEERKRSMPFKKGAAFELVFIVLAEHYKVVVNGNPFYEYGHRLPLQMVTHLQVDGDLQLQSINFIGGQPL","Homo sapiens","LGALS4","Galectin-4","1","5DUV"
"5DUW",,"X-RAY DIFFRACTION",1.87,34.27,"VAPOR DIFFUSION, HANGING DROP",8,"3.5 M sodium formate, 0.1 M Tris",293.15,"10.1038/srep20289",,"5DUW",71.59,"1.7","1.7","Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with lactose-3'-sulfate","MAYVPAPGYQPTYNPTLPYYQPIPGGLNVGMSVYIQGVASEHMKRFFVNFVVGQDPGSDVAFHFNPRFDGWDKVVFNTLQGGKWGSEERKRSMPFKKGAAFELVFIVLAEHYKVVVNGNPFYEYGHRLPLQMVTHLQVDGDLQLQSINFIGGQPL","Homo sapiens","LGALS4","Galectin-4","1","5DUW"
"5DUX",,"X-RAY DIFFRACTION",1.88,34.67,"VAPOR DIFFUSION, HANGING DROP",8,"3.5 M sodium formate, 0.1 M Tris",293.15,"10.1038/srep20289",,"5DUX",71.1,"1.85","1.85","Crystal structure of the human galectin-4 N-terminal carbohydrate recognition domain in complex with 2'-fucosyllactose","MAYVPAPGYQPTYNPTLPYYQPIPGGLNVGMSVYIQGVASEHMKRFFVNFVVGQDPGSDVAFHFNPRFDGWDKVVFNTLQGGKWGSEERKRSMPFKKGAAFELVFIVLAEHYKVVVNGNPFYEYGHRLPLQMVTHLQVDGDLQLQSINFIGGQPL","Homo sapiens","LGALS4","Galectin-4","1","5DUX"
"5DV2",,"X-RAY DIFFRACTION",3.18,61.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.1M ammonium tartrate, 0.2M NDSB-201",293,"10.1002/1873-3468.12160","C5P","5DV2",45.46,"2.07","2.07","Crystal structure of human CNOT6L in complex with cytidine-5'-monophosphate","MLDNLAVHPEQLPPRPWITLKERDQILPSASFTVMCYNVLCDKYATRQLYGYCPSWALNWEYRKKGIMEEIVNCDADIISLQEVETEQYFTLFLPALKERGYDGFFSPKSRAKIMSEQERKHVDGCAIFFKTEKFTLVQKHTVEFNQVAMANSDGSEAMLNRVMTKDNIGVAVVLEVHKELFGAGMKPIHAADKQLLIVANAHMHWDPEYSDVKLIQTMMFVSEVKNILEKASSRPGSPTADPNSIPLVLCADLNSLPDSGVVEYLSNGGVADNHKDFKELRYNECLMNFSCNGKNGSSEGRITHGFQLKSAYENNLMPYTNYTFDFKGVIDYIFYSKTHMNVLGVLGPLDPQWLVENNITGCPHPHIPSDHFSLLTQLELHPPLLPLVNGVHLPNRR","Homo sapiens","CNOT6L, CCR4B","CCR4-NOT transcription complex subunit 6-like","1","5DV2"
"5DV4",,"X-RAY DIFFRACTION",3.2,61.58,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M Hepes, 1.1M ammonium tartrate, 0.2M NDSB-201",293,"10.1002/1873-3468.12160","NMY","5DV4",45.95,"1.8","1.8","Crystal structure of human CNOT6L in complex with neomycin","MLDNLAVHPEQLPPRPWITLKERDQILPSASFTVMCYNVLCDKYATRQLYGYCPSWALNWEYRKKGIMEEIVNCDADIISLQEVETEQYFTLFLPALKERGYDGFFSPKSRAKIMSEQERKHVDGCAIFFKTEKFTLVQKHTVEFNQVAMANSDGSEAMLNRVMTKDNIGVAVVLEVHKELFGAGMKPIHAADKQLLIVANAHMHWDPEYSDVKLIQTMMFVSEVKNILEKASSRPGSPTADPNSIPLVLCADLNSLPDSGVVEYLSNGGVADNHKDFKELRYNECLMNFSCNGKNGSSEGRITHGFQLKSAYENNLMPYTNYTFDFKGVIDYIFYSKTHMNVLGVLGPLDPQWLVENNITGCPHPHIPSDHFSLLTQLELHPPLLPLVNGVHLPNRR","Homo sapiens","CNOT6L, CCR4B","CCR4-NOT transcription complex subunit 6-like","1","5DV4"
"5DVO",,"X-RAY DIFFRACTION",2.53,55.84,"VAPOR DIFFUSION",,"100mM Sodium Acetate pH 4.5 + 2000mM Ammonium Sulfate",294,"10.1016/j.str.2016.02.013",,"5DVO",51.36,"2.5","2.5","Fc K392D/K409D homodimer","DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYDTTPPVLDSDGSFFLYSDLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5DVO"
"5DVX",,"X-RAY DIFFRACTION",2.84,56.69,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris HCl, pH 8.5, 8% (w/v) PEG 8000",290,"10.1021/acs.biochem.6b00243","CL","5DVX",58.08,"1.598","1.598","Crystal structure of the catalytic-domain of human carbonic anhydrase IX at 1.6 angstrom resolution","HWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFSPALRPLELSGFQLPPLPELRLRNNGHSVQLTLPPGLEMKLGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTKYARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVSLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFPAGVDSSPR","Homo sapiens","CA9, G250, MN","Carbonic anhydrase 9","1","5DVX"
"5DW1",,"X-RAY DIFFRACTION",3,59.03,"VAPOR DIFFUSION, SITTING DROP",7,"2.6 M sodium malonate",298,"10.1016/j.bbrc.2016.06.021","5GD","5DW1",55.01,"1.55","1.55","X-ray crystal structure of human BRD2(BD2) in complex with RVX297 to 1.55 A resolution","SMKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5DW1"
"5DW2",,"X-RAY DIFFRACTION",2.12,41.93,"VAPOR DIFFUSION, SITTING DROP",6.6,"30% PEG2000 MME, 0.1 M potassium thiocyanate",298,"10.1016/j.bbrc.2016.06.021","5GD","5DW2",16,"1.12","1.12","X-ray crystal structure of human BRD4(BD1) in complex with RVX297 to 1.12 A resolution","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEETE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5DW2"
"5DWP",,"X-RAY DIFFRACTION",2.17,43.4,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M sodium citrate, 
1.6 M ammonium sulfate, 
pH=5.0",293,"10.1107/S2059798316000954",,"5DWP",25.41,"1.2","1.2","Crystal Structure of human transthyretin (TTR) processed with the CrystalDirect automated mounting and cryo-cooling technology","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNP","Homo sapiens","TTR, PALB","Transthyretin","1","5DWP"
"5DWR",,"X-RAY DIFFRACTION",3.01,59.07,"VAPOR DIFFUSION, HANGING DROP",5.5,"Crystallant:  0.6 to 1.0 mM Ammonium monophosphate (NH4)2HPO4, 200-350 mM sodium chloride, 0.1 M Citrate, pH 5.5, 1ul (10mg/ml) protein : 1ul crystallant",289,"10.1021/acs.jmedchem.5b01275","5H7","5DWR",38.04,"2","2","Identification of N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1,2 and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies","MAHHHHHHLEVLFQGPLLSKINSLAHLRAAPCNDLHATKLAPGKEKEPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLSPGPSK","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5DWR"
"5DX4",,"X-RAY DIFFRACTION",2.45,49.84,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG3350, 0.2M NaNO3, 0.1M HEPES, 10% EtGhly,pH 7.0",277,"10.1021/acs.jmedchem.5b01511","E0C","5DX4",15.63,"2.3","2.3","Crystal Structure of the first bromodomain of human BRD4 in complex with benzo[cd]indol-2(1H)-one ligand","GSNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5DX4"
"5DXJ",,"X-RAY DIFFRACTION",2.43,49.28,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M Ammonium Sulfate, 0.1 M Tris pH 8.5, 18% w/v PEG 3350",291,"10.1021/acschembio.5b00773",,"5DXJ",160.48,"1.95","1.95","Crystal structure of CARM1 and sinefungin","SIARSVFSERTEESSAVQYFQFYGYLSQQQNMMQDYVRTGTYQRAILQNHTDFKDKIVLDVGCGSGILSFFAAQAGARKIYAVEASTMAQHAEVLVKSNNLTDRIVVIPGKVEEVSLPEQVDIIISEPMGYMLFNERMLESYLHAKKYLKPSGNMFPTIGDVHLAPFTDEQLYMEQFTKANFWYQPSFHGVDLSALRGAAVDEYFRQPVVDTFDIRILMAKSVKYTVNFLEAKEGDLHRIEIPFKFHMLHSGLVHGLAFWFDVAFIGSIMTVWLSTAPTEPLTHWYQVRCLFQSPLFAKAGDTLSGTCLLIANKRQSYDISIVAQVDQTGSKSSNLLDLKNPFFRYTGT","Homo sapiens","CARM1, PRMT4","Histone-arginine methyltransferase CARM1","1","5DXJ"
"5DXT",,"X-RAY DIFFRACTION",2.6,52.3,"VAPOR DIFFUSION, HANGING DROP",,"PEG 20000",293,"10.1021/acs.jmedchem.5b01483","5H5","5DXT",112.5,"2.25","2.25","p110alpha with GDC-0326","NREEKILNREIGFAIGMPVCEFDMVKDPEVQDFRRNILNVCKEAVDLRDLNSPHSRAMYVYPPNVESSPELPKHIYNKLDKGQIIVVIWVIVSPNNDKQKYTLKINHDCVPEQVIAEAIRKKTRSMLLSSEQLKLCVLEYQGKYILKVCGCDEYFLEKYPLSQYKYIRSCIMLGRMPNLMLMAKESLYSQLPMDCFTMPSYSRRISTATPYMNGETSTKSLWVINSALRIKILCATYVNVNIRDIDKIYVRTGIYHGGEPLCDNVNTQRVPCSNPRWNEWLNYDIYIPDLPRAARLCLSICSVKGRKGAKEEHCPLAWGNINLFDYTDTLVSGKMALNLWPVPHGLEDLLNPIGVTGSNPNKETPCLELEFDWFSSVVKFPDMSVIEEHANWSVSREAGFSYSHAGLSNRLARDNELRENDKEQLKAISTRDPLSEITEQEKDFLWSHRHYCVTIPEILPKLLLSVKWNSRDEVAQMYCLVKDWPPIKPEQAMELLDCNYPDPMVRGFAVRCLEKYLTDDKLSQYLIQLVQVLKYEQYLDNLLVRFLLKKALTNQRIGHFFFWHLKSEMHNKTVSQRFGLLLESYCRACGMYLKHLNRQVEAMEKLINLTDILKQEKKDETQKVQMKFLVEQMRRPDFMDALQGFLSPLNPAHQLGNLRLEECRIMSSAKRPLWLNWENPDIMSELLFQNNEIIFKNGDDLRQDMLTLQIIRIMENIWQNQGLDLRMLPYGCLSIGDCVGLIEVVRNSHTIMQIQCKGGLKGALQFNSHTLHQWLKDKNKGEIYDAAIDLFTRSCAGYCVATFILGIGDRHNSNIMVKDDGQLFHIDFGHFLDHKKKKFGYKRERVPFVLTQDFLIVISKGAQECTKTREFERFQEMCYKAYLAIRQHANLFINLFSMMLGSGMPELQSFDDIAYIRKTLALDKTEQEALEYFMKQMNDAHHGGWTTKMDWIFHTIKQHALN","Homo sapiens","PIK3CA","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform","1","5DXT"
"5DY4",,"X-RAY DIFFRACTION",2.96,58.46,"VAPOR DIFFUSION, SITTING DROP",7,"27 % PEG 3350",278,"10.1021/acs.jmedchem.5b01517","5GN","5DY4",35.65,"1.77","1.77","Crystal structure of human Sirt2 in complex with a brominated 2nd generation SirReal inhibitor and NAD+","GHMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5DY4"
"5DY5",,"X-RAY DIFFRACTION",2.9,57.66,"VAPOR DIFFUSION, SITTING DROP",7.4,"17.5 % (wt/v) PEG 3350, 0.1 M HEPES",277,"10.1002/anie.201509843","5GR","5DY5",35.43,"1.95","1.95","Crystal structure of human Sirt2 in complex with a SirReal probe fragment","GHMERLLDELTLEGVARYMQSERCRRVICLVGAGISTSAGIPDFRSPSTGLYDNLEKYHLPYPEAIFEISYFKKHPEPFFALAKELYPGQFKPTICHYFMRLLKDKGLLLRCYTQNIDTLERIAGLEQEDLVEAHGTFYTSHCVSASCRHEYPLSWMKEKIFSEVTPKCEDCQSLVKPDIVFFGESLPARFFSCMQSDFLKVDLLLVMGTSLQVQPFASLISKAPLSTPRLLINKEKAGQSDPFLGMIMGLGGGMDFDSKKAYRDVAWLGECDQGCLALAELLGWKKELEDLVRREHASIDAQS","Homo sapiens","SIRT2, SIR2L, SIR2L2","NAD-dependent protein deacetylase sirtuin-2","1","5DY5"
"5DY7",,"X-RAY DIFFRACTION",2.42,49.14,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5GT","5DY7",13.98,"1.69","1.69","Crystal structure of the human BRPF1 bromodomain in complex with SEED4","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5DY7"
"5DYA",,"X-RAY DIFFRACTION",2.45,49.77,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5GV","5DYA",13.99,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with SEED5","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5DYA"
"5DYC",,"X-RAY DIFFRACTION",2.46,49.96,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215",,"5DYC",13.99,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with SEED6","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5DYC"
"5DYE",,"X-RAY DIFFRACTION",3.9,68.45,"VAPOR DIFFUSION, HANGING DROP",7.9,"21% PEG 400, 0.1M Tris pH 7.9, 0.1 M NaCl, 3% 1,6 hexanediol and 4% 1,3-propanediol as additive to the drop only",281,"10.1371/journal.pone.0143027",,"5DYE",113.98,"3.5","3.5","CRYSTAL STRUCTURE OF THE FULL LENGTH S156E MUTANT OF HUMAN AQUAPORIN 5","MKKEVCSVAFLKAVFAEFLATLIFVFFGLGSALKWPSALPTILQIALAFGLAIGTLAQALGPVSGGHINPAITLALLVGNQISLLRAFFYVAAQLVGAIAGAGILYGVAPLNARGNLAVNALNNNTTQGQAMVVELILTFQLALCIFASTDSRRTEPVGSPALSIGLSVTLGHLVGIYFTGCSMNPARSFGPAVVMNRFSPAHWVFWVGPIVGAVLAAILYFYLLFPNSLSLSERVAIIKGTYEPDEDWEEQREERKKTMELTTR","Homo sapiens","AQP5","Aquaporin-5","1","5DYE"
"5DYG",,"X-RAY DIFFRACTION",2.45,49.85,"VAPOR DIFFUSION, SITTING DROP",6,"3.7 M sodium formate, pH 6.0, 8 % glycerol",289,"10.1038/srep20037",,"5DYG",52.82,"2.2","2.2","Structure of p97 N-D1 L198W mutant in complex with ADP","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESWNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNRSHHHHHH","Homo sapiens","VCP","Transitional endoplasmic reticulum ATPase","1","5DYG"
"5DYH",,"X-RAY DIFFRACTION",2.9,57.55,"VAPOR DIFFUSION, SITTING DROP",7.4,"10-13% PEG3350
100 mM Ammonium Citrate buffer",296,"10.1021/jacs.6b01966",,"5DYH",156.66,"2.682","2.682","Ti(IV) bound human serum transferrin","MRLAVGALLVCAVLGLCLAVPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAIAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP","Homo sapiens","TF, PRO1400","Serotransferrin","1","5DYH"
"5DYI",,"X-RAY DIFFRACTION",2.53,51.38,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M sodium citrate, pH 6.0, 0.3 M NaCl, 15.2 % PEG3350, 20 % glycerol, 2 % benzamidine",289,"10.1038/srep20037",,"5DYI",660.1,"3.71","3.71","Structure of p97 N-D1 wild-type in complex with ADP","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGRSHHHHHH","Homo sapiens","VCP","Transitional endoplasmic reticulum ATPase","1","5DYI"
"5DYT",,"X-RAY DIFFRACTION",2.97,58.55,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2 M ammonium acetate, 12% polyethylene glycol 4000.",293,"10.1038/srep39495",,"5DYT",126.47,"2.55","2.55","Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-methylnaphthalene-2-sulfonamide","TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5DYT"
"5DYU",,"X-RAY DIFFRACTION",4.15,70.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5DYU",13.73,"1.65","1.65","Crystal Structure of BAZ2B bromodomain in complex with fragment F39","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5DYU"
"5DYW",,"X-RAY DIFFRACTION",2.7,54.44,"VAPOR DIFFUSION, HANGING DROP",7.4,"0.2 M ammonium acetate, 12% polyethylene glycol 4000.",293,"10.1038/srep39495","5HF","5DYW",128.17,"2.5","2.5","Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)-N-(2-methoxyethyl)naphthalene-2-sulfonamide","TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5DYW"
"5DYX",,"X-RAY DIFFRACTION",4.17,70.49,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5DYX",13.67,"1.85","1.85","Crystal Structure of BAZ2B bromodomain in complex with fragment F59","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5DYX"
"5DYY",,"X-RAY DIFFRACTION",2.97,58.55,"VAPOR DIFFUSION, SITTING DROP",,"200 mM Sodium acetate 12% peg 4K",293,"10.1038/srep39495",,"5DYY",125.77,"2.65","2.65","Crystal structure of human butyrylcholinesterase in complex with N-((1-benzylpiperidin-3-yl)methyl)naphthalene-2-sulfonamide","TEDDIIIATKNGKVRGMNLTVFGGTVTAFLGIPYAQPPLGRLRFKKPQSLTKWSDIWNATKYANSCCQNIDQSFPGFHGSEMWNPNTDLSEDCLYLNVWIPAPKPKNATVLIWIYGGGFQTGTSSLHVYDGKFLARVERVIVVSMNYRVGALGFLALPGNPEAPGNMGLFDQQLALQWVQKNIAAFGGNPKSVTLFGESAGAASVSLHLLSPGSHSLFTRAILQSGSFNAPWAVTSLYEARNRTLNLAKLTGCSRENETEIIKCLRNKDPQEILLNEAFVVPYGTPLSVNFGPTVDGDFLTDMPDILLELGQFKKTQILVGVNKDEGTAFLVYGAPGFSKDNNSIITRKEFQEGLKIFFPGVSEFGKESILFHYTDWVDDQRPENYREALGDVVGDYNFICPALEFTKKFSEWGNNAFFYYFEHRSSKLPWPEWMGVMHGYEIEFVFGLPLERRDNYTKAEEILSRSIVKRWANFAKYGNPNETQNNSTSWPVFKSTEQKYLTLNTESTRIMTKLRAQQCRFWTSFFPKV","Homo sapiens","BCHE, CHE1","Cholinesterase","1","5DYY"
"5DZL",,"X-RAY DIFFRACTION",2.21,44.24,"VAPOR DIFFUSION, HANGING DROP",8,"100 mM Tris 8.0, 25% PEG 3350, 12% glycerol, VAPOR DIFFUSION, SITTING DROP, temperature 298K",298,"10.1038/nature13848",,"5DZL",47.94,"3.4006","3.4006","Crystal structure of the protein human CEACAM1","SQLTTESMPFNVAEGKEVLLLVHNLPQQLFGYSWYKGERVDGNRQIVGYAIGTQQATPGPANSGRETIYPNASLLIQNVTQNDTGFYTLQVIKSDLVNEEATGQFHVY","Homo sapiens","CEACAM1, BGP, BGP1","Carcinoembryonic antigen-related cell adhesion molecule 1","1","5DZL"
"5DZN",,"X-RAY DIFFRACTION",3.04,59.6,"VAPOR DIFFUSION, HANGING DROP",5,"20% (w/v) PEG 6000, 100 mM citric acid/sodium hydroxide, pH 5.0",289,"10.1007/s13238-015-0220-y",,"5DZN",102.29,"2.3","2.3","human T-cell immunoglobulin and mucin domain protein 4","MVTSETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINVRLNLQRA","Homo sapiens","TIMD4, TIM4","T-cell immunoglobulin and mucin domain-containing protein 4","1","5DZN"
"5DZO",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, HANGING DROP",4.6,"1.5 M sodium nitrate, 0.1 M sodium acetate trihydrate, pH 4.6",289,"10.1007/s13238-015-0220-y",,"5DZO",11.99,"1.301","1.301","Crystal structure of human T-cell immunoglobulin and mucin domain protein 1","MVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDTRYKLLGDLSRRDVSLTIENTAVSDSGVYCCRVEHRGWFNDMKITVSLEIVPP","Homo sapiens","HAVCR1, KIM1, TIM1, TIMD1","Hepatitis A virus cellular receptor 1","1","5DZO"
"5DZZ",,"X-RAY DIFFRACTION",2.47,50.13,"VAPOR DIFFUSION, HANGING DROP",6.5,"22% PEG MME 5000, magnesium acetate, MES",295,"10.1371/journal.pone.0147641",,"5DZZ",54.56,"2.6","2.6","Structural characterization of intermediate filaments binding domain of desmoplakin","GAMGSTVDTSKLVFDGLRKKVTAMQLYECQLIDKTTLDKLLKGKKSVEEVASEIQPFLRGAGSIAGASASPKEKYSLVEAKRKKLISPESTVMLLEAQAATGGIIDPHRNEKLTVDSAIARDLIDFDDRQQIYAAEKAITGFDDPFSGKTVSVSEAIKKNLIDRETGMRLLEAQIASGGVVDPVNSVFLPKDVALARGLIDRDLYRSLNDPRDSQKNFVDPVTKKKVSYVQLKERCRIEPHTGLLLLSVQKRSMSFQGIRQPVTVTELVDSGILRPSTVNELESGQISYDEVGERIKDFLQGSSCIAGIYNETTKQKLGIYEAMKIGLVRPGTALELLEAQAATGFIVDPVSNLRLPVEEAYKRGLVGIEFKEKLLSAERAVTGYNDPETGNIISLFQAMNKELIEKGHGIRLLEAQIATGGIIDPKESHRLPVDIAYKRGYFNEELSEILSDPSDDTKGFFDPNTEENLTYLQLKERCIKDEETGLCLLPLKE","Homo sapiens","DSP","Desmoplakin","1","5DZZ"
"5E0F",,"X-RAY DIFFRACTION",2.29,46.27,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM sodium cacodylate, 58% MPD",293,,"5J7","5E0F",56.8,"1.4","1.4","Human pancreatic alpha-amylase in complex with mini-montbretin A","QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL","Homo sapiens","AMY2A","Pancreatic alpha-amylase","1","5E0F"
"5E0R",,"X-RAY DIFFRACTION",2.11,41.83,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.20M Sodium Nitrate, 20% PEG 3350, 10% ethylene glycol",277,,,"5E0R",17.35,"1.352","1.352","Crystal Structure of the first bromodomain of BRD4 in complex with AYC","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5E0R"
"5E0T",,"X-RAY DIFFRACTION",5.33,76.91,"VAPOR DIFFUSION, HANGING DROP",,"100mM sodium acetate, pH4.5, 2M ammonium sulfate",298,"10.1016/j.jmb.2015.11.029",,"5E0T",86.47,"2.6653","2.6653","Human PCNA mutant - S228I","MFEARLVQGSILKKVLEALKDLINEACWDISSSGVNLQSMDSSHVSLVQLTLRSEGFDTYRCDRNLAMGVNLTSMSKILKCAGNEDIITLRAEDNADTLALVFEAPNQEKVSDYEMKLMDLDVEQLGIPEQEYSCVVKMPSGEFARICRDLSHIGDAVVISCAKDGVKFSASGELGNGNIKLSQTSNVDKEEEAVTIEMNEPVQLTFALRYLNFFTKATPLSSTVTLIMSADVPLVVEYKIADMGHLKYYLAPKIEDEEGS","Homo sapiens","PCNA","Proliferating cell nuclear antigen","1","5E0T"
"5E11",,"X-RAY DIFFRACTION",2.16,43.07,"VAPOR DIFFUSION, HANGING DROP",4.5,"27-31% PEG 300, 48 mM citric acid, 35 mM NaH2PO4",293,"10.1038/nature20571",,"5E11",10.31,"1.8","1.8","Second PDZ domain of Ligand of Numb protein X 2 by Laue crystallography (no electric field)","SMEILQVALHKRDSGEQLGIKLVRRTDEPGVFILDLLEGGLAAQDGRLSSNDRVLAINGHDLKYGTPELAAQIIQASGERVNLTIARPGKPEIEL","Homo sapiens","LNX2, PDZRN1","Ligand of Numb protein X 2","1","5E11"
"5E13",,"X-RAY DIFFRACTION",1.69,27.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Sodium Cacodylate, 1.5M Sodium acetate",289,"10.1016/j.bioorg.2015.10.007","5J9","5E13",18.85,"1.34","1.34","Crystal structure of Eosinophil-derived neurotoxin in complex with the triazole double-headed ribonucleoside 11c","MVPKLFTSQICLLLLLGLLAVEGSLHMKPPQFTWAQWFETQHINMTSQQCTNAMQVINNYQRRCKNQNTFLLTTFANVVNVCGNPNMTCPSNKTRKNCHHSGSQVPLIHCNLTTPSPQNISNCRYAQTPANMFYIVACDNRDQRRDPPQYPVVPVHLDRII","Homo sapiens","RNASE2, EDN, RNS2","Non-secretory ribonuclease","1","5E13"
"5E1E",,"X-RAY DIFFRACTION",2.5,50.72,"VAPOR DIFFUSION, HANGING DROP",6,"27% (m/v) PEG6000, 0.1 M MES/NaOH pH 6.0 and 5 mM DTT",277,"10.1016/j.bmcl.2015.11.031","5JG","5E1E",67.92,"2.3","2.3","Human JAK1 kinase in complex with compound 30 at 2.30 Angstroms resolution","VDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK","Homo sapiens","JAK1, JAK1A, JAK1B","Tyrosine-protein kinase JAK1","1","5E1E"
"5E1S",,"X-RAY DIFFRACTION",2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",7.3,"25% PEG 8000, 0.1M TRIS pH 7.3, 50mM NaCl, 5 mM DTT",293,"10.1158/1535-7163.MCT-15-0539","5JA","5E1S",35.48,"2.264","2.264","The Crystal structure of INSR Tyrosine Kinase in complex with the Inhibitor BI 885578","GSVFPSSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRNLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENK","Homo sapiens","INSR","Insulin receptor","1","5E1S"
"5E1T",,"X-RAY DIFFRACTION",2.62,53.07,"VAPOR DIFFUSION, HANGING DROP",,"(NH4)2SO4, NaCl",298,"10.1038/srep25526",,"5E1T",67.94,"2.8","2.8","Crystal structure of TRAF1 TRAF domain","HQSQLDRERILSLEQRVVELQQTLAQKDQALGKLEQSLRLMEEASFDGTFLWKITNVTRRCHESACGRTVSLFSPAFYTAKYGYKLCLRLYLNGDGTGKRTHLSLFIVIMRGEYDALLPWPFRNKVTFMLLDQNNREHAIDAFRPDLSSASFQRPQSETNVASGCPLFFPLSKLQSPKHAYVKDDTMFLKCIVETST","Homo sapiens","TRAF1, EBI6","TNF receptor-associated factor 1","1","5E1T"
"5E1Y",,"X-RAY DIFFRACTION",2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",4.5,"25-29% PEG-300, 57 mM citric acid, 43 mM (Na2HPO4 pH 10.1)",293,"10.1038/nature20571",,"5E1Y",10.31,"1.011","1.011","PDZ2 of LNX2 at 277K, model with alternate conformations","SMEILQVALHKRDSGEQLGIKLVRRTDEPGVFILDLLEGGLAAQDGRLSSNDRVLAINGHDLKYGTPELAAQIIQASGERVNLTIARPGKPEIEL","Homo sapiens","LNX2, PDZRN1","Ligand of Numb protein X 2","1","5E1Y"
"5E21",,"X-RAY DIFFRACTION",2.13,42.25,"VAPOR DIFFUSION, HANGING DROP",,"25-29% PEG-300, 57 mM citric acid, 43 mM (Na2HPO4 pH 10.1)",293,"10.1038/nature20571",,"5E21",10.31,"1.011","1.011","PDZ2 of LNX2 at 277K,single conformer model","SMEILQVALHKRDSGEQLGIKLVRRTDEPGVFILDLLEGGLAAQDGRLSSNDRVLAINGHDLKYGTPELAAQIIQASGERVNLTIARPGKPEIEL","Homo sapiens","LNX2, PDZRN1","Ligand of Numb protein X 2","1","5E21"
"5E22",,"X-RAY DIFFRACTION",2.16,43.07,"VAPOR DIFFUSION, HANGING DROP",4.5,"27-31% PEG-300, 43 mM citric acid, 35 mM NaH2PO4",293,"10.1038/nature20571",,"5E22",20.71,"1.797","1.797","The second PDZ domain of Ligand of Numb protein X 2 in the presence of an electric field of ~1 MV/cm along the crystallographic x axis, with eightfold extrapolation of structure factor differences.","SMEILQVALHKRDSGEQLGIKLVRRTDEPGVFILDLLEGGLAAQDGRLSSNDRVLAINGHDLKYGTPELAAQIIQASGERVNLTIARPGKPEIEL","Homo sapiens","LNX2, PDZRN1","Ligand of Numb protein X 2","1","5E22"
"5E23",,"X-RAY DIFFRACTION",2.14,42.4,"VAPOR DIFFUSION, SITTING DROP",5.5,"Protein: 10mg/ml in .1 M NaCl, .050 M Na acetate, pH 5.5.
Complex: 3 micro-L TTR + 3 micro-L 0.02% azide + 1 micro-L inhibitor (.001 M)
Precipitant: 18% PEG4K, 9% PEG10K, 0.12 M imidazole malate pH 6.0, 0.04 M ammonium  acetate, pH 4.5.
Cryoprotectant: 10 % diethylene glycol + 5 % MPD + 15 % 2,3-butanediol + 5 % 1,4-dioxane, 12.5% MPEG 5K, 0.1 M mixed ( Na acetate, ADA, Bicine) 60% pH 4 / 40% pH 9)",293,"10.3109/14756366.2016.1167048",,"5E23",28.04,"1.41","1.41","Human transthyretin (TTR) complexed with (2,7-Dibromo-fluoren-9-ylideneaminooxy)-acetic acid","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5E23"
"5E26",,"X-RAY DIFFRACTION",2.62,52.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.4M Na Malonate pH 6.5, 0.1M TCEP HCl",291,,,"5E26",165.93,"2.14","2.14","Crystal structure of human PANK2: the catalytic core domain in complex with pantothenate and adenosine diphosphate","GRKKRPLFPWFGLDIGGTLVKLVYFEPKDITAEEEEEEVESLKSIRKYLTSNVAYGSTGIRDVHLELKDLTLCGRKGNLHFIRFPTHDMPAFIQMGRDKNFSSLHTVFCATGGGAYKFEQDFLTIGDLQLCKLDELDCLIKGILYIDSVGFNGRSQCYYFENPADSEKCQKLPFDLKNPYPLLLVNIGSGVSILAVYSKDNYKRVTGTSLGGGTFFGLCCLLTGCTTFEEALEMASRGDSTKVDKLVRDIYGGDYERFGLPGWAVASSFGNMMSKEKREAVSKEDLARATLITITNNIGSIARMCALNENINQVVFVGNFLRINTIAMRLLAYALDYWSKGQLKALFSEHEGYFGAVGALLELLK","Homo sapiens","PANK2, C20orf48","Pantothenate kinase 2, mitochondrial","1","5E26"
"5E28",,"X-RAY DIFFRACTION",2.1,41.52,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1021/acs.jmedchem.5b01771","BC5","5E28",29.34,"1.3","1.3","Crystal structure of human carbonic anhydrase II in complex with the 4-(4-aminophenyl)benzenesulfonamide inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5E28"
"5E2K",,"X-RAY DIFFRACTION",2.12,41.9,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1021/acs.jmedchem.5b01771","BX4","5E2K",29.59,"1.4","1.4","Crystal structure of human carbonic anhydrase II in complex with the 4-(3-aminophenyl)benzenesulfonamide inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5E2K"
"5E2M",,"X-RAY DIFFRACTION",2.26,45.3,"VAPOR DIFFUSION, SITTING DROP",8.4,"Crystallization buffer contains 0.1M TrisHCl (pH 8.5), 0.2M ammonium acetate, 28% of PEG4000",291,"10.1002/cmdc.201600509","ACT, V14","5E2M",58.96,"1.41","1.41","Crystal structure of human carbonic anhydrase isozyme I with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF","Homo sapiens","CA1","Carbonic anhydrase 1","1","5E2M"
"5E2N",,"X-RAY DIFFRACTION",2.15,42.4,"VAPOR DIFFUSION, SITTING DROP",6,"Crystallization buffer: 0.1M sodium citrate (pH 5.5), 0.1M sodium acetate (pH 4.5) and
 26% PEG4000.",291,"10.1002/cmdc.201600509","V14","5E2N",60.98,"1.53","1.53","Crystal structure of human carbonic anhydrase isozyme XIII with 3-(cyclooctylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MMSRLSWGYREHNGPIHWKEFFPIADGDQQSPIEIKTKEVKYDSSLRPLSIKYDPSSAKIISNSGHSFNVDFDDTENKSVLRGGPLTGSYRLRQVHLHWGSADDHGSEHIVDGVSYAAELHVVHWNSDKYPSFVEAAHEPDGLAVLGVFLQIGEPNSQLQKITDTLDSIKEKGKQTRFTNFDLLSLLPPSWDYWTYPGSLTVPPLLESVTWIVLKQPINISSQQLAKFRSLLCTAEGEAAAFLVSNHRPPQPLKGRKVRASFH","Homo sapiens","CA13","Carbonic anhydrase 13","1","5E2N"
"5E2O",,"X-RAY DIFFRACTION",3.45,64.3,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,"10.1016/j.bmcl.2015.11.089","5JM","5E2O",28.87,"2.08","2.08","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-[(N-{(2E)-3-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]prop-2-enoyl}-L-phenylalanyl)amino]benzoic acid","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XIa light chain","1","5E2O"
"5E2P",,"X-RAY DIFFRACTION",3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,"10.1016/j.bmcl.2015.11.089","7P0","5E2P",28.88,"2.11","2.11","FACTOR XIA IN COMPLEX WITH THE INHIBITOR N-[(1S)-1-benzyl-2-[2-[5-chloro-2-(tetrazol-1-yl)phenyl]ethylamino]-2-oxo-ethyl]-4-hydroxy-2-oxo-1H-quinoline-6-carboxamide","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XIa light chain","1","5E2P"
"5E2R",,"X-RAY DIFFRACTION",2.07,40.58,"VAPOR DIFFUSION, HANGING DROP",8.6,"Na-Citrate,  Tris-HCl",293,"10.1021/acs.jmedchem.5b01144","520","5E2R",29.99,"1.6","1.6","The crystal structure of the human carbonic anhydrase II in complex with a 1,1'-biphenyl-4-sulfonamide inhibitor","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5E2R"
"5E2S",,"X-RAY DIFFRACTION",2.09,41.18,"VAPOR DIFFUSION, SITTING DROP",8,"1.5 M sodium citrate, Tris 50 mM",296,"10.1021/acs.jmedchem.5b01771","5CX","5E2S",29.41,"1.5","1.5","Crystal structure of human carbonic anhydrase II in complex with the 4-(2-iso-propylphenyl)benzenesulfonamide inhibitor","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5E2S"
"5E3D",,"X-RAY DIFFRACTION",2.42,49.27,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5JL","5E3D",13.97,"1.71","1.71","Crystal structure of the human BRPF1 bromodomain in complex with SEED7","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5E3D"
"5E3G",,"X-RAY DIFFRACTION",2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium Acetate, pH 5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5JQ","5E3G",13.95,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with SEED8","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5E3G"
"5E4A",,"X-RAY DIFFRACTION",2.01,38.84,"VAPOR DIFFUSION, SITTING DROP",5.5,"Protein: TTR at 5 mg/ml + 1.6 milli-M inhibitor.
Precipitant: 18% PEG4K, 0.08M imidazole
 malate,  pH 6.0 and 13.5% PEG10K, 0.06M ammonium  acetate, pH 4.5
Cryoprotectant: 10% diethylene glycol + 5% MPD + 15% 2,3-butanediol + 5% 1,4-dioxane, 25% MPEG 5K,  0.1 M  mixed (Na acetate, ADA, Bicine - 60% at pH 4/40% at pH 10)
1 milli-M inhibitor.",293,"10.3109/14756366.2016.1167048",,"5E4A",29.8,"1.33","1.33","Human transthyretin (TTR) complexed with (2,7-Dichloro-fluoren-9-ylideneaminooxy)-acetic acid.","CLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPK","Homo sapiens","TTR, PALB","Transthyretin","1","5E4A"
"5E4G",,"X-RAY DIFFRACTION",2.22,44.61,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.18 M magnesium acetate, 0.1 M HEPES, pH 7.5, 22.5% PEG3350, 0.01 M strontium chloride",293,"10.1107/S2053230X16001588",,"5E4G",12.86,"1.5","1.5","Crystal structure of human growth differentiation factor 11 (GDF-11)","NLGLDCDEHSSESRCCRYPLTVDFEAFGWDWIIAPKRYKANYCSGQCEYMFMQKYPHTHLVQQANPRGSAGPCCTPTKMSPINMLYFNDKQQIIYGKIPGMVVDRCGCS","Homo sapiens","GDF11, BMP11","Growth/differentiation factor 11","1","5E4G"
"5E4K",,"X-RAY DIFFRACTION",2.82,56.41,"VAPOR DIFFUSION, SITTING DROP",7.4,"5-7% PEG 3350, 1 mM CaCl2, 100 mM HEPES",293,"10.1042/BCJ20160276",,"5E4K",57.06,"2.58","2.58","Structure of ligand binding region of uPARAP at pH 7.4","RSGAPGDAALPEPNIFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLTRTGHHHHHH","Homo sapiens","MRC2, CLEC13E, ENDO180, KIAA0709, UPARAP","C-type mannose receptor 2","1","5E4K"
"5E4L",,"X-RAY DIFFRACTION",2.99,58.8,"VAPOR DIFFUSION, SITTING DROP",5.3,"8-12% (w/v) PEG 3350, 200 mM NaCl, 35 mM CaCl2, 50 mM sodium acetate",293,,,"5E4L",112.45,"2.44","2.44","Structure of ligand binding region of uPARAP at pH 5.3","RSGAPGDAALPEPNIFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLTRTGHHHHHH","Homo sapiens","MRC2, CLEC13E, ENDO180, KIAA0709, UPARAP","C-type mannose receptor 2","1","5E4L"
"5E4O",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, SITTING DROP",6,"Protein:  5mg/ml TTR and 1 milli-M inhibitor.
Precipitant: 25% PEG4K, 0.2M imidazole malate, pH 6.0. Slow dessication over 18 months, rehydrated over 4 hours.
Cryoprotectant: 40% CryoSol SM1, 25% MPEG 5K, 0.1M (Na acetate, ADA, Bicine, 80% pH 4.0/20% pH 9.0)",293,"10.3109/14756366.2016.1167048",,"5E4O",26.31,"1.5","1.5","Human transthyretin (TTR) complexed with (Z)-((3,4-Dichloro-phenyl)-methyleneaminooxy)-acetic acid","CPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPK","Homo sapiens","TTR, PALB","Transthyretin","1","5E4O"
"5E52",,"X-RAY DIFFRACTION",4.51,72.72,"VAPOR DIFFUSION, HANGING DROP",5,"1M NH4H2PO4, 10% (v/v) Tacsimate pH 5.0",293,"10.1074/jbc.M116.742163",,"5E52",32.6,"2.685","2.685","Crystal structure of human CNTN5 FN1-FN3 domains","PGPPGIVIVEEITESTATLSWSPAADNHSPISSYNLQARSPFSLGWQTVKTVPEIITGDMESAMAVDLNPWVEYEFRVVATNPIGTGDPSTPSRMIRTNEAVPKTAPTNVSGRSGRRHELVIAWEPVSEEFQNGEGFGYIVAFRPNGTRGWKEKMVTSSEASKFIYRDESVPPLTPFEVKVGVYNNKGDGPFSQIVVICSAEGEPSAAPTDVKATSVSVSEILVAWKHIKESLGRPQGFEVGYWKDMEQEDTAETVKTRGNESFVILTGLEGNTLYHFTVRAYNGAGYGPPSSEVSATT","Homo sapiens","CNTN5","Contactin-5","1","5E52"
"5E5B",,"X-RAY DIFFRACTION",3.21,61.62,"VAPOR DIFFUSION, HANGING DROP",,"17% (w/v) PEG 3350, 0.1 M ammonium iodide and 0.1 M sodium acetate pH 5",292,"10.1107/S2053230X15024565",,"5E5B",48.72,"1.84","1.84","Crystal structure of Human Spt16 N-terminal domain","AVTLDKDAYYRRVKRLYSNWRKGEDEYANVDAIVVSVGVDEEIVYAKSTALQTWLFGYELTDTIMVFCDDKIIFMASKKKVEFLKQIANTKGNENANGAPAITLLIREKNESNKSSFDKMIEAIKESKNGKKIGVFSKDKFPGEFMKSWNDCLNKEGFDKIDISAVVAYTIAVKEDGELNLMKKAASITSEVFNKFFKERVMEIVDADEKVRHSKLAESVEKAIEEKKYLAGADPSTVEMCYPPIIQSGGNYNLKFSVVSDKNHMHFGAITCAMGIRFKSYCSNLVRTLMVDPSQEVQENYNFLLQLQEELLKELRHGVKICDVYNAVMDVVKKQKPELLNKITKNLGFGMGIEFREGSLVINSKNQYKLKKGMVFSINLGFSDLTNKEGKKPEEKTYALFIGDTVLVDEDGPATVLTSVKKKVKNVGIFL","Homo sapiens","SUPT16H, FACT140, FACTP140","FACT complex subunit SPT16","1","5E5B"
"5E5V",,"X-RAY DIFFRACTION",1.44,14.85,"VAPOR DIFFUSION, HANGING DROP",,"7 mg/ml in water and mixed with 10% ethanol and 1.5M NaCl",291,"10.1021/acs.jpcb.5b09981",,"5E5V",1.44,"1.24","1.24","Structure of amyloid forming peptide NFGAILS (residues 22-28) from Islet Amyloid Polypeptide","NFGAILS","Homo sapiens",,"NFGAILS (22-28) from islet amyloid polypeptide, synthesized","1","5E5V"
"5E5X",,"X-RAY DIFFRACTION",1.31,6.32,"VAPOR DIFFUSION, HANGING DROP",,"20 mg/ml in water and mixed with 10% (w/v) PEG-8000, 0.1 M Na/K phosphate pH 6.2, and 0.2 M NaCl",291,"10.1021/acs.jpcb.5b09981",,"5E5X",0.7,"1.61","1.61","Structure of the amyloid forming peptide ANFLVH (residues 13-18) from islet amyloid polypeptide","ANFLVH","Homo sapiens",,"ANFLVH (residues 13-18) from islet amyloid polypeptide","1","5E5X"
"5E5Z",,"X-RAY DIFFRACTION",1.32,6.59,"VAPOR DIFFUSION, HANGING DROP",,"20 mg/ml in water and mixed with 0.09 M HEPES pH 7.5, 1.26M tri-sodium citrate, and 10% glycerol",291,"10.1021/acs.jpcb.5b09981",,"5E5Z",0.66,"1.664","1.664","Structure of the amyloid forming peptide LVHSSN (residues","LVHSSN","Homo sapiens",,"LVHSSN (residues 16-21) from islet amyloid polypeptide","1","5E5Z"
"5E61",,"X-RAY DIFFRACTION",1.38,10.68,"VAPOR DIFFUSION, HANGING DROP",,"6.4mg/ml in 20mM Lithium hydroxide and mixed with 0.1M HEPES pH 6.5 and 0.5M Sodium Formate",291,"10.1021/acs.jpcb.5b09981",,"5E61",1.39,"1.79","1.79","Structure of amyloid-forming peptide FGAILSS (residues 23-29) from islet amyloid polypeptide","FGAILSS","Homo sapiens",,"FGAILSS (residues 23-29) from islet amyloid polypeptide","1","5E61"
"5E6H",,"X-RAY DIFFRACTION",2.18,43.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.5 M Ammonium sulfate
100mM Tris-HCl, pH 8.5
12% glycerol",289,"10.1074/jbc.M115.698449","AKG","5E6H",38.33,"2.238","2.238","A Linked Jumonji Domain of the KDM5A Lysine Demethylase","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5E6H"
,,,,,,,,,,,,,,,,,"Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2"
"5E6V",,"X-RAY DIFFRACTION",2.8,56.03,,,,,"10.1073/pnas.1601379113",,"5E6V",25.97,"1.8","1.8","Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit","QECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSIRCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFRRAKGYSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATECIQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKNCEHHH","Homo sapiens","ITGB2, CD18, MFI7","Integrin beta-2","1","5E6V"
"5E6W",,"X-RAY DIFFRACTION",2.45,49.7,,,,,"10.1073/pnas.1601379113",,"5E6W",35.34,"2.2","2.2","Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit","QECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSIRCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFRRAKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATECIQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKNCECQTQGRSSQELEGSCRKDNNSIICSGLGDCVCGQCLCHTSDVPGKLIYGQYCECDTINCERYNGQVCGGPGRGLCFCGKCRCHPGFEGSACQHHHH","Homo sapiens","ITGB2, CD18, MFI7","Integrin beta-2","1","5E6W"
"5E6X",,"X-RAY DIFFRACTION",1.89,34.83,,,,,"10.1073/pnas.1601379113",,"5E6X",31.72,"1.75","1.75","Re-refinement of the Crystal Structure of the Plexin-Semaphorin-Integrin Domain/Hybrid Domain/I-EGF1 Segment from the Human Integrin b2 Subunit","QECTKFKVSSCRECIESGPGCTWCQKLNFTGPGDPDSIRCDTRPQLLMRGCAADDIMDPTSLAETQEDHNGGQKQLSPQKVTLYLRPGQAAAFNVTFRRAKLSSRVFLDHNALPDTLKVTYDSFCSNGVTHRNQPRGDCDGVQINVPITFQVKVTATECIQEQSFVIRALGFTDIVTVQVLPQCECRCRDQSRDRSLCHGKGFLECGICRCDTGYIGKNCECQTQGRSSQELEGSCRKDNNSIICSGLGDCVCGQCLCHTSDVPGKLIYGQYCEHHHHHH","Homo sapiens","ITGB2, CD18, MFI7","Integrin beta-2","1","5E6X"
"5E73",,"X-RAY DIFFRACTION",4.28,71.26,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.5b01757","UO1","5E73",13.85,"1.71","1.71","Crystal Structure of BAZ2B bromodomain in complex with acetylindole compound UZH47","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E73"
"5E74",,"X-RAY DIFFRACTION",4.17,70.48,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acs.jmedchem.5b01757","5KH","5E74",13.98,"1.783","1.783","Crystal Structure of BAZ2B bromodomain in complex with acetylindole compound UZH50","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E74"
"5E7D",,"X-RAY DIFFRACTION",2.65,53.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2M Na2SO4
20w/v PEG_3350
10v/v ethylene_glycol",277,,,"5E7D",59.42,"1.87","1.87","Crystal Structure of the fifth bromodomain of human PB1 in complex with a hydroxyphenyl ligand","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5E7D"
"5E7I",,"X-RAY DIFFRACTION",2.79,55.97,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 3350, sodium citrate",291,"10.1074/jbc.M115.700625",,"5E7I",153.28,"2.223","2.223","Crystal structure of the active catalytic core of the human DEAD-box protein DDX3","EDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIESFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILSQIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVVYGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQIRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVVWVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDREEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGLATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSS","Homo sapiens","DDX3X, DBX, DDX3","ATP-dependent RNA helicase DDX3X","1","5E7I"
"5E7J",,"X-RAY DIFFRACTION",2.43,49.42,"VAPOR DIFFUSION, HANGING DROP",5,"PEG 3000, sodium citrate",291,"10.1074/jbc.M115.700625",,"5E7J",51.44,"2.23","2.23","Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMP","EDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIESFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILSQIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVVYGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQIRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVVWVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDREEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGLATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSS","Homo sapiens","DDX3X, DBX, DDX3","ATP-dependent RNA helicase DDX3X","1","5E7J"
"5E7M",,"X-RAY DIFFRACTION",2.91,57.7,"VAPOR DIFFUSION, HANGING DROP",5,"PEG-3000, sodium citrate",291,"10.1074/jbc.M115.700625",,"5E7M",51.6,"2.304","2.304","Crystal structure of the active catalytic core of the human DEAD-box protein DDX3 bound to AMPPNP","EDDWSKPLPPSERLEQELFSGGNTGINFEKYDDIPVEATGNNCPPHIESFSDVEMGEIIMGNIELTRYTRPTPVQKHAIPIIKEKRDLMACAQTGSGKTAAFLLPILSQIYSDGPGEALRAMKENGRYGRRKQYPISLVLAPTRELAVQIYEEARKFSYRSRVRPCVVYGGADIGQQIRDLERGCHLLVATPGRLVDMMERGKIGLDFCKYLVLDEADRMLDMGFEPQIRRIVEQDTMPPKGVRHTMMFSATFPKEIQMLARDFLDEYIFLAVGRVGSTSENITQKVVWVEESDKRSFLLDLLNATGKDSLTLVFVETKKGADSLEDFLYHEGYACTSIHGDRSQRDREEALHQFRSGKSPILVATAVAARGLDISNVKHVINFDLPSDIEEYVHRIGRTGRVGNLGLATSFFNERNINITKDLLDLLVEAKQEVPSWLENMAYEHHYKGSS","Homo sapiens","DDX3X, DBX, DDX3","ATP-dependent RNA helicase DDX3X","1","5E7M"
"5E7N",,"X-RAY DIFFRACTION",2.07,40.65,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM MES, 200 mM Calcium Acetate, 20% PEG 8000, pH 6.5, VAPOR DIFFUSION, HANGING DROP, temperature 294K",294,"10.1002/cmdc.201500479","5KR","5E7N",13.99,"1.21","1.21","Crystal Structure of RPA70N in complex with VU0085636","GSHMVGQLSRGAIAAIMQKGDTNIKPILQVINIRPITTGNSPPRYRLLMSDGLNTLSSFMLATQLNPLVEEEQLSSNCVCQIHRFIVNTLKDGRRVVILMELEVLKSAEAVGVKIGNPVPYNE","Homo sapiens","RPA1, REPA1, RPA70","Replication protein A 70 kDa DNA-binding subunit","1","5E7N"
"5E7W",,"X-RAY DIFFRACTION",1.89,35,"BATCH MODE",6.3,"The crystals were prepared by a batch method similar to that of Baker et al, 1988 [1], modified as follows: 0.01g of insulin as a fine powder was placed in a clean test tube; 0.02M HCl was added to dissolve the protein; on addition of 0.15 mL of 0.15 M zinc acetate the solution became cloudy due to precipitation of the protein; 0.3 mL of acetone and then 0.5 mL of trisodium citrate together with 0.8 mL of water were added and the solution went clear; the pH was checked and increased with NaOH to a pH between 8 and 9 for different batches, thus ensuring complete dissolution. It was then adjusted to the required value of pH 6.3. If any slight turbidity occurred, it was removed by warming the solution. The solution was then filtered using a Millipore membrane/acetate cellulose acetate filter. This removes any nuclei which will encourage precipitation or formation of masses of small crystals. 

The solution was then warmed to 50 deg C by surrounding the test tube with preheated water in a Dewar. This allowed the solution to cool slowly to room temperature. The test tube was lightly sealed with cling film; crystals formed within a few days and were of suitable size for X-ray diffraction within two weeks; the test tube containing crystals was kept at 4 degC prior to data collection. The crystal used for data collection was about 0.2 mm3.",293,"10.1186/s13065-017-0296-y",,"5E7W",11.89,"0.9519","0.9519","X-ray Structure of Human Recombinant 2Zn insulin at 0.92 Angstrom","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5E7W"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin","2","5E7W"
"5E80",,"X-RAY DIFFRACTION",2.51,50.93,"VAPOR DIFFUSION, SITTING DROP",,"0.2M  Calcium acetate,  20%  (w/v)  PEG 3350",293,"10.1038/ncomms11360",,"5E80",35.4,"2.6","2.6","The crystal structure of PDEd in complex with inhibitor-2a","SAKDERAREILRGFKLNWMNLRDAATGKILWQGTEDLSVPGVEHEARVPKKILKCKAVSRELNFSSTEQMEKFRLEQKVYFKGQCLEEWFFEFGFVIPNSTNTWQSLIEAAPESQMMPASVLTGNVIIETKFFDDDLLVSTSRVRLFYV","Homo sapiens","PDE6D, PDED","Retinal rod rhodopsin-sensitive cGMP 3',5'-cyclic phosphodiesterase subunit delta","1","5E80"
"5E84",,"X-RAY DIFFRACTION",3.72,66.97,"VAPOR DIFFUSION, HANGING DROP",4.5,"8%-12% PEG 3000, 0.1 M acetate acid, pH 4.5, and 0.2 M zinc acetate",277,"10.1016/j.str.2015.10.012",,"5E84",408.34,"2.99","2.99","ATP-bound state of BiP","SEDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGAFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSGDQDTGDLVLLDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSVGGTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISK","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5E84"
"5E85",,"X-RAY DIFFRACTION",2.24,45.19,"VAPOR DIFFUSION, HANGING DROP",4.5,"2.0 M ammonium sulfate, 0.1 M acetate acid, pH 4.5, and 2.67% acetonitrile",297,"10.1016/j.str.2015.10.012",,"5E85",26.63,"2.57","2.57","isolated SBD of BiP","SDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSTASDNQPTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSENLYFQGSNRLLLTG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5E85"
"5E86",,"X-RAY DIFFRACTION",2.08,41.02,"VAPOR DIFFUSION, HANGING DROP",5,"2.5 M ammonium sulfate, 0.1 M acetate acid, pH 5.0, and 66.7 mM sodium malonate, pH 7.0",297,"10.1016/j.str.2015.10.012",,"5E86",26.03,"2.681","2.681","isolated SBD of BiP with loop34 modification","SDVCPLTLGIETVGGVMTKLIPRNTVVPTKKSQIFSVGGTVTIKVYEGERPLTKDNHLLGTFDLTGIPPAPRGVPQIEVTFEIDVNGILRVTAEDKGTGNKNKITITNDQNRLTPEEIERMVNDAEKFAEEDKKLKERIDTRNELESYAYSLKNQIGDKEKLGGKLSSEDKETMEKAVEEKIEWLESHQDADIEDFKAKKKELEEIVQPIISKLYGSENLYFQGSNRLLLTG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5E86"
"5E88",,"X-RAY DIFFRACTION",2.14,42.53,"VAPOR DIFFUSION, HANGING DROP",7,"31% PEG 6000, 100MM MGCL2, 8MM BETA MERCEPTOETHANOL, 100MM TRIS HCL",293,"10.1002/cbic.201600285","5KT","5E88",16.42,"1.6","1.6","Crystal structure of Human galectin-3 CRD in complex with thienyl-1,2,3-triazolyl thiodigalactoside inhibitor","GPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5E88"
"5E89",,"X-RAY DIFFRACTION",2.21,44.22,"VAPOR DIFFUSION, HANGING DROP",7,"31% PEG 6000, 100MM MGCL2, 8MM BETA MERCEPTOETHANOL, 100MM TRIS HCL",293,"10.1002/cbic.201600285","TD2","5E89",16.44,"1.5","1.5","Crystal structure of Human galectin-3 CRD in complex with 3-fluophenyl-1,2,3-triazolyl thiodigalactoside inhibitor","GPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5E89"
"5E8A",,"X-RAY DIFFRACTION",2.2,44.19,"VAPOR DIFFUSION, HANGING DROP",7,"31% PEG 6000, 100MM MGCL2, 8MM BETA MERCEPTOETHANOL, 100MM TRIS HCL",293,"10.1002/cbic.201600285","5KS","5E8A",16.44,"1.5","1.5","Crystal structure of Human galectin-3 CRD in complex with 4-fluophenyl-1,2,3-triazolyl thiodigalactoside inhibitor","GPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5E8A"
"5E8G",,"X-RAY DIFFRACTION",2.71,54.56,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M sodium acetate pH 5.5, 0.1 M Co2+ sulfate heptahydrate, 24% PEG 4000",294,"10.1021/acs.biochem.5b01121",,"5E8G",60.02,"2.7","2.7","Crystal structure of the DNA binding domain of human transcription factor FLI1","GPHMPGSGQIQLWQFLLELLSDSANASCITWEGTNGEFKMTDPDEVARRWGERKSKPNMNYDKLSRALRYYYDKNIMTKVHGKRYAYKFDFHGIAQALQPHPTESSMYKYPSDISYMPSYHAHQQKVN","Homo sapiens","FLI1","Friend leukemia integration 1 transcription factor","1","5E8G"
"5E8M",,"X-RAY DIFFRACTION",2.54,52,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350",293,"10.1038/nsmb.3136",,"5E8M",54.57,"1.75","1.75","Crystal structure of human heparanase","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5E8M"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5E8M"
"5E8R",,"X-RAY DIFFRACTION",2.68,54.15,"VAPOR DIFFUSION, SITTING DROP",5.6,"10% PEG 3350, 0.2M MgCl2, 0.1M Sodium Cacadylate, pH6.5",295,"10.1021/acschembio.5b00839","5L6","5E8R",85.67,"2.55","2.55","Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)","GMSQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIVPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED","Homo sapiens","PRMT6, HRMT1L6","Protein arginine N-methyltransferase 6","1","5E8R"
"5E8S",,"X-RAY DIFFRACTION",2.09,41.02,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8S",34.94,"1.45","1.45","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (WT)","GGTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8S"
"5E8T",,"X-RAY DIFFRACTION",2.05,40.11,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8T",35.44,"1.7","1.7","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D)","GHMTIARDIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8T"
"5E8U",,"X-RAY DIFFRACTION",2.04,39.69,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8U",35.5,"2.03","2.03","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F)","GHMTIARDIVLQESVGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIFQTVMLRHENILGFIAADNKDNGTWTQLWLVTDFHEHGNLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCICDFGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8U"
"5E8V",,"X-RAY DIFFRACTION",2.53,51.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8V",35.93,"1.69","1.69","TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A)","GHMHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLASAMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVASMADNVLADAGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSG","Homo sapiens","TGFBR2","TGF-beta receptor type-2","1","5E8V"
"5E8W",,"X-RAY DIFFRACTION",2.06,40.18,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8W",35.82,"1.86","1.86","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH STAUROSPORINE","GHMTIARDIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8W"
"5E8X",,"X-RAY DIFFRACTION",1.85,33.54,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8X",35.79,"1.45","1.45","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F,S280T, Y282F,S287N,A350C,L352F) IN COMPLEX WITH STAUROSPORINE","GHMTIARDIVLQESVGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIFQTVMLRHENILGFIAADNKDNGTWTQLWLVTDFHEHGNLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCICDFGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8X"
"5E8Y",,"X-RAY DIFFRACTION",2.58,52.3,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8Y",36.31,"2.05","2.05","TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH STAUROSPORINE","GHMHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLASAMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVASMADNVLADAGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSG","Homo sapiens","TGFBR2","TGF-beta receptor type-2","1","5E8Y"
"5E8Z",,"X-RAY DIFFRACTION",2.08,40.99,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E8Z",35.59,"1.51","1.51","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D) IN COMPLEX WITH 3-AMINO-6-[4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE","GHMTIARDIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E8Z"
"5E90",,"X-RAY DIFFRACTION",2.1,41.42,"VAPOR DIFFUSION, HANGING DROP",5.6,"23%(w/v) PEG3350, 3%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E90",35.65,"2.05","2.05","TGF-BETA RECEPTOR TYPE 1 KINASE DOMAIN (T204D,I211V,Y249F, S280T,Y282F,S287N,A350C,L352F) IN COMPLEX WITH 3-AMINO-6- [4-(2-HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL]PYRAZINE-2-CARBOXAMIDE","GHMTIARDIVLQESVGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIFQTVMLRHENILGFIAADNKDNGTWTQLWLVTDFHEHGNLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCICDFGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQEGIKM","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-beta receptor type-1","1","5E90"
"5E91",,"X-RAY DIFFRACTION",2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E91",36.26,"2.42","2.42","TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH 3-AMINO-6-[4-(2- HYDROXYETHYL)PHENYL]-N-[4-(MORPHOLIN-4-YL)PYRIDIN-3-YL] PYRAZINE-2-CARBOXAMIDE","GHMHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLASAMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVASMADNVLADAGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSG","Homo sapiens","TGFBR2","TGF-beta receptor type-2","1","5E91"
"5E92",,"X-RAY DIFFRACTION",2.57,52.2,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mm TRIS-HCl, PH 8.5, 150 mm MgCl2, 24%(w/v) PEG4000, 20%(v/v) glcyerol",277,"10.1107/S2059798316003624",,"5E92",36.4,"2.08","2.08","TGF-BETA RECEPTOR TYPE 2 KINASE DOMAIN (E431A,R433A,E485A,K488A,R493A,R495A) IN COMPLEX WITH AMPPNP","GHMHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLASAMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVASMADNVLADAGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSG","Homo sapiens","TGFBR2","TGF-beta receptor type-2","1","5E92"
"5E97",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2
17% PEG3350",293,"10.1038/nsmb.3136",,"5E97",54.22,"1.63","1.63","Glycoside Hydrolase ligand structure 1","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5E97"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5E97"
"5E98",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2
17% PEG3350",293,"10.1038/nsmb.3136",,"5E98",53.79,"1.63","1.63","Crystal structure of human heparanase in complex with HepMer M04S02a","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5E98"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5E98"
"5E9B",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES [5.5]
0.1 M MgCl2 
17% PEG3350",293,"10.1038/nsmb.3136",,"5E9B",53.91,"1.88","1.88","Crystal structure of human heparanase in complex with HepMer M09S05a","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5E9B"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5E9B"
"5E9C",,"X-RAY DIFFRACTION",2.46,50.02,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M MES pH 5.5, 0.1 M MgCl2, 17% PEG3350",293,"10.1038/nsmb.3136",,"5E9C",54.15,"1.73","1.73","Crystal structure of human heparanase in complex with heparin tetrasaccharide dp4","DPGKKFKNSTYSRSSVDVLYTFANCSGLDLIFGLNALLRTADLQWNSSNAQLLLDYCSSKGYNISWELGNEPNSFLKKADIFINGSQLGEDFIQLHKLLRKSTFKNAKLYGPDVGQPRRKTAKMLKSFLKAGGEVIDSVTWHHYYLNGRTATREDFLNPDVLDIFISSVQKVFQVVESTRPGKKVWLGETSSAYGGGAPLLSDTFAAGFMWLDKLGLSARMGIEVVMRQVFFGAGNYHLVDENFDPLPDYWLSLLFKKLVGTKVLMASVQGSKRRKLRVYLHCTNTDNPRYKEGDLTLYAINLHNVTKYLRLPYPFSNKQVDKYLLRPLGPHGLLSKSVQLNGLTLKMVDDQTLPPLMEKPLRPGSSLGLPAFSYSFFVIRNAKVAACI","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","1","5E9C"
,,,,,,,,,,,,,,,,"DPGQDVVDLDFFTQEPLHLVSPSFLSVTIDANLATDPRFLILLGSPKLRTLARGLSPAYLRFGGTKTDFLIFDPKKE","Homo sapiens","HPSE, HEP, HPA, HPA1, HPR1, HPSE1, HSE1","Heparanase","2","5E9C"
"5E9I",,"X-RAY DIFFRACTION",4.27,71.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5E9I",13.66,"1.96","1.96","Crystal Structure of BAZ2B bromodomain in complex with fragment F60","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E9I"
"5E9J",,"X-RAY DIFFRACTION",4.23,70.89,"VAPOR DIFFUSION, HANGING DROP",7.8,"0.1M Hepes pH 7.8, 15% isopropanol and 6% PEG 4000",277,"10.1093/nar/gkw637",,"5E9J",65.33,"3.47","3.47","Crystal structure of the mRNA cap guanine-N7 methyltransferase - modular lobe (416-456) deletion","SRIFYLRNFNNWMKSVLIGEFLEKVRQKKKRDITVLDLGCGKGGDLLKWKKGRINKLVCTDIADVSVKQCQQRYEDMKNRRDSEYIFSAEFITADSSKELLIDKFRDPQMCFDICSCQFVCHYSFESYEQADMMLRNACERLSPGGYFIGTTPNSFELIRRLEASETESFGNEIYTVKFQKKGDYPLFGCKYDFNLEGVVDVPEFLVYFPLLNEMAKKYNMKLVYKKTFLEFYEEKIKNNENKMLLKRMQGGSGSKSEWEATSIYLVFAFEKQQ","Homo sapiens","RNMT, KIAA0398","mRNA cap guanine-N7 methyltransferase,mRNA cap guanine-N7 methyltransferase","1","5E9J"
,,,,,,,,,,,,,,,,,"Homo sapiens","RNMT, KIAA0398"
"5E9K",,"X-RAY DIFFRACTION",4.18,70.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5E9K",13.63,"2.067","2.067","Crystal Structure of BAZ2B bromodomain in complex with fragment F275","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E9K"
"5E9L",,"X-RAY DIFFRACTION",4.16,70.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5E9L",13.66,"1.9","1.9","Crystal Structure of BAZ2B bromodomain in complex with fragment F103","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E9L"
"5E9M",,"X-RAY DIFFRACTION",4.18,70.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5E9M",13.65,"1.778","1.778","Crystal Structure of BAZ2B bromodomain in complex with N-methyltrimethylacetamide","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E9M"
"5E9V",,"X-RAY DIFFRACTION",2.26,45.72,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M NaNO3, 0.1 M BTProp pH 6.5, 20% PEG 3350, 10% EtGly",277.15,,,"5E9V",29.34,"1.8","1.8","Crystal structure of BRD9 bromodomain in complex with an indolizine ligand","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5E9V"
"5E9W",,"X-RAY DIFFRACTION",2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",,"MES pH 6.5 and 25% PEG 4000,
1/5000 thermolysin",291,"10.1093/nar/gkw637",,"5E9W",148.4,"2.283","2.283","Crystal structure of mRNA cap guanine-N7 methyltransferase obtained by limited proteolysis","SQSRIFYLRNFNNWMKSVLIGEFLEKVRQKKKRDITVLDLGCGKGGDLLKWKKGRINKLVCTDIADVSVKQCQQRYEDMKNRRDSEYIFSAEFITADSSKELLIDKFRDPQMCFDICSCQFVCHYSFESYEQADMMLRNACERLSPGGYFIGTTPNSFELIRRLEASETESFGNEIYTVKFQKKGDYPLFGCKYDFNLEGVVDVPEFLVYFPLLNEMAKKYNMKLVYKKTFLEFYEEKIKNNENKMLLKRMQALEPYPANESSKLVSEKVDDYEHAAKYMKNSQVRLPLGTLSKSEWEATSIYLVFAFEKQQ","Homo sapiens","RNMT, KIAA0398","mRNA cap guanine-N7 methyltransferase","1","5E9W"
"5E9Y",,"X-RAY DIFFRACTION",4.17,70.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG500MME (20%), PEG1000 (2%), PEG3350 (2%), PEG20000 (10%), MPD (2%)",277,"10.1021/acschembio.5b00914",,"5E9Y",13.65,"1.65","1.65","Crystal Structure of BAZ2B bromodomain in complex with MPD","SMSVKKPKRDDSKDLALCSMILTEMETHEDAWPFLLPVNLKLVPGYKKVIKKPMDFSTIREKLSSGQYPNLETFALDVRLVFDNCETFNEDDSDIGRAGHNMRKYFEKKWTDTFKV","Homo sapiens","BAZ2B, KIAA1476","Bromodomain adjacent to zinc finger domain protein 2B","1","5E9Y"
"5EA1",,"X-RAY DIFFRACTION",2.36,47.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG1000 (12.5%), PEG3350 (12.5%), MPD (12.5%)",277,"10.1021/acschembio.5b00914",,"5EA1",47.19,"2","2","Crystal Structure of SMARCA4 bromodomain in complex with MPD","SMLSPNPPNLTKKMKKIVDAVIKYKDSSSGRQLSEVFIQLPSRKELPEYYELIRKPVDFKKIKERIRNHKYRSLNDLEKDVMLLCQNAQTFNLEGSLIYEDSIVLQSVFTSVRQKIEKEDDSEGEESEEEEE","Homo sapiens","SMARCA4, BAF190A, BRG1, SNF2B, SNF2L4","Transcription activator BRG1","1","5EA1"
"5EA2",,"X-RAY DIFFRACTION",2.42,49.14,"VAPOR DIFFUSION, SITTING DROP",7,"PEG3350, Ammonium Citrate",293,"10.1186/s12900-016-0052-x",,"5EA2",127.43,"2.01","2.01","Crystal Structure of Holo NAD(P)H dehydrogenase, quinone 1","GPHMVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKAR","Homo sapiens","NQO1, DIA4, NMOR1","NAD(P)H dehydrogenase [quinone] 1","1","5EA2"
"5EAI",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG3350, sodium potassium tartarate",,"10.1186/s12900-016-0052-x",,"5EAI",449.86,"2.9","2.9","Crystal Structure of NAD(P)H dehydrogenase, quinone 1 complexed with a chemotherapeutic naphthoquinone E6a","GPHMVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGHLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK","Homo sapiens","NQO1, DIA4, NMOR1","NAD(P)H dehydrogenase [quinone] 1","1","5EAI"
"5EAK",,"X-RAY DIFFRACTION",2.87,57.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M BIS-TRIS PH 6.5, 14% PEG3350, 200MM AMM.SULFATE",298,"10.1016/j.bmcl.2016.02.003",,"5EAK",76.51,"2.8","2.8","Optimization of Microtubule Affinity Regulating Kinase (MARK) Inhibitors with Improved Physical Properties","KLNSATSADEQPHIGNYRLLKTIGKGNFAKVKLARHILTGKEVAVKIIDKTQLNSSSLQKLFREVRIMKVLNHPNIVKLFEVIETEKTLYLVMEYASGGEVFDYLVAHGRMKEKEARAKFRQIVSAVQYCHQKFIVHRDLKAENLLLDADMNIKIADFGFSNEFTFGNKLDTFCGSPPYAAPELFQGKKYDGPEVDVWSLGVILYTLVSGSLPFDGQNLKELRERVLRGKYRIPFYMSTDCENLLKKFLILNPSKRGTLEQIMKDRWMNVGHEDDELKPYVEPLPDYKDPRRTELMVSMGYTREEIQDSLVGQRYNEVMATYLLLGYK","Homo sapiens","MARK2, EMK1","Serine/threonine-protein kinase MARK2","1","5EAK"
"5EAL",,"X-RAY DIFFRACTION",2.35,47.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% PEG 5K MME, 0.1 M BisTris pH6.5",291,,"5ML","5EAL",70.64,"1.8","1.8","Crystal structure of human WDR5 in complex with compound 9h","GTQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5EAL"
"5EAM",,"X-RAY DIFFRACTION",2.1,41.37,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG3350, 0.1M NH4SO4, 0.1 M BisTris pH6.5",291,"10.1021/acs.jmedchem.5b01630",,"5EAM",70.04,"1.8","1.8","Crystal structure of human WDR5 in complex with compound 9o","GTQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5EAM"
"5EAP",,"X-RAY DIFFRACTION",2.06,40.34,"VAPOR DIFFUSION, HANGING DROP",6.5,"28% PEG 2K MME, 0.1 M BisTris pH6.5",291,"10.1021/acs.jmedchem.5b01630",,"5EAP",35.16,"1.73","1.73","Crystal structure of human WDR5 in complex with compound 9e","GTQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5EAP"
"5EAR",,"X-RAY DIFFRACTION",2.09,41.29,"VAPOR DIFFUSION, HANGING DROP",5.5,"22% PEG 3350, 0.1M NH4SO4, 0.1 M BisTris pH5.5",291,"10.1021/acs.jmedchem.5b01630",,"5EAR",70.71,"1.8","1.8","Crystal structure of human WDR5 in complex with compound 9d","GTQSKPTPVKPNYALKFTLAGHTKAVSSVKFSPNGEWLASSSADKLIKIWGAYDGKFEKTISGHKLGISDVAWSSDSNLLVSASDDKTLKIWDVSSGKCLKTLKGHSNYVFCCNFNPQSNLIVSGSFDESVRIWDVKTGKCLKTLPAHSDPVSAVHFNRDGSLIVSSSYDGLCRIWDTASGQCLKTLIDDDNPPVSFVKFSPNGKYILAATLDNTLKLWDYSKGKCLKTYTGHKNEKYCIFANFSVTGGKWIVSGSEDNLVYIWNLQTKEIVQKLQGHTDVVISTACHPTENIIASAALENDKTIKLWKSDC","Homo sapiens","WDR5, BIG3","WD repeat-containing protein 5","1","5EAR"
"5EBB",,"X-RAY DIFFRACTION",3.15,56.74,"VAPOR DIFFUSION, SITTING DROP",7.2,"2.08 M disodium malonate pH 7.2, 0.23 M sodium thiocyanate and 0.01 M TCEP",298,"10.1111/febs.13655",,"5EBB",142.71,"2.6","2.6","Structure of human sphingomyelinase phosphodiesterase like 3A (SMPDL3A) with Zn2+","PPAIGQFWHVTDLHLDPTYHITDDHTKVCASSKGANASNPGPFGDVLCDSPYQLILSAFDFIKNSGQEASFMIWTGDSPPHVPVPELSTDTVINVITNMTTTIQSLFPNLQVFPALGNHDYWPQDQLPVVTSKVYNAVANLWKPWLDEEAISTLRKGGFYSQKVTTNPNLRIISLNTNLYYGPNIMTLNKTDPANQFEWLESTLNNSQQNKEKVYIIAHVPVGYLPSSQNITAMREYYNEKLIDIFQKYSDVIAGQFYGHTHRDSIMVLSDKKGSPVNSLFVAPAVTPVKSVLEKQTNNPGIRLFQYDPRDYKLLDMLQYYLNLTEANLKGESIWKLEYILTQTYDIEDLQPESLYGLAKQFTILDSKQFIKYYNYFFVSYDSSVTCDKTCKAFQICAIMNLDNISYADC","Homo sapiens","SMPDL3A, ASML3A","Acid sphingomyelinase-like phosphodiesterase 3a","1","5EBB"
"5EBE",,"X-RAY DIFFRACTION",3.15,57.39,"VAPOR DIFFUSION, SITTING DROP",7.2,"Crystal grew in 2.08 M disodium malonate pH 7.2, 0.23 M sodium thiocyanate and 0.01 M TCEP. But soaked at 2.08M disodium malonate pH 5",298,"10.1111/febs.13655",,"5EBE",146.51,"3","3","Structure of human sphingomyelinase phosphodiesterase like 3A (SMPDL3A) with 5' CMP","PPPAIGQFWHVTDLHLDPTYHITDDHTKVCASSKGANASNPGPFGDVLCDSPYQLILSAFDFIKNSGQEASFMIWTGDSPPHVPVPELSTDTVINVITNMTTTIQSLFPNLQVFPALGNHDYWPQDQLPVVTSKVYNAVANLWKPWLDEEAISTLRKGGFYSQKVTTNPNLRIISLNTNLYYGPNIMTLNKTDPANQFEWLESTLNNSQQNKEKVYIIAHVPVGYLPSSQNITAMREYYNEKLIDIFQKYSDVIAGQFYGHTHRDSIMVLSDKKGSPVNSLFVAPAVTPVKSVLEKQTNNPGIRLFQYDPRDYKLLDMLQYYLNLTEANLKGESIWKLEYILTQTYDIEDLQPESLYGLAKQFTILDSKQFIKYYNYFFVSYDSSVTCDKTCKAFQICAIMNLDNISYADCLKQLYIK","Homo sapiens","SMPDL3A, ASML3A","Acid sphingomyelinase-like phosphodiesterase 3a","1","5EBE"
,,,,,,,,,,,,,,,,"PPPAIGQFWHVTDLHLDPTYHITDDHTKVCASSKGANASNPGPFGDVLCDSPYQLILSAFDFIKNSGQEASFMIWTGDSPPHVPVPELSTDTVINVITNMTTTIQSLFPNLQVFPALGNHDYWPQDQLPVVTSKVYNAVANLWKPWLDEEAISTLRKGGFYSQKVTTNPNLRIISLNTNLYYGPNIMTLNKTDPANQFEWLESTLNNSQQNKEKVYIIAHVPVGYLPSSQNITAMREYYNEKLIDIFQKYSDVIAGQFYGHTHRDSIMVLSDKKGSPVNSLFVAPAVTPVKSVLEKQTNNPGIRLFQYDPRDYKLLDMLQYYLNLTEANLKGESIWKLEYILTQTYDIEDLQPESLYGLAKQFTILDSKQFIKYYNYFFVSYDSSVTCDKTCKAFQICAIMNLDNISYADCLKQL","Homo sapiens","SMPDL3A, ASML3A","Acid sphingomyelinase-like phosphodiesterase 3a","2","5EBE"
"5EBT",,"X-RAY DIFFRACTION",2.44,49.53,"VAPOR DIFFUSION, HANGING DROP",5.8,"14% PEG 20K, 0.1 M PCPT pH5.8",298,"10.1016/j.bmcl.2015.10.079",,"5EBT",99.02,"2.24","2.24","Tankyrase 1 with Phthalazinone 2","MTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTIKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPE","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5EBT"
"5EBZ",,"X-RAY DIFFRACTION",4.93,75.05,"EVAPORATION",,"PEG, Dextran Sulfate",277,"10.1016/j.celrep.2016.10.067","5TL","5EBZ",933.78,"4.5","4.5","Crystal structure of human IKK1","DPEFGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCHEIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGELCTEFVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPKCIFACEEMSGEVRFSSHLPQPNSLCSLIVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRCFVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGISLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPIIQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKLEFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAEIMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRVLKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQ","Homo sapiens","CHUK, IKKA, TCF16","Inhibitor of nuclear factor kappa-B kinase subunit alpha","1","5EBZ"
"5EC3",,"X-RAY DIFFRACTION",2.72,54.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris Propane, 0.2 M Sodium Acetate, 10% Ethylene Glycol, 18% PEG3,350",289,,,"5EC3",45.06,"2.1","2.1","Structural insight into the catalyitc mechanism of human 4-Hydroxyphenylpyruvate dioxygenase","MTTYSDKGAKPERGRFLHFHSVTFWVGNAKQAASFYCSKMGFEPLAYRGLETGSREVVSHVIKQGKIVFVLSSALNPWNKEMGDHLVKHGDGVKDIAFEVEDCDYIVQKARERGAKIMREPWVEQDKFGKVKFAVLQTYGDTTHTLVEKMNYIGQFLPGYEAPAFMDPLLPKLPKCSLEMIDHIVGNQPDQEMVSASEWYLKNLQFHRFWSVDDTQVHTEYSSLRSIVVANYEESIKMPINEPAPGKKKSQIQEYVDYNGGAGVQHIALKTEDIITAIRHLRERGLEFLSVPSTYYKQLREKLKTAKIKVKENIDALEELKILVDYDEKGYLLQIFTKPVQDRPTLFLEVIQRHNHQGFGAGNFNSLFKAFEEEQNLRGNLTNMETNGVVPGM","Homo sapiens","HPD, PPD","4-hydroxyphenylpyruvate dioxygenase","1","5EC3"
"5ECE",,"X-RAY DIFFRACTION",2.56,52.01,"VAPOR DIFFUSION, HANGING DROP",6.5,"25% PEG 3350, 0.1 M MES pH 6.5, 0.2 Sodium Acetate",298,"10.1016/j.bmcl.2015.10.079","5N2","5ECE",99.33,"2.2","2.2","Tankyrase 1 with Phthalazinone 1","AGTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTIKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPEAP","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5ECE"
"5ED3",,"X-RAY DIFFRACTION",2.07,40.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG3350, HEPES",291,"10.1038/s41467-019-12710-8",,"5ED3",28.63,"1.309","1.309","crystal structure of human Hint1 complexing with AP5A","SLMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5ED3"
"5ED6",,"X-RAY DIFFRACTION",2.08,40.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG3350, HEPES",291,"10.1038/s41467-019-12710-8",,"5ED6",28.5,"1.52","1.52","crystal structure of human Hint1 H114A mutant complexing with ATP","SLMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLAVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5ED6"
"5EDB",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pJ 7.5, 2-2.2 M ammonium sulfate",295,"10.1021/acs.jmedchem.5b01875","5M8","5EDB",15.26,"1.18","1.18","human fatty acid binding protein 4 in complex with 6-Chloro-2-methyl-4-phenyl-quinoline-3-carboxylic acid at 1.18A","SHMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5EDB"
"5EDC",,"X-RAY DIFFRACTION",2.18,43.69,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pH 7.5, 2.0-2.2 M ammonium sulfate",295,"10.1021/acs.jmedchem.5b01875","5M7","5EDC",15.47,"1.29","1.29","human FABP4 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid at 1.29A","AMCDAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5EDC"
"5EDE",,"X-RAY DIFFRACTION",2.86,57.06,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295,"10.1021/acs.jmedchem.5b01875",,"5EDE",148.32,"2.2","2.2","human PDE10A in complex with 1-(4-Chloro-phenyl)-3-methyl-1H-thieno[2,3-c]pyrazole-5-carboxylic acid (tetrahydro-furan-2-ylmethyl)-amide at 2.2A","AQGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEEA","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5EDE"
,,,,,,,,,,,,,,,,"AGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEEA","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","2","5EDE"
"5EDG",,"X-RAY DIFFRACTION",2.84,56.76,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES/NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295,"10.1021/acs.jmedchem.5b01875",,"5EDG",148.28,"2.3","2.3","human PDE10A in complex with 3-(2-Chloro-5-phenyl-3H-imidazol-4-yl)-1-(3-trifluoromethoxy-phenyl)-1H-pyridazin-4-one at 2.30A","AQGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5EDG"
,,,,,,,,,,,,,,,,"AQGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEEA","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","2","5EDG"
"5EDH",,"X-RAY DIFFRACTION",2.83,56.59,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES-NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295,"10.1021/acs.jmedchem.5b01875","5MF","5EDH",147.78,"2.03","2.03","human PDE10A, 8-ethyl-5-methyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-1,2,4-triazol-3-yl)ethyl]-[1,2,4]triazolo[1,5-c]pyrimidine, 2.03A, H3, Rfree=22.7%","AAGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEEA","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5EDH"
"5EDI",,"X-RAY DIFFRACTION",2.86,56.92,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES-NaOH pH 7.5, 30% PEG550MME, 50mM MgCl2",295,"10.1021/acs.jmedchem.5b01875","5M9","5EDI",150.23,"2.2","2.2","human PDE10A, 6-Chloro-5,8-dimethyl-2-[2-(2-methyl-5-pyrrolidin-1-yl-2H-[1,2,4]triazol-3-yl)-ethyl]-[1,2,4]triazolo[1,5-a]pyridine, 2.20A, H3, Rfree=23.5%","TSEEWQGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEE","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5EDI"
,,,,,,,,,,,,,,,,"TSEEWQGLMQFTLPVRLCREIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEEA","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","2","5EDI"
"5EDK",,"X-RAY DIFFRACTION",4.8,71.2,"VAPOR DIFFUSION, HANGING DROP",9.1,"0.2 M di-Na hydrogen phosphate and 20% PEG 3350",293,"10.1074/jbc.M115.700401",,"5EDK",64.96,"3.214","3.214","Crystal structure of prothrombin deletion mutant residues 146-167 ( Form II ).","ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTMGPWCYTTDPTVRRQECSIPVCGQEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGEYLE","Homo sapiens","F2","Prothrombin","1","5EDK"
"5EDM",,"X-RAY DIFFRACTION",5.16,73.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M MES, pH 6.5 and 1.6 M MgSO4",293,"10.1074/jbc.M115.700401",,"5EDM",67.01,"2.2","2.2","Crystal structure of prothrombin deletion mutant residues 154-167 ( Form I )","ANTFLEEVRKGNLERECVEETCSYEEAFEALESSTATDVFWAKYTACETARTPRDKLAACLEGNCAEGLGTNYRGHVNITRSGIECQLWRSRYPHKPEINSTTHPGADLQENFCRNPDSSTMGPWCYTTDPTVRRQECSIPVCGQDQVTVAMTEQCVPDRGQQYQGRLAVTTHGLPCLAWASAQAKALSKHQDFNSAVQLVENFCRNPDGDEEGVWCYVAGKPGDFGYCDLNYCEEAVEEETGDGLDEDSDRAIEGRTATSEYQTFFNPRTFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGRIVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGEYLE","Homo sapiens","F2","Prothrombin","1","5EDM"
"5EDP",,"X-RAY DIFFRACTION",3.66,66.39,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1016/j.bmcl.2015.11.078",,"5EDP",37.55,"2.9","2.9","EGFR kinase (T790M/L858R) apo","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EDP"
"5EDQ",,"X-RAY DIFFRACTION",3.66,66.44,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1016/j.bmcl.2015.11.078","5N3","5EDQ",37.93,"2.8","2.8","EGFR kinase (T790M/L858R) with inhibitor compound 15: ~{N}-(7-chloranyl-1~{H}-indazol-3-yl)-7,7-dimethyl-2-(1~{H}-pyrazol-4-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EDQ"
"5EDR",,"X-RAY DIFFRACTION",3.66,66.36,"VAPOR DIFFUSION, SITTING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1016/j.bmcl.2015.11.078","5N4","5EDR",37.91,"2.6","2.6","EGFR kinase (T790M/L858R) with inhibitor compound 27: ~{N}-(1~{H}-indazol-3-yl)-7,7-dimethyl-2-(2-methylpyrazol-3-yl)-5~{H}-furo[3,4-d]pyrimidin-4-amine","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EDR"
"5EDS",,"X-RAY DIFFRACTION",2.38,48.35,"VAPOR DIFFUSION, HANGING DROP",7.3,"20% PEG 3350, 0.1 M Tris (pH 7.3), 0.25 M ammonium sulfate, 2 mM DTT",298,"10.1021/acs.jmedchem.5b01651",,"5EDS",110.51,"2.8","2.8","Crystal structure of human PI3K-gamma in complex with benzimidazole inhibitor 5","SEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSA","Homo sapiens","PIK3CG","Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform","1","5EDS"
"5EFM",,"X-RAY DIFFRACTION",2.85,56.82,"EVAPORATION",5.6,"250mM potassium sodium tartrate tetrahydrate, 2.2 M ammonium sulfate, 100mM sodium citrate tribasic dihydrate (pH 5.6)",293,"10.1021/acs.biochem.5b01264",,"5EFM",3.78,"1.95","1.95","Beclin 1 Flexible-helical Domian (FHD) (141-171)","TDTLLDQLDTQLNVTENECQNYKRCLEILEQ","Homo sapiens","BECN1, GT197","Beclin-1","1","5EFM"
"5EFS",,"X-RAY DIFFRACTION",2.37,48.1,"VAPOR DIFFUSION, HANGING DROP",7.4,"200 mM NaCl, 0.1M NaCitrate pH 5.6, 24%
PEG4K",300,,,"5EFS",47.4,"1.82503","1.82503","The crystal structure of human kynurenine aminotransferase II","MNYARFITAASAARNPSPIRTMTDILSRGPKSMISLAGGLPNPNMFPFKTAVITVENGKTIQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQGLCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKPEDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNKFRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQLMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKVKGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQLIKESL","Homo sapiens","AADAT, KAT2, KYAT2","Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial","1","5EFS"
"5EFX",,"X-RAY DIFFRACTION",2.74,55.07,"VAPOR DIFFUSION, HANGING DROP",6.8,"0.2M Sodium Nitrate, 20% PEG 3350, PH 6.8",289.15,"10.1016/j.bbrc.2016.01.150",,"5EFX",16.6,"2.451","2.451","Crystal structure of Rho GTPase regulator","GARLQEIYNRMDPRAQTPVPGKGPFGREELLRRKLIHDGCLLWKTATGRFKDVLVLLMTDVLVFLQEKDQKYIFPTLDKPSVVSLQNLIVRDIANQEKGMFLISAAPPEMYEVHTASRDDRSTWIRVIQQSVRTCPSREDFPLI","Homo sapiens","ARHGEF2, KIAA0651, LFP40","Rho guanine nucleotide exchange factor 2","1","5EFX"
"5EGG",,"X-RAY DIFFRACTION",2.14,42.44,"VAPOR DIFFUSION, HANGING DROP",,"2% v/v Tacsimate pH 4.0, 0.1 M Sodium acetate  trihydrate pH 4.6, 16% w/v Polyethylene glycol 3350",289,"10.1016/j.apsb.2016.12.008",,"5EGG",17.78,"1.76","1.76","Crystal structure of human ubiquitin-conjugating enzyme UBCH5C","MGHHHHHHGMALKRINKELSDLARDPPAQCSAGPVGDDMFHWQATIMGPNDSPYQGGVFFLTIHFPTDYPFKPPKVAFTTRIYHPNINSNGSICLDILRSQWSPALTISKVLLSICSLLCDPNPDDPLVPEIARIYKTDRDKYNRISREWTQKYAM","Homo sapiens","UBE2D3, UBC5C, UBCH5C","Ubiquitin-conjugating enzyme E2 D3","1","5EGG"
"5EGM",,"X-RAY DIFFRACTION",2.81,56.17,"VAPOR DIFFUSION, HANGING DROP",9,"50 MM CHES, PH 9.0, 1.3 M TRI-SODIUM     
REMARK 280  CITRATE AND 3 MM COMPOUND (CROSS SEEDED WITH CRYSTALS GROWN FROM    
REMARK 280  50 MM TRIS, PH 7.2, 1.45 M AMMONIUM SULFATE, 2.0 M SODIUM           
REMARK 280  CHLORIDE AND 3 MM COMPOUND)",295,"10.1016/j.bmcl.2015.07.078","5NY","5EGM",33.73,"1.841","1.841","Development of a novel tricyclic class of potent and selective FIXa inhibitors","VVGGEDAKPGQFPWQVVLNGKVDAFCGGSIVNEKWIVTAAHCVETGVKITVVAGEHNIEETEHTEQKRNVIRIIPHHNYNAAINKYNHDIALLELDEPLVLNSYVTPICIADKEYTNIFLKFGSGYVSGWGRVFHKGASALVLQYLRVPLVDRATCLRSTKFTIYNNMFCAGFHEGGRDSCQGDSGGPHVTEVEGTSFLTGIISWGEECAMKGKYGIYTKVSRYVNWIKEKTKLT","Homo sapiens","F9","Coagulation factor IX","1","5EGM"
,,,,,,,,,,,,,,,,"MDVTCNIKNGRCEQFCKNSADNKVVCSCTEGYRLAENQKSCEPAVPFPCGRVSVSQTSKLTR","Homo sapiens","F9","Coagulation factor IX","2","5EGM"
"5EGS",,"X-RAY DIFFRACTION",2.56,51.9,"VAPOR DIFFUSION, HANGING DROP",,"25 % PEG 1500; 0.1 M MMT pH 8.0",293,"10.1021/acs.jmedchem.5b01772","5NR","5EGS",171.15,"2.15","2.15","Human PRMT6 with bound fragment-type inhibitor","GMSQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIVPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED","Homo sapiens","PRMT6, HRMT1L6","Protein arginine N-methyltransferase 6","1","5EGS"
"5EGU",,"X-RAY DIFFRACTION",2.59,52.83,"VAPOR DIFFUSION, HANGING DROP",8.5,"Ratio 1:1 (protein:precipitant). 25 mg/mL BRD4_BD1 protein. 1.0 mM inhibitor (in DMSO) final concentration. Protein buffer: 0.01M HEPES (pH 7.5), 0.15M NaCl. Precipitant agent : 0.2M Ammonium sulfate, 0.1M Tris pH 8.5, 25% PEG3350. Cryoprotectant : 10% ethylene glycol.",292,"10.1021/acs.jmedchem.5b01708","5NQ","5EGU",62.4,"2.21","2.21","FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 3-Butyl-8-(6-butyl-5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-2-ylsulfanylmethyl)-7-ethyl-3,7-dihydropurine-2,6-dione","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5EGU"
"5EGY",,"X-RAY DIFFRACTION",2.41,49.04,"VAPOR DIFFUSION, SITTING DROP",8.2,"0.056 M Sodium phosphate monobasic monohydrate, 1.344M Potassium phosphate dibasic, pH- 8.2, 293K",293,"10.1038/srep23787",,"5EGY",81.64,"2.741","2.741","Structure of ligand free human DPP3 in closed form.","MADTQYILPNDIGVSSLDSREAFRLLSPTERLYAYHLSRAAWYGGLAVLLQTSPEAPYIYALLSRLFRAQDPDQLRQHALAEGLTEEEYQAFLVYAAGVYSNMGNYKSFGDTKFVPNLPKEKLERVILGSEAAQQHPEEVRGLWQTCGELMFSLEPRLRHLGLGKEGITTYFSGNCTMEDAKLAQDFLDSQNLSAYNTRLFKEVDGCGKPYYEVRLASVLGSEPSLDSEVTSKLKSYEFRGSPFQVTRGDYAPILQKVVEQLEKAKAYAANSHQGQMLAQYIESFTQGSIEAHKRGSRFWIQDKGPIVESYIGFIESYRDPFGSRGEFEGFVAVVNKAMSAKFERLVASAEQLLKELPWPPTFEKDKFLTPDFTSLDVLTFAGSGIPAGINIPNYDDLRQTEGFKNVSLGNVLAVAYATQREKLTFLEEDDKDLYILWKGPSFDVQVGLHALLGHGSGKLFVQDEKGAFNFDQETVINPETGEQIQSWYRCGETWDSKFSTIASSYEECRAESVGLYLSLHPQVLEIFGFEGADAEDVIYVNWLNMVRAGLLALEFYTPEAFNWRQAHMQARFVILRVLLEAGEGLVTITPTTGSDGRPDARVRLDRSKIRSVGKPALERFLRRLQVLKSTGDVAGGRALYEGYATVTDAPPESFLTLRDTVLLRKESRKLIVQPNTRLEGSDVQLLEYEASAAGLIRSFSERFPEDGPELEEILTQLATADARFW","Homo sapiens","DPP3","Dipeptidyl peptidase 3","1","5EGY"
"5EH0",,"X-RAY DIFFRACTION",3.48,64.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M BisTris Propane pH 7.5
0.2 M MgCl2
0.2M Sodium Formate
20%  PEG3350",291.15,"10.1021/acs.jmedchem.5b01811","5NW","5EH0",32.74,"2.18","2.18","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","QSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQ","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EH0"
"5EH1",,"X-RAY DIFFRACTION",3.51,64.93,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M MES pH 5.0 + 10% PEG 6000, cryoprotected in 20% glycerol",293,"10.1107/S2059798316012237",,"5EH1",27.27,"1.8","1.8","Crystal structure of the extracellular part of receptor 2 of human interferon gamma","RSSQLPAPQHPKIRLYNAEQVLSWEPVALSNSTRPVVYQVQFKYTDSKWFTADIMSIGVNCTQITATECDFTAASPSAGFPMDFNVTLRLRAELGALHSAWVTMPWFQHYRNVTVGPPENIEVTPGEGSLIIRFSSPFDIADTSTAFFCYYVHYWEKGGIQQVKGPFRSNSISLDNLKPSRVYCLQVQAQLLWNKSNIFRVGHLSNISCYETMADASTELQQTGHHHHHHE","Homo sapiens","IFNGR2, IFNGT1","Interferon gamma receptor 2","1","5EH1"
"5EH4",,"X-RAY DIFFRACTION",2.65,53.53,"LIPIDIC CUBIC PHASE",,"20% (w/v)PEG 8000, 0.1 M sodium HEPES pH 7.5 
10 mM TRIS-HCl pH 8, 40 mM NaCl",293,"10.1021/jacs.5b11354",,"5EH4",13.52,"2.81","2.81","Crystal Structure of the Glycophorin A Transmembrane Dimer in Lipidic Cubic Phase","EPEITLIIFGVIAGVIGTILLISYGIRRLC","Homo sapiens","GYPA, GPA","Glycophorin-A","1","5EH4"
"5EH5",,"X-RAY DIFFRACTION",2.06,40.19,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,"10.1021/acs.jmedchem.5b01940","XCZ","5EH5",29.57,"1.207","1.207","human carbonic anhydrase II in complex with ligand","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EH5"
"5EH6",,"X-RAY DIFFRACTION",1.95,37.03,"LIPIDIC CUBIC PHASE",7.5,"0.1 M HEPES, 20% PEG8000, 10 mM Tris, 40 mM NaCl",293,"10.1021/jacs.5b11354",,"5EH6",3.29,"1.918","1.918","Crystal Structure of the Glycophorin A Transmembrane Monomer in Lipidic Cubic Phase","EPEITLIIFGVIAGVIGTILLISYGIRRLC","Homo sapiens","GYPA, GPA","Glycophorin-A","1","5EH6"
"5EH7",,"X-RAY DIFFRACTION",2.1,41.43,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris chloride",280,"10.1021/acs.jmedchem.5b01940","5O5","5EH7",29.67,"1.425","1.425","human carbonic anhydrase II in complex with ligand","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EH7"
"5EH8",,"X-RAY DIFFRACTION",2.08,40.73,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris chloride",280,"10.1021/acs.jmedchem.5b01940","5O6","5EH8",29.59,"1.381","1.381","human carbonic anhydrase II in complex with ligand","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EH8"
"5EHD",,"X-RAY DIFFRACTION",2.16,42.97,"VAPOR DIFFUSION, SITTING DROP",,"25% PEG 400, 0.1 M MES, 0.1 M MgCl2",290,,,"5EHD",253.61,"2.55","2.55","Crystal structure of human nucleophosmin-core in complex with cytochrome c","MSPLRPQNYLFGCELKADKDYHFKVDNDENEHQLSLRTVSLGAGAKDELHIVEAEAMNYEGSPIKVTLATLKMSVQPTVSLGGFEITPPVVLRLKCGSGPVHISGQHLVAVEEDAE","Homo sapiens","NPM1, NPM","Nucleophosmin","1","5EHD"
"5EHE",,"X-RAY DIFFRACTION",2.01,38.5,"VAPOR DIFFUSION, SITTING DROP",7.5,"Crystallization buffer contains 0.1M sodium bicine (pH 9) and 2.6M sodium malonate (pH 7.5)",291,"10.1002/cmdc.201600509","WWO","5EHE",30.24,"1.5","1.5","Crystal structure of human carbonic anhydrase isozyme II with 3-(benzylamino)-2,5,6-trifluoro-4-[(2-hydroxyethyl)sulfonyl]benzenesulfonamide","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EHE"
"5EHL",,"X-RAY DIFFRACTION",2.93,58.02,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M Bis Tris propane pH 7.5
0.2M MgCl2
0.2M Sodium formate
25% PEG3350",291.15,,,"5EHL",36.39,"2.66","2.66","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EHL"
"5EHO",,"X-RAY DIFFRACTION",2.9,57.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M BIS-TRIS Propane pH 7.5, 0.1M Sodium formate, 0.1M MgCl2, 20% PEG 3350",291.15,,"5O1","5EHO",36.62,"2.18","2.18","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EHO"
"5EHP",,"X-RAY DIFFRACTION",2.28,46.04,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG 3350, 200mM Ammonium Phosphate",277,"10.1021/acs.jmedchem.6b00680","5OA","5EHP",122.13,"1.85","1.85","Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP836","SMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETL","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5EHP"
"5EHR",,"X-RAY DIFFRACTION",2.27,45.82,"VAPOR DIFFUSION, SITTING DROP",,"17% PEG3350, 200mM Ammonium Phosphate",277,"10.1038/nature18621","5OD","5EHR",121.94,"1.7","1.7","Non-receptor Protein Tyrosine Phosphatase SHP2 in Complex with Allosteric Inhibitor SHP099","SMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETL","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5EHR"
"5EHV",,"X-RAY DIFFRACTION",2.08,40.81,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,"10.1021/acs.jmedchem.5b01940","5ON","5EHV",29.83,"1.208","1.208","human carbonic anhydrase II in complex with ligand","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EHV"
"5EHW",,"X-RAY DIFFRACTION",2.11,41.79,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, tris-chloride",280,"10.1021/acs.jmedchem.5b01940","5OO","5EHW",29.73,"1.392","1.392","human carbonic anhydrase II in complex with ligand","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EHW"
"5EHY",,"X-RAY DIFFRACTION",3.11,60.42,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1m HEPES pH 7.5
30-45% PEG300",291.15,"10.1021/acs.jmedchem.5b01811","5O4","5EHY",38.94,"2.26","2.26","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EHY"
"5EI0",,"X-RAY DIFFRACTION",2.07,40.67,"VAPOR DIFFUSION, HANGING DROP",7,"20 % (w/v) PEG 3350, 20 % (v/v) isopropanol, 0.1 M imidazole-HCl pH 7.0",295.15,"10.1515/hsz-2015-0229",,"5EI0",95.07,"2.5","2.5","Structure of RCL-cleaved vaspin (serpinA12)","HHHHHHHHHHSSGHIEGRHMKPSFSPRNYKALSEVQGWKQRMAAKELARQNMDLGFKLLKKLAFYNPGRNIFLSPLSISTAFSMLCLGAQDSTLDEIKQGFNFRKMPEKDLHEGFHYIIHELTQKTQDLKLSIGNTLFIDQRLQPQRKFLEDAKNFYSAETILTNFQNLEMAQKQINDFISQKTHGKINNLIENIDPGTVMLLANYIFFRARWKHEFDPNVTKEEDFFLEKNSSVKVPMMFRSGIYQVGYDDKLSCTILEIPYQKNITAIFILPDEGKLKHLEKGLQVDTFSRWKTLLSRRVVDVSVPRLHMTGTFDLKKTLSYIGVSKIFEEHGDLTKIAPHRSLKVGEAVHKAELKMDERGTEGAAGTGAQTLPMETPLVVKIDKPYLLLIYSEKIPSVLFLGKIVNPIGK","Homo sapiens","SERPINA12","Serpin A12","1","5EI0"
"5EI2",,"X-RAY DIFFRACTION",2.73,55,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Bis-Tris propane
0.2 M MgCl2
0.2 M Sodium formate
20% PEG3350",291.15,"10.1021/acs.jmedchem.5b01811","5O7","5EI2",36.48,"2.67","2.67","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EI2"
"5EI4",,"X-RAY DIFFRACTION",2.14,42.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"Ratio 1:1 (protein:precipitant). 12 mg/mL BRD4_BD1 protein. 2.5 mM inhibitor (in DMSO) final concentration. Protein buffer: 0.01M HEPES (pH 7.5), 0.15M NaCl. Precipitant agent : 0.3M Na Formate, 0.1M NaCl, 22% PEG3350, 10% ethylene glycol. Cryoprotectant : 10% ethylene glycol.",292,"10.1021/acs.jmedchem.5b01708","5NV","5EI4",15.59,"1.05","1.05","First domain of human bromodomain BRD4 in complex with inhibitor 8-(5-Amino-1H-[1,2,4]triazol-3-ylsulfanylmethyl)-3-(4-chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5EI4"
"5EI6",,"X-RAY DIFFRACTION",2.84,56.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M BIS-TRIS Propane, 0.2 M MgCl2, 0.2 M Sodium formate, 20% PEG 3350",291.15,"10.1021/acs.jmedchem.5b01811","5OQ","5EI6",36.63,"2.01","2.01","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EI6"
"5EI8",,"X-RAY DIFFRACTION",2.77,55.1,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M BIS-TRIS Propane
0.2 M NgCl2
0.2 M Sodium formate
20 % PEG3350",291.15,"10.1021/acs.jmedchem.5b01811","5OE","5EI8",36.76,"2.17","2.17","Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle kinase 1 (MPS1) Using a Structure-Based Hydridization Approach","MHHHHHHSSGVDLGTENLYFQSMSVKGRIYSILKQIGSGGSSKVFQVLNEKKQIYAIKYVNLEEADNQTLDSYRNEIAYLNKLQQHSDKIIRLYDYEITDQYIYMVMECGNIDLNSWLKKKKSIDPWERKSYWKNMLEAVHTIHQHGIVHSDLKPANFLIVDGMLKLIDFGIANQMQPDTTSVVKDSQVGTVNYMPPEAIKDMSSSRENGKSKSKISPKSDVWSLGCILYYMTYGKTPFQQIINQISKLHAIIDPNHEIEFPDIPEKDLQDVLKCCLKRDPKQRISIPELLAHPYVQIQTHPVNQMAKGTTEE","Homo sapiens","TTK, MPS1, MPS1L1","Dual specificity protein kinase TTK","1","5EI8"
"5EIC",,"X-RAY DIFFRACTION",2.03,39.35,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277,"10.1021/acsmedchemlett.8b00286",,"5EIC",29,"1.5","1.5","Crystal structure of the bromodomain of human CREBBP in complex with AYC","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5EIC"
"5EIG",,"X-RAY DIFFRACTION",2.36,47.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"100mM MES pH6.5
50-100mM Sodium Citratre
25%-30% Isopropanol",277,,,"5EIG",359.41,"2.7","2.7","Engineered human cystathionine gamma lyase (E59T, E339V) to deplet cysteine","MQEKDASSQGFLPHFQHFATQAIHVGQDPEQWTSRAVVPPISLSTTFKQGAPGQHSGFTYSRSGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITHLLKAGDQIICMDDVYGGTNRYFRQVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPTNPTQKVIDIEGCAHIVHKHGDIILVVDNTFMSPYFQRPLALGADISMYSATKYMNGHSDVVMGLVSVNCESLHNRLRFLQNSLGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMAVAQFLESNPWVEKVIYPGLPSHPQHELVKRQCTGCTGMVTFYIKGTLQHAEIFLKNLKLFTLAVSLGGFESLAELPAIMTHASVLKNDRDVLGISDTLIRLSVGLEDEEDLLEDLDQALKAAHPPSGSHS","Homo sapiens","CTH","Cystathionine gamma-lyase","1","5EIG"
,,,,,,,,,,,,,,,,"MQEKDASSQGFLPHFQHFATQAIHVGQDPEQWTSRAVVPPISLSTTFKQGAPGQHSGFTYSRSGNPTRNCLEKAVAALDGAKYCLAFASGLAATVTITHLLKAGDQIICMDDVYGGTNRYFRQVASEFGLKISFVDCSKIKLLEAAITPETKLVWIETPTNPTQKVIDIEGCAHIVHKHGDIILVVDNTFMSPYFQRPLALGADISMYSATKYMNGHSDVVMGLVSVNCESLHNRLRFLQNSLGAVPSPIDCYLCNRGLKTLHVRMEKHFKNGMAVAQFLESNPWVEKVIYPGLPSHPQHELVKRQCTGCTGMVTFYIKGTLQHAEIFLKNLKLFTLAVSLGGFESLAELPAIMTHASVLKNDRDVLGISDTLIRLSVGLEDEEDLLEDLDQALKAAHPPSGSHS","Homo sapiens","CTH","Cystathionine gamma-lyase","2","5EIG"
"5EIJ",,"X-RAY DIFFRACTION",2.15,42.86,"VAPOR DIFFUSION, SITTING DROP",7.8,"1.6M sodium citrate, 50mM Tris",298,"10.1016/j.bmc.2016.01.019","5OT","5EIJ",29.77,"1.99","1.99","Carbonic Anhydrase II in complex with Sulfonamide Inhibitor","HWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EIJ"
"5EIQ",,"X-RAY DIFFRACTION",2.36,47.88,"VAPOR DIFFUSION",5,"0.1 M NaCitrate pH 5.0, 30% PEG 8000",277,"10.1182/blood-2015-08-667055",,"5EIQ",20.73,"2.01","2.01","Human OSCAR ligand-binding domain","SYHPKPWLGAQPATVVTPGVNVTLRCRAPQPAWRFGLFKPGEIAPLLFRDVSSELAEFFLEEVTPAQGGSYRCCYRRPDWGPGVWSQPSDVLELLVTEELPRPSLVALPGPVVGPGANVSLRCAGRLRNMSFVLYREGVAAPLQYRHSAQPWADFTLLGARAPGTYSCYYHTPSAPYVLSQRSEVLVI","Homo sapiens","OSCAR","Osteoclast-associated immunoglobulin-like receptor","1","5EIQ"
"5EIS",,"X-RAY DIFFRACTION",2.15,42.9,"VAPOR DIFFUSION, HANGING DROP",,"ratio 1:1 (protein:precipitant). 16 mg/mL Brd4_BD1 protein.
2.5 mM inhibitor (in DMSO) final concentration.
Protein buffer: 0.1M HEPES (pH 7.5) 0.15 mM NaCl.
Precipitant agent: 19% (w/v) PEG 3350, 0.25M ammonium sulfate, 
0.1M Tris pH 8.5. Cryoprotectant: 10% (w/v) ethylene glycol",292,"10.1021/acs.jmedchem.5b01708","5OU","5EIS",15.53,"1.6","1.6","FIRST DOMAIN OF HUMAN BROMODOMAIN BRD4 IN COMPLEX WITH INHIBITOR 3-(4-Chlorobenzyl)-7-ethyl-3,7-dihydropurine-2,6-dione","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5EIS"
"5EIZ",,"X-RAY DIFFRACTION",2.7,54.53,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,"10.1002/anie.201803191",,"5EIZ",37.47,"1.96","1.96","Crystal structure of Y99A mutant of human macrophage migration inhibitory factor","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYADMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5EIZ"
"5EK2",,"X-RAY DIFFRACTION",3.01,59.19,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291,"10.1021/acs.jmedchem.5b01390","5PJ","5EK2",92.6,"2.68","2.68","Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue","MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG","Homo sapiens","IDO1, IDO, INDO","Indoleamine 2,3-dioxygenase 1","1","5EK2"
"5EK3",,"X-RAY DIFFRACTION",2.82,56.45,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291,"10.1021/acs.jmedchem.5b01390","5PK","5EK3",92.57,"2.209","2.209","Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue","MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG","Homo sapiens","IDO1, IDO, INDO","Indoleamine 2,3-dioxygenase 1","1","5EK3"
"5EK4",,"X-RAY DIFFRACTION",2.83,56.61,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291,"10.1021/acs.jmedchem.5b01390","5PF","5EK4",92.6,"2.64","2.64","Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue","MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG","Homo sapiens","IDO1, IDO, INDO","Indoleamine 2,3-dioxygenase 1","1","5EK4"
"5EK7",,"X-RAY DIFFRACTION",2.53,51.35,"VAPOR DIFFUSION, HANGING DROP",7,"4% Tacsimate, 5%(w/v) PEG3350, 5% 2-propanol",293,,,"5EK7",70.14,"1.901","1.901","Structure of the autoinhibited Epha2 JMS-KD","MGSSHHHHHHSQDPKPLKTYVDPHTYEDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIR","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5EK7"
"5EK9",,"X-RAY DIFFRACTION",2.75,55.35,"VAPOR DIFFUSION, SITTING DROP",5,"20% PEG6000, 0.1M citrate pH5",277,"10.1016/j.bmc.2017.10.042",,"5EK9",27.46,"2.08","2.08","Crystal structure of the second bromodomain of human BRD2 in complex with a tetrahydroquinoline inhibitor","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5EK9"
"5EKD",,"X-RAY DIFFRACTION",2.29,46.26,"VAPOR DIFFUSION, HANGING DROP",,"sodium acetate, glycerol, peg 5000",289,,,"5EKD",78.02,"1.82","1.82","Human mitochondrial tryptophanyl-tRNA synthetase bound by indolmycin and Mn*ATP.","ALHKGSAAAPALQKDSKKRVFSGIQPTGILHLGNYLGAIESWVRLQDEYDSVLYSIVDLHSITVPQDPAVLRQSILDMTAVLLACGINPEKSILFQQSQVSEHTQLSWILSCMVRLPRLQHLHQWKAKTTKQKHDGTVGLLTYPVLQAADILLYKSTHVPVGEDQVQHMELVQDLAQGFNKKYGEFFPVPESILTSMKKVKSLRDPSAKMSKSDPDKLATVRITDSPEEIVQKFRKAVTDFTSEVTYDPAGRAGVSNIVAVHAAVTGLSVEEVVRRSAGMNTARYKLAVADAVIEKFAPIKREIEKLKLDKDHLEKVLQIGSAKAKELAYTVCQEVKKLVGFL","Homo sapiens","WARS2","Tryptophan--tRNA ligase, mitochondrial","1","5EKD"
"5EKH",,"X-RAY DIFFRACTION",2.12,42,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,"10.1002/anie.201508990","5RD","5EKH",29.7,"1.34","1.34","Human Carbonic Anhydrase II complexed with a two-faced guest","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EKH"
"5EKI",,"X-RAY DIFFRACTION",2.06,40.31,"VAPOR DIFFUSION, HANGING DROP",,"Ammonium sulfate, MPD",293.15,"10.1021/acs.biochem.6b00304",,"5EKI",53.67,"1.9","1.9","Crystal Structure of Truncated CCL21","SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAELCADPKELWVQQLMQHLDKTPSPQKPAQG","Homo sapiens","CCL21, SCYA21, UNQ784/PRO1600","C-C motif chemokine 21","1","5EKI"
"5EKJ",,"X-RAY DIFFRACTION",2.11,41.61,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,"10.1002/anie.201508990","TG4","5EKJ",29.77,"1.129","1.129","Human Carbonic Anhydrase II complexed with a two-faced guest","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EKJ"
"5EKM",,"X-RAY DIFFRACTION",2.11,41.78,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 7.0, 1.3 M sodium citrate",294,"10.1002/anie.201508990","TG5","5EKM",29.74,"1.33","1.33","Human Carbonic Anhydrase II complexed with a two-faced guest","MAHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EKM"
"5EKN",,"X-RAY DIFFRACTION",2.33,47.15,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG3350",290,"10.1016/j.bbagen.2016.06.023",,"5EKN",43.02,"2.594","2.594","Crystal structure of MAPK13 complex with inhibitor","MGSSHHHHHHSSGLVPRGSMSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPFQSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGMEFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMTGYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAAQALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPI","Homo sapiens","MAPK13, PRKM13, SAPK4","Mitogen-activated protein kinase 13","1","5EKN"
"5EKO",,"X-RAY DIFFRACTION",2.32,47.02,"VAPOR DIFFUSION, HANGING DROP",6.5,"50 MM AMMONIUM TARTRATE, 18% PEG3350",290,"10.1016/j.bbagen.2016.06.023","N17","5EKO",43,"2","2","Crystal structure of MAPK13 complex with inhibitor","MGSSHHHHHHSSGLVPRGSMSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPFQSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGMEFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMTGYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAAQALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPI","Homo sapiens","MAPK13, PRKM13, SAPK4","Mitogen-activated protein kinase 13","1","5EKO"
"5EL3",,"X-RAY DIFFRACTION",2.47,50.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"Ammonium Sulfate, HEPES, PEG 3350",277,"10.1038/ncomms10355",,"5EL3",52.24,"1.59","1.59","Structure of the KH domain of T-STAR","GAINKNMKLGQKVLIPVKQFPKFNFVGKLLGPRGNSLKRLQEETLTKMSILGKGSMRDKAKEEELRKSGEAKYFHLNDDLHVLIEVFAPPAEAYARMGHALEEIKKFLIPDYN","Homo sapiens","KHDRBS3, SALP, SLM2","KH domain-containing, RNA-binding, signal transduction-associated protein 3","1","5EL3"
"5ELI",,"X-RAY DIFFRACTION",7.41,85.23,"VAPOR DIFFUSION, HANGING DROP",7.1,"2 M NaCl, 0.2 M MgCl2, 0.2 M NDSB 201, 100 mM HEPES pH 7.1",290,"10.7554/eLife.20391",,"5ELI",28.74,"3.0977","3.0977","Triggering receptor expressed on myeloid cells 2","TGHNTTVFQGVAGQSLQVSCPYDSMKHWGRRKAWCRQLGEKGPCQRVVSTHNLWLLSFLRRWNGSTAITDDTLGGTLTITLRNLQPHDAGLYQCQSLHGSEADTLRKVLVEVLADPLGTKHHHHHH","Homo sapiens","TREM2","Triggering receptor expressed on myeloid cells 2","1","5ELI"
"5ELY",,"X-RAY DIFFRACTION",3.29,62.59,"VAPOR DIFFUSION, HANGING DROP",8,"33% (v/v) pentaerythritol propoxylate PO/OH 5/4, 2 % (w/v) PEG 3350, and 100 mM Tris-HCl, pH 8.0",288,"10.1021/acs.jmedchem.5b01806","5PU","5ELY",81.48,"1.81","1.81","X-ray structure of human glutamate carboxypeptidase II (GCPII) in complex with a hydroxamate inhibitor JHU242","KHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAEEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5ELY"
"5EM3",,"X-RAY DIFFRACTION",2.41,48.93,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium-Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5Q0","5EM3",14.12,"1.4","1.4","Crystal structure of the human BRPF1 bromodomain in complex with SEED9","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EM3"
"5EM5",,"X-RAY DIFFRACTION",3.67,66.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acsmedchemlett.5b00428","5Q2","5EM5",38.02,"2.65","2.65","EGFR kinase domain mutant ""TMLR"" with pyridone compound 2: 4-[2-(4-chlorophenyl)ethylamino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EM5"
"5EM6",,"X-RAY DIFFRACTION",3.47,64.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acsmedchemlett.5b00428","5Q3","5EM6",38.07,"2.78","2.78","EGFR kinase domain mutant ""TMLR"" with pyridone compound 19: 4-[(2-azanylpyrimidin-4-yl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EM6"
"5EM7",,"X-RAY DIFFRACTION",3.46,64.46,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acsmedchemlett.5b00428","5Q4","5EM7",38.08,"2.81","2.81","EGFR kinase domain mutant ""TMLR"" with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EM7"
"5EM8",,"X-RAY DIFFRACTION",3.56,65.48,"VAPOR DIFFUSION, HANGING DROP",7,"sodium/potassium tartrate",292,"10.1021/acsmedchemlett.5b00428","5Q4","5EM8",38.08,"2.8","2.8","EGFR kinase domain with pyridone compound 13: 4-[(2-methoxyphenyl)amino]-~{N}-[4-(4-methylpiperazin-1-yl)phenyl]-2-oxidanylidene-1~{H}-pyridine-3-carboxamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5EM8"
"5EMN",,"X-RAY DIFFRACTION",2.28,46.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"100mM MES,pH6.5,50mM CaAc2,0.1M NaCl, 14% PEG4K",292,"10.1074/jbc.M116.716019",,"5EMN",144.28,"2.2","2.2","Crystal Structure of Human NADPH-Cytochrome P450 Reductase(A287P mutant)","GSHMVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWLAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLPAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPVGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS","Homo sapiens","POR, CYPOR","NADPH--cytochrome P450 reductase","1","5EMN"
"5EMS",,"X-RAY DIFFRACTION",2.28,45.97,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M sodium citrate, 0.08% zinc acetate, 2% phenol",298,"10.1074/jbc.M116.761015",,"5EMS",36.33,"2.3","2.3","Crystal Structure of an iodinated insulin analog","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin","1","5EMS"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPLT","Homo sapiens","INS","Insulin","2","5EMS"
"5EMT",,"X-RAY DIFFRACTION",2.02,39.23,"VAPOR DIFFUSION, HANGING DROP",6.1,"100 mM MES, 39% PEG 8000,",293,"10.1016/j.bbrc.2017.07.111",,"5EMT",28.64,"1.5","1.5","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1)-copper complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5EMT"
"5EMV",,"X-RAY DIFFRACTION",2.56,51.9,"VAPOR DIFFUSION, SITTING DROP",7.3,"1.7-2.1 M Sodium Formate",292,"10.1016/j.str.2015.11.005",,"5EMV",53.88,"2","2","Crystal structure of the palmitoylated human TEAD2 transcription factor","GSAWQARGLGTARLQLVEFSAFVEPPDAVDSYQRHLFVHISQHCPSPGAPPLESVDVRQIYDKFPEKKGGLRELYDRGPPHAFFLVKFWADLNWGPSGEEAGAGGSISSGGFYGVSSQYESLEHMTLTCSSKVCSFGKQVVEKVETERAQLEDGRFVYRLLRSPMCEYLVNFLHKLRQLPERYMMNSVLENFTILQVVTNRDTQELLLCTAYVFEVSTSERGAQHHIYRLVRDGNS","Homo sapiens","TEAD2, TEF4","Transcriptional enhancer factor TEF-4","1","5EMV"
"5EMW",,"X-RAY DIFFRACTION",3.04,59.5,"VAPOR DIFFUSION, SITTING DROP",4.5,"100 mM Sodium Acetate, 100 mM Calcium acetate, 12% PEG4000",292,"10.1016/j.str.2015.11.005",,"5EMW",100.67,"2.55","2.55","Crystal structure of the palmitoylated human TEAD3 transcription factor","TIASSRLRLLEYSAFMEVQRDPDTYSKHLFVHIGQTNPAFSDPPLEAVDVRQIYDKFPEKKGGLKELYEKGPPNAFFLVKFWADLNSTIQEGPGAFYGVSSQYSSADSMTISVSTKVCSFGKQVVEKVETEYARLENGRFVYRIHRSPMCEYMINFIHKLKHLPEKYMMNSVLENFTILQVVTSRDSQETLLVIAFVFEVSTSEHGAQHHVYKLVKD","Homo sapiens","TEAD3, TEAD5, TEF5","Transcriptional enhancer factor TEF-5","1","5EMW"
"5EMY",,"X-RAY DIFFRACTION",2.08,40.98,"VAPOR DIFFUSION, HANGING DROP",7.5,"100 mM sodium cacodylate, 58% MPD, obtained crystals were soaked in 100mM glucosyl epi-cyclophellitol solution and incubated for up to two weeks to allow complex formation.",293,"10.1002/1873-3468.12143",,"5EMY",56.35,"1.231","1.231","Human Pancreatic Alpha-Amylase in complex with the mechanism based inactivator glucosyl epi-cyclophellitol","QYSPNTQQGRTSIVHLFEWRWVDIALECERYLAPKGFGGVQVSPPNENVAIYNPFRPWWERYQPVSYKLCTRSGNEDEFRNMVTRCNNVGVRIYVDAVINHMCGNAVSAGTSSTCGSYFNPGSRDFPAVPYSGWDFNDGKCKTGSGDIENYNDATQVRDCRLTGLLDLALEKDYVRSKIAEYMNHLIDIGVAGFRLDASKHMWPGDIKAILDKLHNLNSNWFPAGSKPFIYQEVIDLGGEPIKSSDYFGNGRVTEFKYGAKLGTVIRKWNGEKMSYLKNWGEGWGFVPSDRALVFVDNHDNQRGHGAGGASILTFWDARLYKMAVGFMLAHPYGFTRVMSSYRWPRQFQNGNDVNDWVGPPNNNGVIKEVTINPDTTCGNDWVCEHRWRQIRNMVIFRNVVDGQPFTNWYDNGSNQVAFGRGNRGFIVFNNDDWSFSLTLQTGLPAGTYCDVISGDKINGNCTGIKIYVSDDGKAHFSISNSAEDPFIAIHAESKL","Homo sapiens","AMY2A","Pancreatic alpha-amylase","1","5EMY"
"5EMZ",,"X-RAY DIFFRACTION",2.04,39.64,"VAPOR DIFFUSION, SITTING DROP",,"LiSO
Tris
PEG-3350",298,,,"5EMZ",52.05,"1.66","1.66","Crystal structure of K48-linked diubiquitin with F45W mutation in the proximal unit","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGRQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","1","5EMZ"
,,,,,,,,,,,,,,,,"MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIWAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBB","Polyubiquitin-B","2","5EMZ"
"5EN3",,"X-RAY DIFFRACTION",2.15,42.73,"VAPOR DIFFUSION, HANGING DROP",5.5,"Purified TTR was dialyzed against 10 mM Naphosphate buffer with 100 mM KCl, pH 7.6 and concentrated to 5 mg per ml. Crystallization solution contained 1.3 to 1.6 M sodium citrate and 3.5% glycerol.",291,"10.1371/journal.pone.0153112","7LU","5EN3",28.28,"1.25","1.25","Crystal structure of human transthyretin in complex with luteolin-Cl at 1.25 A resolution","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5EN3"
"5EN4",,"X-RAY DIFFRACTION",2.5,50.9,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 6000 20%
Hepes 0.1M
DMSO 5%",291,"10.1021/acs.jmedchem.6b01436","5Q6","5EN4",29.36,"1.52","1.52","Complex of 17-beta-hydroxysteroid dehydrogenase type 14 with inhibitor.","MATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5EN4"
"5EN9",,"X-RAY DIFFRACTION",3.4,63.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 13% MPD",292,"10.1002/cbic.201500600",,"5EN9",5.82,"1.5","1.5","High resolution x-ray crystal structure of isotope-labeled ester-insulin","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin chain A","1","5EN9"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin chain B","2","5EN9"
"5ENA",,"X-RAY DIFFRACTION",3.39,63.72,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M HEPES, 0.2 M sodium citrate tribasic dihydrate, 11% MPD",292,"10.1002/cbic.201500600",,"5ENA",5.82,"1.35","1.35","Xray crystal structure of isotope-labeled human insulin","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin chain A","1","5ENA"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin chain B","2","5ENA"
"5ENB",,"X-RAY DIFFRACTION",2.16,43.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 30% PEG3350",277,"10.1039/c5sc03115j",,"5ENB",15.89,"1.73","1.73","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with o-Tolylthiourea (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENB"
"5ENC",,"X-RAY DIFFRACTION",2.14,42.56,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENC",15.94,"1.59","1.59","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with N-(2,6-Dichlorobenzyl)acetamide (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENC"
"5ENE",,"X-RAY DIFFRACTION",2.15,42.77,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENE",15.79,"1.49","1.49","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with 5-Amino-2-benzyl-1,3-oxazole-4-carbonitrile (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENE"
"5ENF",,"X-RAY DIFFRACTION",2.16,43.04,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENF",15.88,"1.37","1.37","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with fragment-4 N10142 (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENF"
"5ENG",,"X-RAY DIFFRACTION",2.4,48.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277,"10.1021/acsmedchemlett.8b00286",,"5ENG",14.69,"1.3","1.3","Crystal structure of the bromodomain of human CREBBP in complex with UP39","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5ENG"
"5ENH",,"X-RAY DIFFRACTION",2.14,42.45,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENH",15.8,"1.95","1.95","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-12 N11528 (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENH"
"5ENI",,"X-RAY DIFFRACTION",2.12,41.85,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENI",15.83,"1.69","1.69","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-13 N11537 (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENI"
"5ENJ",,"X-RAY DIFFRACTION",2.15,42.89,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M HEPES pH 7.5 , 0.15M magnesium chloride , 32% PEG3350",277,"10.1039/c5sc03115j",,"5ENJ",15.85,"1.63","1.63","Crystal structure of the second bromodomain of Pleckstrin homology domain interacting protein (PHIP) in complex with compound-14 N11530 (SGC - Diamond I04-1 fragment screening)","YFQSMSYDIQAWKKQCEELLNLIFQCEDSEPFRQPVDLLEYPDYRDIIDTPMDFATVRETLEAGNYESPMELCKDVRLIFSNSKAYTPSKRSRIYSMSLRLSAFFEEHISSVLSDYKSALRFHKRNTITKR","Homo sapiens","PHIP, WDR11, DCAF14","PH-interacting protein","1","5ENJ"
"5ENK",,"X-RAY DIFFRACTION",2.55,51.82,"VAPOR DIFFUSION",,"10% PEG MME 5K, 9% PEG 8K, 0.2 M NH4I, 0.2 M Na-citrate pH 6.4",295,"10.1021/acsmedchemlett.5b00432","5QV","5ENK",50.85,"2.11","2.11","Compound 18","MASMTGGQQMGRGSAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5ENK"
"5ENM",,"X-RAY DIFFRACTION",2.56,51.99,"VAPOR DIFFUSION",,"10% PEG MME 5K, 9% PEG 8K, 0.2 M NH4I, 0.2 M Na-citrate pH 6.4",295,"10.1021/acsmedchemlett.5b00432","5QU","5ENM",50.84,"1.98","1.98","Compound 10","MASMTGGQQMGRGSAGVLPAHGTQHGIRLPLRSGLGGAPLGLRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5ENM"
"5ENN",,"X-RAY DIFFRACTION",3.26,62.27,"VAPOR DIFFUSION, SITTING DROP",7.5,"200nL:200nL well to protein
0.2M Sodium Acetate
0.1M HEPES 7.5
20% PEG 3000",291.15,,"5QS","5ENN",144.71,"2.7","2.7","The crystal structure of Human VPS34 in complex with a selective and potent inhibitor","MSYYHHHHHHDYDIPTTENLYFQGAMGSGIRDQLNIIVSYPPTKQLTYEEQDLVWKFRYYLTNQEKALTKFLKCVNWDLPQEAKQALELLGKWKPMDVEDSLELLSSHYTNPTVRRYAVARLRQADDEDLLMYLLQLVQALKYENFDDIKNGLEPTKKDSQSSVSENVSNSGINSAEIDSSQIITSPLPSVSSPPPASKTKEVPDGENLEQDLCTFLISRACKNSTLANYLYWYVIVECEDQDTQQRDPKTHEMYLNVMRRFSQALLKGDKSVRVMRSLLAAQQTFVDRLVHLMKAVQRESGNRKKKNERLQALLGDNEKMNLSDVELIPLPLEPQVKIRGIIPETATLFKSALMPAQLFFKTEDGGKYPVIFKHGDDLRQDQLILQIISLMDKLLRKENLDLKLTPYKVLATSTKHGFMQFIQSVPVAEVLDTEGSIQNFFRKYAPSENGPNGISAEVMDTYVKSCAGYCVITYILGVGDRHLDNLLLTKTGKLFHIDFGYILGRDPKPLPPPMKLNKEMVEGMGGTQSEQYQEFRKQCYTAFLHLRRYSNLILNLFSLMVDANIPDIALEPDKTVKKVQDKFRLDLSDEEAVHYMQSLIDESVHALFAAVVEQIHKFAQYWRK","Homo sapiens","PIK3C3, VPS34","Phosphatidylinositol 3-kinase catalytic subunit type 3","1","5ENN"
"5EO3",,"X-RAY DIFFRACTION",3.27,62.44,"VAPOR DIFFUSION, HANGING DROP",7.5,"20mM Tris HCl pH 7.5, 200mM NaCl, 5mM DTT",295,,,"5EO3",27.03,"2.6","2.6","Crystal Structure of Pelota C terminal domain from human","RLSDTKAAGEVKALDDFYKMLQHEPDRAFYGLKQVEKANEAMAIDTLLISDELFRHQDVATRSRYVRLVDSVKENAGTVRIFSSLHVSGEQLSQLTGVAAILRFPVPELSDQEGDSSSEED","Homo sapiens","Pelota, PELO, CGI-17","Protein pelota homolog","1","5EO3"
"5EOB",,"X-RAY DIFFRACTION",1.96,37.28,"VAPOR DIFFUSION, HANGING DROP",7.5,"19-20%(w/v)PEG 3350, 200mM MgSO4, 100mM Tris-HCl",293,"10.1016/j.ejmech.2016.03.076","5QQ","5EOB",36.43,"1.75","1.75","Crystal structure of CMET in complex with novel inhibitor","MGSSHHHHHHGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIG","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5EOB"
"5EOG",,"X-RAY DIFFRACTION",3.59,65.69,"VAPOR DIFFUSION, HANGING DROP",,"1M Trisodium citrate
0.1M MES",293,"10.1038/srep27498",,"5EOG",207.26,"3.05","3.05","Structure of full-length human MAB21L1","GAMDIAAQAKLVYHLNKYYNEKCQARKAAIAKTIREVCKVVSDVLKEVEVQEPRFISSLNEMDNRYEGLEVISPTEFEVVLYLNQMGVFNFVDDGSLPGCAVLKLSDGRKRSMSLWVEFITASGYLSARKIRSRFQTLVAQAVDKCSYRDVVKMVADTSEVKLRIRDRYVVQITPAFKCTGIWPRSAAHWPLPHIPWPGPNRVAEVKAEGFNLLSKECHSLAGKQSSAESDAWVLQFAEAENRLQMGGCRKKCLSILKTLRDRHLELPGQPLNNYHMKTLVSYECEKHPRESDWDESCLGDRLNGILLQLISCLQCRRCPHYFLPNLDLFQGKPHSALENAAKQTWRLAREILTNPKSLEKL","Homo sapiens","MAB21L1, CAGR1, Nbla00126","Protein mab-21-like 1","1","5EOG"
"5EOI",,"X-RAY DIFFRACTION",2.09,41.17,"VAPOR DIFFUSION, HANGING DROP",8,"2.4 M ammonium sulphate, Tris 50 mM, HgCl2 2mM",296,,"CL","5EOI",29.47,"1.8","1.8","Crystal structure of copper bound human Carbonic anhydrase II","HHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5EOI"
"5EOL",,"X-RAY DIFFRACTION",3.29,62.67,"VAPOR DIFFUSION, HANGING DROP",8,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277,"10.1021/acsmedchemlett.5b00403","5QO","5EOL",33.61,"2.2","2.2","Crystal structure of human Pim-1 kinase in complex with a macrocyclic quinoxaline-pyrrolodihydropiperidinone inhibitor","MAHHHHHHDEVDGPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5EOL"
"5EOM",,"X-RAY DIFFRACTION",3.31,62.88,"VAPOR DIFFUSION, HANGING DROP",,"1M Trisodium citrate
0.1M MES",293,"10.1038/srep27498",,"5EOM",419.65,"2.55","2.55","Structure of full-length human MAB21L1 with bound CTP","GAMDIAAQAKLVYHLNKYYNEKCQARKAAIAKTIREVCKVVSDVLKEVEVQEPRFISSLNEMDNRYEGLEVISPTEFEVVLYLNQMGVFNFVDDGSLPGCAVLKLSDGRKRSMSLWVEFITASGYLSARKIRSRFQTLVAQAVDKCSYRDVVKMVADTSEVKLRIRDRYVVQITPAFKCTGIWPRSAAHWPLPHIPWPGPNRVAEVKAEGFNLLSKECHSLAGKQSSAESDAWVLQFAEAENRLQMGGCRKKCLSILKTLRDRHLELPGQPLNNYHMKTLVSYECEKHPRESDWDESCLGDRLNGILLQLISCLQCRRCPHYFLPNLDLFQGKPHSALENAAKQTWRLAREILTNPKSLEKL","Homo sapiens","MAB21L1, CAGR1, Nbla00126","Protein mab-21-like 1","1","5EOM"
"5EOP",,"X-RAY DIFFRACTION",1.9,35.41,"VAPOR DIFFUSION",7,"Malic acid/NaOH pH 7.0 
PEG 3350",289,"10.1002/1873-3468.12335",,"5EOP",13.94,"1.35","1.35","Crystal structure of human Angiogenin at 1.35 Angstroms resolution","DNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFRR","Homo sapiens","ANG, RNASE5","Angiogenin","1","5EOP"
"5EP7",,"X-RAY DIFFRACTION",2.02,39.22,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.2M KSCN, 20% PEG3350, 10% EtGly, pH 7.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277,"10.1021/acsmedchemlett.8b00286","5QR","5EP7",14.5,"1.198","1.198","Crystal structure of the bromodomain of human CREBBP in complex with UN32","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5EP7"
"5EPB",,"X-RAY DIFFRACTION",4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 277K",277,,,"5EPB",16.25,"1.5","1.5","Crystal structure of the bromodomain of human ATAD2 in complex with Compound 49","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPase family AAA domain-containing protein 2","1","5EPB"
"5EPC",,"X-RAY DIFFRACTION",3.04,59.52,"VAPOR DIFFUSION, HANGING DROP",8,"Lithium or ammonium sulfate (1.35 - 1.85 M) with 0.1 M Tris, pH 8.0",293,"10.1016/j.jmb.2016.02.032",,"5EPC",130.03,"1.85","1.85","Crystal structure of wild-type human phosphoglucomutase 1","MHHHHHHSSGVDLGTENLYFQSNMVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQSIISTVEPAQRQEATLVVGGDGRFYMKEAIQLIARIAAANGIGRLVIGQNGILSTPAVSCIIRKIKAIGGIILTASHNPGGPNGDFGIKFNISNGGPAPEAITDKIFQISKTIEEYAVCPDLKVDLGVLGKQQFDLENKFKPFTVEIVDSVEAYATMLRSIFDFSALKELLSGPNRLKIRIDAMHGVVGPYVKKILCEELGAPANSAVNCVPLEDFGGHHPDPNLTYAADLVETMKSGEHDFGAAFDGDGDRNMILGKHGFFVNPSDSVAVIAANIFSIPYFQQTGVRGFARSMPTSGALDRVASATKIALYETPTGWKFFGNLMDASKLSLCGEESFGTGSDHIREKDGLWAVLAWLSILATRKQSVEDILKDHWQKYGRNFFTRYDYEEVEAEGANKMMKDLEALMFDRSFVGKQFSANDKVYTVEKADNFEYSDPVDGSISRNQGLRLIFTDGSRIVFRLSGTGSAGATIRLYIDSYEKDVAKINQDPQVMLAPLISIALKVSQLQERTGRTAPTVIT","Homo sapiens","PGM1","Phosphoglucomutase-1","1","5EPC"
"5EPG",,"X-RAY DIFFRACTION",2.42,49.1,"VAPOR DIFFUSION",,"PEG 4000",293.15,"10.1124/dmd.115.068395",,"5EPG",149.82,"3.39","3.39","Human aldehyde oxidase SNP S1271L","MDRASELLFYVNGRKVIEKNVDPETMLLPYLRKKLRLTGTKYGCGGGGCGACTVMISRYNPITKRIRHHPANACLIPICSLYGAAVTTVEGIGSTHTRIHPVQERIAKCHGTQCGFCTPGMVMSIYTLLRNHPEPTLDQLTDALGGNLCRCTGYRPIIDACKTFCKTSGCCQSKENGVCCLDQGINGLPEFEEGSKTSPKLFAEEEFLPLDPTQELIFPPELMIMAEKQSQRTRVFGSERMMWFSPVTLKELLEFKFKYPQAPVIMGNTSVGPEVKFKGVFHPVIISPDRIEELSVVNHAYNGLTLGAGLSLAQVKDILADVVQKLPEEKTQMYHALLKHLGTLAGSQIRNMASLGGHIISRHPDSDLNPILAVGNCTLNLLSKEGKRQIPLNEQFLSKCPNADLKPQEILVSVNIPYSRKWEFVSAFRQAQRQENALAIVNSGMRVFFGEGDGIIRELCISYGGVGPATICAKNSCQKLIGRHWNEQMLDIACRLILNEVSLLGSAPGGKVEFKRTLIISFLFKFYLEVSQILKKMDPVHYPSLADKYESALEDLHSKHHCSTLKYQNIGPKQHPEDPIGHPIMHLSGVKHATGEAIYCDDMPLVDQELFLTFVTSSRAHAKIVSIDLSEALSMPGVVDIMTAEHLSDVNSFCFFTEAEKFLATDKVFCVGQLVCAVLADSEVQAKRAAKRVKIVYQDLEPLILTIEESIQHNSSFKPERKLEYGNVDEAFKVVDQILEGEIHMGGQEHFYMETQSMLVVPKGEDQEMDVYVSTQFPKYIQDIVASTLKLPANKVMCHVRRVGGAFGGKVLKTGIIAAVTAFAANKHGRAVRCVLERGEDMLITGGRHPYLGKYKAGFMNDGRILALDMEHYSNAGASLDESLFVIEMGLLKMDNAYKFPNLRCRGWACRTNLPSNTAFRGFGFPQAALITESCITEVAAKCGLSPEKVRIINMYKEIDQTPYKQEINAKNLIQCWRECMAMSSYSLRKVAVEKFNAENYWKKKGLAMVPLKFPVGLGSRAAGQAAALVHIYLDGSVLVTHGGIEMGQGVHTKMIQVVSRELRMPMSNVHLRGTSTETVPNANISGGSVVADLNGLAVKDACQTLLKRLEPIISKNPKGTWKDWAQTAFDESINLSAVGYFRGYESDMNWEKGEGQPFEYFVYGAACSEVEIDCLTGDHKNIRTDIVMDVGCSINPAIDIGQIEGAFIQGMGLYTIEELNYSPQGILHTRGPDQYKIPAICDMPTELHIALLPPSQNSNTLYSSKGLGELGVFLGCSVFFAIHDAVSAARQERGLHGPLTLNSPLTPEKIRMACEDKFTKMIPRDEPGSYVPWNVPI","Homo sapiens","AOX1, AO","Aldehyde oxidase","1","5EPG"
"5EPR",,"X-RAY DIFFRACTION",2.46,50.07,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5QY","5EPR",13.93,"1.65","1.65","Crystal structure of the human BRPF1 bromodomain in complex with SEED11","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EPR"
"5EPS",,"X-RAY DIFFRACTION",2.42,49.17,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5QX","5EPS",13.93,"1.47","1.47","Crystal structure of the human BRPF1 bromodomain in complex with SEED10","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EPS"
"5EPZ",,"X-RAY DIFFRACTION",2.38,48.29,"VAPOR DIFFUSION",8,"0.1 M Tris/HCl buffer pH 8.0, 2.4 M ammonium sulphate",289,"10.1002/1873-3468.12335",,"5EPZ",14.26,"1.85","1.85","Human Angiogenin in complex with sulphate anions at a basic solution","DNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFR","Homo sapiens","ANG, RNASE5","Angiogenin","1","5EPZ"
"5EQ1",,"X-RAY DIFFRACTION",2.5,50.81,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","BEA","5EQ1",13.96,"1.55","1.55","Crystal structure of the human BRPF1 bromodomain in complex with SEED12","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EQ1"
"5EQE",,"X-RAY DIFFRACTION",2.36,47.78,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium formate, 8-12% PEG 3350",291,"10.1021/acs.jmedchem.5b01552","5R8","5EQE",94.18,"2.4","2.4","Crystal structure of choline kinase alpha-1 bound by [4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]methanamine (compound 11)","GSSHHHHHHSSGLVPRGSPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","Choline kinase alpha","1","5EQE"
"5EQG",,"X-RAY DIFFRACTION",3.86,68.15,"VAPOR DIFFUSION, SITTING DROP",,"30-40% v/v PEG400, 100 mM MES, pH 5.5-6.5, 50-200 mM sodium chloride or magnesium chloride",277.15,"10.1073/pnas.1603735113",,"5EQG",54.55,"2.9","2.9","Human GLUT1 in complex with inhibitor (2~{S})-3-(4-fluorophenyl)-2-[2-(3-hydroxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide","MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV","Homo sapiens","SLC2A1, GLUT1","Solute carrier family 2, facilitated glucose transporter member 1","1","5EQG"
"5EQH",,"X-RAY DIFFRACTION",3.9,68.46,"VAPOR DIFFUSION, SITTING DROP",,"30-40% v/v PEG400, 100 mM MES, pH 5.5-6.5, 50-200 mM sodium chloride or magnesium chloride",277,"10.1073/pnas.1603735113",,"5EQH",54.62,"2.99","2.99","Human GLUT1 in complex with inhibitor (2~{S})-3-(2-bromophenyl)-2-[2-(4-methoxyphenyl)ethanoylamino]-~{N}-[(1~{S})-1-phenylethyl]propanamide","MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV","Homo sapiens","SLC2A1, GLUT1","Solute carrier family 2, facilitated glucose transporter member 1","1","5EQH"
"5EQI",,"X-RAY DIFFRACTION",3.88,68.27,"VAPOR DIFFUSION, SITTING DROP",,"30-40% v/v PEG400, 100 mM MES, pH 5.5-6.5, 50-200 mM sodium chloride or magnesium chloride",277,"10.1073/pnas.1603735113",,"5EQI",54.61,"3.002","3.002","Human GLUT1 in complex with Cytochalasin B","MEPSSKKLTGRLMLAVGGAVLGSLQFGYNTGVINAPQKVIEEFYNQTWVHRYGESILPTTLTTLWSLSVAIFSVGGMIGSFSVGLFVNRFGRRNSMLMMNLLAFVSAVLMGFSKLGKSFEMLILGRFIIGVYCGLTTGFVPMYVGEVSPTALRGALGTLHQLGIVVGILIAQVFGLDSIMGNKDLWPLLLSIIFIPALLQCIVLPFCPESPRFLLINRNEENRAKSVLKKLRGTADVTHDLQEMKEESRQMMREKKVTILELFRSPAYRQPILIAVVLQLSQQLSGINAVFYYSTSIFEKAGVQQPVYATIGSGIVNTAFTVVSLFVVERAGRRTLHLIGLAGMAGCAILMTIALALLEQLPWMSYLSIVAIFGFVAFFEVGPGPIPWFIVAELFSQGPRPAAIAVAGFSNWTSNFIVGMCFQYVEQLCGPYVFIIFTVLLVLFFIFTYFKVPETKGRTFDEIASGFRQGGASQSDKTPEELFHPLGADSQV","Homo sapiens","SLC2A1, GLUT1","Solute carrier family 2, facilitated glucose transporter member 1","1","5EQI"
"5EQO",,"X-RAY DIFFRACTION",2.36,47.87,"VAPOR DIFFUSION",6,"0.1 M sodium cacodylate pH 6.0
2.0 M ammonium sulphate",289,"10.1002/1873-3468.12335",,"5EQO",14.49,"2.4","2.4","Human Angiogenin in complex with sulphate anions at an acidic solution","QDNSRYTHFLTQHYDAKPQGRDDRYCESIMRRRGLTSPCKDINTFIHGNKRSIKAICENKNGNPHRENLRISKSSFQVTTCKLHGGSPWPPCQYRATAGFRNVVVACENGLPVHLDQSIFR","Homo sapiens","ANG, RNASE5","Angiogenin","1","5EQO"
"5EQP",,"X-RAY DIFFRACTION",2.32,46.95,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium formate, 8-12% PEG 3350",291,"10.1021/acs.jmedchem.5b01552","5R9","5EQP",94.22,"2.35","2.35","Crystal structure of choline kinase alpha-1 bound by 6-[(4-methyl-1,4-diazepan-1-yl)methyl]quinoline (compound 37)","GSSHHHHHHSSGLVPRGSPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","Choline kinase alpha","1","5EQP"
"5EQX",,"X-RAY DIFFRACTION",3.08,60.11,"VAPOR DIFFUSION, HANGING DROP",6.7,"15% (w/v) PEG10000, 0.15M ammonium formate pH6.7, 0.01M calcium chloride, 30 (v/v) ethylene glycol (cryoprotectant).",295,"10.1073/pnas.1606272113",,"5EQX",63.47,"3.05","3.05","Crystal structure of human Desmoglein-3 ectodomain","EWVKFAKPCREGEDNSKRNPIAKITSDYQATQKITYRISGVGIDQPPFGIFVVDKNTGDINITAIVDREETPSFLITCRALNAQGLDVEKPLILTVKILDINDNPPVFSQQIFMGEIEENSASNSLVMILNATDADEPNHLNSKIAFKIVSQEPAGTPMFLLSRNTGEVRTLTNSLDREQASSYRLVVSGADKDGEGLSTQCECNIKVKDVNDNFPMFRDSQYSARIEENILSSELLRFQVTDLDEEYTDNWLAVYFFTSGNEGNWFEIQTDPRTNEGILKVVKALDYEQLQSVKLSIAVKNKAEFHQSVISRYRVQSTPVTIQVINVREGIAFRPASKTFTVQKGISSKKLVDYILGTYQAIDEDTNKAASNVKYVMGRNDGGYLMIDSKTAEIKFVKNMNRDSTFIVNKTITAEVLAIDEYTGKTSTGTVYVRVPDFNDNCPTAVLEKDAVCSSSPSVVVSARTLNNRYTGPYTFALEDQPVKLPAVWSITTLNATSALLRAQEQIPPGVYHISLVLTDSQNNRCEMPRSLTLEVCQCDNRGICGTSHHHHHH","Homo sapiens","DSG3, CDHF6","Desmoglein-3","1","5EQX"
"5EQY",,"X-RAY DIFFRACTION",2.35,47.63,"VAPOR DIFFUSION, HANGING DROP",,"0.1M sodium formate, 8-12% PEG 3350",291,"10.1021/acs.jmedchem.5b01552","5RA","5EQY",94.58,"2.5","2.5","Crystal structure of choline kinase alpha-1 bound by 5-[(4-methyl-1,4-diazepan-1-yl)methyl]-2-[4-[(4-methyl-1,4-diazepan-1-yl)methyl]phenyl]benzenecarbonitrile (compound 65)","GSSHHHHHHSSGLVPRGSPQPPADEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","Choline kinase alpha","1","5EQY"
"5ER7",,"X-RAY DIFFRACTION",3.59,65.73,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes, 15 mM Sodium formate, 20 mM CaCl2, 14% (w/v) PEG 3350",298,"10.1038/ncomms9770",,"5ER7",52.36,"3.286","3.286","Connexin-26 Bound to Calcium","MDWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADFVCNTLQPGCKNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVASRRHEKKRKFIKGEIKSEFKDIEEIKTQKVRIEGSLWWTYTSSIFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDCFVSRPTEKTVFTVFMIAVSGICILLNVTELSYLLIRYSSGKSKKPV","Homo sapiens","GJB2","Gap junction beta-2 protein","1","5ER7"
"5ERA",,"X-RAY DIFFRACTION",3.59,65.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1 M Hepes, 15 mM Sodium formate, 14% (w/v) PEG 3350",298,"10.1038/ncomms9770",,"5ERA",52.28,"3.8","3.8","Human Connexin-26 (Calcium-free)","MDWGTLQTILGGVNKHSTSIGKIWLTVLFIFRIMILVVAAKEVWGDEQADFVCNTLQPGCKNVCYDHYFPISHIRLWALQLIFVSTPALLVAMHVASRRHEKKRKFIKGEIKSEFKDIEEIKTQKVRIEGSLWWTYTSSIFFRVIFEAAFMYVFYVMYDGFSMQRLVKCNAWPCPNTVDCFVSRPTEKTVFTVFMIAVSGICILLNVTELSYLLIRYSSGKSKKPV","Homo sapiens","GJB2","Gap junction beta-2 protein","1","5ERA"
"5ERC",,"X-RAY DIFFRACTION",2.95,58.32,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M Calcium acetate, 0.1 M Imidazole pH 8.0, 10% PEG8000",293,"10.1093/nar/gkv1321",,"5ERC",20.04,"2.05","2.05","X-ray crystal structure of BRPF1 PZP domain","AVCCICNDGECQNSNVILFCDMCNLAVHQECYGVPYIPEGQWLCRRCLQSPSRAVDCALCPNKGGAFKQTDDGRWAHVVCALWIPEVCFANTVFLEPIDSIEHIPPARWKLTCYICKQRGSGACIQCHKANCYTAFHVTCAQQAGLYMKMEPVRETGANGTSFSVRKTAYCDIHTPP","Homo sapiens","BRPF1, BR140","Peregrin","1","5ERC"
"5ERD",,"X-RAY DIFFRACTION",4.71,73.89,"VAPOR DIFFUSION, HANGING DROP",8.5,"26% EDO_P8K (Molecular Dimensions), 0.1M Tris-Bicine pH8.5, 0.1M amino acids mix (Molecular Dimensions), 0.01M Calcium chloride",295,"10.1073/pnas.1606272113",,"5ERD",131.62,"2.9","2.9","Crystal structure of human Desmoglein-2 ectodomain","AWITAPVALREGEDLSKKNPIAKIHSDLAEERGLKITYKYTGKGITEPPFGIFVFNKDTGELNVTSILDREETPFFLLTGYALDARGNNVEKPLELRIKVLDINDNEPVFTQDVFVGSVEELSAAHTLVMKINATDADEPNTLNSKISYRIVSLEPAYPPVFYLNKDTGEIYTTSVTLDREEHSSYTLTVEARDGNGEVTDKPVKQAQVQIRILDVNDNIPVVENKVLEGMVEENQVNVEVTRIKVFDADEIGSDNWLANFTFASGNEGGYFHIETDAQTNEGIVTLIKEVDYEEMKNLDFSVIVANKAAFHKSIRSKYKPTPIPIKVKVKNVKEGIHFKSSVISIYVSESMDRSSKGQIIGNFQAFDEDTGLPAHARYVKLEDRDNWISVDSVTSEIKLAKLPDFESRYVQNGTYTVKIVAISEDYPRKTITGTVLINVEDINDNCPTLIEPVQTICHDAEYVNVTAEDLDGHPNSGPFSFSVIDKPPGMAEKWKIARQESTSVLLQQSEKKLGRSEIQFLISDNQGFSCPEKQVLTLTVCECLHGSGCREAHHHHHH","Homo sapiens","DSG2, CDHF5","Desmoglein-2","1","5ERD"
"5ERP",,"X-RAY DIFFRACTION",4.43,72.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% (w/v) EDO_P8K (Molecular Dimensions), 10% amino acids mix (Molecular Dimensions), 0.1M MES-imidazole pH 6.5",295,"10.1073/pnas.1606272113",,"5ERP",106.36,"2.7","2.7","Crystal structure of human Desmocollin-2 ectodomain fragment EC2-5","ENDNYPIFTEETYTFTIFENCRVGTTVGQVCATDKDEPDTMHTRLKYSIIGQVPPSPTLFSMHPTTGVITTTSSQLDRELIDKYQLKIKVQDMDGQYFGLQTTSTCIINIDDVNDHLPTFTRTSYVTSVEENTVDVEILRVTVEDKDLVNTANWRANYTILKGNENGNFKIVTDAKTNEGVLCVVKPLNYEEKQQMILQIGVVNEAPFSREASPRSAMSTATVTVNVEDQDEGPECNPPIQTVRMKENAEVGTTSNGYKAYDPETRSSSGIRYKKLTDPTGWVTIDENTGSIKVFRSLDREAETIKNGIYNITVLASDQGGRTCTGTLGIILQDVNDNSPFIPKKTVIICKPTMSSAEIVAVDPDEPIHGPPFDFSLESSTSEVQRMWRLKAINDTAARLSYQNDPPFGSYVVPITVRDRLGMSSVTSLDVTLCDCITENDCTHRHHHHHH","Homo sapiens","DSC2, CDHF2, DSC3","Desmocollin-2","1","5ERP"
"5ES1",,"X-RAY DIFFRACTION",3.14,60.88,"VAPOR DIFFUSION",8.5,"20% (w/v) PEG 6000, 0.2 M MgCl2, 0.1 M Tris",292,"10.1107/S2053230X15024747",,"5ES1",38.09,"2.8","2.8","CRYSTAL STRUCTURE OF MICROTUBULE AFFINITY-REGULATING KINASE 4 CATALYTIC DOMAIN IN COMPLEX WITH A PYRAZOLOPYRIMIDINE INHIBITOR","GNSIASCPEEQPHVGNYRLLRTIGKGNFAKVKLARHILTGREVAIKIIDKTQLNPSSLQKLFREVRIMKGLNHPNIVKLFEVIETEKTLYLVMEYASAGEVFDYLVSHGRMKEKEARAKFRQIVSAVHYCHQKNIVHRDLKAENLLLDAEANIKIADFGFSNEFTLGSKLDTFCGSPPYAAPELFQGKKYDGPEVDIWSLGVILYTLVSGSLPFDGHNLKELRERVLRGKYRVPFYMSTDCESILRRFLVLNPAKRCTLEQIMKDKWINIGYEGEELKPYTEPEEDFGDTKRIEVMVGMGYTREEIKESLTSQKYNEVTATYLLLGRK","Homo sapiens","MARK4, KIAA1860, MARKL1","MAP/microtubule affinity-regulating kinase 4","1","5ES1"
"5ESA",,"X-RAY DIFFRACTION",2.14,42.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"20% w/v PEG1000, 0.1 M sodium cacodylate/HCl, pH 6.5, 0.2 M magnesium chloride",293,,,"5ESA",46.47,"2.6","2.6","Crystal structure of anti-HCV E2 antibody HC84-26","MQVQLVQSGAEVKKPGSSVKVSCEASGGTLSNYVITWVRQAPGQGLEWMGGFIPTFRTAMYAQGFQGRVTITADESTSIAYMELTNLRSEDTAVYYCARGPLSRGYYDYWGQGTLVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKI","Homo sapiens",,"Anti-HCV E2 glycoprotein Fab heavy chain","1","5ESA"
,,,,,,,,,,,,,,,,"MSYVLTQPPSVSVAPGKTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSSSVVFGGWTKLTVLRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC","Homo sapiens",,"Anti-HCV E2 glycoprotein Fab light chain","2","5ESA"
"5ET5",,"X-RAY DIFFRACTION",2.07,40.49,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10%PEG6000, 10mM Tris",292,"10.1107/S2059798316001765",,"5ET5",36.67,"1.67","1.67","Human muscle fructose-1,6-bisphosphatase in active R-state","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5ET5"
"5ET6",,"X-RAY DIFFRACTION",3.06,59.86,"VAPOR DIFFUSION, HANGING DROP",7,"1.6M ammonium citrate tribasic",292,"10.1107/S2059798316001765",,"5ET6",148.06,"1.845","1.845","Human muscle fructose-1,6-bisphosphatase in inactive T-state in complex with AMP","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5ET6"
"5ET7",,"X-RAY DIFFRACTION",3.62,66.04,"VAPOR DIFFUSION, HANGING DROP",7,"1.6M ammonium citrate tribasic",292,"10.1107/S2059798316001765",,"5ET7",146.67,"2.989","2.989","Human muscle fructose-1,6-bisphosphatase in inactive T-state","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5ET7"
"5ET8",,"X-RAY DIFFRACTION",3.06,59.9,"VAPOR DIFFUSION, HANGING DROP",7.4,"10mM magnesium chloride, 2M sodium chloride, 10%PEG6000, 10mM Tris",292,,,"5ET8",36.93,"1.92","1.92","Human muscle fructose-1,6-bisphosphatase in active R-state in complex with fructose-6-phosphate","TDRSPFETDMLTLTRYVMEKGRQAKGTGELTQLLNSMLTAIKAISSAVRKAGLAHLYGIAGSVNVTGDEVKKLDVLSNSLVINMLQSSYSTCVLVSEENKDAIITAKEKRGKYVVCFDPLDGSSNIDCLASIGTIFAIYRKTSEDEPSEKDALQCGRNIVAAGYALYGSATLVALSTGQGVDLFMLDPALGEFVLVEKDVKIKKKGKIYSLNEGYAKYFDAATTEYVQKKKFPEDGSAPYGARYVGSMVADVHRTLVYGGIFLYPANQKSPKGKLRLLYECNPVAYIIEQAGGLATTGTQPVLDVKPEAIHQRVPLILGSPEDVQEYLTCVQKNQAGS","Homo sapiens","FBP2","Fructose-1,6-bisphosphatase isozyme 2","1","5ET8"
"5ETB",,"X-RAY DIFFRACTION",2.44,49.54,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5RO","5ETB",13.94,"1.33","1.33","Crystal structure of the human BRPF1 bromodomain in complex with SEED13","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5ETB"
"5ETC",,"X-RAY DIFFRACTION",2.91,57.79,"VAPOR DIFFUSION, SITTING DROP",,"1.5 to 1.6 M (NH4)2SO4, 50mM MgCl2 and 50 mM TRIS/HCl pH 8.0",293,,,"5ETC",41.81,"2.422","2.422","Structure of inactive MAPK14 with ordered Activation Loop","MLEMSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVKKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5ETC"
"5ETD",,"X-RAY DIFFRACTION",2.41,48.99,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215",,"5ETD",13.92,"1.4","1.4","Crystal structure of the human BRPF1 bromodomain in complex with SEED14","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5ETD"
"5ETH",,"X-RAY DIFFRACTION",2.21,44.32,"VAPOR DIFFUSION, SITTING DROP",5.5,"21% PEG3350, 0.2M Ammonium Acetate, 0.1M BisTRIS pH 5.5",298,"10.1016/j.bmcl.2016.03.109","5RT","5ETH",53.09,"2.803","2.803","RORy in complex with inverse agonist 3.","GPLTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQ","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5ETH"
"5ETI",,"X-RAY DIFFRACTION",2.89,57.44,"VAPOR DIFFUSION, SITTING DROP",,"3.5 M Na Formate pH 7.0",293,,,"5ETI",42.03,"2.8","2.8","Structure of dead kinase MAPK14","GSHMLEMSQERPTFYRQELNKTIWEVPERYQNLSPVGSGAYGSVCAAFDTKTGLRVAVRKLSRPFQSIIHAKRTYRELRLLKHMKHENVIGLLDVFTPARSLEEFNDVYLVTHLMGADLNNIVKCQKLTDDHVQFLIYQILRGLKYIHSADIIHRDLKPSNLAVNEDCELKILDFGLARHTDDEMTGYVATRWYRAPEIMLNWMHYNQTVDIWSVGCIMAELLTGRTLFPGTDHIDQLKLILRLVGTPGAELLKKISSESARNYIQSLTQMPKMNFANVFIGANPLAVDLLEKMLVLDSDKRITAAQALAHAYFAQYHDPDDEPVADPYDQSFESRDLLIDEWKSLTYDEVISFVPPPLDQEEMES","Homo sapiens","MAPK14, CSBP, CSBP1, CSBP2, CSPB1, MXI2, SAPK2A","Mitogen-activated protein kinase 14","1","5ETI"
"5ETJ",,"X-RAY DIFFRACTION",2.91,57.77,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein (10 mg/mL); Reservoir (0.2 M lithium sulfate, 0.1 M TRIS-HCl, pH 8.5 and 20% (w/v) PEG 4000)",295,"10.1021/jacs.5b12551","IM5","5ETJ",219.37,"2.3","2.3","Crystal structure of purine nucleoside phosphorylase (E258D, L261A) mutant from human complexed with DADMe-ImmG and phosphate","MRGSHHHHHHGMASMTGGQQMGRDLYDDDDKDPTLMENGYTYEDYKNTAEWLLSHTKHRPQVAIICGSGLGGLTDKLTQAQIFDYSEIPNFPRSTVPGHAGRLVFGFLNGRACVMMQGRFHMYEGYPLWKVTFPVRVFHLLGVDTLVVTNAAGGLNPKFEVGDIMLIRDHINLPGFSGQNPLRGPNDERFGDRFPAMSDAYDRTMRQRALSTWKQMGEQRELQEGTYVMVAGPSFETVAECRVLQKLGADAVGMSTVPEVIVARHCGLRVFGFSLITNKVIMDYESLEKANHDEVAAAGKQAAQKLEQFVSILMASIPLPDKAS","Homo sapiens","PNP, NP","Purine nucleoside phosphorylase","1","5ETJ"
"5ETW",,"X-RAY DIFFRACTION",2.77,55.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG, Ammonium Fluoride",291,"10.1021/acs.jmedchem.5b01390","XNL","5ETW",92.59,"2.7","2.7","Crystal structure of the indoleamine 2,3-dioxygenagse 1 (IDO1) complexed with NLG919 analogue","MAHAMENSWTISKEYHIDEEVGFALPNPQENLPDFYNDWMFIAKHLPDLIESGQLRERVEKLNMLSIDHLTDHKSQRLARLVLGCITMAYVWGKGHGDVRKVLPRNIAVPYCQLSKKLELPPILVYADCVLANWKKKDPNKPLTYENMDVLFSFRDGDCSKGFFLVSLLVEIAAASAIKVIPTVFKAMQMQERDTLLKALLEIASCLEKALQVFHQIHDHVNPKAFFSVLRIYLSGWKGNPQLSDGLVYEGFWEDPKEFAGGSAGQSSVFQCFDVLLGIQQTAGGGHAAQFLQDMRRYMPPAHRNFLCSLESNPSVREFVLSKGDAGLREAYDACVKALVSLRSYHLQIVTKYILIPASQQPKENKTSEDPSKLEAKGTGGTDLMNFLKTVRSTTEKSLLKEG","Homo sapiens","IDO1, IDO, INDO","Indoleamine 2,3-dioxygenase 1","1","5ETW"
"5ETY",,"X-RAY DIFFRACTION",2.14,42.57,"VAPOR DIFFUSION, SITTING DROP",5.8,"0.1M Na-Succinate pH 5.8, 6% PEG MME 5000",298,"10.1158/1535-7163.MCT-15-0938","K56","5ETY",119.15,"2.9","2.9","Crystal Structure of human Tankyrase-1 bound to K-756","MHHHHHHSSGVDLGTENLYFQSMQGTNPYLTFHCVNQGTILLDLAPEDKEYQSVEEEMQSTIREHRDGGNAGGIFNRYNVIRIQKVVNKKLRERFCHRQKEVSEENHNHHNERMLFHGSPFINAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPTHKDRSCYICHRQMLFCRVTLGKSFLQFSTIKMAHAPPGHHSVIGRPSVNGLAYAEYVIYRGEQAYPEYLITYQIMKPEAPSQTATAAE","Homo sapiens","TNKS, PARP5A, PARPL, TIN1, TINF1, TNKS1","Tankyrase-1","1","5ETY"
"5EU1",,"X-RAY DIFFRACTION",2.33,47.19,"VAPOR DIFFUSION, HANGING DROP",8.3,"30 % glycerol ethoxylate, 0.1 M Tris",277,"10.1021/acs.jmedchem.5b01865","5SW","5EU1",29.21,"1.6","1.6","CRYSTAL STRUCTURE OF BRD9 IN COMPLEX WITH BI-7273","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","BRD9","1","5EU1"
"5EU9",,"X-RAY DIFFRACTION",2.34,47.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM Bis-Tris, pH 6.5, 200 mM ammonium acetate, 18-22% w/v PEG3350, soak overnight in 2 mM compound, 100 mM Bis-Tris, 200 mM ammonium acetate, 32% w/v PEG3350, pH 6.5",293,,,"5EU9",388.17,"2.047","2.047","Structure of Human Enolase 2 in complex with ((3S,5S)-1,5-dihydroxy-3-methyl-2-oxopyrrolidin-3-yl)phosphonic acid","MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVLHHHHHH","Homo sapiens","ENO2","Gamma-enolase","1","5EU9"
"5EUB",,"X-RAY DIFFRACTION",2.92,57.82,"VAPOR DIFFUSION, SITTING DROP",,"Protein 15 mg/mL, Reservoir 0.2 M magnesium chloride, 20% (w/v) PEG 3350",295,,,"5EUB",33.84,"1.81","1.81","Crystal structure of human 5'-deoxy-5'-methylthioadenosine phosphorylase in complex with 2-amino-MTA and sulfate","MHHHHHHENLYFQSMASGTTTTAVKIGIIGGTGLDDPEILEGRTEKYVDTPFGKPSDALILGKIKNVDCVLLARHGRQHTIMPSKVNYQANIWALKEEGCTHVIVTTACGSLREEIQPGDIVIIDQFIDRTTMRPQSFYDGSHSCARGVCHIPMAEPFCPKTREVLIETAKKLGLRCHSKGTMVTIEGPRFSSRAESFMFRTWGADVINMTTVPEVVLAKEAGICYASIAMATDYDCWKEHEEAVSVDRVLKTLKENANKAKSLLLTTIPQIGSTEWSETLHNLKNMAQFSVLLPRH","Homo sapiens","MTAP, MSAP","S-methyl-5'-thioadenosine phosphorylase","1","5EUB"
"5EUN",,"X-RAY DIFFRACTION",2.4,48.1,"VAPOR DIFFUSION, HANGING DROP",,"Protein (1 uL) at a concentration of 7 mg/mL were mixed with an equal volume of a reservoir solution containing 200 mM NaCl, 0.1M NaCitrate pH 5.6, 24% PEG4K and equilibrated against 1 mL of a reservoir solution at 293 K.",293,"10.3390/ijms17040446",,"5EUN",47.63,"1.825","1.825","The Crystal Structure of Human Kynurenine Aminotransferase II, PLP-bound form, at 1.83 A","MNYARFITAASAARNPSPIRTMTDILSRGPKSMISLAGGLPNPNMFPFKTAVITVENGKTIQFGEEMMKRALQYSPSAGIPELLSWLKQLQIKLHNPPTIHYPPSQGQMDLCVTSGSQQGLCKVFEMIINPGDNVLLDEPAYSGTLQSLHPLGCNIINVASDESGIVPDSLRDILSRWKPEDAKNPQKNTPKFLYTVPNGNNPTGNSLTSERKKEIYELARKYDFLIIEDDPYYFLQFNKFRVPTFLSMDVDGRVIRADSFSKIISSGLRIGFLTGPKPLIERVILHIQVSTLHPSTFNQLMISQLLHEWGEEGFMAHVDRVIDFYSNQKDAILAAADKWLTGLAEWHVPAAGMFLWIKVKGINDVKELIEEKAVKMGVLMLPGNAFYVDSSAPSPYLRASFSSASPEQMDVAFQVLAQLIKESL","Homo sapiens","AADAT, KAT2, KYAT2","Kynurenine/alpha-aminoadipate aminotransferase, mitochondrial","1","5EUN"
"5EV9",,"X-RAY DIFFRACTION",2.51,50.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215",,"5EV9",14.02,"1.45","1.45","Crystal structure of the human BRPF1 bromodomain in complex with SEED15","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EV9"
"5EVA",,"X-RAY DIFFRACTION",2.51,50.93,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5S9","5EVA",14,"1.45","1.45","Crystal structure of the human BRPF1 bromodomain in complex with SEED16","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EVA"
"5EVZ",,"X-RAY DIFFRACTION",2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862","ADP","5EVZ",89.81,"1.85","1.85","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with ADP and inorganic phosphate","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5EVZ"
"5EW3",,"X-RAY DIFFRACTION",2.33,47.25,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M MES pH6.5, 8% w/v PEG 8000, 0.02M LITHIUM ACETATE",290,"10.1021/acs.jmedchem.5b01582","5T2","5EW3",73.13,"2.5","2.5","Human Vascular Endothelial Growth Factor Receptor 2 (KDR) Kinase Domain in complex with AAL993","MDPDELPLDEHCERLPYDASKWEFPRDRLKLGKPLGRGAFGQVIEADAFGIDKTATCRTVAVKMLKEGATHSEHRALMSELKILIHIGHHLNVVNLLGACTKPGGPLMVIVEFCKFGNLSTYLRSKRNEFVPYKVAPEDLYKDFLTLEHLICYSFQVAKGMEFLASRKCIHRDLAARNILLSEKNVVKICDFGLARDIYKDPDYVRKGDARLPLKWMAPETIFDRVYTIQSDVWSFGVLLWEIFSLGASPYPGVKIDEEFCRRLKEGTRMRAPDYTTPEMYQTMLDCWHGEPSQRPTFSELVEHLGNLLQANAQQD","Homo sapiens","KDR, FLK1, VEGFR2","Vascular endothelial growth factor receptor 2","1","5EW3"
"5EW4",,"X-RAY DIFFRACTION",2.08,40.9,"VAPOR DIFFUSION, HANGING DROP",7,"0.04 M sodium cacodylate, 50 mM KCl, 0.04 M LiCl, 0.012 M spermine, 0.08 M strontium chloride, 10% (v/v) (+/-)-2-methyl-2,4-pentanediol, equilibrated against 35% (v/v) (+/-)-2-methyl-2,4-pentanediol",293,"10.1021/acs.biochem.6b00136",,"5EW4",14.34,"1.47","1.47","Crystal structure of C9ORF72 Antisense CCCCGG repeat RNA associated with Lou Gehrig's disease and frontotemporal dementia, crystallized with Sr2+","CCCCGGCCCCGGCCCCGGCCCC","Homo sapiens",,"RNA (5'-R(*CP*CP*CP*CP*GP*GP*CP*CP*CP*CP*GP*GP*CP*CP*CP*CP*GP*GP*CP*CP*CP*C)-3')","1","5EW4"
"5EW6",,"X-RAY DIFFRACTION",3.45,64.35,"VAPOR DIFFUSION, SITTING DROP",7.4,"5-7% PEG 3350, 1 mM CaCl2, 100 mM HEPES, 10% PEG 3350, 5 mM EDTA",293,"10.1042/BCJ20160276",,"5EW6",57.01,"2.29","2.29","Structure of ligand binding region of uPARAP at pH 7.4 without calcium","RSGAPGDAALPEPNIFLIFSHGLQGCLEAQGGQVRVTPACNTSLPAQRWKWVSRNRLFNLGTMQCLGTGWPGTNTTASLGMYECDREALNLRWHCRTLGDQLSLLLGARTSNISKPGTLERGDQTRSGQWRIYGSEEDLCALPYHEVYTIQGNSHGKPCTIPFKYDNQWFHGCTSTGREDGHLWCATTQDYGKDERWGFCPIKSNDCETFWDKDQLTDSCYQFNFQSTLSWREAWASCEQQGADLLSITEIHEQTYINGLLTGYSSTLWIGLNDLDTSGGWQWSDNSPLKYLNWESDQPDNPSEENCGVIRTESSGGWQNRDCSIALPYVCKKKPNATAEPTPPDRWANVKVECEPSWQPFQGHCYRLQAEKRSWQESKKACLRGGGDLVSIHSMAELEFITKQIKQEVEELWIGLNDLKLQMNFEWSDGSLVSFTHWHPFEPNNFRDSLEDCVTIWGPEGRWNDSPCNQSLPSICKKAGQLTRTGHHHHHH","Homo sapiens","MRC2, CLEC13E, ENDO180, KIAA0709, UPARAP","C-type mannose receptor 2","1","5EW6"
"5EW7",,"X-RAY DIFFRACTION",2.11,41.71,"VAPOR DIFFUSION, HANGING DROP",6,"0.04 M sodium cacodylate, 50 mM KCl, 0.08 M NaCl, 0.012 M spermine, 0.02 M barium chloride, 10% (v/v) (+/-)-2-methyl-2,4-pentanediol, equilibrated against 35% (v/v) (+/-)-2-methyl-2,4-pentanediol",293,"10.1021/acs.biochem.6b00136",,"5EW7",14.21,"1.75","1.75","Crystal structure of C9ORF72 Antisense CCCCGG repeat RNA associated with Lou Gehrig's disease and frontotemporal dementia, crystallized with Ba2+","CCCCGGCCCCGGCCCCGGCCCC","Homo sapiens",,"RNA (5'-R(*CP*CP*CP*CP*GP*GP*CP*CP*CP*CP*GP*GP*CP*CP*CP*CP*GP*GP*CP*CP*CP*C)-3')","1","5EW7"
"5EW8",,"X-RAY DIFFRACTION",2.68,54.11,"VAPOR DIFFUSION, HANGING DROP",6.75,"18-20% PEG8000, 200mM Ammonium sulphate, 100mM PCTP, 20% (v/v) ethylene glycol",277,"10.18632/oncotarget.8132",,"5EW8",71.45,"1.63","1.63","FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH JNJ-4275693","GAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","Fibroblast growth factor receptor 1","1","5EW8"
"5EW9",,"X-RAY DIFFRACTION",2.07,40.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"30% PEG3350, 100 mM Bis-Tris",294,"10.3389/fonc.2015.00285","5VC","5EW9",32,"2.181","2.181","Crystal Structure of Aurora A Kinase Domain Bound to MK-5108","GPGSKKRQWALEDFEIGRPLGKGKFGNVYLAREKQSKFILALKVLFKAQLEKAGVEHQLRREVEIQSHLRHPNILRLYGYFHDATRVYLILEYAPLGTVYRELQKLSKFDEQRTATYITELANALSYCHSKRVIHRDIKPENLLLGSAGELKIADFGWSVHAPSSRRTTLCGTLDYLPPEMIEGRMHDEKVDLWSLGVLCYEFLVGKPPFEANTYQETYKRISRVEFTFPDFVTEGARDLISRLLKHNPSQRPMLREVLEHPWITANSSKP","Homo sapiens","AURKA, AIK, AIRK1, ARK1, AURA, AYK1, BTAK, IAK1, STK15, STK6","Aurora kinase A","1","5EW9"
"5EWC",,"X-RAY DIFFRACTION",2.54,51.58,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215",,"5EWC",14,"1.75","1.75","Crystal structure of the human BRPF1 bromodomain in complex with SEED17","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EWC"
"5EWD",,"X-RAY DIFFRACTION",2.44,49.66,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5SH","5EWD",13.92,"1.58","1.58","Crystal structure of the human BRPF1 bromodomain in complex with SEED18","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EWD"
"5EWH",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Sodium Acetate, pH5.5, 0.15 M Sodium Nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00215","5SG","5EWH",13.91,"1.63","1.63","Crystal structure of the human BRPF1 bromodomain in complex with SEED19","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EWH"
"5EWS",,"X-RAY DIFFRACTION",2.14,42.53,"VAPOR DIFFUSION, HANGING DROP",,"sodium citrate, Sodium acetate",298,"10.1093/abbs/gmw089",,"5EWS",239.8,"2","2","Sugar binding protein - human galectin-2","GSHMTGELEVKNMDMKPGSTLKITGSIADGTDGFVINLGQGTDKLNLHFNPRFSESTIVCNSLDGSNWGQEQREDHLCFSPGSEVKFTVTFESDKFKVKLPDGHELTFPNRLGHSHLSYLSVRGGFNMSSFKLK","Homo sapiens","LGALS2","Galectin-2","1","5EWS"
"5EWV",,"X-RAY DIFFRACTION",2.47,50.2,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,,,"5EWV",13.96,"1.67","1.67","Crystal structure of the human BRPF1 bromodomain in complex with SEED20","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EWV"
"5EWW",,"X-RAY DIFFRACTION",2.43,49.33,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-tris propane, pH6.5, 0.2 M Sodium nitrate, 20% PEG3350",277,,,"5EWW",14.02,"1.73","1.73","Crystal structure of the human BRPF1 bromodomain in complex with SEED21","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5EWW"
"5EX5",,"X-RAY DIFFRACTION",2.04,39.79,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862",,"5EX5",89.8,"1.9","1.9","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 7-deaza-ADP and inorganic phosphate","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5EX5"
"5EXL",,"X-RAY DIFFRACTION",3.47,64.55,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,"10.1016/j.bmc.2016.03.062","5SS","5EXL",28.7,"2.3","2.3","FACTOR XIA IN COMPLEX WITH THE INHIBITOR 4-(aminomethyl)-~{N}-[(1~{S})-1-[4-(3-oxidanyl-1~{H}-indazol-5-yl)pyridin-2-yl]-2-phenyl-ethyl]cyclohexane-1-carboxamide","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XIa light chain","1","5EXL"
"5EXM",,"X-RAY DIFFRACTION",3.49,64.74,"VAPOR DIFFUSION, HANGING DROP",4.6,"100 MM SODIUM ACETATE, PH 4.6, 26%(w/v) MEPEG2000, 200 MM AMMONIUM SULFATE",277,"10.1016/j.bmc.2016.03.062","5ST","5EXM",28.59,"2.09","2.09","FACTOR XIA IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[4-(aminomethyl)cyclohexyl]carbonylamino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVGYGDSQRPICLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAVHHHHHH","Homo sapiens","F11","Coagulation factor XIa light chain","1","5EXM"
"5EXN",,"X-RAY DIFFRACTION",2.13,42.39,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 MM SODIUM CITRATE, PH 5.0, 36%(w/v) PEG4000",277,"10.1016/j.bmc.2016.03.062","5SU","5EXN",27.66,"1.49","1.49","FACTOR XIA (C500S [C122S]) IN COMPLEX WITH THE INHIBITOR methyl ~{N}-[4-[2-[(1~{S})-1-[[(~{E})-3-[5-chloranyl-2-(1,2,3,4-tetrazol-1-yl)phenyl]prop-2-enoyl]amino]-2-phenyl-ethyl]pyridin-4-yl]phenyl]carbamate","IVGGTASVRGEWPWQVTLHTTSPTQRHLCGGSIIGNQWILTAAHCFYGVESPKILRVYSGILNQSEIKEDTSFFGVQEIIIHDQYKMAESGYDIALLKLETTVNYTDSQRPISLPSKGDRNVIYTDCWVTGWGYRKLRDKIQNTLQKAKIPLVTNEECQKRYRGHKITHKMICAGYREGGKDACKGDSGGPLSCKHNEVWHLVGITSWGEGCAQRERPGVYTNVVEYVDWILEKTQAV","Homo sapiens","F11","Coagulation factor XIa light chain","1","5EXN"
"5EXO",,"X-RAY DIFFRACTION",2.2,44.13,"VAPOR DIFFUSION, HANGING DROP",7,"31% PEG 6000, 100MM MGCL2, 8MM BETA MERCEPTOETHANOL, 100MM TRIS HCL",293,"10.1021/acs.jmedchem.6b00957",,"5EXO",16.19,"1.502","1.502","Crystal structure of Human galectin-3 CRD in complex with methyl 2-O-acetyl-3-O-(2H-chromene-3-yl-methyl)-a-D-galactopyranoside inhibitor","GPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5EXO"
"5EXQ",,"X-RAY DIFFRACTION",2.38,48.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"Hanging drops of 1 microL of 29.5 mg/mL of reduced protein and 2 microL reservoir buffer were allowed to equilibrate above the reservoir buffer (32% (w/v) polyethylene glycol 5000, 50 mM lithiumsulfate, 50 mM Tris-HCl pH 8.5). The protein solution was 17.5 mM sodium phosphate, 25 mM sodium chloride, 15 mM sodium dithionite (pH 7.6).",291,"10.1042/BCJ20200793",,"5EXQ",24.56,"1.6","1.6","Human cytochrome c Y48H","GDVEKGKKIFIMKCSQCHTVEKGGKHKTGPNLHGLFGRKTGQAPGYSHTAANKNKGIIWGEDTLMEYLENPKKYIPGTKMIFVGIKKKEERADLIAYLKKATNE","Homo sapiens","CYCS, CYC","Cytochrome c","1","5EXQ"
"5EXW",,"X-RAY DIFFRACTION",2.08,40.88,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862","7DT","5EXW",89.72,"1.9","1.9","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 7-deaza-ATP","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5EXW"
"5EY4",,"X-RAY DIFFRACTION",2.02,39.09,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862","DTP","5EY4",89.69,"1.86","1.86","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 2'-deoxy-ATP","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5EY4"
"5EYC",,"X-RAY DIFFRACTION",2.04,39.77,"VAPOR DIFFUSION, HANGING DROP",7.8,"12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)",293,"10.1021/acs.jmedchem.5b01716","5SZ","5EYC",35.61,"1.8","1.8","Crystal structure of c-Met in complex with naphthyridinone inhibitor 5","QNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHHHHHH","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5EYC"
"5EYD",,"X-RAY DIFFRACTION",2.04,39.68,"VAPOR DIFFUSION, HANGING DROP",7.8,"12% PEG 4000, 3% (v/v) ethanol, 6% (v/v) isopropanol, 40 mM beta-mercaptoethanol, 100 mM HEPES (pH 7.8)",293,"10.1021/acs.jmedchem.5b01716","5T1","5EYD",35.68,"1.85","1.85","Crystal structure of c-Met in complex with AMG 337","QNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHHHHHH","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5EYD"
"5EYM",,"X-RAY DIFFRACTION",2.61,52.85,"VAPOR DIFFUSION, HANGING DROP",8,"18 % PEG 4000, 100 mM Tris, 300 mM NaCl",293,"10.1158/1535-7163.MCT-16-0066","5U5","5EYM",81.16,"2.7","2.7","MEK1 IN COMPLEX WITH BI 847325","KKLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLNKFGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQPSTPTHAAGV","Homo sapiens","MAP2K1, MEK1, PRKMK1","Dual specificity mitogen-activated protein kinase kinase 1","1","5EYM"
"5EZ5",,"X-RAY DIFFRACTION",2.7,54.46,"VAPOR DIFFUSION, HANGING DROP",,"Sodium chloride, Tris, Magnessium chloride",293,,,"5EZ5",39.08,"2.4","2.4","Crystal structure of active Rab11A (S20V) in complex with GTP","YDYLFKVVLIGDVGVGKSNLLSRFTRNEFNLESKSTIGVEFATRSIQVDGKTIKAQIWDTAGQERYRAITSAYYRGAVGALLVYDIAKHLTYENVERWLKELRDHADSNIVIMLVGNKSDLRHLRAVPTDEARAFAEKNGLSFIETSALDSTNVEAAFQTILTEIYRI","Homo sapiens","RAB11A, RAB11","Ras-related protein Rab-11A","1","5EZ5"
"5EZ6",,"X-RAY DIFFRACTION",2.87,57.11,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium citrate dibasic, 20% w/v Polyethylene glycol 3350",293,,,"5EZ6",20.98,"1.8","1.8","Crystallization and preliminary X-ray crystallographic analysis of a small GTPase RhoA","MAAIRKKLVIVGDGACGKTCLLIVFSKDQFPEVYVPTVFENYVADIEVDGKQVELALWDTAGQEDYDRLRPLSYPDTDVILMCFSIDSPDSLENIPEKWTPEVKHFCPNVPIILVGNKKDLRNDEHTRRELAKMKQEPVKPEEGRDMANRIGAFGYMECSAKTKDGVREVFEMATRAALQA","Homo sapiens","RHOA, ARH12, ARHA, RHO12","Transforming protein RhoA","1","5EZ6"
"5EZD",,"X-RAY DIFFRACTION",2.43,49.34,"VAPOR DIFFUSION, HANGING DROP",5.5,"28% w/v PEG 2000 MME, 0.1 M sodium acetate pH 5.5, 0.2 M potassium bromide",293,"10.1074/jbc.M115.707240",,"5EZD",33.77,"2.1","2.1","Crystal structure of a Hepatocyte growth factor activator inhibitor-1 (HAI-1) fragment covering the PKD-like 'internal' domain and Kunitz domain 1","KRGIDLKVQPQEPLVLKDVENTDWRLLRGDTDVRVERKDPNQVELWGLKEGTYLFQLTVTSSDHPEDTANVTVTVLSTKQTEDYCLASNKVGRCRGSFPRWYYDPTEQICKSFVYGGCLGNKNNYLREEECILACRGVDHHHHHH","Homo sapiens","SPINT1, HAI1, UNQ223/PRO256","Kunitz-type protease inhibitor 1","1","5EZD"
"5EZI",,"X-RAY DIFFRACTION",3.77,67.39,"VAPOR DIFFUSION, SITTING DROP",6.5,"1.6 M sodium citrate pH 6.5",295,"10.7554/eLife.20383",,"5EZI",49.02,"1.61","1.61","Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - hexagonal form","NVNLLESGGGLVQPGGSLNLSCAASGFDFSRYWMSWARQAPGKGQEWIGEINPGSSTIKYTPSLKDKFIISRDNAKNTLYLQMSKVSSEDTALYYCARYGSYVYAMDYWGPGTSVTVSSAKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPT","Homo sapiens",,"Fab c12 heavy chain","1","5EZI"
,,,,,,,,,,,,,,,,"SIVMTQTPKFLLVSAGDRITITCKASQSVRNDVAWYQQKPGQSPKLLIYFASNRYTGVPDRFTGSGSGTDFTFTISTVQAEDLAVYFCQQGYTSPRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNEC","Homo sapiens",,"Fab c12 Light chain","2","5EZI"
"5EZJ",,"X-RAY DIFFRACTION",2.74,55.19,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M HEPES/NaOH pH 7.0, 20% PEG 8000",295,"10.7554/eLife.20383",,"5EZJ",47.95,"1.95","1.95","Crystal Structure of Fab of parasite invasion inhibitory antibody c1 - orthorhombic form","NVNLLESGGGLVQPGGSLNLSCAASGFDFSRYWMSWARQAPGKGQEWIGEINPGSSTIKYTPSLKDKFIISRDNAKNTLYLQMSKVSSEDTALYYCARYGSYVYAMDYWGPGTSVTVSSAKTTAPSVYPLAPVCGATTGSSVTLGCLVKGYFPEPVTLTWNSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNVAHPASSTKVDKKIEPRGPT","Homo sapiens",,"Fab c12 heavy chain","1","5EZJ"
,,,,,,,,,,,,,,,,"SIVMTQTPKFLLVSAGDRITITCKASQSVRNDVAWYQQKPGQSPKLLIYFASNRYTGVPDRFTGSGSGTDFTFTISTVQAEDLAVYFCQQGYTSPRTFGGGTKLEIKRADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWTDQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIVKSFNRNE","Homo sapiens",,"Fab c12 Light chain","2","5EZJ"
"5EZP",,"X-RAY DIFFRACTION",2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein: 5mg/ML in 0.05 M NaCl, 0.025 M Na acetate, pH 5.5 and 0.001 M 4-hydroxychalcone
Reservoir: 30% PEG4K, 0.1M Tris-HCl, pH 8.5
4 boosts (5 M NaCl)
Cryoprotectant: CryoSol SM1, 25% PEG 4K,  	
0.1 M (Na acetate, ADA, Bicine) Buffer 20% acid / 80% basic 0.01 M ligand.",293,"10.1016/j.jsb.2016.01.007",,"5EZP",108.09,"2.5","2.5","Human transthyretin (TTR) complexed with 4-hydroxy-chalcone","GESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5EZP"
"5EZX",,"X-RAY DIFFRACTION",3.07,59.99,"VAPOR DIFFUSION, HANGING DROP",,"2.5M SODIUM FORMATE, 100MM HEPES",293,"10.1021/acs.jmedchem.5b01875","5T5","5EZX",43.94,"1.9","1.9","CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH {(1R,2R)-2-[(R)-2-Amino-4-(4-difluoromethoxy-phenyl)-4,5-dihydro-oxazol-4-yl]-cyclopropyl}-(5-chloro-pyridin-3-yl)-methanone","RGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVASIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5EZX"
"5EZZ",,"X-RAY DIFFRACTION",3.06,59.75,"VAPOR DIFFUSION, SITTING DROP",7,"2.5M SODIUM FORMATE, 100MM HEPES",298,"10.1021/acs.jmedchem.5b01875","5T6","5EZZ",43.97,"2.1","2.1","CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (4S)-4-[3-(5-chloro-3-pyridyl)phenyl]-4-[4-(difluoromethoxy)-3-methyl-phenyl]-5H-oxazol-2-amine","RGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVASIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5EZZ"
"5F00",,"X-RAY DIFFRACTION",3.15,61.01,"VAPOR DIFFUSION, SITTING DROP",7,"2.5M SODIUM FORMATE, 100MM HEPES",298,"10.1021/acs.jmedchem.5b01875","5T8","5F00",43.9,"1.95","1.95","CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH 5-[3-[(3-chloro-8-quinolyl)amino]phenyl]-5-methyl-2,6-dihydro-1,4-oxazin-3-amine","RGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVASIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5F00"
"5F01",,"X-RAY DIFFRACTION",3.02,59.23,"VAPOR DIFFUSION, SITTING DROP",7,"2.5M SODIUM FORMATE, 100MM HEPES",298,"10.1021/acs.jmedchem.5b01875","5T7","5F01",44.16,"1.52","1.52","CRYSTAL STRUCTURE OF BACE-1 IN COMPLEX WITH (1SR,2SR)-2-((R)-2-amino-5,5-difluoro-4-methyl-5,6-dihydro-4H-1,3-oxazin-4-yl)-N-(3-chloroquinolin-8-yl)cyclopropanecarboxamide","RGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVASIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYN","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5F01"
"5F02",,"X-RAY DIFFRACTION",2.08,40.78,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MAGNESIUM FORMATE, 15 % PEG 3350",298,"10.1021/acs.jmedchem.5b01875",,"5F02",24.87,"1.43","1.43","CATHEPSIN L IN COMPLEX WITH (2S,4R)-4-(2-Chloro-4-methoxy-benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]-pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide","APRSVDWREKGYVTPVKNQGQCGSCWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYSVANDTGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV","Homo sapiens","CTSL, CTSL1","Cathepsin L1","1","5F02"
"5F03",,"X-RAY DIFFRACTION",2.67,53.99,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG 10000, 0.1 M HEPES",293,"10.1021/acs.jmedchem.5b01875",,"5F03",55.85,"1.94","1.94","TRYPTASE B2 IN COMPLEX WITH 5-(3-Aminomethyl-phenoxymethyl)-3-[3-(2-chloro-pyridin-3-ylethynyl)-phenyl]-oxazolidin-2-one; compound with trifluoro-acetic acid","IVGGQEAPRSKWPWQVSLRVHGPYWMHFCGGSLIHPQWVLTAAHCVGPDVKDLAALRVQLREQHLYYQDQLLPVSRIIVHPQFYTAQIGADIALLELEEPVKVSSHVHTVTLPPASETFPPGMPCWVTGWGDVDNDERLPPPFPLKQVKVPIMENHICDAKYHLGAYTGDDVRIVRDDMLCAGNTRRDSCQGDSGGPLVCKVNGTWLQAGVVSWGEGCAQPNRPGIYTRVTYYLDWIHHYVPKKP","Homo sapiens","TPSB2, TPS2, TPSAB1, TPS1, TPSB1","Tryptase beta-2","1","5F03"
"5F09",,"X-RAY DIFFRACTION",3.35,63.3,"VAPOR DIFFUSION, HANGING DROP",8,"33% (v/v) pentaerythritol propoxylate PO/OH 5/4 (Hampton Research, Aliso Viejo, Ca, USA), 1.5% (w/v) PEG 3350 (Merck KGaA, Darmstadt, Germany) and 0.10 M Tris-HCl (Merck KGaA), pH 8.0",288.15,"10.1111/febs.13761",,"5F09",86.67,"1.85","1.85","Structure of inactive GCPII mutant in complex with beta-citryl glutamate","RSGLNDIFEAQKIEWHEGSGSGSENLYFQGRSKSSNEATNITPKHNMKAFLDELKAENIKKFLYNFTQIPHLAGTEQNFQLAKQIQSQWKEFGLDSVELAHYDVLLSYPNKTHPNYISIINEDGNEIFNTSLFEPPPPGYENVSDIVPPFSAFSPQGMPEGDLVYVNYARTEDFFKLERDMKINCSGKIVIARYGKVFRGNKVKNAQLAGAKGVILYSDPADYFAPGVKSYPDGWNLPGGGVQRGNILNLNGAGDPLTPGYPANEYAYRRGIAEAVGLPSIPVHPIGYYDAQKLLEKMGGSAPPDSSWRGSLKVPYNVGPGFTGNFSTQKVKMHIHSTNEVTRIYNVIGTLRGAVEPDRYVILGGHRDSWVFGGIDPQSGAAVVHEIVRSFGTLKKEGWRPRRTILFASWDAAEFGLLGSTEWAEENSRLLQERGVAYINADSSIEGNYTLRVDCTPLMYSLVHNLTKELKSPDEGFEGKSLYESWTKKSPSPEFSGMPRISKLGSGNDFEVFFQRLGIASGRARYTKNWETNKFSGYPLYHSVYETYELVEKFYDPMFKYHLTVAQVRGGMVFELANSIVLPFDCRDYAVVLRKYADKIYSISMKHPQEMKTYSVSFDSLFSAVKNFTEIASKFSERLQDFDKSNPIVLRMMNDQLMFLERAFIDPLGLPDRPFYRHVIYAPSSHNKYAGESFPGIYDALFDIESKVDPSKAWGEVKRQIYVAAFTVQAAAETLSEVA","Homo sapiens","FOLH1, FOLH, NAALAD1, PSM, PSMA, GIG27","Glutamate carboxypeptidase 2","1","5F09"
"5F0K",,"X-RAY DIFFRACTION",2.8,56,"VAPOR DIFFUSION, HANGING DROP",7.6,"1.7 M AmSO4, 2% PEG 1000, 0.1 M Hepes pH 7.6",291,"10.1016/j.cell.2016.10.056",,"5F0K",268.62,"3.074","3.074","Structure of VPS35 N terminal region","GAMGSKLLDEAIQAVKVQSFQMKRCLDKNKLMDALKHASNMLGELRTSMLSPKSYYELYMAISDELHYLEVYLTDEFAKGRKVADLYELVQYAGNIIPRLYLLITVGVVYVKSFPQSRKDILKDLVEMCRGVQHPLRGLFLRNYLLQCTRNILPDEGEPTDEETTGDISDSMDFVLLNFAEMNKLWVRMQHQGHSRDREKRERERQELRILVGTNLVRLSQLEGVNVERYKQIVLTGILEQVVNCRDALAQEYLMECIIQVFPDEFHLQTLNPFLRACAELHQNVNVKNIIIALIDRLALFAHREDGPGIPADIKLFDIFSQQVATVIQSRQDMPSEDVVSLQVSLINLAMKCYPDRVDYVDKVLETTVEIFNKLNLEHIATSSAVSKELTRLLKIPVDTYNNILTVLKLKHFHPLFEYFDYESRKSMSCYVLSNVLDYNTEIVSQDQVDSIMNLVSTLIQD","Homo sapiens","VPS35, MEM3, TCCCTA00141","Vacuolar protein sorting-associated protein 35","1","5F0K"
"5F0W",,"X-RAY DIFFRACTION",3.49,64.74,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M tri-sodium citrate, 20 % (W/V) PEG 3350",293,,,"5F0W",30.51,"2.7","2.7","Crystal structure of human copper homeostatic proteins atox1","MPKHEFSVDMTCGGCAEAVSRVLNKLGGVKYDIDLPNKKVCIESEHSMDTLLATLKKTGKTVSYLGLE","Homo sapiens","ATOX1, HAH1","Copper transport protein ATOX1","1","5F0W"
"5F0X",,"X-RAY DIFFRACTION",2.01,38.88,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862",,"5F0X",90.34,"1.6","1.6","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with 2'-deoxy-ADP and inorganic phosphate","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5F0X"
"5F18",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.07M sodium acetate trihydrate, pH 4.6, 5.6% (w/v) polyethylene glycol 4000, 30% (v/v) glycerol",291,"10.1016/j.cell.2015.12.044",,"5F18",29.44,"2","2","Structural basis of Ebola virus entry: viral glycoprotein bound to its endosomal receptor Niemann-Pick C1","MTTNPVDLWSAPSSQARLEKEYFDQHFGPFFRTEQLIIRAPLTDKHIYQPYPSGADVPFGPPLDIQILHQVLDLQIAIENITASYDNETVTLQDICLAPLSPYNTNCTILSVLNYFQNSHSVLDHKKGDDFFVYADYHTHFLYCVRAPASLNDTSLLHDPCLGTFGGPVFPWLVLGGYDDQNYNNATALVITFPVNNYYNDTEKLQRAQAWEKEFINFVKNYKNPNLTISFTAERSIEDELNRESDSDLEHHHHHH","Homo sapiens","NPC1","Niemann-Pick C1 protein","1","5F18"
"5F19",,"X-RAY DIFFRACTION",2.76,55.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"23-34% PAA-5100, 100mM HEPES (pH 7.5), 20mM MgCl2, 0.6% BoG",296,"10.1021/acs.biochem.5b01378",,"5F19",132.21,"2.04","2.04","The Crystal Structure of Aspirin Acetylated Human Cyclooxygenase-2","KNPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5F19"
"5F1A",,"X-RAY DIFFRACTION",2.76,55.37,"VAPOR DIFFUSION, SITTING DROP",7.5,"22-34% PAA-5100, 100mM HEPES (pH 7.5), 20mM MgCl2, 0.6% BOG",296,"10.1021/acs.biochem.5b01378","SAL","5F1A",131.67,"2.38","2.38","The Crystal Structure of Salicylate Bound to Human Cyclooxygenase-2","KNPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVPD","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5F1A"
"5F1H",,"X-RAY DIFFRACTION",2.29,46.19,"VAPOR DIFFUSION, HANGING DROP",8.3,"glycerol ethoxylate, Tris",277,"10.1021/acs.jmedchem.5b01865","5U6","5F1H",29.21,"1.82","1.82","Crystal structure of the BRD9 bromodamian in complex with BI-9564.","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5F1H"
"5F1L",,"X-RAY DIFFRACTION",2.32,46.92,"VAPOR DIFFUSION, HANGING DROP",8.3,"glycerol ethoxylate, Tris",277,"10.1021/acs.jmedchem.5b01865","5U2","5F1L",29.19,"2.3","2.3","Crystal structure of the bromodomain of BRD9 in complex with compound 9.","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5F1L"
"5F1X",,"X-RAY DIFFRACTION",2.1,41.54,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862","ATP","5F1X",89.73,"1.9","1.9","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with ATP","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5F1X"
"5F1Z",,"X-RAY DIFFRACTION",2.25,45.43,"VAPOR DIFFUSION, SITTING DROP",6,"15% PEG 5000 MME, and 100 mM Sodium Citrate (pH 6.0)",293,"10.1021/acs.jmedchem.5b01857",,"5F1Z",35.2,"2.65","2.65","Structure of TYK2 with inhibitor 16: 3-azanyl-5-[(2~{S})-3-methylbutan-2-yl]-7-[1-methyl-5-(2-oxidanylpropan-2-yl)pyrazol-3-yl]-1~{H}-pyrazolo[4,3-c]pyridin-4-one","MGSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHSQHYIHRNLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYHHHHHH","Homo sapiens","TYK2","Non-receptor tyrosine-protein kinase TYK2","1","5F1Z"
"5F20",,"X-RAY DIFFRACTION",2.31,46.74,"VAPOR DIFFUSION, SITTING DROP",6,"15% PEG 5000 MME, and 100 mM Sodium Citrate (pH 6.0)",293,"10.1021/acs.jmedchem.5b01857","5U4","5F20",35.17,"2.91","2.91","Structure of TYK2 with inhibitor 4: 3-azanyl-5-(2-methylphenyl)-7-(1-methylpyrazol-3-yl)-1~{H}-pyrazolo[4,3-c]pyridin-4-one","MGSPASDPTVFHKRYLKKIRDLGEGHFGKVSLYCYDPTNDGTGEMVAVKALKADCGPQHRSGWKQEIDILRTLYHEHIIKYKGCCEDQGEKSLQLVMEYVPLGSLRDYLPRHSIGLAQLLLFAQQICEGMAYLHSQHYIHRNLAARNVLLDNDRLVKIGDFGLAKAVPEGHEYYRVREDGDSPVFWYAPECLKEYKFYYASDVWSFGVTLYELLTHCDSSQSPPTKFLELIGIAQGQMTVLRLTELLERGERLPRPDKCPCEVYHLMKNCWETEASFRPTFENLIPILKTVHEKYHHHHHH","Homo sapiens","TYK2","Non-receptor tyrosine-protein kinase TYK2","1","5F20"
"5F25",,"X-RAY DIFFRACTION",1.99,38.12,"VAPOR DIFFUSION, HANGING DROP",8.3,"glycerol ethoxylate, Tris",277,"10.1021/acs.jmedchem.5b01865","5TU","5F25",28.98,"1.68","1.68","Crystal structure of the BRD9 bromodomain in complex with compound 4.","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","BRD9","1","5F25"
"5F2E",,"X-RAY DIFFRACTION",2.05,39.85,"VAPOR DIFFUSION, HANGING DROP",10.5,"2.2 M 3:2 NaH2PO4/K2HPO4, 0.2 M Li2SO4, 0.1 M glycine pH=10.5",293,"10.1158/2159-8290.CD-15-1105",,"5F2E",20.51,"1.4","1.4","Crystal Structure of small molecule ARS-853 covalently bound to K-Ras G12C","GMTEYKLVVVGACGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETSLLDILDTAGQEEYSAMRDQYMRTGEGFLLVFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKSDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVREIRKHKEK","Homo sapiens","KRAS, KRAS2, RASK2","GTPase KRas","1","5F2E"
"5F2P",,"X-RAY DIFFRACTION",2.3,46.61,"VAPOR DIFFUSION, HANGING DROP",8.3,"glycerol ethoxylate, Tris",277,"10.1021/acs.jmedchem.5b01865","5TY","5F2P",28.91,"1.8","1.8","Crystal structure of the BRD9 bromodomain in complex with compound 3.","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","BRD9","1","5F2P"
"5F2R",,"X-RAY DIFFRACTION",2.02,39.14,"VAPOR DIFFUSION, HANGING DROP",8.5,"24-26% PEG3350, 0.1 M Tris-HCl, 0.2 M sodium chloride",289,"10.1371/journal.pone.0154862","ACP","5F2R",89.77,"2.15","2.15","Crystal structure of human GRP78 (70kDa heat shock protein 5 / BIP) ATPase domain in complex with AMP-PCP","MHHHHHHSSGRENLYFQGDVGTVVGIDLGTTYSCVGVFKNGRVEIIANDQGNRITPSYVAFTPEGERLIGDAAKNQLTSNPENTVFDAKRLIGRTWNDPSVQQDIKFLPFKVVEKKTKPYIQVDIGGGQTKTFAPEEISAMVLTKMKETAEAYLGKKVTHAVVTVPAYFNDAQRQATKDAGTIAGLNVMRIINEPTAAAIAYGLDKREGEKNILVFDLGGGTFDVSLLTIDNGVFEVVATNGDTHLGGEDFDQRVMEHFIKLYKKKTGKDVRKDNRAVQKLRREVEKAKRALSSQHQARIEIESFYEGEDFSETLTRAKFEELNMDLFRSTMKPVQKVLEDSDLKKSDIDEIVLVGGSTRIPKIQQLVKEFFNGKEPSRGINPDEAVAYGAAVQAGVLSG","Homo sapiens","HSPA5, GRP78","78 kDa glucose-regulated protein","1","5F2R"
"5F2S",,"X-RAY DIFFRACTION",2.54,51.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5TZ","5F2S",171.47,"2.08","2.08","Crystal structure of human KDM4A in complex with compound 15","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F2S"
"5F2W",,"X-RAY DIFFRACTION",2.45,49.81,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5UP","5F2W",170.7,"2.6","2.6","Crystal structure of human KDM4A in complex with compound 16","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F2W"
"5F32",,"X-RAY DIFFRACTION",2.45,49.84,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5V7","5F32",170.01,"2.05","2.05","Crystal structure of human KDM4A in complex with compound 40","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F32"
"5F36",,"X-RAY DIFFRACTION",4.08,69.86,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277,"10.1021/acsmedchemlett.0c00080",,"5F36",15.8,"1.5","1.5","Crystal structure of the bromodomain of human ATAD2 in complex with Compound A12","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPase family AAA domain-containing protein 2","1","5F36"
"5F37",,"X-RAY DIFFRACTION",2.46,50.04,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","N5J","5F37",171.59,"2.22","2.22","Crystal structure of human KDM4A in complex with compound 58","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F37"
"5F39",,"X-RAY DIFFRACTION",2.52,51.13,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5UB","5F39",169.96,"2.65","2.65","Crystal structure of human KDM4A in complex with compound 37","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F39"
"5F3A",,"X-RAY DIFFRACTION",4.1,70.03,"VAPOR DIFFUSION, HANGING DROP",5.5,"2M (NH4)2SO4, 0.1M Bis-Tris pH 5.5",277,,,"5F3A",15.78,"1.599","1.599","Crystal structure of the bromodomain of human ATAD2 in complex with Compound A14","SMQEEDTFRELRIFLRNVTHRLAIDKRFRVFTKPVDPDEVPDYVTVIKQPMDLSSVISKIDLHKYLTVKDYLRDIDLICSNALEYNPDRDPGDRLIRHRACALRDTAYAIIKEELDEDFEQLCEEIQESR","Homo sapiens","ATAD2, L16, PRO2000","ATPase family AAA domain-containing protein 2","1","5F3A"
"5F3C",,"X-RAY DIFFRACTION",2.49,50.5,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5U8","5F3C",170.44,"2.06","2.06","Crystal structure of human KDM4A in complex with compound 52d","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F3C"
"5F3E",,"X-RAY DIFFRACTION",2.47,50.19,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5UO","5F3E",170.02,"2.16","2.16","Crystal structure of human KDM4A in complex with compound 54a","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F3E"
"5F3G",,"X-RAY DIFFRACTION",2.42,49.16,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5UL","5F3G",170.32,"2.5","2.5","Crystal structure of human KDM4A in complex with compound 53a","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F3G"
"5F3I",,"X-RAY DIFFRACTION",2.46,50.03,"VAPOR DIFFUSION, HANGING DROP",7.5,"Crystallisation solution is 0.1M Bis-Tris-Propane pH7.5, 12-16% PEG-4000. Inhibitor is soaked in crystals by addition directly to the drops of DMSO dissolved compound",291,"10.1021/acs.jmedchem.5b01635","5UJ","5F3I",170.26,"2.24","2.24","Crystal structure of human KDM4A in complex with compound 54j","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F3I"
"5F3K",,"X-RAY DIFFRACTION",2.78,55.78,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 micro liter hTRAP1N, 25 mg/ml, in 30 mM TrisHCl pH 8.5, 0.15
M NaCl, and 1 mM TCEP was mixed with an equal volume of reservoir
solution consisting of 100 mM HEPES pH 7.5, 100 mM CaCl2 , 23 percent PEG3350, 4 percent isopropanol, and 0.4 micro liter of 1 M LiCl2.",289,"10.1073/pnas.1516167113",,"5F3K",52.09,"1.82","1.82","X-Ray Crystallographic Structure of hTrap1 N-terminal Domain-apo","AGHSTQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNT","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","5F3K"
"5F4N",,"X-RAY DIFFRACTION",2.72,54.73,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350
DL-malic acid",291.15,"10.1021/acs.jmedchem.5b01938","5UY","5F4N",32.63,"1.91","1.91","Multi-parameter lead optimization to give an oral CHK1 inhibitor clinical candidate: (R)-5-((4-((morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)","MAVPFVEDWDLVQTLGEGAYGEVQLAVNRVTEEAVAVKIVDMKRAVDCPENIKKEICINKMLNHENVVKFYGHRREGNIQYLFLEYCSGGELFDRIEPDIGMPEPDAQRFFHQLMAGVVYLHGIGITHRDIKPENLLLDERDNLKISDFGLATVFRYNNRERLLNKMCGTLPYVAPELLKRREFHAEPVDVWSCGIVLTAMLAGELPWDQPSDSCQEYSDWKEKKTYLNPWKKIDSAPLALLHKILVENPSARITIPDIKKDRWYNKPLKKGA","Homo sapiens","CHEK1, CHK1","Serine/threonine-protein kinase Chk1","1","5F4N"
"5F4Q",,"X-RAY DIFFRACTION",2.24,45.16,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.02 M magnesium chloride, 0.1 M HEPES sodium salt [pH 7.5], 22% (w/v) Polyacrylic acid 5100",295,"10.1038/nature18595",,"5F4Q",99.61,"1.8","1.8","Crystal structure of the human egg surface protein Juno","GDELLNICMNAKHHKRVPSPEDKLYEECIPWKDNACCTLTTSWEAHLDVSPLYNFSLFHCGLLMPGCRKHFIQAICFYECSPNLGPWIQPVGSLGWEVAPSGQGERVVNVPLCQEDCEEWWEDCRMSYTCKSNWRGGWDWSQGKNRCPKGAQCLPFSHYFPTPADLCEKTWSNSFKASPERRNSGRCLQKWFEPAQGNPNVAVARLFASGRLVPR","Homo sapiens","IZUMO1R, FOLR4, JUNO","Sperm-egg fusion protein Juno","1","5F4Q"
"5F4T",,"X-RAY DIFFRACTION",3.49,64.76,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.07 M sodium acetate (pH 4.6), 5.6% (w/v) PEG 4000 and 30% (v/v) glycerol",295,"10.1038/nature18595",,"5F4T",27.4,"3.083","3.083","Crystal structure of the human sperm Izumo1 residues 22-254","CVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSDVKGDLFVKELFWMLHLQKETFATYVARFQKEAYCPNKCGVMLQTLIWCKNCKKEVHACRKSYDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATIINFHVTVLPGRVLPR","Homo sapiens","IZUMO1","Izumo sperm-egg fusion protein 1","1","5F4T"
"5F4V",,"X-RAY DIFFRACTION",2.83,56.46,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.085 M HEPES sodium salt (pH 7.5), 8.5% (v/v) isopropanol, 17% (w/v) PEG 4000 and 15% (v/v) glycerol",295,"10.1038/nature18595",,"5F4V",29,"2.9","2.9","Crystal structure of the human sperm Izumo1 residues 22-268","CVICDPSVVLALKSLEKDYLPGHLDAKHHKAMMERVENAVKDFQELSLNEDAYMGVVDEATLQKGSWSLLKDLKRITDSDVKGDLFVKELFWMLHLQKETFATYVARFQKEAYCPNKCGVMLQTLIWCKNCKKEVHACRKSYDCGERNVEVPQMEDMILDCELNWHQASEGLTDYSFYRVWGNNTETLVSKGKEATLTKPMVGPEDAGSYRCELGSVNSSPATIINFHVTVLPKMIKEEKPSPNIVTGRLVPR","Homo sapiens","IZUMO1","Izumo sperm-egg fusion protein 1","1","5F4V"
"5F4Y",,"X-RAY DIFFRACTION",3.53,65.13,"VAPOR DIFFUSION, SITTING DROP",8.5,"20% PEG 3350, 200 mM Magnesium Chloride, 100 mM Tris pH 8.5",293,"10.1074/jbc.M116.738559",,"5F4Y",42.11,"3.293","3.293","Structure of the SD2 domain of Human Shroom2","SDLDHDLSVKKQELIESISRKLQVLREARESLLEDVQANTVLGAEVEAIVKGVCKPSEFDKFRMFIGDLDKVVNLLLSLSGRLARVENALNNLDDGASPGDRQSLLEKQRVLIQQHEDAKELKENLDRRERIVFDILANYLSEESLADYEHFVKMKSALIIEQRELEDKIHLGEEQLKCLLDSL","Homo sapiens","SHROOM2, APXL","Protein Shroom2","1","5F4Y"
"5F58",,"X-RAY DIFFRACTION",2.03,39.28,"VAPOR DIFFUSION, HANGING DROP",4.5,"30% PEG 4000, 0.1M Ammonium Acetate, 0.1M Sodium Acetate pH = 4.5",298,,,"5F58",31.89,"1.54","1.54","Crystal structure of the Q108K:K40L:T51V:R58F mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.54 Angstrom Resolution","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTLVIDQDGDNFKVKTTSTFFNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5F58"
"5F59",,"X-RAY DIFFRACTION",4.97,75.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris-HCl, pH8.5, 3M NaCl",277,"10.1038/nature16952",,"5F59",18.45,"2.801","2.801","The crystal structure of MLL3 SET domain","SKSSQYRKMKTEWKSNVYLARSRIQGLGLYAARDIEKHTMVIEYIGTIIRNEVANRKEKLYESQNRGVYMFRMDNDHVIDATLTGGPARYINHSCAPNCVAEVVTFERGHKIIISSSRRIQKGEELCYDYKFDFEDDQHKIPCHCGAVNCRKWM","Homo sapiens","KMT2C, HALR, KIAA1506, MLL3","Histone-lysine N-methyltransferase 2C","1","5F59"
"5F5A",,"X-RAY DIFFRACTION",2.39,48.46,"VAPOR DIFFUSION, SITTING DROP",7,"30% PEG3350 , 0.1M HEPES pH 7.0 , 0.25M ammonium sulfate",293,"10.1021/acs.jmedchem.5b01635",,"5F5A",41.56,"1.41","1.41","Crystal Structure of human JMJD2D complexed with KDOAM16","YFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5F5A"
"5F5C",,"X-RAY DIFFRACTION",2.41,49.05,"VAPOR DIFFUSION, SITTING DROP",6.8,"26% PEG3350 , 0.1M HEPES pH 6.8 , 0.2M ammonium sulfate",293,"10.1021/acs.jmedchem.5b01635",,"5F5C",41.01,"1.88","1.88","Crystal Structure of human JMJD2D complexed with KDOPP7","YFQSMETMKSKANCAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQDR","Homo sapiens","KDM4D, JHDM3D, JMJD2D","Lysine-specific demethylase 4D","1","5F5C"
"5F5E",,"X-RAY DIFFRACTION",2.53,51.36,"VAPOR DIFFUSION, HANGING DROP",7,"35% Tacsimate, pH 7.0",277,"10.1038/nature16952","SAH","5F5E",18.69,"1.802","1.802","The Crystal Structure of MLL1 SET domain with N3816I/Q3867L mutation","SDLPMPMRFRHLKKTSKEAVGVYRSPIHGRGLFCKRNIDAGEMVIEYAGIVIRSILTDKREKYYDSKGIGCYMFRIDDSEVVDATMHGNAARFINHSCEPNCYSRVINIDGQKHIVIFAMRKIYRGEELTYDYKFPIEDASNKLPCNCGAKKCRKFLN","Homo sapiens","KMT2A, ALL1, CXXC7, HRX, HTRX, MLL, MLL1, TRX1","Histone-lysine N-methyltransferase 2A","1","5F5E"
"5F5I",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, SITTING DROP",5.9,"0.1M bis-tris pH 5.9 , 0.15M ammonium sulfate , 13% PEG3350",277,"10.1021/acs.jmedchem.5b01635",,"5F5I",85.51,"2.63","2.63","Crystal Structure of human JMJD2A complexed with KDOOA011340","YFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","Lysine-specific demethylase 4A","1","5F5I"
"5F5R",,"X-RAY DIFFRACTION",3.46,64.45,"VAPOR DIFFUSION, HANGING DROP",,"100 mM
sodium citrate pH 5.6, 22% PEG4000, 5% isopropanol",287,"10.1073/pnas.1516167113",,"5F5R",53.15,"1.85","1.85","TRAP1N-ADPNP","AGHSTQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNT","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","5F5R"
"5F5Z",,"X-RAY DIFFRACTION",2.11,41.69,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM, SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM MA2-014",291,"10.1158/1535-7163.MCT-16-0568-T","5VY","5F5Z",15.73,"1.76","1.76","Crystal structure of the first bromodomain of human BRD4 in complex with MA2-014","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5F5Z"
"5F60",,"X-RAY DIFFRACTION",2.19,43.94,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM SG3-014",291,"10.1158/1535-7163.MCT-16-0568-T","5VZ","5F60",15.94,"1.35","1.35","Crystal structure of the first bromodomain of human BRD4 in complex with SG3-014","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5F60"
"5F61",,"X-RAY DIFFRACTION",2.13,42.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM MA4-022-1",291,"10.1158/1535-7163.MCT-16-0568-T","5W0","5F61",31.81,"1.45","1.45","Crystal structure of the first bromodomain of human BRD4 in complex with MA4-022-1","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5F61"
"5F62",,"X-RAY DIFFRACTION",2.17,43.43,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM MA4-022-2",291,"10.1158/1535-7163.MCT-16-0568-T","5W1","5F62",16.03,"1.35","1.35","Crystal structure of the first bromodomain of human BRD4 in complex with MA4-022-2","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5F62"
"5F63",,"X-RAY DIFFRACTION",2.2,43.98,"VAPOR DIFFUSION, HANGING DROP",7.5,"12.5 MG/ML BRD4, 5MM HEPES PH 7.5, 50MM SODIUM CHLORIDE, 0.5MM DTT, 50MM TRIS PH8.5, 0.1M AMMONIUM SULFATE, 12.5% PEG 3,350, 10% DMSO, 1 MM SG3-179",291,"10.1158/1535-7163.MCT-16-0568-T","5W2","5F63",15.83,"1.45","1.45","Crystal structure of the first bromodomain of human BRD4 in complex with SG3-179","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5F63"
"5F66",,"X-RAY DIFFRACTION",2.81,56.3,"VAPOR DIFFUSION, HANGING DROP",7.5,"CRYSTALS WERE GROWN BY MIXING EQUAL VOLUMES OF WELL SOLUTION (100 MM HEPES PH 7.5, 23% PEG 3350, 5 MM TCEP) AND PROTEIN (60 MG/ML IN 20 MM HEPES PH 7.5, 100 MM NACL, 0.5 MM TCEP) IN THE HANGING-DROP FORMAT.",291,"10.1073/pnas.1524048113",,"5F66",18.04,"1.15","1.15","High-resolution isotropic multiconformer synchrotron model of CypA at 273 K","MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGFMCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTEWLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE","Homo sapiens","PPIA, CYPA","Peptidyl-prolyl cis-trans isomerase A","1","5F66"
"5F6B",,"X-RAY DIFFRACTION",2.03,39.3,"VAPOR DIFFUSION, HANGING DROP",4.5,"25 %PEG 4000, 0.1 M Ammonium Acetate, 0.1 M Sodium Acetate pH = 4.5.",298,,,"5F6B",31.91,"1.31","1.31","Crystal structure of the Q108K:K40L:T51V:R58Y:Y19W mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.3 Angstrom Resolution","TRDQNGTWEMESNENFEGWMKALDIDFATRKIAVRLTQTLVIDQDGDNFKVKTTSTFYNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5F6B"
"5F6D",,"X-RAY DIFFRACTION",2.74,55.08,"VAPOR DIFFUSION",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294,"10.1002/anie.201511351",,"5F6D",17.96,"1.553","1.553","Crystal structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 6","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6D"
"5F6E",,"X-RAY DIFFRACTION",2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294,"10.1002/anie.201511351",,"5F6E",17.79,"1.12","1.12","Crystal Structure of human Ubc9 (K48A/K49A/E54A)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6E"
"5F6U",,"X-RAY DIFFRACTION",2.75,55.29,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294,"10.1002/anie.201511351","5VK","5F6U",18.01,"1.552","1.552","Crystal Structure of Ubc9 (K48A/K49A/E54A) complexed with Fragment 8 (JSS190B146)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6U"
"5F6V",,"X-RAY DIFFRACTION",2.71,54.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294,"10.1002/anie.201511351","5VL","5F6V",17.91,"1.492","1.492","Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol from fragment cocktail screen)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6V"
"5F6W",,"X-RAY DIFFRACTION",2.73,54.98,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol",294,"10.1002/anie.201511351","5VL","5F6W",17.91,"1.699","1.699","Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 1 (biphenol)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6W"
"5F6X",,"X-RAY DIFFRACTION",2.73,55.03,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294,"10.1002/anie.201511351",,"5F6X",17.91,"1.56","1.56","Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole from cocktail screen)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6X"
"5F6Y",,"X-RAY DIFFRACTION",2.71,54.68,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris pH 8.5, 8% (w/v) polyethylene glycol 8000",294,"10.1002/anie.201511351",,"5F6Y",17.91,"1.14","1.14","Crystal structure of Ubc9 (K48/K49A/E54A) complexed with Fragment 2 (mercaptobenzoxazole)","SGIALSRLAQERKAWRKDHPFGFVAVPTKNPDGTMNLMNWECAIPGAAGTPWAGGLFKLRMLFKDDYPSSPPKCKFEPPLFHPNVYPSGTVCLSILEEDKDWRPAITIKQILLGIQELLNEPNIQDPAQAEAYTIYCQNRVEYEKRVRAQAKKFAPS","Homo sapiens","UBE2I, UBC9, UBCE9","SUMO-conjugating enzyme UBC9","1","5F6Y"
"5F70",,"X-RAY DIFFRACTION",1.79,31.23,"VAPOR DIFFUSION, SITTING DROP",,"0.1M imidazole. 20%(v/v) Jeffamine ED-2001 (pH 7.0)",291,,,"5F70",11.4,"1.8","1.8","Crystal structures of human TIM members","SVKVGGEAGPSVTLPCHYSGAVTSMCWNRGSCSLFTCQNGIVWTNGTHVTYRKDTRYKLLGDLSRRDVSLTIENTAVSDSGVYCCRVEHRGWFNDMKITVSLE","Homo sapiens","TIMD1, HAVCR1, KIM1, TIM1","Hepatitis A virus cellular receptor 1","1","5F70"
"5F71",,"X-RAY DIFFRACTION",2.28,46.13,"VAPOR DIFFUSION, SITTING DROP",,"0.8M potassium sodium tartrate tetrahydrate, 0.1M sodium HEPES at pH 7.5",291,,,"5F71",24.64,"2.404","2.404","Human T-cell immunoglobulin and mucin domain protein 3 (hTIM-3)","SEVEYRAEVGQNAYLPCFYTPAAPGNLVPVCWGKGACPVFECGNVVLRTDERDVNYWTSRYWLNGDFRKGDVSLTIENVTLADSGIYCCRIQIPGIMNDEKFNLKLVIK","Homo sapiens","TIMD3, HAVCR2, TIM3","Hepatitis A virus cellular receptor 2","1","5F71"
"5F7E",,"X-RAY DIFFRACTION",2.42,49.09,"VAPOR DIFFUSION, SITTING DROP",9.1,"0.1 M Bicine pH 9.1, 10% PEG 1500",298,"10.7554/eLife.13783",,"5F7E",48.19,"1.9","1.9","Crystal structure of germ-line precursor of 3BNC60 Fab","QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCARERSDFWDFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHHHHHH","Homo sapiens",,"Fab heavy chain","1","5F7E"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGTDFTFTISSLQPEDIATYYCQQYEFIGPGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"Fab light chain","2","5F7E"
"5F7F",,"X-RAY DIFFRACTION",2.29,46.27,"VAPOR DIFFUSION, SITTING DROP",,"0.1M phosphate/citrate, 40%(v/v) PEG300",291,,,"5F7F",25.33,"1.502","1.502","Human T-cell immunoglobulin and mucin domain protein 4 (hTIM-4)","SETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINVRLNLQRALV","Homo sapiens","TIMD4, TIM4","T-cell immunoglobulin and mucin domain-containing protein 4","1","5F7F"
"5F7G",,"X-RAY DIFFRACTION",2.01,38.93,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG 4000, 0.1 M Ammonium Acetate, 0.1 M sodium acetate pH = 4.5",298,,,"5F7G",31.94,"1.48","1.48","Crystal structure of the Q108K:K40L:T51V:R58Y:Y19W:Q38L mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.48 Angstrom Resolution","TRDQNGTWEMESNENFEGWMKALDIDFATRKIAVRLTLTLVIDQDGDNFKVKTTSTFYNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5F7G"
"5F7H",,"X-RAY DIFFRACTION",2.97,58.54,"VAPOR DIFFUSION, SITTING DROP",,"hTIM-4 crystals were soaked in reservoir solution with the addition of 20 mM O-Phospho-L-serine (sigma-aldrich) and 5 mM CaCl2 for 20 h.",291,,,"5F7H",77.36,"2.5","2.5","Human T-cell immunoglobulin and mucin domain protein 4 (hTIM-4) complex with phosphoserine","SETVVTEVLGHRVTLPCLYSSWSHNSNSMCWGKDQCPYSGCKEALIRTDGMRVTSRKSAKYRLQGTIPRGDVSLTILNPSESDSGVYCCRIEVPGWFNDVKINVRLNLQRALV","Homo sapiens","TIMD4, TIM4","T-cell immunoglobulin and mucin domain-containing protein 4","1","5F7H"
"5F89",,"X-RAY DIFFRACTION",2.48,50.47,"VAPOR DIFFUSION, HANGING DROP",5.6,"7.5% PEG4000
12.5% Isopropanol
0.1M Sodium Citrate pH5.6
Cryoprotectant: 30% Ethylene Glycol",298.15,"10.1371/journal.ppat.1006074",,"5F89",96.53,"2.7842","2.7842","Structure of the Unliganded Fab from HIV-1 Neutralising Antibody CAP248-2B that Binds to the gp120 C-terminus - gp41 Interface","EVQLQQSGPGLVKPSQTLSLTCNVYGVAISNEDYYWTWIRQHPGKGLEWIGDIYYNSGTTHYNPSLKSRASVSVDLSRNQFTLKVTSVTTADAAVYYCAREASTKITDDGGAFDFWGRGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"CAP248-2B Heavy Chain","1","5F89"
,,,,,,,,,,,,,,,,"QSALTQPASVSGSPGQSISISCTGTSSDIGGYKYVSWYQQHPGRAPKLIIYDVIKRPSGISDRFSGSKSANTASLTISGLQAGDEASYYCSSYTTKKTSFFGPATRAYVFGSGTQVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHKSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"CAP248-2B Light Chain","2","5F89"
"5F8P",,"X-RAY DIFFRACTION",3.24,62.06,"VAPOR DIFFUSION, HANGING DROP",,"10 %(w/v) polyethylene glycol (PEG) 3350, 0.1 M trisodium citrate dehydrate, 3.0 mM N-oxalylglycine (NOG)",293,,"FIJ","5F8P",55.49,"2.2","2.2","A Novel Inhibitor of the Obesity-Related Protein FTO","LESHMTPKDDEFYQQWQLKYPKLILREASSVSEELHKEVQEAFLTLHKHGCLFRDLVRIQGKDLLTPVSRILIGNPGCTYKYLNTRLFTVPWPVKGSNIKHTEAEIAAACETFLKLNDYLQIETIQALEELAAKEKANEDAVPLCMSADFPRVGMGSSYNGQDEVDIKSRAAYNVTLLNFMDPQKMPYLKEEPYFGMGKMAVSWHHDENLVDRSAVAVYSYSCEGPEEESEDDSHLEGRDPDIWHVGFKISWDIETPGLAIPLHQGDCYFMLDDLNATHQHCVLAGSQPRFSSTHRVAECSTGTLDYILQRCQLALQNVCDDVDNDDVSLKSFEPAVLKQGEEIHNEVEFEWLRQFWFQGNRYRKCTDWWCQPMAQLEALWKKMEGVTNAVLHEVKREGLPVEQRNEILTAILASLTARQNLRREWHARCQSRIARTLPADQKPECRPYWEKDDASMPLPFDLTDIVSELRGQLLE","Homo sapiens","FTO, KIAA1752","Alpha-ketoglutarate-dependent dioxygenase FTO","1","5F8P"
"5F94",,"X-RAY DIFFRACTION",3.83,67.87,"VAPOR DIFFUSION",,"Crystals grown in the presence of 25% PEG 1500 and 0.1 M MMT pH 4.0",298,"10.1021/acs.jmedchem.5b01550","3UO","5F94",80.31,"2.51","2.51","Crystal structure of GSK3b in complex with Compound 15: 2-[(cyclopropylcarbonyl)amino]-N-(4-methoxypyridin-3-yl)pyridine-4-carboxamide","KVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQ","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5F94"
"5F95",,"X-RAY DIFFRACTION",3.76,67.27,"VAPOR DIFFUSION",,"Crystals grown in the presence of 25% PEG 1500 and 0.1 M MMT pH 4.0",298,"10.1021/acs.jmedchem.5b01550",,"5F95",80.4,"2.525","2.525","Crystal structure of GSK3b in complex with Compound 18: 2-[(cyclopropylcarbonyl)amino]-N-(4-phenylpyridin-3-yl)pyridine-4-carboxamide","KVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQ","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5F95"
"5F9B",,"X-RAY DIFFRACTION",2.55,51.72,"VAPOR DIFFUSION, SITTING DROP",8,"0.8M NA CITRATE, 0.15M TRIS, PH8.0",293,"10.1038/srep27658",,"5F9B",65.88,"2.25","2.25","X-ray crystal structure of PPARgamma in the complex with caulophyllogenin","GSHMAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY","Homo sapiens","PPARG, NR1C3","Peroxisome proliferator-activated receptor gamma","1","5F9B"
"5F9C",,"X-RAY DIFFRACTION",2.97,58.65,"VAPOR DIFFUSION, HANGING DROP",,"1.5 M ammonium sulfate with 0.15 lithium sulfate and 0.1 CAPS buffer, pH 10.5",293,"10.1016/j.jmb.2016.02.032",,"5F9C",124.34,"2.5","2.5","Crystal structure of the G121R mutant of human phosphoglucomutase 1","MVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQSIISTVEPAQRQEATLVVGGDGRFYMKEAIQLIARIAAANGIGRLVIGQNGILSTPAVSCIIRKIKAIGGIILTASHNPRGPNGDFGIKFNISNGGPAPEAITDKIFQISKTIEEYAVCPDLKVDLGVLGKQQFDLENKFKPFTVEIVDSVEAYATMLRSIFDFSALKELLSGPNRLKIRIDAMHGVVGPYVKKILCEELGAPANSAVNCVPLEDFGGHHPDPNLTYAADLVETMKSGEHDFGAAFDGDGDRNMILGKHGFFVNPSDSVAVIAANIFSIPYFQQTGVRGFARSMPTSGALDRVASATKIALYETPTGWKFFGNLMDASKLSLCGEESFGTGSDHIREKDGLWAVLAWLSILATRKQSVEDILKDHWQKYGRNFFTRYDYEEVEAEGANKMMKDLEALMFDRSFVGKQFSANDKVYTVEKADNFEYSDPVDGSISRNQGLRLIFTDGSRIVFRLSGTGSAGATIRLYIDSYEKDVAKINQDPQVMLAPLISIALKVSQLQERTGRTAPTVIT","Homo sapiens","PGM1","Phosphoglucomutase-1","1","5F9C"
"5F9E",,"X-RAY DIFFRACTION",2.57,52.12,"VAPOR DIFFUSION, HANGING DROP",,"0.1M Hepes pH 7, 0.2M lithium citrate, and 18% PEG M.W. 3,350, 1% hexanediol",290,"10.1016/j.bmc.2016.04.008","5VS","5F9E",84.71,"2","2","Structure of Protein Kinase C theta with compound 10: 2,2-dimethyl-7-(2-oxidanylidene-3~{H}-imidazo[4,5-b]pyridin-1-yl)-1-(phenylmethyl)-3~{H}-quinazolin-4-one","MEPELNKERPSLQIKLKIEDFELHKMLGKGSFGKVFLAEFKKTNQFFAIKALKKDVVLMDDDVECTMVEKRVLSLAWEHPFLTHMFCTFQTKENLFFVMEYLNGGDLMYHIQSCHKFDLSRATFYAAEIILGLQFLHSKGIVYRDLKLDNILLDKDGHIKIADFGMCKENMLGDAKTNEFCGTPDYIAPEILLGQKYNHSVDWWSFGVLLYEMLIGQSPFHGQDEEELFHSIRMDNPFYPRWLEKEAKDLLVKLFVREPEKRLGVRGDIRQHPLFREINWEELERKEIDPPFRPKVKSPFDCSNFDKEFLNEKPRLSFADRALINSMDQNMFRNFSFMNPGMERLISHHHHHH","Homo sapiens","PRKCQ, PRKCT","Protein kinase C theta type","1","5F9E"
"5F9S",,"X-RAY DIFFRACTION",2.14,42.47,"VAPOR DIFFUSION, HANGING DROP",5,"Protein solution; 0.2 M AGT, 18mM potassium phosphate pH7.4, 20mM Hepes pH 7.4, 5% Jeffamine (Hampton), 5mM sodium hydroxylamine.
Reservoir; PEG 6k 12%, 100 mM MES pH 5.0.
Mixing: 1+1 microL 
Cryoprotectant; 25% MPD",294,"10.1038/s41598-017-11948-w",,"5F9S",85.28,"1.7","1.7","Crystal structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) at 1.7 Angstrom; internal aldimine with PLP in the active site","LLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKK","Homo sapiens","AGXT, AGT1, SPAT","Serine--pyruvate aminotransferase","1","5F9S"
"5FA6",,"X-RAY DIFFRACTION",2.34,47.42,"VAPOR DIFFUSION, HANGING DROP",6.5,"MES buffer, PEG 4K, CaAc2 and NaCl",292,"10.1074/jbc.M116.716019","NAP","5FA6",144.14,"2.3","2.3","wild type human CYPOR","GSHMVRESSFVEKMKKTGRNIIVFYGSQTGTAEEFANRLSKDAHRYGMRGMSADPEEYDLADLSSLPEIDNALVVFCMATYGEGDPTDNAQDFYDWLQETDVDLSGVKFAVFGLGNKTYEHFNAMGKYVDKRLEQLGAQRIFELGLGDDDGNLEEDFITWREQFWPAVCEHFGVEATGEESSIRQYELVVHTDIDAAKVYMGEMGRLKSYENQKPPFDAKNPFLAAVTTNRKLNQGTERHLMHLELDISDSKIRYESGDHVAVYPANDSALVNQLGKILGADLDVVMSLNNLDEESNKKHPFPCPTSYRTALTYYLDITNPPRTNVLYELAQYASEPSEQELLRKMASSSGEGKELYLSWVVEARRHILAILQDCPSLRPPIDHLCELLPRLQARYYSIASSSKVHPNSVHICAVVVEYETKAGRINKGVATNWLRAKEPAGENGGRALVPMFVRKSQFRLPFKATTPVIMVGPGTGVAPFIGFIQERAWLRQQGKEVGETLLYYGCRRSDEDYLYREELAQFHRDGALTQLNVAFSREQSHKVYVQHLLKQDREHLWKLIEGGAHIYVCGDARNMARDVQNTFYDIVAELGAMEHAQAVDYIKKLMTKGRYSLDVWS","Homo sapiens","POR, CYPOR","NADPH--cytochrome P450 reductase","1","5FA6"
"5FAE",,"X-RAY DIFFRACTION",2.04,39.7,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M lithium sulfate
0.1 M tris
40% PEG 400",293,"10.1038/srep33463",,"5FAE",13.75,"1.7","1.7","N184K pathological variant of gelsolin domain 2 (trigonal form)","GSHHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFKNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAA","Homo sapiens","GSN","Gelsolin","1","5FAE"
"5FAF",,"X-RAY DIFFRACTION",2.01,38.85,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG 8000
0.1 M MES
0.2 M calcium acetate",293,"10.1038/srep33463",,"5FAF",13.67,"1.05","1.05","N184K pathological variant of gelsolin domain 2 (orthorhombic form)","GSHHVVPNEVVVQRLFQVKGRRVVRATEVPVSWESFKNGDCFILDLGNNIHQWCGSNSNRYERLKATQVSKGIRDNERSGRARVHVSEEGTEPEAMLQVLGPKPALPAGTEDTAKEDAA","Homo sapiens","GSN","Gelsolin","1","5FAF"
"5FAH",,"X-RAY DIFFRACTION",2.12,41.92,"VAPOR DIFFUSION, HANGING DROP",,"0.5 microlitre Protein solution were mixed with 0.5 microlitre RESERVOIR solution. PROTEIN SOLUTION: 24.6 MG/ML KALLIKREIN 7, 50 MM SODIUM ACETATE PH 5.6, 100 MM NACL, 2 MM INHIBITOR, 1.8% DMSO, RESERVOIR SOLUTION: 35% PEG 3350, 100 MM SODIUM ACETATE PH 4.8, 200 MM CALCIUM CHLORIDE. CRYO: FLASH FREEZING IN LIQUID NITROGEN WITHOUT ADDITIONAL CRYO SOLUTION.",293,"10.1038/nchembio.2208","5VT","5FAH",24.97,"1.1","1.1","KALLIKREIN-7 IN COMPLEX WITH COMPOUND1","IIDGAPCARGSHPWQVALLSGNQLHCGGVLVNERWVLTAAHCKMNEYTVHLGSDTLGDRRAQRIKASKSFRHPGYSTQTHVNDLMLVKLNSQARLSSMVKKVRLPSRCEPPGTTCTVSGWGTTTSPDVTFPSDLMCVDVKLISPQDCTKVRKDLLENSMLCAGIPDSKKNACNGDSGGPLVCRGTLQGLVSWGTFPCGQPNDPGVYTQVCKFTKWINDTMKKHR","Homo sapiens","KLK7, PRSS6, SCCE","Kallikrein-7","1","5FAH"
"5FAI",,"X-RAY DIFFRACTION",2.64,53.43,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M di-NH4 Citrate",291,,,"5FAI",26.14,"1.8","1.8","EMG1 N1-Specific Pseudouridine Methyltransferase","GSGGEQAQDWDALPPKRPRLGAGNKIGGRRLIVVLEGASLETVKVGKTYELLNCDKHKSILLKNGRDPGEARPDITHQSLLMLMDSPLNRAGLLQVYIHTQKNVLIEVNPQTRIPRTFDRFCGLMVQLLHKLSVRAADGPQKLLKVIKNPVSDHFPVGCMKVGTSFSIPVVSDVRELVPSSDPIVFVVGAFAHGKVSVEYTEKMVSISNYPLSAALTCAKLTTAFEEVWGVI","Homo sapiens","EMG1, C2F","Ribosomal RNA small subunit methyltransferase NEP1","1","5FAI"
"5FAZ",,"X-RAY DIFFRACTION",2.01,38.91,"VAPOR DIFFUSION, HANGING DROP",4.5,"30 % PEG 4000, 0.1M Ammonium Acetate, 0.1M Sodium acetate pH = 4.5",298,,,"5FAZ",31.85,"1.4","1.4","Crystal structure of the Q108K:K40L:T51V mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.4 Angstrom Resolution","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTLVIDQDGDNFKVKTTSTFRNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5FAZ"
"5FBE",,"X-RAY DIFFRACTION",2.12,42,"VAPOR DIFFUSION, HANGING DROP",,"1 MICROLITER PROTEIN SOLUTION WAS MIXED WITH 1 MICROLITER RESERVOIR SOLUTION. PROTEIN SOLUTION: 18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl; RESERVOIR SOLUTION: 22% PEG3350, 100 mM HEPES pH 7.5; SOAKING AND CRYO: ADDITION of 10 mM COMPOUND2 for 45 min FOLLOWED by the ADDITION OF 0.5 MICROLITER GLYCEROL AND FLASH FREEZING IN LIQUIT NITROGEN.",293,"10.1038/nchembio.2208","5W5","5FBE",25.3,"1.43","1.43","COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND2","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5FBE"
"5FBH",,"X-RAY DIFFRACTION",2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",7,"10% PEG 8000, 200 mM MgCl2, 10 mM CaCl2 and 100 mM Tris-HCl, 0.5 mM GdCl3",294,"10.1126/sciadv.1600241",,"5FBH",130.99,"2.7","2.7","Crystal structure of the extracellular domain of human calcium sensing receptor with bound Gd3+","MRLLTALFAYFIVALILAFSVSAKSMHHHHHHHHSAWSHPQFEKEFYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSN","Homo sapiens","CASR, GPRC2A, PCAR1","Extracellular calcium-sensing receptor","1","5FBH"
"5FBI",,"X-RAY DIFFRACTION",2.14,42.47,"VAPOR DIFFUSION, HANGING DROP",,"1 Microliter of protein solution was mixed with 1 microliter of reservoir solution. Protein solution: 18.3 mg/ml factor D, 10 mM Tris pH 7.0, 100 mM sodium chloride; Reservoir solution: 22% PEG3350, 100 mM HEPES pH 7.5; Soaking and cryo: 0.5 ul 100 mM compound 3b in 90% DMSO was added to the crystal containing drop and incubated for 45 min followed by the addition of 0.5 ul glyerol and flash freezing in liquid nitrogen.",293,"10.1038/nchembio.2208","5WD","5FBI",25.14,"1.47","1.47","COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 3b","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5FBI"
"5FBJ",,"X-RAY DIFFRACTION",2.3,46.49,"EVAPORATION",,"PEG3350
HEPEPS-Na",281,,,"5FBJ",27.72,"2.42","2.42","Complex structure of JMJD5 and substrate","GSTVPRLHRPSLQHFREQFLVPGRPVILKGVADHWPCMQKWSLEYIQEIAGCRTVPVEVGSRYTDEEWSQTLMTVNEFISKYIVNEPRDVGYLAQHQLFDQIPELKQDISIPDYCSLGDGEEEEITINAWFGPQGTISPLHQDPQQNFLVQVMGRKYIRLYSPQESGALYPHDTHLLHNTSQVDVENPDLEKFPKFAKAPFLSCILSPGEILFIPVKYWHYVRALDLSFSVSFWWS","Homo sapiens","KDM8, JMJD5","Lysine-specific demethylase 8","1","5FBJ"
"5FBK",,"X-RAY DIFFRACTION",2.51,51.02,"VAPOR DIFFUSION, HANGING DROP",7,"10% PEG 8000, 200 mM MgCl2, 10 mM CaCl2 and 100 mM Tris-HCl",294,"10.1126/sciadv.1600241",,"5FBK",131.04,"2.1","2.1","Crystal structure of the extracellular domain of human calcium sensing receptor","MRLLTALFAYFIVALILAFSVSAKSMHHHHHHHHSAWSHPQFEKEFYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPFSN","Homo sapiens","CASR, GPRC2A, PCAR1","Extracellular calcium-sensing receptor","1","5FBK"
"5FBN",,"X-RAY DIFFRACTION",2.23,44.83,"VAPOR DIFFUSION, HANGING DROP",5.5,"20% v/v PEG 20000 0.1M NaCl 0.1M Na MES pH 6.5 2.5 mM mM (S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide 5.0 mM (R)-4-(8-amino-3-(1-(3-methyloxetane-3-carbonyl)piperidin-3-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(4-(trifluoromethyl)pyridin-2-yl)benzamide",277,"10.1021/acsmedchemlett.5b00463","5WF","5FBN",66.56,"1.8","1.8","BTK kinase domain with inhibitor 1","GLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5FBN"
"5FBO",,"X-RAY DIFFRACTION",2.28,46.08,"VAPOR DIFFUSION, HANGING DROP",5.5,"5.5 v/v PEG 10000, 0.1M Ammonium Acetate, 0.1M Bis-Tris Cl pH 6.5, 2.5 mM(S)-4-(8-amino-3-(1-(4-(dimethylamino)butanoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(thiazol-2-yl)benzamide",277,"10.1021/acsmedchemlett.5b00463","5WH","5FBO",32.7,"1.894","1.894","BTK-inhibitor co-structure","GLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEES","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5FBO"
"5FBX",,"X-RAY DIFFRACTION",2.31,46.86,"VAPOR DIFFUSION, SITTING DROP",7.8,"20 % PEG 3350, 0.2 M zinc acetate, 0.1 M imidazole pH 7.8",277.15,,"5W4","5FBX",15.42,"1.85","1.85","Crystal structure of the first bromodomain of human BRD4 in complex with PNZ5 isoxazole inhibitor","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5FBX"
"5FC4",,"X-RAY DIFFRACTION",2.12,37.49,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, magnesium chloride, Bis-Tris",292,"10.1021/acs.jmedchem.5b01660","5WL","5FC4",18.13,"1.5","1.5","Mcl-1 complexed with small molecule inhibitor","GDELYRQSLEIISRYLREQATGAKDTKPMGRAGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIANEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIAPLAESITDVLVRTKRDWLVAQRGWDGFVEFFH","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","5FC4"
"5FCK",,"X-RAY DIFFRACTION",1.95,37.01,"VAPOR DIFFUSION, HANGING DROP",,"1 uL FD solution (18 mg/mL FD, 10 mM Tris pH 7.0, 100 mM NaCl) was mixed with 1 uL reservoir solution (25% PEG3350, 100 mM TRIS pH 8.0) and equilibrated against 1 mL reservoir solution.",293,"10.1038/nchembio.2208","5WC","5FCK",25.32,"1.86","1.86","COMPLEMENT FACTOR D IN COMPLEX WITH COMPOUND 5","ILGGREAEAHARPYMASVQLNGAHLCGGVLVAEQWVLSAAHCLEDAADGKVQVLLGAHSLSQPEPSKRLYDVLRAVPHPDSQPDTIDHDLLLLQLSEKATLGPAVRPLPWQRVDRDVAPGTLCDVAGWGIVNHAGRRPDSLQHVLLPVLDRATCNRRTHHDGAITERLMCAESNRRDSCKGDSGGPLVCGGVLEGVVTSGSRVCGNRKKPGIYTRVASYAAWIDSVLASAAA","Homo sapiens","CFD, DF, PFD","Complement factor D","1","5FCK"
"5FCN",,"X-RAY DIFFRACTION",2.41,49,"VAPOR DIFFUSION, SITTING DROP",6,"25% PEG 1500, 0.1M SPG buffer",293.15,"10.1016/j.str.2016.06.011",,"5FCN",15.46,"1.8","1.8","microtubule binding domain of human CEP135","GSNNELYLELMKLREHSDQHVKELKTSLKKCARETADLKFLNNQYAHKLKLLEKESKAKNERIQQ","Homo sapiens","CEP135, CEP4, KIAA0635","Centrosomal protein of 135 kDa","1","5FCN"
"5FCS",,"X-RAY DIFFRACTION",3.48,64.63,"VAPOR DIFFUSION, HANGING DROP",,"0.5M LiSO4
PEG 8000K 15%",300,"10.3390/antib5010006",,"5FCS",53.54,"2.01","2.01","Diabody","QAVVTQEPSLTVSPGGTVTLTCRSSTGAVTTSNYANWVQQKPGQAPRGLIGGTNKRAPWTPARFSGSLLGGKAALTITGAQAEDEADYYCALWYSNLWVFGGGTKLTVLGGGGSGGGGEVQLVQSGAEVKKPGASVKVSCKASGYTFTSYGISWVRQAPGQGLEWMGWISAYNGNTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCATIDTASAFDIWGQGTMVTVSSGGCGGHHHHHH","Homo sapiens",,"Diabody","1","5FCS"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNYVSWYQQLPGTAPKLLIYDNNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAVVFGGGTKLTVLGGGSGGGGEVQLVESGGGLVQPGGSLRLSCAASGFTFNTYAMNWVRQAPGKGLEWVARIRSKYNNYATYYADSVKDRFTISRDDSKNSLYLQMNSLKTEDTAVYYCVRHGNFGNSYVSWFAYWGQGTLVTVSSGGCGGDYKDDDDK","Homo sapiens",,"Diabody","2","5FCS"
"5FCW",,"X-RAY DIFFRACTION",2.51,50.98,"VAPOR DIFFUSION, HANGING DROP",5.3,"4% PEG 3350, 50 mM buffer (MES, pH 5.3)",298,"10.1016/j.jsb.2016.06.023","5YA","5FCW",86.9,"1.979","1.979","HDAC8 Complexed with a Hydroxamic Acid","MEEPEEPADSGQSLVPVYIYSPEYVSMCDSLAKIPKRASMVHSLIEAYALHKQMRIVKPKVASMEEMATFHTDAYLQHLQKVSQEGDDDHPDSIEYGLGYDCPATEGIFDYAAAIGGATITAAQCLIDGMCKVAINWSGGWHHAKKDEASGFCYLNDAVLGILRLRRKFERILYVDLDLHHGDGVEDAFSFTSKVMTVSLHKFSPGFFPGTGDVSDVGLGKGRYYSVNVPIQDGIQDEKYYQICESVLKEVYQAFNPKAVVLQLGADTIAGDPMCSFNMTPVGIGKCLKYILQWQLATLILGGGGYNLANTARCWTYLTGVILGKTLSSEIPDHEFFTAYGPDYVLEITPSCRPDRNEPHRIQQILNYIKGNLKHVVHHHHHH","Homo sapiens","HDAC8, HDACL1, CDA07","Histone deacetylase 8","1","5FCW"
"5FD2",,"X-RAY DIFFRACTION",2.62,53.12,"VAPOR DIFFUSION, HANGING DROP",8.5,"PEG 8000, tacsimate, tris",293,"10.1016/j.bmc.2016.03.055",,"5FD2",69.94,"2.89","2.89","B-Raf wild-type kinase domain in complex with a purinylpyridinylamino-based inhibitor","HHHHHHEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHR","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5FD2"
"5FDC",,"X-RAY DIFFRACTION",2.08,40.81,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulphate, 0.3 M sodium chloride, 0.1 M Tris-HCl, pH 8.4 and 5 mM 4-(hydroxymercurybenzoate)",293,"10.1039/c6ob00803h","5WN","5FDC",30.03,"1.75","1.75","Crystal structure of Human Carbonic Anhydrase II in complex with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog.","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5FDC"
"5FDI",,"X-RAY DIFFRACTION",2.07,40.47,"VAPOR DIFFUSION, HANGING DROP",,"2.5 M ammonium sulphate, 0.3 M sodium chloride, 0.1 M Tris-HCl, pH 8.4 and 5 mM 4-(hydroxymercurybenzoate)",293,"10.1039/c6ob00803h","5WM","5FDI",30.06,"1.85","1.85","Crystal structure of Human Carbonic Anhydrase II with the anticonvulsant sulfamide JNJ-26990990 and its S,S-dioxide analog.","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5FDI"
"5FDO",,"X-RAY DIFFRACTION",3.01,59.19,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, BIS-TRIS, magnesium chloride",292,"10.1021/acs.jmedchem.5b01660","5X2","5FDO",70.59,"2.8","2.8","Mcl-1 complexed with small molecule inhibitor","GDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFH","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","5FDO"
"5FDP",,"X-RAY DIFFRACTION",2.26,45.63,"VAPOR DIFFUSION, SITTING DROP",7,"20% Polyethylene glycol 3350, 10% ethylene glycol, 0.1M Bis-tris propane pH 6.5, 0.2M Sodium Acetate",293.15,"10.1021/acs.jmedchem.6b00140","5WR","5FDP",39.22,"2.25","2.25","Structure of DDR1 receptor tyrosine kinase in complex with D2099 inhibitor at 2.25 Angstroms resolution.","MGHHHHHHSSGVDLGTENLYFQSMPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5FDP"
"5FDR",,"X-RAY DIFFRACTION",2.84,56.64,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Bis-Tris, magnesium chloride",292,"10.1021/acs.jmedchem.5b01660","5X3","5FDR",74.5,"2.6","2.6","Mcl-1 complexed with small molecule inhibitor","GDDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGG","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","5FDR"
"5FDX",,"X-RAY DIFFRACTION",2.33,47.24,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350
10% ethylene glycol
0.1M bis-tris-propane pH6.5
0.2M sodium acetate",293.15,,"5X1","5FDX",78.24,"2.65","2.65","Structure of DDR1 receptor tyrosine kinase in complex with D2164 inhibitor at 2.65 Angstroms resolution.","MGHHHHHHSSGVDLGTENLYFQSMPRVDFPRSRLRFKEKLGEGQFGEVHLCEVDSPQDLVSLDFPLNVRKGHPLLVAVKILRPDATKNARNDFLKEVKIMSRLKDPNIIRLLGVCVQDDPLCMITDYMENGDLNQFLSAHQLEDKAAEGAPGDGQAAQGPTISYPMLLHVAAQIASGMRYLATLNFVHRDLATRNCLVGENFTIKIADFGMSRNLYAGDYYRVQGRAVLPIRWMAWECILMGKFTTASDVWAFGVTLWEVLMLCRAQPFGQLTDEQVIENAGEFFRDQGRQVYLSRPPACPQGLYELMLRCWSRESEQRPPFSQLHRFLAEDALNTV","Homo sapiens","DDR1, CAK, EDDR1, NEP, NTRK4, PTK3A, RTK6, TRKE","Epithelial discoidin domain-containing receptor 1","1","5FDX"
"5FDY",,"X-RAY DIFFRACTION",2.07,40.57,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 6000",277,"10.7554/eLife.10960",,"5FDY",29.54,"1.85","1.85","Crystal structure of the Voltage-gated Sodium Channel Beta 2 subunit extracellular domain, C72A/C75A mutant","SNAMEVTVPATLNVLNGSDARLPCTFNSAYTVNHKQFSLNWTYQEANNASEEMFLQFRMKIINLKLERFQDRVEFSGNPSKYDVSVMLRNVQPEDEGIYNCYIMNPPDRHRGHGKIHLQVLMEEPPE","Homo sapiens","SCN2B, UNQ326/PRO386","Sodium channel subunit beta-2","1","5FDY"
"5FDZ",,"X-RAY DIFFRACTION",3.41,63.93,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719","5X0","5FDZ",29.24,"2.4","2.4","Crystal structure of human PCAF bromodomain in complex with compound BDOMB00091a (compound 14)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FDZ"
"5FE0",,"X-RAY DIFFRACTION",3.38,63.58,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE0",28.72,"2.3","2.3","Crystal structure of human PCAF bromodomain in complex with acetyllysine","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE0"
"5FE1",,"X-RAY DIFFRACTION",3.52,65.09,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719","12Q","5FE1",28.73,"2.22","2.22","Crystal structure of human PCAF bromodomain in complex with fragment BR004 (fragment 1)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE1"
"5FE2",,"X-RAY DIFFRACTION",3.37,63.55,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE2",28.89,"2.25","2.25","Crystal structure of human PCAF bromodomain in complex with fragment BR013 (fragment 3)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE2"
"5FE3",,"X-RAY DIFFRACTION",3.4,63.83,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE3",29.05,"2.12","2.12","Crystal structure of human PCAF bromodomain in complex with fragment MB360 (fragment 4)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE3"
"5FE4",,"X-RAY DIFFRACTION",3.36,63.44,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE4",29.01,"2.15","2.15","Crystal structure of human PCAF bromodomain in complex with fragment MB364 (fragment 5)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE4"
"5FE5",,"X-RAY DIFFRACTION",3.39,63.71,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE5",29.23,"2.12","2.12","Crystal structure of human PCAF bromodomain in complex with fragment MB093 (fragment 7)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE5"
"5FE6",,"X-RAY DIFFRACTION",3.38,63.6,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719","5WZ","5FE6",29.21,"1.77","1.77","Crystal structure of human PCAF bromodomain in complex with fragment ZB1916 (fragment 10)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE6"
"5FE7",,"X-RAY DIFFRACTION",3.42,64.04,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719","5WU","5FE7",28.8,"2.08","2.08","Crystal structure of human PCAF bromodomain in complex with fragment ZB2216 (fragment 11)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE7"
"5FE8",,"X-RAY DIFFRACTION",3.36,63.39,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719",,"5FE8",29.15,"2.1","2.1","Crystal structure of human PCAF bromodomain in complex with compound SL1126 (compound 12)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE8"
"5FE9",,"X-RAY DIFFRACTION",3.39,63.76,"VAPOR DIFFUSION, SITTING DROP",,"21-35% PEG 3350, 0.1 M Bis-Tris pH 5.5-7.0 or 21-40% medium-molecular-weight PEG smears (MMW PEG smears) buffered either with 0.1 M Bis-Tris pH 6.0-7.5 or 0.1 M Tris pH 7.5-8.8",277.15,"10.1021/acs.jmedchem.5b01719","5WS","5FE9",28.94,"2.35","2.35","Crystal structure of human PCAF bromodomain in complex with compound SL1122 (compound 13)","SMGKEKSKEPRDPDQLYSTLKSILQQVKSHQSAWPFMEPVKRTEAPGYYEVIRFPMDLKTMSERLKNRYYVSKKLFMADLQRVFTNCKEYNPPESEYYKCANILEKFFFSKIKEAGLID","Homo sapiens","KAT2B, PCAF","Histone acetyltransferase KAT2B","1","5FE9"
"5FEB",,"X-RAY DIFFRACTION",2.05,40.13,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 6000",277,"10.7554/eLife.10960",,"5FEB",14.65,"1.35","1.35","Crystal structure of the Voltage-gated Sodium Channel Beta 2 subunit extracellular domain","SNAMEVTVPATLNVLNGSDARLPCTFNSAYTVNHKQFSLNWTYQECNNCSEEMFLQFRMKIINLKLERFQDRVEFSGNPSKYDVSVMLRNVQPEDEGIYNCYIMNPPDRHRGHGKIHLQVLMEEP","Homo sapiens","SCN2B, UNQ326/PRO386","Sodium channel subunit beta-2","1","5FEB"
"5FED",,"X-RAY DIFFRACTION",3.44,64,"VAPOR DIFFUSION, SITTING DROP",7.9,"1.35M potassium sodium tartrate, 0.1M HEPES pH 7.9",293,"10.1021/acs.jmedchem.5b01985",,"5FED",37.83,"2.651","2.651","EGFR kinase domain in complex with a covalent aminobenzimidazole inhibitor.","GGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLITQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5FED"
"5FEE",,"X-RAY DIFFRACTION",3.41,64,"VAPOR DIFFUSION, SITTING DROP",7.5,"1.2M potassium sodium tartrate, 0.1M HEPES pH 7.5",294,"10.1021/acs.jmedchem.5b01985",,"5FEE",37.86,"2.7","2.7","EGFR kinase domain T790M mutant in complex with a covalent aminobenzimidazole inhibitor.","GGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5FEE"
"5FEH",,"X-RAY DIFFRACTION",3.13,60.68,"VAPOR DIFFUSION, SITTING DROP",8,"ammonium sulfate, ethylene glycol, PEG 3350",293.15,"10.1016/j.immuni.2017.11.002",,"5FEH",150,"3.1","3.1","Crystal structure of PCT64_35B, a broadly neutralizing anti-HIV antibody","EIGLTQSPGTLSLSPGDRATLSCRATQRVGSDYLAWYQQRPGQSPRLLVYGTSRRAAGIPDRFSGSGSGTDFTLTIDRLEPEDFAVYYCRQYETSFSFGPGTRVDLKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"PCT64_26 Fab light chain","1","5FEH"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVKPGGSLRLSCVGSEFTFSDAWMTWVRQAPGKGLEWVGHMRPTPEGGAKDYAAPVKGRFTVSRDDSKRTLYLQMNSLKIEDTAVYYCMTGVEKGDFWSDDYSQHYNTYLIDVWGKGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDHHHHHH","Homo sapiens",,"PCT64_26 Fab heavy chain","2","5FEH"
"5FEN",,"X-RAY DIFFRACTION",2.02,38.97,"VAPOR DIFFUSION, HANGING DROP",4.5,"30% PEG4000, 0.1M Ammonium Acetate, 0.1 M Sodium Acetate pH 4.5",298,,,"5FEN",31.86,"1.55","1.55","Crystal structure of the Q108K:K40L:T53C mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal after 24 hours of incubation at 1.55 Angstrom Resolution","TRDQNGTWEMESNENFEGYMKALDIDFATRKIAVRLTQTLVIDQDGDNFKTKCTSTFRNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5FEN"
"5FEQ",,"X-RAY DIFFRACTION",3.46,64.4,"VAPOR DIFFUSION, SITTING DROP",7.25,"100mM HEPES pH 7.25, 0.20M Lithium Sulphate, 32% PEG-3350",294,"10.1021/acs.jmedchem.5b01985","5XH","5FEQ",37.87,"3.4","3.4","EGFR KINASE DOMAIN IN COMPLEX WITH A COVALENT AMINOBENZIMIDAZOLE","GGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5FEQ"
"5FEY",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",6,"0.1 M MES pH 6.0 and 5 % PEG 600",291,"10.15252/embj.201593741",,"5FEY",21.66,"2.23","2.23","TRIM32 RING","MSHLNLDALREVLECPICMESFTEEQLRPKLLHCGHTICRQCLEKLLASSINGVRCPFCSKITRITSLTQLTDNLTVLKIIDTAGLSEHHHHHH","Homo sapiens","TRIM32, HT2A","E3 ubiquitin-protein ligase TRIM32","1","5FEY"
"5FFH",,"X-RAY DIFFRACTION",2.03,39.44,"VAPOR DIFFUSION, HANGING DROP",4.5,"25% PEG4000, 0.1M Ammonium Acetate, 0.1M Sodium Acetate",298,,,"5FFH",31.95,"1.68","1.68","Crystal structure of the Q108K:K40L:T51V:R58W:Y19W mutant of human Cellular Retinol Binding Protein II in complex with All-trans-Retinal at 1.68 Angstrom Resolution","TRDQNGTWEMESNENFEGWMKALDIDFATRKIAVRLTQTLVIDQDGDNFKVKTTSTFWNYDVDFTVGVEFDEYTKSLDNRHVKALVTWEGDVLVCVQKGEKENRGWKKWIEGDKLYLELTCGDQVCRQVFKKK","Homo sapiens","RBP2, CRBP2","Retinol-binding protein 2","1","5FFH"
"5FFY",,"X-RAY DIFFRACTION",2.68,54.05,"VAPOR DIFFUSION, SITTING DROP",9,"0.1 M bis tris propane pH 9, 10% ethylene glycol, 0.15 M sodium nitrate",277.15,,,"5FFY",14.08,"1.55","1.55","Crystal structure of the bromodomain of human BRPF1 in complex with a benzimidazole ligand","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5FFY"
"5FG4",,"X-RAY DIFFRACTION",2.67,53.92,"VAPOR DIFFUSION, SITTING DROP",7.4,"25% PEG3350, 0.1M bis-tris propane pH 7.4, 5% ethyleneglycol, 0.15M sodium nitrate",277.15,,"5XE","5FG4",14.14,"1.65","1.65","Crystal structure of the bromodomain of human BRPF1 in complex with OF-1 chemical probe","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5FG4"
"5FG5",,"X-RAY DIFFRACTION",2.61,52.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% PEG3350, 0.25 M sodium nitrate",277.15,,"5XF","5FG5",28.23,"1.5","1.5","Crystal structure of the bromodomain of human BRPF1 in complex with PFI-4 chemical probe","SMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEKMG","Homo sapiens","BRPF1, BR140","Peregrin","1","5FG5"
"5FG6",,"X-RAY DIFFRACTION",2.62,53.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M tri-sodium citrate dihydrate pH 5.6, 1 M ammoinum dihydrogen phosphate",277.15,,"5XE","5FG6",15.7,"1.1","1.1","Crystal structure of the bromodomain of human BRD1 (BRPF2) in complex with OF-1 chemical probe","SMRLTPLTVLLRSVLDQLQDKDPARIFAQPVSLKEVPDYLDHIKHPMDFATMRKRLEAQGYKNLHEFEEDFDLIIDNCMKYNARDTVFYRAAVRLRDQGGVVLRQARREVDSIGLEEASGMHLPERPA","Homo sapiens","BRD1, BRL, BRPF2","Bromodomain-containing protein 1","1","5FG6"
"5FH6",,"X-RAY DIFFRACTION",2.77,55.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M LiSO4, 0.1 M bis-tris pH 6.5, 25% PEG 3350",277.15,"10.1021/acs.jmedchem.5b01997",,"5FH6",59.73,"2.3","2.3","Crystal structure of the fifth bromodomain of human PB1 in complex with compound 10","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5FH6"
"5FH7",,"X-RAY DIFFRACTION",2.95,58.34,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M magnesium formate, 15% PEG 3350",277.15,"10.1021/acs.jmedchem.5b01997","5XL","5FH7",29.97,"1.47","1.47","Crystal structure of the fifth bromodomain of human PB1 in complex with compound 18","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5FH7"
"5FH8",,"X-RAY DIFFRACTION",2.26,45.65,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% MPD, 0.1 M bicine pH 9",277.15,"10.1021/acs.jmedchem.5b01997","5XK","5FH8",59.94,"1.55","1.55","Crystal structure of the fifth bromodomain of human PB1 in complex with compound 28","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5FH8"
"5FHA",,"X-RAY DIFFRACTION",2.28,45.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"5.29mg/mL 114 Fab, 27% PEG 3350, 4.32% isopropanol, 0.1M HEPES pH 7.5, 0.1M calcium chloride, 0.01M sodium bromide",293,"10.1126/science.aad6117",,"5FHA",46.15,"1.973","1.973","Crystal Structure of Protective Ebola Virus Antibody 114","EVQLVESGGGLIQPGGSLRLSCAASGFALRMYDMHWVRQTIDKRLEWVSAVGPSGDTYYADSVKGRFAVSRENAKNSLSLQMNSLTAGDTAIYYCVRSDRGVAGLFDSWGQGILVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK","Homo sapiens",,"Antibody 114 Fab heavy chain","1","5FHA"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRITITCRASQAFDNYVAWYQQRPGKVPKLLISAASALHAGVPSRFSGSGSGTHFTLTISSLQPEDVATYYCQNYNSAPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG","Homo sapiens",,"Antibody 114 Fab light chain","2","5FHA"
"5FHB",,"X-RAY DIFFRACTION",3.15,60.91,"VAPOR DIFFUSION, HANGING DROP",5.5,"3.4mg/ml 100 Fab, 38% PEG 400, 4.75% PEG 3350, 0.1M sodium acetate pH 5.5",293,"10.1126/science.aad6117",,"5FHB",47.46,"1.973","1.973","Crystal Structure of Protective Ebola Virus Antibody 100","QVQLQESGPGLVKPSDTLSLTCTVSGGSLSSFYWSWIRQPPGKGLEWIGYIYYSGSPNYSPSLESRVTMSVDTTRNQISLKLDSVTAADTAVYYCVRASRSYYWGSYRPTAFDSWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"Antibody 100 Fab heavy chain","1","5FHB"
,,,,,,,,,,,,,,,,"YELTQPLSVSVSPGQTAIFTCSGDNLGDKYVCWFQQRPGQSPMLLIYQDNKRPSGIPERFSGSNSGNTATLTISGTQSTDEADYYCQTWDSTVVFGGGTKLTVLGQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTE","Homo sapiens",,"Antibody 100 Fab light chain","2","5FHB"
"5FHH",,"X-RAY DIFFRACTION",4.9,74.91,"VAPOR DIFFUSION, HANGING DROP",6,"3% tacsimate, 0.1M Bis-Tris, 15% glycerol, 15% PEG8000",293,"10.1016/j.celrep.2016.02.008",,"5FHH",97.07,"3.6","3.6","Structure of human Pif1 helicase domain residues 200-641","LPSTKPQLSEEQAAVLRAVLKGQSIFFTGSAGTGKSYLLKRILGSLPPTGTVATASTGVAACHIGGTTLHAFAGIGSGQAPLAQCVALAQRPGVRQGWLNCQRLVIDEISMVEADLFDKLEAVARAVRQQNKPFGGIQLIICGDFLQLPPVTKGSQPPRFCFQSKSWKRCVPVTLELTKVWRQADQTFISLLQAVRLGRCSDEVTRQLQATASHKVGRDGIVATRLCTHQDDVALTNERRLQELPGKVHRFEAMDSNPELASTLDAQCPVSQLLQLKLGAQVMLVKNLSVSRGLVNGARGVVVGFEAEGRGLPQVRFLCGVTEVIHADRWTVQATGGQLLSRQQLPLQLAWAMSIHKSQGMTLDCVEISLGRVFASGQAYVALSRARSLQGLRVLDFDPMAVRCDPRVLHFYATLRRGRSLSLESPDDDEAASDQENMDPIL","Homo sapiens","PIF1, C15orf20","ATP-dependent DNA helicase PIF1","1","5FHH"
"5FHT",,"X-RAY DIFFRACTION",2.49,50.58,"VAPOR DIFFUSION, SITTING DROP",,"MES, NaCl, KH2PO4, NaH2PO4",293,"10.1371/journal.pone.0161526",,"5FHT",36.53,"1.95","1.95","HtrA2 protease mutant V226K","MAVPSPPPASPRSQYNFIADVVEKTAPAVVYIEILDRHPFLGREVPISNGSGFVVAADGLIVTNAHVVADRRRVRVRLLSGDTYEAVVTAVDPKADIATLRIQTKEPLPTLPLGRSADVRQGEFVVAMGSPFALQNTITSGIVSSAQRPARDLGLPQTNVEYIQTDAAIDFGNAGGPLVNLDGEVIGVNTMKVTAGISFAIPSDRLREFLHRGEKKNSSSGISGSQRRYIGVMMLTLSPSILAELQLREPSFPDVQHGVLIHKVILGSPAHRAGLRPGDVILAIGEQMVQNAEDVYEAVRTQSQLAVQIRRGRETLTLYVTPEVTELEHHHHHH","Homo sapiens","HTRA2, OMI, PRSS25","Serine protease HTRA2, mitochondrial","1","5FHT"
"5FHZ",,"X-RAY DIFFRACTION",2.76,55.41,"VAPOR DIFFUSION, SITTING DROP",7,"20% PEG 3350, 0.24 M Na2 malonate pH 7.0, 10 mM TCEP hydrochloride",293.15,"10.1038/srep35710",,"5FHZ",472,"2.9","2.9","Human aldehyde dehydrogenase 1A3 complexed with NAD(+) and retinoic acid","HHHHHHLESTSLYKKAGMATANGAVENGQPDRKPPALPRPIRNLEVKFTKIFINNEWHESKSGKKFATCNPSTREQICEVEEGDKPDVDKAVEAAQVAFQRGSPWRRLDALSRGRLLHQLADLVERDRATLAALETMDTGKPFLHAFFIDLEGCIRTLRYFAGWADKIQGKTIPTDDNVVCFTRHEPIGVCGAITPWNFPLLMLVWKLAPALCCGNTMVLKPAEQTPLTALYLGSLIKEAGFPPGVVNIVPGFGPTVGAAISSHPQINKIAFTGSTEVGKLVKEAASRSNLKRVTLELGGKNPCIVCADADLDLAVECAHQGVFFNQGQCCTAASRVFVEEQVYSEFVRRSVEYAKKRPVGDPFDVKTEQGPQIDQKQFDKILELIESGKKEGAKLECGGSAMEDKGLFIKPTVFSEVTDNMRIAKEEIFGPVQPILKFKSIEEVIKRANSTDYGLTAAVFTKNLDKALKLASALESGTVWINCYNALYAQAPFGGFKMSGNGRELGEYALAEYTEVKTVTIKLGDKNP","Homo sapiens","ALDH1A3, ALDH6","Aldehyde dehydrogenase family 1 member A3","1","5FHZ"
"5FI2",,"X-RAY DIFFRACTION",2.52,51.2,"VAPOR DIFFUSION, HANGING DROP",8,"PEG6000, LiCl, Tris-HCl",293,"10.1016/j.bmc.2016.03.009","5XX","5FI2",238.87,"2.5","2.5","Crystal structure of human GAC in complex with inhibitor UPGL_00009: 2-phenyl-~{N}-[5-[[(3~{R})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol- 2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide","MRGSHHHHHHGSLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5FI2"
"5FI6",,"X-RAY DIFFRACTION",2.61,52.84,"VAPOR DIFFUSION, HANGING DROP",8,"PEG6000, LiCl, Tris-HCl",293,"10.1016/j.bmc.2016.03.009","5XY","5FI6",238.87,"2.52","2.52","Crystal structure of human GAC in complex with inhibitor UPGL_00011: 2-phenyl-~{N}-[5-[[(3~{S})-1-[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]pyrrolidin-3-yl]amino]-1,3,4-thiadiazol-2-yl]ethanamide","MRGSHHHHHHGSLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5FI6"
"5FI7",,"X-RAY DIFFRACTION",2.56,51.91,"VAPOR DIFFUSION, HANGING DROP",8,"PEG6000, LiCl, Tris-HCl",293,"10.1016/j.bmc.2016.03.009","5XZ","5FI7",238.87,"2.5","2.5","Crystal structure of human GAC in complex with inhibitor UPGL_00015: 2-phenyl-~{N}-[5-[(3~{S})-3-[[5-(2-phenylethanoylamino)-1,3,4-thiadiazol-2-yl]oxy]pyrrolidin-1-yl]-1,3,4-thiadiazol-2-yl]ethanamide","MRGSHHHHHHGSLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5FI7"
"5FII",,"X-RAY DIFFRACTION",2.24,77,,,"25% PEG 3350, 0.20M NACL, 0.1M BIS-TRIS PH 5.5",,"10.1038/srep23748",,"5FII",47.47,"1.8","1.8","Structure of a human aspartate kinase, chorismate mutase and TyrA domain.","SMGQETSYIEDNCNQNGAISLIFSLKEEVGALAKVLRLFEENDVNLTHIESRPSRLKKDEYEFFTHLDKRSLPALTNIIKILRHDIGATVHELSRDKKKDTV","Homo sapiens","PAH","PHENYLALANINE-4-HYDROXYLASE","1","5FII"
"5FIT",,"X-RAY DIFFRACTION",2.91,57.79,,6.5,"GROWN FROM AMMONIUM SULFATE, PH 6.5",,"10.1126/science.278.5336.286",,"5FIT",17.41,"2.3","2.3","FHIT-SUBSTRATE ANALOG","MSFRFGQHLIKPSVVFLKTELSFALVNRKPVVPGHVLVCPLRPVERFHDLRPDEVADLFQTTQRVGTVVEKHFHGTSLTFSMQDGPEAGQTVKHVHVHVLPRKAGDFHRNDSIYEELQKHDKEDFPASWRSEEEMAAEAAALRVYFQ","Homo sapiens","FHIT","FRAGILE HISTIDINE TRIAD PROTEIN","1","5FIT"
"5FIW",,"X-RAY DIFFRACTION",2.39,48.54,,6,"15% PEG 3350, 100 MM NACL, pH 6",,,,"5FIW",134.94,"1.7","1.7","CRYSTAL STRUCTURE OF HUMAN MYELOPEROXIDASE AT 1.7 ANGSTROMS RESOLUTION","CPEQDKYRTITGMCNNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTDQLTPDQERSLMFMQWGQLLDHDLDFTPEPAA","Homo sapiens","MPO","MYELOPEROXIDASE","1","5FIW"
,,,,,,,,,,,,,,,,"VNCETSCVQQPPCFPLKIPPNDPRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQLGLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLLREHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYRSYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLEGGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYNAWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPLLACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMSNSYPRDFVNCSTLPALNLASWREA","Homo sapiens","MPO","MYELOPEROXIDASE","2","5FIW"
"5FJH",,"X-RAY DIFFRACTION",2.65,53.6,,7.25,"21% PEG 3350 5% 1,2-ETHANEDIOL 0.2 M NANO3 0.1 M BIS-TRIS PROPANE PH 7.25",,,,"5FJH",82.03,"2.1","2.1","Crystal structure of human JMJD2C catalytic domain in complex with epitherapuetic compound 2-(((2-((2-(dimethylamino)ethyl) (ethyl)amino) -2-oxoethyl)amino)methyl)isonicotinic acid","GPMNVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPRQCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYEDLERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDAFLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRWIDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTK","Homo sapiens","KDM4C, GASC1, JHDM3C, JMJD2C, KIAA0780","LYSINE-SPECIFIC DEMETHYLASE 4C","1","5FJH"
"5FJK",,"X-RAY DIFFRACTION",2.51,50.94,,7.25,"21% PEG 3350, 5% 1,2 ETHANEDIOL, 0.2 M NANO3, 0.1 M BIS-TRIS PROPANE PH 7.25",,,,"5FJK",41.3,"1.66","1.66","Crystal structure of human JMJD2C catalytic domain in complex 6-ethyl- 5-methyl-7-oxo-4,7-dihydropyrazolo(1,5-a)pyrimidine-3-carbonitrile","GPMNVAEVESPLNPSCKIMTFRPSMEEFREFNKYLAYMESKGAHRAGLAKVIPPKEWKPRQCYDDIDNLLIPAPIQQMVTGQSGLFTQYNIQKKAMTVKEFRQLANSGKYCTPRYLDYEDLERKYWKNLTFVAPIYGADINGSIYDEGVDEWNIARLNTVLDVVEEECGISIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHFGEPKSWYAIPPEHGKRLERLAQGFFPSSSQGCDAFLRHKMTLISPSVLKKYGIPFDKITQEAGEFMITFPYGYHAGFNHGFNCAESTNFATVRWIDYGKVAKLCTCRKDMVKISMDIFVRKFQPDRYQLWKQGKDIYTIDHTK","Homo sapiens","KDM4C, GASC1, JHDM3C, JMJD2C, KIAA0780","LYSINE-SPECIFIC DEMETHYLASE 4C","1","5FJK"
"5FJV",,"X-RAY DIFFRACTION",3.05,59.74,,5.5,"100 MM BICINE PH 9.5, 20% PEG 8000",,"10.1073/pnas.1602619113","EPJ","5FJV",126.5,"3.2","3.2","Crystal structure of the extracellular domain of alpha2 nicotinic acetylcholine receptor in pentameric assembly","EDRLFKHLFRGYNRWARPVPNTSDVVIVRFGLSIAQLIDVDEKNQMMTTNVWLKQEWSDYKLRWNPTDFGNITSLRVPSEMIWIPDIVLYNNADGEFAVTHMTKAHLFSTGTVHWVPPAIYKSSCSIDVTFFPFDQQNCKMKFGSWTYDKAKIDLEQMEQTVDLKDYWESGEWAIVNATGTYNSKKYDCCAEIYPDVTYAFVIRRLPHHHHHH","Homo sapiens","CHRNA2","NEURONAL ACETYLCHOLINE RECEPTOR SUBUNIT ALPHA-2","1","5FJV"
"5FL4",,"X-RAY DIFFRACTION",3.41,63.97,"VAPOR DIFFUSION, SITTING DROP",4.5,"1.0 M DI-AMMONIUM HYDROGEN PHOSPHATE, 0.1 M SODIUM ACETATE PH 4.5, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,"10.1021/acs.jmedchem.5b01343","9FK","5FL4",115.11,"1.82","1.82","Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-naphthalen-1-yl-1,2,3-triazol-4-yl)thiophene-2-sulfonamide","GPDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFSPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFP","Homo sapiens","CA9, G250, MN","CARBONIC ANHYDRASE 9","1","5FL4"
"5FL5",,"X-RAY DIFFRACTION",3.39,63.69,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.2 M LITHIUM SULFATE, 1.26 M AMMONIUM SULFATE, TRIS- HCL, PH 8.5, PROTEIN 10 MG/ML, 5-10 MM INHIBITOR(STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,"10.1021/acs.jmedchem.5b01343","82E, SO4","5FL5",116.86,"2.05","2.05","Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methoxyphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide","GPDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFSPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFP","Homo sapiens","CA9, G250, MN","CARBONIC ANHYDRASE IX","1","5FL5"
"5FL6",,"X-RAY DIFFRACTION",3.43,64.14,"VAPOR DIFFUSION, SITTING DROP",4.5,"1.0 M DI-AMMONIUM HYDROGEN PHOSPHATE, 0.1 M SODIUM ACETATE PH 4.5, PROTEIN 10 MG/ML 5-10 MM INHIBITOR (STOCK SOLUTION WAS 100 MM INHIBITOR DISSOLVED IN 100% DIMETHYL SULFOXIDE) VAPOR DIFFUSION, SITTING DROP, TEMPERATURE 294K",294,"10.1021/acs.jmedchem.5b01343","Y0R","5FL6",114.72,"1.95","1.95","Three dimensional structure of human carbonic anhydrase IX in complex with 5-(1-(4-Methylphenyl)-1H-1,2,3-triazol-4-yl)thiophene-2- sulfonamide","GPDQSHWRYGGDPPWPRVSPACAGRFQSPVDIRPQLAAFSPALRPLELLGFQLPPLPELRLRNNGHSVQLTLPPGLEMALGPGREYRALQLHLHWGAAGRPGSEHTVEGHRFPAEIHVVHLSTAFARVDEALGRPGGLAVLAAFLEEGPEENSAYEQLLSRLEEIAEEGSETQVPGLDISALLPSDFSRYFQYEGSLTTPPCAQGVIWTVFNQTVMLSAKQLHTLSDTLWGPGDSRLQLNFRATQPLNGRVIEASFP","Homo sapiens","CA9, G250, MN","CARBONIC ANHYDRASE IX","1","5FL6"
"5FLF",,"X-RAY DIFFRACTION",2.7,54.6,,7.5,"20 PEG 400, 0.75 M AMMONIUM SULPHATE, 0.1 M MAGNESIUM CHLORIDE, 0.1 M HEPES PH 7.5",,"10.18632/oncotarget.8132",,"5FLF",177.74,"2.58","2.58","DISEASE LINKED MUTATION IN FGFR","MVAGVSEYELPEDPRWELPRDRLVLGKPLGEGAFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYSYNPSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNGRLPVKWMAPEALFDGIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQE","Homo sapiens","FGFR1, BFGFR, CEK, FGFBR, FLG, FLT2, HBGFR","FIBROBLAST GROWTH FACTOR RECEPTOR 1","1","5FLF"
"5FLO",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","J4K","5FLO",29.57,"1.66","1.66","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FLO"
"5FLP",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","6J5","5FLP",29.85,"1.71","1.71","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FLP"
"5FLQ",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","IO2","5FLQ",29.69,"1.7","1.7","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FLQ"
"5FLR",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","XCZ","5FLR",29.8,"1.68","1.68","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FLR"
"5FLS",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","6ZX","5FLS",29.63,"1.67","1.67","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FLS"
"5FLT",,"X-RAY DIFFRACTION",2.1,42.1,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","VJJ","5FLT",29.66,"1.67","1.67","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","HUMAN CARBONIC ANHYDRASE 2","1","5FLT"
"5FM2",,"X-RAY DIFFRACTION",2.5,50.83,,,,,"10.1016/j.celrep.2016.11.061","PP1","5FM2",41,"3.3","3.3","Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment","CYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRR","Homo sapiens","RET, CDHF12, CDHR16, PTC, RET51","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1","5FM2"
"5FM3",,"X-RAY DIFFRACTION",2.52,51.17,,,,,"10.1016/j.celrep.2016.11.061","PP1","5FM3",41,"2.95","2.95","Crystal structure of hyper-phosphorylated RET kinase domain with (proximal) juxtamembrane segment","CYHKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWQISQGMQYLAEMKLVHRDLAARNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRR","Homo sapiens","RET, CDHF12, CDHR16, PTC, RET51","PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RET","1","5FM3"
"5FM4",,"X-RAY DIFFRACTION",2.25,45.3,,5.5,"25 % (W/V) PEG 3350 100 MM BIS-TRIS PH 5.5",,"10.1016/j.str.2016.11.015",,"5FM4",73.12,"2.8","2.8","Structure of the C-terminally extended domain My4 of human myomesin (space group P21)","GSTPAAPLDVKCLEANKDYIIISWKQPAVDGGSPILGYFIDKCEVGTDSWSQCNDTPVKFARFPVTGLIEGRSYIFRVRAVNKMGIGFPSRVSEPVAALDPAEKARLKSRPS","Homo sapiens","MYOM1","MYOMESIN-1","1","5FM4"
"5FM8",,"X-RAY DIFFRACTION",3.01,59.18,,8.8,"21 % (W/V) PEG 2000 MME, 10 MM NICL2, 100 MM TRIS/HCL PH 8.8",,"10.1016/j.str.2016.11.015",,"5FM8",48.99,"2.05","2.05","Structure of the C-terminally extended domain My4 of human myomesin (space group P65)","GSTPAAPLDVKCLEANKDYIIISWKQPAVDGGSPILGYFIDKCEVGTDSWSQCNDTPVKFARFPVTGLIEGRSYIFRVRAVNKMGIGFPSRVSEPVAALDPAEKARLKSRPS","Homo sapiens","MYOM1","MYOMESIN-1","1","5FM8"
"5FM9",,"X-RAY DIFFRACTION",3.44,64.23,,8.5,"PH 8.5",,"10.1016/j.str.2016.02.010",,"5FM9",16.72,"2.92","2.92","human Notch 1, EGF 4-7","SAQADPCASNPCANGGQCLPFEASYICHCPPSFHGPTCRQDVNECGQKPGLCRHGGTCHNEVGSYRCVCRATHTGPNCERPYVPCSPSPCQNGGTCRPTGDVTHECACLPGFTGQNCEENIDDCPGNNCKNGGACVDGVNTYNCRCPPEWTGQYCTE","Homo sapiens","NOTCH1, TAN1","NEUROGENIC LOCUS NOTCH HOMOLOG PROTEIN 1","1","5FM9"
"5FMA",,"X-RAY DIFFRACTION",2.76,55.41,,6.5,"pH 6.5",,"10.1016/j.str.2016.02.010",,"5FMA",33.16,"2.46","2.46","human Notch 1, EGF 4-7","QDPCASNPCANGGQCLPFEASYICHCPPSFHGPTCRQDVNECGEKPGLCRHGGTCHNEVGSYRCVCRATHTGPNCERPYVPCSPSPCQNGGTCRPTGDVTHECACLPGFTGQNCEENIDDCPGNNCKNGGACVDGVNTYNCRCPPEWTGQYCTE","Homo sapiens","NOTCH1, TAN1","NEUROGENIC LOCUS NOTCH HOMOLOG PROTEIN 1","1","5FMA"
"5FMH",,"X-RAY DIFFRACTION",1.96,37.2,,7,"20% PEG 3350; 0.2M AMMONIUM ACETATE, pH 7",,,,"5FMH",56.5,"1.8","1.8","Crystal structure of the E405K mutant of human apoptosis inducing factor","LTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVKLAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHED","Homo sapiens","AIFM1, AIF, PDCD8","APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL","1","5FMH"
"5FMI",,"X-RAY DIFFRACTION",2.29,46.28,,4.5,"10% PEG 3350, 0.1M SODIUM ACETATE PH 4.5, 20 MM ZINC ACETATE",,"10.1101/gad.279414.116",,"5FMI",18.5,"1.491","1.491","Human Bak Q77L","SEEQVAQDTEEVFRSYVFYRHQQEQEAEGVAAPADPEMVTLPLQPSSTMGQVGRLLAIIGDDINRRYDSEFQTMLQHLQPTAENAYEYFTKIATSLFESGINWGRVVALLGFGYRLALHVYQHGLTGFLGQVTRFVVDFMLHHSIARWIAQRGGWVAALNLG","Homo sapiens","BAK1, BAK, BCL2L7, CDN1","BCL-2 HOMOLOGOUS ANTAGONIST/KILLER","1","5FMI"
"5FMV",,"X-RAY DIFFRACTION",3.28,62.48,,8,"14% W/V PEG8K, 0.2M (NH4)2SO4, PH=8",,"10.1038/ni.3392",,"5FMV",86.21,"2.9","2.9","Crystal structure of human CD45 extracellular region, domains d1-d4","ETGKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPPQRSFHNFTLCYIKETEKDCLNLDKNLIKYDLQNLKPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKSAPPSQVWNMTVSMTSDNSMHVKCRPPRDRNGPHERYHLEVEAGNTLVRNESHKNCDFRVKDLQYSTDYTFKAYFHNGDYPGEPFILHHSTSGTKHHHHHH","Homo sapiens","PTPRC, CD45","RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE C","1","5FMV"
"5FMW","6.7","ELECTRON MICROSCOPY",,,,,,,"10.1038/ncomms10588",,"5FMW",1266.82,"6.7, 6.7",,"The poly-C9 component of the Complement Membrane Attack Complex","SHIDCRMSPWSEWSQCDPCLRQMFRSRSIEVFGQFNGKRCTDAVGDRRQCVPTEPCEDAEDDCGNDFQCSTGRCIKMRLRCNGDNDCGDFSDEDDCESEPRPPCRDRVVEESELARTAGYGINILGMDPLSTPFDNEFYNGLCNRDRDGNTLTYYRRPWNVASLIYETKGEKNFRTEHYEEQIEAFKSIIQEKTSNFNAAISLKFTPTETNKAEQCCEETASSISLHGKGSFRFSYSKNETYQLFLSYSSKKEKMFLHVKGEIHLGRFVMRNRDVVLTTTFVDDIKALPTTYEKGEYFAFLETYGTHYSSSGSLGGLYELIYVLDKASMKRKGVELKDIKRCLGYHLDVSLAFSEISVGAEFNKDDCVKRGEGRAVNITSENLIDDVVSLIRGGTRKYAFELKEKLLRGTVIDVTDFVNWASSINDAPVLISQKLSPIYNLVPVKMKNAHLKKQNLERAIEDYINEFSVRKCHTCQNGGTVILMDGKCLCACPFKFEGIACEISKQ","Homo sapiens","C9","POLYC9","1","5FMW"
"5FN6",,"X-RAY DIFFRACTION",3.39,64,,6.5,"30% PEG8K, 0.2M (NH4)2SO4, 0.1M NA CACODYLATE, PH=6.5",,"10.1038/ni.3392",,"5FN6",32.08,"3.3","3.3","Crystal structure of human CD45 extracellular region, domains d1-d3","ETGKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEPQIIFCRSEAAHQGVITWNPPQRSFHNFTLCYIKETEKDCLNLDKNLIKYDLQNLKPYTKYVLSLHAYIIAKVQRNGSAAMCHFTTKGTKHHHHHH","Homo sapiens","PTPRC, CD45","RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE C","1","5FN6"
"5FN7",,"X-RAY DIFFRACTION",4.26,71,,8,"0.1M TRIS, PH=8, 2.4M (NH4)2SO4, 6% ETHYLENE GLYCOL",,"10.1038/ni.3392",,"5FN7",44.99,"2.3","2.3","Crystal structure of human CD45 extracellular region, domains d1-d2","ETGIEGRKPTCDEKYANITVDYLYNKETKLFTAKLNVNENVECGNNTCTNNEVHNLTECKNASVSISHNSCTAPDKTLILDVPPGVEKFQLHDCTQVEKADTTICLKWKNIETFTCDTQNITYRFQCGNMIFDNKEIKLENLEPEHEYKCDSEILYNNHKFTNASKIIKTDFGSPGEGTKHHHHHH","Homo sapiens","PTPRC, CD45","RECEPTOR-TYPE TYROSINE-PROTEIN PHOSPHATASE C","1","5FN7"
"5FNA","4.8","ELECTRON MICROSCOPY",,,,,,,"10.1038/nsmb.3199",,"5FNA",76.72,"4.8, 4.8",,"Cryo-EM reconstruction of caspase-1 CARD","ADKVLKEKRKLFIRSMGEGTINGLLDELLQTRVLNKEEMEKVKRENATVMDKTRALIDSVIPKGAQACQICITYICEEDSYLAGT","Homo sapiens","CASP1, IL1BC, IL1BCE","Caspase-1","1","5FNA"
"5FNC",,"X-RAY DIFFRACTION",2.79,55.91,,6.5,"pH 6.5",,"10.1038/nchem.2660","IEE","5FNC",27.14,"2.2","2.2","Dynamic Undocking and the Quasi-Bound State as tools for Drug Design","MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","HEAT SHOCK PROTEIN, HSP90-ALPHA","1","5FNC"
"5FND",,"X-RAY DIFFRACTION",2.67,53.99,,6.5,"pH 6.5",,"10.1038/nchem.2660","IQ5","5FND",27.02,"2","2","Dynamic Undocking and the Quasi-Bound State as tools for Drug Design","MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","HEAT SHOCK PROTEIN, HSP90-ALPHA","1","5FND"
"5FNF",,"X-RAY DIFFRACTION",2.77,55.59,,6.5,"pH 6.5",,"10.1038/nchem.2660","TQL","5FNF",27.02,"2.1","2.1","Dynamic Undocking and the Quasi-Bound State as tools for Drug Design","MPEETQTQDQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","HEAT SHOCK PROTEIN, HSP90-ALPHA","1","5FNF"
"5FNG",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","YIE","5FNG",29.55,"2.05","2.05","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNG"
"5FNH",,"X-RAY DIFFRACTION",2.1,41.8,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940",,"5FNH",30.04,"1.66","1.66","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNH"
"5FNI",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","YIH","5FNI",29.77,"1.6","1.6","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNI"
"5FNJ",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","CL, YI6","5FNJ",30.01,"1.67","1.67","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNJ"
"5FNK",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","5OO","5FNK",29.76,"1.59","1.59","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNK"
"5FNL",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","5ON","5FNL",29.84,"1.59","1.59","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNL"
"5FNM",,"X-RAY DIFFRACTION",2.1,41.4,"VAPOR DIFFUSION, SITTING DROP",8.5,"15 MG/ML PROTEIN WITH 2.7 M AMMONIUM SULFATE, 100 MM TRIS PH 8.5 AT 8 C IN SITTING DROPS.",,"10.1021/acs.jmedchem.5b01940","5O6","5FNM",29.55,"1.59","1.59","Native state mass spectrometry, surface plasmon resonance and X-ray crystallography correlate strongly as a fragment screening combination","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5FNM"
"5FO2",,"X-RAY DIFFRACTION",2.18,43.63,,7.5,"0.1M HEPES PH 7.5, 28% PEG400, 0.2M CACL2",,"10.1038/srep44709",,"5FO2",27.64,"1.449","1.449","Structure of human transthyretin mutant A108I","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIIALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5FO2"
"5FO7",,"X-RAY DIFFRACTION",3.44,64.3,,,"8% PEG 3350 35MM BIS-TRIS PH 5.5",,"10.15252/embj.201593673",,"5FO7",175.91,"2.8","2.8","Crystal Structure of Human Complement C3b at 2.8 Angstrom resolution","SPMYSIITPNILRLESEETMVLEAHDAQGDVPVTVTVHDFPGKKLVLSSEKTVLTPATNHMGNVTFTIPANREFKSEKGRNKFVTVQATFGTQVVEKVVLVSLQSGYLFIQTDKTIYTPGSTVLYRIFTVNHKLLPVGRTVMVNIENPEGIPVKQDSLSSQNQLGVLPLSWDIPELVNMGQWKIRAYYENSPQQVFSTEFEVKEYVLPSFEVIVEPTEKFYYIYNEKGLEVTITARFLYGKKVEGTAFVIFGIQDGEQRISLPESLKRIPIEDGSGEVVLSRKVLLDGVQNPRAEDLVGKSLYVSATVILHSGSDMVQAERSGIPIVTSPYQIHFTKTPKYFKPGMPFDLMVFVTNPDGSPAYRVPVAVQGEDTVQSLTQGDGVAKLSINTHPSQKPLSITVRTKKQELSEAEQATRTMQALPYSTVGNSNNYLHLSVLRTELRPGETLNVNFLLRMDRAHEAKIRYYTYLIMNKGRLLKAGRQVREPGQDLVVLPLSITTDFIPSFRLVAYYTLIGASGQREVVADSVWVDVKDSCVGSLVVKSGQSEDRQPVPGQQMTLKIEGDHGARVVLVAVDKGVFVLNKKNKLTQSKIWDVVEKADIGCTPGSGKDYAGVFSDAGLTFTSSSGQQTAQRAELQCPQPAA","Homo sapiens","C3, CPAMD1","COMPLEMENT C3 BETA CHAIN","1","5FO7"
,,,,,,,,,,,,,,,,"SNLDEDIIAEENIVSRSEFPESWLWNVEDLKEPPKNGISTKLMNIFLKDSITTWEILAVSMSDKKGICVADPFEVTVMQDFFIDLRLPYSVVRNEQVEIRAVLYNYRQNQELKVRVELLHNPAFCSLATTKRRHQQTVTIPPKSSLSVPYVIVPLKTGLQEVEVKAAVYHHFISDGVRKSLKVVPEGIRMNKTVAVRTLDPERLGREGVQKEDIPPADLSDQVPDTESETRILLQGTPVAQMTEDAVDAERLKHLIVTPSGCGEENMIGMTPTVIAVHYLDETEQWEKFGLEKRQGALELIKKGYTQQLAFRQPSSAFAAFVKRAPSTWLTAYVVKVFSLAVNLIAIDSQVLCGAVKWLILEKQKPDGVFQEDAPVIHQEMIGGLRNNNEKDMALTAFVLISLQEAKDICEEQVNSLPGSITKAGDFLEANYMNLQRSYTVAIAGYALAQMGRLKGPLLNKFLTTAKDKNRWEDPGKQLYNVEATSYALLALLQLKDFDFVPPVVRWLNEQRYYGGGYGSTQATFMVFQALAQYQKDAPDHQELNLDVSLQLPSRSSKITHRIHWESASLLRSEETKENEGFTVTAEGKGQGTLSVVTMYHAKAKDQLTCNKFDLKVTIKPAPETEKRPQDAKNTMILEICTRYRGDQDATMSILDISMMTGFAPDTDDLKQLANGVDRYISKYELDKAFSDRNTLIIYLDKVSHSEDDCLAFKVHQYFNVELIQPGAVKVYAYYNLEESCTRFYHPEKEDGKLNKLCRDELCRCAEENCFIQKSDDKVTLEERLDKACEPGVDYVYKTRLVKVQLSNDFDEYIMAIEQTIKSGSDEVQVGQQRTFISPIKCREALKLEEKKHYLMWGLSSDFWGEKPNLSYIIGKDTWVEHWPEEDECQDEENQKQCQDLGAFTESMVVFGCPN","Homo sapiens","C3, CPAMD1","COMPLEMENT C3B ALPHA' CHAIN","2","5FO7"
"5FOR",,"X-RAY DIFFRACTION",3.6,66,,,"0.1 M MES PH 6.5 1-10% PEG400 1.5-2.3 M AMMONIUM SULPHATE .001M I3C",,"10.1074/jbc.M116.761528",,"5FOR",16.82,"2.5","2.5","Cryptic TIR","SNAPRGCDILIVYSPDAEEWCQYLQTLFLSSRQVRSQKILTHRLGPEASFSAEDLSLFLSTRCVVVLLSAELVQHFHKPSLLPLLQRAFHPPHRVVRLLCGVRDSEEFLDFFPDWAHWQELTCDDEPETYVAAVKKAIS","Homo sapiens","PIK3AP1, BCAP","PHOSPHOINOSITIDE 3-KINASE ADAPTER PROTEIN 1","1","5FOR"
"5FP0",,"X-RAY DIFFRACTION",2.44,49.57,,,,,"10.1002/cmdc.201500575","SZC","5FP0",62.49,"2.35","2.35","ligand complex structure of soluble epoxide hydrolase","GMTLRAAVFDLDGVLALPAVFGVLGRTEEALALPRGLLNDAFQKGGPEGATTRLMKGEITLSQWIPLMEENCRKCSETAKVCLPKNFSIKEIFDKAISARKINRPMLQAALMLRKKGFTTAILTNTWLDDRAERDGLAQLMCELKMHFDFLIESCQVGMVKPEPQIYKFLLDTLKASPSEVVFLDDIGANLKPARDLGMVTILVQDTDTALKELEKVTGIQLLNTPAPLPTSCNPSDMSHGYVTVKPRVRLHFVELGSGPAVCLCHGFPESWYSWRYQIPALAQAGYRVLAMDMKGYGESSAPPEIEEYCMEVLCKEMVTFLDKLGLSQAVFIGHDWGGMLVWYMALFYPERVRAVASLNTPFIPANPNMSPLESIKANPVFDYQLYFQEPGVAEAELEQNLSRTFKSLFRASDESVLSMHKVCEAGGLFVNSPEEPSLSRMVTEEEIQFYVQQFKKSGFRGPLNWYRNMERNWKWACKSLGRKILIPALMVTAEKDFVLVPQMSQHMEDWIPHLKRGHIEDCGHWTQMDKPTEVNQILIKWLDSDARN","Homo sapiens","EPHX2","BIFUNCTIONAL EPOXIDE HYDROLASE 2","1","5FP0"
"5FP3",,"X-RAY DIFFRACTION",2.29,46.3,,8,"0.1M TRIS HCL, BICINE PH 8.5, 37.5% MPD, PEG1K, PEG3350, 0.03M MGCL2, 0.03M CACL2",,"10.1021/acs.jmedchem.5b01537","YC8","5FP3",117.67,"2.05","2.05","Cell penetrant inhibitors of the JMJD2 (KDM4) and JARID1 (KDM5) families of histone lysine demethylases","MDVVRASRNAKVKGKFRESYLSPAQSVKPKINTEEKLPREKLNPPTPSIYLESKRDAFSPVLLQFCTDPRNPITVIRGLAGSLRLNLGLFSTKTLVEASGEHTVEVRTQVQQPSDENWDLTGTRQIWPCESSRSHTTIAKYAQYQASSFQESLQEEKESEDEESEEPDSTTGTPPSSAPDPKNHHIIKFGTNIDLSDAKRWKPQLQELLKLPAFMRVTSTGNMLSHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFAVHEHYWETISAFCDRHGVDYLTGSWWPILDDLYASNIPVYRFVQRPGDLVWINAGTVHWVQATGWCNNIAWNVGPLTAYQYQLALERYEWNEVKNVKSIVPMIHVSWNVARTVKISDPDLFKMIKFCLLQSMKHCQVQRESLVRAGKKIAYQGRVKDEPAYYCNECDVEVFNILFVTSENGSRNTYLVHCEGCARRRSAGLQGVVVLEQYRTEELAQAYDAFTLAPASTSRHHHHHH","Homo sapiens","KDM6B, JMJD3, KIAA0346","HUMAN LYSINE-SPECIFIC DEMETHYLASE 6B, JMJD3","1","5FP3"
"5FP4",,"X-RAY DIFFRACTION",2.49,50.62,,7.4,"0.1M HEPES PH 7.4, 2.2M (NH4)2 SO4",,"10.1021/acs.jmedchem.5b01537","YC8","5FP4",39.89,"2","2","Crystal structure of human KDM4D in complex with 3-(4- phenylbutanamido)pyridine-4-carboxylic acid","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","LYSINE-SPECIFIC DEMETHYLASE 4D","1","5FP4"
"5FP5",,"X-RAY DIFFRACTION",2.35,47,,7.4,"10MM HEPES/NAOH PH7.4 15MM NACL PROTEIN CONCENTRATION: 8.6 MG/ML",,"10.1073/pnas.1518946112",,"5FP5",34.3,"2.16","2.16","Structure of cyclin-dependent kinase 2 with small-molecule ligand 4- fluorobenzoic acid (AT222) in an alternate binding site.","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5FP5"
"5FP6",,"X-RAY DIFFRACTION",2.25,45,,7.4,"PROTEIN CONCENTRATION: 13.6 MG/ML, pH 7.4",,"10.1073/pnas.1518946112",,"5FP6",34.46,"1.85","1.85","Structure of cyclin-dependent kinase 2 with small-molecule ligand 3-(4,7-dichloro-1H-indol-3-yl)prop-2-yn-1-ol (AT17833) in an alternate binding site.","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","CYCLIN-DEPENDENT KINASE 2","1","5FP6"
"5FP7",,"X-RAY DIFFRACTION",2.49,50.62,,7.4,"100MM HEPES PH 7.4, 2.3M AMMONIUM SULPHATE",,"10.1021/acs.jmedchem.5b01538","YC8","5FP7",39.89,"2","2","Crystal structure of human KDM4D in complex with 3-4-methylthiophen-2- yl methylaminopyridine-4-carboxylic acid","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","LYSINE-SPECIFIC DEMETHYLASE 4D","1","5FP7"
"5FP8",,"X-RAY DIFFRACTION",2.49,50.6,,7.4,"100MM HEPES PH 7.4, 2.45M AMMONIUM SULPHATE",,"10.1021/acs.jmedchem.5b01537",,"5FP8",39.58,"1.98","1.98","Crystal structure of human KDM4D in complex with 3-4-methylthiophen-2- ylmethylaminopyridine-4-carboxylic acid","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","LYSINE-SPECIFIC DEMETHYLASE 4D","1","5FP8"
"5FP9",,"X-RAY DIFFRACTION",2.49,50.51,,7.4,"0.1M HEPES, PH 7.4, 2.2M AMSO4",,"10.1021/acs.jmedchem.5b01537","4SV","5FP9",39.58,"2","2","Crystal structure of human KDM4D in complex with 3-aminopyridine-4- carboxylic acid","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","HUMAN LYSINE-SPECIFIC DEMETHYLASE 4D JMJC DOMAIN-CONTAINING HISTONE DEMETHYLATION PROTEIN 3D, JUMONJI DOMAIN-CONTAINING PROTEIN 2D, JMJD2D","1","5FP9"
"5FPA",,"X-RAY DIFFRACTION",2.49,50.69,,7.4,"0.1M HEPES, PH 7.4, 2.2M AMSO4",,"10.1021/acs.jmedchem.5b01537",,"5FPA",39.49,"1.96","1.96","Crystal structure of human KDM4D in complex with 3H,4H-pyrido-3,4-d- pyrimidin-4-one","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","LYSINE-SPECIFIC DEMETHYLASE 4D","1","5FPA"
"5FPB",,"X-RAY DIFFRACTION",2.48,50.37,,7.4,"0.1M HEPES PH 7.4, 2.45M AMMONIUM SULPHATE",,"10.1021/acs.jmedchem.5b01537",,"5FPB",39.56,"1.91","1.91","Crystal structure of human KDM4D in complex with 2-1H-pyrazol-4-yloxy- 3H,4H-pyrido-3,4-d-pyrimidin-4-one","GHMAQNPNCNIMIFHPTKEEFNDFDKYIAYMESQGAHRAGLAKIIPPKEWKARETYDNISEILIATPLQQVASGRAGVFTQYHKKKKAMTVGEYRHLANSKKYQTPPHQNFEDLERKYWKNRIYNSPIYGADISGSLFDENTKQWNLGHLGTIQDLLEKECGVVIEGVNTPYLYFGMWKTTFAWHTEDMDLYSINYLHLGEPKTWYVVPPEHGQRLERLARELFPGSSRGCGAFLRHKVALISPTVLKENGIPFNRITQEAGEFMVTFPYGYHAGFNHGFNCAEAINFATPRWIDYGKMASQCSCGEARVTFSMDAFVRILQPERYDLWKRGQD","Homo sapiens","KDM4D, JHDM3D, JMJD2D","LYSINE-SPECIFIC DEMETHYLASE 4D","1","5FPB"
"5FPD",,"X-RAY DIFFRACTION",2.31,46.3,,8,"1.0M NACL, 0.1M TRIS/HCL PH=8, 20.0% W/V PEG 8000. PROTEIN CONC. = 9MG/ML.",,"10.1073/pnas.1518946112",,"5FPD",85.01,"1.97","1.97","Structure of heat shock-related 70kDA protein 2 with small-molecule ligand pyrazine-2-carboxamide (AT513) in an alternate binding site.","GSHMRGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTIFDAKRLIGRKFEDATVQSDMKHWPFRVVSEGGKPKVQVEYKGETKTFFPEEISSMVLTKMKEIAEAYLGGKVHSAVITVPAYFNDSQRQATKDAGTITGLNVLRIINEPTAAAIAYGLDKKGCAGGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVSHLAEEFKRKHKKDIGPNKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGVDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILIGD","Homo sapiens","HSPA2","HEAT SHOCK-RELATED 70KDA PROTEIN 2","1","5FPD"
"5FPE",,"X-RAY DIFFRACTION",2.3,46.14,,8,"1.0M NACL, 0.1M TRIS/HCL PH=8, 20.0% W/V PEG 8000. PROTEIN CONC. = 11MG/ML.",,"10.1073/pnas.1518946112",,"5FPE",85.1,"1.96","1.96","Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 1H-1,2,4-triazol-3-amine (AT485) in an alternate binding site.","GSHMRGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTIFDAKRLIGRKFEDATVQSDMKHWPFRVVSEGGKPKVQVEYKGETKTFFPEEISSMVLTKMKEIAEAYLGGKVHSAVITVPAYFNDSQRQATKDAGTITGLNVLRIINEPTAAAIAYGLDKKGCAGGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVSHLAEEFKRKHKKDIGPNKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGVDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILIGD","Homo sapiens","HSPA2","HEAT SHOCK-RELATED 70KDA PROTEIN 2","1","5FPE"
"5FPF",,"X-RAY DIFFRACTION",2.16,43,,8.5,"0.1M BICINE PH 9.0, 16% PEG6000",,,"5ZI","5FPF",55.43,"2.6","2.6","Crystal structure of human tankyrase 2 in complex with TA-91","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAM","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5FPF"
,,,,,,,,,,,,,,,,"MAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","2","5FPF"
"5FPG",,"X-RAY DIFFRACTION",2.2,44,,9,"0.1M BICINE PH 9.0, 16% PEG6000",,,"Q28","5FPG",55.69,"2.75","2.75","Crystal structure of human tankyrase 2 in complex with TA-92","MHHHHHHSSGVDLGTENLYFQSMLNTSGSGTILIDLSPDDKEFQSVEEEMQSTVREHRDGGHAGGIFNRYNILKIQKVCNKKLWERYTHRRKEVSEENHNHANERMLFHGSPFVNAIIHKGFDERHAYIGGMFGAGIYFAENSSKSNQYVYGIGGGTGCPVHKDRSCYICHRQLLFCRVTLGKSFLQFSAMKMAHSPPGHHSVTGRPSVNGLALAEYVIYRGEQAYPEYLITYQIMRPEG","Homo sapiens","TNKS2, PARP5B, TANK2, TNKL","TANKYRASE-2","1","5FPG"
"5FPL",,"X-RAY DIFFRACTION",4.05,69.65,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1021/acs.jmedchem.5b01635",,"5FPL",56,"2.35","2.35","Crystal structure of human JARID1B in complex with CCT363901","MFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPKLFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FPL"
"5FPM",,"X-RAY DIFFRACTION",2.3,46.14,,8,"1.0M NACL, 0.1M TRIS/HCL PH=8, 20.0% W/V PEG 8000. PROTEIN CONC. = 11MG/ML.",,"10.1073/pnas.1518946112",,"5FPM",85.12,"1.96","1.96","Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 5-phenyl-1,3,4-oxadiazole-2-thiol (AT809) in an alternate binding site.","GSHMRGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTIFDAKRLIGRKFEDATVQSDMKHWPFRVVSEGGKPKVQVEYKGETKTFFPEEISSMVLTKMKEIAEAYLGGKVHSAVITVPAYFNDSQRQATKDAGTITGLNVLRIINEPTAAAIAYGLDKKGCAGGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVSHLAEEFKRKHKKDIGPNKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGVDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILIGD","Homo sapiens","HSPA2","HEAT SHOCK-RELATED 70KDA PROTEIN 2","1","5FPM"
"5FPN",,"X-RAY DIFFRACTION",2.3,46,,8,"1.0M NACL, 0.1M TRIS/HCL PH=8, 20.0% W/V PEG 8000. PROTEIN CONC. = 11 MG/ML.",,"10.1073/pnas.1518946112",,"5FPN",141.03,"1.96","1.96","Structure of heat shock-related 70kDA protein 2 with small-molecule ligand 3,5-dimethyl-1H-pyrazole-4-carboxylic acid (AT9084) in an alternate binding site.","GSHMRGPAIGIDLGTTYSCVGVFQHGKVEIIANDQGNRTTPSYVAFTDTERLIGDAAKNQVAMNPTNTIFDAKRLIGRKFEDATVQSDMKHWPFRVVSEGGKPKVQVEYKGETKTFFPEEISSMVLTKMKEIAEAYLGGKVHSAVITVPAYFNDSQRQATKDAGTITGLNVLRIINEPTAAAIAYGLDKKGCAGGEKNVLIFDLGGGTFDVSILTIEDGIFEVKSTAGDTHLGGEDFDNRMVSHLAEEFKRKHKKDIGPNKRAVRRLRTACERAKRTLSSSTQASIEIDSLYEGVDFYTSITRARFEELNADLFRGTLEPVEKALRDAKLDKGQIQEIVLVGGSTRIPKIQKLLQDFFNGKELNKSINPDEAVAYGAAVQAAILIGDKSENVQDLLLLDVTPLSLGIETAGGVMTPLIKRNTTIPTKQTQTFTTYSDNQSSVLVQVYEGERAMTKDNNLLGKFDLTGIPPAPRGVPQIEVTFDIDANGILNVTAADKSTGKENKITITNDKGRLSKDDIDRMVQEAERYKSEDEANRDRVAAKNALESYTYNIKQTVEDEKLRGKISEQDKNKILDKCQEVINWLDRNQMAEKDEYEHKQKELERVCNPIISKLYQGGPGGGSGGGGSGASGGPTIEEVD","Homo sapiens","HSPA2","HEAT SHOCK-RELATED 70 KDA PROTEIN 2","1","5FPN"
"5FPQ",,"X-RAY DIFFRACTION",4.31,71.44,,7,"PH 7",,"10.1073/pnas.1523362113",,"5FPQ",119.37,"2.4","2.4","Structure of Homo sapiens acetylcholinesterase phosphonylated by sarin.","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","ACETYLCHOLINESTERASE","1","5FPQ"
"5FPU",,"X-RAY DIFFRACTION",3.98,69.12,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","K0I","5FPU",56.83,"2.24","2.24","Crystal structure of human JARID1B in complex with GSKJ1","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FPU"
"5FPV",,"X-RAY DIFFRACTION",2.6,52.75,,5.9,"0.1M BIS-TRIS PH 5.9, 0.15M AMMONIUM SULFATE, 11% PEG3350",,"10.1038/nchembio.2087",,"5FPV",339.13,"2.44","2.44","Crystal structure of human JMJD2A in complex with compound KDOAM20A","SMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5FPV"
"5FQL",,"X-RAY DIFFRACTION",3.5,65,,6.1,"0.1 M MES PH=6.1 1.0 M LICL 20% PEG6K",,"10.1038/ncomms15786",,"5FQL",62.58,"2.3","2.3","Insights into Hunter syndrome from the structure of iduronate-2- sulfatase","SETQANSTTDALNVLLIIVDDLRPSLGCYGDKLVRSPNIDQLASHSLLFQNAFAQQAVAAPSRVSFLTGRRPDTTRLYDFNSYWRVHAGNFSTIPQYFKENGYVTMSVGKVFHPGISSNHTDDSPYSWSFPPYHPSSEKYENTKTCRGPDGELHANLLCPVDVLDVPEGTLPDKQSTEQAIQLLEKMKTSASPFFLAVGYHKPHIPFRYPKEFQKLYPLENITLAPDPEVPDGLPPVAYNPWMDIRQREDVQALNISVPYGPIPVDFQRKIRQSYFASVSYLDTQVGRLLSALDDLQLANSTIIAFTSDHGWALGEHGEWAKYSNFDVATHVPLIFYVPGRTASLPEAGEKLFPYLDPFDSASQLMEPGRQSMDLVELVSLFPTLAGLAGLQVPPRCPVPSFHVELCREGKNLLKHFRFRDLEEDPYLPGNPRELIAYSQYPRPSDIPQWNSDKPSLKDIKIMGYSIRTIDYRYTVWVGFNPDEFLANFSDIHAGELYFVDSDPLQDHNMYNDSQGGDLFQLLMP","Homo sapiens","IDS, SIDS","IDURONATE-2-SULFATASE","1","5FQL"
"5FQP",,"X-RAY DIFFRACTION",2.07,40.5,,,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acsmedchemlett.5b00413","GQD","5FQP",28.62,"1.88","1.88","Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 1.","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR ALPHA","1","5FQP"
"5FQR",,"X-RAY DIFFRACTION",2.07,40.5,,,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acsmedchemlett.5b00413","QHG","5FQR",28.59,"1.88","1.88","Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 2.","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKSKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5FQR"
"5FQS",,"X-RAY DIFFRACTION",2.07,40.5,,,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acsmedchemlett.5b00413","J0W","5FQS",28.62,"1.94","1.94","Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 3.","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR","1","5FQS"
"5FQT",,"X-RAY DIFFRACTION",2.07,40.5,,,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acsmedchemlett.5b00413","7QN","5FQT",28.62,"1.99","1.99","Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 4.","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR ALPHA","1","5FQT"
"5FQV",,"X-RAY DIFFRACTION",2.07,40.5,,,"0.1 M PCTP, PH 6.5 (0.04 M SODIUM PROPIONATE, 0.02 M SODIUM CACODYLATE, 0.04 M BIS-TRIS PROPANE), 22% PEG3350, 0.2M MGCL2",,"10.1021/acsmedchemlett.5b00413","VQI","5FQV",28.62,"1.74","1.74","Selective estrogen receptor downregulator antagonists: Tetrahydroisoquinoline phenols 5.","ALSLTADQMVSALLDAEPPILYSEYDPTRPFSEASMMGLLTNLADRELVHMINWAKRVPGFVDLTLHDQVHLLESAWLEILMIGLVWRSMEHPGKLLFAPNLLLDRNQGKSVEGMVEIFDMLLATSSRFRMMNLQGEEFVCLKSIILLNSGVYTFLSSTLKSLEEKDHIHRVLDKITDTLIHLMAKAGLTLQQQHQRLAQLLLILSHIRHMSNKGMEHLYSMKCKNVVPSYDLLLEMLDAHRLHAPTS","Homo sapiens","ESR1, ESR, NR3A1","ESTROGEN RECEPTOR ALPHA","1","5FQV"
"5FR6",,"X-RAY DIFFRACTION",2.95,58.29,,6.5,"100MM MES, PH 6.5, 50MM MGCL2, 7% ISOPROPANOL, 6% PEG 4000",,"10.1038/ncomms13343",,"5FR6",14.1,"2.51","2.51","The structure of polycomb ULD complex","DKRIITDDEIISLSIEFFDQNRLDRKVNKDKEKSKEEVNDKRYLRCPAAMTVMHLRKFLRSKMDIPNTFQIDVMYEEEPLKDYYTLMDIAYIYTWRRNGPLPLKYRVRPTCKRMK","Homo sapiens","BMI1, PCGF4, RNF51","POLYCOMB COMPLEX PROTEIN BMI-1","1","5FR6"
"5FRI",,"X-RAY DIFFRACTION",2.08,40.99,"VAPOR DIFFUSION, SITTING DROP",,"SITTING DROP METHOD. DROPS PROTEIN-PRECIPITANT 1-1, PROTEIN: 10MG/ML ALK5, PRECIPITANT: 20-30% PEG8K, 100 MM PCTP BUFFER PH 8.5-9.2, 0.2 M NAAC",,,,"5FRI",34.84,"2","2","ALK5 in complex witha an N-(4-anilino-2-pyridyl)acetamide inhibitor.","GGTIARTIVLQESIGKGRFGEVWRGKWRGEEVAVKIFSSREERSWFREAEIYQTVMLRHENILGFIAADNKDNGTWTQLWLVSDYHEHGSLFDYLNRYTVTVEGMIKLALSTASGLAHLHMEIVGTQGKPAIAHRDLKSKNILVKKNGTCCIADLGLAVRHDSATDTIDIAPNHRVGTKRYMAPEVLDDSINMKHFESFKRADIYAMGLVFWEIARRCSIGGIHEDYQLPYYDLVPSDPSVEEMRKVVCEQKLRPNIPNRWQSCEALRVMAKIMRECWYANGAARLTALRIKKTLSQLSQQ","Homo sapiens","TGFBR1, ALK5, SKR4","TGF-BETA RECEPTOR TYPE-1","1","5FRI"
"5FS6",,"X-RAY DIFFRACTION",2.81,56.3,,7.5,"0.2 M AMMONIUM ACETATE, 0.1M HEPES, PH 7.5, AND 20% POLY-ETHYLENE GLYCOL 3350",,"10.1016/j.jmb.2016.05.004",,"5FS6",114.32,"1.9","1.9","Crystal structure of the V243L mutant of human apoptosis inducing factor","GLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMLKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLVPR","Homo sapiens","AIFM1, AIF, PDCD8","APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL","1","5FS6"
"5FS7",,"X-RAY DIFFRACTION",2.82,56.5,,8.5,"0.2 M LITHIUM SULFATE, 0.1M TRIS, PH 8.5, AND 25% POLY-ETHYLENE GLYCOL 3350",,"10.1016/j.jmb.2016.05.004",,"5FS7",114.11,"1.85","1.85","Crystal structure of the G262S mutant of human apoptosis inducing factor","GLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGSTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLVPR","Homo sapiens","AIFM1, AIF, PDCD8","APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL","1","5FS7"
"5FS8",,"X-RAY DIFFRACTION",2.45,49.75,,7.5,"0.2 M AMMONIUM ACETATE AND 20% POLY-ETHYLENE GLYCOL, pH 7.5",,"10.1016/j.jmb.2016.05.004",,"5FS8",57.12,"1.4","1.4","Crystal structure of the G308E mutant of human apoptosis inducing factor","GLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGEGFLGSELACALGRKARALGTEVIQLFPEKGNMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESRASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLVPR","Homo sapiens","AIFM1, AIF, PDCD8","APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL","1","5FS8"
"5FS9",,"X-RAY DIFFRACTION",2.83,56.58,,8.5,"0.2 M LITHIUM SULFATE, 0.1M TRIS, PH 8.5, AND 25% POLY-ETHYLENE GLYCOL 3350",,"10.1016/j.jmb.2016.05.004",,"5FS9",114.38,"1.75","1.75","Crystal structure of the G338E mutant of human apoptosis inducing factor","GLTPEQKQKKAALSASEGEEVPQDKAPSHVPFLLIGGGTAAFAAARSIRARDPGARVLIVSEDPELPYMRPPLSKELWFSDDPNVTKTLRFKQWNGKERSIYFQPPSFYVSAQDLPHIENGGVAVLTGKKVVQLDVRDNMVKLNDGSQITYEKCLIATGGTPRSLSAIDRAGAEVKSRTTLFRKIGDFRSLEKISREVKSITIIGGGFLGSELACALGRKARALGTEVIQLFPEKENMGKILPEYLSNWTMEKVRREGVKVMPNAIVQSVGVSSGKLLIKLKDGRKVETDHIVAAVGLEPNVELAKTGGLEIDSDFGGFRVNAELQARSNIWVAGDAACFYDIKLGRRRVEHHDHAVVSGRLAGENMTGAAKPYWHQSMFWSDLGPDVGYEAIGLVDSSLPTVGVFAKATAQDNPKSATEQSGTGIRSESETESEASEITIPPSTPAVPQAPVQGEDYGKGVIFYLRDKVVVGIVLWNIFNRMPIARKIIKDGEQHEDLNEVAKLFNIHEDLVPR","Homo sapiens","AIFM1, AIF, PDCD8","APOPTOSIS-INDUCING FACTOR 1, MITOCHONDRIAL","1","5FS9"
"5FSI",,"X-RAY DIFFRACTION",2.01,38.74,,,"25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5",,"10.1371/journal.pone.0151154",,"5FSI",18.49,"1.63","1.63","MTH1 substrate recognition: Complex with 8-oxo-dGTP.","MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSI"
"5FSK",,"X-RAY DIFFRACTION",1.98,37.75,,,,,"10.1371/journal.pone.0151154",,"5FSK",18.84,"1.56","1.56","MTH1 substrate recognition: Complex with 8-oxo-dGTP.","GSHMGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSK"
"5FSL",,"X-RAY DIFFRACTION",2.01,38.74,,,"25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5",,"10.1371/journal.pone.0151154","UAN","5FSL",18.25,"1.24","1.24","MTH1 substrate recognition: Complex with a methylaminopurinone","MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSL"
"5FSM",,"X-RAY DIFFRACTION",2.01,38.74,,,"25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5",,"10.1371/journal.pone.0151154","N91","5FSM",18.45,"1.67","1.67","MTH1 substrate recognition: Complex with a methylbenzimidazolyl acetamide.","MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSM"
"5FSN",,"X-RAY DIFFRACTION",2.01,38.93,,,"25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5",,"10.1371/journal.pone.0151154","6Q3","5FSN",18.29,"1.69","1.69","MTH1 substrate recognition: Complex with a aminomethylpyrimidinyl oxypropanol.","MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSN"
"5FSO",,"X-RAY DIFFRACTION",2.01,38.77,,,"25% (W/V) PEG3350 200MM LITHIUM SULPHATE 100MM SODIUM ACETATE PH4.5",,"10.1371/journal.pone.0151154","S76","5FSO",18.33,"1.67","1.67","MTH1 substrate recognition: Complex with a methylaminopyrimidinedione.","MGASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-DIHYDRO-8-OXOGUANINE TRIPHOSPHATASE","1","5FSO"
"5FTA",,"X-RAY DIFFRACTION",2.33,47,,8.4,"20% PEG3350, 0.1M TRIS PH 8.4, 0.2M MAGNESIUM CHLORIDE",,"10.1042/BCJ20170527",,"5FTA",51.2,"2.64","2.64","Crystal structure of the N-terminal BTB domain of human KCTD10","SMGTSPSSKYVKLNVGGALYYTTMQTLTKQDTMLKAMLSGRMEVLTDSEGWILIDRCGKHFGTILNYLRDGAVPLPESRREIEELLAEAKYYLVQGLVEECQAALQNKDTYE","Homo sapiens","KCTD10, ULR061, MSTP028","BTB/POZ DOMAIN-CONTAINING ADAPTER FOR CUL3-MEDIATED RHOA DEGRADATION PROTEIN 3","1","5FTA"
"5FTG",,"X-RAY DIFFRACTION",2.28,46.03,,7.5,"pH 7.5",,"10.1038/srep23793","NBR","5FTG",45.57,"1.45","1.45","Human choline kinase a1 in complex with compound 1-[[4-[2-[4-[[4-(dimethylamino)pyridin-1- yl]methyl]phenoxy]ethoxy]phenyl]methyl]-N,N- dimethyl-pyridin-4-amine (compound 10a)","DEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","CHOLINE KINASE ALPHA","1","5FTG"
"5FTJ","2.3","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aad7974","OJA","5FTJ",544.53,"2.3, 2.3",,"Cryo-EM structure of human p97 bound to UPCDC30245 inhibitor","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE","1","5FTJ"
"5FTK","2.4","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aad7974",,"5FTK",541.75,"2.4, 2.4",,"Cryo-EM structure of human p97 bound to ADP","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE","1","5FTK"
"5FTL","3.3","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aad7974",,"5FTL",541.75,"3.3, 3.3",,"Cryo-EM structure of human p97 bound to ATPgS (Conformation I)","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE","1","5FTL"
"5FTM","3.2","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aad7974",,"5FTM",542.47,"3.2, 3.2",,"Cryo-EM structure of human p97 bound to ATPgS (Conformation II)","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE","1","5FTM"
"5FTN","3.3","ELECTRON MICROSCOPY",,,,,,,"10.1126/science.aad7974",,"5FTN",543.19,"3.3, 3.3",,"Cryo-EM structure of human p97 bound to ATPgS (Conformation III)","MASGADSKGDDLSTAILKQKNRPNRLIVDEAINEDNSVVSLSQPKMDELQLFRGDTVLLKGKKRREAVCIVLSDDTCSDEKIRMNRVVRNNLRVRLGDVISIQPCPDVKYGKRIHVLPIDDTVEGITGNLFEVYLKPYFLEAYRPIRKGDIFLVRGGMRAVEFKVVETDPSPYCIVAPDTVIHCEGEPIKREDEEESLNEVGYDDIGGCRKQLAQIKEMVELPLRHPALFKAIGVKPPRGILLYGPPGTGKTLIARAVANETGAFFFLINGPEIMSKLAGESESNLRKAFEEAEKNAPAIIFIDELDAIAPKREKTHGEVERRIVSQLLTLMDGLKQRAHVIVMAATNRPNSIDPALRRFGRFDREVDIGIPDATGRLEILQIHTKNMKLADDVDLEQVANETHGHVGADLAALCSEAALQAIRKKMDLIDLEDETIDAEVMNSLAVTMDDFRWALSQSNPSALRETVVEVPQVTWEDIGGLEDVKRELQELVQYPVEHPDKFLKFGMTPSKGVLFYGPPGCGKTLLAKAIANECQANFISIKGPELLTMWFGESEANVREIFDKARQAAPCVLFFDELDSIAKARGGNIGDGGGAADRVINQILTEMDGMSTKKNVFIIGATNRPDIIDPAILRPGRLDQLIYIPLPDEKSRVAILKANLRKSPVAKDVDLEFLAKMTNGFSGADLTEICQRACKLAIRESIESEIRRERERQTNPSAMEVEEDDPVPEIRRDHFEEAMRFARRSVSDNDIRKYEMFAQTLQQSRGFGSFRFPSGNQGGAGPSQGSGGGTGGSVYTEDNDDDLYG","Homo sapiens","VCP","TRANSITIONAL ENDOPLASMIC RETICULUM ATPASE","1","5FTN"
"5FTO",,"X-RAY DIFFRACTION",2.3,47,,8.5,"18% PEG3350, 0.1 M TRIS/HCL PH 8.5",,"10.1021/acs.jmedchem.6b00064","YMX","5FTO",35.9,"2.22","2.22","Crystal structure of the ALK kinase domain in complex with Entrectinib","GPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEE","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5FTO"
"5FTQ",,"X-RAY DIFFRACTION",2.28,46,,,"18% PEG3350, 0.1 M TRIS/HCL PH 8.5",,"10.1021/acs.jmedchem.6b00064","U4W","5FTQ",36,"1.7","1.7","Crystal structure of the ALK kinase domain in complex with Cmpd 17","GPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEE","Homo sapiens","ALK","ALK TYROSINE KINASE RECEPTOR","1","5FTQ"
"5FUN",,"X-RAY DIFFRACTION",3.98,70.37,,8,"0.1M HEPES PH 8.0, 0.8M POTASSIUM PHOSPHATE-DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","GZA","5FUN",56.57,"2.3","2.3","Crystal structure of human JARID1B in complex with GSK467","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKINK","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FUN"
"5FUP",,"X-RAY DIFFRACTION",2.01,38.94,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087",,"5FUP",56.43,"2.15","2.15","Crystal structure of human JARID1B in complex with 2-oxoglutarate.","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FUP"
"5FUQ",,"X-RAY DIFFRACTION",2.32,47,,9,"CAPILLARY COUNTERDIFFUSION METHOD: 30% OF PEG 3350, 200 MM SODIUM-ACETATE, 100 MM SODIUM-TRICINE AT PH 9.0",,,,"5FUQ",64.67,"2.04","2.04","CRYSTAL STRUCTURE OF THE H80R VARIANT OF NQO1 BOUND TO DICOUMAROL","MVGRRALIVLAHSERTSFNYAMKEAAAAALKKKGWEVVESDLYAMNFNPIISRKDITGKLKDPANFQYPAESVLAYKEGRLSPDIVAEQKKLEAADLVIFQFPLQWFGVPAILKGWFERVFIGEFAYTYAAMYDKGPFRSKKAVLSITTGGSGSMYSLQGIHGDMNVILWPIQSGILHFCGFQVLEPQLTYSIGHTPADARIQILEGWKKRLENIWDETPLYFAPSSLFDLNFQAGFLMKKEVQDEEKNKKFGLSVGHHLGKSIPTDNQIKARK","Homo sapiens","NQO1, DIA4, NMOR1","NAD(P)H DEHYDROGENASE [QUINONE] 1","1","5FUQ"
"5FUT",,"X-RAY DIFFRACTION",2.33,47.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"HSCKALPHA1 AT 20 MG/ML WAS PREINCUBATED AT ROOM TEMPERATURE WITH 12 MM OF COMPOUND BR25 IN BUFFER 25 MM TRIS/HCL, 150 MM NACL PH 7.5 (DMSO IS AT 5% FINAL CONCENTRATION IN THE MIX). THE SITTING-DROP VAPOUR DIFFUSION METHOD WAS USED TO PRODUCE CRYSTALS BY MIXING 0.5 MICROL OF THE PROTEIN SOLUTION AND AN EQUAL VOLUME OF MOTHER LIQUOR (20% PEG 5000 MME AND 0.2 M KSCN). TETRAGONAL CRYSTALS (SPACE GROUP P43212) GREW WITHIN 2-4 DAYS AND THEN WERE SOAKED FOR ONE DAY WITH 20 MM COMPOUND BR25 SOLVED IN 100% DMSO. THE CRYSTALS USED IN THIS STUDY WERE CRYOPROTECTED IN MOTHER LIQUOR SOLUTIONS CONTAINING 20 % ETHYLENGLYCOL AND FROZEN IN A NITROGEN GAS STREAM COOLED TO 100 K.",,"10.1038/srep33189","PQ7","5FUT",45.53,"1.6","1.6","Human choline kinase a1 in complex with compound 4-(dimethylamino)-1-{4-[4-(4-{[4-(pyrrolidin- 1-yl)pyridinium-1-yl]methyl}phenyl)butyl]benzyl}pyridinium (compound BR25)","DEQPEPRTRRRAYLWCKEFLPGAWRGLREDEFHISVIRGGLSNMLFQCSLPDTTATLGDEPRKVLLRLYGAILQMRSCNKEGSEQAQKENEFQGAEAMVLESVMFAILAERSLGPKLYGIFPQGRLEQFIPSRRLDTEELSLPDISAEIAEKMATFHGMKMPFNKEPKWLFGTMEKYLKEVLRIKFTEESRIKKLHKLLSYNLPLELENLRSLLESTPSPVVFCHNDCQEGNILLLEGRENSEKQKLMLIDFEYSSYNYRGFDIGNHFCEWMYDYSYEKYPFFRANIRKYPTKKQQLHFISSYLPAFQNDFENLSTEEKSIIKEEMLLEVNRFALASHFLWGLWSIVQAKISSIEFGYMDYAQARFDAYFHQKRKLGV","Homo sapiens","CHKA, CHK, CKI","CHOLINE KINASE ALPHA","1","5FUT"
"5FUZ",,"X-RAY DIFFRACTION",3.3,63,,,"2 M DL-MALIC ACID",,"10.1080/19420862.2016.1185581",,"5FUZ",48.32,"2.68","2.68","Extending the half-life of a Fab fragment through generation of a humanised anti-Human Serum Albumin (HSA) Fv domain: an investigation into the correlation between affinity and serum half-life","EVQLLESGGGLVQPGGSLRLSCAVSGIDLSNYAINWVRQAPGKGLEWIGIIWASGTTFYATWAKGRFTISRDNSKNTVYLQMNSLRAEDTAVYYCARTVPGYSTAPYFDLWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH","Homo sapiens",,"645 FAB, HEAVY CHAIN","1","5FUZ"
,,,,,,,,,,,,,,,,"DIQMTQSPSSVSASVGDRVTITCQSSPSVWSNFLSWYQQKPGKAPKLLIYEASKLTSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCGGGYSSISDTTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"645 FAB, LIGHT CHAIN","2","5FUZ"
"5FV3",,"X-RAY DIFFRACTION",2,38.66,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,"10.1038/nchembio.2087","OGA","5FV3",57.06,"2.37","2.37","Crystal structure of human JARID1B construct c2 in complex with N- Oxalylglycine.","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGGFEQAARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FV3"
"5FV7",,"X-RAY DIFFRACTION",,,,7.5,"25% PEG3350, 0.1M MOPS 7.0, 5% 2-PROPANOL, 2% GLYCEROL, pH 7.5",,"10.1038/nchembio.2148","R3Z","5FV7",80.36,"2.84","2.84","Human Fen1 in complex with an N-hydroxyurea compound","MGIQGLAKLIADVAPSAIRENDIKSYFGRKVAIDASMSIYQFLIAVRQGGDVLQNEEGETTSHLMGMFYRTIRMMENGIKPVYVFDGKPPQLKSGELAKRSERRAEAEKQLQQAQAAGAEQEVEKFTKRLVKVTKQHNDECKHLLSLMGIPYLDAPSEAEASCAALVKAGKVYAAATEDMDCLTFGSPVLMRHLTASEAKKLPIQEFHLSRILQELGLNQEQFVDLCILLGSDYCESIRGIGPKRAVDLIQKHKSIEEIVRRLDPNKYPVPENWLHKEAHQLFLEPEVLDPESVELKWSEPNEEELIKFMCGEKQFSEERIRSGVKRLSKSRQGSTLEVLFQGPGGGHHHHHH","Homo sapiens","FEN1, RAD2","FLAP ENDONUCLEASE 1","1","5FV7"
"5FV9",,"X-RAY DIFFRACTION",2.28,46.06,,,,,"10.1002/chem.201600467","Y6W","5FV9",394.57,"2.07","2.07","Crystal structure of GalNAc-T2 in complex with compound 16d","MRRRSRMLLCFAFLWVLGIAYYMYSGGGSALAGGAGGGAGRKEDWNEIDPIKKKDLHHSNGEEKAQSMETLPPGKVRWPDFNQEAYVGGTMVRSGQDPYARNKFNQVESDKLRMDRAIPDTRHDQCQRKQWRVDLPATSVVITFHNEARSALLRTVVSVLKKSPPHLIKEIILVDDYSNDPEDGALLGKIEKVRVLRNDRREGLMRSRVRGADAAQAKVLTFLDSHCECNEHWLEPLLERVAEDRTRVVSPIIDVINMDNFQYVGASADLKGGFDWNLVFKWDYMTPEQRRSRQGNPVAPIKTPMIAGGLFVMDKFYFEELGKYDMMMDVWGGENLEISFRVWQCGGSLEIIPCSRVGHVFRKQHPYTFPGGSGTVFARNTRRAAEVWMDEYKNFYYAAVPSARNVPYGNIQSRLELRKKLSCKPFKWYLENVYPELRVPDHQDIAFGALQQGTNCLDTLGHFADGVVGVYECHNAGGNQEWALTKEKSVKHMDLCLTVVDRAPGSLIKLQGCREDDSRQKWEQIEGNSKLRHVGSNLCLDSRTAKSGGLSVEVCGPALSQQWKFTLNLQQ","Homo sapiens","GALNT2","GALNAC-T2","1","5FV9"
"5FVO",,"X-RAY DIFFRACTION",2.48,50.4,,5.8,"20-24% PEG3350, 0.1M MES 0.14-0.20M AMMONIUM ACETATE, 10% ETHYLENE GLYCOL, 30UM SDS 5 MM GSH, pH 5.8",,"10.1021/acs.jmedchem.6b00273","D8H","5FVO",50.04,"2.12","2.12","Structure of rat neuronal nitric oxide synthase heme domain in complex with 6-(2-(5-(3-methoxypropylamino)pyridin-3-yl)ethyl)-4- methylpyridin-2-amine","CPRFLKVKNWETDVVLTDTLHLKSTLETGCTEHICMGSIMLPSQHTRKPEDVRTKDQLFPLAKEFLDQYYSSIKRFGSKAHMDRLEEVNKEIESTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKAPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFDWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMDLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWKG","Homo sapiens",,"NITRIC OXIDE SYNTHASE, BRAIN","1","5FVO"
"5FVU",,"X-RAY DIFFRACTION",2.74,55.2,,6.2,"8-9% PEG3350 40 MM CITRIC ACID 60 MM BISTRISPROPANE 10% GLYCEROL 5 MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.6b00273","W64","5FVU",100.03,"2.224","2.224","Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(4-methylpiperazin-1-yl)pyridin-3-yl)ethyl) pyridin-2-amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5FVU"
"5FVV",,"X-RAY DIFFRACTION",2.74,50.7,,6.2,"8-9% PEG3350 40 MM CITRIC ACID 60 MM BISTRISPROPANE 10% GLYCEROL 5 MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.6b00273","H65","5FVV",99.97,"2.05","2.05","Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(1-methylpiperidin-4-yl)pyridin-3-yl)ethyl) pyridin-2-amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5FVV"
"5FVW",,"X-RAY DIFFRACTION",2.74,50.7,,5.8,"8-9% PEG3350 40 MM CITRIC ACID 60 MM BISTRISPROPANE 10% GLYCEROL 5 MM TCEP, pH 5.8",,"10.1021/acs.jmedchem.6b00273","W66","5FVW",99.92,"2.2","2.2","Structure of human nNOS R354A G357D mutant heme domain in complex with 4-methyl-6-(2-(5-(3-(methylamino)propyl)pyridin-3-yl)ethyl) pyridin-2-amine","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5FVW"
"5FVX",,"X-RAY DIFFRACTION",2.74,50.7,,6.2,"8-9% PEG3350 40 MM CITRIC ACID 60 MM BISTRISPROPANE 10% GLYCEROL 5 MM TCEP, pH 6.2",,"10.1021/acs.jmedchem.6b00273","W67","5FVX",99.95,"2.3","2.3","Structure of human nNOS R354A G357D mutant heme domain in complex with with 6-(2-(5-(3-(DIMETHYLAMINO)PROPYL) PYRIDIN-3-YL)ETHYL)-4-METHYLPYRIDIN-2-AMINE","CPRFLKVKNWETEVVLTDTLHLKSTLETGCTEYICMGSIMHPSQHARRPEDVATKDQLFPLAKEFIDQYYSSIKRFGSKAHMERLEEVNKEIDTTSTYQLKDTELIYGAKHAWRNASRCVGRIQWSKLQVFDARDCTTAHGMFNYICNHVKYATNKGNLRSAITIFPQRTDGKHDFRVWNSQLIRYAGYKQPDGSTLGDPANVQFTEICIQQGWKPPRGRFDVLPLLLQANGNDPELFQIPPELVLEVPIRHPKFEWFKDLGLKWYGLPAVSNMLLEIGGLEFSACPFSGWYMGTEIGVRDYCDNSRYNILEEVAKKMNLDMRKTSSLWKDQALVEINIAVLYSFQSDKVTIVDHHSATESFIKHMENEYRCRGGCPADWVWIVPPMSGSITPVFHQEMLNYRLTPSFEYQPDPWNTHVWK","Homo sapiens","NOS1","NITRIC OXIDE SYNTHASE, BRAIN","1","5FVX"
"5FW6",,"X-RAY DIFFRACTION",2.18,43.68,,,,,"10.1038/srep44709",,"5FW6",27.61,"1.3","1.3","Structure of human transthyretin mutant A108V","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIVALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5FW6"
"5FW7",,"X-RAY DIFFRACTION",2.2,44.1,,,,,,,"5FW7",27.61,"1.2","1.2","Structure of human transthyretin mutant A109V","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAVLLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5FW7"
"5FW8",,"X-RAY DIFFRACTION",2.13,42.25,,,,,,,"5FW8",27.55,"1.6","1.6","Structure of human transthyretin mutant E89K","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHKHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","TRANSTHYRETIN","1","5FW8"
"5FW9",,"X-RAY DIFFRACTION",2.43,49.31,,,,,,,"5FW9",7.24,"1.55","1.55","Human Spectrin SH3 domain D48G, E7Y, K60Y","MDETGKYLVLALYDYQEKSPREVTMKKGDILTLLNSTNKDWWKVEVNGRQGFVPAAYVKYLD","Homo sapiens","SPTAN1, NEAS, SPTA2","SPECTRIN ALPHA CHAIN, NON-ERYTHROCYTIC 1","1","5FW9"
"5FWB",,"X-RAY DIFFRACTION",2.43,49.21,,,,,,,"5FWB",7.21,"1.5","1.5","Human Spectrin SH3 domain D48G, E7F, K60F","MDETGKFLVLALYDYQEKSPREVTMKKGDILTLLNSTNKDWWKVEVNGRQGFVPAAYVKFLD","Homo sapiens","SPTAN1, NEAS, SPTA2","SPECTRIN ALPHA CHAIN, NON-ERYTHROCYTIC 1","1","5FWB"
"5FWC",,"X-RAY DIFFRACTION",2.47,50.14,,,,,,,"5FWC",7.2,"1.4","1.4","Human Spectrin SH3 domain D48G, E7A, K60A","MDETGKALVLALYDYQEKSPREVTMKKGDILTLLNSTNKDWWKVEVNGRQGFVPAAYVKALD","Homo sapiens","SPTAN1, NEAS, SPTA2","SPECTRIN ALPHA CHAIN, NON-ERYTHROCYTIC 1","1","5FWC"
"5FWI",,"X-RAY DIFFRACTION",3.92,68.6,,,"15% PEG 3350 0.2M NA CITRATE",,"10.1016/j.jsb.2016.05.005",,"5FWI",78.8,"3.4","3.4","structure of usp7 catalytic domain and three ubl-domains","GPLGSKKHTGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEAHLYMQVQIVAEDQFCGHQGNDMYDEEKVKYTVFKVLKNSSLAEFVQSLSQTMGFPQDQIRLWPMQARSNGTKRPAMLDNEADGNKTMIELSDNENPWTIFLETVDPELAASGATLPKFDKDHDVMLFLKMYDPKTRSLNYCGHIYTPISCKIRDLLPVMCDRAGFIQDTSLILYEEVKPNLTERIQDYDVSLDKALDELMDGDIIVFQKDDPENDNSELPTAKEYFRDLYHRVDVIFCDKTIPNDPGFVVTLSNRMNYFQVAKTVAQRLNTDPMLLQFFKSQGYRDGPGNPLRHNYEGTLRDLLQFFKPRQPKKLYYQQLK","Homo sapiens","USP7, HAUSP","UBIQUITIN CARBOXYL-TERMINAL HYDROLASE 7","1","5FWI"
"5FWJ",,"X-RAY DIFFRACTION",2.78,55.78,,5.5,"0.1M BIS-TRIS PH 5.5 -- 25% PEG3350 -- 0.25M MAGNESIUM CHLORIDE",,"10.1038/nchembio.2087","MMK","5FWJ",109.52,"2.1","2.1","Crystal structure of human JARID1C in complex with KDM5-C49","SMFLPPPECPVFEPSWAEFRDPLGYIAKIRPIAEKSGICKIRPPADWQPPFAVEVDNFRFTPRIQRLNELEAQTRVKLGGGGGFEQATREYTLQSFGEMADSFKADYFNMPVHMVPTELVEKEFWRLVNSIEEDVTVEYGADIHSKEFGSGFPVSDSKRHLTPEEEEYATSGWNLNVMPVLEQSVLCHINADISGMKVPWLYVGMVFSAFCWHIEDHWSYSINYLHWGEPKTWYGVPSLAAEHLEEVMKKLTPELFDSQPDLLHQLVTLMNPNTLMSHGVPVVRTNQCAGEFVITFPRAYHSGFNQGYNFAEAVNFCTADWLPAGRQCIEHYRRLRRYCVFSHEELICKMAACPEKLDLNLAAAVHKEMFIMVQEERRLRKALLEKGITEAEREAFELLPDDERQCIKCKTTCFLSALACYDCPDGLVCLSHINDLCKCSSSRQYLRYRYTLDELPAMLHKLKVRAESFDT","Homo sapiens","KDM5C, DXS1272E, JARID1C, SMCX, XE169","HISTONE DEMETHYLASE JARID1C","1","5FWJ"
"5FWQ",,"X-RAY DIFFRACTION",2.23,44.75,"VAPOR DIFFUSION, HANGING DROP",,"PROTEIN SOLUTION: 10 MM TRIS-HCL, 25 MM KCL, 4-8 MG/ML PROTEIN (PH8); PRECIPITATE SOLUTION: 0,15M IMIDAZOL/HCL PH6.5; 0,1 M NAACETAT, 14% PEG8000, 5 MM YBCL3 AND 25 MM 5-CHLORO-3-HYDROXYPYRIDINE; HANGING DROP VAPOR-DIFFUSION AT 290.55 K",290.55,"10.1016/j.bmc.2016.08.047",,"5FWQ",73.19,"2.047","2.047","Apo structure of human Leukotriene A4 hydrolase","MASMTGGQQMGRGSMPEIVDTCSLASPASVCRTKHLHLRCSVDFTRRTLTGTAALTVQSQEDNLRSLVLDTKDLTIEKVVINGQEVKYALGERQSYKGSPMEISLPIALSKNQEIVIEISFETSPKSSALQWLTPEQTSGKEHPYLFSQCQAIHCRAILPCQDTPSVKLTYTAEVSVPKELVALMSAIRDGETPDPEDPSRKIYKFIQKVPIPCYLIALVVGALESRQIGPRTLVWSEKEQVEKSAYEFSETESMLKIAEDLGGPYVWGQYDLLVLPPSFPYGGMENPCLTFVTPTLLAGDKSLSNVIAHEISHSWTGNLVTNKTWDHFWLNEGHTVYLERHICGRLFGEKFRHFNALGGWGELQNSVKTFGETHPFTKLVVDLTDIDPDVAYSSVPYEKGFALLFYLEQLLGGPEIFLGFLKAYVEKFSYKSITTDDWKDFLYSYFKDKVDVLNQVDWNAWLYSPGLPPIKPNYDMTLTNACIALSQRWITAKEDDLNSFNATDLKDLSSHQLNEFLAQTLQRAPLPLGHIKRMQEVYNFNAINNSEIRFRWLRLCIQSKWEDAIPLALKMATEQGRMKFTRPLFKDLAAFDKSHDQAVRTYQEHKASMHPVTAMLVGKDLKVDLEHHHHHH","Homo sapiens","LTA4H, LTA4","HUMAN LEUKOTRIENE A4 HYDROLASE","1","5FWQ"
"5FWS",,"X-RAY DIFFRACTION",2,38,,7.5,"2.0 M AMMONIUM SULFATE, 5 %V/V ISO-PROPANOL, pH 7.5",,"10.1016/j.str.2016.06.020",,"5FWS",45.35,"1.9","1.9","Wnt modulator Kremen crystal form I at 1.90A","MGILPSPGMPALLSLVSLLSVLLMGCVAETGAPSPGLGPGPECFTANGADYRGTQNWTALQGGKPCLFWNETFQHPYNTLKYPNGEGGLGEHNYCRNPDGDVSPWCYVAEHEDGVYWKYCEIPACQMPGNLGCYKDHGNPPPLTGTSKTSNKLTIQTCISFCRSQRFKFAGMESGYACFCGNNPDYWKYGEAASTECNSVCFGDHTQPCGGDGRIILFDTLVGACGGNYSAMSSVVYSPDFPDTYATGRVCYWTIRVPGASHIHFSFPLFDIRDSADMVELLDGYTHRVLARFHGRSRPPLSFNVSLDFVILYFFSDRINQAQGFAVLYQAVKEEGSENLYFQGGSLPQERPAVNQTVAEVITEQANLSVSAARSSKVLYVITTSPSHPPQTVPGTHHHHHHHHHH","Homo sapiens","KREMEN1, KREMEN, KRM1","KREMEN PROTEIN 1","1","5FWS"
"5FWT",,"X-RAY DIFFRACTION",2,38,,5.6,"1.000 M (NH4)H2PO4 0.100 M NA3CITRATE PH 5.6",,"10.1016/j.str.2016.06.020",,"5FWT",45.35,"2.1","2.1","Wnt modulator Kremen crystal form I at 2.10A","MGILPSPGMPALLSLVSLLSVLLMGCVAETGAPSPGLGPGPECFTANGADYRGTQNWTALQGGKPCLFWNETFQHPYNTLKYPNGEGGLGEHNYCRNPDGDVSPWCYVAEHEDGVYWKYCEIPACQMPGNLGCYKDHGNPPPLTGTSKTSNKLTIQTCISFCRSQRFKFAGMESGYACFCGNNPDYWKYGEAASTECNSVCFGDHTQPCGGDGRIILFDTLVGACGGNYSAMSSVVYSPDFPDTYATGRVCYWTIRVPGASHIHFSFPLFDIRDSADMVELLDGYTHRVLARFHGRSRPPLSFNVSLDFVILYFFSDRINQAQGFAVLYQAVKEEGSENLYFQGGSLPQERPAVNQTVAEVITEQANLSVSAARSSKVLYVITTSPSHPPQTVPGTHHHHHHHHHH","Homo sapiens","KREMEN1, KREMEN, KRM1","KREMEN PROTEIN 1","1","5FWT"
"5FWU",,"X-RAY DIFFRACTION",2.4,47.7,,5.6,"0.1 M NA3CITRATE, 1.0 M MGSO4, FINAL PH 5.6",,"10.1016/j.str.2016.06.020",,"5FWU",45.07,"2.8","2.8","Wnt modulator Kremen crystal form II at 2.8A","MGILPSPGMPALLSLVSLLSVLLMGCVAETGAPSPGLGPGPECFTANGADYRGTQNWTALQGGKPCLFWNETFQHPYNTLKYPNGEGGLGEHNYCRNPDGDVSPWCYVAEHEDGVYWKYCEIPACQMPGNLGCYKDHGNPPPLTGTSKTSNKLTIQTCISFCRSQRFKFAGMESGYACFCGNNPDYWKYGEAASTECNSVCFGDHTQPCGGDGRIILFDTLVGACGGNYSAMSSVVYSPDFPDTYATGRVCYWTIRVPGASHIHFSFPLFDIRDSADMVELLDGYTHRVLARFHGRSRPPLSFNVSLDFVILYFFSDRINQAQGFAVLYQAVKEEGSENLYFQGGSLPQERPAVNQTVAEVITEQANLSVSAARSSKVLYVITTSPSHPPQTVPGTHHHHHHHHHH","Homo sapiens","KREMEN1, KREMEN, KRM1","KREMEN PROTEIN 1","1","5FWU"
"5FWV",,"X-RAY DIFFRACTION",3.3,62.6,,7.5,"0.1 M HEPES/MOPS 7.5 30 % P550MME_P20K DRIED OUT",,"10.1016/j.str.2016.06.020",,"5FWV",45.17,"3.2","3.2","Wnt modulator Kremen crystal form III at 3.2A","MGILPSPGMPALLSLVSLLSVLLMGCVAETGAPSPGLGPGPECFTANGADYRGTQNWTALQGGKPCLFWNETFQHPYNTLKYPNGEGGLGEHNYCRNPDGDVSPWCYVAEHEDGVYWKYCEIPACQMPGNLGCYKDHGNPPPLTGTSKTSNKLTIQTCISFCRSQRFKFAGMESGYACFCGNNPDYWKYGEAASTECNSVCFGDHTQPCGGDGRIILFDTLVGACGGNYSAMSSVVYSPDFPDTYATGRVCYWTIRVPGASHIHFSFPLFDIRDSADMVELLDGYTHRVLARFHGRSRPPLSFNVSLDFVILYFFSDRINQAQGFAVLYQAVKEEGSENLYFQGGSLPQERPAVNQTVAEVITEQANLSVSAARSSKVLYVITTSPSHPPQTVPGTHHHHHHHHHH","Homo sapiens","KREMEN1, KREMEN, KRM1","KREMEN PROTEIN 1","1","5FWV"
"5FXQ",,"X-RAY DIFFRACTION",2.36,47.85,,,,,"10.1021/acs.jmedchem.6b00203","GD5","5FXQ",35.62,"2.3","2.3","IGFR-1R complex with a pyrimidine inhibitor.","SYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENK","Homo sapiens","IGF1R","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","1","5FXQ"
"5FXR",,"X-RAY DIFFRACTION",2.41,48.99,,,,,"10.1021/acs.jmedchem.6b00203","8LN","5FXR",35.59,"2.4","2.4","IGFR-1R complex with a pyrimidine inhibitor.","GYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENK","Homo sapiens","IGF1R","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","1","5FXR"
"5FXS",,"X-RAY DIFFRACTION",2.41,49.01,,,,,"10.1021/acs.jmedchem.6b00203",,"5FXS",35.85,"1.9","1.9","IGFR-1R complex with a pyrimidine inhibitor.","SYFSAADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPEMENNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRAIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEEPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENK","Homo sapiens","IGF1R","INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR","1","5FXS"
"5FXV",,"X-RAY DIFFRACTION",2.9,57.68,,7.2,"0.1M HEPES PH 7.2 -- 25% PEG3350",,,,"5FXV",111.13,"1.91","1.91","Crystal structure of JmjC domain of human histone demethylase UTY in complex with N05859b","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FXV"
"5FXW",,"X-RAY DIFFRACTION",2.89,57.49,,7.8,"0.1M HEPES PH 7.8 -- 0.25M TRIMETHYLAMINE N-OXIDE -- 15% PEG3350",,,,"5FXW",111.42,"2.09","2.09","Crystal structure of JmjC domain of human histone demethylase UTY in complex with fumarate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FXW"
"5FXX",,"X-RAY DIFFRACTION",2.99,58.94,,7.2,"0.1M HEPES PH 7.2 -- 25% PEG3350",,,,"5FXX",111.57,"1.99","1.99","Crystal structure of JmjC domain of human histone demethylase UTY in complex with oxaloacetate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FXX"
"5FXZ",,"X-RAY DIFFRACTION",3.02,59.24,,7.2,"0.1M HEPES PH 7.2 -- 25% PEG3350",,,,"5FXZ",111.69,"1.98","1.98","Crystal structure of JmjC domain of human histone demethylase UTY in complex with citrate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FXZ"
"5FY0",,"X-RAY DIFFRACTION",3.02,59.31,,6.5,"0.1M BIS-TRIS PH 6.5 -- 25% PEG3350",,,,"5FY0",111.45,"2.14","2.14","Crystal structure of JmjC domain of human histone demethylase UTY in complex with L-malate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FY0"
"5FY1",,"X-RAY DIFFRACTION",2.93,58.04,,7.2,"0.1M HEPES PH 7.2 -- 25% PEG3350",,,,"5FY1",112.65,"1.78","1.78","Crystal structure of JmjC domain of human histone demethylase UTY in complex with N08619b","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FY1"
"5FY4",,"X-RAY DIFFRACTION",2.11,41.86,,7,"0.1M HEPES PH 7.0, 0.5M POTASSIUM PHOSPHATE DIBASIC, 0.5M SODIUM PHOSPHATE MONOBASIC",,,,"5FY4",56.1,"2.1","2.1","Crystal structure of the catalytic domain of human JARID1B in complex with succinate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FY4"
"5FY5",,"X-RAY DIFFRACTION",4.01,69.36,,7,"PH 7.0",,,,"5FY5",56.35,"2.47","2.47","Crystal structure of the catalytic domain of human JARID1B in complex with fumarate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FY5"
"5FY7",,"X-RAY DIFFRACTION",2.97,58.67,,7.2,"0.1M HEPES PH 7.2, 25% PEG3350",,,,"5FY7",111.48,"1.86","1.86","Crystal structure of JmjC domain of human histone demethylase UTY in complex with succinate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FY7"
"5FY8",,"X-RAY DIFFRACTION",2.65,53.59,,6,"0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 28% PEG3350",,,,"5FY8",89.88,"2.343","2.343","Crystal structure of human JMJD2A in complex with D-threo-isocitrate","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5FY8"
"5FY9",,"X-RAY DIFFRACTION",2.11,41.64,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FY9",56.39,"2.03","2.03","Crystal structure of the catalytic domain of human JARID1B in complex with pyruvate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FY9"
"5FYB",,"X-RAY DIFFRACTION",2.1,41.49,,7.5,"0.1M HEPES PH 7.5, 0.8M POTASSIUM PHOSPHATE DIBASIC, 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYB",57.45,"1.87","1.87","Crystal structure of the catalytic domain of human JARID1B in complex with MC1648","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYB"
"5FYC",,"X-RAY DIFFRACTION",2.7,54.48,,6,"0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 22% PEG3350",,,,"5FYC",89.82,"2.261","2.261","Crystal structure of human JMJD2A in complex with succinate","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5FYC"
"5FYH",,"X-RAY DIFFRACTION",2.64,53.43,,6,"0.1M BIS-TRIS PH 6.0 -- 0.15M AMMONIUM SULFATE -- 22% PEG3350",,,,"5FYH",89.57,"2.348","2.348","Crystal structure of human JMJD2A in complex with fumarate","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5FYH"
"5FYI",,"X-RAY DIFFRACTION",2.64,53.44,,6,"0.1M BIS-TRIS PH 6.0 -- 0.2M AMMONIUM SULFATE -- 28% PEG3350",,,,"5FYI",90.57,"2.096","2.096","Crystal structure of human JMJD2A in complex with pyruvate","MHHHHHHSSGVDLGTENLYFQSMASESETLNPSARIMTFYPTMEEFRNFSRYIAYIESQGAHRAGLAKVVPPKEWKPRASYDDIDDLVIPAPIQQLVTGQSGLFTQYNIQKKAMTVREFRKIANSDKYCTPRYSEFEELERKYWKNLTFNPPIYGADVNGTLYEKHVDEWNIGRLRTILDLVEKESGITIEGVNTPYLYFGMWKTSFAWHTEDMDLYSINYLHFGEPKSWYSVPPEHGKRLERLAKGFFPGSAQSCEAFLRHKMTLISPLMLKKYGIPFDKVTQEAGEFMITFPYGYHAGFNHGFNCAESTNFATRRWIEYGKQAVLCSCRKDMVKISMDVFVRKFQPERYKLWKAGKDNTVIDHTLPTPEAAEFLKESEL","Homo sapiens","KDM4A, JHDM3A, JMJD2, JMJD2A, KIAA0677","LYSINE-SPECIFIC DEMETHYLASE 4A","1","5FYI"
"5FYM",,"X-RAY DIFFRACTION",2.84,56.76,,7.4,"0.1M HEPES PH 7.4, 0.2M TRIMETHYLAMINE N-OXIDE, 15% PEG3350",,,,"5FYM",112.29,"2","2","Crystal structure of JmjC domain of human histone demethylase UTY in complex with D-2-hydroxyglutarate","MLPKDKLNPPTPSIYLENKRDAFFPPLHQFCTNPKNPVTVIRGLAGALKLDLGLFSTKTLVEANNEHMVEVRTQLLQPADENWDPTGTKKIWRCESNRSHTTIAKYAQYQASSFQESLREENEKRTQHKDHSDNESTSSENSGRRRKGPFKTIKFGTNIDLSDNKKWKLQLHELTKLPAFARVVSAGNLLTHVGHTILGMNTVQLYMKVPGSRTPGHQENNNFCSVNINIGPGDCEWFVVPEDYWGVLNDFCEKNNLNFLMSSWWPNLEDLYEANVPVYRFIQRPGDLVWINAGTVHWVQAVGWCNNIAWNVGPLTACQYKLAVERYEWNKLKSVKSPVPMVHLSWNMARNIKVSDPKLFEMIKYCLLKILKQYQTLREALVAAGKEVIWHGRTNDEPAHYCSICEVEVFNLLFVTNESNTQKTYIVHCHDCARKTSKSLENFVVLEQYKMEDLIQVYDQFTLALSLSSSSAENLYFQ","Homo sapiens","UTY, KDM6C","HISTONE DEMETHYLASE UTY","1","5FYM"
"5FYS",,"X-RAY DIFFRACTION",2.12,42.06,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYS",56.75,"1.89","1.89","Crystal structure of the catalytic domain of human JARID1B in complex with D-2-hydroxyglutarate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYS"
"5FYT",,"X-RAY DIFFRACTION",2.1,41.34,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYT",57.09,"1.87","1.87","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-yl)acetic acid (N09996a)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYT"
"5FYU",,"X-RAY DIFFRACTION",2.1,41.44,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYU",56.72,"2.06","2.06","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-Amino-4-methyl-1,3-dihydro-2H-indol-2-one (N10042a)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYU"
"5FYV",,"X-RAY DIFFRACTION",2.13,42.16,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYV",56.89,"1.87","1.87","Crystal structure of the catalytic domain of human JARID1B in complex with oxaloacetate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYV"
"5FYY",,"X-RAY DIFFRACTION",2.11,41.61,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYY",57.1,"2.18","2.18","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3-pyridin-3-ylaniline (N05798a) (ligand modelled based on PANDDA event map)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGAKDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYY"
"5FYZ",,"X-RAY DIFFRACTION",2.11,41.62,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FYZ",56.67,"1.75","1.75","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-(2-oxo-2,3-dihydro-1H-indol-3-yl)acetonitrile (N10063a)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FYZ"
"5FZ0",,"X-RAY DIFFRACTION",2.19,43.84,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ0",56.57,"2.42","2.42","Crystal structure of the catalytic domain of human JARID1B in complex with 2,5-dichloro-N-(pyridin-3-yl)thiophene-3-carboxamide (N08137b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ0"
"5FZ1",,"X-RAY DIFFRACTION",4.1,70.03,,7.5,"PH 7.5",,,,"5FZ1",56.74,"2.39","2.39","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 2,4-dichloro-N-pyridin-3-ylbenzamide (E48115b) (ligand modelled based on PANDDA event map)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ1"
"5FZ3",,"X-RAY DIFFRACTION",2.17,43.3,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ3",56.59,"2.5","2.5","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 3,6-Dihydroxybenzonorbornane (N08776b) (ligand modelled based on PANDDA event map)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ3"
"5FZ4",,"X-RAY DIFFRACTION",2.1,41.4,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ4",56.63,"2.07","2.07","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment (3R)-1-[(3-phenyl-1,2,4-oxadiazol-5-yl)methyl]pyrrolidin-3-ol (N10057a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ4"
"5FZ6",,"X-RAY DIFFRACTION",2.17,43.38,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ6",56.75,"2.33","2.33","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment N05859b (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ6"
"5FZ7",,"X-RAY DIFFRACTION",2.15,42.92,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ7",56.59,"2.3","2.3","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment ethyl 2-amino-4-thiophen-2-ylthiophene-3- carboxylate (N06131b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ7"
"5FZ8",,"X-RAY DIFFRACTION",2.13,42.2,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ8",56.46,"1.86","1.86","Crystal structure of the catalytic domain of human JARID1B in complex with malate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ8"
"5FZ9",,"X-RAY DIFFRACTION",2.18,43.62,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZ9",56.87,"2.06","2.06","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment thieno(3,2-b)thiophene-5-carboxylic acid (N06263b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZ9"
"5FZA",,"X-RAY DIFFRACTION",2.11,41.72,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZA",56.61,"2.099","2.099","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 2-piperidin-4-yloxy-5-(trifluoromethyl)pyridine (N10072a) (ligand modelled based on PANDDA event map)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZA"
"5FZB",,"X-RAY DIFFRACTION",2.17,43.28,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZB",56.68,"2.18","2.18","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4-Pyridylthiourea (N06275b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRLKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZB"
"5FZC",,"X-RAY DIFFRACTION",2.18,43.65,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZC",56.85,"2.05","2.05","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZC"
"5FZD",,"X-RAY DIFFRACTION",2.1,41.57,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZD",56.72,"2.05","2.05","Crystal structure of the catalytic domain of human JARID1B in complex with L-2-hydroxyglutarate","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZD"
"5FZE",,"X-RAY DIFFRACTION",2.07,40.73,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZE",56.79,"2.02","2.02","Crystal structure of the catalytic domain of human JARID1B in complex with MC3960","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZE"
"5FZF",,"X-RAY DIFFRACTION",2.07,40.67,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZF",57.55,"1.97","1.97","Crystal structure of the catalytic domain of human JARID1B in complex with MC3962","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZF"
"5FZG",,"X-RAY DIFFRACTION",2.09,41.19,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZG",57.01,"1.96","1.96","Crystal structure of the catalytic domain of human JARID1B in complex with MC3948","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZG"
"5FZH",,"X-RAY DIFFRACTION",2.17,43.71,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZH",56.62,"2.09","2.09","Crystal structure of the catalytic domain of human JARID1B in complex with Maybridge fragment 4,5-dihydronaphtho(1,2-b)thiophene-2- carboxylicacid (N11181a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZH"
"5FZI",,"X-RAY DIFFRACTION",2.09,41.11,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZI",57.16,"1.95","1.95","Crystal structure of the catalytic domain of human JARID1B in complex with MC3095","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZI"
"5FZK",,"X-RAY DIFFRACTION",2.12,41.88,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZK",56.41,"2.05","2.05","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment N,3-dimethyl-N-(pyridin-3-ylmethyl)-1,2-oxazole-5- carboxamide (N10051a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZK"
"5FZL",,"X-RAY DIFFRACTION",2.1,41.58,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZL",56.37,"2.55","2.55","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 3-methyl-N-pyridin-4-yl-1,2-oxazole-5-carboxamide (N09954a) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGARDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZL"
"5FZM",,"X-RAY DIFFRACTION",2.1,41.41,,7.5,"0.1M HEPES PH 7.5 -- 0.8M POTASSIUM PHOSPHATE DIBASIC -- 0.8M SODIUM PHOSPHATE MONOBASIC",,,,"5FZM",56.46,"2.49","2.49","Crystal structure of the catalytic domain of human JARID1B in complex with 3D fragment 5-(2-fluorophenyl)-1,3-oxazole-4-carboxylic acid (N09989b) (ligand modelled based on PANDDA event map, SGC - Diamond I04-1 fragment screening)","SMFLPPPECPVFEPSWEEFADPFAFIHKIRPIAEQTGICKVRPPPDWQPPFACDVDKLHFTPRIQRLNELEAQTRVKLGGGGASDYTLRTFGEMADAFKSDYFNMPVHMVPTELVEKEFWRLVSTIEEDVTVEYGADIASKEFGSGFPVRDGKIKLSPEEEEYLDSGWNLNNMPVMEQSVLAHITADICGMKLPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPGYAAEQLENVMKKLAPELFVSQPDLLHQLVTIMNPNTLMTHEVPVYRTNQCAGEFVITFPRAYHSGFNQGFNFAEAVNFCTVDWLPLGRQCVEHYRLLHRYCVFSHDEMICKMASKADVLDVVVASTVQKDMAIMIEDEKALRETVRKLGVIDSERMDFELLPDDERQCVKCKTTCFMSAISCSCKPGLLVCLHHVKELCSCPPYKYKLRYRYTLDDLYPMMNALKLRAESYNEWALNVNEALEAKI","Homo sapiens","KDM5B, JARID1B, PLU1, RBBP2H1","LYSINE-SPECIFIC DEMETHYLASE 5B, LYSINE-SPECIFIC DEMETHYLASE 5B","1","5FZM"
"5FZO",,"X-RAY DIFFRACTION",2.69,54.26,,8.5,"20% PEG3350 -- 10% ETHYLENE GLYCOL -- 0.1M BIS-TRIS-PROPANE PH 8.5 -- 0.2M POTASSIUM CITRATE TRIBASIC",,,,"5FZO",81.14,"1.84","1.84","Crystal structure of the catalytic domain of human JmjD1C","MIPHSWICEKHILWLKDYKNSSNWKLFKECWKQGQPAVVSGVHKKMNISLWKAESISLDFGDHQADLLNCKDSIISNANVKEFWDGFEEVSKRQKNKSGETVVLKLKDWPSGEDFKTMMPARYEDLLKSLPLPEYCNPEGKFNLASHLPGFFVRPDLGPRLCSAYGVVAAKDHDIGTTNLHIEVSDVVNILVYVGIAKGNGILSKAGILKKFEEEDLDDILRKRLKDSSEIPGALWHIYAGKDVDKIREFLQKISKEQGLEVLPEHDPIRDQSWYVNKKLRQRLLEEYGVRTCTLIQFLGDAIVLPAGALHQVQNFHSCIQVTEDFVSPEHLVESFHLTQELRLLAENLYFQ","Homo sapiens","JMJD1C, JHDM2C, KIAA1380, TRIP8","PROBABLE JMJC DOMAIN-CONTAINING HISTONE DEMETHYLATION PROT EIN 2C","1","5FZO"
,,,,,,,,,,,,,,,,"MIPHSWICEKHILWLKDYKNSSNWKLFKECWKQGQPAVVSGVHKKMNISLWKAESISLDFGDHQADLLNCKDSIISNANVKEFWDGFEEVSKRQKNKSGETVVLKLKDWPSGEDFKTMMPARYEDLLKSLPLPEYCNPEGKFNLASHLPGFFVRPDLGPRLCSAYGVVAAKDHDIGTTNLHIEVDDVVNILVYVGIAKGNGILSKAGILKKFEEEDLDDILRKRLKDSSEIPGALWHIYAGKDVDKIREFLQKISKEQGLEVLPEHDPIRDQSWYVNKKLRQRLLEEYGVRTCTLIQFLGDAIVLPAGALHQVQNFHSCIQVTEDFVSPEHLVESFHLTQELRLLAENLYFQ","Homo sapiens","JMJD1C, JHDM2C, KIAA1380, TRIP8","PROBABLE JMJC DOMAIN-CONTAINING HISTONE DEMETHYLATION PROT EIN 2C","2","5FZO"
"5G01",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",8.5,"200 NL PLUS 200 NL OF PROTEIN AT 5 MGS/ML AND RESERVOIR IN SITTING DROP PLATES. RESERVOIR WAS 2.6 TO 2.8 M AMMONIUM SULFATE WITH 100 MM TRIS PH 8.5",,"10.1021/acs.jmedchem.6b00443","SO4, OE2","5G01",30.18,"1.4","1.4","An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFKVNFDDSQDKAVLKGGPLDGTYRLTQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDASKASQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLNETVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5G01"
"5G03",,"X-RAY DIFFRACTION",2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",8.5,"150 NL PROTEIN AT 5.5 MG/ML PLUS 120 NL RESERVOIR AND 30 NL SEEDS IN SITTING DROP PLATES. RESERVOIR WAS 2.6 TO 2.8 M AMMONIUM SULFATE PLUS 100 MM TRIS PH 8.5",,"10.1021/acs.jmedchem.6b00443","SO4, OE2","5G03",29.77,"1.35","1.35","An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVDKALQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAEGVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5G03"
"5G0B",,"X-RAY DIFFRACTION",2.09,41.2,"VAPOR DIFFUSION, SITTING DROP",8.5,"SITTING DROPS WITH 150 NL PROTEIN AT 5.5 MG/ML WITH 120 NL RESERVOIR AND 30 NL SEEDS. THE RESERVOIR HAD 2.6 TO 2.8 M AMMONIUM SULFATE WITH 100 MM TRIS PH 8.5",,"10.1021/acs.jmedchem.6b00443","SO4, CL","5G0B",29.61,"1.55","1.55","An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFQVTFDDSQDKAVLKGGPLDGTYRLLQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDVDKALQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTEGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLAEGVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5G0B"
"5G0C",,"X-RAY DIFFRACTION",2.08,40.9,"VAPOR DIFFUSION, SITTING DROP",8.5,"SITTING DROP PLATES WITH 200 NL PROTEIN AT 5 MG/ML AND 200 NL RESERVOIR WITH 2.6 TO 2.8 M AMMONIUM SULFATE AND 100 MM TRIS AT PH 8.5",,"10.1021/acs.jmedchem.6b00443","SO4","5G0C",29.7,"1.28","1.28","An unusual natural product primary sulfonamide: synthesis, carbonic anhydrase inhibition and protein x-ray structure of Psammaplin C","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHSFKVNFDDSQDKAVLKGGPLDGTYRLTQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDASKASQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLNETVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","CARBONIC ANHYDRASE 2","1","5G0C"
"5G1N",,"X-RAY DIFFRACTION",2.1,41,,,"10% ZNCL2, 15% PEG6000, 50 MM SODIUM ACETATE PH 4.8",,"10.1016/j.str.2016.05.001","PAL","5G1N",211.12,"2.1","2.1","Aspartate transcarbamoylase domain of human CAD bound to PALA","GPMSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF","Homo sapiens","CAD","CAD PROTEIN","1","5G1N"
"5G1O",,"X-RAY DIFFRACTION",2.1,41,,,"0.1 M TRIS PH 8.5, 6% PEG 8000, 11% ETHYLENE GLYCOL",,"10.1016/j.str.2016.05.001",,"5G1O",209.96,"2.1","2.1","Aspartate transcarbamoylase domain of human CAD in apo form","GPMSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF","Homo sapiens","CAD","CAD PROTEIN","1","5G1O"
"5G1P",,"X-RAY DIFFRACTION",2.1,41,,,"0.1 M TRIS PH 8.5, 6% PEG 8000, 11% ETHYLENE GLYCOL",,"10.1016/j.str.2016.05.001",,"5G1P",210.31,"3.19","3.19","Aspartate transcarbamoylase domain of human CAD bound to carbamoyl phosphate","GPMSPLLHSLVGQHILSVQQFTKDQMSHLFNVAHTLRMMVQKERSLDILKGKVMASMFYEVSTRTSSSFAAAMARLGGAVLSFSEATSSVQKGESLADSVQTMSCYADVVVLRHPQPGAVELAAKHCRRPVINAGDGVGEHPTQALLDIFTIREELGTVNGMTITMVGDLKHGRTVHSLACLLTQYRVSLRYVAPPSLRMPPTVRAFVASRGTKQEEFESIEEALPDTDVLYMTRIQKERFGSTQEYEACFGQFILTPHIMTRAKKKMVVMHPMPRVNEISVEVDSDPRAAYFRQAENGMYIRMALLATVLGRF","Homo sapiens","CAD","CAD PROTEIN","1","5G1P"
"5G2N",,"X-RAY DIFFRACTION",2.46,50.01,,,"19% PEG4000,0.15M (NH4)2SO4, 0.1M TRIS PH7.5",,"10.1002/cmdc.201600148","6E2","5G2N",112.68,"2.68","2.68","X-ray structure of PI3Kinase Gamma in complex with Copanlisib","MLLGSSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSEQDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSAEFGLVPRGSGHHHHHH","Homo sapiens","PIK3CG","PHOSPHATIDYLINOSITOL-4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT GAMMA ISOFORM","1","5G2N"
"5G3M",,"X-RAY DIFFRACTION",2.22,44.63,,,"40% PEG 400, 0.1 M BIS-TRIS PH 6.0",,"10.1021/acsmedchemlett.6b00188","9JH","5G3M",29.74,"1.85","1.85","Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.","GILELAGTVGCVGPRTPIAYMKYGCFCGLGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGPAENKCQELLCKCDQEIANCLAQTEYNLKYLFYPQFLCEPDSPKCD","Homo sapiens","PLA2G10","GROUP 10 SECRETORY PHOSPHOLIPASE A2","1","5G3M"
"5G3N",,"X-RAY DIFFRACTION",2.25,45.27,,,"3.0-3.5M SODIUM FORMATE AND 100MM HEPES PH 7.5",,"10.1021/acsmedchemlett.6b00188","X28","5G3N",29.41,"1.8","1.8","Discovery of a novel secreted phospholipase A2 (sPLA2) inhibitor.","ALVNFHRMIKLTTGKEAALSYGFYGCHCGVGGRGSPKDATDRCCVTHDCCYKRLEKRGCGTKFLSYKFSNSGSRISCAKQDSCRSQLCECDKAAATCFARNKTTYNKKYQYYSNKHCRGSTPRCGHH","Homo sapiens","PLA2G2A, PLA2B, PLA2L, RASF-A","PHOSPHOLIPASE A2, MEMBRANE ASSOCIATED","1","5G3N"
"5G3Q",,"X-RAY DIFFRACTION",2.76,55.43,,,"20% PEG3350 -- 10% ETHYLENE GLYCOL -- 0.1M BIS-TRIS-PROPANE PH 6.5 -- 0.2M SODIUM FORMATE",,,,"5G3Q",20.56,"1.613","1.613","Crystal structure of a hypothetical domain in WNK1","SMTSRPKLRILNVSNKGDRVVECQLETHNRKMVTFKFDLDGDNPEEIATIMVNNDFILAIERESFVDQVREIIEKADEMLSEDVSVEPE","Homo sapiens",,"WNK1","1","5G3Q"
"5G4M",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: SATURATED SOLUTION OF COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1021/acschembio.6b00315","O82","5G4M",49.86,"1.38","1.38","Crystal structure of the p53 cancer mutant Y220C in complex with a monofluorinated derivative of the small molecule stabilizer Phikan083","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5G4M"
"5G4N",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: SATURATED SOLUTION OF COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL",294,"10.1021/acschembio.6b00315","O83","5G4N",49.83,"1.35","1.35","Crystal structure of the p53 cancer mutant Y220C in complex with a difluorinated derivative of the small molecule stabilizer Phikan083","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5G4N"
"5G4O",,"X-RAY DIFFRACTION",2.5,51,"VAPOR DIFFUSION, SITTING DROP",,"SITTING-DROP VAPOR DIFFUSION AT 21 DEGREE C. PROTEIN SOLUTION: 6 MG/ML PROTEIN IN 25 MM SODIUM PHOSPHATE, PH 7.2, 150 MM KCL, 5 MM DTT. RESERVOIR BUFFER: 100 MM HEPES, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 5 MM DTT. SOAKING BUFFER: SATURATED SOLUTION OF COMPOUND IN 100 MM HEPES, PH 7.2, 10 MM SODIUM PHOSPHATE, PH 7.2, 19% (W/V) POLYETHYLENE GLYCOL 4000, 20 % (V/V) GLYCEROL, 150 MM KCL.",294,"10.1021/acschembio.6b00315","O80","5G4O",49.81,"1.48","1.48","Crystal structure of the p53 cancer mutant Y220C in complex with a trifluorinated derivative of the small molecule stabilizer Phikan083","SSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPALNKLFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAPPQHLIRVEGNLRAEYLDDRNTFRHSVVVPCEPPEVGSDCTTIHYNYMCYSSCMGGMNRRPILTIITLEDSSGNLLGRDSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALPNNT","Homo sapiens","TP53, P53","CELLULAR TUMOR ANTIGEN P53","1","5G4O"
"5G4P",,"X-RAY DIFFRACTION",2.38,48,,5.5,"0.1 M SODIUM CITRATE TRIBASIC DIHYDRATE PH 5.5, 18% V/V 2-PROPANOL, 16% W/V PEG 4000",,"10.1093/hmg/ddx133",,"5G4P",45.15,"2.42","2.42","Crystal structure of human hippocalcin at 2.4 A resolution","MGKQNSKLRPEMLQDLRENTEFSELELQEWYKGFLKDCPTGILNVDEFKKIYANFFPYGDASKFAEHVFRTFDTNSDGTIDFREFIIALSVTSRGRLEQKLMWAFSMYDLDGNGYISREEMLEIVQAIYKMVSSVMKMPEDESTPEKRTEKIFRQMDTNNDGKLSLEEFIRGAKSDPSIVRLLQCDPSSASQF","Homo sapiens","HPCA, BDR2","Neuron-specific calcium-binding protein hippocalcin","1","5G4P"
"5G4R",,"X-RAY DIFFRACTION",2.28,46.11,,8.5,"30% P550MME_P20K, 0.1M BUFFER 3, PH8.5, 10% ETHYLENE GLYCOLS",,"10.1021/acsmedchemlett.6b00092","LF1","5G4R",57.34,"1.96","1.96","BROMODOMAIN OF HUMAN BRPF1 WITH N-1,3-dimethyl-6-2R-2- methylpiperazin-1-yl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl-2- methoxybenzamide","GQQIAMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEK","Homo sapiens","BRPF1, BR140","PEREGRIN","1","5G4R"
"5G4S",,"X-RAY DIFFRACTION",2.8,56.07,,6.5,"0.1M MORPHEUS BUFFER 1, PH 6.5 37.5% MPD_P1K_P3350 10% MORPHEUS NITRATE-PHOSPHATE-SULPHATE",,"10.1021/acsmedchemlett.6b00092","8VI","5G4S",14.43,"1.6","1.6","BROMODOMAIN OF HUMAN BRPF1 WITH N-1,3-dimethyl-6-2R-2- methylpiperazin-1-yl-2-oxo-2,3-dihydro-1H-1,3-benzodiazol-5-yl-N- ethyl-2-methoxybenzamide","GQEIAMEMQLTPFLILLRKTLEQLQEKDTGNIFSEPVPLSEVPDYLDHIKKPMDFFTMKQNLEAYRYLNFDDFEEDFNLIVSNCLKYNAKDTIFYRAAVRLREQGGAVLRQARRQAEK","Homo sapiens","BRPF1, BR140","PEREGRIN","1","5G4S"
"5G55",,"X-RAY DIFFRACTION",2.21,44.24,,,,,"10.1021/acs.jmedchem.6b00519",,"5G55",111.18,"2.45","2.45","3-Quinoline Carboxamides inhibitors of Pi3K","MSEESQAFQRQLTALIGYDVTDVSNVHDDELEFTRRGLVTPRMAEVASRDPKLYAMHPWVTSKPLPEYLWKKIANNCIFIVIHRSTTSQTIKVSPDDTPGAILQSFFTKMAKKKSLMDIPESQSERDFVLRVCGRDEYLVGETPIKNFQWVRHCLKNGEEIHVVLDTPPDPALDEVRKEEWPLVDDCTGVTGYHEQLTIHGKDHESVFTVSLWDCDRKFRVKIRGIDIPVLPRNTDLTVFVEANIQHGQQVLCQRRTSPKPFTEEVLWNVWLEFSIKIKDLPKGALLNLQIYCGKAPALSSKASAESPSSESKGKVQLLYYVNLLLIDHRFLLRRGEYVLHMWQISGKGEDQGSFNADKLTSATNPDKENSMSISILLDNYCHPIALPKHQPTPDPEGDRVRAEMPNQLRKQLEAIIATDPLNPLTAEDKELLWHFRYESLKHPKAYPKLFSSVKWGQQEIVAKTYQLLARREVWDQSALDVGLTMQLLDCNFSDENVRAIAVQKLESLEDDDVLHYLLQLVQAVKFEPYHDSALARFLLKRGLRNKRIGHFLFWFLRSEIAQSRHYQQRFAVILEAYLRGCGTAMLHDFTQQVQVIEMLQKVTLDIKSLSAEKYDVSSQVISQLKQKLENLQNSQLPESFRVPYDPGLKAGALAIEKCKVMASKKKPLWLEFKCADPTALSNETIGIIFKHGDDLRQDMLILQILRIMESIWETESLDLCLLPYGCISTGDKIGMIEIVKDATTIAKIQQSTVGNTGAFKDEVLNHWLKEKSPTEEKFQAAVERFVYSCAGYCVATFVLGIGDRHNDNIMITETGNLFHIDFGHILGNYKSFLGINKERVPFVLTPDFLFVMGTSGKKTSPHFQKFQDICVKAYLALRHHTNLLIILFSMMLMTGMPQLTSKEDIEYIRDALTVGKNEEDAKKYFLDQIEVCRDKGWTVQFNWFLHLVLGIKQGEKHSAHHHHHH","Homo sapiens","PIK3CG","PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE 3-KINASE CATALYTIC SUBUNIT GAMMA ISOFORM","1","5G55"
"5G58",,"X-RAY DIFFRACTION",2.38,48,,5.5,"0.1 M SODIUM CITRATE TRIBASIC DIHYDRATE PH 5.5, 18% V/V 2-PROPANOL, 16% W/V PEG 4000",,"10.1093/hmg/ddx133",,"5G58",45.21,"2.54","2.54","Crystal structure of A190T mutant of human hippocalcin AT 2.5 A resolution","MGKQNSKLRPEMLQDLRENTEFSELELQEWYKGFLKDCPTGILNVDEFKKIYANFFPYGDASKFAEHVFRTFDTNSDGTIDFREFIIALSVTSRGRLEQKLMWAFSMYDLDGNGYISREEMLEIVQAIYKMVSSVMKMPEDESTPEKRTEKIFRQMDTNNDGKLSLEEFIRGAKSDPSIVRLLQCDPSSTSQF","Homo sapiens","HPCA, BDR2","Neuron-specific calcium-binding protein hippocalcin","1","5G58"
"5G5J",,"X-RAY DIFFRACTION",2.27,45.86,,7,"12% PEG 3350, 0.1M SODIUM ACETATE PH 7.0",,"10.1016/j.chembiol.2017.08.009",,"5G5J",56.5,"2.6","2.6","Crystal structure of human CYP3A4 bound to metformin","MAYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGAHHHH","Homo sapiens","CYP3A4, CYP3A3","CYTOCHROME P450 3A4","1","5G5J"
"5G64",,"X-RAY DIFFRACTION",3.22,62,,,"4% PEG 8000 AND 0.03M SODIUM FLUORIDE. CRYSTALS WERE CRYOPROTECTED WITH 4M TMAO",,"10.1074/jbc.M117.776476",,"5G64",171.89,"3.715","3.715","The complex between human IgE-Fc and two anti-IgE Fab fragments","DIVASRDFTPPTVKILQSSCDGGGHFPPTIQLLCLVSGYTPGTIQITWLEDGQVMDVDLSTASTTQEGELASTQSELTLSQKHWLSDRTYTCQVTYQGHTFEDSTKKCADSNPRGVSAYLSRPSPFDLFIRKSPTITCLVVDLAPSKGTVQLTWSRASGKPVNHSTRKEEKQRNGTLTVTSTLPVGTRDWIEGETYQCRVTHPHLPRALMRSTTKTSGPRAAPEVYAFATPEWPGSRDKRTLACLIQNFMPEDISVQWLHNEVQLPDARHSTTQPRKTKGSGFFVFSRLEVTRAEWEQKDEFICRAVHEAASPSQTVQRAVSVNPGK","Homo sapiens",,"IG EPSILON CHAIN C REGION","1","5G64"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVQPGGSLRLSCAVSGYSITSGYSWNWIRQAPGKGLEWVASITYDGSTNYNPSVKGRITISRDDSKNTFYLQMNSLRAEDTAVYYCARGSHYFGHWHFAVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB FRAGMENT","2","5G64"
,,,,,,,,,,,,,,,,"DIQLTQSPSSLSASVGDRVTITCRASQSVDYDGDSYMNWYQQKPGKAPKLLIYAASYLESGVPSRFSGSGSGTDFTLTISRLRPEDFATYYCQQSHEDPYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNAPQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB FRAGMENT","3","5G64"
"5G6U",,"X-RAY DIFFRACTION",2.4,45,,7,"HEPES PH7, 100 MM MGCL2, 150 MM NACL, 20% PEG3350",,"10.1021/acschembio.7b00958","SGN","5G6U",121.33,"1.844","1.844","Crystal structure of langerin carbohydrate recognition domain with GlcNS6S","MGTISDVKTNVQLLKGRVDNISTLDSEIKKNSDGMEAAGVQIQMVNESLGYVRSQFLKLKTSVEKANAQIQILTRSWEEVSTLNAQIPELKSDLEKASALNTKIRALQGSLENMSKLLKRQNDILQVVSQGWKYFKGNFYYFSLIPKTWYSAEQFCVSRNSHLTSVTSESEQEFLYKTAGGLIYWIGLTKAGMEGDWSWVDDTPFNKVQSVRFWIPGEPNNAGNNEHCGNIKAPSLQAWNDAPCDKTFLFICKRPYVPSEP","Homo sapiens","CD207, CLEC4K","LANGERIN","1","5G6U"
"5G6V",,"X-RAY DIFFRACTION",2.44,49.51,,5.5,"25% PEG MEDIUM SMEAR (PEG 2000, PEG 3350, PEG 4000, PEG 5000MME) AND 0.1 M CITRATE PH 5.5",,,,"5G6V",75.97,"2.2","2.2","Crystal structure of the PCTAIRE1 kinase in complex with inhibitor","METYIKLDKLGEGTYATVYKGKSKLTDNLVALKEIRLEHEEGAPCTAIREVSLLKDLKHANIVTLHDIIHTEKSLTLVFEYLDKDLKQYLDDCGNIINMHNVKLFLFQLLRGLAYCHRQKVLHRDLKPQNLLINERGELKLADFGLARAKSIPTKTYDNEVVTLWYRPPDILLGSTDYSTQIDMWGVGCIFYEMATGRPLFPGSTVEEQLHFIFRILGTPTEETWPGILSNEEFKTYNYPKYRAEALLSHAPRLDSDGADLLTKLLQFEGRNRISAEDAMKHPFFLSLGERIHKLPDTTSIFALKEIQLQKEASLRSAHHHHHH","Homo sapiens","CDK16, PCTAIRE1, PCTK1","CYCLIN-DEPENDENT KINASE 16","1","5G6V"
"5GAL",,"X-RAY DIFFRACTION",2.2,43,"VAPOR DIFFUSION, HANGING DROP",8.1,"CRYSTALS WERE GROWN USING THE HANGING DROP METHOD FROM DROPS CONTAINING 9 MG/ML PROTEIN AT PH 8.1 IN 50 MM SODIUM PHOSPHATE BUFFER, 0.3 M SODIUM CHLORIDE, 20 MM IMIDAZOLE, 8.5% PEG 3350. DROPS WERE EQUILIBRATED AGAINST RESERVOIRS CONTAINING 50 MM SODIUM PHOSPHATE BUFFER, 0.3 M SODIUM CHLORIDE, 20 MM IMIDAZOLE, 17% PEG 3350. GALECTIN-7 CRYSTALS WERE THEN SOAKED WITH 50 MM N-ACETYLLACTOSAMINE FOR 3 DAYS., vapor diffusion - hanging drop",,"10.1021/bi981056x",,"5GAL",30.32,"2","2","CRYSTAL STRUCTURE OF HUMAN GALECTIN-7 IN COMPLEX WITH N-ACETYLLACTOSAMINE","SNVPHKSSLPEGIRPGTVLRIRGLVPPNASRFHVNLLCGEEQGSDAALHFNPRLDTSEVVFNSKEQGSWGREERGPGVPFQRGQPFEVLIIASDDGFKAVVGDAQYHHFRHRLPLARVRLVEVGGDVQLDSVRIF","Homo sapiens","LGALS7, PIG1, LGALS7B","GALECTIN-7","1","5GAL"
"5GDS",,"X-RAY DIFFRACTION",2.4,49,"VAPOR DIFFUSION",7,"THE CRYSTALS OF THROMBIN:HIRUNORM V COMPLEX WERE GROWN, AS DESCRIBED BY SKRZYPEZAK ET AL. (1991) J. MOL. BIOL.,221,1379-1393 BY VAPOR DIFFUSION METHODS AT 4 C. A 6 MICROLITER DROP, CONTAINING 0.05 M SODIUM HEPES (PH 7.0) 10% (W/V) PEG 4000 0.02% NAN3, 20 MG/ML. THROMBIN:HIRUNORM V COMPLEX WAS EQUILIBRATED AGAINST A PRECIPITATING SOLUTION CONTAINING 0.1 M SODIUM HEPES (PH 7.0) 20% (W/V) PEG 4000 0.04% NAN3. CRYSTAL OF THROMBIN:HIRUGEN COMPLEX WERE CRUSHED AND INDIVIDUAL SEEDS WERE USED FOR CROSS-SEEDING EXPERIMENTS., vapor diffusion, temperature 277K",277,"10.1002/pro.5560070203",,"5GDS",37.06,"2.1","2.1","HIRUNORMS ARE TRUE HIRUDIN MIMETICS. THE CRYSTAL STRUCTURE OF HUMAN ALPHA-THROMBIN:HIRUNORM V COMPLEX","IVEGSDAEIGMSPWQVMLFRKSPQELLCGASLISDRWVLTAAHCLLYPPWDKNFTENDLLVRIGKHSRTRYERNIEKISMLEKIYIHPRYNWRENLDRDIALMKLKKPVAFSDYIHPVCLPDRETAASLLQAGYKGRVTGWGNLKETWTANVGKGQPSVLQVVNLPIVERPVCKDSTRIRITDNMFCAGYKPDEGKRGDACEGDSGGPFVMKSPFNNRWYQMGIVSWGEGCDRDGKYGFYTHVFRLKKWIQKVIDQFGE","Homo sapiens","F2","ALPHA-THROMBIN","2","5GDS"
,,,,,,,,,,,,,,,,"TFGSGEADCGLRPLFEKKSLEDKTERELLESYIDGR","Homo sapiens","F2","ALPHA-THROMBIN","1","5GDS"
,,,,,,,,,,,,,,,,"XVATDAGXPESHXGGDYEEIPAAYAE",,,"HIRUNORM V","3","5GDS"
"5GGF",,"X-RAY DIFFRACTION",2.88,57.24,"VAPOR DIFFUSION, HANGING DROP",6.5,"1.4-1.6M Na malonate",277,"10.1073/pnas.1525545113",,"5GGF",196.65,"2.49","2.49","Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase form II","GSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAEEAECHWADTELNRRRRRFCSKVEGYGSVCSCKDPTPIEFSPDPLPDNKVLNVPVAVIAGNRPNYLYRMLRSLLSAQGVSPQMITVFIDGYYEEPMDVVALFGLRGIQHTPISIKNARVSQHYKASLTATFNLFPEAKFAVVLEEDLDIAVDFFSFLSQSIHLLEEDDSLYCISAWNDQGYEHTAEDPALLYRVETMPGLGWVLRRSLYKEELEPKWPTPEKLWDWDMWMRMPEQRRGRECIIPDVSRSYHFGIVGLNMNGYFHEAYFKKHKFNTVPGVQLRNVDSLKKEAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLVVGVPASPYSVKKPPSVTPIFLEPPPKEEGAPGAPEQTLELEVLFQG","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGF"
"5GGG",,"X-RAY DIFFRACTION",4.49,72.64,"VAPOR DIFFUSION, HANGING DROP",6.5,"Na malonate",277,"10.1073/pnas.1525545113",,"5GGG",65.55,"3","3","Crystal structure of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase form I","GSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAEEAECHWADTELNRRRRRFCSKVEGYGSVCSCKDPTPIEFSPDPLPDNKVLNVPVAVIAGNRPNYLYRMLRSLLSAQGVSPQMITVFIDGYYEEPMDVVALFGLRGIQHTPISIKNARVSQHYKASLTATFNLFPEAKFAVVLEEDLDIAVDFFSFLSQSIHLLEEDDSLYCISAWNDQGYEHTAEDPALLYRVETMPGLGWVLRRSLYKEELEPKWPTPEKLWDWDMWMRMPEQRRGRECIIPDVSRSYHFGIVGLNMNGYFHEAYFKKHKFNTVPGVQLRNVDSLKKEAYEVEVHRLLSEAEVLDHSKNPCEDSFLPDTEGHTYVAFIRMEKDDDFTTWTQLAKCLHIWDLDVRGNHRGLWRLFRKKNHFLVVGVPASPYSVKKPPSVTPIFLEPPPKEEGAPGAPEQTLELEVLFQG","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGG"
"5GGJ",,"X-RAY DIFFRACTION",2.34,47.52,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293,"10.1073/pnas.1525545113","PNA","5GGJ",35.85,"1.424","1.424","Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-alpha-pNP","GPLGSGSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAE","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGJ"
"5GGK",,"X-RAY DIFFRACTION",2.39,48.44,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris-HCl, PEG-10000",293,"10.1073/pnas.1525545113","MBE","5GGK",36.36,"1.3","1.3","Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with Man-beta-pNP","GPLGSGSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAE","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGK"
"5GGL",,"X-RAY DIFFRACTION",2.29,46.29,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-8000",293,"10.1073/pnas.1525545113","6ZC","5GGL",35.93,"1.27","1.27","Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-alpha-pNP","GPLGSGSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAE","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGL"
"5GGM",,"SOLUTION NMR",,,,,,,,,"5GGM",17,,,"The NMR structure of calmodulin in CTAB reverse micelles","ADQLTEEQIAEFKEAFSLFDKDGDGTITTKELGTVMRSLGQNPTEAELQDMINEVDADGDGTIDFPEFLTMMARKMKDTDSEEEIREAFRVFDKDGNGYISAAELRHVMTNLGEKLTDEEVDEMIREADIDGDGQVNYEEFVQMMTAK","Homo sapiens","CALM, CAM, CALM1, CAM1","Calmodulin","1","5GGM"
"5GGN",,"X-RAY DIFFRACTION",2.51,51.09,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293,"10.1073/pnas.1525545113","LEC","5GGN",35.93,"1.211","1.211","Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GlcNAc-beta-pNP","GPLGSGSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAE","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGN"
"5GGO",,"X-RAY DIFFRACTION",2.38,48.26,"VAPOR DIFFUSION, HANGING DROP",8.8,"Tris-HCl, PEG-6000",293,"10.1073/pnas.1525545113",,"5GGO",36.4,"1.502","1.502","Crystal structure of N-terminal domain of human protein O-mannose beta-1,2-N-acetylglucosaminyltransferase in complex with GalNac-beta1,3-GlcNAc-beta-pNP","GPLGSGSGPRRVLDVEVYSSRSKVYVAVDGTTVLEDEAREQGRGIHVIVLNQATGHVMAKRVFDTYSPHEDEAMVLFLNMVAPGRVLICTVKDEGSFHLKDTAKALLRSLGSQAGPALGWRDTWAFVGRKGGPVFGEKHSKSPALSSWGDPVLLKTDVPLSSAE","Homo sapiens","POMGNT1, MGAT1.2, UNQ746/PRO1475","Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1","1","5GGO"
"5GGQ",,"X-RAY DIFFRACTION",2.54,51.63,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M citric acid, pH 3.5, 2.0 M ammonium sulfate",293,"10.1038/ncomms13354",,"5GGQ",47.67,"1.9","1.9","Crystal structure of Nivolumab Fab fragment","EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQSSNWPRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"nivolumab light chain","1","5GGQ"
,,,,,,,,,,,,,,,,"QVQLVESGGGVVQPGRSLRLDCKASGITFSNSGMHWVRQAPGKGLEWVAVIWYDGSKRYYADSVKGRFTISRDNSKNTLFLQMNSLRAEDTAVYYCATNDDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHHHHHH","Homo sapiens",,"nivolumab heavy chain","2","5GGQ"
"5GGU",,"X-RAY DIFFRACTION",2.38,48.38,"VAPOR DIFFUSION, HANGING DROP",,"50 mM Tris, pH 8.5, 30% PEG4,000, 0.2 M ammonium chloride, 10 mM CaCl2",293,"10.1038/ncomms13354",,"5GGU",98.72,"2.292","2.292","Crystal structure of tremelimumab Fab","QVQLVESGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAVIWYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDPRGATLYYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTHHHHHH","Homo sapiens",,"heavy chain","1","5GGU"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCRASQSINSYLDWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYSTPFTFGPGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"light chain","2","5GGU"
"5GGZ",,"X-RAY DIFFRACTION",3.12,60.62,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris, 0.2 M MgCl2, 26% Peg 4000",277,"10.1021/acs.jmedchem.6b00912","6TN","5GGZ",95.63,"2.015","2.015","Crystal structure of novel inhibitor bound with Hsp90","EVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGVDISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKK","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5GGZ"
"5GHB",,"SOLUTION NMR",,,,,,,,,"5GHB",12.28,,,"SOLUTION STRUCTURE OF LYS42 ACETYLATED HUMAN SUMO2","MGSSHHHHHHSQDPMADEKPKEGVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG","Homo sapiens","SUMO2, SMT3B, SMT3H2","Small ubiquitin-related modifier 2","1","5GHB"
"5GHC",,"SOLUTION NMR",,,,,,,,,"5GHC",12.28,,,"SOLUTION STRUCTURE OF LYS33 ACETYLATED HUMAN SUMO2","MGSSHHHHHHSQDPMADEKPKEGVKTENNDHINLKVAGQDGSVVQFKIKRHTPLSKLMKAYCERQGLSMRQIRFRFDGQPINETDTPAQLEMEDEDTIDVFQQQTGG","Homo sapiens","SUMO2, SMT3B, SMT3H2","Small ubiquitin-related modifier 2","1","5GHC"
"5GHD",,"SOLUTION NMR",,,,,,,,,"5GHD",12.81,,,"SOLUTION STRUCTURE OF LYS39 ACETYLATED HUMAN SUMO1","MGSSHHHHHHSQDPMSDQEAKPSTEDLGDKKEGEYIKLKVIGQDSSEIHFKVKMTTHLKKLKESYCQRQGVPMNSLRFLFEGQRIADNHTPKELGMEEEDVIEVYQEQTGG","Homo sapiens","SUMO1, SMT3C, SMT3H3, UBL1, OK/SW-cl.43","Small ubiquitin-related modifier 1","1","5GHD"
"5GHI",,"X-RAY DIFFRACTION",1.89,35.09,"VAPOR DIFFUSION, HANGING DROP",6.5,"sodium citrate, sodium cacodylate, NaCl",293,"10.1074/jbc.M116.749713",,"5GHI",37.2,"1.211","1.211","Crystal structure of human MTH1(G2K mutant) in complex with 8-oxo-dGTP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHI"
"5GHJ",,"X-RAY DIFFRACTION",1.89,34.75,"VAPOR DIFFUSION, HANGING DROP",6.5,"sodium citrate, sodium cacodylate, NaCl",293,"10.1074/jbc.M116.749713",,"5GHJ",37.17,"1.2","1.2","Crystal structure of human MTH1(G2K mutant) in complex with 2-oxo-dATP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDDSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHJ"
"5GHM",,"X-RAY DIFFRACTION",1.87,34.35,"VAPOR DIFFUSION, HANGING DROP",7,"Sodium citrate, Tris, NaCl",293,"10.1074/jbc.M116.749713",,"5GHM",37.15,"1.5","1.5","Crystal structure of human MTH1(G2K/D120N mutant) in complex with 8-oxo-dGTP at pH 7.0","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDNSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHM"
"5GHN",,"X-RAY DIFFRACTION",1.87,34.05,"VAPOR DIFFUSION, HANGING DROP",7,"Sodium citrate, Tris, NaCl",293,"10.1074/jbc.M116.749713",,"5GHN",37.17,"1.391","1.391","Crystal structure of human MTH1(G2K/D120N mutant) in complex with 2-oxo-dATP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDNSYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHN"
"5GHO",,"X-RAY DIFFRACTION",1.88,34.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293,"10.1074/jbc.M116.749713",,"5GHO",36.66,"1.191","1.191","Crystal structure of human MTH1(G2K/D120A mutant) in complex with 8-oxo-dGTP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDASYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHO"
"5GHP",,"X-RAY DIFFRACTION",1.87,34.17,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293,"10.1074/jbc.M116.749713",,"5GHP",36.05,"1.192","1.192","Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDASYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHP"
"5GHQ",,"X-RAY DIFFRACTION",1.88,34.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"Sodium citrate, Sodium cacodylate, NaCl",293,"10.1074/jbc.M116.749713",,"5GHQ",37.08,"1.181","1.181","Crystal structure of human MTH1(G2K/D120A mutant) in complex with 2-oxo-dATP under high concentrations of 2-oxo-dATP","MKASRLYTLVLVLQPQRVLLGMKKRGFGAGRWNGFGGKVQEGETIEDGARRELQEESGLTVDALHKVGQIVFEFVGEPELMDVHVFCTDSIQGTPVESDEMRPCWFQLDQIPFKDMWPDASYWFPLLLQKKKFHGYFKFQGQDTILDYTLREVDTV","Homo sapiens","NUDT1, MTH1","7,8-dihydro-8-oxoguanine triphosphatase","1","5GHQ"
"5GHV",,"X-RAY DIFFRACTION",2.07,40.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"10~20%(V/V) PEG3350, 100 MM TRIS-HCL",278,"10.1111/febs.13831","X5G","5GHV",68.76,"2.8","2.8","Crystal structure of an inhibitor-bound Syk","EEIRPKEVYLDRKLLTLEDKELGSGNFGTVKKGYYQMKKVVKTVAVKILKNEANDPALKDELLAEANVMQQLDNPYIVRMIGICEAESWMLVMEMAELGPLNKYLQQNRHVKDKNIIELVHQVSMGMKYLEESNFVHRDLAARNVLLVTQHYAKISDFGLSKALRADENYYKAQTHGKWPVKWYAPECINYYKFSSKSDVWSFGVLMWEAFSYGQKPYRGMKGSEVTAMLEKGERMGCPAGCPREMYDLMNLCWTYDVENRPGFAAVELRLRNYYYDVVNLEHHHHHHHH","Homo sapiens","SYK","Tyrosine-protein kinase SYK","1","5GHV"
"5GIK",,"X-RAY DIFFRACTION",2.38,48.27,"VAPOR DIFFUSION, HANGING DROP",,"PEG 1000, reagent alcohol, sodium-phosphate dibasic/citric acid",291,,,"5GIK",16.95,"1.49","1.49","Modulation of the affinity of a HIV-1 capsid-directed ankyrin towards its viral target through critical amino acid editing","DLGKKLLEAARAGQDDEVRLLLEHGADVNARDYIGSTPLHLAAYYGHLEIVRLLLEHGADVNARDSTGTTPLHYAARLGHLEIVRLLLEHGADVNARDAMGWTPLHLAAKKGHLEIVRLLLKHGADVNANDHFGKTAFDISIDNGNEDLAEILQ","Homo sapiens",,"Artificial ankyrin repeat protein_Ank(GAG)1D4 mutant -S45Y","1","5GIK"
"5GIT",,"X-RAY DIFFRACTION",2.25,45.45,"EVAPORATION",,"0.2 M lithium acetate, 16% PEG 3350",293,"10.1089/ars.2016.6885",,"5GIT",15.66,"2.19","2.19","BTB domain of KEAP1 in complex with XX3","GSHMGNRTFSYTLEDHTKQAFGIMNELRLSQQLCDVTLQVKYQDAPAAQFMAHKVVLASSSPVFKAMFTNGLREQGMEVVSIEGIHPKVMERLIEFAYTASISMGEKCVLHVMNGAVMYQIDSVVRACADFLVQQLD","Homo sapiens","KEAP1, INRF2, KIAA0132, KLHL19","Kelch-like ECH-associated protein 1","1","5GIT"
"5GIW",,"SOLUTION NMR",,,,,,,"10.1016/j.bbrc.2016.06.114",,"5GIW",2.69,,,"Solution NMR structure of Humanin containing a D-isomerized serine residue","MAPRGFSCLLLLTSEIDLPVKRRA","Homo sapiens","MT-RNR2, HN","Humanin","1","5GIW"
"5GIX",,"X-RAY DIFFRACTION",2.5,50.85,"EVAPORATION",7.4,"PEG3350, 50 mM potassium phosphate (pH 7.5), 5% glycerol, and 4% DMSO.",293,"10.1021/acs.jmedchem.6b00509",,"5GIX",136.24,"2.801","2.801","Human serum albumin-Palmitic acid-Fe(Hn3piT)Cl2","HKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAAL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","5GIX"
"5GIY",,"X-RAY DIFFRACTION",2.52,51.17,"EVAPORATION",7,"28 PEG3350, 6% glycerol, 4% DMSO.",293,,,"5GIY",68.55,"2.543","2.543","HSA-Palmitic acid-[RuCl5(ind)]2-","HKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAAL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","5GIY"
"5GJJ",,"SOLUTION NMR",,,,,,,,,"5GJJ",27.86,,,"Glutathionylated hHsp70 SBD","SENVQDLLLLDVAPLSLGLETAGGVMTALIKRNSTIPTKQTQIFTTYSDNQPGVLIQVYEGERAMTKDNNLLGRFELSGIPPAPRGVPQIEVTFDIDANGILNVTATDKSTGKANKITITNDKGRLSKEEIERMVQEAEKYKAEDEVQRERVSAKNALESYAFNMKSAVEDEGLKGKISEADKKKVLDKCQEVISWLDANTLAEKDEFEHKRKELEQVCNPIISGLYQGAGGPGPGGFGAQGPKGGSGSGPTIEEVD","Homo sapiens","HSPA1A, HSP72, HSPA1, HSX70","Heat shock 70 kDa protein 1A","1","5GJJ"
"5GKS",,"X-RAY DIFFRACTION",2.22,44.61,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG 8000, 0.1M Phosphate-citrate (pH 4.2), 0.2M NaCl",293,"10.1038/s41598-017-16681-y",,"5GKS",92.88,"2.05","2.05","Crystal structure of SLE patient-derived anti-DNA antibody","QVQLQESGPGLVKSSETLSLTCTVSGGSISSYFWSWIRQPPGKGLEWIGYIYYSGSTNYNPSLKSRVTISLHTSKNQFSLKLSSVTAADTAVYYCARHRNWLFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVDHKPSNTKVDKTVERKC","Homo sapiens",,"IgG2, Fab (heavy chain)","1","5GKS"
,,,,,,,,,,,,,,,,"QSALTQPRSVSGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKVMIYDVSKRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYCCSYAGSYTYVFGTGTKVTVLGQPKANPTVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADGSPVKAGVETTKPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"lambda, Fab (light chain)","2","5GKS"
"5GL7",,"X-RAY DIFFRACTION",2.6,52.7,"VAPOR DIFFUSION, SITTING DROP",7.5,"100mM Tris pH 7.5, 200mM magnesium chloride, 5mM DTT, 21% PEG 8000",294,,,"5GL7",71.36,"2.013","2.013","Crystal structure of a truncated human cytosolic methionyl-tRNA synthetase","MSEEEELATLSEEEIAMAVTAWEKGLESLPPLRPQQNPVLPVAGERNVLITSALPYVNNVPHLGNIIGCVLSADVFARYSRLRQWNTLYLCGTDEYGTATETKALEEGLTPQEICDKYHIIHADIYRWFNISFDIFGRTTTPQQTKITQDIFQQLLKRGFVLQDTVEQLRCEHCARFLADRFVEGVCPFCGYEEARGDQCDKCGKLINAVELKKPQCKVCRSCPVVQSSQHLFLDLPKLEKRLEEWLGRTLPGSDWTPNAQFITRSWLRDGLKPRCITRDLKWGTPVPLEGFEDKVFYVWFDATIGYLSITANYTDQWERWWKNPEQVDLYQFMAKDNVPFHSLVFPCSALGAEDNYTLVSHLIATEYLNYEDGKFSKSRGVGVFGDMAQDTGIPADIWRFYLLYIRPEGQDSAFSWTDLLLKNNSELLNNLGNFINRAGMFVSKFFGGYVPEMVLTPDDQRLLAHVTLELQHYHQLLEKVRIRDALRSILTISRHGNQYIQVNEPWKRIKGSEADRQRAGTVTGLAVNIAALLSVMLQPYMPTVSATIQAQLQLPPPACSILLTNFLCTLPAGHQIGTVSPLFQKLENDQIESLRQRFGGGQAKTSPKPAVVETVLEHHHHHH","Homo sapiens","MARS, MARS1","Methionine--tRNA ligase, cytoplasmic","1","5GL7"
"5GLI",,"X-RAY DIFFRACTION",2.82,56.45,"LIPIDIC CUBIC PHASE",6.3,"MES, PEG 350 MME, (NH4)2SO4, 1,4-butanediol",293,"10.1038/nature19319",,"5GLI",53.56,"2.5","2.5","Human endothelin receptor type-B in the ligand-free form","GGGLAPAEVPKGDRTAGSPPRTISPPPCQGPIEIKETFKYINTVVSCLVFVLGIIGNSTLLYIIYKNKCMRNGPNILIASLALGDLLHIVIAIPINVYKLLAEDWPFGAEMCKLVPFIQKASVGITVLSLCALSIDRYRAVASWSRIKGIGVPKWTAVEIVLIWVVSVVLAVPEAIGFDIITMDYKGSYLRICLLHPVQKTAFMQFYATAKDWWLFSFYFCLPLAITAFFYTLMTCEMLRKNIFEMLRIDEGGGSGGDEAEKLFNQDVDAAVRGILRNAKLKPVYDSLDAVRRAALINMVFQMGETGVAGFTNSLRMLQQKRWDEAAVNLAKSRWYNQTPNRAKRVITTFRTGTWDAYLNDHLKQRREVAKTVFCLVLVFALCWLPLHLARILKLTLYNQNDPNRCELLSFLLVLDYIGINMASLNSCANPIALYLVSKRFKNAFKSALCCWAQSPSSENLYFQ","Homo sapiens","EDNRB, ETRB","Endothelin Receptor Subtype-B","1","5GLI"
"5GLJ",,"X-RAY DIFFRACTION",1.95,36.95,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.2 M Magnesium chloride hexahydrate , 0.1 M BIS-TRIS pH5.5, 25 % w/v Polyethylene glycol 3350",293,"10.1016/j.bbrc.2016.08.095",,"5GLJ",40.6,"1.6","1.6","Crystal Structure of PDZ1 Domain of Human Protein Tyrosine Phosphatase PTP-Bas","GHMSPEREITLVNLKKDAKYGLGFQIIGGEKMGRLDLGIFISSVAPGGPADLDGCLKPGDRLISVNSVSLEGVSHHAAIEILQNAPEDVTLVISQP","Homo sapiens","PTPN13, PNP1, PTP1E, PTPL1","Tyrosine-protein phosphatase non-receptor type 13","1","5GLJ"
"5GMM",,"X-RAY DIFFRACTION",2.45,49.79,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M HEPES pH 6.7~8.2, 0.5~1.4 M tri-Na citrate.",277,"10.1016/j.bbrc.2016.07.114","949","5GMM",60.18,"2.003","2.003","Crystal structure of human Carbonic anhydrase I in complex with polmacoxib","MASPDWGYDDKNGPEQWSKLYPIANGNNQSPVDIKTSETKHDTSLKPISVSYNPATAKEIINVGHSFHVNFEDNDNRSVLKGGPFSDSYRLFQFHFHWGSTNEHGSEHTVDGVKYSAELHVAHWNSAKYSSLAEAASKADGLAVIGVLMKVGEANPKLQKVLDALQAIKTKGKRAPFTNFDPSTLLPSSLDFWTYPGSLTHPPLYESVTWIICKESISVSSEQLAQFRSLLSNVEGDNAVPMQHNNRPTQPLKGRTVRASF","Homo sapiens","CA1","Carbonic anhydrase 1","1","5GMM"
"5GMN",,"X-RAY DIFFRACTION",1.87,34.16,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris pH 6.5, 28% PEGmme2K",277,"10.1016/j.bbrc.2016.07.114","949","5GMN",29.72,"1.8","1.8","Crystal structure of human carbonic anhydrase II in complex with polmacoxib","MSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5GMN"
"5GMP",,"X-RAY DIFFRACTION",3.39,63.73,"VAPOR DIFFUSION, HANGING DROP",8,"150mM KCl, 0.1M HEPES (pH 8.0), 38% PEG 300, 50mM Glycyl-glycyl-glycine, 10mM Co-enzyme A (pH 8.0), 2mM TCEP",293,"10.1016/j.ejmech.2016.12.006","F62","5GMP",38.18,"2.797","2.797","Crystal structure of EGFR 696-1022 T790M in complex with XTF-262","GAMGGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5GMP"
"5GN8",,"X-RAY DIFFRACTION",3.64,66.25,"VAPOR DIFFUSION",,"0.1 M imidazol-HCl at pH 7.5, 10% reagent alcohol (15%) and 0.2 M MgCl2",300,"10.1021/acsnano.6b06235",,"5GN8",37.71,"2.805","2.805","Structure of a 48-mer protein nanocage fabricated from its 24-mer analogue by subunit interface redesign","TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLIKELGDHV","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","2","5GN8"
,,,,,,,,,,,,,,,,"TTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5GN8"
"5GNH",,"X-RAY DIFFRACTION",2.2,44.08,"VAPOR DIFFUSION, HANGING DROP",,"100mM HEPES pH 7.5, 10% (v/v) polyethylene glycol 6000",295,,,"5GNH",132.35,"2.6","2.6","Myotubularin-related protein 2","MEEPPLLPGENIKDMAKDVTYICPFTGAVRGTLTVTNYRLYFKSMERDPPFVLDASLGVINRVEKIGGASSRGENSYGLETVCKDIRNLRFAHKPEGRTRRSIFENLMKYAFPVSNNLPLFAFEYKEVFPENGWKLYDPLLEYRRQGIPNESWRITKINERYELCDTYPALLVVPANIPDEELKRVASFRSRGRIPVLSWIHPESQATITRCSQPMVGVSGKRSKEDEKYLQAIMDSNAQSHKIFIFDARPSVNAVANKAKGGGYESEDAYQNAELVFLDIHNIHVMRESLRKLKEIVYPNIEETHWLSNLESTHWLEHIKLILAGALRIADKVESGKTSVVVHSSDGWDRTAQLTSLAMLMLDGYYRTIRGFEVLVEKEWLSFGHRFQLRVGHGDKNHADADRSPVFLQFIDCVWQMTRQFPTAFEFNEYFLITILDHLYSCLFGTFLCNSEQQRGKENLPKRTVSLWSYINSQLEDFTNPLYGSYSNHVLYPVASMRHLELWVGYYIRWNPRMKPQEPIHNRYKELLAKRAELQKKVEELQREISNRSTSSSERASSPAQCVTPVQTVV","Homo sapiens","MTMR2, KIAA1073","Myotubularin-related protein 2","1","5GNH"
"5GNI",,"X-RAY DIFFRACTION",3.7,66.8,"VAPOR DIFFUSION, SITTING DROP",,"0.1M MES pH6.5, 1.8M (NH4)2SO4, 0.01M CoCl2",291.15,"10.1038/srep38655",,"5GNI",49.1,"3.008","3.008","The crystal structure of PECAM-1 IgL1-2 trans-homophilic dimer","QENSFTINSVDMKSLPDWTVQNGKQLTLQCFADVSTTSHVKPQHQMLFYKDDVLFYQISSMKSTESYFIPEVRIYDSGTYKCTVIVNNKEKTTAEYQLLVEGVPSPRVTLDKKEAIQGGIVRVQCSVPEEKAPIHFTIEKLELNEKMVKLKREKNSRDQNFVILEFPVEEQDRVLSFRCQARIISGIHMQTSESTKSELVTVTESTGHHHHHH","Homo sapiens","PECAM1","Platelet endothelial cell adhesion molecule","1","5GNI"
"5GNK",,"X-RAY DIFFRACTION",3.06,59.83,"VAPOR DIFFUSION, HANGING DROP",6.5,"4.8M NaNO3 ,0.1M B-Tris propone pH 6.5, 5mM TCEP",293,"10.1021/acs.jmedchem.6b01907",,"5GNK",36.2,"1.796","1.796","Crystal structure of EGFR 696-988 T790M in complex with LXX-6-34","GAMGGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMH","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5GNK"
"5GNR",,"X-RAY DIFFRACTION",2.67,53.9,"VAPOR DIFFUSION, HANGING DROP",,"200 mM ammonium fluoride, 20% (w/v) PEG 3350",291,,,"5GNR",47.78,"2.65","2.65","the structure of mini-MFN1 K88A in complex with GDP","MAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGASSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDGSGSGSGGSEIARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GNR"
"5GNS",,"X-RAY DIFFRACTION",2.68,54.07,"VAPOR DIFFUSION, HANGING DROP",,"200mM sodium phosphate monobasic monohydrate, 20%(w/v) PEG3350",289,,,"5GNS",47.86,"2.702","2.702","Structures of human Mitofusin 1 provide insight into mitochondrial tethering","MAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGASSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDGSGSGSGGSEIARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GNS"
"5GNT",,"X-RAY DIFFRACTION",2.53,51.43,"VAPOR DIFFUSION, HANGING DROP",,"200 mM sodium sulfate decahydrate and 20% (w/v) PEG 3350",289,,,"5GNT",47.84,"2.665","2.665","BDLP-like folding of Mitofusin 1","MAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDGSGSGSGGSEIARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GNT"
"5GNU",,"X-RAY DIFFRACTION",2.81,56.21,"VAPOR DIFFUSION, HANGING DROP",,"200mM ammonium sulfate, 100mM Tris (pH 8.5), and 25%(w/v) PEG 3350",289,,,"5GNU",47.39,"4.113","4.113","the structure of mini-MFN1 apo","MAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDGSGSGSGGSEIARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GNU"
"5GO4",,"X-RAY DIFFRACTION",3.46,64.47,"VAPOR DIFFUSION, HANGING DROP",,"0.2M sodium citrate tribasic dehydrate and 20~22% PEG3350",293,"10.1038/nature21077",,"5GO4",48.42,"2.202","2.202","Truncated mitofusin-1, nucleotide-free","GPHMGGSMAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDKSAASAASAASAASAAARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GO4"
,,,,,,,,,,,,,,,,,"Homo sapiens","MFN1"
"5GOE",,"X-RAY DIFFRACTION",2.55,51.75,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium citrate tribasic and 20% PEG 3350",293,"10.1038/nature21077","GDP","5GOE",48.26,"1.801","1.801","Truncated mitofusin-1, GDP-bound","GPHMGGSMAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDKRHYSARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GOE"
,,,,,,,,,,,,,,,,,"Homo sapiens","MFN1"
"5GOF",,"X-RAY DIFFRACTION",2.74,55.11,"VAPOR DIFFUSION, HANGING DROP",,"1mM ZnCl2, 100mM Tris-HCl (pH 8.0~9.0), 15~16% PEG 3350, 10~15% glycerol",293,"10.1038/nature21077","GTP","5GOF",48.43,"1.604","1.604","Truncated mitofusin-1, GTP-bound","GPHMGGSMAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDKRHYSARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GOF"
,,,,,,,,,,,,,,,,,"Homo sapiens","MFN1"
"5GOM",,"X-RAY DIFFRACTION",2.57,52.05,"VAPOR DIFFUSION, HANGING DROP",,"100mM MES (pH 6.0), 240mM NaCl, 36% pentaerythriol propoxylate (5/4 PO/OH)",293,"10.1038/nature21077",,"5GOM",96.67,"2.802","2.802","Truncated mitofusin-1, transition-like state","GPHMGGSMAEPVSPLKHFVLAKKAITAIFDQLLEFVTEGSHFVEATYKNPELDRIATEDDLVEMQGYKDKLSIIGEVLSRRHMKVAFFGRTSSGKSSVINAMLWDKVLPSGIGHITNCFLSVEGTDGDKAYLMTEGSDEKKSVKTVNQLAHALHMDKDLKAGCLVRVFWPKAKCALLRDDLVLVDSPGTDVTTELDSWIDKFCLDADVFVLVANSESTLMNTEKHFFHKVNERLSKPNIFILNNRWDASASEPEYMEDVRRQHMERCLHFLVEELKVVNALEAQNRIFFVSAKEVLSARKQKAQGMPESGVALAEGFHARLQEFQNFEQIFEECISQSAVKTKFEQHTIRAKQILATVKNIMDSVNLAAEDKRHYSARLPKEIDQLEKIQNNSKLLRNKAVQLENELENFTKQFLPSSNEES","Homo sapiens","MFN1","Mitofusin-1","1","5GOM"
,,,,,,,,,,,,,,,,,"Homo sapiens","MFN1"
"5GOU",,"X-RAY DIFFRACTION",2.51,51.07,"VAPOR DIFFUSION",,"1% PEG 4K, 1% MPD, 0.1M NaAC",300,"10.1002/anie.201609517",,"5GOU",352.63,"2.91","2.91","Structure of a 16-mer protein nanocage fabricated from its 24-mer analogue by subunit interface redesign","MTTASTSQVRQNYHQDSEAAINRQINLELYASYVYLSMSYYFDRDDVALKNFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIKKPDCDDWESGLNAMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLLNEQVKANEQVKAIKELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES","Homo sapiens","FTH1, FTH, FTHL6, OK/SW-cl.84, PIG15","Ferritin heavy chain","1","5GOU"
"5GOX",,"X-RAY DIFFRACTION",2.47,50.3,"VAPOR DIFFUSION, HANGING DROP",8.7,"28 - 30% PEG 600, 0.1 M bis-tris propane, 3% 1, 6-hexanediol, 5 mM DTT",291,"10.1038/nsmb.3369",,"5GOX",44.09,"2.405","2.405","Eukaryotic Rad50 Functions as A Rod-shaped Dimer","GSHMKEINQTRDRLAKLNKELASSEQNKNHINNELKRKEEQLSSYEDKLFDVCGSQDFESDLDRLKEEIEKSSKQRAMLAGATAVYSQFITQLTDENQSCCPVCQRVFQTEAELQEVISDLQSKLRLAPDKLKSTESELKKKEKRRDEMLGLVPMRQSIIDLKEKEIPELRNKLQNVNRDIQRLKN","Homo sapiens","RAD50","DNA repair protein RAD50","1","5GOX"
"5GOY",,"X-RAY DIFFRACTION",2.63,53.25,"VAPOR DIFFUSION, SITTING DROP",7.5,"100 mM Tris pH8.0, 200 mM magnesium chloride, 100 mM potassium sodium tartrate tetrahydrate, 16% PEG8000",294,,,"5GOY",71.32,"2.278","2.278","The crystal structure of human cytosolic methionyl-tRNA synthetase in complex with methionine","MSEEEELATLSEEEIAMAVTAWEKGLESLPPLRPQQNPVLPVAGERNVLITSALPYVNNVPHLGNIIGCVLSADVFARYSRLRQWNTLYLCGTDEYGTATETKALEEGLTPQEICDKYHIIHADIYRWFNISFDIFGRTTTPQQTKITQDIFQQLLKRGFVLQDTVEQLRCEHCARFLADRFVEGVCPFCGYEEARGDQCDKCGKLINAVELKKPQCKVCRSCPVVQSSQHLFLDLPKLEKRLEEWLGRTLPGSDWTPNAQFITRSWLRDGLKPRCITRDLKWGTPVPLEGFEDKVFYVWFDATIGYLSITANYTDQWERWWKNPEQVDLYQFMAKDNVPFHSLVFPCSALGAEDNYTLVSHLIATEYLNYEDGKFSKSRGVGVFGDMAQDTGIPADIWRFYLLYIRPEGQDSAFSWTDLLLKNNSELLNNLGNFINRAGMFVSKFFGGYVPEMVLTPDDQRLLAHVTLELQHYHQLLEKVRIRDALRSILTISRHGNQYIQVNEPWKRIKGSEADRQRAGTVTGLAVNIAALLSVMLQPYMPTVSATIQAQLQLPPPACSILLTNFLCTLPAGHQIGTVSPLFQKLENDQIESLRQRFGGGQAKTSPKPAVVETVLEHHHHHH","Homo sapiens","MARS, MARS1","Methionine--tRNA ligase, cytoplasmic","1","5GOY"
"5GPH",,"SOLUTION NMR",,,,,,,,,"5GPH",13.11,,,"Solution structure of the Pin1-PPIase (S138A) mutant","GSHMEPARVRCSHLLVKHSQSRRPSSWRQEKITRTKEEALELINGYIQKIKSGEEDFESLASQFSDCSSAKARGDLGAFSRGQMQKPFEDAAFALRTGEMSGPVFTDSGIHIILRTE","Homo sapiens","PIN1","Peptidyl-prolyl cis-trans isomerase NIMA-interacting 1","1","5GPH"
"5GRN",,"X-RAY DIFFRACTION",1.61,23.71,"VAPOR DIFFUSION, SITTING DROP",,"0.2M KCl, 20% PEG 3350, pH 7.0",293,,,"5GRN",41.28,"1.77","1.77","Crystal structure of PDGFRA in Complex with WQ-C-159","GAMDKQKPRYEIRWRVIESISPDGHEYIYVDPMQLPYDSRWEFPRDGLVLGRVLGSGAFGKVVEGTAYGLSRSQPVMKVAVKMLKPTARSSEKQALMSELKIMTHLGPHLNIVNLLGACTKSGPIYIITEYCFYGDLVNYLHKNRDSFLSHKKKSMLDSEVKNLLSDDNSEGLTLLDLLSFTYQVARGMEFLASKNCVHRDLAARNVLLAQGKIVKICDFGLARDIMHDSNYVSKGSTFLPVKWMAPESIFDNLYTTLSDVWSYGILLWEIFSLGGTPYPGMMVDSTFYNKIKSGYRMAKPDHATSEVYEIMVKCWNSEPEKRPSFYHLSEIVENLLPGQYKKSYEKIHLDFLKSD","Homo sapiens","PDGFRA, PDGFR2, RHEPDGFRA","Platelet-derived growth factor receptor alpha","1","5GRN"
,,,,,,,,,,,,,,,,,"Homo sapiens","PDGFRA, PDGFR2, RHEPDGFRA"
"5GRT",,"X-RAY DIFFRACTION",2.76,55.38,,8,"0.57-0.90 M AMMONIUM SULFATE, 100 MM POTASSIUM PHOSPHATE, PH 8.0, AND 0.5% 1-N-BETA-OCTYL-D-GLUCOPYRANOSIDE HANGING DROP VAPOR DIFFUSION, CRYSTAL SOAKED IN ARTIFICIAL MOTHER LIQUOR AT PH 8.0,CONTAINING 0.5% BETA-OCTYL GLUCOSIDE AND 42 MM GLUTATHIONYLSPERMIDINE.",,"10.1021/bi963074p",,"5GRT",51.72,"2.4","2.4","HUMAN GLUTATHIONE REDUCTASE A34E, R37W MUTANT, GLUTATHIONYLSPERMIDINE COMPLEX","VASYDYLVIGGGSGGLESAWRAAELGARAAVVESHKLGGTCVNVGCVPKKVMWNTAVHSEFMHDHADYGFPSCEGKFNWRVIKEKRDAYVSRLNAIYQNNLTKSHIEIIRGHAAFTSDPKPTIEVSGKKYTAPHILIATGGMPSTPHESQIPGASLGITSDGFFQLEELPGRSVIVGAGYIAVEMAGILSALGSKTSLMIRHDKVLRSFDSMISTNCTEELENAGVEVLKFSQVKEVKKTLSGLEVSMVTAVPGRLPVMTMIPDVDCLLWAIGRVPNTKDLSLNKLGIQTDDKGHIIVDEFQNTNVKGIYAVGDVCGKALLTPVAIAAGRKLAHRLFEYKEDSKLDYNNIPTVVFSHPPIGTVGLTEDEAIHKYGIENVKTYSTSFTPMYHAVTKRKTKCVMKMVCANKEEKVVGIHMQGLGCDEMLQGFAVAVKMGATKADFDNTVAIHPTSSEELVTLR","Homo sapiens","GSR, GLUR, GRD1","GLUTATHIONE REDUCTASE","1","5GRT"
"5GRV",,"X-RAY DIFFRACTION",3.98,69.07,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES pH 6.5, 2.3 M Sodium acetate, 
5% glycerol",296,"10.1038/srep34515",,"5GRV",26.88,"2.3","2.3","Crystal structure of homo-specific diabody","DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"homo-specific diabody light chain","2","5GRV"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLIAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGS","Homo sapiens",,"homo-specific diabody heavy chain","1","5GRV"
"5GRW",,"X-RAY DIFFRACTION",2.95,58.29,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M Sodium citrate pH 4.5, 0.3 M Ammonium acetate, 30% PEG 4000",296,"10.1038/srep34515",,"5GRW",53.8,"2.8","2.8","Crystal structure of homo-specific diabody","EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLFAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGSDIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"homo-specific diabody protein","1","5GRW"
"5GRX",,"X-RAY DIFFRACTION",2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",3.5,"0.1 M Citric acid pH 3.5, 22% PEG 10000",296,"10.1038/srep34515",,"5GRX",53.66,"2.002","2.002","Crystal structure of disulfide-bonded diabody","EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTACDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGSDIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"diabody protein","1","5GRX"
"5GRY",,"X-RAY DIFFRACTION",2.8,56.06,"VAPOR DIFFUSION, SITTING DROP",3.5,"0.1 M Citric acid pH 3.5, 1.0 M Sodium chloride, 30% 2-methyl-2,4-pentanediol",296,"10.1038/srep34515",,"5GRY",53.72,"1.639","1.639","Crystal structure of disulfide-bonded diabody","EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYACSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSCGGGGSDIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"diabody","1","5GRY"
"5GRZ",,"X-RAY DIFFRACTION",2.44,49.59,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M Tris HCl pH 8.5, 0.15 M Magnesium chloride, 32% PEG 3350",296,"10.1038/srep34515",,"5GRZ",53.67,"2.7","2.7","Crystal structure of disulfide-bonded diabody","EVQLVESGGGLVQCGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVCGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGSDIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"diabody","1","5GRZ"
"5GS1",,"X-RAY DIFFRACTION",2.8,56.07,"VAPOR DIFFUSION, SITTING DROP",4.6,"0.1 M Sodium citrate pH 4.6, 0.2 M Ammonium sulfate, 18% PEG 8000",296,"10.1038/srep34515",,"5GS1",348.24,"2","2","Crystal structure of homo-specific diabody","DIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK","Homo sapiens",,"light chain","1","5GS1"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGS","Homo sapiens",,"heavy chain","2","5GS1"
,,,,,,,,,,,,,,,,"EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGSDIVLTQSPATLSLSPGERATLSCRASQSVSSNYLAWYQQKPGQAPRLLIYDSSSRATGVPARFSGSGSGTDFTLTISSLEPEDFAVYYCHQYSDISPTFGQGTKVEIK","Homo sapiens",,"diabody","3","5GS1"
"5GS3",,"X-RAY DIFFRACTION",2.76,55.37,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M Ammonium sulfate, 10% PEG 8000",296,"10.1038/srep34515",,"5GS3",53.36,"1.698","1.698","Crystal structure of diabody","EVQLVESGGGLVQPGGSLRLSCAASGFTFRNSAMHWVRQAPGKGLEWVSSIWYSGSNTYYADSVKGRFTISRDNSKNTLYLQMNSLTAEDTAVYYCARFAGGWGAYDVWGQGTLVTVSSGGGGSDIQMTQSPSSLSASVGDRVTITCRASQSIGLYLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGNTLSYTFGQGTKVEIKSGRLVPRGSRSHHHHHH","Homo sapiens",,"diabody protein","1","5GS3"
"5GS9",,"X-RAY DIFFRACTION",2.29,46.25,"VAPOR DIFFUSION, HANGING DROP",5,"0.1M sodium citrate (pH 5.0), 20% (w/v) PEG 8000",289,"10.1038/celldisc.2016.35","ARG","5GS9",150.22,"2.5","2.5","Crystal structure of CASTOR1-arginine","MELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIAGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLASLEHHHHHH","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","1","5GS9"
"5GSQ",,"X-RAY DIFFRACTION",2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",4.5,"0.1M sodium acetate trihydrate, pH4.5, 30% (w/v) PEG 3350",293,"10.1021/acschembio.7b00140",,"5GSQ",106.42,"1.85","1.85","Crystal structure of IgG Fc with a homogeneous glycoform and Antibody-Dependent Cellular Cytotoxicity","THTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5GSQ"
"5GSS",,"X-RAY DIFFRACTION",2.56,52,,5.8,"pH 5.8",,"10.1006/jmbi.1997.1364",,"5GSS",47.69,"1.95","1.95","HUMAN GLUTATHIONE S-TRANSFERASE P1-1, COMPLEX WITH GLUTATHIONE","PPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GTP_HUMAN, GSTP1, FAEES3, GST3","GLUTATHIONE S-TRANSFERASE P1-1","1","5GSS"
"5GT4",,"X-RAY DIFFRACTION",2.63,53.21,"EVAPORATION",6.5,"50mM Mes, 1.4M ammonium sulphate",277,,,"5GT4",29.45,"1.83","1.83","Crystal structure of the human vitamin D receptor ligand binding domain complexed with (1R,2S,3R,5Z,7E,14beta,17alpha)-2-cyanopropoxy-9,10-secocholesta-5,7,10-triene-1,3,25-triol","DSLRPKLSEEQQRIIAILLDAHHKTYDPTYSDFCQFRPPVRVNDGGGSVTLELSQLSMLPHLADLVSYSIQKVIGFAKMIPGFRDLTSEDQIVLLKSSAIEVIMLRSNESFTMDDMSWTCGNQDYKYRVSDVTKAGHSLELIEPLIKFQVGLKKLNLHEEEHVLLMAICIVSPDRPGVQDAALIEAIQDRLSNTLQTYIRCRHPPPGSHLLYAKMIQKLADLRSLNEEHSKQYRCLSFQPECSMKLTPLVLEVFG","Homo sapiens","VDR, NR1I1","Vitamin D3 receptor","1","5GT4"
"5GT7",,"X-RAY DIFFRACTION",2.5,46.09,"VAPOR DIFFUSION",,"5 % (w/v) PEG3350, 0.1 M Na Malonate pH 5.0",291,"10.1016/j.bbrc.2018.11.147",,"5GT7",148.72,"2.048","2.048","Crystal Structure of Arg-bound CASTOR1","AGSGHMMELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIAGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLAS","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","1","5GT7"
"5GT8",,"X-RAY DIFFRACTION",2.19,43.76,"VAPOR DIFFUSION, HANGING DROP",,"21%(w/v) PEG3350, 0.1M Tris pH 5.0, 0.2M MgCl2, 0.2% n- dodecyl- N, N- dimethylamine-N-oxide",291,"10.1016/j.bbrc.2018.11.147",,"5GT8",147.45,"2.8","2.8","Crystal Structure of apo-CASTOR1","AGSGHMMELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIAGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLAS","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","1","5GT8"
,,,,,,,,,,,,,,,,"AGSGHMMELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIIGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLAS","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","2","5GT8"
"5GTJ",,"X-RAY DIFFRACTION",2.41,48.86,"MICROBATCH",,"0.1M Tris-HCl pH 8.5, 0.9M potassium thiocyanate",291,"10.1371/journal.pone.0162115",,"5GTJ",83.12,"2","2","CRYSTAL STRUCTURE OF CATALYTICALLY ACTIVE FORM OF HUMAN DUSP26","QHPFLNVFELERLLYTGKTACNHADEVWPGLYLGDQDMANNRRELRRLGITHVLNASHSRWRGTPEAYEGLGIRYLGVEAHDSPAFDMSIHFQTAADFIHRALSQPGGKILVHSAVGVSRSATLVLAYLMLYHHLTLVEAIKKVKDHRGIIPNRGFLRQLLALDRRLRQGLEALEHHHHHH","Homo sapiens","DUSP26, DUSP24, LDP4, MKP8, NATA1, SKRP3","Dual specificity protein phosphatase 26","1","5GTJ"
"5GTM",,"X-RAY DIFFRACTION",3.48,68.96,"VAPOR DIFFUSION, HANGING DROP",,"100mM ammonium citrate tribasic (pH 7.0), 12% PEG 3350",291,"10.1038/ncomms15744",,"5GTM",136.86,"2.896","2.896","Modified human MxA, nucleotide-free form","PGSVAENNLCSQYEEKVRPCIDLIDSLRALGVEQDLALPAIAVIGDQSSGKSSVLEALSGVALPRGSGIVTRCPLVLKLKKLVNEDKWRGKVSYQDYEIEISDASEVEKEINKAQNAIAGEGMGISHELITLEISSRDVPDLTLIDLPGITRVAVGNQPADIGYKIKTLIKKYIQRQETISLVVVPSNVDIATTEALSMAQEVDPEGDRTIGILTKPDLVDKGTEDKVVDVVRNLVFHLKKGYMIVKCRGQQEIQDQLSLSEALQREKIFFENHPYFRDLLEEGKATVPCLAEKLTSELITHICKSLPLLENQIKETHQRITEELQKYGVDIPEDENEKMFFLSDKINAFNQDITALMQGEETVGEEDIRLFTRLRHEFHKWSTIIENNFQEGHKILSRKIQKFENQAAAAELPGFVNYRTFETIVKQQIKALEEPAVDMLHTVTDMVRLAFTDVSIKNFEEFFNLHRTAKSKIEDIRAEQEREGEKLIRLHFQDEQIVYGAFQSSSATDSSMEEIFQHLMAYHQEASKRISSHIPLIIQFFMLQTYGQQLQSAMSQLSQDKDTYSWLLKERSDTSDKRKFLKERLARLTQARRRLAQFPG","Homo sapiens","MX1","Interferon-induced GTP-binding protein Mx1","1","5GTM"
"5GTY",,"X-RAY DIFFRACTION",2.08,40.74,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.05M CaCl2, 0.1M B-Tris pH 6.2, 24% PEG 550MME, 5mM TCEP",293,"10.18632/oncotarget.15443",,"5GTY",305.48,"3.14","3.14","Crystal structure of EGFR 696-1022 T790M in complex with LXX-6-26","GAMGGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5GTY"
"5GTZ",,"X-RAY DIFFRACTION",3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",,"150 mM KCl, 0.1 M HEPES pH 8.0, 38% PEG 300, 50mM Glycyl-glycyl-glycine, 10 mM Co-enzyme A (pH 8.0), 2 mM TCEP",293,,,"5GTZ",38.69,"2.999","2.999","Crystal structure of EGFR 696-1022 T790M in complex with JTS-1-39","GAMGGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5GTZ"
"5GU6",,"X-RAY DIFFRACTION",3.07,59.94,"VAPOR DIFFUSION, SITTING DROP",7.2,"Polyethylene glycol (PEG) 8000",277,"10.1073/pnas.1621426114",,"5GU6",43.87,"2","2","Crystal structure of Human ERp44 form I","GSHMASEITSLDTENIDEILNNADVALVNFYADWCRFSQMLHPIFEEASDVIKEEFPNENQVVFARVDCDQHSDIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTLDRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVREITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFKDVLIPGKLKQFVFDLHSGKLHREFHHGPDPTDTAPGEQAQDVASSPPESSFQKLAPSEYRYTLLRD","Homo sapiens","ERP44, KIAA0573, TXNDC4, UNQ532/PRO1075","Endoplasmic reticulum resident protein 44","1","5GU6"
"5GU7",,"X-RAY DIFFRACTION",2.98,58.69,"VAPOR DIFFUSION, SITTING DROP",6.5,"Na/K tartrate",277,"10.1073/pnas.1621426114",,"5GU7",45.72,"2.05","2.05","Crystal Structure of human ERp44 form II","MGSSHHHHHHSSGLVPRGSHMASEITSLDTENIDEILNNADVALVNFYADWCRFSQMLHPIFEEASDVIKEEFPNENQVVFARVDCDQHSDIAQRYRISKYPTLKLFRNGMMMKREYRGQRSVKALADYIRQQKSDPIQEIRDLAEITTLDRSKRNIIGYFEQKDSDNYRVFERVANILHDDCAFLSAFGDVSKPERYSGDNIIYKPPGHSAPDMVYLGAMTNFDVTYNWIQDKCVPLVREITFENGEELTEEGLPFLILFHMKEDTESLEIFQNEVARQLISEKGTINFLHADCDKFRHPLLHIQKTPADCPVIAIDSFRHMYVFGDFKDVLIPGKLKQFVFDLHSGKLHREFHHGPDPTDTAPGEQAQDVASSPPESSFQKLAPSEYRYTLLRD","Homo sapiens","ERP44, KIAA0573, TXNDC4, UNQ532/PRO1075","Endoplasmic reticulum resident protein 44","1","5GU7"
"5GV2",,"X-RAY DIFFRACTION",2.25,45.38,"VAPOR DIFFUSION, HANGING DROP",,"PEG 3350, Magnesium acetate tetrahydrate",287,"10.1038/celldisc.2016.51",,"5GV2",77.3,"2.06","2.06","Crystal structure of Arginine-bound CASTOR1 from Homo sapiens","MGSHHHHHHSSGLVPRGSHMELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIAGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLASR","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","1","5GV2"
"5GVA",,"X-RAY DIFFRACTION",3.44,64.2,"VAPOR DIFFUSION, HANGING DROP",,"1.8M Ammonium citrate tribasic pH7.5",289,"10.1074/jbc.M116.758524",,"5GVA",38.02,"1.851","1.851","WD40 domain of human AND-1","MGHHHHHHHMEFGSMPATRKPMRYGHTEGHTEVCFDDSGSFIVTCGSDGDVRIWEDLDDDDPKFINVGEKAYSCALKSGKLVTAVSNNTIQVHTFPEGVPDGILTRFTTNANHVVFNGDGTKIAAGSSDFLVKIVDVMDSSQQKTFRGHDAPVLSLSFDPKDIFLASASCDGSVRVWQISDQTCAISWPLLQKCNDVINAKSICRLAWQPKSGKLLAIPVEKSVKLYRRESWSHQFDLSDNFISQTLNIVTWSPCGQYLAAGSINGLIIVWNVETKDCMERVKHEKGYAICGLAWHPTCGRISYTDAEGNLGLLENVCDPSGKTSSSKVSSRVEKDYNDLFDGD","Homo sapiens","WDHD1, AND1","WD repeat and HMG-box DNA-binding protein 1","1","5GVA"
"5GVB",,"X-RAY DIFFRACTION",3.21,61.66,"VAPOR DIFFUSION, HANGING DROP",,"2.5M sodium formate pH7.0",289,"10.1074/jbc.M116.758524",,"5GVB",50.51,"2.75","2.75","SepB domain of human AND-1","MSQRPFYDGPMPTPRQKPFQSGSTPLHLTHRFMVWNSIGIIRCYNDEQDNAIDVEFHDTSIHHATHLSNTLNYTIADLSHEAILLACESTDELASKLHCLHFSSWDSSKEWIIDLPQNEDIEAICLGQGWAAAATSALLLRLFTIGGVQKEVFSLAGPVVSMAGHGEQLFIVYHRGTGFDGDQCLGVQLLELGKKKKQILHGDPLPLTRKSYLAWIGFSAEGTPCYVDSEGIVRMLNRGLGNTWTPICNTREHCKGKSDHYWVVGIHENPQQLRCIPCKGSRFPPTLPRPAVAILSFKLPYCQIATEKGQMEEQFWRSVIFHNHLDYLAKNGYEYEESTKNQATKEQQELLMKMLALSCKLEREFRCVELADLMTQNAVNLAIKYASRSRKLILAQKLSELAVEKAAELTATQVEEEEEEEDFRKKLNAGYSNTATHHHHHH","Homo sapiens","WDHD1, AND1","WD repeat and HMG-box DNA-binding protein 1","1","5GVB"
"5GVC",,"X-RAY DIFFRACTION",2.72,54.83,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES-Na, 0.2 M MgCl2, 25% PEG3350",277,"10.1038/srep42123",,"5GVC",138.68,"2.436","2.436","Human Topoisomerase IIIb topo domain","PGHMKTVLMVAEKPSLAQSIAKILSRGSLSSHKGLNGACSVHEYTGTFAGQPVRFKMTSVCGHVMTLDFLGKYNKWDKVDPAELFSQAPTEKKEANPKLNMVKFLQVEGRGCDYIVLWLDCDKEGENICFEVLDAVLPVMNKAHGGEKTVFRARFSSITDTDICNAMACLGEPDHNEALSVDARQELDLRIGCAFTRFQTKYFQGKYGDLDSSLISFGPCQTPTLGFCVERHDKIQSFKPETYWVLQAKVNTDKDRSLLLDWDRVRVFDREIAQMFLNMTKLEKEAQVEATSRKEKAKQRPLALNTVEMLRVASSSLGMGPQHAMQTAERLYTQGYISYPRTETTHYPENFDLKGSLRQQANHPYWADTVKRLLAEGINRPRKGHDAGDHPPITPMKSATEAELGGDAWRLYEYITRHFIATVSHDCKYLQSTISFRIGPELFTCSGKTVLSPGFTEVMPWQSVPLEESLPTCQRGDAFPVGEVKMLEKQTNPPDYLTEAELITLMEKHGIGTDASIPVHINNICQRNYVTVESGRRLKPTNLGIVLVHGYYKIDAELVLPTIRSAVEKQLNLIAQGKADYRQVLGHTLDVFKRKFHYFVDSIAGMDELMEVSFS","Homo sapiens","TOP3B, TOP3B1","DNA topoisomerase 3-beta-1","1","5GVC"
"5GVD",,"X-RAY DIFFRACTION",3.1,60.38,"VAPOR DIFFUSION, SITTING DROP",5.6,"1.26 M NaH2PO4 and 0.14 M K2HPO4 (pH 5.6)",293,"10.1038/srep42123",,"5GVD",35.96,"1.623","1.623","Human TDRD3 DUF1767-OB domains","GPGHMAQVAGAALSQAGWYLSDEGIEACTSSPDKVNVNDIILIALNTDLRTIGKKFLPSDINSGKVEKLEGPCVLQIQKIRNVAAPKDNEESQAAPRMLRLQMTDGHISCTAVEFSYMSKISLNTPPGTKVKLSGIVDIKNGFLLLNDSNTTVLGGEVEHLIEKW","Homo sapiens","TDRD3","Tudor domain-containing protein 3","1","5GVD"
"5GVQ",,"SOLUTION NMR",,,,,,,"10.1002/pro.3080",,"5GVQ",11.38,,,"Solution structure of the first RRM domain of human spliceosomal protein SF3b49","GSSGSSGPISERNQDATVYVGGLDEKVSEPLLWELFLQAGPVVNTHMPKDRVTGQHQGYGFVEFLSEEDADYAIKIMDMIKLYGKPIRVNKASAHNKNLSGPSSG","Homo sapiens","SF3B4, SAP49","Splicing factor 3B subunit 4","1","5GVQ"
"5GVR",,"X-RAY DIFFRACTION",2.57,52.12,"VAPOR DIFFUSION",,"DL-malic acid",277,"10.1038/srep34756",,"5GVR",26.31,"1.5","1.5","Crystal structure of the DDX41 DEAD domain in an apo closed form","ILVEGDGIPPPIKSFKEMKFPAAILRGLKKKGIHHPTPIQIQGIPTILSGRDMIGIAFTGSGKTLVFTLPVIMFCLEQEKRLPFSKREGPYGLIICPSRELARQTHGILEYYCRLLQEDSSPLLRCALCIGGMSVKEQMETIRHGVHMMVATPGRLMDLLQKKMVSLDICRYLALDEADRMIDMGFEGDIRTIFSYFKGQRQTLLFSATMPKKIQNFAKSALVKPVTINVGRAG","Homo sapiens","DDX41, ABS","Probable ATP-dependent RNA helicase DDX41","1","5GVR"
"5GVS",,"X-RAY DIFFRACTION",2.26,45.64,"VAPOR DIFFUSION, SITTING DROP",,"tri-ammonium citrate,
PEG 3350",277,"10.1038/srep34756",,"5GVS",103.56,"2.2","2.2","Crystal structure of the DDX41 DEAD domain in an apo open form","ILVEGDGIPPPIKSFKEMKFPAAILRGLKKKGIHHPTPIQIQGIPTILSGRDMIGIAFTGSGKTLVFTLPVIMFCLEQEKRLPFSKREGPYGLIICPSRELARQTHGILEYYCRLLQEDSSPLLRCALCIGGMSVKEQMETIRHGVHMMVATPGRLMDLLQKKMVSLDICRYLALDEADRMIDMGFEGDIRTIFSYFKGQRQTLLFSATMPKKIQNFAKSALVKPVTINVG","Homo sapiens","DDX41, ABS","Probable ATP-dependent RNA helicase DDX41","1","5GVS"
"5GW0",,"X-RAY DIFFRACTION",3.67,66.49,"VAPOR DIFFUSION",7.5,"31mM Citric, 69mM Bis-tris Propanol, 18% PEG 5000, 70mM NaF, 2mM TCEP",277,"10.1016/j.str.2017.06.015",,"5GW0",128.71,"3.3","3.3","Crystal structure of SNX16 PX-Coiled coil","TVNWEDRPSTPTILGYEVMEERAKFTVYKILVKKTPEESWVVFRRYTDFSRLNDKLKEMFPGFRLALPPKRWFKDNYNADFLEDRQLGLQAFLQNLVAHKDIANCLAVREFLCLDDPPGPFDSLEESRAFCETLEETNYRLQKELLEKQKEMESLKKLLSEKQLHIDTLENRIRTLSLE","Homo sapiens","SNX16","Sorting nexin-16","1","5GW0"
"5GW1",,"X-RAY DIFFRACTION",3.18,61.32,"VAPOR DIFFUSION",7.5,"31mM Citric, 69mM Bis-tris Propanol, 18% PEG 5000, 70mM NaF, 2mM TCEP",277,"10.1016/j.str.2017.06.015",,"5GW1",171.61,"3.35","3.35","Crystal structure of SNX16 PX-Coiled coil in space group P212121","TVNWEDRPSTPTILGYEVMEERAKFTVYKILVKKTPEESWVVFRRYTDFSRLNDKLKEMFPGFRLALPPKRWFKDNYNADFLEDRQLGLQAFLQNLVAHKDIANCLAVREFLCLDDPPGPFDSLEESRAFCETLEETNYRLQKELLEKQKEMESLKKLLSEKQLHIDTLENRIRTLSLE","Homo sapiens","SNX16","Sorting nexin-16","1","5GW1"
"5GW6",,"X-RAY DIFFRACTION",3,58.98,"VAPOR DIFFUSION, HANGING DROP",5,"20% PEG 5000 MME, 100MM TRIS BIS PH 5.0, 0.05M AMMONIUM SULPHATE",289,"10.1016/j.str.2016.11.006",,"5GW6",22.98,"1.97","1.97","Water-Bridge Mediates Recognition of mRNA Cap in eIF4E","MESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDAANARGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV","Homo sapiens","EIF4E, EIF4EL1, EIF4F","Eukaryotic translation initiation factor 4E","1","5GW6"
"5GW9",,"X-RAY DIFFRACTION",2.72,54.76,"EVAPORATION",,"0.4M Ammonium sulfate",293,"10.1016/j.bbrc.2018.04.045",,"5GW9",70.39,"1.65","1.65","Crystal structure of C163, a backbone circularized G-CSF","SQSFLLKSLEQVRKIQGDGAALQEKLCATYKLCHPEELVLLGHSLGIPWAPLSSCPSQALQLAGCLSQLHSGLFLYQGLLQALEGISPELGPTLDTLQLDVADFATTIWQQMEELGMAPALQPTQGAMPAFASAFQRRAGGVLVASHLQSFLEVSYRVLRHLG","Homo sapiens","CSF3, C17orf33, GCSF","Granulocyte colony-stimulating factor","1","5GW9"
"5GWL",,"SOLUTION NMR",,,,,,,"10.1021/jacs.6b06897",,"5GWL",2.54,,,"Structure of two CCTG repeats","CCTGCCTG","Homo sapiens",,"DNA (5'-D(*CP*CP*TP*GP*CP*CP*TP*G)-3')","1","5GWL"
"5GWN",,"X-RAY DIFFRACTION",2.46,50,"VAPOR DIFFUSION, HANGING DROP",,"0.1M BIS-TRIS 5.5, 0.2M (NH4)2SO4, 16% PEG 3350",293,"10.1038/onc.2017.306",,"5GWN",48.44,"1.309","1.309","Crystal structure of human RCC2","GAMGSEHTKERVKLEGSKCKGQLLIFGATNWDLIGRKEVPKQQAAYRNLGQNLWGPHRYGCLAGVRVRTVVSGSCAAHSLLITTEGKLWSWGRNEKGQLGHGDTKRVEAPRLIEGLSHEVIVSAACGRNHTLALTETGSVFAFGENKMGQLGLGNQTDAVPSPAQIMYNGQPITKMACGAEFSMIMDCKGNLYSFGCPEYGQLGHNSDGKFIARAQRIEYDCELVPRRVAIFIEKTKDGQILPVPNVVVRDVACGANHTLVLDSQKRVFSWGFGGYGRLGHAEQKDEMVPRLVKLFDFPGRGASQIYAGYTCSFAVSEVGGLFFWGATNTSRESTMYPKAVQDLCGWRIRSLACGKSSIIVAADESTISWGPSPTFGELGYGDHKPKSSTAAQEVKTLDGIFSEQVAMGYSHSLVIARDESETEKEKIKKLPEYNPRTL","Homo sapiens","RCC2, KIAA1470, TD60","Protein RCC2","1","5GWN"
"5GXO",,"X-RAY DIFFRACTION",2.54,51.58,"VAPOR DIFFUSION, SITTING DROP",7,"1.5M potassium phosphate pH 7.0",289,"10.1016/j.freeradbiomed.2017.07.012",,"5GXO",44.66,"2.3","2.3","Discovery of a compound that activates SIRT3 to deacetylate Manganese Superoxide Dismutase","KHSLPDLPYDYGALEPHINAQIMQLHHSKHHAAYVNNLNVTEEKYQEALAKGDVTAQIALQPALKFNGGGHINHSIFWTNLSPNGGGEPKGELLEAIKRDFGSFDKFKEKLTAASVGVQGSGWGWLGFNKERGHLQIAACPNQDPLQGTTGLIPLLGIDVWEHAYYLQYKNVRPDYLKAIWNVINWENVTERYMACKK","Homo sapiens","SOD2","Superoxide dismutase [Mn], mitochondrial","1","5GXO"
"5GYN",,"X-RAY DIFFRACTION",2.48,50.42,"VAPOR DIFFUSION, SITTING DROP",7,"16% PEG 4000, 20 mM magnesium chloride, 100 mM HEPES pH7.0",294,,,"5GYN",32.22,"1.995","1.995","Crystal structure of human pyridoxal 5'-phosphate phosphatase (Chronophin) mutant - C221S","GAMDPMARCERLRGAALRDVLGRAQGVLFDCDGVLWNGERAVPGAPELLERLARAGKAALFVSNNSRRARPELALRFARLGFGGLRAEQLFSSALCAARLLRQRLPGPPDAPGAVFVLGGEGLRAELRAAGLRLAGDPSAGDGAAPRVRAVLVGYDEHFSFAKLREACAHLRDPECLLVATDRDPWHPLSDGSRTPGTGSLAAAVETASGRQALVVGKPSPYMFESITENFSIDPARTLMVGDRLETDILFGHRCGMTTVLTLTGVSRLEEAQAYLAAGQHDLVPHYYVESIADLTEGLED","Homo sapiens","PDXP, CIN, PLP, PLPP","Pyridoxal phosphate phosphatase","1","5GYN"
"5GZC",,"X-RAY DIFFRACTION",2.23,44.86,"VAPOR DIFFUSION, HANGING DROP",,"PEG 2000MME",298,"10.3390/ijms17122088",,"5GZC",17.32,"1.08","1.08","Crystal structure of Galectin-8 N-CRD with part of linker","NLQNIIYNPVIPFVGTIPDQLDPGTLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNTLINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRIGPEKIDTLGIYGKVNIHSIGFSFSSDLQ","Homo sapiens","LGALS8","Galectin-8","1","5GZC"
"5GZD",,"X-RAY DIFFRACTION",1.92,35.97,"VAPOR DIFFUSION, HANGING DROP",,"PEG 2000MME",298,"10.3390/ijms17122088",,"5GZD",17.11,"1.19","1.19","Galectin-8 N-terminal domain carbohydrate recognition domain","NLQNIIYNPVIPFVGTIPDQLDPGTLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNTLINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRIGPEKIDTLGIYGKVNIHSIGFSFS","Homo sapiens","LGALS8","Galectin-8","1","5GZD"
"5GZE",,"X-RAY DIFFRACTION",1.91,35.55,"VAPOR DIFFUSION, HANGING DROP",,"PEG 2000MME",298,"10.3390/ijms17122088",,"5GZE",17.11,"1.32","1.32","Galectin-8 N-terminal domain carbohydrate recognition domain","NLQNIIYNPVIPFVGTIPDQLDPGTLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNTLINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRIGPEKIDTLGIYGKVNIHSIGFSFS","Homo sapiens","LGALS8","Galectin-8","1","5GZE"
"5GZF",,"X-RAY DIFFRACTION",2.25,45.3,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH 8.5, 0.01M NiCl2, 20% (W/V) PEG 2000 MME",298,"10.3390/ijms17122088",,"5GZF",21.63,"2.002","2.002","Galectin-8 N-terminal domain carbohydrate recognition domain","GSHMMLSLNNLQNIIYNPVIPFVGTIPDQLDPGTLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNTLINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRIGPEKIDTLGIYGKVNIHSIGFSFSSDLQSTQASSLELTEISRENVPKSGTPQLRLP","Homo sapiens","LGALS8","Galectin-8","1","5GZF"
"5GZG",,"X-RAY DIFFRACTION",2.27,45.85,"VAPOR DIFFUSION, SITTING DROP",,"0.1M Tris pH 8.5, 0.01M NiCl2,20% (W/V) PEG2000 MME",298,"10.3390/ijms17122088",,"5GZG",21.63,"1.997","1.997","Galectin-8 N-terminal domain carbohydrate recognition domain","GSHMMLSLNNLQNIIYNPVIPFVGTIPDQLDPGTLIVIRGHVPSDADRFQVDLQNGSSMKPRADVAFHFNPRFKRAGCIVCNTLINEKWGREEITYDTPFKREKSFEIVIMVLKDKFQVAVNGKHTLLYGHRIGPEKIDTLGIYGKVNIHSIGFSFSSDLQSTQASSLELTEISRENVPKSGTPQLRLP","Homo sapiens","LGALS8","Galectin-8","1","5GZG"
"5H08",,"X-RAY DIFFRACTION",2.6,52.68,"VAPOR DIFFUSION, SITTING DROP",8.5,"10%(w/v) PEG8000, 20%(v/v) ethylene glycol, 30mM sodium fluoride, 30mM sodium bromide, 30mM sodium iodide. NAZ2329 was soaked into the crystal.",277,"10.1038/s41598-017-05931-8",,"5H08",34.46,"2.53","2.53","Human PTPRZ D1 domain complexed with NAZ2329","GPAIPIKHFPKHVADLHASSGFTEEFEEVQSCTVDLGITADSSNHPDNKHKNRYINIVAYDHSRVKLAQLAEKDGKLTDYINANYVDGYNRPKAYIAAQGPLKSTAEDFWRMIWEHNVEVIVMITNLVEKGRRKCDQYWPADGSEEYGNFLVTQKSVQVLAYYTVRNFTLRNTKIKKGSQKGRPSGRVVTQYHYTQWPDMGVPEYSLPVLTFVRKAAYAKRHAVGPVVVHCSAGVGRTGTYIVLDSMLQQIQHEGTVNIFGFLKHIRSQRNYLVQTEEQYVFIHDTLVEAILSKETEV","Homo sapiens","PTPRZ1, HTPZP2, PTPRZ, PTPRZ2, PTPZ","Receptor-type tyrosine-protein phosphatase zeta","1","5H08"
"5H09",,"X-RAY DIFFRACTION",2.3,46.58,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293,"10.1016/j.bmc.2017.05.053","OOO","5H09",52.54,"1.945","1.945","Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-ethyl2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoate","GAMGSGIRIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYEEIP","Homo sapiens","HCK","Tyrosine-protein kinase HCK","1","5H09"
"5H0B",,"X-RAY DIFFRACTION",2.34,47.44,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293,"10.1016/j.bmc.2017.05.053","OOQ","5H0B",52.51,"1.651","1.651","Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanoic acid","GAMGSGIRIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYEEIP","Homo sapiens","HCK","Tyrosine-protein kinase HCK","1","5H0B"
"5H0E",,"X-RAY DIFFRACTION",2.31,46.66,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25M ammonium formate, 12-22% PEG 3350",293,"10.1016/j.bmc.2017.05.053","OOS","5H0E",52.51,"2.1","2.1","Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-4-methylpentanamide","GAMGSGIRIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYEEIP","Homo sapiens","HCK","Tyrosine-protein kinase HCK","1","5H0E"
"5H0G",,"X-RAY DIFFRACTION",2.32,46.93,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293,"10.1016/j.bmc.2017.05.053","OOU","5H0G",52.53,"1.8","1.8","Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,4-dimethylpentanamide","GAMGSGIRIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYEEIP","Homo sapiens","HCK","Tyrosine-protein kinase HCK","1","5H0G"
"5H0H",,"X-RAY DIFFRACTION",2.32,46.87,"VAPOR DIFFUSION, SITTING DROP",,"0.22-0.25 M ammonium formate, 12-22 % PEG 3350",293,"10.1016/j.bmc.2017.05.053","OOV","5H0H",52.54,"1.72","1.72","Crystal structure of HCK complexed with a pyrrolo-pyrimidine inhibitor (S)-2-(((1r,4S)-4-(4-amino-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclohexyl)amino)-N,N,4-trimethylpentanamide","GAMGSGIRIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEEWFFKGISRKDAERQLLAPGNMLGSFMIRDSETTKGSYSLSVRDYDPRQGDTVKHYKIRTLDNGGFYISPRSTFSTLQELVDHYKKGNDGLCQKLSVPCMSSKPQKPWEKDAWEIPRESLKLEKKLGAGQFGEVWMATYNKHTKVAVKTMKPGSMSVEAFLAEANVMKTLQHDKLVKLHAVVTKEPIYIITEFMAKGSLLDFLKSDEGSKQPLPKLIDFSAQIAEGMAFIEQRNYIHRDLRAANILVSASLVCKIADFGLARVIEDNEYTAREGAKFPIKWTAPEAINFGSFTIKSDVWSFGILLMEIVTYGRIPYPGMSNPEVIRALERGYRMPRPENCPEELYNIMMRCWKNRPEERPTFEYIQSVLDDFYTATESQYEEIP","Homo sapiens","HCK","Tyrosine-protein kinase HCK","1","5H0H"
"5H0P",,"X-RAY DIFFRACTION",1.83,32.71,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M trimethlyamine-N-oxide dihydrate, 0.1 M Tris-HCl (pH 8.5), 20% (w/v) PEG 2000 MME",290,"10.1016/j.bbrc.2016.12.124",,"5H0P",13.83,"1.862","1.862","Crystal structure of EF-hand protein mutant","GAMGSGEPQSPSRRVFNPYTEFKEFSRKQIKDMEKMFKQYDAGRDGFIDLMELKLMMEKLGAPQTHLGLKNMIKEVDEDFDSKLSFREFLLIFRKAAAGELQEDSGLCVLARLSEIDVES","Homo sapiens","EFHD2, SWS1","EF-hand domain-containing protein D2","1","5H0P"
"5H0V",,"X-RAY DIFFRACTION",2.1,41.52,"VAPOR DIFFUSION, SITTING DROP",4.6,"16% (+/-)-2-methyl-2,4-pentanediol, 0.2 M MgCl2, 0.1 M sodium acetate",293,"10.1002/1873-3468.12704",,"5H0V",55.9,"1.58","1.58","Crystal structure of H88A mutated human transthyretin","AHHHHHHMSPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFAEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5H0V"
"5H0W",,"X-RAY DIFFRACTION",1.99,38.28,"VAPOR DIFFUSION, SITTING DROP",6,"2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES",293,"10.1002/1873-3468.12704",,"5H0W",14.08,"1.904","1.904","Crystal structure of H88F mutated human transthyretin","AHHHHHHMSPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFFEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5H0W"
"5H0X",,"X-RAY DIFFRACTION",2.08,40.88,"VAPOR DIFFUSION, SITTING DROP",4.8,"1.8 M ammonium sulfate, 25% glycerol, 0.1 M sodium acetate",293,"10.1002/1873-3468.12704",,"5H0X",27.85,"1.573","1.573","Crystal structure of H88S mutated human transthyretin","AHHHHHHMSPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFSEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5H0X"
"5H0Y",,"X-RAY DIFFRACTION",1.97,37.69,"VAPOR DIFFUSION, SITTING DROP",6,"2.0 M ammonium sulfate, 25% glycerol, 0.1 M MES",293,"10.1002/1873-3468.12704",,"5H0Y",14.13,"1.8","1.8","Crystal structure of H88Y mutated human transthyretin","AHHHHHHMSPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFYEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5H0Y"
"5H0Z",,"X-RAY DIFFRACTION",2.02,39.23,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.6 M Ammonium sulfate, 0.1 M sodium acetate",293,"10.1002/1873-3468.12704",,"5H0Z",14.08,"1.735","1.735","Crystal structure of P113A mutated human transthyretin","AHHHHHHMSPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSAYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5H0Z"
"5H13",,"X-RAY DIFFRACTION",2.15,42.71,"VAPOR DIFFUSION, SITTING DROP",,"3.3 M Na formate, 0.01 M Yttrium chloride hexahydrate",293,"10.1371/journal.pone.0169855","LQA","5H13",44.1,"1.9","1.9","EED in complex with PRC2 allosteric inhibitor EED396","GILENLYFQGKKCKYSFKCVNSLKEDHNQPLFGVQFNWHSKEGDPLVFATVGSNRVTLYECHSQGEIRLLQSYVDADADENFYTCAWTYDSNTSHPLLAVAGSRGIIRIINPITMQCIKHYVGHGNAINELKFHPRDPNLLLSVSKDHALRLWNIQTDTLVAIFGGVEGHRDEVLSADYDLLGEKIMSCGMDHSLKLWRINSKRMMNAIKESYDYNPNKTNRPFISQKIHFPDFSTRDIHRNYVDCVRWLGDLILSKSCENAIVCWKPGKMEDDIDKIKPSESNVTILGRFDYSQCDIWYMRFSMDFWQKMLALGNQVGKLYVWDLEVEDPHKAKCTTLTHHKCGAAIRQTSFSRDSSILIAVCDDASIWRWDRLR","Homo sapiens","EED","Polycomb protein EED","1","5H13"
"5H1D",,"X-RAY DIFFRACTION",2.36,47.9,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 1500",293,"10.1016/j.bbagen.2016.10.003",,"5H1D",16.43,"1.494","1.494","Crystal structure of C-terminal of RhoGDI2","HMDPKAPNVVVTRLTLVCESAPGPITMDLTGDLEALKKETIVLKEGSEYRVKIHFKVNRDIVSGLKYVQHTYRTGVKVDKATFMVGSYGPRPEEYEFLTPVEEAPKGMLARGTYHNKSFFTDDDKQDHLSWEWNLSIKKEWTE","Homo sapiens","ARHGDIB, GDIA2, GDID4, RAP1GN1","Rho GDP-dissociation inhibitor 2","1","5H1D"
"5H1J",,"X-RAY DIFFRACTION",2.46,50.05,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M Sodium malonate (pH 7.0), 12% polyethylene glycol (PEG) 3350",289,"10.1101/gad.291377.116",,"5H1J",81.43,"2","2","Crystal structure of WD40 repeat domains of Gemin5","GAMGIRNSMGQEPRTLPPSPNWYCARCSDAVPGGLFGFAARTSVFLVRVGPGAGESPGTPPFRVIGELVGHTERVSGFTFSHHPGQYNLCATSSDDGTVKIWDVETKTVVTEHALHQHTISTLHWSPRVKDLIVSGDEKGVVFCYWFNRNDSQHLFIEPRTIFCLTCSPHHEDLVAIGYKDGIVVIIDISKKGEVIHRLRGHDDEIHSIAWCPLPGEDCLSINQEETSEEAEITNGNAVAQAPVTKGCYLATGSKDQTIRIWSCSRGRGVMILKLPFLKRRGGGIDPTVKERLWLTLHWPSNQPTQLVSSCFGGELLQWDLTQSWRRKYTLFSASSEGQNHSRIVFNLCPLQTEDDKQLLLSTSMDRDVKCWDIATLECSWTLPSLGGFAYSLAFSSVDIGSLAIGVGDGMIRVWNTLSIKNNYDVKNFWQGVKSKVTALCWHPTKEGCLAFGTDDGKVGLYDTYSNKPPQISSTYHKKTVYTLAWGPPVPPMSLGGEGDRPSLALYSCGGEGIVLQHNPWKLSGEAFDINKLIRDTNSIKYKLPVHTEISWKADGKIMALGNEDGSIEIFQIPNLKLICTIQQHHKLVNTISWHHEHGSQPELSYLMASGSNNAVIYVHNLKTVIESSPESPVTITEPYRTLSGHTAKITSVAWSPHHDGRLVSASYDGTAQVWDALREEPLCNFRGHRGRLLCVAWSPLDPDCIYSGADDFCVHKWLTSMQDHSRPPQGKKS","Homo sapiens","GEMIN5","Gem-associated protein 5","1","5H1J"
"5H1M",,"X-RAY DIFFRACTION",2.44,49.67,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.1M HEPES (pH 7.5), 14% PEG 8000, 25mM MgCl2",289,"10.1101/gad.291377.116",,"5H1M",81.89,"2.492","2.492","Crystal structure of WD40 repeat domains of Gemin5 in complex with M7G","GAMGIRNSMGQEPRTLPPSPNWYCARCSDAVPGGLFGFAARTSVFLVRVGPGAGESPGTPPFRVIGELVGHTERVSGFTFSHHPGQYNLCATSSDDGTVKIWDVETKTVVTEHALHQHTISTLHWSPRVKDLIVSGDEKGVVFCYWFNRNDSQHLFIEPRTIFCLTCSPHHEDLVAIGYKDGIVVIIDISKKGEVIHRLRGHDDEIHSIAWCPLPGEDCLSINQEETSEEAEITNGNAVAQAPVTKGCYLATGSKDQTIRIWSCSRGRGVMILKLPFLKRRGGGIDPTVKERLWLTLHWPSNQPTQLVSSCFGGELLQWDLTQSWRRKYTLFSASSEGQNHSRIVFNLCPLQTEDDKQLLLSTSMDRDVKCWDIATLECSWTLPSLGGFAYSLAFSSVDIGSLAIGVGDGMIRVWNTLSIKNNYDVKNFWQGVKSKVTALCWHPTKEGCLAFGTDDGKVGLYDTYSNKPPQISSTYHKKTVYTLAWGPPVPPMSLGGEGDRPSLALYSCGGEGIVLQHNPWKLSGEAFDINKLIRDTNSIKYKLPVHTEISWKADGKIMALGNEDGSIEIFQIPNLKLICTIQQHHKLVNTISWHHEHGSQPELSYLMASGSNNAVIYVHNLKTVIESSPESPVTITEPYRTLSGHTAKITSVAWSPHHDGRLVSASYDGTAQVWDALREEPLCNFRGHRGRLLCVAWSPLDPDCIYSGADDFCVHKWLTSMQDHSRPPQGKKS","Homo sapiens","GEMIN5","Gem-associated protein 5","1","5H1M"
"5H1T",,"X-RAY DIFFRACTION",2.38,48.24,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,"10.1111/febs.14041","7FF","5H1T",86.43,"1.951","1.951","Complex structure of TRIM24 PHD-bromodomain and inhibitor 1","PNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYP","Homo sapiens","TRIM24, RNF82, TIF1, TIF1A","Transcription intermediary factor 1-alpha","1","5H1T"
"5H1U",,"X-RAY DIFFRACTION",2.36,47.96,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,"10.1111/febs.14041","6KT","5H1U",86.46,"1.901","1.901","Complex structure of TRIM24 PHD-bromodomain and inhibitor 2","PNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYP","Homo sapiens","TRIM24, RNF82, TIF1, TIF1A","Transcription intermediary factor 1-alpha","1","5H1U"
"5H1V",,"X-RAY DIFFRACTION",2.39,48.43,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES sodium, 2%(v/v) Polyethylene glycol 400, 2.0 M Ammonium sulfate",293,"10.1111/febs.14041","7FU","5H1V",43.25,"2.002","2.002","Complex structure of TRIM24 PHD-bromodomain and inhibitor 6","PNEDWCAVCQNGGELLCCEKCPKVFHLSCHVPTLTNFPSGEWICTFCRDLSKPEVEYDCDAPSHNSEKKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYP","Homo sapiens","TRIM24, RNF82, TIF1, TIF1A","Transcription intermediary factor 1-alpha","1","5H1V"
"5H1Y",,"X-RAY DIFFRACTION",2.19,38.8,"VAPOR DIFFUSION, HANGING DROP",,"0.2M ammonium sulfate, 25% PEG 3,350, 0.1M Bis-Tris, pH 6.5",289.15,"10.1007/s13238-016-0351-9",,"5H1Y",63.68,"2.26","2.26","Crystal structure of the DDX41 DEAD domain in complex with SO42- and Mg2+","MHHHHHHSSGVDLGTENLYFQSNLSMSEERHERVRKKYHILVEGDGIPPPIKSFKEMKFPAAILRGLKKKGIHHPTPIQIQGIPTILSGRDMIGIAFTGSGKTLVFTLPVIMFCLEQEKRLPFSKREGPYGLIICPSRELARQTHGILEYYCRLLQEDSSPLLRCALCIGGMSVKEQMETIRHGVHMMVATPGRLMDLLQKKMVSLDICRYLALDEADRMIDMGFEGDIRTIFSYFKGQRQTLLFSATMPKKIQNFAKSALVKPVTINVGRAGAASLDVIQ","Homo sapiens","DDX41, ABS","Probable ATP-dependent RNA helicase DDX41","1","5H1Y"
"5H21",,"X-RAY DIFFRACTION",1.83,32.68,"VAPOR DIFFUSION, SITTING DROP",,"10-15% glycerol, 4M sodium formate",289,"10.1039/c7md00083a",,"5H21",17.02,"1.591","1.591","Trimethoxy-ring inhibitor in complex with the first bromodomain of BRD4","MGHHHHHHENLYFQMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5H21"
"5H2U",,"X-RAY DIFFRACTION",2.53,51.48,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M tri-Lithium citrate, 20 %(w/v) PEG 3350",298,"10.1016/j.bbrc.2016.12.030","1N1","5H2U",126.52,"2.24","2.24","Crystal structure of PTK6 Kinase Domain complexed with Dasatinib","MERPREEFTLCRKLGSGYFGEVFEGLWKDRVQVAIKVISRDNLLHQQMLQSEIQAMKKLRHKHILALYAVVSVGDPVYIITELMAKGSLLELLRDSDEKVLPVSELLDIAWQVAEGMCYLESQNYIHRDLAARNILVGENTLCKVGDFGLARLIKEDVYLSHDHNIPYKWTAPEALSRGHYSTKSDVWSFGILLHEMFSRGQVPYPGMSNHEAFLRVDAGYRMPCPLECPPSVHKLMLTCWCRDPEQRPTFKALRERLSSFTSHHHH","Homo sapiens","PTK6, BRK","Protein-tyrosine kinase 6","1","5H2U"
"5H2Z",,"X-RAY DIFFRACTION",3.44,64.28,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293,,,"5H2Z",43.92,"1.58","1.58","Crystal structure of Human Dihydroorotate Dehydrogenase (DHODH) with 7GF","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5H2Z"
"5H31",,"X-RAY DIFFRACTION",2.66,53.69,"EVAPORATION",8.5,"100 mM sodium chloride, 100 mM Tris, 21% PEG3350, 10 mM Sarcosine,",293,,,"5H31",89.37,"3.16953525699","3.16953525699","Structural basis for dimerization of the death effector domains of Caspase-8","MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKALLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSS","Homo sapiens","CASP8, MCH5","Caspase-8","1","5H31"
"5H33",,"X-RAY DIFFRACTION",2.91,57.75,"EVAPORATION",8.5,"50mM sodium chloride, 100mM Tris pH 8.5, 22.5% PEG3350",293,,,"5H33",44.69,"3.60013805027","3.60013805027","Structural basis for dimerization of the death effector domains of Caspase-8","MDFSRNLYDIGEQLDSEDLASLKFLSLDYIPQRKQEPIKDALMLFQRLQEKRMLEESNLSFLKELLFRINRLDLLITYLNTRKEEMERELQTPGRAQISAYRVMLYQISEEVSRSELRSFKALLQEEISKCKLDDDMNLLDIFIEMEKRVILGEGKLDILKRVCAQINKSLLKIINDYEEFSKERSSS","Homo sapiens","CASP8, MCH5","Caspase-8","1","5H33"
"5H3D","14","ELECTRON MICROSCOPY",,,,,,,"10.1371/journal.pcbi.1007081",,"5H3D",173.34,"14",,"Helical structure of membrane tubules decorated by ACAP1 (BARPH doamin) protein by cryo-electron microscopy and MD simulation","GPLGSMTVKLDFEECLKDSPRFRASIELVEAEVSELETRLEKLLKLGTGLLESGRHYLAASRAFVVGICDLARLGPPEPMMAECLEKFTVSLNHKLDSHAELLDATQHTLQQQIQTLVKEGLRGFREARRDFWRGAESLEAALTHNAEVPRRRAQEAEEAGAALRTARAGYRGRALDYALQINVIEDKRKFDIMEFVLRLVEAQATHFQQGHEELSRLSQYRKELGAQLHQLVLNSAREKRDMEQRHVLLKQKELGGEEPEPSLREGPGGLVMEGHLFKRASNAFKTWSRRWFTIQSNQLVYQKKYKDPVTVVVDDLRLCTVKLCPDSERRFCFEVVSTSKSCLLQADSERLLQLWVSAVQSSIASAFSQARLDDSPRGPGQ","Homo sapiens","ACAP1, CENTB1, KIAA0050","Arf-GAP with coiled-coil, ANK repeat and PH domain-containing protein 1","1","5H3D"
"5H3M",,"SOLUTION NMR",,,,,,,"10.1038/srep45230",,"5H3M",14.97,,,"Solution structure of human Gelsolin protein domain 1 at pH 5.0","EHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQ","Homo sapiens","GSN","Gelsolin","1","5H3M"
"5H3N",,"SOLUTION NMR",,,,,,,"10.1038/srep45230",,"5H3N",14.97,,,"Solution structure of human Gelsolin protein domain 1 at pH 7.3","EHPEFLKAGKEPGLQIWRVEKFDLVPVPTNLYGDFFTGDAYVILKTVQLRNGNLQYDLHYWLGNECSQDESGAAAIFTVQLDDYLNGRAVQHREVQGFESATFLGYFKSGLKYKKGGVASGFKHVVPNEVVVQ","Homo sapiens","GSN","Gelsolin","1","5H3N"
"5H3Q",,"X-RAY DIFFRACTION",3.97,68.99,"VAPOR DIFFUSION, SITTING DROP",8.5,"1.2M Sodium Tartrate, 100mM Tris-HCl pH 8.5, 5 mM DTT",293,"10.1016/j.bmcl.2017.01.056","7HF","5H3Q",37.33,"2.1","2.1","Crystal Structure of TrkA kinase with ligand","GSSLSPTEGKGSGLQGHIIENPQYFSDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAPPVYLDVLG","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5H3Q"
"5H3S",,"X-RAY DIFFRACTION",2.35,47.66,"VAPOR DIFFUSION, HANGING DROP",6.2,"0.1 M Na/K phosphate, 20% PEG 3350",288,"10.1038/cr.2016.133",,"5H3S",164.68,"3","3","apo form of GEMIN5-WD","MGQEPRTLPPSPNWYCARCSDAVPGGLFGFAARTSVFLVRVGPGAGESPGTPPFRVIGELVGHTERVSGFTFSHHPGQYNLCATSSDDGTVKIWDVETKTVVTEHALHQHTISTLHWSPRVKDLIVSGDEKGVVFCYWFNRNDSQHLFIEPRTIFCLTCSPHHEDLVAIGYKDGIVVIIDISKKGEVIHRLRGHDDEIHSIAWCPLPGEDCLSINQEETSEEAEITNGNAVAQAPVTKGCYLATGSKDQTIRIWSCSRGRGVMILKLPFLKRRGGGIDPTVKERLWLTLHWPSNQPTQLVSSCFGGELLQWDLTQSWRRKYTLFSASSEGQNHSRIVFNLCPLQTEDDKQLLLSTSMDRDVKCWDIATLECSWTLPSLGGFAYSLAFSSVDIGSLAIGVGDGMIRVWNTLSIKNNYDVKNFWQGVKSKVTALCWHPTKEGCLAFGTDDGKVGLYDTYSNKPPQISSTYHKKTVYTLAWGPPVPPMSLGGEGDRPSLALYSCGGEGIVLQHNPWKLSGEAFDINKLIRDTNSIKYKLPVHTEISWKADGKIMALGNEDGSIEIFQIPNLKLICTIQQHHKLVNTISWHHEHGSQPELSYLMASGSNNAVIYVHNLKTVIESSPESPVTITEPYRTLSGHTAKITSVAWSPHHDGRLVSASYDGTAQVWDALREEPLCNFRGHRGRLLCVAWSPLDPDCIYSGADDFCVHKWLTSMQDHSRPPQGKKSIELEKKRLSQPKAK","Homo sapiens","GEMIN5","Gem-associated protein 5","1","5H3S"
"5H3T",,"X-RAY DIFFRACTION",2.36,47.96,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M Bis-Tris propane, 0.2 M Na/K phosphate, 20% PEG 3350",288,"10.1038/cr.2016.133",,"5H3T",331.52,"2.571","2.571","m7G cap bound to GEMIN5-WD","MGQEPRTLPPSPNWYCARCSDAVPGGLFGFAARTSVFLVRVGPGAGESPGTPPFRVIGELVGHTERVSGFTFSHHPGQYNLCATSSDDGTVKIWDVETKTVVTEHALHQHTISTLHWSPRVKDLIVSGDEKGVVFCYWFNRNDSQHLFIEPRTIFCLTCSPHHEDLVAIGYKDGIVVIIDISKKGEVIHRLRGHDDEIHSIAWCPLPGEDCLSINQEETSEEAEITNGNAVAQAPVTKGCYLATGSKDQTIRIWSCSRGRGVMILKLPFLKRRGGGIDPTVKERLWLTLHWPSNQPTQLVSSCFGGELLQWDLTQSWRRKYTLFSASSEGQNHSRIVFNLCPLQTEDDKQLLLSTSMDRDVKCWDIATLECSWTLPSLGGFAYSLAFSSVDIGSLAIGVGDGMIRVWNTLSIKNNYDVKNFWQGVKSKVTALCWHPTKEGCLAFGTDDGKVGLYDTYSNKPPQISSTYHKKTVYTLAWGPPVPPMSLGGEGDRPSLALYSCGGEGIVLQHNPWKLSGEAFDINKLIRDTNSIKYKLPVHTEISWKADGKIMALGNEDGSIEIFQIPNLKLICTIQQHHKLVNTISWHHEHGSQPELSYLMASGSNNAVIYVHNLKTVIESSPESPVTITEPYRTLSGHTAKITSVAWSPHHDGRLVSASYDGTAQVWDALREEPLCNFRGHRGRLLCVAWSPLDPDCIYSGADDFCVHKWLTSMQDHSRPPQGKKSIELEKKRLSQPKAK","Homo sapiens","GEMIN5","Gem-associated protein 5","1","5H3T"
"5H4J",,"X-RAY DIFFRACTION",3.38,63.59,"VAPOR DIFFUSION, HANGING DROP",,"15~20% PEG 4000, 50mM Tris, 150mM Sodium Acetate, 5mM Zn Acetate",298,"10.1158/1535-7163.MCT-17-0911","FKM","5H4J",18.44,"1.8","1.8","Crystal structure of Human dUTPase in complex with N-[(1R)-1-[3-(Cyclopentyloxy)-phenyl]-ethyl]-3-[(3,4-dihydro-2,4-dioxo-1(2H)-pyrimidinyl)methoxy]-1-propanesulfonamide","MPCSEETPAISPSKRARPAEVGGMQLRFARLSEHATAPTRGSARAAGYDLYSAYDYTIPPMEKAVVKTDIQIALPSGCYGRVAPRSGLAAKHFIDVGAGVIDEDYRGNVGVVLFNFGKEKFEVKKGDRIAQLICERIFYPEIEEVQALDDTERGSGGFGSTGKN","Homo sapiens","DUT","Deoxyuridine 5'-triphosphate nucleotidohydrolase, mitochondrial","1","5H4J"
"5H4Y",,"X-RAY DIFFRACTION",2.08,40.89,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1M calcium acetate, 0.1M sodium acetate pH 5.6, 12.5%(w/v) PEG4000",284,"10.1016/j.ijbiomac.2016.10.083",,"5H4Y",17.36,"1.9","1.9","Crystal structure of human synaptotagmin 5 C2A domain","MGHHHHHHMQVADKHELGQLQYSLDYDFQSGQLLVGILQAMGLAALDLGGSSDPYVRVYLLPDKRRRYETKVHRQTLNPHFGETFAFKVPYVELGGRVLVMAVYDFDRFSRNDAIGEVRVPMSSVDLGRPVQAWRELQAAPREEQEKLGD","Homo sapiens","SYT5","Synaptotagmin-5","1","5H4Y"
"5H4Z",,"X-RAY DIFFRACTION",3.6,71.18,"VAPOR DIFFUSION, SITTING DROP",4,"0.1M calcium acetate, 0.1M sodium acetate pH 4.0, 10%(w/v) PEG4000",287,"10.1016/j.ijbiomac.2016.10.083",,"5H4Z",34.58,"3.01","3.01","Crystal structure of S202G mutant of human SYT-5 C2A domain","MGHHHHHHMQVADKHELGQLQYSLDYDFQSGQLLVGILQAMGLAALDLGGSSDPYVRVYLLPDKRRRYETKVHRQTLNPHFGETFAFKVPYVELGGRVLVMAVYDFDRFGRNDAIGEVRVPMSSVDLGRPVQAWRELQAAPREEQEKLGD","Homo sapiens","SYT5","Synaptotagmin-5","1","5H4Z"
"5H52",,"X-RAY DIFFRACTION",3.9,68.45,"VAPOR DIFFUSION, SITTING DROP",,"PIPES-Na 0.1M, PEG 3350 17%, disodium malonate 8mM, glycerol 18%",298,"10.1007/s00775-018-1557-5",,"5H52",75.67,"3","3","Structure of Titanium-bound human serum transferrin","VPDKTVRWCAVSEHEATKCQSFRDHMKSVIPSDGPSVACVKKASYLDCIRAIAANEADAVTLDAGLVYDAYLAPNNLKPVVAEFYGSKEDPQTFYYAVAVVKKDSGFQMNQLRGKKSCHTGLGRSAGWNIPIGLLYCDLPEPRKPLEKAVANFFSGSCAPCADGTDFPQLCQLCPGCGCSTLNQYFGYSGAFKCLKDGAGDVAFVKHSTIFENLANKADRDQYELLCLDNTRKPVDEYKDCHLAQVPSHTVVARSMGGKEDLIWELLNQAQEHFGKDKSKEFQLFSSPHGKDLLFKDSAHGFLKVPPRMDAKMYLGYEYVTAIRNLREGTCPEAPTDECKPVKWCALSHHERLKCDEWSVNSVGKIECVSAETTEDCIAKIMNGEADAMSLDGGFVYIAGKCGLVPVLAENYNKSDNCEDTPEAGYFAVAVVKKSASDLTWDNLKGKKSCHTAVGRTAGWNIPMGLLYNKINHCRFDEFFSEGCAPGSKKDSSLCKLCMGSGLNLCEPNNKEGYYGYTGAFRCLVEKGDVAFVKHQTVPQNTGGKNPDPWAKNLNEKDYELLCLDGTRKPVEEYANCHLARAPNHAVVTRKDKEACVHKILRQQQHLFGSNVTDCSGNFCLFRSETKDLLFRDDTVCLAKLHDRNTYEKYLGEEYVKAVGNLRKCSTSSLLEACTFRRP","Homo sapiens","TF, PRO1400","Serotransferrin","1","5H52"
"5H73",,"X-RAY DIFFRACTION",3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",4.8,"30% glycerol, 2.4M Ammonium sulfate, PH4.8, 0.1M Acetate, 40mM UDAO, 20.8mM DDAO",293,,,"5H73",43.97,"1.58","1.58","Crystal structure of human DHODH with 18F","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5H73"
"5H7N",,"X-RAY DIFFRACTION",2.32,46.94,"VAPOR DIFFUSION, HANGING DROP",4.6,"30% PEG 550, 0.2M Ammonium Sulfate, NaAc 4.6",298,"10.1038/srep40991",,"5H7N",107.41,"1.849","1.849","Crystal structure of human NLRP12-PYD with a MBP tag","MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPAAAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYAAGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSAVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDAALAAAQTNAARAAALCRLSTYLEELEAVELKKFKLYLGTATELGEGKIPWGSMEKAGPLEMAQLLITHFGPEEAWRLALSTFERINRKDLWERGQREDLVRDTPPGGPSSLEHHHHHH","Homo sapiens","NLRP12, NALP12, PYPAF7, RNO","NLRP12-PYD with MBP tag","1","5H7N"
"5H7Q",,"X-RAY DIFFRACTION",2.38,48.31,"VAPOR DIFFUSION, HANGING DROP",8,"20% PEG 4000, 0.1M Tris-HCl pH8.0",298,"10.1038/srep40991",,"5H7Q",53.48,"1.451","1.451","Crystal structure of human MNDA PYD domain with MBP tag","MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPAAAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYAAGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSAVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDAALAAAQTNAARAFAAAEYKKILLLKGFELMDDYHFTSIKSLLAYDLGLTTKMQEEYNRIKITDLMEKKFQGVACLDKLIELAKDMPSLKNLVNNLRKEKSKVAKKIKTQEKLEHHHHHH","Homo sapiens","MNDA","MNDA PYD domain with MBP tag","1","5H7Q"
"5H7R",,"X-RAY DIFFRACTION",3.53,65.12,"VAPOR DIFFUSION, HANGING DROP",6,"0.1 M MES monohydrate pH 6.0, 0.05 M calcium chloride dihydrate, 45 % polyethylene glycol 200",298,"10.1016/j.jmb.2018.02.016",,"5H7R",14.89,"1.7","1.7","Structural basis of the flanking zinc-finger motifs crucial for the E3 ligase activity of the LNX1 RING domain","EPLCAVCGQAHSLEENHFYSYPEEVDDDLICHICLQALLDPLDTPCGHTYCTLCLTNFLVEKDFCPMDRKPLVLQHCKKSSILVNKLLNKLLVTCPFREHCTQVLQRCDLEHHFQTSCKGASHYGLTK","Homo sapiens","LNX1, LNX, PDZRN2, UNQ574/PRO1136","E3 ubiquitin-protein ligase LNX","1","5H7R"
"5H7V",,"X-RAY DIFFRACTION",3.01,59.14,"VAPOR DIFFUSION, SITTING DROP",4.6,"1.6M ammonium sulfate, 20% (v/v) glycerol, 0.08M sodium acetate, pH 4.6",293,"10.1074/jbc.M117.779256",,"5H7V",47.3,"3.82","3.82","Structure of full-length extracellular domain of HAI-1 at pH 4.6","RSPWPGPPPAPPGLPAGADCLNSFTAGVPGFVLDTNASVSNGATFLESPTVRRGWDCVRACCTTQNCNLALVELQPDRGEDAIAACFLINCLYEQNFVCKFAPREGFINYLTREVYRSYRQLRTQGFGGSGIPKAWAGIDLKVQPQEPLVLKDVENTDWRLLRGDTDVRVERKDPNQVELWGLKEGTYLFQLTVTSSDHPEDTANVTVTVLSTKQTEDYCLASNKVGRCRGSFPRWYYDPTEQICKSFVYGGCLGNKNNYLREEECILACRGVQGPSMERRHPVCSGTCQPTQFRCSNGCCIDSFLECDDTPNCPDASDEAACEKYTSGFDELQRIHFPSDKGHCVDLPDTGLCKESIPRWYYNPFSEHCARFTYGGCYGNKNNFEEEQQCLESCRGISKKDVFGLRREIPTRTGHHHHHH","Homo sapiens","SPINT1, HAI1, UNQ223/PRO256","Kunitz-type protease inhibitor 1","1","5H7V"
"5H84",,"X-RAY DIFFRACTION",2.02,39.05,"VAPOR DIFFUSION, HANGING DROP",9,"20% (v/v) ethanol, 100 mM Tris, pH 9.0",293,"10.1107/S2059798316007907",,"5H84",20.48,"2","2","Human Gcn5 bound to propionyl-CoA","GSGIIEFHVIGNSLTPKANRRVLLWLVGLQNVFSHQLPRMPKEYIARLVFDPKHKTLALIKDGRVIGGICFRMFPTQGFTEIVFCAVTSNEQVKGYGTHLMNHLKEYHIKHNILYFLTYADEYAIGYFKKQGFSKDIKVPKSRYLGYIKDYEGATLMECELNPRIPYT","Homo sapiens","KAT2A, GCN5, GCN5L2, HGCN5","Histone acetyltransferase KAT2A","1","5H84"
"5H85",,"X-RAY DIFFRACTION",2.04,39.56,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.15M KSCN, 20% PEG 3350, 10% EtGly",277,"10.1021/acsmedchemlett.8b00286","5XS","5H85",14.52,"1.701","1.701","Crystal structure of the bromodomain of human CREBBP in complex with UO37D","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5H85"
"5H86",,"X-RAY DIFFRACTION",2.03,39.53,"VAPOR DIFFUSION, HANGING DROP",7.8,"10% (v/v) 2-propanol, 3% glycerol, 100 mM HEPES, pH 7.8, and 11% (w/v) PEG 4,000",293,"10.1107/S2059798316007907","BCO","5H86",20.31,"2.08","2.08","Human Gcn5 bound to butyryl-CoA","GSGIIEFHVIGNSLTPKANRRVLLWLVGLQNVFSHQLPRMPKEYIARLVFDPKHKTLALIKDGRVIGGICFRMFPTQGFTEIVFCAVTSNEQVKGYGTHLMNHLKEYHIKHNILYFLTYADEYAIGYFKKQGFSKDIKVPKSRYLGYIKDYEGATLMECELNPRIPYT","Homo sapiens","KAT2A, GCN5, GCN5L2, HGCN5","Histone acetyltransferase KAT2A","1","5H86"
"5H8B",,"X-RAY DIFFRACTION",3.13,60.72,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293,"10.1021/acsmedchemlett.5b00452","5Y2","5H8B",83.06,"2.55","2.55","Crystal structure of CK2 with compound 2","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQAR","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5H8B"
"5H8E",,"X-RAY DIFFRACTION",3.14,60.89,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293,"10.1021/acsmedchemlett.5b00452","5Y3","5H8E",83.58,"2.15","2.15","Crystal structure of CK2 with compound 7h","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQAR","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5H8E"
"5H8G",,"X-RAY DIFFRACTION",1.93,36.4,"VAPOR DIFFUSION, HANGING DROP",6.5,"22-26% PEG 6K, 200 mM ammonium sulfate, 100 mM MES, pH 6.5",293,"10.1021/acsmedchemlett.5b00452","5Y4","5H8G",41.51,"2","2","Crystal structure of CK2 with compound 7b","MSGPVPSRARVYTDVNTHRPREYWDYESHVVEWGNQDDYQLVRKLGRGKYSEVFEAINITNNEKVVVKILKPVKKKKIKREIKILENLRGGPNIITLADIVKDPVSRTPALVFEHVNNTDFKQLYQTLTDYDIRFYMYEILKALDYCHSMGIMHRDVKPHNVMIDHEHRKLRLIDWGLAEFYHPGQEYNVRVASRYFKGPELLVDYQMYDYSLDMWSLGCMLASMIFRKEPFFHGHDNYDQLVRIAKVLGTEDLYDYIDKYNIELDPRFNDILGRHSRKRWERFVHSENQHLVSPEALDFLDKLLRYDHQSRLTAREAMEHPYFYTVVKDQAR","Homo sapiens","CSNK2A1, CK2A1","Casein kinase II subunit alpha","1","5H8G"
"5H8S",,"X-RAY DIFFRACTION",2.51,51,"VAPOR DIFFUSION, HANGING DROP",6.5,"1:2 v/v protein to mother liquor (0.1 M HEPES, pH 7.0, 10-13% PEG8000, 2 mM calcium acetate)",277,"10.1016/j.neuron.2016.01.016","5YC","5H8S",89.2,"1.703","1.703","Structure of the human GluA2 LBD in complex with GNE3419","GSNKTVVVTTILESPYVMMKKNHEMLEGNERYEGYCVDLAAEIAKHCGFKYKLTIVGDGKYGARDADTKIWNGMVGELVYGKADIAIAPLTITLVREEVIDFSKPFMSLGISIMIKKGTPIESAEDLSKQTEIAYGTLDSGSTKEFFRRSKIAVFDKMWTYMRSAEPSVFVRTTAEGVARVRKSKGKYAYLLESTMNEYIEQRKPCDTMKVGGNLDSKGYGIATPKGSSLGNAVNLAVLKLSEQGLLDKLKNKWWYDKGECGS","Homo sapiens","GRIA2, GLUR2","Glutamate receptor 2,Glutamate receptor 2","1","5H8S"
,,,,,,,,,,,,,,,,,"Homo sapiens","GRIA2, GLUR2"
"5H8T",,"X-RAY DIFFRACTION",2.17,43.21,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, pH 5.5, 25% PEG 6000",297,"10.1074/jbc.M116.714535","RTL","5H8T",16.86,"1.21","1.21","Crystal structure of human cellular retinol binding protein 1 in complex with all-trans-retinol","PVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQHHHHHH","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5H8T"
"5H8X",,"X-RAY DIFFRACTION",2.13,42.29,"VAPOR DIFFUSION, HANGING DROP",6,"10 % PEG 6000, 0.2M MES/NAOH, 1M NA      
REMARK 280  PHOSPHATE, PH 6.0",293,"10.1080/14756366.2016.1217853","5XT, 7FY","5H8X",19.2,"1.3","1.3","Crystal structure of the complex MMP-8/BF471 (catechol inhibitor)","MLTPGNPKWERTNLTYRIRNYTPQLSEAEVERAIKDAFELWSVASPLIFTRISQGEADINIAFYQRDHGDNSPFDGPNGILAHAFQPGQGIGGDAHFDAEETWTNTSANYNLFLVAAHEFGHSLGLAHSSDPGALMYPNYAFRETSNYSLPQDDIDGIQAIYG","Homo sapiens","MMP8, CLG1","Neutrophil collagenase","1","5H8X"
"5H9A",,"X-RAY DIFFRACTION",2.03,39.45,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, 25% PEG 6000",298,"10.1074/jbc.M116.714535",,"5H9A",16.78,"1.381","1.381","Crystal structure of the Apo form of human cellular retinol binding protein 1","PVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQHHHHHH","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5H9A"
"5H9M",,"X-RAY DIFFRACTION",2.22,44.54,"VAPOR DIFFUSION, SITTING DROP",7.5,"25% PEG8000, 0.2 M NaCl, 0.1 M Hepes pH7.5",298,,,"5H9M",43.6,"1.761","1.761","Crystal structure of siah2 SBD domain","GASAVLFPCKYATTGCSLTLHHTEKPEHEDICEYRPYSCPCPGASCKWQGSLEAVMSHLMHAHKSITTLQGEDIVFLATDINLPGAVDWVMMQSCFGHHFMLVLEKQEKYEGHQQFFAIVLLIGTRKQAENFAYRLELNGNRRRLTWEATPRSIHDGVAAAIMNSDCLVFDTAIAHLFADNGNLGINVTIST","Homo sapiens","SIAH2","E3 ubiquitin-protein ligase SIAH2","1","5H9M"
"5H9P",,"X-RAY DIFFRACTION",1.89,34.96,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M Tris pH 8.0, 0.2 M LiSO4, 30% (w/v) PEG 4000",298,"10.1038/srep29457","TD2","5H9P",18.52,"2.04","2.04","Crystal Structure of Human Galectin-3 CRD in Complex with TD139","GSSHHHHHHSSGLVPRGSHMPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5H9P"
"5H9Q",,"X-RAY DIFFRACTION",1.79,31.23,"VAPOR DIFFUSION, HANGING DROP",8,"0.22 M Mg Acetate, 21% (w/v) PEG3350",298,"10.1038/srep29457","TD2","5H9Q",34.92,"1.931","1.931","Crystal Structure of Human Galectin-7 in Complex with TD139","GSSHHHHHHSSGLVPRGSHMSNVPHKSSLPEGIRPGTVLRIRGLVPPNASRFHVNLLCGEEQGSDAALHFNPRLDTSEVVFNSKEQGSWGREERGPGVPFQRGQPFEVLIIASDDGFKAVVGDAQYHHFRHRLPLARVRLVEVGGDVQLDSVRIF","Homo sapiens","LGALS7, PIG1, LGALS7B","Galectin-7","1","5H9Q"
"5H9R",,"X-RAY DIFFRACTION",1.87,34.26,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris pH8.5, 0.2 M MgCl2, 30% (w/v) PEG 3350",298,"10.1038/srep29457","TGZ","5H9R",18.38,"1.58","1.58","Crystal Structure of Human Galectin-3 CRD in Complex with TAZTDG","GSSHHHHHHSSGLVPRGSHMPLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5H9R"
"5H9S",,"X-RAY DIFFRACTION",1.85,33.54,"VAPOR DIFFUSION, HANGING DROP",8,"0.22 M MgAcetate, 21% (w/v) PEG 3350",298,"10.1038/srep29457","TGZ","5H9S",34.78,"1.821","1.821","Crystal Structure of Human Galectin-7 in Complex with TAZTDG","GSSHHHHHHSSGLVPRGSHMSNVPHKSSLPEGIRPGTVLRIRGLVPPNASRFHVNLLCGEEQGSDAALHFNPRLDTSEVVFNSKEQGSWGREERGPGVPFQRGQPFEVLIIASDDGFKAVVGDAQYHHFRHRLPLARVRLVEVGGDVQLDSVRIF","Homo sapiens","LGALS7, PIG1, LGALS7B","Galectin-7","1","5H9S"
"5HA1",,"X-RAY DIFFRACTION",2.04,39.61,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, 25% PEG 6000",298,"10.1074/jbc.M116.714535","RNE","5HA1",16.85,"1.35","1.35","Crystal structure of human cellular retinol binding protein 1 in complex with retinylamine","PVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQHHHHHH","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5HA1"
"5HA6",,"X-RAY DIFFRACTION",1.58,22.38,"VAPOR DIFFUSION, HANGING DROP",4.5,"5% (w/v) PEG 3350, 0.1 M Sodium Acetate-HCl",298,,,"5HA6",26.71,"2.0006","2.0006","Crystal structure of human syncytin-1 fusion subunit","MAHHHHHHVDDDDKMLVPRGSSGGSTQFYYKLSQELNGDMERVADSLVTLQDQLNSLAAVVLQNRRALDLLTAERGGTCLFLGEECSYYVNQSGIVTEKVKEIRDRIQRRAEELRNT","Homo sapiens","ERVW-1, ERVWE1","Syncytin-1","1","5HA6"
"5HA7",,"X-RAY DIFFRACTION",2.6,52.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"2.04 M Ammonium Sulfate, 0.1M HEPES pH 7.5, 7% polyethylene glycol 400",277,"10.1038/srep34394","NAP, WY1","5HA7",74.7,"1.65","1.65","Human Aldose Reductase in Complex with NADP+ and WY14643 in Space Group P212121","MASRILLNNGAKMPILGLGTWKSPPGQVTEAVKVAIDVGYRHIDCAHVYQNENEVGVAIQEKLREQVVKREELFIVSKLWCTYHEKGLVKGACQKTLSDLKLDYLDLYLIHWPTGFKPGKEFFPLDESGNVVPSDTNILDTWAAMEELVDEGLVKAIGISNFNHLQVEMILNKPGLKYKPAVNQIECHPYLTQEKLIQYCQSKGIVVTAYSPLGSPDRPWAKPEDPSLLEDPRIKAIAAKHNKTTAQVLIRFPMQRNLVVIPKSVTPERIAENFKVFDFELSSQDMTTLLSYNRNWRVCALLSCTSHKDYPFHEEF","Homo sapiens","AKR1B1, ALDR1, ALR2","Aldose reductase","1","5HA7"
"5HA9",,"X-RAY DIFFRACTION",2.3,46.47,"VAPOR DIFFUSION, HANGING DROP",7.2,"2.1 M AMMONIUM SULFATE, 100mM TRIS",291,"10.1038/s41598-016-0007-2",,"5HA9",79.69,"4.01","4.01","Crystal structure-based design and disovery of a novel PARP1 antiagonist (BL-PA10) that induces apoptosis and inhibits metastasis in triple negative breast cancer","MKSKLPKPVQDLIKMIFDVESMKKAMVEYEIDLQKMPLGKLSKRQIQAAYSILSEVQQAVSQGSSDSQILDLSNRFYTLIPHDFGMKKPPLLNNADSVQAKVEMLDNLLDIEVAYSLLRGGSDDSSKDPIDVNYEKLKTDIKVVDRDSEEAEIIRKYVKNTHATTHNAYDLEVIDIFKIEREGECQRYKPFKQLHNRRLLWHGSRTTNFAGILSQGLRIAPPEAPVTGYMFGKGIYFADMVSKSANYCHTSQGDPIGLILLGEVALGNMYELKHASHISKLPKGKHSVKGLGKTTPDPSANISLDGVDVPLGTGISSGVNDTSLLYNEYIVYDIAQVNLKYLLKLKFNFKT","Homo sapiens","PARP1, ADPRT, PPOL","Poly [ADP-ribose] polymerase 1","1","5HA9"
"5HBF",,"X-RAY DIFFRACTION",2.09,41.16,"VAPOR DIFFUSION",,"15% PEG3350, 0.02 M HEPES, pH 6.8, 0.2% MPD, 0.2% 1,2,3-heptanetriol, 0.2% diethylenetriaminepentakis, 0.2% D-sorbitol, 0.2% glycerol",293,"10.1371/journal.pone.0154190",,"5HBF",107.19,"1.95","1.95","Crystal structure of human full-length chitotriosidase (CHIT1)","MVRSVAWAGFMVLLMIPWGSAAKLVCYFTNWAQYRQGEARFLPKDLDPSLCTHLIYAFAGMTNHQLSTTEWNDETLYQEFNGLKKMNPKLKTLLAIGGWNFGTQKFTDMVATANNRQTFVNSAIRFLRKYSFDGLDLDWEYPGSQGSPAVDKERFTTLVQDLANAFQQEAQTSGKERLLLSAAVPAGQTYVDAGYEVDKIAQNLDFVNLMAYDFHGSWEKVTGHNSPLYKRQEESGAAASLNVDAAVQQWLQKGTPASKLILGMPTYGRSFTLASSSDTRVGAPATGSGTPGPFTKEGGMLAYYEVCSWKGATKQRIQDQKVPYIFRDNQWVGFDDVESFKTKVSYLKQKGLGGAMVWALDLDDFAGFSCNQGRYPLIQTLRQELSLPYLPSGTPELEVPKPGQPSEPEHGPSPGQDTFCQGKADGLYPNPRERSSFYSCAAGRLFQQSCPTGLVFSNSCKCCTWNLVPRGSLEHHHHHH","Homo sapiens","CHIT1","Chitotriosidase-1","1","5HBF"
"5HBS",,"X-RAY DIFFRACTION",2.05,40.11,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1 M Bis-Tris, 25% PEG 6000",300,"10.1074/jbc.M116.714535","RTL","5HBS",16.86,"0.89","0.89","Crystal structure of human cellular retinol binding protein 1 in complex with all-trans-retinol at 0.89 angstrom.","PVDFTGYWKMLVNENFEEYLRALDVNVALRKIANLLKPDKEIVQDGDHMIIRTLSTFRNYIMDFQVGKEFEEDLTGIDDRKCMTTVSWDGDKLQCVQKGEKEGRGWTQWIEGDELHLEMRVEGVVCKQVFKKVQHHHHHH","Homo sapiens","RBP1, CRBP1","Retinol-binding protein 1","1","5HBS"
"5HCG",,"X-RAY DIFFRACTION",2.34,47.34,"VAPOR DIFFUSION, HANGING DROP",,"HEPES 0,1M, PEG 2000 MME 17.5%",292,"10.1080/19420862.2016.1162932",,"5HCG",73.45,"2.68","2.68","CRYSTAL STRUCTURE OF FREE-CODV.","AVQLQQSGPELVKPGASVKISCKASGYSFTSYWIHWIKQRPGQGLEWIGMIDPSDGETRLNQRFQGRATLTVDESTSTAYMQLRSPTSEDSAVYYCTRLKEYGNYDSFYFDVWGAGTLVTVSSSEVQLKESGPGLVAPGGSLSITCTVSGFSLTDSSINWVRQPPGKGLEWLGMIWGDGRIDYADALKSRLSISKDSSKSQVFLEMTSLRTDDTATYYCARDGYFPYAMDFWGQGTSVTVSSRTSATKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPK","Homo sapiens",,"CODV heavy-chain","1","5HCG"
,,,,,,,,,,,,,,,,"DIVLTQSPASLAVSLGQRATISCRASESVDSYGQSYMHWYQQKAGQPPKLLIYLASNLESGVPARFSGSGSRTDFTLTIDPVQAEDAATYYCQQNAEDSRTFGGGTKLEIKGQPKAAPDIQMTQSPASLSVSVGDTITLTCHASQNIDVWLSWFQQKPGNIPKLLIYKASNLHTGVPSRFSGSGSGTGFTLTISSLQPEDIATYYCQQAHSYPFTFGGGTKLEIKTKGPSRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTMSFNR","Homo sapiens",,"CODV light chain","2","5HCG"
"5HCK",,"SOLUTION NMR",,,,,,,"10.1006/jmbi.1998.1690",,"5HCK",8.24,,,"HUMAN HCK SH3 DOMAIN, NMR, MINIMIZED AVERAGE STRUCTURE","GIREAGSEDIIVVALYDYEAIHHEDLSFQKGDQMVVLEESGEWWKARSLATRKEGYIPSNYVARVDSLETEE","Homo sapiens","RESIDUES G72-E143 OF HUMAN HCK, HCK","HEMATOPOIETIC CELL KINASE","1","5HCK"
"5HCL",,"X-RAY DIFFRACTION",2.14,42.57,"VAPOR DIFFUSION, HANGING DROP",7.5,"0.20M Sodium Nitrate, 20% PEG 3350, 10% ethylene glycol",277,"10.1038/srep42108","5Y9","5HCL",15.25,"1.5","1.5","Crystal Structure of the first bromodomain of BRD4 in complex with DMA","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HCL"
"5HCV",,"X-RAY DIFFRACTION",2.22,44.53,"VAPOR DIFFUSION, HANGING DROP",8,"1uL of protein complex at 8-10mg protein/ml is mixed with an equal volume of reservoir solution composed of 100mM Tris-HCl pH=8.0, 200mM NaCl, 5% (v/v) glycerol, 16%(w/v) PEG3350",294,"10.1016/j.bmc.2016.02.014","60R","5HCV",90.78,"2.5","2.5","Identification of Spirooxindole and Dibenzoxazepine Motifs as Potent Mineralocorticoid Receptor Antagonists","GSHMRALTPSPVMVLENIEPEIVYAGYDSSKPDTAENLLSTLNRLAGKQMIQVVKWAKVLPGFKNLPLEDQITLIQYSWMSLSSFALSWRSYKHTNSQFLYFAPDLVFNEEKMHQSAMYELCQGMHQISLQFVRLQLTFEEYTIMKVLLLLSTIPKDGLKSQAAFEEMRTNYIKELRKMVTKCPNNSGQSWQRFYQLTKLLDSMHDLVSDLLEFCFYTFRESHALKVEFPAMLVEIISDQLPKVESGNAKPLYFHRK","Homo sapiens","NR3C2, MCR, MLR","Mineralocorticoid receptor","1","5HCV"
"5HCX",,"X-RAY DIFFRACTION",3.51,64.92,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acs.jmedchem.6b00995",,"5HCX",38.08,"2.6","2.6","EGFR kinase domain mutant ""TMLR"" with azabenzimidazole compound 7","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HCX"
"5HCY",,"X-RAY DIFFRACTION",3.5,64.82,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acs.jmedchem.6b00995","60D","5HCY",38.2,"2.46","2.46","EGFR kinase domain mutant ""TMLR"" with 3-carboxamide azaindole compound 13","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HCY"
"5HCZ",,"X-RAY DIFFRACTION",3.49,64.71,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1021/acs.jmedchem.6b00995",,"5HCZ",38.2,"2.62","2.62","EGFR kinase domain mutant ""TMLR"" with 3-azetidinyl azaindazole compound 21","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HCZ"
"5HD0",,"X-RAY DIFFRACTION",2.95,58.36,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, 200mM K/Na tatrate, 100mM Hepes, pH 7.0",277,"10.1021/acs.jmedchem.5b01995","60Y","5HD0",93.7,"1.65","1.65","BACE-1 in complex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoropyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HD0"
"5HDE",,"X-RAY DIFFRACTION",2.64,53.41,"VAPOR DIFFUSION, HANGING DROP",,"0.04M potassium phosphate, 16% w/v PEG 8000, 20% v/v glycerol",289,,,"5HDE",36.5,"1.62","1.62","Crystal Structure of PTPN12 Catalytic Domain","GSHMASMEQVEILRKFIQRVQAMKSPDHNGEDNFARDFMRLRRLSTKYRTEKIYPTATGEKEENVKKNRYKDILPFDHSRVKLTLKTPSQDSDYINANFIKGVYGPKAYVATQGPLANTVIDFWRMIWEYNVVIIVMACREFEMGRKKCERYWPLYGEDPITFAPFKISCEDEQARTDYFIRTLLLEFQNESRRLYQFHYVNWPDHDVPSSFDSILDMISLMRKYQEHEDVPICIHCSAGCGRTGAICAIDYTWNLLKAGKIPEEFNVFNLIQEMRTQRHSAVQTKEQYELVHRAIAQLFEKQLQLY","Homo sapiens","PTPN12","Tyrosine-protein phosphatase non-receptor type 12","1","5HDE"
"5HDG",,"X-RAY DIFFRACTION",2.16,43.04,"VAPOR DIFFUSION, HANGING DROP",7.2,"0.2M sodium formate, pH 7.2, 22%(w/v) PEG3350",293,,,"5HDG",13.18,"1.7","1.7","crystal structure of heat shock factor 1-DBD","HHHHHHVPAFLTKLWTLVSDPDTDALICWSPSGNSFHVFDQGQFAKEVLPKYFKHNNMASFVRQLNMYGFRKVVHIEQGGLVKPERDDTEFQHPCFLRGQEQLLENIKRKVT","Homo sapiens","HSF1, HSTF1","Heat shock factor protein 1","1","5HDG"
"5HDH",,"X-RAY DIFFRACTION",4.67,73.64,"VAPOR DIFFUSION, SITTING DROP",,"ammonium sulfate, sodium acetate, glycerol",293,"10.1073/pnas.1516000113",,"5HDH",95.3,"2.6","2.6","Crystal structure of human TLR8 with an uncleaved Z-loop","EENFSRSYPCDEKKQNDSVIAECSNRRLQEVPQTVGKYVTELDLSDNFITHITNESFQGLQNLTKINLNHNPNVQHQNGNPGIQSNGLNITDGAFLNLKNLRELLLEDNQLPQIPSGLPESLTELSLIQNNIYNITKEGISRLINLKNLYLAWNCYFNKVCEKTNIEDGVFETLTNLELLSLSFNSLSHVPPKLPSSLRKLFLSNTQIKYISEEDFKGLINLTLLDLSGNCPRCFNAPFPCVPCDGGASINIDRFAFQNLTQLRYLNLSSTSLRKINAAWFKNMPHLKVLDLEFNYLVGEIASGAFLTMLPRLEILDLSFNYIKGSYPQHINISRNFSKLLSLRALHLRGYVFQELREDDFQPLMQLPNLSTINLGINFIKQIDFKLFQNFSNLEIIYLSENRISPLVKDTRQSYANSSSFQRHINQSNSTDFEFDPHSNFYHFTRPLIKPQCAAYGKALDLSLNSIFFIGPNQFENLPDIACLNLSANSNAQVLSGTEFSAIPHVKYLDLTNNRLDFDNASALTELSDLEVLDLSYNSHYFRIAGVTHHLEFIQNFTNLKVLNLSHNNIYTLTDKYNLESKSLVELVFSGNRLDILWNDDDNRYISIFKGLKNLTRLDLSLNRLKHIPNEAFLNLPASLTELHINDNMLKFFNWTLLQQFPRLELLDLRGNKLLFLTDSLSDFTSSLRTLLLSHNRISHLPSGFLSEVSSLKHLDLSSNLLKTINKSALETKTTTKLSMLELHGNPFECTCDIGDFRRWMDEHLNVKIPRLVDVICASPGDQRGKSIVSLELTTCVSDVT","Homo sapiens","TLR8, UNQ249/PRO286","Toll-like receptor 8","1","5HDH"
"5HDK",,"X-RAY DIFFRACTION",1.92,35.94,"VAPOR DIFFUSION, HANGING DROP",8.4,"0.1 M Tris, pH 8.4 and 1.25 M potassium sodium tartrate",293,,,"5HDK",54.17,"1.32","1.32","Crystal structure of heat shock factor 2-DBD","HHHHHHVPAFLSKLWTLVEETHTNEFITWSQNGQSFLVLDEQRFAKEILPKYFKHNNMASFVRQLNMYGFRKVVHIDSGIVKQERDGPVEFQHPYFKQGQDDLLENIKRKVS","Homo sapiens","HSF2, HSTF2","Heat shock factor protein 2","1","5HDK"
"5HDU",,"X-RAY DIFFRACTION",2.94,58.2,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60W","5HDU",93.76,"1.58","1.58","BACE-1 incomplex with (7aR)-7a-(4-(3-cyanophenyl)thiophen-2-yl)-6-(5-fluoro-4-methoxypyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HDU"
"5HDV",,"X-RAY DIFFRACTION",2.95,58.34,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60V","5HDV",93.48,"1.71","1.71","BACE-1 incomplex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HDV"
"5HDW",,"X-RAY DIFFRACTION",1.96,37.27,"VAPOR DIFFUSION, HANGING DROP",8.5,"100mM Tris-HCl pH 8.5
20% w/v PEG 8000
200mM MgCl2 * 6H2O",298,"10.1111/febs.13721",,"5HDW",15.24,"2","2","ApaG Domain of FBxo3","SEFVATTGDITVSVSTSFLPELSSVHPPHYFFTYRIRIEMSKDALPEKACQLDSRYWRITNAKGDVEEVQGPGVVGEFPIISPGRVYEYTSCTTFSTTSGYMEGYYTFHFLYFKDKIFNVAIPRFHMACPTFR","Homo sapiens","FBXO3, FBX3","F-box only protein 3","1","5HDW"
"5HDX",,"X-RAY DIFFRACTION",2.94,58.19,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60U","5HDX",93.36,"1.602","1.602","BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(4-ethoxy-5-fluoro-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HDX"
"5HDZ",,"X-RAY DIFFRACTION",2.97,58.54,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","954","5HDZ",93.36,"1.49","1.49","BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylthio)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HDZ"
"5HE4",,"X-RAY DIFFRACTION",2.94,58.15,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60T","5HE4",93.49,"1.53","1.53","BACE-1 in complex with (4aR,7aS)-7a-(2,6-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HE4"
"5HE5",,"X-RAY DIFFRACTION",2.94,58.22,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60S","5HE5",93.63,"1.55","1.55","BACE-1 in complex with (7aR)-7a-(5-cyanothiophen-2-yl)-6-(5-fluoro-4-methyl-6-(methylamino)pyrimidin-2-yl)-3-methyl-4-oxooctahydro-2H-pyrrolo[3,4-d]pyrimidin-2-iminium","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HE5"
"5HE7",,"X-RAY DIFFRACTION",2.95,58.32,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200mM Na/K tartrate, 100mM Hepes",277,"10.1021/acs.jmedchem.5b01995","60X","5HE7",93.34,"1.71","1.71","BACE-1 in complex with (4aR,7aS)-7a-(2,4-difluorophenyl)-6-(5-fluoro-4-methoxy-6-methylpyrimidin-2-yl)-2-imino-3-methyloctahydro-4H-pyrrolo[3,4-d]pyrimidin-4-one","LRLPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HE7"
"5HEL",,"X-RAY DIFFRACTION",2.41,48.91,"VAPOR DIFFUSION, SITTING DROP",7.5,"20% PEG smear high, 0.1 M Mes pH 6.5",277,,,"5HEL",15.08,"1.45","1.45","Crystal structure of the N-terminus Y153H bromodomain mutant of human BRD2","SMKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQPMDMGTIKRRLENNYYWAASECMQDFNTMFTNCHIYNKPTDDIVLMAQTLEKIFLQKVASMPQEEQELVVTIPKN","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5HEL"
"5HEM",,"X-RAY DIFFRACTION",2.25,45.29,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% PEG3350, 0.1M bis-tris propane pH 6.6, 10% ethylene glycol, 0.15M sodium acetate",277,,,"5HEM",30.38,"1.65","1.65","Crystal structure of the N-terminus D161Y bromodomain mutant of human BRD2","SMKPGRVTNQLQYLHKVVMKALWKHQFAWPFRQPVDAVKLGLPDYHKIIKQPMDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDYIVLMAQTLEKIFLQKVASMPQEEQELVVTIPKN","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5HEM"
"5HEN",,"X-RAY DIFFRACTION",2.45,49.93,"VAPOR DIFFUSION, SITTING DROP",7.5,"1 M ammonium sulfate, 0.1 M MES pH 6.3",277,,,"5HEN",44.8,"1.79","1.79","Crystal structure of the N-terminus R100L bromodomain mutant of human BRD2","SMKPGRVTNQLQYLHKVVMKALWKHQFAWPFLQPVDAVKLGLPDYHKIIKQPMDMGTIKRRLENNYYWAASECMQDFNTMFTNCYIYNKPTDDIVLMAQTLEKIFLQKVASMPQEEQELVVTIPKN","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5HEN"
"5HES",,"X-RAY DIFFRACTION",3.08,60.08,"VAPOR DIFFUSION, SITTING DROP",6.5,"100 mM bis-tris-propane pH 6.5, 200 mM sodium malonate, 20% PEG3350, 10% ethylene glycol",277,"10.1021/acschembio.6b00043","032","5HES",71.57,"2.14","2.14","Human leucine zipper- and sterile alpha motif-containing kinase (ZAK, MLT, HCCS-4, MRK, AZK, MLTK) in complex with vemurafenib","SMGASFVQIKFDDLQFFENCGGGSFGSVYRAKWISQDKEVAVKKLLKIEKEAEILSVLSHRNIIQFYGVILEPPNYGIVTEYASLGSLYDYINSNRSEEMDMDHIMTWATDVAKGMHYLHMEAPVKVIHRDLKSRNVVIAADGVLKICDFGASRFHNHTTHMSLVGTFPWMAPEVIQSLPVSETCDTYSYGVVLWEMLTREVPFKGLEGLQVAWLVVEKNERLTIPSSCPRSFAELLHQCWEADAKKRPSFKQIISILESMSNDTSLPDKCNSFLHNKAEWRCEIEATLERLKKLERDLSFKEQELK","Homo sapiens","ZAK, MLTK, HCCS4, MAP3K20","Mitogen-activated protein kinase kinase kinase MLT","1","5HES"
"5HEX",,"X-RAY DIFFRACTION",2.83,56.54,"VAPOR DIFFUSION",5,"protein conditions: 10mgs/mL, 50mM TRIS HCL, pH 7.5, 250mM NaCl, 2mM DTT, 2mM MgCl2. and 1mM cmpd30
Reservoir: 0.1M Na Citrate pH=5, 14% PEG 3350, 10 % ethylene glycol 
Cryo protectant 20% ethylene glycol in mother liquor",296,"10.1021/acsmedchemlett.5b00214",,"5HEX",208.4,"2.734","2.734","Crystal Structure of Human Hexokinase 2 with cmpd 30, a 2-amino-6-benzenesulfonamide glucosamine","MGSSHHHHHHSSGLENLYFQGSDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQR","Homo sapiens","HK2","Hexokinase-2","1","5HEX"
"5HEZ",,"X-RAY DIFFRACTION",3.68,66.6,"VAPOR DIFFUSION, HANGING DROP",7,"1.9 M sodium malonate, 10 mM ZnCl2",291,"10.1126/scitranslmed.aag1974","1M3","5HEZ",146.16,"2.66","2.66","JAK2 kinase (JH1 domain) mutant P1057A in complex with TG101209","GSSGAFEDRDPTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIEILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQICKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFWYAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSAPAEFMRMIGNDKQGQMIVFHLIELLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5HEZ"
"5HF5",,"X-RAY DIFFRACTION",4.33,71.56,"VAPOR DIFFUSION, SITTING DROP",7,"15 - 18% PEG3350, 0.2M potassium nitrate",295,"10.1002/prot.25073",,"5HF5",121.21,"2.152","2.152","Crystal structure of human acetylcholinesterase in complex with paraoxon in the unaged state (predominant acyl loop conformation)","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","Acetylcholinesterase","1","5HF5"
"5HF6",,"X-RAY DIFFRACTION",4.41,72.11,"VAPOR DIFFUSION, SITTING DROP",7,"15 - 18% PEG3350, 0.2M potassium nitrate",295,"10.1002/prot.25073",,"5HF6",120.76,"2.3","2.3","Crystal structure of human acetylcholinesterase in complex with paraoxon in the aged state","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","Acetylcholinesterase","1","5HF6"
"5HF8",,"X-RAY DIFFRACTION",4.38,71.91,"VAPOR DIFFUSION, SITTING DROP",7,"15 - 18% PEG3350, 0.2M potassium nitrate",295,"10.1002/prot.25073",,"5HF8",121.1,"2.8","2.8","Crystal structure of human acetylcholinesterase in complex with paraoxon (alternative acyl loop conformation)","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","Acetylcholinesterase","1","5HF8"
"5HF9",,"X-RAY DIFFRACTION",4.44,72.32,"VAPOR DIFFUSION, SITTING DROP",7,"15 - 18% PEG3350, 0.2M potassium nitrate",295,"10.1002/prot.25073","HI6","5HF9",121.79,"2.2","2.2","Crystal structure of human acetylcholinesterase in complex with paraoxon and HI6","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","Acetylcholinesterase","1","5HF9"
"5HFA",,"X-RAY DIFFRACTION",4.31,71.48,"VAPOR DIFFUSION, SITTING DROP",7,"15 - 18% PEG3350, 0.2M potassium nitrate",295,"10.1002/prot.25073",,"5HFA",121.26,"2.201","2.201","Crystal structure of human acetylcholinesterase in complex with paraoxon and 2-PAM","GREDAELLVTVRGGRLRGIRLKTPGGPVSAFLGIPFAEPPMGPRRFLPPEPKQPWSGVVDATTFQSVCYQYVDTLYPGFEGTEMWNPNRELSEDCLYLNVWTPYPRPTSPTPVLVWIYGGGFYSGASSLDVYDGRFLVQAERTVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENVAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAVLQSGAPNGPWATVGMGEARRRATQLAHLVGCPPGGTGGNDTELVACLRTRPAQVLVNHEWHVLPQESVFRFSFVPVVDGDFLSDTPEALINAGDFHGLQVLVGVVKDEGSYFLVYGAPGFSKDNESLISRAEFLAGVRVGVPQVSDLAAEAVVLHYTDWLHPEDPARLREALSDVVGDHNVVCPVAQLAGRLAAQGARVYAYVFEHRASTLSWPLWMGVPHGYEIEFIFGIPLDPSRNYTAEEKIFAQRLMRYWANFARTGDPNEPRDPKAPQWPPYTAGAQQYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSAT","Homo sapiens","ACHE","Acetylcholinesterase","1","5HFA"
"5HFQ",,"X-RAY DIFFRACTION",2.29,46.31,"VAPOR DIFFUSION, SITTING DROP",7.5,"2% (v/v) dioxane, 10% PEG 20000, 0.1M bicine pH 9",277,,,"5HFQ",13.39,"1.4","1.4","Crystal structure of the second bromodomain Q443H mutant of human BRD2","SMGKLSEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLHDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5HFQ"
"5HFR",,"X-RAY DIFFRACTION",2.97,58.59,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium nitrate, 10 % PEG 3350, 5 % EDO, 0.1 M bis tris prop. pH 6.5",277,,,"5HFR",53.62,"1.7","1.7","Crystal structure of the second bromodomain H395R mutant of human BRD3","SMGKLSEHLRYCDSILREMLSKKHAAYAWPFYKPVDAEALELHDYHDIIKHPMDLSTVKRKMDGREYPDAQGFAADVRLMFSNCYKYNPPDREVVAMARKLQDVFEMRFAKMP","Homo sapiens","BRD3, KIAA0043, RING3L","Bromodomain-containing protein 3","1","5HFR"
"5HFU",,"X-RAY DIFFRACTION",2.82,56.35,"VAPOR DIFFUSION",6,"protein: 10mgs/mL in 50mM TrisHCL pH = 7.5, 250mM NaCl, 2mM DTT, 2mM MgCl2
Well solution: 0.1M Na Citrate pH = 6, 16 % PEG3350, 10 % Ethylene glycol
Cryo: 20 % ethylene glycol in well",296,"10.1021/acsmedchemlett.5b00214",,"5HFU",208.3,"2.923","2.923","Crystal Structure of Human Hexokinase 2 with cmpd 27, a 2-amido-6-benzenesulfonamide glucosamine","MGSSHHHHHHSSGLENLYFQGSDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQR","Homo sapiens","HK2","Hexokinase-2","1","5HFU"
"5HG1",,"X-RAY DIFFRACTION",4.83,74.56,"VAPOR DIFFUSION",,"protein: 6.6 mgs/mL, 10mM Tris HCL, pH=8, 0.1 M NaCl, 1mM DTT, 20mM MgCl2
Well: 0.2 M Na Citrate pH 5.5, 14-24 % PEG3350, 20 % ethylene glycol",296,"10.1021/acsmedchemlett.5b00214",,"5HG1",104.15,"2.76","2.76","Crystal Structure of Human Hexokinase 2 with cmpd 1, a C-2-substituted glucosamine","MGSSHHHHHHSSGLENLYFQGSDQVQKVDQYLYHMRLSDETLLEISKRFRKEMEKGLGATTHPTAAVKMLPTFVRSTPDGTEHGEFLALDLGGTNFRVLWVKVTDNGLQKVEMENQIYAIPEDIMRGSGTQLFDHIAECLANFMDKLQIKDKKLPLGFTFSFPCHQTKLDESFLVSWTKGFKSSGVEGRDVVALIRKAIQRRGDFDIDIVAVVNDTVGTMMTCGYDDHNCEIGLIVGTGSNACYMEEMRHIDMVEGDEGRMCINMEWGAFGDDGSLNDIRTEFDQEIDMGSLNPGKQLFEKMISGMYMGELVRLILVKMAKEELLFGGKLSPELLNTGRFETKDISDIEGEKDGIRKAREVLMRLGLDPTQEDCVATHRICQIVSTRSASLCAATLAAVLQRIKENKGEERLRSTIGVDGSVYKKHPHFAKRLHKTVRRLVPGCDVRFLRSEDGSGKGAAMVTAVAYRLADQHRARQKTLEHLQLSHDQLLEVKRRMKVEMERGLSKETHASAPVKMLPTYVCATPDGTEKGDFLALDLGGTNFRVLLVRVRNGKWGGVEMHNKIYAIPQEVMHGTGDELFDHIVQCIADFLEYMGMKGVSLPLGFTFSFPCQQNSLDESILLKWTKGFKASGCEGEDVVTLLKEAIHRREEFDLDVVAVVNDTVGTMMTCGFEDPHCEVGLIVGTGSNACYMEEMRNVELVEGEEGRMCVNMEWGAFGDNGCLDDFRTEFDVAVDELSLNPGKQRFEKMISGMYLGEIVRNILIDFTKRGLLFRGRISERLKTRGIFETKFLSQIESDCLALLQVRAILQHLGLESTCDDSIIVKEVCTVVARRAAQLCGAGMAAVVDRIRENRGLDALKVTVGVDGTLYKLHPHFAKVMHETVKDLAPKCDVSFLQSEDGSGKGAALITAVACRIREAGQ","Homo sapiens","HK2","Hexokinase-2","1","5HG1"
"5HG5",,"X-RAY DIFFRACTION",2.09,41.05,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) Sodium acetate trihydrate (pH 7.50), 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol, 0.2 M (2.8571428571 uL of stock 3.5 M) Ammonium sulfate",286,"10.1021/acs.jmedchem.5b01633",,"5HG5",38.24,"1.52","1.52","EGFR (L858R, T790M, V948R) in complex with N-{3-[(2-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy]phenyl}prop-2-enamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HG5"
"5HG7",,"X-RAY DIFFRACTION",1.85,33.35,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 0.2 M (2.5 uL of stock 4.0 M) Ammonium sulfate, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000",286,"10.1021/acs.jmedchem.5b01633",,"5HG7",38.11,"1.85","1.85","EGFR (L858R, T790M, V948R) in complex with 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988)","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HG7"
"5HG8",,"X-RAY DIFFRACTION",2.05,39.97,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 0.2 M (2.8571428571 uL of stock 3.5 M) Ammonium sulfate, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 10.0 %v/v (5.0 uL of stock 100.0 %v/v) iso-propanol",286,"10.1021/acs.jmedchem.5b01633",,"5HG8",38.24,"1.42","1.42","EGFR (L858R, T790M, V948R) in complex with N-[3-({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HG8"
"5HG9",,"X-RAY DIFFRACTION",1.86,33.81,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M (2.5 uL of stock 4.0 M) Ammonium sulfate, 20.0 %w/v (20.0 uL of stock 50.0 %w/v) PEG 8000, 0.1 M (5.0 uL of stock 1.0 M) HEPES (pH 7.50), 10.4545454545 %v/v (5.2272727272 uL of stock 100.0 %v/v) iso-propanol",286,"10.1021/acs.jmedchem.5b01633",,"5HG9",38.49,"2.15","2.15","EGFR (L858R, T790M, V948R) in complex with 1-[(3R,4R)-3-[({2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-(trifluoromethyl)pyrrolidin-1-yl]prop-2-en-1-one","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMRKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQG","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HG9"
"5HGI",,"X-RAY DIFFRACTION",3.04,59.53,"VAPOR DIFFUSION, HANGING DROP",9,"Crystallization buffer: 25 mM Bis-Tris Propane pH 9, 39% PEG 200, 250 mM CsCl, 10% glycerol. After setting up the crystallization drop with the mother liquor in a 1:1 uL ratio using the liquid bridge method, 2-mercaptoethanol was added to the reservoir at a final concentration of 143 mM. Crystals were cryoprotected in the same reservoir crystallization buffer.",277,"10.1021/acschembio.5b00940",,"5HGI",50.62,"2.584","2.584","Crystal structure of apo human IRE1 alpha","GSSPSLEQDDGDEETSVVIVGKISFCPKDVLGHGAEGTIVYRGMFDNRDVAVKRILPECFSFADREVQLLRESDEHPNVIRYFCTEKDRQFQYIAIELCAATLQEYVEQKDFAHLGLEPITLLQQTTSGLAHLHSLNIVHRDLKPHNILISMPNAHGKIKAMISDFGLCKKLAVGRHSFSRRSGVPGTEGWIAPEMLSEDCKENPTYTVDIFSAGCVFYYVISEGSHPFGKSLQRQANILLGACSLDCLHPEKHEDVIARELIEKMIAMDPQKRPSAKHVLKHPFFWSLEKQLQFFQDVSDRIEKESLDGPIVKQLERGGRAVVKMDWRENITVPLQTDLRKFRTYKGGSVRDLLRAMRNKKHHYRELPAEVRETLGSLPDDFVCYFTSRFPHLLAHTYRAMELCSHERLFQPYYFHEPPEPQPPVTPDAL","Homo sapiens","ERN1, IRE1","Serine/threonine-protein kinase/endoribonuclease IRE1","1","5HGI"
"5HGJ",,"X-RAY DIFFRACTION",2.12,42.09,"VAPOR DIFFUSION, HANGING DROP",8,"PEG 8000, Tris-HCl, Calcium Chloride, Sodium Chloride, Glycerol",278,"10.1038/s41598-018-21231-1",,"5HGJ",43.92,"1.399","1.399","Structure of integrin alpha1beta1 and alpha2beta1 I-domains explain differential calcium-mediated ligand recognition","QLDIVIVLDGSNSIYPWDSVTAFLNDLLERMDIGPKQTQVGIVQYGENVTHEFNLNKYSSTEEVLVAAKKIVQRGGRQTMTALGIDTARKEAFTEARGARRGVKKVMVIVTDGESHDNHRLKKVIQDCEDENIQRFSIAILGSYNRGNLSTEKFVEEIKSIASEPTEKHFFNVSDELALVTIVKTLGERIFALEA","Homo sapiens","ITGA1","Integrin alpha-1","1","5HGJ"
"5HGU",,"X-RAY DIFFRACTION",2.47,50.11,"EVAPORATION",7.2,"0.1 M HEPES pH 7.2, 2.4 M sodium formate",293,"10.1038/nchembio.2036",,"5HGU",54.77,"2.046","2.046","Crystal structure of human transcription factor TEAD2 in complex with palmitate","AWQARGLGTARLQLVEFSAFVEPPDAVDSYQRHLFVHISQHCPSPGAPPLESVDVRQIYDKFPEKKGGLRELYDRGPPHAFFLVKFWADLNWGPSGEEAGAGGSISSGGFYGVSSQYESLEHMTLTCSSKVCSFGKQVVEKVETERAQLEDGRFVYRLLRSPMCEYLVNFLHKLRQLPERYMMNSVLENFTILQVVTNRDTQELLLCTAYVFEVSTSERGAQHHIYRLVRDHHHHHH","Homo sapiens","TEAD2, TEF4","Transcriptional enhancer factor TEF-4","1","5HGU"
"5HGZ",,"X-RAY DIFFRACTION",1.9,35.23,"LIQUID DIFFUSION",4,"10mM Tris pH 8.0, 75mM NaCl, 0.5% glycerol, 3%(v/v) Tacsimate pH4.0 (Hampton Research) and 7.5%(w/v) polyethylene glycol 3350 (PEG 3350)",293.15,"10.1038/srep31425",,"5HGZ",28.71,"1.383","1.383","Crystal structure of human Naa60 in complex with acetyl-CoA","SMTEEERSSALSEVSLRLLCHDDIDTVKHLCGDWFPIEYPDSWYRDITSNKKFFSLAATYRGAIVGMIVAEIKNRTKIHKEDGDILASNFSVDTQVAYILSLGVVKEFRKHGIGSLLLESLKDHISTTAQDHCKAIYLHVLTTNNTAINFYENRDFKQHHYLPYYYSIRGVLKDGFTYVLYINGGHPPWTILDYIQHLGSALASLSPCSIPHRVYRQAHSLLCSFLPWSGISSKSGIEYSRTM","Homo sapiens","NAA60, HAT4, NAT15, UNQ2771/PRO7155","N-alpha-acetyltransferase 60","1","5HGZ"
"5HH0",,"X-RAY DIFFRACTION",2.32,46.87,"LIQUID DIFFUSION",7.5,"0.2 M L-Proline, 0.1 M HEPES pH7.5, 10% w/v PEG 3350",293.15,"10.1038/srep31425",,"5HH0",23.74,"1.6","1.6","Crystal structure of human Naa60 in complex with CoA","SMTEEERSSALSEVSLRLLCHDDIDTVKHLCGDWFPIEYPDSWYRDITSNKKFFSLAATYRGAIVGMIVAEIKNRTKIHKEDGDILASNFSVDTQVAYILSLGVVKEFRKHGIGSLLLESLKDHISTTAQDHCKAIYLHVLTTNNTAINFYENRDFKQHHYLPYYYSIRGVLKDGFTYVLYINGGHPPWTILDYIQHLGS","Homo sapiens","NAA60, HAT4, NAT15, UNQ2771/PRO7155","N-alpha-acetyltransferase 60","1","5HH0"
"5HH1",,"X-RAY DIFFRACTION",2.35,47.58,"LIQUID DIFFUSION",8.5,"0.2M Lithium Sulfate monohydrate, 0.1M Tris pH 8.5, 20%(w/v) PEG3350",293.15,"10.1038/srep31425",,"5HH1",23.66,"1.803","1.803","Crystal structure of human Naa60 mutant - F34A in complex with CoA","SMTEEERSSALSEVSLRLLCHDDIDTVKHLCGDWAPIEYPDSWYRDITSNKKFFSLAATYRGAIVGMIVAEIKNRTKIHKEDGDILASNFSVDTQVAYILSLGVVKEFRKHGIGSLLLESLKDHISTTAQDHCKAIYLHVLTTNNTAINFYENRDFKQHHYLPYYYSIRGVLKDGFTYVLYINGGHPPWTILDYIQHLGS","Homo sapiens","NAA60, HAT4, NAT15, UNQ2771/PRO7155","N-alpha-acetyltransferase 60","1","5HH1"
"5HHE",,"X-RAY DIFFRACTION",2.49,50.61,"EVAPORATION",7.5,"39% 2-methyl-2, 4-pentadiol, 9% PEG400 and 100 mM Tris buffer, pH 7.5.",293,"10.1021/acs.biochem.6b00246",,"5HHE",22.57,"1.46","1.46","Human Beclin 1 coiled-coil domain","DDSEQLQMELKELALEEERLIQELEDVEKNRKIVAENLEKVQAEAERLDQEEAQYQREYSEFKRQQLELDDELKSVENQMRYAQTQLDKLKLE","Homo sapiens","BECN1, GT197","Beclin-1","1","5HHE"
"5HHW",,"X-RAY DIFFRACTION",2.58,52.24,"VAPOR DIFFUSION",7.5,"18% Peg3000, 0.1M Tris pH7.5",298,"10.1016/j.bmcl.2016.02.074",,"5HHW",35.45,"1.79","1.79","Crystal structure of insulin receptor kinase domain in complex with cis-(R)-7-(3-(azetidin-1-ylmethyl)cyclobutyl)-5-(3-((tetrahydro-2H-pyran-2-yl)methoxy)phenyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine.","MVFPSSVYVPDEWEVSREKITLLRELGQGSFGMVYEGNARDIIKGEAETRVAVKTVNESASLRERIEFLNEASVMKGFTCHHVVRLLGVVSKGQPTLVVMELMAHGDLKSYLRSLRPEAENNPGRPPPTLQEMIQMAAEIADGMAYLNAKKFVHRNLAARNCMVAHDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMAPESLKDGVFTTSSDMWSFGVVLWEITSLAEQPYQGLSNEQVLKFVMDGGYLDQPDNCPERVTDLMRMCWQFNPKMRPTFLEIVNLLKDDLHPSFPEVSFFHSEENK","Homo sapiens","INSR","Insulin receptor","1","5HHW"
"5HHY",,"X-RAY DIFFRACTION",2.15,42.78,"VAPOR DIFFUSION, HANGING DROP",5,"Protein solution; 0.2 M AGT, 18mM potassium phosphate pH7.4, 20mM Hepes pH 7.4, 5% Jeffamine (Hampton), 5mM sodium hydroxylamine.
Reservoir; PEG 6k 12%, 100 mM MES pH 5.0.
Mixing: 1+1 microL 
Cryoprotectant; 25% MPD",294,"10.1038/s41598-017-11948-w",,"5HHY",85.25,"1.7","1.7","Structure of human Alanine:Glyoxylate Aminotransferase major allele (AGT-Ma) showing X-Ray induced reduction of PLP internal aldimine to 4'-deoxy-piridoxine-phosphate (PLR)","LLVTPPKALLKPLSIPNQLLLGPGPSNLPPRIMAAGGLQMIGSMSKDMYQIMDEIKEGIQYVFQTRNPLTLVISGSGHCALEAALVNVLEPGDSFLVGANGIWGQRAVDIGERIGARVHPMTKDPGGHYTLQEVEEGLAQHKPVLLFLTHGESSTGVLQPLDGFGELCHRYKCLLLVDSVASLGGTPLYMDRQGIDILYSGSQKALNAPPGTSLISFSDKAKKKMYSRKTKPFSFYLDIKWLANFWGCDDQPRMYHHTIPVISLYSLRESLALIAEQGLENSWRQHREAAAYLHGRLQALGLQLFVKDPALRLPTVTTVAVPAGYDWRDIVSYVIDHFDIEIMGGLGPSTGKVLRIGLLGCNATRENVDRVTEALRAALQHCPKKK","Homo sapiens","AGXT, AGT1, SPAT","Serine--pyruvate aminotransferase","1","5HHY"
"5HI2",,"X-RAY DIFFRACTION",2.24,45.02,"VAPOR DIFFUSION, HANGING DROP",6.8,"20% PEG 3350, and 0.2M Potassium Nitrate",292,"10.1016/j.ccell.2016.02.010","BAX","5HI2",32.82,"2.512","2.512","BRAF Kinase domain b3aC loop deletion mutant in complex with sorafenib","MHHHHHGSRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5HI2"
"5HI7",,"X-RAY DIFFRACTION",2.12,42.1,"VAPOR DIFFUSION, SITTING DROP",,"SMYD3 crystallization and soaking of GSK2807: SMYD3 (1-428) expressed in baculovirus and with SAH in the SAM-binding site was crystallized in sitting drops at 22C using 1uL fresh protein at 8.9mg/mL with the addition of 1uL mother liquor (200mM MgOAc Tetrahydrate, 20% PEG 3350). Crystals grew to a large size but varied in quantity when set up in replicates.  A seed stock was formed from these crystals and added at 20% to the mother liquor solution prior to plate setup. Crystals of large size were then created with 1.3uL protein and 1.3uL of mother liquor containing seeds in a sitting drop MRC-2 plate (Hampton Research).  Crystal nucleation occurred overnight and reached maximum size in 4 days",295,"10.1016/j.str.2016.03.010","62X","5HI7",50.32,"2.15","2.15","Co-crystal structure of human SMYD3 with an aza-SAH compound","GSFTMEPLKVEKFATANRGNGLRAVTPLRPGELLFRSDPLAYTVCKGSRGVVCDRCLLGKEKLMRCSQCRVAKYCSAKCQKKAWPDHKRECKCLKSCKPRYPPDSVRLLGRVVFKLMDGAPSESEKLYSFYDLESNINKLTEDKKEGLRQLVMTFQHFMREEIQDASQLPPAFDLFEAFAKVICNSFTICNAEMQEVGVGLYPSISLLNHSCDPNCSIVFNGPHLLLRAVRDIEVGEELTICYLDMLMTSEERRKQLRDQYCFECDCFRCQTQDKDADMLTGDEQVWKEVQESLKKIEELKAHWKWEQVLAMCQAIISSNSERLPDINIYQLKVLDCAMDACINLGLLEEALFYGTRTMEPYRIFFPGSHPVRGVQVMKVGKLQLHQGMFPQAMKNLRLAFDIMRVTHGREHSLIEDLILLLEECDANIRAS","Homo sapiens","SMYD3, ZMYND1, ZNFN3A1","Histone-lysine N-methyltransferase SMYD3","1","5HI7"
"5HIA",,"X-RAY DIFFRACTION",2.18,43.55,"VAPOR DIFFUSION, HANGING DROP",,"0.3 M sodium acetate, 17.5% PEG 3350",291,"10.1021/acschembio.7b00916","YPG","5HIA",103.69,"1.773","1.773","Human hypoxanthine-guanine phosphoribosyltransferase in complex with [3R,4R]-4-guanin-9-yl-3-((S)-2-hydroxy-2-phosphonoethyl)oxy-1-N-(phosphonopropionyl)pyrrolidine","HHHHHHMATRSPGVVISDDEPGYDLDLFAIPNHYAEDLERVFIPHGLIMDRTERLARDVMKEMGGHHIVALCVLKGGYKFFADLLDYIKALNRNSDRSIPMTVDFIRLKSYCNDQSTGDIKVIGGDDLSTLTGKNVLIVEDIIDTGKTMQTLLSLVRQYNPKMVKVASLLVKRTPRSVGYKPDFVGFEIPDKFVVGYALDYNEYFRDLNHVAVISETGKAKYKA","Homo sapiens","HPRT1, HPRT","Hypoxanthine-guanine phosphoribosyltransferase","1","5HIA"
"5HIB",,"X-RAY DIFFRACTION",3.48,64.64,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1016/j.ccell.2016.02.010",,"5HIB",37.93,"2.85","2.85","EGFR kinase domain mutant ""TMLR"" with a pyrazolopyrimidine inhibitor","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HIB"
"5HIC",,"X-RAY DIFFRACTION",3.48,64.7,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 10K, ethylene glycol",292,"10.1016/j.ccell.2016.02.010",,"5HIC",38.07,"2.6","2.6","EGFR kinase domain mutant ""TMLR"" with a imidazopyridinyl-aminopyrimidine inhibitor","GSGEAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGRAKLLGAAAAEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIPQQGNS","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5HIC"
"5HID",,"X-RAY DIFFRACTION",2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",,"20% PEG 3350, and 0.2M Potassium Nitrate",292,"10.1016/j.ccell.2016.02.010","B1E","5HID",65.83,"2.5","2.5","BRAF Kinase domain b3aC loop deletion mutant in complex with AZ628","MHHHHHGSRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5HID"
"5HIE",,"X-RAY DIFFRACTION",2.41,48.88,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1M Tris pH8.5, 19.3% PEG 8K, 500 mM NaCl",292,"10.1016/j.ccell.2016.02.010","P06","5HIE",141.02,"3","3","BRAF Kinase domain b3aC loop deletion mutant in complex with dabrafenib","MDRGSHHHHHHGSEDRNRMKTLGRRDSSDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHIIETKFEMIKLIDIARQTAQGMDYLHAKSIIHRDLKSNNIFLHEDLTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDKNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIFMVGRGYLSPDLSKVRSNCPKAMKRLMAECLKKKRDERPLFPQILASIELLARSLPKIHR","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5HIE"
"5HIN",,"X-RAY DIFFRACTION",3.42,64.01,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293,,,"5HIN",44.3,"1.6","1.6","Crystal structure of human dihydroorotate dehydrogenase (DHODH) with 18L compound","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5HIN"
"5HJ2",,"X-RAY DIFFRACTION",2.6,52.63,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, HEPES, calcium chloride, glycerol",278,"10.1038/s41598-018-21231-1",,"5HJ2",130.81,"2.153","2.153","Integrin alpha2beta1 I-domain","PSLIDVVVVCDESNSIYPWDAVKNFLEKFVQGLDIGPTKTQVGLIQYANNPRVVFNLNTYKTKEEMIVATSQTSQYGGDLTNTFGAIQYARKYAYSAASGGRRSATKVMVVVTDGESHDGSMLKAVIDQCNHDNILRFGIAVLGYLNRNALDTKNLIKEIKAIASIPTERYFFNVSDEAALLEKAGTLGEQIFSIEG","Homo sapiens","ITGA2, CD49B","Integrin alpha-2","1","5HJ2"
"5HJG",,"X-RAY DIFFRACTION",2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter.",291,"10.1371/journal.pone.0153529","XDI","5HJG",28.67,"1.4","1.4","Crystal Structure of Human Transthyretin in Complex with Tetrabromobisphenol A (TBBPA)","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5HJG"
"5HK1",,"X-RAY DIFFRACTION",3.87,68.25,"LIPIDIC CUBIC PHASE",6.5,"Reconstituted in 10:1 monoolein:cholesterol mix. Precipitant solution: 40-50% PEG 300, 220-250 mM lithium sulfoxide, 0.1 M MES pH 6.5.",293,"10.1038/nature17391","61W","5HK1",81.03,"2.5051","2.5051","Human sigma-1 receptor bound to PD144418","GPGSMQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYAGLDHELAFSRLIVELRRLHPGHVLPDEELQWVFVNAGGWMGAMCLLHASLSEYVLLFGTALGSRGHSGRYWAEISDTIISGTFHQWREGTTKSEVFYPGETVVHGPGEATAVEWGPNTWMVEYGRGVIPSTLAFALADTVFSTQDFLTLFYTLRSYARGLRLELTTYLFGQDP","Homo sapiens","SIGMAR1, OPRS1, SRBP, AAG8","Sigma non-opioid intracellular receptor 1","1","5HK1"
"5HK2",,"X-RAY DIFFRACTION",3.94,68.8,"LIPIDIC CUBIC PHASE",6.5,"Reconstituted in 10:1 monoolein: cholesterol mix. Precipitant solution: 30-40% PEG 300, 220-250 mM lithium sulfide, 0.1 M MES pH 6.5",293,"10.1038/nature17391","61V","5HK2",81.25,"3.2","3.2","Human sigma-1 receptor bound to 4-IBP","GPGSMQWAVGRRWAWAALLLAVAAVLTQVVWLWLGTQSFVFQREEIAQLARQYAGLDHELAFSRLIVELRRLHPGHVLPDEELQWVFVNAGGWMGAMCLLHASLSEYVLLFGTALGSRGHSGRYWAEISDTIISGTFHQWREGTTKSEVFYPGETVVHGPGEATAVEWGPNTWMVEYGRGVIPSTLAFALADTVFSTQDFLTLFYTLRSYARGLRLELTTYLFGQDP","Homo sapiens","SIGMAR1, OPRS1, SRBP, AAG8","Sigma non-opioid intracellular receptor 1","1","5HK2"
"5HKG",,"X-RAY DIFFRACTION",2.51,51.04,"VAPOR DIFFUSION, HANGING DROP",7,"16 % PEG 8K, 10% Glycerol, 500 mM KCl, 100 mM Hepes",293,"10.1002/pro.3051","RAP","5HKG",12.94,"1.5","1.5","Total chemical synthesis, refolding and crystallographic structure of a fully active immunophilin: calstabin 2 (FKBP12.6).","GVEIETISPGDGRTFPKKGQTCVVHYTGMLQNGKKFDSSRDRNKPFKFRIGKQEVIKGFEEGAAQMSLGQRAKLTCTPDVAYGATGHPGVIPPNATLIFDVELLNLE","Homo sapiens","FKBP1B, FKBP12.6, FKBP1L, FKBP9, OTK4","Peptidyl-prolyl cis-trans isomerase FKBP1B","1","5HKG"
"5HKM",,"X-RAY DIFFRACTION",3.35,63.33,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM TRIS-HCl, 1.8 M NH4-sulfate",298,"10.1016/j.bmcl.2016.05.005","61Y","5HKM",35.93,"2.1","2.1","DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS","MDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5HKM"
"5HKW",,"X-RAY DIFFRACTION",3.36,63.39,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG 3350, 0.2M sodium citrate dibasic trihyrate",293,,,"5HKW",107.18,"2.25","2.25","Crystal Structure of Apo c-Cbl TKBD Refined to 2.25 A Resolution","SNAPPGTVDKKMVEKCWKLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFMENLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFRITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTG","Homo sapiens","CBL, CBL2, RNF55","E3 ubiquitin-protein ligase CBL","1","5HKW"
"5HKX",,"X-RAY DIFFRACTION",2.36,47.98,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% (w/v) PEG 5000 MME, 0.1M MES, 12% (v/v) 1-propanol",293,,,"5HKX",45.38,"1.85","1.85","Crystal Structure of c-Cbl TKBD-RING domains (Y371E mutant) Refined to 1.85 A Resolution","SNAPPGTVDKKMVEKCWKLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFMENLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFRITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTGLCEPTPQDHIKVTQEQYELECEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQESEGQGCPFCRCEIKGTEPIVVDPFD","Homo sapiens","CBL, CBL2, RNF55","E3 ubiquitin-protein ligase CBL","1","5HKX"
"5HL1",,"X-RAY DIFFRACTION",2.57,52.14,"VAPOR DIFFUSION, HANGING DROP",8,"10% PEG6000",293,,"63J","5HL1",238.97,"2.4","2.4","Crystal structure of glutaminase C in complex with inhibitor CB-839","MRGSHHHHHHGSLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTVDGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5HL1"
"5HLN",,"X-RAY DIFFRACTION",3.48,64.65,"VAPOR DIFFUSION, SITTING DROP",6,"14% (W/V) PEG 8000, 100 mM MES, pH 6.0 and 100 mM magnesium acetate",298,"10.1021/acschembio.6b00306","65C","5HLN",95.73,"3.1","3.1","X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH CHIR99021","GSPGMSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5HLN"
"5HLO",,"X-RAY DIFFRACTION",2.87,57.2,"VAPOR DIFFUSION, SITTING DROP",6.5,"5 mM ZnCl2, 0.1 M Na cacodylate pH 6.5, 8% PEG 8000",293,"10.1186/s12900-016-0058-4",,"5HLO",45.34,"2.1","2.1","Crystal structure of calcium and zinc-bound human S100A8 in space group C2221","MALTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE","Homo sapiens","S100A8, CAGA, CFAG, MRP8","Protein S100-A8","1","5HLO"
"5HLP",,"X-RAY DIFFRACTION",3.02,59.27,"VAPOR DIFFUSION, SITTING DROP",6,"10% (W/V) PEG 5000 MME, 50 mM citric acid and 50 mM bis-tris propane, pH 5.0, 5 mM TCEP",298,"10.1021/acschembio.6b00306","65A","5HLP",95.19,"2.45","2.45","X-RAY CRYSTAL STRUCTURE OF GSK3B IN COMPLEX WITH BRD3937","GSPGMSGRPRTTSFAESCKPVQQPSAFGSMKVSRDKDGSKVTTVVATPGQGPDRPQEVSYTDTKVIGNGSFGVVYQAKLCDSGELVAIKKVLQDKRFKNRELQIMRKLDHCNIVRLRYFFYSSGEKKDEVYLNLVLDYVPETVYRVARHYSRAKQTLPVIYVKLYMYQLFRSLAYIHSFGICHRDIKPQNLLLDPDTAVLKLCDFGSAKQLVRGEPNVSYICSRYYRAPELIFGATDYTSSIDVWSAGCVLAELLLGQPIFPGDSGVDQLVEIIKVLGTPTREQIREMNPNYTEFKFPQIKAHPWTKVFRPRTPPEAIALCSRLLEYTPTARLTPLEACAHSFFDELRDPNVKLPNGRDTPALFNFTTQELSSNPPLATILIPPHARIQAAASTPTNATAASDANTGDRGQTNNAASASASNST","Homo sapiens","GSK3B","Glycogen synthase kinase-3 beta","1","5HLP"
"5HLS",,"X-RAY DIFFRACTION",2.07,40.55,"VAPOR DIFFUSION, SITTING DROP",7.8,"3.4-3.8 M sodium formate, 0.1 M Tris pH 7.8, and 10% glycerol",277,"10.1021/acs.jmedchem.5b01882","62G","5HLS",15.49,"2.182","2.182","Crystal structure of the first bromodomain of human BRD4 bound to CPI-0610","GSTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HLS"
"5HLV",,"X-RAY DIFFRACTION",2.47,50.3,"VAPOR DIFFUSION, SITTING DROP",4,"0.2 M ammonium acetate, 0.1 M Na acetate pH 4.0, 15% PEG 3350, 0.4% 2,2,2-trifluoroethanol",293,"10.1186/s12900-016-0058-4",,"5HLV",88.99,"2.2","2.2","Crystal structure of calcium and zinc-bound human S100A8 in space group P212121","MALTELEKALNSIIDVYHKYSLIKGNFHAVYRDDLKKLLETECPQYIRKKGADVWFKELDINTDGAVNFQEFLILVIKMGVAAHKKSHEESHKE","Homo sapiens","S100A8, CAGA, CFAG, MRP8","Protein S100-A8","1","5HLV"
"5HLW",,"X-RAY DIFFRACTION",2.48,50.4,"VAPOR DIFFUSION, HANGING DROP",8,"Tris 100mM-MPD20%-pH8",293,"10.1021/acs.jmedchem.6b00280","62E","5HLW",34.48,"1.97","1.97","Crystal structure of c-Met mutant Y1230H in complex with compound 14","ALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMHDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNAT","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HLW"
"5HLY",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",6.5,"25% w/v polyethylene glycol 1000, 100 mM MES pH 6.5; cryo: 15% v/v PEG 400 added",292,"10.1038/ncomms12052",,"5HLY",43.7,"2.302","2.302","Structure of Pro-Activin A Precursor at 2.3 A Resolution","MSHHHHHHSMSAAPDSPSSALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGEEKEQSHRPFLMLQARQSEDHPHRRRRRGLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS","Homo sapiens","INHBA","Inhibin beta A chain","1","5HLY"
"5HLZ",,"X-RAY DIFFRACTION",1.67,26.24,"VAPOR DIFFUSION, SITTING DROP",8,"20% w/v polyethylene glycol 3350, 0.2 M calcium chloride; cryo: 15% v/v PEG 400 added",292,"10.1038/ncomms12052",,"5HLZ",173.06,"2.851","2.851","Structure of Pro-Activin A Complex at 2.85 A resolution","MSHHHHHHSMSAAPDSPSSALAALPKDVPNSQPEMVEAVKKHILNMLHLKKRPDVTQPVPKAALLNAIRKLHVGKVGENGYVEIEDDIGRRAEMNELMEQTSEIITFAESGTARKTLHFEISKEGSDLSVVERAEVWLFLKVPKANRTRTKVTIRLFQQQKHPQGSLDTGEEAEEVGLKGERSELLLSEKVVDARKSTWHVFPVSSSIQRLLDQGKSSLDVRIACEQCQESGASLVLLGEEKEQSHRPFLMLQARQSEDHPHLEVLFQGP","Homo sapiens","INHBA","Inhibin beta A chain","1","5HLZ"
,,,,,,,,,,,,,,,,"GLECDGKVNICCKKQFFVSFKDIGWNDWIIAPSGYHANYCEGECPSHIAGTSGSSLSFHSTVINHYRMRGHSPFANLKSCCVPTKLRPMSMLYYDDGQNIIKKDIQNMIVEECGCS","Homo sapiens","INHBA","Inhibin beta A chain","2","5HLZ"
"5HM0",,"X-RAY DIFFRACTION",2.08,40.78,"VAPOR DIFFUSION, SITTING DROP",,"3.4-3.8 M sodium formate, 0.1 M Tris pH 7.8, and 10% glycerol.",277,"10.1021/acs.jmedchem.5b01882","62V","5HM0",15.44,"1.395","1.395","Crystal structure of the first bromodomain of human BRD4 bound to benzoisoxazoloazepine 3","GSTNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HM0"
"5HM7",,"X-RAY DIFFRACTION",2.06,40.36,"VAPOR DIFFUSION, HANGING DROP",7.2,"22% PEG 3350, 0.2M Magnesium chloride, 0.1M HEPES 7.0",298,"10.1073/pnas.1707547114",,"5HM7",57.89,"1.93","1.93","The Intracellular domain of Butyrophilin 3A1 protein","MGQQQEEKKTQFRKKKREQELREMAWSTMKQEQSTRVKLLEELRWRSIQYASRGERHSAYNEWKKALFKPADVILDPKTANPILLVSEDQRSVQRAKEPQDLPDNPERFNWHYCVLGCESFISGRHYWEVEVGDRKEWHIGVCSKNVQRKGWVKMTPENGFWTMGLTDGNKYRTLTEPRTNLKLPKPPKKVGVFLDYETGDISFYNAVDGSHIHTFLDVSFSEALYPVFRILTLEPTALTICPA","Homo sapiens","BTN3A1, BTF5","Butyrophilin subfamily 3 member A1","1","5HM7"
"5HMH",,"X-RAY DIFFRACTION",2.25,45.32,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.8-2.2 Ammonium sulfate",303,"10.1021/acsmedchemlett.5b00472","62R","5HMH",24.77,"1.79","1.79","HDM2 in complex with a 3,3-Disubstituted Piperidine","ASASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLYYLGQYIMTKRLYDEKQQHIVHCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSAGA","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5HMH"
"5HMI",,"X-RAY DIFFRACTION",2.21,44.39,"VAPOR DIFFUSION, SITTING DROP",4.2,"1.8-2.2 M ammonium sulfate, 100 mM NaCitrate/Citric acid",303,"10.1021/acsmedchemlett.5b00472","62T","5HMI",25.53,"1.74","1.74","HDM2 in complex with a 3,3-Disubstituted Piperidine","QIQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLYYLGQYIMTKRLYDEKQQHIVHCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSAGA","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5HMI"
"5HMK",,"X-RAY DIFFRACTION",2.17,43.24,"VAPOR DIFFUSION, SITTING DROP",4,"1.8-2.2 M ammonium sulfate, 100 mM Na Citrate/citric acid",303,"10.1021/acsmedchemlett.5b00472","62Q","5HMK",26.47,"2.17","2.17","HDM2 in complex with a 3,3-Disubstituted Piperidine","SQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLYYLGQYIMTKRLYDEKQQHIVHCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSEN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5HMK"
"5HMP",,"X-RAY DIFFRACTION",2.55,51.74,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 8000, MES, DMSO",277,"10.1038/ncomms12456",,"5HMP",174.11,"2.397","2.397","Myosin Vc pre-powerstroke state","ELYTQYNRVWIPDPEEVWKSAEIAKDYRVGDKVLRLLLEDGTELDYSVNPESLPPLRNPDILVGENDLTALSYLHEPAVLHNLRIRFAESKLIYTYSGIILVAMNPYKQLPIYGDAIIHAYSGQNMGDMDPHIFAVAEEAYKQMARNNRNQSIIVSGESGAGKTVSARYAMRYFATVSKSGSNAHVEDKVLASNPITEAVGNAKTTRNDNSSRFGKYTEISFDEQNQIIGANMSTYLLEKSRVVFQSENERNYHIFYQLCASAQQSEFKHLKLGSAEEFNYTRMGGNTVIEGVNDRAEMVETQKTFTLLGFKEDFQMDVFKILAAILHLGNVQITAVGNERSSVSEDDSHLKVFCELLGLESGRVAQWLCNRKIVTSSETVVKPMTRPQAVNARDALAKKIYAHLFDFIVERINQALQFSGKQHTFIGVLDIYGFETFDVNSFEQFCINYANEKLQQQFNMHVFKLEQEEYMKEDIPWTLIDFYDNQPVIDLIEAKMGILELLDEECLLPHGTDENWLQKLYNNFVNRNPLFEKPRMSNTSFVIQHFADKVEYKCEGFLEKNRDTVYDMLVEILRASKFHLCANFFQENPTPPSPFGSMITVKSAKQVIKPNSKHFRTTVGSKFRSSLYLLMETLNATTPHYVRCIKPNDEKLPFEFDSKRIVQQLRACGVLETIRISAQSYPSRWTYIEFYSRYGILMTKQELSFSDKKEVCKVVLHRLIQDSNQYQFGKTKIFFRAGQVAYLEKLRLD","Homo sapiens","MYO5C","Unconventional myosin-Vc","1","5HMP"
"5HMS",,"X-RAY DIFFRACTION",2.36,47.9,"VAPOR DIFFUSION, HANGING DROP",6.3,"0.1 M MES pH 6.2 - 6.5, 1 - 1.6 M ammonium sulphate, 10 mM dithiothreitol, 100 microM zinc chloride, 0 - 10 % dioxane.",293,"10.1107/S2059798316019525",,"5HMS",72.81,"2.8","2.8","X-ray structure of human recombinant 5-aminolaevulinic acid dehydratase (hrALAD).","MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVTDVPDDIQPITSLPGVARYGVKRLEEMLRPLVEEGLRCVLIFGVPSRVPKDERGSAADSEESPAIEAIHLLRKTFPNLLVACDVCLCPYTSHGHCGLLSENGAFRAEESRQRLAEVALAYAKAGCQVVAPSDMMDGRVEAIKEALMAHGLGNRVSVMSYSAKFASCFYGPFRDAAKSSPAFGDRRCYQLPPGARGLALRAVDRDVREGADMLMVKPGMPYLDIVREVKDKHPDLPLAVYHVSGEFAMLWHGAQAGAFDLKAAVLEAMTAFRRAGADIIITYYTPQLLQWLKEE","Homo sapiens","ALAD","Delta-aminolevulinic acid dehydratase","1","5HMS"
"5HN1",,"X-RAY DIFFRACTION",3.07,59.92,"VAPOR DIFFUSION, HANGING DROP",4.5,"2.1 M ammonium sulfate and 0.1 M sodium acetate (pH 4.5)",293.15,"10.1126/sciimmunol.aaj1548",,"5HN1",39.43,"2.25","2.25","Crystal structure of Interleukin-37","GSVHTSPKVKNLNPKKFSIHDQDHKVLVLDSGNLIAVPDKNYIRPEIFFALASSLSSASAEKGSPILLGVSKGEFCLYCDKDKGQSHPSLQLKKEKLMKLAAQKESARRPFIFYRAQVGSWNMLESAAHPGWFICTSCNCNEPVGVTDKFENRKHIEFSFQPVCKAEMSPSEVSD","Homo sapiens","IL37, FIL1Z, IL1F7, IL1H4, IL1RP1","Interleukin-37","1","5HN1"
"5HNE",,"X-RAY DIFFRACTION",2.34,47.5,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acsmedchemlett.5b00389","EL2","5HNE",85.74,"2.04","2.04","X-RAY CRYSTAL STRUCTURE OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A 2-ARYL BENZIMIDAZOLE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5HNE"
"5HNG",,"X-RAY DIFFRACTION",3.01,59.09,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM Tris-HCl, 1.8 M NH4-sulfate",298,"10.1016/j.bmcl.2016.05.005",,"5HNG",35.83,"3.01","3.01","DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS","MDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5HNG"
"5HNI",,"X-RAY DIFFRACTION",2.22,44.57,"VAPOR DIFFUSION, HANGING DROP",7,"Hepes 100mM, isopropanol 11%, PEG5000 MME 6%",277,"10.1021/acs.jmedchem.6b00280","63B","5HNI",71.48,"1.71","1.71","CRYSTAL STRUCTURE OF CMET WT with compound 3","NTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKFLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEFDSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVK","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HNI"
"5HNR",,"X-RAY DIFFRACTION",2.75,55.2,"VAPOR DIFFUSION, HANGING DROP",6.3,"10 mg/ml protein concentration in 10 milliM Tris pH 7.4, 10 milliM diothiothreitol and 100 microM zinc chloride. 5 microlitres of this were mixed with an equal volume of 0.1 M MES pH range 6.2 - 6.5, 1.0 - 1.6 M ammonium sulphate and 0 - 10 % dioxane.",293,"10.1107/S2059798316019525",,"5HNR",73.05,"2.83","2.83","The X-ray structure of octameric human native 5-aminolaevulinic acid dehydratase.","MQPQSVLHSGYFHPLLRAWQTATTTLNASNLIYPIFVTDVPDDIQPITSLPGVARYGVKRLEEMLRPLVEEGLRCVLIFGVPSRVPKDERGSAADSEESPAIEAIHLLRKTFPNLLVACDVCLCPYTSHGHCGLLSENGAFRAEESRQRLAEVALAYAKAGCQVVAPSDMMDGRVEAIKEALMAHGLGNRVSVMSYSAKFASCFYGPFRDAAKSSPAFGDRRCYQLPPGARGLALRAVDRDVREGADMLMVKPGMPYLDIVREVKDKHPDLPLAVYHVSGEFAMLWHGAQAGAFDLKAAVLEAMTAFRRAGADIIITYYTPQLLQWLKEE","Homo sapiens","ALAD","Delta-aminolevulinic acid dehydratase","1","5HNR"
"5HNS",,"X-RAY DIFFRACTION",3.36,63.37,"VAPOR DIFFUSION, SITTING DROP",7.4,"30% polyethylene glycol mono-ethyl Ether 2000 and 0.1 M potassium thiocyanate",293,"10.1002/1873-3468.12089",,"5HNS",60.73,"2.45","2.45","Structure of glycosylated NPC1 luminal domain C","ETGQARLEKEYFDQHFGPFFRTEQLIIRAPLTDKHIYQPYPSGADVPFGPPLDIQILHQVLDLQIAIENITASYDNETVTLQDICLAPLSPYNTNCTILSVLNYFQNSHSVLDHKKGDDFFVYADYHTHFLYCVRAPASLNDTSLLHDPCLGTFGGPVFPWLVLGGYDDQNYNNATALVITFPVNNYYNDTEKLQRAQAWEKEFINFVKNYKNPNLTISFTAERSIEDELNRESDTGTLEVLFQ","Homo sapiens","NPC1","Niemann-Pick C1 protein","1","5HNS"
"5HNT",,"X-RAY DIFFRACTION",2.08,40.73,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, NaCl, MES",289,,"QAP","5HNT",73.85,"2","2","Crystal Structure of AKR1C3 complexed with CAPE","QCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYS","Homo sapiens","AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS","Aldo-keto reductase family 1 member C3","1","5HNT"
"5HNU",,"X-RAY DIFFRACTION",2.06,40.33,"VAPOR DIFFUSION, HANGING DROP",,"PEG 8000, NaCl, MES",289,,,"5HNU",73.57,"2","2","Crystal Structure of AKR1C3 complexed with octyl gallate","QCVKLNDGHFMPVLGFGTYAPPEVPRSKALEVTKLAIEAGFRHIDSAHLYNNEEQVGLAIRSKIADGSVKREDIFYTSKLWSTFHRPELVRPALENSLKKAQLDYVDLYLIHSPMSLKPGEELSPTDENGKVIFDIVDLCTTWEAMEKCKDAGLAKSIGVSNFNRRQLEMILNKPGLKYKPVCNQVECHPYFNRSKLLDFCKSKDIVLVAYSALGSQRDKRWVDPNSPVLLEDPVLCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTAEDMKAIDGLDRNLHYFNSDSFASHPNYPYS","Homo sapiens","AKR1C3, DDH1, HSD17B5, KIAA0119, PGFS","Aldo-keto reductase family 1 member C3","1","5HNU"
"5HO6",,"X-RAY DIFFRACTION",2.27,45.91,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100mM - MPD 20% - pH8.5",277,"10.1021/acs.jmedchem.6b00280","63K","5HO6",35.86,"1.97","1.97","CRYSTAL STRUCTURE OF CMET IN COMPLEX WITH CMPD.","NTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKFLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEFDSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVK","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HO6"
"5HO7",,"X-RAY DIFFRACTION",2.96,58.45,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM Tris-HCl, 1.8 M NH4-sulfate",298,"10.1016/j.bmcl.2016.05.005","63L","5HO7",35.74,"3","3","DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS","MDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5HO7"
"5HO8",,"X-RAY DIFFRACTION",2.91,57.71,"VAPOR DIFFUSION, HANGING DROP",8.6,"100 mM Tris-HCl, 1.8 M NH4-sulfate",298,"10.1016/j.bmcl.2016.05.005","63E","5HO8",36.08,"2.7","2.7","DISCOVERY OF NOVEL 7-AZAINDOLES AS PDK1 INHIBITORS","MDGTAAEPRPGAGSLQHAQPPPQPRKKRPEDFKFGKILGEGSFSTVVLARELATSREYAIKILEKRHIIKENKVPYVTRERDVMSRLDHPFFVKLYFTFQDDEKLYFGLSYAKNGELLKYIRKIGSFDETCTRFYTAEIVSALEYLHGKGIIHRDLKPENILLNEDMHIQITDFGTAKVLSPESKQARANSFVGTAQYVSPELLTEKSACKSSDLWALGCIIYQLVAGLPPFRAGNEYLIFQKIIKLEYDFPEKFFPKARDLVEKLLVLDATKRLGCEEMEGYGPLKAHPFFESVTWENLHQQTPPKLT","Homo sapiens","PDPK1, PDK1","3-phosphoinositide-dependent protein kinase 1","1","5HO8"
"5HOA",,"X-RAY DIFFRACTION",2.22,44.55,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100 mM, MPD 24%, pH8.5",277,"10.1021/acs.jmedchem.6b00280","63K","5HOA",35.84,"2.14","2.14","Crystal structure of c-Met L1195V in complex with SAR125844","NTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKFVASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEFDSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVK","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HOA"
"5HOB",,"X-RAY DIFFRACTION",2.11,41.63,"VAPOR DIFFUSION, SITTING DROP",7.5,"15% w/v PEG Smear Medium, 0.1 M HEPES pH 7.5, 0.2 M magnesium chloride, 5 % 2-propanol, 10 % ethylene glycol",277,,,"5HOB",48.3,"1.22001298703","1.22001298703","p73 homo-tetramerization domain mutant I","GSDEDTYYLQVRGRKNFEILMELKRSLELMELVPQPLVDSYEQQQQLLQR","Homo sapiens","TP73, P73","Tumor protein p73","1","5HOB"
"5HOC",,"X-RAY DIFFRACTION",2.42,49.22,"VAPOR DIFFUSION, SITTING DROP",7.5,"2 M Sodium chloride, 0.1 M sodium phosphate, 0.1 M potassium phosphate , 0.1 M HEPES pH 7.5",277,"10.1038/cdd.2016.83",,"5HOC",12.1,"1.36007789334","1.36007789334","p73 homo-tetramerization domain mutant II","GSDEDTYYLQVRGRRNFEILMELKRSLELMELVPQPLVDSYDQQQQLLQR","Homo sapiens","TP73, P73","Tumor protein p73","1","5HOC"
"5HOR",,"X-RAY DIFFRACTION",2.24,45.13,"VAPOR DIFFUSION, HANGING DROP",8.5,"Tris 100mM, MPD 20%, pH8.5",277,"10.1021/acs.jmedchem.6b00280","63K","5HOR",35.83,"2.2","2.2","Crystal structure of c-Met-M1250T in complex with SAR125844.","NTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKFLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEFDSVHNKTGAKLPVKWTALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIGEHYVHVNATYVNVK","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HOR"
"5HOW",,"X-RAY DIFFRACTION",4.71,73.9,"VAPOR DIFFUSION, HANGING DROP",6.4,"0.1 M HEPES Buffer, 31% (v/v) Jeffamine M-600",296,"10.1021/jacs.6b01332",,"5HOW",14.21,"2.295","2.295","X-ray crystallographic structure of an Abeta 17-36 beta-hairpin. LV(PHI)FAEDCGSNKCAII(SAR)L(ORN)V","ALVFFAEDCGSNKCAIIGLAV","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5HOW"
"5HOX",,"X-RAY DIFFRACTION",4.71,73.9,"VAPOR DIFFUSION, HANGING DROP",7.1,"0.1 M HEPES Buffer, 29% (v/v) Jeffamine M-600",296,"10.1021/jacs.6b01332",,"5HOX",14.16,"1.9","1.9","X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. Synchrotron data set. (LVFFAEDCGSNKCAII(SAR)LMV).","ALVFFAEDCGSNKCAIIGLMV","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5HOX"
"5HOY",,"X-RAY DIFFRACTION",4.75,74.1,"VAPOR DIFFUSION, HANGING DROP",6.9,"0.1 M HEPES Buffer, 27% (v/v) Jeffamine M-600",296,"10.1021/jacs.6b01332",,"5HOY",14.16,"2.295","2.295","X-ray crystallographic structure of an A-beta 17_36 beta-hairpin. X-ray diffractometer data set. (LVFFAEDCGSNKCAII(SAR)LMV).","ALVFFAEDCGSNKCAIIGLMV","Homo sapiens","APP, A4, AD1","Amyloid beta A4 protein","1","5HOY"
"5HP5",,"X-RAY DIFFRACTION",2.84,56.63,"VAPOR DIFFUSION, HANGING DROP",4.5,"50 mM citric acid, 0.2 M CaCl2, 15%(w/v) PEG3350, 14%(v/v) glycerol",293,"10.1016/j.jmb.2016.06.018",,"5HP5",154.9,"3.198","3.198","Srtucture of human peptidylarginine deiminase type I (PAD1)","MGHHHHHHHHHHSSGHIEGRHMAPKRVVQLSLKMPTHAVCVVGVEAHVDIHSDVPKGANSFRVSGSSGVEVFMVYNRTRVKEPIGKARWPLDTDADMVVSVGTASKELKDFKVRVSYFGEQEDQALGRSVLYLTGVDISLEVDTGRTGKVKRSQGDKKTWRWGPEGYGAILLVNCDRDNHRSAEPDLTHSWLMSLADLQDMSPMLLSCNGPDKLFDSHKLVLNVPFSDSKRVRVFCARGGNSLSDYKQVLGPQCLSYEVERQPGEQEIKFYVEGLTFPDADFLGLVSLSVSLVDPGTLPEVTLFTDTVGFRMAPWIMTPNTQPPEELYVCRVMDTHGSNEKFLEDMSYLTLKANCKLTICPQVENRNDRWIQDEMEFGYIEAPHKSFPVVFDSPRNRGLKDFPYKRILGPDFGYVTREIPLPGPSSLDSFGNLDVSPPVTVGGTEYPLGRILIGSSFPKSGGRQMARAVRNFLKAQQVQAPVELYSDWLSVGHVDEFLTFVPTSDQKGFRLLLASPSACLKLFQEKKEEGYGEAAQFDGLKHQAKRSINEMLADRHLQRDNLHAQKCIDWNRNVLKRELGLAESDIVDIPQLFFLKNFYAEAFFPDMVNMVVLGKYLGIPKPYGPIINGRCCLEEKVQSLLEPLGLHCIFIDDYLSYHELQGEIHCGTNVRRKPFPFKWWNMVP","Homo sapiens","PADI1, PAD1, PDI1","Protein-arginine deiminase type-1","1","5HP5"
"5HPB",,"X-RAY DIFFRACTION",2.55,51.73,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 30% sat AmSO4, 3% v/vEtOH",287,,,"5HPB",22.64,"1.65","1.65","human dihydrofolate reductase complex with NADPH and 5-methyl-6-(phenylthio-4'trifluoromethyl)thieno[2,3-d]pyrimidine-2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HPB"
"5HPG",,"X-RAY DIFFRACTION",2.51,42,,7,"24% (W/V) PEG 8000, 0.1 M NA-HEPES, PH 7.0, 0.15 M LI2(SO4)",,"10.1021/bi972284e",,"5HPG",18.79,"1.66","1.66","STRUCTURE AND LIGAND DETERMINANTS OF THE RECOMBINANT KRINGLE 5 DOMAIN OF HUMAN PLASMINOGEN","DCMFGNGKGYRGKRVTTVTGTPCQDWAAQEPHRHSIFTPETNPRAGLEKNYCRNPDGDVGGPWCYTTNPRKLYDYCDVPQCAAP","Homo sapiens","PLG","PLASMINOGEN","1","5HPG"
"5HPH",,"X-RAY DIFFRACTION",3.48,64.69,"VAPOR DIFFUSION, HANGING DROP",6.25,"1.8M Ammonium Sulfate, 0.1M MES, 1% dioxane",287,"10.1107/S2059798316009906",,"5HPH",115.81,"2.429","2.429","Structure of TRAP1 fragment","GAMGSSTQTAEDKEEPLHSIISSTESVQGSTSKHEFQAETKKLLDIVARSLYSEKEVFIRELISNASDALEKLRHKLVSDGQALPEMEIHLQTNAEKGTITIQDTGIGMTQEELVSNLGTIARSGSKAFLDALQNQAEASSKIIGQFGVGFYSAFMVADRVEVYSRSAAPGSLGYQWLSDGSGVFEIAEASGVRTGTKIIIHLKSDCKEFSSEARVRDVVTKYSNFVSFPLYLNGRRMNTLQAIWMMDPKDVREWQHEEFYRYVAQAHDKPRYTLHYKTDAPLNIRSIFYVPDMKPSMFDVSRELGSSVALYSRKVLIQTKATDILPKWLRFIRGVVDSEDIPLNLSRELLQESALIRKLRDVLQQRLIKFFIDQSKKDAEKYAKFFEDYGLFMREGIVTATEQEVKEDIAKLLRYESSALPSGQLTSLSEYASRMRAGTRNIYYLCAPNRHLAEHSPYYEAMKKKDTEVLFCFEQFDELTLLHLREFDKKKLISVETDI","Homo sapiens","TRAP1, HSP75","Heat shock protein 75 kDa, mitochondrial","1","5HPH"
"5HPP",,"X-RAY DIFFRACTION",2.03,39.3,"VAPOR DIFFUSION, HANGING DROP",5.3,"0.1 M NaOAc pH 5.3, 0.2 M CaCl2, and
31% isopropanol",297,"10.1039/c6sc01927g",,"5HPP",1.79,"2.082","2.082","Crystal structure of a macrocyclic beta-sheet peptide derived from transthyretin (106-121) - (ORN)TIA(MAA)LLS(ORN)S(PHI)STTAV","ATIAALLSASFSTTAV","Homo sapiens",,"ORN-THR-ILE-ALA-MAA-LEU-LEU-SER-ORN-SER-PHI-SER-THR-THR-ALA-VAL","1","5HPP"
"5HPR",,"X-RAY DIFFRACTION",3.42,64.05,"VAPOR DIFFUSION, SITTING DROP",8,"300 mM Tris, 0.5 mM zinc acetate, 8.5% acetone, 0.5 M sodium citrate",295,"10.1021/jacs.7b00794",,"5HPR",5.95,"1.33","1.33","Insulin with proline analog HyP at position B28 in the T2 state","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin A-Chain","1","5HPR"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin B-Chain","2","5HPR"
"5HPU",,"X-RAY DIFFRACTION",2.07,40.57,"VAPOR DIFFUSION, SITTING DROP",8,"300 mM Tris, 17 mM zinc acetate, 1% phenol, 1.95 M sodium citrate",295,"10.1021/jacs.7b00794",,"5HPU",12.06,"2.2","2.2","Insulin with proline analog HyP at position B28 in the R6 state","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin, chain A","1","5HPU"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin, chain B","2","5HPU"
"5HQ3",,"X-RAY DIFFRACTION",3.28,62.51,"VAPOR DIFFUSION, HANGING DROP",6,"8% PEG 6000
0.1M MgCl2
0.1M MES pH=6",277,"10.1016/j.molcel.2016.06.012",,"5HQ3",123.16,"2.6","2.6","Stable, high-expression variant of human acetylcholinesterase","MEGREDAELLVTTRGGRLRGIRLTTPGGPVSAFLGIPFAEPPVGPRRFRPPEPKQPWSGVWDATTFQNVCYQYVDTLYPGFEGTEMWNPNRNLSEDCLYLNVWTPYPRPKNPAPVMVWIYGGGFYSGSSSLDVYDGRFLVRTERVVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENIAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAILQSGAPNAPWAYVSREEARRRALQLAKLVGCPPGGTGGNDTELVACLRNRPPQELVNHEWHVLPQESVFRFSFVPVVDGDFLPDTPEALINNGDFKGLDVLVGVNKDEGSYFLVYGAPGFSKDNESLISREEFLEGVRVGVPQVSDLAAEAIVLHYTDWLHPEDPAKNRDALSDVVGDHNVICPVAQFAQRYAANGARVYAYVFEHRSSTLPWPEWMGVPHGYEIEFIFGIPLDPSRNYTKEEKIFARRLMRYWANFARTGDPNEPRDPKAPQWPPYTADEQKYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLD","Homo sapiens","ACHE","Acetylcholinesterase","1","5HQ3"
,,,,,,,,,,,,,,,,"MEGREDAELLVTTRGGRLRGIRLTTPGGPVSAFLGIPFAEPPVGPRRFRPPEPKQPWSGVWDATTFQNVCYQYVDTLYPGFEGTEMWNPNRNLSEDCLYLNVWTPYPRPKNPAPVMVWIYGGGFYSGSSSLDVYDGRFLVRTERVVLVSMNYRVGAFGFLALPGSREAPGNVGLLDQRLALQWVQENIAAFGGDPTSVTLFGESAGAASVGMHLLSPPSRGLFHRAILQSGAPNAPWAYVSREEARRRALQLAKLVGCPPGGTGGNDTELVACLRNRPPQELVNHEWHVLPQESVFRFSFVPVVDGDFLPDTPEALINNGDFKGLDVLVGVNKDEGSYFLVYGAPGFSKDNESLISREEFLEGVRVGVPQVSDLAAEAIVLHYTDWLHPEDPAKNRDALSDVVGDHNVICPVAQFAQRYAANGARVYAYVFEHRSSTLPWPEWMGVPHGYEIEFIFGIPLDPSRNYTKEEKIFARRLMRYWANFARTGDPNEPRDPKAPQWPPYTADEQKYVSLDLRPLEVRRGLRAQACAFWNRFLPKLLSATDTLDE","Homo sapiens","ACHE","Acetylcholinesterase","2","5HQ3"
"5HQ5",,"X-RAY DIFFRACTION",2.18,43.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"3.6M Naformate, 10% glycerol",293,,,"5HQ5",15.34,"1.6","1.6","Crystal structure of fragment bound with Brd4","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HQ5"
"5HQ6",,"X-RAY DIFFRACTION",1.99,38.11,"VAPOR DIFFUSION, HANGING DROP",6.5,"3.6M Naformate, 10% glycerol",293,,,"5HQ6",15.02,"1.95","1.95","Crystal structure of fragment bound with Brd4","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPT","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HQ6"
"5HQ7",,"X-RAY DIFFRACTION",2.03,39.28,"VAPOR DIFFUSION, HANGING DROP",6.5,"3.6M Naformate, 10% glycerol",293,,,"5HQ7",15.12,"1.9","1.9","Crystal structure of fragment bound with Brd4","MNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5HQ7"
"5HQE",,"X-RAY DIFFRACTION",3.42,64.04,"VAPOR DIFFUSION, HANGING DROP",4.8,"0.1M acetate, 40mM C11DAO, 20.8mM N,N-dimethyldecylamine-N-oxide (DDAO), 2mM DHO, 1.6-1.8 M ammonium sulfate",293,,,"5HQE",44.04,"1.62","1.62","Crystal structure of human dihydroorotate dehydrogenase (DHODH) with compound 18T","MGHHHHHHHHHHSSGHIDDDDKHMATGDERFYAEHLMPTLQGLLDPESAHRLAVRFTSLGLLPRARFQDSDMLEVRVLGHKFRNPVGIAAGFDKHGEAVDGLYKMGFGFVEIGSVTPKPQEGNPRPRVFRLPEDQAVINRYGFNSHGLSVVEHRLRARQQKQAKLTEDGLPLGVNLGKNKTSVDAAEDYAEGVRVLGPLADYLVVNVSSPNTAGLRSLQGKAELRRLLTKVLQERDGLRRVHRPAVLVKIAPDLTSQDKEDIASVVKELGIDGLIVTNTTVSRPAGLQGALRSETGGLSGKPLRDLSTQTIREMYALTQGRVPIIGVGGVSSGQDALEKIRAGASLVQLYTALTFWGPPVVGKVKRELEALLKEQGFGGVTDAIGADHRR","Homo sapiens","DHODH","Dihydroorotate dehydrogenase (quinone), mitochondrial","1","5HQE"
"5HQG",,"X-RAY DIFFRACTION",2.24,45.13,"VAPOR DIFFUSION, HANGING DROP",,"sodium nitrate 0.5M
10% PEG 3350",293,"10.1016/j.str.2016.03.002",,"5HQG",40.95,"2","2","WD40 domain of Human E3 Ubiquitin Ligase COP1 (RFWD2)","HHHHHHMSRISDDSRTASQLDEFQECLSKFTRYNSVRPLATLSYASDLYNGSSIVSSIEFDRDCDYFAIAGVTKKIKVYEYDTVIQDAVDIHYPENEMTCNSKISCISWSSYHKNLLASSDYEGTVILWDGFTGQRSKVYQEHEKRCWSVDFNLMDPKLLASGSDDAKVKLWSTNLDNSVASIEAKANVCCVKFSPSSRYHLAFGCADHCVHYYDLRNTKQPIMVFKGHRKAVSYAKFVSGEEIVSASTDSQLKLWNVGKPYCLRSFKGHINEKNFVGLASNGDYIACGSENNSLYLYYKGLSKTLLTFKFDTVKSVLDKDRKEDDTNEFVSAVCWRALPDGESNVLIAANSQGTIKVLELV","Homo sapiens","RFWD2, COP1, RNF200","E3 ubiquitin-protein ligase RFWD2","1","5HQG"
"5HQI",,"X-RAY DIFFRACTION",3.42,64.04,"VAPOR DIFFUSION, SITTING DROP",8.25,"462.5 mM sodium citrate, 100 mM HEPES",295,"10.1021/jacs.7b00794",,"5HQI",5.83,"0.97","0.97","Insulin with proline analog HzP at position B28 in the T2 state","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin A-Chain","1","5HQI"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin B-Chain","2","5HQI"
"5HQY",,"X-RAY DIFFRACTION",2.59,52.43,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KP04, 60% AmSO4, 3%v/v ETOH",287,,,"5HQY",22.78,"1.46","1.46","human dihydrofolate reductase complex with NADPH and 5-methyl-6-(2',3',4'-trifluorophenylthio)thieno[2,3-d]pyrimidine-2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HQY"
"5HQZ",,"X-RAY DIFFRACTION",2.5,50.72,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mMKPO4, 30% sat AmSO4, 3% ETOH",287,,,"5HQZ",22.47,"1.46","1.46","Fluorine substituted 5-methyl-6-(4'-trifluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HQZ"
"5HRQ",,"X-RAY DIFFRACTION",2.32,46.93,"VAPOR DIFFUSION, SITTING DROP",8,"300 mM Tris, 17 mM zinc acetate, 1% phenol, 7.5% acetone, 2.675 M sodium citrate",295,"10.1021/jacs.7b00794",,"5HRQ",35.77,"1.28","1.28","Insulin with proline analog HzP at position B28 in the R6 state","GIVEQCCTSICSLYQLENYCN","Homo sapiens","INS","Insulin A-Chain","1","5HRQ"
,,,,,,,,,,,,,,,,"FVNQHLCGSHLVEALYLVCGERGFFYTPKT","Homo sapiens","INS","Insulin B-Chain","2","5HRQ"
"5HRV",,"X-RAY DIFFRACTION",2.88,57.32,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M tris-sodium citrate dihydrate pH 5.6, 20% isopropanol, 20% PEG4K",277,"10.1021/acs.jmedchem.6b00355",,"5HRV",14.92,"1.7","1.7","Crystal structure of the fifth bromodomain of human PB1 in complex with 1-ethylisochromeno[3,4-c]pyrazol-5(2H)-one) compound","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5HRV"
"5HRW",,"X-RAY DIFFRACTION",2.19,43.88,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M ammonium sulfate, 0.1 M MES pH 6.5, 30% PEGMME5k",277,"10.1021/acs.jmedchem.6b00355",,"5HRW",30.16,"1.8","1.8","Crystal structure of the fifth bromodomain of human PB1 in complex with 1-propylisochromeno[3,4-c]pyrazol-5(2H)-one) compound","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5HRW"
"5HRX",,"X-RAY DIFFRACTION",2.18,43.51,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1M lithium sulfate monohydrate, 0.1 M Tris pH 8.5, 30% PEG4K",277,"10.1021/acs.jmedchem.6b00355",,"5HRX",29.9,"1.73","1.73","Crystal structure of the fifth bromodomain of human PB1 in complex with 1-butylisochromeno[3,4-c]pyrazol-5(2H)-one) compound","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5HRX"
"5HS3",,"X-RAY DIFFRACTION",2.32,46.94,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1 M sodium cacodylate, 15% PEG 4000",298,"10.1038/ncomms11040",,"5HS3",201.7,"3.103","3.103","Human thymidylate synthase complexed with dUMP and 3-amino-2-benzoyl-4-methylthieno[2,3-b]pyridin-6-ol","MPPHGELQYLGQIQHILRCGVRKDDRTGTGTLSVFGMQARYSLRDEFPLLTTKRVFWKGVLEELLWFIKGSTNAKELSSKGVKIWDANGSRDFLDSLGFSTREEGDLGPVYGFQWRHFGAEYRDMESDYSGQGVDQLQRVIDTIKTNPDDRRIIMCAWNPRDLPLMALPPCHALCQFYVVNSELSCQLYQRSGDMGLGVPFNIASYALLTYMIAHITGLKPGDFIHTLGDAHIYLNHIEPLKIQLQREPRPFPKLRILRKVEKIDDFKAEDFQIEGYNPHPTIKMEMAV","Homo sapiens","TYMS, TS, OK/SW-cl.29","Thymidylate synthase","1","5HS3"
"5HS6",,"X-RAY DIFFRACTION",2.39,48.49,"VAPOR DIFFUSION, SITTING DROP",,"CHES 0.1M, tri-sodium citrate 1M",291,"10.1021/acs.jmedchem.6b00293",,"5HS6",29.64,"2.02","2.02","Human 17beta-hydroxysteroid dehydrogenase type 14 in complex with Estrone","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5HS6"
"5HSF",,"X-RAY DIFFRACTION",1.73,28.74,"VAPOR DIFFUSION, SITTING DROP",8.3,"Protein: 11.0 mg/ml, 0.25M Sodium chloride,  0.1M Tris HCl (pH 8.3);
Screen: PEGs II (F4), 0.2M Ammonium sulfate, 0.1M Sodium acetate, 22% (w/v) PEG 4000",295,,,"5HSF",30.34,"1.52","1.52","1.52 Angstrom Crystal Structure of Fc fragment of Human IgG1.","KAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKSEKDELGENLYFQSAGHHHHHH","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5HSF"
"5HSH",,"X-RAY DIFFRACTION",2.94,58.12,"VAPOR DIFFUSION, HANGING DROP",9.7,"~1.0M Sodium Citrate, 0.1M CHES Buffer pH 9.7.",292,"10.1016/j.jmb.2016.02.032",,"5HSH",123.72,"2.65","2.65","Crystal structure of the G291R mutant of human phosphoglucomutase 1","MVKIVTVKTQAYQDQKPGTSGLRKRVKVFQSSANYAENFIQSIISTVEPAQRQEATLVVGGDGRFYMKEAIQLIARIAAANGIGRLVIGQNGILSTPAVSCIIRKIKAIGGIILTASHNPGGPNGDFGIKFNISNGGPAPEAITDKIFQISKTIEEYAVCPDLKVDLGVLGKQQFDLENKFKPFTVEIVDSVEAYATMLRSIFDFSALKELLSGPNRLKIRIDAMHGVVGPYVKKILCEELGAPANSAVNCVPLEDFGGHHPDPNLTYAADLVETMKSGEHDFGAAFDGDRDRNMILGKHGFFVNPSDSVAVIAANIFSIPYFQQTGVRGFARSMPTSGALDRVASATKIALYETPTGWKFFGNLMDASKLSLCGEESFGTGSDHIREKDGLWAVLAWLSILATRKQSVEDILKDHWQKYGRNFFTRYDYEEVEAEGANKMMKDLEALMFDRSFVGKQFSANDKVYTVEKADNFEYSDPVDGSISRNQGLRLIFTDGSRIVFRLSGTGSAGATIRLYIDSYEKDVAKINQDPQVMLAPLISIALKVSQLQERTGRTAPTVIT","Homo sapiens","PGM1","Phosphoglucomutase-1","1","5HSH"
"5HSR",,"X-RAY DIFFRACTION",2.52,51.18,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, pH 6.9, 60% sat AmSO4, 3% v/v ETOH",287,,,"5HSR",22.78,"1.21","1.21","Fluorine substituted 5-methyl-6-(3',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HSR"
"5HSU",,"X-RAY DIFFRACTION",2.55,51.76,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4 60% sat AmSO4, 3% v/v ETOH",287,,,"5HSU",22.44,"1.46","1.46","Fluorine substituted 5-methyl-6-(2',4'-difluoromethoxyphenythio)thieno[2,3-d]pyrimidine-2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HSU"
"5HT4",,"X-RAY DIFFRACTION",2.55,51.74,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KSO4, 60% sat AmSO4, 3%ETOH",283,,"65J","5HT4",22.62,"1.6","1.6","6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HT4"
"5HT5",,"X-RAY DIFFRACTION",2.56,51.9,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, pH 6.9, 60 % sat AmSO4,3% v/v ETOH",287,,"65H","5HT5",22.41,"1.9","1.9","6-substituted pyrrolo[2,3-d]pyrimidine 6-thieno-(4-methoxyphenyl)","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HT5"
"5HT6",,"X-RAY DIFFRACTION",2.2,44.01,"VAPOR DIFFUSION, SITTING DROP",,"0.2M NH4Cl, 12 % (w/v) PEG 3350",293,"10.1371/journal.pone.0165139",,"5HT6",32.21,"2.093","2.093","Crystal structure of the SET domain of the human MLL5 methyltransferase","GPTNNLLFKPPVESHIQKNKKILKSAKDLPPDALIIEYRGKFMLREQFEANGYFFKRPYPFVLFYSKFHGLEMCVDARTFGNEARFIRRSCTPNAEVRHEIQDGTIHLYIYSIHSIPKGTEITIAFDFDYGNAKYKVD","Homo sapiens","KMT2E, MLL5","Histone-lysine N-methyltransferase 2E","1","5HT6"
"5HTI",,"X-RAY DIFFRACTION",2.19,43.9,"VAPOR DIFFUSION, HANGING DROP",7.1,"10-11% PEG5000MME, 11% isopropanol, 0.1M HEPES pH 7.1",293,,,"5HTI",36.62,"1.66","1.66","Crystal structure of c-Met kinase domain in complex with LXM108","MGSSHHHHHHGDSDISSPLLQNTVHIDLSALNPELVQAVQHVVIGPSSLIVHFNEVIGRGHFGCVYHGTLLDNDGKKIHCAVKSLNRITDIGEVSQFLTEGIIMKDFSHPNVLSLLGICLRSEGSPLVVLPYMKHGDLRNFIRNETHNPTVKDLIGFGLQVAKGMKYLASKKFVHRDLAARNCMLDEKFTVKVADFGLARDMYDKEYYSVHNKTGAKLPVKWMALESLQTQKFTTKSDVWSFGVLLWELMTRGAPPYPDVNTFDITVYLLQGRRLLQPEYCPDPLYEVMLKCWHPKAEMRPSFSELVSRISAIFSTFIG","Homo sapiens","MET","Hepatocyte growth factor receptor","1","5HTI"
"5HTK",,"X-RAY DIFFRACTION",3.45,64.3,"VAPOR DIFFUSION, SITTING DROP",6,"100mM MES, 0.5-3.0% polyethylene glycol 8000, 13-16% polyethylene glycol 3350, and 3% dioxane",285,"10.1002/prot.25204","FLC","5HTK",120.34,"2.01","2.01","Human Heart 6-Phosphofructo-2-Kinase/Fructose-2,6-Bisphosphatase (PFKFB2)","MSGASSSEQNNNSYETKTPNLRMSEKKCSWASYMTNSPTLIVMIGLPARGKTYVSKKLTRYLNWIGVPTKVFNLGVYRREAVKSYKSYDFFRHDNEEAMKIRKQCALVALEDVKAYLTEENGQIAVFDATNTTRERRDMILNFAEQNSFKVFFVESVCDDPDVIAANILEVKVSSPDYPERNRENVMEDFLKRIECYKVTYRPLDPDNYDKDLSFIKVINVGQRFLVNRVQDYIQSKIVYYLMNIHVQPRTIYLCRHGESEFNLLGKIGGDSGLSVRGKQFAQALRKFLEEQEITDLKVWTSQLKRTIQTAESLGVPYEQWKILNEIDAGVCEEMTYAEIEKRYPEEFALRDQEKYLYRYPGGESYQDLVQRLEPVIMELERQGNVLVISHQAVMRCLLAYFLDKGADELPYLRCPLHTIFKLTPVAYGCKVETIKLNVEAVNTHRDKPTNNFPKNQTPVRMRRNSFTPLSSSNTIRRPRNYSVGSRPLKPLSPLRAQDMQEGAD","Homo sapiens","PFKFB2","6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 2","1","5HTK"
"5HTZ",,"X-RAY DIFFRACTION",2.96,58.44,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277,"10.1021/acs.jmedchem.6b00307","66J","5HTZ",92.78,"1.95","1.95","BACE1 in complex with (S)-5-(3-chloro-5-(5-(prop-1-yn-1-yl)pyridin-3-yl)thiophen-2-yl)-2,5-dimethyl-1,2,4-thiadiazinan-3-iminium 1,1-dioxide","LPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HTZ"
"5HU0",,"X-RAY DIFFRACTION",2.94,58.1,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277,"10.1021/acs.jmedchem.6b00307","66H","5HU0",93.01,"1.83","1.83","BACE1 in complex with 4-(3-(furan-2-carboxamido)phenyl)-1-methyl-5-oxo-4-phenylimidazolidin-2-iminium","LPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HU0"
"5HU1",,"X-RAY DIFFRACTION",2.99,58.89,"VAPOR DIFFUSION, HANGING DROP",,"15% PEG 3350, 200MM NA/K TARTRATE, 100MM HEPES PH7",277,"10.1021/acs.jmedchem.6b00307","66F","5HU1",92.78,"1.5","1.5","BACE1 in complex with (R)-N-(3-(3-amino-2,5-dimethyl-1,1-dioxido-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl)-4-fluorophenyl)-5-fluoropicolinamide","LPRETDEEPEEPGRRGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDEST","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5HU1"
"5HU9",,"X-RAY DIFFRACTION",2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",8,"0.1M  Potassium thiocyanate, 28% PEG2000",293,"10.18632/oncotarget.10037","66K","5HU9",33.95,"1.529","1.529","Crystal structure of ABL1 in complex with CHMFL-074","GAMGSSPNYDKWEMERTDITMKHKLGGGQYGEVYEGVWKKYSLTVAVKTLKEDTMEVEEFLKEAAVMKEIKHPNLVQLLGVCTREPPFYIITEFMTYGNLLDYLRECNRQEVNAVVLLYMATQISSAMEYLEKKNFIHRDLAARNCLVGENHLVKVADFGLSRLMTGDTYTAHAGAKFPIKWTAPESLAYNKFSIKSDVWAFGVLLWEIATYGMSPYPGIDLSQVYELLEKDYRMERPEGCPEKVYELMRACWQWNPSDRPSFAEIHQAFETMFQES","Homo sapiens","ABL1, ABL, JTK7","Tyrosine-protein kinase ABL1","1","5HU9"
"5HUI",,"X-RAY DIFFRACTION",2.58,52.38,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 60& sat AmSO4, 3% v/v ETOH",287,,,"5HUI",22.54,"1.46","1.46","6-substituted pyrido[3,2-d]pyrimidine--6-4'-trifluoromethoxyphenyl)","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HUI"
"5HUZ",,"SOLUTION NMR",,,,,,,,,"5HUZ",11.58,,,"Solution structure of coiled coil domain of myosin binding subunit of myosin light chain phosphatase","DFKKLYEQILAENEKLKAQLHDTNMELTDLKLQLEKATQRQERFADRS","Homo sapiens","PPP1R12A, MBS, MYPT1","Protein phosphatase 1 regulatory subunit 12A","1","5HUZ"
"5HV9",,"X-RAY DIFFRACTION",5.66,78.28,"VAPOR DIFFUSION, SITTING DROP",6.5,"2.0 M NH4SO4, 0.2 M NaCl, 0.1 M Na-cacodylate, pH 6.5",298,"10.1074/jbc.M116.735647",,"5HV9",17.86,"3","3","Human LTC4S mutant-S36E","MHHHHHHKDEVALLAAVTLLGVLLQAYFSLQVISARRAFRVEPPLTTGPPEFERVYRAQVNCSEYFPLFLATLWVAGIFFHEGAAALCGLVYLFARLRYFQGYARSAQLRLAPLYASARALWLLVALAALGLLAHFLPAALRAALLGRLRTLLPWA","Homo sapiens","LTC4S","Leukotriene C4 synthase","1","5HV9"
"5HVB",,"X-RAY DIFFRACTION",2.56,51.95,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, 60% sat AmSO4, 3%ETOH",287,,,"5HVB",22.43,"1.6","1.6","5-methyl-6-(1-naphthylthio)thieno[2,3-d]pyrimidine 2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HVB"
"5HVE",,"X-RAY DIFFRACTION",2.53,51.38,"VAPOR DIFFUSION, HANGING DROP",6.9,"100 mM KPO4, ph 6.9, 60% sat AmSO4, 3% ETOH",283,,,"5HVE",22.47,"1.46","1.46","5-methyl-6-(3'-trifluromethoxyphenylthio)[2,3-d]pyrimidine 2,4-diamine","VGSLNCIVAVSQNMGIGKNGDLPWPPLRNEFRYFQRMTTTSSVEGKQNLVIMGKKTWFSIPEKNRPLKGRINLVLSRELKEPPQGAHFLSRSLDDALKLTEQPELANKVDMVWIVGGSSVYKEAMNHPGHLKLFVTRIMQDFESDTFFPEIDLEKYKLLPEYPGVLSDVQEEKGIKYKFEVYEKND","Homo sapiens","DHFR","Dihydrofolate reductase","1","5HVE"
"5HVJ",,"X-RAY DIFFRACTION",2.17,43.28,"VAPOR DIFFUSION, HANGING DROP",,"18-24% PEG 3350, 0.2 M potassium citrate",298,"10.1016/j.molcel.2016.04.001",,"5HVJ",73.29,"2.2","2.2","Crystal structure of LIMK1 D460N mutant in complex with AMP-PNP","GAMGSRPHRIFRPSDLIHGEVLGKGCFGQAIKVTHRETGEVMVMKELIRFDEETQRTFLKEVKVMRCLEHPNVLKFIGVLYKDKRLNFITEYIKGGTLRGIIKSMDSQYPWSQRVSFAKDIASGMAYLHSMNIIHRNLNSHNCLVRENKNVVVADFGLARLMVDEKTQPEGLRSLKKPDRKKRYTVVGNPYWMAPEMINGRSYDEKVDVFSFGIVLCEIIGRVNADPDYLPRTMDFGLNVRGFLDRYCPPNCPPSFFPITVRCCDLDPEKRPSFVKLEHWLETLRMHLAGHLPLGPQLEQLDRGFWETYRRGESG","Homo sapiens","LIMK1, LIMK","LIM domain kinase 1","1","5HVJ"
"5HVS",,"X-RAY DIFFRACTION",2.16,42.97,"VAPOR DIFFUSION, HANGING DROP",8,"2.0M ammonium sulfate, 0.1M Tris-HCl pH 8, 3% isopropanol",293.15,"10.1021/jacs.6b04910","65V","5HVS",39.15,"1.75","1.75","Crystal Structure of Macrophage Migration Inhibitory Factor (MIF) with a Biaryltriazole Inhibitor (3i-305)","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5HVS"
"5HVT",,"X-RAY DIFFRACTION",3.74,67.07,"VAPOR DIFFUSION, HANGING DROP",7,"2.0 M Ammonium Sulfate, 3% isopropanol and 0.1 M Tris pH 7.0",293.15,"10.1021/jacs.6b04910","NVS","5HVT",38.91,"1.75","1.75","Crystal Structure of Macrophage Migration Inhibitory Factor (MIF) with a Potent Inhibitor (NVS-2)","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5HVT"
"5HVU",,"X-RAY DIFFRACTION",4.5,72.68,"VAPOR DIFFUSION, HANGING DROP",5.5,"4.5% PEG3350, 100mM MES, pH 5.5, 50mM CaCl2, 10mM DTT, 0.45 mM protein, VAPOR DIFFUSION, HANGING DROP, temperature 298K",298,"10.1016/j.bmcl.2018.06.043","65R","5HVU",96.9,"2.8","2.8","Rho-associated protein kinase 1 (ROCK 1) in complex with a pyridine thiazole piperidine inhibitor","GSLHMSFETRFEKMDNLLRDPKSEVNSDCLLDGLDALVYDLDFPALRKNKNIDNFLSRYKDTINKIRDLRMKAEDYEVVKVIGRGAFGEVQLVRHKSTRKVYAMKLLSKFEMIKRSDSAFFWEERDIMAFANSPWVVQLFYAFQDDRYLYMVMEYMPGGDLVNLMSNYDVPEKWARFYTAEVVLALDAIHSMGFIHRDVKPDNMLLDKSGHLKLADFGTCMKMNKEGMVRCDTAVGTPDYISPEVLKSQGGDGYYGRECDWWSVGVFLYEMLVGDTPFYADSLVGTYSKIMNHKNSLTFPDDNDISKEAKNLICAFLTDREVRLGRNGVEEIKRHLFFKNDQWAWETLRDTVAPVVPDLSSDIDTSNFDDLEEDKGEEETFPIPKAFVGNQLPFVGFTYYSNRRYLSSANPNDNR","Homo sapiens","ROCK1","Rho-associated protein kinase 1","1","5HVU"
"5HVV",,"X-RAY DIFFRACTION",2.76,55.48,"VAPOR DIFFUSION, HANGING DROP",7.5,"2 M ammonium sulfate, 3% 2-propanol, 0.1 M Tris-HCl, pH 7.5",293,,,"5HVV",36.75,"1.9","1.9","Crystal structure of Pro1 deletion and M2A double mutant of Macrophage Migration Inhibitory Factor","AFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5HVV"
"5HVW",,"X-RAY DIFFRACTION",2.8,53,"VAPOR DIFFUSION",,"9 mM ZnCl2, 90 mM Hepes, pH 7.0, 18% PEG 6000 (w/v)",293,"10.1371/journal.pone.0160345",,"5HVW",25.75,"1.95","1.95","Monomeric IgG4 Fc","LGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTFPPSQEEMTKNQVSLRCLVKGFYPSDIAVEWESNGQPENNYKTTKPVLDSDGSFRLESRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLS","Homo sapiens","IGHG4","Ig gamma-4 chain C region","1","5HVW"
"5HWL",,"X-RAY DIFFRACTION",2.21,44.26,"VAPOR DIFFUSION, HANGING DROP",,"0.02 M Magnesium Chloride, 0.1M HEPES,pH 6.8, polyacrylic acid sodium salt 5100",293,,,"5HWL",52.56,"1.6","1.6","Human glutathione s-transferase Mu2 complexed with BDEA, monoclinic crystal form","PMTLGYWNIRGLAHSIRLLLEYTDSSYEEKKYTMGDAPDYDRSQWLNEKFKLGLDFPNLPYLIDGTHKITQSNAILRYIARKHNLCGESEKEQIREDILENQFMDSRMQLAKLCYDPDFEKLKPEYLQALPEMLKLYSQFLGKQPWFLGDKITFVDFIAYDVLERNQVFEPSCLDAFPNLKDFISRFEGLEKISAYMKSSRFLPRPVFTKMAVWGNK","Homo sapiens","GSTM2, GST4","Glutathione S-transferase Mu 2","1","5HWL"
"5HX4",,"X-RAY DIFFRACTION",1.98,37.82,"VAPOR DIFFUSION, SITTING DROP",,"Tacsimate pH5.0, PEG3350, Glycerol",298,"10.1016/j.jmb.2016.04.026",,"5HX4",46.72,"1.92","1.92","Zinc-Free APOBEC3F Catalytic Domain Crystal Structure","GPLGSPGIPGKEILRNPMEAMDPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETGRHAERCFLSWFADDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIKTARLYYFDDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWDGLDYNFLDLDSKLQEILE","Homo sapiens","APOBEC3F","DNA dC->dU-editing enzyme APOBEC-3F","1","5HX4"
"5HX5",,"X-RAY DIFFRACTION",1.97,37.57,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350, MgCl2",298,"10.1016/j.jmb.2016.04.026",,"5HX5",46.85,"2.33","2.33","APOBEC3F Catalytic Domain Crystal Structure","GPLGSPGIPGKEILRNPMEAMDPHIFYFHFKNLRKAYGRNESWLCFTMEVVKHHSPVSWKRGVFRNQVDPETGRHAERCFLSWFADDILSPNTNYEVTWYTSWSPCPECAGEVAEFLARHSNVNLTIKTARLYYFDDTDYQEGLRSLSQEGASVEIMGYKDFKYCWENFVYNDDEPFKPWDGLDYNFLDLDSKLQEILE","Homo sapiens","APOBEC3F","DNA dC->dU-editing enzyme APOBEC-3F","1","5HX5"
"5HX6",,"X-RAY DIFFRACTION",2.04,39.84,"VAPOR DIFFUSION",7.5,"Well solution 26 % PEG 4K, 0.1 M HEPES pH 7.5; co-crystallized with NEC-4 and cmpd 8 back soaked into crystals at 5mM concentration
Cryo was transfer 6 % to 25 % glycerol added to well solution",310,"10.1021/acs.jmedchem.5b01898","65U","5HX6",69.95,"2.23","2.23","Crystal structure of RIP1 kinase with a benzo[b][1,4]oxazepin-4-one","MDYKDDDDKMQPDMSLNVIKMKSSDFLESAELDSGGFGKVSLAFHRTQGLMIMKTVYKGPNCIEHNEALLEEAKMMNRLRHSRVVKLLGVIIEEGKYSLVMEYMEKGNLMHVLKAEMSTPLSVKGRIILEIIEGMAYLHGKGVIHKDLKPENILVDNDFHIKIADLGLASFKMWSKLNNEEHNELREVDGTAKKNGGTLYYMAPEHLNDVNAKPTEKSDVYSFAVVLWAIFANKEPYENAIAEQQLIMAIKSGNRPDVDDITEYCPREIISLMKLCWEANPEARPTFPGIEEKFRPFYLSQLE","Homo sapiens","RIPK1, RIP, RIP1","Receptor-interacting serine/threonine-protein kinase 1","1","5HX6"
"5HX8",,"X-RAY DIFFRACTION",2.39,48.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"100mM MES pH 6.25, 33 % PEG 6000",298,"10.1016/j.bmcl.2016.02.035","66P","5HX8",70.14,"2.2","2.2","Jak1 complex with 4-[(4-aminocyclohexyl)amino]-3-(1H-benzimidazol-2-yl)-1H-pyridin-2-one","GDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDNTGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLPSGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIGDFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDSDSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRTSFQNLIEGFEALLK","Homo sapiens","JAK1, JAK1A, JAK1B","Tyrosine-protein kinase JAK1","1","5HX8"
"5HY9",,"X-RAY DIFFRACTION",3.63,66.12,"VAPOR DIFFUSION, SITTING DROP",4.5,"2.5 M sodium chloride, 0.1 M acetate",293,"10.1093/protein/gzx041",,"5HY9",53.81,"2.7","2.7","Glycosylated, disulfide-linked Knob-into-Hole Fc fragment","DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5HY9"
,,,,,,,,,,,,,,,,"DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","2","5HY9"
"5HYD",,"X-RAY DIFFRACTION",2.07,46,"VAPOR DIFFUSION, SITTING DROP",7,"0.1 M sodium cacodylate, 0.2 M sodium acetate, 30% PEG 8000",293,"10.1007/s00775-017-1437-4",,"5HYD",46.55,"2.3","2.3","Crystal structure of calcium-free human S100Z","MPTQLEMAMDTMIRIFHRYSGKERKRFKLSKGELKLLLQRELTEFLSCQKETQLVDKIVQDLDANKDNEVDFNEFVVMVAALTVACNDYFVEQLKKKGK","Homo sapiens","S100Z","Protein S100-Z","1","5HYD"
"5HYE",,"X-RAY DIFFRACTION",2.65,53.61,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.0 M ammonium phosphate, 0.1 M citrate, 0.2 M sodium chloride",293,"10.1093/protein/gzx041",,"5HYE",54.62,"1.89","1.89","Glycosylated Knob-Knob Fc fragment (P212121)","DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5HYE"
"5HYF",,"X-RAY DIFFRACTION",2.86,56.96,"VAPOR DIFFUSION, SITTING DROP",4.5,"2.5 M sodium chloride, 0.1 M acetate",293,"10.1093/protein/gzx041",,"5HYF",27.31,"1.8","1.8","Glycosylated Knob-Knob Fc fragment (P6122)","DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5HYF"
"5HYI",,"X-RAY DIFFRACTION",3.61,65.92,"VAPOR DIFFUSION, SITTING DROP",4.2,"20% PEG8000, 0.1 M phosphate-citrate, 0.2 M sodium chloride, 0.55% n-dodecyl-N,N-dimethylamine-N-oxide",293,"10.1093/protein/gzx041",,"5HYI",108.11,"2.9","2.9","Glycosylated, disulfide-linked Hole-Hole Fc fragment","DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVCTLPPSRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5HYI"
"5HYK",,"X-RAY DIFFRACTION",2.19,43.87,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 3350 20%, 0,2 M Mg acetate",291,"10.1038/srep34792",,"5HYK",31.03,"1.83","1.83","Crystal structure of the complex PPARalpha/AL26-29","GSHTADLKSLAKRIYEAYLKNFNMNKVKARVILSGKASNNPPFVIHDMETLCMAEKTLVAKLVANGIQNKEAEVRIFHCCQCTSVETVTELTEFAKAIPGFANLDLNDQVTLLKYGVYEAIFAMLSSVMNKDGMLVAYGNGFITREFLKSLRKPFCDIMEPKFDFAMKFNALELDDSDISLFVAAIICCGDRPGLLNVGHIEKMQEGIVHVLRLHLQSNHPDDIFLFPKLLQKMADLRQLVTEHAQLVQIIKKTESDAALHPLLQEIYRDMY","Homo sapiens","PPARA, NR1C1, PPAR","Peroxisome proliferator-activated receptor alpha","1","5HYK"
"5HZ5",,"X-RAY DIFFRACTION",2.47,50.14,"VAPOR DIFFUSION, SITTING DROP",,,295,"10.1016/j.bmcl.2016.08.071","65X","5HZ5",15.62,"1.4","1.4","FABP5 in complex with 6-Chloro-4-phenyl-2-piperidin-1-yl-3-(1H-tetrazol-5-yl)-quinoline","ATVQQLEGRWRLVDSKGFDEYMKELGVGIALRKMGAMAKPDCIITCDGKNLTIKTESTLKTTQFSCTLGEKFEETTADGRKTQTVCNFTDGALVQHQEWDGKESTITRKLKDGKLVVECVMNNVTCTRIYEKVE","Homo sapiens","FABP5","Fatty acid-binding protein, epidermal","1","5HZ5"
"5HZ6",,"X-RAY DIFFRACTION",2.1,41.49,"VAPOR DIFFUSION, SITTING DROP",,,295,"10.1016/j.bmcl.2016.08.071","65Y","5HZ6",14.89,"1.14","1.14","FABP4 in complex with 6-Chloro-2-isopropyl-4-(3-isopropyl-phenyl)-quinoline-3-carboxylic acid","AGAFVGTWKLVSSENFDDYMKEVGVGFATRKVAGMAKPNMIISVNGDVITIKSESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTIKRKREDDKLVVECVMKGVTSTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5HZ6"
"5HZ8",,"X-RAY DIFFRACTION",2.44,49.53,"VAPOR DIFFUSION, SITTING DROP",,,295,"10.1016/j.bmcl.2016.08.071","65Z","5HZ8",15.77,"1.12","1.12","FABP4_3 in complex with 6,8-Dichloro-4-phenyl-2-piperidin-1-yl-quinoline-3-carboxylic acid","GSHMCDAFVGTWKLVSSENFDDYMKELGVGFATRKVAGMAKPNTIISVNGDVITLKTESTFKNTEISFILGQEFDEVTADDRKVKSTITLDGGVLVHVQKWDGKSTTLKRKREDDKLVLELVMKGVTCTRVYERA","Homo sapiens","FABP4","Fatty acid-binding protein, adipocyte","1","5HZ8"
"5HZ9",,"X-RAY DIFFRACTION",4.13,70.19,"VAPOR DIFFUSION, SITTING DROP",,,295,"10.1016/j.bmcl.2016.08.071","5M8","5HZ9",127.79,"2.3","2.3","human FABP3 in complex with 6-Chloro-2-methyl-4-phenyl-quinoline-3-carboxylic acid","SHMVDAFLGTWKLVDSKNFDDYMKSLGVGFATRQVASMTKPTTIIEKNGDILTLKTHSTFKNTEISFKLGVEFDETTADDRKVKSIVTLDGGKLVHLQKWDGQETTLVRELIDGKLILTLTHGTAVCTRTYEKEA","Homo sapiens","FABP3, FABP11, MDGI","Fatty acid-binding protein, heart","1","5HZ9"
"5HZC",,"X-RAY DIFFRACTION",2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",8,"Sodium citrate 0.8 M, Tris base 0.15 M",291,"10.1038/srep34792",,"5HZC",66,"2","2","Crystal structure of the complex PPARgamma/AL26-29","GSHMAEISSDIDQLNPESADLRALAKHLYDSYIKSFPLTKAKARAILTGKTTDKSPFVIYDMNSLMMGEDKIKFKHITPLQEQSKEVAIRIFQGCQFRSVEAVQEITEYAKSIPGFVNLDLNDQVTLLKYGVHEIIYTMLASLMNKDGVLISEGQGFMTREFLKSLRKPFGDFMEPKFEFAVKFNALELDDSDLAIFIAVIILSGDRPGLLNVKPIEDIQDNLLQALELQLKLNHPESSQLFAKLLQKMTDLRQIVTEHVQLLQVIKKTETDMSLHPLLQEIYKDLY","Homo sapiens","PPARG, NR1C3","Peroxisome proliferator-activated receptor gamma","1","5HZC"
"5HZE",,"X-RAY DIFFRACTION",2.45,49.75,"VAPOR DIFFUSION, HANGING DROP",8,"0.1 M Tris pH 8.0, 180 mM CaCl2, 14-18% PEG 4000. Co-crystallized with 1mM ATPgammaS (30 mM stock formulated in H2O). Crystals backsoaked for 2 weeks in 1 mM compound 3.3% DMSO final.",277,,,"5HZE",39.36,"2.4","2.4","Mek1 adopts DFG-out conformation when bound to an analog of E6201.","GLEELELDEQQRKRLEAFLTQKQKVGELKDDDFEKISELGAGNGGVVFKVSHKPSGLVMARKLIHLEIKPAIRNQIIRELQVLHECNSPYIVGFYGAFYSDGEISICMEHMDGGSLDQVLKKAGRIPEQILGKVSIAVIKGLTYLREKHKIMHRDVKPSNILVNSRGEIKLCDFGVSGQLIDSMANSFVGTRSYMSPERLQGTHYSVQSDIWSMGLSLVEMAVGRYPIPPPDAKELELMFGCQVEGDAAETPPRPRTPGRPLNKFGMDSRPPMAIFELLDYIVNEPPPKLPSGVFSLEFQDFVNKCLIKNPAERADLKQLMVHAFIKRSDAEEVDFAGWLCSTIGLNQ","Homo sapiens","MAP2K1, MEK1, PRKMK1","Dual specificity mitogen-activated protein kinase kinase 1","1","5HZE"
"5HZM",,"X-RAY DIFFRACTION",2.89,57.42,"VAPOR DIFFUSION, SITTING DROP",8.5,"10% PEG 8000, 0.1 M Tris-HCL pH8.5",293,"10.1042/BCJ20160537",,"5HZM",42.46,"2.02","2.02","Human HMT1 hnRNP methyltransferase-like protein 6 (S. cerevisiae)","GMSQPKKRKLESGGGGEGGEGTEEEDGAEREAALERPRRTKRERDQLYYECYSDVSVHEEMIADRVRTDAYRLGILRNWAALRGKTVLDVGAGTGILSIFCAQAGARRVYAVEASAIWQQAREVVRFNGLEDRVHVLPGPVETVELPEQVDAIVSEWMGYGLLHESMLSSVLHARTKWLKEGGLLLPASAELFIVPISDQMLEWRLGFWSQVKQHYGVDMSCLEGFATRCLMGHSEIVVQGLSGEDVLARPQRFAQLELSRAGLEQELEAGVGGRFRCSCYGSAPMHGFAIWFQVTFPGGESEKPLVLSTSPFHPATHWKQALLYLNEPVQVEQDTDVSGEITLLPSRDNPRRLRVLLRYKVGDQEEKTKDFAMED","Homo sapiens","PRMT6, HRMT1L6","Protein arginine N-methyltransferase 6","1","5HZM"
"5HZN",,"X-RAY DIFFRACTION",2.97,58.63,"VAPOR DIFFUSION, HANGING DROP",6.25,"25% PEG8000, 0.1M MES PH6.25, 0.2 M AMMONIUM SULFATE, 4% GLYCEROL",293,"10.1016/j.bmcl.2016.02.074","66A","5HZN",282.32,"2.2","2.2","Structure of NVP-AEW541 in complex with IGF-1R kinase","AADVYVPDEWEVAREKITMSRELGQGSFGMVYEGVAKGVVKDEPETRVAIKTVNEAASMRERIEFLNEASVMKEFNCHHVVRLLGVVSQGQPTLVIMELMTRGDLKSYLRSLRPAMANNPVLAPPSLSKMIQMAGEIADGMAYLNANKFVHRDLAARNCMVAEDFTVKIGDFGMTRDIYETDYYRKGGKGLLPVRWMSPESLKDGVFTTYSDVWSFGVVLWEIATLAEQPYQGLSNEQVLRFVMEGGLLDKPDNCPDMLFELMRMCWQYNPKMRPSFLEIISSIKEEMEPGFREVSFYYSEENK","Homo sapiens","IGF1R","Insulin-like growth factor 1 receptor","1","5HZN"
"5HZQ",,"X-RAY DIFFRACTION",2.44,49.63,"VAPOR DIFFUSION, SITTING DROP",,"20% (w/v) PEG3350 and 200 mM KH2PO4, cryoprotected using solution of same condition diluted with glycerol to 30% final glycerol concentration",293,"10.1021/jacs.6b02960",,"5HZQ",32.87,"1.75","1.75","Crystal structure of cellular retinoic acid binding protein 2 (CRABP2)-aryl fluorosulfate covalent conjugate","GHMPNFSGNWKIIRSENFEELLKVLGVNVMLRKIAVAAASKPAVEIKQEGDTFYIKTSTTVRTTEINFKVGEEFEEQTVDGRPCKSLVKWESENKMVCEQKLLKGEGPKTSWTRELTNDGELILTMTADDVVCTRVYVRE","Homo sapiens","CRABP2","Cellular retinoic acid-binding protein 2","1","5HZQ"
"5I05",,"X-RAY DIFFRACTION",3.81,67.77,"VAPOR DIFFUSION, HANGING DROP",3.5,"1.0 M LiCl, 4% (v/v) PEG6000, 0.1 M NA-CITRATE",293,"10.1016/j.celrep.2017.05.011",,"5I05",12.29,"1.87","1.87","Crystal structure of human BMP9 at 1.87 A resolution","SAGAGSHCQKTSLRVNFEDIGWDSWIIAPKEYEAYECKGGCFFPLADDVTPTKHAIVQTLVHLKFPTKVGKACCVPTKLSPISVLYKDDMGVPTLKYHYEGMSVAECGCR","Homo sapiens","GDF2, BMP9","Growth/differentiation factor 2","1","5I05"
"5I0B",,"X-RAY DIFFRACTION",2.78,55.71,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.8M sodium potassium tartrate, 0.1M TRIS pH 8.5",293,"10.1016/j.bmcl.2016.04.037",,"5I0B",33.75,"3.09","3.09","Structure of PAK4","GSHMSHEQFRAALQLVVDPGDPRSYLDNFIKIGEGSTGIVCIATVRSSGKLVAVKKMDLRKQQRRELLFNEVVIMRDYQHENVVEMYNSYLVGDELWVVMEFLEGGALTDIVTHTRMNEEQIAAVCLAVLQALSVLHAQGVIHRDIKSDSILLTHDGRVKLSDFGFCAQVSKEVPRRKSLVGTPYWMAPELISRLPYGPEVDIWSLGIMVIEMVDGEPPYFNEPPLKAMKMIRDNLPPRLKNLHKVSPSLKGFLDRLLVRDPAQRATAAELLKHPFLAKAGPPASIVPLMRQNRTR","Homo sapiens","PAK4, KIAA1142","Serine/threonine-protein kinase PAK 4","1","5I0B"
"5I0H",,"X-RAY DIFFRACTION",2.59,52.47,"VAPOR DIFFUSION, HANGING DROP",7.5,"10% PEG 8000, 50mM Tris pH 7.5, 1mM TCEP and 125mM Lithium sulfate",277,"10.1038/ncomms12456",,"5I0H",173.87,"1.8","1.8","Crystal structure of myosin X motor domain in pre-powerstroke state","MDNFFTEGTRVWLRENGQHFPSTVNSCAEGIVVFRTDYGQVFTYKQSTITHQKVTAMHPTNEEGVDDMASLTELHGGSIMYNLFQRYKRNQIYTYIGSILASVNPYQPIAGLYEPATMEQYSRRHLGELPPHIFAIANECYRCLWKRHDNQCILISGESGAGKTESTKLILKFLSVISQQSLELSLKEKTSCVERAILESSPIMEAFGNAKTVYNNNSSRFGKFVQLNICQKGNIQGGRIVDYLLEKNRVVRQNPGERNYHIFYALLAGLEHEEREEFYLSTPENYHYLNQSGCVEDKTISDQESFREVITAMDVMQFSKEEVREVSRLLAGILHLGNIEFITAGGAQVSFKTALGRSAELLGLDPTQLTDALTQRSMFLRGEEILTPLNVQQAVDSRDSLAMALYACCFEWVIKKINSRIKGNEDFKSIGILDIFGFENFEVNHFEQFNINYANEKLQEYFNKHIFSLEQLEYSREGLVWEDIDWIDNGECLDLIEKKLGLLALINEESHFPQATDSTLLEKLHSQHANNHFYVKPRVAVNNFGVKHYAGEVQYDVRGILEKNRDTFRDDLLNLLRESRFDFIYDLFEHVSSRNNQDTLKCGSKHRRPTVSSQFKDSLHSLMATLSSSNPFFVRCIKPNMQKMPDQFDQAVVLNQLRYSGMLETVRIRKAGYAVRRPFQDFYKRYKVLMRNLALPEDVRGKCTSLLQLYDASNSEWQLGKTKVFLRESLEQKLEKRREEE","Homo sapiens","MYO10, KIAA0799","Unconventional myosin-X","1","5I0H"
"5I0L",,"X-RAY DIFFRACTION",2.15,42.82,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-inhibitor complex:  hMMP12 0.631 milli-M + 0.010 M Acetohydroxamic acid + 0.005 M inhibitor DC27, 10% DMSO.
precipitant: 34% PEG 4K, 1.5 M imidazole piperidine, pH 8.5, Dioxane 25%
Cryoprotectant: 40% Cryomix: (12.5 % diethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 12.5 % 2,3-butanediol + 25 % DMSO + 30 % 1,4-dioxane), 25% MPEG 6K, 0.1 M AAB (Na acetate, ADA, Bicine: 10% acid/90% basic), pH 8.5",293,"10.1002/cmdc.201600235","H27","5I0L",37.71,"2.45","2.45","Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHEIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5I0L"
"5I12",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, SITTING DROP",7.25,"protein solution: 415.2 micro-M MMP9 WT + 0.120 M Acetohydroxamic acid in 20 mM Tris pH 7.0 with 0.001 M inhibitor DC27 and 10% DMSO.
precipitant: 40% MPEG 5K ; 0.1 M bicine ; pH 7.25
sitting drops of 1 micro-L protein solution and 1 micro-L precipitant solution.
cryoprotectant:_40% cryomix CM2 (25 % di-ethylene glycol + 25 % glycerol + 25 % 1,2-propanediol), 10% PEG 10K, 200 milli-M NaCl, 100 milli-M Na propionate, Na cacodylate, Bis-Tris-propane (PCTP 50% acid/50% basic) pH 7.0 + 0.001 M inhibitor DC27.",293,"10.1002/cmdc.201600235","H27","5I12",18.82,"1.59","1.59","Crystal structure of the catalytic domain of MMP-9 in complex with a selective sugar-conjugated arylsulfonamide carboxylate water-soluble inhibitor (DC27).","DLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYG","Homo sapiens","MMP9, CLG4B","Matrix metalloproteinase-9,Matrix metalloproteinase-9","1","5I12"
,,,,,,,,,,,,,,,,,"Homo sapiens","MMP9, CLG4B"
"5I15",,"X-RAY DIFFRACTION",4.67,74,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES PH 6.5, 5.0 M SODIUM FORMATE",293,"10.1080/19420862.2016.1190060",,"5I15",47.68,"2.6","2.6","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV1-39","QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I15"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I15"
"5I16",,"X-RAY DIFFRACTION",2.44,50,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES PH 6.5, 25% PEG 3350, 0.2 M SODIUM FORMATE",293,"10.1080/19420862.2016.1190060",,"5I16",95.85,"1.9","1.9","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV3-11","EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I16"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I16"
"5I17",,"X-RAY DIFFRACTION",3.77,67,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES PH 6.5, 2.0 M AMMONIUM SULFATE, 5% MPD",293,"10.1080/19420862.2016.1190060",,"5I17",95.19,"3.3","3.3","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV3-20","EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I17"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I17"
"5I18",,"X-RAY DIFFRACTION",2.39,48,"VAPOR DIFFUSION, SITTING DROP",7.5,"10% PEG 8K, 8% ETHYLENE GLYCOL, 0.1 M HEPES PH 7.5",293,"10.1080/19420862.2016.1190060",,"5I18",48.92,"1.92","1.92","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV1-69/IGKV4-1","MDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I18"
,,,,,,,,,,,,,,,,"QVQLVQSGAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGIIPIFGTANYAQKFQGRVTITADESTSTAYMELSSLRSEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I18"
"5I19",,"X-RAY DIFFRACTION",2.6,53,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350, 0.2 M LITHIUM CITRATE",293,"10.1080/19420862.2016.1190060",,"5I19",47.45,"2.8","2.8","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV1-39","DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I19"
,,,,,,,,,,,,,,,,"EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I19"
"5I1A",,"X-RAY DIFFRACTION",2.82,56,"VAPOR DIFFUSION, SITTING DROP",4.5,"2 M AMMONIUM SULFATE, 5% PEG 400, 0.1 M NA ACETATE PH 4.5",293,"10.1080/19420862.2016.1190060",,"5I1A",95.69,"2","2","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV3-11","EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"CNTO388 LIGHT CHAIN","1","5I1A"
,,,,,,,,,,,,,,,,"EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"CNTO388 HEAVY CHAIN","2","5I1A"
"5I1B",,"X-RAY DIFFRACTION",3.32,62.9,,,,,,,"5I1B",17.4,"2.1","2.1","A COMPARISON OF THE HIGH RESOLUTION STRUCTURES OF HUMAN AND MURINE INTERLEUKIN-1B","APVRSLNCTLRDSQQKSLVMSGPYELKALHLQGQDMEQQVVFSMSFVQGEESNDKIPVALGLKEKNLYLSCVLKDDKPTLQLESVDPKNYPKKKMEKRFVFNKIEINNKLEFESAQFPNWYISTSQAENMPVFLGGTKGGQDITDFTMQFVSS","Homo sapiens","IL1B, IL1F2","INTERLEUKIN-1 BETA","1","5I1B"
"5I1C",,"X-RAY DIFFRACTION",3.6,66,"VAPOR DIFFUSION, SITTING DROP",6.5,"16% PEG 3K, 0.2 M AMMONIUM ACETATE, 0.1 M MES PH 6.5",293,"10.1080/19420862.2016.1190060",,"5I1C",47.76,"2.25","2.25","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV3-20","EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1C"
,,,,,,,,,,,,,,,,"EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1C"
"5I1D",,"X-RAY DIFFRACTION",2.87,57,"VAPOR DIFFUSION, SITTING DROP",7.5,"2.0 M AMMONIUM SULFATE, 2% PEG 400, 0.1 M HEPES PH 7.5",293,"10.1080/19420862.2016.1190060",,"5I1D",97.06,"2","2","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-23/IGKV4-1","DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1D"
,,,,,,,,,,,,,,,,"EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSAISGSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1D"
"5I1E",,"X-RAY DIFFRACTION",2.57,52,"VAPOR DIFFUSION, SITTING DROP",,"16% PEG 3K, 0.2 M AMMONIUM SULFATE, 5% DIOXANE",293,"10.1080/19420862.2016.1190060",,"5I1E",47.73,"2.7","2.7","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV1-39","DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1E"
,,,,,,,,,,,,,,,,"EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1E"
"5I1G",,"X-RAY DIFFRACTION",2.64,53,"VAPOR DIFFUSION, SITTING DROP",4.5,"0.1 M NA ACETATE PH 4.5, 25% PEG 3350, 0.2 M LITHIUM SULFATE",293,"10.1080/19420862.2016.1190060",,"5I1G",47.76,"2.3","2.3","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV3-11","EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1G"
,,,,,,,,,,,,,,,,"EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1G"
"5I1H",,"X-RAY DIFFRACTION",2.57,52,"VAPOR DIFFUSION, SITTING DROP",4.5,"19% PEG 4K, 0.2 M AMMONIUM SULFATE, 0.1 M SODIUM ACETATE PH 4.5",293,"10.1080/19420862.2016.1190060",,"5I1H",47.81,"2.222","2.222","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV3-20","EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1H"
,,,,,,,,,,,,,,,,"EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1H"
"5I1I",,"X-RAY DIFFRACTION",2.64,53,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M MES PH 6.5, 17% PEG 3K, 0.2 M SODIUM FORMATE, 5% MPD",293,"10.1080/19420862.2016.1190060",,"5I1I",48.47,"2.5","2.5","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV3-53/IGKV4-1","DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1I"
,,,,,,,,,,,,,,,,"EVQLVETGGGLIQPGGSLRLSCAASGFTVSSNYMSWVRQAPGKGLEWVSVIYSGGSTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1I"
"5I1J",,"X-RAY DIFFRACTION",2.56,52,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.1 M TRIS PH 8.5, 25% PEG 3350, 0.2 M MAGNESIUM CHLORIDE",293,"10.1080/19420862.2016.1190060",,"5I1J",48.06,"2.5","2.5","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV3-11","EIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1J"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1J"
"5I1K",,"X-RAY DIFFRACTION",2.54,51,"VAPOR DIFFUSION, SITTING DROP",9.5,"1.0 M AMMONIUM SULFATE, 0.1 M CHES PH 9.5",293,"10.1080/19420862.2016.1190060",,"5I1K",48.97,"1.65","1.65","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV3-20","EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1K"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1K"
"5I1L",,"X-RAY DIFFRACTION",2.28,46,"VAPOR DIFFUSION, SITTING DROP",8.5,"24% PEG 3K, 0.2 M AMMONIUM ACETATE, 0.1 M TRIS PH 8.5",293,"10.1080/19420862.2016.1190060",,"5I1L",97.73,"1.95","1.95","CRYSTAL STRUCTURE OF HUMAN GERMLINE ANTIBODY IGHV5-51/IGKV4-1","EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARYDGIYGELDFWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCHHHHHH","Homo sapiens",,"FAB HEAVY CHAIN","2","5I1L"
,,,,,,,,,,,,,,,,"DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSTPLTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"FAB LIGHT CHAIN","1","5I1L"
"5I1Q",,"X-RAY DIFFRACTION",2.61,52.79,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M ammonium nitrate, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00264","67C","5I1Q",16.91,"1.5","1.5","Second bromodomain of TAF1 bound to a pyrrolopyridone compound","GSPLLDDDDQVAFSFILDNIVTQKMMAVPDSWPFHHPVNKKFVPDYYKVIVNPMDLETIRKNISKHKYQSRESFLDDVNLILANSVKYNGPESQYTKTAQEIVNVCYQTLTEYDEHLTQLEKDICTAKEAALEEAELESLDPMT","Homo sapiens","TAF1, BA2R, CCG1, CCGS, TAF2A","Transcription initiation factor TFIID subunit 1","1","5I1Q"
"5I29",,"X-RAY DIFFRACTION",2.54,51.67,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M calcium chloride, 20% PEG3350",277,"10.1021/acs.jmedchem.6b00264","67B","5I29",16.91,"1.21","1.21","TAF1(2) bound to a pyrrolopyridone compound","GSPLLDDDDQVAFSFILDNIVTQKMMAVPDSWPFHHPVNKKFVPDYYKVIVNPMDLETIRKNISKHKYQSRESFLDDVNLILANSVKYNGPESQYTKTAQEIVNVCYQTLTEYDEHLTQLEKDICTAKEAALEEAELESLDPMT","Homo sapiens","TAF1, BA2R, CCG1, CCGS, TAF2A","Transcription initiation factor TFIID subunit 1","1","5I29"
"5I2C",,"X-RAY DIFFRACTION",2.25,45.42,"VAPOR DIFFUSION, HANGING DROP",5,"0.1 M sodium acetate, 0.25 M ammonium acetate, 22.5% PEG 3350",291.15,"10.1038/nature19079",,"5I2C",146.17,"1.801","1.801","Arginine-bound CASTOR1 from Homo sapiens","MELHILEHRVRVLSVARPGLWLYTHPLIKLLFLPRRSRCKFFSLTETPEDYTLMVDEEGFKELPPSEFLQVAEATWLVLNVSSHSGAAVQAAGVTKIARSVIAPLAEHHVSVLMLSTYQTDFILVREQDLSVVIHTLAQEFDIYREVGGEPVPVTRDDSSNGFPRTQHGPSPTVHPIQSPQNRFCVLTLDPETLPAIATTLIDVLFYSHSTPKEAASSSPEPSSITFFAFSLIEGYISIVMDAETQKKFPSDLLLTSSSGELWRMVRIGGQPLGFDECGIVAQIAGPLAAADISAYYISTFNFDHALVPEDGIGSVIEVLQRRQEGLAS","Homo sapiens","GATSL3, CASTOR1","GATS-like protein 3","1","5I2C"
"5I2E",,"X-RAY DIFFRACTION",2.01,38.81,"VAPOR DIFFUSION",6.1,"100 mM MES, 35% PEG 8000",293,"10.1021/acsmedchemlett.6b00169","67D","5I2E",28.83,"1.6","1.6","Human Histidine Triad Nucleotide Binding Protein 1 (Hint1) with Bound Sulfamate Inhibitor 3a:3-(5-O-{[3-(1H-indol-3-yl)propanoyl]sulfamoyl}-beta-D-ribofuranosyl)-3H-imidazo[2,1-i]purine","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5I2E"
"5I2F",,"X-RAY DIFFRACTION",2.03,39.5,"VAPOR DIFFUSION",6.9,"100 mM MES, 33% PEG 8000",293,"10.1021/acsmedchemlett.6b00169",,"5I2F",28.89,"1.25","1.25","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) with bound sulfamide inhibitor Bio-AMS","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5I2F"
"5I2L",,"X-RAY DIFFRACTION",1.99,33.19,"VAPOR DIFFUSION",8.5,"23% PEG 4000, 0.16M Na-acetate, 3% dioxane, 0.1 M Tris-HCl, pH 8.5",293,"10.1038/srep39095",,"5I2L",13.79,"1.85","1.85","Structure of EF-hand containing protein","GAMGSGEPQSPSRRVFNPYTEFKEFSRKQIKDMEKMFKQYDAGRDGFIDLMELKLMMEKLGAPQTHLGLKNMIKEVDEDFDSKLSFREFLLIFRKAAAGELQEDSGLCVLARLSEIDVSS","Homo sapiens","EFHD2, SWS1","EF-hand domain-containing protein D2","1","5I2L"
"5I2O",,"X-RAY DIFFRACTION",1.84,33.3,"VAPOR DIFFUSION",8.5,"0.1M Tris-HCl, pH8.5, 32% PEG 2000",293,"10.1038/srep39095",,"5I2O",13.69,"1.952","1.952","Structure of EF-hand containing protein","GAMGSGEPQSPSRRVFNPYTEFKEFSRKQIKDMEKMFKQYDAGRDGFIDLMALKLMMEKLGAPQTHLGLKNMIKEVDEDFDSKLSFREFLLIFRKAAAGELQEDSGLCVLARLSEIDVSS","Homo sapiens","EFHD2, SWS1","EF-hand domain-containing protein D2","1","5I2O"
"5I2Q",,"X-RAY DIFFRACTION",1.88,34.7,"VAPOR DIFFUSION",8.5,"0.1 M Tris-HCl, pH8.5, 23 % PEG 2000",293,"10.1038/srep39095",,"5I2Q",13.69,"1.935","1.935","Structure of EF-hand containing protein","GAMGSGEPQSPSRRVFNPYTEFKEFSRKQIKDMEKMFKQYDAGRDGFIDLMELKLMMEKLGAPQTHLGLKNMIKEVDEDFDSKLSFRAFLLIFRKAAAGELQEDSGLCVLARLSEIDVSS","Homo sapiens","EFHD2, SWS1","EF-hand domain-containing protein D2","1","5I2Q"
"5I2R",,"X-RAY DIFFRACTION",2.87,57.15,"VAPOR DIFFUSION, SITTING DROP",,"none",295,"10.1021/acs.jmedchem.5b01875","67A","5I2R",149.05,"2.5","2.5","human PDE10A in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one","AQGLMQFTLPVRLCKEIELFHFDIGPFENMWPGIFVYMVHRSCGTSCFELEKLCRFIMSVKKNYRRVPYHNWKHAVTVAHCMYAILQNNHTLFTDLERKGLLIACLCHDLDHRGFSNSYLQKFDHPLAALYSTSTMEQHHFSQTVSILQLEGHNIFSTLSSSEYEQVLEIIRKAIIATDLALYFGNRKQLEEMYQTGSLNLNNQSHRDRVIGLMMTACDLCSVTKLWPVTKLTANDIYAEFWAEGDEMKKLGIQPIPMMDRDKKDEVPQGQLGFYNAVAIPCYTTLTQILPPTEPLLKACRDNLSQWEKVIRGEETAT","Homo sapiens","PDE10A","cAMP and cAMP-inhibited cGMP 3',5'-cyclic phosphodiesterase 10A","1","5I2R"
"5I2V",,"SOLUTION NMR",,,,,,,"10.1074/jbc.M117.781906",,"5I2V",7.06,,,"NMR structure of a new G-quadruplex forming sequence within the KRAS proto-oncogene promoter region","AGGGCGGTGTGGGAATAGGGAA","Homo sapiens",,"DNA (5'-D(*AP*GP*GP*GP*CP*GP*GP*TP*GP*TP*GP*GP*GP*AP*AP*TP*AP*GP*GP*GP*AP*A)-3')","1","5I2V"
"5I2X",,"X-RAY DIFFRACTION",4.34,71.65,"VAPOR DIFFUSION, HANGING DROP",8,"3.6 M sodium formate, 100 mM Tris-Cl pH 8.0",289,"10.1073/pnas.1605685113",,"5I2X",34.86,"3","3","Crystal Structure of TPP1 K170del","SGRLVLRPWIRELILGSETPSSPRAGQLLEVLQDAEAAVAGPSHAPDTSDVGATLLVSDGTHSVRCLVTREALDTSDWEEEFGFRGTEGRLLLLQDCGVHVQVAEGGAPAEFYLQVDRFSLLPTEQPRLRVPGCNQDLDVQKKLYDCLEEHLSESTSSNA","Homo sapiens","ACD, PIP1, PTOP, TINT1, TPP1","Adrenocortical dysplasia protein homolog","1","5I2X"
"5I2Y",,"X-RAY DIFFRACTION",4.35,71.71,"VAPOR DIFFUSION, HANGING DROP",7,"3.7 M sodium formate, 100 mM Tris-Cl pH 7.0, 2% methanol",289,"10.1073/pnas.1605685113",,"5I2Y",35,"3","3","Crystal Structure of TPP1 K170A","SGRLVLRPWIRELILGSETPSSPRAGQLLEVLQDAEAAVAGPSHAPDTSDVGATLLVSDGTHSVRCLVTREALDTSDWEEAEFGFRGTEGRLLLLQDCGVHVQVAEGGAPAEFYLQVDRFSLLPTEQPRLRVPGCNQDLDVQKKLYDCLEEHLSESTSSNA","Homo sapiens","ACD, PIP1, PTOP, TINT1, TPP1","Adrenocortical dysplasia protein homolog","1","5I2Y"
"5I2Z",,"X-RAY DIFFRACTION",2.8,56.02,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand:  hMMP12 F67D E219Q at 465 micro-M, 20 milli-M  acetohydroxamic acid in 0.020M Tris-HCl, 3 milli-M CaCl2, 0.2M NaCl, pH 7.5, 0.2 milli-M inhibitor (DC24) 10% DMSO
Precipitant: 35% PEG4K, 0.2M imidazole piperidine, 15% dioxane, pH 8.5.
Cryoprotectant: 
40% cryomix: (25 % diethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % 1,4-dioxane) 25% PEG 6K, 100mM TRIS HCl, pH 8.0",293,"10.1002/cmdc.201600235",,"5I2Z",74.73,"2.3","2.3","Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelating water-soluble inhibitor (DC24).","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHQIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5I2Z"
"5I35",,"X-RAY DIFFRACTION",2.44,49.61,"VAPOR DIFFUSION, HANGING DROP",7.5,"One part of ADCK3 R611K, 0.2 mM, AMPPNP 2 mM, MgCl2, 4mM, mixed with an equal volume of sodium polyacrylate 5100, 26%; magnesium chloride, 20 mM; HEPES, 100 mM, pH 7.5",293,"10.1016/j.molcel.2016.06.030",,"5I35",46.43,"2.3","2.3","Structure of the Human mitochondrial kinase COQ8A R611K with AMPPNP (Cerebellar Ataxia and Ubiquinone Deficiency Through Loss of Unorthodox Kinase Activity)","SSEANAERIVRTLCKVRGAALKLGQMLSIQDDAFINPHLAKIFERVRQSADFMPLKQMMKTLNNDLGPNWRDKLEYFEERPFAAASIGQVHLARMKGGREVAMKIQYPGVAQSINSDVNNLMAVLNMSNMLPEGLFPEHLIDVLRRELALECDYQREAACARKFRDLLKGHPFFYVPEIVDELCSPHVLTTELVSGFPLDQAEGLSQEIRNEICYNILVLCLRELFEFHFMQTDPNWSNFFYDPQQHKVALLDFGATREYDRSFTDLYIQIIRAAADRDRETVRAKSIEMKFLTGYEVKVMEDAHLDAILILGEAFASDEPFDFGTQSTTEKIHNLIPVMLRHRLVPPPEETYSLHKKMGGSFLICSKLKARFPCKAMFEEAYSNYCKRQAQQ","Homo sapiens","ADCK3, CABC1, PP265, COQ8A","Atypical kinase ADCK3, mitochondrial","1","5I35"
"5I3M",,"X-RAY DIFFRACTION",2.19,43.96,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: hMMP12 F67D E219Q 465 micro-M, 0.02M acetohydroxamic acid 0.5 milli-M inhibitor (DC31) 10% DMSO.
Precipitant: 32.4% PEG 4K, 8% dioxane, 0.2M imidazole piperidine, pH 8.5.
Cryoprotectant: 
40% cryomix:(12.5 % diethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 25 % DMSO + 25 % 1,4-dioxane) 12% PEG 4K, 10% Dioxane, 0.1 M imidazole piperidine pH 8.5.",293,"10.1002/cmdc.201600235",,"5I3M",74.65,"2.17","2.17","Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated thiourea-linked carboxylate zinc-chelator water-soluble inhibitor (DC31).","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHQIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5I3M"
"5I3O",,"X-RAY DIFFRACTION",2.87,57.19,"VAPOR DIFFUSION, SITTING DROP",6,"0.1M MES pH 6; 0.2M ammonium chloride, 20% PEG 8000, 10% ethylene glycol",293.15,,,"5I3O",69.02,"2.4","2.4","Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor","RVFAVGRHQVTLEESLAEGGFSTVFLVRTHGGIRCALKRMYVNNMPDLNVCKREITIMKELSGHKNIVGYLDCAVNSISDNVWEVLILMEYCRAGQVVNQMNKKLQTGFTEPEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLNDGGNYVLCDFGSATNKFLNPQKDGVNVVEEEIKKYTTLSYRAPEMINLYGGKPITTKADIWALGCLLYKLCFFTLPFGESQVAICDGNFTIPDNSRYSRNIHCLIRFMLEPDPEHRPDIFQVSYFAFKFAAADCPVSNINNSSIPSALPEPMTA","Homo sapiens","BMP2K, BIKE, HRIHFB2017","BMP-2-inducible protein kinase","1","5I3O"
"5I3R",,"X-RAY DIFFRACTION",2.88,57.36,"VAPOR DIFFUSION, SITTING DROP",6,"20% PEG 8000; 0.2 M Ammonium chloride; 10% Ethyleneglycol; 0.1M MES pH 6.0",293.15,,,"5I3R",69.04,"2.4","2.4","Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor","RVFAVGRHQVTLEESLAEGGFSTVFLVRTHGGIRCALKRMYVNNMPDLNVCKREITIMKELSGHKNIVGYLDCAVNSISDNVWEVLILMEYCRAGQVVNQMNKKLQTGFTEPEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLNDGGNYVLCDFGSATNKFLNPQKDGVNVVEEEIKKYTTLSYRAPEMINLYGGKPITTKADIWALGCLLYKLCFFTLPFGESQVAICDGNFTIPDNSRYSRNIHCLIRFMLEPDPEHRPDIFQVSYFAFKFAAADCPVSNINNSSIPSALPEPMTA","Homo sapiens","BMP2K, BIKE, HRIHFB2017","BMP-2-inducible protein kinase","1","5I3R"
"5I3V",,"X-RAY DIFFRACTION",2.84,56.76,"VAPOR DIFFUSION",6.6,"20% polyethylene glycol 5000 MME, 0.2 M ammonium iodide, 0.17 M sodium citrate (pH 6.6), 3% DMSO",298,"10.1021/acs.jmedchem.5b01917","68M","5I3V",46.7,"1.62","1.62","Crystal structure of BACE1 in complex with aminoquinoline compound 1","LPRETDEEPEEPGKKGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDES","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5I3V"
"5I3W",,"X-RAY DIFFRACTION",2.81,56.16,"VAPOR DIFFUSION",6.6,"20% polyethylene glycol 5000 MME, 200 mM ammonium iodide, 170 mM sodium citrate (pH 6.6), 3% DMSO",298,"10.1021/acs.jmedchem.5b01917","68L","5I3W",46.88,"2.15","2.15","Crystal structure of BACE1 in complex with 2-aminooxazoline-3-azaxanthene inhibitor 2","LPRETDEEPEEPGKKGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDES","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5I3W"
"5I3X",,"X-RAY DIFFRACTION",2.84,56.67,"VAPOR DIFFUSION",6,"1.5 M ammonium sulfate, 0.2 M lithium chloride, 0.1 M MES (pH 6.0)",298,"10.1021/acs.jmedchem.5b01917","68J","5I3X",46.51,"1.85","1.85","Crystal structure of BACE1 in complex with aminoquinoline inhibitor 6","LPRETDEEPEEPGKKGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDES","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5I3X"
"5I3Y",,"X-RAY DIFFRACTION",2.83,56.6,"VAPOR DIFFUSION",5.5,"1.5 M ammonium sulfate, 0.2 M lithium chloride, 0.1 M bis-tris (pH 5.5)",298,"10.1021/acs.jmedchem.5b01917","68K","5I3Y",46.44,"2.15","2.15","Crystal structure of BACE1 in complex with aminoquinoline inhibitor 9","LPRETDEEPEEPGKKGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDES","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5I3Y"
"5I40",,"X-RAY DIFFRACTION",2.45,49.79,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2 M sodium formate 
10-15% PEG3350",277.1,"10.1021/acs.jmedchem.6b00264","67N","5I40",12.36,"1.0402","1.0402","BRD9 in complex with Cpd1 (6-methyl-1,6-dihydro-7H-pyrrolo[2,3-c]pyridin-7-one)","STPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSK","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5I40"
"5I43",,"X-RAY DIFFRACTION",2.2,44.2,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: hMMP12 F171D E219Q 465 micro-M in 0.020 M Tris-HCl, 3 milli-M CaCl2, 0.2 M NaCl, 0.02 M acetohydroxamic acid, 10% DMSO, pH 7.5, 0.5 milli-M inhibitor (DC31).
Precipitant: 40% PEG4K, 9% dioxane, 0.18 M imidazole piperidine,  pH 8.5.
Cryoprotectant: 40% cryomix SM2:(12.5 % ethylene glycol + 12.5 % glycerol + 12.5 % 1,2-propanediol + 25 % DMSO + 37.5 % 1,4-dioxane), 22.5% MPEG 4K, 5% dioxane, 100 mM imidazole piperidine pH 8.5.",295,"10.1002/cmdc.201600235",,"5I43",76.71,"1.95","1.95","Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate chelator water-soluble inhibitor (DC32).","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHQIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5I43"
"5I46",,"X-RAY DIFFRACTION",3.9,68.47,"VAPOR DIFFUSION, HANGING DROP",6,"100 mM MES, pH 6.0, 20 mM CACL2, 17.5%(W/V) PEG 6000",277,"10.1021/acs.jmedchem.6b00244",,"5I46",35.2,"2.06","2.06","Factor VIIA in complex with the inhibitor (2R,15R)-2-[(1-aminoisoquinolin-6-yl)amino]-8-fluoro-7-hydroxy-4,15,17-trimethyl-13-oxa-4,11-diazatricyclo[14.2.2.1~6,10~]henicosa-1(18),6(21),7,9,16,19-hexaene-3,12-dione","IVGGKVCPKGECPWQVLLLVNGAQLCGGTLINTIWVVSAAHCFDKIKNWRNLIAVLGEHDLSEHDGDEQSRRVAQVIIPSTYVPGTTNHDIALLRLHQPVVLTDHVVPLCLPERTFSERTLAFVRFSLVSGWGQLLDRGATALELMVLNVPRLMTQDCLQQSRKVGDSPNITEYMFCAGYSDGSKDSCKGDSGGPHATHYRGTWYLTGIVSWGQGCATVGHFGVYTRVSQYIEWLQKLMRSEPRPGVLLRAPFP","Homo sapiens","F7","Coagulation factor VII (Heavy Chain)","1","5I46"
,,,,,,,,,,,,,,,,"ICVNENGGCEQYCSDHTGTKRSCRCHEGYSLLADGVSCTPTVEYPCGKIPILEKR","Homo sapiens","F7","Coagulation factor VII (Light Chain)","2","5I46"
"5I4H",,"X-RAY DIFFRACTION",2.17,43.33,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.11 M HEPES, pH 7.5, 2.14 M ammonium sulfate",277,"10.1002/1873-3468.12140",,"5I4H",24.58,"1.42","1.42","Caught in the Act: The Crystal Structure of cleaved Cathepsin L bound to the active site of Cathepsin L","DAGFVDIPKQEKALMKAVATVGPISVAIDAGHESFLFYKEGIYFEPDCSSEDMDHGVLVVGYGFESTESDNNKYWLVKNSWGEEWGMGGYVKMAKDRRNHCGIASAASYPTV","Homo sapiens","CTSL, CTSL1","Cathepsin L1","2","5I4H"
,,,,,,,,,,,,,,,,"EAPRSVDWREKGYVTPVKNQGQCGSSWAFSATGALEGQMFRKTGRLISLSEQNLVDCSGPQGNEGCNGGLMDYAFQYVQDNGGLDSEESYPYEATEESCKYNPKYS","Homo sapiens","CTSL, CTSL1","Cathepsin L1","1","5I4H"
"5I4N",,"X-RAY DIFFRACTION",2.63,53.22,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M TRIS, 0.2M SODIUM ACETATE, 22% PEG 4000",277,"10.1042/BCJ20160085",,"5I4N",33.87,"1.54","1.54","Crystal Structure of the E596A V617F Mutant JAK2 Pseudokinase Domain Bound to Mg-ATP","MVFHKIRNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFAAASMMSKLSHKHLVLNYGVCFCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAAAMHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVPPECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKAAELANLINNCMDYEPDHRPSFRAIIRDLNSLFTPDLVPRGSHHHHHH","Homo sapiens","JAK2","Tyrosine-protein kinase JAK2","1","5I4N"
"5I4O",,"X-RAY DIFFRACTION",2.22,44.54,"VAPOR DIFFUSION, SITTING DROP",8.5,"Protein-ligand: 465 micro-M hMMP12 F171D E219Q, 0.020 M acetohydroxamic acid,  10% DMSO, 0.5 milli-M inhibitor (DC28).
Precipitant: 40.5% PEG4K,  10% dioxane, 2% ethylene glycol, 0.18 M imidazole piperidine, pH 8.5.
Cryoprotectant:40% cryomix CM12: (,25 % diethylene glycol + 12.5 % glycerol + 25 % 1,2-propanediol + 12.5 % 1,4-dioxane), 25% PEG 6K, 0.1 M TRIS HCl, pH 8.0.",293,"10.1002/cmdc.201600235",,"5I4O",73.93,"2.05","2.05","Crystal structure of the catalytic domain of MMP-12 in complex with a selective sugar-conjugated triazole-linked carboxylate zinc-chelator water-soluble inhibitor (DC28).","MGPVWRKHYITYRINNYTPDMNREDVDYAIRKAFQVWSNVTPLKFSKINTGMADILVVFARGAHGDDHAFDGKGGILAHAFGPGSGIGGDAHFDEDEFWTTHSGGTNLFLTAVHQIGHSLGLGHSSDPKAVMFPTYKYVDINTFRLSADDIRGIQSLYG","Homo sapiens","MMP12, HME","Macrophage metalloelastase","1","5I4O"
"5I4Z",,"X-RAY DIFFRACTION",2.88,57.31,"VAPOR DIFFUSION, SITTING DROP",6,"MES, potassium sodium tartrate",293.15,"10.1038/onc.2016.354",,"5I4Z",28.53,"1.95","1.95","Structure of apo OmoMYC","MKHHHHHHPMSDYDIPTTENLYFQGAMATEENVKRRTHNVLERQRRNELKRSFFALRDQIPELENNEKAPKVVILKKATAYILSVQAETQKLISEIDLLRKQNEQLKHKLEQLRNSCA","Homo sapiens","MYC, BHLHE39","Myc proto-oncogene protein","1","5I4Z"
"5I5S",,"X-RAY DIFFRACTION",2.35,47.55,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT.",293,"10.1021/acs.jmedchem.5b01607","NVU","5I5S",85.23,"2.06","2.06","X-RAY CRYSTAL STRUCTURE AT 2.06A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BENZISOXAZOLE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5S"
"5I5T",,"X-RAY DIFFRACTION",2.37,48,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","67X","5I5T",85.05,"2.31","2.31","X-RAY CRYSTAL STRUCTURE AT 2.31A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TETRAHYDROQUINOLINE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5T"
"5I5U",,"X-RAY DIFFRACTION",2.36,47.82,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","67Y","5I5U",84.95,"2.404","2.404","X-RAY CRYSTAL STRUCTURE AT 2.40A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A TETRAHYDRONAPHTHALENYL COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5U"
"5I5V",,"X-RAY DIFFRACTION",2.35,47.6,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","68A","5I5V",85.67,"1.94","1.94","X-RAY CRYSTAL STRUCTURE AT 1.94A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A THIENOPYRIMIDINE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5V"
"5I5W",,"X-RAY DIFFRACTION",2.35,47.67,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","68B","5I5W",85.14,"2.4","2.4","X-RAY CRYSTAL STRUCTURE AT 2.40A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIARYL AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5W"
"5I5X",,"X-RAY DIFFRACTION",2.34,47.55,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","68C","5I5X",85.89,"1.65","1.65","X-RAY CRYSTAL STRUCTURE AT 1.65A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A THIAZOLE COMPOUND AND PMP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5X"
"5I5Y",,"X-RAY DIFFRACTION",2.31,46.7,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT",293,"10.1021/acs.jmedchem.5b01607","68D","5I5Y",85.42,"1.81","1.81","X-RAY CRYSTAL STRUCTURE AT 1.81A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH AN ARYL ACETATE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I5Y"
"5I60",,"X-RAY DIFFRACTION",2.35,47.59,"VAPOR DIFFUSION, HANGING DROP",6.5,"MDL MORPHEUS SCREEN CONDITION B2, DTT.",293,"10.1021/acs.jmedchem.5b01607","67W","5I60",85.22,"2.12","2.12","X-RAY CRYSTAL STRUCTURE AT 2.12A RESOLUTION OF HUMAN MITOCHONDRIAL BRANCHED CHAIN AMINOTRANSFERASE (BCATM) COMPLEXED WITH A BIARL AMIDE COMPOUND AND AN INTERNAL ALDIMINE LINKED PLP COFACTOR.","GSHMASSSFKAADLQLEMTQKPHKKPGPGEPLVFGKTFTDHMLMVEWNDKGWGQPRIQPFQNLTLHPASSSLHYSLQLFEGMKAFKGKDQQVRLFRPWLNMDRMLRSAMRLCLPSFDKLELLECIRRLIEVDKDWVPDAAGTSLYVRPVLIGNEPSLGVSQPTRALLFVILCPVGAYFPGGSVTPVSLLADPAFIRAWVGGVGNYKLGGNYGPTVLVQQEALKRGCEQVLWLYGPDHQLTEVGTMNIFVYWTHEDGVLELVTPPLNGVILPGVVRQSLLDMAQTWGEFRVVERTITMKQLLRALEEGRVREVFGSGTACQVCPVHRILYKDRNLHIPTMENGPELILRFQKELKEIQYGIRAHEWMFPV","Homo sapiens","BCAT2, BCATM, BCT2, ECA40","Branched-chain-amino-acid aminotransferase, mitochondrial","1","5I60"
"5I6J",,"X-RAY DIFFRACTION",2.55,51.69,"VAPOR DIFFUSION, HANGING DROP",7.25,"F-BARx-WT was eluted from the anion exchange column (MonoQ-GL10/100, GE Healthcare) in buffer containing 5% Glycerol, 25 mM Tris buffer pH=7.4, 5 mM ?-mercaptoethanol, and ~0.16 M NaCl at the elution peak and concentrated to 18 mg/ml. F-BARx-WT crystals grew in 0.2 M ammonium citrate tribasic pH=7.25, 35% PEG1500.",293.15,"10.1093/molbev/msx094",,"5I6J",56.56,"2.7","2.7","Crystal Structure of SRGAP2 F-BARx","MTSPAKFKKDKEIIAEYDTQVKEIRAQLTEQMKCLDQQCELRVQLLQDLQDFFRKKAEIEMDYSRNLEKLAERFLAKTRSTKDQQFKKDQNVLSPVNCWNLLLNQVKRESRDHTTLSDIYLNNIIPRFVQVSEDSGRLFKKSKEVGQQLQDDLMKVLNELYSVMKTYHMYNADSISAQSKLKEAEKQEEKQIGKSVKQEDRQTPRSPDSTANVRIEEKHVRRSSVKKIEKMKEKRQAKYTENKLKAIKARNEYLLALEATNASVFKYYIHDLSDLIDQCCDLGYHASLNRALRTFLSAELNLEQSKHEGLDAIENAVENLDATSDKQRLMEMYNNVFCPPMKFEFQPHMGDMASQLCAQQPVQSELVQRCQQLQSRLSTLKIENEEVKKTMEATLQTIQDIVTVEDFDVSDCFQYSNSMESVKSTVSETFMSKPSIAKRRANQQETEQFYFTKMKEYLEGRNLITKLQAKHDLLQKTLGESQRT","Homo sapiens","SRGAP2, ARHGAP34, FNBP2, KIAA0456, SRGAP2A","SLIT-ROBO Rho GTPase-activating protein 2","1","5I6J"
"5I6R",,"X-RAY DIFFRACTION",2.32,46.92,"VAPOR DIFFUSION, HANGING DROP",5.5,"F-BARx-C280Y was eluted in 25 mM phosphate buffer pH 8, 120 mM NaCl, 1 mM DTT, concentrated to 12 mg/ml, and crystallized in 5% v/v Tacsimate pH=5.5, 12% w/v PEG 3350.",293,,,"5I6R",57.02,"2.15","2.15","Crystal Structure of srGAP2 F-BARx WT Form-1","MTSPAKFKKDKEIIAEYDTQVKEIRAQLTEQMKCLDQQCELRVQLLQDLQDFFRKKAEIEMDYSRNLEKLAERFLAKTRSTKDQQFKKDQNVLSPVNCWNLLLNQVKRESRDHTTLSDIYLNNIIPRFVQVSEDSGRLFKKSKEVGQQLQDDLMKVLNELYSVMKTYHMYNADSISAQSKLKEAEKQEEKQIGKSVKQEDRQTPRSPDSTANVRIEEKHVRRSSVKKIEKMKEKRQAKYTENKLKAIKARNEYLLALEATNASVFKYYIHDLSDLIDQCYDLGYHASLNRALRTFLSAELNLEQSKHEGLDAIENAVENLDATSDKQRLMEMYNNVFCPPMKFEFQPHMGDMASQLCAQQPVQSELVQRCQQLQSRLSTLKIENEEVKKTMEATLQTIQDIVTVEDFDVSDCFQYSNSMESVKSTVSETFMSKPSIAKRRANQQETEQFYFTKMKEYLEGRNLITKLQAKHDLLQKTLGESQRT","Homo sapiens","SRGAP2, ARHGAP34, FNBP2, KIAA0456, SRGAP2A","SLIT-ROBO Rho GTPase-activating protein 2","1","5I6R"
"5I6V",,"X-RAY DIFFRACTION",2.23,44.93,"VAPOR DIFFUSION",,"0.2M Sodium Malonate, pH7.0, 20% w/v PEG3350",297,"10.1021/acs.biochem.5b01287",,"5I6V",120.56,"1.87","1.87","Structure of F285S, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2","MTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPSDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETL","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5I6V"
"5I7D",,"X-RAY DIFFRACTION",3.05,59.65,"VAPOR DIFFUSION, HANGING DROP",,"F-BARx eluted in 5% Glycerol, 25 mM Tris buffer pH=8.5, 1 mM DTT, and ~0.2 M NaCl at the elution peak, concentrated to ~15 mg/ml and crystallized in 0.2 M Ammonium citrate tribasic pH 6.5, 0.2 M Guanidine, 0.3 M NaCl, 16% PEG 3350",293,,,"5I7D",113.11,"3.95","3.95","Crystal Structure of srGAP2 F-BARx WT Form-2","MTSPAKFKKDKEIIAEYDTQVKEIRAQLTEQMKCLDQQCELRVQLLQDLQDFFRKKAEIEMDYSRNLEKLAERFLAKTRSTKDQQFKKDQNVLSPVNCWNLLLNQVKRESRDHTTLSDIYLNNIIPRFVQVSEDSGRLFKKSKEVGQQLQDDLMKVLNELYSVMKTYHMYNADSISAQSKLKEAEKQEEKQIGKSVKQEDRQTPRSPDSTANVRIEEKHVRRSSVKKIEKMKEKRQAKYTENKLKAIKARNEYLLALEATNASVFKYYIHDLSDLIDQCCDLGYHASLNRALRTFLSAELNLEQSKHEGLDAIENAVENLDATSDKQRLMEMYNNVFCPPMKFEFQPHMGDMASQLCAQQPVQSELVQRCQQLQSRLSTLKIENEEVKKTMEATLQTIQDIVTVEDFDVSDCFQYSNSMESVKSTVSETFMSKPSIAKRRANQQETEQFYFTKMKEYLEGRNLITKLQAKHDLLQKTLGESQRT","Homo sapiens","SRGAP2, ARHGAP34, FNBP2, KIAA0456, SRGAP2A","SLIT-ROBO Rho GTPase-activating protein 2","1","5I7D"
"5I7J",,"X-RAY DIFFRACTION",2.9,57.62,"VAPOR DIFFUSION, HANGING DROP",8.5,"6M Ammonium Nitrate, 0.1M Tris-HCL, pH 8.5",310,"10.1021/acs.biochem.6b00271",,"5I7J",49.91,"2.544","2.544","Crystal Structure of Human SPLUNC1 Disulfide Mutant M3 (I76C, V214C)","SNAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNGLLSGGLLGILENLPLLDCLKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERIHLVLGDCTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKCLPELVQGNVCPLVNEVLRGLDITLVHDIVNMLIHGLQFVIKV","Homo sapiens","BPIFA1, LUNX, NASG, PLUNC, SPLUNC1, SPURT, UNQ787/PRO1606","BPI fold-containing family A member 1","1","5I7J"
"5I7K",,"X-RAY DIFFRACTION",2.9,57.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"6M Ammonium Nitrate, and 0.1M Tris HCL pH 8.5",310,"10.1021/acs.biochem.6b00271",,"5I7K",50.27,"2.552","2.552","Crystal Structure of Human SPLUNC1 Dolphin Mutant D1 (G58A, S61A, G62E, G63D, G66D, I67T)","SNAQFGGLPVPLDQTLPLNVNPALPLSPTGLAGSLTNALSNALLAEDLLDTLENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERIHLVLGDCTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVCPLVNEVLRGLDITLVHDIVNMLIHGLQFVIKV","Homo sapiens","BPIFA1, LUNX, NASG, PLUNC, SPLUNC1, SPURT, UNQ787/PRO1606","BPI fold-containing family A member 1","1","5I7K"
"5I7L",,"X-RAY DIFFRACTION",2.88,57.31,"VAPOR DIFFUSION, HANGING DROP",8.5,"6M Ammonium Nitrate, 0.1M Tris-HCL, pH 8.5",310,"10.1021/acs.biochem.6b00271",,"5I7L",49.99,"2.598","2.598","Crystal Structure of SPLUNC1 Disulfide Mutant M2 (A48C, V253C)","SNAQFGGLPVPLDQTLPLNVNPALPLSPTGLCGSLTNALSNGLLSGGLLGILENLPLLDILKPGGGTSGGLLGGLLGKVTSVIPGLNNIIDIKVTDPQLLELGLVQSPDGHRLYVTIPLGIKLQVNTPLVGASLLRLAVKLDITAEILAVRDKQERIHLVLGDCTHSPGSLQISLLDGLGPLPIQGLLDSLTGILNKVLPELVQGNVCPLVNEVLRGLDITLVHDIVNMLIHGLQFCIKV","Homo sapiens","BPIFA1, LUNX, NASG, PLUNC, SPLUNC1, SPURT, UNQ787/PRO1606","BPI fold-containing family A member 1","1","5I7L"
"5I7M",,"X-RAY DIFFRACTION",2.75,55.3,"VAPOR DIFFUSION, HANGING DROP",6.5,"75 mg/mL p58C Y345F in 20 mM MES, pH 6.5, 50 mM sodium chloride, reservoir solution: 100 mM Tris, pH 8.5, 150 mM lithium sulfate, 18% PEG3350",277,"10.1126/science.aag1789",,"5I7M",44.22,"1.93","1.93","Crystal structure of Y345F mutant of human primase p58 iron-sulfur cluster domain","PNSLDQIDLLSTKSFPPCMRQLHKALRENHHLRHGGRMQYGLFLKGIGLTLEQALQFWKQEFIKGKMDPDKFDKGFSYNIRHSFGKEGKRTDYTPFSCLKIILSNPPSQGDYHGCPFRHSDPELLKQKLQSYKISPGGISQILDLVKGTHYQVACQKYFEMIHNVDDCGFSLNHPNQFFCESQRILNG","Homo sapiens","PRIM2, PRIM2A","DNA primase large subunit","1","5I7M"
"5I7U",,"X-RAY DIFFRACTION",3.06,59.81,"VAPOR DIFFUSION, HANGING DROP",8,"0.27-0.30 M sodium acetate
17-18% polyethylene glycol 3350
0.1 M tris hydrochloride pH 8.0",291,"10.1021/acsmedchemlett.6b00027","6AJ","5I7U",174.55,"1.95","1.95","Human DPP4 in complex with a novel tricyclic hetero-cycle inhibitor","TRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP","Homo sapiens","DPP4, ADCP2, CD26","Dipeptidyl peptidase 4","1","5I7U"
"5I7X",,"X-RAY DIFFRACTION",2.45,49.75,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris, pH 6.5, 
20% PEG 2000 monomethylether",277,"10.1021/acs.jmedchem.6b00264","67B","5I7X",12.02,"1.1752","1.1752","BRD9 in complex with Cpd2 (N,N-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide)","STPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5I7X"
"5I7Y",,"X-RAY DIFFRACTION",2.45,49.75,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1M Bis-Tris, pH 6.5, 
20% PEG 2000 monomethylether",277,"10.1021/acs.jmedchem.6b00264","69G","5I7Y",12.06,"1.4514","1.4514","BRD9 in complex with Cpd4 ((E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide)","STPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5I7Y"
"5I80",,"X-RAY DIFFRACTION",2.13,42.33,"VAPOR DIFFUSION, SITTING DROP",6.8,"20% ethylene glycol, 
0.1 M Bis-Tris pH 6.8, 
20% polyethylene glycol (PEG) 3350",,"10.1021/acs.jmedchem.6b00264","67B","5I80",15.44,"1.4501","1.4501","BRD4 in complex with Cpd2 (N,N-dimethyl-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)benzamide)","STNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5I80"
"5I81",,"X-RAY DIFFRACTION",3.7,66.72,"VAPOR DIFFUSION, SITTING DROP",5.5,"1.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.0-5.5, 12% glycerol",294,"10.1038/ncomms13082",,"5I81",69.16,"2.25","2.25","aSMase with zinc","LSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC","Homo sapiens","SMPD1, ASM","Sphingomyelin phosphodiesterase","1","5I81"
"5I83",,"X-RAY DIFFRACTION",2.54,51.52,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277.15,"10.1021/acsmedchemlett.6b00075","68Y","5I83",14.35,"1.35","1.35","Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02773986","GSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5I83"
"5I85",,"X-RAY DIFFRACTION",3.62,66.02,"VAPOR DIFFUSION, SITTING DROP",,"phosphocholine soaked in well solution containing 1.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.0-5.5, 12% glycerol.",294,"10.1038/ncomms13082",,"5I85",69.07,"2.5","2.5","aSMase with zinc and phosphocholine","LSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC","Homo sapiens","SMPD1, ASM","Sphingomyelin phosphodiesterase","1","5I85"
"5I86",,"X-RAY DIFFRACTION",2.35,47.72,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium thiocyanate, 0.1 M Bis-Tris, pH 5.5, 5% v/v ethylene glycol, 23% PEG3350",277.15,"10.1021/acsmedchemlett.6b00075","69A","5I86",28.78,"1.05","1.05","Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02778174","GSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5I86"
"5I87",,"X-RAY DIFFRACTION",,,"VAPOR DIFFUSION, SITTING DROP",6,"MES, tri-potassium citrate, PEG10000",292.15,"10.1038/ncomms11196",,"5I87",118.47,"3.7","3.7","Crystal structure of BT-CD domains of human acetyl-CoA carboxylase","XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"BT-CD domains of human acetyl-CoA carboxylase","1","5I87"
,,,,,,,,,,,,,,,,"XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX","Homo sapiens",,"BT-CD domains of human acetyl-CoA carboxylase","2","5I87"
"5I88",,"X-RAY DIFFRACTION",2.16,43.08,"VAPOR DIFFUSION, SITTING DROP",6.8,"20% ethylene glycol, 
0.1 M Bis-Tris pH 6.8, 
20% polyethylene glycol (PEG) 3350",277,"10.1021/acs.jmedchem.6b00264","69G","5I88",15.72,"1.4","1.4","BRD4 in complex with Cpd4 ((E)-3-(6-(but-2-en-1-yl)-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)-N,N-dimethylbenzamide)","STNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5I88"
"5I89",,"X-RAY DIFFRACTION",2.26,45.53,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M calcium acetate hydrate, and 20% w/v PEG3350",277.15,"10.1021/acsmedchemlett.6b00075","69B","5I89",14.44,"1.07","1.07","Crystal structure of the bromodomain of human CREBBP bound to the benzodiazepinone G02857790","GSKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5I89"
"5I8A",,"X-RAY DIFFRACTION",2.76,55.47,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.1M Bis-Tris pH 6.5, 2.3M Ammonium Acetate",298,"10.1016/j.bmcl.2016.04.021",,"5I8A",34.34,"2.33","2.33","TrkA with (6~{R})-3-methylsulfanyl-6-phenyl-1-(1~{H}-pyrazol-3-yl)-6,7-dihydro-5~{H}-thieno[3,4-c]pyridin-4-one","SDACVHHIKRRDIVLKWELGEGAFGKVFLAECHNLLPEQDKMLVAVKALKEASESARQDFQREAELLTMLQHQHIVRFFGVCTEGRPLLMVFEYMRHGDLNRFLRSHGPDAKLLAGGEDVAPGPLGLGQLLAVASQVAAGMVYLAGLHFVHRDLATRNCLVGQGLVVKIGDFGMSRDIYSTDYYRVGGRTMLPIRWMPPESILYRKFTTESDVWSFGVVLWEIFTYGKQPWYQLSNTEAIDCITQGRELERPRACPPEVYAIMRGCWQREPQQRHSIKDVHARLQALAQAHHHHHH","Homo sapiens","NTRK1, MTC, TRK, TRKA","High affinity nerve growth factor receptor","1","5I8A"
"5I8B",,"X-RAY DIFFRACTION",2.36,47.94,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 8,
 0.2 M sodium thiocyanate 
19-23% PEG 3350",277,"10.1021/acsmedchemlett.6b00075","69F","5I8B",32.5,"1.5218","1.5218","CBP in complex with Cpd23 ((R)-6-(3-(benzyloxy)phenyl)-4-methyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)","MHHHHHHGSLVPRGSMDYKDDDDKENLYFQGSRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCL","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5I8B"
"5I8G",,"X-RAY DIFFRACTION",2.34,47.41,"VAPOR DIFFUSION, HANGING DROP",8,"containing 0.1 M Bis-Tris pH 8, 
0.2 M sodium thiocyanate 
19-23% PEG 3350",277,"10.1021/acsmedchemlett.6b00075","69E","5I8G",32.63,"1.41","1.41","CBP in complex with Cpd637 ((R)-4-methyl-6-(1-methyl-3-(1-methyl-1H-pyrazol-4-yl)-1H-indazol-5-yl)-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one)","MHHHHHHGSLVPRGSMDYKDDDDKENLYFQGSRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLGYCCGRKYEFSPQTLCCYGKQLCTIPRDAAYYSYQNRYHFCEKCFTEIQGENVTLGDDPSQPQTTISKDQFEKKKNDTLDPEPFVDCKECGRKMHQICVLHYDIIWPSGFVCDNCL","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5I8G"
"5I8K",,"X-RAY DIFFRACTION",2.44,49.56,"VAPOR DIFFUSION, SITTING DROP",,"15-19% (v/v) Isopropanol, 15-24.5% (w/v) PEG 3350, 0.075 M MES pH 5.5-6.0",293,,,"5I8K",46.45,"1.771","1.771","HHH1 Fab fragment","ELDMTQTPASVSAAVGGTVTISCQSSRSVWNNNFLSWYQQKPGQPPKLLISDASKLASGVPSRFKGSGSGTQFTLTISDLESDDAATYYCAGDLSDWIHTFGGGTEVVVKRTVGAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"HHH1 Fab Light chain","1","5I8K"
,,,,,,,,,,,,,,,,"QEQLVESGGGLVTPGGTLTLTCTASGFTISNYHMSWVRQAPGKGLEWIGFIDTGGSAAYAPWAKGRFTISRTSTTVALKITSPTTEDTATYFCARGAPAWGTANVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDRRVEPKSCDKT","Homo sapiens",,"HHH1 Fab Heavy chain","2","5I8K"
"5I8N",,"SOLUTION NMR",,,,,,,"10.1016/j.bbapap.2016.08.008",,"5I8N",26.5,,,"Solution Structure of human calcium-binding S100A9 (C3S) protein","MTSKMSQLERNIETIINTFHQYSVKLGHPDTLNQGEFKELVRKDLQNFLKKENKNEKVIEHIMEDLDTNADKQLSFEEFIMLMARLTWASHEKMHEGDEGPGHHHKPGLGEGTP","Homo sapiens","S100A9, CAGB, CFAG, MRP14","Protein S100-A9","1","5I8N"
"5I8O",,"X-RAY DIFFRACTION",2.37,48.15,"VAPOR DIFFUSION, SITTING DROP",,"15-25 mM LiSO4, 15-26.5% (w/v) PEG 3350, 0.1M Tris or HEPES pH 7.0-8.5, 18 mM Fuca1-3GlcNAca1-OMe",292,,,"5I8O",46.62,"1.8","1.8","HMM5 Fab in complex with disaccharide","QSLEESGGRLVTPGTPLTLTCTVSGFSLSTYNIHWVRQAPGKGLEWIGVIDTGGGTYFASWAKGRFAISKTSSTTVDLKMTSLTAADTATYFCAKGFDYSASTNLWGPGTLVTISSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDRRVEPKSC","Homo sapiens",,"HMM5 antibody heavy chain","1","5I8O"
,,,,,,,,,,,,,,,,"ELDMTQTPSSVSAPVGGSVTINCQSSQSVYGNNYLAWYQQKAGQPPKLLIYRASTLASGAPSRFKGSGSGTQFTLTISDLESDDAATYYCLGYYNGVINVFGGGTNVEIKRTVGAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"HMM5 antibody light chain","2","5I8O"
"5I8P",,"X-RAY DIFFRACTION",2.48,50.43,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293,"10.1021/acs.jmedchem.6b00282","VQ7","5I8P",88.97,"2.37","2.37","Crystal structure of LP_PLA2 in complex with novel inhibitor","GPLGSAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHI","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5I8P"
"5I8R",,"X-RAY DIFFRACTION",6.4,81,"VAPOR DIFFUSION, SITTING DROP",,"1.5 M ammonium sulfate, 0.1 M sodium acetate pH 5.0-5.5, 12% glycerol",294,"10.1038/ncomms13082",,"5I8R",201.86,"3.646","3.646","aSMase with zinc","LSDSRVLWAPAEAHPLSPQGHPARLHRIVPRLRDVFGWGNLTCPICKGLFTAINLGLKKEPNVARVGSVAIKLCNLLKIAPPAVCQSIVHLFEDDMVEVWRRSVLSPSEACGLLLGSTCGHWDIFSSWNISLPTVPKPPPKPPSPPAPGAPVSRILFLTDLHWDHDYLEGTDPDCADPLCCRRGSGLPPASRPGAGYWGEYSKCDLPLRTLESLLSGLGPAGPFDMVYWTGDIPAHDVWHQTRQDQLRALTTVTALVRKFLGPVPVYPAVGNHESTPVNSFPPPFIEGNHSSRWLYEAMAKAWEPWLPAEALRTLRIGGFYALSPYPGLRLISLNMNFCSRENFWLLINSTDPAGQLQWLVGELQAAEDRGDKVHIIGHIPPGHCLKSWSWNYYRIVARYENTLAAQFFGHTHVDEFEVFYDEETLSRPLAVAFLAPSATTYIGLNPGYRVYQIDGNYSGSSHVVLDHETYILNLTQANIPGAIPHWQLLYRARETYGLPNTLPTAWHNLVYRMRGDMQLFQTFWFLYHKGHPPSEPCGTPCRLATLCAQLSARADSPALCRHLMPDGSLPEAQSLWPRPLFC","Homo sapiens","SMPD1, ASM","Sphingomyelin phosphodiesterase","1","5I8R"
"5I94",,"X-RAY DIFFRACTION",2.51,50.99,"VAPOR DIFFUSION, HANGING DROP",8,"10% PEG6000, LiCl, Tris-HCl, pH8.0",293,"10.1016/j.bmc.2016.03.009","69V","5I94",238.79,"2.983","2.983","Crystal structure of human glutaminase C in complex with the inhibitor UPGL-00019","MRGSHHHHHHGSLSSSPSEILQELGKGSTHPQPGVSPPAAPAAPGPKDGPGETDAFGNSEGKELVASGENKIKQGLLPSLEDLLFYTIAEGQEKIPVHKFITALKSTGLRTSDPRLKECMDMLRLTLQTTSDGVMLDKDLFKKCVQSNIVLLTQAFRRKFVIPDFMSFTSHIDELYESAKKQSGGKVADYIPQLAKFSPDLWGVSVCTADGQRHSTGDTKVPFCLQSCVKPLKYAIAVNDLGTEYVHRYVGKEPSGLRFNKLFLNEDDKPHNPMVNAGAIVVTSLIKQGVNNAEKFDYVMQFLNKMAGNEYVGFSNATFQSERESGDRNFAIGYYLKEKKCFPEGTDMVGILDFYFQLCSIEVTCESASVMAATLANGGFCPITGERVLSPEAVRNTLSLMHSCGMYDFSGQFAFHVGLPAKSGVAGGILLVVPNVMGMMCWSPPLDKMGNSVKGIHFCHDLVSLCNFHNYDNLRHFAKKLDPRREGGDQRHSFGPLDYESLQQELALKETVWKKVSPESNEDISTTVVYRMESLGEKS","Homo sapiens","GLS, GLS1, KIAA0838","Glutaminase kidney isoform, mitochondrial","1","5I94"
"5I95",,"X-RAY DIFFRACTION",2.61,52.8,"VAPOR DIFFUSION, HANGING DROP",6.5,"200 mM magnesium acetate, 100 mM sodium cacodylate, pH 6.5, 20% PEG8000",291,"10.1158/2159-8290.CD-16-1034",,"5I95",49.49,"1.54","1.54","Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase R140Q Mutant Homodimer bound to NADPH and alpha-Ketoglutaric acid","MADKRIKVAKPVVEMDGDEMTRIIWQFIKEKLILPHVDIQLKYFDLGLPNRDQTDDQVTIDSALATQKYSVAVKCATITPDEARVEEFKLKKMWKSPNGTIQNILGGTVFREPIICKNIPRLVPGWTKPITIGRHAHGDQYKATDFVADRAGTFKMVFTPKDGSGVKEWEVYNFPAGGVGMGMYNTDESISGFAHSCFQYAIQKKWPLYMSTKNTILKAYDGRFKDIFQEIFDKHYKTDFDKNKIWYEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDILAQGFGSLGLMTSVLVCPDGKTIEAEAAHGTVTRHYREHQKGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAMTKDLAGCIHGLSNVKLNEHFLNTTDFLDTIKSNLDRALGRQLEHHHHHHHH","Homo sapiens","IDH2","Isocitrate dehydrogenase [NADP], mitochondrial","1","5I95"
"5I96",,"X-RAY DIFFRACTION",2.12,41.85,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1 M Tris-HCl, pH 8.5, 0.25 M CaCl2, 25% PEG4000",291,"10.1158/2159-8290.CD-16-1034","69Q","5I96",106.23,"1.55","1.55","Crystal Structure of Human Mitochondrial Isocitrate Dehydrogenase (IDH2) R140Q Mutant Homodimer in Complex with AG-221 (Enasidenib) Inhibitor.","MAGYLRVVRSLCRASGSRPAWAPAALTAPTSQEQPRRHYADKRIKVAKPVVEMDGDEMTRIIWQFIKEKLILPHVDIQLKYFDLGLPNRDQTDDQVTIDSALATQKYSVAVKCATITPDEARVEEFKLKKMWKSPNGTIQNILGGTVFREPIICKNIPRLVPGWTKPITIGRHAHGDQYKATDFVADRAGTFKMVFTPKDGSGVKEWEVYNFPAGGVGMGMYNTDESISGFAHSCFQYAIQKKWPLYMSTKNTILKAYDGRFKDIFQEIFDKHYKTDFDKNKIWYEHRLIDDMVAQVLKSSGGFVWACKNYDGDVQSDILAQGFGSLGLMTSVLVCPDGKTIEAEAAHGTVTRHYREHQKGRPTSTNPIASIFAWTRGLEHRGKLDGNQDLIRFAQMLEKVCVETVESGAMTKDLAGCIHGLSNVKLNEHFLNTTDFLDTIKSNLDRALGRQHHHHHH","Homo sapiens","IDH2","Isocitrate dehydrogenase [NADP], mitochondrial","1","5I96"
"5I9I",,"X-RAY DIFFRACTION",2.37,48.06,"VAPOR DIFFUSION, HANGING DROP",6.6,"0.1M MOPS pH 6.6, 0.4M Li2SO4, 27% (w/v) (NH4)2SO4, 1M Na-Ac, 1.4% 1,4-butanediol",293,"10.1021/acs.jmedchem.6b00282","5HV","5I9I",89.34,"2.7","2.7","Crystal structure of LP_PLA2 in complex with Darapladib","GPLGSAAASFGQTKIPRGNGPYSVGCTDLMFDHTNKGTFLRLYYPSQDNDRLDTLWIPNKEYFWGLSKFLGTHWLMGNILRLLFGSMTTPANWNSPLRPGEKYPLVVFSHGLGAFRTLYSAIGIDLASHGFIVAAVEHRDRSASATYYFKDQSAAEIGDKSWLYLRTLKQEEETHIRNEQVRQRAKECSQALSLILDIDHGKPVKNALDLKFDMEQLKDSIDREKIAVIGHSFGGATVIQTLSEDQRFRCGIALDAWMFPLGDEVYSRIPQPLFFINSEYFQYPANIIKMKKCYSPDKERKMITIRGSVHQNFADFTFATGKIIGHMLKLKGDIDSNVAIDLSNKASLAFLQKHLGLHKDFDQWDCLIEGDDENLIPGTNINTTNQHI","Homo sapiens","PLA2G7, PAFAH","Platelet-activating factor acetylhydrolase","1","5I9I"
"5I9J",,"X-RAY DIFFRACTION",3.2,61,"VAPOR DIFFUSION, HANGING DROP",9.1,"0.85 M sodium/potassium tartrate, 0.2 M lithium sulfate, 0.1 M CHES, 0.01 M dithiothreitol. Cryostabilizer: 18% ethylene glycol, 5% ethanol in addition to 0.8M sodium/potassium tartrate, 0.1 M CHES pH 9.1, 0.2 M lithium sulfate, 0.01 M dithiothreitol. Crystals were frozen in propane and stored under liquid nitrogen",295,"10.1107/S2053230X16010694",,"5I9J",26.42,"1.74","1.74","Structure of the cholesterol and lutein-binding domain of human STARD3 at 1.74A","GSDNESDEEVAGKKSFSAQEREYIRQGKEATAVVDQILAQEENWKFEKNNEYGDTVYTIEVPFHGKTFILKTFLPCPAELVYQEVILQPERMVLWNKTVTACQILQRVEDNTLISYDVSAGAAGGVVSPRDFVNVRRIERRRDRYLSSGIATSHSAKPPTHKYVRGENGPGGFIVLKSASNPRVCTFVWILNTDLKGRLPRYLIHQSLAATMFEFAFHLRQRISELGAR","Homo sapiens","STARD3, CAB1, MLN64","StAR-related lipid transfer protein 3","1","5I9J"
"5I9U",,"X-RAY DIFFRACTION",1.97,37.6,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M Amino Acids, 0.1 M Bicine/Trizma base pH 8.5",291,"10.1021/acschembio.6b00709",,"5I9U",34.52,"1.889","1.889","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9U"
"5I9V",,"X-RAY DIFFRACTION",1.93,36.31,"VAPOR DIFFUSION, SITTING DROP",,"33.75 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Buffer3 pH 8.5",291,"10.1021/acschembio.6b00709",,"5I9V",34.99,"1.458","1.458","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with AGS","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9V"
"5I9W",,"X-RAY DIFFRACTION",1.96,37.16,"VAPOR DIFFUSION, SITTING DROP",,"30 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M HEPES pH 7.0",291,"10.1021/acschembio.6b00709",,"5I9W",35.09,"1.359","1.359","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with ANP","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9W"
"5I9X",,"X-RAY DIFFRACTION",1.97,37.51,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M MES pH 6.0",291,"10.1021/acschembio.6b00709","DB8","5I9X",35.24,"1.427","1.427","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with bosutinib (SKI-606)","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9X"
"5I9Y",,"X-RAY DIFFRACTION",1.97,37.46,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Hepes pH 6.5",291,"10.1021/acschembio.6b00709","1N1","5I9Y",35.14,"1.228","1.228","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with dasatinib","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9Y"
"5I9Z",,"X-RAY DIFFRACTION",1.95,36.85,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Tris pH 6.5",291,"10.1021/acschembio.6b00709","627","5I9Z",35,"1.698","1.698","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with danusertib (PHA739358)","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5I9Z"
"5IA0",,"X-RAY DIFFRACTION",2.49,50.68,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.3 M Carboxylic Acids, 0.1 M BufferSystem3 pH 8.5",291,"10.1021/acschembio.6b00709","A5B","5IA0",106.19,"1.948","1.948","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with alisertib (MLN8237)","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA0"
"5IA1",,"X-RAY DIFFRACTION",1.95,37.03,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Bicin pH 7.6",291,"10.1021/acschembio.6b00709","ZZL","5IA1",35,"2.036","2.036","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with MLN8054","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA1"
"5IA2",,"X-RAY DIFFRACTION",1.98,37.76,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M Amino Acids, 0.1 M MES pH 7.0",291,"10.1021/acschembio.6b00709","L66","5IA2",35.07,"1.619","1.619","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with compound 66","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA2"
"5IA3",,"X-RAY DIFFRACTION",1.96,37.34,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.2 M Amino Acids, 0.1 M Buffer3 pH 8.5",291,"10.1021/acschembio.6b00709","P17","5IA3",34.91,"1.788","1.788","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with PD173955","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA3"
"5IA4",,"X-RAY DIFFRACTION",2.11,41.82,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M MES pH 6.0",291,"10.1021/acschembio.6b00709","88Z","5IA4",35.16,"1.797","1.797","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with foretinib (XL880)","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA4"
"5IA5",,"X-RAY DIFFRACTION",2.11,41.84,"VAPOR DIFFUSION, SITTING DROP",,"37.5 % MPD_P1k_P3350, 0.1 M AminoAcidsMix, 0.1 M Tris pH 6.5",291,"10.1021/acschembio.6b00709","GV0","5IA5",35.28,"1.776","1.776","Crystal Structure of Ephrin A2 (EphA2) Receptor Protein Kinase with golvatinib (E7050)","GDPNQAVLKFTTEIHPSCVTRQKVIGAGEFGEVYKGMLKTSSGKKEVPVAIKTLKAGYTEKQRVDFLGEAGIMGQFSHHNIIRLEGVISKYKPMMIITEYMENGALDKFLREKDGEFSVLQLVGMLRGIAAGMKYLANMNYVHRDLAARNILVNSNLVCKVSDFGLSRVLEDDPEATYTTSGGKIPIRWTAPEAISYRKFTSASDVWSFGIVMWEVMTYGERPYWELSNHEVMKAINDGFRLPTPMDCPSAIYQLMMQCWQQERARRPKFADIVSILDKLIRAPDSLKTLADFDPRVSIRLPSTSG","Homo sapiens","EPHA2, ECK","Ephrin type-A receptor 2","1","5IA5"
"5IA7",,"X-RAY DIFFRACTION",2.32,46.88,"VAPOR DIFFUSION, HANGING DROP",,"0.2M Ammonium acetate, 0.1M Sodium citrate tribasic dihydrate and 30% PEG 4000",293.15,"10.1038/s41598-017-00610-0",,"5IA7",17.88,"2","2","Crystal structure of Ubiquitin fold modifier 1 (Ufm1)","MSKVSFKITLTSDPRLPYKVLSVPESTPFTAVLKFAAEEFKVPAATSAIITNDGIGINPAQTAGNVFLKHGSELRIIPRDRVG","Homo sapiens","UFM1, C13orf20, BM-002","Ubiquitin-fold modifier 1","1","5IA7"
"5IBM",,"X-RAY DIFFRACTION",2.21,44.45,"VAPOR DIFFUSION, HANGING DROP",8,"100 mM Tris, 20% PEG 3350 and 1 mM TCEP",293,"10.1021/acs.biochem.5b01287",,"5IBM",120.69,"2.18","2.18","Structure of S502P, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2","SMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAELVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRPGMVQTEAQYRFIYMAVQHYIETL","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5IBM"
"5IBN",,"X-RAY DIFFRACTION",2.3,46.53,"VAPOR DIFFUSION, SITTING DROP",7.3,"30% PEG MME 2000, 20% glycerol, 50mM NaCl, 50mM Tris pH 7.5",300,"10.1371/journal.pone.0156344",,"5IBN",13.85,"0.94","0.94","Ultra high resolution crystal structure of the apo- form of second bromodomain of BRD2.","ANPEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPD","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5IBN"
"5IBS",,"X-RAY DIFFRACTION",2.42,49.22,"VAPOR DIFFUSION, HANGING DROP",8,"100 mM Tris, 20% PEG 3350 and 1 mM TCEP",293,"10.1021/acs.biochem.5b01287",,"5IBS",120.67,"2.32","2.32","Structure of E76Q, a Cancer-Associated Mutation of the Oncogenic Phosphatase SHP2","SMTSRRWFHPNITGVEAENLLLTRGVDGSFLARPSKSNPGDFTLSVRRNGAVTHIKIQNTGDYYDLYGGEKFATLAQLVQYYMEHHGQLKEKNGDVIELKYPLNCADPTSERWFHGHLSGKEAEKLLTEKGKHGSFLVRESQSHPGDFVLSVRTGDDKGESNDGKSKVTHVMIRCQELKYDVGGGERFDSLTDLVEHYKKNPMVETLGTVLQLKQPLNTTRINAAEIESRVRELSKLAETTDKVKQGFWEEFETLQQQECKLLYSRKEGQRQENKNKNRYKNILPFDHTRVVLHDGDPNEPVSDYINANIIMPEFETKCNNSKPKKSYIATQGCLQNTVNDFWRMVFQENSRVIVMTTKEVERGKSKCVKYWPDEYALKEYGVMRVRNVKESAAHDYTLRELKLSKVGQGNTERTVWQYHFRTWPDHGVPSDPGGVLDFLEEVHHKQESIMDAGPVVVHCSAGIGRTGTFIVIDILIDIIREKGVDCDIDVPKTIQMVRSQRSGMVQTEAQYRFIYMAVQHYIETL","Homo sapiens","PTPN11, PTP2C, SHPTP2","Tyrosine-protein phosphatase non-receptor type 11","1","5IBS"
"5IBT",,"X-RAY DIFFRACTION",2.5,50.84,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.5 M NaCl, 0.05 M Tris-HCL pH 8.5, 22% PEG 4000 and 20% glycerol as a cryoprotectant",293.15,"10.1038/nm.4223",,"5IBT",48.26,"2.4","2.4","UCA Fab (unbound) from 6515 Lineage","EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"UCA Light Chain","2","5IBT"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKKPGESLKISCKGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPGDSDTRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYCARVVADREGFGYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"UCA Heavy Chain","1","5IBT"
"5IBU",,"X-RAY DIFFRACTION",2.65,53.6,"VAPOR DIFFUSION, HANGING DROP",5.6,"0.1 M NaCitrate pH 5.6, 20% PEG 4K, 20% Isopropanol and 10% glycerol as a cryoprotectant",293.15,"10.1038/nm.4223",,"5IBU",96.54,"1.71","1.71","6652 Fab (unbound)","EIVLTQSPGTLSLSPGERATLSCRASQSVFSTFLAWYQQKPGQAPRLLIYAASRRAAGIPDRFSGSESGTDFTLTISRLEPEDFAVYYCQQSESSPWTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"6652 Light Chain","1","5IBU"
,,,,,,,,,,,,,,,,"EVQLVQSGAEVKMPGESLRISCKVSGYNFVKFWIAWVRQKPGKGLEWMGVIHPGDSDSTYNPSFQGHVSISADKSINTAYLQWNSLKASDTAMYFCARVVGDREGFGYHYGLDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDK","Homo sapiens",,"6652 Heavy Chain","2","5IBU"
"5ICM",,"X-RAY DIFFRACTION",2.4,49.9,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 6000 20%; Hepes 0.1 M pH 7.00; DMSO 5%",291,"10.1021/acs.jmedchem.6b00293","F45","5ICM",29.87,"1.68","1.68","17beta-hydroxysteroid dehydrogenase type 14 in complex with a non-steroidal inhibitor","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRATIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5ICM"
"5ICS",,"X-RAY DIFFRACTION",2.5,49.9,"VAPOR DIFFUSION, SITTING DROP",4.6,"Sodium acetate 0.1 M; PEG 400 30%; ammonium acetate 0.2 M.",291,"10.1021/acs.jmedchem.6b00293",,"5ICS",114.67,"1.52","1.52","Crystal structure of 17beta-hydroxysteroid dehydrogenase type 14 apoenzyme.","GHMATGTRYAGKVVVVTGGGRGIGAGIVRAFVNSGARVVICDKDESGGRALEQELPGAVFILCDVTQEDDVKTLVSETIRRFGRLDCVVNNAGHHPPPQRPEETSAQGFRQLLELNLLGTYTLTKLALPYLRKSQGNVINISSLVGAIGQAQAVPYVATKGAVTAMTKALALDESPYGVRVNCISPGNIWTPLWEELAALMPDPRASIREGMLAQPLGRMGQPAEVGAAAVFLASEANFCTGIELLVTGGAELGYGCKASRSTPVDAPDIPSGS","Homo sapiens","HSD17B14, DHRS10, SDR3, SDR47C1, UNQ502/PRO474","17-beta-hydroxysteroid dehydrogenase 14","1","5ICS"
"5ICW",,"X-RAY DIFFRACTION",2.24,45,"VAPOR DIFFUSION, HANGING DROP",,"3% Tascimate, 0.1 M Bistris pH 6.5 and 16% PEG 3350",293.15,"10.1016/j.str.2016.04.020",,"5ICW",86.28,"1.951","1.951","Crystal structure of human NatF (hNaa60) homodimer bound to Coenzyme A","EVVPSSALSEVSLRLLCHDDIDTVKHLCGDWFPIEYPDSWYRDITSNKKFFSLAATYRGAIVGMIVAEIKNRTKIHKEDGDILASNFSVDTQVAYILSLGVVKEFRKHGIGSLLLESLKDHISTTAQDHCKAIYLHVLTTNNTAINFYENRDFKQHHYLPYYYSIRGVLKDGFTYVLYINGG","Homo sapiens","NAA60, HAT4, NAT15, UNQ2771/PRO7155","N-alpha-acetyltransferase 60","1","5ICW"
"5ID7",,"X-RAY DIFFRACTION",2.2,44.17,"VAPOR DIFFUSION, HANGING DROP",7.5,"28% PEG3350, 50 mM phosphate buffer",293,"10.1042/BSR20160089",,"5ID7",136.28,"2.26","2.26","Crystal structure of human serum albumin in complex with phosphorodithioate derivative of myristoyl cyclic phosphatidic acid (cPA)","DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","5ID7"
"5IDZ",,"X-RAY DIFFRACTION",2.24,45.06,"VAPOR DIFFUSION, HANGING DROP",6.5,"200 mM ammonium acetate, 100 mM Bis-Tris, 18-22% w/v PEG3350, 6.5, overnight crystal soak in reservoir solution supplemented with 4 mM compound",293,,,"5IDZ",97.04,"2.63","2.63","Structure of Human Enolase 2 in complex with (S)-(1-hydroxy-2-oxopiperidin-3-yl)phosphonate","MSIEKIWAREILDSRGNPTVEVDLYTAKGLFRAAVPSGASTGIYEALELRDGDKQRYLGKGVLKAVDHINSTIAPALISSGLSVVEQEKLDNLMLELDGTENKSKFGANAILGVSLAVCKAGAAERELPLYRHIAQLAGNSDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGAESFRDAMRLGAEVYHTLKGVIKDKYGKDATNVGDEGGFAPNILENSEALELVKEAIDKAGYTEKIVIGMDVAASEFYRDGKYDLDFKSPTDPSRYITGDQLGALYQDFVRDYPVVSIEDPFDQDDWAAWSKFTANVGIQIVGDDLTVTNPKRIERAVEEKACNCLLLKVNQIGSVTEAIQACKLAQENGWGVMVSHRSGETEDTFIADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEELGDEARFAGHNFRNPSVLHHHHHH","Homo sapiens","ENO2","Gamma-enolase","1","5IDZ"
"5IE1",,"X-RAY DIFFRACTION",2.8,56.1,"VAPOR DIFFUSION, HANGING DROP",,"20% polyethylene glycol 5000 MME, 200 mM ammonium iodide, 170 mM sodium citrate (pH 6.6)",293,"10.1021/acs.jmedchem.5b01917","6BS","5IE1",46.9,"2.298","2.298","Crystal structure of BACE1 in complex with 3-(2-amino-6-(o-tolyl)quinolin-3-yl)-N-(3,3-dimethylbutyl)propanamide","LPRETDEEPEEPGKKGSFVEMVDNLRGKSGQGYYVEMTVGSPPQTLNILVDTGSSNFAVGAAPHPFLHRYYQRQLSSTYRDLRKGVYVPYTQGKWEGELGTDLVSIPHGPNVTVRANIAAITESDKFFINGSNWEGILGLAYAEIARPDDSLEPFFDSLVKQTHVPNLFSLQLCGAGFPLNQSEVLASVGGSMIIGGIDHSLYTGSLWYTPIRREWYYEVIIVRVEINGQDLKMDCKEYNYDKSIVDSGTTNLRLPKKVFEAAVKSIKAASSTEKFPDGFWLGEQLVCWQAGTTPWNIFPVISLYLMGEVTNQSFRITILPQQYLRPVEDVATSQDDCYKFAISQSSTGTVMGAVIMEGFYVVFDRARKRIGFAVSACHVHDEFRTAAVEGPFVTLDMEDCGYNIPQTDES","Homo sapiens","BACE1, BACE, KIAA1149","Beta-secretase 1","1","5IE1"
"5IEI",,"X-RAY DIFFRACTION",2.06,40.43,"VAPOR DIFFUSION, HANGING DROP",7,"2.0 M Ammonium Sulphate, 0.1M Bis-(2-hydroxyethyl)imino-tris(hydroxymethyl methane, pH 7.0.",291,"10.1073/pnas.1513023113",,"5IEI",15.96,"2.8","2.8","X-ray crystallographic structure of a high affinity IGF2 antagonist (Domain11 AB5 RHH) based on human IGF2R domain 11","MKSNEHDDCQVTNPSTGHLFDLSSLSGRAGFTAAYAKGWGVYMSICGENENCPPGVGACFGRTRISVGKANKRLRYVDQVLQLVYKDGSHCPSKHGLSYKSVISFVCRPEAGPTNRPMLISLDKQTCTLFFSWHTPLACELA","Homo sapiens","IGF2R, MPRI","Cation-independent mannose-6-phosphate receptor","1","5IEI"
"5IEM",,"SOLUTION NMR",,,,,,,"10.1261/rna.056523.116",,"5IEM",18.27,,,"NMR structure of the 5'-terminal hairpin of the 7SK snRNA","GGGAUCUGUCACCCCAUUGAUCGCCUUCGGGCUGAUCUGGCUGGCUAGGCGGGUCCC","Homo sapiens",,"7SK snRNA","1","5IEM"
"5IES",,"X-RAY DIFFRACTION",4.06,69.73,"VAPOR DIFFUSION, SITTING DROP",5,"0.1 M citric acid (pH 4.0), 20% (w/v) PEG6000 with an overall pH 5.0 of the solution, cryo-protected with 25% glycerol",293.15,"10.1126/science.aad9195",,"5IES",68.04,"2.16","2.16","Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.16 A","QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"VRC01cHuGL2 Fab heavy chain","1","5IES"
,,,,,,,,,,,,,,,,"DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLRSPVTKSFNRGEC","Homo sapiens",,"VRC01cHuGL2 Fab light chain","2","5IES"
,,,,,,,,,,,,,,,,"DTITLPCRPAPPPHCSSNITGLILTRQGGYSNANTVIFRPSGGDWRDIARCQIAGTVVSTQLFLNGSLAEEEVVIRSEDWRDNAKSICVQLATSVEIACTGAGHCAISRAKWANTLKQIASKLREQYGAKTIIFKPSSGGDPEFVNHSFNCGGEFFYCASTQLFASTWFASTGTGTKHHHHHH","Homo sapiens",,"Germline-targeting HIV-1 gp120 engineered outer domain eOD-GT8","3","5IES"
"5IEV",,"X-RAY DIFFRACTION",2.07,40.62,"VAPOR DIFFUSION, HANGING DROP",7.8,"7.25% PEG 4000, 0.2M ammonium acetate, 100mM Hepes pH 7.8",293.15,"10.1021/acschembio.6b00074",,"5IEV",34.41,"2.03","2.03","Crystal structure of BAY 1000394 (Roniciclib) bound to CDK2","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5IEV"
"5IEX",,"X-RAY DIFFRACTION",2.04,39.67,"VAPOR DIFFUSION, HANGING DROP",7.8,"10% PEG 3350, 0.2M ammonium acetate, 100mM HEPES pH 7.8",293.15,"10.1021/acschembio.6b00074",,"5IEX",34.42,"2.03","2.03","Crystal structure of (R,S)-S-{4-[(5-Bromo-4-{[(2R,3R)-2-hydroxy-1-methylpropyl]oxy}- pyrimidin-2-yl)amino]phenyl}-S-cyclopropylsulfoximide bound to CDK2","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5IEX"
"5IEY",,"X-RAY DIFFRACTION",2.02,39.18,"VAPOR DIFFUSION, HANGING DROP",7.8,"7.25% PEG 4000, 0.2 M ammonium acetate, 0.2 M HEPES pH 7.8",293.15,"10.1021/acschembio.6b00074",,"5IEY",34.31,"1.66","1.66","Crystal structure of a CDK inhibitor bound to CDK2","MENFQKVEKIGEGTYGVVYKARNKLTGEVVALKKIRLDTETEGVPSTAIREISLLKELNHPNIVKLLDVIHTENKLYLVFEFLHQDLKKFMDASALTGIPLPLIKSYLFQLLQGLAFCHSHRVLHRDLKPQNLLINTEGAIKLADFGLARAFGVPVRTYTHEVVTLWYRAPEILLGCKYYSTAVDIWSLGCIFAEMVTRRALFPGDSEIDQLFRIFRTLGTPDEVVWPGVTSMPDYKPSFPKWARQDFSKVVPPLDEDGRSLLSQMLHYDPNKRISAKAALAHPFFQDVTKPVPHLRL","Homo sapiens","CDK2, CDKN2","Cyclin-dependent kinase 2","1","5IEY"
"5IEZ",,"X-RAY DIFFRACTION",2.34,47.45,"VAPOR DIFFUSION, HANGING DROP",6.6,"PEG 3350, magnesium chloride, Bis-Tris",292,"10.1002/1873-3468.12497","6AL","5IEZ",74.62,"2.6","2.6","Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design","GADDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGG","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","5IEZ"
"5IF0",,"X-RAY DIFFRACTION",3.97,69.04,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M potassium dihydrogen phosphate, 20% (w/v) PEG3350 and cryo-protected with 25% glycerol",293.15,"10.1126/science.aad9195",,"5IF0",135.62,"2.44","2.44","Crystal structure of VRC01c-HuGL2 Fab from an HIV-1 naive donor in complex with with a germline-targeting gp120 engineered outer domain eOD-GT8 at 2.44 A","QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"VRC01cHuGL2 Fab heavy chain","1","5IF0"
,,,,,,,,,,,,,,,,"DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLRSPVTKSFNRGEC","Homo sapiens",,"VRC01c-HuGL2 Fab light chain","2","5IF0"
,,,,,,,,,,,,,,,,"DTITLPCRPAPPPHCSSNITGLILTRQGGYSNANTVIFRPSGGDWRDIARCQIAGTVVSTQLFLNGSLAEEEVVIRSEDWRDNAKSICVQLATSVEIACTGAGHCAISRAKWANTLKQIASKLREQYGAKTIIFKPSSGGDPEFVNHSFNCGGEFFYCASTQLFASTWFASTGTGTKHHHHHH","Homo sapiens",,"Germline-targeting HIV-1 gp120 engineered outer domain eOD-GT8","3","5IF0"
"5IF4",,"X-RAY DIFFRACTION",2.58,52.32,"VAPOR DIFFUSION, HANGING DROP",7.5,"PEG 3350, Bis-Tris, Magnesium chloride",292,"10.1002/1873-3468.12497","6AK","5IF4",37.5,"2.392","2.392","Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) inhibitors using Structure-Based Design","GADDELYRQSLEIISRYLREQATGAKDTKPMGRSGATSRKALETLRRVGDGVQRNHETAFQGMLRKLDIKNEDDVKSLSRVMIHVFSDGVTNWGRIVTLISFGAFVAKHLKTINQESCIEPLAESITDVLVRTKRDWLVKQRGWDGFVEFFHVEDLEGG","Homo sapiens","MCL1, BCL2L3","Induced myeloid leukemia cell differentiation protein Mcl-1","1","5IF4"
"5IFA",,"X-RAY DIFFRACTION",2.48,49.96,"VAPOR DIFFUSION, SITTING DROP",,"0.2M lithium sulfate and 20% (w/v)
PEG3350, and cryo-protected with 25% glycerol",293,"10.1126/science.aad9195",,"5IFA",49.32,"1.821","1.821","Crystal structure of unbound VRC01c-HuGL2 Fab from an HIV-1 naive donor at 1.82 A","QVQLVQSGAEVKKPGASVKVSCKASGYTFTGYYMHWVRQAPGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSISTAYMELSRLRSDDTAVYYCAKISGSYSFDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSC","Homo sapiens",,"VRC01c-HuGL2 Fab heavy chain","1","5IFA"
,,,,,,,,,,,,,,,,"DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLRSPVTKSFNRGEC","Homo sapiens",,"VRC01c-HuGL2 Fab light chain","2","5IFA"
"5IFH",,"X-RAY DIFFRACTION",2.46,50,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.1 M BisTris pH 5.5, 200 mM MgCl2, 20% PEG 3350",293,"10.1038/ncomms15746",,"5IFH",46.98,"2.293","2.293","Crystal structure of the BCR Fab fragment from subset #2 case P11475","EVQLVESGGGLVKPGGSLRLSCAASGFTFRSYSMNWVRQAPGKGLEWVSSIISSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYCARDQNAMDVWGQGTTVTVSSDSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITFSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPV","Homo sapiens",,"Heavy chain of the Fab fragment from BCR derived from the P11475 CLL clone","1","5IFH"
,,,,,,,,,,,,,,,,"SYELTQPPSVSVAPGKTARITCAGNNIGSKSVHWYQQKPGQAPVLVIYYDSDRPSGIPERFSGSNSGNTATLTISRVEAGDEADYYCQVWDSGSDHPWVFGGGTKLTVLRQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS","Homo sapiens",,"Light chain of the Fab fragment from BCR derived from the P11475 CLL clone","2","5IFH"
"5IFM",,"X-RAY DIFFRACTION",2.58,52.28,"VAPOR DIFFUSION, SITTING DROP",8,"0.1 M HEPES pH 8.0 and 20% w/v PEG 3350",293,"10.1107/S2059798316005830",,"5IFM",363.66,"2.6","2.6","Human NONO (p54nrb) Homodimer","GEGLTIDLKNFRKPGEKTFTQRSRLFVGNLPPDITEEEMRKLFEKYGKAGEVFIHKDKGFGFIRLETRTLAEIAKVELDNMPLRGKQLRVRFACHSASLTVRNLPQYVSNELLEEAFSVFGQVERAVVIVDDRGRPSGKGIVEFSGKPAARKALDRCSEGSFLLTTFPRPVTVEPMDQLDDEEGLPEKLVIKNQQFHKEREQPPRFAQPGSFEYEYAMRWKALIEMEKQQQDQVDRNIKEAREKLEMEMEAARHEHQVMLM","Homo sapiens","NONO, NRB54","Non-POU domain-containing octamer-binding protein","1","5IFM"
"5IFN",,"X-RAY DIFFRACTION",2.23,44.84,"VAPOR DIFFUSION, HANGING DROP",7,"100 mM (D/L) malic acid pH 7.0
28% PEG 3350 
100 mM Tris pH 7.0",293,,,"5IFN",59.89,"3.17","3.17","Human PSPC1 Homodimer","MGFTIDIKSFLKPGEKTYTQRCRLFVGNLPTDITEEDFKRLFERYGEPSEVFINRDRGFGFIRLESRTLAEIAKAELDGTILKSRPLRIRFATHGAALTVKNLSPVVSNELLEQAFSQFGPVEKAVVVVDDRGRATGKGFVEFAAKPPARKALERCGDGAFLLTTTPRPVIVEPMEQFDDEDGLPEKLMQKTQQYHKEREQPPRFAQPGTFEFEYASRWKALDEMEKQQREQVDRNIREAKEKLEAEMEAARHEHQLMLM","Homo sapiens","PSPC1, PSP1","Paraspeckle component 1","1","5IFN"
"5IFO",,"X-RAY DIFFRACTION",2.28,46.14,"VAPOR DIFFUSION, HANGING DROP",7.4,"75-120 mg/ml protein, 50 mM potassium phosphate, 25-30% PEG4000, 150 mM KCl, 5 mM sodium azide",293,"10.1021/acs.jmedchem.6b00600",,"5IFO",68.14,"3.2","3.2","X-ray structure of HSA-Myr-KP1019","DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","5IFO"
"5IG3",,"X-RAY DIFFRACTION",2.18,43.5,"VAPOR DIFFUSION, SITTING DROP",7.3,"35 % (v/v) MPD, 0.1 M HEPES pH 7.3",295,"10.7554/eLife.13405",,"5IG3",105.12,"2.75","2.75","Crystal structure of the human CaMKII-alpha hub","GSSHHHHHHSSGLEVLFQGPHMVRKQEIIKVTEQLIEAISNGDFESYTKMCDPGMTAFEPEALGNLVEGLDFHRFYFENLWSRNSKPVHTTILNPHIHLMGDESACIAYIRITQYLDAGGIPRTAQSEETRVWHRRDGKWQIVHFHRSGAPSV","Homo sapiens","CAMK2A, CAMKA, KIAA0968","Calcium/calmodulin-dependent protein kinase type II subunit alpha","1","5IG3"
"5IG6",,"X-RAY DIFFRACTION",2.22,44.62,"VAPOR DIFFUSION, SITTING DROP",7.5,"30% PEG MME 2000, 50mM Tris-HCl pH 7.5, 50mM NaCl, 20% glycerol",300,"10.1371/journal.pone.0156344","6B3","5IG6",14.17,"0.91","0.91","Ultra-high resolution crystal structure of second bromodomain of BRD2 in complex with inhibitor 6B3","GSHMQDPEQLKHCNGILKELLSKKHAAYAWPFYKPVDASALGLHDYHDIIKHPMDLSTVKRKMENRDYRDAQEFAADVRLMFSNCYKYNPPDHDVVAMARKLQDVFEFRYAKMPA","Homo sapiens","BRD2, KIAA9001, RING3","Bromodomain-containing protein 2","1","5IG6"
"5IGK",,"X-RAY DIFFRACTION",2.24,45.07,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M Na/K(tart), 0.1 M BTProp pH 8.5, 20% PEG3350, 10% EtGly",277,"10.1126/sciadv.1600760","BMF","5IGK",15.57,"1.7","1.7","Crystal structure of the first bromodomain of human BRD4 in complex with bromosporine (BSP)","SMNPPPPETSNPNKPKRQTNQLQYLLRVVLKTLWKHQFAWPFQQPVDAVKLNLPDYYKIIKTPMDMGTIKKRLENNYYWNAQECIQDFNTMFTNCYIYNKPGDDIVLMAEALEKLFLQKINELPTEE","Homo sapiens","BRD4, HUNK1","Bromodomain-containing protein 4","1","5IGK"
"5IGL",,"X-RAY DIFFRACTION",3.22,61.81,"VAPOR DIFFUSION, SITTING DROP",7.5,"63%(v/v) MPD, 0.1M MMT pH 7.5",277,"10.1126/sciadv.1600760","BMF","5IGL",18.43,"2.1","2.1","Crystal structure of the second bromodomain of human TAF1L in complex with bromosporine (BSP)","MHHHHHHSSGVDLGTENLYFQSMQVAFSFILDNIVTQKMMAVPDSWPFHHPVNKKFVPDYYKMIVNPVDLETIRKNISKHKYQSRESFLDDVNLILANSVKYNGPESQYTKTAQEIVNICYQTITEYDEHLTQLEKDICTAKEAALEEAELESLD","Homo sapiens","TAF1L","Transcription initiation factor TFIID subunit 1-like","1","5IGL"
"5IGM",,"X-RAY DIFFRACTION",2.31,46.74,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M bis tris pH 5.5, 0.2 M sodium chloride, 25% PEG3350",277,"10.1126/sciadv.1600760","BMF","5IGM",29.31,"1.6","1.6","Crystal structure of the bromodomain of human BRD9 in complex with bromosporine (BSP)","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5IGM"
"5IGN",,"X-RAY DIFFRACTION",2.1,41.55,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.2 M sodium nitrate, 0.1 M bis tris propane pH 8.5, 20% PEG 3350, 10% ethylene glycol",277,,"6B2","5IGN",29.53,"1.7","1.7","Crystal structure of human BRD9 bromodomain in complex with LP99 chemical probe","SMLKLSAENESTPIQQLLEHFLRQLQRKDPHGFFAFPVTDAIAPGYSMIIKHPMDFGTMKDKIVANEYKSVTEFKADFKLMCDNAMTYNRPDTVYYKLAKKILHAGFKMMSKERLLALKRSMS","Homo sapiens","BRD9, UNQ3040/PRO9856","Bromodomain-containing protein 9","1","5IGN"
"5IH4",,"X-RAY DIFFRACTION",2.79,55.95,"VAPOR DIFFUSION, SITTING DROP",9.5,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES (pH 9.5)",277.15,"10.1016/j.chembiol.2016.02.015",,"5IH4",34.61,"1.9","1.9","Human Casein Kinase 1 isoform delta apo (kinase domain)","MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","1","5IH4"
"5IH5",,"X-RAY DIFFRACTION",2.71,54.69,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES",277,"10.1016/j.chembiol.2016.02.015","AUE","5IH5",34.9,"2.25","2.25","Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A","MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","1","5IH5"
"5IH6",,"X-RAY DIFFRACTION",2.79,55.99,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Li2SO4, 0.7 - 0.8 M Na-K tartrate, 0.1 M CHES",277,"10.1016/j.chembiol.2016.02.015","AUG","5IH6",34.95,"2.3","2.3","Human Casein Kinase 1 isoform delta (kinase domain) in complex with Epiblastin A derivative","MELRVGNRYRLGRKIGSGSFGDIYLGTDIAAGEEVAIKLECVKTKHPQLHIESKIYKMMQGGVGIPTIRWCGAEGDYNVMVMELLGPSLEDLFNFCSRKFSLKTVLLLADQMISRIEYIHSKNFIHRDVKPDNFLMGLGKKGNLVYIIDFGLAKKYRDARTHQHIPYRENKNLTGTARYASINTHLGIEQSRRDDLESLGYVLMYFNLGSLPWQGLKAATKRQKYERISEKKMSTPIEVLCKGYPSEFATYLNFCRSLRFDDKPDYSYLRQLFRNLFHRQGFSYDYVFDWNMLK","Homo sapiens","CSNK1D, HCKID","Casein kinase I isoform delta","1","5IH6"
"5IH8",,"X-RAY DIFFRACTION",2.53,51.37,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes pH 7.5, 0.2M sodium chloride, 25% PEG 3350",293,"10.1021/acs.jmedchem.6b00052","6BJ","5IH8",39.31,"1.85","1.85","MELK in complex with NVS-MELK1","MDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5IH8"
"5IH9",,"X-RAY DIFFRACTION",2.86,56.94,"VAPOR DIFFUSION, SITTING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277,"10.1021/acs.jmedchem.6b00052","6BF","5IH9",39.39,"1.79","1.79","MELK in complex with NVS-MELK8A","MDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5IH9"
"5IHA",,"X-RAY DIFFRACTION",2.6,52.62,"VAPOR DIFFUSION, HANGING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277,"10.1021/acs.jmedchem.6b00052","6BE","5IHA",39.35,"1.96","1.96","MELK in complex with NVS-MELK8F","MDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5IHA"
"5IHB",,"X-RAY DIFFRACTION",3.03,59.34,"VAPOR DIFFUSION, SITTING DROP",8.5,"2% PEG 20,000, 4% PEG MME 500, 100 mM Bicine/Tris base pH 8.5, 1xMorpheus amino acids",295.15,,,"5IHB",102.86,"2.24","2.24","Structure of the immune receptor CD33","ETGFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISGDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTGTKHHHHHH","Homo sapiens","CD33, SIGLEC3","Myeloid cell surface antigen CD33","1","5IHB"
"5IHC",,"X-RAY DIFFRACTION",2.59,52.56,"VAPOR DIFFUSION, HANGING DROP",,"100mM Hepes, pH 7.6, 0.2M NaCl, 4.5-16.5% PEG3350",277,"10.1021/acs.jmedchem.6b00052","6BB","5IHC",39.31,"2.14","2.14","MELK in complex with NVS-MELK12B","MDYDELLKYYELHETIGTGGFAKVKLACHILTGEMVAIKIMDKNTLGSDLPRIKTEIEALKNLRHQHICQLYHVLETANKIFMVLEYCPGGELFDYIISQDRLSEEETRVVFRQIVSAVAYVHSQGYAHRDLKPENLLFDEYHKLKLIDFGLCAKPKGNKDYHLQTCCGSLAYAAPELIQGKSYLGSEADVWSMGILLYVLMCGFLPFDDDNVMALYKKIMRGKYDVPKWLSPSSILLLQQMLQVDPKKRISMKNLLNHPWIMQDYNYPVEWQSKNPFIHLDDDCVTELSVHHRNNRQTMEDLISLWQYDHLTATYLLLLAKKARGKPVHHHHHH","Homo sapiens","MELK, KIAA0175","Maternal embryonic leucine zipper kinase","1","5IHC"
"5IHH",,"X-RAY DIFFRACTION",2.13,42.38,"VAPOR DIFFUSION, HANGING DROP",,"Purified TTRwt was dialyzed against 10 mM sodiumphosphate buffer with 100 mM KCl pH 7.6 and concentrated to 5 mg per ml. 7MeOLut was added at 5 x molar excess to the protein. The reservoir contained 1.3 to 1.6 M sodium citrate and 3.5 percent glycerol at pH 5.5. Drop size 3 plus 3 microliter",291,"10.1371/journal.pone.0153112","6B5","5IHH",28.18,"1.35","1.35","Crystal structure of human transthyretin in complex with luteolin-MeO at 1.35 A resolution","GPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE","Homo sapiens","TTR, PALB","Transthyretin","1","5IHH"
"5IHZ",,"X-RAY DIFFRACTION",2.72,54.75,"VAPOR DIFFUSION, SITTING DROP",,"20 %w/v Polyethylene Glycol 3350, 0.200 M Potassium Sulphate",293,"10.1172/jci.insight.93961",,"5IHZ",187.07,"1.64","1.64","Crystal structure of anti-gliadin 1002-1E01 Fab fragment","EVQLLESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVRQAPGKGLEWVSGISGSGGSTYYADSVKGRFTTSRDNSKNTLYLQMNSLRAEDTAVYYCAKFSGKDCSGTSCRDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"1E01 Fab fragment heavy chain","1","5IHZ"
,,,,,,,,,,,,,,,,"QLVLTQSPSASASLGASVRLTCTLSSGHSSYVIAWHQQQSEKGPRYLMKVNSDGSHSKGDGIPDRFSGSSSGAERYLTISSLQSEDEADYYCQTWGAGILVFGGGTKLTVLSQPKAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEC","Homo sapiens",,"1E01 Fab fragment light chain","2","5IHZ"
"5II1",,"X-RAY DIFFRACTION",2.16,42.95,"VAPOR DIFFUSION, SITTING DROP",8.1,"18% PEG_3350
0.15M Na_malonate_pH7.0
10v/v ethylene_glycol
0.1M bis_tris_propane pH 8.1",277,"10.1021/acs.jmedchem.6b00355",,"5II1",29.7,"2.02","2.02","Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 1-methylisochromeno[3,4-c]pyrazol-5(3H)-one","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5II1"
"5II2",,"X-RAY DIFFRACTION",2.87,57.08,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.20M K3(cit)
0.1M BTProp pH 7.5
20.0% PEG 3350
10.0% EtGly",277,"10.1021/acs.jmedchem.6b00355","LU2","5II2",30.14,"2.1","2.1","Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5II2"
"5IID",,"X-RAY DIFFRACTION",2.79,55.85,"VAPOR DIFFUSION, SITTING DROP",8.5,"0.20M Na2SO4
0.1M BTProp pH 8.5
20.0% PEG 3350
10.0% EtGly",277,"10.1021/acs.jmedchem.6b00355",,"5IID",29.84,"2.4","2.4","Crystal Structure of the fifth bromodomain of human polybromo (PB1) in complex with 2-(3,4-dihydroxyphenyl)-5-hydroxy-4H-chromen-4-one","SMSGISPKKSKYMTPMQQKLNEVYEAVKNYTDKRGRRLSAIFLRLPSRSELPDYYLTIKKPMDMEKIRSHMMANKYQDIDSMVEDFVMMFNNACTYNEPESLIYKDALVLHKVLLETRRDLEGD","Homo sapiens","PBRM1, BAF180, PB1","Protein polybromo-1","1","5IID"
"5IIE",,"X-RAY DIFFRACTION",2.3,46.7,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.1 M HEPES pH 6.5, 20% PEG 6,000",293,"10.1016/j.celrep.2017.02.003",,"5IIE",95,"2.8","2.8","STRUCTURE OF THE UNLIGANDED ANTI-HIV ANTIBODY DH501 THAT BINDS GP120 V3 GLYCAN AND THE BASE OF V3","QVTLKEFGPALVKPTQPLTLTCSFSGFSLRSSDTAVVWIRQPPGKALEWLAAIYWDDVEHINPSLKSRLSISKDSPNSLVVLTMANMDPVDTATYYCGRVRFVSGGYYTDRIDSWGPGLLVTVSSASTKGPSVFPLAPSSRSTSESTAALGCLVKDYFPEPVTVSWNSGSLTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYVCNVNHKPSNTKVDKRVEIKTCGG","Homo sapiens",,"antibody DH501 FabH chain","1","5IIE"
,,,,,,,,,,,,,,,,"QSVLTQPPSVSGAPGQRVTISCAGTKSNIGDCSVSWYQQLPGATPRLLIYQNNNRPSGVSDRFSGSKSGTSASLAITGLQTEDEADYFCLSYDTSFSGWRFGGGTRLTVLGQPKASPTVTLFPPSSEELQANKATLVCLISDFYPGVVKVAWKADGSAVNAGVETTTPSKQSNNKYAASSYLSLTSDQWKSHKSYSCQVTHEGSTVEKTVAPAECS","Homo sapiens",,"antibody DH501 light chain","2","5IIE"
"5IIS",,"X-RAY DIFFRACTION",3.47,64.56,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.5-1.0 mM (NH4)2HPO4; 0.1 M Sodium citrate pH 5.5; 250 mM Sodium chloride",298,"10.1016/j.bmcl.2016.03.037","6CB","5IIS",32.53,"2.1","2.1","Design, synthesis and structure activity relationship of potent pan-PIM kinase inhibitors derived from the pyridyl-amide scaffold","EPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLHSLS","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5IIS"
"5IIW",,"X-RAY DIFFRACTION",2.43,49.43,"VAPOR DIFFUSION, HANGING DROP",5,"reservoir contained 13% PEG 6000, 0.2M Sodium Citrate",298,"10.1073/pnas.1705091114",,"5IIW",9.74,"2","2","Corkscrew assembly of SOD1 residues 28-38 without potassium iodide","KVKVWGSIKGL","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn]","1","5IIW"
"5IJF",,"X-RAY DIFFRACTION",2.51,51.05,"VAPOR DIFFUSION, SITTING DROP",9,"0.2 ul of 90 mg/ml protein in 20 mM K2HPO4 pH 7.5 buffer was mixed with 0.2 ul of the well condition (0.1 M MMT Buffer pH 9.0, 23 % PEG 1500, 1 mM ZnCl2) and equilibrated against well solution in 96 Well 3 drop Crystallization Plate (Swissci)",289,"10.1039/c6sc02267g",,"5IJF",66.64,"2.65","2.65","Crystal structure of Human Serum Albumin in the presence of 0.5 mM zinc at pH 9.0","DAHKSEVAHRFKDLGEENFKALVLIAFAQYLQQCPFEDHVKLVNEVTEFAKTCVADESAENCDKSLHTLFGDKLCTVATLRETYGEMADCCAKQEPERNECFLQHKDDNPNLPRLVRPEVDVMCTAFHDNEETFLKKYLYEIARRHPYFYAPELLFFAKRYKAAFTECCQAADKAACLLPKLDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSKLVTDLTKVHTECCHGDLLECADDRADLAKYICENQDSISSKLKECCEKPLLEKSHCIAEVENDEMPADLPSLAADFVESKDVCKNYAEAKDVFLGMFLYEYARRHPDYSVVLLLRLAKTYETTLEKCCAAADPHECYAKVFDEFKPLVEEPQNLIKQNCELFEQLGEYKFQNALLVRYTKKVPQVSTPTLVEVSRNLGKVGSKCCKHPEAKRMPCAEDYLSVVLNQLCVLHEKTPVSDRVTKCCTESLVNRRPCFSALEVDETYVPKEFNAETFTFHADICTLSEKERQIKKQTALVELVKHKPKATKEQLKAVMDDFAAFVEKCCKADDKETCFAEEGKKLVAASQAALGL","Homo sapiens","ALB, GIG20, GIG42, PRO0903, PRO1708, PRO2044, PRO2619, PRO2675, UNQ696/PRO1341","Serum albumin","1","5IJF"
"5IJH",,"X-RAY DIFFRACTION",2.56,51.86,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.4M AmSO4, 0.1M Tris, 16% glycerol",298,"10.1126/science.aad9858",,"5IJH",50.91,"2.43","2.43","Structure of the SPX domain of the human phosphate transporter XPR1 in complex with a sulfate ion","MKFAEHLSAHITPEWRKQYIQYEAFKDMLYSAQDQAPSVEVTDEDTVKRYFAKFEEKFFQTCEKELAKINTFYSEKLAEAQRRFATLQNELQSSLDAQKESTGVTTLRQRRKPVFHLSHEERVQHRNIKDLKLAFSEFYLSLILLQNYQNLNFTGFRKILKKHDKILETSRGADWRVAHVEVAPFYTCKKINQLISETEAVVTNELEHHHHHH","Homo sapiens","XPR1, SYG1, XR","Xenotropic and polytropic retrovirus receptor 1","1","5IJH"
"5IJR",,"X-RAY DIFFRACTION",2.05,39.96,"VAPOR DIFFUSION, HANGING DROP",7.9,"28% w/v PEG3350, 0.2 M AmCl",293,"10.1111/febs.14405",,"5IJR",35.71,"1.52","1.52","X-ray structure of neuropilin-1 b1 domain complexed with Arg-1 ligand.","MFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5IJR"
"5IJT",,"X-RAY DIFFRACTION",2.63,58.09,"VAPOR DIFFUSION, SITTING DROP",,"6.1% PEG 3350, 0.1 M sodium acetate pH 4.1, 0.2 M zinc acetate",298,"10.1074/jbc.RA117.001690",,"5IJT",219.45,"2.148","2.148","Human Peroxiredoxin 2 Oxidized (SS)","MASGNARIGKPAPDFKATAVVDGAFKEVKLSDYKGKYVVLFFYPLDFTFVCPTEIIAFSNRAEDFRKLGCEVLGVSVDSQFTHLAWINTPRKEGGLGPLNIPLLADVTRRLSEDYGVLKTDEGIAYRGLFIIDGKGVLRQITVNDLPVGRSVDEALRLVQAFQYTDEHGEVCPAGWKPGSDTIKPNVDDSKEYFSKHN","Homo sapiens","PRDX2, NKEFB, TDPX1","Peroxiredoxin-2","1","5IJT"
"5IK3",,"X-RAY DIFFRACTION",2.41,48.98,"VAPOR DIFFUSION, SITTING DROP",,"0.2M Ammonium sulfate, 30% PEK 8000",293,"10.1172/jci.insight.93961",,"5IK3",97.41,"1.65","1.65","Crystal structure of anti-gliadin 1002-1E03 Fab fragment","EVQLVESGGGLVKPGGSLRLSCAASGFTFSNAWFNWVRQAPGKGLEWVGRIKTNTDGGTTDYAAPVKGRFTISRDDSKNTLYLQMNSLKTEDTAVYYCTTGEPLVNHITILDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"1E03 Fab fragment heavy chain","1","5IK3"
,,,,,,,,,,,,,,,,"DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYRTPPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"1E03 Fab fragment light chain","2","5IK3"
"5IKO",,"X-RAY DIFFRACTION",2.69,54.31,"VAPOR DIFFUSION, HANGING DROP",7.5,"28 % (v/v) PEG 400, 0.2 M calcium chloride, and 0.1 M HEPES, pH 7.5",290,"10.1074/jbc.M116.738898",,"5IKO",98.11,"2.5","2.5","Crystal structure of human brain glycogen phosphorylase","GSHMAKPLTDSEKRKQISVRGLAGLGDVAEVRKSFNRHLHFTLVKDRNVATPRDYFFALAHTVRDHLVGRWIRTQQHYYERDPKRIYYLSLEFYMGRTLQNTMVNLGLQNACDEAIYQLGLDLEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKIVNGWQVEEADDWLRYGNPWEKARPEYMLPVHFYGRVEHTPDGVKWLDTQVVLAMPYDTPVPGYKNNTVNTMRLWSAKAPNDFKLQDFNVGDYIEAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTCFETFPDKVAIQLNDTHPALSIPELMRILVDVEKVDWDKAWEITKKTCAYTNHTVLPEALERWPVSMFEKLLPRHLEIIYAINQRHLDHVAALFPGDVDRLRRMSVIEEGDCKRINMAHLCVIGSHAVNGVARIHSEIVKQSVFKDFYELEPEKFQNKTNGITPRRWLLLCNPGLADTIVEKIGEEFLTDLSQLKKLLPLVSDEVFIRDVAKVKQENKLKFSAFLEKEYKVKINPSSMFDVHVKRIHEYKRQLLNCLHVVTLYNRIKRDPAKAFVPRTVMIGGKAAPGYHMAKLIIKLVTSIGDVVNHDPVVGDRLKVIFLENYRVSLAEKVIPAADLSQQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGAENLFIFGLRVEDVEALDRKGYNAREYYDHLPELKQAVDQISSGFFSPKEPDCFKDIVNMLMHHDRFKVFADYEAYMQCQAQVDQLYRNPKEWTKKVIRNIACSGKFSSDRTITEYAREIWGVEPSDLQIPPPNIPRD","Homo sapiens","PYGB","Glycogen phosphorylase, brain form","1","5IKO"
"5IKP",,"X-RAY DIFFRACTION",2.71,54.63,"VAPOR DIFFUSION, HANGING DROP",7.5,"28 % (v/v) PEG 400, 0.2 M calcium chloride, and 0.1 M HEPES, pH 7.5",290,"10.1074/jbc.M116.738898",,"5IKP",97.7,"3.4","3.4","Crystal structure of human brain glycogen phosphorylase bound to AMP","GSHMAKPLTDSEKRKQISVRGLAGLGDVAEVRKSFNRHLHFTLVKDRNVATPRDYFFALAHTVRDHLVGRWIRTQQHYYERDPKRIYYLSLEFYMGRTLQNTMVNLGLQNACDEAIYQLGLDLEELEEIEEDAGLGNGGLGRLAACFLDSMATLGLAAYGYGIRYEFGIFNQKIVNGWQVEEADDWLRYGNPWEKARPEYMLPVHFYGRVEHTPDGVKWLDTQVVLAMPYDTPVPGYKNNTVNTMRLWSAKAPNDFKLQDFNVGDYIEAVLDRNLAENISRVLYPNDNFFEGKELRLKQEYFVVAATLQDIIRRFKSSKFGCRDPVRTCFETFPDKVAIQLNDTHPALSIPELMRILVDVEKVDWDKAWEITKKTCAYTNHTVLPEALERWPVSMFEKLLPRHLEIIYAINQRHLDHVAALFPGDVDRLRRMSVIEEGDCKRINMAHLCVIGSHAVNGVARIHSEIVKQSVFKDFYELEPEKFQNKTNGITPRRWLLLCNPGLADTIVEKIGEEFLTDLSQLKKLLPLVSDEVFIRDVAKVKQENKLKFSAFLEKEYKVKINPSSMFDVHVKRIHEYKRQLLNCLHVVTLYNRIKRDPAKAFVPRTVMIGGKAAPGYHMAKLIIKLVTSIGDVVNHDPVVGDRLKVIFLENYRVSLAEKVIPAADLSQQISTAGTEASGTGNMKFMLNGALTIGTMDGANVEMAEEAGAENLFIFGLRVEDVEALDRKGYNAREYYDHLPELKQAVDQISSGFFSPKEPDCFKDIVNMLMHHDRFKVFADYEAYMQCQAQVDQLYRNPKEWTKKVIRNIACSGKFSSDRTITEYAREIWGVEPSDLQIPPPNIPRD","Homo sapiens","PYGB","Glycogen phosphorylase, brain form","1","5IKP"
"5IKQ",,"X-RAY DIFFRACTION",2.76,55.4,"VAPOR DIFFUSION, SITTING DROP",7.5,"34% PAA 5100, 100mM HEPES, 20mM MgCl2",298,"10.1074/jbc.M116.725713","JMS","5IKQ",131.57,"2.41","2.41","The Structure of Meclofenamic Acid Bound to Human Cyclooxygenase-2","NPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5IKQ"
"5IKR",,"X-RAY DIFFRACTION",3.43,64.15,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 400, 100mM HEPES, 300mM Ammonium Phosphate",293,"10.1074/jbc.M116.725713","ID8","5IKR",131.45,"2.342","2.342","The Structure of Mefenamic Acid Bound to Human Cyclooxygenase-2","NPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5IKR"
"5IKT",,"X-RAY DIFFRACTION",3.37,63.5,"VAPOR DIFFUSION, SITTING DROP",7,"32% PEG 400, 100 mM HEPES, 300mM ammonium phosphate",293,"10.1074/jbc.M116.725713",,"5IKT",131.43,"2.451","2.451","The Structure of Tolfenamic Acid Bound to Human Cyclooxygenase-2","NPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5IKT"
"5IKV",,"X-RAY DIFFRACTION",3.36,63.35,"VAPOR DIFFUSION, SITTING DROP",7,"32% PEG 400, 100mM HEPES, 300mM Ammonium phosphate",293,"10.1074/jbc.M116.725713","FLF","5IKV",130.72,"2.508","2.508","The Structure of Flufenamic Acid Bound to Human Cyclooxygenase-2","NPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFLTRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADYGYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGSNMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKYQIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCDVLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQNRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRVAGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEALYGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEVGFQIINTASIQSLICNNVKGCPFTSFSVP","Homo sapiens","PTGS2, COX2","Prostaglandin G/H synthase 2","1","5IKV"
"5IKW",,"X-RAY DIFFRACTION",2.75,55.25,"VAPOR DIFFUSION, SITTING DROP",7,"10% (v/v) Broad MW PEG smear; 3.2 M MgCl2, 100 mM Hepes pH 7.0",291.15,,,"5IKW",35.19,"2.41","2.41","Crystal Structure of BMP-2-inducible kinase in complex with an Indazole inhibitor","SMSVGVRVFAVGRHQVTLEESLAEGGFSTVFLVRTHGGIRCALKRMYVNNMPDLNVCKREITIMKELSGHKNIVGYLDCAVNSISDNVWEVLILMEYCRAGQVVNQMNKKLQTGFTEPEVLQIFCDTCEAVARLHQCKTPIIHRDLKVENILLNDGGNYVLCDFGSATNKFLNPQKDGVNVVEEEIKKYTTLSYRAPEMINLYGGKPITTKADIWALGCLLYKLCFFTLPFGESQVAICDGNFTIPDNSRYSRNIHCLIRFMLEPDPEHRPDIFQVSYFAFKFAAADCPVSNINNSSIPSALPEPMTASE","Homo sapiens","BMP2K, BIKE, HRIHFB2017","BMP-2-inducible protein kinase","1","5IKW"
"5ILS",,"X-RAY DIFFRACTION",2.1,41.46,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 5000 MME, 200 mM (NH4)2SO4, 100 mM MES",293,"10.1093/nar/gkx068",,"5ILS",12,"1.399","1.399","Autoinhibited ETV1","SLQLWQFLVALLDDPSNSHFIAWTGRGMEFKLIEPEEVARRWGIQKNRPAMNYDKLSRSLRYYYEKGIMQKVAGERYVYKFVCDPEALFSMAFPDNQRPLL","Homo sapiens","ETV1, ER81","ETS translocation variant 1","1","5ILS"
"5ILU",,"X-RAY DIFFRACTION",2.24,45.05,"VAPOR DIFFUSION, SITTING DROP",4.3,"1000 mM (NH4)2HPO4, 100 mM C2H3NaO2, pH 4.3",293,"10.1093/nar/gkx068",,"5ILU",11.45,"1.101","1.101","Autoinhibited ETV4","ALQLWQFLVALLDDPTNAHFIAWTGRGMEFKLIEPEEVARLWGIQKNRPAMNYDKLSRSLRYYYEKGIMQKVAGERYVYKFVCEPEALFSLAFPDNQ","Homo sapiens","ETV4, E1AF, PEA3","ETS translocation variant 4","1","5ILU"
"5ILV",,"X-RAY DIFFRACTION",2.28,45.99,"VAPOR DIFFUSION, SITTING DROP",5,"20% PEG 3350, 200 mM (NH4)2SO4, pH 5.0",277,"10.1093/nar/gkx068",,"5ILV",10.88,"1.8","1.8","Uninhibited ETV5","GSLQLWQFLVTLLDDPANAHFIAWTGRGMEFKLIEPEEVARRWGIQKNRPAMNYDKLSRSLRYYYEKGIMQKVAGERYVYKFVCDPDALFSM","Homo sapiens","ETV5, ERM","ETS translocation variant 5","1","5ILV"
"5IM0",,"X-RAY DIFFRACTION",1.83,32.86,"VAPOR DIFFUSION, HANGING DROP",6.5,"PEG 3350, HEPES",293,"10.1155/2016/3286191",,"5IM0",19.66,"1.7","1.7","Crystal structure of the RNA recognition motif of mRNA decay regulator AUF1","MSKNEEMEGKMFIGGLSWDTTKKDLKDYFSKFGEVVDCTLKLDPITGRSRGFGFVLFKESESVDKVMDQKEHKLNGKVIDPKRAKAM","Homo sapiens","HNRNPD, AUF1, HNRPD","Heterogeneous nuclear ribonucleoprotein D0","1","5IM0"
,,,,,,,,,,,,,,,,"MEGKMFIGGLSWDTTKKDLKDYFSKFGEVVDCTLKLDPITGRSRGFGFVLFKESESVDKVMDQKEHKLNGKVIDPKRAKAMA","Homo sapiens","HNRNPD, AUF1, HNRPD","Heterogeneous nuclear ribonucleoprotein D0","2","5IM0"
"5IM8",,"SOLUTION NMR",,,,,,,"10.1111/febs.13795",,"5IM8",7.76,,,"Solution Structure of the Microtubule-Targeting COS Domain of MID1","LKENDHARFLQTAKNITERVSMATASSQVLIPEINLNDTFDTFALDFSREKKLLECLDYLHHHHHH","Homo sapiens","MID1, FXY, RNF59, TRIM18, XPRF","E3 ubiquitin-protein ligase Midline-1","1","5IM8"
"5IME",,"X-RAY DIFFRACTION",2.36,47.79,"VAPOR DIFFUSION, SITTING DROP",7,"crystals were grown at 19  C from 1.0 uL + 1.0 uL vapor diffusion drops containing 10 mg/mL protein, 1 mM ligand, 0.15 M DL-Malic Acid, 20% - 30% PEG 3350, 4% 1,3-Propanediol and 0.1 M Sodium Malonate, pH 7.0, VAPOR DIFFUSION, SITTING DROP, temperature 292K",292,"10.1021/acs.jmedchem.6b00638","6BZ","5IME",67.99,"2.217","2.217","Crystal structure of P21-activated kinase 1 (PAK1) in complex with compound 9","SDEEILEKLRSIVSVGDPKKKYTRFEKIGQGASGTVYTAMDVATGQEVAIKQMNLQQQPKKELIINEILVMRENKNPNIVNYLDSYLVGDELWVVMEYLAGGSLTDVVTETCMDEGQIAAVCRECLQALEFLHSNQVIHRNIKSDNILLGMDGSVKLTDFGFCAQITPEQSKRSEMVGTPYWMAPEVVTRKAYGPKVDIWSLGIMAIEMIEGEPPYLNENPLRALYLIATNGTPELQNPEKLSAIFRDFLNRCLEMDVEKRGSAKELLQHQFLKIAKPLSSLTPLIAAAKEATKNNHGNS","Homo sapiens","PAK1","Serine/threonine-protein kinase PAK 1","1","5IME"
"5IMX",,"X-RAY DIFFRACTION",2.08,40.81,"VAPOR DIFFUSION, SITTING DROP",8.5,"18% PEG 3350, 0.1 M Tris-HCl, PH 8.5",293,"10.1016/j.bmcl.2016.03.017","CZ4","5IMX",37.49,"2.12","2.12","Anaplastic lymphoma kinase (ALK) catalytic domain complexed with novel inhibitor 3-sulfonylpyrazol-4-amino pyrimidine","MAHHHHHHNPNYCFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEKV","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","5IMX"
"5IN3",,"X-RAY DIFFRACTION",2.8,56.06,"VAPOR DIFFUSION, SITTING DROP",,"0.2M ammonium sulfate -- 30%(w/v) PEG 8000",286,"10.1093/hmg/ddw091",,"5IN3",94.99,"1.73","1.73","Crystal structure of glucose-1-phosphate bound nucleotidylated human galactose-1-phosphate uridylyltransferase","MHHHHHHSSGVDLGTENLYFQSMSRSGTDPQQRQQASEADAAAATFRANDHQHIRYNPLQDEWVLVSAHRMKRPWQGQVEPQLLKTVPRHDPLNPLCPGAIRANGEVNPQYDSTFLFDNDFPALQPDAPSPGPSDHPLFQAKSARGVCKVMCFHPWSDVTLPLMSVPEIRAVVDAWASVTEELGAQYPWVQIFENKGAMMGCSNPHPHCQVWASSFLPDIAQREERSQQAYKSQHGEPLLMEYSRQELLRKERLVLTSEHWLVLVPFWATWPYQTLLLPRRHVRRLPELTPAERDDLASIMKKLLTKYDNLFETSFPYSMGWHGAPTGSEAGANWNHWQLHAHYYPPLLRSATVRKFMVGYEMLAQAQRDLTPEQAAERLRALPEVHYHLGQKDRETATIA","Homo sapiens","GALT","Galactose-1-phosphate uridylyltransferase","1","5IN3"
"5IN4",,"X-RAY DIFFRACTION",2.19,43.75,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M potassium fluoride and 20% PEG 3350. The crystals were briefly transferred to a cryoprotectant consisting of 0.2 M potassium fluoride, 20% PEG 3350, and 20% glycerol and flash frozen in liquid nitrogen",293,"10.1021/acschembio.6b00460","6CK","5IN4",173.92,"1.6","1.6","Crystal Structure of GDP-mannose 4,6 dehydratase bound to a GDP-fucose based inhibitor","MHHHHHHENLYFQGRNVALITGITGQDGSYLAEFLLEKGYEVHGIVRRSSSFNTGRIEHLYKNPQAHIEGNMKLHYGDLTDSTCLVKIINEVKPTEIYNLGAQSHVKISFDLAEYTADVDGVGTLRLLDAVKTCGLINSVKFYQASTSELYGKVQEIPQKETTPFYPRSPYGAAKLYAYWIVVNFREAYNLFAVNGILFNHESPRRGANFVTRKISRSVAKIYLGQLECFSLGNLDAKRDWGHAKDYVEAMWLMLQNDEPEDFVIATGEVHSVREFVEKSFLHIGKTIVWEGKNENEVGRCKETGKVHVTVDLKYYRPTEVDFLQGDCTKAKQKLNWKPRVAFDELVREMVHADVELMRTNPNA","Homo sapiens","GMDS","GDP-mannose 4,6 dehydratase","1","5IN4"
"5IN5",,"X-RAY DIFFRACTION",2.19,43.91,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M MES pH5.0, 10% PEG 6000, a final cryoprotectant containing 0.1 M MES pH5.0, 10% PEG6K, 20% glycerol",293,"10.1021/acschembio.6b00460","GFB","5IN5",173.8,"1.9","1.9","Crystal Structure of GDP-mannose 4,6 dehydratase in complex with natural inhibitor GDP-Fucose","MHHHHHHENLYFQGRNVALITGITGQDGSYLAEFLLEKGYEVHGIVRRSSSFNTGRIEHLYKNPQAHIEGNMKLHYGDLTDSTCLVKIINEVKPTEIYNLGAQSHVKISFDLAEYTADVDGVGTLRLLDAVKTCGLINSVKFYQASTSELYGKVQEIPQKETTPFYPRSPYGAAKLYAYWIVVNFREAYNLFAVNGILFNHESPRRGANFVTRKISRSVAKIYLGQLECFSLGNLDAKRDWGHAKDYVEAMWLMLQNDEPEDFVIATGEVHSVREFVEKSFLHIGKTIVWEGKNENEVGRCKETGKVHVTVDLKYYRPTEVDFLQGDCTKAKQKLNWKPRVAFDELVREMVHADVELMRTNPNA","Homo sapiens","GMDS","GDP-mannose 4,6 dehydratase","1","5IN5"
"5IN7",,"X-RAY DIFFRACTION",2.61,52.88,"EVAPORATION",,"crystals were either obtained out of 20mM CAPS pH 10.5, 100 mM NaCl, 5 mM TCEP or 20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT",293,"10.1074/jbc.M116.726547",,"5IN7",24.25,"2.48","2.48","X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN","LSNEKKAKKVRFYRNGDRYFKGIVYAVSSDRFRSFDALLADLTRSLSDNINLPQGVRYIYTIDGSRKIGSMDELEEGESYVCSSDNFFDDVEYTKNVNPNWSVNV","Homo sapiens","DCX, DBCN, LISX","Neuronal migration protein doublecortin","1","5IN7"
"5IO1",,"X-RAY DIFFRACTION",2.42,49.11,"EVAPORATION",6.5,"20-30% PEG8000, 0.2M NACL, 0.1M
 MES, PH 6.5, EVAPORATION, TEMPERATURE 298K",293,"10.1074/jbc.M116.727826",,"5IO1",90.46,"3.34","3.34","CRYSTAL STRUCTURE OF RECOMBINANT HUMAN Z ALPHA-1-ANTITRYPSIN","RSHHHHHHGDAAQKTDTSHHDQDHPTFNKITPNLAEFAFSLYRQLAHQSNSTNIFFSPVSIATAFAMLSLGTKADTHDEILEGLNFNLTEIPEAQIHEGFQELLRTLNQPDSQLQLTTGNGLFLSEGLKLVDKFLEDVKKLYHSEAFTVNFGDTEEAKKQINDYVEKGTQGKIVDLVKELDRDTVFALVNYIFFKGKWERPFEVKDTEEEDFHVDQVTTVKVPMMKRLGMFNIQHCKKLSSWVLLMKYLGNATAIFFLPDEGKLQHLENELTHDIITKFLENEDRRSASLHLPKLSITGTYDLKSVLGQLGITKVFSNGADLSGVTEEAPLKLSKAVHKAVLTIDKKGCEAAGAMFLEAIPRSIPPEVKFNKPFVFLMIEQNTKSPLFMGKVVNPTQK","Homo sapiens","SERPINA1, AAT, PI, PRO0684, PRO2209","Alpha-1-antitrypsin","1","5IO1"
"5IO9",,"X-RAY DIFFRACTION",2.09,41.1,"VAPOR DIFFUSION",,"crystals were either obtained out of 20mM CAPS pH 10.5, 100 mM NaCl, 5 mM TCEP or 20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT",293,"10.1074/jbc.M116.726547",,"5IO9",24.41,"1.3","1.3","X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN","LVPRGSHMAKKVRFYRNGDRYFKGIVYAVSSDRFRSFDALLADLTRSLSDNINLPQGVRYIYTIDGSRKIGSMDELEEGESYVCSSDNFFDDVEYTKNVNPNWSVN","Homo sapiens","DCX, DBCN, LISX","Neuronal migration protein doublecortin","1","5IO9"
"5IOI",,"X-RAY DIFFRACTION",3.87,68.19,"VAPOR DIFFUSION",,"N-DCXDD crystals were either obtained out of 20mM CAPS pH 10.5, 100 mM NaCl, 5 mM TCEP or 20 mM HEPES pH 7.5, 100 mM NaCl, 5 mM DTT",293,"10.1074/jbc.M116.726547",,"5IOI",73.82,"2.4","2.4","X-RAY STRUCTURE OF THE N-TERMINAL DOMAIN OF HUMAN DOUBLECORTIN","LVPRGSHMAKKVRFYRNGDRYFKGIVYAVSSDRFRSFDALLADLTRSLSDNINLPQGVRYIYTIDGSRKIGSMDELEEGESYVCSSDNFFDDVEYTKNVNPNWSVNV","Homo sapiens","DCX, DBCN, LISX","Neuronal migration protein doublecortin","1","5IOI"
"5ION",,"SOLUTION NMR",,,,,,,"10.1016/j.bbrc.2016.03.034",,"5ION",3.3,,,"Solution Structure of Miz-1 Zinc Finger 13","HILYACDSCGDKFLDANSLAQHVRIHTAQ","Homo sapiens","ZBTB17, MIZ1, ZNF151, ZNF60","Zinc finger and BTB domain-containing protein 17","1","5ION"
"5IP5",,"X-RAY DIFFRACTION",3.07,59.99,"MICROBATCH",6.5,"1.5 M sodium potassium tartrate, 3.5 M ammonium sulfate, 0.1 M Na-Cacodylate",295,,,"5IP5",20.3,"1.66","1.66","Human DJ-1 complexed with Na-K-tartrate","MASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQCSRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFGSKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD","Homo sapiens","PARK7","Protein deglycase DJ-1","1","5IP5"
"5IPB",,"X-RAY DIFFRACTION",2.21,44.38,"VAPOR DIFFUSION",6.7,"100 mM MES, 33% PEG 8000",293,"10.1021/acs.biochem.7b00148",,"5IPB",28.22,"1.55","1.55","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5IPB"
"5IPC",,"X-RAY DIFFRACTION",2.05,40.03,"VAPOR DIFFUSION",6.5,"100 mM MES, 37% PEG 8000",293,"10.1021/acs.biochem.7b00148","6CE","5IPC",28.89,"1.3","1.3","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) H112N mutant nucleoside thiophosphoramidate substrate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVNLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5IPC"
"5IPD",,"X-RAY DIFFRACTION",2.07,40.47,"VAPOR DIFFUSION",6.4,"100 mM MES, 34% PEG 8000",293,"10.1021/acs.biochem.7b00148",,"5IPD",28.57,"1.75","1.75","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) nucleoside thiophosphoramidate covalent intermediate complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5IPD"
"5IPE",,"X-RAY DIFFRACTION",2.05,39.97,"VAPOR DIFFUSION",6.1,"100 mM MES, 39% PEG 8000",293,"10.1021/acs.biochem.7b00148",,"5IPE",28.73,"1.45","1.45","Human Histidine Triad Nucleotide Binding Protein 1 (hHint1) nucleoside thiophosphoramidate catalytic product complex","SNAMADEIAKAQVARPGGDTIFGKIIRKEIPAKIIFEDDRCLAFHDISPQAPTHFLVIPKKHISQISVAEDDDESLLGHLMIVGKKCAADLGLNKGYRMVVNEGSDGGQSVYHVHLHVLGGRQMHWPPG","Homo sapiens","HINT1, HINT, PKCI1, PRKCNH1","Histidine triad nucleotide-binding protein 1","1","5IPE"
"5IPJ",,"X-RAY DIFFRACTION",3.34,63.19,"VAPOR DIFFUSION, HANGING DROP",8,"1.0M LiCl, 0.1M TRIS pH8.0, 20% PEG6K",277,"10.1021/acs.jmedchem.6b00610","6CD","5IPJ",33.71,"2.1","2.1","Crystal structure of human Pim-1 kinase in complex with a quinazolinone-pyrrolopyrrolone inhibitor.","MAHHHHHHDEVDGPLESQYQVGPLLGSGGFGSVYSGIRVSDNLPVAIKHVEKDRISDWGELPNGTRVPMEVVLLKKVSSGFSGVIRLLDWFERPDSFVLILERPEPVQDLFDFITERGALQEELARSFFWQVLEAVRHCHNCGVLHRDIKDENILIDLNRGELKLIDFGSGALLKDTVYTDFDGTRVYSPPEWIRYHRYHGRSAAVWSLGILLYDMVCGDIPFEHDEEIIRGQVFFRQRVSSECQHLIRWCLALRPSDRPTFEEIQNHPWMQDVLLPQETAEIHLH","Homo sapiens","PIM1","Serine/threonine-protein kinase pim-1","1","5IPJ"
"5IPZ",,"X-RAY DIFFRACTION",2.21,43.9,"VAPOR DIFFUSION, SITTING DROP",6.5,"Crystallization buffer was 0.2 M ammonium sulfate, 0.1 M sodium MES (pH 6.5) and 20% PEG MME 2,000",291,"10.1007/s00249-017-1256-0",,"5IPZ",123.11,"2.1","2.1","Crystal structure of human carbonic anhydrase isozyme IV with 5-(2-amino-1,3-thiazol-4-yl)-2-chlorobenzenesulfonamide","MAESHWCYEVQAESSNYPCLVPVKWGGNCQKDRQSPINIVTTKAKVDKKLGRFFFSGYDKKQTWTVQNNGHSVMMLLENKASISGGGLPAPYQAKQLHLHWSDLPYKGSEHSLDGEHFAMEMHIVHEKEKGTSRNVKEAQDPEDEIAVLAFLVEAGTQVNEGFQPLVEALSNIPKPEMSTTMAESSLLDLLPKEEKLRHYFRYLGSLTTPTCDEKVVWTVFREPIQLHREQILAFSQKLYYDKEQTVSMKDNVRPLQQLGQRTVIKS","Homo sapiens","CA4","Carbonic anhydrase 4","1","5IPZ"
"5IQP",,"X-RAY DIFFRACTION",2.3,46.9,"VAPOR DIFFUSION, HANGING DROP",6.4,"24% PEG4K, 140 mM LI2SO4, 4 % of 
SATURATED NACL IN 80 mM MES AT pH 6.4; PROTEIN 7 mg/ml",291,"10.1038/376188a0",,"5IQP",55.78,"2.602","2.602","14-3-3 PROTEIN TAU ISOFORM","MEKTELIQKAKLAEQAERYDDMATCMKAVTEQGAELSNEERNLLSVAYKNVVGGRRSAWRVISSIEQKTDTSDKKLQLIKDYREKVESELRSICTTVLELLDKYLIANATNPESKVFYLKMKGDYFRYLAEVACGDDRKQTIDNSQGAYQEAFDISKKEMQPTHPIRLGLALNFSVFYYEILNNPELACTLAKTAFDEAIAELDTLNEDSYKDSTLIMQLLRDNLTLWTSDSAGEECDAAEGAEN","Homo sapiens","YWHAQ","14-3-3 protein theta","1","5IQP"
"5IQQ",,"X-RAY DIFFRACTION",2.7,54.51,"EVAPORATION",7.5,"0.1 M Hepes pH 7.5, 150 mM KCl, 1.4 M tri-sodium citrate",292,"10.1107/S2053230X16006129",,"5IQQ",50.58,"2.52","2.52","Crystal structure of the human RBM7 RRM domain","MGAAAAEADRTLFVGNLETKVTEELLFELFHQAGPVIKVKIPKDKDGKPKQFAFVNFKHEVSVPYAMNLLNGIKLYGRPIKIQFRSGSSHA","Homo sapiens","RBM7","RNA-binding protein 7","1","5IQQ"
"5IQZ",,"X-RAY DIFFRACTION",2.05,40.1,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M Sodium cacodylate, pH 5.5, 25% w/v PEG 4000",291,"10.1002/prot.25085",,"5IQZ",49.51,"2.334","2.334","Crystal structure of N-terminal domain of Human SIRT7","MKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIKVTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTWDAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEPYFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAEAAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKELAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIPQMSAFWYAVRTAVINAASGRQTVDEALAAAQTNAAHMGLSRSERKAAERVRRLREEQQRERLRQVSRILRKAAAERSAEEGRLLAESADLVTELQGRSRRREGLKRLE","Homo sapiens","SIRT7, SIR2L7","SIRT7 protein","1","5IQZ"
"5IR3",,"X-RAY DIFFRACTION",2.43,49.5,"VAPOR DIFFUSION, HANGING DROP",7,"0.1M Sodium cacodylate pH 6.5; 1.4M Sodium acetate",291,"10.1111/febs.14265",,"5IR3",11.99,"1.7","1.7","Crystal structure of the recombinant highest fibrillogenic natural mutant (obtained from patient AR) derived from lambda 6 light chain variable domain","DFMLTQPHSVSESPGKTVTFSCTGSGGSIADSFVQWYQQRPGSAPTTVIYDDNQRPSGVPDRFSGSIDDSANSASLTISGLKTEDEADYYCQSYNSNHHVVFGGGTKVTVLG","Homo sapiens","IGLV6-57","Ig lambda chain V-VI region AR","1","5IR3"
"5IRQ",,"X-RAY DIFFRACTION",2.6,52.77,"VAPOR DIFFUSION, HANGING DROP",,"175 mM Tris-HCl, pH 8.0, 30% w/v PEG3350, 200 mM lithium sulfate, 12% glycerol",293,"10.1124/dmd.117.075317","6D7, 7D6","5IRQ",226.66,"2.202","2.202","Human cytochrome P450 17A1 bound to inhibitors (R)- and (S)- orteronel","MAKKTGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGSTHHHH","Homo sapiens","CYP17A1, CYP17, S17AH","Steroid 17-alpha-hydroxylase/17,20 lyase","1","5IRQ"
"5IRS",,"X-RAY DIFFRACTION",2.32,46.94,"VAPOR DIFFUSION, SITTING DROP",,"PEG4000, Sodium acetate",293,"10.1016/j.str.2016.05.018",,"5IRS",16.92,"1.796","1.796","crystal structure of the proteasomal Rpn13 PRU-domain","TTSGALFPSLVPGSRGASNKYLVEFRAGKMSLKGTTVTPDKRKGLVYIQQTDDSLIHFCWKDRTSGNVEDDLIIFPDDCEFKRVPQCPSGRVYVLKFKAGSKRLFFWMQEPKTDQDEEHCRKVNEYLNNPPMPGALGASGSSGHELSAL","Homo sapiens","ADRM1, GP110","Proteasomal ubiquitin receptor ADRM1","1","5IRS"
"5IRV",,"X-RAY DIFFRACTION",2.65,58.26,"VAPOR DIFFUSION, HANGING DROP",,"100 mM sodium cacodylate trihydrate, pH 6.5, 200 mM ammonium sulfate, 30% w/v PEG8000",298,"10.1124/dmd.117.075317","6D8","5IRV",227.02,"3.098","3.098","Human cytochrome P450 17A1 bound to inhibitor VT-464","MAKKTGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMATFALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQAKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNEKEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGSTHHHH","Homo sapiens","CYP17A1, CYP17, S17AH","Steroid 17-alpha-hydroxylase/17,20 lyase","1","5IRV"
"5IRY",,"X-RAY DIFFRACTION",3.23,61.87,"VAPOR DIFFUSION, HANGING DROP",8.5,"30% (w/v) PEG20000, 0.1M Tris-Bicine pH8.5, 5% (v/v) ethyleneglycol, 0.06M Calcium chloride, 20% (w/v) glycerol (cryoprotectant, added before freezing)",293,"10.1073/pnas.1606272113",,"5IRY",127.25,"3.095","3.095","Crystal structure of human Desmocollin-1 ectodomain","RWAPIPASLMENSLGPFPQHVQQIQSDAAQNYTIFYSISGPGVDKEPFNLFYIEKDTGDIFCTRSIDREKYEQFALYGYATTADGYAPEYPLPLIIKIEDDNDNAPYFEHRVTIFTVPENCRSGTSVGKVTATDLDEPDTLHTRLKYKILQQIPDHPKHFSIHPDTGVITTTTPFLDREKCDTYQLIMEVRDMGGQPFGLFNTGTITISLEDENDNPPSFTETSYVTEVEENRIDVEILRMKVQDQDLPNTPHSKAVYKILQGNENGNFIISTDPNTNEGVLCVVKPLNYEVNRQVILQVGVINEAQFSKAASSQTPTMCTTTVTVKIIDSDEGPECHPPVKVIQSQDGFPAGQELLGYKALDPEISSGEGLRYQKLGDEDNWFEINQHTGDLRTLKVLDRESKFVKNNQYNISVVAVDAVGRSCTGTLVVHLDDYNDHAPQIDKEVTICQNNEDFAVLKPVDPDGPENGPPFQFFLDNSASKNWNIEEKDGKTAILRQRQNLDYNYYSVPIQIKDRHGLVATHMLTVRVCDCSTPSECRMKHHHHHH","Homo sapiens","DSC1, CDHF1","Desmocollin-1","1","5IRY"
"5ISL",,"X-RAY DIFFRACTION",2.21,44.23,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","MMK","5ISL",38.46,"1.694","1.694","Linked KDM5A Jmj Domain Bound to the Inhibitor C49 (2-{[(2-{[(E)-2-(dimethylamino)ethenyl](ethyl)amino}-2-oxoethyl)amino]methyl}pyridine-4-carboxylic acid)","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5ISL"
"5ISM",,"X-RAY DIFFRACTION",3.03,59.38,"VAPOR DIFFUSION, HANGING DROP",8,"20-25% PEG4000, 200 mM sodium acetate, 100 mM Tris, pH 8.0",293,"10.1016/j.bmcl.2016.04.020","6DG","5ISM",173.57,"2","2","Human DPP4 in complex with a novel 5,5,6-tricyclic pyrrolidine inhibitor","TRKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLP","Homo sapiens","DPP4, ADCP2, CD26","Dipeptidyl peptidase 4","1","5ISM"
"5IT2",,"X-RAY DIFFRACTION",2.59,52.45,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.1M Tris, pH=8.5, 20%v/v Ethanol",293,"10.1038/nm.2656",,"5IT2",47.89,"1.7","1.7","Structure of a transglutaminase 2-specific autoantibody 693-10-B06 Fab fragment","EVQLVQSGAEVKKPGESLKISCRGSGYSFTSYWIGWVRQMPGKGLEWMGIIYPADSDTRYSPSFQGQVTISADKSINTAYLQWSSLKASDTAMYYCARLRMIGFDKNAPLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD","Homo sapiens",,"heavy chain","1","5IT2"
,,,,,,,,,,,,,,,,"DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKTPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSYSNLMYSFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"light chain","2","5IT2"
"5IT3",,"X-RAY DIFFRACTION",1.76,29.95,"EVAPORATION",8.5,"0.1 M MgCl2, 0.1 M Tris, 25%(w/v) PEG 3350",293,,,"5IT3",19.92,"1.4","1.4","Swirm domain of human Lsd1","LPHDRMTSQEAACFPDIISGPQQTQKVFLFIRNRTLQLWLDNPKIQLTFEATLQQLEAPYNSDTVLVHRVHSYLERHGLINFGIY","Homo sapiens","KDM1A, AOF2, KDM1, KIAA0601, LSD1","Lysine-specific histone demethylase 1A","1","5IT3"
"5ITA",,"X-RAY DIFFRACTION",2.22,44.5,"VAPOR DIFFUSION, SITTING DROP",,"PEG3350",291.1,,"6DC","5ITA",68.26,"1.95","1.95","Crystal Structure of BRAF Kinase Domain Bound to AZ-VEM","MGSSHHHHHHSSGLVPRGSHMDDWEIPDGQITVGQRIGSGSFGTVYKGKWHGDVAVKMLNVTAPTPQQLQAFKNEVGVLRKTRHVNILLFMGYSTKPQLAIVTQWCEGSSLYHHLHASETKFEMKKLIDIARQTARGMDYLHAKSIIHRDLKSNNIFLHEDNTVKIGDFGLATVKSRWSGSHQFEQLSGSILWMAPEVIRMQDSNPYSFQSDVYAFGIVLYELMTGQLPYSNINNRDQIIEMVGRGSLSPDLSKVRSNCPKRMKRLMAECLKKKRDERPSFPRILAEIEELARELSG","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5ITA"
"5ITB",,"X-RAY DIFFRACTION",2.18,43.58,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG3350, 50 mM zinc acetate",293,"10.1073/pnas.1609449113",,"5ITB",46.89,"2","2","Crystal structure of the anti-RSV F Fab 14N4","VESGGGLIQPGGSLRLSCAVSGFTVSSKYMTWVRQAPGKGLEWVSVIYGGGSTYYADSVVGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCASRLGVRATTGDLDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSC","Homo sapiens",,"anti-RSV F Fab 14N4 Heavy chain","1","5ITB"
,,,,,,,,,,,,,,,,"SDIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNTYSWWTFGQGTKVDIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC","Homo sapiens",,"anti-RSV F Fab 14N4 Light chain","2","5ITB"
"5ITQ",,"X-RAY DIFFRACTION",2.62,53.03,"EVAPORATION",6.5,"0.1M cacodylic acid (pH 7.0), 0.1M NaCl, 0.05 M MgCl2, 24%(w/v) PEG 8000",277,"10.1073/pnas.1604591113",,"5ITQ",32.74,"1.48","1.48","Crystal Structure of Human NEIL1, Free Protein","MPEGPELHLASQFVNEACRALVFGGCVEKSSVSRNPEVPFESSAYRISASARGKELRLILSPLPGAQPQQEPLALVFRFGMSGSFQLVPREELPRHAHLRFYTAPPGPRLALCFVDIRRFGRWDLGGKWQPGRGPCVLQEYQQFRESVLRNLADKAFDRPICEALLDQRFFNGIGNYLRAEILYRLKIPPFEKARSVLEALQQHRPSPELTLSQKIRTKLQNPDLLELCHSVPKEVVQLGGRGYGSESGEEDFAAFRAWLRCYGMPGMSSLQDRHGRTIWFQGDPGPLAP","Homo sapiens","NEIL1","Endonuclease 8-like 1","1","5ITQ"
"5IU2",,"X-RAY DIFFRACTION",2.38,48.3,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH 7, 1.7 m ammonium sulfate, 0.01 M proline. Protein solution (COT:compound 1:1) was mixed with an equal volume (1 uL) of reservoir solution. Equilibration was done over 500 uL reservoir solution.",298,"10.1021/acs.jmedchem.6b00598","6DA","5IU2",76.29,"2.7","2.7","Discovery of imidazoquinolines as a novel class of potent, selective and in vivo efficacious COT kinase inhibitors","GPSGQEVPWLSSVRYGTVEDLLAFANHISNTAKHFYGQRPQESGILLNMVITPQNGRYQIDSDVLLIPWKLTYRNIGSDFIPRGAFGKVYLAQDIKTKKRMACKLIPVDQFKPSDVEIQACFRHENIAELYGAVLWGETVHLFMEAGEGGSVLEKLESCGPMREFEIIWVTKHVLKGLDFLHSKKVIHHDIKPSNIVFMSTKAVLVDFGLSVQMTEDVYFPKDLRGTEIYMSPEVILCRGHSTKADIYSLGATLIHMQTGTPPWVKRYPRSAYPSYLYIIHKQAPPLEDIADDCSPGMRELIEASLERNPNHRPRAADLLKHEALNPPREDQ","Homo sapiens","MAP3K8, COT, ESTF","Mitogen-activated protein kinase kinase kinase 8","1","5IU2"
"5IUG",,"X-RAY DIFFRACTION",2.04,39.81,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG2000 MME, 0.1 M Tris-HCl pH 8.6",277,"10.1021/acs.jmedchem.6b00106","729","5IUG",37.4,"1.93","1.93","Crystal Structure of Anaplastic Lymphoma Kinase (ALK) in complex with 5a","RTSTIMTDYNPNYSFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEK","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","5IUG"
"5IUH",,"X-RAY DIFFRACTION",2.07,40.55,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG 2000 MME, 0.1 M Tris-HCl pH 8.6",277,"10.1021/acs.jmedchem.6b00106","34Y","5IUH",37.39,"2.1","2.1","Crystal Structure of the Anaplastic Lymphoma Kinase (ALK) in complex with 5d","RTSTIMTDYNPNYSFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEK","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","5IUH"
"5IUI",,"X-RAY DIFFRACTION",2.12,42.05,"VAPOR DIFFUSION, SITTING DROP",8.6,"18% PEG 2000 MME, 0.1M Tris-HCl pH 8.6",277,"10.1021/acs.jmedchem.6b00106","45Q","5IUI",37.24,"1.88","1.88","Crystal Structure of Anaplastic Lyphoma Kinase (ALK) in complex with 4","RTSTIMTDYNPNYSFAGKTSSISDLKEVPRKNITLIRGLGHGAFGEVYEGQVSGMPNDPSPLQVAVKTLPEVCSEQDELDFLMEALIISKFNHQNIVRCIGVSLQSLPRFILLELMAGGDLKSFLRETRPRPSQPSSLAMLDLLHVARDIACGCQYLEENHFIHRDIAARNCLLTCPGPGRVAKIGDFGMARDIYRASYYRKGGCAMLPVKWMPPEAFMEGIFTSKTDTWSFGVLLWEIFSLGYMPYPSKSNQEVLEFVTSGGRMDPPKNCPGPVYRIMTQCWQHQPEDRPNFAIILERIEYCTQDPDVINTALPIEYGPLVEEEEK","Homo sapiens","ALK","ALK tyrosine kinase receptor","1","5IUI"
"5IUQ",,"X-RAY DIFFRACTION",2.06,40.17,"VAPOR DIFFUSION, HANGING DROP",7.8,"9 mg/ml Gal3C with a reservoir of 100 mM Tris-HCl pH 7.8, 300 mM NaSCN, 100 mM MgCl2, 32% [w/v] PEG6000, 20 mM 2-Mercaptoethanol) cocrystallised with lactose (10 mM). Lactose displaced by soaking with ligand.",293,,,"5IUQ",16.47,"1.121","1.121","Galectin-3c in complex with Bisamido-thiogalactoside derivative 4","PLIVPYNLPLPGGVVPRMLITILGTVKPNANRIALDFQRGNDVAFHFNPRFNENNRRVIVCNTKLDNNWGREERQSVFPFESGKPFKIQVLVEPDHFKVAVNDAHLLQYNHRVKKLNEISKLGISGDIDLTSASYTMI","Homo sapiens","LGALS3, MAC2","Galectin-3","1","5IUQ"
"5IV3",,"X-RAY DIFFRACTION",2.32,47,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium acetate pH 4.8
200 mM tri-sodium-citrate
15% (w/v) PEG 4000
10% (v/v) glycerol",277.15,"10.1038/nchembio.2151",,"5IV3",55.69,"1.86","1.86","Crystal structure of human soluble adenylyl cyclase in complex with alpha,beta-methyleneadenosine-5'-triphosphate and the allosteric inhibitor LRE1","MNTPKEEFQDWPIVRIAAHLPDLIVYGHFSPERPFMDYFDGVLMFVDISGFTAMTEKFSSAMYMDRGAEQLVEILNYHISAIVEKVLIFGGDILKFAGDALLALWRVERKQLKNIITVVIKCSLEIHGLFETQEWEEGLDIRVKIGLAAGHISMLVFGDETHSHFLVIGQAVDDVRLAQNMAQMNDVILSPNCWQLCDRSMIEIESVPDQRAVKVNFLKPPPNFNFDEFFTKCTTFMHYYPSGEHKNLLRLACTLKPDPELEMSLQKYVMESILKQIDNKQLQGYLSELRPVTIVFVNLMFEDQDKAEEIGPAIQDAYMHITSVLKIFQGQINKVFMFDKGCSFLCVFGFPGEKVPDELTHALECAMDIFDFCSQVHKIQTVSIGVASGIVFCGIVGHTVRHEYTVIGQKVNLAARMMMYYPGIVTCDSVTYNGSNLPAYFFKELPKKVMKGVADSGPLYQYWGRTEKVHHHHHH","Homo sapiens","ADCY10, SAC","Adenylate cyclase type 10","1","5IV3"
"5IV4",,"X-RAY DIFFRACTION",2.3,47,"VAPOR DIFFUSION, HANGING DROP",6.5,"100 mM sodium acetate pH 4.8
200 mM tri-sodium-citrate
15% (w/v) PEG 4000
10% (v/v) glycerol",277.15,"10.1038/nchembio.2151",,"5IV4",55.53,"1.79","1.79","Crystal structure of the human soluble adenylyl cyclase in complex with the allosteric inhibitor LRE1","MNTPKEEFQDWPIVRIAAHLPDLIVYGHFSPERPFMDYFDGVLMFVDISGFTAMTEKFSSAMYMDRGAEQLVEILNYHISAIVEKVLIFGGDILKFAGDALLALWRVERKQLKNIITVVIKCSLEIHGLFETQEWEEGLDIRVKIGLAAGHISMLVFGDETHSHFLVIGQAVDDVRLAQNMAQMNDVILSPNCWQLCDRSMIEIESVPDQRAVKVNFLKPPPNFNFDEFFTKCTTFMHYYPSGEHKNLLRLACTLKPDPELEMSLQKYVMESILKQIDNKQLQGYLSELRPVTIVFVNLMFEDQDKAEEIGPAIQDAYMHITSVLKIFQGQINKVFMFDKGCSFLCVFGFPGEKVPDELTHALECAMDIFDFCSQVHKIQTVSIGVASGIVFCGIVGHTVRHEYTVIGQKVNLAARMMMYYPGIVTCDSVTYNGSNLPAYFFKELPKKVMKGVADSGPLYQYWGRTEKVHHHHHH","Homo sapiens","ADCY10, SAC","Adenylate cyclase type 10","1","5IV4"
"5IVB",,"X-RAY DIFFRACTION",2.23,44.76,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006",,"5IVB",38.51,"1.389","1.389","A High Resolution Structure of a Linked KDM5A Jmj Domain with Alpha-Ketoglutarate","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A,Lysine-specific demethylase 5A","1","5IVB"
,,,,,,,,,,,,,,,,,"Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2"
"5IVC",,"X-RAY DIFFRACTION",2.22,44.53,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6E7","5IVC",38.63,"1.573","1.573","Linked KDM5A Jmj Domain Bound to the Inhibitor N3 (4'-[(2-phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid)","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVC"
"5IVE",,"X-RAY DIFFRACTION",2.24,45.15,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6E8","5IVE",38.22,"1.783","1.783","Linked KDM5A Jmj Domain Bound to the Inhibitor N8 ( 5-methyl-7-oxo-6-(propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile)","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVE"
"5IVF",,"X-RAY DIFFRACTION",2.22,44.71,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6EB","5IVF",38.35,"1.683","1.683","Linked KDM5A Jmj Domain Bound to the Inhibitor N10 8-(1-methyl-1H-imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVF"
"5IVJ",,"X-RAY DIFFRACTION",2.24,45.18,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6ED","5IVJ",38.59,"1.569","1.569","Linked KDM5A Jmj Domain Bound to the Inhibitor N11 [3-({1-[2-(4,4-difluoropiperidin-1-yl)ethyl]-5-fluoro-1H-indazol-3-yl}amino)pyridine-4-carboxylic acid]","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVJ"
"5IVV",,"X-RAY DIFFRACTION",2.22,44.6,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6EN","5IVV",38.27,"1.848","1.848","Linked KDM5A Jmj Domain Bound to the Inhibitor N12 [3-((1-methyl-1H-pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid]","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVV"
"5IVY",,"X-RAY DIFFRACTION",2.25,45.26,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6EO","5IVY",38.29,"1.45","1.45","Linked KDM5A Jmj Domain Bound to the Inhibitor N16 [3-(2-(4-chlorophenyl)acetamido)isonicotinic acid]","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IVY"
"5IW0",,"X-RAY DIFFRACTION",2.24,45.09,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","6EP","5IW0",38.8,"1.63","1.63","Linked KDM5A Jmj Domain Bound to the Inhibitor N19 [2-(5-((4-chloro-2-methylbenzyl)oxy)-1H-pyrazol-1-yl)isonicotinic acid]","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A","1","5IW0"
"5IW3",,"X-RAY DIFFRACTION",2.75,55.21,"VAPOR DIFFUSION, SITTING DROP",,"30% PEG 400, 0.1 M NaAc pH4.6, 0.1M CdSO4",291,,,"5IW3",25.52,"2.05","2.05","anti-CD20 monoclonal antibody Fc fragment","GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5IW3"
"5IW6",,"X-RAY DIFFRACTION",2.92,57.91,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 12000, Na HEPES",291,,,"5IW6",50.11,"2.34","2.34","anti-CD20 monoclonal antibody Fc fragment","GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLS","Homo sapiens","IGHG1","Ig gamma-1 chain C region","1","5IW6"
,,,,,,,,,,,,,,,,"SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSL","Homo sapiens","IGHG1","Ig gamma-1 chain C region","2","5IW6"
"5IWF",,"X-RAY DIFFRACTION",2.23,44.87,"VAPOR DIFFUSION, SITTING DROP",,"1.2-1.35 M (NH4)2SO4,
0.1 M Tris-HCl (pH 8.6-9.2)
0-20% glycerol 
25 mM (Na/K) dibasic/monobasic phosphate",289,"10.1016/j.chembiol.2016.06.006","LQT","5IWF",38.31,"2.289","2.289","Linked KDM5A Jmj Domain Bound to the Inhibitor 2-(((2-((2-(dimethylamino)ethyl)(ethyl)amino)-2-oxoethyl)amino)methyl)isonicotinamid","HNMAGVGPGGYAAEFVPPPECPVFEPSWEEFTDPLSFIGRIRPLAEKTGICKIRPPKDWQPPFACEVKSFRFTPRVQRLNELEAMTRVRPREAFGFEQAVREYTLQSFGEMADNFKSDYFNMPVHMVPTELVEKEFWRLVSSIEEDVIVEYGADISSKDFGSGFPVKDGRRKILPEEEEYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCT","Homo sapiens","KDM5A, JARID1A, RBBP2, RBP2","Lysine-specific demethylase 5A,Lysine-specific demethylase 5A","1","5IWF"
"5IWG",,"X-RAY DIFFRACTION",2.54,51.52,"VAPOR DIFFUSION, SITTING DROP",6.5,"PEG 400, potassium phosphate",293,"10.1016/j.bmc.2016.06.040","IWX","5IWG",129.27,"1.66","1.66","HDAC2 WITH LIGAND BRD4884","GKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLP","Homo sapiens","HDAC2","Histone deacetylase 2","1","5IWG"
"5IX0",,"X-RAY DIFFRACTION",2.51,51.07,"VAPOR DIFFUSION, SITTING DROP",5.5,"PEG 400, potassium phosphate",293,"10.1016/j.bmc.2016.06.040","6EZ","5IX0",131.25,"1.72","1.72","HDAC2 WITH LIGAND BRD7232","GGKKKVCYYYDGDIGNYYYGQGHPMKPHRIRMTHNLLLNYGLYRKMEIYRPHKATAEEMTKYHSDEYIKFLRSIRPDNMSEYSKQMQRFNVGEDCPVFDGLFEFCQLSTGGSVAGAVKLNRQQTDMAVNWAGGLHHAKKSEASGFCYVNDIVLAILELLKYHQRVLYIDIDIHHGDGVEEAFYTTDRVMTVSFHKYGEYFPGTGDLRDIGAGKGKYYAVNFPMRDGIDDESYGQIFKPIISKVMEMYQPSAVVLQCGADSLSGDRLGCFNLTVKGHAKCVEVVKTFNLPLLMLGGGGYTIRNVARCWTYETAVALDCEIPNELPYNDYFEYFGPDFKLHISPSNMTNQNTPEYMEKIKQRLFENLRMLP","Homo sapiens","HDAC2","Histone deacetylase 2","1","5IX0"
"5IXB",,"X-RAY DIFFRACTION",2.06,40.22,"VAPOR DIFFUSION, HANGING DROP",4.5,"100 mM Tris/HCl, pH 8.2, 20% MPD, 8% PEG 8000",291,"10.1038/srep25119",,"5IXB",24.82,"1.39","1.39","Structure of human Melanoma Inhibitory Activity (MIA) Protein in complex with Pyrimidin-2-amine","MGPMPKLADRKLCADQECSHPISMAVALQDYMAPDCRFLTIHRGQVVYVFSKLKGRGRLFWGGSVQGDYYGDLAARLGYFPSSIVREDQTLKPGKVDVKTDKWDFYCQ","Homo sapiens","MIA","Melanoma-derived growth regulatory protein","1","5IXB"
"5IXC",,"X-RAY DIFFRACTION",2.4,48.7,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES (pH 6.0-6.2), 50 mM sodium acetate, and 10-14% (v/v) PEG20K",277,"10.1016/j.jmb.2016.05.012",,"5IXC",184.4,"2.65","2.65","Human GIVD cytosolic phospholipase A2 in complex with Methyl gamma-Linolenyl Fluorophosphonate","GAMGSESLSPGGPPGHPYQGEASTCWQLTVRVLEARNLRWADLLSEADPYVILQLSTAPGMKFKTKTLTDTSHPVWNEAFRFLIQSQVKNVLELSIYDEDSVTEDDICFKVLYDISEVLPGKLLRKTFSQSPQGEEELDVEFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELELVLKGSYEDTQTSFLGTASAFRFHYMAALETELSGRLRSSRSNGWNGDNSAGYLTVPLRPLTIGKEVTMDVPAPNAPGVRLQLKAEGCPEELAVHLGFNLCAEEQAFLSRRKQVVAKALKQALQLDRDLQEDEVPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVTYFSGISGSTWTMAHLYGDPEWSQRDLEGPIRYAREHLAKSKLEVFSPERLASYRRELELRAEQGHPTTFVDLWALVLESMLHGQVMDQKLSGQRAALERGQNPLPLYLSLNVKENNLETLDFKEWVEFSPYEVGFLKYGAFVPPELFGSEFFMGRLMRRIPEPRICFLEAIWSNIFSLNLLDAWYDLTSSGESWKQHIKDKTRSLEKEPLTTSGTSSRLEASWLQPGTALAQAFKGFLTGRPLHQRSPNFLQGLQLHQDYCSHKDFSTWADYQLDSMPSQLTPKEPRLCLVDAAYFINTSSPSMFRPGRRLDLILSFDYSLSAPFEALQQTELYCRARGLPFPRVEPSPQDQHQPRECHLFSDPACPEAPILLHFPLVNASFKDHSAPGVQRSPAELQGGQVDLTGATCPYTLSNMTYKEEDFERLLRLSDYNVQTSQGAILQALRTALKHRTLE","Homo sapiens","PLA2G4D","Cytosolic phospholipase A2 delta","1","5IXC"
"5IXK",,"X-RAY DIFFRACTION",2.15,42.89,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.1M BisTRIS pH 5.5
0.2M NH3 Acetate
20% PEG3350",298,"10.1186/s12900-016-0059-3","6EW","5IXK",54.08,"2.35","2.35","RORgamma in complex with inverse agonist BIO399.","GPTPEAPYTEIEHLVQSVCKSYRETCQLRLEDLLRQRSNIFSREEVTGYQRKSMWEMWERCAHHLTEAIQYVVEFAKRLSGFMELCQNDQIVLLKAGAMEVVLVRMCRAYNADNRTVFFEGKYGGMELFRALGCSELISSIFDFSHSLSALHFSEDEIALYTALVLINAHRPGLQEKRKVEQLQYNLELAFHHHLCKTHRQSILAKLPPKGKLRSLCSQHVERLQIFQ","Homo sapiens","RORC, NR1F3, RORG, RZRG","Nuclear receptor ROR-gamma","1","5IXK"
"5IXS",,"X-RAY DIFFRACTION",2.15,42.8,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 3350, sodium malonate",292,"10.1021/acsmedchemlett.6b00190","6EY","5IXS",151.9,"2.05","2.05","Lactate Dehydrogenase in complex with hydroxylactam inhibitor compound 9: (6R)-3-[(2-chlorophenyl)sulfanyl]-4-hydroxy-6-(3-hydroxyphenyl)-6-(thiophen-3-yl)-5,6-dihydropyridin-2(1H)-one","ATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF","Homo sapiens","LDHA, PIG19","L-lactate dehydrogenase A chain","1","5IXS"
"5IXY",,"X-RAY DIFFRACTION",2.19,43.82,"VAPOR DIFFUSION, SITTING DROP",7,"PEG 3350, sodium malonate",292,"10.1021/acsmedchemlett.6b00190",,"5IXY",151.74,"3","3","Lactate Dehydrogenase in complex with hydroxylactam inhibitor compound 31: (2~{S})-5-(2-chlorophenyl)sulfanyl-2-(4-morpholin-4-ylphenyl)-4-oxidanyl-2-thiophen-3-yl-1,3-dihydropyridin-6-one","ATLKDQLIYNLLKEEQTPQNKITVVGVGAVGMACAISILMKDLADELALVDVIEDKLKGEMMDLQHGSLFLRTPKIVSGKDYNVTANSKLVIITAGARQQEGESRLNLVQRNVNIFKFIIPNVVKYSPNCKLLIVSNPVDILTYVAWKISGFPKNRVIGSGCNLDSARFRYLMGERLGVHPLSCHGWVLGEHGDSSVPVWSGMNVAGVSLKTLHPDLGTDKDKEQWKEVHKQVVESAYEVIKLKGYTSWAIGLSVADLAESIMKNLRRVHPVSTMIKGLYGIKDDVFLSVPCILGQNGISDLVKVTLTSEEEARLKKSADTLWGIQKELQF","Homo sapiens","LDHA, PIG19","L-lactate dehydrogenase A chain","1","5IXY"
"5IYY",,"X-RAY DIFFRACTION",2.17,43.23,"VAPOR DIFFUSION, HANGING DROP",7.9,"30% w/v PEG3350, 0.2 M AmCl",293,"10.1111/febs.14405",,"5IYY",36.45,"1.6","1.6","X-ray structure of neuropilin-1 b1 domain complexed with Arg-4 ligand.","GHMFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5IYY"
"5IZ5",,"X-RAY DIFFRACTION",3.45,64.34,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Bis-Tris-propane (pH 7.0-7.5), 1.4-1.5 M Lithium Sulphate",290,"10.1016/j.jmb.2016.05.012",,"5IZ5",183.91,"2.2","2.2","Human GIVD cytosolic phospholipase A2","GAMGSESLSPGGPPGHPYQGEASTCWQLTVRVLEARNLRWADLLSEADPYVILQLSTAPGMKFKTKTLTDTSHPVWNEAFRFLIQSQVKNVLELSIYDEDSVTEDDICFKVLYDISEVLPGKLLRKTFSQSPQGEEELDVEFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELELVLKGSYEDTQTSFLGTASAFRFHYMAALETELSGRLRSSRSNGWNGDNSAGYLTVPLRPLTIGKEVTMDVPAPNAPGVRLQLKAEGCPEELAVHLGFNLCAEEQAFLSRRKQVVAKALKQALQLDRDLQEDEVPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVTYFSGISGSTWTMAHLYGDPEWSQRDLEGPIRYAREHLAKSKLEVFSPERLASYRRELELRAEQGHPTTFVDLWALVLESMLHGQVMDQKLSGQRAALERGQNPLPLYLSLNVKENNLETLDFKEWVEFSPYEVGFLKYGAFVPPELFGSEFFMGRLMRRIPEPRICFLEAIWSNIFSLNLLDAWYDLTSSGESWKQHIAAATRSLEKEPLTTSGTSSRLEASWLQPGTALAQAFKGFLTGRPLHQRSPNFLQGLQLHQDYCSHKDFSTWADYQLDSMPSQLTPKEPRLCLVDAAYFINTSSPSMFRPGRRLDLILSFDYSLSAPFEALQQTELYCRARGLPFPRVEPSPQDQHQPRECHLFSDPACPEAPILLHFPLVNASFKDHSAPGVQRSPAELQGGQVDLTGATCPYTLSNMTYKEEDFERLLRLSDYNVQTSQGAILQALRTALKHRTLE","Homo sapiens","PLA2G4D","Cytosolic phospholipase A2 delta","1","5IZ5"
"5IZK",,"X-RAY DIFFRACTION",2.73,54.87,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Tris pH 8.5, 0.2 M NaI, 0.2 M KI, 18% (w/v) PEG 3,350",285,"10.1038/ncomms12941",,"5IZK",136.01,"3.25","3.25","The crystal structure of human eEFSec in complex with GDP","MGSSHHHHHHSSGLVPRGSHMAGRRVNVNVGVLGHIDSGKTALARALSTTASTAAFDKQPQSRERGITLDLGFSCFSVPLPARLRSSLPEFQAAPEAEPEPGEPLLQVTLVDCPGHASLIRTIIGGAQIIDLMMLVIDVTKGMQTQSAECLVIGQIACQKLVVVLNKIDLLPEGKRQAAIDKMTKKMQKTLENTKFRGAPIIPVAAKPGGPEAPETEAPQGIPELIELLTSQISIPTRDPSGPFLMSVDHCFSIKGQGTVMTGTILSGSISLGDSVEIPALKVVKKVKSMQMFHMPITSAMQGDRLGICVTQFDPKLLERGLVCAPESLHTVHAALISVEKIPYFRGPLQTKAKFHITVGHETVMGRLMFFSPAPDNFDQEPILDSFNFSQEYLFQEQYLSKDLTPAVTDNDEADKKAGQATEGHCPRQQWALVEFEKPVTCPRLCLVIGSRLDADIHTNTCRLAFHGILLHGLEDRNYADSFLPRLKVYKLKHKHGLVERAMDDYSVIGRSLFKKETNIQLFVGLKVHLSTGELGIIDSAFGQSGKFKIHIPGGLSPESKKILTPALKKRARAGRGEATRQEESAERSEPSQHVVLSLTFKRYVFDTHKRMVQSP","Homo sapiens","EEFSEC, SELB","Selenocysteine-specific elongation factor","1","5IZK"
"5IZL",,"X-RAY DIFFRACTION",3.37,63.45,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.6, 0.25 M ammonium sulfate, 18% (w/v) PEG 3,350, 0.02 M glycine, 2% dextran sulfate",285,"10.1038/ncomms12941",,"5IZL",136.22,"2.72","2.72","The crystal structure of human eEFSec in complex with GDPCP","MGSSHHHHHHSSGLVPRGSHMAGRRVNVNVGVLGHIDSGKTALARALSTTASTAAFDKQPQSRERGITLDLGFSCFSVPLPARLRSSLPEFQAAPEAEPEPGEPLLQVTLVDCPGHASLIRTIIGGAQIIDLMMLVIDVTKGMQTQSAECLVIGQIACQKLVVVLNKIDLLPEGKRQAAIDKMTKKMQKTLENTKFRGAPIIPVAAKPGGPEAPETEAPQGIPELIELLTSQISIPTRDPSGPFLMSVDHCFSIKGQGTVMTGTILSGSISLGDSVEIPALKVVKKVKSMQMFHMPITSAMQGDRLGICVTQFDPKLLERGLVCAPESLHTVHAALISVEKIPYFRGPLQTKAKFHITVGHETVMGRLMFFSPAPDNFDQEPILDSFNFSQEYLFQEQYLSKDLTPAVTDNDEADKKAGQATEGHCPRQQWALVEFEKPVTCPRLCLVIGSRLDADIHTNTCRLAFHGILLHGLEDRNYADSFLPRLKVYKLKHKHGLVERAMDDYSVIGRSLFKKETNIQLFVGLKVHLSTGELGIIDSAFGQSGKFKIHIPGGLSPESKKILTPALKKRARAGRGEATRQEESAERSEPSQHVVLSLTFKRYVFDTHKRMVQSP","Homo sapiens","EEFSEC, SELB","Selenocysteine-specific elongation factor","1","5IZL"
"5IZM",,"X-RAY DIFFRACTION",3.25,62.15,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M HEPES pH 7.6, 0.3 M ammonium sulfate, 16% (w/v) PEG 3,350, 0.02 M glycine, 4% dextran sulfate",285,"10.1038/ncomms12941",,"5IZM",137.88,"3.4","3.4","The crystal structure of human eEFSec in complex with GDPNP","MGSSHHHHHHSSGLVPRGSHMAGRRVNVNVGVLGHIDSGKTALARALSTTASTAAFDKQPQSRERGITLDLGFSCFSVPLPARLRSSLPEFQAAPEAEPEPGEPLLQVTLVDCPGHASLIRTIIGGAQIIDLMMLVIDVTKGMQTQSAECLVIGQIACQKLVVVLNKIDLLPEGKRQAAIDKMTKKMQKTLENTKFRGAPIIPVAAKPGGPEAPETEAPQGIPELIELLTSQISIPTRDPSGPFLMSVDHCFSIKGQGTVMTGTILSGSISLGDSVEIPALKVVKKVKSMQMFHMPITSAMQGDRLGICVTQFDPKLLERGLVCAPESLHTVHAALISVEKIPYFRGPLQTKAKFHITVGHETVMGRLMFFSPAPDNFDQEPILDSFNFSQEYLFQEQYLSKDLTPAVTDNDEADKKAGQATEGHCPRQQWALVEFEKPVTCPRLCLVIGSRLDADIHTNTCRLAFHGILLHGLEDRNYADSFLPRLKVYKLKHKHGLVERAMDDYSVIGRSLFKKETNIQLFVGLKVHLSTGELGIIDSAFGQSGKFKIHIPGGLSPESKKILTPALKKRARAGRGEATRQEESAERSEPSQHVVLSLTFKRYVFDTHKRMVQSP","Homo sapiens","EEFSEC, SELB","Selenocysteine-specific elongation factor","1","5IZM"
"5IZQ",,"X-RAY DIFFRACTION",3.34,63.2,"VAPOR DIFFUSION, SITTING DROP",6.5,"10% (w/v) polyethylene glycol 10K, 0.1 M BIS-TRIS pH 6.5, 0.2 M potassium sodium tartrate tetrahydrate",293,"10.1021/acs.jmedchem.6b00594",,"5IZQ",224.82,"3.6","3.6","Crystal structure of human folate receptor alpha in complex with novel antifolate AGF183","MAQRMTTQLLLLLVWVAVVGEAQTRIAWARTELLNVCMNAKHHKEKPGPEDKLHEQCRPWRKNACCSTNTSQEAHKDVSYLYRFNWNHCGEMAPACKRHFIQDTCLYECSPNLGPWIQQVDQSWRKERVLNVPLCKEDCEQWWEDCRTSYTCKSNWHKGWNWTSGFNKCAVGAACQPFHFYFPTPTVLCNEIWTHSYKVSNYSRGSGRCIQMWFDPAQGNPNEEVARFYAAAMSGTLV","Homo sapiens","FOLR1, FOLR","Folate receptor alpha","1","5IZQ"
"5IZR",,"X-RAY DIFFRACTION",2.47,50.24,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES (pH 6.0-6.2), 10-14% (v/v) PEG20K and 50 mM sodium acetate",277,"10.1016/j.jmb.2016.05.012",,"5IZR",369.54,"3.25","3.25","Human GIVD cytosolic phospholipase A2 in complex with Methyl gamma-Linolenyl Fluorophosphonate inhibitor and Terbium Chloride","GAMGSESLSPGGPPGHPYQGEASTCWQLTVRVLEARNLRWADLLSEADPYVILQLSTAPGMKFKTKTLTDTSHPVWNEAFRFLIQSQVKNVLELSIYDEDSVTEDDICFKVLYDISEVLPGKLLRKTFSQSPQGEEELDVEFLMEETSDRPENLITNKVIVARELSCLDVHLDSTGSTAVVADQDKLELELVLKGSYEDTQTSFLGTASAFRFHYMAALETELSGRLRSSRSNGWNGDNSAGYLTVPLRPLTIGKEVTMDVPAPNAPGVRLQLKAEGCPEELAVHLGFNLCAEEQAFLSRRKQVVAKALKQALQLDRDLQEDEVPVVGIMATGGGARAMTSLYGHLLALQKLGLLDCVTYFSGISGSTWTMAHLYGDPEWSQRDLEGPIRYAREHLAKSKLEVFSPERLASYRRELELRAEQGHPTTFVDLWALVLESMLHGQVMDQKLSGQRAALERGQNPLPLYLSLNVKENNLETLDFKEWVEFSPYEVGFLKYGAFVPPELFGSEFFMGRLMRRIPEPRICFLEAIWSNIFSLNLLDAWYDLTSSGESWKQHIKDKTRSLEKEPLTTSGTSSRLEASWLQPGTALAQAFKGFLTGRPLHQRSPNFLQGLQLHQDYCSHKDFSTWADYQLDSMPSQLTPKEPRLCLVDAAYFINTSSPSMFRPGRRLDLILSFDYSLSAPFEALQQTELYCRARGLPFPRVEPSPQDQHQPRECHLFSDPACPEAPILLHFPLVNASFKDHSAPGVQRSPAELQGGQVDLTGATCPYTLSNMTYKEEDFERLLRLSDYNVQTSQGAILQALRTALKHRTLE","Homo sapiens","PLA2G4D","Cytosolic phospholipase A2 delta","1","5IZR"
"5J06",,"X-RAY DIFFRACTION",2.93,58,"VAPOR DIFFUSION, HANGING DROP",8.5,"2% PEG 20,000, 4% PEG MME 500, 100 MM BICINE/TRIS BASE PH 8.5, 1XMORPHEUS AMINO ACIDS. CRYSTALS SOAKED IN 20 MM 3'-SIALYLLACTOSE IN MOTHER LIQUOR FOR 10 DAYS.",295.15,,,"5J06",104.11,"2.66","2.66","Structure of the immune receptor CD33 in complex with 3'-sialyllactose","ETGFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISGDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTGTKHHHHHH","Homo sapiens","CD33, SIGLEC3","Myeloid cell surface antigen CD33","1","5J06"
"5J07",,"X-RAY DIFFRACTION",2.12,41.95,"EVAPORATION",5,"0.1 M MIB buffer
pH 5.0
25 % w/v PEG 1500",293,"10.1021/jacs.6b05151",,"5J07",22.64,"2","2","Monomeric Human Cu,Zn Superoxide dismutase, loops IV and VII deleted, apo form, circular permutant P1/2","APVQGIINFEQKESNGPVKVWGSIKGLTEGLHGFHVHGAGGDLGNVTADKDGVADVSIEDSVISLSGDHSIIGRTLVVHEKAGAGAGSRLASGVIGIAQAGAGATKAVAVLKGDG","Homo sapiens","SOD1","Superoxide dismutase [Cu-Zn],Superoxide dismutase [Cu-Zn],Superoxide dismutase [Cu-Zn],Superoxide dismutase [Cu-Zn]","1","5J07"
,,,,,,,,,,,,,,,,,"Homo sapiens","SOD1"
,,,,,,,,,,,,,,,,,"Homo sapiens","SOD1"
,,,,,,,,,,,,,,,,,"Homo sapiens","SOD1"
"5J0A",,"X-RAY DIFFRACTION",4.46,72.39,"VAPOR DIFFUSION, SITTING DROP",,"0.2 M lithium sulfate, 2.0 M ammonium sulfate, 0.1 M CAPS",277,"10.1016/j.bbrc.2016.05.166",,"5J0A",69.25,"2.74","2.74","Crystal structure of PDZ-binding kinase","GSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGEKSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKKLLHGDIKSSNVVIKGDFETIKICDVGVSLPLDENMEVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINLSNDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVCTNEDPKDRPSAAHIVEALETA","Homo sapiens","PBK, TOPK","Lymphokine-activated killer T-cell-originated protein kinase","1","5J0A"
,,,,,,,,,,,,,,,,"GSVLCSTPTINIPASPFMQKLGFGTGVNVYLMKRSPRGLSHSPWAVKKINPICNDHYRSVYQKRLMDEAKILKSLHHPNIVGYRAFTEANDGSLCLAMEYGGEKSLNDLIEERYKASQDPFPAAIILKVALNMARGLKYLHQEKKLLHGDIKSSNVVIKGDFETIKICDVGVSLPLDENMEVTDPEACYIGTEPWKPKEAVEENGVITDKADIFAFGLTLWEMMTLSIPHINLSNDDDDEDKTFDESDFDDEAYYAALGTRPPINMEELDESYQKVIELFSVCTNEDPKDRPSAAHIVEALEAA","Homo sapiens","PBK, TOPK","Lymphokine-activated killer T-cell-originated protein kinase","2","5J0A"
"5J0B",,"X-RAY DIFFRACTION",2.8,56.1,"VAPOR DIFFUSION, HANGING DROP",8.5,"2% PEG 20,000, 4% PEG MME 500, 100 MM BICINE/TRIS BASE PH 8.5, 1XMORPHEUS AMINO ACIDS. CRYSTALS SOAKED IN 20 MM 6'-SIALYLLACTOSE IN MOTHER LIQUOR FOR 10 DAYS.",295.15,,,"5J0B",104.52,"2.48","2.48","Structure of the immune receptor CD33 in complex with 6'-sialyllactose","ETGFWLQVQESVTVQEGLCVLVPCTFFHPIPYYDKNSPVHGYWFREGAIISGDSPVATNKLDQEVQEETQGRFRLLGDPSRNNCSLSIVDARRRDNGSYFFRMERGSTKYSYKSPQLSVHVTDLTHRPKILIPGTLEPGHSKNLTCSVSWACEQGTPPIFSWLSAAPTSLGPRTTHSSVLIITPRPQDHGTNLTCQVKFAGAGVTTERTIQLNVTGTKHHHHHH","Homo sapiens","CD33, SIGLEC3","Myeloid cell surface antigen CD33","1","5J0B"
"5J0D",,"X-RAY DIFFRACTION",2.22,44.59,"VAPOR DIFFUSION",7.5,"25% PEG3350, 0.2 M MgCl2, 0.1M BisTris pH 7.5",277,"10.1021/acs.jmedchem.6b00774","6F9","5J0D",14.89,"1.05","1.05","Crystal structure of the bromodomain of human CREBBP in complex with a benzoxazepine compound","SMRKKIFKPEELRQALMPTLEALYRQDPESLPFRQPVDPQLLGIPDYFDIVKNPMDLSTIKRKLDTGQYQEPWQYVDDVWLMFNNAWLYNRKTSRVYKFCSKLAEVFEQEIDPVMQSLG","Homo sapiens","CREBBP, CBP","CREB-binding protein","1","5J0D"
"5J17",,"SOLUTION NMR",,,,,,,"10.1016/j.cell.2016.03.045",,"5J17",10.31,,,"Solution structure of Ras Binding Domain (RBD) of B-Raf","GSLEVLFQGPSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPL","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5J17"
"5J18",,"SOLUTION NMR",,,,,,,"10.1016/j.cell.2016.03.045",,"5J18",10.76,,,"Solution structure of Ras Binding Domain (RBD) of B-Raf complexed with Rigosertib (Complex I)","GSLEVLFQGPSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPL","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5J18"
"5J1F",,"X-RAY DIFFRACTION",2.97,58,"VAPOR DIFFUSION, HANGING DROP",6,"A protein solution at 30 mg/ml in 10 mM Tris-Hcl (pH 7.5), 50 mM NaCl, 1 mM DTT was mixed with an equal volume of crystallization solution 0.1 M Bis-Tris-Propane (pH 6.0), 18% PEG 3350, 0.2 Na malonate",277,"10.1074/jbc.M116.732909",,"5J1F",44.65,"3","3","Structure of the spectrin repeats 5 and 6 of the plakin domain of plectin","GSHMAYAQFFSDVREAEGQLQKLQEALRRKYSCDRSATVTRLEDLLQDAQDEKEQLNEYKGHLSGLAKRAKAVGSGNQEAQEAVTRLEAQHQALVTLWHQLHVDMKSLLAWQSLRRDVQLIRSWSLATFRTLKPEEQRQALHSLELHYQAFLRDSQDAGGFGPEDRLMAEREYGSCSHHYQQLLQSLEQGAQEE","Homo sapiens","PLEC, PLEC1","Plectin,Plectin","1","5J1F"
,,,,,,,,,,,,,,,,,"Homo sapiens","PLEC, PLEC1"
"5J1G",,"X-RAY DIFFRACTION",3.32,64,"VAPOR DIFFUSION, HANGING DROP",7.7,"A protein solution at 27 mg/ml in 10 mM Tris-HCl (pH 7.5), 50 mM NaCl was mixed with an equal volume of crystallization solution 50 mM Tris-HCl (pH 7.7), 0.2 M NaF, 18% PEG 3350",298,"10.1074/jbc.M116.732909",,"5J1G",53.5,"1.8","1.8","Structure of the spectrin repeats 7 and 8 of the plakin domain of plectin","GSHMQEESRCQRCISELKDIRLQLEACETRTVHRLRLPLDKEPARECAQRIAEQQKAQAEVEGLGKGVARLSAEAEKVLALPEPSPAAPTLRSELELTLGKLEQVRSLSAIYLEKLKTISLVIRGTQGAEEVLRAHEEQLKEAQAVPATLPELEATKASLKKLRAQAEAQQPTFDALRDELRGAQEVGERLQQRHGERDVEVERWRERVAQLLERWQAVLAQTDVRQRELEQLG","Homo sapiens","PLEC, PLEC1","Plectin","1","5J1G"
"5J1H",,"X-RAY DIFFRACTION",3.33,63,"VAPOR DIFFUSION, SITTING DROP",7.5,"Protein at 30 mg/ml in 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT was mixed with an equal volume of the crystallization solution 0.2 M Na/K tartrate, 20% PEG3350",277,"10.1074/jbc.M116.732909",,"5J1H",44.94,"2.8","2.8","Structure of the spectrin repeats 5 and 6 of the plakin domain of plectin","GSHMAYAQFFSDVREAEGQLQKLQEALRRKYSCDRSATVTRLEDLLQDAQDEKEQLNEYKGHLSGLAKRAKAVGSGSGNQEAQEAVTRLEAQHQALVTLWHQLHVDMKSLLAWQSLRRDVQLIRSWSLATFRTLKPEEQRQALHSLELHYQAFLRDSQDAGGFGPEDRLMAEREYGSCSHHYQQLLQSLEQGAQEE","Homo sapiens","PLEC, PLEC1","Plectin,Plectin","1","5J1H"
,,,,,,,,,,,,,,,,,"Homo sapiens","PLEC, PLEC1"
"5J1I",,"X-RAY DIFFRACTION",3.04,60,"VAPOR DIFFUSION, HANGING DROP",8,"Protein solution at 12 mg/ml in 10 mM Tris-HCl (pH 7.5), 50 mM NaCl, 1 mM DTT was mixed with crystallization solution 0.1 M Bis-Tris-propane (pH 8.0), 16% PEG 3350, 0.3 M Na/K tartrate",298,"10.1074/jbc.M116.732909",,"5J1I",85.78,"2.801","2.801","Structure of the spectrin repeats 7, 8, and 9 of the plakin domain of plectin","GSHMQEESRCQRCISELKDIRLQLEACETRTVHRLRLPLDKEPARECAQRIAEQQKAQAEVEGLGKGVARLSAEAEKVLALPEPSPAAPTLRSELELTLGKLEQVRSLSAIYLEKLKTISLVIRGTQGAEEVLRAHEEQLKEAQAVPATLPELEATKASLKKLRAQAEAQQPTFDALRDELRGAQEVGERLQQRHGERDVEVERWRERVAQLLERWQAVLAQTDVRQRELEQLGRQLRYYRESADPLGAWLQDARRRQEQIQAMPLADSQAVREQLRQEQALLEEIERHGEKVEECQRFAKQYINAIKDYELQLVTYKAQLEPVASPAKKPKVQSGSESVIQEYVDLRTHYSELTTLTSQYIKFISETLRRME","Homo sapiens","PLEC, PLEC1","Plectin","1","5J1I"
"5J1V",,"X-RAY DIFFRACTION",2.45,49.86,"VAPOR DIFFUSION, SITTING DROP",,"30% 1,2-propanediol, 10% glycerol and 50 mM Na/K phosphate pH 7.2",277.15,"10.1016/j.ejmech.2016.04.004","6FD","5J1V",119.56,"2.52","2.52","Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW29 (compound 13)","SMHLICQSGDVLSARYEIVDTLGEGAFGKVVECIDHKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNTTDPNSTFRCVQMLEWFEHHGHICIVFELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNFLHSNKLTHTDLKPENILFVQSDYTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWDEHSSAGRYVSRACKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLLKKSI","Homo sapiens","CLK1, CLK","Dual specificity protein kinase CLK1","1","5J1V"
"5J1W",,"X-RAY DIFFRACTION",2.51,51.04,"VAPOR DIFFUSION, SITTING DROP",,"30% 1,2-propanediol, 10% glycerol and 50 mM Na/K phosphate pH 7.2",277.15,"10.1016/j.ejmech.2016.04.004","6FB","5J1W",120.55,"2.42","2.42","Crystal structure of human CLK1 in complex with pyrido[3,4-g]quinazoline derivative ZW31 (compound 14)","SMHLICQSGDVLSARYEIVDTLGEGAFGKVVECIDHKAGGRHVAVKIVKNVDRYCEAARSEIQVLEHLNTTDPNSTFRCVQMLEWFEHHGHICIVFELLGLSTYDFIKENGFLPFRLDHIRKMAYQICKSVNFLHSNKLTHTDLKPENILFVQSDYTEAYNPKIKRDERTLINPDIKVVDFGSATYDDEHHSTLVSTRHYRAPEVILALGWSQPCDVWSIGCILIEYYLGFTVFPTHDSKEHLAMMERILGPLPKHMIQKTRKRKYFHHDRLDWDEHSSAGRYVSRACKPLKEFMLSQDVEHERLFDLIQKMLEYDPAKRITLREALKHPFFDLLKKSI","Homo sapiens","CLK1, CLK","Dual specificity protein kinase CLK1","1","5J1W"
"5J1X",,"X-RAY DIFFRACTION",2.14,42.6,"VAPOR DIFFUSION, HANGING DROP",7.9,"18% w/v PEG3350, 0.2M NH4Cl",289,"10.1111/febs.14405",,"5J1X",72.84,"2.1","2.1","X-ray structure of neuropilin-1 b1 domain complexed with Arg-5 ligand.","GHMFKCMEALGMESGEIHSDQITASSQYSTNWSAERSRLNYPENGWTPGEDSYREWIQVDLGLLRFVTAVGTQGAISKETKKKYYVKTYKIDVSSNGEDWITIKEGNKPVLFQGNTNPTDVVVAVFPKPLITRFVRIKPATWETGISMRFEVYGCKIT","Homo sapiens","NRP1, NRP, VEGF165R","Neuropilin-1","1","5J1X"
"5J20",,"X-RAY DIFFRACTION",3.27,62.35,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M sodium fluoride
0.1 M Bis Tris propane
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6FJ","5J20",23.63,"1.76","1.76","HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide","AVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J20"
"5J27",,"X-RAY DIFFRACTION",3.24,62.08,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M sodium fluoride
0.1 M Bis Tris propane
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6FF","5J27",23.81,"1.7","1.7","HSP90 in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide","EVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEK","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J27"
"5J2R",,"SOLUTION NMR",,,,,,,"10.1016/j.cell.2016.03.045",,"5J2R",10.76,,,"Solution structure of Ras Binding Domain (RBD) of B-Raf","GSLEVLFQGPSPQKPIVRVFLPNKQRTVVPARCGVTVRDSLKKALMMRGLIPECCAVYRIQDGEKKPIGWDTDISWLTGEELHVEVLENVPL","Homo sapiens","BRAF, BRAF1, RAFB1","Serine/threonine-protein kinase B-raf","1","5J2R"
"5J2V",,"X-RAY DIFFRACTION",3.49,64.76,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w",,"5J2V",23.21,"1.59","1.59","Crystal Structure of Hsp90-alpha Apo N-domain","AVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J2V"
"5J2X",,"X-RAY DIFFRACTION",3.16,61.13,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane pH 8.5, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6DL","5J2X",23.7,"1.22","1.22","Crystal Structure of Hsp90-alpha N-domain in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one","AVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEK","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J2X"
"5J39",,"X-RAY DIFFRACTION",2.25,45.22,"VAPOR DIFFUSION, SITTING DROP",5.5,"15% PEG-8000, 0.2 M magnesium chloride, 0.1 sodium cacodylate. A putative peptide ligand was added to the protein but not found during crystal structure analysis.",291,"10.1073/pnas.1711486114",,"5J39",47.54,"1.95","1.95","Crystal Structure of the extended TUDOR domain from TDRD2","MHHHHHHSSGRENLYFQGEVYVSASEHPNHFWIQIVGSRSLQLDKLVNEMTQHYENSVPEDLTVHVGDIVAAPLPTNGSWYRARVLGTLENGNLDLYFVDFGDNGDCPLKDLRALRSDFLSLPFQAIECSLARIAPSGDQWEEEALDEFDRLTHCADWKPLVAKISSYVQTGISTWPKIYLYDTSNGKKLDIGLELVHKGYAIELPED","Homo sapiens","TDRKH, TDRD2","Tudor and KH domain-containing protein","1","5J39"
"5J3J",,"X-RAY DIFFRACTION",2.7,54.38,"EVAPORATION",8,"100mM Tris pH 8, 18% PEG 3350, 200mM NaCl",289,,"HL1","5J3J",172.45,"2.75","2.75","Crystal Structure of human DPP-IV in complex with HL1","RKTYTLTDYLKNTYRLKLYSLRWISDHEYLYKQENNILVFNAEYGNSSVFLENSTFDEFGHSINDYSISPDGQFILLEYNYVKQWRHSYTASYDIYDLNKRQLITEERIPNNTQWVTWSPVGHKLAYVWNNDIYVKIEPNLPSYRITWTGKEDIIYNGITDWVYEEEVFSAYSALWWSPNGTFLAYAQFNDTEVPLIEYSFYSDESLQYPKTVRVPYPKAGAVNPTVKFFVVNTDSLSSVTNATSIQITAPASMLIGDHYLCDVTWATQERISLQWLRRIQNYSVMDICDYDESSGRWNCLVARQHIEMSTTGWVGRFRPSEPHFTLDGNSFYKIISNEEGYRHICYFQIDKKDCTFITKGTWEVIGIEALTSDYLYYISNEYKGMPGGRNLYKIQLSDYTKVTCLSCELNPERCQYYSVSFSKEAKYYQLRCSGPGLPLYTLHSSVNDKGLRVLEDNSALDKMLQNVQMPSKKLDFIILNETKFWYQMILPPHFDKSKKYPLLLDVYAGPCSQKADTVFRLNWATYLASTENIIVASFDGRGSGYQGDKIMHAINRRLGTFEVEDQIEAARQFSKMGFVDNKRIAIWGWSYGGYVTSMVLGSGSGVFKCGIAVAPVSRWEYYDSVYTERYMGLPTPEDNLDHYRNSTVMSRAENFKQVEYLLIHGTADDNVHFQQSAQISKALVDVGVDFQAMWYTDEDHGIASSTAHQHIYTHMSHFIKQCFSLPGHHHHHH","Homo sapiens","DPP4, ADCP2, CD26","Dipeptidyl peptidase 4","1","5J3J"
"5J3P",,"X-RAY DIFFRACTION",2.67,53.92,"VAPOR DIFFUSION, HANGING DROP",,"100 mM Bis-Tris propane pH 7.0, 
0.5 M NaCl, 
0.05 M magnesium acetate, 
1.5% v/v Trimethylamine N-oxide",293,"10.1042/BCJ20160180",,"5J3P",57.79,"3.1","3.1","Crystal structure of the catalytic domain of human tyrosyl DNA phosphodiesterase 2","GSHMFSLITWNIDGLDLNNLSERARGVCSYLALYSPDVIFLQEVIPPYYSYLKKRSSNYEIITGHEEGYFTAIMLKKSRVKLKSQEIIPFPSTKMMRNLLCVHVNVSGNELCLMTSHLESTRGHAAERMNQLKMVLKKMQEAPESATVIFAGDTNLRDREVTRSGGLPNNIVDVWEFLGKPKHCQYTWDTQMNSNLGITAACKLRFDRIFFRAAAEEGHIIPRSLDLLGLEKLDCGRFPSDHWGLLCNLDIIL","Homo sapiens","TDP2, EAP2, TTRAP, AD-022","Tyrosyl-DNA phosphodiesterase 2","1","5J3P"
"5J3S",,"X-RAY DIFFRACTION",2.61,52.84,"VAPOR DIFFUSION, HANGING DROP",,"1.2M D/L-Malic acid pH7.0,
0.1M Bis-Tris propane pH 7.0,
3% v/v DMSO",273,"10.1042/BCJ20160180","6FQ","5J3S",29.21,"3.4","3.4","Crystal structure of the catalytic domain of human tyrosyl DNA phosphodiesterase 2 in complex with a small molecule inhibitor","GSHMFSLITWNIDGLDLNNLSERARGVCSYLALYSPDVIFLQEVIPPYYSYLKKRSSNYEIITGHEEGYFTAIMLKKSRVKLKSQEIIPFPSTKMMRNLLCVHVNVSGNELCLMTSHLESTRGHAAERMNQLKMVLKKMQEAPESATVIFAGDTNLRDREVTRSGGLPNNIVDVWEFLGKPKHCQYTWDTQMNSNLGITAACKLRFDRIFFRAAAEEGHIIPRSLDLLGLEKLDCGRFPSDHWGLLCNLDIIL","Homo sapiens","TDP2, EAP2, TTRAP, AD-022","Tyrosyl-DNA phosphodiesterase 2","1","5J3S"
"5J3X",,"X-RAY DIFFRACTION",3.22,61.79,"VAPOR DIFFUSION, HANGING DROP",8.5,"Equal volume protein at 10 mg/mL + well containing 3.0-3.1 M sodium formate
0.1 M Tris-HCl, pH 8.5
5 mM DTT",281.15,"10.1186/s12915-016-0298-6",,"5J3X",271.37,"2.822","2.822","Structure of c-CBL Y371F","GSPPGTVDKKMVEKCWKLMDKVVRLCQNPKLALKNSPPYILDLLPDTYQHLRTILSRYEGKMETLGENEYFRVFMENLMKKTKQTISLFKEGKERMYEENSQPRRNLTKLSLIFSHMLAELKGIFPSGLFQGDTFRITKADAAEFWRKAFGEKTIVPWKSFRQALHEVHPISSGLEAMALKSTIDLTCNDYISVFEFDIFTRLFQPWSSLLRNWNSLAVTHPGYMAFLTYDEVKARLQKFIHKPGSYIFRLSCTRLGQWAIGYVTADGNILQTIPHNKPLFQALIDGFREGFYLFPDGRNQNPDLTGLCEPTPQDHIKVTQEQYELFCEMGSTFQLCKICAENDKDVKIEPCGHLMCTSCLTSWQESEGQGCPFCRCEIKGTEPIVVDPFD","Homo sapiens","CBL, CBL2, RNF55","E3 ubiquitin-protein ligase CBL","1","5J3X"
"5J41",,"X-RAY DIFFRACTION",2.58,52.4,"VAPOR DIFFUSION, HANGING DROP",,"1.6M ammonium sulfate, 100mM MES pH 6.5",293,"10.1074/jbc.M116.750299",,"5J41",47.98,"1.19035345576","1.19035345576","Glutathione S-transferase bound with hydrolyzed Piperlongumine","PPYTVVYFPVRGRCAALRMLLADQGQSWKEEVVTVETWQEGSLKASCLYGQLPKFQDGDLTLYQSNTILRHLGRTLGLYGKDQQEAALVDMVNDGVEDLRCKYISLIYTNYEAGKDDYVKALPGQLKPFETLLSQNQGGKTFIVGDQISFADYNLLDLLLIHEVLAPGCLDAFPLLSAYVGRLSARPKLKAFLASPEYVNLPINGNGKQ","Homo sapiens","GSTP1, FAEES3, GST3","Glutathione S-transferase P","1","5J41"
"5J48",,"X-RAY DIFFRACTION",2.42,49.23,"VAPOR DIFFUSION, HANGING DROP",,"30% PEG 400, 200 mM CaAc, 0.1M NaAc pH 4.5-4.8",277,"10.1021/acschembio.7b00369","6FW","5J48",31.53,"1.49","1.49","PKG I's Carboyl Terminal Cyclic Nucleotide Binding Domain (CNB-B) in a complex with 8-pCPT-cGMP","GSTGLIKHTEYMEFLKSVPTFQSLPEEILSKLADVLEETHYENGEYIIRQGARGDTFFIISKGTVNVTREDSPSEDPVFLRTLGKGDWFGEKALQGEDVRTANVIAAEAVTCLVIDRDSFKHLIGGLDDVSNKAY","Homo sapiens","PRKG1, PRKG1B, PRKGR1A, PRKGR1B","cGMP-dependent protein kinase 1","1","5J48"
"5J4O",,"X-RAY DIFFRACTION",2.37,48.09,"VAPOR DIFFUSION, SITTING DROP",6.5,"Molecular Dimensions Morpheus crystallisation screen, condition A2:
0.03M MgCl2, 0.03M CaCl2, 0.1M MES/Imidazole pH 6.5, 20% v/v Ethylene glycol, 10% v/v PEG 8000.",277,,,"5J4O",27.39,"1.54","1.54","Structure of human erythrocytic Spectrin alpha chain repeats 16-17","GPGKGKKLNEASRQQRFNTSIRDFEFWLSEAETLLAMKDQARDLASAGNLLKKHQLLEREMLAREDALKDLNTLAEDLLSSGTFNVDQIVKKKDNVNKRFLNVQELAAAHHEKLKEAYALFQFFQDLDDEESWIEEKLIRVSSQDYGRDLQGVQNLLKKHKRLEGELVAHEPAIQNVLDMAEKLKDKAAVGQEEIQLRLAQFVEHWEKLKELAKARGLKLEESLEYLQFMQ","Homo sapiens","SPTA1, SPTA","Spectrin alpha chain, erythrocytic 1","1","5J4O"
"5J5E",,"X-RAY DIFFRACTION",2.75,55.28,"VAPOR DIFFUSION, HANGING DROP",8.5,"100 mM Tris, pH 8.5 and 16% PEG8000",277,"10.1016/j.molimm.2016.10.012",,"5J5E",48.75,"2.8","2.8","crystal structure of antigen-ERAP1 domain complex","GFPLITITVRGRNVHMKQEHYMKGSDGAPDTGYLWHVPLTFITSKSDMVHRFLLKTKTDVLILPEEVEWIKFNVGMNGYYIVHYEDDGWDSLTGLLKGTHTAVSSNDRASLINNAFQLVSIGKLSIEKALDLSLYLKHETEIMPVFQGLNELIPMYKLMEKRDMNEVETQFKAFLIRLLRDLIDKQTWTDEGSVSERMLRSQLLLLACVHNYQPCVQRAEGYFRKWKESNGNLSLPVDVTLAVFAVGAQSTEGWDFLYSKYQFSLSSTEKSQIEFALCRTQNKEKLQWLLDESFKGDKIKTQEFPQILTLIGRNPVGYPLAWQFLRKNWNKLVQKFELGSSSIAHMVMGTTNQFSTRTRLEEVKGFFSSLKENGSQLRCVQQTIETIEENIGWMDKNFDKIRVWLQSEKLERMIINFEKL","Homo sapiens","ERAP1, APPILS, ARTS1, KIAA0525, UNQ584/PRO1154","Endoplasmic reticulum aminopeptidase 1","1","5J5E"
"5J5T",,"X-RAY DIFFRACTION",2.03,39.44,"VAPOR DIFFUSION, SITTING DROP",5.5,"0.8M Ammonium Sulfate, 0.1M BisTRIS pH 5.5",298,"10.1002/pro.3062",,"5J5T",42.59,"2.85","2.85","GLK co-crystal structure with aminopyrrolopyrimidine inhibitor","GSQEDFELIQRIGSGTYGDVYKARNVNTGELAAIKVIKLEPGEDFAVVQQEIIMMKDCKHPNIVAYFGSYLRRDKLWICMEFCGGGSLQDIYHVTGPLSELQIAYVSRETLQGLYYLHSKGKMHRDIKGANILLTDNGHVKLADFGVSAQITATIAKRKAFIGTPYWMAPEVAAVERKGGYNQLCDLWAVGITAIELAELQPPMFDLHPMRALFLMTKSNFQPPKLKDKMKWSNSFHHFVKMALTKNPKKRPTAEKLLQHPFVTQHLTRSLAIELLDKVNNPDHSTYHDFDDDDPEPLVAVPHRIHSTSRNVREEKTRSEITFGQVKFDPPLRKETEPHHELPDSDGFLDSSEEIYYTARSNLDLQLEYG","Homo sapiens","MAP4K3, RAB8IPL1","Mitogen-activated protein kinase kinase kinase kinase 3","1","5J5T"
"5J5Z",,"X-RAY DIFFRACTION",2.91,57.75,"VAPOR DIFFUSION, SITTING DROP",8.1,"reservoir solution: 1.6 M NaH2PO4/K2HPO4 buffer, pH 8.1 (K2HPO4 was titrated with NaH2PO4 to pH 8.1)",293.15,"10.1016/j.freeradbiomed.2018.06.008",,"5J5Z",107.28,"1.84","1.84","Crystal structure of the D444V disease-causing mutant of the human dihydrolipoamide dehydrogenase","MASWSHPQFEKGALEVLFQGPGADQPIDADVTVIGSGPGGYVAAIKAAQLGFKTVCIEKNETLGGTCLNVGCIPSKALLNNSHYYHMAHGKDFASRGIEMSEVRLNLDKMMEQKSTAVKALTGGIAHLFKQNKVVHVNGYGKITGKNQVTATKADGGTQVIDTKNILIATGSEVTPFPGITIDEDTIVSSTGALSLKKVPEKMVVIGAGVIGVELGSVWQRLGADVTAVEFLGHVGGVGIDMEISKNFQRILQKQGFKFKLNTKVTGATKKSDGKIDVSIEAASGGKAEVITCDVLLVCIGRRPFTKNLGLEELGIELDPRGRIPVNTRFQTKIPNIYAIGDVVAGPMLAHKAEDEGIICVEGMAGGAVHIDYNCVPSVIYTHPEVAWVGKSEEQLKEEGIEYKVGKFPFAANSRAKTNADTDGMVKILGQKSTDRVLGAHILGPGAGEMVNEAALALEYGASCEVIARVCHAHPTLSEAFREANLAASFGKSINF","Homo sapiens","DLD, GCSL, LAD, PHE3","Dihydrolipoyl dehydrogenase, mitochondrial","1","5J5Z"
"5J64",,"X-RAY DIFFRACTION",3.12,60.63,"VAPOR DIFFUSION, HANGING DROP",8.5,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6G7","5J64",25.94,"1.38","1.38","Crystal Structure of Hsp90-alpha N-domain in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J64"
"5J67",,"X-RAY DIFFRACTION",4.11,70.04,"VAPOR DIFFUSION, SITTING DROP",,"12% PEG 20000, 150 mM KSCN, 0.1 M Bis-tris propane pH7.5 - 8.5",293,"10.1098/rsob.160053",,"5J67",269.67,"3.16","3.16","Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development","KFNDTLFGEMLHGYNNRTQHVNQGQVFQMTFRENNFIKDFPQLADGLLVIPLPVEEQCRGVLSEPLPDLQLLTGDIRYDEAMGYPMVQQWRVRSNLYRVKLSTITLAAGFTNVLKILTKESSREELLSFIQHYGSHYIAEALYGSELTCIIHFPSKKVQQQLWLQYQKETTELGSKKELKSMPFITYLSGLLTAQMLSDDQLISGVEIRCEEKGRCPSTCHLCRRPGKEQLSPTPVLLEINRVVPLYTLIQDNGTKEAFKSALMSSYWCSGKGDVIDDWCRCDLSAFDANGLPNCSPLLQPVLRLSPTVEPSSTVVSLEWVDVQPAIGTKVSDYILQHKKVDEYTDTDLYTGEFLSFADDLLSGLGTSCVAAGRSHGEVPEVSIYSVIFKCLEPDGLYKFTLYAVDTRGRHSELSTVTLRTACPLVDDNKAEEIADKIYNLYNGYTSGKEQQMAYNTLMEVSASMLFRVQHHYNSHYEKFGDFVWRSEDELGPRKAHLILRRLERVSSHCSSLLRSAYIQSRVETVPYLFCRSEEVRPAGMVWYSILKDTKITCEEKMVSMARNTYGESKGR","Homo sapiens","ASTN2, KIAA0634","Astrotactin-2","1","5J67"
"5J68",,"X-RAY DIFFRACTION",6.31,80.51,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M MES, pH 5.0 to 6.0, 5% PEG 6000",293,"10.1098/rsob.160053",,"5J68",67.42,"5.221","5.221","Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development","KFNDTLFGEMLHGYNNRTQHVNQGQVFQMTFRENNFIKDFPQLADGLLVIPLPVEEQCRGVLSEPLPDLQLLTGDIRYDEAMGYPMVQQWRVRSNLYRVKLSTITLAAGFTNVLKILTKESSREELLSFIQHYGSHYIAEALYGSELTCIIHFPSKKVQQQLWLQYQKETTELGSKKELKSMPFITYLSGLLTAQMLSDDQLISGVEIRCEEKGRCPSTCHLCRRPGKEQLSPTPVLLEINRVVPLYTLIQDNGTKEAFKSALMSSYWCSGKGDVIDDWCRCDLSAFDANGLPNCSPLLQPVLRLSPTVEPSSTVVSLEWVDVQPAIGTKVSDYILQHKKVDEYTDTDLYTGEFLSFADDLLSGLGTSCVAAGRSHGEVPEVSIYSVIFKCLEPDGLYKFTLYAVDTRGRHSELSTVTLRTACPLVDDNKAEEIADKIYNLYNGYTSGKEQQMAYNTLMEVSASMLFRVQHHYNSHYEKFGDFVWRSEDELGPRKAHLILRRLERVSSHCSSLLRSAYIQSRVETVPYLFCRSEEVRPAGMVWYSILKDTKITCEEKMVSMARNTYGESKGR","Homo sapiens","ASTN2, KIAA0634","Astrotactin-2","1","5J68"
"5J69",,"X-RAY DIFFRACTION",3.54,65.21,"VAPOR DIFFUSION, SITTING DROP",,"0.1 M Citric buffer pH 4.0 to 4.5 20% PEG 1000",293,"10.1098/rsob.160053",,"5J69",61.72,"3.63","3.63","Structure of Astrotactin-2, a conserved vertebrate-specific and perforin-like membrane protein involved in neuronal development","KFNDTLFGEMLHGYNNRTQHVNQGQVFQMTFRENNFIKDFPQLADGLLVIPLPVEEQCRGVLSEPLPDLQLLTGDIRYDEAMGYPMVQQWRVRSNLYRVKLSTITLAAGFTNVLKILTKESSREELLSFIQHYGSHYIAEALYGSELTCIIHFPSKKVQQQLWLQYQKETTELGSKKELKSMPFITYLSGLLTAQMLSDDQLISGVEIRCEEKGRCPSTCHLCRRPGKEQLSPTPVLLEINRVVPLYTLIQDNGTKEAFKSALMSS","Homo sapiens","ASTN2, KIAA0634","Astrotactin-2","1","5J69"
"5J6A",,"X-RAY DIFFRACTION",3.22,61.84,"VAPOR DIFFUSION, HANGING DROP",5.6,"100 mM sodium acetate pH 5.6
9% Isopropanol
100 mM megnesium chloride
50 mM Ammonium Sulfate",293,"10.1021/acs.jmedchem.6b01540","P46","5J6A",45.73,"2.045","2.045","Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS46","SKNASLAGAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5J6A"
"5J6D",,"X-RAY DIFFRACTION",2.04,39.76,"VAPOR DIFFUSION, SITTING DROP",8.4,"20% PEG 3350, CBTP pH 8.4, 2.5 mM TCEP",293,"10.1016/j.bmcl.2016.04.057","6H5","5J6D",72.54,"1.9","1.9","Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors","METVPWFPKKISDLDHCANRVLMYGSELDADHPGFKDNVYRKRRKYFADLAMNYKHGDPIPKVEFTEEEIKTWGTVFQELNKLYPTHACREYLKNLPLLSKYCGYREDNIPQLEDVSNFLKERTGFSIRPVAGYLSPRDFLSGLAFRVFHCTQYVRHSSDPFYTPEPDTCHELLGHVPLLAEPSFAQFSQEIGLASLGASEEAVQKLATCYFFTVEFGLCKQDGQLRVFGAGLLSSISELKHALSGHAKVKPFDPKITCKQECLITTFQDVYFVSESFEDAKEKMREFTKTIKRPFGVKYNHHHHHH","Homo sapiens","TPH1, TPH, TPRH, TRPH","Tryptophan 5-hydroxylase 1","1","5J6D"
"5J6L",,"X-RAY DIFFRACTION",3.25,62.16,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6GC","5J6L",26.02,"1.75","1.75","Crystal Structure of Hsp90-alpha N-domain in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDEAE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J6L"
"5J6M",,"X-RAY DIFFRACTION",3.15,60.94,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6FJ","5J6M",25.84,"1.64","1.64","Crystal Structure of Hsp90-alpha N-domain L107 mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-N-furan-2-ylmethyl-2,4-dihydroxy-N-methyl-benzamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J6M"
"5J6N",,"X-RAY DIFFRACTION",3.17,61.18,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w",,"5J6N",25.84,"1.9","1.9","Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-N-propyl-benzenesulfonamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDDE","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J6N"
"5J6S",,"X-RAY DIFFRACTION",2.82,56.43,"VAPOR DIFFUSION",6.3,"7 %(w/v) PEG 8000, 20 %(v/v) ethylene glycol, 59 mM MES, 41 mM imidazole",277,"10.1021/acsmedchemlett.6b00505","6GA","5J6S",229.26,"2.8","2.8","Crystal structure of Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) in complex with a hydroxamic derivative ligand","MFHSSAMVNSHRKPMFNIHRGFYCLTAILPQICICSQFSVPSSYHFTEDPGAFPVATNGERFPWQELRLPSVVIPLHYDLFVHPNLTSLDFVASEKIEVLVSNATQFIILHSKDLEITNATLQSEEDSRYMKPGKELKVLSYPAHEQIALLVPEKLTPHLKYYVAMDFQAKLGDGFEGFYKSTYRTLGGETRILAVTDFEPTQARMAFPCFDEPLFKANFSIKIRRESRHIALSNMPKVKTIELEGGLLEDHFETTVKMSTYLVAYIVCDFHSLSGFTSSGVKVSIYASPDKRNQTHYALQASLKLLDFYEKYFDIYYPLSKLDLIAIPDFAPGAMENWGLITYRETSLLFDPKTSSASDKLWVTRVIAHELAHQWFGNLVTMEWWNDIWLNEGFAKYMELIAVNATYPELQFDDYFLNVCFEVITKDSLNSSRPISKPAETPTQIQEMFDEVSYNKGACILNMLKDFLGEEKFQKGIIQYLKKFSYRNAKNDDLWSSLSNSCLESDFTSGGVCHSDPKMTSNMLAFLGENAEVKEMMTTWTLQKGIPLLVVKQDGCSLRLQQERFLQGVFQEDPEWRALQERYLWHIPLTYSTSSSNVIHRHILKSKTDTLDLPEKTSWVKFNVDSNGYYIVHYEGHGWDQLITQLNQNHTLLRPKDRVGLIHDVFQLVGAGRLTLDKALDMTYYLQHETSSPALLEGLSYLESFYHMMDRRNISDISENLKRYLLQYFKPVIDRQSWSDKGSVWDRMLRSALLKLACDLNHAPCIQKAAELFSQWMESSGKLNIPTDVLKIVYSVGAQTTAGWNYLLEQYELSMSSAEQNKILYALSTSKHQEKLLKLIELGMEGKVIKTQNLAALLHAIARRPKGQQLAWDFVRENWTHLLKKFDLGSYDIRMIISGTTAHFSSKDKLQEVKLFFESLEAQGSHLDIFQTVLETITKNIKWLEKNLPTLRTWLMVNTRHHHHHH","Homo sapiens","ERAP2, LRAP","Endoplasmic reticulum aminopeptidase 2","1","5J6S"
"5J6Z",,"SOLUTION NMR",,,,,,,"10.1021/acs.biochem.7b00633",,"5J6Z",13.39,,,"Structure of anastellin bound to beta-strands A and B from the third type III domain of fibronectin","GSQTTAPDAPPDPTVDQVDDTSIVVRWSRP","Homo sapiens","FN1, FN","Fibronectin","1","5J6Z"
,,,,,,,,,,,,,,,,"MRGSNAPQPSHISKYILRWRPKNSVGRWKEATIPGHLNSYTIKGLKPGVVYEGQLISIQQYGHQEVTRFDFTTTSTSTPGSRSHHHHHH","Homo sapiens","FN1, FN","Anastellin","2","5J6Z"
"5J71",,"X-RAY DIFFRACTION",3.87,68.25,"VAPOR DIFFUSION, HANGING DROP",4.6,"0.9 M ammonium tartrate, 0.1 M sodium acetate pH 4.6",293,"10.1021/acs.jmedchem.6b01540","P35","5J71",45.77,"1.65","1.65","Crystal structure of pyruvate dehydrogenase kinase isoform 2 in complex with inhibitor PS35","SKNASLAGAPKYIEHFSKFSPSPLSMKQFLDFGSSNACEKTSFTFLRQELPVRLANIMKEINLLPDRVLSTPSVQLVQSWYVQSLLDIMEFLDKDPEDHRTLSQFTDALVTIRNRHNDVVPTMAQGVLEYKDTYGDDPVSNQNIQYFLDRFYLSRISIRMLINQHTLIFDGSTNPAHPKHIGSIDPNCNVSEVVKDAYDMAKLLCDKYYMASPDLEIQEINAANSKQPIHMVYVPSHLYHMLFELFKNAMRATVESHESSLILPPIKVMVALGEEDLSIKMSDRGGGVPLRKIERLFSYMYSTAPTPQPGTGGTPLAGFGYGLPISRLYAKYFQGDLQLFSMEGFGTDAVIYLKALSTDSVERLPVYNKSAWRHYQTIQEAGDWCVPSTEPKNTSTYRVS","Homo sapiens","PDK2, PDHK2","[Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 2, mitochondrial","1","5J71"
"5J74",,"X-RAY DIFFRACTION",2.74,55.11,"VAPOR DIFFUSION, SITTING DROP",,"32% PEG monomethyl ether 5000
0.2M potassium dihydrogen phosphate",298,"10.1177/1087057115609145",,"5J74",56.08,"2.7","2.7","Fluorogen activating protein AM2.2 in complex with TO1-2p","QVQLVESEAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGTIPIFGTADYAQEFQGRVTITTDESTSTAYMELSGLRSEDTAVYYCVLLGTTMVTGHYFDYWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSNFMLTQPPSASGTPGQSVTISCSGSGSNIGNNKVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDGLSGYVFGTGTKLTVLAASGADHHHHHH","Homo sapiens",,"scFv AM2.2","1","5J74"
"5J75",,"X-RAY DIFFRACTION",2.24,45.14,"VAPOR DIFFUSION, SITTING DROP",,"20% PEG 3350
0.2M sodium nitrate",298,"10.1177/1087057115609145","6GQ","5J75",55.67,"2","2","Fluorogen Activating Protein AM2.2 in complex with ML342","QVQLVESEAEVKKPGSSVKVSCKASGGTFSSYAISWVRQAPGQGLEWMGGTIPIFGTADYAQEFQGRVTITTDESTSTAYMELSGLRSEDTAVYYCVLLGTTMVTGHYFDYWGQGTLVTVSSGILGSGGGGSGGGGSGGGGSNFMLTQPPSASGTPGQSVTISCSGSGSNIGNNKVNWYQQLPGTAPKLLIYSNNQRPSGVPDRFSGSKSGTSASLAISGLQSEDEADYYCAAWDDGLSGYVFGTGTKLTVLAASGADHHHHHH","Homo sapiens",,"scFv AM2.2","1","5J75"
"5J79",,"X-RAY DIFFRACTION",3.69,66.7,"VAPOR DIFFUSION, HANGING DROP",,"1.5M Ammonium sulphate, 25% glycerol",293,"10.1021/acs.jmedchem.6b00211","6GE","5J79",76.35,"2.69","2.69","The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, Compound 3 complex","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","1","5J79"
"5J7B",,"X-RAY DIFFRACTION",3.61,65.91,"VAPOR DIFFUSION",7,"100mM Mes pH7, 12% PEG 400, 250mM CaCl2. Crystals soaked in compound for 2 hours.",293,"10.1021/acs.jmedchem.6b00211",,"5J7B",76.01,"2.53","2.53","The identification and pharmacological characterization of 6-(tert-butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a highly potent and selective inhibitor of RIP2 Kinase, GSK583 complex","MDYKDDDDKENLYFQGMNGEAICSALPTIPYHKLADLRYLSRGASGTVSSARHADWRVQVAVKHLHIHTPLLDSERKDVLREAEILHKARFSYILPILGICNEPEFLGIVTEYMPNGSLNELLHRKTEYPDVAWPLRFRILHEIALGVNYLHNMTPPLLHHDLKTQNILLDNEFHVKIADFGLSKWRMMSLSQSRSSKSAPEGGTIIYMPPENYEPGQKSRASIKHDIYSYAVITWEVLSRKQPFEDVTNPLQIMYSVSQGHRPVINEESLPYDIPHRARMISLIESGWAQNPDERPSFLKCLIELEPVLRTFEEITFLEAVIQLK","Homo sapiens","RIPK2, CARDIAK, RICK, RIP2, UNQ277/PRO314/PRO34092","Receptor-interacting serine/threonine-protein kinase 2","1","5J7B"
"5J7E",,"X-RAY DIFFRACTION",1.94,36.52,"VAPOR DIFFUSION, SITTING DROP",7.5,"20 mM Tris-HCl, 200 mM NaCl, 5 mM DTT",291,,,"5J7E",101.64,"1.9","1.9","hEAG PAS domain","MTMAGGRRGLVAPQNTFLENIVRRSNDTNFVLGNAQIVDWPIVYSNDGFCKLSGYHRAEVMQKSSTCSFMYGELTDKDTIEKVRQTFENYEMNSFEILMYKKNRTPVWFFVKIAPIRNEQDKVVLFLCTFSDITAFKQPIEDDSCK","Homo sapiens","KCNH1, EAG, EAG1","Potassium voltage-gated channel subfamily H member 1","1","5J7E"
"5J7F",,"X-RAY DIFFRACTION",2.2,44.05,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M HEPES pH 7.5 with 0.2 M NaCl and 25% PEG 3350",277,"10.1021/acs.jmedchem.7b00104","6GG","5J7F",59.35,"2","2","Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.","MCNTNMSVPTDGAVTTSQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSEN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5J7F"
"5J7G",,"X-RAY DIFFRACTION",2.33,47.11,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Na HEPES pH 7.5 with 10% isopropanol and 20% PEG 4000",277,"10.1021/acs.jmedchem.7b00104","6GG","5J7G",53.04,"1.85","1.85","Structure of MDM2 with low molecular weight inhibitor with aliphatic linker.","MQIPASEQETLVRPKPLLLKLLKSVGAQKDTYTMKEVLFYLGQYIMTKRLYDEKQQHIVYCSNDLLGDLFGVPSFSVKEHRKIYTMIYRNLVVVNQQESSDSGTSVSEN","Homo sapiens","MDM2","E3 ubiquitin-protein ligase Mdm2","1","5J7G"
"5J7P",,"X-RAY DIFFRACTION",3.69,66.63,"VAPOR DIFFUSION, HANGING DROP",7,"2.2 M Ammonium Sulfate, 3% isopropanol and 0.1 M Tris pH 7.0",293.15,"10.1016/j.bmcl.2016.04.074",,"5J7P",39.02,"1.85","1.85","Macrophage Migration Inhibitory Factor bound to Covalent Inhibitor RDR03785","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5J7P"
"5J7Q",,"X-RAY DIFFRACTION",2.73,54.88,"VAPOR DIFFUSION, HANGING DROP",7,"2.4 M Ammonium Sulfate, 3% isopropanol and 0.1 M Tris pH 7.0",293.15,"10.1016/j.bmcl.2016.04.074","6H2","5J7Q",38.21,"2.05","2.05","Macrophage Migration Inhibitory Factor bound to Inhibitor K664 Derivative","PMFIVNTNVPRASVPDGFLSELTQQLAQATGKPPQYIAVHVVPDQLMAFGGSSEPCALCSLHSIGKIGGAQNRSYSKLLCGLLAERLRISPDRVYINYYDMNAANVGWNNSTFA","Homo sapiens","MIF, GLIF, MMIF","Macrophage migration inhibitory factor","1","5J7Q"
"5J7T",,"X-RAY DIFFRACTION",3.73,67.02,"VAPOR DIFFUSION, HANGING DROP",8.3,"PEG 3350, 0.2M tri-potassium citrate",289,"10.1016/j.str.2016.05.020",,"5J7T",77.86,"3.2001","3.2001","Molecular Understanding of USP7 Substrate Recognition and C-Terminal Activation","TGYVGLKNQGATCYMNSLLQTLFFTNQLRKAVYMMPTEGDDSSKSVPLALQRVFYELQHSDKPVGTKKLTKSFGWETLDSFMQHDVQELCRVLLDNVENKMKGTCVEGTIPKLFRGKMVSYIQCKEVDYRSDRREDYYDIQLSIKGKKNIFESFVDYVAVEQLDGDNKYDAGEHGLQEAEKGVKFLTLPPVLHLQLMRFMYDPQTDQNIKINDRFEFPEQLPLDEFLQKTDPKDPANYILHAVLVHSGDNHGGHYVVYLNPKGDGKWCKFDDDVVSRCTKEEAIEHNYGGHDDDLSVRHCTNAYMLVYIRESKLSEVLQAVTDHDIPQQLVERLQEEKRIEAQKRKERQEAHLYMQVQIVAEDQFCGHQGNDMYDEEKVKYTVFKVLKNSSLAEFVQSLSQTMGFPQDQIRLWPMQARSNGTKRPAMLDNEADGNKTMIELSDNENPWTIFLETVDPELAASGATLPKFDKDHDVMLFLKMYDPKTRSLNYCGHIYTPISCKIRDLLPVMCDRAGFIQDTSLILYEEVKPNLTERIQDYDVSLDKALDELMDGDIIVFQKDDPENDNSELPTAKEYFRDLYHRVDVIFCDKTIPNDPGFVVTLSNRMNYFQVAKTVAQRLNTDPMLLQFFKSQGYRDGPGNPLRHNYEGTLRDLLQFFKPRQPKKLYYQQL","Homo sapiens","USP7, HAUSP","Ubiquitin carboxyl-terminal hydrolase 7","1","5J7T"
"5J80",,"X-RAY DIFFRACTION",2.99,58.92,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w",,"5J80",25.29,"1.17","1.17","Crystal Structure of Apo Hsp90-alpha N-domain L107A mutant","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J80"
"5J82",,"X-RAY DIFFRACTION",3.28,62.44,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6GV","5J82",25.75,"2.17","2.17","Crystal Structure of Hsp90-alpha N-domain in complex 5-[4-(2-Fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-isopropyl-N-methyl-benzenesulfonamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J82"
"5J86",,"X-RAY DIFFRACTION",3.19,61.45,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride, 0.1 M Bis Tris propane, pH 8.5, 20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6GW","5J86",25.76,"1.87","1.87","Crystal Structure of Hsp90-alpha N-domain in complex with 2,4-Dihydroxy-N-methyl-5-(5-oxo-4-o-tolyl-4,5-dihydro-1H-[1,2,4]triazol-3-yl)-N-thiophen-2-ylmethyl-benzamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J86"
"5J87",,"X-RAY DIFFRACTION",2.29,46.36,"EVAPORATION",6.5,"0.2M magnesium chloride ,0.1M sodium cacodylate pH6.5, 31% PEG 2000 , 0.1M sodium iodide",298,"10.1016/j.ejmech.2017.03.001","N42","5J87",130.06,"1.59","1.59","Discovery of N-(3-(5-((3-acrylamido-4-(morpholine-4-carbonyl)phenyl)amino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-2-methylphenyl)-4-(tert-butyl)benzamide (CHMFL-BTK-01) as a Highly Selective Irreversible BTK Kinase Inhibitor","PSTAGLGYGSWEIDPKDLTFLKELGTGQFGVVKYGKWRGQYDVAIKMIKEGSMSEDEFIEEAKVMMNLSHEKLVQLYGVCTKQRPIFIITEYMANGCLLNYLREMRHRFQTQQLLEMCKDVCEAMEYLESKQFLHRDLAARNCLVNDQGVVKVSDFGLSRYVLDDEYTSSVGSKFPVRWSPPEVLMYSKFSSKSDIWAFGVLMWEIYSLGKMPYERFTNSETAEHIAQGLRLYRPHLASEKVYTIMYSCWHEKADERPTFKILLSNILDVMDEE","Homo sapiens","BTK, AGMX1, ATK, BPK","Tyrosine-protein kinase BTK","1","5J87"
"5J89",,"X-RAY DIFFRACTION",2.1,41.41,"VAPOR DIFFUSION, SITTING DROP",8,"0.01M Tris pH=8.5, 0.3M sodium chloride, 27% (w/v) PEG 4000",293,"10.18632/oncotarget.8730","6GX","5J89",67.84,"2.2","2.2","Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor","RIFAVFIFMTYWHLLNAFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHHHHHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5J89"
"5J8C",,"X-RAY DIFFRACTION",2.2,44.12,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.2M Ammonium Chloride
28% PEG 3350
0.1M BisTris-HCL pH 6.5",293,"10.1074/jbc.M116.736264",,"5J8C",36.3,"2.17","2.17","Human MOF C316S, E350Q crystal structure","MGSSHHHHHHDYDIPTTENLYFQGSKYVDKIHIGNYEIDAWYFSPFPEDYGKQPKLWLCEYCLKYMKYEKSYRFHLGQCQWRQPPGKEIYRKSNISVYEVDGKDHKIYCQNLCLLAKLFLDHKTLYFDVEPFVFYILTEVDRQGAHIVGYFSKEKESPDGNNVASILTLPPYQRRGYGKFLIAFSYELSKLESTVGSPQKPLSDLGKLSYRSYWSWVLLEILRDFRGTLSIKDLSQMTSITQNDIISTLQSLNMVKYWKGQHVICVTPKLVEEHLKSAQYKKPPITVDSVCLKWAPPKHKQVKLSKK","Homo sapiens","KAT8, MOF, MYST1, PP7073","Histone acetyltransferase KAT8","1","5J8C"
"5J8E",,"X-RAY DIFFRACTION",1.92,36.03,"VAPOR DIFFUSION, HANGING DROP",,"2 M sodium formate, 0.1 M sodium acetate pH 4.6",293,"10.1083/jcb.201604002",,"5J8E",37.43,"1.7","1.7","Crystal structure of human Hook3's conserved Hook domain","GPLGSMFSVESLERAELCESLLTWIQTFNVDAPCQTVEDLTNGVVMAQVLQKIDPAYFDENWLNRIKTEVGDNWRLKISNLKKILKGILDYNHEILGQQINDFTLPDVNLIGEHSDAAELGRMLQLILGCAVNCEQKQEYIQAIMMMEESVQHVVMTAIQELMSK","Homo sapiens","HOOK3","Protein Hook homolog 3","1","5J8E"
"5J8F",,"X-RAY DIFFRACTION",2.19,43.77,"VAPOR DIFFUSION, HANGING DROP",6.5,"0.28M Ammonium Chloride
26%PEG 3350
0.1M BisTris-HCl pH 6.5",293,"10.1074/jbc.M116.736264",,"5J8F",36.2,"2.6","2.6","Human MOF K274P crystal structure","MGSSHHHHHHDYDIPTTENLYFQGSKYVDKIHIGNYEIDAWYFSPFPEDYGKQPKLWLCEYCLKYMKYEKSYRFHLGQCQWRQPPGKEIYRKSNISVYEVDGKDHKIYCQNLCLLAKLFLDHPTLYFDVEPFVFYILTEVDRQGAHIVGYFSKEKESPDGNNVACILTLPPYQRRGYGKFLIAFSYELSKLESTVGSPEKPLSDLGKLSYRSYWSWVLLEILRDFRGTLSIKDLSQMTSITQNDIISTLQSLNMVKYWKGQHVICVTPKLVEEHLKSAQYKKPPITVDSVCLKWAPPKHKQVKLSKK","Homo sapiens","KAT8, MOF, MYST1, PP7073","Histone acetyltransferase KAT8","1","5J8F"
"5J8M",,"X-RAY DIFFRACTION",3.05,59.66,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6DL","5J8M",51.3,"1.9","1.9","Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(5-Bromo-2,4-dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J8M"
"5J8O",,"X-RAY DIFFRACTION",2.38,48.22,"VAPOR DIFFUSION, SITTING DROP",8,"0.2 M ammonium formate and 20% (w/v) PEG 3350",293,"10.18632/oncotarget.8730","6GZ","5J8O",28.75,"2.3","2.3","Structure of human Programmed cell death 1 ligand 1 (PD-L1) with low molecular mass inhibitor","AFTVTVPKDLYVVEYGSNMTIECKFPVEKQLDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPYAAALEHH","Homo sapiens","CD274, B7H1, PDCD1L1, PDCD1LG1, PDL1","Programmed cell death 1 ligand 1","1","5J8O"
"5J8P",,"X-RAY DIFFRACTION",2.07,40.56,"VAPOR DIFFUSION, SITTING DROP",6.5,"0.2M magnesium acetate tetrahydrate, 0.1M sodium cacodylate trihydrate, pH 6.5, 20% PEG 8000",291,,,"5J8P",17.17,"1.554","1.554","Lys27-linked diubiquitin","MQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGG","Homo sapiens","UBA52, UBCEP2","ubiquitin","1","5J8P"
,,,,,,,,,,,,,,,,"LQIFVKTLTGKTITLEVEPSDTIENVKAKIQDKEGIPPDQQRLIFAGKQLEDGRTLSDYNIQKESTLHLVLRLRGA","Homo sapiens","UBA52, UBCEP2","D-ubiquitin","2","5J8P"
"5J8R",,"X-RAY DIFFRACTION",3.06,59.75,"VAPOR DIFFUSION, HANGING DROP",7,"3.5M Sodium formate",277.15,"10.1016/j.celrep.2016.04.016",,"5J8R",148.19,"2.043","2.043","Crystal Structure of the Catalytic Domain of Human Protein Tyrosine Phosphatase non-receptor Type 12 - K61R mutant","HHHHHHMEQVEILRKFIQRVQAMKSPDHNGEDNFARDFMRLRRLSTKYRTEKIYPTATGEKEENVKRNRYKDILPFDHSRVKLTLKTPSQDSDYINANFIKGVYGPKAYVATQGPLANTVIDFWRMIWEYNVVIIVMACREFEMGRKKCERYWPLYGEDPITFAPFKISCEDEQARTDYFIRTLLLEFQNESRRLYQFHYVNWPDHDVPSSFDSILDMISLMRKYQEHEDVPICIHCSAGCGRTGAICAIDYTWNLLKAGKIPEEFNVFNLIQEMRTQRHSAVQTKEQYELVHRAIAQLFEKQLQLYEIHG","Homo sapiens","PTPN12","Tyrosine-protein phosphatase non-receptor type 12","1","5J8R"
"5J8U",,"X-RAY DIFFRACTION",3.07,59.88,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6DL","5J8U",51.3,"1.75","1.75","Crystal Structure of Hsp90-alpha N-domain L107A mutant in complex with 5-(2,4-Dihydroxy-phenyl)-4-(2-fluoro-phenyl)-2,4-dihydro-[1,2,4]triazol-3-one","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNAGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J8U"
"5J8Z",,"X-RAY DIFFRACTION",2.07,40.64,"VAPOR DIFFUSION, HANGING DROP",8.5,"1.3 M sodium citrate, 0.1 M TRIS-HCl",293.15,"10.1016/j.bmc.2016.06.005","6KE, FC4","5J8Z",30.61,"1.7","1.7","Human carbonic anhydrase II in complex with ligand","MGMSHHWGYGKHNGPEHWHKDFPIAKGERQSPVDIDTHTAKYDPSLKPLSVSYDQATSLRILNNGHAFNVEFDDSQDKAVLKGGPLDGTYRLIQFHFHWGSLDGQGSEHTVDKKKYAAELHLVHWNTKYGDFGKAVQQPDGLAVLGIFLKVGSAKPGLQKVVDVLDSIKTKGKSADFTNFDPRGLLPESLDYWTYPGSLTTPPLLECVTWIVLKEPISVSSEQVLKFRKLNFNGEGEPEELMVDNWRPAQPLKNRQIKASFK","Homo sapiens","CA2","Carbonic anhydrase 2","1","5J8Z"
"5J94",,"X-RAY DIFFRACTION",2.1,41.5,"VAPOR DIFFUSION, HANGING DROP",5.5,"0.2 M ammonium sulfate, 30% PEG 8000, pH 5.5, VAPOR DIFFUSION, SITTING DROP, temperature 293K",293,"10.1038/ncomms4287",,"5J94",24.89,"2.22002456664","2.22002456664","Human cathepsin K mutant C25S in complex with the allosteric effector NSC13345","YIPEWEGRAPDSVDYRKKGYVTPVKNQGQCGSSWAFSSVGALEGQLKKKTGKLLNLSPQNLVDCVSENDGCGGGYMTNAFQYVQKNRGIDSEDAYPYVGQEESCMYNPTGKAAKCRGYREIPEGNEKALKRAVARVGPVSVAIDASLTSFQFYSKGVYYDESCNSDNLNHAVLAVGYGIQKGNKHWIIKNSWGENWGNKGYILMARNKNNACGIANLASFPKM","Homo sapiens","CTSK, CTSO, CTSO2","Cathepsin K","1","5J94"
"5J95",,"X-RAY DIFFRACTION",2.49,50.7,"VAPOR DIFFUSION, HANGING DROP",,"0.1 M Bis-Tris pH=6.5, 0.2 M NaCl, 18% PEG 3350",277,,,"5J95",71.86,"2.5","2.5","MAP4K4 in complex with inhibitor","ANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTRKKR","Homo sapiens","MAP4K4, HGK, KIAA0687, NIK","Mitogen-activated protein kinase kinase kinase kinase 4","1","5J95"
"5J97",,"X-RAY DIFFRACTION",2.68,54.14,"VAPOR DIFFUSION, HANGING DROP",8,"20% PEG8000, 0.1 M Tris (pH8.0), 10% glycerol",298,,,"5J97",31.63,"2.55","2.55","Dimerization domain of cytoplasmic activation/proliferation-associated protein-2 (caprin-2)","GPSSPSQRREHMLKLEAEKKKLRTILQVQYVLQNLTQEHVQKDFKGGLNGAVYLPSKELDYLIKFSKLTCPERNESLSVEDQMEQSSLYFWDLLEGSEKAVVGTTYKHLKDLLSKLLNSGYFESIPVPKNAKEKEVP","Homo sapiens","CAPRIN2, C1QDC1, EEG1, KIAA1873, RNG140","Caprin-2","1","5J97"
"5J9F",,"X-RAY DIFFRACTION",3.64,66.23,"VAPOR DIFFUSION, SITTING DROP",7.5,"0.1 M Tris (pH 7.5), 0.333 mM NaCl, 18% polyethylene glycol (PEG) 3350, and 2% PEG 400",277,"10.1021/acs.jmedchem.6b00594","83A","5J9F",23.48,"2.1","2.1","Human GAR transformylase in complex with GAR and (4-{[2-(2-Amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-6-yl)ethyl]amino}benzoyl)-L-glutamic acid (AGF183)","MARVAVLISGTGSNLQALIDSTREPNSSAQIDIVISNKAAVAGLDKAERAGIPTRVINHKLYKNRVEFDSAIDLVLEEFSIDIVCLAGFMRILSGPFVAKWNGKMLNIHPSLLPSFKGSNAHEQALETGVTVTGCTVHFVAEDVDAGQIILQEAVPVKRGDTVATLSERVKLAEHKIFPAALQLVASGTVQLGENGKICWVKEEHHHHHH","Homo sapiens","GART, PGFT, PRGS","Trifunctional purine biosynthetic protein adenosine-3","1","5J9F"
"5J9X",,"X-RAY DIFFRACTION",3.3,62.7,"VAPOR DIFFUSION, HANGING DROP",,"0.2 M sodium fluoride
0.1 M Bis Tris propane
pH 8.5
20 % w/v PEG 3350",277.15,"10.1038/s41467-017-02258-w","6GC","5J9X",25.81,"1.8","1.8","HSP90 in complex with N-Butyl-5-[4-(2-fluoro-phenyl)-5-oxo-4,5-dihydro-1H-[1,2,4]triazol-3-yl]-2,4-dihydroxy-N-methyl-benzamide","DQPMEEEEVETFAFQAEIAQLMSLIINTFYSNKEIFLRELISNSSDALDKIRYESLTDPSKLDSGKELHINLIPNKQDRTLTIVDTGIGMTKADLINNLGTIAKSGTKAFMEALQAGADISMIGQFGVGFYSAYLVAEKVTVITKHNDDEQYAWESSAGGSFTVRTDTGEPMGRGTKVILHLKEDQTEYLEERRIKEIVKKHSQFIGYPITLFVEKERDKEVSDD","Homo sapiens","HSP90AA1, HSP90A, HSPC1, HSPCA","Heat shock protein HSP 90-alpha","1","5J9X"
"5J9Y",,"X-RAY DIFFRACTION",3.39,63.75,"VAPOR DIFFUSION, HANGING DROP",,"100 mM MES, 
900 mM - 1100 mM Na/K-tartrate",293,"10.1002/anie.201605011","6HL","5J9Y",37.36,"2.8","2.8","EGFR-T790M in complex with pyrazolopyrimidine inhibitor 1b","EAPNQALLRILKETEFKKIKVLGSGAFGTVYKGLWIPEGEKVKIPVAIKELREATSPKANKEILDEAYVMASVDNPHVCRLLGICLTSTVQLIMQLMPFGCLLDYVREHKDNIGSQYLLNWCVQIAKGMNYLEDRRLVHRDLAARNVLVKTPQHVKITDFGLAKLLGAEEKEYHAEGGKVPIKWMALESILHRIYTHQSDVWSYGVTVWELMTFGSKPYDGIPASEISSILEKGERLPQPPICTIDVYMIMVKCWMIDADSRPKFRELIIEFSKMARDPQRYLVIQGDERMHLPSPTDSNFYRALMDEEDMDDVVDADEYLIP","Homo sapiens","EGFR, ERBB, ERBB1, HER1","Epidermal growth factor receptor","1","5J9Y"
